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The early work in this thesis utilizes the general approach of comparative analysis.  In 
order to find out the relationship between entities (either functional or genetic) my colleagues 
and I have attempted to identify the important elements by detecting similarity between those 
entities that act in a similar manner.  The philosophy behind this approach is simply that when 
two distinct objects perform a similar process then the requirements essential for that process 
will be revealed as similarities between those objects above a noise of difference between 
them.  The use of comparative analysis in biological systems is an attempt to identify natural 
order from apparent chaos.   
This work includes but is not limited to :- 
   1. discovery of the family of kallikrein genes and exploration of their roles in biology, 
   2. identification of the DNA sequence elements required for hormonal and heavy metal  
       control of metallothionein gene expression 
   3. discovery of at least some of the necessary and sufficient conditions for the appearance of  
       fragile sites on chromosomes, and their consequent contributions to disease, 
   4. the molecular properties of repeat DNA sequence expansion that lead to dynamic  
       mutation and consequent fragile site expression and / or disease pathogenesis. 
In a sense the use of genetic animal models in order to study gene function and 
pathogenesis follows similar logic of comparative analysis – the mutation of a single 
endogenous gene or the expression of a single introduced mutated gene in a (presumed) 
constant genetic background to enable the biological consequences of the genetic mutation or 
aberrant gene expression by comparing animals from the ‘wild-type’ or parent line with those 
that now carry the mutation or altered gene.  This approach has been utilized in the most 
recent work contained herein as a means to determine gene function and / or to model human 
genetic disease pathogenesis, specifically pathogenic mechanisms of the protein WWOX in 
cancer and expanded repeat RNAs in neurodegenerative diseases. 
The culmination of this recent work is the development of an hypothesis –  
   4. that expanded repeat double-stranded RNA leads to neurodegeneration through its 
recognition by the RNA-binding pattern recognition receptors as a ‘non-self’ or foreign nucleic 
acid due to a paucity of RNA modification.  
The resultant pathogenic mechanism is therefore autoinflammatory disease. Given the 
wide range and variety of evidence of inflammatory activation in neurodegenerative diseases 
in general, this mechanism is therefore hypothesized to be the general causal mechanism for 
most (or all) of these diseases. 
A specific Introduction - highlighting the nature and significance of the work, and a 
Conclusion – of how this work has contributed to knowledge, are given at the start of each 
chapter, while the impact of the various components of this work is indicated by the number of 
citations for each of the included publications. Authorship contributions to each of the 
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Section I  Gene Families: 
 
Chapter 1. Kallikrein gene family and the Angiotensinogen gene: Candidate 





This project began in 1980 when I identified a cDNA clone from a mouse salivary gland 
cDNA library that showed 57% sequence homology to pig pancreatic kallikrein (ref #1).  This 
finding was my first experience at how useful computer analysis could be in biology and 
preceded by many years the discipline now known as ‘bioinformatics’.  Dr Adrian Gibbs at the 
Research School of Biological Sciences at ANU had developed a program (which he called 
‘SEQ’) for searching for strings of homology – this was a precursor to the now widely used 
‘BLAST’ algorithm.  I used the SEQ program to search the Dayhoff database collection of 
known (at the time) protein sequences and found 57% sequence identity between the amino 
acid sequence predicted by an open reading frame of one of the mouse salivary gland cDNA 
clones with the amino acid sequence of pig pancreatic kallikrein.  This finding also initiated an 
interest in genes that might have roles in important biological functions – such as blood 
pressure regulation.  I was fortunately able to take this project with me when I left the ANU in 
Canberra and took up a position at the Howard Florey Institute of Experimental Physiology and 
Medicine in Melbourne.  This project included the efforts of the PhD students Tony Mason, 
Catherine Drinkwater, Ian Lyons, Matthew Digby, Bill Cloustin, Mario Congiu and the post-
doctoral fellows Bronwyn Evans and Barbara van Leeuwen – all of whom I supervised. 
 
This work resulted in publications in the journals Nature (ref 2), J. Biol. Chem. (refs #4, 5, 
10), Biochemistry (refs #7, 9), EMBO Journal (refs #3, 6) and Trends in Biochemistry (ref #15) 
as well as invitations to speak at Gordon Research Conferences and specialist international 
Kallikrein-Kinin conferences. 
 
 Bill Clouston initiated, and Mario Congiu completed, a series of genetic studies on the 
mouse angiotensinogen gene and its regulation (refs #16-20). 
 
A) KALLIKREIN GENES: 
 
1. Mouse glandular kallikrein genes : Nucleotide sequence of cloned cDNA coding for a 
member of the kallikrein-arginyl esteropeptidase group of serine proteases. 
Journal of Biological Chemistry (1982) 257: 2758-2761. 
Richards, R.I., Catanzaro, D.F., Mason, A.J., Morris, B., Baxter, J.D., Shine, J. 
 
This project arose out of attempts to find a different gene (that encoding renin) and the 
serendipitous finding enabled me to develop a project specifically analysing kallikrein genes.  I 
was therefore in the fortunate position of being able to pursue and oversee this project 
independently of other projects being conducted in my post-doctoral supervisors’ (Drs Shine 
and Baxter) laboratories. I conducted the majority of the experimental work, analysed and 
interpreted the data and wrote the manuscript.     Citations 67 
 
2. Structure of the mouse glandular kallikrein gene family suggests a role in the 
processing of biologically active peptides. 
Nature (1983) 303: 300-307. 
Mason, A.J., Evans, B.A., Cox, D., Shine, J., Richards, R.I. 
 
This work was a key part of Tony Mason’s PhD thesis. I oversaw the entire project. I 
established the collaboration with David Cox. I conducted some of the experimental work, 
supervised the project, analysed and interpreted the data, conceived of the  








3. Genes for the alpha & gamma subunits of mouse nerve growth factor are contiguous. 
EMBO Journal (1985) 4: 133-138. 
Evans, B.A., Richards, R.I. 
 
I oversaw the entire project. I conducted some of the experimental work, supervised the 
project, analysed and interpreted the data, conceived of the overall content of the paper and 
co-wrote the manuscript.        Citations 77 
 
 
4. Mouse glandular kallikrein genes : Identification, structure and expression of the 
renal kallikrein gene. 
Journal of Biological Chemistry (1986) 261: 5529-5535. 
Van Leeuwen, B.H., Evans, B.A., Tregear, G.W., Richards, R.I. 
 
I oversaw the entire project. I supervised the experimental work, analysed and interpreted the 
data, conceived of the overall content of the paper and co-wrote the manuscript. Citations 104 
 
 
5. Mouse glandular kallikrein genes : Structure and partial sequence analysis of the 
kallikrein gene locus. 
Journal of Biological Chemistry (1987) 262: 8027-8034. 
Evans, B.A., Drinkwater, C.C., Richards, R.I. 
  
I oversaw the entire project. I supervised the experimental work, analysed and interpreted the 
data, conceived of the overall content of the paper and co-wrote the manuscript. Citations 174 
 
 
6. Cellular basis for the differential response of mouse kallikrein genes to hormonal 
induction. 
EMBO Journal  (1987) 6: 1705-1713. 
van Leeuwen, B.H., Penschow, J.D., Coghlan, J.P., Richards, R.I. 
  
I oversaw the entire project. I co-supervised the experimental work, analysed and interpreted 
the data, conceived overall content of the paper and co-wrote the manuscript.  Citations 44 
 
 
7. Mouse glandular kallikrein genes : Identification and characterization of the genes  
encoding the EGF-binding protein(s). 
Biochemistry (1987) 26: 6750-6756. 
Drinkwater, C.C., Evans, B.A., Richards, R.I. 
 
This work was a key part of Cathy Drinkwater’s PhD thesis. I oversaw the entire project. I 
supervised the experimental work, analysed and interpreted the data, conceived of the overall 
content of the paper and co-wrote the manuscript.     Citations 67  
 
 
8. Sequence of the mouse glandular kallikrein gene, mGK-5. 
Nucleic Acids Research (1987) 15: 10052. 
Drinkwater, C.C., Richards, R.I. 
 
I oversaw the entire project. I supervised the experimental work and interpreted the data and 










9. Structure and chromosomal localization of the human renal kallikrein gene. 
Biochemistry (1988) 27: 3124-3129. 
Evans, B.A., Zhang, X-Y, Close, J.A., Tregear, G.W., Kitamura, N., Nakanishi, S., Callen, D.F., 
Baker, E., Hyland, V.J., Sutherland, G.R., Richards, R.I. 
 
I oversaw the majority of the project and negotiated the collaborations with Grant Sutherland 
and Shigetada Nakanishi. I supervised and conducted much of the experimental work, 
analysed and interpreted the data, conceived of the overall content of the paper and wrote the 
manuscript.          Citations 160 
 
 
10. Sequence and expression of mouse gamma-renin. 
Journal of Biological Chemistry (1988) 263: 8565-8569. 
Drinkwater, C.C., Evans, B.A., Richards, R.I. 
 
This work was a key part of Cathy Drinkwater’s PhD thesis. I oversaw the project.  I 
supervised the experimental and interpreted the data, conceived of the overall  
content of the paper and co-wrote the manuscript.      Citations 17 
 
 
11. Human prostate specific antigen is a member of the glandular kallikrein gene  
family at 19q13. 
Cytogenetics and Cell Genetics (1988) 48: 205-207. 
Sutherland, G.R., Baker, E., Hyland, V.J., Callen, D.F., Close, J.A., Tregear, G.W., Evans, 
B.A., Richards, R.I. 
 
I oversaw the majority of the project and negotiated the collaboration with Grant Sutherland. I 
supervised part of the experimental work, supervised the project, analysed and interpreted the 
data, conceived of the overall content of the paper and co-wrote the manuscript. Citations 42 
 
 
12. Nucleotide sequence of the mouse glandular kallikrein gene mGK-11. 
Nucleic Acids Research (1988) 16: 10918. 
Drinkwater, C.C., Richards, R.I. 
 
I oversaw the project.  I supervised the experimental work, analysed and interpreted the data, 
and the manuscript is purely descriptive.       Citations 5 
 
 
Differential binding of thyroid hormone receptors to mouse glandular kallikrein gene 
promoters: Evidence for multiple binding sites in the mGK-6 gene. 
Journal of Molecular Endocrinology (1989) 3: 79-84.  
Barlow, J.W., Raggat, L.E., Drinkwater, C.C., Lyons, I.G., Richards, R.I.  
 
 
13. Human prostate specific antigen (PSA) gene: Structure and linkage to the kallikrein-
like gene hGK-1 
Nucleic Acids Research (1989) 17: 2137. 
Digby, M., Zhang, X-Y, Richards, R.I. 
  
This work was a key part of Matthew Digby’s PhD thesis. I oversaw the project.  I supervised 
the experimental work, analysed and interpreted the data, and the manuscript is purely 
descriptive.       .    Citations 41 
 
Thyroid hormone receptors from IM-9 cells but not HeLa cells bind to promoters of  
T3-responsive genes. 
Molecular and Cellular Endocrinology (1990). 69: 129-134. 





14. Human glandular kallikrein genes : Genetic and physical mapping of the KLK1 locus 
using a highly polymorphic microsatellite marker. 
Genomics (1991) 11: 77-82. 
Richards, R.I., Holman, K., Shen, Y., Harley, H., Brook, D., Shaw, D. 
  
I oversaw the project and negotiated the collaboration with Helen Harley and Duncan Shaw.  I 
conducted the majority of the experimental work, analysed and interpreted the data, and wrote 
the manuscript.          Citations 40 
  
The kallikrein multigene family :  Specific processing of biologically active peptides. 
Cold Spring Harbor Symposia on Quantitative Biology 48: Molecular Neurobiology 419-426 
(1983). Shine, J., Mason, A.J., Evans, B.A., Richards, R.I. 
 
15.  Kallikreins, kinins and growth factor biosynthesis. 
Trends in Biochemical Sciences 13: 169-172 (1988). 
Drinkwater, C.C., Evans, B.A., Richards, R.I. 
 
I conceived of the review and lead the writing of the manuscript.   Citations 51 
 
Molecular biology of the glandular kallikrein genes of mouse and man. 
 in: 'The Kallikrein-Kinin System in Health and Disease' (Fritz, H., Schmidt, I., Dietze, G. eds.)  
Limbach-Verlag Braunschweig, (1989) pp.215-225. 






B) ANGIOTENSINOGEN GENE: 
 
 
16. Molecular cloning of the mouse angiotensinogen gene.    
Genomics (1988) 2: 240-248. 
Clouston, W.M., Evans, B.A., Haralambidis, J., Richards, R.I. 
 
This work was a key part of Bill Clouston’s PhD thesis. I initiated and oversaw the project.  I 
supervised the experimental work, contributed to the analysis and interpretation of the data, 
conceived of the overall content of the paper and made a minor contribution to the writing of 
the manuscript.         Citations 66 
 
 
An alleic polymorphism of the angiotensinogen gene in mice.    
Nucleic Acids Research (1989) 17: 822. 
Clouston, W.M., Richards, R.I. 
 
 
17. Tissue-specific hormonal control of angiotensinogen minigenes in transgenic mice. 
EMBO Journal (1989) 8: 3337-3344. 
Clouston, W.M., Lyons, I.G., Richards, R.I. 
 
This work was a key part of Bill Clouston’s PhD thesis. I oversaw the project. I supervised the 
experimental work, contributed to the analysis and interpretation of the data, conceived of the 
overall content of the paper and made a minor contribution to the writing of the manuscript.








18. The angiotensinogen gene is located on mouse chromosome 8. 
FEBS Letters (1989) 255: 419-422. 
Clouston, W.M., Fournier, R.E.K., Richards, R.I. 
 
This work was a key part of Bill Clouston’s PhD thesis. I supervised part of the experimental 
work, Bill Clouston wrote the first draft and I had a minor role in the writing of the manuscript.
             Citations 15 
 
 
19. Inducible antisense RNA for angiotensinogen in stably-transformed hepatoma cells. 
Journal of Molecular Endocrinology (1990) 4: 107-117. 
Clouston, W.M., Lloyd, C.J., Richards, R.I. 
 
This work was a key part of Bill Clouston’s PhD thesis. I oversaw the project. I supervised the 
experimental work, contributed to the analysis and interpretation of the data, conceived of the 
overall content of the paper and Bill Clouston wrote the manuscript.   Citations 7 
 
 
20. The functions of conserved elements in the promoter of the mouse angiotensinogen 
gene. 
Journal of Molecular Endocrinology  (1992) 9: 19-30. 
Congiu, M., Clouston, W.M., Fernley, R.T., Richards, R.I. 
This work was a key part of Mario Congiu’s PhD thesis. I co-supervised the experimental work, 
co-supervised the project and I had minor role in writing the manuscript.    
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Mouse  Glandular  Kallikrein  Genes 
NUCLEOTIDE SEQUENCE OF CLONED cDNA 
CODING FOR A  MEMBER OF THE KALLIKREIN 
ARGINYL ESTEROPEPTIDASE GROUP OF SERINE 
PROTEASES* 
(Received for publication, August 10, 1981, and in revised form, 
November 16,  1981) 
Robert I. Richards@l, Daniel F. Catanzaro(1, 
Anthony J. Masong, Brian J. Morrisll**, 
John D. BaxterySS, and  John Shine8 
From  the  §Department of Genetics, Research  School of 
Biological Sciences, Australian  National University, 
Canberra,  Australian  Capital  Territory 2601, Australia, 
THoward Hughes  Medical  Institute  Laboratories,  the 
Departments of Medicine and  Biochemistry a n d  
Biophysics, the  Metabolic  Research Unit, University of 
California, Sun  Francisco,  California 94143, a n d  the 
IlDepartment of Physiology, The University of Sydney, 
New South Wales 2006, Australia 
A  library  of  cloned cDNA to  male  mouse  submaxil- 
lary  gland poly(A)-containing RNA was constructed in 
the  plasmid pBR322. Inserts containing  sequences es- 
timated to be in the  1-5%  abundance class were  iden- 
tified  by  hybridization  to  radiolabeled cDNA and ex- 
amined by nucleotide sequence analysis. A sequence 
coding for a peptide with 57% homology to the only 
complete kallikrein sequence reported to date (from 
pig  pancreas) was identified  by  a  computer  search  pro- 
gram. This insert  appears  to  code  for  the COOH-ter- 
minall49 amino  acids  of  a  protein  presumed  therefore 
to be  a  serine protease. Comparison of the predicted 
amino acid sequence of this protein with analogous 
sequences in the  three  characterized  members  of  the 
mouse submaxillary gland kallikrein arginyl estero- 
peptidase  group  of  enzymes  revealed xtensive homol- 
ogy, although  not  complete identity. Thus, there  are  at 
least four  members  of this enzyme  family expressed in 
the  mouse  submaxillary  gland. 
The serine  proteases are a family of closely related enzymes 
of probably common ancestry that have evolved to perform a 
wide variety of essential physiologic functions in higher eu- 
karyotic organisms. Members of this group play an important 
role in digestion, blood coagulation, blood pressure regulation, 
and  the processing of precursors to polypeptide hormones  and 
growth factors (1, 2). One group of these enzymes, the glan- 
dular kallikreins, cleaves kininogen to release the potent vaso- 
* The  costs of publication of this article were defrayed  in part by 
the  payment of page charges. This  article  must therefore  be hereby 
marked  “advertisement” in  accordance  with 18 U.S.C. Section 1734 
solely to indicate this fact. 
$ To whom correspondence  should be addressed at  the  Department 
of Genetics,  Research  School of Biological Sciences,  Australian Na- 
tional  University, P. 0. Box 475, Canberra City, A. C. T. 2601, 
Australia. 
* *  Recipient of a grant from the National Health and Medical 
Research Council of Australia and  the Children’s Assistance Fund. .+* Recipient of Grant  HL 16918-08 from the  National  Institutes of 
Health. 
dilators  termed kinins (3). Glandular kallikreins are known to 
be synthesized in the pancreas, kidney, and submaxillary 
glands, and possibly other organs (4). The genes coding for 
the kallikreins and related peptides are thus of particular 
interest, both because of these functions and because they 
represent a closely related family, the members of which are 
expressed in a tissue-specific fashion that in some cases is 
responsive to steroid hormones (5). 
The mouse submaxillary gland is the site of synthesis of a 
group of these enzymes of remarkably similar amino acid 
composition (6). Two of these  (nerve growth factor y-subunit 
and epidermal growth factor-binding protein)  act specifically 
to convert precursor forms of either PNGF’ or EGF  to  the 
mature protein (2, 7), and all members appear to have some 
degree of kallikrein activity (8). In this study we report the 
cloning and nucleotide sequence of cDNA transcribed from 
submaxillary gland mRNA that codes for one of the members 
of this enzyme group. 
EXPERIMENTAL PROCEDURES 
Materials-[c~-~*P]dCTP and [cY-~*P]~ATP (2000-3000 Ci/mmol) 
were from The Radiochemical Centre, Amersham, United Kingdom. 
Restriction  endonucleases from New England Biolabs, Inc., and Be- 
thesda Research Laboratories were used in accordance with the 
suppliers’ recommendations.  Ribonuclease  A and pronase were from 
Sigma.  DNA  Polymerase  I  (“large”  fragment) was from  Boehringer- 
Mannheim. Oligo(dT)12.18 and oligo(dT)-cellulose were from P-L Bio- 
chemicals. Reverse transcriptase was provided by Life Sciences, Inc. 
All other chemicals were reagent grade. 
mRNA Isolation-Submaxillary glands were surgically removed 
from adult male  Quackenbush mice and  the RNA was extracted using 
guanidine thiocyanate  and centrifugation through CsCl (9).  Poly(A)- 
containing RNA was purified by two cycles of hybridization to 
oIigo(dT)-cellulose (10). 
cDNA Synthesis and Cloning-High specific activity, single- 
stranded cDNA was transcribed from total poly(A)-RNA isolated 
from male Quackenbush mouse submaxillary glands as previously 
described (11). Double-stranded cDNA to the same template was 
synthesized by sequential reverse transcriptase reactions as described 
by Ullrich et  al. (12). Synthetic “linker”  DNA encoding the  HindIII 
recognition  sequence (5”CCAAGCTTGG-3’) was ligated to  the cDNA 
before insertion into  the  HindIII  site of plasmid pBR322 (13). Chi- 
meric  DNA was used to transform Escherichia coli strain  RRI,  and 
recombinants were selected on the basis of a  tetracycline-sensitive, 
ampicillin-resistant  phenotype. All manipulations  with  recombinant 
DNA were performed  in  accordance  with the recommendations of the 
Australian Academy of Sciences Committee  on Recombinant DNA. 
Analysis of Cloned cDNA-Bacterial colonies containing  recom- 
binant plasmids were transferred  onto 0.45-pm nitrocellulose  filters, 
essentially as described by Grunstein  and Hogness (14). Immobilized 
colonies were hybridized with  ‘”P-labeled,  single-stranded  cDNA 
probe  synthesized  from  male  Quackenbush mouse submaxillary gland 
poly(A)-RNA. Clones were selected by their  extent of hybridization 
to  the cDNA  probe.  Plasmid  DNA was prepared by a modification of 
the  Triton lysis method (15).  After the lysis and centrifugation, the 
supernatant was incubated at  37 “C for 15 min with 20 pg/ml of 
ribonuclease A (previously treated at 80 “C for 20 min to destroy, 
DNAse activity). Pronase was then added to 20 pg/ml, and the 
incubation was continued at  37 “C for  a further 15 min. The incuba- 
tion mixture was then extracted with an equal volume of phenol- 
chloroform  (1:l; v/v),  and  the  aqueous  phase was dialyzed overnight 
against three changes of 4 liters of  0.3 M NaCl, 10 mM Tris-HC1 (pH 
7.5), 1 mM EDTA. Plasmid  DNA was analyzed by both agarose and 
acrylamide gel electrophoresis after cleavage with the restriction 
I The abbreviations used are: NGF, nerve growth factor; EGF, 
epidermal  growth factor. 
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T h r  A s p  Val V a l  L y s  P r o  I l e  A l a  Leu  Pro T h r  G l u  G l u  P r o  L y s  Lcu G l y  Ser T h r  C y s  Leu A l a  
A C A  GAT GTT crG AAG ccc ATC GCC CTG CCT ACT GAG GAG ccc AAG CTG GGG AGC ACA TGC CTA GCC 
90 120 
Ser G l y  T r p  G l y  Ser I l e  T h r  P r o  T h r  I v y  Trp G l n  L y s  Ser Asp Asp L e u  G l n  C y s  V a l  P h e  I l e  
TCA GGC TW GGC AGC ATT ACA ccc ACA AGA TGC; CAA AAG TCA GAT GAT CTT CAG 'Per G K  TTC ATC 
1 5 0  180 
T h r  Leu  Leu  Pro Asn G l u  A s "  Cys A l a  L y s  V a l  T y r  Leu G l n  L y s  Val T h r  A s p  V a l  Met L e u  C y s  
ACG c rc  CTC ccc AAT GAG AAC TGT GCC AAA GTC TAC CTA CAG AAA GTC ACA GAT GTC ATG CTG TGT 
210 240 
A l a  G l y  G l u  Met G l y  G l y  G l y  Lys Asp T h r  C y s  A l a  G l y  A s p  S e r  G l y  G l y  P r o  Leu I l e  C y s  A s p  
GCA GGA GAG ATG G G T  GGA GGC A M  GAC ACT T G T  GCG GGT GAC T C C  GGA GGC CCA C X  A T T  T G T  G A T  
2 7 0  3 0 0  
G l y  I l e  Leu G i n  G l y   T h r  T h r  S e r  As" G l y  P r o  G l u  P r o  C y s   G l y   L y S  P ro  G l y  Val Pro A l a  I l C  
GGT ATT c'rc CAG GGA ACC ACA TCA MT GGC CCT GAA CCA TGC GGT AAA cc'r GGT GTA CCA GCC ATC 
360  39n 
498-base pair  cDNA cloned in pMK- 
FIG. 1. Nucleotide sequence of the 
1. The predicted amino acid sequence 
encoded by the mRNA is shown above 
the nucleotide sequence. Nucleotides de- 
rived from synthetic oligonucleotide 
"linker" addition are underlined. The 
ubiquitous AATAAA sequence in the 3' 
untranslated region (21) is ouerlined. 
1 eo 1 ?O 1 4 0  
pMK.1 P E Y D Y S N D L M L L R L S K P A D I T D V V K P I A L ~ T E E ~ K L G S T C L A S G W G S ~ ~ P T  
EGF-BP -]X- 
y-Renin 
.(-NGF L ( E Y D Y S N D L M L L R L S K P A D I T D ~ T ~ T ~ ~ P T E ~ P K L G ~ T C L A ~ G W G S I T P T ~  
P . P . K a l 1 .  D G K [ D Y l D  L M L L R L l Q  S ~ A l K [ ~ ~ A ~ V  L E m O m E m E ] A  8 G W G 5 IIEmG 
Trypsin  - G N T L D I N ] l [ K [ I  K B S D T  L N 5 R a A  T V S D R  5 C A A Am1 E O I V I N  T K S S 
t 
160 
t t  
180 
pMK.1 R - - W q K S D D L Q C V F I T L L P N E N C A K V Y L Q K V T D V M L C A G E M G G G K D T C A G D  
EGF-BP F E N A K-~N L K - ] D ~  
y-Renin ~ P ~ ] M ~ T  KIL L P N E N C ~ H ~ A  H I L ~ ~ L ~ ~ x  x I ~ X  E 
Y-NGF K - - F ~ F  T ~ Y ~ N  L K ~ D ~ A  H I E ~ J A D I [ M  t c A G E r q l n m \ K m  
P . P . K a l 1 .  P D D F E F P a E  I Em4 L m Q m T   F a H  A B P D I X I E  S m l Y  L P [ T M a  
Trypsin G - - S S Y P S L ~ L K A P V ~ S n S S ~ K S A ~ P G q I ~ G N ~ I ~ V ~ F L E ~ ~ S ~ O ~  
2po 220 240 
t t r )  
p M K . l  S G G P L I C D G I L ~ G T T S N G P E P C G K P G V P A I Y T N L l K F N S W l K O T M M K N A  
EGF-BP 
y-Renin 
I - N G F  IS G G P L I C D GlV~lGlI~]W~]H T w ] E m D   M U G   V m K m N I K T ] T [ S  W I K 0 T M I A D P  
P . P . K a l 1 .  I S  G G P L 1 C ] N a M  WD]IW]WBH T m S  A  N K H S [ m ] K m F  Y L BRI T QOP 
Trypsin m V  V m N l q Q m I   V m W m Y  - G m A  Q K N KOG V D K  V C N Y V NWQ QaI A A m -  . . .. t t  
FIG. 2. Comparison of amino  acid sequences in  the serine proteases. Aligned to maximize homology with the peptide encoded by 
pMK-1 are  the partial amino acid sequences of y-renin (a serine protease with renin  activity3)  and EGF-binding protein (24) from mouse 
submaxillary gland, and the complete sequences of porcine pancreatic kallikrein (4), mouse submaxillary gland NGF y-subunit (23), and 
porcine pancreatic  trypsin (25). Residues common to  the pMK-1  amino acid sequence are boxed. Residues common to all characterized serine 
proteases are indicated by a star (1). Numbers refer to residues in the porcine pancreatic kallikrein sequence (4). 
endonucleases HindIII or  HueIII or both. For DNA sequence analysis, 
5 pg  of recombinant plasmid DNA was cleaved with restriction 
endonuclease HindIII.  The termini were radioactively labeled with 
[a-"P]dATP using reverse transcriptase (I6), and the DNA was then 
cleaved with restriction endonuclease HueIII and subjected to elec- 
trophoresis on a  preparative 5% acrylamide gel in 50 mM Tris-borate, 
pH 8.3 (17). Radioactively labeled DNA specific to the inserted cDNA 
sequence was excised from the gel, electro-eluted,  and  subjected to 
sequence analysis ( 18-20). 
RESULTS 
A library of cloned cDNA was constructed from cDNA 
transcribed  from  male  Quackenbush  mouse  submaxillary 
gland poly(A)-RNA. Five  hundred  recombinants  were 
screened for their ability to hybridize to total 3'P-labeled 
cDNA from the same source.  As  a  first step in the character- 
ization of sequences present in this library,  particularly those 
coding for peptides  whose mRNAs are present  at  a relatively 
low abundance, clones that hybridized weakly but whose 
cDNA inserts  still  exceeded 400 base  pairs  were  subjected to 
sequence analysis. The polarity of the inserts was established 
by the location of poly(A) and 5'-AATAAA-3' sequences (21) 
derived from the 3'-end of the mRNA. Possible  reading  frames 
derived from the 5'-end of mRNA sequences were  compared 
by a computer program (kindly provided by Dr. A. Gibbs') 
against all the peptide sequences of Dayhoff (22). 
One  reading  frame  from the cDNA insert of a  plasmid (later 
designated pMK-1) was found to have 65% homology with 
amino  acid  residues 95 to 124 of porcine  pancreatic  kallikrein 
This computer program, designated SEQ, is available upon re- 
quest to: Dr. A. J. Gibbs; Research School of Biological Sciences; 
Australian National University; P. 0. Box 475; Canberra City, 
A.  C. T.; Australia. 
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(4). The complete nucleotide sequence of this cDNA insert 
was subsequently derived and  the deduced peptide sequence 
found to have 57% homology with the corresponding sequence 
from porcine pancreatic kallikrein (Fig. 1). 
The cloned sequence contains the complete 3’ untranslated 
region (51 nucleotides) and  the coding region for the COOH- 
terminal 149 amino acids of a serine protease-like peptide 
(normally about 245 amino acids (1)). The codon utilization 
of this  part of the mRNA indicates a slight preference for 
codons ending in Cyt (NNC, 33.3%; NNU, 24.6%; NNG, 21.3%; 
NNA, 20.6%). 
During this  study, the complete amino acid sequences of 
the y-subunit of NGF and partial amino acid sequences of 
EGF-binding protein and  an enzyme with renin-like activity 
(all from mouse submaxillary glands) were made available to 
us (23,  24).3 A comparison of the predicted peptide sequence 
derived from pMK-1 with sequences from these other mem- 
bers of the serine  protease family is shown in  Fig. 2. Although 
the amino acid sequence encoded in pMK-1 clearly belongs to 
the glandular kallikrein arginyl esteropeptidase family (4,23), 
it is not completely homologous with any of the submaxillary 
gland members for which sequence data  are available. 
DISCUSSION 
In an effort to characterize the protein products of the 
submaxillary glands, we constructed  a bank of cloned cDNA 
to mRNA isolated from this tissue. Analysis of the bank by 
hybridization and nucleic acid sequenckg led to  the identifi- 
cation of a cDNA insert coding for a peptide sequence with 
homology with porcine pancreatic kallikrein (4),  the y-subunit 
of NGF (23), EGF-binding protein (24), and y-renin3 (only a 
partial sequence was available for these  last two peptides). 
The exact abundance of the mRNA from which this cDNA 
sequence was derived has not been quantified but is presumed 
to be between 1 and 5%. 
This range is based on rescreening of the cDNA library 
with the  pMK-1 insert as a probe and assessing the frequency 
of homologous, although not necessarily identical, cDNA 
clones. A total of 24 positive clones were detected out of the 
500 screened but the strength of the signal varied. This 
appeared to be due to  the length of the cloned sequence as 
well as  the degree of homology with pMK-1. Five clones gave 
quite  strong signals, but at  least one of these is not completely 
identical to pMK-1  and probably codes for a different specific 
a~t iv i ty .~  
Thus,  the mRNA from which pMK-1 was derived appears 
to encode a member of the kallikrein arginyl esteropeptidase 
subgroup of the serine protease gene family. Nevertheless, the 
protein encoded by pMK-1 is probably not the major form of 
mouse glandular kallikrein activity. Bothwell et al. (8) have 
shown that PNGF-endopeptidase and most of the submaxil- 
lary gland kallikrein activity co-purify, and  they have con- 
cluded that  the  same peptide is responsible for both activities. 
Although sequence data for this protein are not available, a 
comparison of the amino acid composition of PNGF-endopep- 
tidase (6)  with the sequence encoded by pMK-1 suggests that 
they are not identical. For example, PNGF-endopeptidase 
contains 4 Met and 12 Thr residues, whereas the pMK-1 
sequence, which does not contain the complete structure 
coding for the active peptide, has one more of each of these 
residues. Further, pMK-1 differs from porcine pancreatic kal- 
likrein at  residue 225 (Fig. 2), which is involved in substrate 
specificity (1). 
Thus,  the protein encoded by pMK-1 appears  to be kalli- 
,’ C. D. Bennett and M. Poe, personal communication. 
S. K. Nordeen, A. J. Mason, R. I. Richards, J. Shine, and J. D. 
Baxter, manuscript submitted to  Science. 
krein-like but different from any of the characterized members 
of this enzyme group in the submaxillary gland. This suggests 
that  there  are  at least four members of this enzyme family 
expressed in  this tissue. 
Although similar in overall structure, the various members 
of the serine protease family display certain unique features 
related to  their differing cleavage specificities. Trypsin, with 
a broad range of substrate specificity, and the kallikreins, 
whose specifkity is very selective, have relatively similar 
chemical compositions when compared with the  other serine 
proteases (4). Although the Cys residues at  positions 127 and 
231 (Fig. 2) are unique to trypsin, the Cys at position 157 is 
common to both  trypsin  and kallikrein-like activities and is 
also found in pMK-1 but not in any of the other serine 
proteases (1,4). This common location suggests some similar- 
ity in the  tertiary  structure for kallikrein and trypsin  (4). 
Residues at positions 214 and 225 (Fig. 2) have been impli- 
cated  in the determination of the serine proteases’ substrate 
specificity (1). Position 214 is a Gly residue in  pMK-1 and  the 
other sequences shown in Fig. 2. (In elastase, this residue is 
Ala (l).) Position 225 is occupied by a Gly  in trypsin and  the 
y-subunit of NGF, a  Ser  in porcine pancreatic kallikrein, and 
an Ala in pMK-1. Such amino acid substitutions  may reflect 
some of these enzymes’ differences. 
The very similar chemical and physical properties of the 
mouse submaxillary gland arginyl esteropeptidases have 
hindered their characterization to  the extent that  it  has been 
difficult to determine just how many of these genes are 
expressed in this tissue. Heterogeneity observed by  gel elec- 
trophoresis can be  due  to protein modification (e.g. proteoly- 
sis) as well as to separate gene products (23). Different mem- 
bers of this group have been found to cross-react immunolog- 
ically, reflecting their very similar amino acid sequences. 
Purification has been afforded by use of the  substrate speci- 
ficity and  substrate-binding  properties of these enzymes (e.g. 
7 S NGF contains two a-subunits, as yet uncharacterized, two 
P-subunits  (with  neurite growth-promoting activity), and two 
y-subunits (the arginyl esteropeptidase-processing enzymes 
specific for propNGF)). Studies of this enzyme family at  the 
DNA level should avoid many of the difficulties encountered 
in the protein characterization. Of note is the fact that our 
identification of pMK-1 as a kallikrein-like protein encoding 
sequence was expedited by computer programming-a further 
illustration of the importance of this technology in molecular 
genetics. 
Cross-hybridization of the pMK-1 sequence with other ho- 
mologous members of the gene family should facilitate their 
isolation from cloned genomic DNA libraries. In  this context, 
we have found in preliminary studies that pMK-1 does hy- 
bridize to  at least 12 different EcoRI restriction endonuclease 
digest fragments of chromosomal DNA from the mouse ge- 
n ~ m e . ~  The characterization of this cDNA clone is of partic- 
ular significance, therefore, in its use as a probe to isolate 
genomic DNA sequences of  thiG>omologous group of enzyme 
activities and subsequently to identify the tissues in which 
these genes are actively expressed. 
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Genes for the ca and -y subunits of mouse nerve growth factor
are contiguous
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Here we describe the structure and linkage of genes encoding
the a and -y subunits of mouse nerve growth factor (NGF).
These genes are members of the highly homologous glandular
kallikrein multigene family. Together with the ,B subunit, the
a and ey proteins constitute the high mol. wt. (7S) form of
NGF isolated from mouse submandibular gland. The -y
subunit is an active serine protease and is thought to cleave
pro-f-NGF to generate the mature growth factor. The a
subunit has no detectable proteolytic activity, but is essential
for the stable formation of 7S NGF. Lack of enzyme activity
of the a subunit can be attributed, at least in part, to the dele-
tion of 15 nucleotides in a highly conserved coding region
which is normally involved in the activation of serine pro-
teases from their inactive zymogen form.
Key words: a and ey NGF genes/DNA sequence/kallikreins/
mouse salivary gland
Introduction
Sympathetic and sensory neurons are thought to require
nerve growth factor (NGF) for their growth and survival
(Bradshaw, 1978; Yanker and Shooter, 1982). NGF has been
isolated from the submandibular gland of adult male mice as
a high mol. wt. complex (7S NGF) comprising six polypep-
tides, y0272, and 1 -2 g-atoms of Zn2+ (Varon et al., 1968;
Stach et al., 1980). It is the chains of 7S NGF which account
for its observed growth-promoting activity (Bradshaw, 1978).
Both the a and -y subunits have been shown by sequence
homology to belong to the family of glandular kallikreins, a
subset of the mammalian serine proteases (Ronne et al., 1984;
Thomas et al., 1981; Dayhoff, 1978). 'y NGF shows the
arginylesteropeptidase activity characteristic of kallikreins
(Greene et al., 1969), and is believed to cleave pro-f-NGF at
two or more sites to generate the active growth factor (Berger
and Shooter, 1977; Scott et al., 1983). The a subunit, on the
other hand, shows no measurable enzymatic activity, though
its presence is apparently necessary for the formation of
stable 7S complex (Varon et al., 1968; Greene et al., 1968).
We have undertaken a systematic analysis of the multigene
family encoding mouse glandular kallikreins, to assess the
possible physiological roles of different members, and to ex-
amine mechanisms for the regulation of their tissue-specific
expression. Our analysis has shown the gene family to com-
prise at least 24 non-allelic genes (B.A.Evans and R.I.
Richards, in preparation), all of which are located on
chromosome 7 (Mason et at., 1983). The finding that most of
the genes are closely linked supports the idea that the
() IRL Press Limited, Oxford, England.
kallikrein gene family represents a single genetic locus in the
mouse. A second important observation is that although dif-
ferent kallikrein genes show a high degree of overall
nucleotide sequence homology (80-900/o), there is marked
variability in certain coding regions. This variability is cor-
related with amino acid residues involved in determining
substrate specificity. We have suggested previously, there-
fore, that members of the kallikrein gene family may have
roles in the proteolytic activation of a variety of different
growth factors and other peptides (Mason et al., 1983). Here
we describe the linkage and structure of two kallikrein genes
encoding the a and -y subunits of mouse nerve growth factor.
Results
Identification of linked a and 7y NGF genes
Limited nucleotide sequence analysis of a number of kalli-
krein genes has facilitated the identification of those which
encode products already characterized by amino acid sequen-
cing. Using this approach, we have identified the genes
mGK-4 and mGK-3 as those encoding the a and-y subunits of
NGF, respectively. The two genes are contiguous, transcribed
from the same DNA strand, and are separated by 5.3 kb of
intergenic DNA (Figure 1). We have not yet isolated any
genomic DNA clones which map 5' to mGK-3. There are,
however, two more kallikrein genes, mGK-5 and 6, which are
5.2 and 14.2 kb 3' to mGK-4, respectively (data not shown).
Neither of these genes shows any greater homology to mGK-3
or 4 than that observed between all members of the kallikrein
gene family (van Leeuwen and Drinkwater, personal com-
munications).
Nucleotide sequence of the a and -y NGF genes
For both mGK-3 and mGK-4, we have determined the com-
plete nucleotide sequence of coding regions and of introns B,
C and D, as well as 400 bp of 5'-flanking DNA (Figure 2).
The assignment of coding regions and intervening sequences
was made initially by comparison of the two nucleotide se-
quences with that of mGK-1 (Mason et al., 1983). These
assignments were then checked by aligning the translation
products of coding regions with the known amino acid se-
quences of a and ey NGF (Ronne et al., 1984; Isackson and
Bradshaw, 1984; Thomas et al., 1981).
The predicted amino acid sequence of the protein encoded
by mGK-3 is identical to that determined for -y NGF by
Thomas et al. (1981). In addition, the nucleotide sequence of
the mGK-3 coding regions is virtually identical to that of a
partial ey NGF cDNA clone (Howles et al., 1984). The only
difference between the two sequences is a T to A change in
the cDNA, resulting in glutamate-179 instead of aspartate. It
is most likely that this single discrepancy reflects a polymor-
phism between the different strains of mice used in these
studies (BALB/c, DBA/2J and Swiss Webster).
Our initial identification of mGK-4 as the gene encoding a
NGF was based on partial amino acid sequences determined
















Fig. 1. Restriction map of cloned mouse genomic DNA fragments containing the a and -y NGF genes. Linkage of the genes encoding a and -Y NGF is
demonstrated by the isolation of a series of overlapping genomic clones (designated XMSP), four of which contain at least part of both mGK-3 and mGK-4.
Vertical bars denote the five exons of each gene, while arrows above the map show the direction of transcription. Restriction sites shown are: EcoRl (E),
HindIII (H), BamHI (B), BgllI (Bg), and Sacl (S).
As shown in Figure 3, our predicted a NGF protein sequence
shows two discrepancies, at positions 25 and 121, with the se-
quence of Ronne et al. (1984). We find, however, that the
mGK-4 encoded a NGF has an amino acid sequence identical
to those regions determined by Isackson and Bradshaw
(1984), and to that predicted from a cDNA clone recently
isolated by Isackson et al. (1985). There are five silent nucleo-
tide changes between mGK-4 and the a NGF cDNA, again
probably reflecting strain differences.
Comparison of the coding regions of mGK-3 and mGK-4
with cDNA clones for -y and a NGF (Howles et al., 1984;
Isackson et al., 1985) confirms that these genes have exon-
intron boundaries which are identical to those of mGK-1
(Mason et al., 1983).
Structure of the a NGFprotein
The DNA sequence of mGK-4 indicates that the a NGF pro-
tein has an altered N terminus (Ronne et al., 1984) due to
small deletions whic'. result in the loss of 15 nucleotides from
exon 2 (Figure 4). The simplest explanation for the observed
mGK4 sequence is a series of five deletions, varying from
one to eight nucleotides. Due to sequence redundancy in this
region, however, there are at least 120 different combinations
of deletion events which could give rise to the observed out-
come.
No other mutation events in mGK-4 affect the a NGF pro-
tein to the same extent as those in exon 2. Most of the amino
acid differences between, for example, the a and -y subunits
of NGF, occur in regions which are characteristically variable
amongst members of the kallikrein family (Figure 3). The
principal exceptions to this observation are a lysine to serine
change at position 182, an aspartate to tyrosine change at
position 183, and a glycine to histidine change at position 187.
All of these residues are in close proximity to the serine-189
which participates in formation of the active site (Dayhoff,
1978; Krieger et al., 1974).
Comparison of our sequence with the protein (Ronne et
134
al., 1984; Isackson and Bradshaw, 1984) and cDNA
(Isackson et al., 1985) sequences indicates that the mGK-4
transcript is initiated, terminated and processed correctly.
Discussion
Sequencing of the a and -y NGF genes allows us to predict the
complete amino acid sequence of the precursor forms of these
subunits. In conjunction with the analysis of cDNA clones
for mouse prepro-f3 NGF (Scott et al., 1983; Ullrich et al.,
1983), our data provide a structural description of all the
components of 7S NGF.
The relationship between the amino acid sequences of the a
and y subunits of NGF is of particular interest. Both of these
subunits bind specifically to NGF, albeit at different sites
(Silverman and Bradshaw, 1982), but only the y subunit
shows any catalytic activity (Varon et al., 1968). We have
shown that a series of deletions in exon 2 of mGK-4 result in
profound changes in the amino acid sequence of the N ter-
minus of a NGF. One consequence of the deletions is that
glutamine replaces the arginine (position - 1, Figure 3) re-
quired for cleavage of the zymogen peptide. It is thought that
removal of this peptide is accompanied by a conformational
change necessary for serine protease activation (Bode, 1983).
In addition, the amino acids normally at the N terminus of
the mature enzyme, namely Ile-Ile, Ile-Val or Val-Val, have
been implicated in stabilization of the active site (Bode, 1979).
In the case of a NGF, the usual N-terminal isoleucine/valine
residue is absent.
The precise cause of lack of enzyme activity cannot be
assigned at this stage to any particular mutation, since addi-
tional changes affect residues close to the serine- 189 involved
in active site formation. The deletion events in exon 2 are uni-
que, however, compared with other members of the kallikrein
gene family (Mason et al., 1983, and unpublished observa-
tions). Other amino acid changes in the coding region are the



















GTGGTTCCTGATCCTGTTCCTAGCCCTGTCCCTAGGAGGGATTG 8 AGATGAGGGAATGGGAGGGATCACAGCCCTGACTCTCCTGCTGCTTTGCCCTG 500
GCCCATCCCTTTCCCCGCTCTCCTCACCGGAGCTACATCATGAGCACCACCTGCTCCTCTCTGGCCCTGTACACTGCCAAGTCCCTCACAGTTCTTGCTCC 600
CAGGACAGGCCCTTGTTCCCTCCCACTTTCCAGAACTTTCACCTCTTCCTTAGATAGCTGACCATCTCTGGCGCTCTCTCCAGTCTTTCTAAGGTACCCA 700







































































































Fig. 2. Nucleotide sequence of the a and Py NGF genes. The sequence of the transcribed DNA strand of the -y NGF (a, mGK-3) and ae NGF (b, mGK-4)
genes is shown. Figures at the right of each section refer to nucleotide numbers. The splice sites around each exon, and the termination codons are boxed.
Numbers above both amino acid sequences refer to the position relative to the N-terminal isoleucine of mature Py NGF (see Figure 3). Asterisks denote the
first residue of the zymogen sequence. Amino acids preceding this residue constitute the signal peptide. The CAT boxes (Benoist et al., 1980) and the variant
5'-TTTAAA-3' boxes (Corden et al., 1980; common to mGK-1, Mason et al., 1983) preceding mGK-3 and mGK-4 are overlined. An alternative 5'-TATAA-
3' box preceding mGK-3 is also marked. Putative transcription initiation sites are shown by arrows (Mason et al., 1983). The polyadenylation signals (Proud-




Genes for mouse a and -y NGF
+ 20 40
MWFLILFLALSLGGIDAAPPVQSRIVCGFK EKNSQPWHVAVYR YKEI CGGVLLDANWVLTAAHC
MWFLILFLALSLCGIDAAPPVQSRI VGGFKEC NSQPWHVAVYR TQY LCGVLLDPNWVLTAAHC
I VGGFKCEK NSQPWHVAVYR TQYLCGGVLLD PNWVLTAAHC
MWFLILFLALSLCGIDAAPPVQS Q-V D---CE- NSQPWHVAVYR FNK YQCGGVLLDRNWVLTAAHC
liii ~~~~~~NWVLTAAHC
APPVQS Q -VD---CE- NSQPWHVAVYR FNKLCCC
*** ** ............ ..**. * **.*
60 80 00
YYEKNN WLKNN YQ EPSQHR VSK FL Y NMSLHRNRIQNPQD DYSYDLMLLRLSKPADI
YDDNYK|VWLGKNN LFK DEPS QHR VSKAIP H FNMSLMRKHIRFLEYDYSNDLMLLRLSKPADI
YDDNYK|VWLCKNNLFK DEPSIAQHR VSK AIPHPC NMSLMR FLEY DYSNDLMLLRLSKPADI
YNDKYQVWLGKNN;FLE EPSDQ HR' VSKiAIP H DFNMSLLNEHTPQPED DYSNDLMLLRLSKPADIYNDKYQVWLGKNNF LE BZPSIJZHR VSKAIP H DFNMSL LNEHTPQPED DYS NDLMLLRLSKPADI
SNDLMLLRLSKPADI
*--- * *-*****- *- --- * *-
1 20 1 40 1 60
mgk-1 VVKPIAiLPTEEPKLGSTCLASGWGSII[VJFQYAKD'C VNLKLLPNEDCDKAYV KVTDVLC
mgk-3 Tr VKPITLPTEEPKLGSTCLASGWCSITPTKFQFTrDLYCVNLKLLPNEDCAKAHIEKVTDAMLC
Y-NCF TrTVKPITLPTEEPKLGSTCLASGWGSITPTKFQ FTIDLjYCVNLKLLPNEDCAjKAjHIE KVTDAMLC|
mgk-4 TE VVKPILPTEEPKLGSTCLASGWGSTTPIKFKYPIDL|CVNLKLLPNEDCDKAHEMKVTDAMLC
cx-NGF(a) TrVVKPITLPTEEPKLGSTCLASGWG YPD CVNLKLLPNEDC DKAHEMKVTDAMLC








AGEMD GK DTCK DSGGPLICDGVLQGITSWGHTPCGEP DPC YTK LNK FSWIK MAKNP
AGEMDCGKDTCKGDSGGPLICDGVLQGITSWGHTPCGEP D GVYTKLNKFTSWIKDTMAKNP
ACEMD GSY CEHDSGGPLICDGI QGITSWGPEPCGET VYTK 1K SWIR MI?|HNP
*EMDY*EHDSGGPLICD
Fig. 3. Comparison of the amino acid sequences of mGK- 1, mGK-3 and mGK-4 gene products with those of a and y NGF. The -y NGF sequence is that
determined by Thomas et al. (1981). Partial a NGF sequences are those of (a) Isackson and Bradshaw (1984) and (b) Ronne et al. (1984). Boxed areas repre-
sent amino acid residues which are identical in mGK-1 (Mason et al., 1983), mGK-3/-y NGF and mGK4/a NGF. Numbers refer to the position relative to
the N-terminal isoleucine of mature y NGF, and are consistent with those in Figure 2. The arrow represents the first residue of the zymogen peptide or, in the
case of a NGF, the N-terminal residue of the mature protein (see text). Asterisks below each set of sequences indicate residues which are identical in all the
following members of the glandular kallikrein family: mouse -y NGF, EGF-binding protein type B (Ronne et al., 1983) and -y renin (Poe et al., 1983), rat pan-
creatic and submaxillary gland kallikrein (Swift et al., 1982), porcine pancreatic kallikrein (Tschesche et al., 1979), and the proteins encoded by pMK-l
(Richards et al., 1982), mGK-l and mGK-2 (Mason et al., 1983). The residues necessary in formation of the serine protease active site are histidine-41,
aspartate-96 and serine-189 (Dayhoff, 1978; Krieger et al., 1974).
tion between different kallikreins (Figure 3). We think it likely
therefore that the exon 2 deletion events preceded the point
mutations, which could subsequently occur in conserved
regions because of the prior loss of the functional constraint
of enzyme activity.
We have suggested that differences in the amino acid se-
quences of members of the kallikrein family are functionally
related to their substrate specificity (Mason et al., 1983). In
the case of the a and -y subunits, divergence of the two adja-
cent genes has resulted in recognition of a common substrate
but at different sites. In addition, one gene has lost its ability
to encode a functional serine protease. The proximity of the
two genes and their complementary roles in NGF biosynthesis
support the notion that they evolved by a duplication event
from a common ancestor itself involved in this process. The
availability of the cloned a and -y subunit genes should
facilitate an analysis of their respective roles in NGF biosyn-
thesis. Substitution of the mutated region (exon 2) of the ca
gene with the corresponding region from the -y gene, and
subsequent expression in heterologous cells (Karin et al.,
1983; Richards et al., 1984), would allow us to determine
whether the resulting gene product has enzyme activity. If this
were the case, newly acquired cleavage sites for the chimeric
product may reflect the binding sites of the original a subunit
on NGF (Scott et al., 1983).
In addition to functional studies on NGF biosynthesis, we
are interested in examining the expression of the ae and -y
subunits, since both are found in equimolar amounts in the
7S complex of mouse salivary gland. The tight linkage of the
mGK-3 and mGK-4 genes raises the possibility of coordinate
control of transcription through a single cis-acting element,
since no other kallikrein gene with a different expression
phenotype separates these two members of the gene family.
Examination of this possibility will require gene transfer ex-
periments into cell lines expressing these genes (Walker et al.,
1983). Alternatively, a trans-acting factor may regulate the
expression of both genes by binding to a regulatory sequence
(Karin et al., 1984) common to the a and e subunit genes but
not to other members of the kallikrein gene family. A com-
parison of the 5'-flanking regions of mouse glandular
kallikrein genes reveals a high degree of homology (>75%)
extending >400 bp from the start of transcription (Figure 2,
Mason et al., 1983, and unpublished results). The overall
homology between the 5'-flanking regions of the a and -y
subunit genes is somewhat higher (850Wo), with one particular
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r.GK-4 GCACCTCCTGTCCAGTCTC.AA..GT.GGAC....... TGTGAG ...AATTCCCAACCCTGGCATGTG
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ZYMOGEN PEPTIDE
Fig. 4. Nucleotide deletions in mGK-4 affecting the N-terminal structure of a NGF. Partial exon 2 nucleotide sequences are aligned to maximize homology
(denoted by asterisks) between mGK-4 and mGK-3 or mGK-1 (Mason et al., 1983). This alignment results in only two single base pair mismatches between
mGK-4 and mGK-3, comparable with the observed differences between mGK-3 and mGK-l.
homology (in contrast to 780/o or 76Wo if either of these
respective sequences from mGK-3 or mGK-4 are compared
with that of mGK-1; Mason et al., 1983). While the greater
general degree of flanking region homology may be due to re-
cent duplication of the ancestor to the a and ey subunit genes,
the localized conservation of DNA sequence ( - 145 to - 95)
may reflect a common regulatory role in the coordinate ex-
pression of these two genes.
Finally, the nucleotide sequence analysis of the ax and 'y
subunit genes allows us to design oligodeoxynucleotides com-
plementary to the regions which are most variable relative to
other members of the kallikrein gene family. These oligo-
deoxynucleotides then represent 'gene-specific' probes which
can be used to examine tissue-specific expression of a and -y
NGF.
Materials and methods
Mouse genomic DNA libraries
Two different mouse genomic libraries were screened by the procedure of
Benton and Davis (1977), using the kallikrein cDNA, pMK-l (Richards et al.,
1982), as a hybridization probe. An embryonic BALB/c mouse DNA library,
in the bacteriophage vector Charon 28, was the gift of Dr. P.Leder. The
clones XMSP-19, 22 and 26 (Figure 1) were isolated from this library. We con-
structed a second BALB/c library using mouse liver DNA subjected to limited
Sau3A digestion. This DNA was treated with bacterial alkaline phosphatase
(65°C for 10 min) and fractionated over a 5-24% NaCI gradient (37 000
r.p.m. for 4.5 h at 25°C, in an SW41 rotor). DNA fragments of 15-22 kb
were then inserted into the EMBL3A vector (Frischauf et al., 1983) and
packaged in vitro (Enquist and Sternberg, 1979). Screening of an unamplified
library of 250 000 phage with pMK-1 gave a total of 45 positives including
XMSP-28, 51 and 53. All the positives were analysed by digestion of the DNA
with a panel of restriction enzymes (EcoRI, HindlII, BamHI, BglII, Sacl, Sanl
and SmaI), followed by Southern blotting (Southern, 1975) and hybridization
with a series of exon-specific probes (Mason et al., 1983).
Nuckeotide sequencing
The nucleotide sequence of the -y NGF (mGK-3) and a NGF (mGK4) genes
was obtained from a series of overlapping subclones in the plasmid pUC13
(Messing, 1983; see Figure 1). These were used as a source of DNA restriction
fragments for cloning into M13.mplO or mpl 1 (Messing, 1983), and sequenc-
ing by the chain termination method (Sanger et al., 1977).
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Glandular kallikreins are  ahighly  homologous 
subfamily  of serine proteases  encoded by 25 genes  in 
the mouse. Several of the gene products have been 
implicated as having specific roles in growth factor 
biosynthesis,  suggesting  a  general  role  for members  of 
this gene  family  in  the  generation  of  biologically a tive
peptides  (Mason, A. J., Evans, B. A., Cox, D. R., Shine, 
J., and  Richards, R. I. (1983) Nature 303,300-307). 
Here we describe the identification, structure, and 
expression of the renal kallikrein gene, the major 
kinin-generating member of the family. Kinins are 
potent vasodilators implicated in regulation of local 
blood flow and  ion  transport. A gene-specific oligode- 
oxyribonucleotide  probe was designed  and  chemically 
synthesized  from  the  renal kallikrein gene  sequence  to 
distinguish this gene’s  transcripts  from  those  of  other 
members of the  gene  family.  Differential  expression 
phenotypes  were  found  between  the  renal kallikrein 
gene and  other  members  of  the kallikrein gene  family. 
There is a distinct subgroup of the serine  proteases closely 
related to glandular kallikrein (see review, Schachter, 1980). 
In  the mouse they  are encoded by a large highly homologous 
multigene family of 25 genes, all located on chromosome 7 
(Mason et aL, 1983). Members of this family which have been 
characterized include the genes encoding a- ,and y-nerve 
growth factor (NGFl) (Evans and Richards, 1985) and epi- 
dermal growth factor (EGF)-binding protein type B.2 The 
products of these genes have been isolated from male mouse 
salivary glands (Greene et al., 1968; Anundi et al., 1982) along 
with other closely related  serine proteases: EGF-binding  pro- 
tein  type A (Anundi et al., 1982), y-renin  (Poe et al., 1983), 
and 0-NGF endopeptidase (Wilson and Shooter, 1979). Al- 
though  these  proteins  are closely related at the amino acid 
sequence level, they  exhibit a high degree of substrate speci- 
ficity (Bothwell et al., 1979; Server  and  Shooter, 1976). 
These salivary gland proteins are related to kallikreins 
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epidermal growth factor. 
results. 
present  in the pancreas  and kidney of various species 
(Tschesche et al., 1979; Proud et al., 1977). Kallikrein was 
described first as a substance in urine having hypotensive 
activity when injected into experimental animals (Frey, 1926). 
This  activity was found later to be mediated by kinins, which 
are generated by kallikrein cleavage of the substrate kininogen 
(Bhoola et al., 1962). Kinins  are  potent vasodilators, acting 
on blood  vessel smooth muscle, and cause diuresis and  natri- 
uresis. Therefore, the kallikrein-kinin system has been pos- 
tulated to play a role in  the regulation of  blood pressure, local 
blood  flow, and ion transport.  The rapid clearance of kinins 
from the circulation and  the abundance of plasma kininogen 
and inhibitors of kininogenase activity  (Schachter, 1980) sug- 
gest that a key step  in the functioning of the kallikrein-kinin 
system is the de novo synthesis  and release of active enzyme. 
The identification of which member of the kallikrein gene 
family is responsible for kininogenase activity in vivo and 
analysis of the sites  and regulation of its expression is, there- 
fore, of considerable physiological significance. 
The initial aim of the work described here was to identify 
the gene encoding the major kininogenase member of the 
kallikrein gene family which was originally identified in urine. 
The kidney appears to be the site of biosynthesis of urinary 
kallikrein (Nustad, 1970; Mills et aZ., 1975; van Leeuwen et 
al., 1984) and, therefore, the approach adopted was to con- 
struct  and screen a cDNA library from kidney mRNA with a 
general kallikrein hybridization probe, the cDNA  clone pMK- 
1 (Richards et al., 1982). All sequences detected were derived 
from the same gene, mGK-6, which we, therefore, concluded 
to be the renal kallikrein gene. A gene-specific oligodeoxyri- 
bonucleotide probe was designed and chemically synthesized 
from the mGK-6 gene sequences. Use of this probe has ena- 
bled identification of sites of expression of this gene and an 
assessment of the relative level of expression at each site. 
EXPERIMENTAL PROCEDURES 
mRNA Preparation-Kidneys were surgically removed from 
BALB/c mice and homogenized in 5 M guanidinium thiocyanate. 
RNA was extracted by centrifugation through a CsCl cushion (Chirg- 
win et al., 1979), and polyadenylated RNA  was isolated by passage of 
total RNA over an oligo(dT)-cellulose column (Aviv and Leder, 1972). 
cDNA Library Construction-Double-strandedcDNA was prepared 
by sequential reverse transcriptase reactions (Ullrich et al., 1977). 
After protection of internal EcoRI sites by methylation, synthetic 
linker DNA encoding the EcoRI recognition sequence was ligated to 
the cDNA. The cDNA was size fractionated on a 6% polyacrylamide 
gel, and fragments larger than 400 base pairs were inserted into the 
EcoRI site of X g t l O  DNA (Huynh et al., 1985). E. coli strain C600/ 
Hfl cells were transfected with the chimeric DNA packaged into 
bacteriophage X (Enquist and Sternberg, 1979). Bacterial colonies 
containing recombinant phage were screened by in  situ hybridization 
(Benton and Davis, 1979). Phage were transferred to 0.45-pm nitro- 
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cellulose filters, lysed, and  the DNA  was denatured by the method of 
Maniatis et al. (1982). 
The probe used to screen the kidney cDNA clones was pMK-1,  a 
mouse salivary gland cDNA which codes for exons 3-5  of a kallikrein 
gene (Richards et al., 1982) and hybridizes to all members of the 
kallikrein gene family (Mason et al., 1983). To identify full-length 
kallikrein cDNA clones, a genomic DNA fragment containing exon 1 
of a kallikrein gene was used, These probes were labeled to a specific 
activity of approximately 10' dpm/pg by a modification of the method 
of Taylor et al. (1976) using random primed DNA polymerase I 
Klenow extension. Isolated insert DNA was denatured in  the presence 
of 100 pg of random primers (prepared from herring sperm DNA) by 
boiling for 2 min and cooling on ice. The DNA  was incubated at 37 "C 
for 30 min with deoxyribonucleotide triphosphates (1 mM dATP, 
dTTP,  and  dGTP), 25  pCi of [LY-~'P]~CTP (2000 Ci/mmol, Biotech 
Research Enterprises of South Australia), and 1 unit of DNA polym- 
erase I Klenow fragment (Boehringer Mannheim)  in buffer (50 mM 
Tris-HC1, pH 8.3, 7 mM MgClz,  20 mM KC1, 20 mM P-mercaptoeth- 
anol).  Unincorporated nucleotides were separated from the DNA by 
chromatography on Sephadex G-50 in 10 mM Tris-HC1, pH 7.5, 1 
mM EDTA, 0.1 M NaCl. Hybridization to  the denatured probes was 
carried out  at 65 "C for 18 h. The filters were then washed in  2 X 
ssc (0.3 M NaC1, 0.3 M sodium citrate) at room temperature, air 
dried, and exposed for autoradiography at -70 "C with intensifying 
screens. 
OligodeoxyribonucZeotides-30-mer oligodeoxyribonucleotides cor- 
responding to variable regions of the DNA sequence in the coding 
region of the genes mGK-3, -4, and -6 were chemically synthesized 
by the solid phase  phosphoramidite method (Camthers et al., 1982) 
in an Applied Biosystems Inc. model 380A DNA synthesizer. The 
probes were purified by anion-exchange high pressure liquid chro- 
matography (Scanlon et al., 1984) and labeled at  the 5' terminus to a 
specific activity of approximately 10' dpmlpg using T4 polynucleotide 
kinase by a modification of the method of Maniatis et al. (1982). 
Approximately 100  ng of the purified 30-mer was denatured  in 40 pl 
of buffer I (final concentration, 20 mM Tris-HC1, pH 9.5, 1 mM 
spermidine, 0.1 mM EDTA) by heating at 70 "C for 30 s and  then 
chilling on ice. The buffer was adjusted by addition of 5 pl of buffer 
11 (final concentration, 50 mM Tris-HC1, pH 9.5, 10 mM MgC12,5 mM 
dithiothreitol, 5% glycerol). The DNA was incubated for 2  h a t  37 "C 
with 50 pCi of [y3'P]ATP (5000 Ci/mmol, Amersham Corp.) and 1 
unit of T4 polynucleotide kinase (Amersham Corp.). 
The specificity of the oligodeoxyribonucleotide probes was tested 
by hybridization to a DNA blot of restriction  fragments of X clones 
which contain exon 4 from each member of the mouse glandular 
kallikrein gene family? Each of the gene-specific oligodeoxyribonu- 
cleotide probes was derived from sequences in  this exon. The X clones 
were digested with Sal-EcoRI and fractionated  on an agarose gel. The 
DNA  was depurinated  in 0.2 M HCl (5-10 min), rinsed in water, and 
denatured in 0.5 M NaOH, 0.5 M NaCl (30-60 rnin). The gel was 
neutralized by washing in 0.5 M Tris-HC1, pH 7.2, 2 M NaCl (30-60 
min). The denatured DNA was transferred to a 0.45-pm nitrocellulose 
filter by blotting the gel in 20 X SSC for 15 h. The filter was washed 
in 2 X SSC, air dried, and baked at 80 "C in uacm for 2 h. After 
hybridization to  the labeled oligodeoxyribonucleotide at 4 "C for 48 h 
the filter was washed in  2 X SSC at successively higher temperatures 
to determine the stringency of washing required. 
Genomic Library Screening-The isolation, restriction, and linkage 
mapping of the mouse glandular kallikrein gene family will be de- 
scribed in  detail elsewhere? Briefly, BALB/c mouse liver DNA was 
subjected to limited Sau3A digestion, and a genomic library was 
constructed using the EMBL3A vector (Evans and Richards, 1985). 
Clones which hybridized to  pMK-1 were analyzed by digestion of the 
DNA with a panel of restriction enzymes, followed by Southern 
transfer to nitrocellulose and hybridization to a series of exon-specific 
probes (Mason et al., 1983). Partial nucleotide sequences of most of 
the genes has enabled identification of family members for which 
amino acid sequence data is available (Evans and Richards, 1985): 
DNA Sequence Analysis-The chain termination method of se- 
quencing (Sanger et al., 1977) was used after cloning of DNA restric- 
tion  fragments into M13  mplO or mpl l  (Messing, 1983). 
RNA Dot Blots-Polyadenylated RNA was prepared from mouse 
salivary glands, kidney, pancreas, liver, brain, spleen, and testis, as 
described earlier. The RNA was denatured with formaldehyde for 10 
B.  A. Evans, unpublished results. 
B. A. Evans and R. I. Richards, unpublished results. 
min at  60 "C by the method of White and Bancroft (1982). Serial 
dilutions in 15 X SSC were dotted  onto nitrocellulose using a 
Schleicher and Schuell Minifold apparatus.  Transfer RNA dilutions 
and 33 pg of tRNA added to salivary gland RNA dilutions were 
included as controls. To check that the hybridization signal was 
specific the RNA from salivary glands, kidney, pancreas, and liver 
was treated with DNase I (20 pg/ml) or ribonuclease A (20 pg/ml) 
for 30 min at 37 "C prior to denaturation. DNase I treatment had  no 
effect on the level of hybridization of pMK-1, whereas ribonuclease 
A eliminated the signal from all tissues (data not shown). 
Nitrocellulose filters were prehybridized for 2-4 h at 42 "C in  a 
solution of 5 X SSC, 50 mM sodium phosphate, pH 6.5,0.02% bovine 
serum albumin, Fraction V, 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 
30  pg/ml denatured calf thymus DNA, 50% formamide. For the 30- 
mer probes, hybridizations were performed at 4 "C for 48 h and  the 
filters washed in 2 X. SSC at room temperature (2 X 15 min) and 
then at  60 "C (30 min). For pMK-1 hybridization was performed at 
42 "C for 18 h and washes at room temperature  in 2 X SSC (3 X 15 
min). Filters were then air dried and exposed for autoradiography at 
-70 "C with intensifying screens. 
RESULTS 
Identification of Renal Kallikrein cDNA Clones-A cDNA 
library was constructed by cloning of sequential reverse tran- 
scriptase cDNA synthesis  products from kidney-polyadeny- 
lated RNA into  the bacteriophage vector X g t l O  (Huynh et aL, 
1985). The primary plating of this library of approximately 
350,000 clones was screened with the general kallikrein probe, 
pMK-1  (Richards et al., 1982). Of the 40 positive clones three 
also hybridized to  an exon 1-specific probe, and  partial  se- 
quencing revealed that they were nearly full-length cDNA. 
These cDNA clones all  had identical sequences except for 5'- 
end  errors introduced by  cDNA synthesis  reactions  (Richards 
et al., 1979). The longest of these cDNA clones was designated 
cMRK-1  and was subjected to complete sequence analysis. 
A 30-mer oligodeoxyribonucleotide shown to be  specific for 
one kallikrein gene, mGK-6 (see later), was used to demon- 
strate  that  the r maining kidney kallikrein cDNA clones were 
derived from the same gene transcript. The two exceptions 
were sequenced and found to be aberrant due to rearrange- 
ments  during cDNA cloning resulting in the lack of sequences 
corresponding to  the unique probe region. Thus, within the 
limits of the cDNA screening undertaken, only one member 
of the kallikrein gene family, mGK-6, appears to be expressed 
in  the kidney and is, therefore, renal kallikrein. 
Chemical Synthesis of a Renal Kallikrein-specific Probe- 
To detect mRNA transcripts specifically derived from mGK- 
6 it was necessary to design and  test  a gene-specific  probe. 
This was accomplished by the chemical synthesis of a 30-mer 
oligodeoxyribonucleotide from a consistently more variable 
region of the kallikrein genes (Fig. L4). The average number 
of nucleotide differences over the whole coding region is 4/30 
bases, whereas the region chosen contains 5-8 changes over 
the 30-mer sequence. 
In order to determine the specificity of this probe and  the 
hybridization conditions necessary for its use, a DNA blot of 
restriction endonuclease digests of X clones containing the 
entire complement of  25 nonallelic mouse glandular kallikrein 
genes was probed with the 32P-labeled renal kallikrein 30- 
mer.  Fig. 1B shows that when this blot is washed at 30 "C in 
2 X SSC most of the genes still cross-hybridize to  the probe; 
however, at 60 "C only the DNA fragment corresponding to 
mGK-6 remains hybridized. Under these conditions the 30- 
mer can, therefore, be used as  a specific probe to detect mGK- 
6 RNA transcripts. The likelihood of cross-hybridization with 
nonkallikrein mRNA sequences is not  anticipated to be 
greater than with the use of cDNA probes because the mar- 
ginal difference in washing conditions with that normally 
used (60 "C, cf. 65 "C) should be somewhat compensated for 
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FIG. 1. Specificity of the synthetic oligodeoxyribonucleo- 
tide probes. A ,  comparison of the  kallikrein gene sequences  in  the 
region from which the synthetic oligodeoxyribonucleotide 30-mers 
were  derived. Only  bases which  differ from  the  sequence of mGK-6 
are  shown for the  other  genes  (Mason et ul., 1983; Evans  and  Richards, 
1985). Synthetic  probes were complementary to  the  sequences shown. 
The  first base in  the  mGK-6  sequence  corresponds  to nucleotide 2139 
in Fig. 2, at  the beginning of exon 4. B, DNA blot of restriction 
fragments of X clones which contain  exon 4 of all of the kallikrein 
genes, after  hybridization to  the  mGK-6 30-mer and  washing a t  30 or 
60 "C in 2 X SSC. Lunes 1 and I7 are X markers (Hind111 digest). The 
X clones contain  the  kallikrein genes: mGK-1  and 2 (lune 2) ,  mGK-3 
a n d 4  (lane 3),mGK-5  and 6 (lune 4) ,  mGK-7 a n d 8  (lune5),  mGK- 
9 (lane 6), mGK-10 (lune 7), mGK-11  and 12 (lune 8), mGK-13  and 
22 (lune 9), mGK-15 (lune IO), mGK-16 (lune I I ) ,  mGK-17  and 24 
(lane 12), mGK-18 (lune 13), mGK-14 (lune 14),  mGK-19 (lune 15) 
and mGK-20 and 21 (lane 16). mGK-23 and 25 have been tested 
separately  and show no  hybridization to  the  mGK-6 30-mer. 
by greater  opportunity  for  hybridization  to  fortuitously  simi- 
lar sequences evident  in longer DNA  probes  (Ullrich  et al., 
1985). 
The specific oligodeoxyribonucleotides corresponding to 
mGK-3 and -4 were synthesized from this same region of 
coding  sequence of the respective  genes (Evans  and  Richards, 
1985) as shown in Fig. lA and were similarly shown to be 
specific under  the  conditions used for  the  mGK-6 probe. 
Identification of the Renal Kallikrein Gene-Partial se- 
quences have been determined from most of the kallikrein 
genes.2 Comparison of these sequences with  that of cMRK-1, 
the  kidney  kallikrein  cDNA, showed that  the coding region 
of only one gene was identical  to  the  cDNA sequence. The 
five exons of this gene, mGK-6, were sequenced completely 
as was 902 base  pairs of 5' flanking  DNA  and  126  base  pairs 
of 3' flanking  DNA (Fig. 2). The  exon-intron  boundaries of 
this gene are  identical  to  those of all  members of this gene 
family so far determined. The CAT box and variant 5'- 
TTTAAA-3' box are  also  the  same as in  mGK-1, -3, and  -4 
(Mason  et al., 1983; Evans  and  Richards, 1985). 
Comparison of the 5' flanking region sequences of mGK-1, 
-3, and -4 with  that of mGK-6 shows that  the only  differences 
are  point  mutations  and single base  insertions  and deletions. 
Therefore,  any differences in 5' flanking regulatory elements 
which might  control  the  expression f these genes are  not  due 
to gross rearrangements of DNA sequences. 
Fig. 3  shows that  mGK-6  is  in a group of four contiguous 
kallikrein genes, two of which  encode the y and a subunits of 
nerve growth factor  (mGK-3  and -4,  respectively). These four 
genes each comprise 5 exons spanning approximately 4.5 
kilobase pairs  and  are encoded on  the  same  strand 4-5 kilo- 
base  pairs  apart. 
Amino Acid Sequence Homology of Kallikreins-The com- 
plete structure of the mGK-6 gene demonstrates that this 
kallikrein is  synthesized  in a pre-pro  form of 261 amino acids. 
Unlike  the cDNA of the  rat  pancreatic  preprokallikrein  (Swift 
et al., 1982) there  is only one ATG codon at   the 5' end of 
both  the cDNA and  mGK-6 gene which  defines the  N-termi- 
nal  methionyl residue of the  translation product. The  length 
of the  pre-  and  pro-peptides  can be  assigned by analogy with 
other members of the kallikrein gene family (Evans and 
Richards, 1985; Mason  et al., 1983). 
Fig. 4  shows a comparison of the coding potential of mGK- 
6 with other sequenced kallikrein genes, a rat pancreatic 
kallikrein cDNA  clone (Swift  et al., 1982), and  the  amino acid 
sequences of EGF-binding  protein  type B (Lundgren  et al., 
1984) and pig pancreatic kallikrein (Tschesche  et al., 1979). 
Overall homology between the mouse protein sequences is 75- 
80%. The homology between mouse renal  kallikrein  and  rat 
pancreatic kallikrein is  68%  and between  mouse renal kalli- 
krein  and pig pancreatic kallikrein is  59%. 
Expression of mGK-6 in Mouse Tissues-To determine if 
mGK-6  is expressed in  other  tissues  as well as  the kidney, the 
specific 30-mer was used to  probe  dot  blots of polyadenylated 
RNA  prepared  from mouse salivary glands, pancreas, liver, 
brain, spleen, and  testis.  RNA  blots were also hybridized to 
the general kallikrein probe pMK-1  and  to  an oligodeoxyri- 
bonucleotide 30-mer shown to be specific for  another kalli- 
krein gene, mGK-4 (Fig. 5). The control RNA dilutions of 
tRNA  alone  and salivary  gland RNA  with  added  tRNA show 
that  the hybridization  signal  for each  probe  is specific. Fig. 
5A shows that pMK-1 hybridizes to RNA from all of the 
tissues  tested,  indicating  that some members of the kallikrein 
family are expressed in  each of these tissues, though  in very 
different amounts. Comparison of dilutions of the mRNA 
shows that expression of all kallikreins  in  the salivary  glands 
is 30-100 times that in the kidney and pancreas and 3-4 
orders of magnitude  greater  than  in  the  other tissues. How- 
ever, both  the  pattern  and relative levels of hybridization are 
different  for  the specific mGK-6 30-mer. The kallikrein gene 
mGK-6  is expressed in  the salivary  glands,  kidney, and  pan- 
creas  and  also  in  the spleen, but  no expression was detected 
in  the liver, brain, or testis (Fig. 5B) .  In  contrast mGK-4 is 
expressed in the salivary glands, pancreas, and testis (Fig. 
5C). While expression of mGK-4 in the salivary glands is 
anticipated  since  this gene encodes a-NGF which has been 
purified from this tissue, its expression in pancreas (albeit 
low compared  with  mGK-6)  is  unexpected,  as kallikrein 
expression in  this  tissue  has previously  been thought  to be 
restricted  to a single  gene (Swift  et al., 1982), similar  to  the 
kidney. Expression of mGK-4  in  the  testis  is  consistent  with 
the  observation of NGF  in  seminal fluid (Harper  et al., 1982). 
Although Fig. 5C suggests that  mGK-4  is expressed at  a very 
low level in  the kidney  (less than  3%  that of mGK-6)  this  has 
not been confirmed by the  presence of any cDNA  clones and 
may  reflect the  limits of the  experimental  technique. 
Sexual Dimorphism of Kallikrein Gene Expression-We 
have used gene-specific oligodeoxyribonucleotide probes to 
detect expression of particular  members of the mouse glan- 
dular kallikrein  gene  family in male and female  salivary 
glands. Fig. 6A shows that  there  is a 10-fold  difference in  total 
expression of kallikrein  genes in  the salivary  glands  between 
male and female, but  the expression in  the kidney and  pan- 
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FIG. 2. Sequence of the mouse renal  kallikrein gene, mGK-6. The nucleotide and encoded amino acid 
sequences are shown. The numbers  on the right refer to  the nucleotide residues. The splice sites  around each exon 
and  the initiation and termination codons are boxed. The coding sequence has been translated, and numbers above 
the  amino acid sequence refer to  the position relative to  the N-terminal isoleucine of the mature protein. The 
asterisk denotes the first residue of the zymogen peptide. The CAT box (Benoist et al., 1980) and  the variant 
TATA box (Corden et aL, 1980) are ouerlined. Putative  transcription  initiation  sites (Mason et al., 1983) are shown 
by arrows. The polyadenylation signal (Proudfoot and Brownlee, 1976) is underlined, and  the triangle indicates 
the transcription  termination site (Mason et ul., 1983). 
creas is  not similarly sex linked. No difference in expression 
of mGK-6 between male and female tissues is seen in  the 
salivary gland, kidney, or pancreas. Fig. 6B shows that when 
specific probes directed against a-NGF (mGK-4) and  7-NGF 
(mGK-3) transcripts  are used, about 100 times as much of 
these mRNAs are detected in  the male salivary glands com- 
pared to those of the female. Therefore, the sexual dimorph- 
ism of mouse salivary gland kallikrein gene expression is not 
due to differences in mGK-6 expression. Other kallikrein 
genes, such as (U-NGF and y-NGF, give rise to  the previously 
observed (Angeletti et al., 1967; Chao and Margolius, 1983) 
differences in kallikrein levels. 
DISCUSSION 
The mouse glandular kallikrein genes are  a very homolo- 
gous multigene family whose members exhibit diversity of 
function and expression. As such, it provides an excellent 
system in which to undertake  a comparative structural  anal- 
ysis of the different genes, the high degree of homology 
reducing the likelihood of observing silent amino acid changes 
or permissive nucleotide point  mutations. 
Analysis of kallikrein expression by classical biochemical 
approaches has been hindered by this homology. Protein 
activity measurements based on arginyl esterase activity are, 
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FIG. 3. Restriction map showing the linkage of the  renal  kallikrein gene. Linkage of the genes mGK- 
3, -4, -5, and -6 is  demonstrated by the isolation of a series of overlapping genomic clones (designated XMSP). 
Vertical bars denote the five exons of each gene, and  the arrows above the map show the direction of transcription. 
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FIG. 4. Comparison of kallikrein amino acid sequences. The amino acid sequence of the mGK-6 gene 
product (kidney kallikrein) is compared to those of mGK-3 (y-NGF) and -4 (a-NGF) (Evans and Richards, 1985), 
mGK-1  (Mason et al., 19831, and a rat pancreatic kallikrein mRNA (Swift et  al., 1982). The amino acid sequences 
of mouse EGF-binding  protein type B (Lundgren et al., 1984) and pig pancreatic kallikrein (Tschesche et al., 1979) 
are also shown. Residues which are identical between at least five out of the seven sequences are boxed. Numbers 
refer to  the position relative to  the N-terminal isoleucine residue of mouse renal kallikrein. The asterisk denotes 
the first residue of the zymogen peptide. The gap in the sequence of pig pancreatic kallikrein at residues 81-87 is 
the autolysis loop. 
at best, nonspecific. Immunological detection, particularly 
using polyclonal antibodies, is  not necessarily specific for one 
member of the kallikrein family because of the extensive 
amino acid sequence conservation. Different kallikreins share 
common antigenic  sites, as demonstrated by the cross-reac- 
tion of antibodies raised against /3-NGF endopeptidase with 
y-NGF  and  EGF-binding  protein (Bothwell et aL, 1979). At 
the nucleotide sequence level the high degree of homology 
seen  in coding regions (SO-SO%) extends  both to introns  and 
to 5’ and 3’ untranslated regions. Even under  stringent hy- 
bridization conditions DNA probes such as cDNA clones or 
genomic DNA fragments are found to cross-react with all 
members of the kallikrein gene family (Mason et aL, 1983). 
We, therefore, sought to develop and utilize chemically syn- 
thesized oligodeoxyribonucleotides as probes for specific 
genes. The most consistently variable region from the avail- 
able gene sequences was chosen, and synthetic sequences 
complementary to  the mRNA sequence were constructed. By 
hybridization to  the cloned kallikrein genes we were able to 
determine the conditions that would lead to  the “gene-spe- 
cific” hybridization of the probe. The stringency of hybridi- 
zation ultimately adopted is only marginally different from 
that used for cloned DNA probes, and  it is no more probable 
that the synthetic oligodeoxyribonucleotides would cross- 
react with nonkallikrein mRNAs than a longer cloned DNA 
probe. The comparable level of hybridization of the cDNA 
probe, pMK-1, and the specific mGK-6 30-mer to kidney 
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FIG. 5. Analysis of kallikrein mRNA in mouse tissues. Dot 
blots of polyadenylated  RNA from male mouse salivary glands,  kid- 
ney, pancreas, liver, brain,  spleen,  and  testis.  The  amount of RNA 
loaded is shown at   the bottom of the figure. The  tRNA  dilutions  and 
tRNA  added  to  salivary  gland  RNA  dilutions  are  controls.  Duplicate 
blots were  hybridized to  pMK-1 (panel A )  or the  mGK-6 specific  30- 
mer (panel B) .  Salivary gland dilutions start at 0.33 pg of RNA, 
kidney and  pancreas  at 10 pg, and  the  other  tissues  at 33 pg. The  blot 
hybridized to the mGK-4 specific 30-mer (panel C )  was prepared 
separately;  salivary gland dilutions start at 0.1 pg of RNA  and  the 
other  tissues a t  33 pg. 
sensitivity  in  detection of kallikrein  expression by using oli- 
godeoxyribonucleotide  probes. 
The principal aim of the present study was to identify 
which member of the mouse kallikrein gene family is ex- 
pressed in the kidney. This gene product gives rise to  the 
urinary kallikrein originally described by Frey, in 1926, as 
having  potent  hypotensive  properties  when  injected back into 
experimental  animals. Analysis of cDNA  clones  derived from 
kidney mRNA suggests that only one member of the gene 
family, mGK-6, is abundantly  expressed  in  this tissue. If any 
other  kallikrein gene is  expressed  in  the kidney its level of 
expression  is  much less than  that of mGK-6. This  is  supported 
by the  result  that  the  RNA  hybridization signal from gene- 
specific probes for other  kallikrein genes is a t  least 2 orders 
of magnitude lower than  that of mGK-6 (Fig. 
'B. H. van Leeuwen, B. A. Evans, G. W. Tregear, and R. I. 
Richards,  unpublished  results. 
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FIG. 6. Sexual dimorphism of kallikrein gene expression. 
Dot blots of polyadenylated RNA from male and female mouse 
salivary glands,  kidney, and  pancreas.  The  amount of RNA loaded is 
shown under the dot blots. A,  blots hybridized to pMK-1- or the 
mGK-6-specific 30-mer. Salivary gland dilutions start a t  10 ng of 
RNA  (pMK-1,  male) 33 ng  (pMK-1,  female) or 3.3 pg (mGK-6 30- 
mer, male and  female).  Kidney  and  pancreas  dilutions  start a 3.3 pg 
of RNA. B, blots of salivary gland RNA hybridized to  the  30-mers 
specific for mGK-3, -4, and -6. The RNA dilutions for male and 
female  start  at 3.3 pg. 
The  predicted  amino acid sequence of mouse renal kalli- 
krein is, as expected, highly homologous to those of other 
kallikrein genes. The residues  necessary  for the  formation of 
a serine  protease  catalytic  site, His-41,  Ser-189, and Asp-96, 
are  in regions  which are conserved  between  all of the kalli- 
kreins.  The residues that  are believed to  line  the  substrate- 
binding  pocket  are  frequently  in variable  regions of the se- 
quence  and presumably  confer the  substrate specificity attrib- 
uted to each kallikrein (Mason et al., 1983). The three ki- 
ninogenases (mouse renal kallikrein, rat  and pig pancreatic 
kallikreins) have identical residues in some of these areas: 
Tyr-93, Ser-135, Glu-142, and His-164. However, only the 
Glu a t  position 142 is  not  shared by one  or more of the  other 
kallikrein family members. Therefore, this residue may be 
important  in  the  binding of kininogen substrate  to  the  en- 
zyme. Although these  observations  are speculative and subject 
to species  differences, the  tentative  identification of residues 
which  may  be  involved in  substrate  binding will be  useful  in 
determining sites for in uitro mutagenesis experiments to 
investigate  the  interaction of enzyme and  substrate. 
The high amino acid sequence homology between kalli- 
kreins would account  for  the  frequently observed  cross-reac- 
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tion of antibodies. This cross-reactivity has undoubtedly led 
t o  confusion over which members of the kallikrein gene family 
were being expressed in  a  particular tissue. The use of the 
oligodeoxyribonucleotide probes specific for  mGK-6 and 
mGK-4 demonstrates that  the kallikrein genes have different 
expression phenotypes. The kallikreinb) expressed in the 
brain  and liver, as  detected by the general probe pMK-1, are 
not accounted for by mGK-6 expression. This finding in  the 
brain is in  contrast with the demonstration by Chao et al. 
(1983) of a kallikrein in rat brain indistinguishable from 
urinary kallikrein by immunological and enzymatic assays. 
The use of gene-specific probes for each member of the mouse 
kallikrein family will ultimately enable identification of the 
particular gene(s) whose expression gives rise to  the signals 
in  the  brain  and liver detected by pMK-1. 
Sexual dimorphism of kallikrein  content in mouse and  rat 
salivary glands has been reported, although the difference 
between male and female varies from 2- to 20-fold depending 
on the assay used, whether esteroproteolytic activity or im- 
munoreactivity (Angeletti et al., 1967; Chao and Margolius, 
1983). No sex-linked differences were found when kininogen- 
ase activity was measured (Bhoola et ai., 1973) though the 
presence of kininases  in  tissue  extracts makes interpretation 
of these  results difficult. The use of the gene-specific probes 
enables the contribution to  the sexual dimorphism of each of 
the closely related kallikrein-like proteins to be determined. 
While the  total level of kallikrein gene expression is much 
higher in male than female, the levels of mGK-6 expression 
in the salivary gland are virtually identical. Clearly, other 
members of the gene family, including mGK-3 and mGK-4, 
are responding to hormones (such as testosterone) to which 
mGK-6 is not. This is in  spite of the close linkage of these 
genes and  the extensive homology of their 5' flanking DNA 
sequences. The difference in the regulation of expression of 
these members of the kallikrein gene family may reflect the 
different physiological roles of the gene products. The rela- 
tively constant level of mGK-6 (kininogenase) expression 
between male and female salivary glands is  consistent with 
its postulated role in local kinin  generation  (and, therefore, 
control of local blood flow) in  this  and  other tissues. Sexual 
dimorphism of expression of other kallikrein genes, particu- 
larly those involved in growth factor biosynthesis, may con- 
tribute  to  further anatomical  and/or physiological differences 
between the sexes. 
The data presented in this paper show that there are 
distinct differences in  the tissue-specific patterns  and regu- 
latory responses of gene expression between members of the 
kallikrein gene family. In  the case of the human  metallothi- 
onein gene family such differences are  due to distinct pro- 
moter elements controlling the expression of the different 
genes (Richards et aL, 1984). Gene transfer experiments of 
kallikrein gene promoter regions into  transgenic  animals  and 
cultured cell lines will  allow identification of the particular 
nucleotide sequence changes between these genes giving rise 
to  the observed expression phenotypes. 
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Mouse glandular kallikreins are  encoded by a  family 
of closely linked genes which are located  on  chromo- 
some 7 at  a site corresponding  to  the genetically de- 
fined Tam-l,  Prt-4, and Prt-6 loci. We have  character- 
ized 24 kallikrein genes  by  genomic  cloning  and re- 
striction mapping of 310 kilobase pairs of BALBfc 
mouse DNA. Most of these  genes  are  highly  homolo- 
gous, have  the  same  exonfintron  organization,  and  are 
linked  in  clusters  of up to 11 genes. Partial sequence 
analysis of the kallikrein genes has facilitated identi- 
fication of  those  members  of  the  family  for  which  pro- 
tein  sequence  data exist and  assignment  of  those  which 
are pseudogenes  or  encode  proteins  of  unknown  func- 
tion. We find  that  a  maximum  of 14 mouse kallikrein 
genes have  the  potential to encode  functional  proteins. 
~ ~~ ~ 
The enzymes which bring about  maturation of growth fac- 
tors  and polypeptide hormones are of interest because they 
represent  potential regulatory steps in the conversion of in- 
active precursors to biologically active peptides. Maturation 
of polypeptide hormones has been shown to involve proteo- 
lytic cleavage of a  protein precursor to give one or  a number 
of active products. For example, cleavage of the neural peptide 
precursor, pro-opiomelanocortin, gives rise to  the hormones 
ACTH, p-LPH, a- 'and @-MSH, @-endorphin, and met-en- 
kephalin (Nakanishi et al., 1979). Hormones such as insulin 
(Ullrich et al., 1977) and relaxin (Hudson et al., 1981) are 
activated by the removal of a single internal pro-peptide 
segment from a higher molecular weight precursor. Similarly, 
an essential step in the maturation of nerve growth factor 
(NGF)'  and epidermal growth factor is the proteolytic release 
of the carboxyl-terminal segment of a larger polypeptide 
(Scott et al., 1983; Gray et al., 1983). 
There  are only a few cases in which a  particular enzyme 
has been shown directly to cleave a specific hormone or growth 
factor precursor. One example is the release of angiotensin I 
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from angiotensinogen due to  the action of renin (Skeggs et 
al,, 1980). It is interesting that renin exists largely in a 
precursor form which must in turn be activated by an  un- 
known protease (Fritz et al., 1986). Further examples of 
processing involve the class of glandular kallikreins. These 
are glycoproteins of molecular weight 25,000-40,000 in which 
the apparent heterogeneity is due to varying levels  of  glyco- 
sylation and different patterns of internal cleavage. They  are 
related to trypsin and other serine proteases, although unlike 
trypsin, kallikreins show a high  degree of substrate specificity. 
The major glandular kallikrein, found in kidney, pancreas, 
and salivary gland, cleaves the precursor kininogen to release 
bradykinin, a vasoactive peptide which  may  be important in 
regulating local blood flow (Schachter, 1980). Other  charac- 
terized members of the kallikrein family include the a- and 
y-subunits of NGF, epidermal growth factor-binding protein, 
and  y-renin, which  mimics the action of renin in vitro (Poe 
et al., 1983). 
To date, we have isolated genes encoding mouse renal 
kallikrein (van Leeuwen et al., 19861, and the a- and y- 
subunits of NGF  (Evans  and Richards, 1985). Another gene, 
mGK-1, was shown to encode a functional protein  and to be 
expressed in male mouse salivary gland, although no physio- 
logical role could be ascribed to  the product (Mason et al., 
1983). Comparison of the amino acid sequences of different 
kallikreins indicated that although the proteins are highly 
homologous overall, regions of greater diversity are correlated 
with residues thought to be important in determining sub- 
strate specificity. This observation and the finding that kal- 
likreins are encoded by a large multigene family led us to 
propose that these  proteins may  play a role in the processing 
of a wide variety of hormone and growth factor precursors 
(Mason et al., 1983). 
In order to determine a  potential limit for the kallikrein 
system in the maturation of biologically active peptides, we 
have characterized the mouse glandular kallikrein gene family 
both  in  terms of the  total number of genes and in their ability 
to encode active serine proteases. We find that 14 kallikrein 
genes have the potential to encode functional proteins while 
a  further 10 are pseudogenes. These results are discussed in 
relation to  the observed expression of members of the kalli- 
krein gene family and the characteristics of this family in 
other mammalian species. 
EXPERIMENTAL  PROCEDURES 
Isolation of Genomic DNA-A crude  nuclear fraction was  prepared 
from 5 g of BALB/c mouse liver  by homogenizing the minced tissue 
in 20 ml of NKM solution containing 0.15 M NaCl, 5 mM KC1, and 2 
mM MgCl,, followed by centrifugation at 2000 rpm for 5 min in a 
bench centrifuge. The nuclei were resuspended in 20 ml of NKM 
solution and the suspension added dropwise to 40 ml of a buffer 
containing 10 mM Tris-HC1 (pH S), 10 mM NaCl, 10 mM EDTA, 
0.5% sodium dodecyl sulfate, and 100 pg/ml pronase. This addition 
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was carried out over several hours, with the solution stored at 37 "C, 
then incubation was continued overnight a t  37  "C. The DNA suspen- 
sion was  allowed to cool to room temperature and was gently extracted 
with 30 ml of phenol, and 30  ml of chloroform. The aqueous phase 
was dialyzed overnight at 4  "C  against several changes of TE (10 mM 
Tris-HC1, pH  8, 1 mM EDTA), and  then  the solution was incubated 
at 37  "C for 2 h with 20 pg/ml ribonuclease A. The phenol/chloroform 
extraction and dialysis were repeated as before and  the DNA stored 
at  4 "C over 10 ml  of chloroform. We find that this procedure 
involving minimal handling consistently gives  high molecular weight 
DNA at  a concentration of 0.3-0.5 mg/ml which can be cleaved 
readily with restriction enzymes. 
Genomic Library Construction-Procedures for construction of the 
EMBL 3A library were essentially as described by Kaiser and Murray 
(1985). BALB/c genomic DNA was partially digested with Sau3A 
(Amersham Corp.) under conditions giving a maximum number of 
molecules in the size range 10-25 kb. Trial digestions were carried 
out using 35 pg  of DNA in  a total volume of  500 pl, and scaling-up 
was done by setting up 10 such reactions with slightly varying 
amounts of Sau3A (e.g. 3-5 units). Following incubation at 37 "C for 
45 min, 12.5 pl of 1 M Tris-HC1 (pH 8) and 2 units of bacterial 
alkaline phosphatase (Sigma type IIIS, activated by dialysis against 
10 mM Tris-HC1 (pH 8), 1 mM MgCI,, 0.1 mM ZnC12) were added to 
each tube. The solutions were incubated at 65 'C for 15 min, cooled 
briefly in ice, and extracted with phenol/chloroform, then  the DNA 
was ethanol  precipitated overnight at -20  "C. To check the efficiency 
of dephosphorylation, an additional 5 pg of DNA was digested to 
completion with Sau3A. This solution was split and one-half treated 
with alkaline phosphatase  under the same conditions as above. Fol- 
lowing phenol/chloroform extraction and ethanol precipitation, 1 pg 
of each DNA sample was treated with T4 DNA ligase, and these were 
compared with unligated samples by electrophoresis on  a 0.8% agarose 
gel.  DNA treated with alkaline  phosphatase showed no increase in 
size following the ligation reaction, whereas the untreated DNA self- 
ligated to give  molecules longer than 5 kb. 
The 350 pg of Sau3A-digested, dephosphorylated genomic DNA 
was pooled in 400 pl of TE buffer and fractionated by centrifugation 
over a 5-24% NaCl gradient (37,000 rpm for 4.5 h a t  25  "C, in an  SW 
41 rotor). Fractions were analyzed by electrophoresis on a 0.5% 
agarose gel, and DNA fragments of  15-23 kb were inserted into  the 
EMBL 3A vector (Frischauf et al., 1983) then packaged in uitm 
(Maniatis et al., 1982). Using the host LE392 (Maniatis et al., 1982), 
recombinant phage were plated out a t  a density of 15,000/9-cm plate 
and screened with kallikrein probes. 
Hybridization Analysis of Genomic and Cloned DNA-Genomic 
DNA or kanikrein-positive clones were digested with appropriate 
restriction enzymes (see "Results" section, enzymes from P. L. Bio- 
chemicals, Pharmacia) and  then electrophoresed overnight (1.5 V/ 
cm)  on 0.9% agarose gels in TBE buffer (Maniatis et al., 1982). The 
DNA  was transferred to 0.45-pm nitrocellulose filters by the method 
of Southern (1975), and hybridized to probes prepared either by 
et al., 1986) in the presence of [a-"PIdCTP (from Bresa, Adelaide, 
Klenow-extension of random-primed DNA fragments  (van Leeuwen 
Australia), or 5"labeling of oligodeoxyribonucleotides (Maniatis et 
al., 1982) using T4 polynucleotide kinase and  [T-~'P]ATP (Amersham 
Corp.). Nitrocellulose filters were prehybridized for 2-4 h at 65 "C in 
a buffer containing 50 mM HEPES  (pH 71, 3 X SSC, 0.1% sodium 
dodecyl sulfate, 1 mM EDTA, 0.2% Ficoll 400,0.2% polyvinylpyrrol- 
idone, 0.2% bovine serum albumin, and 50 pg/ml sonicated herring 
sperm DNA. Following addition of the probe, hybridization was 
continued in the same buffer overnight at 65 'C for random-primed 
probes or room temperature for oligodeoxyribonucleotides. Filters 
were washed in  2 X SSC, at room temperature for X clone blots  or 
65 "C for genomic DNA blots hybridized with random-primed probes 
and varying temperatures as required for blots probed with oligode- 
oxyribonucleotides (van Leeuwen et al., 1986). The filters were then 
exposed at  -80 "C with intensifying screens to Kodak XAR-5 film. 
Partial Sequencing of Kallikrein Genes-In most cases, clones 
containing 1 or 2 kallikrein genes were digested with Sau3A and 
subcloned into dephosphorylated, BamHI-cut M13 mp18 or 19 (Mess- 
ing, 1983). The efficiency of this procedure was increased by using a 
molar excess of the DNA, favoring multiple inserts. In those cases 
where a Sau3A site was found to occur in the coding region, subclon- 
ing was carried out on the basis of defined restriction  sites (Fig. 2). 
Because our sequencing strategy relied on the use of kallikrein 
primers, rather than  the usual 17 mer complementary to M13, the 
presence of very long or multiple inserts was unimportant. Two 
oligodeoxyribonucleotides were chemically synthesized (van Leeuwen 
et al., 1986); UKP-2 (Fig. lB), a 27 mer complementary to the 
conserved region in exon 2 corresponding to nucleotides 1556-1582 
of mGK-6 (van Leeuwen et al., 1986), and UKP-3,  a 30 mer comple- 
mentary to a conserved region in exon 3 (nucleotides 1934-1963 of 
mGK-6). These were initially used as probes for hybridization anal- 
ysis of M13 subclones. Positive recombinants were then sequenced 
by the chain  termination method (Sanger et dl., 1977), using [a-35S] 
dATP (Amersham Corp.) with either UKP-2 or -3 as  the primer. 
RESULTS 
Structure of the Mouse Glandular Kallikrein Gene Family- 
As shown in Fig. lA, digestion of mouse  genomic DNA with 
both EcoRI and  BamHI  results  in  a complex array of bands 
hybridizing to  the  pMK-1 probe (Richards et al., 1982). In 
approaching the isolation of the complete mouse kallikrein 
locus, our aim was to assign all of these  bands to particular 
genes. To this  end, we screened two different bacteriophage 
libraries and a cosmid library, each containing clones suffi- 
cient to represent at least two haploid genomes. Restriction 
mapping of the kallikrein clones from these libraries is shown 
in Fig. 2. 
We had previously isolated 2 kallikrein-positive clones 
(XMSP 1 and 2) from a Quakenbush genomic library con- 
structed  in the Charon 28 vector (Mason et al., 1983). One of 
these clones contained  a complete gene (mGK-1) of 4.5 kb, 
which was  fully sequenced and found to consist of 5 exons, 
with lengths of 82, 160, 287, 137, and 181 bp, separated by 
introns of 2418,821,96,  and 372 bp (Fig. 1B). In  constructing 
maps of the bacteriophage and cosmid clones shown in Fig. 2, 
we routinely used the pMK-1 probe, and a HindIIIISmaI 
fragment from mGK-1 covering exon 1 (fragment IV, Mason 
et al.,  1983). In cases where there was any ambiguity in the 
map, probes specific for exons 2  and 5 were also used. The 
position of exon 1 relative to  the remainder of each gene  was 
determined by its presence or absence in overlapping clones 
and hybridization of the exon 1 probe to one or more restric- 
tion fragments. Each clone  was digested singly and pairwise 
with EcoRI, HindIII, BamHI, SacI, and SalI. It is striking 
that in the 310 kb of DNA covered  by the overlapping clones, 
not  a single SalI  site was  observed. 
Variation between the genes occurs with respect to the 
length of introns, particularly A and  to a lesser extent B and 
D (Fig. 1B). Sequence data for the genes mGK-1 (Mason et 
al., 1983), mGK-3  and 4 (Evans and Richards, 1985), mGK-5 
and 9: mGK-6 (van Leeuwen et al., 1986), and mGK-13 and 
2z3 show, however, that exonlintron boundaries occur at 
identical positions of the coding region for all exons. This 
observation is confirmed for exons 2 and  3 of other kallikrein 
genes by the data shown in Fig. 4. With the exception of 
mGK-7 and 17, restriction mapping and partial sequence 
analysis of the other 11 complete kallikrein genes (Fig. 2) give 
results in agreement with the  exonlintron organization shown 
for mGK-1 (Fig. 1B). It is interesting that intron positions in 
the mouse coding regions are the same as those of a rat 
kallikrein gene (rGK-1),4 whereas the number and position of 
introns in other serine protease genes, even within a single 
species, vary considerably (Rogers, 1985). 
Except for mGK-17, all genes within the kallikrein locus 
were found to be linked to  at least one other gene. The largest 
cluster is that containing 11 genes (Fig. 2 A ) ,  while the cluster 
shown in Fig. 2B has five  closely linked genes. All  of the genes 
in these two clusters are transcribed in the same direction 
relative to each other. In fact the only exception to this 
observation is the linkage of mGK-14 and 15, which are 
C. Drinkwater, unpublished result. 
C. Drinkwater, B. Evans, R. Richards, manuscript  in  preparation. 
' B. Evans, unpublished data. 
36
Mouse Glandular Kallikrein Genes 8029 




6 6 -  
U,K P- 
, I  
i n t r o n  A B ’,\,’ C D 
4 4 -  exon 11 _.= 2 ”._ 3 L  5 
-. -. -. -. 
22 k b  I 4  10.0 k b  
9.2 3 .  4 9.2 
8.4 7 8 .0  
7.4 I 7.0 
6.6 5. 6 6.5 
4.2 9 5.6 
3.4 19 4.7 
3 .1   13  4 . 1  
2.4  2. 8.  10. 1 1 .  3 .3  
16. 22. 24 
2. 10. 1 4 .  24. 
( 8 .  16) 
e-- - 
2 3 -  m- 
2 . 0  ,_””’ , 
exon 2: AAPPVQSRIVCCFKCEK~SQPUHVAVYRYKEYICCCVLLD~~WVLTA~HCYYE 2.2 2 1  2.8 4. ( 3 .  9 )  
zymogen 
p e p t l d e  ‘% I .8 I2 2.6 1 .  I t  -7 2.3 7. 9 
0 . 5 6 .  
r \ 
coding  sequence: 5 ‘  AACTCCCTTCTCACACCTCCCCACTCC 3‘  
UKP-2: 3’  TTCACCCAAGAGTCTCGACCCCTCACG 5 ’  I .o (10)  
FIG. 1. Genomic blot analysis of mouse glandular kallikrein genes. A, BALB/c mouse genomic DNA 
was digested with the restriction enzymes EcoRI and BamHI and analyzed by Southern  blotting using the general 
kallikrein cDNA probe, pMK-1. This probe hybridizes to most of exon 3 and to exons 4 and 5. Numbers to  the left 
of the blot indicate the size in kilobase pairs of markers derived from Hind111 digestion of XcI857 DNA. E, a 
physical map of mGK-1 (Mason et al., 1983), showing the exon 2 amino acid sequence, and  the oligodeoxyribonu- 
cleotide (UKP-2) used for rapid partial sequencing of this exon from other kallikrein genes.  Also shown is the 
position of the  UKP-3 oligodeoxyribonucleotide (see “Experimental Procedures”). C, hybridizing bands observed 
following EcoRI and BamHI digestion of mouse DNA are aligned with fragments isolated from the genomic clones 
shown in Fig. 2. Dashes indicate fragments for which no gene assignment can be made. Numbers in brackets 
indicate genes in which exon 5 is separated from other exons by a BamHI site  in  intron D, and which therefore 
generate separate weakly hybridizing fragments. There  are additional weak signals corresponding to a 0.6-kb EcoRI 
fragment from mGK-12, and 0.5-kb BamHI fragments from mGK-10 and 24. 
separated by 21 kb of spacer DNA. In general, intergenic 
spacer regions vary between 3.3 and 7 kb, the only other long 
spacer (24 kb) being between mGK-25 and mGK-7. 
Our attempt  to isolate the complete kallikrein locus was 
made more difficult by the very biased distribution of bacte- 
riophage clones (Fig. 2). For example, the mGK-4 gene is 
present in 11 X clones, whereas mGK-17 and 19 were found 
only once. In general, genes within the large clusters  A and B 
are significantly overrepresented. This  cannot be explained 
by variability of hybridization signals during  screening of the 
libraries, since we were careful to include even weakly hybrid- 
izing plaques in our selection. One possible explanation is 
that  there  is a  greater  abundance of Sau3A sites within the 
gene clusters than in the flanking regions, although this is 
not reflected by any bias in  the distribution of BamHI sites. 
A second possibility is that  certain regions either  cannot be 
propagated in bacteriophage vectors or give rise to such  small 
plaques that no hybridization signal can be detected. This 
suggestion is in  agreement  with the observations of Wyman 
et al. (1985), who showed that 8.9% of a  random selection of 
human bacteriophage clones were unable to grow on standard 
rec+ hosts  (such as LE392). A third explanation is that regions 
in the vicinity of the kallikrein gene clusters could have a 
higher density of EcoK sites and therefore might be lost  during 
in vitro packaging due to EcoK activity (Rosenberg, 1985). 
We attempted  to obtain  additional data on the kallikrein 
locus by screening a BALB/c cosmid library (Cory et al., 1985; 
provided by  M. Graham of the  Walter  and Eliza Hall Institute, 
Melbourne). With the exception of cMSP-18  and 20, all 11 
positive clones covered the same regions which were highly 
represented in the bacteriophage libraries. In addition, the 
clones cMSP-8  and 21 contained more than one insert (Fig. 
2.4). It is interesting that no single bacteriophage or cosmid 
clone contained kallikrein genes in an opposite orientation 
with respect to each  other. This would be at  least  consistent 
with the conclusion of Wyman et al. (1985) that failure to 
propagate in a rec+ host is associated with the presence of 
inverted repeats. 
Genomic  Blot Analysis of the Kallikrein Locus-Comparison 
of the restriction  fragments generated by each kallikrein gene 
with the genomic blot shown in Fig. LA indicates that we can 
account for all of the EcoRI bands  and most of the BamHI 
bands hybridizing to  pMK-1 (Fig. 1C). The size of the EcoRI 
fragments  generated by the genes mGK-15 and 17 cannot be 
determined from the available mapping data. It is possible 
that mGK-15 represents an eighth gene containing the 2.4- 
kb EcoRI fragment or else an additional gene carrying  a 4.2- 
kb fragment. The EcoRI fragment from mGK-17 must be a t  
least 5.7 kb (Fig. 2E), and may be a component of the 
relatively strong  band a t  6.6  kb. The results of BamHI diges- 
tion  are complicated somewhat by the fact that in  12 different 
kallikrein genes, there is a Bam site within the fourth  intron 
(Fig. 2). Despite this, it  can be seen that  there  are only two 
bands, of  4.7 and 4.1  kb, for which there is no defined gene 
fragment. Again, these  bands could be accounted for by the 
genes mGK-15 and mGK-21. 
We have denoted the exon 1 which is downstream from 
mGK-19 as a separate gene, mGK-20, although it is likely 
that  this simply represents the beginning of one of mGK-15, 
21, or 23, and  that we have therefore isolated 24 rather  than 
25 distinct genes. The present gaps in  our structural  data are 
that neither of the strongly hybridizing genes mGK-15 or 21 
has been isolated in full and  that we have been unable to 
demonstrate linkage of the different gene clusters. We are 
confident, however, that we have isolated at  least  portions of 
all the homologous mouse kallikrein genes and  thus have a 
reasonable basis on which to draw conclusions concerning 
their possible range of functions. 
Characterization of Mouse Kallikrein Genes-We had pre- 
viously sequenced the complete coding regions of the genes 
mGK-1  (Mason et al., 1983), mGK-3 and 4 (which encode the 
y- and  a-subunits of NGF, Evans  and Richards, 1985), and 
the renal kallikrein gene, mGK-6 (van Leeuwen et al., 1986), 
as well as considerable regions of flanking and intervening 
sequence. In order to determine which of the remaining 20 
genes have the potential to encode active kallikreins, we 
19 
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FIG. 2. Restriction map of the mouse glandular kallikrein locus. The  organization of mouse  kallikrein 
genes is  demonstrated by the  isolation of overlapping  genomic  clones in  bacteriophage (XMSP) and cosmid (cMSP) 
vectors. Clones AMSP-3-26 were isolated from an embryonic BALB/c library provided by Dr. P. Leder, while 
remaining A clones were from the  EMBL 3A library described under "Experimental Procedures." Vertical burs 
denote  exons  and arrows above each gene  show the  direction of transcription. Dotted lines above the genes mGK- 
17, 18, 19, 23, and 25 indicate an organization or pattern of hybridization different from those of functional 
kallikrein genes (see  text).  Gene  cluster A extends  continuously  from  mGK-25  to mGK-18. The relative positions 
of regions A to G within  the  kallikrein locus have  not been determined. 
devised a strategy for the rapid sequencing of exons 2 and 3 active peptide. Given that this region is usually the most 
from each gene. Both of these  exons  contain regions which accessible to  amino acid  sequence analysis, we maximize the 
are variable  between different  kallikreins,  as well as regions likelihood of being able to match a particular gene with a 
which are highly conserved. Exon 2 was chosen in  particular protein of known function. 
since this gives the sequence of the NH2-terminus of the Fig. 3 shows the  amino acid  sequences predicted from the 
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FIG. 3. Predicted amino acid sequence from exons 2 and 3 of the mouse glandular  kallikrein genes. 
Assignment of the reading frame for each exon is analogous to that of previously sequenced kallikrein genes 
(Mason et al., 1983; Evans and Richards, 1985; van Leeuwen et al., 1986). Boxed areas represent amino acid 
residues which are identical for at least 75% of the  sequences.  Numbers  refer  to  the  position  relative  to  the NH,- 
terminal  residue of mature mouse renal kallikrein.  The arrow denotes the first  residue of the zymogen peptide. 
exon 2 and  3 nucleotide sequences of mouse kallikrein genes 
(Fig. 4). It was not possible to obtain exon 2 sequences from 
some genes, in two cases (mGK-15 and 23) because no ge- 
nomic clones carried the complete gene. The genes mGK-7, 
17, and 25, although isolated in full, showed  no  homology with 
either  UKP-2 or another exon 2-specific oligodeoxyribonucle- 
otide, UKP-2R  (data  not shown). As well, mGK-17, 18, and 
23 did not hybridize to  the exon 3-specific 30 mer, UKP-3 
(Fig. 1B). We investigated this lack of hybridization by  more 
detailed sequence analysis of these genes and found in each 
case that gross rearrangements have occurred. For example, 
in the case of mGK-7, continuous sequence from intron A 
through to exon 3 was obtained, showing the absence of exon 
2 to be caused by a deletion of 831 bp relative to mGK-1 
(Mason et al., 1983), beginning 19 bp upstream from the 
normal intron/exon  junction,  and ending in intron  B 175 bp 
upstream from the start of exon 3. We can exclude the 
possibility of cloning artifacts  both for this gene and for mGK- 
18, since multiple X clones gave identical restriction maps and 
showed the lack of hybridization to appropriate exon-specific 
probes. mGK-7 was also sequenced from two different X clones 
(XMSP-25 and  67).  In the case of mGK-23, hybridization to 
the entire pMK-1 probe was extremely weak compared to 
that of the neighboring mGK-16. In conjunction with the 
rearrangement observed in XMSP-55, this provides evidence 
that mGK-23 is not  a functional kallikrein gene.  We  believe 
that  the rearrangement found in mGK-17 is unlikely to rep- 
resent a cloning artifact, since the 5.6 kb BamHI fragment 
from XMSP-11  is present in mouse  genomic  DNA (Fig. IC). 
Thus, we conclude that  mGK-7,17, 18, 23, and 25 are pseu- 
dogenes. From the predicted amino acid sequences, mGK-2, 
10,12,15,19,  and 25 are also pseudogenes due to  the presence 
of in-phase  termination codons. Hence a  total of 10 mouse 
glandular kallikrein genes are unable to encode functional 
proteins. 
From the table of amino acid sequences, we have been able 
to show that mGK-13 and 22 encode EGF-binding  proteins 
(Anundi et al., 1982) and that mGK-16 encodes y-renin  (Poe 
et al., 1983). The complete sequences of these genes  will  be 
reported el~ewhere.~ mGK-5 and  9 have been sequenced and 
are found to be expressed in mouse salivary gland: while 
mGK-8 corresponds to a cDNA clone isolated from a salivary 
gland library (Fahnestock et al., 1986). The four remaining 
unidentified genes, mGK-11,14,21,  and 24, have no apparent 
rearrangements  or in-phase termination codons which would 
indicate that they were nonfunctional. From our present  data, 
we cannot rule out the possibility of mutations in exons 1, 4, 
or 5 .  In general, however, it is likely that pseudogenes under 
no selective pressure would carry at least one in-phase ter- 
mination codon within the 261 nucleotide region for which 
sequence was determined (Fig. 4). Using gene-specific oligo- 
deoxyribonucleotides derived from our sequence data, we are 
currently investigating whether mGK-11, 14, 21, and 24 are 
expressed in salivary gland or any other mouse tissues. 
DISCUSSION 
To define the genetic limits of functional diversity for the 
glandular kallikreins, we set  out to isolate the complete mul- 
tigene family from mouse.  We have identified 24 genes most 
of which  show a high  degree of homology. Although we have 
not been able to demonstrate linkage of all these genes, we 
believe that they form a single genetic locus on chromosome 
7. This proposal is supported by the work of Howles et al. 
(1984), who used a mouse y-NGF cDNA to probe genomic 
DNA  from recombinant inbred mouse lines. Like pMK-1, the 
y N G F  probe detects  all mouse kallikrein genes. The results 
of this analysis indicated that five observed EcoRI fragment 
polymorphisms between the  strains C57BL/6J and DBA/2J 
are genetically inseparable from each other and from the 
Tam-1 locus. If we compare the restriction fragments from 
these  strains with those for BALB/c mice (Fig. IC), we find 
that fragments of  7.4 and 3.4 kb are  absent in DBA/2J mice, 
which instead have unique EcoRI fragments of 2.7, 2.1, and 
1.9  kb. Although we cannot determine the exact correspond- 
ence of polymorphic fragments from the  three different 
strains, we can state  that  the genes mGK-1  and mGK-19 are 
subject to polymorphism. This means that mGK-19 is genet- 
ically linked to the 11 gene cluster containing mGK-1. In 
' C. Drinkwater, unpublished  results. 
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FIG. 4. Nucleotide sequences of the mouse glandular kalli- 
krein  genes  aligned to maximize homology. Splice  acceptor sites 
a t   the  5'  exonlintron  junctions  are boxed. 
addition, EcoRI fragments carrying the genes mGK-15 and 
17 are likely to be polymorphic and  thus linked to  the re- 
maining kallikrein genes. 
We propose that  the mouse kallikrein gene locus encom- 
passes the genetically defined loci Tam-1 (Skow, 1978), Prt- 
4, and  Prt-5  (Otto  and von Deimling, 1981). These loci are 
linked on chromosome 7, and  their gene products  share with 
characterized members of the kallikrein family the properties 
of cleavage of synthetic  esters of arginine, expression in the 
male mouse salivary gland, and induction by testosterone. It 
is possible that each of the Tam-1, Prt-4, and Prt-5 loci 
represents a particular kallikrein gene, since the products 
demonstrate  a number of biochemical differences (Otto  and 
von Deimling, 1981). Alternatively, given the occurrence of 
polymorphisms at all three loci, it may be that different 
strains of mice express a unique subset of kallikreins in the 
salivary gland which are detectable by the TAMase assay 
(Skow, 1978). For example, in BALB/c mice, the mGK-10 
gene is unable to encode a functional protein due to the 
presence of point  mutations resulting in termination codons 
(Fig. 3). However, other  strains may carry an mGK-10 gene 
which encodes a product with TAMase activity. 
To further define the mouse kallikrein family, we obtained 
sequences from exons 2  and  3 of the genes. The  data presented 
in Fig. 3 indicate that in BALB/c  mice, 10 of the kallikrein 
genes are pseudogenes, while  14  have the potential to encode 
functional proteins. Of the latter, 10 are known to be ex- 
pressed in salivary gland (Table I). If  we compare the coding 
regions of functional genes with those of strongly hybridizing 
pseudogenes such as mGK-2, 10, and 12, the nucleotide se- 
quence homologies vary between 82 and 93%. This degree of 
similarity indicates that gene conversion and unequal cross- 
ing-over events may play a role in maintaining the mouse 
kallikrein gene family. As previously noted, however, different 
kallikreins display localized regions of divergence which often 
coincide with residues important in determining substrate 
specificity (Mason et al., 1983). We suggest that gene conver- 
sion and unequal crossing-over are counterbalanced by selec- 
tion toward functional diversity. 
A corollary of this proposal is that between 10 and 14 
functional mouse kallikrein genes, if not essential for survival, 
at least confer some selective advantage. In  this  context, we 
should consider the number of kallikrein genes found in other 
mammalian species. Using hybridization kinetics, Ashley and 
MacDonald (1985) estimated that  there  are  at least eight rat 
kallikrein genes. Genomic blot analysis of DNA cleaved with 
EcoRI, BarnHI, or HindIII was found to give 7-10 cross- 
hybridizing bands. We have obtained a similar result using a 
rat probe derived from exon 4 of rGK-1, although HindIII 
digestion of rat genomic DNA gave 15 bands of varying 
intensity  (data  not  shown). As in mouse, rat kallikreins appear 
TABLE I 
Characterization of muse ghndulnr kallikrein genes - 
Potentially 
Known function Unidentified, functionai, expressed no expression Pseudogenes 
data ___ 
mGK-3  (y-N F)  mGK-1 mGK-11 mGK-2 
mGK-4  (a-N F)  mGK-5 mGK-14 mGK-7 
mGK-6  (renal  kallikrein)  mGK-8 mGK-21 mGK-10 
mGK-13  (EGF-binding  protein)"  mGK-9 mGK-24  mGK-12 
mGK-16 (y-renin) 







EGF, epidermal  growth factor. 
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to be encoded by a large multigene family. In contrast, Howles 
et al. (1984) suggested that  another rodent, the Chinese ham- 
ster, has as few as two kallikrein genes. Southern blots of 
genomic DNA were probed with the mouse y-NGF cDNA, 
which  like pMK-1 (Mason et al., 1983), may not cross-hybrid- 
ize with most hamster genes. In  our experience, mouse probes 
hybridize rather weakly to  rat kallikrein genes,  giving signals 
10- to 20-fold less intense than  the  rGK-1 probe, even though 
the overall sequence homology is at least 75%. This  appears 
to reflect the absence of regions of very high homology  which 
are seen between different kallikrein genes within a given 
species. Thus  the lack of hybridization between mouse y N G F  
and  hamster genes does not necessarily detract from the  latter 
species possessing functionally equivalent genes. 
Two different groups have used human kallikrein cDNA 
clones to probe genomic blots of human DNA (Baker and 
Shine, 1985; Fukushima et al., 1985). In both cases, only three 
bands were detected following digestion of the DNA with 
EcoRI, BamHI, and  HindIII. Although this  result should be 
clear-cut since a homologous probe was used, two lines of 
evidence indicate that  the human genome  may also contain  a 
much larger kallikrein gene family. First, when Fukushima et 
al. (1985) screened a human genomic library using a pan- 
creatic cDNA probe, they  obtained 54 positive clones.  Given 
that  the library contained 300,000 clones, sufficient to repre- 
sent 1.5  genomes, this  result is comparable to those obtained 
by us  in screening mouse libraries. Second, sequencing of one 
of these human genomic clones (hKK-3) by Fukushima  and 
co-workers showed that  it shares only 68% amino acid se- 
quence homology with the pancreatic cDNA. It is interesting 
that a human prostate-specific antigen (Watt et al., 1986), 
which is a member of the same family, shows only 60% 
homology with the renal/pancreatic kallikrein, although it 
shares 87% homology with the hKK-3 gene. Thus in the 
human genome, there is a greater divergence between kalli- 
krein genes. It is important to note that whenever we found 
a weakly hybridizing mouse kallikrein gene, it was always a 
pseudogene. In  contrast,  there  are at least two human kalli- 
krein genes which encode functional  proteins  but which  would 
hybridize relatively weakly to  the cDNA probes used. It is 
thus possible that under the more stringent conditions re- 
quired to obtain  a clear genomic blot  not all human kallikrein 
genes  would  be detected. 
In our view, the mouse and possibly rat kallikrein gene 
families are unusual, in that all members retain  a very  high 
degree of homology. Comparison of equivalent proteins from 
different species, such as  the mouse and  human renal kalli- 
kreins which  show only 61% amino acid sequence homology, 
suggests that  the homologies of 73 to 83% seen between mouse 
kallikreins are  not  essential for enzyme function. Nucleotide 
sequence homology, particularly as detected by hybridization 
experiments, may in reality represent  a poor definition of a 
multigene family. 
We  have proposed previously that  the kallikrein gene family 
may encode as many as 30 proteases involved in a wide variety 
of peptide processing pathways (Mason et al., 1983). The 
present study, however, limits the functional diversity to  just 
14 genes. It will  be important  to establish physiological roles 
for the eight apparently functional but unidentified genes in 
the mouse (Table I), and also to determine the number of 
functional genes present  in  other mammalian species. 
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The expression of many mouse kallikrein genes in the salivary
gland is sexually dimorphic and inducible in females by ad-
ministration of testosterone or thyroxine. Induction is slow
(3-7 days) and is accompanied by the non-uniform differen-
tiation of the cell type expressing these genes from striated
duct (SD) cells (female) to granular convoluted tubule (GCT)
cells (male). One kallikrein gene, mGK-6, is expressed at an
apparently constant total level in male and female and is not
induced by either hormone. In situ hybridization histochem-
istry shows that all kallikrein genes analyzed exhibit uniform
cellular distribution of expression in the SD cells of the female.
The hormonally mediated differentiation of some, but not all,
of these cells has different effects on kallikrein gene expression
- mGK-6 is repressed while other kallikreins are induced
leading to non-uniform distribution of expression.
Key words: sexual dimorphism/hormone response/kallikrein
genes
Introduction
Most studies on regulation of expression of genes from complex,
multicellular eukaryotes have been carried out on tissue culture
cell lines. These studies suffer from two major problems. Firstly,
the cell lines are clonal and do not grow in the environment of
their normal whole animal counterpart (e.g. lack cell-cell con-
tact with non-homologous cells). Secondly, analysis of gene ex-
pression is usually an average determination of a large number
of cells (e.g. nuclear run-off or RNA blot analysis) which need
not reflect the situation in individual cells. These studies assume
homogeneity of a given cell type. Previous studies using RNA
extracted from whole tissues also give results which average-
out variations in response that may occur in the different cells
present. We have attempted to overcome these problems by
analysis of expression in the cells of an experimental animal and
by the use of in situ hybridization histochemistry techniques. This
approach allows for a determination of the relative level of gene
expression in individual cells in their 'natural' cellular environ-
ment. In conjunction with RNA blot analysis to quantify changes
in expression a more complete picture of regulatory control in
vivo can be gained.
A large number of substances, including proteins encoded by
the kallikrein multigene family, have been found to exhibit sexual
dimorphism in the mouse salivary gland (Barka, 1980). Various
studies have addressed the effect of testosterone or thyroxine on
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the level of these proteins, and in general, treatment of female
mice with either of these hormones raises the level of the proteins
to (or beyond) that of the male (Barka, 1980; Chao and Margo-
lius, 1983; Catanzaro et al., 1985). We have reported previously
that the expression of some kallikrein genes exhibits this sexual
dimorphism in the salivary gland whereas expression of the renal
kallikrein gene (mGK-6) is virtually the same in both sexes (van
Leeuwen et al., 1986). The level of expression of the kallikrein
genes mGK-3 and 4 which encode the 'y- and a-subunits of nerve
growth factor (NGF), and mGK-13 which encodes an epidermal
growth factor (EGF)-associated binding protein, are 30-100
times greater in the male than in the female (van Leeuwen et
al., 1986; C.C.Drinkwater, B.A.Evans and R.I.Richards, un-
published data). This difference is similar to that of protein levels
of the kallikrein-associated growth factors, EGF and NGF,
reported for male and female salivary gland (Barka, 1980).
In this study the cellular distribution of these different genes
was further investigated using in situ hybridization histochemistry
techniques. The duct cells which express kallikrein genes appear
to comprise two distinct populations. The first expresses mGK-6
constitutively. Conversely, hormonally responsive cells turn off
expression of mGK-6 at a time when expression of the other kalli-
krein genes is induced. The latter cell type is only found in the
submandibular gland, while the former is found in the parotid
and sublingual glands in addition to the submandibular gland.
This complex distribution of different cellular phenotypes is a
major contributor to the differential response of mouse kallikrein
genes to hormonal induction.
Results
Differential response to hormone induction
To investigate the difference in expression of kallikrein genes
between male and female mice we have treated female mice with
either testosterone or thyroxine. The testosterone induction of
expression of the kallikrein genes mGK-3, 4, 5 and 6 and the
genes encoding NGF and EGF is shown in Figure 1. Dot blots
were used to compare more rigorously the total amount of each
mRNA expressed in the salivary glands. The integrity of this
RNA is apparent from the Northern blot data presented in Figure
2. Although quantitation of polyadenylated RNA by u.v. ab-
sorption was the same for each group of mice the hybridization
of the thymidine 30-mer [oligo(dT)] to the RNA blot shows
that the actual amount of polyadenylated RNA loaded was less
for the male mice. The specificity of each probe was determined
by Southern blot analysis as described by van Leeuwen et al.
(1986); no detectable cross-reactivity was observed under the
conditions of hybridization used. Total kallikrein gene expression
as measured by hybridization to the ubiquitous kallikrein 27-mer
(Materials and methods) exhibits testosterone induction of female
levels up to male levels. The expression of the growth factors
NGF and EGF, and the kallikrein genes mGK-3, 4 and 5 in
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Fig. 1. Testosterone induction of gene expression. Dot blots of polyadenylated RNA from female (9 ), testosterone-treated females (T 9) and male (0o) mice.
The amount of RNA loaded is shown at the bottom of the figure. Identical blots were hybridized to the oligo(dT) 30-mer, or an 'ubiquitous' 30-mer which
hybridizes with all of the kallikrein genes (UK), or 30-mers specific for EGF, NGF or the kallikrein genes mGK-3, 4, 5 or 6. The filter hybridized to the
oligo(dT) probe was autoradiographed for only 1 h at -70°C whereas the other filters were exposed to film for 18 h at -70°C.
ing those seen in the male. Figure 1 also shows that mGK-6 levels
are higher in the female than levels of other kallikrein genes,
that there is little difference in mGK-6 expression between the
sexes (allowing for the amount of polyadenylated RNA loaded)
and that testosterone had no apparent effect on inducing the ex-
pression of this gene.
Figure 2 shows that the administration of thyroxine to-female
mice has a similar effect on the expression of mGK-3 and pre-
proEGF (and other kallikrein and growth factor genes, data not
shown), whereas expression of mGK-6 is again unaffected. This
lack of specificity suggests that induction by either of the hor-
mones involves a general and perhaps common mechanism.
Mechanism of hormone induction
Perhaps the simplest explanation for the differential response to
hormonal induction by members of the glandular kallikrein gene
family might be the presence of hormone responsive elements
in the vicinity of hormone responsive genes (e.g. mGK-3) and
their absence from non-responsive genes (e.g. mGK-6). This cor-
relation has been previously demonstrated for the differential
response of the human metallothionein genes to glucocorticoids
(Richards et al., 1984).
Primary transcriptional responses to hormone induction are
usually rapid, reaching a maximum in - 12 h (Karin et al.,
1980). To ascertain whether testosterone acts directly on the target
genes to increase transcription we compared expression of the
kallikrein genes mGK-3 and 6, and the growth factor EGF, with
levels of tubulin at various times after testosterone treatment. The
polyadenylated RNA from salivary glands of male, female and
testosterone-treated female mice were subjected to Northern blot
analysis.
Figure 3 shows that expression of 3-tubulin stays relatively
constant during testosterone treatment. The expression of mGK-6
parallels that of tubulin whereas expression of mGK-3 and EGF
increases from barely detectable levels in the female up to levels
comparable with those measured in the male. Induction of these
genes is first apparent - 24 h after administration of testosterone,
increasing to male levels between 3 and 7 days. While these
experiments do not rule out a role for specific direct hormonal
stimulation of transcription, the slow time course, the generality
of the response and the accompanying differentiation of the re-
sponsive cells suggest that induction is probably not a primary
response (Yamamoto and Alberts, 1976).
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Fig. 2. Northern blot analysis of hormnone induction of gene expression.
Polyadenylated RNA (10 tig) from male (lanes a and d), 7-day testosterone-
treated females (lane b), control female (lanes c and f) and thyroxine-
treated female (lane e) mice were electrophoresed on 1.5% agarose gels,
transferred to nitrocellulose and probed with either the mGK-6-specific
30-mer probe (A) or a mixture of the mGK-3-specific 30-mer and the
preproEGF-specific probe (B).
Serial sections of salivary gland were also hybridized to these
30-mer probes, using in situ hybridization histochemistry, to
determine whether this induction of expression was a general ef-
fect in all cells of the salivary gland or restricted to a limited
cell population. Figures 4 and 5 show that the induction of ex-
pression appears to occur unifonnly over the whole submandibu-
lar gland with no detectable expression of the inducible genes
in the sublingual or parotid glands. In contrast the level of
hybridization to the mGK-6-specific probe decreases slightly over
the time course. The apparent discrepancy with dot-blot (Figure
1) and Northern analysis (Figures 2 and 3) may be due to the
testosterone induced increase in gland weight (-20%; Chretien,
1977). This increase is largely due to storage granules (i.e. non-
cellular material) and therefore the 5-Atm section contains a cor-
respondingly smaller percentage of cellular material. The changes
seen using hybridization histochemistry are only semi-quantitative
as the amount of hybridization depends on the thickness of the
section as well as the number and distribution of the different
cell types represented in the section (Coghlan et al., 1985).
Figure 5 also shows that there is detectable expression of mGK-
6 in the sublingual and parotid glands although at a lower total
level than in the submandibular gland. In contrast, sections probed
with the mGK-3-specific probe show expression confined to the
submandibular gland.-
Differentiation of duct cells
The effect of testosterone and thyroxine to induce differentiation
of the striated duct cells in the female salivary gland and the effect
of testosterone withdrawal (by castration) to reverse it in the male
has been well documented (Chretien, 1977). Essentially these
hormones catalyze the transition between two cellular phenotypes:
uninduced (striated duct cells) and induced (granular convoluted
Fig. 3. Northern blot analysis of time course of testosterone induction of
gene expression. A Northern blot of salivary gland RNA after hybridization
to 03-tubulin and the mGK-3 30-mer (18-h exposure shown). The blot was
then washed at 70'C for 30 min in 2 x SSC to remove these probes and
then hybridized to the pro-EGF 30-mer (18-h exposure shown) and the
mGK-6 30-mer (1-h exposure shown). Polyadenylated RNA loaded was
from untreated females ( 9), testosterone-treated females (3, 6, 9, 12, 18,
24, 48, 72 and 168 h after testosterone treatment), and miale (a') m-ice. The
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Fig. 4. In situ hybridization histochemistry over the time course of
testosterone induction. Serial salivary gland sections from untreated female
(9), testosterone-treated females (1 8 h, 40 h, 3 days and 7 days after
testosterone treatment), and male (a') mice, hybridized to the 30-mer
oligodeoxyribonucleotide probes for proEGF, mGK-3 and mGK-6. The
sections from male and 7-day testosterone-treated female mice were
overexposed in order to visualize hybridization at the early time points of
induction.
tubule cells). There is no evidence of cell replication or DNA
synthesis during this differentiation and so the alteration in the
levels of various proteins seen in these cells must be a conse-
quence of altered transcriptional activity rather than the selection
and multiplication of a clonal cell population expressing these
inducible proteins. The typical appearance of uninduced duct cells
is of centrally located nuclei and very few granules; the mito-
chondria aligned along the basal membrane of the cells gives them
their striated appearance.- In contrast the taller and wider induced
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Fig. 5. In situ hybridization histochemistry of hormone-induced salivary glands. Serial salivary gland sections of testosterone-treated females (a and d), male
(b), thyroxine-treated (c and f) and control female (e) mice probed with either the mGK-6-specific 30-mer (A) or the mGK-3-specific 30-mer (B). The
component glands from the testosterone-treated female section (a) are illustrated (C) in order to identify mGK-6 expression (and the lack of mGK-3
expression) in the sublingual and parotid glands.
cells contain many granules and their nuclei are basally located.
The latter cells normally develop out of the distal convoluted
portions of the striated ducts during the growth and development
of the male mouse (Chretien, 1977).
The morphological changes in the submandibular gland at dif-
ferent time periods after testosterone treatment are shown in
Figure 6. In the female (Figure 6a) the nuclei of the striated duct
cells have a bead-like appearance around the lumen of the duct
and a degree of cellular disorganization occurs 18 h after testos-
terone treatment (Figure 6b) which is still evident at 40 h (Figure
6c). However, after 3 days (Figure 6d) the duct cells have in-
creased in size and the nuclei are more basally located. At 7 days
(Figure 6e) the appearance of the cells is identical to the male
submandibular gland (Figure 6f) in that the duct cells have now
taken on the typical appearance of the larger granular convoluted
tubule cells with the granules looking diffuse and pink in colour.
The acinar cells now occupy much less of the total volume of
the gland.
Cell-specific expression
Figure 7 shows liquid emulsion autoradiographs of salivary gland
sections from male, female and testosterone-treated female mice
after hybridization to the probes specific for the kallikrein genes
mGK-3 and mGK-6. This figure shows that these two genes are
expressed (albeit at different levels) in the same cell types: the
granular convoluted tubule cells in the male and the striated duct
cells in the female.
In the female the striated duct cells are evenly, but weakly
labelled when the mGK-3 probe is used. The exposure time for
the female section treated with the mGK-3 probe is - 10 times
that of the other sections. The higher level of expression of
mGK-3 in males and testosterone-treated females is manifest as
an increase in the number of silver grains (mRNA molecules)
per cell. The labelling of the granules is relatively evenly dis-
tributed over all granular convoluted tubule cells in the sections.
Similar to mGK-3 in the female, of all of the striated duct cells
label with the mGK-6 probe and the density of labelling is rela-
tively consistent (but higher than mGK-3) over these cells. How-
ever, the pattern of localization of mGK-6 transcripts is different
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in the male and testosterone-treated female mice. The same mor-
phological changes seen in the sections hybridized to the mGK-3
probe are evident, but now not all duct cells have labelled with
the mGK-6 probe.
Two distinct alternatives could have given rise to this pattern
of expression. Either a small population of striated duct cells has
failed to undergo differentiation to granular convoluted tubule
cells, or differentiation was complete and is accompanied by the
inactivation of the mGK-6 gene in most but not all cells. The
morphology of the cell types in the male and treated-female ducts
appears to be consistent. However, the sublingual and parotid
glands contain mGK-6 expressing duct cells which are refractory
to hormone induction (Figure 8). In this figure it is evident that
there are two types of duct present in the male and testosterone-
induced female. Striated ducts containing only non-responsive
cells are in the minority in the submandibular gland but comprise
all secretory ducts seen in the sublingual and parotid (not shown)
glands, while granular convoluted tubules comprise mainly re-
sponsive cells and are more predominant in the submandibular
gland. This suggests that the striated duct cells of the female
mouse salivary gland comprise a mixture of hormone responsive
and non-responsive cell types. Cells that respond to testosterone
or thyroxine undergo differentiation which is accompanied by
induction of responsive genes (such as EGF, NGF and certain
kallikreins, e.g. mGK-3 and mGK-4) and inactivation of the
kallikrein gene mGK-6. Cells that do not undergo hormone-
induced differentiation continue to express mGK-6 and may in
fact increase the level of expression of this gene since the total
glandular level of mGK-6 expression does not appear to alter
as dramatically as the decrease in the number of cells expressing
this gene.
Discussion
Administration of testosterone or thyroxine to female mice causes
an increase in salivary gland levels of biologically active proteins,
including members of the glandular kallikrein family (Barka,
1980). We have previously demonstrated, by quantitative dot-
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Fig. 6. Morphological changes induced by testosterone. Four-micron paraffin sections showing morphology of submandibular gland from (A) untreated female,
(B-E) females treated with testosterone for 18, 40, 72 (3 days) and 168 h (7 days) respectively, and (F) male mice. The lumen of a single duct in each field
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Cellular control of kallikrein gene expression
Fig. 8. Expression of the mGK-6 gene in the duct cells of the submandibular and sublingual glands. Autoradiographs of 5-,um sections from mouse salivary
glands hybridized with a 32P-labelled oligodeoxyribonucleotide probe specific for mGK-6. The sections show a portion of both sublingual (upper) and
submandibular (lower) glands, delineated by open arrows. Striated ducts and granular convoluted tubules are indicated by solid, straight and curved arrows
respectively. Dark-field photomicrographs show a single field of (left panel) female, (centre panel) 7-day testosterone-treated female and (right panel) male.
Magnification x 250.
sexual dimorphism of expression. We have used the hormone ferentiation of some, but not all ot these cell
induction regimen in order to study the difference in regulation of expression of these genes.
of the closely linked and highly homologous genes mGK-3, 4,
5 and 6. Differences in expression of these genes could have been Testosterone induction of gene expression
due to a number of possible factors including differences in the In order to ascertain whether the hormones
sites of expression or hormone-responsiveness of gene transcrip- effect directly on the responsive genes via re
tion. The use of in situ hybridization histochemistry showed that actions (Karin et al., 1984) we first analy
all of these genes are expressed (albeit at different levels) in the of induction. Primary induction is usually ra
same cell type in the female but that the hormone-dependent dif- both testosterone and thyroxine induction wa
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7 days and was associated with a change in morphology of the
cells expressing the responsive genes. This change in morphology
involved differentiation of the cells rather than selective prolifera-
tion of a particular cell type. In addition the induction kinetics
of the responsive genes, including two non-kallikrein genes, ap-
peared to be identical. Taken together these results imply that
these hormones are not necessarily acting directly on the respon-
sive genes and that the induction may involve a fairly general
increase in transcription from a quiescent (SD) to an active (GCT)
state.
Expression of mGK-6
The major sites of expression of mGK-6 are the kidney, pancreas
and both male and female salivary glands, whereas the major
site of other kallikrein gene expression is the male salivary gland
(van Leeuwen et al., 1986). In addition, we have shown here
that mGK-6 expression is not induced in female mice by admin-
istration of testosterone or thyroxine as are the other genes. In
fact in certain cells, in which expression of many kallikrein genes
is induced, the expression of mGK-6 is reduced. These results
suggest that a molecular mechanism exists to regulate the ex-
pression of mGK-6 in the salivary gland in a different manner
to that of the other members of this multigene family.
The differential response of the kallikrein genes to hormones
may reflect their diverse functions: namely, kinin generation by
mGK-6 and biosynthesis of growth factors by mGK-3 and 4 (as
discussed in van Leeuwen et al., 1986). Recent experiments by
Tsutsumi et al. (1986) indicate a permissive role for salivary gland
EGF in spermiogenesis. The regulation ofEGF biosynthesis (pro-
EGF and EGF-binding proteins) by testosterone suggests that
EGF may mediate some of the stimulatory effects of this steroid
on spermiogenesis. The sexual dimorphism of expression of a
large variety of substances in salivary glands (including other
kallikrein-like proteins) may similarly contribute to further ana-
tomical and physiological differences between the sexes.
Through analysis of the cellular distribution of expression of
kallikrein genes in the mouse salivary glands we have observed
a previously undescribed complexity which can largely account
for the differential response of these genes to testosterone in-
duction. It will be important to establish the generality of this
phenomenon since models for the control of gene expression are
based on studies in clonal cell lines and may therefore not reflect
the diversity which is apparent in vivo.
Materials and methods
RNA preparation
Salivary glands were surgically removed from Balb/c mice and homogenized in
5 M guanidinium thiocyanate. RNA was extracted by centrifugation through a
CsCl cushion (Chirgwin et al., 1979) and polyadenylated RNA was isolated by
passage of total RNA over an oligo(dT)-cellulose column (Aviv and Leder, 1972).
Oligodeoxyribonucleotide probes
In order to measure total kallikrein mRNA (from all family members) an oligo-
deoxyribonucleotide complementary to a highly conserved part of kallikrein genes
(from nucleotide number 1556 to 1582 of mGK-6) was chemically synthesized
as described by van Leeuwen et al. (1986). This ubiquitous 27-mer hybridizes
to 24 of the 25 members of the mouse kallikrein gene family (C.C.Drinkwater,
B.A.Evans and R.I.Richards, unpublished results). Gene-specific 30-mers for
members of the kallikrein gene family were synthesized and tested as previously
described (van Leeuwen et al., 1986). Specific 30-mers complementary to nucleo-
tides 264-293 of mouse NGF (Scott et al., 1983a) and nucleotides 399-428
of mouse EGF (Scott et al., 1983b) were used to detect the respective mRNA
sequences (NGF - 1300, EGF -4700 bases). The oligodeoxyribonucleotides
were radioactively labelled to a specific activity of _ 108 c.p.m./4g with [-_32p]_
ATP (5000 Ci/mmol, Amersham) and T4 polynucleotide kinase (Amersham) as
previously described (van Leeuwen et al., 1986).
Dot-blot analysis
Polyadenylated RNA was denatured with formaldehyde for 10 min at 60°C by
a modification of the method of White and Bancroft (1982) as previously described
(van Leeuwen et al., 1986). Serial dilutions in 15 x SSC (1 x SSC is 0.15 M
NaCl, 0.15 M Na citrate) were dotted onto nitrocellulose using a Schleicher and
Schuell Minifold apparatus.
Northern blot analysis
Polyadenylated salivary gland RNA (10 jig) from mice killed 3, 6, 9, 12, 18,
24, 48, 72 and 144 h after testosterone treatment or after 7 days thyroxine treat-
ment was loaded onto 1% agarose gel in 2.2 M formaldehyde. After electrophor-
esis the gel was blotted onto nitrocellulose filters by the method of Thomas (1980).
Filter hybridization
After baking at 80°C for 2 h under vacuum, the nitrocellulose filters were pre-
hybridized for 3 h at 42°C in buffer containing 5 x SSC, 50 mM sodium phos-
phate, pH 6.5, 0.02% bovine serum albumin, 0.02% Ficoll, 0.05%
polyvinylpyrrolidone, 30 Ag/mr denatured calf thymus DNA, 50% formamide.
Hybridization to the labelled 30-mer oligodeoxyribonucleotides was performed
for 48 h at 4°C, blots were washed in 2 x SSC at room temperature (2 x 15 min)
and then at 60°C (30 min). Filters were exposed for autoradiography at -80°C
with intensifying screens.
To enable more accurate comparison of RNA loaded onto the dot blot from
different groups of animals, an identical blot was hybridized to a thymidine 30-mer
[oligo(dT)] probe. Because of the lower hybridization affinity of the oligo(dT)
30-mer, this hybridization was allowed to proceed for at least 72 h at 4°C, and
the filters washed at room temperature only.
(3-tubulin cDNA was used as an internal standard on the Northern blot and
was labelled by a modification of the random-primed method (van Leeuwen et
al., 1986).
Hormone treatment
For testosterone treatment adult female Balb/c mice were injected s.c. with 0.1 ml
testosterone enanthate (Primoteston Depot, Schering P/L), 5 mg/ml in sesame
oil. Mice (n = 10) were given one injection 7 days prior to sacrifice and the
salivary gland RNA prepared for dot blots. For the time course of testosterone
induction, mice were injected 3, 6, 9, 12, 18, 24, 48, 72 (3 days) and 168 h
(7 days) prior to sacrifice.
For thyroxine treatment adult female Balb/c mice (n = 6) were injected daily
i.p. with 50 Al thyroxine (Oroxine, Wellcome Australia Ltd) 0.2 mg/ml in normal
saline for a period of 7 days.
Groups of untreated female and male mice were killed at the same time as
the hormone-treated mice and their salivary glands processed identically. As the
thyroxine-treated experiment was performed at a later date a new set of untreated
mice was included for this group as control.
In situ hybridization histochemistry
Mouse salivary glands were excised, frozen in liquid propane and freeze-dried
at -450C and 5 x 10-2 Torr for 72 h. Tissues were warmed to 20°C, removed
from vacuum, fixed in paraformaldehyde vapour at 37°C for 2 h, vacuum infil-
trated with paraplast (Lancer, St Louis) for 30 min at 600C and embedded in
paraplast. Sections cut at 5 Am were floated onto submerged slides (coated with
1% gelatine hardened with 0.25% formaldehyde), allowed to dry at 40°C and
stored at -20°C. After dewaxing and three rinses in absolute ethanol, hybridiz-
ation and subsequent procedures were as described by Coghlan et al. (1985).
Tissue morphology
Mouse salivary glands were fixed at room temperature in 4% formaldehyde in
0.1 M phosphate, pH 7.2, with 9 g/l NaCl. Tissues were dehydrated and embedded
in paraffin by conventional procedures. Four-micron sections were stained with
hematoxylin and eosin.
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abstract: Previously, three proteins have been separately identified as the mouse epidermal growth factor
binding protein (EGF-BP). We have identified and sequenced the coding regions of three distinct genes
encoding these EGF-BPs from the BALB/c strain. The genes are all members of the glandular kallikrein
gene family, which encodes a highly homologous group of serine proteases. Expression of the EGF-BP genes
was detected in mouse salivary gland only and was at a relatively similar level for each gene. The isolation
of three distinct genes from the one mouse strain indicates that the conflicting data previously reported in
the literature are not a result of allelic polymorphisms or strain differences.
IV^ouse epidermal growth factor (EGF)1 ****is a 53 amino acid
protein that stimulates the proliferation and differentiation
of various mammalian cells (Carpenter & Cohen, 1979;
Schlessinger et al., 1983). The major source of mouse EGF
is the adult male salivary gland (Cohen, 1962), where it is
almost entirely found in a high molecular weight complex of
approximately 74000 (Taylor et al., 1970). This complex
consists of two molecules of mature EGF bound to two
molecules of a 29 000-dalton arginyl esterase known as the
EGF binding protein (EGF-BP). Prepro-EGF, a 130000-
dalton protein, is processed by a series of steps to a 9000-dalton
EGF precursor (Burmeister et al., 1984), which is then cleaved
at the carboxy terminus by EGF-BP to produce the mature
growth factor (Frey et al., 1979). The interaction of EGF and
its binding protein is highly specific. Although the 7-subunit
of the 7S nerve growth factor (NGF) complex is structurally
related to EGF-BP, both proteins being members of the mouse
glandular kallikrein family (Evans et al., 1987), neither it nor
trypsin has any effect on the 9000-dalton EGF precursor (Frey
et al., 1979). Likewise, EGF-BP is unable to substitute for
7-NGF in the analogous /3-NGF processing system (Server
& Shooter, 1976).
It has been reported that purification of EGF-BP from
salivary glands of adult male NMRI mice (an outbred strain)
yields two distinct polypeptides, designated EGF-BP type A
and EGF-BP type B (Anundi et al., 1982; Ronne et al., 1983).
It was not determined, however, whether these two proteins
represent alleles or are encoded by separate genes. More
recently, another protease, whose sequence differs from both
EGF-BP type A and EGF-BP type B, was reported as the only
EGF-BP purified from the high molecular weight complex in
male Swiss ICR mouse salivary glands (Isackson et al., 1987).
Furthermore, this protein was shown to be able to associate
with EGF and reconstitute the high molecular weight complex,
a property not demonstrated for either EGF-BP type A or
EGF-BP type B. For the purposes of this paper, the EGF-BP
isolated by Isackson et al. (1987) shall be referred to as
EGF-BP type C.
1 This work was supported by grants to the Howard Florey Institute
from the National Health and Medical Research Council of Australia,
the Ian Potter Foundation, and the Myer Family Trusts. C.C.D. is the
recipient of a Commonwealth Postgraduate Research Award.
* Address correspondence to this author.
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In view of these anomalies in the identity of the EGF pro-
cessing enzyme(s), we have characterized the genes encoding
the respective proteins. We have previously reported a sys-
tematic analysis of the mouse glandular kallikrein gene family,
in which 24 nonallelic genes were isolated, mapped, and
partially sequenced, thus defining the limits of functional
diversity (Evans et al., 1987). In this paper, we present the
further characterization of those members of the kallikrein
gene family that encode EGF-BP type A, type B, and type C.
The complete predicted amino acid sequences from all three
genes were compared in an effort to identify residues which
specify binding to the 9000-dalton EGF precursor. The
identification of three distinct genes in the one mouse strain
(BALB/c) indicates that the different proteins are not the
result of allelic polymorphism.
Experimental Procedures
Preparation and Isolation of Genomic Clones. Kallikrein
clones were isolated from a mouse genomic library constructed
by using the EMBL3A vector as described previously (Evans
et al., 1987).
Nucleotide Sequence Analysis. Restriction fragments of
the X clones were subcloned into M13 mp 18 or 19 (Messing,
1983) and sequenced by the chain termination method (Sanger
et al., 1977) using [a-32P]dATP and either the standard Ml3
17-mer or specific oligodeoxyribonucleotides (Evans et al.,
1987) as primers.
Oligodeoxyribonucleotides. Oligodeoxyribonucleotides
corresponding to variable regions of the DNA sequence from
coding regions of the genes mGK-9, -13, and -22, to residues
3315-3344 of the mouse prepro-EGF gene (Scott et al., 1983;
Gray et al., 1983), and to regions conserved between all the
kallikrein genes (Evans et al., 1987) were synthesized by the
solid-phase phosphoramidite procedure as previously described
(van Leeuwen et al., 1986).
Specificity of the oligodeoxyribonucleotides for mGK-9, -13,
and -22 was tested by hybridization of the probes to nitro-
cellulose filters prepared in the following manner. Two mi-
croliters each of X clones (approximately 108 PFU/mL)
containing either one or two kallikrein genes and representing
1 Abbreviations: EGF, epidermal growth factor; EGF-BP, epidermal
growth factor binding protein; NGF, nerve growth factor; 7-NGF, 7-
subunit of the 7S NGF complex; PFU, plaque-forming unit(s); kDa,
kilodalton(s).
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mGK-24 mGK-3 mGK-4 mGK-5 mGK-6
mGK-20 mGK-23 mGK-16
10Kb
figure 1: Linkage map of the mouse glandular kallikrein gene family. Genes (five exons and four introns) are denoted by solid bars, and
the arrows above each gene show the direction of transcription. The relative positions of each cluster of genes within the kallikrein locus have
not been determined [adapted from Evans et al. (1987)].
the complete gene family was spotted onto a lawn of LE392
cells and incubated at 37 °C overnight. The phage were then
transferred to 0.45-^m nitrocellulose filters and lysed, and the
DNA was denatured by the method of Maniatis et al. (1982).
The filters were washed in 2 X SSC, air-dried, and baked in
vacuo for 2 h at 80 °C. After hybridization to the oligo-
deoxyribonucleotide probe, the filters were washed in 2 X SSC
at successively increasing temperatures to determine the
uniqueness of and appropriate stringency for each probe.
mRNA Preparation and Northern Blots. Polyadenylated
RNA was isolated from mouse salivary gland, kidney, pan-
creas, brain, and testis as detailed elsewhere (van Leeuwen
et al., 1986). Ten-microgram aliquots were then denatured
in formaldehyde, electrophoresed on 1% agarose-formaldehyde
gels, and transferred to nitrocellulose as described by Maniatis
et al. (1982).
Hybridization Analysis. Oligodeoxyribonucleotide probes
were labeled at the 5' terminus using T4 polynucleotide kinase
and [y-32P] ATP by a modification (van Leeuwen et al., 1986)
of the method of Maniatis et al. (1982). Nitrocellulose filters
were prehybridized for 2-4 h at 42 °C in a solution of 5 X
SSC, 50 mM sodium phosphate, pH 6.8, 1 mM sodium py-
rophosphate, 50 pg/mL sonicated herring sperm DNA, 0.02%
bovine serum albumin, 0.02% Ficoll, 0.02% polyvinyl-
pyrrolidone), 100 juM ATP, and 20% formamide. Hybrid-
ization to the oligodeoxyribonucleotide probes was performed
at room temperature overnight, and the filters were washed
in 2 X SSC at the appropriate temperature as determined by
the specificity test described earlier. Filters were then air-dried
and exposed to Kodak X-AR film at -80 °C with intensifying
screens.
Results
Identification of the Genes Encoding EGF-BP Types A, B,
and C. A simplified map of the mouse glandular kallikrein
gene family is shown in Figure 1. Partial sequence from the
coding region of all members of the gene family has been
obtained (Evans et al., 1987). By comparing these coding
regions with partial amino acid sequences (Anundi et al., 1982;
Isackson et al., 1987), we were able to identify the genes
encoding the EGF-BPs. The complete coding sequence of each
of these genes was subsequently determined (Figure 2).
In the case of EGF-BP type A, there is only one amino acid
residue difference between the N-terminal protein sequence
(27-kDa peptide; Anundi et al., 1982) and the predicted amino
acid sequence of the gene mGK-22 (Figure 3A). No other
kallikrein gene has less than five differences from the 27-kDa
peptide sequence (Evans et al., 1987), and we suggest that the
observed difference is possibly due to polymorphism between
the different strains of mice used (outbred NMRI and inbred
BALB/c). An oligodeoxyribonucleotide complementary to
residues 1148-1174 (Figure 2a), corresponding to amino acids
19-27 of the protein sequence (Anundi et al., 1982), was
subsequently synthesized and used to screen the complete
kallikrein gene family. Only mGK-22 hybridized to this probe
at the relatively low washing stringency of 37 °C (Figure 4),
further supporting its designation as the gene encoding
EGF-BP type A. The nucleotide sequence of the coding re-
gions of the gene was determined, as well as 541 base pairs
of 5' flanking DNA (Figure 2a).
An oligodeoxyribonucleotide complementary to nucleotide
residues 334-363 of an EGF-BP type B cDNA clone (Lund-
gren et al., 1984) was synthesized and used to screen an array
of X clones representing the complete mouse glandular kal-
likrein gene family. When washed in 2 X SSC at 60 °C, only
one gene, mGK-13, remained bound to the probe (Figure 4).
The five exons of this gene were subsequently sequenced, as
well as 362 base pairs of 5' flanking DNA (Figure 2b).
Comparison of the predicted amino acid sequence of mGK-13
with the N-terminal sequence of EGF-BP type B (17-kDa
peptide; Anundi et al., 1982) showed only one amino acid
difference (Figure 3). All other kallikrein genes have three
or more differences from the 17-kDa peptide sequence (Evans
et al., 1987). Although mGK-13 differs at 11 nucleotide
residues from the EGF-BP type B cDNA clone determined
by Lundgren et al. (1984), homology between the gene and
the cDNA is 99%, which is significantly greater than that
between any two members of the kallikrein gene family
(80-90%). We again assume that these changes are a result
of polymorphic strain differences.
The gene mGK-9 was identified as encoding EGF-BP type
C by comparison of the protein sequence (Isackson et al., 1987)
with the predicted amino acid sequences of the kallikrein genes.
The nucleotide sequence of the coding regions and 505 base
pairs of 5' flanking DNA was determined (Figure 2c). The
sequence of mGK-9 is virtually identical with a cDNA clone
for EGF-BP type C (Blaber et al., 1987) with four nucleotide
changes, two in the 5' untranslated region and two in the 3'
untranslated region. An oligodeoxyribonucleotide corre-
sponding to nucleotides 2277-2306 was synthesized and proved
specific to the gene when washed in 2 X SSC at 25 °C (Figure
4).
Structure of the Genes. The exon-intron boundaries of
mGK-9, -13, and -22 are identical with those of all other
members of the kallikrein gene family (Evans et al., 1987).
All three genes have the variant 5'-TTTAAA-3' box typical
to kallikrein promoter regions (Mason et al., 1983; Evans &
Richards, 1985; van Leeuwen et al., 1986) and polyadenylation
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figure 2: Sequence of the EGF-BP genes. The nucleotide and encoded amino acid sequences of the EGF-BP type A [(a) mGK-22], EGF-BP
type B [(b) mGK-13], and EGF-BP type C [(c) mGK-9] genes are shown. Numbers to the right refer to nucleotide residues. The splice sites
around each exon and the initiation and termination codons are boxed. The coding sequences refer to the position relative to the N-terminal
isoleucine (a, c) or valine (b) of the mature proteins. Asterisks denote the first residue of the zymogen peptides, and the amino acids preceding
this constitute the signal peptides. The variant TATA boxes (Corden et al., 1980) and the polyadenylation signals (Proudfoot & Brownlee,
1976) are underlined. Putative transcription initiation sites are shown by arrows, and the triangles indicate the transcription termination site
(Mason et al., 1983).
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figure 3: Comparison of EGF-BP amino acid sequences. (A) The
deduced amino acid sequences of mGK-22 and mGK-13 are compared
to the 27-kDa peptide fragment of EGF-BP type A and the 17-kDa
peptide fragment of EGF-BP type B as determined by Anundi et al.
(1982). (B) The deduced amino acid sequences of mGK-9 and -13
are compared to the 6- and 10-kDa B fragments of Anundi et al.
(1982). Asterisks denote differences between residues.
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figure 4: Specificity of the synthetic oligodeoxyribonucleotide probes.
DNA from X clones containing all the kallikrein genes was transferred
to nitrocellulose filters. These were hybridized to (A) the mGK-22
27-mer, (B) the mGK-13 30-mer, and (C) the mGK-9 30-mer and
washed in 2 X SSC at the temperatures shown. The X clones contain
the kallikrein genes: (1) mGK-7 and -8; (2) mGK-8 and -2; (3)
mGK-8, -2, and -1; (4) mGK-2 and -1; (5) mGK-1 and -9; (6)
mG K-9; (7) mGK-10; (8) mGK-11 and -12; (9) mGK-12 and -13;
(10) mGK-13; (11) mGK-3 and -4; (12) mGK-4; (13) mGK-4 and
-5; (14) mGK-5 and -6; (15) mGK-6; (16) mGK-14; (17) mGK-15;
(18) mGK-16 and -23; (19) mGK-17; (20) mGK-18; (21) mGK-19;
(22) mGK-21 and -22; (23) mGK-22. Clones containing mGK-24
and -25 were tested separately by Southern blotting and showed no
hybridization to any of the probes.
signals (Proudfoot & Brownlee, 1976) in the 3' untranslated
region. Exon three of mGK-22 is 6 base pairs shorter than
the other kallikrein genes, with the resultant deletion of two
amino acid residues from EGF-BP type A occurring within
the region referred to as the autolysis loop (Tschesche et al.,
1979). Four amino acids are removed from this region of
7-NGF (Thomas et al., 1981). This cleavage step is not
thought necessary for protease activity, since other members
of this homologous family, such as mouse renal kallikrein, are
active in a 27 000-dalton single-chain form (Bothwell et al.,
1979). Thus, the structure of this region is not crucial to the











figure 5: Expression of EGF-BP genes in mouse tissues. Northern
blots were prepared from 10 »ig of polyadenylated RNA from mouse
male (lane I) and female (lane 2) salivary glands, male kidney (lane
3). pancreas (lane 4), brain (lane 5), and testis (lane 6). Blots were
hybridized to the pro-EGF 30-mer, mGK-22 27-mer, mGK-13 30-mer,
mGK-9 30-mer, and mGK-6 30-mcr (van Leeuwen et al., 1986). Sizes
of the mRNA bands are shown on the right. Hybridization conditions
for all blots were as detailed under Experimental Procedures, with
washes in 2 X SSC at 60 °C. Tracks containing male salivary gland
mRNA hybridized to mGK-9, -13, and -22 were exposed for 5 h, while
the remaining five tracks in each case were exposed for 30 h in order
to detect any low levels of hybridization.
function of the resultant serine protease, and the absence of
two amino acids should not affect the activity of EGF-BP type
A.
Expression of the EGF-BP Genes in Mouse. For production
of mature EGF, there must be coordinate expression of the
prepro-EGF and EGF-BP genes. Though prepro-EGF mRNA
synthesis has been described in a number of tissues (Rail et
al., 1985), processed EGF has only been isolated from adult
mouse salivary gland (Cohen, 1962), implying that EGF-BP
is only expressed in this tissue. Consequently, we analyzed
the expression profiles of the three EGF-BP genes in an at-
tempt to resolve the discrepancies in the reported identity of
the protein. If any of the genes were inappropriately expressed
in tissues other than salivary gland, we could then infer that
the resultant gene product is not the specific EGF-processing
enzyme. Northern blots of mRNA from mouse salivary
glands, kidney, pancreas, brain, and testis were screened with
the gene-specific oligodeoxyribonucleotide probes. 30-mers
specific for the prepro-EGF gene and the renal kallikrein gene,
mGK-6 (van Leeuwen et al., 1986), were also used to probe
the RNA blots (Figure 5). Expression of the EGF gene was
detected in salivary gland and kidney, whereas all three
EGF-BP genes were only expressed in salivary gland. This
is in contrast to another member of the family, renal kallikrein,
which was expressed in salivary gland, kidney, and pancreas.
Levels of expression of each of the EGF-BP genes in the mouse
salivary gland were investigated. From RNA blot analysis,
each of the genes appears to be expressed at a similar level.
However, the isolation of clones from a cDNA library, using
the gene-specific oligodeoxyribonucleotide probes, showed that
EGF-BP type B mRNA is about twice as abundant as that
of type A or type C (type A, 8 clones; type B, 14 clones; type
C, 8 clones2). Expression of both EGF and the binding
2 Catherine C. Drinkwater, unpublished results.
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proteins in the salivary glands is sexually dimorphic; however,
no difference in the expression of EGF between male and
female kidney is detected.2
Discussion
Confusion has surrounded the identity of mouse EGF-BP,
with three separate proteins being purified from different
strains, namely, EGF-BP type A and type B (Anundi et al.,
1982) and the protein we have designated EGF-BP type C
(Isackson et al., 1987). In this study, we have identified three
distinct members of the mouse glandular kallikrein gene family
that encode these proteins.
Comparison of the N-terminal amino acid sequence of
EGF-BP type A and type B (Anundi et al., 1982) with the
predicted amino acid sequence of the corresponding genes,
mGK-22 and mGK-13, shows only one amino acid residue
difference in each case. These differences may be due to strain
polymorphism, as we have assumed, or to errors in amino acid
assignment. In this regard, it is worth noting that each of the
discrepancies corresponds to the analogous residue in the se-
quence of the copurified peptide (Figure 3A). Anundi et al.
(1982) reported additional amino acid sequence data from both
an internal peptide (6 kDa) and a heterogeneous C-terminal
fragment (10 kDa B). The sequence of the 6-kDa peptide
shows significant differences from a cDNA sequence for
EGF-BP type B reported by Lundgren et al. (1984) in the
same laboratory and from our EGF-BP type A sequence.
However, the sequence is identical with that encoded by
mGK-9 (Figure 3B). Furthermore, the heterogeneous C-
terminal peptide appears to be a mixture of EGF-BP type B
and type C, not, as claimed, type A. Again, most of the
differences between the protein sequence and the predicted
amino acid sequence correspond to the analogous residue in
the copurified protein (Figure 3B).
The genes mGK-9 (EGF-BP type C) and mGK-13 (EGF-
BP type B) are separated by 2 pseudogenes and 1 potentially
functional gene in a group of 11 linked kallikrein genes [see
Figure 1 and Evans et al. (1987)]. Though mGK-22 (EGF-BP
type A) is not directly linked to mGK-9 or -13, its gene product
is only 11% homologous to either of their gene products. This
falls well within the normal range of homology between
members of the mouse glandular kallikrein family (70-90%);
accordingly, mGK-22 is not an allele of either mGK-9 or
mGK-13. Furthermore, mGK-22 is linked to another kalli-
krein gene, mGK-21, whose sequence homology to either
mGK-1 or mGK-12, the genes adjacent to mGK-9 and -13,
respectively, is no greater than normal. Therefore, though two
of the three proteins described as EGF-BPs were identified
in a different mouse strain than the third, all three are actually
encoded by nonallelic genes in the BALB/c strain.
We have previously isolated and partially sequenced 24
glandular kallikrein genes, forming a single genetic locus on
chromosome 7 in the mouse (Evans et al., 1987). Sequence
and expression data obtained indicate that in BALB/c mice
there are at least 10 genes that are expressed in the salivary
gland, in addition to 10 pseudogenes and another 4 genes that
have the potential to encode functional proteins. All members
of the gene family exhibit a high degree of homology, though
they contain localized regions of variability. These divergent
regions often contain residues thought to be involved in the
formation of the substrate binding site, which may therefore
be important in determining substrate specificity (Mason et
al., 1983). A comparison of these regions in the EGF-BP genes
could therefore establish which residues may be important in
binding the 9000-dalton EGF precursor. Consequently, we
sequenced the entire coding region of each gene and deter-
mined the structure of the proteins they encode.
All three genes encode the histidine, serine, and aspartate
residues essential for the formation of a serine protease cat-
alytic site (Young et al., 1978) as well as the aspartate residue
required for cleavage at basic amino acids (Krieger et al.,
1974). No residues were observed to be identical between the
three proteins, apart from those in regions conserved between
the majority of the kallikreins. Thus, there are no primary
structural similarities between the three EGF-BPs which would
indicate residues that are important in specifying the binding
of the 9000-dalton EGF precursor to the enzyme(s). Blaber
et al. (1987) have postulated that the amino acid residue at
position 215 is important for specificity. This residue, however,
is different in all three genes, being Lys in mGK-9, Ala in
mGK-22, and Val in mGK-13.
The 5' flanking regions of mGK-9, -13, and -22 were also
compared to each other and to mGK-1 (Mason et al., 1983),
mGK-3 and -4 (Evans & Richards, 1985), and mGK-52 and
mGK-6 (van Leeuwen et al., 1986). Again there were no
obvious similarities which could be implicated in regulation
of the three genes, and the only changes from the other kal-
likrein genes consisted of point mutations and single base
insertions and deletions (data not shown).
We had previously shown that, as well as in salivary glands,
there are kallikrein genes expressed in mouse kidney, pancreas,
brain, liver, testis, and spleen (van Leeuwen et al., 1986). To
further characterize the EGF-BP genes, we examined their
expression in various tissues. While the prepro-EGF gene is
expressed in salivary gland and kidney, mGK-9, -13, and -22
are only expressed in the salivary glands. Immunologically
reactive forms of EGF and prepro-EGF mRNA have been
detected in several tissues (Byyny et al., 1972; Rail et al.,
1985); however, mature EGF as determined by bioassay has
only been isolated from salivary glands in the mouse (Cohen,
1962). Thus, even though another member of the mouse
glandular kallikrein gene family (mGK-6) is expressed in
kidney, this enzyme is not able to process pro-EGF. In the
mouse, biologically active EGF is only found where the
EGF-BP genes are expressed. All three genes appear to be
expressed in relatively similar amounts.
The most obvious explanation of the differing reports on the
identity of EGF-BP is that it comprises a mixture of three
proteins—type A, type B, and type C, encoded by the genes
mGK-22, -13, and -9, respectively. All three proteins appear
to be present in the EGF-BP mixture isolated and partially
sequenced by Anundi et al. (1982). As yet, we have no means
of differentiating whether one, two, or all of the binding
proteins are directly involved in the cleavage of mouse EGF.
The stoichiometry of the high molecular weight complex (two
molecules of EGF/two molecules of EGF-BP) precludes the
combined interaction of all three binding proteins with the
substrate. Thus, it may be that each protein is capable of
acting as an EGF-processing enzyme. This apparent redun-
dancy is somewhat surprising, given the high substrate spe-
cificity of other members of the mouse glandular kallikrein
family. For example, y-NGF cannot process the 9000-dalton
EGF precursor (Frey et al., 1979), yet is no more divergent
from the EGF-BPs than type A, type B, and type C are from
each other. Were all three proteins active, this redundancy
could account in part for the observed variation in the number
of kallikrein genes between different species (Evans et al.,
1987). Expression of the EGF-BP genes in cultured cell lines
would permit the elucidation of the exact role of their products.
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The mouse glandular kallikrein gene, mGK-5, is expressed in salivary
glands in a sexually dimorphic fashion (1). This is in contrast to the
neighbouring gene, mGK-6, which encodes renal kallikrein, or kininogenase,
and is expressed at equal levels in salivary glands of both sexes (1,2).
Nucleotide sequence from the five exons and 607 bp of 5' flanking DNA from
mGK-5 was determined by the enzymatic method (3). mGK-5 and mGK-6 are the
most closely related of the mouse glandular kallikrein genes, being 95%
homologous. Exon-intron boundaries of mGK-5 (boxed) are identical to those of
all other mouse glandular kallikrein genes (4). The gene also has the variant
5'-TTTAAA-3' box typical to kallikrein promoter regions and a normal poly-
adenylation signal (5, both underlined). By analogy with mGK-6 (2), the
protein encoded by mGK-5 (numbers in italics, Ile-l arrowed) has a hydropho-
bic signal sequence (-24 to -8) followed by a zymogen peptide (-7 to -1). The
mature protein is 237 amino acids long and contains residues essential to an
active serine protease. His-41, Asp-96 and Ser-189 form the charge-relay sys-
tem (6), whilst Asp-183 is believed to direct cleavage at basic residues (7).
mGK-5 expression was examined in several mouse tissues but only detected in
salivary gland (not shown). Since mGK-5 and mGK-6 are regulated differently
(1) their 5' flanking regions were compared. No differences apart from single
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ABSTRACT: Glandular kallikreins are a family of proteases encoded by a variable number of genes in different 
mammalian species. In all species examined, however, one particular kallikrein is functionally conserved 
in its capacity to release the vasoactive peptide, Lys-bradykinin, from low molecular weight kininogen. This 
kallikrein is found in the kidney, pancreas, and salivary gland, showing a unique pattern of tissue-specific 
expression relative to other members of the family. We have isolated a genomic clone carrying the human 
renal kallikrein gene and compared the nucleotide sequence of its promoter region with those of the mouse 
renal kallikrein gene and another mouse kallikrein gene expressed in a distinct cell type. We find four sequence 
elements conserved between renal kallikrein genes from the two species. We have also shown that the human 
gene is localized to 19q13, a position analogous to that of the kallikrein gene family on mouse chromosome 
7. 
Glandu la r  kallikreins are a subgroup of the serine protease 
family that, unlike trypsin, demonstrate a high degree of 
substrate specificity. This property, in addition to the finding 
of a large multigene family in the mouse, led to the suggestion 
that different kallikreins may play diverse roles in the pro- 
teolytic activation of peptide hormones and growth factors 
(Bothwell et al., 1979; Schachter, 1980; Powers & Nasjletti, 
1982; Mason et al., 1983). The major kallikrein found in all 
mammalian species cleaves the precursor kininogen to generate 
Lys-bradykinin, a vasoactive peptide (Schachter, 1980). In 
the mouse, several members of the family expressed in male 
salivary gland appear to be involved in the processing of nerve 
growth factor (Berger & Shooter, 1977) and epidermal growth 
factor (Frey et al., 1979). A general role for kallikreins in 
the specific processing of a range of growth factors seems 
unlikely, however, since the size of the gene family encoding 
these enzymes varies widely between different mammalian 
species. 
The mouse carries an extensive multigene family, with 12 
functional kallikrein genes and a further 12 pseudogenes 
(Evans et al., 1987; Drinkwater, 1987). A similar family of 
15-20 kallikrein genes is found in the rat, where at least 4 
genes are known to be expressed (Gerald et al., 1986; Ashley 
& MacDonald, 1985). In both rodent species, members of 
the kallikrein family are sufficiently homologous that a given 
gene cross-hybridizes with all other genes to a similar extent 
(Evans et al., 1987). On the other hand, genomic blot analysis 
of human DNA using a human renal kallikrein cDNA probe 
gives only three distinct bands (Fukushima et al., 1985; Baker 
'This work was supported by grants to the Howard Florey Institute 
from the National Health and Medical Research Council of Australia, 
the Ian Potter Foundation, and the Myer Family Trusts. 
* Correspondence should be addressed to this author. 
f University of Melbourne. 
5 Kyoto University Faculty of Medicine. 
Adelaide Children's Hospital. 
& Shine, 1985). If there are more than three human kallikrein 
genes, they are far less conserved than those in mouse and rat. 
Despite the large number of functional kallikreins in the 
mouse, only two patterns of gene expression are observed. A 
single gene, mGK-6, encoding the major kininogenase, is ex- 
pressed in kidney, pancreas, and both the submandibular and 
parotid glands (van Leeuwen et al., 1986). Interestingly, this 
gene is also expressed in the pituitary-derived mouse cell line, 
AtT20 (Herbert et al., 1984). Expression of the remaining 
11 kallikrein genes appears to be confined in adult mice to the 
male submandibular gland, with little or no expression in 
female salivary glands or in other tissues (Drinkwater, 1987). 
Within the submandibular gland, expression of mGK-6 occurs 
in a different cell type to that of the other kallikrein genes (van 
Leeuwen et al., 1987). 
As in the mouse, the major human kininogenase, referred 
to here as renal kallikrein, is identical with the enzyme present 
in pancreas and salivary gland (Fukushima et al., 1985; Baker 
& Shine, 1985). A second member of the human kallikrein 
family is found only in the prostate gland (Watt et al., 1986; 
Stamey et al., 1987; Lundwall & Lilja, 1987); Two other 
human genomic sequences, hKK-3 (Fukushima et al., 1985) 
and hGK-1 (Schedlich et al., 1987), show 95% amino acid 
sequence homology and may represent polymorphic variants 
of a single gene. The expression of hKK-3 or hGK-1 has not 
been demonstrated in any human tissue. 
To examine mechanisms behind the distinct patterns of 
tissue-specific expression, we have identified a genomic clone 
carrying the human renal kallikrein gene and determined its 
nucleotide sequence. This allows comparison of the promoter 
regions of the mouse (van Leeuwen et al., 1986) and human 
renal kallikrein genes, which show equivalent expression, with 
that of a related mouse gene (mGK-1; Mason et al., 1983), 
which is expressed in a distinct cell type. We have further 
characterized the human renal kallikrein gene by determining 
its chromosomal localization. 
0006-2960/88/0427-3124$01.50/0 0 1988 American Chemical Society 
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MATERIALS AND METHODS 
Screening of a Human Parotid Gland cDNA Library. 
Poly(A) RNA was isolated from human parotid gland ac- 
cording to the procedures of Chirgwin et al. (1979) and Aviv 
and Leder (1972). A cDNA library of 50000 clones in the 
Agt10 vector was constructed as described by van Leeuwen 
et al. (1 986). The library was screened with an oligodeoxy- 
ribonucleotide probe (HK-1) designed to detect all human 
kallikrein genes. The probe corresponds to amino acids 85-107 
predicted from the renal kallikrein cDNA (Fukushima et al., 
1985). All oligodeoxyribonucleotide probes were synthesized 
in an Applied Biosystems Inc. Model 380A DNA synthesizer 
and purified by polyacrylamide gel electrophoresis. 
Identification of the Human Renal Kallikrein Gene. The 
probe used (HRK-1) was a 30-mer corresponding to amino 
acids 142-151 of human renal kallikrein (Fukushima et al., 
1985). The oligodeoxyribonucleotide was labeled with T4 
polynucleotide kinase (Pharmacia) and [y3*P] ATP (Am- 
ersham Corp.). 
Phage suspensions (1 pL) corresponding to 54 kallikrein- 
positive genomic clones (Fukushima et al., 1985) were spotted 
onto a lawn of LE392 cells and incubated at 37 OC overnight. 
Phage DNA was transferred to nitrocellulose, and the filters 
were prehybridized at 42 OC for 4 h in the 20% formamide 
buffer described by Ullrich et al. (1984). Following addition 
of the probe, hybridization was continued overnight at 42 OC; 
then the filters were washed in 2 X standard saline citrate at 
60 OC and exposed at -80 OC with intensifying screens to 
Kodak XAR-5 film. 
Restriction Mapping and Nucleotide Sequencing. Phage 
DNA from the genomic clone AHGK-43 was digested with 
a range of restriction enzymes (Pharmacia; see Figure l), the 
fragments were separated on 0.9% agarose gels, and the DNA 
was transferred to nitrocellulose filters by the method of 
Southern (1975). The filters were hybridized as described 
above with either oligodeoxyribonucleotide probes or insert 
DNA from the human kallikrein cDNA labeled with random 
primers (van Leeuwen et al., 1986) and [ ~ x - ~ ~ P I ~ C T P  ( B r a ) .  
Oligodeoxyribonucleotide probes used were HRK-1 (exon 4), 
HKElB, a 20-mer complementary to the region in exon 1 
corresponding to amino acids 10-16 of the signal peptide 
(Fukushima et al., 1985; see Figure 2), and HKE2B, a 20-mer 
complementary to the exon 2 sequence encoding amino acids 
34-40 of human renal kallikrein (Fukushima et al., 1985). The 
exon positions of HRK-1, HKElB, and HKE2B were pre- 
dicted from the known organization of mouse kallikrein genes. 
Templates for nucleotide sequencing were prepared by 
subcloning the cDNA insert or fragments from AHGK-43 into 
the M13 vectors mp18 and mp19 (Yanisch-Perron et al., 
1985). DNA was sequenced by the chain termination method 
(Sanger et al., 1977). 
Primer Extension Analysis. The oligodeoxyribonucleotide 
HKE2B was labeled at the 5' end as described above; then 2 
ng was hybridized for 1 h at 50 OC with 2.5 pg of poly(A) 
RNA from human parotid gland. The hybridization buffer 
and primer extension reaction were as described by Bodner 
and Karin (1 987). Products were electrophoresed on a 7 M 
urea/6% polyacrylamide sequencing gel. 
Chromosomal Localization of the Human Renal Kallikrein 
Gene. We mapped the renal kallikrein gene by two methods, 
both using insert DNA from the parotid gland cDNA clone 
described under Results. First, the cDNA was labeled with 
[ C Y - ~ ~ P ] ~ C T P  and hybridized to Southern transfers of TaqI- 
digested DNA from a series of mouse/human hybrid cells 
(Callen, 1986) and from normal human leukocytes as controls. 
5' - 3' 
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FIGURE 1: Restriction map and transcription initiation site of the 
human renal kallikrein gene. (A) The genomic clone XHGK-43 was 
mapped with the enzymes BumHI (B), BglII (BG), XbaI (X), and 
Hid111 (H); then subclones were characterized with the enzymes 
shown. The direction of transcription is shown by an arrow, and exons 
are numbered. (B) The 20-mer HKE2B (Y-AGCAGCTG- 
TGAGCACCCACT-3') was annealed to 2.5 pg of poly(A) RNA from 
human parotid gland, at 50 OC for 1 h. Following primer extension, 
the products (lane 2) were electrophoresed on a denaturing 6% po- 
lyacrylamide gel. Markers (lane l )  are end-labeled HpuII fragments 
of pBR322. 
Details of the methods and the human chromosomes present 
in the hybrid cells are given in Sutherland et al. (1988). 
Second, the cDNA probe was tritium labeled to a specific 
activity of approximately 6.5 X lo7 cpm/pg and hybridized 
at a concentration of 0.2 pg/mL to metaphases from two 
normal males. The autoradiographic emulsion was developed 
after 20 days of exposure. 
REsULTs 
Screening of a human parotid gland cDNA library with the 
oligodeoxyribonucleotide HK- 1 gave six overlapping clones 
corresponding to a single mRNA species. One of these clones 
spanned amino acids 79-238 and was found to be identical 
in nucleotide sequence (data not shown) with the pancreatic 
and renal kallikrein cDNAs (Fukushima et al., 1985; Baker 
& Shine, 1985), with one exception. The glutamate at position 
162 predicted by the latter sequences is replaced by a lysine, 
due to a change in codon from GAA to AAA. The virtual 
identity of cDNA clones from the three different tissues, 
however, confirms the previous observation that these kalli- 
kreins are encoded by a single human gene (Fukushima et al., 
1985). 
In order to isolate this gene, we reexamined 54 positive 
clones obtained by screening a human genomic library with 
the rat pancreatic kallikrein cDNA probe, prKK1 (Fukushima 
et al., 1985). We designed an oligodeoxyribonucleotide probe 
(HRK-1) based on a region of the human cDNA (Fukushima 
et al., 1985) showing low amino acid sequence homology with 
human prostate antigen (Watt et al., 1986). One of the 54 
kallikrein-positive clones, AHGK-43, gave strong hybridization 
with this probe and was examined further by restriction 
mapping (Figure 1 A) and nucleotide sequence analysis (Figure 
These data confirm that AHGK-43 carries the human renal 
kallikrein gene. The gene consists of five exons, with coding 
2). 
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FIGURE 2: Nucleotide sequence of the human kallikrein gene. The sequence of the sense strand is shown. Numbers at the end of each line 
refer to nucleotides, while those above the amino acid sequence give the position relative to the N-terminal isoleucine of mature renal kallikrein. 
The alanine marked with an asterisk is the first amino acid of the zymogen peptide (Evans & Richards, 1985). The CATCT and TTTAAA 
boxes are overlined, and the polyadenylation signal AGTAAA is underlined. The major transcription initiation site determined by primer 
extension (Figure 1B) is marked with an arrow, and triangles show the beginning and end of the pancreatic kallikrein cDNA clone described 
by Fukushima et al. (1985). 
regions interrupted in positions identical with those observed 
in the mouse renal kallikrein gene, mGK-6 (van Leeuwen et 
al., 1986), all other mouse kallikrein genes analyzed (Evans 
et al., 1987), and the human gene hGK-1 (Schedlich et al., 
1987). The exon sequences of the human renal kallikrein gene 
are identical with those reported for the pancreatic and renal 
cDNA clones (Fukushima et al., 1985; Baker & Shine, 1985), 
except that the same change to lysine at position 162 occurs 
in the gene as in the salivary gland cDNA. This discrepancy 
is somewhat surprising, given that not even silent nucleotide 
changes are seen in the remainder of the coding region. The 
transition to lysine, however, is conservative in the sense that 
a charged residue is retained and is unlikely to affect the 
overall structure or function of the active protein since amino 
acid 162 is found on the surface of the molecule (Bode et al., 
1983; Chen & Bode, 1983). It is thus possible that position 
162 represents a common polymorphic site in the human 
kallikrein gene. 
Sequences flanking exons 1 and 5 of the kallikrein gene 
include the signals required for eukaryote gene expression 
(Figure 2). The 3' untranslated region contains the variant 
polyadenylation signal, AGTAAA, observed in the full-length 
cDNA of Fukushima et al. (1985). No other possible poly- 
adenylation signal is seen in a further 380 nucleotides of 
flanking DNA. The 5' flanking region contains the element 
CATCT (Benoist et al., 1980) as well as the variant TTTAAA 
box seen in mouse kallikrein genes (Mason et al., 1983; Evans 
& Richards, 1985). 
We carried out primer extension analysis to determine the 
cap site for the human renal kallikrein gene (Figure 1B). 
Using parotid gland poly(A) RNA as the template, we ob- 
tained a major band corresponding to the A residue marked 
in Figure 2. There is a second minor band resulting from a 
transcription product that is shorter by two nucleotides; how- 
ever, it is unclear whether this is due to heterogeneity in the 
5' ends of kallikrein mRNAs or simply represents premature 
termination of the reverse transcriptase reaction. The pan- 
creatic cDNA clone isolated by Fukushima et al. (1985) begins 
a further nucleotide downstream, at the T residue marked in 
Figure 2. It seems most likely that the sequence AGTTCC 
represents a single transcription start site in both pancreas and 
salivary gland. This sequence is repeated 8 base pairs (bp) 
upstream, but there is no corresponding band observed in the 
primer extension experiment. The finding of a single cap site 
is in contrast to the mouse kallikrein gene, mGK-1, where both 
homologues of a similar repeated element, AGCTC, are in- 
volved in transcription initiation (Mason et al., 1983). In this 
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FIGURE 3: Conserved elements in the promoters of the human and mouse renal kallikrein genes. Parts A-C show graphic displays derived 
from the DIAGON program of the Staden database system (Staden, 1982; Melbourne University version modified by Dr. A. Kyne, Walter and 
Eliza Hall Institute of Medical Research, Melbourne). The parameters used were a span length of 15 and a proportional matching score of 
11. Numbers below each diagram refer to nucleotide position relative to the transcription start site. The region between the asterisk (diagram 
A) and the transcription start site is required for expression of mGK-6. The nucleotide sequences corresponding to elements I-IV (diagram 
A) for each of the three genes are shown in part D, with matches indicated by colons. hRKALL, human renal kallikrein gene; mGK-6, mouse 
renal kallikrein gene; mGK-1, a mouse kallikrein gene expressed only in submandibular gland. 
TTTAAA, whereas in the human gene, the first of the repeated 
elements is only 14 bp downstream from the TTTAAA box 
while the second element is 22 bp downstream. 
To identify conserved elements that may determine the 
tissue-specific expression of renal kallikrein genes, we have 
compared the promoter of the human gene with those of mouse 
kallikrein genes that have similar (mGK-6) or distinct 
(mGK-1) expression phenotypes. Diagrams of the dot matrix 
obtained by comparison of 870 bp of the 5‘ flanking region 
plus exon 1 from each pair of genes are shown in Figure 3. 
All three genes show extensive homology in the vicinity of the 
CATCT and TTTAAA boxes. If we consider the mouse and 
human renal kallikrein genes, there are an additional four 
distinct regions of homology upstream from the CATCT box 
(elements I-IV, Figure 3A). A comparison of the human renal 
kallikrein gene with mGK-1, on the other hand, indicates very 
little homology between nucleotides -400 and -100 (Figure 
3B). The actual sequences of the four elements in the renal 
kallikrein genes and mGK-1 are shown in Figure 3D. Ele- 
ments I and IV require gaps for optimal alignment between 
the human kallikrein gene and mGK-6, whereas elements I1 
and I11 show either perfect homology or differences involving 
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Chromosomes 
FIGURE 4: Distribution of silver grains over chromosomes in 40 metaphases after in situ hybridization with the salivary gland kallikrein cDNA 
probe. 
purine to purine or pyrimidine to pyrimidine changes. In all 
four cases, the homology of the human kallikrein gene with 
mGK-6 is clearly greater than with mGK- 1. Also, despite the 
overall similarity between the two mouse promoters (Figure 
3C), the four elements show greater homology between the 
human renal kallikrein gene and mGK-6 than between mGK-6 
and mGK-1. 
We have examined the chromosomal localization and en- 
vironment of the human renal kallikrein gene. First, the 
genomic clone XHGK-43 carries 8.1 kb of 5’ flanking DNA 
and 3.2 kb of 3‘ flanking DNA, neither region showing any 
evidence of another kallikrein gene. The long intergenic region 
5’ to the human gene contrasts with the mouse, where the renal 
kallikrein gene mGK-6 is located only 4.5 kb downstream from 
another gene, mGK-5 (van Leeuwen et al., 1986). 
The salivary gland kallikrein cDNA was used for Southern 
blot analysis of a panel of mouse-human hybrid cell lines 
carrying human chromosomes 1, 3, 4, 7, 8, 10, 12, 13, 16, 17, 
20, 21, 22, X, and llpter-llql4 (Sutherland et al., 1988). 
Whereas total human DNA digested with TuqI gave bands 
at 3.1, 0.8, and 0.5 kb, none of the hybrid cell lines showed 
any signal (data not shown). This result excludes the renal 
kallikrein gene from the above chromosomes. The in situ 
hybridization results (Figure 4) show that from 40 metaphases 
on which there were 237 silver grains, 34 (16.7%) were on the 
long arm of chromosome 19. The presence of silver grains on 
other chromosomes was found to be statistically insignificant 
and in most cases corresponded to positions that had been 
excluded by data from the hybrid cell lines. Similar results 
were obtained from hybridization to the chromosomes of the 
second male (data not shown). The distribution of the silver 
grains suggests that the renal kallikrein gene is at or close to 
19qter, most likely in the region q13.2-ql3.4. The kallikrein 
cDNA used as a probe cross-hybridizes with the prostate 
antigen and hKK-3 genes, although somewhat weakly (Baker 
& Shine, 1985; Fukushima et al., 1985; our unpublished data). 
Thus the finding of the only one region of in situ hybridization 
suggests that all human kallikrein genes may be localized in 
a single locus on chromosome 19. 
DISCUSSION 
The glandular kallikreins provide a system in which to study 
mechanisms underlying the differential tissue-specific ex- 
pression of a set of closely related genes. We have undertaken 
an analysis of the human renal kallikrein gene, since this 
provides us with a comparison of the same gene from two 
different species, as well as the comparison with other mouse 
kallikrein genes showing a distinct expression phenotype. We 
intend to use the isolated promoter regions from these genes 
to study transcriptional activation mediated by the binding of 
cell-specific factors. On the basis of nucleotide sequence 
comparisons, however, we can make predictions on elements 
that may interact with such factors. 
As outlined in Figure 3, the mouse and human renal kal- 
likrein genes share four sequence elements upstream from the 
CATCT box that show much greater homology than the 
corresponding regions between the human gene and mGK- 1. 
The conservation of elements I1 and I11 is particularly striking. 
All four elements lie within the region between nucleotide -460 
and the TTTAAA box, which is necessary and sufficient for 
tissue-specific expression of the mouse renal kallikrein gene 
mGK-6 in AtT20 cells (J. Close and R. Richards, unpublished 
data). 
We can place these findings in context by considering the 
example of the growth hormone gene. Comparison of the 
human (DeNoto et al., 1981) and rat (Barta et al., 1981) 
promoter sequences indicates four regions upstream from the 
TATAAA box that show significant homology. It is inter- 
esting that two of these regions have been shown to bind the 
cell-specific factor GHF-1 and to be necessary for transcrip- 
tional activation (Bodner & Karin, 1987). We propose that 
the four elements shared by the human and mouse renal 
kallikrein gene promoters similarly represent strong candidate 
sequences for the regulation of tissue-specific expression. 
We have mapped the human renal kallikrein gene to the 
long arm of chromosome 19. This region carries a number 
of genetic markers, including glucosephosphate isomerase 
(GPI), cytochrome P-450 (CYPl), and transforming growth 
factor 0 (TGFB; Naylor et al., 1985). These markers all 
appear on chromosome 7 in the mouse and, in the case of Gpi-1 
and Coh (corresponding to GPI and CYPl), map to a region 
adjacent to the Tam-1, or kallikrein gene locus (Searle et al., 
1987; Lalley & McKusick, 1985; Evans et al., 1987). The 
human renal kallikrein gene, and possibly the entire gene 
family, is thus localized in a chromosomal region analogous 
to the position of the kallikrein locus in mouse. The major 
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difference between kallikreins in the two species is therefore 
the extensive duplication and gene conversion occurring within 
the mouse gene family. It will be interesting to determine 
whether the change in chromosomal environment imposed by 
the close linkage of mGK-6 with other mouse kallikrein genes 
has any higher order effects on expression compared to the 
human renal kallikrein gene. 
Finally, although chromosome 19 in humans is relatively 
well mapped (Naylor et al., 1985), there are only a few probes 
defining restriction fragment length polymorphisms (RFLP’s; 
Donis-Keller et al., 1987). The localization of the human renal 
kallikrein gene to 19q13.2-ql3.4, as well as observed RFLP’s 
(Baker & Shine, 1985), provides a useful addition to the 
repertoire of chromosome 19 markers. 
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Mouse y-renin is a member of the group of serine 
proteases  known as glandular kallikreins. These 
highly homologous proteins process a diverse range 
of  growth factors and  hormones  to  their biologically 
active form, usually by cleavage at a basic residue. 
y-Renin, however, cleaves at a Leu-Leu bond in a 
similar fashion to renin. We have identified and se- 
quenced  the  gene  and  a  cDNA  encoding y-renin. The 
complete predicted amino acid sequence was deter- 
mined,  and  residues  that  may  be  important in the un- 
usual cleavage pattern exhibited by y-renin are dis- 
cussed.  The  nucleotide  sequence  enabled  design  of  a 
gene-specific oligodeoxyribonucleotide which was 
used to determine in which mouse tissues y-renin is 
expressed. 
The serine protease y-renin was originally isolated from 
adult male mouse submaxillary gland (1). On the basis of 
molecular mass, arginyl esterase activity, inhibition profile, 
and  partial amino acid sequence (l) ,  y-renin  has been included 
in a highly homologous group of trypsin-like  serine  proteases 
known as the mouse glandular kallikreins (2, 3). Though 
members of this family are closely related  structurally, they 
process a diverse range of hormones and growth factors, 
usually with stringent substrate specificity (3-5). The low 
proportion of variable amino acid residues between mouse 
glandular kallikreins with different functions makes these 
enzymes an ideal system for comparative structural  and func- 
tional analysis of serine  proteases at a  particularly rigorous 
level. 
Most mouse glandular kallikreins show trypsin-like speci- 
ficity, cleaving at basic residues (6). However, y-renin has 
been shown to cleave synthetic  tetradecapeptide  renin  sub- 
strate  at a Leu-Leu bond  (1). This is the same bond processed 
by renin as  the first cleavage step in the generation of angio- 
tensin (7). Amino acid residues of y-renin  important  to  this 
cleavage event should be unique when compared to other 
glandular kallikreins. 
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As previously reported, we have isolated and partially char- 
acterized the  entire mouse glandular kallikrein gene family 
(2). In  this paper we present the identification of the gene 
encoding y-renin  and subsequent isolation of a corresponding 
cDNA. The complete primary structure of y-renin, derived 
from the nucleotide sequence, is compared to  other members 
of the mouse glandular kallikrein family, thus indicating any 
amino acid residues that contribute to  the unusual substrate 
specificity and catalytic  activity of y-renin. Expression of the 
y-renin gene in various mouse tissues was also examined. 
EXPERIMENTAL PROCEDURES 
Kallikrein clones were isolated from a BALB/c mouse genomic 
library constructed using the EMBL3A vector as described previously 
(2). Polyadenylated RNA was isolated from the submandibular gland 
of adult male BALB/c  mice (8, 9),  and double-stranded cDNA  was 
prepared from a 2-pg aliquot by sequential treatment with reverse 
transcriptase (10) and a combination of ribonuclease H, Escherichia 
coli DNA polymerase I, and T4 DNA ligase (11). Methylation of 
internal EcoRI sites, addition of EcoRI linkers, and ligation of cDNA 
to  the X g t l O  vector were based on the procedure of Huynh et al. (12). 
The resulting DNA  was packaged in vitro (13) and plated  out  on E. 
coli strain CSOO/hfl. Restriction fragments of the X clones were 
subcloned into M13 mp 18 or 19 (14) and sequenced by the chain 
termination method (15) using [cx-~‘S]~ATP and either the  standard 
M13 17-mer or kallikrein-specific oligodeoxyribonucleotides (2) as 
primers. Oligodeoxyribonucleotides corresponding to a variable region 
of the DNA sequence from exon 3 of the gene mGK-16 (complemen- 
tary  to nucleotides 860-2389, Fig. 2) and  to regions conserved between 
all the kallikrein genes (2) were synthesized by the solid-phase 
phosphoramidite procedure as detailed elsewhere (16). Specificity of 
the oligodeoxyribonucleotide for mGK-16 was tested by hybridization 
to nitrocellulose filters as described previously (17). 10-pg aliquots of 
polyadenylated RNA from mouse salivary gland, kidney, pancreas, 
brain, and testis were denatured  in formaldehyde, electrophoresed on 
1% agarose formaldehyde gels, and transferred to nitrocellulose (18). 
The Northern blots were hybridized to oligodeoxyribonucleotides 
labeled at the 5’ terminus with [Y-~’P]ATP as detailed elsewhere 
(17). 
RESULTS AND DISCUSSION 
Identification of the  y-Renin Gene-The two fragments of 
amino acid sequence from y-renin, sequence A and sequence 
B (l), correspond to regions encoded by exons 2 and 4 of the 
mouse glandular kallikrein genes (2, 19). Partial nucleotide 
sequence from exon 2 for all mouse glandular kallikrein genes 
has been obtained (2). The predicted amino acid sequences 
were, therefore, compared to sequence A of y-renin. None of 
the genes encoded the exact sequence as published; however, 
the proteins encoded by several genes differed at  only a few 
residues. To clarify the situation, the nucleotide sequence 
from exon 4 of all potentially functional mouse glandular 
kallikrein genes was determined, and the predicted amino 
acid sequences were compared to sequence B (Fig. 1). This 
allowed the identification of mGK-16 as  the gene encoding y- 
renin. 
Peptides  A and B had been sequenced as a mixture, with 
assignation of residues at  each position being made on the 
basis of relative yields and by comparison to  the sequence of 
porcine pancreatic kallikrein (1). Difficulties in the assign- 
ment of some of these residues were mentioned  (1).  When the 
peptide sequences are compared to those encoded by exons 2 
and 4 of mGK-16 (Fig. l), it is clear that 4 amino acid residues 
have been assigned incorrectly to  the corresponding position 
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FIG. 1. A, nucleotide sequences from exon 4 of all potentially 
functional mouse glandular kallikrein genes aligned to maximize 
homology. Sequences not included are  from kallikrein genes shown 
to be pseudogenes either due to gross rearrangements or characterized 
by nucleotide substitutions, insertions, or deletions in  exons 2 and 3 
that give rise to in-phase termination codons (2). Splice acceptor sites 
at the 5”intron-exon junction are  boxed. The dashed box indicates a 
potential alternative splice acceptor site for mGK-14. B,  predicted 
amino acid sequences from exon 4. Boxed areas indicate residues 
which are identical for at least 85% of the genes. Numbers refer to 
the position relative to the amino terminus of  mature mouse y-nerve 
growth factor (34). C, comparison of the amino acid sequence of y- 
renin (1) to predicted amino acid sequences from exons 2 and 4 of 
mGK-16. The sequences are aligned relative to the NHz-terminal 
amino acid of each peptide, so that corresponding residues are directly 
above each other. Asterisks denote differences between residues. The 
tryptophan residue in parentheses is actually encoded by the end of 
exon 3 as well as  the beginning of exon 4 (see Fig. 2) but is included 
in  the comparison for completeness. 
. .. 
in the  other peptide. Furthermore, no gene other than mGK- 
16 encodes a protein with fewer than 10 amino acid differences 
from the published sequence (Fig. 1 and Ref.  2). 
Isohtion of a cDNA Encoding y-Renin-A BALB/c mouse 
salivary gland cDNA library was subsequently screened for 
clones encoding y-renin. Initially, the primary plating of 
about 60,000 recombinants was screened with pMK-1, a kal- 
likrein cDNA that hybridizes to exons 3, 4, and 5 of all 
members of the gene family (19,20). 90 of the 169 kallikrein- 
positive cDNA clones were purified and subjected to further 
screening with a gene-specific oligodeoxyribonucleotide de- 
signed from a region in exon 3 unique to mGK-16 (comple- 
mentary to nucleotides 860-889,  Fig. 2). Four positives were 
identified, one of which, pMK-19, also hybridized to an exon 
1 probe (fragment IV,  Ref. 19) and was therefore chosen for 
isolation and characterization. 
Nucleotide Sequence Encoding y-Renin-Fig. 2 depicts the 
composite cDNA and gene sequences encoding y-renin. The 
cDNA clone is almost full-length, starting 10 base pairs from 
the second putative  transcription  initiation site. 526 base pairs 
of DNA 5’ to pMK-19 were derived from the gene  mGK-16. 
Positions of exon-intron boundaries were determined from 
mGK-16.  However, the sequence from introns is not  presented 
here. The boundary locations are identical to those of all  other 
characterized functional mouse kallikrein genes (2,16,  17,19, 
21). mGK-16 also contains the variant 5’-TTTAAA-3’ se- 
quence typical of kallikrein promoter regions (16, 17, 19, 21) 
and a normal polyadenylation signal (22). Since the cDNA 
clone encoding y-renin  is  not completely full-length, it was 
not possible to determine which of the two potential  transcrip- 
tion  initiation  sites (19) is used. 
Expression of y-Renin in Mouse  Tissues-The expression 
profile of y-renin was of interest because of its renin-like 
action in vitro. A brain renin-angiotensin system has been 
described in several animals (for review, see Ref.  23). In mouse 
brain, however, renin  synthesis is undetectable (24) though 
other components of the renin-angiotensin system have been 
detected (24,25). The possibility therefore arises that  another 
enzyme processes angiotensinogen in mouse brain. Glandular 
kallikrein(s) have been detected in mouse (16) and  rat (26) 
brain. Therefore, we investigated the possibility that y-renin 
is responsible for the first cleavage step of angiotensin pro- 
duction in the brain. 
The gene-specific oligodeoxyribonucleotide for mGK-16 
was used as a probe on mRNA from male and female salivary 
gland, male kidney, pancreas, testis, and brain of BALB/c 
mice  (Fig. 3). A 1-kilobase band was detected in salivary gland 
at much higher levels in the male tissue. This expression 
phenotype is exhibited by most mouse glandular kallikrein 
genes, with the exception of renal kallikrein which is ex- 
pressed at equal levels in both male and female salivary glands 
(16, 27). Exposure of the blot for longer periods failed to 
detect any hybridization to brain mRNA (not shown). Thus, 
y-renin does not  represent the predominant mouse glandular 
kallikrein@) expressed in brain (16). Although the lack of 
detection of y-renin in the brain using Northern blots (as 
well as  in  situ hybridization histochemistry)’ does not  pre- 
clude the possibility of  low level expression, it would appear 
to be too low to support an important role in angiotensin 
biosynthesis in mouse brain. 
Structure of y-Renin-Determination of the complete se- 
quence of pMK-19 allows the structure of y-renin to be 
predicted. The coding potential  indicates that  the protein  is 
synthesized as a larger precursor, from which presumably a 
leader sequence of 17 hydrophobic residues (the signal pep- 
’ J. Penschow, personal communication. 
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FIG. 2. The nucleotide sequence encoding y-renin determined from pMK-19 and the 6'-flanking 
region of mGK-16 is shown. Numbers to  the right refer to nucleotide residues. The solid triangk denotes the 
first nucleotide of pMK-19. The coding region has been translated, and numbers above the amino acid sequence 
refer to  the position relative to  the NH1-terminal isoleucine of the mature  protein (1). Intron positions are marked 
by open arrows. The asterisk denotes the first residue of the zymogen peptide, and  the residues preceding this 
constitute the signal peptide. The  variant TATA box (35) and polyadenylation signal (22) are underlined. Putative 
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FIG. 3. Expression of y-renin  in mouse tissues. The mGK- 
16-specific 30-mer was used as a hybridization probe on  a  Northern 
blot containing 10 pg of mRNA from BALB/c mouse male salivary 
gland (d), female salivary gland ( O ) ,  kidney ( K ) ,  pancreas (P), testis (n, and brain (B). After hybridization, the blot was washed in 2 X 
SSC at 60 "C and exposed to x-ray film at -80 "C with an intensifying 
screen overnight. After exposure to x-ray film for 1 week, hybridiza- 
tion to female salivary gland mRNA also could be detected (not 
shown). kb, kilobase. 
tide)  and  a  short zymogen peptide are subsequently cleaved 
in a manner analogous to other glandular kallikreins. 
The general structure of the glandular kallikreins is known 
from crystallization analysis of porcine pancreatic kallikrein 
(28,29). Though a  rat kallikrein, tonin,  has also been crystal- 
lized, the active site was distorted from its native conforma- 
tion by interaction with Zn2+ (30). The following discussion 
of y-renin  structure  is therefore confined to comparisons with 
the tertiary  structure of porcine kallikrein. 
y-Renin contains the amino acid residues necessary for 
formation of the serine protease charge-relay system, His-41; 
Asp-96, and Ser-189 (6,31). However, amino acid residue 183 
in y-renin is glycine instead of the aspartic acid thought 
responsible for directing cleavage after basic amino acids (6). 
This helps to explain the cleavage pattern of y-renin. While 
y-renin readily  cleaves the Leu-Leu bond normally processed 
by renin, there was no indication that  it also cleaves after the 
arginine residue in the synthetic  renin  substrate (l), as might 
be expected for the glandular kallikreins. 
While Gly-183  would give no selective advantage for bind- 
ing or cleavage at  basic residues, it would certainly not provide 
any disadvantage. The substrate binding pocket could still 
accommodate an arginyl side chain. Therefore, it is  not  sur- 
prising that y-renin is able to cleave the synthetic arginyl 
ester, Nu-benzoyl-DL-arginine-p-nitroanilide (l), which  would 
not be subject to  the steric  and  other sequence-related re- 
straints of a polypeptide substrate. As would be expected, 
given the less favorable interactions of an arginyl side chain 
with Gly-183 than with Asp-183, the  rate of N--benzoyl-DL- 
arginine-p-nitroanilide hydrolysis by y-renin ( Vmm; 0.18 
pmol/min/mg protein (1)) is lower than  that for the y  subunit 
of nerve growth factor, another member of the glandular 
The amino acid residue numbering for y-renin  is relative to  the 
amino-terminal isoleucine of the mature  protein (see Fig. 2). 
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kallikrein family ( Vmm; 0.38 Fmol/min/mg protein (32)). 
Originally, 29 amino acid residues were identified as  invar- 
iant for all serine proteases (6). Once the complete sequence 
of porcine pancreatic kallikrein was determined (33), this was 
reduced to 27 invariant residues. 26  of these  are conserved in 
y-renin. However, the amino acid at position 176 is  not glycine 
but isoleucine. Furthermore, 5 residues in this region are 
different from those conserved in other mouse glandular 
kallikreins. The substitutions  are  threonine for Ala-175, iso- 
leucine for Gly-176, glutamic acid for Gly-180, aspartic acid 
for Gly-181, and proline for Thr-184. The substitution of 
threonine for alanine at position 175 should have little effect 
on the protein  structure  and binding capabilities. However, 
depending on its  orientation, the side chain of Ile-176 may 
have an effect, protruding into the specificity pocket and 
interfering with substrate binding. Being toward the outside 
of the protein Glu-180 and Asp-181 should have little effect 
on the conformation of the active site (28). The porcine 
pancreatic kallikrein threonine residue corresponding to  Thr- 
184 forms a hydrogen bond with the terminal ammonium 
group of the lysine side chain  in bovine pancreatic  trypsin 
inhibitor (29) and would thereby stabilize the primary inter- 
action of the side chain with Asp-183. Since y-renin does not 
have Asp-183, however, the substitution of the proline at 
position 184  becomes less relevant for direct intermolecular 
bonding, though it may affect the shape of the binding pocket. 
Model-building studies  incorporating  both  this  substitution 
and Ile-176 would  be necessary to determine the full extent 
of their effects. 
The other potentially significant region in which y-renin 
differs from all or most of the mouse glandular kallikreins is 
at positions 203 and 205 in  the secondary binding site (28) of 
the enzyme. Valine is found at position 203 in  y-renin,  though 
all  other mouse kallikreins have Thr-203. The corresponding 
residue in both bovine and porcine trypsin is valine. There- 
fore, this substitution would not affect the serine protease 
activity of y-renin. Though Trp-205 is highly conserved 
among the serine proteases, y-renin  has  an isoleucine at this 
position, which  may  have some effect on its specificity. Again, 
detailed model-building studies would  be required to properly 
address the effects of these  substitutions. 
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Like most members of the mouse glandular kallikrein gene family (for
review see 1), expression of mGK-11 shows sexual dimorphism in the salivary
glands, the level in males being about 30-fold greater than that in females.
Nucleotide sequence from the five exons and 625 bp of the 5' flanking region
was determined using the enzymatic method2. The exon-intron boundaries of
mGK-11 (boxed) are identical to those of all other mouse glandular
kallikrein genes (see 1, 3 and references therein). The gene also has the
variant 5'-TTTAAA-3' box typical to kallikrein promoter regions and a normal
polyadenylation signal (both underlined). By analogy with known glandular
kallikreins, the mGK-11 gene product has a hydrophobic signal sequence (-24
to -6., numbering relative to Ile-1 of the mature protein) followed by a
seven residue zymogen peptide. The mature protein is 237 amino acids long
and contains the three residues believed necessary for serine protease
activity (His-41, Asp-96 and Ser-189) as well as Asp-183 which is thought to
direct cleavage at basic residues, giving trypsin-like specificity.
Expression of mGK-11 was examined in several mouse tissues by Northern blot
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hGK-1
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Prostate Specific Antigen (PSA) is a member of the glandular
kallikrein subfamily of serine proteases (1). Its expression is apparently
confined to the duct cells of the prostate and as such is potentially useful
as a serum marker for the treatment of prostate derived tumours (2). Using
a PSA cDNA clone (3) as a probe, we have isolated a series of overlapping
cosmid clones containing kallikrein-like sequences. By restriction mapping
of these clones we have found that the PSA gene is located 12kb upstream
from the hGK-l gene (4), which is also expressed in the prostate (5). The
human cosmid library was constructed by and an aliquot obtained from Dr. K.
Choo, Murdoch Institute. No overlap was obtained with the renal kallikrein
(KLK) gene which also maps to chromosome 19q13 (3,6). The PSA gene sequence
depicted (determined by the enzymatic method (7)) shows all exon and 5' and
3' flanking sequences. Variant TATA and polyadenylation sequences are
underlined, splice donor and acceptor sequences are boxed. Numbers refer to
distance from initiation of transcription, by analogy with the KLK gene (6).
Coding regions are translated.
cccTAGAAA0GTclCATGAOCTAcA88000Cll0l1ATGATCTAATcATTGCAGAACAcCACTOCTAGOrTc7cccTTcc7rCCACA0CTCT1G
CCAM=GCACCA TAa OGGTCllACTTGC =AGGCAGrXNGCNGCCTA TGANrrMATArE;CTCcTtxl
NetTrpValProVaIVaIPheLeuThrLeuSerVaIThrTrpIleG
CTTACCAC/ACCTGGAAGCT C C GA CGTACC A lr AT G G lmlA1RL-
GCCCGACTGTCAAOCTAGGTCTTTTT-1-O---I.kbCC8C8CTTTTCAAACCCACATCCTAAAT,?8C1rTtTcNCWCA'rCCTl
IyAIaAIaProlu1l1eLeuSerArglIeVaIGIyGlyTrpGl CyaGluysRisS0rGInProTrpGI nVaLeu
TCCCCTGTCTAOCNCA OC G C CG Al A AAGrATTcCCrWI=r8AOGTOCTT
ArgAlaVaICysGlyGlyValLeuValHisProGlnTrpValLeuThrAIaAlalisCysuleArgAs
A8GGGC4CTC2C0CA GGO0CCTCACAGw ACTGCCCAC AGTAGxcrlT0rl0T- - - - 566 - 7---0T
nLysSerValI leLeuLeuGlyArgRiaSerLeuPheIisProGI uAspThrGIyGI nVallP
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We describe a highly polymorphic microsatellite repeat 
sequence, KLKl AC, which is located 3’to the human glan- 
dular kallikrein gene (KLKl) at lSq13.3-13.4. A multi- 
plex PCR was developed to simultaneously genotype the 
KLKZ AC repeat length polymorphism and a similar re- 
peat at the adjacent APOC2 locus at lSq13.2. Genotypes 
from these two loci in the 40 large kindred pedigrees from 
the Centre d’Etude du Polymorphisme &main were used 
in conjunction with the background genetic map to estab- 
lish a multipoint linkage map. The KLKl locus was also 
localized physically using somatic cell hybrid DNA tem- 
plates for polymerase chain reaction analysis. Both genetic 
and physical mapping studies are consistent with the as- 
signment ten-APOC2-KLKl-Dl9522-qter. The linkage 
map places KLKl approximately 10 CM distal to APOC2. 
These markers therefore flank the myotonic dystrophy 
gene and may be useful for diagnosis. o 1991 Academic PRBS, IUC. 
INTRODUCTION 
Genetic linkage mapping has, until recently, relied 
in large part upon restriction fragment length poly- 
morphisms (RFLPs) to provide markers for pedigree 
analysis. These markers are not, in general, highly 
informative and are laborious to type. The advent of 
polymerase chain reaction (PCR) technology has al- 
lowed the analysis of length polymorphisms present 
in microsatellite sequences of the type (AC * GT), 
(Weber and May, 1989; Litt and Luty, 1989). There 
are approximately 50,000 such sequences in the hu- 
man genome which appear to be randomly dispersed. 
Sequence data from this article have been deposited with the 
EMBL/GenBank Data Libraries under Accession No. M65145. 
1 On leave from the International Peace Maternity and Child 
Health Hospital of China Welfare Institute, Shanghai, People’s 
Bepublic of China. 
The majority of these sequences exhibit length varia- 
tion leading to heterozygosity values significantly 
higher than is common for RFLPs (Weber and May, 
1989). There are two approaches to utilizing these se- 
quences to establish genetic linkage. One is to isolate 
AC repeat sequences at random throughout the ge- 
nome or for a specific chromosome (Luty et al, 1990). 
A sufficient number of these markers randomly dis- 
tributed will eventually allow linkage to be estab- 
lished by segregation in large affected pedigrees. The 
second approach is to target particular candidate 
genes for a disorder and characterize AC repeat se- 
quences in close physical proximity for use as highly 
informative genetic markers. In this study we have 
characterized an AC repeat sequence in the vicinity of 
the human renal kallikrein (KLKI) gene (Sutherland 
et al., 1988, Evans et al., 1988), a candidate for genetic 
predisposition to hypertension. Oligodeoxyribonu- 
cleotide primers were designed from unique sequences 
flanking the microsatellite and used in PCR to type 
length variation at this locus. Reaction conditions 
were established for the simultaneous typing of the 
KLKl and APOC2 AC repeats, allowing rapid analy- 
sis of these markers through 40 pedigrees from the 
Centre d’Etude du Polymorphisme Humain (CEPH). 
These data were then used to construct a multipoint 
linkage map of KLKl AC in relation to other genetic 
markers at 19q13. 
MATERIALS AND METHODS 
Synthetic poly(AC - GT) was purchased from Phar- 
macia P.L. and radioactively labeled in a multiprime 
reaction (Amersham) using [cx-32P]dCTP (3000 Ci/ 
mmol, Amersham). This probe was then used to lo- 
cate (AC - GT), sequences in the vicinity of KLKl on 
a Southern blot of various restriction enzyme digests 
of the plasmid pHRK8.8 (which contains the intact 
77 OSSS-7543/91$3.00 
Copyright 0 1991 by Academic Press, Inc. 
All rights of reproduction in any form reserved. 
81
78 RICHARDS ET AL. 
A 5 KLKI 3' 
b W.GT),, 
1 2 34 5 
1 I I II I v I 
I I I I II I I I 
BarnHI BarnHI sac I SacI Xbal SacI XbaI Hlnda EcoRl 
B GATCAACACC ACTGCACTCC AGCCTGGGCA ACAGAGCGAG ACTCCATCTT AAAAAAAAAA 
AAAAAAAAAG AAGAAGAAAG AAAGAAATGA TTGAGGTGAT TCTGTGGGGT AACCTTGAGG 
100 
ATGAGTGGGA TGACCTTTGG GGGGTCCTCT GTGGGGTGAC CTTGGGGGGT GTGTGGGATT 
ATGAGAGTGT CTGAGAATTG AGTTTTAGGT TAAGTAGGGG TGATTTGGGA CAACTCTAAG 
200 
GGTGTGACTG GGGGATGACT TTAGGGGTCC CTGGGGTGAC CTTGTGAGTG AGATTGGAGT 
300 
TTCTTTGGGG TTTCTAGGAG GTGACTTTGG GGAGGTGAGT AGGGGTGATT TTGAGGATGT 
GCCAGAGCTT TGGGGTTGTC TGTTGGGCTG CTTGTGGGTA TCAGCAGAGA TGACTTTGAA 
400 
GGGTGACCAA GAGGGGTATC TGGGGGTATC TGGGGGGTGA CTCTGGGGCC CCTGTCCCCT 
sequencing primer ---> 
CTCCCCAGTJ CTCATCCATA TGAGCAAGGG CTTCATGTTA CTGGCCGTGG CCGTGTGCTG 
500 
AGTCCTCCTC CCGCCCATGC CCTCTGCCTC CTGGCCAGTG TCCTCCGCCT GAACAATGTC 
600 
TTCAGTTTCC TCTGCCTCGG CATTGGTAGG TGTTGGCTTG GGGGGTGGGG GCCCTCCCTA 
ACCCCAGCCC TGCTCTCTGG CTTTCTGGAG GTGTATCTAG ACTTCCGTGC TGCTCCCCTC 
KLK-F ---> 700 
GGGGCCTCGT CTTAGCATGT CTCTGGS CTCTGACTCA GTTCTACTCT ETGTGGGA 
TGTCTCTCTC CCCCACTCTC TGTTTCCCTT TCTTTTTTTG TCCCCTCTCT CCAGGTATCT 
800 
TTCTGTCTGT TGTGAGGGCG TGTGTGTGTG TGTGTGTGTG TGTGTGTGTG TGTGTCTGCT 
<--- KLK-R 900 
TGTCACGGE GGTGGGAGAG GATGTCTCAG ECCTCTTTT CTTACTGGGG GCATAGGGCT 
CACTGTCCAG CCTTCTGCTG CTCTGCCCAC CCATGCAGGC TCCGATTCTC TTCAGCCTGA 
1000 
GCCCTCTTTC AGTAACGCAA GGCGTGCACC CAAGCCGTGT GCACGGACTC AC 
FIG. 1. Location and sequence of the KLKl AC repeat. (A) Physical map of pHRK8.8 indicating the exons and direction of transcription 
(thin arrow) of the KLKl gene and the location of the AC repeat. Orientation of the sequenced region (thick arrow) was determined by the 
position of X&I (696) and Sac1 (748) restriction endonuclease recognition sequences. (B) Sequence of the &u&AI restriction fragment 
containing the KLKl AC repeat sequence. Also shown are the sequences used for a specific sequencing primer to extend the sequence to the 
AC repeat region and the sequences of the two primers used in PCR to type the AC repeat length polymorphism. 
KLKl gene on 8.8 kb of genomic DNA) and to screen 
bacteriophage Ml3 subclones of a Sau3A digest of 
pHRK8.8. Positive clones were subjected to dideoxyr- 
ibonucleotide sequence analysis (Sanger et aZ., 1977) 
using initially a universal sequencing primer and sub- 
sequently a specific sequencing primer to determine 
(AC), and flanking sequences. The location of the 
(AC),) microsatellite repeat and the deduced nucleo- 
tide sequence from the Sau3A subclone are illustrated 
in Fig. 1. 
Oligodeoxyribonucleotide primers were designed 
from the deduced sequence and synthesized on an Ap- 
plied Biosystems PCR-mate Synthesizer. These 
primers were located approximately 190 bases apart 
to allow simultaneous genotyping of the APOC2 AC 
repeat that is also located at 19q13. The length of the 
previouslycharacterizedAPOC2ACrepeat PCRprod- 
ucts range from 129 to 165 bases (Weber and May, 
1989). 
The KLKl AC and APOC2 AC repeats were typed 
in a lo-p1 polymerase chain reaction according to Ko- 
gan et al. (1987) and including 1 &i of [a-32P]dCTP. 
Reaction products were subjected to electrophoresis 
on 6% sequencing gels and autoradiography for 2 days 
using an intensifying screen. 
Somatic cell hybrids used for physical localiza- 
tion included G35F3B (G35), which contains 
19ptereq13.2, and GM89A99c7B (GMSS), which 
contains 19q13.2-*qter. G35 and GM89 were gener- 
ated from a translocation of t(X19) that breaks in the 
CKMM locus on 19q13.2 and therefore contain an en- 
tire human chromosome 19 between them. GM89 is a 
mouse cell hybrid. The third hybrid 2OXP-3542-1-4 
(20XP) contains a fragment of human chromosome 
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KLK 
- 186 bp 
B 123456789iOll 
I- --am +6 
*- +4 
2- 0 +2 
3- *rr*L -2 
-6 
-10 
FIG. 2. Simultaneous typing of KLKI and APOCZ AC repeats. (A) Autoradiograph of multiplex PCR of KLKI and APOC2 AC repeat 
markers after electrophoresis on a 6% polyacrylamide gel. Members of CEPH family 35 are shown in the pedigree above the corresponding 
lanes of the gel. Both parents are heterozygous for both AC markers. 1,2, and 3 refer to the major products seen for each of the three alleles 
observed on each locus. The length of the most common allele (3 for each locus) is given in base pairs. (B) Range of alleles at KLKl AC. 
Autoradiograph of KLKlAC PCRs after electrophoresis on a 6% polyacrylamide gel. Chromosomal DNA from individuals exhibiting 
multiple alleles of the AC repeat were genotyped. Assignments were as follows lane 1, 0, -10, lane 2,0, -6; lane 3,0, -2; lane 4,0,0; lane 5, 
f2, +2; lane 13, 0, +4; lane 7, 0, +6; lane 8, +4, +8; lane 9, 0, +lO; lane 10, 0, +12; lane 11, 0, +14. 
19 that includes the BCL3, APOC2, CKMM, and quences to be determined. Forward and reverse oligo- 
ERCCl genes but not D19S22 (Harley et al., unpub- deoxyribonucleotide primers suitable for PCR deter- 
lished results) and is a CHO hybrid that was obtained mination of length polymorphism of the AC repeat 
from Dr. M. Sicilian0 (University of Texas). were designed, optimizing for GC composition and 
RESULTS 
AC repeat sequences were identified at the KLKl 
locus by hybridization to restriction digests of cloned 
chromosomal DNA from the region (Evans et al., 
1988, Digby et al., 1989) with radioactivity labeled 
poly(AC - GT). One of these sequences (pHRK8.8) 
contained the glandular kallikrein gene and the AC 
repeat containing sequence mapped approximately 1 
kb from the 3’ end of the KLKl gene. The AC repeat 
and its flanking sequences were determined by sub- 
cloning a Sau3AI digest of pHRK8.8 into M13mp18. 
Positive clones were all found to have the insert in the 
same orientation with the repeat sequence greater 
than 600 bp from the sequence priming site. To reach 
the repeat sequence a specific sequencing primer was 
designed and synthesized corresponding to residues 
488 to 516 (Fig. 1). Sequencing from this priming site 
enabled the repeat sequence and its flanking se- 
TABLE 1 
KLKl Allele Frequency 
(124 Unrelated Individuals) 
Allele Frequency 
-10 Not observed 
-8 Not observed 
-6 0.004 
-4 0.004 
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(Lathrop et al., 1984). A plot of the location of KLKl 
AC on the background genetic map is shown in Fig. 3, 
as are the order of loci and the odds against inversion 
of adjacent loci in Table 2. 
Physical mapping of the KLKl locus to human 
chromosome 19 somatic cell hybrids was also under- 
taken using the KLKl AC PCR marker with the 
APOC2 AC PCR marker as an internal control. The 
cell lines GM89 and G35 are reciprocal translocations 
of t(X;19) with a breakpoint at the CKMM locus 
(Brook et al., 1984, 1991), while 20XP has a break- 
point distal to ERCCl but does not contain D19S22 
(Stallings et al., 1988, and unpublished results). Prod- 
0 10 20 30 40 50 
LOCATION (CM) 
ucts from the KLKl locus were present in the hybrid 
GM89 and absent in the hybrids G35 and 2OXP, con- 
FIG. 3. Computed location of the KLKl locus. Plot of the prob- 
ability of the location of the KLKl locus in relation to other genetic 
markers at 19q13. 
sistent with the genetic localization (Fig. 4). 
DISCUSSION 
product length so as to allow for simultaneous geno- 
typing of the KLKl AC and adjacent APOC2 AC re- 
peats (Fig. 2). The PCR conditions of Kogan et al. 
(1987) were utilized as these have been successfully 
applied to multiplex reactions (Chamberlain et al., 
1988). As with other AC repeat genotypes, multiple 
bands were observed for each allele (Fig. 2). One of 
these additional bands is most likely the GT-contain- 
ing strand (with reduced autoradiographic signal due 
to lower incorporation of [a-32P]dCTP than its AC 
containing counterpart). The origin of additional 
faint bands at each allele is not known although they 
are a common feature of these repeats (Weber and 
May, 1989; Litt and Luty, 1989). 
The simultaneous typing of the APOC2 and KLKl 
AC repeats allowed rapid analysis of both loci through 
the CEPH pedigrees. An example of this analysis 
(CEPH family 35) is shown in Fig. 2 as is a range of 
the alleles exhibited by this locus. The allele frequen- 
cies for unrelated individuals in the CEPH pedigrees 
are shown in Table 1. Certain rare alleles, including 
some of those illustrated in Fig. 2, have only been 
observed in further population studies (Richards and 
Soubrier, unpublished). The high heterozygosity of 
these AC markers results in 36 of the 40 CEPH fami- 
lies being informative for KLKl AC and only 2 of 
these were uninformative for APOC2 AC. In addition 
the multiple alleles at each locus mean that the infor- 
mation content is frequently retained when both par- 
ents are heterozygous. All of these factors combine to 
give extraordinarily high probabilities for the resul- 
tant linkage map, for example, the odds against inver- 
sion of the APOCB and KLKl loci are 6 X 1O35 to 1. 
The multipoint linkage map of KLKl AC in rela- 
tion to other genetic markers at 19q13 was performed 
using the LINKAGE (version 4.9) computer program 
The majority of RFLPs have relatively low infor- 
mation contents, providing only low probabilities 
that a pedigree will be simultaneously informative at 
two loci. Length polymorphisms observed for se- 
quences of the type (AC. GT),, where n is 315, have 
polymorphism information content values usually in 
the range 0.5 to 0.8, making them very attractive for 
use as genetic markers (Weber and May, 1989). In 
addition their frequency in the human genome 
(-50,000 copies) supports their general application 
as genetic markers, providing that they are indeed 
randomly distributed. 
The glandular (renal) kallikrein gene is one of a 
number of candidates as sites for mutation leading to 
genetic predisposition to hypertension (Berry et aZ., 
1989). Its gene product is an enzyme responsible for 
the generation of kinins which are potent vasodila- 
tors. In an effort to identify the gene(s) responsible 
for the genetic component of hypertension we have 
begun to characterize highly polymorphic markers in 
the vicinity of such candidate genes. These markers, 
TABLE 2 
Genetic Linkage Map of KLKl AC 
Order of loci 
em 0.07 0.023 0.036 0.034 0.097 0.052 0.102 
pIJ2-ATPlA3-D19S8-D19S19-APOC2-KLK1-D19S22-PKCG 
ef 0.062 0.027 0.043 0.04 0.112 0.061 0.118 
z 6.7 22.7 4.25 9.62 26.76 11.7 7.3 
Sex difference 1.18 
Inversion of adjacent loci 
1 x lo6 290 6x10'- 1 x lo* 
plJ~-hl~-~S~-I!U9Sl~-~-l$-~l9S2~-~KCG 
650 306 1x10' 
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A 123456 
KLKl 
B APOC2 CKMM ERCCl KLKl D19S50 D19S22 
- - - - - - 
G35 ---I 
APOC2 GM99 I ---- 
2oxp --- --- J 
FIG. 4. Physical localization of the KLKl locus. (A) PCR products from the KLKl and APOCZ AC repeats using somatic celi hybrid 
DNAs as templates. Lanes 1 and 6, G35; lane 2, GMSS; lane 3,2OXP; lane 4, mouse; lane 5, human. (B) Portions of human chromosome 19 
contained in somatic cell hybrids used to physically locate KLKl AC sequences. The location of other 19q13 loci in relation to the chromo- 
some 19 breakpoints is also shown. 
being more informative than RFLPs, will increase the 
probability of observing linkage between the disorder 
and the genetic marker in an affected pedigree. Such 
pedigrees have now been described by two laborato- 
ries (Berry et al., 1989; Cambien et al., 1988) and their 
analysis is in progress. 
The APOCZ AC repeat has previously been de- 
scribed (Taylor et al., 1989) as a diagnostic marker 
suitable for linkage analysis of myotonic dystrophy 
(DM). The KLKl and APOC2 AC repeats flank the 
DM locus and therefore the simultaneous typing of 
these repeats ought to provide a rapid and accurate 
means of following the mutant DM allele through af- 
fected families. Such a clinical application will be de- 
scribed elsewhere. 
Physical mapping of sequences to the long arm of 
human chromosome 19 has been mainly by in situ 
hybridization. In some cases somatic cell hybrids with 
breakpoints in this region have been used in conjunc- 
tion with in situ hybridization, allowing the order of 
some loci to be determined. This region of the human 
genome is not frequently involved in translocations 
and so the number of breakpoints that divide up the 
region is relatively small (Schonk et al., 1990). Since 
the gene for myotonic dystrophy is located at 
19q13.2-q13.3 there has been intense interest in both 
physical and genetic maps of the region and a large 
number of genes and anonymous DNA fragments 
have been mapped. Where restriction fragment 
length polymorphisms have been identified using 
these sequences as hybridization probes then their ge- 
netic location and hence physical order have been es- 
tablished. (Le Beau et al., 1989; Ropers and Pericak- 
Vance, 1990). 
The band at human chromosome 19q13 contains 
nine loci that map to a region of synteny on mouse 
chromosome 7. Analysis of such syntenic regions has 
been suggested as a means to identify specific disease 
genes and in this particular case the gene responsible 
for myotonic dystrophy. For such an approach to be 
successful it is essential that the order of the genes in 
the respective syntenic regions be maintained. The 
human genetic mapping of the KLKl AC repeat 
places this locus between ERCC and PRKCG. Genetic 
mapping of the mouse kallikrein gene family, which 
includes Ngfg, places the mouse locus outside of, and 
distal to, this interval in the vicinity of the Lhb 
(Saunders and Seldin, 1990). The human LHB locus 
also maps outside and distal to the ERCC-PRKCG 
interval and therefore while the clustering of analo- 
gous genes to syntenic regions is frequently observed 
conservation of the order of these genes may well be 
lost due to inversion events. 
The general application of microsatellite markers 
shows a great deal of promise, providing that they are 
randomly distributed, to enable the establishment of 
a 1-CM map of the entire human genome. While analy- 
sis of affected pedigrees for polymorphisms associated 
with candidate disease genes may only succeed in 
eliminating these loci as sites for genetic predisposi- 
tion to the disorder, the ultimate “saturation” of the 
human genetic map will succeed in establishing the 
site(s) of such lesions should a true heritable basis for 
the disorder exist. 
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We describe here the cloning, restriction mapping, 
and sequencing of the mouse angiotensinogen gene. 
The 5’ flanking region contains consensus sequences 
for several hormone-responsive elements and viral- 
like enhancers within 750 bp of the cap site. The de- 
duced amino acid sequence shows 87% identity with 
rat angiotensinogen, but there is a discrepancy in the 
number of cysteine residues in the mature protein 
among rat (n = 3), human (n = 4), and mouse (n = 4). 
Because angiotensinogen is homologous to other 
members of the serine protease inhibitor family, we 
aligned the putative reactive center of angiotensino- 
gens from various species. This alignment shows that 
the inhibitor site in human angiotensinogen is differ- 
ent from its rodent counterpart, but the role of this 
sequence divergence in the pathogenesis of human 
disease remains to be established. 0 1SSS Academic 
Prm, Inc. 
INTRODUCTION 
The renin-angiotensin-aldosterone system plays an 
essential role in the regulation of blood pressure, so- 
dium homeostasis, and thirst. Angiotensinogen is a 
glycoprotein secreted predominantly by the liver, and 
after cleavage by renin liberates angiotensin I. Hydro- 
lysis of this decapeptide by angiotensin-converting en- 
zyme produces the biologically active peptide angio- 
tensin II. Enzyme kinetic data from several species 
suggest that the plasma concentration of angiotensin- 
ogen is a rate-limiting factor in the generation of the 
angiotensin peptides (for review, see Reid et al, 1978). 
Hepatic production of angiotensinogen can be in- 
creased by a variety of physiological stimuli, including 
angiotensin II (Sernia and Reid, 1980), glucocorti- 
coids, estrogen, thyroxine, and bilateral nephrectomy 
(Campbell et al., 1984). Angiotensinogen messenger 
RNA is present in many tissues besides the liver, no- 
tably brain and kidney (Ohkubo et aZ., 1986; Dzau et 
al., 1987). Expression of the angiotensinogen gene is 
Sequence data from this article has been deposited with the 
EMBL//GenBank Data Libraries under Accession No. 503046. 
differentially regulated in various tissues (Campbell 
and Haebener, 1986). For example, glucocorticoids in- 
crease angiotensinogen mRNA in the liver and brain, 
but not in the kidney (Kalinyak and Perlman, 1987); 
lipopolysaccharide exerts effects in the liver, but not 
in the brain (Kageyama et al., 1985); and a decrease in 
plasma sodium concentration induces angiotensino- 
gen mRNA predominantly in the kidney (Ingelfinger 
et al., 1986). The molecular basis of this differential 
expression has not been defined. 
An unexpected observation that followed the deter- 
mination of the rat angiotensinogen protein sequence 
was its homology to members of the serine protease 
inhibitor family, especially cul-antitrypsin (Doolittle, 
1983). Subsequently, the rat angiotensinogen gene 
was shown to have structural features in common 
with the cwi-antitrypsin gene (Tanaka et al., 1984). 
However, the physiological basis for this sequence ho- 
mology remains to be definitively established. It has 
been suggested that des-AI-angiotensinogen may 
function as a renin inhibitor (Poulsen and Jacobsen, 
1986), despite the fact that renin is an acid protease 
and not a serine protease. 
We describe here the cloning and molecular anat- 
omy of the mouse angiotensinogen gene. Because of 
the differentially regulated expression of angioten- 
sinogen in a number of organs, a major reason for 
undertaking this project was to provide a completely 
homologous system for characterizing the tissue-spe- 
cific enhancers flanking the gene using transgenic 
mice. Our comparative analysis of the two available 
angiotensinogen promoter sequences, namely, rat 
(Ohkubo et al., 1986) and mouse, has defined the po- 
sition of shared consensus sequences for several en- 
hancers and a highly conserved palindromic sequence 
(5’-dTCTGTACAGA-3’) upstream of the start of 
transcription. 
MATERIALS AND METHODS 
Mice 
BALB/c mice used in this study were obtained from 
three sources. For the construction of the cDNA li- 
brary, BALB/c mice were purchased from the Mon- 
033%7543/33 $3.00 
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ash University Animal House, Clayton, Victoria, 
Australia. DNA for the construction of the X genomic 
libraries was prepared (while our group was at the 
Australian National University) from BALB/c mice 
obtained at the John Curtin School of Medical Re- 
search, Canberra, Australia. Dr. M. Graham con- 
structed his BALB/c mouse cosmid library from ani- 
mals bred at the Walter and Eliza Hall Institute of 
Medical Research, Melbourne, Australia. 
Hormone Treatment 
In order to enrich for the low-abundance angioten- 
sinogen mRNA, mice were given a combination of 
ethynylestradiol (0.3 mg/kg subcutaneously) for 3 
days and dexamethasone (6.7 mg/kg intraperitone- 
ally) 12 and 24 h before death. In addition, the ani- 
mals were bilaterally nephrectomized 24 h before 
death (Campbell et al., 1984). 
mRNA Preparation 
Livers were surgically removed and homogenized in 
5 M guanidinium thiocyanate. RNA was extracted by 
centrifugation through a C&l cushion and enriched 
for polyadenylated RNA by affinity chromatography 
on oligo(dT)-cellulose (Maniatis et al., 1982). 
Northern Blots 
Polyadenylated RNA (10 Mg) from induced and 
control mouse liver was electrophoresed through a 
1.2% agarose gel containing 2.1 M formaldehyde. The 
gel was stained with ethidium bromide to visualize the 
size markers, and the RNA was subsequently trans- 
ferred to nitrocellulose (Maniatis et aZ., 1982). 
Oligodeoxyribonudeotides 
The sequences of the two oligodeoxyribonucleo- 
tides used to probe the Northern blot and the cDNA 
library were based on conserved regions of the rat and 
human angiotensinogen cDNA sequences (Ohkubo et 
aZ., 1983; Kageyama et al, 1984). The exon 2 probe 
(5’-dGAGATGAAAGGGGTGGATGTATACGCG- 
GTCCCCAGC-3’) was from the angiotensin I coding 
region including 6 bases upstream in the signal pep- 
tide region, and the exon 3 probe (5’-dCACT- 
GAGGTGCTGTTGTCCACCCAGAACTC-3’) spans 
a glycosylation site. Probes were chemically synthe- 
sized on an Applied Biosystems Inc. Model 380A DNA 
synthesizer by the solid-phase phosphoramidite 
method (Beaucage and Caruthers, 1981) and purified 
by polyacrylamide gel electrophoresis. Probes were 
labeled at the 5’ terminus using T4 polynucleotide 
kinase and [T-~~P]ATP (Maniatis et al., 1982). Filters 
were prehybridized for 2-4 h at 42°C in the 20% form- 
amide buffer described by Ullrich et al. (1984) and 
subsequently hybridized to the 32P-labeled oligodeox- 
yribonucleotide for 16-18 h under the same condi- 
tions. The filters were then washed to a stringency of 
0.5~ SSC (0.075 M NaCl, 0.0075 M sodium citrate) at 
42”C, air-dried, and autoradiographed overnight at 
-80°C with a single intensifying screen. 
cDNA Library Construction 
A cDNA library was constructed from induced liver 
mRNA in the bacteriophage vector XgtlO using an 
RNaseH second-strand synthesis (Watson and Jack- 
son, 1985). Recombinant phage were screened by in 
situ hybridization on duplicate 0.45~pm nitrocellulose 
filters which were probed under the same conditions 
as those used for the Northern blots. All experiments 
using recombinant DNA were performed under Cl 
conditions according to the guidelines of the recombi- 
nant DNA Monitoring Committee of Australia. 
Genomic Southern Blots 
Southern blots of genomic DNA digested with Hin- 
dIII and BamHI (Pharmacia Molecular Biologic&) 
were hybridized at high stringency with the 800-bp 
mouse angiotensinogen cDNA, which had been la- 
beled using random primers, [ar-32P]dATP, and [a- 
32P)dCTP exactly as described by Shine et al. (1983). 
Genomic Library Screening 
Two genomic libraries were constructed in the 
EMBL3 vector using the method of Kaiser and Mur- 
ray (1985). Briefly, BALB/c mouse liver DNA was 
subjected to partial digestion with Sau3A, dephos- 
phorylated with bacterial alkaline phosphatase to 
prevent multiple inserts, and size-fractionated on a 
5-24% NaCl gradient. DNA in the size range of 14-22 
kb was ligated to EMBL3 arms. Library 1 was pack- 
aged using BHB2688/BHB2690-derived extracts 
(Maniatis et al., 1982) and plated on the recA+ Esche- 
richia coli strain LE392. Library 2 was packaged using 
Gigapak-Gold (Stratagene Inc., La Jolla CA) and 
plated on the recombination-deficient E. coli strain 
DB1255 (Wyman et al., 1985) obtained from Dr. R. 
Chiu, San Diego, California. An amplified BALB/c 
mouse cosmid library was obtained from Dr. M. Gra- 
ham, Walter and Eliza Hall Institute of Medical Re- 
search, Melbourne, Australia. 
The libraries were screened with the mouse angio- 
tensinogen, cDNA probe under the high-stringency 
conditions described for the genomic Southern blots. 
Positive clones were mapped by digestion of the DNA 
with a panel of restriction enzymes, followed by 
transfer to nitrocellulose and hybridization to a series 
of exon-specific oligodeoxyribonucleotide probes de- 
rived from the rat (Ohkubo et al., 1983) and mouse 
cDNA sequences. To assist with the mapping of frag- 
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ments at either end of the cosmid clones, we used a 
strategy analogous to that previously described for 
bacteriophage X (Rackwitz et al., 1984; Clouston et aZ., 
1987). Briefly, asymmetrical vector “arms” were cre- 
ated by digestion of the unique SalI site in the vector 
pJB8. After complete digestion with a second enzyme 
followed by Southern blotting, restriction fragments 
containing the vector arms were identified with spe- 
cific oligodeoxyribonucleotides complementary to ei- 
ther arm. 
DNA Sequence Analysis 
DNA restriction fragments were cloned into 
M13mp18 or mp19 (Yanisch-Perron et al, 1985) and 
sequenced by the chain-termination method (Sanger 
et al., 1977). Sequencing reactions were routinely in- 
cubated at 50°C to minimize effects of secondary 
structure. Any remaining GC compressions were re- 
solved using deoxy-7-deazaguanosine (Mizusawa et 
al., 1986). 
Primer Extension 
An oligodeoxyribonucleotide (5’-dTGCTCTTG- 
TTGTGGTAAAGGAGATGGAAGG-3’) was synthe- 
sized complementary to residues 998 to 1027 (accord- 
ing to the numbering of Fig. 5). This is equivalent to 
residues 153 to 182 from the putative cap site of 
spliced mRNA. After 5’-end-labeling, the oligodeox- 
yribonucleotide was used for primer extension with 10 
pg of polyadenylated liver RNA according to the 
method of Bodner and Karin (1987). 
RESULTS AND DISCUSSION 
Identification of a Mouse Angiotensinogen cDNA Clone 
In order to enrich for the low-abundance angioten- 
sinogen mRNA, mice were nephrectomized and given 
estrogen and dexamethasone. The exon 2 probe hy- 
bridizes to a mRNA of correct size when compared to 
other species (Ohkubo et al., 1983), and this mRNA is 
inducible by estrogen and dexamethasone (Fig. 1). A 
cDNA library constructed in XgtlO from this induced 
liver mRNA contained 10’ individual recombinants. 
This library contained no cDNAs extending to where 
the exon 2 probe would hybridize. Only one clone, 
designated XMAI, hybridized to the exon 3 oligodeox- 
yribonucleotide, which is in agreement with previous 
estimates (0.01%) (Ohkubo et al., 1983) of angioten- 
sinogen mRNA abundance. This clone is 800 bp in 
length and spans exons 3,4, and 5 as well as 158 bp of 
3’ untranslated region prior to the poly(A) tail. 
Cloning of the Mouse Angiotenhwgen Gene 
It was necessary to screen three genomic libraries 
with the mouse angiotensinogen cDNA probe to iso- 
FIG. 1. Northern blot of mouse liver poly(A)+ RNA (10 pgl 
track) probed with the exon 2 oligodeoxyribonucleotide spanning 
the angiotensin I coding region. Lanes 2 and 4 are from control 
animals. Lanes 1, 3, and 5 are from nephrectomized mice treated 
with dexamethasone and estrogen. Exposure was for 16 h with an 
intensifying screen. 
late the entire angiotensinogen gene. Two unampli- 
fied libraries were constructed in EMBL3, consisting 
of a total of 1.5 X lo6 recombinants. This is equivalent 
to six mouse genomes, and yielded one clone, desig- 
nated XgMA2 which contained exons 3,4, and 5 (Fig. 
2). A 2.1-kb Sr&EcoRl fragment from the 5’ end of 
XgMA2 was unsuitable for chromosome walking be- 
cause it contained repetitive elements. Accordingly, 
250,000 colonies from an amplified BALB/c mouse 
cosmid library were screened with the angiotensino- 
gen cDNA probe. Of eight positive clones, the three 
hybridizing to our cDNA clone as well as exon l- and 
exon 2-specific oligodeoxyribonucleotide probes were 
subjected to restriction mapping (Fig. 2). This map 
shows that the mouse angiotensinogen gene spans ap- 
proximately 15 kb of the 70 kb of genomic DNA repre- 
sented in these overlapping cosmid and X clones. 
Angiotensinogen Is Encoded by a Single-Copy Gene 
Genomic Southern blots of BALB/c mouse DNA 
digested with Hind111 and BamHI were probed with 
the mouse angiotensinogen cDNA, which contains 
exons 3, 4, and 5 (Fig. 3). The 11-kb Hind111 frag- 
ment is identical to that containing exons 2-5 in the 
cosmid clones (Fig. 2). Similarly, the 6.3-kb BamHI 
fragment contains exons 2 and 3, and the 3.6-kb 
BamHI fragment contains exon 5 and part of exon 4 
(Figs. 2 and 3). A 0.28-kb BamHI fragment contain- 
ing 40 bp of exon 4 is beyond the resolving power of 
the 0.9% agarose gel used for electrophoresis of the 
genomic DNA, but has been confirmed by DNA se- 
quencing (Fig. 4B). 
Structural Organization of the Mouse 
Angiotensinogen Gene 
The five exons, as well as 750 bp of 5’ flanking 
region and 404 bp of 3’ untranslated region, were se- 
quenced (Figs. 4 and 5). The exon-intron boundaries 
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FIG. 2. Restriction map of the mouse angiotensinogen ge- 
nomic clones. cMA2, cMAl8, and cMA20 were from the cosmid 
library; XgMA2 was isolated from an EMBL3 library. The arrow 
above the map shows the direction of transcription, and vertical 
bars denote the 5 exons. 
of the mouse angiotensinogen gene are identical to 
those from the rat (Tanaka et al., 1984). 
The position of the transcription initiation site was 
confirmed by primer extension. Using a 30-mer syn- 
thetic oliodeoxyribonucleotide complementary to res- 
idues 153 to 182 from the putative cap site of spliced 
mRNA, a major band of 182 bp was synthesized from 
liver RNA (Fig. 6). The TATA box is located 30 bp 
upstream of the cap site, but there is no CAAT box 
(Fig. 5). Instead, 71 bp from the transcription start 
site is a long inverted repeat (5’-dTCTGTACAGA-3’) 
H 




FIG. 3. Genomic Southern blot of BALBlc mouse DNA (10 
@g/track) digested with either Hind111 (H) or BamHI (B) and 
probed with the mouse angiotensinogen cDNA. Size markers are 
Xc1857 digested with HindHI. Exposure was for 4 days with an 
intensifying screen. 
B. 
EXON 2 EXON 3 EXON 4 EXON 5 
FIG. 4. (A) Detailed restriction map of the 5’ flanking region of 
the mouse angiotensinogen gene. The 6.8-kb Hi&III-BamHI frag- 
ment containing exon 1 was derived from the cosmid clone cMA2. 
The strategy for sequencing is indicated by horizontal arrows. (B) 
Sequencing strategy for exons 2 to 5. Sequences taken from the 
mouse angiotensinogen cDNA originate with vertical bars: those 
from genomic clones begin with either circles (Ml3 universal 
primer) or squares (specific primers). 
which is also found in the rat angiotensinogen pro- 
moter (Ohkubo et al., 1986). 
The 5’ untranslated region contains two putative 
glucocorticoid-responsive elements complementary to 
the sequence 5’-dTGTTCT-3’ (Fig. 5; Schneidereit et 
oz., 1983), both of which are present in the rat pro- 
moter (Ohkubo et al., 1986). In addition, elements 
complementary to a core sequence found in several 
viral enhancers (Weiher et al., 1983; 5’-dGTGGTTT/ 
AAA-3’) are at positions 127 to 133 and positions 194 
to 200 with reference to the numbering of Fig. 5. A 
long stretch of T residues found in both the rat albu- 
min (Heard et al., 1987) and the rat angiotensinogen 
promoters (Ohkubo et al., 1986) is present in neither 
of the mouse counterparts (Heard et aZ., 1987; Fig. 5). 
When the rat and mouse angiotensinogen promoters 
are compared (Fig. 7), a striking degree of sequence 
homology emerges, which is 83% overall and extends 
to the 5’ end of the published rat sequence. This se- 
quence conservation suggests that there may be other 
regulatory elements further upstream. 
The polyadenylation signal AATAAA at position 
2727 is functional in. uiuo, as it is 17 bp upstream of the 
poly(A) tail in our mouse liver cDNA clone (Fig. 5). 
Because multiple polyadenylation sites contribute to 
the known size heterogeneity of rat angiotensinogen 
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FIG. 6. Sequence of the mouse angiotensinogen gene. The nucleotide and deduced amino acid sequences are shown. The numbers on the 
right refer to the nucleotide residues. The splice donor and acceptor sites around each exon are boxed. The numbers above the amino acid 
sequence refer to the position relative to the N-terminal aspartic acid of the mature protein. The transcription initiation site is shown by a 
vertical arrow. The TATA box (Corden et al., 1980) is outlined. The duplicated inverted repeat sequences (5’-dCTGTACAG-3’) in the 5 
untranslated region are indicated by horizontal arrows starting at the center of the palindrome. Sequences complementary to the consensus 
sequence (5’-dTGTTCT-3’) of glucocorticoid responsive elements (Schneidereit et al., 1933) are overlined. Polyadenylation signals are 
underlined. The end of the mouse liver cDNA is shown by a triangle. 
mRNA (Ohkubo et al., 1966), we compared the se- 
quences of the 3’ untranslated regions from both spe- 
cies. While the proximal and distal polyadenylation 
signals are identical in rat and mouse, the middle site 
in the rat sequence (see Fig. 5 of Ohkubo et aZ., 1966) 
corresponds to ACCAAA in the mouse gene, which is 
unlikely to be functional (Birnsteil et al., 1985). In 
contrast, the 3’ untranslated region from human an- 
giotensinogen is 266 bp longer than that in the mouse, 
and contains two polyadenylation sites (Kageyama et 
al., 1964). The most distal polyadenylation signal in 
the rodents (ATTAAA) is the only one in common for 
all three species and is the predominant site of 
poly(A) addition in the human. 
Amino Acid Sequence Homology of Angiotensinogens 
The deduced amino acid sequence of mouse angio- 
tensinogen comprises 477 amino acids, including a 24 
amino acid leader sequence (Fig. 5). In agreement with 
previous physiological evidence from other nonprimate 
species (Reid et al., 1978), there is a Leu-Leu bond at 
the site of cleavage of angiotensin I from precursor 
angiotensinogen by renin. Potential glycosylation sites 
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FIG. 6. Determination of the transcription initiation site. A 
30-mer oligodeoxyribonucleotide complementary to residues 153 to 
182 from the cap site of spliced RNA was annealed to 10 pg 
poly(A)+ liver RNA at 60°C for 1 h. The primer extension products 
(lane 1) were analyzed on a denaturing 8% polyacrylamide gel. Size 
markers (lane 2) are end-labeled HpaII fragments of pBR322. A 
single band of 182 bp is present in lane 1. 
conforming to the canonical Asn-X-SerA’hr sequence 
are located at residues 14,23, and 295. 
Several polymorphisms were noted when the mouse 
angiotensinogen genomic sequence was compared to 
its cDNA counterpart. Silent changes were at posi- 
tions 2203 (T to C), 2244 (C to T), and 2475 (G to A). 
A single amino acid change from Ser to Asn resulted 
from a G to A substitution at position 2288 (Fig. 5). It 
seems unusual that polymorphisms have been ob- 
served from an inbred mouse strain, but we note in 
retrospect that the BALB/c mice used for the con- 
struction of the libraries came from different breeding 
colonies. Furthermore, a polymorphism in the de- 
duced amino acid sequence of human angiotensinogen 
has recently been reported (Kunapuli and Kumar, 
1986). 
The distribution of protein sequence identity for 
angiotensinogen from mouse, rat (Ohkubo et al., 
1983), and human (Kageyama et al., 1984) was exam- 
ined (Figs. 8a and 8b). The angiotensin I sequence is 
identical for all three species. Adjacent to the site of 
angiotensin I cleavage by renin is a region of sequence 
divergence, which is especially pronounced when 
human and mouse are compared (Fig. 8b), and occurs 
to a lesser extent for mouse and rat (Fig. 8a). This 
divergent region is likely to play a role in determining 
the substrate specificity for renin from different 
mammalian species. Despite the variation in sequence 
identity throughout the remainder of the molecule 
(Figs. 8a and 8b), there is appreciable similarity in the 
hydropathy plots of mouse and human angiotensino- 
gen (Fig. 8~). This suggests that the three-dimen- 
sional configuration of the molecule will be conserved. 
There is a discrepancy in the number of cysteine 
residues in the mature protein between the rat (n = 3; 
Ohkubo et al., 1983), human (n = 4; Kageyama et al., 
19&Q, and mouse (n = 4). The cysteine within the 
signal peptide and the first two cysteines of the ma- 
ture protein at residues 18 and 137 are conserved in all 
three species. The disparity observed between rat and 
mouse is because of a single base change from CGC to 
TGC at position 1963 of the nucleic acid sequence. 
The C-terminal pair of cysteines in human angioten- 
sinogen cannot be aligned with either the rat or the 
mouse sequences. The pattern of disulfide bonding 
within angiotensinogen has not been determined for 
any species, but has important implications for pro- 
tein folding. 
Relationship of Angiotensinogen to the Serine 
Protease Inhibitors 
Because of the known homology between angioten- 
sinogen and the serine protease inhibitors (Doolittle, 
1983), we examined the putative protease inhibitor 
site in mouse, rat, and human angiotensinogens. 
Computerized alignment of new members of the ser- 
ine protease inhibitor family is unable to predict ex- 
actly the position of the P1 and Pi residues at the 
reactive center because of the variable length of this 
crucial part of inhibitors with different substrate 
specificity. This limitation is evidenced by the differ- 
ent positioning of gaps in this region by various au- 
thors (compare Doolittle, 1983; Bock et al., 1986; 
Ragg, 1986). However, a serine residue is most often 
at the Pi position (Carrel1 et al., 1982; Hill et al, 1984) 
and this is the case for the alignment of rat angioten- 
sinogen to the serine protease inhibitors proposed by 
Tanaka et al. (1984). When this alignment is extended 
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FIG. 7. Comparison of the 5’untranslated regions of the mouse 
(horizontal axis) and rat (vertical axis) angiotensinogen genes. The 
graphic display was derived from a modification (by Dr. A. Kyne, 
Walter and Eliza Hall Institute of Medical Research, Melbourne) of 
the DIAGON program (Staden, 1982). The parameters used were a 
span length of 15 and a proportional matching score of 11. Posi- 
tions of the cap site, TATA box, putative glucocorticoid responsive 
elements (GRE), and the inverted repeat 5’-dCTGTACAG-3’ (I.R.) 
are shown. A stretch of T residues within the rat promoter is indi- 
cated (T). 
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FIG. 8. (a) Comparison of the percentage protein sequence identity of mouse and rat angiotensinogen, relative to a span length of 9 
amino acids. The graphic display is from the SEQMATCH program written for the Melbourne Data Base System by Dr. A. Kyne (Walter and 
Eliza Hall Institute of Medical Research, Melbourne). The position of angiotensin I (AI) is shown by a solid bar, and the residue numbers are 
identical to those for th6 mouse protein sequence shown in Fig. 5. Note that this algorithm does not show the 4 residues at either end of the 
molecule. (b) The percentage protein sequence identity of mouse and human angiotensinogen was plotted using the same parameters 
described in (a). This comparison takes into account gaps in the alignment at position 92 in the mouse sequence and positions 218 and 439 in 
the human sequence. The second potential initiation methionine in the human sequence was used to allow comparison of signal peptides of 
identical length. (c) Hydropathy plot (Kyte and Doolittle, 1982) of mouse (solid line) and human (dashed line) angiotensinogens using a span 
length of 9 residues. Note that the scale of they axis is slightly different for the two species. The position of angiotensin I is again shown by a 
solid bar. 
to angiotensinogens from other species (Fig. 9), both 
mouse and rat have glycine and serine at the P1 and P1 
positions. Human angiotensinogen is different, with 
asparagine and lysine at the P1 and P1 positions. This 
divergence within the reactive center is further high- 
lighted by examining the 25 residues surrounding the 
active site between the highly conserved glutamic acid 
at position 404 and the invariable phenylalanine at 
position 428. There are only 3 mismatches between 
rat and mouse, but 11 mismatches when the mouse 
sequence is compared to the human (Fig. 9). 
Divergence within the reactive center region be- 
tween humans and mice has been described for other 
serine protease inhibitors (Hill et ai., 19&i; Hill and 
Hastie, 1987). In the case of al-antitrypsin, this dif- 
ference does not change the inhibitory specificity for 
elastase. Conversely, mouse contrapsin differs in 
specificity from its human counterpart, a+ntichy- 
motrypsin (for commentary, see Leigh-Brown, 1987). 
The role of such sequence diversity within the inhibi- 
tor site of the angiotensinogens merits further physio- 
logical study. 
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FIG. 9. Alignment of the putative serine protease inhibitor reactive centers from mouse, rat, and human angiotensinogens. Human 
cyl-antitrypsin (Carrel1 et al., 1982) and antithrombin III (Chandra et aL, 1983) are included for comparison. With reference to the numbering 
from mouse angiotensinogen (Fig. 5), the serine at position 416 has been designated as the P” residue, and the proposed site of cleavage is 
shown by a vertical arrow. Conserved residues between the angiotensinogens and the two reference serine protease inhibitors are boxed. 
Finally, because several serine protease inhibitors 
in the mouse are genetically linked (Hill et al., 1985), 
we probed Southern blots of our cosmid clones at low 
stringency with the mouse angiotensinogen cDNA 
probe. There are no additional hybridizing bands to 
suggest the presence of related sequences. The 
Southern blots also showed no hybridization to syn- 
thetic oligodeoxyribonucleotides based on published 
sequences for mouse aI-antitrypsin (Krauter et aZ., 
1986; Hill et al., 19&I), mouse contrapsin (Hill et al., 
1984), or human leuserpin (Rag@;, 1986). This impor- 
tant question will be answered by chromosomal as- 
signment of the angiotensinogen gene. 
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An allelic polymorphism of tbe angtotensinogen gene in mice
W.M.Clouston and R.I.Richards
The Howard Rorey Institute of Experimental Physiology and Medicine, University of Melbourne,
Parkvflle 3052, Australia
SOURCE AND DESCRIPTION OF CLONE: pANG.71 is a 0.71 kb £coRI to
fragment of the mouse angiotensinogen gene (1), containing part of intron A
and adjacent exon 2 cloned into pUC19. A 397 bp StuI - BsmHl fragment of
pANG.71 was used for the probe.
POLYMORPHISM: While screening random bred Swiss mice for the presence of a
transgene, we noted 2 alleles of the angiotensinogen gene in BacHl digested
genoaic DNA (Figure 1). The 1.7 kb band is also present in BALB/cJ,
C57BL/6J, SWR/J and CBA/J and has been named the Ang°  allele. The 2.1 kb
band found in AKR/J, C3H/HeJ, and C57L/J has been named the ^
NOT POLYMORPHIC FOR: In BALB/cJ, C57BL/6J and AKR/J, there is no
polymorphism for PstI, Bglll or Ncol.
FREQUENCY: Estimated from 52 random bred Swiss mice:- Angs/Angs 0.15;
Ang^/Ang^ 0.62;
Angb/Angb 0.23.
CHROMOSOMAL LOCALIZATION: Hunan not known; currently being mapped in mice.
PROBE AVAILABILITY: For collaborative studies.
OTHER COMMENTS: The occurence of this allelic polymorphism for
angiotensinogen in Inbred mice is independent of the renin gene duplication
(2).
REFERENCES: (1) Clouston W.M. at al. (1988) Genomics 2: 240-248.
(2) Piccini, N. at al. (1982) Cell 30: 205-213.
ACKNOWLEDGEMENT: We thank Dr B.A. Taylor for providing genomic DNA from
the inbred mouse strains.
FIGURE 1 RFLP for angiotensinogen in BanHI-digested genomic DNA from 5
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Tissue-specific and hormonal regulation of
angiotensinogen minigenes in transgenic mice
W.M.Clouston, I.G.Lyons and R.I.Richards'
Howard Florey Institute of Experimental Physiology and Medicine,
University of Melbourne, Parkville 3052, Australia
'Present address: Cytogenetics Unit, Adelaide Children's Hospital, 72
King William Road, North Adelaide 5006, South Australia
Communicated by P.Seeburg
Angiotensinogen is the precursor of the potent vasoactive
peptide angiotensin II, and is therefore an important
determinant of blood pressure and electrolyte homeo-
stasis. In order to map the tissue-specific and inducible
enhancer elements governing angiotensinogen gene
expression in transgenic mice, we constructed minigenes
containing either 0.75 kb or 4 kb of 5' flanking DNA from
the BALB/c angiotensinogen gene. Sequences necessary
and sufficient to mediate induction by glucocorticoids,
oestrogen and bacterial endotoxin were contained on the
minigene bearing 0.75 kb of DNA upstream of the cap-
site. This construct was also able to confer tissue
specificity in the majority of organs producing angio-
tensinogen. In the testis and salivary gland, differences
between the donor (BALB/c) and recipient (Swiss) strains
were responsible for the apparently aberrant expression
of the minigene constructs. The genetic lesion responsible
for these expression polymorphisms has been character-
ized using recombinant inbred mice. An EcoRl restric-
tion fragment length polymorphism which co-segregates
with the angiotensinogen expression phenotypes into
many inbred mouse strains is also described.
Key words: angiotensinogen/minigenes/transgenic mice
Introduction
Angiotensinogen is the only known precursor of the
biologically active peptide angiotensin II, which plays an
essential role in blood pressure and electrolyte homeostasis
(Campbell, 1987). Production of angiotensinogen in the liver
is closely coupled to physiological stimuli, as the protein is
constitutively secreted with minimal hepatic storage (Clauser
et al., 1983; Richoux et al., 1983). In cultured cells the
angiotensinogen gene is transcriptionally regulated by
glucocorticoids (Brasier et al., 1986). Angiotensinogen
mnRNA levels are induced by a variety of other stimuli
including oestrogen, thyroxine, angiotensin II and bilateral
nephrectomy (Campbell et al., 1984; Klett et al., 1988). This
gene also responds to an acute phase stimulant, bacterial
lipopolysaccharide (Kageyama et al., 1985).
Recent interest has centred on the production of angio-
tensinogen mRNA in many extrahepatic tissues (Ohkubo et
al., 1986; Campbell and Habener, 1986; Dzau et al., 1987),
where it may participate in local renin - angiotensin systems
(Dzau, 1988). Of particular relevance is the de novo synthesis
of angiotensinogen in the brain (Lynch et al., 1986; Buckley,
©cIRL Press
1988), because this 55 kd protein cannot cross the blood-
brain barrier.
Whilst the angiotensinogen gene has now been cloned from
rat (Tanaka et al., 1984), mouse (Clouston et al., 1988) and
human (Gaillard et al., 1989), there have been no functional
studies of the enhancer elements controlling its expression.
In the present study, we chose to map the tissue-specific and
inducible enhancers of the angiotensinogen gene in transgenic
mice using a minigene as the reporter of transcription. The
use of a minigene reporter has been successfully exploited
to map the developmentally-regulated enhancers governing
expression of the alpha-fetoprotein gene in transgenic mice
(Hammer et al., 1987), and to study expression of the
troponin T and dihydrofolate reductase genes in tissue culture
(Breitbart and Nadal-Ginard, 1987; Crouse et al., 1988).
This approach has two main advantages. Firstly, by deleting
the central portion of the coding region to create the
minigene, complete homology of the 5' and 3' flanking
regions is preserved. Secondly, the relative expression of
the endogenous and mini-RNAs can be directly compared
on a Northern blot using the same radiolabelled probe to
determine whether all sequences necessary for reproduction
of the endogenous mRNA level have been included in the
construct. In contrast to in vitro transient expression assays
in cultured cell lines, it is possible to use the minigene to
survey expression in many organs from the one animal.
For the present study, we constructed two angiotensinogen
minigenes containing different amounts of 5' flanking region.
The longer minigene contains 4 kb of DNA upstream of the
cap-site, and was designated 4.0 A/2. This amount of 5'
flanking DNA was included to screen for far-upstream
enhancer elements in an analogous fashion to those recently
characterized from the mouse albumin and alpha-fetoprotein
genes (Pinkert et al., 1987; Hammer et al., 1987). The
shorter angiotensinogen minigene (0.75 A/2) contains
0.75 kb of 5' flanking DNA and was designed to test the
proximal promoter elements, which are sufficient to direct
tissue-specific expression of genes such as elastase (Ornitz
et al., 1985) and atrial natriuretic peptide (Field, 1988).
We show that the shorter minigene (0.75 A/2) contains
sufficient information to direct appropriate expression of the
construct in the majority of organs examined, with the
exception of the testis and salivary gland. We subsequently
demonstrate that strain polymorphisms are responsible for
aberrant expression of our BALB/c angiotensinogen mini-
genes in these latter two organs from Swiss mice. This
observation again highlights the importance of genetic
background in determining expression patterns of genes used
for production of transgenic mice (Mullins et al., 1988).
Results
Design of the minigenes
We placed several constraints on the design of the angio-
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Fig. 1. Angiotensinogen minigene constructs. The top line shows a
restriction map of the BALB/c angiotensinogen gene, with the exons
numbered 1-5. The dotted lines indicate regions deleted from the
endogenous gene to construct minigenes containing either 4 kb (4.0
A/2) or 0.75 kb (0.75 A/2) of 5' flanking DNA. Restriction sites
shown are HindIlI (H), BamHI (B), EcoRI (E), XbaI (X) and PstI (P).
The EcoRI site in brackets is derived from the vector pJB8. The PstI
site is not unique.
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Fig. 2. Northern blot of total RNA (45 Ag/track) extracted from livers
of dexamethasone-treated transgenic mice. Expression of the
endogenous and mini-angiotensinogen mRNAs from eight separate
transgenic lines is shown, as is the copy number of the transgene in
each line. Size markers are an in vitro synthesized RNA ladder (BRL).
Autoradiographic exposure was for 5 h with an intensifying screen.
methionine and leader sequence were preserved in order to
prevent the intracellular accumulation of a truncated protein.
A deletion within the coding region was made to allow
experimental discrimination on the basis of mol. wt between
the endogenous and transgenic angiotensinogen mRNAs.
This deletion within the coding region was made to preserve
the translational reading frame so that the same termination
signal would be used, thereby exposing identical
3'-untranslated regions on the mRNAs derived from both
the endogenous angiotensinogen gene and the minigene. This
should endow the mini-angiotensinogen RNA with similar
stability to the normal RNA.
Liver expression
Fl animals from eight separate transgenic lines were
analysed. Lines containing the 4.0 A/2 construct were
designated S, T, U, V and W. Those containing the 0.75
A/2 minigene were named X, Y and Z. Expression of the
transgene in each line was initially examined in the liver after
dexamethasone treatment in order to enhance detection of
3338
Fig. 3. Induction of endogenous and mini-angiotensinogen mRNA
levels in livers of mice from four separate transgenic lines.
(A) Reponse 6 h after a single i.p. injection of either dexamethasone
(DEX; 7 mg/kg) or the acute phase stimulant Ecoli lipopolysaccharide
(LPS; 1 mg/kg) is compared to control levels (CON) is sex-matched
littermates. (B). Induction by oestrogen (0.3 mg/kg) given s.c. for 2
days. Autoradiographic exposures were 2.5 h (A) or 5 h (B) with an
intensifying screen.
both the endogenous and mini-angiotensinogen mRNAs
(Figure 2). Six out of the eight lines showed high levels of
expression of the minigenes in the liver, but the expression
was not proportional to copy number. In other studies, this
lack of copy number-dependent expression has been
attributed to site of integration effects (Palmiter and Brinster,
1986).
Hormonal induction
In order to map the inducible enhancer elements controlling
angiotensinogen expression in the liver, sex-matched
littermates from several different transgenic lines were
treated with agents known to induce the gene. Animals from
two separate transgenic lines for each construct were studied
to control for integration site effects on the degree of
induction. The shorter construct (0.75 A/2) contains
sufficient information to respond to dexamethasone,
oestrogen, and the acute phase stimulant Escherichia coli
lipopolysaccharide (Figure 3A and B). For each stimulus,
the degree of induction was greater for the mini-RNA than
the endogenous angiotensinogen mRNA. This excessive
induction can be partially explained by transcription from
multiple copies of the transgene. Because the response was
not directly proportional to copy number, other factors such
as the proximity of many copies of the putative enhancer
elements, as well as integration site effects, may be
contributing to the variation in response among the different
transgenic lines.
Tissue-specific expression
The major objective of this study was to map the tissue-
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Fig. 4. Tissue-specific expression of angiotensinogen mRNA (upper
band) and the mini-RNA (lower band) in four separate transgenic
mouse lines. Animals were treated with dexamethasone for 2 days to
enhance detection in tissues expressing low levels of angiotensinogen.
Autoradiographic exposures ranged from 16 to 24 h with an
intensifying screen.
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Fig. 5. Northern blot showing the relative expression of the
endogenous and mini-angiotensinogen mRNAs in the ovary and
salivary gland of untreated females from four transgenic lines. Salivary
gland RNA from non-transgenic Swiss and BALB/c adult male mice is
included for comparison. Autoradiographic exposure was for 12 h with
an intensifying screen. The same blot was reprobed with a tubulin
cDNA to control of the quantity (45 Ag) and integrity of the RNA
loaded in each track.
expression. Two separate lines from each construct were
used to control for site of integration effects on expression.
In order to compensate for lower levels of angiotensinogen
gene expression in extrahepatic tissues (Campbell and
Habener, 1986), more RNA was loaded from these tissues
than from the liver. Animals were also pre-treated with
dexamethasone to enhance detection of the endogenous and
introduced mRNAs in organs expressing low levels of
angiotensinogen.
Fig. 6. Variability of angiotensinogen gene expression in testis and
salivary gland from different inbred mouse strains. The Swiss mice are
homozygous for either the Angj (s) or Angb (b) alleles of the
angiotensinogen gene. BALB/c and A/J mice have low levels of
angiotensinogen mRNA in both organs. Control probes are tubulin for
the testis and the glandular kallikrein mGK-3 for the salivary gland.
With few exceptions, both the short (0.75 A/2) and long
(4.0 A/2) minigenes were expressed at similar levels to the
normal gene in liver, brain, kidney and brown adipose tissue
(Figure 4; Campbell and Habener, 1987). There was no
ectopic expression of the constructs in the pancreas, but two
transgenic lines showed low levels of stray expression of
the minigene in the small intestine. The normal angio-
tensinogen mRNA was present in heart and lung at low levels
(- 10% of liver), but two out of four lines did not show
expression of the transgene in the heart (Figure 4).
Expression of the minigenes in the gonad differed between
males and females. None of the lines examined showed
expression of the transgene in the testis despite very high
levels of endogenous angiotensinogen mRNA (Figure 4).
Ovarian minigene expression was analysed in these same
transgenic lines without dexamethasone pre-treatment (Figure
5). The minigene was expressed at detectable but low levels
in ovaries from lines U, V and Y, and at higher than normal
levels in line Z. These findings suggest that the BALB/c
minigene constructs lack a testis-specific enhancer element.
The level of expression of the BALB/c minigenes was
consistently higher than the endogenous Swiss angio-
tensinogen gene in the salivary gland of all lines examined,
excluding the site of integration as the basis of this
phenomenon (Figures 4 and 5). This over-expression of the
minigene occurred at similar levels in both male and female
transgenic mice (Figures 4 and 5). Endogenous angio-
tensinogen mRNA levels were variable in the salivary glands
of the random bred Swiss animals, but were higher than in
non-transgenic BALB/c mice (Figure 5). Therefore, the
over-expression of the BALB/c minigene in the Swiss
salivary gland is paradoxical. This finding, as well as the
lack of expression of the BALB/c minigene in the testis, led
us to systematically examine strain polymorphisms of


















Variability of angiotensinogen gene expression in
different mouse strains
The salivary gland and testis represented the extremes of
expression of the minigenes and were therefore the focus
of the strain survey. The survey included two random bred
Swiss mice which had been genotyped for a BamHI allelic
polymorphism of the angiotensinogen gene (Clouston and
Richards, 1989). One animal was an Angs/Angs
homozygote and the other was an Angb/Angb homozygote.
BALB/c mice from three different sources were used to
confirm that the low expression phenotypes of this strain
were reproducible.
The strain survey of testicular angiotensinogen mRNA
showed a spectrum of expression (Figure 6). In contrast to
the high levels of angiotensinogen mRNA in testis of Swiss
mice there were very low levels in the testis of BALB/c and
A/J animals. This suggests that the absence of expression
of the BALB/c minigenes in testis of Swiss mice is due to
a difference in a cis-acting enhancer element between these
strains. In this context, the BamHI allelic polymorphism of
the Swiss angiotensinogen gene did not appreciably affect
testicular expression (Figure 6).
Expression of angiotensinogen in the male salivary gland
was similar in all strains examined except BALB/c and A/J,
where the mRNA was of very low abundance (Figure 6).
This is in contrast to the over-expression of the BALB/c
minigene when placed into a Swiss genetic background
(Figures 4 and 5). There are two possible explanations for
this phenomenon. The first is deletion of a repressor element
from the BALB/c minigene, thereby causing over-expression
in the Swiss salivary gland. An alternative hypothesis to
explain the over-expression of the BALB/c minigene is the
presence of a trans-acting factor in the salivary gland of
Swiss but not BALB/c mice.
Genetic analysis of angiotensinogen expression
phenotypes using recombinant inbred mice
We sought an alternative form of analysis because the gene
transfer experiments could not definitively distinguish
between cis and trans interactions as the basis of the salivary
gland expression phenotpes. Recombinant inbred mice were
used because they allow genetic discrimination between cis
and trans interactions controlling expression phenotypes
(Bailey, 1981). Based on the results of the strain survey
(Figure 6), we chose the CXB recombinant inbred set for
this analysis. The progenitor strain C57BL/6By has high
expression of angiotensinogen in testis and salivary gland,
while the BALB/cBy progenitor has low expression in both
organs. To determine the genotype of angiotensinogen in
the CXB recombinant inbred set, we used an EcoRI
restriction fragment length polymorphism (RFLP) identified
by the mouse angiotensinogen exon 2 cDNA probe (Figure
7). In the C57BL/6By progenitor (designated 'B' by Bailey
1981) there is a 4.8 kb band, whereas in the BALB/cBy
progenitor (abbreviated as 'C' by Bailey, 1981) there is a
3.9 kb band. Therefore, the angiotensinogen genotype of the
CXB recombinant inbred strains D to K is B C B C B B B
(Figure 7).
We next determined the expression phenotype of angio-
tensinogen in salivary gland and testis of the CXB recom-
binant inbred mice by Northern analysis (Figure 8). The
strain distribution pattern of angiotensinogen mRNA in both
organs is B C B C B B B. This is identical to the angio-
Fig. 7. Genotype of angiotensinogen in CXB recombinant inbred mice.
A Southern blot of EcoRI-digested genomic DNA from the parental
strains C57BL/6By (B) and BALB/cBy (C), and the CXB recombinant
inbred stains D to K was probed with the mouse angiotensinogen exon
2 cDNA. Size markers are X DNA digested with HindIII.
Fig. 8. Northen blot showing angiotensinogen expression phenotypes
in the testis and salivary gland of CXB recombinant inbred strains
D-K. Ribosomal RNA size-markers are shown. The strain
distribution patterns of expression are identical in both organs.
tensinogen genotype (Figure 7). This concordance between
genotype and phenotype suggests that mutant cis-acting
elements in the BALB/c angiotensinogen gene determ-ine the
expression phenotypes observed in both testis and salivary
gland.
To characterize further this genetic lesion within the
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Fig. 9. Genomic Southern blot showing segregation of an EcoRI
restriction fragment length polymorphism (RFLP) for angiotensinogen
into different mouse strains. The lower mol. wt band (designated the
Ang1 allele) shows concordance with low angiotensinogen expression in
the salivary gland and testis of BALB/c and A/J mice. Conversely, the
higher mol. wt band (designated the Anghl allele) is present in strains
having high levels of angiotensinogen expression. The difference in
intensity of the bands is due to variation in amounts of DNA loaded,
as judged by ethidium bromide staining (data not shown). Size markers
are X DNA digested with HindIH.
segregating with the expression phenotypes in various inbred
mouse strains. A BamHI RFLP recognized by the angio-
tensinogen exon 2 probe (Clouston and Richards, 1989) does
not correlate with the expression patterns (Figure 6).
However, the EcoRI RFLP used to genotype the CXB
recombinant inbred mice (Figure 7) also segregates with the
angiotensinogen expression phenotypes observed in the
salivary gland and testis of inbred mouse strains (Figures
6 and 9). The alleles recognized by this RFLP have been
designated Ang' and Angh (Figure 9). The Ang' allele is
associated with low expression in strains BALB/c and A/J,
whereas the Angh allele is associated with the high
expression seen in all other strains tested.
Discussion
We have shown that the 0.75 A/2 minigene contains
sufficient information to direct appropriate expression in the
majority of mouse tissues which produce angiotensinogen.
The deletion mutants allowed us to map the hormone and
acute-phase response elements to the shorter construct.
Finally, this analysis has identified and characterized strain
polymorphisms affecting angiotensinogen expression in the
testis and salivary gland.
Recent interest has centred on the design of transgenic
constructs capable of directing copy number-dependent
expression free of positional interference. For the human
3-globin gene, this was achieved by the assembly of a
minilocus containing far upstream DNase I-hypersensitive
sites to produce a dominant expression phenotype (Grosveld
et al., 1987; van Assendelft et al., 1989). In the case of the
human CD2 gene, inclusion of 3' flanking sequences resulted
in position-independent expression in the thymus but not in
the brain (Greaves et al., 1989). Our angiotensinogen
transgenic lines responded to a variety of stimuli at greater
levels than the endogenous gene, suggesting that multiple
copies of the minigene were transcriptionally active (Figure
3). However, the fact that this response was not proportional
to copy number, and the observation that two out of the eight
transgenic lines expressed the construct poorly suggests that
these minigenes are not capable of position-independent
expression. DNase I hypersensitivity analysis of the angio-
tensinogen gene will help to determine whether other regions
are required to achieve independence of integration site
effects. Another potential mechanism contributing to site of
integration effects is transcriptional interference (Proudfoot,
1986), and this may be overcome by including strong
transcription termination sequences upstream of the construct
(Heard et al., 1987).
Our genetic analysis using both transgenic and recombinant
inbred mice has defined strain polymorphisms affecting
angiotensinogen expression in the testis and salivary gland.
This may not be unique to inbred mouse strains as the rat
angiotensinogen gene is also expessed in the ovary, but not
in testis or salivary gland (Ohkubo et al., 1986; Campbell
and Habener, 1986). The evidence supporting a cis-
interaction as the basis of the testicular expression phenotypes
in mice is strong and consistent (Figures 4-8). In the
salivary gland, the over-expression of the minigene is
paradoxical because the BALB/c angiotensinogen gene is
expressed at low levels in this tissue. The recombinant inbred
analysis suggests that the genetic lesion in the salivary gland
is also in cis, and this conclusion is supported by the
identification of an EcoRI RFLP co-segregating with the
expression phenotypes into inbred mouse strains (Figure 9).
Based on these findings, deletion of a repressor element from
the minigene is the most likely explanation for the over-
expression observed in the salivary gland. Using the
informative EcoRI RFLP, it will now be possible to
backcross the BALB/c angiotensinogen gene into a Swiss
genetic background to produce congenic strains, which will
provide definitive proof of this hypothesis. It should be
possible to subsequently isolate the mutant region, as we have
already cloned the BALB/c angiotensinogen gene (Clouston
et al., 1988).
There are several precedents for deletions and insertions
affecting the tissue-specific expression of mouse genes. The
Slp gene is closely linked to the complement C4 gene, and
by virtue of an insertion 2 kb upstream of the cap-site, has
acquired androgen-responsiveness (Loreni et al., 1988). A
retroviral insertion has recently been identified as the cause
of the hairless mutation (Stoye et al., 1988). By analysis
of a revertant of the mutation, excision of this retroviral
element was proven by DNA sequencing (Stoye et al., 1988).
The renin gene in mice shows sexually dimorphic expression
in the salivary gland (Wilson et al., 1978). In this case, there
is a gene duplication event, with the Reni gene being
expressed in the kidney and the duplicated Ren2 gene being
expressed in the male salivary gland at high levels, as well
as in the kidney (Piccini et al., 1982; Field and Gross, 1985).
DNA sequence analysis of the Ren2 promoter shows the
insertion of two repetitive elements (Nakamura et al., 1988),
one of which interrupts a potential cyclic AMP response
element.
We conclude that the expression polymorphisms observed
for the BALB/c angiotensinogen minigene and the
endogenous Swiss angiotensinogen gene (Figures 5 and 6)
illustrate a potentially important cause of variability in
expression of other genes in transgenic mice. Such variability




Brinster, 1986). Most transgenic laboratories use outbred
or F2 hybrid zygotes to make transgenic mice, because mice
of a genetically heterogenous background yield greater
zygote numbers, and these give higher transformation rates
(Brinster et al., 1985). The disadvantage of this approach
is that it does not control for heterogeneity of trans-acting
factors between the parental strains of the F2 cross (Donner
et al., 1988; Duncan et al., 1988). This heterogeneity can
only be dissected by subsequent backcrossing to produce
ongenic lines. In selected cases, it may be worth accepting
the lower breeding and transformation efficiency offered by
inbred mouse lines to produce more uniform results.
Materials and methods
Mice
Random bred Swiss, DBA/2J, SJL, A/J, C57BL/6By, BALB/cBy, BALB/cJ
and CXB recombinant inbred mice were obtained from the Animal Resources
Centre, Perth, Australia. C3H/HeJ, CBA, BALB/cJ and AKR/J adult male
mice were purchased from the Department of Pathology, University of
Melbourne, Australia.
DNA
Genomic DNA from SWR/J, DBA/2J, C57L/J, C57BL/6J, C3H/HeJ and
AKR/J mice used in Figure 9 was generously provided by Dr B.A.Taylor,
The Jackson Laboratory, Bar Harbor, Maine.
Constructs
Our BALB/c mouse genomic clones (Clouston et al., 1988) were the starting
material for the constructs (Figure 1). To make a minigene with 4 kb of
5' flanking region (4.0 A/2), a 3.3 kb BamHI-HindIll fragment containing
exon S and part of exon 4 was subcloned from XgMA2 into pJB8 (see Figures
2 and 4 of Clouston et al., 1988 for a detailed restriction map). A 0.71 kb
EcoRI-BamHI fragment from cosmid c2, containing the 5' end of exon
2 was then fused to the exon 4 and 5-containing plasmid. This in-phase
fusion of exons 2 and 4 was confirmed by DNA sequencing, and effectively
deleted 720 bp from the centre of the mature mRNA. The resulting 4-kb
EcoRI -HindlIl fragment containing the fused exons 2-4 and 5 was then
ligated to a 6.8 kb HindIII-EcoRI fragment from cosmid c2, which had
4.0 kb of 5' flanking DNA upstream of exon I (Figure 1), using HindIll-
cut, dephosphorylated pJB8 as a vector. The resulting construct was
designated 4.0 A/2. Note that there is also a deletion of 1.6 kb in the first
intron which contains a cluster of restriction sites. This deletion is well
upstream of the splice acceptor sequences of this intron.
To construct a shortened version of the minigene, a 5.6 kb XbaI-HindIII
fragment spanning the exon 2/4 fusion was isolated from the 4.0 A/2 plasmid,
and ligated to a 2.1 kb PstI-XbaI fragment containing exon I (see Figure
4A of Clouston et al., 1988). This construct contains 0.75 kb of 5' flanking
DNA, and was designated 0.75 A/2 (Figure 1).
All vector sequences were removed for microinjection, which was
performed essentially as described by Hogan et al. (1986), except that a
compressed air system (I.Lyons, in preparation) was used for microinjection.
The BALB/c minigene constructs were microinjected at a concentration of
200 copies/pl into fertilized ova from random bred Swiss mice.
DNA analysis of transgenic animals
For genomic Southern identification of positive animals, tail DNA was
digested with BamHI and probed with a 397 bp StuI-BamHI fragment from
exon 2 of the mouse angiotensinogen gene. This probe identifies an allelic
polymorphism of the endogenous angiotensinogen gene, with 2.1 kb and
1.7 kb alleles (Clouston and Richards, 1989). The diagnostic BamHI
minigene fragment identified by this probe is 0.71 kb (Figure 1). Copy
number of positive transformants was estimated by a molecular dynamics
computing densitometer, with reference to the signal from a single allele
of the endogenous gene.
For screening tail DNA of Fl and F2 animals by dot-blot analysis, we
identified a unique area of the construct at the fusion of exons 2 and 4.
A 24mer synthetic oligodeoxyribonucleotide containing 12 base pairs on
either side of the exon 2/4 junction (5'-dCAGATTGTAGGATCCAAG-
GTAGAA-3') discriminated single-copy transformants from negative animals
when used under high-stringency conditions (hybridization at 42° C in 30%
formamide and washing at 55° C in I x SSC).
RNA analysis
Total RNA was isolated by homogenization of tissue in 5 M guanidinium
thiocyanate, with subsequent centrifugation through a 5.7 M CsCI cushion
(Chirgwin et al., 1979). Northern blots were hybridized with a 30mer
synthetic mouse angiotensinogen oligodeoxyribonucleotide (5'-dTGCTCT-
TGTTGTGGTAAAGGAGATGGAAGG-3' at 42° C in the 30% formamide
buffer described by Ullrich et al. (1984) and washed to a stringency of
0.5 x SSC at 42° C. Control probes were a /3-tubulin cDNA (Valenzuela
et al., 1981) and a gene-specific oligodeoxyribonucleotide for the mouse
glandular kallikrein mGK-3 (5'-dTCACACAGTAGAGATCATCTGT-
GAATTGGA-3'; van Leeuwen et al., 1986). RNA size markers were
purchased from Bethesda Research Laboratories.
Hormone treatment
For the tissue surveys and initial screening of expression in the liver, mice
were treated with dexamethasone (David Bull Laboratories; 7 mg/kg i.p.
twice daily for 2 days) to enhance detection of the endogenous and mini-
angiotensinogen mRNAs. For studies of acute induction of gene expression,
a single dose of either dexamethasone (7 mg/kg; Campbell et al., 1984)
or lipopolysaccharide (Sigma; I mg/kg; Kageyama et al., 1985) was given
by i.p. injection 6 h prior to RNA isolation. For induction by oestrogen,
animals were given 0.3 mg/kg of s.c. ethinyl oestradiol (Wyeth Laboratories;
dissolved in 95% peanut oil and 5% benzoic acid) in a single daily dose
for 2 days prior to tissue extraction (Darby, 1986).
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We have recently identified a c&acting genetic lesion affecting angiotensinogen gene expression in testis and salivary 
gland. Accordingly, the an~otensinogen gene was assigned to mouse chromosome 8 by screening a series of hybrid cell 
lines for retention of mouSe angiotensinogen sequences by genomic Southern analysis. In AKXD recombinant inbred 
mice, the angiotensinogen gene is 2.4+ 1.8 centiMorgan from Rn7S-&a 7S RNA gene located on chromosome 8 (Taylor, 
B.A., personal communication). However, the segregation of salivary and testicular angiotensinogen expression pheno- 
types into inbred mouse strains was not concordant with the known chromosome 8 proviruses Emv-2. Mtv-21, Xmv-I2 
or Xmv-26. 
Angiotensinogen; Chromosome mapping; Hybrid cell (Mouse, inbred strain) 
1. INTRODUCTION 
Angiotensinogen is the only precursor of the 
vasoactive peptide angiotensin II, and is therefore 
an important determinant of blood pressure and 
electrolyte homeostasis [l]. The liver is the pre- 
dominant site of production of angiotensinogen, 
but recent interest has centered on synthesis of 
angiotensinogen in many other tissues, including 
brain, kidney and brown adipose tissue where it 
may participate in local angiotensin-generating sys- 
tems [2]. 
We have recently identified a genetic lesion af- 
fecting angiotensinogen gene expression in testis 
and salivary gland of transgenic mice [3]. Subse- 
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centiMorgan; D, DBARJ; Rb, Robertsonian translocation; 
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quently, two angiotensinogen expression pheno- 
types were defined in inbred mouse strains. Low 
angiotensinogen mRNA levels were found in testis 
and salivary gland of BALB/c and A/J mice, 
whereas high angiotensinogen mRNA levels were 
present in the same organs from C57BL/6, 
C3H/HeJ, AKR/J, CBA, DBA/2J, SJL and Swiss 
mice [3]. This variability of angiotensinogen gene 
expression among inbred mouse strains was 
characterized further using CXB recombinant in- 
bred mice [3]. Concordance between the angioten- 
sinogen genotype and expression phenotypes in tes- 
tis and salivary gland of the CXB mice suggested 
that the genetic lesion was in cis. We subsequently 
identified an EcoRI restriction fragment length 
polymorphism which cosegregated with the angio- 
tensinogen expression phenotypes into inbred 
mouse strains [3]. 
In the present study, we determine the chromo- 
somal location of the mouse angiotensinogen gene. 
The major reason for undertaking this study was to 
see if the angiotensinogen gene was linked to a 
known mutation or retroviral insertion, which may 
account for the observed variability of angioten- 
sinogen gene expression among different mouse 
Published by Ekevier Science Publishers B. V. (Biomedical Division) 
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strains. We were also interested to see if the angio- 
tensinogen gene was linked to the serine protease 
inhibitor locus on mouse chromosome 12, because 
angiotensinogen shares significant protein se- 
quence identity with other serine protease in- 
hibitors [4]. 
2. MATERIALS AND METHODS 
2.1. DNA 
High molecular weight genomic DNAs from inbred mouse 
strains BALB/cBy and C57BL/6By; the AKXD recombinant 
inbred set; and congenics B6.C-H-19’/By and B6.C-H-29C/By 
were purchased from Dr Benjamin Taylor, The Jackson 
Laboratory, Bar Harbor, ME 04609, USA. Microcell hybrids 
used in this study (table 1) have been described previously [5,6]. 
2.2. Genomic Southern analysis 
10 fig of genomic DNA was digested to completion with either 
EcoRI or BumHI, electrophoresed through 0.8% agarose gels 
and subsequently transferred in 0.4 M NaOH onto Biotrace RP 
nylon membranes (Gelman Sciences, Ann Arbor, MI). Blots 
were prehybridized for 2-4 h at 65°C in a solution of 3 X SSC, 
1% sodium dodecyl sulphate, 0.4% non-fat milk powder and 
0.5 pg/ml freshly denatured herring sperm DNA. Blots were 
then hybridized overnight with a 397 bp StuI-BarnHI fragment 
from exon 2 of the mouse angiotensinogen gene [7,8] which was 
labeled with [cu-32P]dATP and [cr-‘*P]dCTP using the random 
primer method 191. Posthybridization washes were taken to a 
stringency of 0.5 x SSC at 65°C. Blots were autoradiographed 
using Kodak XARS film at -7O’C with a single intensifying 
screen. 
3. RESULTS AND DISCUSSION 
3.1. Strain distribution patterns for 
a~giotensi~ogen in recombinant inbred mice 
The previously determined strain distribution 
pattern for the angiotensinogen gene in CXB 
recombinant inbred strains D to K is BCBCBBB 
[3]. Inspection of all chromosomal assignments for 
the CXB recombinant inbred set (kindly provided 
by Dr B.A. Taylor) showed that this angioten- 
sinogen genotype was identical to that determined 
for the mouse skeletal muscle a: actin gene on 
chromosome 3 [ 10,111, but also RP-IO on chromo- 
some 7 [12]. However, there is a 5% probability of 
a false-positive linkage using the CXB recombinant 
inbred set alone [ 131, because this set contains only 
7 strains. 
In order to resolve this ambiguity, we used a 
BarnHI allelic polymorphism recognized by the 
mouse angiotensinogen exon 2 probe [8] to geno- 
type the large AKXD recombinant inbred set. The 
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Fig. 1. Southern blot of BarnHI-digested genomic DNA showing 
the strain distribution pattern for angiotensinogen in AKXD 
recombinant inbred mice. 
strain distribution pattern for the angiotensinogen 
gene in AKXD recombinant inbred mice (fig.1) 
shows no linkage to markers Pim-I [14] or Crya-I 
[15] on chromosome 17. Unfortunately, the AKXD 
set contains no published markers on chromosome 
3, 10, 14 or 16 [16]. Accordingly, the chromosomal 
localization of the angiotensinogen gene was deter- 
mined using microcell hybrids. 
3.2. Chromosomal localization of the 
angiotensinogen gene using hybrid cell lines 
Based on the recombinant inbred analysis, we in- 
itially analysed microcell hybrids containing mouse 
chromosomes 3 or 17 carried as Robertsonian 
translocations onto chromosome 8 [5,6]. Microcell 
hybrids containing mouse chromosome 8 alone 
were intended to serve as negative controls, as were 
the parental rat and hamster cell lines (table 1). 
Fig.2 demonstrates that microcell hybrids bearing 
either mouse chromosome 8 alone, Rb(8.17) or 
Rb(3.8) all contain a 4.5 kb EcoRI fragment 
specific for exon 2 of the mouse angiotensinogen 
gene. Taken together, these results show that the 
an~otensinogen gene is located on chromosome 8. 
This conclusion is reinforced by the fact that the 
monochromosom~ microcell hybrids 8D-1 and 
F(8)D were independently derived by positive selec- 
tion for APRT activity carried on chromosome 8 
[5,6]. Furthermore, the mouse angiotensinogen 
gene segregated condordantly with mouse chromo- 
some 8 when the primary F(8)D and F(8)E cell lines 
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Table 1 















































FB(8)D and FB(8)E were derived by backselection for the APRT- phenotype in medium contain- 
ing 2,6 diaminopurine [6] 
were backselected for the APRT- phenotype in 
medium containing 2,6 diaminopurine (fig.3A and 
table 1). This chromosomal localization for angio- 
tensinogen excludes linkage to the serine protease 
inhibitor locus on chromosome 12 [17], 
3.3. Linkage of the ang~o~e~~n~gen gene 
When the CXB recombinant inbred set was used 
to specifically examine markers on chromosome 8, 
the strain distribution pattern of the ecotropic 
murine leukaemia virus Emv-2 [ 18,191 showed only 
one mismatch to that determined for angioten- 
( kb 1 
Fig.%. Southern blot of EcoRI-digested DNA from microcell 
hybrids described in table 1, showing segregation of mouse 
angiotensinogen sequences with chromosome 8. Angioten- 
sinogen bands derived from parental rat and hamster cell lines 
Fig.3. Southern blot of EcoRI-digested genomic DNA. (A) 
Segregation of angiotensinogen sequences after back selection 
for the APRT- phenotype in cell lines FB(8)E and FB(8)D. (B) 
Lack of segregation of the BALB/c angiotensinogen allele with 
BALB/c chromosome 8 histocompatibility loci H-19’ and 
are also present. H-29’ into congenics B6.C-H-19’ and B6.C-H-29’. 
sinogen. The an~ote~inogen gene is linked to two 
unpublished markers on chromosome 8 in AKXD 
recombinant inbred mice. The strain distribution 
pattern for angiotensinogen (fig.1) showed only 2 
mismatches out of 24 with Rn7S-8, a 7s RNA gene 
(B.A. Taylor, personal communication), and 5 
mismatches out of 24 with Mpmv-21, a non- 
ecotropic murine retrovirus (W.N. Frankel, J.P. 
Stoye, B.A. Taylor and J.M. Coffin (1989), in 
preparation). Using established formulae [20] we 
estimate that the angiotensinogen gene is 
2.4 f 1.8 CM from Rn7S-8, and 7.5 + 4.4 CM from 
Mpmv-21. A definitive determination of the order 
HY SRI0 CELLS MICE 
rat - 
mouse - 
c - 2.3 
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of these genes on chromosome 8 requires analysis 
of a linkage cross. The BALB/c angiotensinogen 
gene did not segregate with the BALB/c chromo- 
some 8 histocompatibility markers H-19’ and 
H-29’ into congenic strains B6.C-H-19”/By and 
B6.CH-29’/By (fig.3B). 
Finally, the segregation of salivary gland and 
testicular angiotensinogen expression phenotypes 
into inbred mouse strains [3] was not concordant 
with known chromosome 8 retroviral insertions 
Emv-2 [18], A&v-21 [21], Xmv-12 or Xmv-26 [16]. 
We conclude that the nature of the &acting 
genetic lesion affecting tissue-specific expression of 
the angiotensinogen gene will be best defined using 
molecular cloning techniques. 
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 This work began from my interest in the hormonal regulation of gene expression.  I was a 
post-doctoral fellow in the laboratories of Dr John Shine (ANU, Canberra) and Dr John Baxter 
(University of California, San Francisco) primarily working on the structure and regulation of 
the growth hormone gene.  I made a minor contribution to this area (ref #21), however I was 
able to initiate a collaboration with a fellow post-doc, Dr Michael Karin, which spanned 10 
years and produced an extensive characterisation of the structure of the human 
metallothionein gene family and the regulation of these genes by glucocorticoid hormones and 
heavy metals (refs #22-28).  Subsequently an additional study, looking at negative regulation 
by glucocorticoids, was undertaken as collaborative project (ref Medcalf et al., 1986).  
Ironically it has turned out that the negative regulation of gene expression by glucocorticoids 
has a more important role to play in biology than the positive regulation however this served as 
an important paradigm for the general mechanism by which steroids regulate gene expression.  
It would be fair to say that Michael Karin was the main driver in the metallothionein project and 
that it was both a pleasure and an inspiration to try to keep up with him! 
 This work produced several publications in the journals Nature and Cell. It also resulted in 
the first ever identification and DNA sequence motif of a DNA regulatory element for a steroid 
receptor (the Glucocorticoid Regulatory Element). 
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ABSTRACT The rat growth hormone gene was isolated on a
cloned 11.4-kilobase EcoRI-generated DNA fragment from a bac-
teriophage "library" of chromosomal DNA. The structural gene
sequence, -2. 1 kilobases long, was identified by hybridization to
the corresponding cloned rat growth hormone cDNA and shown
to contain four intervening sequences. The complete primary
structure of the gene and the 5'- and 3'-flanking regions was de-
termined. The mosaic structure of exons and introns can be re-
lated to the different biological activities of growth hormone and
to the evolution from ancestral sequences of a gene that was the
precursor to the growth hormone and the related prolactin and
placental lactogen (chorionic somatomammotropin) genes. The
largest intron was found to contain a dispersed repetitive DNA
sequence flanked by perfect 18-base pair direct repeats. The mo-
bility of sequences of this kind could play a role in the observed
variation of intron sizes and in rearrangements of mammalian
genes.
Growth hormone (GH) is a member of a set of structurally re-
lated peptide hormones that includes prolactin (Prl) and pla-
cental lactogen (PL; chorionic somatomammotropin) (1, 2).
Analysis of the primary structures of the proteins and ofcDNAs
to each of their mRNAs suggests that these hormone genes
evolved from a common precursor (3-6). There are also regions
of internal homology within each protein suggesting that the
precursor of this gene family was formed by duplications of a
smaller ancestral gene (3). Human (h) GH has been found to be
a mixture of slightly different proteins (7). Although some ofthe
heterogeneities may be explained by posttranslational modifi-
cations, others may reflect variant genes or differences in pro-
cessing of the same mRNA (8). Thus, knowledge of the primary
GH gene structure may provide information about the evolution
of this family of genes and about the mechanisms by which sev-
eral hormone forms can be produced. The GH gene is expressed
in the pituitary and in cultured rat pituitary tumor cells (2). This
expression is regulated by hormones and other factors (2). Thus,
the gene is also ofinterest to study hormone action. Knowledge
of its primary structure should facilitate such investigations.
This paper presents the complete nucleotide sequence of the
cloned rat (r) GH gene isolated from a chromosomal DNA
library.
MATERIALS AND MB'rHODS
Hybridization Probes and Screening of the Rat DNA Li-
brary. The rat chromosomal DNA library, which has been de-
scribed by Sargent et al. (9) and was provided by that group,
was composed of a partial EcoRI digest of rat liver DNA cloned
into the bacteriophage A Charon 4A. Screening of the library
was carried out as described (10). The rGH cDNA fragment
isolated from the recombinant plasmid pRGH-1 (5) was used
as hybridization probe after radioactive labeling with random
DNA primers (11). Nitrocellulose filters were pretreated and
hybridized as described (12). Positive plaques were purified by
two further cycles of plating at much lower densities. A Charon
4A phage were grown and purifed as described (13).
DNA Sequence Analysis. DNA sequence analysis was car-
ried out by either the chemical degradation method (14) or the
chain termination method (15). In the latter case, fragments of
the cloned DNA were subeloned into the bacteriophage M13
mp7 (16) and analyzed by using a synthetic primer comple-
mentary to the codons for amino acids 13-17 of the ,B-galacto-
sidase gene (kindly provided by R. Crea).
Biosafety Conditions. All experiments involving recombi-
nant plasmids and phages were carried out under containment
conditions recommended by ASCORD (Australia) or National
Institutes of Health guidelines for recombinant DNA research.
RESULTS AND DISCUSSION
Isolation of Cloned rGH Sequences. A cloned rGH cDNA
probe was used to screen the rat chromosomal DNA library. Of
the 8 x 105 recombinant plaques screened, five clones hybrid-
ized with the 32P-labeled cloned cDNA. Restriction endonu-
clease analysis of DNA isolated from these clones showed that
they fall into two groups. The first group contains both an 11.4-
kilobase (kb) and a 1.5-kb EcoRI fragment. The 11.4-kb frag-
ment hybridizes strongly with the rGH cDNA and contains the
GH gene. The GH gene on an 11.4-kb EcoRI fragment was also
found in DNA from rat liver and cultured pituitary (GH3) cells.
This fragment appears to be identical to that characterized by
heteroduplex and restriction endonuclease mapping by Chien
and Thompson (17). The second, type of clone contains four
EcoRI fragments (1.7, 2.1, 3.6, and 4 kb). Only the 4-kb frag-
ment hybridizes (albeit only weakly) with the rGH cDNA
probe, and it probably does not contain the rGH gene as no
additional EcoRI fragment of this size could be detected on au-
toradiography of the genomic blots. Digestion of this type of
clone with several other restriction endonucleases also gave rise
to a completely different pattern of fragments than that found
in the rGH gene (Fig. 1). The nature of these sequences is un-
known; they could conceivably encode the closely related PL
gene or a GH "pseudogene."
One clone (ArGH-13) carrying the rGH gene was analyzed
further. Digestion of the 11.4-kb EcoRI fragment ofArGH-13
with HindIII gives rise to a 5.8-kb fragment that hybridizes to
the cloned rGH cDNA. This fragment (prGHeh 5.8) was sub-
cloned into the EcoRI/HindIII site ofpBR322 for further char-
Abbreviations: GH, growth hormone; kb, kilobase(s); rGH and hGH,
rat and human growth hormones, respectively; PL, placental lactogen;
Prl, prolactin; bp, base pair(s).
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FIG. 1. Map of the rGH gene. (A) Restriction endonuclease map of GH gene derived from rat liver DNA. (B) Schematic of the A-rGH-13 clone
containing two EcoRI fragments; the 11.4-kb fragment comprised the rGH gene. R and L, right and left arms, respectively, of A Charon 4A. (C)
Enlargement of the 5.8-kb EcoRI/HindllI fragment, which contained the structural GH sequences and was subcloned in pBR322 (prGHeh 5.8).
(D) Fragments of pRGH-1 used for establishing the restriction map. *, coding regions; f, 5'- and 3'-untranslated regions. For clarity, only a few
restriction endonuclease sites are shown in B and C. kbp, kilobase pairs.
acterization. The structure of this fragment and rGH cDNA is
compared with the restriction endonuclease sites in ArGH-13
in Fig. 1. This comparison shows at least four intervening se-
quences interrupting the rGH coding region. The arrangement
of introns and exons in this gene was determined-by using spe-
cific fragments ofthe cloned cDNA to hybridize with restriction
digests ofprGHeh 5.8 that had been fractionated by agarose gel
electrophoresis and transferred to nitrocellulose filters (18).
Similar digestions and hybridizations were carried out on DNA
isolated from rat liver and GH3 cells; by these criteria, the struc-
tural organization of the cloned rGH gene is identical to that
found in normal liver and is indistinguishable from that in cul-
tured pituitary tumor cells in which the gene is expressed (Fig.
1).
Primary Structure of GH Gene. The complete nucleotide
sequence of the gene (2088 bp) and adjacent regions (400 bp at
the 5' and 70 bp at the 3' end of the gene) in prGHeh 5.8 was
determined (Fig. 2). All restriction sites previously determined
in the gene and the surrounding regions from mapping data
were confirmed by this analysis. The first intron -of the gene
(IA) interrupts the coding sequence at codon -23 (where it splits
the GAC that encodes aspartate). The other introns, IB, Ic, and
ID occur between codons 31/32, 70/71, and 124/125,
respectively.
The GH mRNA sequence contained in the five exons agrees
completely with that determined from the cDNA sequence ex-
cept that the codon for the first amino acid ofthe mature protein
was found to be that for phenylalanine (UUC), as originally pre-
dicted from protein-sequence data (4), instead ofthat for leucine
(UUA) found in rGH cDNA and that an extra ribosylthymine
residue occurs in the cDNA clone between position 2075 and
2076 in the 3'-untranslated region.
Putative Promoter Region ofrGH Gene. A feature common
to eukaryotic genes is the Goldberg-Hogness box found 27-33
nucleotides to the 5' side of the initiation point ofmRNA tran-
scription (19). In the rGH gene such a sequence (5' T-A-T-A-
A-A) occurs in the anticipated position (-30) with respect to the
putative mRNA cap site. We assigned nucleotide 1 as the pu-
tative cap site as, in preliminary studies, reverse transcription
of GH mRNA (from cultured rat pituitary GH3 cells) primed
with a rGH cDNA fragment terminated at the nucleotide at
position 1 (data not shown).
If GH mRNA transcription initiates as indicated in Fig. 2,
then the largest RNA precursor should be -2100 nucleotides.
Although mRNA precursors of this size have been identified,
much larger precursor forms have also been reported (20) and
identified by G. Cathala (personal communication). The nature
of such large mRNA precursors is currently unkown.
The 5' end of the gene is of interest in terms ofpossible struc-
tures that may be important in regulating its expression. Apart
from the Goldberg-Hogness box, the region around nucleotide
-80 has been found to be conserved in other mammalian gene
families (21, 22). Although the structure ofotherGH (or related)
genes has not been published, a partial 5' sequence of one of
'the hGH genes made available to us by P. H. Seeburg (personal
communication) shows that the sequence between nucleotides
-88 and -74-C-C-A-T-G-A-A-T-A-A-A-T-G-T-A-is com-
pletely conserved in the human gene except for a cytidine sub-
stitution at position -83. Therefore, the question must be
raised of whether this structure has importance for GH gene
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90 100 110 120 124
Gin Phe Lau Ser Arq Ile The Tr Amn Ser Iu Met Phe Gly Thr Ser Asp Arg Val Tyr Glu Lys Leu Lys Asp Leu Glu Glu Gly Ile Gin Ala Leu Met Gin
CM T'r" Cy AKr AM MC 7T Ar AG Ar CM MG TT MAC( 713CC7 MCK RGAG AAAACM AA GAG CM GAA GM GM AM CMG GGT CAG MG CMG GT







Glu Lou Glu Asp Gly Ser Pro Arg Ile Gly Gln Ile Leu Lys Gln Thr Tyr Asp
GM CIG GMA GC 0OC AGC OXc CGT ATT GM2 AC M TC AMG CAA ACC TAT GAC
1800 1830
150 160 170
Lys Phe Asp Ala Asn Met Arg Ser Asp Asp Ala Leu Leu Lys Asn Tyr Gly Leu Lou Ser Cys Phe Lys Lys Asp Leu His Lys Ala Glu Thr Tyr Leu Arg Val Met
AMG mTT GMOc AMC A 0 CAO CGAGAT GW aOT dIG CTC AM AAC TAT GM0dIG CTl ITC 17E TIC AAG AG GAC cm CAC AKA: GA G AN MC dIGCoGGIC AmG
1860 1890 1920 19
180 190
Lys Cvs Ara Arq Phe Ala Glu Ser Ser Cys Ala Phe MI








FIG. 2. Sequence of the rGH gene and adjacent regions. Translation into the amino acid sequence of rat pre-GH is shown; amino acid 1 indicates
the first amino acid of the mature protein and amino acids -26 to -1 represent the signal peptide sequence. The Goldberg-Hogness sequence T-
A-T-A-A-A starting at position -30 is underlined. Nucleotide + 1 represents the putative 5' end of the mRNA (capping site) and is designated "CAP."
The poly(A) addition site is indicated by an arrow. In intron B (nucleotides 417-1133), the three long repeated sequences are underlined; asterisks
indicate the start of each repeat. The 18-bp direct repeats flanking these long repeated structures are overlined.
expression. By contrast, comparison of the GH gene structure
with that of the ovalbumin gene (also regulated by steroids) did
not show obvious similarities.
Termination Region of rGH Gene. As determined previ-
ously from cloned rGH cDNA, the 3'-untranslated region of the
mRNA is 100 nucleotides long and contains the characteristic
A-A-U-A-A-A sequence (23). This portion of the mRNA is con-
tiguous in the gene and is immediately followed by a region rich
in ribosylthymine residues with two stretches of poly(T)11. Sim-
ilar structures have been observed in the 3'-flanking region of
some, but not all, eukaryotic genes (24).
Evolution of GH Gene Family-Structure-Function Rela-
tionships. It is of interest to compare the GH gene with those
of the related PL and Prl genes. Although complete sequence
data for these other genes have not been reported, some com-
parisons can be made from heteroduplex mapping data (17),
partial sequence data of the rPrl gene (25), and the unpublished
observations of N. Cooke (rPrl) and P. H. Seeburg (hGH). Like
the rGH gene, the hGH and hPrl genes both contain four in-
trons, although the introns of the Prl gene are larger than those
ofthe GH genes. Further, the exon-intron junctions in all three
genes occur at identical locations when the coding regions are
aligned to maximize amino acid homology (6). The similar or-
ganization of these genes is thus consistent with the hypothesis
that they have a common evolutionary origin. It is of interest
to compare regions of internal homology previously observed
in GH, Prl, and PL (3) to the location of the exons (Fig. 3). As
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E3
FIG. 3. Schematic of the structural organization of the rGH geie. Exons (E1-Ed) are shown as boxes and introns and flanking regions are shown
as bars. 20K refers to a deletion form of hGH that omits amino acids 32-46. a3 peptide, site (positions 136-145) at which hGH is proteolytically
cleaved to a form that shows enhanced growth-promoting activity; U, untranslated gene sequences; m, homologous sequences; numbers in paren-
theses represent amino acid numbers.
is conceivable that the gene did evolve by duplications after
which an intron separating the third and fourth regions of ho-
mology in exon 5 was removed (Fig. 4). The absence of a ho-
mologous region in exon 3 suggests that it was added after du-
plication of the ancestral sequence, perhaps with the addition
of a new biological function.
The physiological actions ofGH can be divided into growth-
promoting and "anti-insulin-like" (diabetogenic). Several pro-
teolytically modified forms ofhGH have been examined (7). A
peptide (amino acids 44-77) containing mainly amino acids
coded by exon 3 (amino acids 32-70) has anti-insulin-like but
not growth-promoting activity (26). Thus, this activity may be
contained completely within exon 3. This idea is further sup-
ported by the demonstration that a variant form of hGH (20K
variant) lacking amino acids 32-46 (coded for by exon 3) does
not possess certain anti-insulin-like but does have growth-pro-
moting activity (Fig. 3; ref. 7).
Proteolytic cleavage ofGH can remove amino acids 135-146
(Fig. 3) to yield a two-chain structure connected by a disulfide
bridge. This a3 peptide shows enhanced growth-promoting ac-
tivity although destruction of the cysteine-53 (exon 3) - cys-
teine 165 (exon 5) bond abolishes this activity (7). Thus, although
sequences contained in exon 3 appear to be responsible for dia-




FIG. 4. Model for the evolution of GR, Prl, and PL genes. R, reg-
ulatory sequence; A. and B, coding sequences.
involved, along with some other portion of the molecule, in
maintenance of the structure needed for growth~promoting ac-
tivity. Exon 3 might therefore have been used initially to gen-
erate the tertiary strucure required for the activity of the prod-
uct of the gene that was the precursor ofGH and related genes.
The possible sequence of events in evolution of the GH gene
family shown in Fig. 4 suggests that the most primitive gene
may have included regulatory sequences (R) required for
expression, as well as coding sequences (A) that later were du-
plicated. Exon R carries the promoter region as well as the se-
quences for the 5'-untranslated region of the mRNA. The pres-
ence of an intron separating a "regulatory exon" at the 5' end
of the gene from the functional domains of the coding portion
is also seen in other mammalian genes (22, 24, 27, 28). Addi-
tional coding sequences (B) were.added later. The intron sep-
arating the last two, homologous regions of coding sequences
may have been removed. Genes that have this overall structure
appear to be the precursor for the entire GH gene family. Based
on the cDNA (4-6) and protein structural analysis (3), it appears
that the first duplication of this precursor led to one gene that
became the Prl gene and a second one that served as the pre-
cursor to both GH and PL.
Structure ofIntrons in the rGH Gene. The border sequences
of all four introns in the rGH gene are in good agreement with
the consensus sequence for such regions (29). As with intron-
exon junctions of other eukaryotic genes, there are ambiguities
in the precise splicing points, but each intron begins with G-T
at the 5' terminus and ends with A-.G at the 3' terminus. Note-
worthy is that the human 20K variant protein (lacking amino
-acids 32-46; Fig. 3) does not arise by proteolytic cleavage. In-
stead, from a previous partial sequence of the hGH gene (8),
it appears that a second RNA splicing point in exon 3 can account
for removal of the codons on the 5' portion ofthe exon and gen-
eration ofthe 20K form. Such a potential alternative RNA splic-
ing point ending in A-G and containing other.nucleotides con-
sistent with a consensus sequence (29) for RNA splicing is also
found in the rat.gene, although whether or not RNA.splicing
at this.alternative point occurs in the rat. is not known.
Three oftherGH gene introns are relatively small and.similar
in size, (IA, 194 bp; Ic, 160 bp; ID, 213 bp)-while the second is
much larger (IB, 718 bp). Intron B also has a lower G-C content
(45.5%) than the other introns (56%). This results from three
long A-T-rich regions in IB.
IB also exhibits some interesting structural features. It con-
tains a 195-bp tandem repeat; these repeats have 96% homology
(eight nucleotide substitutions and three insertions/dele-
tions). This structure is immediately followed by a 73-bp frag-
ment homologous (66%) to the. first part of the 195-bp repeat
(Fig. 2). Each repeat ends with a long poly(A) stretch. The 508-
bp segment of DNA containing the three long repeats is
bounded by perfect 18-bp repeats (Fig. 2). The sequence of this
repeat, 5' A-A-C-A-G-T-A-A-T-G-A-C-A-G-A-G-A-G, itself
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contains a palindromic symmetry with the center between the
7th and 8th residues.
The overall structure of this 508-bp DNA segment resembles
that of dispersed repeated sequences in mammalian DNA
(30-32). Such sequences are present in =-3 X 105 copies in the
haploid mammalian genome (30-32). The biological signifi-
cance of these sequences is not known, although they can be
transcribed, and it has been proposed that they play a role in
processing of pre-mRNA (30). For instance, the Alu family of
dispersed repetitive sequences in humans contains (i) internal
repeats with various levels of homology, (ii) 3'-teminal adeno-
sine-rich regions, and (iii) direct terminal repeats. The terminal
repeats differ in each case analyzed so far, suggesting that they
were generated during insertion (30, 32) and represent dupli-
cated chromosomal DNA sequences where insertion occurred.
Thus, the data raise the possibility that the 508-bp structure of
IB occurs elsewhere in the rat genome. Preliminary results us-
ing IB as a hybridization probe indicate that this sequence is a
member of the dispersed repetitive sequences and is further-
more found in at least three other positions in the next 7 kb on
the 3' side of the rGH gene. It is of interest in this respect that
intron B of the hGH gene is only 200 bp long and does not con-
tain large repeated sequences (P. H. Seeburg, personal
communication).
Although the 508-bp sequence in IB is a member of a family
ofdispersed repetitive sequences, it is somewhat unusual in that
the length of such sequences in the eukaryotic genome are
usually "300 bp (30). One explanation may lie in the structure
of the IB insertion itself. As the 195-bp tandem repeat is 96%
homologous, its duplication (via unequal crossing over) must
have occurred recently, possibly after the insertion into the in-
tron. If this is the case, then the inserted sequence was only 313
bp long, which is similar to the size of interspersed repeated
sequences. However, we cannot exclude the possibility that this
duplication event occurred elsewhere in the DNA and that the
whole 508-bp fragment was inserted into the intron.
The finding of repetitive DNA in an intron suggests mech-
anisms whereby such sequences can affect intron size. This
could be due not only to the insertion itself but also to the po-
tential for the sequences, once inserted, to be duplicated or
deleted. Short stretches of simple repeated sequences such as
A-T-A-T-A-T, adenosine-rich regions and the three long repeats
themselves found in the gene are factors that can increase the
frequency ofunequal crossing over and deletions (33, 34). Anal-
ysis of the same repetitive sequences lying 3' to the rGH gene
should provide information as to whether the terminal direct
repeats are an integral part of this sequence or are created on
insertion.
It has been proposed that dispersed repetitive sequences are
"hot spots" for genetic recombination and may be responsible
for rearrangements of genes and exons (35). The idea that these
sequences could be involved in the movement of genes is con-
sistent with the findings in this and other (22, 32) studies ofsuch
sequences in the proximity of particular genes. However, the
proposal that these repetitive sequences are involved in the
rearrangements of particular exons requires that they occur
between exons; the current finding of such sequences in an in-
tron of the rGH gene is consistent with such an idea.
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ABSTRACT
From a cDNA clone bank prepared from cadmium-treated HeLa
cells, we isolated clones representing mRNAs whose concentration
is increased after cadmium induction. Several metallothionein
cDNA clones were isolated by cross-hybridization to mouse metallo-
thionein-I cDNA. The nucleotide sequence of one of these clones,
containing a nearly full-length cDNA copy of human metallothionein-
II mRNA, was determined. The homology between the human and mouse
metallothionein sequences is strictly limited to the coding region
of the mRNA. Codon usage in metallothionein mRNA is not random.
Seventy-nine percent of the codons have G or C residues at the
third position, resulting in a GC-rich sequence.
INTRODUCTION
Metallothioneins (MT) are a family of low-molecular-weight,
heavy metal binding proteins, characterized by a high cysteine
content and the lack of aromatic amino acids. Metallothioneins
bind 6 to 7 moles of heavy metals, such as Zn, Cd, Cu and Hg, per
mole of protein. They are ubiquitously distributed in the animal
and plant kingdoms and are also found in prokaryotes (1). Human
MTs have been isolated from the liver, where they are present as
two major forms known as MT-I and MT-II (2). The regulation of
human MT synthesis has been studied in several human cell lines,
including the well characterized HeLa cells. In HeLa cells, MT
synthesis can be induced by either Zn++ or Cd++ (3) and by gluco-
corticoid hormones (4). In the past we have shown that either
heavy metals or glucocorticoids are "primary" inducers (5) of the
genes and lead to a rapid increase in the amount of translatable
MT mRNA (6). In order to investigate the molecular mechanisms
regulating MT genes' expression, it is necessary to have specific
hybridization probes for the genes and the mRNAs. In this commun-




ication we describe the molecular cloning and primary structure of
the mRNA for human MT-II.
MATERIALS AND METHODS
Total RNA was extracted by the method of Chirgwin et al. (7)
from HeLa cells maximally induced to synthesize MT by incubation
-5 -in 10 M CdCl2 and 10 4M cycloheximide for 8 hr before harvest
(5,6). Poly(A)-containing RNA was selected by hybridization to
oligo(dT)-cellulose (8) and used as template for the synthesis of
double-stranded cDNA by sequential reverse transcriptase reactions.
After removal of hair-pin loops by SI nuclease digestion, homo-
polymeric tracts (tails) with an average of 12 dCMP residues were
added to the 3' termini of the cDNA by incubation with terminal
transferase (Ratcliffe) and dCTP (9). The double-stranded, dCMP-
tailed cDNA sequences were annealed to plasmid pBR322 DNA, pre-
viously linearized with restriction endonuclease Pst I (BRL) and
3'-tailed with an average of 10 dGMP residues. The resultant chi-
meric plasmid DNA was used to transform E. coli RRI. The yield of
recombinant colonies was 4 x 103/pg cDNA, greater than 90% being
of Amp, Tetr phenotype. Bacterial colonies containing recombi-
nant plasmids were grown and fixed on 0.45-p, nitrocellulose fil-
ters, essentially as described by Grunstein and Hogness (10).
Duplicate filters were hybridized with 32P-labelled cDNA synthe-
sized from poly(A)-containing RNA from either induced or uninduced
HeLa cells, as described above. Twenty-four colonies were judged
by radioautography to give a stronger hybridization signal with
induced cDNA. Plasmid DNA was prepared from each of these colo-
nies and digested with Bam HI and Ava II. Four colonies were
found to contain a Bam HI site within the cloned insert sequence
and also to hybridize relatively strongly with a restriction frag-
ment of a cloned mouse MT-I cDNA (11) containing only coding se-
quences. The identity of these sequences as coding for human MT
was verified by nucleic acid sequence analysis.
RESULTS AND DISCUSSION
Construction and isolation of the cDNA clone
Maximal levels of MT-mRNA are achieved 8 hr after addition of




can be further increased by inclusion of 10 M cycloheximide
during the induction period (5). Under these conditions, MT-mRNA
is estimated to constitute about 2% of the mRNA. The starting
material for the cloning experiment was total RNA isolated from
HeLa cells, induced with Cd and cycloheximide as described above.
Messenger RNA was selected by oligo(dT)-cellulose chromatography
(8) and served as template for the synthesis of double-stranded
cDNA, which was subsequently cloned into the Pst I site of the
cloning vehicle pBR322, as described in Methods.
Seven hundred of the resultant recombinants were initially
screened by colony hybridization (10), using a nick-translated
(12) mouse MT-I cDNA probe (kindly provided by Dr. Richard
Palmiter). We failed to detect signals significantly higher than
background--a result that was not too surprising since the mouse
MT-I cDNA hybridizes to a large number of sequences in the mouse
genome (11) and weakly cross-hybridizes to a large number of human
sequences as well (R. Palmiter, personal communication). There-
fore, we have used a less direct approach for the detection of
human MT-mRNA clones. Single-stranded 32P-cDNA probes were tran-
scribed from poly(A)+-RNA from induced and uninduced HeLa cells.
The mRNA from the induced cells should have an approximately 50-
fold higher content of MT-mRNA than control cells (6). A clone
containing MT-cDNA sequences should therefore preferentially hy-
bridize with the "induced" 32P-cDNA probe. After hybridization of
duplicate nitrocellulose filters with "induced" and "uninduced"
32P-cDNA probes, 24 positive colonies were selected by virtue of
stronger hybridization signals with induced over uninduced probe
(Fig. 1).
The amino terminal of all mammalian MTs sequenced has the
structure N-Acetyl-Met-Asp-Pro. The corresponding nucleotide se-
quence is therefore either ATG GAC CCN or ATG GAT CCN, containing,
respectively, either an Ava II or a Bam HI restriction endonuclease
recognition site. Restriction endonuclease mapping of the selected
plasmids revealed that none of the insert sequences contained an
Ava II site, whereas a Bam HI site was found within the inserted
sequence of four recombinants. For nucleic acid sequencing, re-
striction fragments were end-labelled by either polynucleotide
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cal degradation by the method of Maxam and Gilbert (13). These
four plasmids also gave relatively strong hybridization signals
with mouse MT-cDNA probe (11) on a Southern blot (15) (data not
shown). Of these plasmids, the one with the longest insert was
chosen for further analysis.
The nucleotide sequence of MT-II mRNA
Plasmid DNA was prepared from the clone described above; it
was labelled at its Bam HI site with a-32P-dGTP and reverse tran-
scriptase (14), and the nucleotide sequence around this site was
determined by the method of Maxam and Gilbert (13). The sequence
in one direction encoded almost the complete peptide sequence
(amino acids 3 - 61) of human MT-II. This insert sequence was
subsequently completely derived (Fig. 2) and the plasmid desig-
nated phMTii-3. The coding region in phMTii-3 is flanked by 57-
and 128-nucleotide-long 5' and 3' untranslated regions, respec-
tively.
The coding region predicts a peptide sequence clearly identi-
cal to human MT-II, as previously reported (16), with the excep-
tion of residues 58 and 59, which are actually conserved with
respect to the rodent MT sequences (1,18) and have recently been
reassigned in the human (Kagi, J.H.R., personal communication).
Both the location of the Pvu II site and repeated nucleotide se-
quence analysis across this region verified the sequence shown
(Fig. 2). The 5' untranslated region, although apparently almost
full-length (73 nucleotides in mouse MT-I; ref. 19), may contain
ambiguities introduced during the cloning procedure (20,21) and
will therefore require verification by sequence analysis of the
chromosomal gene. The 3' untranslated region may also be incom-
plete since it lacks a poly(A) tract. Nevertheless, it does con-
tain two AAUAA sequences commonly found near the 3' end of eukary-
otic mRNA sequences (17).
Amino acid position 11 in the human MT-II sequence is an
aspartic acid residue (16) and its codon (GAY) forms part of a
Figure 1. Identification of cloned cDNA sequences coding for
human MT. Shown is one of seven triplicate sets of filters used
to screen the HeLa cell cDNA library with A. "induced" 32P-cDNA,
B. "uninduced" 32p-cDNA, and C. 32P-nick-translated Bam HI-
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Figure 2. Nucleotide sequence of human MT-II mRNA, as deduced
from the cloned cDNA insert in plasmid phMT1i-3. (Top) The se-
quencing strategy and physical map of the phMTII-3 insert sequence
cloned into the Pst I site of pBR322, as described in Methods.
Both Pst I sites were lost during the cloning procedure, probably
due to exonuclease contamination of terminal transferase. (Bot-
tom) Nucleotide sequence of human MT-II mRNA showing coding po-
tential for the MT-II protein sequence (ref. 16; Kagi, J.H.R.,
personal communication). Nucleotides are numbered from the AUG
initiation codon. Restriction endonuclease recognition sites dis-
cussed in the text are underlined, as are the AAUAA sequences
commonly found in the 3' untranslated regions of eukaryote mRNA
sequences (17). The cloned sequence is flanked by 21 G residues




Hinf I restriction endonuclease recognition site (Fig. 2). In the
human MT-I sequence this amino acid residue is a glycine (GGN)
(1), and therefore this Hinf I site should be absent. In each of
the cloned MT cDNA sequences analyzed, this Hinf I site is pres-
ent; we therefore conclude that they all encode the MT-II peptide
and not MT-I.
Table I shows the codon usage in human MT-II mRNA. Codon
usage is not random: 78.5% of the codons have G or C residues at
the third position; 90% of the cysteine codons, for example, end
with C. Similar observations have been made for the mouse MT-I
mRNA (11). The two MTs are 81% and 85% homologous in their
nucleotide coding regions and amino acid sequences, respectively.
The homology is strictly limited to the coding region of the
mRNAs; the 3' and 5' untranslated regions do not exhibit any
homology whatsoever.
Using phMTii-3 as a specific hybridization probe for the dif-
ferent human MT genes, we can now: a) isolate cDNA clones of the
other human MT mRNAs; b) isolate bacteriophage clones of human
genomic DNA, containing the MT genes; c) investigate the molecu-
TABLE I
Codon Utilization of Human MT-II mRNA
Nucleotide base of codon
2
U C A G
Phe Ser Tyr Cys 2 U
U Phe Ser 4 Tyr Cys 18 C
Leu Ser Term Term 1 A
Leu Ser 2 Term Trp G
Leu Pro 1 His Arg U
C Leu Pro 1 His Arg C
Leu Pro GluN 1 Arg A
Leu Pro GluN Arg G
Ile Thr 1 AspN Ser U
A Ile 1 Thr 1 AspN 1 Ser 2 C
Ile Thr Lys 5 Arg A
Met 1 Thr Lys 3 Arg G
Val Ala Asp 1 Gly 2 U
G Val Ala 6 Asp 2 Gly 2 C
Val Ala Glu Gly A




lar mechanisms involved in regulation of MT mRNA synthesis by
heavy metals and glucocorticoid hormones; and d) determine whether
the inherited defects in human trace-metal metabolism, such as
Wilson's disease, acrodermatitis enteropathica and Menkes' kinky
hair syndrome, are due to mutations in the MT gene(s), as has
been proposed (22-24).
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Summary 
We describe a region of human DNA containing four 
metallothionein (hMT) genes. One of these genes, 
hMT-IA, was found to encode a functional protein 
that confers heavy metal resistance to NIH 3T3 cells 
after transfer on a bovine papilloma virus-derived 
vector. This gene is expressed in cultured human 
cell lines, but at a lower basal level than the hMT-lln 
gene; it shows a different induction response to 
heavy metals and glucocorticoids than the hMT-II* 
gene. Induction of the human MT family therefore 
does not represent an equivalent elevation in the 
level of expression of individual genes, but is the 
sum of the differential responses of active members. 
The differential response is due to functional differ- 
ences of the respective promoter/regulatory regions 
of the genes as shown by gene-fusion experiments. 
While the hMT-IIn promoter is responsive to Cd++, 
Zn++, and glucocorticoids, the hMT-I,, promoter me- 
diates response only to Cd++. 
Introduction 
Metallothioneins (MTs) are low molecular weight, cysteine- 
rich, heavy metal-binding proteins (See Kagi and Nordberg, 
1979 for review). They are widely distributed among both 
animal and plant species, in which their synthesis is in- 
duced by the metal ions to which they bind, i.e., Cd”, 
Zn++, Hg++, Cu’, Ag+, and Au+. In mammals, MTs are 
also induced by treatment with glucocorticoid hormones 
(Karin and Herschman, 1979). Heavy metal ions and glu- 
cocorticoid hormones both act as inducers by elevating 
the transcription rates of MT genes (Durnam and Palmiter, 
1981; Hager and Palmiter, 1981; Karin et al., 1984a). 
In all mammals studied, MTs exist in two electrophoret- 
ically distinguishable forms, designated as MT-I and MT-II 
(Kagi and Nordberg, 1979) although several other variants 
have recently been described (Klauser et al., 1983). The 
induction of MTs by heavy metal ions is thought to be a 
monolytic response, i.e., all the variants are thought to be 
coordinately induced (Kagi and Nordberg, 1979). 
In man, MTs comprise a multigene family consisting of 
about lo-12 members (Karin and Richards, 1982b). How- 
ever, only half of these genes appear to be expressed at 
the protein level (J. Kagi, M. Kimura, personal communi- 
cations). We have isolated most of the human MT genes 
and have determined the nucleotide sequence of the 
unique functional hMT& gene and the processed pseu- 
dogene derived from it, hMT-lls (Karin and Richards, 
1982b). 
To address the questions of coordinate gene expression 
and possible functional differences between the different 
human MT genes, we have begun to characterize the 
structure and expression of the various hMT-l-like genes. 
Here we describe the characterization of a region of human 
DNA containing four tandemly arranged hMT-l-like genes, 
hMT-I,+ hMT&, hMT-lc, and hMT-I,,. One of these genes, 
hMT-I+,, encodes a functional protein, which, after transfer 
on an autonomously replicating mammalian plasmid vec- 
tor, confers heavy metal resistance to cultured mouse 
fibroblasts. We have also examined the expression of both 
the endogenous hMT-IA and hMT-lln genes in cultured 
human cells and found them to be differentially induced 
by various metal ions and glucocorticoid hormones, indi- 
cating the possibility of different functional roles for the 
two classes of MT genes. Gene-fusion experiments linking 
the 5’-flanking DNA of either the hMT& or hMT-IIA genes 
to the herpes simplex virus (HSV) thymidine kinase (TK) 
gene conferred the corresponding expression phenotype 
to the TK sequences. It is concluded that the differential 
expression of the two genes is due to functional differ- 
ences in their respective promoter/regulatory regions, 
Results 
Structure of the hMT-In Gene 
Isolation of human chromosomal DNA clones containing 
MT genes has previously been described (Karin and Rich- 
ards, 198213). One of these clones, XhMT-35, was selected 
for detailed analysis because of the presence of multiple 
restriction fragments hybridizing to the coding region of an 
hMT-lIA cDNA clone (Karin and Richards, 1982a); yet none 
of these fragments hybridized to either the 5’ or 3’ untrans- 
lated regions of hMT-II cDNA (R. R. and M. K., unpublished 
results). Southern blot analysis (Southern, 1975) of multiple 
restriction digests and partial DNA sequence determina- 
tions allowed assignment of the location and direction of 
transcription of four tandemly arranged hMT genes (Figure 
1). 
Two of these genes, hMT& and hMT&, are pseudo- 
genes. They have in-phase termination codons and/or 
single-base-pair deletions affecting the reading frame (not 
shown). All four genes have a coding capacity more 
homologous to the hMT-I protein’s consensus sequence 
(Kissling and Kagi, 1979) than to the hMT-II protein se- 
quence (Kissling and Kagi, 1977). Therefore, they were 
assigned to the hMT-l-like class on that basis. The hMT-IA 
gene appeared to be a functional gene and was therefore 
subjected to complete structural and functional analysis, 
Further characterization of the hMT-I, gene is required to 
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Figure 1, Restriction Map of XhMT-35 
The physical map was established by restriction enzyme analysis of AhMT- 
35 and subclones (in pBR328) of the three Eco RI fragments contained in 
XhMT-35. Partial nucleotide sequence analysis, by the chemical degradation 
(Maxam and Gilbert, 1980) and dideoxynucleotide (Sanger et al., 1977) 
sequencing methods, established the position and orientation of the four 
genes. 
The complete nucleotide sequence of the hMT-IA gene 
is shown in Figure 2. This gene contains two introns that 
are located at exactly the same positions as the introns in 
the mouse MT-I (Glanville et al., 1981) and the human MT- 
llA (Karin and Richards, 1982b) genes. However, the sec- 
ond intron of the hMT-IA gene is larger (about 500 bp) than 
the second introns of either the mouse MT-I or the human 
MT-II, genes (about 200 bp each). 
In the 5’-flanking region, a variant of the TATA consen- 
sus sequence (M. Goldberg, Ph.D. thesis, Stanford Uni- 
versity, 1979) CATAA, is located 24 bp upstream from 
the start of transcription. Upstream from the TATA box 
there are several regions of dyad symmetry, as has been 
observed earlier for the mouse MT-I (Glanville et al., 1981) 
and the human MT&, genes (Karin and Richards, 198213). 
The 61 amino acid sequence derived from the hMT-In 
nucleotide sequence deviates from the published amino 
acid sequence of human MT-Is (Kissling and Kagi, 1979) 
in four positions: Thr vs. Ala at amino acid position 17, Asn 
vs. Thr at position 27, Met vs. Val at position 39, and Ser 
vs. Gly at position 40. Because of these differences, we 
were concerned about the accuracy of the nucleotide 
sequence and have repeated the sequencing of the am- 
biguous regions several times from both strands; the 
results were identical in all experiments. Although the four 
amino acid changes would appear to have a negligible 
effect on the tertiary structure of the protein (Boulanger et 
al., 1983) one possibility was that the hMT-In gene is a 
mutated hMT-l-like gene encoding a nonfunctional protein. 
Therefore, we have examined the functionality of this gene 
and consequently its encoded protein by gene-transfer 
experiments. 
The hMT-IA Gene Encodes a Functional Protein 
Recently we found that rodent fibroblasts harboring a 
bovine-papilloma virus (BPV)-hMT-II* recombinant plasmid 
became more resistant to the toxic effects of Cd++. The 
resistance is due to high levels of expression of the 
episomally carried human hMT-lln gene (Karin et al., 1983). 
In the absence of any known enzymatic activity for MTs, 
the increased resistance to Cd+’ of cultured cells express- 
ing high levels of a cloned MT gene can be used as a 
criterion to assess the functionality of such genes. There- 
fore, we constructed the vector phMTln-BPV (Figure 3A) 
and introduced it into mouse NIH3T3 fibroblasts by trans- 
fection. To test whether the hMT-In gene is functional or 
not, the transfected cells were grown on medium contain- 
ing 10 PM Cd++ and 10 PM Zn++, concentrations that are 
sufficient to kill the parental NIH3T3 or BPV-transformed 
NIH3T3 cells. After 2 weeks of growth under selective 
conditions, many (about 50 per plate) Cd++-resistant col- 
onies consisting of morphologically transformed cells ap- 
peared. The extent of resistance to Cd’+ of a mixed 
population of cells derived from about 50 different clones 
containing the phMTIJBPV vector was compared to a 
mixed population of cells containing phMTIIA-BPV vector 
(Karin et al., 1983) and to the parental NIH3T3 cells, using 
a colony-formation assay. As indicated in Figure 36, the 
cells transformed with phMTkBPV are considerably more 
resistant than the wild-type cells but are not as resistant 
as the cells transformed with the phMTlL-BPV vector. 
The Cd++-resistant cultures transformed with either 
phMTkBPV or phMTII,-BPV were examined for the expres- 
sion of human MT mRNA using hybridization probes de- 
rived from unique regions of the respective genes that 
hybridize neither to mouse MT mRNA nor to each other 
(see Experimental Procedures). Both types of cultures 
express human MT mRNA, the level of which is regulated 
by the Cd++ concentration in the medium. The cells trans- 
formed with phMTIIA-BPV express about twice as much 
hMT mRNA as the cells transformed with phMTln-BPV (M. 
K. and H. Holtgreve, unpublished results). This difference 
in mRNA production is reflected in the levels of MT protein. 
In cells transformed with phMTln-BPV, newly synthesized 
hMT& protein (during an 8 hr labeling period) accounted 
for approximately 7% of the soluble proteins, while in cells 
transformed with phMTlln-BPV, newly synthesized hMT-lln 
was about 12% of the soluble proteins after induction. In 
the parental NIH3T3 cells, the mMTs account for only 1.7% 
of the newly synthesized soluble protein after induction. 
Expression of the hMT& Gene in Human Cells 
The experiments described above indicated that hMT& is 
a functional gene in terms of its encoded protein capabili- 
ties in mouse NIH3T3 cells. To determine whether the 
hMT& gene is normally active and inducible, we examined 
the expression of the endogenous gene in human skin 
fibroblasts and compared it to the expression and regula- 
tion of the hMT& gene. Human skin fibroblasts (culture 
GM 969) were treated with inducers of MT mRNA, and 
total cytoplasmic RNA was extracted and examined for 
the presence of either hMT-I,, or hMT-IIA mRNAs using two 
specific hybridization probes recognizing the 3’ untrans- 
lated regions of the two mRNAs, (see Experimental Pro- 
cedures for detail). As indicated in Figure 4, the two genes 
are expressed in human fibroblasts, but while the hMT-lla 
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Figure 2. Sequence of the Human MT-I, Gene Region 
The entire sequence of the Eco RI-km HI fragment, containing the hMT-I* gene and used in the BPV transformation experiments, is shown. The sequence 
was detenined by a combination of the chemical degradation (Maxam and Gilbert, 1980) and dideoxynucleotide sequencing methods (Sanger et al., 1977). 
Restriction sites used in this analysis are underlined. CATAAA and AATAAA sequences are boxed. Presumptive sites of initiation of transcription and poly(A) 
addition are indicated by arrows. Coding sequences are translated. 
gene is maximally induced by dexamethasone (a potent than the hMT-IA gene before or after Cd++ induction. In 
synthetic glucocorticoid), Zn++, and Cd++, the hMT-lA gene HeLa cells, as in fibroblasts, the hMT-IIA gene is much 
is maximally induced only by Cd”, and is only weakly more responsive to dexamethasone than the hMT-IA gene 
induced by dexamethasone or Zn++ (see Table 1). In (see Figure 4). 
comparing the exposure times required to produce auto- Since the induction of MTs by heavy metal ions was 
radiographic signals of similar intensity, we find the hMT- thought to be a monolytic response (see Kagi and Nord- 
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Figure 3. Functional Analysis of the hMT-In Gene Product 
(A) Structure of phMT-lx-BPV. An Eco RI (Ft-Barn HI(B) fragment containing 
the hMT& gene, the Barn HI-Hand III(H) 69% transforming fragment of BPV 
(Sarver et al., 1981) and the large Hind Ill-Eco RI fragment of pBR322 were 
ligated to generate the vector phMT-I,-BPV. Unlike phMT-II,-BPV (Karin et 
al., 1983) phMT-IA-BPV cannot replicate as such in mammalian calls, and 
It is necessary to remove the pBR322 sequences prior to transfection. This 
can be accomplished by partial Eco RI digestion, followed by complete 
digestion with Sal I. 
(B) Comparison of the sensttrvrtres to Cd++ of NIH3T3 cells, hMT-I*-BPV 
transformed cells, and hMT-IIn-BPV transformed cells. Mixed populations of 
NIH313 cells containing hMT-In-BPV (0) hMT-II,-BPV (0) were originally 
selected for survival in 10 rM Cd++. These cells and the parental NIH3T3(X) 
cells were plated in various dilutrons and grown for 2 weeks in increasing 
Cd++ concentratrons. The number of surviving colonies was determined 
and converted to percentage of the plating efficiency in the absence of 
Cd”. 
IA and hMT-IIA genes have a differential response to Zn++. 
To characterize this difference in greater detail we ex- 
tended the initial observations made with primary human 
fibroblasts and HeLa cells to another human cell line: 143 
TK- (derived from an osteosarcoma, Croce et al., 1979). 
The dose-response relationships between Cd++ and 
Zn++ to MT mRNA induction in 143 TK- cells were exam- 
ined in detail. Confluent cultures were incubated for 10 hr 
with various concentrations of Zn++ or Cd+’ or with 10e6 
M dexamethasone. Equal amounts of total cytoplasmic 
RNA from treated cells were subjected to electrophoresis 
on agarose gels and transferred onto nitrocellulose. Dupli- 
cate blots were probed with either the hMT-IA- or hMT-IIA- 
specific probes (Figure 5A). While the two genes seem to 
be almost equally responsive to Cd+‘, the hMT-In gene 
does not show significant induction with Zn++ until the 
cells are incubated in 2 X 10V4 M Zn++. The hMT-IIn gene, 
on the other hand, shows a more sensitive response to 
Zn++ and is half-maximally induced at 10m4 M, as revealed 
by the densitometric quantitation of autoradiography sig- 
nals (Figure 5B). As observed for primary fibroblasts, the 
dexamethasone treatment only leads to minor induction of 
the hMT-IA gene, while it fully induces the hMT-lln gene. 
We have also measured the induction kinetics of the 
two genes in HeLa cells and found them to be identical 
and similar to our previously published kinetics for total MT 
mRNA (Karin et al., 1981a, 1981 b). 
Differential Expression of the Two MT Genes Is 
Dictated by Their 5’-Flanking Regions 
The differential response of the two MT genes could be 
due to factors such as differences in mRNA stability or the 
transcriptional response of their respective promoter se- 
quences The identical induction kinetics of the two genes 
by Cd” tend to rule out differences in mRNA stability and 
implicates the promoter regions of the two genes as 
responsible for the observed effects. To test the role of 
promoter regions directly we have used the gene-fusion 
approach (Mayo et al., 1982). Two hybrid MT-thymidine 
kinase (MTK) genes were constructed. The first one, 
hMTK-IIA, utilizes the hMT-lln promoter to express the TK 
gene (this construct was referred to previously as hMTK, 
see Karin et al., 1984b). The second fusion, hMTK&, 
utilizes the hMT-IA promoter (Figure 6A). Previously we 
found the hMTK-lln fusion gene to respond to both glucor- 
corticoid hormones and heavy metal ions (after transfer 
into TK- rat 2 cells) as does the endogenous hMT& gene 
in HeLa cells (Karin et al., 1984a). Using the same assay 
(transfer into TK- rat 2 cells and analysis of the expression 
phenotype of TK transcripts) we tested whether the hMTK- 
IA gene is also responsive to both ligands. None of the 18 
individual TK+ clones examined responded to dexameth- 
asone with induction of 1.3 kb TK mRNA, yet 16 of these 
clones were responsive to Cd” (Figure 6B). When TK+ 
clones containing the hMTK-IIn gene are examined for 
hormonal induction, at least 50% of them are responsive 
(Karin et al., 1984a). 
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Figure 4. Expression of the hMT-I* and the hMT-II* Genes in Human Skin Fibroblasts and in HeLa Cells 
Primary cultures of human fibroblasts (culture GM-969, at passage 17) were incubated for either 8 (lanes labeled 8) or 18 (lanes labeled 18) hr in normal 
culture medium (CON) or in the presence of lo* M dexamethasone (DEX), lo-’ M .Zn++ (Zn), lo4 M Cu++ (Cu), or lo+ M Cd++ (Cd). HeLa cells (lanes 
labeled HeLa) were incubated for 8 hr in either normal culture medium (CON) or in the presence of lOa M dexamethasone (DEX). Cytoplasmic RNA was 
extracted and 40 @g samples were analyzed by electrophoresis on 1.5% agarose gels and Northern hybridization (Thomas, 1980) using as probe the 3’ 
untranslated regions of either hMT-lln (A: 14 hr exposure) or hMT-I* (B: 72 hr exposure). 
Table 1. Relative Induction of Human Metallothionein Genes by Heavy 
Metals and Glucocorticoid Hormone 








’ Values were detenined from densitometer traces of the autoradiographs 
shown in Figure 4. Control levels were the averages of 8 and 18 hr 
experiments and were arbitrarily assigned the unit value to simplify the 
comparison. The hMT-I& autoradiograph was exposed for five times longer 
than hMT-II,. (to achieve a linear exposure region); therefore basal and 
maximal levels of hMT-I* expression are approximately one-fifth that of hMT- 
IL+ Values are averages of two different induction experiments (8 and 18 
hr) determined for multiple exposures to insure linearity. 
To characterize further the differences between the 
hMTK-I, and hMTK-IIn fusion genes, we have examined 
the dose-response relationships of their induction by both 
Zn++ and Cd+‘. As shown in Figure 7A, the major transcript 
of the hMTK& gene is 1.3 kb in length as previously 
described (Karin et al., 1984a). The level of this transcript 
in the mixed culture analyzed is elevated after incubation 
with 10m6 M dexamethasone, 200 X lO-‘j M Zn++, and 
0.5-2 x low6 M Cd++. In cell lines containing the hMTK& 
gene, on the other hand, several transcripts can be de- 
tected (Figure 7B). Before induction none of them corre- 
sponds to the 1.3 kb transcript expected for initiation at 
the hMT-In promoter. This transcript becomes apparent 
only after induction with 5 X 10m6 M Cd++. The predomi- 
nant transcript of the hMTK-IA gene is 0.9 kb in length and 
corresponds to initiation from an endogenous promoter 
within the structural portion of the TK gene, previously 
described by Roberts and Axel (1982). Since the level of 
the 0.9 kb transcript varied slightly among the different 
samples loaded on the gel, we have examined the same 
samples using a probe for the oc-actin gene (kindly pro- 
vided by Dr. N. Davidson), a gene that does not respond 
to either heavy metal ions or glucocorticoids. The results 
presented in Figure 7C indicate that the observed variation 
in the level of the 0.9 kb transcript corresponds to the 
nonspecific variation in the actin signal, and therefore is 
not modulated by either glucocorticoid or heavy metal 
ions. 
Discussion 
Expression of the hMT-IA Gene 
In most animal species analyzed MTs are found in two 
major forms, referred to as MT-I and MT-II. Extensive 
biochemical and biophysical analyses have not led to 
detection of functional differences between those forms. 
Therefore it has been assumed that the various isoproteins 
and the genes encoding them are functionally identical 
(see Kagi and Nordberg, 1979). However, Suzuki and 
Yamamura (1980a, 1980b) have examined the ratios of 
MT-l to MT-II in rat liver after administration of either Cd++ 
or Zn++; and found that while Cd++ led to higher relative 
accumulation of MT-I, Zn++ led to higher accumulation of 
MT-II. More recently Winge and Miklossy (1982) found that 
rat MT-II has a higher affinity for zinc than MT-I. Our findings 
concerning the expression of the hMT-In and hMT-II+, genes 
support and further extend those results, While the hMT- 
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Figure 5. MT Gene Expression in Human Osteosarcoma-143TK- Cells 
(A) 143TK- cells were incubated for 10 hr in either normal growth medium 
without any additions (CON), or in the presence of 10” M dexamethasone 
(Dex), 20, 40, 70, 100, and 200 AM Zn++ (Zn), or 0.5, 2, and 5 AM Cd++ 
(Cd). Total cytoplasmic RNA was extracted and equal aliquots (40 ag) 
were fractionated on a 1.5% agarose gel and transferred onto nitrocellulose. 
One-half of the blot was hybridized to the hMT-I,-specific probe (2.106 
CPM/ml) and the film was exposed for 5 days. The other half was hybridized 
to the hMT-II,-specific probe (2.1@ CPM/ml) and the film was exposed for 
4 hr. (70 NM Zn++ sample is not present on the hMT-II* blot.) 
(B) Induction of hMT mRNA as a function of extracellular Zn++ concentra- 
tion. The autoradiographic signals shown in (A) were quantified by densi- 
tometry and converted to the fold increase over the basal level of expression 
(in the absence of any added metal ions). The fold inductron for hMT& (0) 
and hMT& (0) mRNAs was plotted as a function of the extracellular zinc 
concentration. 
hMT-In gene seems to be responsive mainly to Cd+’ (see 
Figures 4 and 5) and is induced only at extremely high 
Zn++ concentrations. 
The differential expression of the two characterized 
human MT genes is due to inherent differences in their 
promoters and regulatory elements. These elements, lo- 
cated in the 5’.flanking regions, satisfactorily account for 
the response of MT genes to various inducers such as 
heavy metal ions and glucocorticoid hormones (Karin et 
al., 1984a, 1984b). By fusing the promoters of the two 
genes to a common marker gene (TK of the herpes simplex 
virus) we have demonstrated that the induction phenotype 
of the hybrid gene is largely determined by its 5’ control 
regions, Therefore, while the hMTK-lIA fusion containing the 
hMT-IIA promoter responds to Cd++, Zn++, and dexameth- 
asone, the hMTK-IA fusion gene containing the hMT-IA 
promoter responds well only to Cd++ but does not respond 
to Zn++ or dexamethasone. While the exact molecular 
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Figure 6. Expression of the hMTK-I, Fusion Gene 
(A) Structure of the hMTK-In and hMTK-II* genes. Construction of the hMTK- 
lx gene is described in Experimental Procedures, and that of the hMTK-lln 
gene in Karin et al. (1984a). Hatched bars indicate MT gene DNA; solid 
bars indicate HSV-TK flankrng DNA; stippled bars indicate HSV-TK structural 
sequences; thin lines indicate plasmid sequences. The numbers refer to 
the nucleotide position of the respective genes. 
(B) Expression of the hMTK-Ix gene in individual TK+ transfectants. TK- rat 
2 cells were transfected with the hMTK-I, gene and individual TK+ colonies 
were randomly selected (a total of 18) and propagated into mass cultures, 
These cultures were incubated for 8-10 hr in either normal growth medium 
(0). or in the presence of IO+ M dexamethasone (Dx) or 5 x 10” M Cd++ 
(Cd). Total cytoplasmrc RNA was extracted and 25 pg was subjected to 
electrophoresis on 1.5% agarose gels and transferred to nitrocellulose 
(Thomas, 1980). The hybridization patterns for six of the clones after 
probing the filter with a radioactive probe derived from HSV-TK DNA are 
shown. 
basis for these differences between human MT genes is 
not clear at this point, we note the absence of a consensus 
sequence known to be involved in glucocorticoid receptor 
binding, from the 5’-flanking region of the hMT+, gene. 
This structural element is found between nucleotides -263 
and -238 of the hMT-IIA gene (Karin et al., 1984b). 
The results presented here may explain the differences 
between our previous findings, that the hMT-IIA gene is 
inducible by both dexamethasone and Cd++ after transfec- 
tion (Karin et al., 1984a) and those of Palmiter’s and 
Hamer’s groups who failed to observe hormonal induction 
of the transfected mouse MT-I gene (Mayo et al., 1982; 
Hamer and Walling, 1982). 
We believe that the differences described for the expres- 
sion of the two human MT genes are related to the different 
physiological roles of the two classes of MT genes. We 
propose that the hMT-IIA gene, which is highly inducible by 
dexamethasone and zinc (two physiological agents), has 
its main role in zinc metabolism. Its induction by zinc during 
periods of zinc excess would lead to the storage of surplus 
metal in the form of intracellular zinc-thionein. The physio- 
logical role of glucocorticoid induction of MT genes is not 
yet known; however, it has been observed that stress can 
lead to hypozincemia due to induction of MT in the liver 
(Subocinski et al., 1978). 
The hMT-I genes on the other hand, may function as a 
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The differences in the promoter strengths of the two MT 
genes are particularly evident when the expression of the 
hMTK fusion genes is analyzed. The hMTK-lln gene is 
expressed in relatively high levels in the absence of in- 
ducers, the 1.3 kb TK transcript derived from the hMT& 
promoter being the major transcript. On the other hand, in 
cells transformed with the hMT-In gene, the major TK 
transcript is a 0.9 kb RNA derived from an endogenous 
TK promoter (Roberts and Axel, 1982). The 1.3 kb tran- 
script derived from the hMT-IA promoter is barely detectable 




Figure 7. Comparisons of hMTK-I* and hMTK-llx Gene Expression 
A representative hMTK&-expressing cell line (AH7 see Figure 6B) was 
grown for 8-10 hr in either normal growth medium (0) or in the presence 
of IO* M dexamethasone (dex), 7 x 10m5 M, lo-’ M, 2 x lo+ Zn++ (Zn), 
5 x lo-’ or 5 x 10” M Cd++ (Cd). A mixed culture derived from many 
(2200) hMTK-IL-expressing clones was also subjected to the same treat- 
ments. 40 pg samples of total cytoplasmic RNA were separated on 1.5% 
agarose gels, transferred onto nitrocellulose, and hybridized against a TK- 
gene-specific probe (TK probe) or a-actin 3’ untranslated region-specific 
probe. 1.3 and 0.9 kb indicate the sizes of the various TK gene transcripts. 
(A) expression of the hMTK-II* gene. (B) expression of the hMTK& gene. 
(C) expression of the endogenous a-actin gene. 
protection system that is turned on after exposure to toxic 
heavy metal ions, such as cadmium or extremely high 
concentrations of zinc. This hypothesis is also supported 
by the large number of tandemly arranged hMT-l-like 
genes, Analysis of overlapping genomic DNA fragments 
contained in other X clones has shown that there are three 
further hMT-l-like genes located 5’ to the hMT& gene (R. 
I. R., unpublished data). Therefore there are at least seven 
hMT-l-like genes in this locus. More extensive analysis is 
needed to show how many hMT-l-like genes there are and 
how many of these are functional. This situation is in 
contrast to that of hMT-II, which is encoded by a single 
functional gene. 
The two genes also differ in their basal level of expres- 
sion. In human cells the hMT-lln gene is expressed about 
five times more efficiently than the hMT-IA gene. Since all 
the MT-I variants together make up about 50% of the total 
human MT protein (Karin and Herschman, 1980) it seems 
reasonable to assume that the low level of expression of 
the hMT& gene is characteristic of the other MT-I genes. 
The low relative transcriptional efficiency is compensated 
for by higher copy number. An analogous situation exists 
within the interferon gene family. The single human /I- 
interferon gene is expressed in higher levels than the 
multiple a-interferon genes (Hayes et al., 1979; Goeddel 
et al., 1981). 
Structure of the Human MT-IA Gene 
The hMT& gene is located within a cluster of at least 
seven tandemly arranged hMT-I like genes. Since the 
amino acid sequence of the proteins encoded by this gene 
differs from the published amino acid sequence of the 
human MT-I protein (Kissling and Kagi, 1979) at four 
positions, we were concerned about its functionality. How- 
ever the hMT& protein was found to be functional since it 
can confer cadmium resistance upon mouse fibroblasts 
after gene transfer on a BPV-derived vector (Karin et al., 
1983). 
The four amino acid differences between the sequence 
of hMT-I+, and the published amino acid sequence of the 
human MT-I proteins occur in positions that are probably 
not directly involved in metal binding (Kagi and Nordberg, 
1979; Boulanger et al., 1983). Since at least five different 
species of MT proteins are expressed in human liver (J. 
Kagi, M. Kimura, personal communications) it is very likely 
that hMT-IA encodes a new MT variant not previously 
described. 
The consistent difference between MT-I and MT-II protein 
sequences is the substitution of a gly at position IO or 11 
in MT-I for an asp in MT-II (Kagi and Nordberg, 1979; 
Griffith et al., 1983). The functional basis (if any) for this 
difference is unknown. The hMT-IA gene has gly codons 
at positions 10 and 11 (Figure 2) and was designated 
hMT-l-like on this basis. 
In addition, the 5’ untranslated region of the hMT& gene 
shows significantly greater homology to the mouse MT-I 
gene (59%) than to the hMT& gene (43%). In contrast, 
the human MT-IA 3’ untranslated region exhibits greater 
homology to the corresponding region of the hMT-IIn gene 
(113 out of 145 residues [78%] with 23 insertions or 
deletions to maximize homology) than that of the mouse 
MT-I gene (88 out of 136 residues [65%] with 41 insertions 
or deletions to maximize homology). The evolutionary re- 
lationship between all of these genes therefore remains 
unclear. 
The Consensus Sequence for Heavy Metal 
Induction 
By testing the heavy metal inducibility of in vitro-con- 
structed deletion mutants of the mouse MT-I gene pro- 
moter, it was revealed that the important regulatory se- 




Figure 8. Comparison of MT Gene 5’.Flanking Regions 
The 5’.flanking sequences of the human MT-I* and MT-II* and mouse MT-I 
genes are aligned to show homology in the region responsible for metal 
induction. Nucleotides identical with all three sequences are indicated. 
Regions of symmetry are overfined. TATA sequences are boxed. 
start site (Brinster et al., 1982; A. Carter and D. Hamer, 
personal communications). Using a similar approach, we 
found that an in vitro-constructed deletion mutant of the 
hMT-IIn gene containing only 50 nucleotides of its 5’- 
flanking region retains full inducibility with Cd++ (Karin et 
al., 1984b). A comparison of the relevant regions of three 
functional MT genes-the human MT&, MT-l+,, and the 
mouse MT-I genes-is shown in Figure 8. In addition to 
the conserved residues, the -40 to -110 region of all 
three genes is GC-rich (human MT&, 74%; human MT&, 
77%; mouse MT-I, 69%). A region in the hMT-IA sequence 
capable of forming a hairpin structure is located in a 
conserved position with respect to the mouse MT-I and 
human MT-IA genes. These homologies suggest that the 
MT induction region may be composed of both primary 
(residues -43 to -67) and secondary structural elements, 
similar to that of the regulatory promoter element of the 
heat-shock protein genes of Drosophila melanogaster (Pel- 
ham, 1982). Extensive homology has also been found 
between the induction regions of human o(, and /3 inter- 
feron genes (Ragg and Weissman, 1983) which suggests 
that eucaryotic gene regulatory elements will frequently 
comprise specific nucleotide recognition sequences in 
close proximity (within hundreds of bases) and 5’ to the 
transcription unit. 
Experimental Procedures 
isolation of XhMT-35 
The rsolation of cloned human chromosomal DNA containing MT sequences 
from a human bacteriophage h library (Lawn et al., 1978) has been 
described previously (Karin and Richards, 1982a). Digestion of purified X 
DNA (Benton and Davis, 1977) from each of 53 isolates, wrth Eco RI 
restriction endonuclease and subsequent blotting and hybridization analy- 
sis, enabled the rdentificatron of clones containing multiple hMT regions. 
One of these, XhMT-35, was subjected to further restriction site mapping 
to Identify four hMT hybndizrng regions. 
Growth of A DNA 
A rapid DNA extraction technique was utilrzed in order to analyze the high 
number of MT-positive bacteriophage A clones. Bacteriophages (105 pfu) 
were adsorbed to 0.1 ml of stationary E. coli strain LE392 in 1 ml of LM 
broth at 37°C for 30 min. The infected culture was diluted to 40 ml with 
prewarmed LM broth and incubated at 37°C with vigorous shaking until 
lysis had occurred (6 hr). 
Cell debris was removed by centnfugation and the supernatant treated 
with IO ag/ml DNAase I (Sigma) and IO pg/ml ribonuclease A (Sigma) for 
30 min at 37°C. Bacteriophage particles were precrprtated overnight by the 
addition of polyethyleneglycol to 5% and NaCl to 2.5 M at 4°C. After 
centrifugation, the bacteriophage particles were resuspended in 0.01 M 
Tns-HCI (pH 7.4), 0.1 M NaCI, 0.5% sodium dodecyl sulphate. and rncu- 
bated with IO pg/ml pronase for 30 min. To avord coprecipitation of RNA, 
X DNA was recovered by phenol-chloroform extraction and ethanol precip- 
itatron at room temperature. 
Subcloning of XhMT-35 Restriction Fragments 
Three Eco RI restriction fragments comprised the entire 16.5 kb Insert of 
human DNA in XhMT-35. These fragments were purified by electrophoresis 
through low-gellrng-temperature agarose and extraction using the CTAB 
method of Langrrdge et al. (1980) and inserted into the Eco RI site of the 
chloramphenrcol-resistancegene of pBR328 (Soberon et al., 1980). Detailed 
restriction sate mapping and sequence analysis was performed on these 
recombinant plasmids. 
Sequence Analysis of the hMT-lr Gene Region 
The sequence of the 2.9 kb Eco RI-Barn HI restriction fragment, containing 
the hMT-I gene and flanking regions, was determined by a combination of 
the chemical degradation (Maxam and Gilbert, 1980) and dideoxynucleotide 
(Sanger et al., 1977) sequencing methods. For the chemical analysis, 
restnctron-digest fragments were labeled at 3’ termrni using either the end- 
fillrng technique (Cooke et al., 1981) with the appropriate a-?dNTP 
(Amersham and New England Nuclear) and AMV reverse transcriptase, or 
n-=P cordycepin (Amersham) and terminal transferase (Tu and Cohen, 
1980). For dideoxynucleotide analysrs, restriction-digest fragments were 
subcloned into appropriately cleaved Ml3 DNA (mp8 and mpg; Vteira and 
Messing, 1983). Most of the sequence was detenined rn both directions 
and, where ambiguous, was determined at least twrce. 
hMT Gene-Specific Hybridization Probes 
The specific hybridrzation probes used to detect specific hMT gene tran- 
scripts were derived from the 3’ untranslated and flanking regions of the 
human MT-I* and MT-II* genes. For the hMT& It was contained within a 
Pvu II-Hand Ill fragment 390 bp rn length, and for hMT-II* it was contained 
within a Pvu II-Pvu I fragment from phMT-Ifa- (Karin and Rrchards, 1982a), 
280 bp in length. On Southern blot analysis of human chromosomal DNA, 
the hMT-I,-specrfic probe hybridized to a 14 kb Eco RI restriction fragment, 
whrle the hMT-lIA probe hybridized to a 5.7 kb Eco RI fragment. Under the 
stringent hybndrzation and washing conditions used the specific probes 
did not hybndrze with other members of the human MT gene famrly or to 
any of the mouse MT genes. We also used an hMT-la 5’ untranslated- 
region-specific probe derived from the Sma I-Sau 3A (nucleotrde posrtron 
-250 to +50) fragment and a TK-specific probe derived from a Pvu II 
fragment containing TK structural sequences (McKnight. 1980) for analysrs 
of hMTK fusion-gene expressron. 
Construction of Recombinant Plasmids 
phMT-la-BPV was constructed by ligating a 2.9 kb Eco RI-Barn HI fragment 
containrng the hMT-IA gene (see Figure 2) a 5.7 kb Bam HI-Hind III 
subgenomic transforming fragment of BPV (Sarver et al., 1981). and a 4.3 
kb Hind Ill-Eco RI fragment containing most of pBR322. Cloning techniques 
were as previously described (Karin et al., 1983) and were according to 
NIH guidelines for recombinant DNA research. 
Unlike phMT-IIn-BPV, whrch efficiently transforms rodent fibroblasts whrle 
containrng pBR322 sequences, phMT-In-BPV fails to do so unless pBR322 
sequences are removed. This can be accomplished by partial digestion 
wrth the restrrction enzyme Eco RI followed by complete Sal I drgestion, 
generating an 8.3 kb Eco RI-Sal I fragment containing only a small portion 
of pBR322. 
To construct the hMTK-In gene, an Eco RI-Sau 3AI fragment containing 
the 5’.flanking region of the hMT& gene was cloned between the Eco RI 
sate of pBR322 and the Bgl II site of the HSV-TK gene (McKnight. 1980). 
For this construction the HSV-TK gene was on plasmid pV4 (kindly provided 
by Dr. John Majors), a derivative of pTK that has only one Barn HI site due 
to deletron of the fragment between the Pvu II sate in the 3’.flanking DNA 
of the HSV-TK gene and the Pvu II site of pBR322 (J. Majors, personal 
communication). 
Cell Culture, Transfection, and Selection 
All cell lines used were grown in Dulbecco’s modified Eagle’s medrum 
supplemented with 10% fetal bovine serum (Sterile Systems), penicillrn, 
streptomycin, and gentamycin. TK+ cells were selected and marntarned in 
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the same medium supplemented with lo4 M hypoxanthrne, lo-@ ameth- 
optenn, and 1.6 x 10e5 M thymidine (HAT medium). Cadmium-resistant 
cells were selected and maintained in medium supplemented with IO pM 
CdC12 and IO pM ZnQ. DNA transfectrons were done as described by 
Wrgler et al. (1979) usrng l-2 pg of plasmid DNA and 15 pg of carrier 
DNA (calf thymus) per 1 ml of calcium phosphate precipitate. 
Analysis of hMT mRNA 
Total cytoplasmic RNA was extracted (Karin et al., 1980) and analyzed by 
Northern hybridization afler electrophoresis on 1.5% agarose gels as 
described (Karin et al., 1983). Autoradiographs were exposed for various 
lengths of trme to assure a linear response of the film and were scanned 
with a Zeineh soft-laser densitometer in order to determine relative hybridi- 
zation signal and, subsequently, RNA abundance. 
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The human metallothionein (MT) IB gene (hMT-IB) is located in a region of human DNA containing at least
four tandemly arranged MT genes. As deduced from its sequence, hMT-I] is likely to encode a functional
protein. However, the predicted amino acid sequence differed from the hMT-I amino acid sequence in four
positions. Most remarkable was the presence of an additional cysteine. Like other MT genes, hMT-IB has at
least two copies of the metal-responsive element upstream from the transcription initiation site. These elements
probably are responsible for the metal responsiveness of the hMT-IB promoter, leading to inducible expression
of fused heterologous genes. Unlike the hMT-IIA and hMT-IA genes described previously, which are expressed
in many different cell types, a high level of expression of the endogenous hMT-In gene could be detected only
in human hepatoma and renal carcinoma cell lines. Therefore, this is the first MT gene described which exhibits
tissue specificity of expression. This specificity is controlled by a cis-acting mechanism involving methylation,
since incubation of nonexpressing cells with an inhibitor of DNA methylation led to activation of the hMT-IB
gene. In support of this notion, we found that the 5' flanking region of the hMT-IB gene was highly methylated
in HeLa cells, a nonexpressing cell type, but it was not methylated in a hepatoma (expressing) cell line.
Metallothioneins (MTs) are ubiquituous low-molecular-
weight proteins with a high cysteine content and a selective
capacity to bind heavy metal ions (15). They can be classified
into two major groups, MT-I and MT-II, according to their
electrophoretic behavior. The MT-I subgroup can be further
resolved into several isoforms, known as MT-IA, MT-IB, etc.
Although the exact function of MTs is not clear, it is thought
that they play a central role in the regulation of trace metal
metabolism and in the storage of these ions in the liver. They
also may have a protective role against free hydroxyl radi-
cals (39). MT synthesis is induced by heavy metal ions and
glucocorticoid hormones at the transcriptional level (18, 20),
and by a variety of stressful stimuli, such as the injection of
bacterial lipopolysaccharide or UV irradiation. The lipopoly-
saccharide a,nd UV response suggests that MTs may have a
role in the acute-phase response (17), a pleiotropic response
to tissue injury and inflammation (25). The role of MTs in the
acute-phase response is supported by the fact that MT gene
expression is elevated by interferon (8, 9) and interleukin I
(21). Interleukin I is known to increase the expression of a
number of liver-specific genes during the acute-phase re-
sponse (25, 31, 35).
The multiplicity ofMT forms is confirmed by the fact that
in vertebrates they are encoded by a multigene family (12,
22, 34). The human MT (hMT) family consists of at least 12
genes, of which the functional members are located on
chromosome 16 (19). There are at least seven functional
genes (22, 32; unpublished data) and two mutant MT se-
quences clustered at 16q22 (27). MT sequences located on
other chromosomes are processed pseudogenes (22; unpub-
lished data). The expression and regulation of two of the
functional members, hMT-IA and hMT-IIA, have been stud-
ied in detail (20, 32). They exhibit different induction phe-
* Corresponding author.
t Present address: School of Medicine, M-13H, University of
California at San Diego, La Jolla, CA 92093.
notypes mainly due to substantial differences in their respec-
tive promoter elements effecting differential transcription
control. Despite these differences, expression of both genes
has been detected in all cell types tested. In light of the
multiplicity of human MT genes, we reasoned that certain
functional members may have evolved tissue-specific ex-
pression patterns to accommodate a wider-spectrum of
control of trace metal metabolism necessary in different cell
types. One gene, hMT-IB, exhibited a differential expression
phenotype and was therefore characterized in detail. We
found that this gene encodes an apoprotein of the MT-I type,
but with an additional cysteine residue at a unique location.
The hMT-IB gene has a functional promoter containing
structural features necessary for heavy metal induction. The
endogenous gene is expressed in high levels in human
hepatoma and renal carcinoma cell lines, while it is practi-
cally silent in HeLa cells, B-cell lines, and primary cultures
of human fibroblasts. This tissue specificity of expression
seems to be determined by a cis-acting mechanism involving
gene-specific methylation. This is the first example of an MT
gene whose expression is limited to selected cell types.
MATERIALS AND METHODS
Sequence analysis. The sequence of the region containing
the hMT-IB gene was determined by the dideoxynucleotide
sequencing method (33). Restriction digest fragments were
subcloned into M13 DNA (mp8 and mp9) (13). The
sequencing strategy is depicted in Fig. 1. The sequence was
determined for both strands to eliminate ambiguities.
Construction of recombinant plasmids. To construct the
hMTK-IB gene (an MT-Tk fusion), an 875-base-pair (bp)
HindIII-BamHI fragment containing the 5' flanking se-
quence of hMT-I1 was subcloned into pUC8 (40) cut with the
appropriate restriction enzymes. The resulting plasmid,
PUCIB5', was linearized at its unique BamHI site,
dephosphorylated, and used as a vector for cloning a 3.6-
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FIG. 1. Structure of the hMT-IB gene. (A) Physical map of A hMT-35, which contains four MT-I genes (32), showing the relative position
of the hMT-IB gene within the cluster. The exons are denoted by thick lines. (B) Restriction map of hMT-IB. The arrows indicate the strategy
followed to sequence this gene. Straight arrows are sequences originating at the indicated restriction sites, broken arrows are sequences of
clones generated by Bal31 deletions, and broken arrows are sequences of clones generated by random cloning of sonicated DNA.
kilobase BglII-BamHI fragment containing the coding region
and 3' untranslated region of the herpes simplex virus
thymidine kinase (TK) gene (29). The correct orientation
was determined by restriction mapping (Fig. 2A). For the
chloramphenicol acetyltransferase (CAT) constructions, a
BglII-BamHI fragment containing the CAT structural se-
quences (11) was cloned into pUC13 and was used as a
vector to insert the different hMT promoter/regulatory se-
quences (see Fig. 6). pUCAT2 is a subclone of the simian
virus 40 promoter and the CAT gene from pAlOCAT (26)
into pUC8.
Cell culture. All but two cell lines used were grown in
Dulbecco modified Eagle medium supplemented with 10%
fetal bovine serum (Hyclone), penicillin, and streptomycin.
The exceptions were the primary human foreskin fibroblasts
(a gift from J. Landolph), which were grown in a mixture of
Ham F12 medium and Dulbecco modified Eagle medium
(1:1) supplemented with 15% fetal bovine serum and the
above mentioned antibiotics, and the B-cell lines, which
were grown in RPMI 1640 medium supplemented with 10%
fetal bovine serum.
Transfections, selection, and CAT assays. phMTK-IB was
transfected into tk- Rat2 cells (1 ,ug ofDNA per plate) by the
calcium phosphate precipitate technique (41). tk+ colonies
were selected and maintained in Dulbecco modified Eagle
medium plus 10% fetal bovine serum supplemented with
l0' M hypoxanthine, 10-6 M aminopterin, and 1.6 x 10-5
M thymidine. Transfections of HeLa and Hep-G2 cells were
done with 10 ,ug of hMT-CAT plasmid DNA per dish
(containing approximately 106 cells) for 4 h. The transfected
cells were then shocked with 15% glycerol in lx HEBS
buffer (41) for 2 to 3 min. Cells were harvested 24 h after
transfection. The CAT enzymatic activity was determined as
described before (11).
RNA extraction and analysis. Total cytoplasmic RNA was
extracted from several hMTK-IB-transformed tk+ colonies
as described before (18). Samples (25 or 40 ,ug) ofRNA were
run on 1.5% agarose gels and blotted onto nitrocellulose
membrane (38) or Gene Screen Plus hybridization transfer
membranes (New England Nuclear Corp.). The blots were
hybridized to nick-translated gene-specific probes. For S1
nuclease mapping of hMT-IB mRNA, a probe was prepared
by end labeling the unique BamHI site at nucleotide +73
with [y32P]ATP, using T4 polynucleotide kinase (P-L
Biochemicals, Inc.), and digesting with Hinfl (site at -87).
The resulting 160-bp fragment was strand separated on an
8% strand-separating polyacrylamide gel. The specific activ-
ity of the probe was 5 x 106 cpm/pmol. For S1 analysis of
hMT-IIA mRNA, a probe was made by end labeling a unique
BamHI site at nucleotide +76 as described above and then
digesting with TaqI. The resulting 400-bp fragment was
strand separated on a 5% strand-separating polyacrylamide
gel. The specific activity was 6 x 105 cpm/pmol. A total of 30
,ug of RNA (per sample) was hybridized overnight to 50,000
cpm of the corresponding probes in buffer containing 80%
deionized formamide, 0.4 M NaCl, 40 mM PIPES
[piperazine-N,N'-bis(2-ethanesulfonic acid)], pH 6.4, and 1
mM EDTA. S1 digestions were carried out with 300 U of
enzyme (P-L Biochemicals, Inc.) per ml in a volume of 0.3
ml for 2 h at 37°C. The samples were resolved on a 6%
polyacrylamide-7 M urea sequencing gel.
Isolation of DNA and Southern blotting. High-molecular-
weight DNA was isolated from HeLa and Hep-G2 cells as
described before (22). The restriction enzymes EcoRI,
HpaII, and MspI were obtained from Boehringer Mannheim
Biochemicals. DNA (10 ,ug) was digested with 3 U of
enzyme per ,ug of DNA for 12 h, run on a 0.7% agarose gel,
and transferred to nitrocellulose filters (Schleicher &
Schuell, Inc.) as described before (37). To verify the com-
pletion of digestion, 500 ng of K DNA was included in
duplicate samples and visualized by staining with ethidium
bromide. The filters were hybridized with a nick-translated
probe derived from the 5' leader and flanking region of the
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FIG. 2. Expression of the hMTK-IB fusion gene. (A) Structure. Its construction is described in the text. Symbols: I?ZZI, hMT-IB DNA;
E: :, herpes simplex virus coding sequences; _, herpes simpex virus TK 3' flanking sequences. Thin lines represent pUC8 sequences. The
numbers indicate the nucleotide positions at the respective genes. (B) Expression in individual transfectants. A total of 12 tk+ colonies were
randomly picked and propagated into mass cultures. These cultures were incubated for 8 h in either normal growth medium (-) or in the
presence of 5 x 10-6 M cadmium chloride (+). A total of 40 jig of total cytoplasmic RNA extracted from these cultures was analyzed by the
Northern blot technique (38). The hybridization pattern of five representative clones, after probing the membrane with a TK-specific probe
(29), is shown. The arrow indicates the size of TK mRNA. The filter was exposed for 16 h. As a control for the amount of RNA loaded on
the gel, the same blot was hybridized to an actin probe, which did not reveal any significant differences (data not shown).
RESULTS
Structure of the hMT-IB gene. The structure of the hMT-I
gene cluster that contains the hMT-IB gene is shown in Fig.
1A. The hMT-IB gene is separated from the previously
described hMT-IA by two pseudogenes, lPhMT-Ic and
tPhMT-ID. The restriction map of hMT-IB and the sequencing
strategy are shown in Fig. 1B, and the complete nucleotide
sequence of this gene is shown in Fig. 3. This gene contains
two introns at exactly the same positions as the introns in
other MT genes (10, 22, 32, 34). However, the introns in both
hMT-IA and hMT-IB are larger (approximately 550 bp) than
their counterparts in the mouse MT (mMT) genes or hMT-
IIA. A TATAAA consensus sequence is present 29 bp
upstream of the initiation site of transcription, as determined
by the S1 nuclease protection technique (Fig. 4). Upstream
from the TATA box, between nucleotides -54 and -41,
there is the sequence TCTGCACCCCACCA, and further
upstream, from nucleotide -114 to -127, the sequence
ACTGCTCATGGCCC is found. Variants of these se-
quences are present in all MT genes described to date,
located in at least two distinct regions, around nucleotides
-150 to -130 and around the -50 region (4, 10, 18, 32, 34).
These sequences correspond to the metal-responsive ele-
ment (MRE) necessary for heavy metal inducibility (4, 22,
36).
The 61-amino-acid sequence derived from the hMT-IB
nucleotide sequence deviates from the published amino acid
sequence of human MT-I (24) at four positions: Ala versus
Thr at position 8, Cys versus Ser at position 32, Val versus
Ile at position 49, and Ser versus Thr or Ala at position 53.
The unique location of a cysteine residue at position 32 in
hMT-IB is of particular interest because of the involvement
of cysteine residues in metal binding. While at this stage we
do not know whether any of the amino acid differences have
any significance regarding the function of the protein, the
addition of a cysteine residue is a type of change expected to
affect metal binding.
Cloned hMT-IB gene has a functional metal-responsive
promoter. To investigate whether the cloned hMT-IB pro-
moter was functional and to begin the characterization of its
regulatory elements, we transfected an hMT-IB-TK fusion
gene (Fig. 2A) into Rat2 tk- fibroblasts. Expression of the
fusion gene was induced by Cd2+ in most of the cell lines
analyzed (Fig. 2B), indicating that the hMT-IB gene has a
functional metal-inducible promoter.
Expression of the endogenous hMT-IB gene in human cells.
We investigated the expression of the hMT-IB gene in
various cultured human cells to detect possible differences in
basal expression and in cadmium responsiveness. For this
purpose, total RNA was extracted from induced and
uninduced HeLa and Hep-G2 (a human hepatoma cell line)
(1) cells and from primary human foreskin fibroblasts. RNA
transcripts were analyzed by the S1 nuclease protection
technique (2) with a specific probe derived from the 5'
flanking and leader regions of the hMT-IB gene. We also
compared the expression of this gene with expression of the
hMT-IIA gene, since the latter is known to be expressed in
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FIG. 3. Nucleotide sequence of the hMT-IB gene region. The complete sequence of the 5' flanking, coding, and 3' flanking regions is
shown. The gaps in the sequence correspond to short regions within the introns. The sequence was determined by the dideoxynucleotide
method (33). TATAAA and AATAAA sequences are boxed. The initiation site of transcription is indicated by an arrow. Coding sequences
are translated.
high levels, and its transcription is induced by Cd2+ in all cell hMT-IIA gene. The basal level is very low but detectable in
lines we have tested (A. Heguy, G. Wong, and M. Karin, longer exposures of the same gel (data not shown). No basal
unpublished data). Figure 4 shows the results of such com- expression of hMT-IB could be detected in either HeLa cells
parative Si analysis. The hMT-IIA gene is expressed in high or primary cultures of human fibroblasts, even after very
levels in all three cell types, and its mRNA levels are long exposures. However, in Cd2+ induced HeLa cells or
elevated by Cd2+ treatment. Interestingly, the basal level of primary fibroblasts, a low level of hMT-IB-specific mRNA
hMT-IIA expression is considerably higher in the human could be detected. This level is at least 10-fold lower than
fibroblasts than in the other cell types we have tested. In that detected in induced Hep-G2 cells. These results indi-
contrast, the hMT-IB gene is expressed in high levels only in cated that the hMT-IB gene was preferentially transcribed in
cadmium-induced Hep-G2 cells, although the absolute level human hepatoma cells and suggested a cell type-specific
of expression is at least fivefold lower than that of the expression.
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FIG. 4. Comparison of hMT-IB and hMT-IIA gene expression by S1 nuclease analysis. Total cytoplasmic RNA from HeLa cells, Hep-G2
cells, and primary cultures of human fibroblasts was extracted after incubating the cells for 8 h in normal growth medium (-) or in the
presence of 5 x 10-6 M CdCl2 (+). RNA (40 p.g) from each sample was analyzed for either hMT-IB or hMT-IIA mRNA by the S1 nuclease
protection technique. The length of the protected fragment is 73 bases for hMT-IB and 76 bases for hMT-IIA. The HpaII digestion products
of pBR322 were used as size markers. The gel was exposed for 72 h.
To gain further knowledge on the cell type-specific expres-
sion of the hMT-IB gene, we analyzed total cellular RNA
from uninduced and induced human cell cultures by North-
ern hybridization. In addition to the cell lines examined
above, we analyzed another hepatoma cell line (Hep-3B),
two kidney carcinoma cell lines (A498 and A1212), and three
B-cell lines (Loukes, Namalwa, and IB4). The Northern
blots were hybridized with a probe specific for hMT-IIA,
derived from the 3' untranslated region of the phMT-413
cDNA clone (23) or with a hMT-IB-specific probe derived
from its 5' untranslated region. The hMT-IB-specific probe
does not hybridize to the mRNAs of the hMT-IIA, hMT-IA,
or to other hMT-I genes expressed in HeLa cells. While the
hMT-IIA gene was expressed in high levels in all of the cell
lines (Fig. 5), expression of the hMT-IB gene could be
detected only in both liver cell lines (data for Hep-3B is not
shown because it is identical to that obtained for Hep-G2)
and in the two kidney-derived cell lines. Hybridization of the
same blots with an hMT-IA-specific probe revealed a pattern
of expression similar to that of hMT-IIA, excluding the
response to dexamethasone (data not shown). Like the
hMT-IA gene (32), the hMT-IB 5' flanking region does not
contain a sequence resembling the glucocorticoid-responsive
element present in the hMT-IIA regulatory region (20). In
agreement with this observation, we could not detect induc-
tion of hMT-IB mRNA in dexamethasone-treated renal car-
cinoma cells, while hMT-IIA mRNA was induced (Fig. 5).
These results suggest that the hMT-IB gene is preferentially
transcribed in liver and kidney cells.
Tissue-specific expression of hMT-IB is controlled in cis. The
tissue-specific expression of the hMT-IB gene could be due
to the presence of tissue-specific promoter and regulatory
elements recognized by liver- and kidney-specific trans-
acting factors. Since in the past we found that the expression
phenotypes of the hMT-IIA and hMT-IA genes were con-
trolled by their respective 5' promoter/regulatory regions
(32), we examined the 5' flanking region of the hMT-IB gene
for the presence of tissue-specific regulatory and promoter
elements by fusing it to a convenient reporter gene coding
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FIG. 5. Expression of hMT-IB and hMT-IIA genes in human cells. Total cytoplasmic RNA from the cell lines indicated was extracted after
a 12-h incubation with 10-6 M dexamethasone (dex)-2 x 10-' M ZnC12 (Zn)-5 x 10-6 M CdCl2 (Cd). RNA (25 ,ug) from each sample was
analyzed by the Northern blot technique, using hMT-IIA-specific or hMT-IB-specific probes as indicated. While hMT-IIA mRNA could be
detected in all the cell lines, hMT-IB-specific mRNA was present only in Hep-G2, A498, and A1212 cells. The autoradiogram shown in the
upper panel is the result of a 12-h exposure; the one in the lower panel was exposed for 10 days.
gene was compared with that of the hMT-IIA-CAT and
hMT-IA-CAT fusion genes after transfections into cells
which either express (Hep-G2) or do not express (HeLa) the
endogenous hMT-IB gene. To our surprise, the hMT-IB-CAT
fusion gene was expressed to the same relative extent in both
cell lines (Fig. 6).
The lack of tissue specificity of expression of the hMT-IB-
CAT gene fusion could then be due to either of these two
possibilities: (i) the elements which control tissue specificity
of hMT-IB gene are not present in its 5' flanking region; or (ii)
the expression of the endogenous hMT-Il gene is controlled
in cis by tissue-specific structural modifications of the gene
itself. Since the expression of hMT-IIA and hMT-IIA is fully
controlled by their 5' flanking regions (20, 32), we consider
the second alternative more likely. However, Southern blot
analysis did not detect any gross differences in hMT-IB gene
copy number and arrangement between HeLa, Hep-G2, and
H x E
,I
primary fibroblasts (data not shown). We next considered
methylation, a structural modification known to alter gene
expression (14). To test the involvement of methylation in
the control of hMT-IB gene expression, we treated HeLa
cells with 5'-azacytidine (5'azaC), an inhibitor of cytosine
methylation, and examined the expression of the hMT-IB
and hMT-IIA genes by S1 nuclease protection analysis.
Incubation with 10-6 M 5'azaC for 24 h led to a considerable
increase in the expression of the Cd-induced hMT-IB gene
without affecting the pattern of hMT-IIA expression (Fig. 7).
A direct demonstration that the hMT-IB gene is methyl-
ated in HeLa cells is provided in Fig. 8. MspI versus HpaII
digestion demonstrated that the 5' flanking region of the
hMT-IB gene, detected by a specific hybridization probe, is
highly methylated in nonexpressing HeLa cells, but not in
expressing Hep-G2 cells. We are currently mapping the























FIG. 6. Expression of transfected hMT-CAT genes in HeLa and Hep-G2 cells. The upper line represents the structure of the hMT-CAT
constructions. Symbols: i221, hMT promoter sequences; =zI, CAT transcription unit. Thin lines represent pUC13 sequences. Major
restriction sites are indicated: H, HindIII; E, EcoRI; X, XbaI; B, BamHI; S, Sacl. n, and n2 the 5' and 3' borders, respectively, of the hMT
5' flanking sequences present in the constructions: in phMT-IB-CAT, n, is at -796 and n2 is at +73; in phMT-IA-CAT, n, is at -860 and n2
is at +49; in phMT-IIA-CAT, n, is at -764 and n2 is at +69. pUCAT2 was used as a negative control. CAT activities measured after
transfection into either HeLa or Hep-G2 cells are expressed in picomoles of acetylchloramphenicol per milligram of protein per hour.
Columns: (-), CAT activities in extracts from uninduced cells; (+), in cells induced with 5 x 10-6 CdCl2 for 12 h. Since transfection efficiency
varies with the cell type, only relative CAT activities should be compared.








FIG. 7. Expression of hMT-IB and hMT-IIA in 5' azaC-treated
HeLa cells. Exponentially growing HeLa cells (5 x 105 cells per
dish) were treated with 10-6 M 5'azaC for 24 h, then incubated with
fresh medium without (-) or with (+) 5 x 10-6 M CdCl2 for 8 h, and
harvested. Total cytoplasmic RNA (30 ,ug) was used in an S1
nuclease protection assay with either an hMT-IB-specific probe or an
hMT-IIA probe as indicated.
indirect end labeling, and we are investigating the methyla-
tion status of other neighboring hMT-I genes in different
human cell lines and tissues.
DISCUSSION
Structure of the human MT-IB gene. The substitution of a
Gly in position 10 or 11 in the MT-I protein sequences for an
Asp in MT-II is the only consistent difference between the
two major forms of MT (15). Based on this criterion we
placed the hMT-IB gene in the MT-I subfamily because it has
Gly codons at positions 10 and 11, as is the case for the
hMT-IA gene (32). The significance of these four differences
between the deduced amino acid sequence of hMT-IB and
the published amino acid sequence of a mixture of at least
three different MT-I proteins (24) is not known. However,
the substitutions occur in positions which are probably not
essential for heavy metal binding (3). On the other hand, the
presence of an additional Cys residue at position 32 could
have an effect on the metal-binding capacity of the protein.
There are several forms of MT-I in human liver, and at least
four of them are resolved by chromatographic procedures
(16). Interestingly, although closely linked in the genome,
the hMT-IA and the hMT-IB genes are quite divergent: the
amino acid sequences predicted from their respective nucle-
otide sequences differ in 10 of 61 positions, suggesting that
they encode functionally different MT-I isoforms.
The hMT-IB gene has a functional promoter capable of
rendering a heterologous gene responsive to cadmium induc-
tion, as we have demonstrated by gene fusion experiments.
The 5' flanking DNA contains at least two MREs, very
similar to those identified for the mMT-I (4, 34, 36). mMT-II
(34), hMT-IIA (20), and hMT-IA genes (32). The MREs are
highly conserved in all MT genes so far described, and
mutagenesis experiments (4, 20, 36) have demonstrated that
the presence of this conserved sequence is necessary for
metal induction. However, a formal proof of the role of the
MREs in mediating hMT-IB Cd2+ responsiveness would
require mutational analysis as described above.
Cell type-specific expression of hMT-IB. Since there are
several isoforms of hMT-I protein and several genes encod-
ing these variants, it was interesting to investigate whether
these genes were expressed preferentially in different cell
types. We favored the hypothesis that different MT-I genes























FIG. 8. Tissue-specific differences in methylation of the 5'
flanking region of the hMT-IB gene. DNA was extracted from HeLa
and Hep-G2 cells, and 10-p.g samples were digested with either
EcoRI alone, EcoRI plus MspI, or EcoRI plus HpaII. The digested
DNA was separated electrophoretically and transferred onto nitro-
cellulose filters which were probed with the 5' flanking region
(HindIII-BamHI) of the hMT-IB gene. M, Position and sites of
HindIII cleavage products of A DNA used as a marker. MspI and
HpaII share the same recognition site, 5'CCGG, but MspI is not
sensitive to CpG methylation, and HpaII is sensitive.
the multiplicity of MT-I genes and would be a way to
increase the potential for differential and cell type-specific
regulation of Zn and Cu metabolism (17). We have previ-
ously shown that both hMT-IIA and hMT-IA genes are
expressed in HeLa cells and human fibroblasts, although
their regulation is different, and the level of expression is at
least five times lower for the hMT-IA gene (32). The hMT-IB
gene also is expressed in approximately a fivefold-lower
level than hMT-IIA, but unlike hMT-IA, hMT-IB is expressed
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primarily in human hepatoma and renal carcinoma cell lines.
This gene is expressed at extremely low levels, if at all, in
HeLa cells (which are of epithelial origin), B-cell lines, and
primary fibroblasts. Therefore, it is possible that the hMT-IB
gene is cell type specific, or at least preferentially expressed
in liver and kidney cells. Interestingly, these tissues also
exhibit the highest MT content in vivo (15).
At this point, the tissue-specific expression of the hMT-IB
gene is suggested by studying a large number of cultured cell
lines. We assume that these results reflect the in vivo
expression patterns of the gene. However, direct demonstra-
tion of tissue-specific expression in vivo requires the analy-
sis of human tissues. This is nearly impossible because the
basal level of expression of hMT-IB, even in Hep-G2 cells, is
very low, and hMT-IB mRNA can be clearly observed only
after induction by Cd2 . We hope to solve this problem by
performing studies on primary cultures of human organs.
However, we have shown that hMT-IB transcripts are absent
not only in certain transformed cell lines but also in primary
cultures of human foreskin fibroblasts, indicating that the
tissue-specific expression of hMT-IB is not a phenomenon
arising from the long-term passage of cell lines, but is of
physiological relevance.
Unlike other liver-specific genes which are controlled by
trans-acting factors specific to liver cells (5, 7, 30), hMT-IB
tissue-specific expression is not determined in trans. An
hMT-IB-CAT fusion is expressed both in Hep-G2 and HeLa
cells; the endogenous gene is expressed only in Hep-G2.
Since the expression of hMT-IB is increased dramatically
after incubation of HeLa cells with 5'azaC, an inhibitor of
cytosine methylation (14), it appears that methylation keeps
the hMT-IB gene in a nonactive state in this cell line and
probably in others. In fact, when DNA extracted from HeLa
cells is analyzed by digestion with a methylation-sensitive
enzyme, the 5' flanking region of the hMT-IB gene appears to
be much more extensively methylated in these cells than in
Hep-G2 cells. The very low level of hMT-IB expression
which can be detected after long exposure of RNA samples
from Cd-induced HeLa and fibroblast cultures could there-
fore be due to a small subpopulation of cells which fail to
methylate their hMT-IB gene. Compere and Palmiter (6) have
previously shown that the mMT-I gene is shut off in W7
thymoma cells by cytosine methylation. However, in that
case the methylation was not selective and also led to
inhibition of mMT-II gene expression (28). Moreover, the
inhibition of mMT gene expression by methylation is unique
to the W7 cell line (R. Palmiter, personal communication).
On the other hand, the hMT-IB gene is not active in the
majority of the cell lines and primary cultures that we have
examined, and the closely linked hMT-IA and hMT-IIA genes
are not affected. We are currently investigating which regu-
latory sites on the hMT-I gene are specifically affected by
methylation and whether the same elements are present in
the hMT-IA and hMT-IIA genes. In any case the current
results suggest the existence of a novel mechanism for
control of gene activity within a multigene family by gene:
specific and tissue-specific methylation events.
Although the mechanisms involved in control of tissue-
specific gene expression by methylation are not yet clear, the
hMT-IB gene represents the first example of a tissue-specific
MT gene. It is possible that in multigene families which arose
by recent duplication events, like the hMT family, some of
the members have not yet sufficiently diverged to allow
recognition of their promoter/regulatory elements by dif-
ferent factors. In such a case, controlled methylation and
demethylation events may constitute a mechanism for tis-
sue-specific expression which does not require new specific-
ities of promoter recognition by tissue-limited regulatory
factors. It would be interesting to investigate the possibility
of a correlation between methylation of specific sites in the
control region of hMT-IB and the binding of specific tran-
scription factors. As discussed earlier (17), different tissues
and cell types are likely to have different requirements for
zinc and copper ions, whose availability is controlled by MT.
Understanding the full physiological significance of selective
expression of the hMT-IB gene and the amino acid differ-
ences of its cognate protein will require purification of the
latter protein and comparison of its biochemical properties
with those of other human MT-I isoforms.
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Suppression of plasminogen activator (PA) activity has been
invoked as being part of the general anti-inflammatory ac-
tion of glucocorticoids. Low concentrations of the synthetic
glucocorticoid, dexamethasone (Dex), reduce urokinase-type
PA mRNA levels in two cell types, namely a human fibro-
sarcoma line, HT1080, and synovial fibroblast-like cells
isolated from human joints. Conversely, metallothionein IHa
(MTIIa) mRNA levels in these cells are raised by Dex. These
findings, by suggesting that it is possible to suppress uro-
kinase-type PA activity at the level of gene expression, may
have therapeutic inplications for diseases such as rheumatoid
arthritis where proteases may be contributing to the exten-
sive tissue damage and inflammation.




Human plasminogen activators (PAs) are serine proteases of two
types, a urokinase-type and a tissue-type, which cleave
plasminogen to another serine protease, plasmin (Collen, 1980).
PA activity has been correlated many times with the processes
of tissue re-modelling, inflammation and cell migration (Reich,
1978). As an example with clinical relevance, the PA/plasmin
system is likely to be important in the pathogenesis of rheumatoid
arthritis. The evidence for this possibility includes the presence
of the proteases in rheumatoid synovial tissue and fluids (Mochan
and Uhl, 1984; Van de Putte et al., 1977; Werb et al., 1977),
and the ability of plasmin to degrade cartilage (Lack and Rogers,
1958; Mochan and Keler, 1984) and to activate both a latent col-
lagenase (Werb et al., 1977) and certain enzyme cascades likely
to be important in the development of inflammatory processes
(Hamilton, 1983; Hamilton and Slywka, 1981).
Low concentrations of glucocorticoids, including dexa-
methasone (Dex), reduce the PA activity of a number of cell types
(Coleman et al., 1982; Hamilton, 1983; Hamilton et al., 1981;
Littlefield et al., 1985; Vassalli et al., 1976; Werb, 1978). This
modulation in cells such as synovial fibroblast-like cells and
macrophages may help to explain the anti-inflammatory proper-
ties and clinical efficacy of glucocorticoids in diseases such as
rheumatoid arthritis (Hamilton et al., 1981; Vassalli et al., 1976).
The mechanism by which these steroids regulate cellular PA en-
zyme activity is unknown.
Results
The HT1080 cells secrete high levels of PA activity as evidenc-
ed by the plasminogen-dependent fibrinolytic activity of the con-
ditioned medium. As judged by inhibition with anti-urokinase
antibody and by mol. wt determination with the fibrin-agar
overlay technique (Granelli-Pipemo and Reich, 1978), the detec-
table extracellular and cell-associated PA activity is of the uro-
kinase-type (and not the tissue-type) and most likely secreted as
the pro-urokinase form which is activated during the fibrinolysis
assay (Saksela et al., 1984; Wun et al., 1982). We also have
evidence using similar approaches that the HT1080 cell line us-
ed in the current studies secrete predominantly urokinase-type
PA (data not shown). Using a unique 32P-labelled 30-mer to
tissue-type PA, we have found that the HT1080 cells do have
tissue-type PA mRNA. However, tissue-type PA activity is not
detectable in the supernatants due to the presence of an inhibitor.
The urokinase-type PA activity in the HT1080 cells is reduced
markedly by low concentrations of the glucocorticoid, Dex
(Figure la). The effect of glucocorticoids on tissue-type PA
mRNA will be reported elsewhere.
To determine whether this reduction in PA activity by Dex
might be occurring at the level of mRNA, a 32P-labelled cDNA
probe to human urokinase was hybridized to mRNA both from
untreated HT1080 cells and also from cells treated with different
concentrations of Dex. As seen in Figure lb, cells from control
cultures gave a band of PA mRNA migrating at - 22S, agree-
ing with previous reports for the size of urokinase-type PA
mRNA (Nagamine et al., 1983; Verde et al., 1984). The levels
of this mRNA were reduced quite dramatically by Dex in a dose-
dependent manner. Scanning laser densitometry of the bands
(Figure ic) indicated that 10-7 M Dex reduces the PA mRNA
levels by -75%. From Figure la - c, it can be observed that
the effects of Dex on both the PA enzyme activity and on the
PA mRNA levels were quite dramatic and were evident at similar
drug concentrations. These results strongly suggest that the reduc-
tion in the PA activity is due to a significant extent to a reduc-
tion in PA mRNA levels.
To show that the Dex was not having a general inhibitory or
perhaps toxic effect on the cells, the same nitrocellulose filters
were probed with a 32P-labelled cDNA to human metallothio-
nein Ha (MTIIa). As with several other cells (Karin et al., 1980),
Dex caused a dose-dependent increase in the MTIIa mRNA
(Figure lb and c). The inverse effects of Dex on the PA mRNA
and the MTIIa mRNA levels occurred at similar concentrations.
In support of the non-toxic nature of the Dex effect it was found
that the PA enzyme activity, the PA mRNA levels and the MTIIa
mRNA levels were almost completely restored to control values
if the cells were treated for 8 h with 10-7 M Dex at 37°C and
then incubated in the absence of the drug for a further 16 h (data
not shown).
For a number of cell types, it is the glucocorticoids but not
other steroids which lower the PA activity (Coleman et al., 1982;
Hamilton, 1983; Hamilton et al., 1981; Littlefield et al., 1985;
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Fig. 1. Effect of dexamethasone on PA activity and PA mRNA levels in
HT1080 cells. (a) Suppression of PA activity by Dex. HT1080 cells were
cultured for 24 h in the presence of Dex (10-10- 10-7 M) (see Materials
and methods). Pooled conditioned medium from four flasks was diluted
1:256 and assayed for PA activity by the 125I-fibrin plate method (see
Materials and methods). The values are the means, with range of variation,
of duplicate assays and are expressed as a percent of the total radioactivity
removable from the assay well by trypsin. Under the assay conditions, 0.4
Ploug units of urokinase (Leo Pharmaceutical Products, Ballerup, Denmark)
gave a value of 50% fibrinolysis. (b) Reduction in PA mRNA levels by
Dex. Northern analysis (see Materials and methods) of PA mRNA and
MTIIa mRNA from the HTl080 cultures of (a). 18S and 28S ribosomal
markers are indicated. (c) Quantitation of changes in PA mRNA and MTIIa
mRNA levels due to Dex. The intensity of the bands shown in (b) are
expressed as a relative intensity, the band with the highest intensity being
assigned an arbitrary score of 1.0. Each band was scanned at four different
positions (see Materials and methods) and the intensity scores averaged after
subtraction of the background intensity. 21, intensity of PA mRNA bands;
R2, intensity of MTIIa mRNA bands.
Roblin and Young, 1980; Vassalli et al., 1976; Werb, 1978);
there is evidence that they act in these situations via a glucocor-
ticoid receptor (Hamilton, 1983; Hamilton et al., 1981; Littlefield
et al., 1985; Roblin and Young, 1980; Vassalli et al., 1976;
Werb, 1978). Consistent with these findings, we found that
hydrocortisone (10-7 M), but neither aldosterone nor pro-
gesterone at the same concentration, lowered the PA activity and
the PA mRNA levels in HT1080 cells.
In Figure 2a and b, the rate of change in mRNA levels resulting
from the action of 10-7 M Dex is depicted. A reduction in the
PA mRNA levels occurred within 2 h and was virtually complete
if the cells were exposed to Dex for 8 h. Conversely, increases
in the MTIIa mRNA levels occurred with similar kinetics.
To determine whether there was a requirement for protein syn-
thesis for the suppressive effect of Dex, HT1080 cells were
treated with cycloheximide for 8 h as well as with the gluco-
corticoid. It is evident from Figure 3a that cycloheximide by itself
could increase the steady state PA mRNA levels when compared
to control cultures. This observation may be due to a general
effect of cycloheximide on gene expression previously noted in
some other systems including the MTIIa gene (Friedman et al.,
1984; Ringold et al., 1984). In spite of this increase, Dex was
still able to lower the mRNA levels in the presence of cyclo-
heximide, the relative reduction due to Dex being similar for the
cycloheximide- and non-cycloheximide-treated cultures (as judged
by scanning densitometry, 35% cf. 25%, respectively). This find-
ing suggests that Dex is having a direct effect on the PA mRNA
levels, possibly via PA gene transcription (see below). Likewise,
Dex still increased MTIIa mRNA levels in the presence of
cycloheximide (Figure 3a). As shown by [3H]leucine incorpora-
tion into protein over an 8-h period, the cycloheximide suppressed
protein synthesis by about 80% whilst Dex alone had no effect.
Cycloheximide also reduced the PA enzyme activity in the con-
ditioned medium by 80% (data not shown).
We found in previous work with murine macrophages that ac-
tinomycin D inhibited the Dex-mediated decrease in PA enzyme
activity, suggesting that RNA synthesis was required for the ef-
fect of Dex (Vassalli et al., 1976). The approach adopted in the
current study allowed us to test this concept more directly.
HT1080 cells were next treated with the glucocorticoid for 8 h
but also in the presence of actinomycin D. As observed in Figure
3b and c, Dex no longer suppressed the PA activity nor the PA
mRNA levels in the presence of actinomycin D. Yields of mRNA
prepared from cells treated with actinomycin D were -50%
lower than the mRNA yields from both control cultures and
cultures treated with Dex alone, even though there was no loss
in cell number. To compensate for this difference in mRNA
yields, the amount of mRNA loaded for Northern analysis in all
of the tracks was made proportional to the yield of mRNA ob-
tained for each culture. This approach allows the data to be ex-
pressed, as in the other figures, relative to the number of cells
in culture (i.e. on a per cell basis). Given that Dex no longer
suppresses PA mRNA levels in the presence of actinomycin D
it suggests that the action of Dex is likely to be via a direct in-
hibition of PA gene transcription rather than by an increase in
the breakdown of PA mRNA. Likewise, Dex could not elevate
the MTIIa levels in the presence of actinomycin D (Figure 3c),
as noted before with other cells (Karin et al., 1980).
We are using the HT1080 human fibrosarcoma line, which
was derived from an invasive tumour in acetabulum cartilage and
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Fig. 2. Kinetics of the reduction in PA mRNA levels by dexamethasone in HT1080 cells. (a) Northern analysis. The autoradiogram depicts PA mRNA and
MTIIa mRNA bands from HT1080 cells cultured as in Figure 1 but in the presence of 10-7 M Dex for different periods of time (0-8 h). The same
protocols as for Figure lb. were used except that 2 jig mRNA was blotted and exposure with the X-ray film was for 4 h. (b) Quantitation of Northern
analysis. As for Figure Ic, the intensity of the bands are expressed as a relative intensity, the band with the highest intensity being assigned an arbitrary score
of 1.0. 1, intensity of PA mRNA bands; ES, intensity of MTIIa mRNA bands.
of an extracellular matrix using the PA/plasmin system (Laug
et al., 1983), as a convenient model cell type to understand the
mechanism of the glucocorticoid reduction in PA activity in
human synovial fibroblast-like cells (Hamilton, 1983; Hamilton
et al., 1981). Having established the above findings with the
HT1080 line, experiments were performed to determine whether
Dex could lower the PA mRNA levels in fibroblast-like cells
derived from human joints. Human synovial fibroblasts generally
secrete low levels of urokinase-type PA activity (again as a la-
tent form) (Medcalf and Hamilton, 1986) which can be elevated
quite dramatically, for example, by all-trans retinoic acid
(Hamilton, 1982). As Figure 4a and b shows cultures contain-
ing both retinoic acid and 10-7 M Dex have lower PA enzyme
activities and PA mRNA levels than those containing retinoic
acid alone. The cultures were treated with the retinoid since it
raises the PA mRNA levels in the synovial cells (unpublished
observations). The effect of glucocorticoids on the PA activity
of human synovial cells has been studied in detail in prior publica-
tions and occurs without a general inhibition of RNA and pro-
tein synthesis (Hamilton, 1983; Hamilton et al., 1981). As for
the HT1080 cells above, Dex raised the MTIIa mRNA levels
in these cells (Figure 4b).
Discussion
The above results show that low concentrations of Dex reduce
the urokinase-type PA mRNA levels of human fibrosarcoma cells
and synovial fibroblasts while at the same time raising the MTIIa
levels. For the HT1080 fibrosarcoma cells, the reduction in PA
mRNA levels was rapid, reversible, and required RNA synthesis
but not protein synthesis. For both cell types, the reduction in
PA mRNA levels was paralleled by a lowering of the uro-
kinase-type PA enzyme activity in the conditioned media.
Low concentrations of glucocorticoids, such as Dex, can lower
the PA activity of a number of cell types (Coleman et al., 1982;
Hamilton, 1983; Hamilton et al., 1981; Littlefield et al., 1985;
Roblin and Young, 1980; Vassalli et al., 1976; Werb, 1978),
including human synovial fibroblasts (Hamilton 1983; Hamilton
et al., 1981). The mechanism of this suppression is unknown,
although most likely involves the glucocorticoid receptor
(Hamilton, 1983; Hamilton et al., 1981; Littlefield et al., 1985;
Roblin and Young, 1980; Vassalli et al., 1976; Werb, 1978).
The data above are the first to demonstrate in any cell type that
glucocorticoids can directly lower the level of PA mRNA. Since
the effects of Dex on PA activity and PA mRNA levels are both
2219



































Fig. 3. Role of protein and RNA synthesis in the effect of Dex on PA mRNA levels and PA activity in HT1080 cells. (a) Protein synthesis and PA mRNA
cells. Northern analysis of PA mRNA and MTIIa mRNA bands from HT1080 cells cultured for 8 h as in Figure 1 but in the presence of 10-7 M Dex and/or
1 ,ug/ml cycloheximide (Sigma). Control cells were cultured in the absence of drugs. (b) RNA synthesis and PA activity. Conditioned media were collected
from HT1080 cells cultures as in Figure 1 but in the presence of 10-7 M Dex and/or 1 gg/ml actinomycin D (Sigma). Control cells were cultured in the
absence of drugs. (c) RNA synthesis and PA mRNA levels. Northern analysis of PA mRNA and MTIIa mRNA bands from the HT1080 cells in (b). Both
cycloheximide and actinomycin D were added for 30 min prior to the addition of Dex for 8 h. The same Northem analysis protocols as for Figure lb were
used.
dramatic and appear to require transcription, it is likely that the
reduction in PA activity is due to a significant extent to the reduc-
tion in the mRNA levels resulting from a pre-translational effect
on PA gene expression. Although it is likely that changes in trans-
cription rates account for these changes in mRNA levels, there
is, as yet, no direct evidence for this conclusion. It is also possi-
ble that Dex could also raise the levels of an inhibitor(s) in either
or both of the cells under study which could contribute in part
to the loss of PA activity. For the synovial cells and also for
2220
other cells, no evidence was found (Hamilton et al., 1981; Lit-
tlefield et al., 1985; Vassalli et al., 1976) for increased levels
of an inhibitor to account for the effect but there are cases where
such evidence has been provided (Coleman et al., 1982; Little-
field et al., 1985).
PA is one of the few cellular products whose levels are lowered
rather than raised by glucocorticoids and for which there is now
evidence of a lowering at the level of the mRNA (Rousseau,






























activity has been invoked as being part of the general anti-
inflammatory action of glucocorticoids (Vassalli et al., 1976).
In rheumatoid disease, synovial lining cells, including the fibro-
blastic or type B cells used here (Hamilton, 1983; Hamilton and
Slywka, 1981), become hyperplastic and invasive and have been
implicated in the destruction of cartilage and bone occurring in
the affected joints (Fassbender et al., 1980; Harris, 1976); sup-
pression of PA activity by glucocorticoids in such cells may be
relevant to their therapeutic action in rheumatoid disease
(Hamilton et al., 1981). Since other currently used anti-rheumatic
drugs also have unsatisfactory side-effects and are usually only
partially effective (Hauder and Bunch, 1982), means may also
have to be found to limit selectively and effectively the produc-
tion in the affected joints of potentially harmful mediators, such
as proteolytic enzymes. The findings reported above indicate that
it may be possible in the future to control selectively with more
clinically suitable drugs the PA activity of synovial and other






Fig. 4. Suppression of PA activity and PA mRNA levels by Dex in human
synovial fibroblasts. (a) Suppression of PA activity by Dex. Human synovial
fibroblasts were cultured for 24 h in the presence of 10-6 M retinoic acid
(ret. acid) in the presence or absence of 10-7 M Dex and the PA activity
assayed by the 1251-fibrin plate method. (b) Reduction in PA mRNA levels
by Dex. Northern analysis of PA mRNA and MTIIa mRNA of the synovial
cell cultures of (a). Ribosomal markers are indicated at 18S and 28S.
general suppression of cellular metabolism or even to a toxic ef-
fect of the drug since it did not suppress total protein synthesis
and, in fact, raised the MTIIa mRNA levels. Furthermore, Dex
has been shown previously not to reduce general protein syn-
thesis in human synovial fibroblasts over a 9-h period (Hamilton
et al., 1981). The opposite effect of Dex on the amounts of PA
mRNA and MTIIa mRNA is quite striking and presumably in-
dicates that either transduction of the signal from the glucocorti-
coid receptor to the nucleus is transmitted by multiple
mechanisms, or that the regulatory sequences for the positively
regulated (MTIIa) or the negatively regulated (PA) genes res-
pond differently to the same signal. To our knowledge this is
the first report for the converse effects of glucocorticoids on the
expression for two known gene products in the one cell type.
The regulatory nucleotide sequences governing the Dex induc-
tion of MTIIa have been determined and shown to be where the
glucocorticoid receptor binds to the promoter region of the MTLIa
gene (Karin et al., 1984). However, it is not known whether the
same sequences are involved in the promoter region of other
genes for which Dex can reduce the transcriptional rate but this
question should be accessible to analysis by gene transfer.
Glucocorticoids have been used to treat rheumatoid arthritis
although they have serious side-effects when administered
chronically. The mode of action is unknown. Suppression of PA
Cells
The HT1080 cell line was originally derived from a fibrosarcoma and a clone,
C (Laug et al., 1983), was obtained from Dr P.Jones, Childrens Hospital of Los
Angeles. The cells were cultured in Eagles' basal medium (EBM) (Flow
Laboratories) and allowed to reach confluence. The experiments were commenced
by washing twice with ice-cold, Ca2+, Mg2+-free phosphate-buffered saline
(PBS), pH 7.4, and cultured at 37°C in EBM or a-minimum essential medium
(a-MEM) (Flow) containing 1% acid-treated fetal bovine serum (FBS) from which
plasminogen (P) had been removed (FBS-P) (Hamilton, 1983; Hamilton and
Slywka, 1981). These culture conditions enable PA activity to be measured in the
cell supernatants, which were kept frozen at -70°C until assayed. Synovial
'fibroblast-like' cells were derived as before (Hamilton, 1983; Hamilton and
Slywka, 1981) from explanted synovial tissue obtained by menisectomy from
the knee of a patient free from known rheumatoid or degenerative disease. The
passaging and growth to confluence in 175-cm2 flasks (Lux) was as published
(Hamilton, 1983; Hamilton and Slywka, 1981). The same culture medium as
in Figure la was used for the generation of the supernatants containing PA activity.
Measurement of PA activity
50 lil of diluted cell supernatant was assayed (90 min at 37°C) for PA activity
in 1251-fibrin-coated, 96-well tissue culture plates (Disposable Products, South
Australia) as a plasminogen-dependent fibrinolytic activity by published procedures
(Hamilton, 1982; Hamilton, 1983; Hamilton and Slywka, 1981). Only values
in the linear range of the assay with respect to both time and activity were used
(Hamilton, 1983). The plasminogen-independent activity was always < 10% of
the plasminogen-dependent activity.
Preparation of mRNA
The isolation of mRNA from cell cultures was by a modification of a described
procedure (Gonda et al., 1982). After removal of the conditioned medium, the
cell layer was washed in PBS, removed by mild trypsinization and counted. After
resuspension of the cells in 6 ml of buffer (0.1 M NaCl, 10 mM Tris-HCI, pH
7.4, and 1 mM EDTA) 10% SDS (300 A1) and proteinase K (60 pi of 20 mg/mi
in H20) were added. The suspension was vortexed and incubated at 37°C for
60 min, homogenized using a polytron homogenizer (30 s, highest setting) and
then adjusted to 0.5 M NaCI. One milliliter of a slurry of 40 mg/ml oligo(dT)
cellulose (Pharmacia, grade 7) in binding buffer (0.5 M NaCl, 10 mM Tris-HCl,
pH 7.4, 1 mM EDTA and 0.1% SDS) was added to the lysates and the mixture
shaken at 37°C for 1 h to allow the mRNA to bind to the oligo(dT) cellulose.
The oligo(dT) cellulose was pelleted by centrifugation (3300 r.p.m. for 5 min),
the supernatant aspirated and the oligo(dT) cellulose washed twice with 6 ml bind-
ing buffer.
The mRNA was extracted from the cellulose by gently swirling in 4 x 1.5 ml
of elution buffer (10 mM Tris-HCl, pH 7.4, 0.1 mM EDTA and 0.1% SDS).
After centrifugation, the supernatants were added to 14 ml of ethanol containing
600 ul 3 M sodium acetate and precipitated overnight at -20°C or by cooling
rapidly on dry ice for 30 min. The mRNA pellets were collected by centrifuga-
tion in Eppendorf tubes, rinsed with 3 x 100 tl of sterile 10 mM Tris-HCl,
pH 7.4, containing 1 mM EDTA (TE) and again centrifuged to remove trace
amounts of oligo(dT) cellulose. The mRNA was quantitated by spectrophotometry
at 260 nm, ethanol precipitated and stored in TE. Using this procedure, -50





Northern analysis, pre-hybridization and probing for PA and MTIIa mRNA
Poly(A)+ RNA was applied to an 0.85% agarose gel containing 20% for-
maldehyde and run overnight using a constant current of 10 mA and blotted to
nitrocellulose filter paper using standard procedures (Ullrich et al., 1984). 10
,ug poly(A)+ RNA was used in Figure lb while 1 -4 itg was applied for the
experiments in the remaining Figures. After baking, the filters were pre-hybridized
at 40'C for 1 h using a pre-hybridizing buffer previously described (Ullrich et
al., 1984) but containing 50% formamide.
The cDNA clone to human urokinase (Verde et al., 1984) was generously pro-
vided by Dr F.Blasi (Naples). The probe used to detect MTIIa mRNA was derived
from a BamHI -PvuII restriction fragment of the cDNA clone pH MT-1I3 (Karin
and Richards, 1982). Both probes were labelled with 32P-a ATP and 32P-a CTP
using the random primer procedure (Maniatis et al., 1982). Hybridization with
the probes was performed overnight at 40°C. Filters were then washed three
times for 10 min at room temperature with 300 ml of 2 x standard saline citrate
(SSC) containig 0.1% SDS, and then twice for 30 min at 40°C with 500 ml of
0.1 x SSC containig 0.1% SDS. The filter was then exposed to Kodak XAR-5
X-ray film for 90 min using an intensifying screen.
Scanning densitometry
The intensity of the bands present on the autoradiogram were read on a scanning
laser densitometer (LKB model 2202). The intensity of each band was measured
at four different positions, and the results averaged and expressed as a percent
of the maximum signal obtained.
Reagents
Steroid (Sigma, St Louis, Missouri) and all-trans retinoic acid (Hofmann-la Roche,
Nutley, New Jersey) stock solutions were prepared as previously described
(Hamilton, 1982; Hamilton, 1983; Vassalli et al., 1976).
Acknowledgements
This work was supported by grants from the National Health and Medical Research
Council of Australia, University of Melbourne, Utah Foundation, Clive and Vera
Ramaciotti Foundation, Jack Brockhoff Foundation, and William Buckland Foun-
dation. John A.Hamilton is a Senior Research Fellow, National Health and Medical
Research Council of Australia. K.Shanks is thanked for typing the manuscript,
S.Lingelbach and G.Vitti for technical assistance and J.Bartlett for providing
synovial specimens.
References
Coleman,P.L., Barouski,P.A. and Gelehrter,T.D. (1982) J. Biol. Chem., 257,
4260-4264.
Collen,D. (1980) Thromb. Haemost., 43, 77-89.
Fassbender,H.G., Simmling-Annefeld,M. and Stofft,E. (1980) Verh. Dtsch. Ges.
Pathol., 64, 193 - 212.
Freidman,R.L., Manly,S.P., McMahon,M., Kerr,I.M. and Stark,G.R. (1984)
Cell, 38, 745 - 755.
Gonda,T.J., Sheiness,D.K. and Bishop,J.M. (1982) Mol. Cell. Biol., 2, 617-624.
Granelli-Piperno,A. and Reich,E. (1978) J. Exp. Med., 148, 223 -234.
Hamilton,J.A. (1982) Arthritis Rheum., 25, 432-440.
Hamilton,J.A. (1983) J. Rheumatol., 10, 872-880.
Hamilton,J.A. and Slywka,J. (1981) J. Immunol., 126, 851-855.
Hamilton,J.A., Bootes,A.J., Phillips,P.E. and Slywka,J. (1981) Arthritis Rheum.,
24, 1296-1303.
Harris,E.D.,Jr (1976) Arthritis Rheum., 19, 68-72.
Hauder,G.G. and Bunch,T.W. (1982) Bull. Rheum. Dis., 32, 1-5.
Karin,M. and Richards,R. (1982) Nature, 299, 797-802.
Karin,M., Andersen,R.D., Slater,E., Smith,K. and Herschman,H.R. (1980)
Nature, 286, 295-297.
Karin,M., Haslinger,A., Holtgreve,H., Richards,R.I., Krauter,P., Westphal,H.M.
and Beato,M. (1984) Nature, 308, 513-519.
Lack,C.H. and Rogers,H.J. (1958) Nature, 182, 948-949.
Laug,W.E., DeClerck,Y.A. and Jones,P.A. (1983) Cancer Res., 43, 1827- 1834.
Littlefield,B.A., Johnston,L.J., Manzer,D.S. and Roche,P.C. (1985) En-
docrinology, 117, 1100-1109.
Maniatis,T., Fritsch,E.F. and Sambrook,J. (eds) (1982) Molecular Cloning. A
Laboratory Manual. Cold Spring Harbor Laboratory.
Medcalf,R.L. and Hamilton,J.A. (1986) Arthritis Rheum., in press.
Mochan,E. and Keler,T. (1984) Biochim. Biophys. Acta, 800, 312-3 15.
Mochan,E. and Uhl,J. (1984) J. Rheumatol., 11, 123- 128.
Nagamine,Y., Sudol,M. and Reich,E. (1983) Cell, 32, 1181-1190.
Reich,E. (1978) In Berlin,R.D., Herrimann,H., Lepow,I.H. and Tanzer,J.M.
(eds), Molecular Basis ofBiological Degradation Processes. Academic Press
Inc., New York, pp. 155-169.
Ringold,G.M., Dieckmann,B., Vannice,J.L., Trahey,M. and McCormick,F.
(1984) Proc. Natl. Acad. Sci. USA, 81, 3964-3968.
Roblin,R. and Young,P.L. (1980) Cancer Res., 40, 2706-2713.
Rousseau,G.G. (1984) Biochem. J., 224, 1-12.
Saksela,O., Vaheri,A., Schleuning,W.-D., Mignatti,P. and Barlatti,S. (1984) Int.
J. Cancer, 33, 609-616.
Ullrich,A., Berman,C.H., Dull,T.J., Gray,A. and Lee,J.M. (1984) EMBO J.,
3, 361-364.
Van de Putte,L.B.A., Hegt,V.N. and Overbeek,T.E. (1977) Arthritis Rheum.,
20, 671 -678.
Vassalli,J.-D., Hamilton,J.A. and Reich,E. (1976) Cell, 8, 271 -281.
Verde,P., Stoppelli,M.P., Galeffi,P., DiNocera,P.P. and Blasi,F. (1984) Proc.
Natl. Acad. Sci. USA, 81, 4727-4731.
Werb,Z. (1978) J. Exp. Med., 147, 1695-1712.
Werb,Z., Mainardi,C.L., Vater,C.A. and Harris,E.D.,Jr. (1977) N. Engl. J.
Med., 296, 1017-1023.
Wun,T.-C., Ossowski,L. and Reich,E. (1982) J. Biol. Chem., 257, 7262 -7268.
Received on 14 May 1986; revised on 16 June 1986
2222
194
GENOMICS 8, 513-518 (19%‘) 
Human Metallothionein Genes: Structure of the 
Functional Locus at 16ql3 
A. K. WEST,*,’ R. STALLINGS,t C. E. tiILDEBRAND,t R. CHIU,* M. KARIN,* AND R. I. RICHARDS~ 
*Department of Biochemistry, University of Tasmania, Australia; tGenetics Group, Life Sciences Division, Los Alamos National 
Laboratory, New Mexico; *School of Medicine, University of California, San Diego, California; and Kytogenetics Unit, 
Department of Histopathology, Adelaide Children’s Hospital, North Adelaide, South Australia, Australia 
Received March 6, 1990; revised June 25. 1990 
The functional human metallothionein (MT) genes are 
located on chromosome 16q13. We have physically mapped 
the functional human MTlocus by isolation and restriction 
digest mapping of cloned DNA. The mapped region con- 
tains all sequences on chromosome 16 that hybridize to me- 
tallothionein gene probea and comprises 14 tightly linked 
MT genes, 6 of which have not been previously described. 
This analysis deflnes the genetic limits of metallothionein 
functional diversity in the human genome. o 1800 Academic 
Preso, Inc. 
INTRODUCTION 
Metallothioneins (MTs) are small, cysteine-rich 
proteins that bind heavy metals (reviewed in Kagi 
and Kojima, 1987). They are found in all animals and 
have been implicated in the detoxification and homeo- 
stasis of heavy metals (Hamer, 1986), although other 
roles have been postulated (Karin, 1985). Several 
closely related isoforms of MT exist and the number 
present in humans is unknown, although at least 6 
isoforms have been described in human liver (Hun- 
ziker and Kagi, 1985). Southern blot analysis shows 
that these proteins are encoded by a multigene family 
of at least 12-15 members (Karin and Richards, 
1982b) which are distributed to 5 autosomes (Schmidt 
et aZ., 1984). A locus on chromosome 16 that contains 
all functional human MT genes (Karin et al., 1984) 
has been partially mapped (Richards et al., 1984; 
Varshney et al., 1986) and it is likely that the chromo- 
somal loci external to this site are inactive processed 
pseudogenes such as MT233 (Karin and Richards, 
1982b), which is found on chromosome 4 (Schmidt et 
al., 1984). The functional MT locus was originally as- 
signed to 16q22 by in situ hybridization (Le Beau et 
’ To whom correspondence should be addressed at Department 
of Biochemistry, G.P.O. Box 252C, Hobart, Australia 7001. 
al., 1985) but more recent reports suggest a location at 
16q13 (Simmers et al., 1987; Sutherland et al., 1990). 
The complete nucleotide sequence of several hu- 
man MT genes has been determined and their expres- 
sion pattern characterized in detail (Karin and 
Richards, 1982b; Richards et al., 1984; Schmidt et al., 
1985; Schmidt and Hamer, 1986; Heguy et al., 1986; 
Sadhu and Gedamu, 1988; Foster et al., 1988), but the 
total number of genes, both functional and nonfunc- 
tional, and their organization in the locus on chromo- 
some 16 have not been investigated. 
In this report, we present the structure of the func- 
tional human locus on chromosome 16. The locus 
contains 14 linked MT genes within an 82.1-kb re- 
gion, which includes all expressed human MT genes 
identified to date. 
MATERIALS AND METHODS 
Isolation of Genomic Clones 
Lambda and cosmid clones used in this study were 
obtained by screening four genomic libraries and a 
chromosome 16-specific cosmid library (Deaven et al., 
1986; Langmire et al., in preparation) with several 
MT gene-specific probes. Charon 4a clones (Xs 1, 4, 
35,39,42,47,48,66,69,74, and 95) were isolated from 
the library of Lawn et al. (1978) using a general MT 
gene probe derived from a MT2A cDNA clone (Karin 
and Richards, 1982a). EMBL-3 clones, propagated in 
the recA red3 recC host DB1255 (kindly supplied by 
Dr. D. Botstein), were obtained from a primary plat- 
ing of a library constructed by B. A. Evans: clones 
XDBl and 7 were selected using an 800-bp BumHI/ 
HindIII restriction fragment containing the 5’ flank- 
ing region of MT2A as a probe (Karin and Richards, 
1982b); clone XDBlO was isolated using a probe de- 
rived from a 220-bp SucI/ApuI fragment from intron 
1 of MTlE (Schmidt et al., 1985). Cosmid clones were 
isolated by screening two libraries provided by Choo 
513 03@3-7543/90 $3.00 
Copyright 0 1990 by Academic Press, Inc. 
All rights of reproduction in any form reserved. 
195
WEST ET AL. 
- - ---,- - --* -, e-, + - 
BamHl 1 11 I I III1 II I I I 
ti,nd III JI 1 I I I I I II II I I II I II I I I I I 
sac, 11 I I I II Ill I llll I I II II I l I II I Ill I I II IIII I II 
I lADB7 ( ChMT-5 
-lDBl t 1 CHMT-6 
mr39 m A35 I-la47 
I--_---- -l 15 4.48.67 Al- 
l-1 A 74 CHMT-10 ( I 
l-liDB10 
I  4 6 8 10*1 t-1 A66 
I 1 I I I I -A95 
FIG. 1. Physical map of the human metallothionein locus on chromosome 16. The restriction map of the locus was derived from analysis 
of lambda and cosmid genomic clones as shown: BarnHI, HindHI, and Sac1 cleavage sites are indicated below and EcoRI sites are designated 
within the map (E). The size (kb) of each EcoRI fragment is shown above. The position and transcriptional orientation of the MT genes 
(arrows) were established by use of exon-specific probes (exons are represented by vertical bars and are arbitrarily positioned within the 
smallest hybridizing restriction fragment): 2 genes (MTIJ and MTID) did not hybridize to the exon l-specific probe. MT genes character- 
ized previously are indicated by an asterisk. Xs 4, 48, and 67 are not depicted individually-the structure of their putative parental clone is 
shown and the region in which deletions were observed is dotted (see Fig. 3 and text). 
et al. (1986), one in the vector pCVOO1 which yielded The membrane was washed three times in 2~ SSC at 
chMT-10 (isolated by J. Savige) and one in the vector room temperature and then in 0.1X SSC, 1% SDS at 
pAVCV007 from which chMT-5 and chMT-6 were increasing temperatures up to 65°C. High stringency 
isolated. Cosmid chMT-51 was isolated from a chro- washes were continued until excess counts on the 
mosome 16-specific cosmid library, based on the vec- membrane were reduced to background. Autoradiogra- 
tor SCOS-1 (Evans et al., 1989). In all, approximately phy was performed at room temperature for l-3 days 
18 genomic equivalents were screened. using Kodak X-AR film. 
XDNA was prepared by a “mini-prep” procedure 
described earlier (Richards et al., 1984), and cosmid 
DNA was isolated by the alkaline lysis method (Man- 
iatis et al., 1982). Restriction fragments bearing MT 
genes were subcloned into pUC13 or pUC19 and re- 
striction analysis was carried out by standard tech- 
niques. 
Exon-Specific Probes for Human MT Genes 
Southern Blots 
Genomic Southern blotting was performed by a 
modification of the alkaline-blot procedure of Reed 
and Mann (1985). Human placental DNA (lo-20 pg) 
was digested to completion with EcoRI and electro- 
phoresed through a 0.75% agarose gel in 2X TBE (100 
mM Tris-HCl, pH 8.3, 84 mM boric acid, 2 mM 
EDTA). After ethidium bromide staining and photog- 
raphy, the DNA was transferred to Zeta-probe nylon 
membranes (Bio-Rad) using 0.4 M NaOH as the blot- 
ting medium. After two rinses in 2~ SSC (20x is 3 M 
NaCl, 0.3 M Na citrate), the membrane was prehy- 
bridized at 60°C in 1.5~ SSPE (0.27 M NaCl, 15 n&f 
sodium phosphate, pH 7.0, 15 miW EDTA), 1% SDS, 
and 0.5% milk powder (Diploma nonfat). After 6 h, a 
radiolabeled probe (approximately 10’ cpm/pg) was 
added and hybridization continued for 24 h at 68°C. 
The nucleotide sequences of all available human 
MT genes were compared to derive consensus se- 
quences unique for each of the three exons. Comple- 
mentary oligodeoxyribonucleotides were synthesized 
for each of these sequences (exon 1, 5’ CTGGAG- 
CAGTTGGGGTCCAT 3’; exon 2,5’ CTTCTTGCA- 
GGAGGTGCATTTGCA 3’; exon 3,5’ GAGCCC- 
ACGGGGCAGCAGGAGCAGCAGC 3’). After end- 
labeling and hybridization under conditions described 
by Ullrich et al. (1984), these probes enabled mapping 
of specific exons to restriction fragments. 
RESULTS AND DISCUSSION 
Lambda and cosmid clones containing MT genes 
were obtained by screening four human genomic li- 
braries and a chromosome 16-specific cosmid library 
with a cDNA clone of MT2A (Karin and Richards, 
1982a), a probe that is likely to hybridize to all 
members of the MT gene family. Alternatively, 
EMBL-3 clones were identified with two region-spe- 
cific probes as described under Materials and Meth- 
ods. Sixty-two positive clones survived several rounds 
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FIG. 2. Southern blot analysis of the human MT locus. EcoRI- 
digested genomic DNA was fractionated by electrophoresis 
through a 0.75% agarose gel and then blotted onto a nylon mem- 
brane. The membrane was hybridized to the MT2A cDNA probe: 
15 major bands can be visualized. In particular, the upper section 
of the autoradiograph can be resolved into 5 hybridizing fragments 
of 27.7, 18.0, 14.0,12.5, and 10.2 kb. An asterisk (*) denotes EcoRI 
fragments that are derived from the chromosome 16 locus (see text 
and Fig. 1). 
of purification and were sorted into two groups on the 
basis of the number of restriction fragments that hy- 
bridized to the general MT probe (data not shown). 
One group, which probably comprised clones of pro- 
cessed pseudogenes, gave rise to only one hybridizing 
restriction fragment following digestion with 6-bp re- 
striction enzymes suggesting that one, intron-less 
gene was present. Sequence analysis of one such X 
clone, X42, confirmed that the hybridizing region was 
a processed pseudogene (data not shown), which 
showed marked homology to the transcribed portions 
of the functional gene MTlF (Schmidt et al., 1985). 
Two examples of human MT processed pseudogenes 
have been described previously (Karin and Richards, 
198213; Varshney and Gedamu, 1984). The remaining 
clones had several hybridizing fragments, indicating 
the likelihood of introns and, in most cases, that mul- 
tiple MT genes were present. Restriction mapping 
and the use of end fragment probes demonstrated 
that clones from this latter group overlapped and rep- 
resented a region of 82.1 kb which contained 14 
tightly linked MT genes (Fig. 1). Exon-specific oligo- 
deoxyribonucleotide probes were used to map individ- 
ual exons to show that all genes, with the exception of 
MTlG, share the same orientation. Following sub- 
cloning into plasmid vectors, each gene was identified 
by detailed restriction mapping or by partial or com- 
plete nucleotide sequencing. The structure and ex- 
pression of some of these genes have been reported 
previously: the functional genes MT2A (Karin and 
Richards, 1982b), MTlA (Richards et al., 1984), 
MTlB (Heguy et al., 1986), MTlE and MT1 F 
(Schmidt et al., 1985), and MTlG (Varshney et al., 
1986); and the nonfunctional genes MT1 C and MTlD 
(Richards et al., 1984). This work has therefore iden- 
tified 6 novel MT genes, MT1 H, MTlI, MT1 J, 
MTlK, MTIL, and MT1 X. The presence of MT2A 
and MTlA in the cluster confirms that the region of 
DNA illustrated in Fig. 1 is derived from the func- 
tional MT locus on chromosome 16 (Karin et al., 
1984). Interestingly, one Charon 4a clone described 
here, X69, appears to be similar to a clone 14VS re- 
ported by Varshney et al. (1986). Since both clones 
were isolated from separate platings of the same 
Charon 4a library (Lawn et aZ., 1978), it is probable 
that X69 and 14VS represent different isolates of the 
same clone. 
The restriction map presented here accounts for 
seven intact EcoRI fragments that contain MT genes 
from the functional locus. We would therefore expect 
the MT2A cDNA probe to hybridize to bands on a 
genomic Southern blot at 27.7, 14.0, 12.5, 10.2, 7.2, 
5.9, and 4.6 kb. This prediction can be compared to 
the results of Schmidt et al. (1984), who performed 
Southern blots on DNA from rodent/human somatic 
cell hybrids and were able to assign EcoRI fragments 
containing MT genes to specific human chromo- 
somes. These workers concluded that MT genes from 
chromosome 16 were located on five EcoRI restriction 
fragments of 25, 14.5, 10.2, 6.8, and 5.9 kb which, ex- 
cepting the omission of the 4.6-kb fragment and the 
12.5-kb fragment containing MTlB, is in good agree- 
ment with the present work. The 4.6-kb fragment 
containing MTlD was not detected by Schmidt et al. 
(1984) because it was consistently obscured by a 4.6- 
kb fragment from chromosome 4 that contains the 
processed pseudogene MT2B: each hybrid used by 
these workers that retained chromosome 16 also had 
chromosome 4. To reconcile the mapping data with 
the structure of the locus in situ, particularly with 
respect to the predicted 14.0-, 12.5-, and 10.2-kb 
EcoRI fragments, a Southern blot experiment was 
performed. The high-resolution blotting technique of 
Reed and Mann (1985) was used and, as shown in Fig. 
2, demonstrates that the EcoRI fragment assigned to 
14.5 kb in earlier reports (Karin and Richards, 198213; 
Schmidt et al., 1984; Varshney et al., 1986) can be 
resolved as two discrete bands of 14.0 and 12.5 kb. To 
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FIG. 3. Restriction analysis of X4,48,67, and 74. (a) The structure of Charon 4a clones X4,48,67, and 74. Analysis of the restriction map 
of these clones was aided by use of exon-specific oligodeoxyribonucleotide probes and by use of a restriction fragment probe, SacI-ApaI 
fragment from intron 1, MTlE (22), which hybridized to homologous regions of MTlK and MTlJ (speckled). The polymorphic Sac1 site, 
present in X4,48, and 67 but not in X74 (or XDBlO) is depicted in parentheses. The structure of the three clones X4,48, and 67 suggests that 
they are derived from a precursor clone which has undergone deletions of 6.8, 2.8, and 3.1 kb, respectively. The structure of the putative 
precursor clone is predicted from a comparison of X4,48, and 67 with X74. (b) Xs 48 and 67 may have arisen following deletions (dotted lines) 
of 2.8 and 3.1 kb, respectively, from the putative precursor clone. A similar argument can be constructed for the origin of X4. 
demonstrate that these new bands and the 10.2-kb 
band were not artifacts and to confirm their origin 
from the functional MT locus on chromosome 16, the 
Southern blots were reprobed with radiolabeled re- 
striction fragments identified from the restriction 
maps of this region. Under stringent hybridization 
conditions, each of these probes cross-reacted specifi- 
tally with the predicted EcoRI fragment consistent 
with the structure shown in Fig. 1 (data not shown). 
The relative intensities of the EcoRI bands in Fig. 2 
do not correlate strongly with the number of MT 
genes mapped to each restriction fragment, suggest- 
ing that other factors such as sequence divergence be- 
tween individual MT1 genes and the MT2A cDNA 
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probe and the efficiency of Southern transfer were 
important. Indeed, the relative intensities of MT 
EcoRI fragments are not always constant between 
different experiments (e.g., see Sutherland et al., 
1990) but this is most likely due to variables such as 
transfer method, hybridization stringency, and the 
particular MT probe used. It is not possible, however, 
to rule out interindividual variation in MT gene copy 
number, although we feel that this is unlikely because 
mapping of overlapping genomic clones from five in- 
dependent libraries gave consistent results with re- 
gard to copy number. 
A pertinent observation about the nature of the lo- 
cus around MTlK was made during the analysis of a 
group of clones from this region--X clones 4,48, and 
67. The inserts of these Charon 4a clones had identi- 
cal left and right termini and shared a polymorphic 
Sac1 site absent in independent, overlapping clones 
(e.g., X74 and XDBlO), but each differed in their inter- 
nal structure (Fig. 3). Comparison of their restriction 
maps suggested that these clones are each derived 
from a common parental precursor phage that has 
undergone a variety of internal deletions between ho- 
mologous regions during amplification of the original 
library. The structure of the parental phage can be 
surmised from the composite structures of X4,48, and 
67 and from the restriction maps of X74 and XDBlO, 
which include part of the same region. The restriction 
map of this region was confirmed following the subse- 
quent analysis of the independent cosmid clone 
chMT-51. The unstable nature of some genomic 
clones during propagation in standard Escherichia 
coli hosts has been noted previously (Wyman et al., 
1985). 
It is likely that Fig. 1 represents the entire func- 
tional MT locus. DNA extending 17 kb upstream of 
MT2A and 16.4 kb downstream of MTlX has been 
cloned but no further MT genes were identified (data 
not shown). Given the tight linkage within the gene 
cluster, it is probable that MT2A and MTlX are the 
terminal members of the locus. In support of this, the 
cloned region accounts for all MT-gene-bearing 
EcoRI fragments from chromosome 16 identified by 
Schmidt et al. (1984). In addition, all functional MT 
genes characterized so far have been assigned in this 
work. It is highly unlikely that any functional MT 
genes remain undetected by hybridization to the 
MT2A cDNA probe because of the high level of amino 
acid (and nucleotide) sequence conservation of all 
known metallothioneins (Kagi and Kojima, 1987) and 
the observation that divergent nonfunctional MT 
pseudogenes within the functional MT locus (e.g., 
MTlD; Richards et al., 1984) were readily detected by 
hybridization. 
Elucidation of the structure of the functional MT 
locus will permit the continuing analysis of the molec- 
ular biology and physiology of human metallothio- 
neins. It will be possible to design a complete panel of 
gene-specific probes to investigate tissue- and devel- 
opmental-dependent expression of each functional 
member, analogous to the studies with MTlF and 
MTlE reported by Schmidt and Hamer (1986). This 
information may assist in determining the physiologi- 
cal role of metallothionein. Furthermore, it will now 
be possible to investigate regulatory mechanisms 
such as those involving chromatin structure and 
methylation which may operate on the locus as a 
whole. The completion of the map of the functional 
human MT locus sets an upper limit of 12 possible 
functional genes encoding metallothioneins. The 
physiological requirement for this large number of 
genes is not clear. Potential differences in function of 
the encoded proteins may now be addressed by manip- 
ulated expression of individual cloned genes (Clous- 
ton et al., 1990). This will overcome problems encoun- 
tered in attempts to purify individual MT proteins for 
functional studies. Of particular interest in this re- 
gard will be the most divergent MT genes in the locus 
which appear to be coincidentally located at the ex- 
tremities of the gene cluster (i.e., MT2A and MTlX; 
West and Richards, unpublished data). 
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The Human Metllothionein Gene Family:
Structure and Expression
by Michael Karin* and Robert 1. Richardst
Metallothioneins (MTs) are encoded by a multigene family in man. We have isolated
those genes and analyzed the structure of some of them. The MT-II variant is encoded by a
single functional gene: MT-IIA. The MT-IIB gene is a processed pseudogene derived from a
reverse transcript of MT-II mRNA. On the other hand, the MT-I class of variants are
encoded by a large number of genes, arranged in tandem. The MT-IIA and the MT-IA genes
show a differential response to glucocorticoid hormones and heavy metals, yet they are
both expressed in primary human fibroblasts and in HeLa cells. Expression of both of
those genes, in high level after transfer on bovine papilloma virus vectors, leads to
increased resistance of the host cells to cadmium-induced toxicity.
Introduction
Metallothioneins (MTs) are a group of low mo-
lecular weight heavy metal binding proteins,
unique in their high cysteine content. MTs specifi-
cally bind heavy metals such as zinc, cadmium,
copper and mercury (1). MTs were discovered in
1957 by Margoshes and Valee (2), who have iso-
lated a Cd2+ and Zn2+ binding protein from horse
kidney. In 1966 Pulido et al. (3) isolated MTs from
human liver. Since then, MTs were isolated and
characterized from a larger number of species.
In 1964, Piscator (4) found that MT was present
in elevated levels in the liver ofrabbits exposed to
cadmium. He postulated that the biosynthesis of
the protein is induced by Cd2+ and that MT acts
as a detoxifying agent by binding of Cd2+. The
induction of MTs after administration of various
heavy metal ions was demonstrated in many dif-
ferent animal species and in cultured cells (1). In
1979 Karin and Herschman (5) demonstrated
that the synthesis of MTs in cultured cells is
induced not only by heavy metal ions, but also by
glucocorticoid hormones. This finding strongly
supports the proposal that MTs have an impor-
tant role in regulation of trace element metabo-
*Department of Microbiology, Univerisity of Southern Cali-
fornia School of Medicine, 2011 Zonal Avenue, Los Angeles,
CA 90033.
tDepartment of Genetics, Research School of Biological Sci-
ences, Australian National University Canberra, ACT 2601,
Australia.
lism and, that glucocorticoids by elevating the
rate of synthesis of MTs, control Cd2+ and Zn2+
homeostasis.
In this paper, we will review our studies con-
cerning the structure and expression of the genes
encoding MTs in man.
Structure of the Human MT Gene
Family
Tb define the structure and understand the reg-
ulation of human MT genes, it was necessary to
obtain cDNA clones ofhuman MT mRNA. A good
source ofhuman MT mRNA are HeLa cells which
were found to express high levels of MTs in re-
sponse to Cd2+ (6). We have constructed a cDNA
library from Cd2+ induced HeLa cells and by
differential hybridization isolated a number of
cDNA clones which preferentially hybridized to
mRNA from Cd2+ induced cells. Using a mouse
MT-I cDNA clone (7), we have identified among
those clones several cDNA clones of human MT
mRNA. The full nucleotide sequence of one of the
clones was determined and it was found to be a
nearly full-length cDNA clone of human MT-fl
mRNA (8). The coding region of that cDNA was
used as a hybridization probe for detection of
human MT genes in digests of human genomic
DNA and their isolation from a genomic DNA
library. To our surprise, we found human DNA to
contain at least 12 different EcoRI fragments
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hybridizing to the coding region probe. Also the
frequency of bacteriophage clones hybridizing to
the same probe was about 11 per genome equiva-
lent, suggesting that in man MTs are encoded by
a multigene family (9). Tb identify those genes
encoding the MT-II form (10) we have screened all
of the genomic clones isolated, for hybridization
to the 5' and 3' untranslated regions of MT-
IIcDNA. Only three of the genomic clones were
positive by these criteria: one of them contained
the functional MT-IIA gene and two of them were
overlapping clones containing a processed
pseudogene named MT-IIB (9). We are fairly confi-
dent that the MT-IIA gene is the only functional
human MT-II gene. Complete nucleotide sequence
determination has demonstrated the presence of
an open reading frame, interrupted by two in-
trons, encoding the MT-II form (9).
The MT-IIB is a nonfunctional processed gene
derived from MT-II mRNA, by its conversion into
a full length cDNA by a yet unidentified enzy-
matic activity in the germ line, and the integra-
tion of that cDNA into a staggered break in the
genomic DNA. Although the MT-IIB gene encodes
a potentially functional MT, it is not expressed
(9), due to the absence of a promoter element
(M. Karin, unpublished).
More recently we have begun the characteriza-
tion ofgenomic clones containing MT-I like genes.
The MT-I genes are tightly clustered and, so far,
we have identified seven such genes, tandemly
iterated within a 30 Kb region. Not all of those
genes are necessarily functional and, so far, we
have found two of them to be pseudogenes due to
the presence of frameshift and nonsense muta-
tions resulting in the introduction of premature
termination codons (R. Richards and M. Karin,
unpublished). However, one of the genes, named
MT-IA was found to be a functional gene by using
an assay described in the next section.
Increased Resistance to Cd2+
of Cells Expressing High Levels
of MT
Bovine papilloma virus (BPV) is a DNA tumor
virus with several unique properties making it
useful as a mammalian plasmid vector. First, this
virus does not integrate into the cellular genome
and instead it maintains itself as a free replicat-
ing nuclear plasmid. Second, it does not lead to
the lysis ofthe cells in which it replicates (11). We
have used these properties of the virus and li-
gated a fragment of it to the cloned human MT-IIA
gene to generate the vector pMTII-BPV. Cells
transformed with this vector express high levels
of human MT-II mRNA and protein. That expres-
sion is regulated by the concentration of Cd2+ in
the growth medium, even though the human gene
is present in an episomal state. Moreover, due to
the high level of expression of human MT-II, the
transformed cells become highly resistant to
Cd2+. In fact, while the relative plating efficiency
of the parental cells drops to 10% at 1 p M Cd2+,
the relative plating efficiency of cells containing
pMTII-BPV drops to 10% only at 25 ji M Cd2+
(12). Actually, the cells transformed with pMTII-
BPV are Zn2+ dependent due to the high level of
synthesis ofhuman MT-II (about 12% of the solu-
ble protein).
In the absense of any recognized enzymatic
activity, we consider the increased Cd2+ resist-
ance of cells harboring BPV-MT plasmids, a crite-
ria for the functionality of a MT gene and the
protein it encodes. This assay has turned out to be
quite useful in the characterization of human MT
genes. For example, we have recently determined
the full nucleotide sequence of the MT-IA gene
(R. Richards and M. Karin, in preparation) and
found the amino acid sequence of the encoded
protein to deviate from the published sequence of
human MT-I's (13). We were concerned whether
this gene is functional or not and therefore have
inserted it into the BPV vector. Mouse cells trans-
formed with this vector (pMTIA-BPV) were found
to be Cd2+-resistant, indicating that the MT-IA
gene is functional (R. Richards and M. Karin, in
preparation). This illustrates the usefulness of
the BPV vector system to the functional analysis
of a multigene family. Since the MT-BPV trans-
formed cells produce very high levels of MT, they
can serve as a convenient source for the isolation
of large amounts of relatively homogenous MT
variants for biochemical studies.
Expression of Human MT Genes
Addition of Cd2+, Zn2+ and Cu2+ to the culture
medium of human HeLa or primary fibroblast
cells leads to rapid induction of MT mRNA (14
and Richards and Karin, in preparation). The
same mRNA's species are also induced by the
addition of glucocorticoid hormones (14 and M.
Karin, unpublished). Both heavy metal ions and
hormonal inductions are considered to be primary
induction responses, since they lead to an in-
crease in mRNA levels even in the absence of
concurrent protein synthesis (15). Palmiter and
co-workers have demonstrated that in mouse cells
both classes of inducers act by increasing the
transcription rate of the MT-I gene (16,17). Re-
cently, we found that the human MT-IA and MT-
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IIA genes respond differently to different inducers,
indicating possible functional differences between
those genes (R. Richards and M. Karin, in prepa-
ration).
The kinetics of induction of MT mRNA by a
typical heavy metal ion inducer such as Zn2+ and
dexamethasone, a synthetic glucocorticoid, are
different. Both inducers lead to rapid induction of
MT mRNA, but while the response to metal is
biphasic and the level ofthe mRNA declines after
prolonged exposure, the response to the hormone
is persistent and once a new elevated steady state
level of MT mRNA is achieved, it is maintained
as long as the hormone is present (14,18). The
transient induction observed with Zn2+ is not due
to a cytotoxic effect of the metal or to disappear-
ance of the inducer due to MT induction. Another
difference between the two responses is in the
way they are affected by inhibition of protein
synthesis. While hormonal induction of MT
mRNA is only slightly elevated in the absence of
protein synthesis, the induction by Zn2+ is
augmented about threefold. Also, the basal level
ofMT mRNA is increased threefold by inhibition
of protein synthesis (15). Mayo and Palmiter
found that the cycloheximide effect is exerted at
the level oftranscription, by comparing transcrip-
tion rates of the mouse MT-I gene in the presence
and absence of cycloheximide (19).
These observations led us to suggest that (a)
heavy metal ions and glucocorticoid hormones
increase the transcription rates of MT genes by
different mechanisms and (b) heavy metal induc-
tion is mediated through the removal of a repres-
sor of MT gene expression. However, as a conse-
quence of metal induction the level of the
repressor is increased causing a transient induc-
tion response. Inhibition of the synthesis of this
putative repressor by cycloheximide causes a
large augmentation of the induction response to
metal ions. In our simplest working hypothesis
the repressor is apothionein (see Fig. 1), which
explains the specificity of the induction response,
since only metal ions that bind to the apoprotein
can lead to induction. This induction is due to the
conversion of apotheionein, the active repressor
form, to metallothionein, the inactive repressor
form. After a while, the level of MT in the cell is
increased, but so does the level of the apoprotein,
the putative repressor, leading to a decrease in
the transcription rate of the MT genes, and re-
sulting in a transient induction response. Induc-
tion by glucocorticoids bypasses this pathway and
leads to persistent activation of the genes, as long
as, the hormone receptor complex is bound to
DNA (18).
A MODEL FOR METALLOTHIONEIN
GENE ACTIVATION BY HEAVY METALS
PROMOTER REGION
MT a INACTIVE REPRESSOR
1iI I + METAL
apoT a ACTIVE REPRESSOR
t
_ MTmRNA
p . > % I)~~~---NA
NTIATION METALLOTHIONEIN GENE (MT)
SITE
FIGURE 1. A model for metallothionein gene activation by
heavy metals.
More recently we have compared the expres-
sion of the MT-IIA and the MT-IA genes in human
cells. We find that while the MT-IIA gene is in-
duced to the same extent by Cd2+, Zn2+, Cu2+ and
dexamethasone, the MT-IA gene is only fully in-
duced by Cd2+. These results suggest that the
various MT genes are regulated differently from
each, most likely due to the different functions
they serve.
Localization of the Regulatory
Elements of Human MT Genes
As indicated, both the human MT-IA and the
MT-IIA genes are still inducible by heavy metal
ions after transfer into rodent cells on BPV de-
rived sectors (12). While being appropriate for
studying metal induction, this sytem is not suit-
able for studying the hormonal regulation of
cloned MT genes, since the episomal state pre-
cludes glucocorticoid induction. On the other
hand, cotransfer (with the Herpes simplex virus
thymidine kinase gene) of the human MT-IIA
gene, into rat fibroblasts leading to stable inte-
gration into the host genome, results in retention
of full responsiveness to both glucocorticoid hor-
mones and heavy metal ions.
To test whether the regulatory DNA elements
controlling MT-IIA gene expression are found
within the 800 bp 5' flanking region of the cloned
fragment used in the transfection experiments
mentioned above, we have fused this region to the
structural portion of the Herpes simplex virus
(HSV) thymidine kinase (TK) gene. The tran-
scription of TK mRNA from this fusion gene
(hMTK) is under the control of the human MT-IIA
gene promoter. The hMTK fusion gene was intro-
duced into TK- rat fibroblasts by transfection and
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selection for the TK+ phenotype. The expression
of TK mRNA in those cells was found to be both
heavy metal and hormone inducible. These
results indicate that the important regulatory
elements for both heavy metal and glucocorticoid
inductions are found within 800 bp of the 5'
flanking region of the human MT-IIA gene. Mea-
suring the rate of synthesis ofMTK mRNA under
different induction conditions demonstrated tran-
scriptional control by both Cd2+ and dexametha-
sone (20). More recently by performing sequential
deletions of 5' flanking nucleotides of the hMTK
gene we found that only 300 bp are sufficient for
maintenance of both hormone and metal induc-
tion (M. Karin et al., unpublished).
Conclusions
By applying recombinant DNA technology to
study of structure and function of MT genes in
man we were able to demonstrate that: (a) this
group of proteins is encoded by a large gene
family, (b) different MT genes vary in their re-
sponse to various inducers, (c) overexpression of
MT genes leads to protection of cultured cells
against the toxic effect of Cd2+ and (d) the regula-
tory DNA elements controlling the expression of
the human MT-IIA gene are located within 300 bp
of 5' flanking DNA whose primary structure is
known.
The differences in the response of the MT-IIA
and MT-IA gene to various inducers suggest that
the two genes have different functions. Since the
MT-IIA gene is the one which is highly inducible
by glucocorticoids and zinc, we believe this gene
serves a homeostatic role. The modulation of
MT-II expression by zinc, copper and glucocorti-
coids help to maintain zinc and copper homeosta-
sis. During periods of high availability, zinc and
copper stimulate the transcription of the MT-IIA
gene, leading to increased production of MT-II,
mostly in the liver, which results in the storage of
the excess amounts of those essential trace
metals. Glucocorticoids, by increasing the expres-
sion of MT-II, cause mobilization of zinc and prob-
ably copper from the circulation into the liver and
other organs, leading eventually to hypozince-
mia.
On the other hand, the expression of the MT-IA
gene, and possibly of the other MT-I genes, as
well, is not highly stimulated by glucocorticoids
and zinc or copper. Only cadmium seems to be a
potent inducer of those genes. Therefore, we be-
lieve the MT-I genes serve a protective role. This
hypothesis is supported by the multiplicity of
MT-I genes in most mammals except rodents.
Primates have at least four functional MT-I
genes (J. Kagi and M. Kimura, personal com-
munications). If all of those genes are activated
by Cd2+, this would constitute an efficient protec-
tive response, due to a massive increase in the
synthesis MT-I resulting in the chelating of the
toxic Cd2+ ions.
In the future we plan to further characterize all
the different MT genes and study their organiza-
tion within the genome. We hope to be able to
understand the genetic mechanism which has led
to the generation of multiple MT-I genes in man.
We also plan to investigate whether there are any
tissue-specific variations in the expression of the
different human MT genes. Finally we hope to be
able to reconstitute an in vitro induction system,
consisting of cloned MT genes, a few regulatory
proteins and RNA polymerase-II. By using such a
system it should be possible to determine how
heavy metals control gene expression.
Work in Dr. Karin's laboratory is supported by grant No. R-
810531-01-0 from the U. S. Environmental Protective Agency.
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Section II Genetic Contributions to Human Disease 
 
Chapter 3. Genetic Markers and Disease Gene Identification:  
  Application to studies on Human Chromosome 16 - including - 
The genes causing Familial Mediterranean Fever and Pseudoxanthoma Elasticum 




 In 1989 I moved from the Howard Florey Institute in Melbourne to the Department of 
Cytogenetics and Molecular Genetics at what was then known as the Adelaide Children’s 
Hospital.  One of the attractions to move to this department was the opportunity to work on 
various aspects of what was then the fledgling ‘Human Genome Project’.  A major contribution 
of the department to the Human Genome Project was the construction of a physical and 
genetic map of human chromosome 16.  My role on this project was to supervise the isolation 
of genetic markers from human chromosome 16 and to implement their use in both the 
construction of these maps and in the positional cloning of disease genes on this 
chromosome.  In practice this meant a variety of contributions to numerous projects.  I was 
able to make a commitment to the positional cloning of the gene for FMF as part of a 
consortium of laboratories with this common interest.  This collaboration led to the successful 
identification of the pyrin gene as the cause of FMF.  Yang Shen was a PhD student working 
with me from 1991-1994 and a number of the publications (refs #30, 31) will therefore have 
appeared in her PhD thesis.  Other students (H. Kozman, S. Apostolou and J. Balow) were 
supervised by collaborators. The identification of the FMF gene was published in the journal 
Cell and is the subject of a patent on which I am a co-inventor. Another of these 
collaborations, for Pseudoxanthoma Elasticum, was successful in characterising the spectrum 
of mutations that give rise to the disease. 
 
 
A) HUMAN CHROMOSOME 16 : PHYSICAL AND GENETIC MAP 
 
29. Human Chromosome 16 Physical Map :  Mapping of Somatic Cell Hybrids Using 
Multiplex PCR Deletion Analysis of Sequence-Tagged Sites. 
Genomics (1991) 10: 1047-1052. 
Richards, R.I., Holman, K., Lane, S., Sutherland, G., Callen, D.F. 
  
A major contribution of the Adelaide Children’s Hospital to the international Human Genome 
Project was the construction of a physical and genetic map of human chromosome 16. I was 
responsible for the Molecular Genetic component of this project – others were responsible for 
the Cytogenetics and Linkage Mapping.   In the work described in this manuscript I conducted 
the majority of the experimental work, analysed and interpreted the data and wrote the 
manuscript           Citations 10 
 
 
30. Isolation and characterisation of (AC)n microsatellite genetic markers from human 
chromosome 16. 
Genomics (1992) 13: 402-408 
Thompson, AD, Shen, Y., Holman, K., Sutherland, GR, Callen, D.F, Richards, R.I. 
 
I supervised the experimental work, supervised the project, analysed and interpreted the data, 
conceived of the overall content of the paper and co-wrote the manuscript Citations 112 
 
Four dinucleotide repeat polymorphisms on human chromosome 16 at D16S289, D16S318, 
D16S319 and D16S320.   Human Molecular Genetics (1992) 1: 773.  
Shen, Y., Thompson, AD., Holman, K., Callen, DF., Sutherland, GR., Richards, R.I. 






Five dinucleotide repeat polymorphisms on human chromosome 16q24.2-q24.3. 
Human Molecular Genetics (1993) 2: 1504.  
Shen, Y., Holman, K., Doggett, N.A., Callen, D.F., Sutherland, G.R., Richards, R.I. 
 
Six dinucleotide repeat polymorphisms on human chromosome 16q12.1-q24.1. 
Human Molecular Genetics (1993) 2: 1505. 
Shen, Y., Holman, K., Doggett, N.A., Callen, D.F., Sutherland, G.R., Richards, R.I. 
 
Three dinucleotide repeat polymorphisms on human chromosome 16p13.11- p13.3. 
Human Molecular Genetics (1993) 2: 1506. 
Shen, Y., Holman, K., Doggett, N.A., Callen, D.F., Sutherland, G.R., Richards, R.I. 
 
Four dinucleotide repeat polymorphisms on human chromosome 16.   
Human Molecular Genetics (1993) 2: 1745.     
Shen, Y., Holman, K., Doggett, N.A., Callen, D.F., Sutherland, G.R., Richards, R.I. 
 
Dinucleotide repeat polymorphisms D16S525, D16S359, D16S531 and D16S522 
Human Molecular Genetics (1994) 3: 210. 
Shen, Y., Holman, K., Doggett, N.A., Callen, D.F., Sutherland, G.R., Richards, R.I. 
 
31.  A PCR-based genetic linkage map of human chromosome 16. 
Genomics (1994) 22: 68-76. 
Shen, Y., Kozman, H., Thompson, A., Phillips, H.A., Holman, K., Nancarrow, J., Lane, S., 
Chen, L.-Z., Apostolou, S., Doggett, N., Callen, D.F., Mulley, J.C., Sutherland, G.R., 
Richards, R.I. 
 
This work was a key part of Yang Shen’s PhD thesis. I supervised the experimental work, 
supervised the project, analysed and interpreted the data, conceived of the overall content of 




B) POSITIONAL CLONING and MUTATION CHARACTERISATION:  
Familial Mediterranean Fever and Pseudoxanthoma Elasticum 
 
A third Wilms' tumour locus on chromosome 16q. 
Cancer Research (1992) 52: 3094-3098. 
Maw, M.A., Grundy, P.E., Millow, L.J., Eccles, M.R., Dunn, R.S., Smith, P.J., Feinberg, A.P., 
Law, D.J., Paterson, M.C., Telzerow, P.E., Callen, D.F., Thompson, A.D., Richards, R.I., 
Reeve, A.E.          
 
Fine genetic mapping of the Batten disease locus (CLN3) by haplotype analysis and 
demonstration of allelic association with chromosome 16p microsatellite loci. 
Genomics (1993) 16: 455-460. 
Mitchison, H.M., Thompson, A.D., Mulley, J.C., Kozman, H.M., Richards, R.I., Callen, DF, 
Stallings, RL, Doggett, NA, Attwood, J, McKay, TR, Sutherland, G.R., Gardiner, R.M.  
 
 
32. Refined mapping of the gene causing familial Mediterranean fever by linkage and 
homozygosity studies. 
American Journal of Human Genetics (1993) 53: 451-461. 
Aksentijevich, I., Pras, E., Gruberg, L., Shen, Y., Holman, K., Helling, S., Prosen, L., 
Sutherland, GR., Richards, R.I., Ramsburg, M., Dean, M, Pras, M, Amos, CI, Kastner, DL 
 
I participated in consortium planning meetings and I supervised our lab’s contribution to the 







33. Familial Mediterranean fever in Moroccan Jews : Demonstration of a founder effect 
by extended haplotype analysis. 
American Journal of Human Genetics (1993) 53: 644-651. 
Aksentijevich, I., Pras, E., Gruberg, L., Shen, Y., Holman, K., Helling, S., Prosen, L., 
Sutherland, G.R., Richards, R.I., Dean, M., Pras, M., Kastner, D.L.    
 
I participated in consortium planning meetings and I supervised our lab’s contribution to the 
experimental work and I had minor role in writing the manuscript.   Citations 35 
 
 
34. Linkage disequilibrium mapping places the gene causing Familial Mediterranean 
Fever close to D16S246. 
American Journal of Human Genetics  (1996) 58: 523-534. 
Levy, E.N., Shen, Y., Kupelian, A., Krugliak, L., Aksentijevich, I., Pras, E., Balow,  J.E., 
Linzer, B, Pras, M, Shohat, M., Rotter, J.I., Fischel-Ghodsian, N., Richards, R.I., Kastner, D.L. 
  
I participated in consortium planning meetings and I supervised our lab’s contribution to the 
experimental work and I had minor role in writing the manuscript.   Citations 26 
 
35.  Construction of a 1Mb restriction-mapped cosmid contig containing the candidate 
region for Familial Mediterranean Fever (MEFV) on 16p13.3.   
Genomics (1997) 42:83-95. 
Sood, R., Blake, T., Aksentijevich, I., Wood, G., Chen, X., Gardner, D., Shelton, D.A., 
Mangelsdorf, M., Orsborn,A., Pras, E., Balow, J.E., Centola, M., Deng, Z., Zaks, N., Chen, X., 
Richards, N., Fischel-Ghodsian, N., Rotter, J.I., Pras, M., Shohat, M., Deaven, L.L., Gumucio, 
DL, Callen, DF, Richards, R.I.,  Collins, F.S., Liu, PP, Kastner, D.L., Doggett, N.A.   
 
I participated in consortium planning meetings and I supervised our lab’s contribution to the 
experimental work and I had minor role in writing the manuscript.   Citations 26 
 
36.  A high-resolution genetic map of the Familial Mediterranean Fever candidate  
region allows identification of haplotype-sharing among ethnic groups.   
Genomics (1997) 44:280-291. 
 Balow J.E., Shelton, D.A., Orsborn, A., Mangelsdorf, M., Aksentijevich, I., Blake, T., Sood, R., 
Gardner, D., Liu, R., Pras, E., Levy, E., Centola, M., Deng, Z., Zaks, N., Wood, G., Chen, X., 
Richards, N., Shohat, M., Livneh, A., Pras, M., Doggett, N.A., Collins, F.S., Liu, P.P., Rotter, 
J.I., Fischel-Ghodsian, N., Gumucio, D., Richards, R.I., Kastner, D.L.    
 
I participated in consortium planning meetings and I supervised our lab’s contribution to the 
experimental work and I had minor role in writing the manuscript.   Citations 48 
 
37.  Ancient Missense Mutations in a New Member of the RoRet gene Family Are Likely 
to Cause Familial Mediterranean Fever.   
 Cell (1997) 90:797-807.      The International FMF Consortium (labs numbered) -  
 I  Aksentijevich, I., Centola, M., Deng, Z., Sood, R., Balow J.E., Wood, G., Zaks, N., 
Mansfield, E., Raben, N., Eisenberg, S., Pras, E., Pras, M., Kastner, D.L.;  
 II  Blake, T., Braxevanis, A., Collins, F.S., Liu, P.P.;  
 III  Chen, X., Shohat, M., Rotter, J.I., Fischel-Ghodsian, N.;  
 IV  Richards, N., Shelton, D.A., Gumucio, D.;  
 V  Yokoyama, Y., Mangelsdorf, M., Orsborn, A., Richards, R.I.;  
       VI  Ricke, D.O., Buckingham, J.M., Moyzis, R.K., Deaven, L.L., Doggett, N.A.  
 
I participated in consortium planning meetings and I supervised our lab’s contribution to the 








38.  Construction of a 700 kb transcript map around the Familial Mediterranean Fever 
locus on Human chromosome 16p13.3.   
Genome Research  (1998) 8: 1172-1191. 
 Centola, M., Chen, X., Sood, R., Deng, Z., Aksentijevitch, I., Blake, T., Ricke, D.O., Chen, X., 
Wood, G., Zaks, N., Richards, N., Krizman, D., Mansfield, E., Apostolou, S., Liu, J., Shafran, 
N., Vedula, A., Gumucio, D., Callen, D.F., Richards, R.I., Doggett, N, Moyzis, R, Collins, F.S., 
Liu, P.P., Fischel-Ghodsian, N., Kastner, D.L. 
       
I participated in consortium planning meetings and I supervised our lab’s contribution to the 
experimental work and I had minor role in writing the manuscript.   Citations 12 
 
39. A 500 Kb Region on chr 16p13.1 Contains the Pseudoxanthoma Elasticum Locus: 
High Resolution Mapping and Genomic Structure  
Journal of Molecular Medicine (2000) 78: 36-46. 
Cai, L., Struk, B., Adams, M.D., Ji, W., Haaf, T., Kang, H-L., Dho, S.H., Xu, X., Ringpfeil, F., 
Nancarrow, J., Züch, S., Schaen, L., Niu, T., Chung, J., Lunze, K., Verrecchia, B., Goldsmith, 
L.A., Viljoen, D., Figuera, L.E., Fuchs, W., Lebwoh, M., Uitto, J., Richards, R.I., Hohl, D., 
Ramesar, R., Callen, D.F., Kim, U-J., Doggett, N.A., Neldner K.H. and Lindpaintner, K.  
 
I participated in collaboration planning meetings and I supervised our lab’s contribution to the 
experimental work and I had minor role in writing the manuscript.   Citations 78 
 
40. Mutations in the Gene Encoding the Transmembrane Transporter Protein, ABC-C6, 
Cause Pseudoxanthoma Elasticum  
Journal of Molecular Medicine (2000) 78: 282-286. 
Struk, B., Cai, L., Zach, S., Ji, W., Chung, J., Lumsden, A., Stumm, M., Schaen, L., Kim, C-A. 
Goldsmith, L.A., Viljoen, D., Figuera, L.E., Fuchs, W., Ramesar, R., Hohl, D., Richards, R.I., 
Neldner K.H. and Lindpaintner, K. 
 
I supervised our lab’s contribution to the experimental work and I had minor role in writing the 
manuscript.          Citations 135 
 
41. A novel mutation exists the Transmembrane Transporter Protein, ABC-C6 and its 
pseudogene  – Implications for mutation analysis in Pseudoxanthoma Elasticum  
Journal of Molecular Medicine (2001) 79: 536-546. 
Cai, L., Lumsden, A. L., Guenther, U.P., Neldner S.A., Zuch, S., Ramesar, R., Hohl, D., 
Callen, DF., Neldner KH., Lindpaintner, K., Richards, R.I., and Struk, B. 
 
I supervised part of the experimental work and I had substantial role in writing and re-writing 
the manuscript.         Citations 53 
 
42. Molecular Genetics of Pseudoxanthoma Elasticum : Types and Frequencies of 
Mutation in ABCC6 
Human Mutation (2005) 26: 235-248. 
Miksch, S., Lumsden, A. L., Guenther, U.P., Foernzler, , D., Christen-Zäch, S., Daugherty , C., 
Ramesar, R., Lebwohl, M., Thierfelder, L., Hohl, D., Neldner K.H., Lindpaintner, K., Richards, 
R.I., and Struk, B.    
I supervised part of the experimental work, analysed and interpreted the data, and I had 




43. DNA Repeats: A treasury of human variation. 
New England Journal of Medicine (1994) 331: 191-193. 
Sutherland, G.R., Richards, R.I.        
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Physical mapping of human chromosome 16 has been un- 
dertaken using somatic cell hybrid DNAs as templates for 
polymerase chain reaction (PCR) deletion analysis of se- 
quence tagged sites (STSs). A panel of 29 somatic cell hy- 
brids was analyzed, confirming and refining previous 
chromosome 16 breakpoint orders and distinguishing be- 
tween the locations of breakpoints in new hybrids. Ten 
STS markers were coamplified in three multiplex reac- 
tions allowing the rapid, simultaneous deletion analysis of 
nine different loci. The locations of the protamine (PRAf1), 
sialophorin (SPN), complement component receptor 3A 
(CR3A), NAD(P)H menadione oxidoreductase 1 (NIMORI), 
and calbindin (CALB2) genes were refined. o 1991 Academic 
Press, Inc. 
INTRODUCTION 
The physical mapping of the human genome has 
relied, in large part, on the hybridization of cloned 
DNA sequences to panels of somatic cell hybrids or in 
situ to metaphase chromosomes (Callen et aZ., 1988, 
1989). Somatic cell hybrids containing regions of a 
human chromosome of interest are commonly gener- 
ated from patients with cytogenetically defined trans- 
locations or interstitial deletions or, alternatively, by 
radiation-induced fragmentation of the chromosome. 
The resolution obtained by these cell panels usually 
exceeds that of in situ hybridization but is dependent 
upon the availability of cell hybrids with breakpoints 
in the vicinity of the sequence to be mapped. In cer- 
tain circumstances, for example, the four fragile sites 
on chromosome 16, in situ hybridization is able to 
make aunique contribution (Callen et aZ., 1988). Cyto- 
genetic in situ hybridization analysis therefore com- 
plements Southern blot hybridization experiments by 
providing specific physical signposts along the chro- 
mosome. Screening somatic cell hybrids with DNA 
probes then produces an order of breakpoints be- 
tween these physical landmarks and positions the 
DNA probes between the breakpoints. 
Our studies on human chromosome 16 are based on 
somatic cell hybrids derived from fusion of a mouse 
parent APRT-deficient cell line and human cells from 
patients with chromosome 16 rearrangements. Thirty 
different breakpoints in this chromosome are repre- 
sented in 29 somatic cell hybrids. These breakpoints 
have been ordered by deletion analysis of more than 
170 DNA probes. These analyses were undertaken by 
probing Southern blots of the hybrid cell panel with 
each new DNA probe to be mapped (Callen, 1986; 
Callen et al., 1988,1989). This is a laborious approach 
that also necessitates the analysis of each newly gen- 
erated somatic cell hybrid with an array of DNA 
probes. Multiplex PCR deletion analysis was de- 
scribed in principle and applied in practice to analysis 
of deletion mutants of the dystrophin locus (Cham- 
berlain et al., 1988). In this report we describe the use 
of this approach to order the breakpoints of the hy- 
brid cell panel of chromosome 16 and to position loci 
between these breakpoints. 
MATERIALS AND METHODS 
Somatic Cell Hybrids 
The construction of the somatic cell hybrids and 
details of the human parental cell lines from which 
they were derived have been described previously 
(Callen, 1986; Callen et al., 1990). Hybrid cell lines 
were constructed by fusing the mouse uprt- cell line 
A9 or 585MEL with various human cell lines contain- 
ing translocations or deletions of chromosome 16 and 
selecting for the human APRT gene at 16q24. 
Polymeruse Chain Reactions 
Oligodeoxyribonucleotide primers were synthe- 
sized on an Applied Biosystems PCR-mate synthe- 
1047 o&%3-7543/91 $3.00 
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sizer. The pairs of primer sequences and predicted 
lengths of their PCR products are shown in Table 1. 
The ZO-~1 PCR mix was based on that of Kogan et aZ. 
(1987) and consisted of 16.6 n&f ammonium sulfate; 
67 mA4 Tris-HCl, pH 8.8; 10 mAf /3-mercaptoethanol; 
6.7 &V EDTA; 170 pg/ml bovine serum albumin; 10% 
dimethyl sulfoxide; 1.5 mMdATP; 1.5 mMdGTP; 1.5 
mM dTTP; 1.5 n&f dCTP; 6.0 mM MgCl, (multiplex 
l), 7.5 mM MgCI, (multiplexes 2 and 3 and the 
NMOR plus APRT reaction), or 4.5 mM MgCl, 
(CALI plus HP reaction); 140 ng each primer; 100 
ng genomic DNA, and 1 unit of ampliTaq (Perkin- 
Elmer Cetus). The reaction mix was overlaid with one 
drop of mineral oil and heated at 94°C for 3 min. PCR 
incubations were carried out in a Perkin-Elmer Cetus 
thermal cycler for 10 cycles of 60°C 2 min; 72°C 3 
min; 94”C, 2 min, followed by 25 cycles of 55”C, 2 min; 
72”C, 3 min; 94”C, 2 min, and then 55”C, 2 min; and 
72”C, 10 min. Ten microliters of the reaction was 
then subjected to electrophoresis on 1.4% agarose gels 
and stained with ethidium bromide. 
RESULTS AND DISCUSSION 
Synthetic oligodeoxyribonucleotides were designed 
and synthesized specifically as primers suitable for 
polymerase chain reactions. The majority of these 
were 25 nucleotides in length and of approximately 
50% GC content (Table 1). In addition, sequences 
were chosen to generate different size products in the 
range 180-500 bp from each of the different loci ana- 
lyzed so that multiple PCR products could be detected 
simultaneously. These products could be easily sepa- 
rated and visualized by agarose gel electrophoresis 
(Fig. 1). The majority of primers were derived from 
noncoding regions (introns or flanking sequences) to 
minimize cross-hybridization with mouse gene homo- 
logs. Individual pairs of PCR primers were tested 
against human blood bank DNA, to verify the antici- 
pated size of the PCR product; against the somatic 
cell hybrid CY18, which contains only human chro- 
mosome 16, to verify the correct chromosomal assign- 
ment of the locus; and against mouse A9 cell DNA, to 
ascertain whether mouse PCR products might be gen- 
erated by the primers, and if so, whether these would 
interfere with mapping of the human locus. The reac- 
tion conditions of Kogan et at. (1987) for multiplex 
PCR were used. A variety of combinations of the 10 
PCR primer pairs were tested in multiplex PCRs. 
Three multiplex reactions were derived with compati- 
ble combinations of primers and product sizes (Fig. 1 
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FIG. 1. (A) Multiplex reaction 1 with somatic cell hybrid 
DNAs as templates. Lane 1, CY14; 2, CY7; 3, CY125; 4, CY4; 6, 
CY2; 6, CY3; 7, A9 (mouse parent cell line used to generate most of 
the somatic cell hybrids); 8, human blood bank DNA. A mouse- 
derived PCR product is present in some reactions (lanes 1,6, and 
7); however, it can be readily distinguished from the STS PCR 
products and therefore does not interfere with the deletion analy- 
sis. The composition and sizes of multiplex 1 PCR products are 
given in Table 1. (B) Multiplex reactions 2 (lanes 1 to 7) and 3 
(lanes 8 to 14) with somatic cell hybrid DNAs as templates. Lanes 
1 and 8, human blood bank DNA; lane 2, CY14; lane 3, CY15; 
lanes 4 and 10, CY8; lanes 5 and 12, CY2; lanes 6 and 13, CY3; 
lanes 7 and 14, mouse A9 cell line; lane 9, CY12; lane 11, CY4; 
lane 16, HpaII-cut pUC19. The composition and sizes of multiplex 
2 and 3 PCR products are given in Table 1. Artifactual PCR prod- 
ucts of unknown origin are present in multipex 2 (- 140 bp) in 
lanes l-5 and primer dimer products are present in all reactions 
including mouse DNA controls. None of these bands interferes 
with the assignment of any locus. (C) Mapping NMORl using 
APRT (403) PCR product as positive control. Lane 1, CY18; lane 
2, CY6; lane 3, CY5. (D) Mapping CALBZ using HP PCR product 
as positive control. Lane 1, CY18; lane 2, CY5; lane 3, CY170. 
and Table 2). PCR products were electrophoresed in 
1.4% agarose gels and stained with ethidium bromide. 
Each of the multiplex reactions was optimized for 
Mg2+ concentration over the range of 3 to 9 mM 
MgCl, at 1.5 mA4 intervals (data not shown). The rela- 
tively high optimum Mg2+ concentrations for these 
reactions are due to the high nucleotide concentra- 
tions used (Kogan et al., 1987) which favor multiplex- 
ing (Chamberlain et ab, 1988). 
The somatic cell hybrid panel was derived using 
alanosine and adenine selection for APRT+ pheno- 
type on an uprt- A9 mouse cell line background (Cal- 
len, 1986). The human chromosomes were derived 
from cell lines containing various translocations or 
deletions of chromosome 16. The human APRT gene 
maps to the distal tip of the long arm of chromosome 
16 and all but one of the hybrids tested contain this 
locus. These hybrids therefore have breakpoints that 
map either on the short arm or proximal to the APRT 
locus on the long arm. The one hybrid that does not 
contain APRT is CY3, which was constructed by se- 
lection of the HPRT gene present on the X chromo- 
some, as the chromosome 16 material in this hybrid 
originated from an X;16 translocation (Callen, 1986). 
The PCR marker for the APRT gene was used as an 
internal positive control to verify negative results 
from the analysis of other loci. Two APRT PCR 
markers were designed utilizing the same forward 
primer but different reverse primers, and generated a 
200- or 403-bp PCR product (Table 1). This allowed 
for greater flexibility in the design of multiplex reac- 
tions (Table 2). Additional STSs were chosen from 
available DNA sequences of genes known to map to 
chromosome 16 and, where possible, from evenly 
spaced intervals over the length of the chromosome. 
In those cases where only cDNA sequence was avail- 
able, primer sequences were synthesized from the 3’ 
untranslated region in an attempt to avoid spanning 
introns. 
In all but one instance the size of the PCR product 
matched the published nucleotide sequence. The 
CR3A product was predicted to be 569 bp but was 
found to give a 490-bp product. This gene mapped to 
the 16pll-qll region, which is consistent with its 
previous localization (Corbi et cd., 1988). The se- 
quence between the two PCR primers at this locus 
contains about 200 bp which comprise mainly GT di- 
nucleotide repeats. Such repeats are frequently poly- 
morphic (Weber and May, 1989) and this may ac- 
TABLE 2 
Multiplex 
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FIG. 2. Order of breakpoints and location of genes on human chromosome 16. (A) Giemsa banding pattern of the chromosome. (B) 
Locations of physical landmarks including fragile sites. (C) Approximate locations of breakpoints determined cytogenetically. (D) Somatic 
cell hybrid containing chromosome breakpoint. P, proximal, and D, distal ends of interstitial deletions. (E) The number of DNA markers 
that have been mapped to each breakpoint interval (Callen et al., (4); Chen et al., submitted; Callen et a& submitted, and this study). An 
additional 65 probes have been mapped to chromosome 16 but not within single breakpoint interval resolution. (F) Location of gene loci by 
PCR to intervals defined by somatic cell hybrid breakpoints. 
count for the difference between the predicted and editing the original sequence data because of its 
observed product lengths. However, no CR3A poly- highly repetitious composition. 
morphism was observed in the amplification of chro- The NMORl and CALB2 polymerase chain reac- 
mosome 16 DNAs from 16 different individuals and tions proved intractable to multiplexing. Readable 
therefore the difference may be due to difficulties in products were obtained from the NMORl primers 
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only when they were present in fourfold molar excess 
over APRT (403) PCR primers (Fig. 1). Nevertheless, 
this reaction allowed the deletion mapping of the 
NMORl locus, refining its localization compared to 
that previously published (Jaiswal et al., 1988). The 
CALB2 primers did not give reproducible results with 
either set of APRT primers. Fortunately, a reaction 
with CALBB and HP was successful in generating 
gene products (Fig. 1) and allowed mapping of the 
CALB2 locus to the interval defined by CY5 and 
CY170, again refining its localization over that 
previously reported (Parmentier et al., 1989). 
Many of the breakpoints represented in this hybrid 
panel have been mapped extensively by Southern blot 
hybridization with cloned DNA probes (Callen et al, 
1988,1989,1990; Chen et aZ., submitted). The order of 
the breakpoints with respect to the idiogram of chro- 
mosome 16 and the location of the genes mapped by 
PCR are indicated in Fig. 2. The physical locations of 
the fragile sites are well defined by cytogenetic analy- 
sis. The breakpoints represented in the hybrid panel 
are unambiguously ordered but the exact localization 
of their breakpoints cannot always be accurately de- 
termined due to the limitations of cytogenetic anal- 
ysis. 
The loci defined by the genes PRMl, SPN, CR3A, 
CALB2, and NMORl are new additions to our 
previous probe repertoire and their mapping to the 
hybrid panel refines their previous localizations (see 
references in Table 1). The localization of PRMl con- 
firms the findings of Viguie et al. (1990) of a distal 16p 
assignment by in situ hybridization and contradicts 
the 16q21 assignment of Krawetz et al. (1989). PCR 
described for the HBA, PKCB, MT, LCAT, HP, and 
APRT genes replaces the use of cloned DNA probes 
and Southern hybridization in characterizing newly 
generated somatic cell hybrids. The breakpoints of 
the hybrid CY 180A could be uniquely located between 
SPN and CR3A without recourse to Southern hybrid- 
ization. 
The multiplex PCR analysis of STSs described 
here has several important advantages over the 
previous Southern blot analysis which was used to 
map the chromosome breakpoints represented in the 
somatic cell hybrid panel. These include the rapidgen- 
eration and reproducibility of results and elimination 
of the need to purify and label cloned DNA probes. 
The PCR approach uses far less hybrid cell DNA, and 
for several hybrids the breakpoint was localized using 
DNA isolated from the primary hybrid clones of the 
somatic cell hybrids. This enables multiple hybrid 
clones to be tested for retention of the translocated 
human chromosome 16, since hybrids containing the 
translocated human chromosome 16 with the human 
APRT gene as the only human chromosome 16 mate- 
rial present will be positive for APRT and negative for 
HBA. The multiplex reaction has thus become a rou- 
tine screening test for newly generated somatic cell 
hybrids and dramatically reduces the time taken for 
analysis. 
Further application of PCR will necessitate the de- 
termination of DNA sequences from a probe in each 
of the breakpoint intervals to act as an STS. It is 
likely that in the future the majority of new physical 
markers will be mapped using this approach. 
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A cosmid library of human chromosome 16 has been sub- 
cloned, and (AC), microsatellite positive clones have been 
identified and sequenced. Oligonucleotide primers flanking 
the repeat were designed and synthesized for (AC), microsat- 
ellites with n > 16. These microsatellite loci were then mapped 
by PCR using a somatic cell hybrid panel of human chromo- 
some 16, and their heterozygosities and allele frequencies de- 
termined. Fourteen (AC), microsatellites were mapped to dis- 
crete physical intervals of human chromosome 16 defined by a 
mouse/human hybrid panel. Nine of these have expected he- 
terozygosities ranging between 0.60 and 0.79, four have ex- 
pected heterozygosities between 0.02 and 0.49, and one de- 
tected three loci where the alleles could not be resolved. 
8 1992 Academic Press, Inc. 
INTRODUCTION 
(AC), microsatellite loci are distributed along the 
length of human chromosome 16 at a frequency of ap- 
proximately one locus every 30 kb (Stallings et al., 1991). 
The number of dinucleotide (AC) pairs at these loci has 
been shown to be polymorphic (Litt and Luty, 1989; 
Weber and May, 1989; Luty et al., 1990). They comprise 
either uninterrupted or interrupted runs of consecutive 
(AC) dinucleotide pairs. Other simple repeats may be 
present in addition to the (AC),, repeat. Weber (1990) 
has assigned these repeats to three classes, perfect, im- 
perfect, and compound respectively, and shown that 
their PIC value is proportional to the length of the per- 
fect repeat (Weber, 1990). 
These microsatellites are therefore an abundant 
source of highly informative PCR-based genetic 
markers that appear to be evenly distributed throughout 
the human genome. Traditional RFLPs with high PIC 
values tend to be VNTRs that are usually clustered near 
the telomeres. For chromosome 16, only seven single- 
enzyme RFLPs with PIC values of greater than 0.50 
have been reported (Reeders and Hildebrand, 1989; 
Reeders et al., 1990), but of four (AC), microsatellite 
probes mapped to chromosome 16, three had PIC values 
greater than 0.50, and the fourth had a PIC value of 0.44 
(Reeders et al., 1990). 
(AC),, microsatellites are ideal polymorphic loci for 
the construction of high-resolution genetic maps of hu- 
man chromosomes. They also provide a means of mak- 
ing candidate disease gene loci informative, allowing seg- 
regation analysis in affected pedigrees (Richards et al., 
1991a,b,c). To meet these two complementary require- 
ments (AC), microsatellites have been isolated by two 
approaches: either by sequence analysis of previously 
characterized genes and anonymous DNA sequences or 
by isolation at random from human DNA libraries. In 
this report the latter approach has been applied to chro- 
mosome 16. 
MATERIALS AND METHODS 
Subcloning of human chromosome 16 for sequencing. Total DNA 
was prepared from a cosmid library of human chromosome 16 (Stal- 
lings et al., 1990). This library was constructed from flow-sorted chro- 
mosomes from the mouse-human somatic cell hybrid CY18, which 
has chromosome 16 as its only human chromosome (Callen, 1986). 
The DNA was digested to completion with Sau3AI (New England 
Biolabs) and ligated into the BamHI site of M13mp18. A preliminary 
experiment used total digested DNA and a range of insert-to-vector 
ratios. Subsequently, the Sau3ALdigested DNA was size-fractionated 
on a 1.4% low-melting-point agarose gel, and the size range 200-500 
bp ligated with the M13mpl8-BamHI vector at a threefold molar ex- 
cess of vector. 
Selection of (AC),positive clones. M13mp18 cosmid library ligated 
DNA was transformed into Escherichia coli strain BB4 (Bullock et al., 
1987), and plaque lifts were made using Hybond N+ gridded nylon 
filters (Amersham). Filters were hybridized in the absence of carrier 
DNA at 65°C in 1 M sodium phosphate (pH 7.0), 7% SDS and probed 
with poly(AC),/(GT), (Pharmacia) labeled with [ol-32P]dCTP (Amer- 
sham) using a multiprime labeling kit (Amersham). Washes were per- 
formed to a maximum stringency of 30 mM NaCl, 2.3 mM NaH2P0,, 
0.25 mM EDTA, 0.1% (v/v) SDS (adjusted to pH 7.4 with NaOH). 
From a preliminary experiment, single-stranded DNA was prepared 
from all plaques showing strong hybridization to the probe and se- 
quenced. In the subsequent experiment, all positive plaques were spot- 
ted onto a fresh bacterial lawn and screened a second time as described 
above. Single-stranded DNA prepared from these second-screen posi- 
tives was spotted onto GeneScreen Plus (DuPont). The dot-blot filter 
was screened with the poly(AC),/(GT), probe, and those clones giving 
the strongest signals were selected for sequencing. 
Oligodeoxyribonucleotides. Initially, primers were designed for 
(AC),, repeats when n was >16 for both perfect and imperfect repeats, 
but later only for perfect repeats with n > 16. Primers were usually 25 
bases in length and as close to 50% GC content as the flanking se- 
quence allowed. Primer pairs were designed to give PCR products 
0888.7543/92 $5.00 
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ranging from 100 to 200 bp in length to facilitate the simultaneous 
PCR amplification of two or more loci (Weber and May, 1989). 
Panel of chromosome 16 somatic cell hybrid breakpoints. The panel 
of somatic cell hybrids containing breakpoints of human chromosome 
16 has been documented elsewhere (Callen, 1986; Callen et al., 1990; 
Richards et al., 1991d; Callen et al., unpublished results). The posi- 
tions of hybrid breakpoints have, on many occasions, been determined 
by negative results from Southern blot analysis. In some instances 
PCR analysis has given results inconsistent with the Southern blot 
data. For CY 123 and CY 140, further Southern blot analysis confirmed 
the presence of more of chromosome 16 than the initial results sug- 
gested, and their breakpoint locations have been altered accordingly 
(Callen et al., unpublished results). 
PCR Mapping and characterization of (AC), loci. PCR was per- 
formed on a Perkin-Elmer/Cetus DNA thermal cycler using the reac- 
tion conditions of Kogan et al. (1988) with the addition of 5 &i of 
[cu-3ZP]dCTP for polymorphism typing. The 10.~1 reaction mixture 
contained 16.6 mM ammonium sulfate; 67 mM Tris-HCl (pH 8.8); 10 
mM P-mercaptoethanol; 6.7 PM EDTA; 170 Fg/ml bovine serum albu- 
min; 100 ng genomic DNA, 1.5 mM each dATP, dCTP, dGTP, and 
dTTP; 75 ng each oligodeoxyribonucleotide primer; 10% (v/v) di- 
methyl sulfoxide; 5 &i [a-32P]dCTP (3000 Ci/mmol, Amersham); and 
0.5 unit Tag polymerase (Perkin-Elmer/Cetus). The magnesium chlo- 
ride concentration was optimized for each marker by analysis of the 
above reaction without [ol-32P]dCTP on 1.4 or 2% agarose gels. The 
optimum magnesium chloride concentration for each marker is given 
in Table 1. All mapping and polymorphism typing reactions employed 
a step cycle file comprising 10 cycles of 94°C X 1 min, 60°C X 1.5 min, 
72°C X 1.5 min, followed by 25 cycles of 94°C X 1 min, 55°C X 1.5 min, 
72°C X 1.5 min, and a 10.min extension at 72°C. 
The physical location of each marker was determined by PCR analy- 
sis using DNAs from a human chromosome 16 somatic cell hybrid 
panel (Callen et al., 1990; Richards et al., 1991d; Callen et al., unpub- 
lished results) as templates. PCR products were resolved on 1.4 or 
2.0% agarose gels and visualized by ethidium bromide staining. This 
allowed mapping of the marker to a specific breakpoint interval by 
virtue of the presence or the absence of a PCR product with somatic 
cell hybrid DNAs as templates in the PCR. PCR for hybrid DNAs 
with breakpoints that flanked this interval helped to confirm the phys- 
ical assignment. 
Heterozygosities and allele frequencies were determined by PCR of 
DNAs from unrelated Caucasian individuals and/or CEPH (Centre 
d’Etude du Polymorphisme Humain, Paris) parent DNAs. PCR prod- 
ucts were resolved on 5% denaturing polyacrylamide gels following 
the addition of a threefold excess of formamide loading buffer and 
heating at 94°C for 3 min. Electrophoresis of PCR products on dena- 
turing polyacrylamide gels was essential to distinguish alleles that 
frequently differ by as little as 2 bp in length. 
RESULTS 
Subcloning and Sequencing of (AC), Positive Clones 
Of the 48 clones sequenced, 44 were unique and 4 were 
independently subcloned from the chromosome 16 cos- 
mid library twice. Oligodeoxyribonucleotides were de- 
signed for 23 (AC), repeats and are given in Table 1. Of 
the remainder, 2 contained no discernible repeat and 11 
were rejected as too short, having perfect repeats of n < 
16. Three had repeats too close to the cloning site to 
design primers, 2 were flanked by repetitive sequence, 2 
needed very long sequencing runs, and the last was a 
mixed or unstable clone. 
Physical Mapping of (AC), Markers 
Physical mapping proceeded in two stages. First, 
DNAs from a set of hybrids comprising CY2, CY4, CY8, 
CY115, CY 165, and CY196 were used as templates, al- 
lowing localization to a broad interval. A second round 
of PCR was then performed with each of the hybrid 
breakpoint DNAs that either localized within or flanked 
the initial broad interval. In this manner the physical 
location of a marker was defined by a minimum of two 
hybrid breakpoints on either side of the interval to 
which it mapped. 
From the 23 (AC), microsatellite loci for which 
primers were designed, 14 were physically mapped to 
discrete intervals of the human chromosome 16 by PCR 
analysis of DNAs from a somatic cell hybrid panel of 
chromosome 16 (Fig. 1). PCR amplification of CY18 
DNA (which contains a single intact human chromo- 
some 16 and no other human chromosomes; Callen et al., 
1990) showed that two of these primer pairs detected 
more than one locus. In both cases each locus was within 
the same physical interval defined by the hybrid panel. 
16AC5.4 detected two loci whose PCR products resolved 
well and could be typed independently, but 16AC6.16 
detected three loci whose PCR products had similar mo- 
bilities. Since specific alleles could not be assigned to 
specific loci, 16AC6.16 could not be used as a genetic 
marker. 
16AC1.8 mapped to human chromosome 16, but gen- 
erated a complex pattern when used against the hybrid 
panel. Both CY18 DNA and total human DNA gave a 
ladder of PCR products, indicating that 16AC1.8 detects 
a number of loci on chromosome 16. 
Four of the remaining eight unmapped (AC), micro- 
satellite primer pairs, AC2, 1.16,6.18, and 6.24, gave dis- 
crete bands with mouse control DNA but not with hu- 
man DNA. Clones 1.17 and 2.1 gave multiple bands on 
background smears for both human and mouse genomic 
DNA. 6.10 gave faint multiple bands on a background 
smear for human and CY18 DNA, but not mouse, and 
6.7 gave inconsistent results with human and CY18 
DNA, but no products with mouse DNA. 
Allele frequencies and heterozygosities were deter- 
mined (Table 2) for all (AC), microsatellite loci mapped 
to discrete intervals of the human chromosome 16 hy- 
brid panel except for the three loci detected by 
16AC6.16. Primers for two different (AC), repeats were 
often combined in a multiplex reaction, thereby increas- 
ing the efficiency of typing multiple individuals. 
DISCUSSION 
Thirteen human (AC), microsatellites have been iso- 
lated from a cosmid library of human chromosome 16 
and characterized with regard to their allele frequencies 
and heterozygosities. Nine of these represented perfect 
(AC), repeats of n > 18 and heterozygosities of >0.60. 
The remaining four had perfect (AC),, repeats of n < 11, 
but imperfect repeats of 24 < n < 32, and heterozygosi- 
ties ranging from 0.02 to 0.49. These four repeats were 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































q13 Dl6S306 (16AC5.4) 
CY4 D16S30106AC 6.21) 
(J-1 q22.1 r 
FRAI6D 
CYl8A (P) i I q24.1 I 
\ D16S303 (16AC6.26) 
FIG. 1. Idiogram of chromosome 16 showing the distribution of (AC), loci. Translocation and deletion breakpoints contained in the hybrid 
panel are shown on the left denoted by CY and a number. Fragile sites are given as FRAIG and a letter. Arrows indicate the direction of DNA 
(from the breakpoint indicated to the telomere) contained in the hybrid, unless indicated by (P) or (D), which indicate the extent of proximal 
and distal boundaries, respectively. In the direction of the long arm the tip of the arrow touches the breakpoint, while in the direction of the 
short arm the base of the arrow touches the breakpoint. The positions of the breakpoints in the hybrids CY123 and CY 140 have been reassessed 
since their previous publication (Richards et al., 1991d). In both cases more of chromosome 16 was found to be present in the hybrid than 
previously thought. 
after their low heterozygosities were observed only per- 
fect repeats of n > 16 were selected subsequently. These 
results concur with the findings of Weber (1990) that the 
length of the perfect repeat is a better indicator of infor- 
mativeness than the length of the imperfect repeat. 
Three of the 15 PCR primer pairs amplifying human 
chromosome 16 (AC), repeats detected three or more 
loci per individual. This is higher than the 7% cited by 
Weber (1990) and may reflect the small sample number 
reported here. Only one of the three, 16AC5.4, could be 
used as a genetic marker. 
The large number of mouse (AC), microsatellites iso- 
lated was an unexpected problem. Four of the 19 primer 
pairs that worked well represented mouse-derived (AC), 
microsatellites. This is greater than the level of mouse 
DNA contamination of the cosmid library, which has 
been reported to be 7% (Stallings et al., 1990). A possible 
explanation is that mouse (AC), repeats appear on the 
average to be longer than human repeats, and therefore 
selection on the basis of length in the dot-blot screening 
step selected more strongly for mouse sequences than for 
human. It has also been reported that (AC),, microsatel- 
219
406 THOMPSON ET AL. 
TABLE 2 
Informativeness of Human Chromosome 16 (AC), Repeat Loci 
Locus Repeat Alleles* Frequencies 
Expected 
















































140 0.56 0.49(156) 0.37 
138 0.44 


























111 0.99 0.02 (80) 0.02 
109 0.01 



















16AC1.18 PCW 167 0.01 0.77 (92) 0.73 









P(9) + l(24) + J(19, 244 0.90 0.18 (124)d 0.16 
max P(6) + max P(7) 242 0.10 





















16AC6.26 102) 115 0.07 0.43 (212) 0.40 





a P(25), perfect repeat of 25 repeat units; I, imperfect; c, compound. 
b The size of the different alleles is given in base pairs. 
’ The number of chromosomes scored is given in parentheses. 
d Although 16AC5.4 detects two loci, of 200 and 244 bp, only the larger one was polymorphic. The size of the larger band was estimated by 
comparison with the mobilities of sequences of known length in sequencing gels. 
(AC), MARKERS FROM HUMAN CHROMOSOME 16 407 
TABLE 2-Continued 
Locus Repeat Allelesb Frequencies 
Expected 
heterozygosity PIC value 
lites occur approximately twice as frequently in the 
mouse genome as in the human genome (Hamada et al., 
1982). 
Other problems were that 17% of primer pairs failed 
to give satisfactory results with either human or mouse 
genomic DNA, and four clones were independently iso- 
lated and sequenced twice. Although a 17% primer fail- 
ure rate is far from desirable, it is much lower than 
others have experienced (Cornall et al., 1991). Nonran- 
dom amplification of the cosmid library is most likely 
the reason that identical clones were independently iso- 
lated. 
specific to this chromosome. Fourteen (AC), microsatel- 
lite loci have been mapped to 12 discrete intervals on the 
hybrid panel. Six of these loci have heterozygosities of 
>0.70, the cutoff proposed for index markers, and a fur- 
ther 3 were between 0.60 and 0.70. Gaps in the resulting 
genetic map could then be filled by employing a “target- 
ted” approach, identifying and subcloning (AC),, repeats 
from lambda and cosmid clones previously mapped to 
the desired interval. This is possible only if detailed 
correlations exist between physical and genetic maps, as 
is the case with human chromosome 16 (Kozman et al., 
unpublished results). 
In conclusion, the strategy of randomly isolating The characterization of AC repeat microsatellite 
(AC), microsatellite loci from a human chromosome markers therefore shows a great deal of promise for pro- 
16-specific library was successful in identifying highly viding a high-resolution, PCR-based, genetic linkage 
informative and randomly distributed genetic markers map for human chromosome 16, and ultimately for the 
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entire human genome. In this regard it is worthwhile to 
compare the results presented here with those of Iizuka 
et al. (1992), where chromosome ll-specific Alu-SSCP 
polymorphisms were characterized. Of the 16 AL-SSCP 
markers characterized, only 3 had PIC values >0.50 
(only one > 0.70), and 7 markers were not polymorphic. 
While these AL-SSCP polymorphisms will no doubt be 
a valuable new source of genetic markers, the AC repeat 
microsatellites, despite some difficulties in their charac- 
terization, are more likely to fulfill the role of PCR- 
based index markers for the human genome. 
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Summary
Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by attacks of fever and
serosal inflammation; the biochemical basis is unknown. We recently reported linkage of the gene causing FMF
(designated "MEF") to two markers on chromosome 16p. To map MEF more precisely, we have now tested
nine 16p markers. Two-point and multipoint linkage analysis, as well as a study of recombinant haplotypes,
placed MEF between D16S94 and D16S80, a genetic interval of about 9 cM. We also examined rates of
homozygosity for markers in this region, among offspring of consanguineous marriages. For eight of nine
markers, the rate of homozygosity among 26 affected inbred individuals was higher than that among their 20
unaffected sibs. Localizing MEF more precisely on the basis of homozygosity rates alone would be difficult, for
two reasons: First, the high FMF carrier frequency increases the chance that inbred offspring could have the
disease without being homozygous by descent at MEF. Second, several of the markers in this region are relatively
nonpolymorphic, with a high rate of homozygosity, regardless of their chromosomal location.
Introduction
Familial Mediterranean fever (FMF) is an autosomal
recessive disease characterized by recurrent, self-lim-
ited attacks of fever with sterile peritonitis, pleurisy,
and/or synovitis. The disease is most common in non-
Ashkenazi Jewish (Sohar et al. 1967), Armenian
(Schwabe and Peters 1974), Turkish (Ozdemir and Sok-
men 1969), and Middle Eastern Arab (Barakat et al.
1986) populations. Before the introduction of colchi-
cine prophylaxis, a large percentage of Israeli and Tur-
kish FMF patients developed systemic amyloidosis, in-
evitably leading to chronic renal failure and death or
dialysis (Ozdemir and Sokmen 1969; Pras et al. 1982).
Although the biochemical basis of this disease is un-
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known, the clinical manifestations of FMF suggest a
lesion in a molecule important to the understanding of
inflammation in general.
We have recently mapped the FMF susceptibility
gene, designated by the gene symbol "MEF" (McAlpine
et al. 1991), to the short arm of chromosome 16 in
non-Ashkenazi Jewish families from Israel (Pras et al.
1992). Multipoint linkage analysis placed MEF centro-
meric to DI 6S84, with a maximal lod score greater than
19, but did not establish flanking markers for MEF.
Shohat et al. (1992) have subsequently shown that the
FMF susceptibility gene is also linked to chromosome
16p in Armenian families.
Our initial study also made use of the strategy of
homozygosity mapping (Smith 1953; Lander and Bot-
stein 1987). This approach relies on the fact that, in
inbred families, children with rare recessive diseases
usually inherit both copies of the disease gene, along
with markers on adjacent chromosomal intervals, from
a common ancestor. Most affected offspring of con-




gous by descent for DNA markers on either side of a
recessive disease susceptibility gene. In the case of
FMF, the gene frequency in our study population (ap-
proximately .045) is sufficiently high that some inbred
affected individuals may not be homozygous by de-
scent at the disease locus. Such individuals would not
be expected to be homozygous at MEF-associated
marker loci. Nevertheless, among 19 affected offspring
of consanguineous marriages, we found a much higher
rate of homozygosity at both chromosome 16 loci than
we would have predicted on the basis of chance alone
(Pras et al. 1992).
In the present study we have sought to define the
boundaries of the MEF region of chromosome 16. To
this end, we examined seven additional DNA polymor-
phisms and expanded our study panel to 31 non-Ash-
kenazi Jewish families. Regional localization was ac-
complished by classical likelihood methods and by the
analysis of recombinant haplotypes. We also studied
locus homozygosity among affected offspring of inbred
marriages, in order to identify an area of overlap among
the homozygous chromosomal regions defined for each
inbred individual. This overlap zone should correspond
to the MEF candidate region established by more tradi-
tional methods. In addition, we investigated the effects
of varying disease gene frequency and marker heterozy-
gosity on the applicability of this approach.
Subjects and Methods
Families and DNA Samples
Families were recruited from a clinic at the Sheba
Medical Center, Tel-Hashomer, Israel; FMF was diag-
nosed according to established clinical criteria (Sohar et
al. 1967). This project was approved by the Human
Experimentation Committee at the Sheba Medical
Center. The study included 31 pedigrees (200 individ-
uals, 94 of whom were affected). Peripheral blood lym-
phocytes were immortalized with Epstein-Barr virus
(Anderson and Gusella 1984). DNA was purified from
cell lines by SDS-proteinase K digestion, extraction
with phenol and chloroform, and ethanol precipitation
(Davis et al. 1986).
Southern Analysis
Southern blot analyses were carried out using stan-
dard techniques (Cavenee et al. 1984; Reed and Mann
1985). DNA probes were 32P-labeled by random prim-
ing (Oligo-labeling kit; Pharmacia) according to the
manufacturer's instructions. Hybridizations were per-
formed at 420C overnight in the presence of 0.25 mg of
human placental DNA/ml. Two 30-min high-strin-
gency washes were performed with 0.1 X SSC, 0.1%
SDS at 60'C. Films were exposed for 1-10 d at -700C.
PCR Amplification
The (AC), marker D16S283 was typed by PCR using
published primers (Harris et al. 1991). One primer was
end-labeled with 32P by using polynucleotide kinase
(New England Biolabs). PCR was carried out in a 10-jil
volume containing 50 ng of genomic DNA, with 13.4
ng of each unlabeled primer, 20 M dNTP, 0.08 ng of
32P-labeled primer, in 15 mmol MgCl2 PCR buffer, with
1.2 U of TaqI polymerase (Perkin-Elmer). Thirty cycles
were performed (94°C for 1 minm 57°C for 1 min, and
72°C for 30 s), followed by a final extension of 10 min
at 72°C. Aliquots of amplified DNA were mixed with 1
vol of loading buffer, denatured at 94°C for 4 min, and
electrophoresed on a standard 8% polyacrylamide gel.
On every gel a control DNA sequence (Sequenase 2.0
kit; United States Biochemical) was run as a molecular-
weight standard. Typing for D16S291 was performed
as described elsewhere (Thompson et al. 1992).
An (AC)n marker at D16S94 was identified by
screening restriction digests of lambda VK5 (Hyland et
al. 1989) with 32P-labeled (Amersham Multiprime kit)
poly-(AC.GT) (Pharmacia). A HaeIII digest of lambda
VK5 was subcloned into SmaI-cut M13mpl8, and the
(AC)n-containing sequence was identified by hybridiza-
tion to 32P-labeled poly-(AC.GT). Sequence analysis
allowed the design of PCR primers VKSACF 5' GAGC-
CCACAGACTTCTTTCCTGGG 3' and VKSACR 5'
CCCACACCATGTACAGCCAGTAGGTA 3' with
which to type copy-number polymorphism in the (AC)n
repeat. The parental generation (160 chromosomes)
from the CEPH (Centre d'Etude du Polymorphisme
Humain, Paris) pedigrees was genotyped to reveal the
following allele frequencies: 82 bp, .01; 84 bp, .01; 86
bp, .62; 88 bp, .35; and 90 bp, .02. The expected hetero-
zygosity was .51, and the observed heterozygosity was
.58. For genotyping the FMF families, each gel con-
tained the subcloned M13 (86-bp) allele as a size
marker. PCR cycle times and reaction conditions were
as described by Richards et al. (1991).
Linkage Analysis
Lod scores were calculated using the LINKAGE
package of programs (version 5.10) (Lathrop et al.
1984). We used a model in which FMF is inherited as an
autosomal recessive trait with a 95% penetrance in
males, 70% penetrance in females, and gene frequency






Pairwise Lod Scores between MEF and Chromosome I6p Markers
9b
MAXIMAL LOD
Locus PIca .00 .01 .02 .05 .10 .15 SCOREc Od Omd
HBA (5'HVR/Rsal) ................. .70 -.79 10.47 12.61 14.62 14.42 12.90 15.70 .01 .11
D16S83 (EKMDA2.1/RsaI) .......... .23 9.30 11.39 11.70 11.56 10.38 8.36 11.38 .02 .03
D16S84 (CMM65/Taql) ............ .36 6.20 9.09 9.55 9.62 8.70 7.43 10.15 .001 .05
D16S291 (AC2.5, PCR marker) ...... .77 11.52 15.83 16.71 17.10 16.10 13.80 17.16 .03 .04
D16S283 (SM7, PCR marker) ........ .63 16.87 20.49 21.08 20.88 18.91 16.26 21.24 .01 .03
D16S94 (VK5, PCR marker) ......... .41 13.17 13.83 13.88 13.37 11.84 10.14 14.21 .04 .001
D16S80 (24-1/Taql) ................. .31 6.55 9.77 10.38 10.69 9.88 8.60 11.25 .001 .07
D16S82 (41-1/Sacl) ................. .27 3.66 4.57 4.94 5.25 4.99 4.37 5.73 .10 .001
D16S37 (16/02/Mspl) ....... ....... .37 -19.65 -11.82 -9.14 -5.35 2.64 -1.36 .00 .50 .50
NOTE.-Data were calculated from 31 non-Ashkenazi Jewish families by using a recessive-disease model with a 95% male penetrance and
70% female penetrance.
a Source: Williamson et al. (1991).
b Sex-averaged recombination frequencies.
c When sex-specific recombination frequencies are allowed to vary independently.
d Sex-specific recombination frequency for maximal lod score.
from published sources (Williamson et al. 1991). Re-
combination frequencies were transformed to map dis-
tances by Kosambi's (1944) formula.
Results
Linkage Analysis
Table 1 is a summary of sex-averaged and sex-speci-
fic two-point lod scores between MEF and nine
markers mapped to chromosome 16p, tested in 31 non-
Ashkenazi Jewish families. Figure 1 depicts the relative
map positions of these loci. All but one of the markers
demonstrated linkage to MEF. Only D16S37, which is
closest to the centromere, was not linked. D16S94, an
(AC)n marker with a PIC of .41, gave a maximal sex-






mative D16S283 had a higher maximal sex-averaged
lod score, 21.20, at 0 = .03. For six of the eight markers
showing linkage, sex-specific recombination frequen-
cies were consistent with the excess in male recombina-
tion observed near the telomere of chromosome 16p
(Breuning et al. 1990; Julier et al. 1990; Keith et al.
1990; Reeders et al. 1991).
In order to place MEF on the map, relative to other
markers, we performed multipoint linkage analysis. For
highly polymorphic markers, we were only able to use
two fixed marker loci, because of the prohibitive com-
putational times required for multipoint analysis in
consanguineous families with several unknown typings.
We chose D16S80 and D16S283 as fixed markers, on
the basis of their map positions and informativeness.
Using the ILINK computer program, we estimated the
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VK5 SM7 AC2.5 CMM65 EKMDA2.1 5'HVR
Figure I Order of polymorphic sites within the MEF candidate region. Locus names and corresponding plasmid or microsatellite names
are shown only for polymorphisms used in the present study. Sex-averaged recombination frequencies are taken from published sources
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Figure 2 Multipoint linkage analysis between )
chromosome 16p markers, for 31 families. D16S80()
assigned position 0, and D16S283 was placed at 10 clPv
of ILINK calculations with our panel of families. Iv
scores were calculated every 2 cM within the interval
to D16S283. The maximal multipoint lod score was o
centromeric to D16S283.
recombination frequency between D16
D16S80 in our families as .10, with no dif
tween sexes. The maximal multipoint lo(
23.89 placed MEF between these two loci, a
centromeric to D16S283 (fig. 2.) In light of t
D16S94 is only about 200 kb centromeric ti
(Harris et al. 1991; Germino et al. 1992), ME
is in the interval between D16S94 and D16
Recombinant Families
Figure 3 is a family-by-family summary c
nants between MEF and chromosome 16 m
combinant families are designated by blacke
and nonrecombinant families are designat
blackened circles. All of the families excep
and 14 showed linkage to one or more loci
two families were either recombinant or uni
at all of the loci tested thus far. The true stat
families relative to chromosome 16 is un(
each family was uninformative for five o
markers in our panel.
A maternal crossover in family 15, present
but not at D16S82, placed MEF centr
D16S94. Families 33, 38, and 72 were not informative
for D16S94, but in each of these families there were
crossovers at D 16S283 that were not present at
D16S80 (families 33 and 38) or D16S37 (family 72).
The analysis of recombinant families was therefore
consistent with the multipoint data placing MEF cen-
tromeric to D16S94.
A paternal crossover in family 27, present at D16S80
but not at D16S94, placed MEF telomeric to D16S80.
Moreover, in families 13 and 25 there were crossovers
at D16S80 that were not present at D16S283. When
the centromeric and telomeric recombinants were con-
sidered together, the most likely position for MEF was
between D16S80 and D16S94.
I
Homozygosity Mapping
20 30 Our panel of 31 non-Ashkenazi Jewish families in-
cluded 12 consanguineous marriages, depicted in figure
:) 4. There were seven first-cousin marriages, with a total
of 18 affected offspring, and there were two uncle-
MvaE and two niece marriages, with 3 affected offspring. In one other
1as arbtrharily family (family 72) the offspring of half-sibs married, and
i,on the basis in two families the exact relationship of intermarriage/lultipoint lod
from D16S80 was unknown. Altogether, the panel included 26 af-
.btaincd 4 cM fected offspring of inbred marriages.
Figure 5 shows whether each of these individuals was
homozygous at the nine loci that we studied. Individ-
uals 25-06, 27-11, and 38-08 were heterozygous at
5283 and D16S80 but homozygous at D16S94. Individuals 2-07
ference be- and 72-05 were heterozygous at D16S94 but homozy-
d score of gous at D16S80 and D16S82. There was no locus for
ibout 4 cM which all affected individuals were homozygous.
he fact that We also evaluated whether the percentage of homo-
o D16S283 zygous individuals increased as we moved closer to the
IF probably MEF region (table 2). The left side of the table shows
S80. the fraction of homozygous individuals among the 26
affected and 20 unaffected offspring in our consan-
guineous families. For every locus except D16S37
f recombi- (which was not linked to MEF by two-point linkage
arkers. Re- analysis), the percentage homozygous among affected
ned circles, persons was greater than the percentage homozygous
ted by un- among unaffected siblings. For certain markers (HBA,
t families 2 D16S83, D16S291, and D16S283), this difference was
The latter quite substantial. For other markers (D16S84, D16S94,
informative D16S80, and D16S82), the difference was not as great,
tus of these owing largely to a high rate of homozygosity in the
clear, since unaffected sibs.
f the nine The right side of table 2 shows the rate of homozy-
gosity predicted for each marker, regardless of linkage
at D16S94 to MEF and solely on the basis of chance, for various
romeric to degrees of inbreeding. These values are close to the
454
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0 = Recombination; 0 = No recombination; ? - uninformative or not done
Figure 3 Study of recombinants among 31 FM F families. Markers are ordered as in fig. 1. Family 15 defined the telomeric limit (D l6S94)
for the MEF candidate region, while families 13, 25, and 27 defined the centromeric limit (D16S80). The centromeric crossover in pedigree 33
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Figure 4 Twelve consanguineous families used in the present study. D)NA was available for each numbered individual.
percentages of homozygosity observed in the unaf-
fected siblings in our inbred families. For relatively
nonpolymorphic markers, high rates of homozygosity,
even in unaffected individuals, are expected.
We derived a mathematical relationship (see the Ap-
pendix) to evaluate further the impact of disease gene
frequency and marker polymorphism on the expected
rates of homozygosity for markers linked to recessive
disease genes. The value PH includes both the probabil-
ity of observing marker homozygosity due to linkage
between disease and marker loci and the probability of
observing marker homozygosity by chance, indepen-
dent of linkage between disease gene and marker locus.
Figure 6 shows PH as a function of 0 for three disease
gene frequencies and three marker heterozygosities, for
affected offspring of first-cousin marriages. Panels A-C
correspond, respectively, to the gene frequency for
MEF in our population, the frequency of the cystic
fibrosis allele in the United States (Boat et al. 1989), and
the gene frequency for a rare recessive disease. Increas-
ing disease gene frequency decreases PH, because of an
increased probability that carriers will marry into in-
breeding loops. Increasing marker heterozygosity also
decreases PH, because this reduces the chances of ob-
serving homozygosity by state in the absence of homo-
zygosity by descent.
Discussion
The data in this paper confirm and substantially ex-
tend our previous report of linkage between MEF and
two markers on the short arm of chromosome 16. We
have added three RFLP markers and three PCR poly-
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Figure 5 Status of each individual for each locus, shown by shading of the appropriate block. These data are consistent with MEF
mapping between D16S94 and D16S8O.
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Homozygosity Rates for Affected Offspring of Consanguineous Marriages
OBSERVED HOMOZYGOSITY "( HANCE" HOMOZYGOSITYc
Affected Unaffected Uncle- First Second
MARKER Oa (N = 26) (N = 20) b Niece Cousins Cousins
HBA (5'HVR) ........... .12 .59 .05 .70 .39 .34 .31
D16'S83 (EKMDA) .09 .94 .33 .61 .47 .43 .40
D16S84 (CMM65) ...... .06 .96 .70 .47 .59 .56 .54
D116S291 (16A( 2.5) ..... .04 .83 .22 .79 .31 .26 .22
D16S28,3 (SM7) ......... .03 .85 .37 .63 .45 .41 .38
D16S94 (VKS) .......... .02 .92 .63 .50 .56 .53 .51
D 16S80 (24- 1) .......... .04 .88 .71 .34 .70 .68 .67
D 16S82 (41 - 1) .......... .04 .77 .62 .32 .72 .70 .69
D)16S37 (16/02) ......... .5( .30 .47 .41 .64 .62 .60
aSex-asveraged recombination between marker and MEL, based on the present study and published maps (Breuning et al. 1990; julicr et al.
1990; Keith et al. 1990; Rcders et al. 1991).
b Heterozygosity.
c Homozygosity expected for a random probe with heterozygosity h, for children of an inbred marriage, is 1 -(11 )b, where F is the
coefficient of inbreeding (Hartl 1988).
linkage analysis and the study of recombinant families,
we place MEF in the interval between D16S94 and
D16S80. None of the published maps of this region
estimates this genetic interval (Breuning et al. 1990; Ju-
lier et al. 1990; Keith et al. 1990; Reeders et al. 1991).
Our family data for 200 individuals indicate that the
genetic distance between D16S283 (which is very close
to D16S94, both physically and genetically) and










We have also typed 505 individuals from the CEPH
reference pedigrees for D I 6S283 and DI 6S80 and have
found the sex-averaged distance between these markers
to be 9.6 cM. On the basis of the radiation hybrid data
of Ceccherini et al. (1992) this interval is about 2.6 Mb,
but the accuracy of such estimates remains uncertain.
There are no known candidate genes that map to this
region.
Among the 31 non-Ashkenazi families that we stud-
.0 .1 .2 .3 .4 .5 .0 .1 .2 .3 .4 .5 .0 .1 .2 .3 .4 .5
RECOMBINATION FREQUENCY
Figure 6 Expected rate of homozygosity (i.e., PH) plotted against recombination frequency (i.e., 0) in the affected offspring of first-cou-
sin marriages. Each curve is calculated for a given disease allele frequency (q) and marker hetero7ygosity (Ib), according to the formula in the
Appendix. PH includes both the probability of observing marker homozygosity due to linkage between disease and marker loci and the
probability of observing marker homozygosity independent of linkage between disease gene and marker locus. This figure shows that homozy-




ied here, 12 were consanguineous. In those families
where the relationship between parents was known,
inbreeding loops were taken into account when likeli-
hoods were calculated with the LINKAGE program. In
many cases, this profoundly increased the information
available for detecting linkage. All individuals in the
inbreeding loops contribute informative meioses if a
rare disease and a rare marker are segregating in a fam-
ily. For instance, inclusion of the inbreeding loop con-
necting the uncle-niece marriage in family 25 led to a
nearly fourfold increase in the lod score for D16S283 at
0.
For relatively rare recessive diseases, markers in the
chromosomal region encompassing the disease gene
should be homozygous by descent in affected inbred
individuals (Smith 1953; Lander and Botstein 1987).
Hence, it may be possible to map a recessive disease
gene with a panel of such individuals by searching for
the area of overlap among homozygous chromosomal
intervals. This approach was recently used to localize
Werner syndrome to a 10-cM interval on chromosome
8 (Goto et al. 1992). Given the high frequency of the
FMF susceptibility gene in our study population, we
were unsure how useful this approach might be for us.
However, in our initial study reporting linkage to chro-
mosome 16, we observed very high rates of homozygos-
ity for HBA and D16S84 (Pras et al. 1992).
The data presented in figure 5 and table 2 confirm
the utility of this strategy to demonstrate linkage to the
short arm of chromosome 16. Rates of homozygosity
were higher for affected inbreds than for their unaf-
fected siblings, at eight of the nine markers that
we examined. The data were particularly striking
for the more polymorphic markers-HBA, D16S83,
D16S291, and DI6S283. The low rates of homozygos-
ity at these markers for unaffected siblings argue against
the possibility that locus homozygosity in affected indi-
viduals might be an inbreeding artifact independent of
linkage to MEF.
However, as illustrated in figure 6, we encountered
two limitations in the analysis of marker homozygosity
alone for the fine localization of this gene. First, be-
cause of the high frequency of the FMF susceptibility
gene in our study population, a substantial number of
affected individuals need not be homozygous by de-
scent. In light of a gene frequency of .045, the probabil-
ity a that the affected child of an inbred marriage
would be homozygous by descent at MEF is .76, .60,
and .26 for uncle-niece, first-cousin, and second-cousin
marriages, respectively (see the Appendix). Therefore,
there may be no marker locus for which all of our
inbred affected persons can be expected to be homozy-
gous by descent. The second problem is that some of
the relevant 16p markers are not very polymorphic and
therefore have a high rate of homozygosity, especially
in consanguineous families. This, coupled with the first
problem, may give rise to a substantial percentage of
affected inbred individuals who are homozygous for
marker loci, regardless of the latters' map position.
For FMF, analysis of homozygous chromosome 16p
intervals was consistent with the regional localization
deduced from linkage studies and the analysis of recom-
binants. However, for the reasons discussed above, it
would not have been possible, solely on the basis of
marker homozygosity for our set of affected inbred
individuals, to define the FMF interval as D16S94-
D16S80. As has been the case for other disease genes,
recombinant families will take on an increasingly im-
portant role as the FMF interval is narrowed further.
Nevertheless, our experience with homozygosity map-
ping provides important insights, since it is one of the
first practical applications of this strategy in human dis-
ease gene mapping.
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Appendix
The probability of homozygosity in affected inbred
individuals, for marker loci, is given by PH = c43
+ a(I-1)(l-b) + (1-a)[1 -(1-F)hI, where a = proba-
bility that an affected child of the inbred marriage is
homozygous by descent at the disease locus; 3 = proba-
bility of homozygosity by descent at the marker locus,
given homozygosity by descent at the disease locus; F
= coefficient of inbreeding; and h = heterozygosity of
the marker locus in the general population. The proba-
bility a can be calculated by a = Fq/[Fq+(l-F)q2],
where q is the disease gene frequency (Lander and Bot-
stein 1987). On the basis of the analysis of Smith (1953),
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it can be shown that, for first-cousin marriages, =
(1-0)6 + 02(1- )4 + 02(1-0)2/2, where 0 is the recom-
bination frequency between disease locus and marker
locus.
The first term of the equation for PH is the probabil-
ity that the affected child is homozygous by descent at
both the disease locus and the marker locus. The sec-
ond term is the probability of an affected child being
homozygous by descent at the disease locus but homo-
zygous at the marker locus, by inheriting the same
marker allele from different ancestors. The third term is
the probability of an affected child being homozygous
at the marker locus, given that he or she is not homozy-
gous by descent at the disease locus. Thus, PH includes
both the probability that an affected child is homozy-
gous at the marker locus because of homozygosity by
descent at a linked disease locus (first term) and the
probability of homozygosity at the marker locus regard-
less of linkage to the disease locus (second and third
terms).
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Summary
Familial Mediterranean fever (FMF) is an autosomal recessive disease causing attacks of fever and serositis. The
FMF gene (designated "MEF") is on 16p, with the gene order 16cen-D16S80-MEF-D16S94-D16S283-
D16S291-16pter. Here we report the association of FMF susceptibility with alleles at D16S94, D16S283, and
D16S291 among 31 non-Ashkenazi Jewish families (14 Moroccan, 17 non-Moroccan). We observed highly
significant associations at D16S283 and D16S291 among the Moroccan families. For the non-Moroccans, only
the allelic association at D16S94 approached statistical significance. Haplotype analysis showed that 18/25
Moroccan FMF chromosomes, versus 0/21 noncarrier chromosomes, bore a specific haplotype for D16S94-
D16S283-D16S291. Among non-Moroccans this haplotype was present in 6/26 FMF chromosomes versus 1/28
controls. Both groups of families are largely descended from Jews who fled the Spanish Inquisition. The strong
haplotype association seen among the Moroccans is most likely a founder effect, given the recent origin and
genetic isolation of the Moroccan Jewish community. The lower haplotype frequency among non-Moroccan
carriers may reflect differences both in history and in population genetics.
Introduction
Familial Mediterranean fever (FMF) is an autosomal
recessive disease of unknown etiology, characterized by
recurrent, self-limited attacks of fever with sterile peri-
tonitis, pleurisy, and/or synovitis (Sohar et al. 1967).
Patients may also develop systemic amyloidosis. Al-
though the biochemical basis of this disease is un-
known, the clinical manifestations of FMF suggest a
lesion in a molecule important to the understanding of
inflammation in general. We recently mapped the FMF
susceptibility gene, designated by the gene symbol
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"MEF" (McAlpine et al. 1991), to chromosome 16p
(Pras et al. 1992). Subsequent genetic linkage analysis of
31 non-Ashkenazi Jewish families from Israel placed
MEF between D16S80 and D16S94, a genetic interval
of about 9 cM (Aksentijevich et al., in press). The map-
ping of MEF to chromosome 16p has been confirmed
in Armenian families from California (Shohat et al.
1992).
Data associating particular alleles of marker loci with
disease-causing mutations are sometimes helpful in the
refined localization of a disease gene. Theoretically,
there should be an inverse relationship between the de-
gree of allelic association and physical or genetic dis-
tance (Hill and Robertson 1968). Allelic associations
have focused interest on the appropriate physical map
interval for the positional cloning of the genes causing
cystic fibrosis (Kerem et al. 1989) and Huntington dis-
ease (Huntington's Disease Collaborative Research
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Group 1993). Linkage disequilibrium studies have also
supported the mapping of the genes causing Friedreich
ataxia (Fujita et al. 1990) and myotonic dystrophy
(Harley et al. 1991).
In addition, when allelic or haplotype associations
are uniquely found in specific subpopulations, this may
provide evidence for a founder effect. Examples of this
include choroideremia among Finns (Sankila et al.
1987), Friedreich ataxia among Louisiana Acadians
(Sirugo et al. 1992) and southern Italians (Pandolfo et
al. 1990), myotonic dystrophy among French Cana-
dians (Harley et al. 1991), idiopathic torsion dystonia
among Ashkenazi Jews (Ozelius et al. 1992), and cystic
fibrosis among Hutterites (Fujiwara et al. 1989).
In the present study we examined allelic associations
between FMF and chromosome 16p markers in a panel
of 31 non-Ashkenazi Jewish families, in the hope that
linkage disequilibrium would help further localize the
disease gene within the D1 6S80-D1 6S94 interval. Since
a sizable subset of these families (14) had emigrated to
Israel from Morocco, we looked for evidence of a
founder effect in this separate group.
The possibility of a founder effect among Moroccan
Jews appeared reasonable, given the history and genet-
ics of this population. Most of the Moroccan Jewish
community is relatively new, having been established by
Jews who left Spain and Portugal around the time of the
Spanish Inquisition (1492). There have been subsequent
population "bottlenecks" due to religious persecution
(Roth 1972). Genetically, Moroccan Jews have been
relatively isolated. They have a much higher rate of
Tay-Sachs disease than do other non-Ashkenazi popula-
tions, and mutations seen in Moroccan patients are dif-
ferent from those seen in Ashkenazi Jewish Tay-Sachs
patients (Navon and Proia 1991). The Moroccan Jew-
ish community also has a high rate of consanguinity
(Sohar et al. 1961), which tends to obscure recombina-
tion and thereby extends the detection of founder
chromosomes over more generations. The relatively re-
cent origin, genetic isolation, and inbreeding in the
Moroccan Jewish population all favor the identifica-
tion of founder effects.
Subjects and Methods
Families and DNA Samples
Families were recruited from a clinic at the Sheba
Medical Center, Tel-Hashomer, Israel. This project was
approved by the Human Experimentation Committee
at that institution. The study included 31 families with
a total of 200 individuals (94 affected). Peripheral blood
lymphocytes were immortalized with Epstein-Barr
virus, and DNA was extracted by standard techniques.
Among the 31 non-Ashkenazi families, 14 were of
Moroccan origin (41 affected individuals); 9 were of
Libyan, Tunisian, or Egyptian origin (33 affected indi-
viduals); 7 were of Iraqi or Kurdish origin (18 affected
individuals); and 1 was of Greek origin (2 affected indi-
viduals). Our panel included 12 consanguineous fami-
lies, with seven first-cousin, one half-first-cousin, and
two uncle-niece marriages, as well as two marriages
where the exact relationship of the partners was un-
known.
DNA Markers
The following probes were used for DNA markers
flanking the MEF candidate region: D16S84 (CMM65/
TaqI), D16S80 (24-1/TaqI), and D16S82 (41-1/Sacl)
as RFLP markers; and D16S291 (16AC2.5), D16S283
(SM7), and D16S94 (VK5) as PCR markers. The latter
three were typed as 8-allele, 11-allele, and 6-allele poly-
morphisms, respectively. In our study population we
observed 44 haplotypes derived from these three loci.
DNA analysis by Southern blotting was performed
by conventional procedures (Pras et al. 1992). PCR typ-
ing was done by using the published primers (Harris et
al. 1991; Callen et al. 1992; Thompson et al. 1992), and
reaction conditions were as described elsewhere (Ak-
sentijevich et al., in press).
Statistical Analysis
For each pedigree, we identified the parental alleles
associated with disease susceptibility. For the 12 con-
sanguineous marriages in the panel (see above), MEF
and the associated chromosomal region usually ap-
peared to be derived from a single ancestral chromo-
some. In these cases the disease-associated allele was
counted only once. Control allele distributions were
drawn from the noncarrier chromosomes in the same
families. Haplotypes were derived so as to minimize
recombinants.
To evaluate linkage disequilibrium, the Yule associa-
tion coefficient was calculated according to the for-
mula
IA = (ad-bc)/(ad+bc)
where a is the number of noncarrier chromosomes with
allele A, b is the number of FMF chromosomes with
allele A, c is the number of noncarrier chromosomes
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Figure I Genetic map of the relevant region of chromosome 16p, showing the markers used in this study. Sex-averaged recombination
frequencies are taken from published sources (Breuning et al. 1990; Reeders et al. 1991) and from our own data.
somes with allele B. The SD of the Yule coefficient was
estimated according to Bishop et al. (1975). For mul-
tiallelic loci, the Yule coefficient was calculated for the
allele that was overrepresented on FMF chromosomes,
compared with all other alleles combined.
A X2 test of the null hypothesis of no linkage disequi-
librium was calculated for biallelic loci, with 1 df. The
Yates correction was used where appropriate.
For multiallelic loci, two different x2 statistics were
calculated. In the "combined allele" method, the allele
that was overrepresented among FMF chromosomes
was defined as one allele, and all of the other alleles
were combined to form a second allele. A standard X2
statistic was then calculated, with 1 df. In the "multial-
lele" method, we used a X2 statistic previously defined
for multiallelic loci by Hill (1975) and Weir and Cock-
erham (1978). This is given by the formula
m n
%2= N z z D2/plq,
i=1 j=1
where N is the total number of gametes in the sample,
m is the number of alleles at the marker locus, n (= 2) is
the number of alleles at MEF, pi are the observed allele
frequencies at the marker locus, q, are the observed
frequencies of carrier and noncarrier chromosomes,
and Di, = pij- piq. This statistic has (m-1) x (n-1) df.
Since n = 2, df = m - 1. When there are only 2 alleles,
this x2 formula yields the same result as a conventional
2 X 2X2 statistic.
Results
Allelic Associations for All Non-Ashkenazi Families
Our previous study of recombinants among 31 non-
Ashkenazi Jewish families placed MEF in the interval
between D16S80 and D16S94 (fig. 1; Aksentijevich et
al., in press). We have subsequently analyzed allele fre-
quencies in the same 31 families for the four telomeric
and two centromeric loci shown in figure 1. Data for
the highly polymorphic microsatellites at the telomeric
end of the MEF interval are shown in table 1. When it is
taken into account that we tested allelic associations at
six different loci, the appropriate P value for signifi-
cance is .0083.
The 86-bp allele for D1 6S94 was associated with dis-
ease susceptibility in 43 of 56 (77%) carrier chromo-
somes and was found in 25 of 48 (52%) noncarrier
chromosomes. When allowance is made for multiple
comparisons, this association approached (but did not
reach) significance by both the combined allele and
multiallele X2 statistics. About 200 kb more telomeric
(Harris et al. 1991; Germino et al. 1992), the 93-bp
allele for D16S283 was significantly associated with
FMF susceptibility. At D16S291, still more telomeric,
the 162-bp allele was associated with susceptibility
(52% of carrier chromosomes vs. 23% of noncarrier
chromosomes). This latter association was significant
only by the combined allele method. There was no sig-
nificant allelic association for D16S84, the most telo-
meric marker examined, nor were there significant asso-
ciations for either centromeric marker (not shown).
Allelic Associations for Moroccan Families
Families that had emigrated from Morocco to Israel
constituted the largest single subpopulation of our sam-
ple (14 families). For D1 6S94, the percentages of carrier
and noncarrier chromosomes bearing the 86-bp allele
were nearly the same in the Moroccans as in the whole
panel (table 2), and the Yule coefficients were nearly
the same (0.47 vs. 0.51). The disease association for the
86-bp allele at D1 6S94 did not approach statistical sig-
nificance, mainly because of the smaller size of the
Moroccan subset. For both D16S283 and D16S291,
allelic associations were much higher among the Mor-
occans than in the whole panel and were highly signifi-
cant. These latter results are consistent with a founder
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Table I
Allelic Associations for 31 Non-Ashkenazi Jewish Families
No. (%) OF FMF X2 a
CHROMOSOMES
MARKER Combined Multiallele
AND ALLELE Carrier Noncarrier Allele (P) (P) IAIb
D1 6S94:
92bp.... 0(0) 1 (2) 1
90bp.... 1 (2) 3 (6)
88 bp.... 6 (11) 15 (31) > 5.63 (.018) 12.07 (.034) .51 ± .15
86 bpc... 43 (77) 25 (52)
84bp.... 2(4) 3 (6)
82 bp.... 4(7) 1 (2) J
D1 6S283:
103 bp.... 2(3) 0(0)
101 bp.... 1 (2) 0 (0)
99bp.... 2(3) 2 (3)
97bp.... 1 (2) 1 (2)
95 bp.... 0 (0) 0 (0)
93 bpc... 31 (53) 9 (16) 17.97 (.000023) 28.82 (.0013) .72 ±.11
91 bp.... 17 (29) 25 (43)
89 bp.... 4 (7) 16 (28)
87 bp.... 0 (0) 2 (3)
73 bp.... 0 (0) 1 (2)
65bp.... 0 (0) 2(3)
D1 6S291:
168 bp.... 0 (0) 1 (2)
166 bp.... 5 (10) 8 (16)
164bp.... 13 (26) 14 (29)
162 bpc... 26 (52) 11 (23) 8.81 (.003) 11.44 (.12) .57 .15
160 bp..... 1 (2) 3 (6)
158 bp.... 2 (4) 4 (8)
156 bp.... 3 (6) 6 (12)
152bp.... 0 (0) 1 (2)
ax2 test of the null hypothesis of no linkage disequilibrium, calculated as described in Subjects
and Methods. Significance levels are in parentheses. When allowance is made for the fact that
we studied allelic associations for six loci, the appropriate P value for significance is .0083.
bThe Yule association coefficient ± SD.
c FMF-associated allele.
significant allelic associations for D1 6S84, nor for ei-
ther centromeric locus.
Allelic Associations for Non-Moroccan Families
Given the foregoing data, we hypothesized that the
strong allelic associations in the Moroccan subpopula-
tion might be the basis for the somewhat weaker associ-
ations in the full panel of families. Table 3 shows the
data for just the 17 non-Moroccan families. Again us-
ing a critical P value of .0083, we did not observe signifi-
cant allelic associations among these non-Moroccan
families. Only for the 86-bp allele at D16S94 did the
data approach significance. These findings are consis-
tent with the hypothesis that, for D16S283 and
D16S291, allelic associations observed in the whole
panel of families result from a founder effect among
Moroccans.
Haplotype Associations
Extended haplotypes for D16S94-D16S283-D1 6S291
were constructed to identify possible founder haplo-
types. Of a possible 528 haplotypes, 44 were observed
in our study population. Among Moroccans, the 86-
93-162 haplotype accounted for 18/25 (72%) of the
carrier chromosomes, whereas this haplotype was not
observed among 22 Moroccan noncarrier chromo-
somes. Among non-Moroccans, 6/26 (23%) carrier





Allelic Associations for 14 Moroccan Jewish Families
No. (%) OF FMF X2 a
CHROMOSOMES
MARKER Combined Multiallele




86 bpc... 21 78) 15 (56) 3.00 (.083) 4.33 (.50) .47 ± .25
84bp.... 1(4) 3(11)
82 bp.... 0 (0) 0 (0) J
D1 6S283:
103 bp.... 1 (4) 0 (0)
101 bp.... 0(0) 0(0)
99 bp.... 0 (0) 0 (0)
97bp.... 1 (4) 1 (4)
95 bp.... 0 (0) 0 (0)
93 bpc ... 22 (79) 4 (15) 19.93 (.000008) 26.01 (.0037) .91 ± .06
91 bp.... 2 (7) 11 (41)
89 bp.... 2 (7) 10 (37)
87bp.... 0(0) 1 (4)
73 bp.... 0(0) 0(0)
65bp.... 0(0) 0(0)
D16S291:
168 bp.... 0 (0) 1 (4)
166 bp.... 1 (4) 5 (21)
164 bp.... 1 (4) 7 (29)
162 bpc... 20(80) 5 (21) 17.15 (.000035) 20.48 (.0046) .88 .08
160 bp.... 1 (4) 0 (0)
158 bp.... 1 (4) 2 (8)
156bp.... 1 (4) 3 (12)
152bp.... 0(0) 1(4)
aX2 test of the null hypothesis of no linkage disequilibrium, calculated as described in Subjects
and Methods. Significance levels are in parentheses. When allowance is made for the fact that
we studied allelic associations for six loci, the appropriate P value for significance is .0083.
bThe Yule association coefficient ± SD.
c FMF-associated allele.
carrier chromosomes. The six non-Moroccan haplo-
type-positive carrier chromosomes included one from a
Tunisian family, one from a Libyan family, two from
separate Egyptian families, one from a Greek family,
and one from an Iraqi family.
Discussion
In 14 Moroccan Jewish families, we have found
highly significant allelic and haplotype associations be-
tween FMF susceptibility and chromosome 16p
markers. These markers-D16S94, D16S283, and
D16S291-are tightly linked with one another at the
telomeric end of the MEF interval.
Although recombinant events identify D1 6S94 as the
closest of the three markers to MEF (Aksentijevich et
al., in press), there was no significant allelic association
for this locus among the Moroccans. This is most likely
because the 86-bp D16S94 allele associated with FMF
was also the most common allele in noncarrier chromo-
somes. In contrast, the 93-bp allele at D1 6S283 and the
162-bp allele at D16S291 were relatively uncommon in
noncarriers. Tests of linkage disequilibrium are much
more powerful when a disease gene is associated with a
marker allele that is rare in the general population
(Thompson et al. 1988).
Our data are consistent with the hypothesis that
most FMF carrier chromosomes in the Moroccan Jew-
648
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Table 3
Allelic Associations for 17 Non-Moroccan Jewish Families
No. (%) oFFMF X2a
CHROMOSOMES
MARKER Combined Multiallele
AND ALLELE Carrier Noncarrier Allele (P) (P) IA lb
D1 6S94:
92bp.... 0(0) 1 (5)
90bp.... 1(3) 1(5)
86 bp... 22 (76) 10 48 4.22 (.04) 12.79 (.025) .55 ±.21
84bp.... 1 (3) 0(0)
82 bp.... 4 (14) 1 (5) J
D1 6S283:
103 bp.... 1 (3) 0 (0)
101 bp.... 1 (3) 0 (0)
99bp.... 2(7) 2(6)
97bp.... 0 (0) 0 (0)
95 bp.... 0 (0) 0 (0)
93 bpc ... 9 (30) 5 (16) 1.66 (.20) 9.16 (.52) .39 .27
91 bp.... 15 (50) 14 (45)
89 bp.... 2 (7) 6 (19)
87 bp.... 0 (0) 1 (3)
73 bp.... 0 (0) 1 (3)
65bp.... 0(0) 2(6)
D16S291:
168 bp.... 0 (0) 0 (0)
166 bp.... 4 (16) 3 (13)
164 bp.... 12 (48) 7 (29)
162 bp'... 6 (24) 6 (25) .007 (.93) 4.97 (.66) .03 ± .33
160Obp.... 0 (0) 3 (13)
158 bp.... 1(4) 2 (8)
156 bp.... 2 (8) 3 (13)
152bp.... 0(0) 0(0)
a test of the null hypothesis of no linkage disequilibrium, calculated as described in Subjects
and Methods. Significance levels are in parentheses. When allowance is made for the fact that
we studied allelic associations for six loci, the appropriate P value for significance is .0083.
bThe Yule association coefficient ± SD.
c FMF-associated allele.
ish population are derived from a common ancestor.
The 86-93-162 haplotype for D16S94-D16S283-
D16S291 was present in 72% of 25 randomly chosen
Moroccan carrier chromosomes. On the basis of allele
frequencies in our Moroccan control chromosomes,
and by assuming linkage equilibrium among these
marker loci, we would have expected a haplotype fre-
quency of .21 X .15 X .56, or 1.8%. On the basis of
allele frequencies from other control populations
(Harris et al. 1991; Thompson et al. 1992), the figure
would be .25 X .04 X .62, or 0.6%. The 86-93-162
haplotype was therefore present in vast excess among
Moroccan FMF carrier chromosomes.
To exclude the possibility that the families we stud-
ied were not representative of the broader Moroccan
FMF population, we determined the city or village of
origin for the parental generation of each of these fami-
lies. We were able to trace the ancestry of these 14
families to 10 different communities, encompassing
most of the habitable areas of Morocco. Moreover,
none of the families reported any known common an-
cestry with any other family in the panel.
It is unclear whether the allelic and haplotype associa-
tions we observed at the telomeric end of the MEF
interval actually place the disease gene closer to
D16S94 than to D16S80. Both of the centromeric
markers we examined, D16S80 and D16S82, are rela-
tively nonpolymorphic, and in both cases the allele as-
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sociated with FMF was the common allele in the gen-
eral population (data not shown). Given the size of our
sample, it would be difficult to establish significant al-
lelic associations at these loci, and thus it is probably
premature to use linkage disequilibrium data to infer
that MEF is closer to D1 6S94 than to D1 6S80.
The allelic and haplotype associations described here
may also provide a basis for carrier screening for FMF.
With a frequency of about 70% in Moroccan carriers,
the 86-93-162 haplotype is not sensitive enough for
diagnostic purposes at present. However, since we did
not observe this haplotype at all among 22 Moroccan
control chromosomes, the specificity may be very high,
and this haplotype might be used to confirm diagnoses.
Identification of new markers in the candidate region
may broaden the applicability of this approach in se-
lected groups.
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Summary
This report presents refined genetic mapping data for
the gene causing familial Mediterranean fever (FMF), a
recessively inherited disorder of inflammation. We sam-
pled 65 Jewish, Armenian, and Arab families and typed
them for eight markers from chromosome 16p. Using a
new algorithm that permits multipoint calculations for
a dense map of markers in consanguineous families, we
obtained a maximal LOD score of 49.2 at a location
1.6 cM centromeric to D16S246. A specific haplotype
at D16S283-D16S94-D16S246 was found in 76% of
Moroccan and 32% of non-Moroccan Jewish carrier
chromosomes, but this haplotype was not overrepre-
sented in Armenian or Arab FMF carriers. Moreover,
the 2.5-kb allele at D16S246was significantly associated
with FMF in Moroccan and non-Moroccan Jews but
not in Armenians or Arabs. Since the Moroccan Jewish
community represents a relatively recently established
and genetically isolated founder population, we ana-
lyzed the Moroccan linkage-disequilibrium data by us-
ing Luria-Delbruck formulas and simulations based on
a Poisson branching process. These methods place the
FMF susceptibility gene within 0.305 cM of D16S246
(2-LOD-unit range 0.02-0.64 cM).
Introduction
Familial Mediterranean fever (FMF) is a recessively in-
herited disease occurring primarily in non-Ashkenazi
Jews (Sohar et al. 1967), Armenians (Schwabe and Pe-
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ters 1974), Turks (Ozdemir and Sokmen 1969), and
Middle Eastern Arabs (Barakat et al. 1986). It is charac-
terized by recurrent, self-limited attacks of fever with
sterile peritonitis, pleurisy, and/or synovitis (Sohar et al.
1967). Patients with FMF may also develop systemic
amyloidosis. The molecular basis of this disorder is not
known.
We have mapped the FMF susceptibility gene, desig-
nated MEF, to chromosome 16p in non-Ashkenazi Jew-
ish families from Israel (Pras et al. 1992) and in Arme-
nian families from California (Shohat et al. 1992).
Subsequent analysis of 31 non-Ashkenazi Jewish fami-
lies placed MEF between D1 6S94 and D1 6S80, a genetic
interval of 9 cM (Aksentijevich et al. 1993b). Studies
of Armenian (Fischel-Ghodsian et al. 1993) and Arab
families (Pras et al. 1994) were consistent with this map
location. Although there is no evidence for locus hetero-
geneity in FMF, allelic heterogeneity is possible, since
there are clinical differences among the various affected
populations (Sohar et al. 1967; Ozdemir and Sokmen
1969; Schwabe and Peters 1974; Barakat et al. 1986).
Part of our strategy for the refined genetic localization
of MEF has relied on the use of homozygosity mapping
(Smith 1953; Lander and Botstein 1987) in several con-
sanguineous non-Ashkenazi Jewish families (Aksentijev-
ich et al. 1993b). For rare recessive diseases, inbred
families are more informative than comparable noncon-
sanguineous families, because the children of inbred
marriages usually inherit two copies of the disease-caus-
ing mutation and closely linked markers from a common
ancestor. Therefore, meioses that are inferred from in-
breeding loops contribute to the overall LOD scores
calculated for such families, and these meioses are a
potential source of recombination events. Nevertheless,
we have heretofore not been able to take full advantage
of this powerful strategy for three reasons (Aksentijevich
et al. 1993b): (a) the gene frequency of MEF is relatively
high in the non-Ashkenazi Jewish population; (b) some
of the markers in the candidate region have limited poly-
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morphism; and (c) there are significant computational
constraints associated with multipoint linkage analysis
in consanguineous families (Farral 1993; Terwilliger and
Ott 1994). However, the latter problem has recently
been reduced substantially by Kruglyak et al. (1995),
who described a new algorithm for multipoint analysis
in inbred families.
Allelic associations of marker loci with a disease are
also sometimes helpful in refining the localization of
the susceptibility gene. Theoretically, there is an inverse
relationship between the degree of allelic association and
the physical or genetic distance (Hill and Robertson
1968). In our previous studies of FMF, we have found
highly significant haplotype associations with FMF in
the Moroccan Jewish population (Aksentijevich et al.
1993a). Thus, in the Moroccan Jewish population it
appears that most FMF is caused by a single founder
chromosome. Undoubtedly the history of this popula-
tion has favored the observation of this founder effect:
Jews first settled in Spain -2,000 years ago, and a series
of persecutions led to the migration of a large part of
the population to Morocco, especially in the 7th, 14th,
and 15th centuries (Roth 1972; Goodman 1979). In
Morocco the Jewish population has remained geneti-
cally isolated until their recent migration to Israel.
New quantitative methods have been described for
estimating genetic distances on the basis of linkage dis-
equilibrium in recently founded populations in which
there is one major disease-associated haplotype. One
approach is an adaptation of Luria and Delbruck's
mathematical analysis of mutation rates in bacterial cul-
tures (Luria and Delbruck 1943; Hastbacka et al. 1992),
using allelic associations and information about the his-
tory of a population to estimate the genetic distance
from a disease locus to closely linked markers. Luria-
Delbruck analysis was recently used in the positional
cloning of the gene causing diastrophic dysplasia (Hast-
backa et al. 1994) and has also been employed in the
refined mapping of several other recessively inherited
disorders (Lehesjoki et al. 1993; Aaltonen et al. 1994;
Haataja et al. 1994; Kestila et al. 1994; Pigg et al. 1994;
Sulisalo et al. 1994; Mitchison et al. 1995). Kaplan et
al. (1995) have also recently described a method of simu-
lating disease populations, based on a Poisson branching
process, to estimate the recombination fraction between
marker and disease loci. We reasoned that these strate-
gies should be applicable to FMF in Moroccan Jews.
The present report summarizes our progress in refin-
ing the localization of MEF. By establishing a consor-
tium of laboratories interested in FMF, we have assem-
bled a panel of 65 families of Jewish, Armenian, or Arab
ancestry. We genotyped these families for eight markers
on chromosome 16p, including five not examined in
previous reports. By using the algorithm described by
Kruglyak et al. (1995), we have markedly improved our
ability to perform multipoint linkage analysis on our
consanguineous families. Moreover, we analyzed allelic
associations for each ethnic group separately and per-
formed Luria-Delbruck-type analyses and simulations
of linkage disequilibrium in the Moroccan Jewish popu-
lation.
Subjects and Methods
Patients and DNA Samples
Non-Ashkenazi Jewish and Arab families were re-
cruited from a clinic at the Chaim Sheba Medical Center,
Tel-Hashomer, Israel; Armenian families were recruited
from a clinic at the Cedars-Sinai Medical Center, Los
Angeles. FMF was diagnosed according to established
clinical criteria (Sohar et al. 1967). This study was ap-
proved by the human experimentation committees at
both institutions. Table 1 summarizes the ethnic compo-
sition of our panel. Informative meioses were deter-
mined for each family, on the basis of the assumption
of a fully informative marker and a recessive disease
susceptibility gene. Peripheral blood lymphocytes were
immortalized with Epstein-Barr virus, and DNA was
extracted from cell lines by standard techniques.
Southern Analysis
Southern blots were prepared as described (Pras et
al. 1992). Plasmid probes 24-1 (D16S80) and 218EP6
(D16S246) were labeled with a-32P-dCTP by random-
priming (Oligolabeling Kit, Pharmacia). Hybridizations
were performed at 420C overnight in the presence of
0.25 mg of human placental DNA/ml and followed by
two 30-min washes with 0.1 x SSC, 0.1% SDS at 600C.
PCR Amplification
The following (AC), markers were typed using pre-
viously published primers and conditions: D1 6S283
(SM7, Harris et al. 1991); D16S94 (VK5, Aksentijevich
et al. 1993b); D16S523 (13H1, Shen et al. 1993a);
D16S453 (301G12, Shen et al. 1993b); D16S63 (CRI
0327, E. N. Levy and D. L. Kastner, unpublished
information); and D1 6S423 (AFM249ycS, Weissenbach
et al. 1992). For each marker, one primer was end-
labeled with y-32P-ATP by using polynucleotide kinase
(New England Biolabs), and PCR amplification was car-
ried out in a 10-ll volume containing 50 ng of geno-
mic DNA.
Linkage Analysis
Pairwise LOD scores were calculated using the LINK-
AGE package of programs (Lathrop et al. 1984), using
an FMF gene frequency and penetrances as described
elsewhere (Pras et al. 1992). Recombination fractions








Ethnic Background No. of Families No. of Individuals No. of Affecteds Meioses
Jewish:
Moroccan 18 108 47 78
Non-Moroccan 29 188 96 144
Total 47 296 143 222
Armenian 13 68 25 44
Arab 5 40 18 2 28
Grand total 65 404 186 294
Multipoint LOD scores were calculated using the HO-
MOZ program (Kruglyak et al. 1995). This program
permits multipoint linkage analysis for both consanguin-
eous and nonconsanguineous nuclear families, for a
dense map of highly polymorphic markers. For the seven
extended families in our panel, the pedigrees were bro-
ken into separate nuclear families. There were no recom-
binants in these families.
Allelic Associations and Haplotype Analysis
Parental alleles associated with disease susceptibility
were identified in each pedigree. In consanguineous fam-
ilies, in which MEF and the flanking chromosomal re-
gion were derived from a single ancestral chromosome,
the disease-associated allele was counted only once.
Control allele distributions were determined from the
noncarrier chromosomes in the same families. Haplo-
types were inferred so as to minimize recombinants. The
significance of allelic associations at single loci was de-
termined by the x2 statistic for multiallelic loci (Hill
1975; Weir and Cockerham 1978), as described else-
where (Aksentijevich et al. 1993a). We used the Bonfer-
roni procedure (Weir 1990) to adjust for multiple com-
parisons.
Estimating Genetic Distances by Linkage
Disequilibrium
The Luria-Delbruck analysis of bacterial mutations
has been adapted to the study of linkage disequilibrium
in human founder populations, as described elsewhere
(Hastbacka et al. 1992; Lehesjoki et al. 1993; Mitchison
et al. 1995). In brief, this method assumes that most
present-day carrier chromosomes are descended from a
single founder chromosome that has been expanding
exponentially in number. For diastrophic dysplasia, the
growth rate, d, of carrier chromosomes was estimated
by n = noegd (Hastbacka et al. 1992), where n is the
total number of chromosomes in the present-day Finnish
population, no is the total number of chromosomes in
the founding population, and g is the number of genera-
tions since the population was founded. Israeli census
data allow us to estimate n as 106 (most Moroccan Jews
emigrated to Israel in the 1950s), and historical accounts
set g at 100 generations (assuming 20 years/generation),
but there are insufficient historical data to allow an in-
formed estimate of no. We therefore estimated d by sim-
ulating the expansion of a single founder chromosome
carrying the mutation to N present-day MEF chromo-
somes (see below).
The fraction of FMF carrier chromosomes descended
from a common ancestor is a, which is given by a = 1
- mlq (Mitchison et al. 1995). q is the gene frequency
of the FMF gene in the Moroccan Jewish population,
which, under Hardy-Weinberg equilibrium, is .038
(based on the total number of Moroccan Jewish cases
at the central referral clinic for FMF in Israel). m is
the likely number of MEF chromosomes carrying new
mutations, which is given bym = (Wd)ln(106'pid), where
A, the average mutation rate for MEF, was taken as 5
x 10-6/generation (Hastbacka et al. 1992). The quantity
as represents the fraction of MEF chromosomes de-
scended from a common ancestor that have not had a
recombination between MEF and a given marker locus.
The quantity as can be estimated by the statistic Pexcess
(Lehesjoki et al. 1993), which is given by
(1)Pexcess (Paffected - Pnormal )/(1 - Pnormal) 5
where Paffected is the allele frequency of the MEF-associ-
ated allele at a given locus among FMF carrier chromo-
somes and Pnormal is the frequency of the same allele
among noncarrier chromosomes. Thus, following Hast-
backa et al. (1992), we calculated iteratively the value
of 0 between MEF and marker loci by the equation
1 - ltobs = (0/d)ln(38,0000/d) + 2(0/d), (2)
where 7obs = pexcess/a and 38,000 is the number of MEF
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Simulations
The growth of the disease population was modeled
as a Poisson branching process (Kaplan et al. 1995).
Starting with a single disease chromosome, we simulated
the number of disease chromosomes in subsequent gen-
erations on which no recombination events between the
marker and the disease have occurred, by choosing the
number X(t + 1) in generation t + 1 from a Poisson
distribution with mean (1 + d)(1 - 0)X(t), where X(t)
is the number in generation t. The number of disease
chromosomes on which a recombination event has oc-
curred was generated similarly, with 0 in place of (1 -
0). One hundred thousand simulations were carried out
for each of a range of d and 0 values. The simulations
were run for 100 generations. We then recorded the
total number of disease chromosomes, as well as the
proportion of chromosomes on which no recombination
between the marker and the disease has occurred, in the
final generation (today's population).
In the current population, roughly 40,000 FMF chro-
mosomes are observed, and 82% of these appear not to
have undergone a recombination event with D16S246.
We assumed that simulation outcomes within the range
of 20,000-60,000 disease chromosomes and 80%-
84% unrecombined chromosomes were consistent with
these observations, although the actual choice of ranges
does not significantly affect the results (unpublished
data). We therefore took the number of simulations that
fall in this range to be a measure of likelihood of the
values of d and 0 that were used in that set of simula-
tions. The best joint estimate of d and 0 was obtained
by running simulations for d values between .05 and
.17 and 0 values between 0 and .01 and choosing the
combination of d and 0 that yielded the most simulations
within the acceptable range. The 1-and 2-LOD-unit
bounds were obtained by looking for parameters that
gave 10-fold and 100-fold fewer simulations, respec-




We genotyped a panel of 65 families (table 1) for eight
markers mapped to the area of interest on chromosome
16p (fig. 1). Table 2 summarizes sex-averaged and sex-
specific pairwise LOD scores, broken down by ethnic
group. All markers demonstrated linkage to MEF. Max-
imal LOD scores over all families ranged from 14.56 to
40.7. LOD scores >3 were obtained for at least one
marker in each of the ethnic groups we studied, con-
firming that the FMF susceptibility gene is encoded on
16p in both Jewish and non-Jewish populations.
Multipoint linkage data, calculated with the HO-
MOZ program (Kruglyak et al. 1995), are shown in
0.4 1cM
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Figure 1 Map of polymorphic markers on chromosome 16p.
Sex-averaged map distances are indicated between markers and are
based on CEPH data (Kozman et al. 1995) or are estimated from the
present study.
figure 2. This program permitted the computation of
multipoint LOD scores for 65 families that included 10
first-cousin and 3 uncle-niece marriages, using eight
markers as fixed points simultaneously. The maximal
LOD score of 49.2 occurs 1.6 cM centromeric to
D1 6S246, and the 1-LOD-unit support interval lies en-
tirely within the 4.1 cM between D16S246 and
D1 6S523.
Analysis of Recombinant Families
Table 3 depicts each individual with at least one re-
combination event for the markers under study. Two
individuals, 72-05 and 203-10, were recombinant from
HBA (5'HVR) to D16S246 (218EP6). Individual 203-
10 was nonrecombinant at D16S523 (13H1), whereas
72-05 was uninformative at this locus but nonrecombi-
nant at informative loci centromeric to D16S523. This
analysis places MEF centromeric to D16S246.
Conversely, individuals 25-06 and 25-07 both showed
paternal recombinations at D16S453 (301G12) and
D16S80 (24-1) but not at D16S246, placing MEF te-
lomeric to D16S453. These recombinations were in-
ferred on the basis of homozygosity mapping. Individual
25-06 is the single affected child of an uncle-niece mar-
riage. He was homozygous for D16S246 and more te-
lomeric markers but was heterozygous for D1 6S453 and
more centromeric markers. Individual 25-07 is one of
two unaffected children of the same marriage. This per-
son was heterozygous for D16S246 and more telomeric
markers but homozygous for D1 6S453 and more cen-
tromeric loci. The other unaffected child in this consan-
guineous family was heterozygous across the entire re-
gion.
Four other individuals (13-10, 112-13, 121-03, and
144-07) were recombinant at D1 6S523. Although they
were uninformative at D1 6S246, their typings were con-
sistent with the placement of MEF telomeric to
D1 6S523/D1 6S453. Definite placement of D1 6S523 te-
lomeric to D1 6S453 was not possible on the basis of
our families alone, but CEPH data support that marker
order (Kozman et al. 1995).
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Table 2
Pairwise LOD Scores between MEF and Chromosome 1i6p Markers
MARKER (1oCUS) LOD SCORES AT 0 =
[heterozygosity] AND ETHNIC MAXIMAL
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a This ethnic group was not genotyped for this marker.
In summary, the most likely position ofMEF is within
the interval flanked by D16S246 and D16S523. There
were two definite and four possible recombinants (7-06,
38-07, 125-05, and 213-05) at D16S246. Moreover,
there were four definite and three possible recombinants
(25-06, 25-07, and 102-05) at D16S523.
Allelic Associations
We have determined the allele distributions for
marker loci among FMF carrier and noncarrier chromo-
somes, for Moroccan Jews, non-Moroccan Jews, Arme-
nians, and Arabs (table 4). Adjusting for multiple com-
parisons by the Bonferroni procedure, a p value of .002
is statistically significant.
The data confirm, in a larger panel of families, our
previous observation of a founder effect in the Moroc-
can Jewish population (Aksentijevich et al. 1993a).
There was an overrepresentation of the 93-bp allele for
D16S283 in Moroccan Jews but not in non-Moroccan
Jews, Armenians, or Arabs.
Moving toward MEF, the 86-bp allele for D1 6S94



























































Figure 2 Multipoint linkage analy,
on chromosome 16p for 65 families. SU
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though these associations were
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The Moroccan Jewish carrier (
notable for a modest increasei
83-bp and 125-bp alleles of D
respectively, although these ass(
significance. Taken together, the
data suggest that MEF is locates
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Haplotype Analysis
We also performed haplotype
and noncarrier chromosomesc
group. Among the Moroccan
haplotype comprised of the 93
the 86-bp allele at D16S94, an
at D16S246 was observed in,
chromosomes, but in only 11 /
chromosomes. The 93-86-2.5 h
in 32% (19/59) of non-Morocca
and 6% (3/53) of non-Morocc
somes.
We found no evidence for overrepresentation of this
founder chromosome in either the Armenian or Arab
population. The 93-86-2.5 haplotype was observed in
2/29 Armenian carrier chromosomes and in 2/26 Arme-
nian noncarrier chromosomes. This haplotype was not
observed in 14 Arab carrier chromosomes or 8 Arab
noncarrier chromosomes. Moreover, no other haplotype
was significantly overrepresented among Armenian or
Arab carrier chromosomes.
Estimating Genetic Distances by Linkage
AFM249wc5 Disequilibrium
The haplotype data strongly support the view that a
high proportion of Moroccan Jewish FMF carrier chro-
mosomes descend from a common ancestor, a critical
n (cM) assumption in applying Luria-Delbruck equations to the
sis between MEF and markers study of linkage disequilibrium. For individual marker
17 (D16S283) was arbitrarily loci, the statistic Pexcess, calculated from allele frequen-cores were calculated at each cies in affected and normal chromosomes, approximates
y spaced points within each air, where a is the proportion of chromosomes that de-
iltipoint LOD score was ob- scend from the common ancestor and it is the proportion
D16S246). of disease-causing chromosomes descended from the
common ancestor that have not undergone recombina-
tion between MEF and the marker locus (Lehesjoki et
Lt of the high frequency al. 1993). Among the markers we studied, Pexcess was
rier chromosomes, these highest at D1 6S246, with a value of .82. For all values
ficance. of d (see below),a was calculated to be >.99, and thus
ng marker for the MEF itob, is .82 for D1 6S246.
ent was significantly as- Once iobs is determined, an estimate of the recombina-
y in both the Moroccan tion fraction 0, as well as confidence bounds, may be
lations. The 2.8-kb and obtained either from the Luria-Delbruck equations (Has-
re also overrepresented tbacka et al. 1992, 1994) or from simulations (Kaplan
lations, respectively, al- et al. 1995). In both cases, two parameters are im-
not statistically signifi- portant: g, the number of generations since the original
all sample size. mutation, and d (denoted as X by Kaplan et al. [1995]),
chromosomes were also the growth rate of the number of disease chromosomes.
in the frequency of the The parameter g is usually estimated from historical
16523 and D16S453, records. Although a minimal estimate for the age of the
ociations did not reach Moroccan Jewish population is 500 years (based on the
- linkage disequilibrium last major migration of Jews from Spain and Portugal
I closer to D16S246, at to Morocco in 1492), a more ancient founding date
ate interval. appears more appropriate. Jewish traders are known to
have settled in both Spain and Morocco in Biblical times
(Roth 1972), and at the Council of Bishops in Spain in
analysis on the carrier 301 A.D. there were decrees forbidding Christians from
leduced in each ethnic associating with the local Jewish population (Goodman
Jewish population, the 1979). Since FMF is seen today in other Jewish popula-
-bp allele at D16S283, tions that remained in the Middle East, it is likely that
id the 2.5-kb fragment it was brought by an ancient settler, rather than having
76% (26/34) of carrier arisen anew in Spain or Morocco. Religious persecutions
Vo (4/36) of noncarrier over the centuries forced the migration of the larger
aplotype was also seen Spanish Jewish community to Morocco, among other
in carrier chromosomes places. Since the 93-86-2.5 haplotype can be seen in
:an noncarrier chromo- non-Moroccan FMF patients descended from Spanish
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Table 4
Allelic Associations between MEF and Chromosome 16p Flanking Markers
Carrier Noncarrier
Locus Population Allele Chromosomes Chromosomes 2 p (df)
{Moroccan 93 bp 27/35 (77%) 5/35 (14%) 32.03 .0014 (12)a
D16S283 (SM7) Non-Moroccan 91 bp 26/61 (43%) 25155 (46%) 17.16 .14 (12)
Armenian 91 bp 15/31 (48%) 11/29 (38%) 6.62 .88 (12)
Arab 91 bp 6/13 (46%) 5/8 (63%) 2.37 .99 (12)
Moroccan 86 bp 27/33 (82%) 19/35 (54%) 7.28 .20 (5)
D16S94 (VK5) Non-Moroccan 86 bp 46/55 (84%) 34/53 (64%) 7.97 .16 (5)
Arab 88 bp 7/12 (58%) 3/8 (38%) 3.61 .61 (5)
Moroccan 2.5 kb 30/33 (91%) 17/35 (49%) 14.44 .00073 (2)'
D16S246 (218EP6) Non-Moroccan 2.5 kb 50/56 (89%) 30/53 (57%) 14.89 .00058 (2)'
Armenian 2.8 kb 14/31 (45%) 6/28 (21%) 3.70 .16 (2)
Arab 2.4kb 5/13 (39%) 1/8 (13%) 1.78 .41 (2)
Moroccan 83 bp 24/35 (69%) 19/35 (54%) 3.67 .72 (6)
D16S523 (13H1) Non-Moroccan 83 bp 31/57 (54%) 30/54 (56%) 3.79 .71 (6)Armenian 83 bp 16/31 (52%) 19/29 (66%) 7.47 .28 (6)
Arab 77bp 6/13 (46%) 4/8 (50%) .73 .99 (6)
Moroccan 125 bp 28/34 (82%) 20/35 (57%) 5.52 .063 (2)
D16S453 (301G12) Non-Moroccan 125 bp 36/56 (65%) 42/52 (81%) 6.61 .037 (2)
Armenian 125 bp 23/31 (74%) 18/29 (62%) 2.43 .30 (2)
Moroccan 3.8 kb 25/36 (69%) 25/35 (71%) .04 .98 (2)
D16S80 (24-1 Non-Moroccan 3.8 kb 34/51 (67%) 38/47 (81%) 4.12 .13 (2)
D16S80(24-1) 1 Armenian 3.8 kb 26/28 (93%) 21/24 (88%) .56 .76 (2)
Arab 3.8 kb 9/12 (75%) 6/8 (75%) .83 .66 (2)
{Moroccan 229 bp 13/36 (36%) 4/35 (11%) 16.53 .28 (14)
D16S63 (16AC327) Non-Moroccan 229 bp 25/63 (40%) 12/57 (21%) 18.17 .20 (14)
Armenian 225 bp 9/31 (29%) 4/31 (13%) 19.87 .13 (14)
Arab 229 bp 5/13 (39%) 0/8 (0%) 12.52 .56 (14)
D16S423 (AFM249) {Moroccan 127 bp 10/34 (29%) 12/31 (39%) 10.34 .67 (13)Non-Moroccan 129 bp 15/62 (24%) 10/55 (18%) 19.07 .12 (13)
a Statistically significant at the .05 level, adjusted for multiple comparisons by the Bonferroni procedure.
probably dates to the ancient Spanish Jewish commu-
nity. Therefore, we estimated the population age as
2,000 years, with g = 100 (assuming 20 years/genera-
tion).
Estimating d is less straightforward. In general, d =
r + s, where r is the growth rate of the population
and s is the possible selective advantage of carriers over
normals (Kaplan et al. 1995). If we assume a single
founder chromosome carrying the mutation, and if there
are N disease chromosomes in the present-day popula-
tion, d may be estimated from N = (1 + d)912d (Kaplan
et al. 1995). Simulations show that this estimate of d
has high variance. In the case of FMF, if we assume N
= 38,000 and g = 100, the best estimate of d was .091,
but values in the range of .07 to .13 were within 1 LOD
unit, and values in the range of .06 to .16 were within
2 LOD units. In the absence of additional information
about the value of d, we decided to estimate d and 0
jointly in our simulations. We show below that the
choice of d has a clear effect on estimates of 0.
If we assume no selective advantage for carriers, d is
equal to r, the growth rate of the population. In this case
d may be estimated from n = no (1 + d)9, where no is the
total number of chromosomes in the founding population
and n is the number in the present-day population, pro-
vided no is not too small (Kaplan et al. 1995; for practical
purposes, nod > 1). However, the size of the original popu-
lation is usually unknown and can only be estimated
roughly from historical records. Alternatively, once d is
determined from the growth of the FMF chromosomes as
above, this relation may be used to estimate the total size
of the founding population. For example, in the absence
of selection, a d value of .091 corresponded to a founding
population of 83, on the basis of 100 generations and a
present-day population of 500,000 (106 chromosomes).
In light of the relatively high gene frequency in affected
populations, it is possible that a selective advantage to
carriers exists for FMF; that would affect the estimates of
the founding population size (moving them upward) but
not the estimates of 0.
We estimated the recombination fraction 0 between
MEF and D16S246 assuming a single ancestral disease
530
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Table 5
Estimation of the Genetic Distance between MEF and D16S246,
on the Basis of Luria-Delbruck Calculations for the Moroccan
Jewish Population
da no12b 0C Ranged
.060 1,474 .00151 .00120-.00201
.070 576 .00177 .00140-.00236
.091 83 .00232 .00185-.00310
.130 ...' .00335 .00267- .00447
.160 ... .00415 .00330-.00552
a Growth rate of the no. of disease chromosomes, estimated by
simulating the expansion of one founder chromosome to 38,000 pres-
ent-day MEF chromosomes, assuming g = no. of generations = 100.
b No. of individuals in founding population, calculated by n
= no (1 + d)9, assuming n = total no. of present-day chromosomes =
106, g = 100, and no selective advantage for MEF.
'Moment estimate for 0, by solving for 0:
1 - pexcess/a = (0/d)ln[38,000(0/d)]
d Range for 0, by solving for 0:
1 - Pexcess/a = (0/d)ln[38,000(0/d)] ± 2(0/d) .
'In the absence of selection, the value is sufficiently small that an
accurate estimate is not possible.
chromosome 100 generations ago that expanded to the
currently observed 38,000 disease chromosomes. Table
5 gives estimates of 0 from the Luria-Delbruck formulas.
Calculations were based on the maximum-likelihood es-
timate of d (.091) as well as the 1-LOD-unit and 2-
LOD-unit ranges for d. Based on the assumption of no
selective advantage for FMF, the values of no/2 (the
number of individuals in the founding population) cor-
responding to each value of d are also shown; higher
values of d led to implausible no's, unless there is selec-
tion for FMF. For d = .091, the moment estimate for 0
was .00232 (.232 cM), and the two-sigma bounds for
0 were .00185-.00310 (.185-.310 cM). The Luria-Del-
bruck bounds broadened if the 2-LOD-unit range of d
values was considered.
Figure 3 shows the results of simulations, under the
same assumptions as the Luria-Delbruck analysis, esti-
mating d and 0 jointly. Our best joint estimate was d =
.091, 0 = .00305 (.305 cM). The 1-LOD-unit range for
d was .07-.13, and the 2-LOD-unit range was .06-.16,
although, in the absence of selection, the higher values
of d may be unlikely for historical reasons, as noted
above. The 1-LOD-unit range for 0 was .001-.005 (.1-
.5 cM), and the 2-LOD-unit range was .0002-.0064
(.02-.64 cM). For any given d, the 2-LOD-unit range
for 0 by simulations was broader than the two-sigma
range by Luria-Delbruck formulas (comparing table 5
with fig. 3), as previously noted by Kaplan et al. (1995).
We also investigated the effect of varying g on esti-
mates of 0. We performed calculations for g = 75 and
g = 125, corresponding to founding populations living
1,500 and 2,500 years ago, respectively. For g = 75,
the maximum-likelihood estimate for d was .13. As ex-
pected, this resulted in higher estimates for 0; Luria-
Delbruck formulas produced an estimate of .00335
(two-sigma range .00267-.00447), and simulations
yielded an estimate of .004 (2-LOD-unit range .0002-
.008). For g = 125, the maximum-likelihood estimate
for d was .07, yielding a Luria-Delbruck estimate for
0 of .00177 (two-sigma range .00140-.00236), and a
Poisson-based estimate of .0024 (2-LOD-unit range
.0001-.0052).
Discussion
This report represents the first attempt to assemble a
panel of FMF families from several affected ethnic
groups, for the purpose of refined recombinational map-
ping and linkage disequilibrium studies. The present
data support the view that a single locus causes FMF in
the Jewish, Armenian, and Arab populations. Pooling
data from all 65 families, we observed recombinants
that place the gene in the 4.1-cM (sex-averaged) interval
between D16S246 and D16S523.
Earlier studies of several consanguineous families in
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for markers in this region of chromosome 16p, but the
analysis of such families has been of limited value in
the refined mapping of MEF because of computational
constraints and the limited polymorphism of some of
the markers in the region. The HOMOZ program,
which uses a newly described algorithm for the analysis
of recessive diseases in nuclear families (Kruglyak et al.
1995), allowed us to calculate multipoint LOD scores
between MEF and eight polymorphic markers in this
region. Moreover, with an increased density of markers
in the region, we were able to identify important recom-
binants by homozygosity mapping.
Since our present panel of families includes two Jew-
ish subpopulations as well as Armenians and Arabs,
it was possible to test whether common alleles or hap-
lotypes are seen in these different groups. For markers
sufficiently close to the disease gene, one would expect
this to be the case if there was one major ancient
FMF mutation. We had previously observed a strong
haplotype association among Moroccan Jews (Aksen-
tijevich et al. 1993a), and we confirmed this observa-
tion in the present study for D16S283-D16S94-
D16S246. This haplotype was also overrepresented,
but to a lesser extent, in the non-Moroccan Jewish
population, but was not associated with FMF in Ar-
menian or Arab populations. Moreover, the closest
flanking locus in this haplotype, D16S246, showed a
highly significant association of the 2.5-kb allele
among both Moroccan and non-Moroccan Jews. Dif-
ferent alleles were increased in frequency among the
Armenians and Arabs, although not to the level of
statistical significance. Such data suggest that the same
mutation may be found in a large percentage of Mo-
roccan and non-Moroccan Jewish FMF patients but
that other mutations may be found in Armenians and
Arabs. The higher frequency of the ancestral haplo-
type in present-day Moroccan Jews, relative to non-
Moroccans, may be due to several factors, including
consanguinity, bottlenecks, and the smaller size and
genetic isolation of the Moroccan Jewish community.
Since there is good evidence that most Moroccan Jew-
ish FMF carrier chromosomes are descended from a
common ancestor, we applied Luria-Delbruck formulas
and related simulations to the Moroccan linkage dis-
equilibrium data. In assessing whether these analyses
would be appropriate in the present case, we considered
whether certain basic assumptions are satisfied. Our
Moroccan haplotype data were consistent with the re-
quirement that most disease-causing chromosomes be
descended from a common ancestor, and the genetic
isolation of the Moroccan Jewish population (Roth
1972) has favored founder effects (Navon and Proia
1991). Moreover, the estimated population age of 2,000
years is old enough for the region of strongest linkage
disequilibrium to be relatively small. Finally, we have
shown elsewhere that the Moroccan Jewish families in
our panel represent a random sampling of the popula-
tion, in that they trace their ancestry to communities
encompassing most of the habitable areas of Morocco,
and none of the families have any known recent com-
mon ancestry with any other family in the panel (Aksen-
tijevich et al. 1993a).
Genetic distances calculated by Luria-Delbruck for-
mulas or simulations vary inversely with the age of the
population. Our estimated population age of 2,000
years is supported by historical data placing Jews in the
western Mediterranean early in the Christian era and
haplotype data suggesting that many Moroccan and
non-Moroccan FMF carrier chromosomes are de-
scended from a common ancestral chromosome in
pre-Inquisition Spain. Unfortunately, it has not been
possible to determine the relative proportions of our
Moroccan Jewish families descended from the various
migrations from Spain that are known to have occurred
over the past 2,000 years. We therefore estimated 0 for
a range of possible population ages.
There are other potential sources of error. The high
rate of consanguinity in the Moroccan Jewish popula-
tion may increase estimates of linkage disequilibrium
(and thereby decrease estimates of genetic distance) by
obscuring recombination. High rates of mutation at
marker loci would tend to have the opposite effect (Hast-
backa et al. 1992), but we have not observed any new
mutations at any of the marker loci we have examined
in our 65 families, and under usual circumstances muta-
tion at marker loci does not appreciably affect estimates
of 0 (Kaplan and Weir 1995). If a substantial percentage
of FMF chromosomes descend from individuals who
immigrated to Morocco (from countries other than
Spain) during the past 2,000 years, we may have overes-
timated a, creating inflated estimates of genetic distance.
Finally, although simulations may accurately represent
evolutionary processes, this approach does not entail
statistical sampling from populations, and therefore the
variation in the resulting estimates may be reduced (see
also Kaplan and Weir 1995).
The present analysis has avoided other potential
sources of error. For many of the applications of Luria-
Delbruck formulas to the Finnish population, the rate
of growth d of the number of disease chromosomes has
been estimated from r, the growth rate of the popula-
tion. However, for Moroccan Jews there are insufficient
historical data to estimate no, the total number of
founder chromosomes, and so we have derived values
of d based solely on the expansion of a single founder
FMF chromosome to the present-day 38,000 Moroccan
Jewish FMF chromosomes. The corresponding values of
no can then be calculated.
Moreover, we have used both Luria-Delbruck formu-
las and Poisson-branching simulations to estimate 0 (be-
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tween MEF and D1 6S246) from the Moroccan Jewish
population. The estimates obtained by the two methods
were very similar, although the Luria-Delbruck esti-
mates were more sensitive to the choice of d. As noted
elsewhere (Kaplan et al. 1995; Kaplan and Weir 1995),
two-sigma Luria-Delbruck bounds are narrower than
the 2-LOD-unit confidence interval identified by simula-
tion, which more closely reflects the 95% confidence
region for the gene's location.
Based on the genome-wide average of 1 cM = 1 Mb,
our analysis of the Moroccan Jewish population sug-
gests that MEF is within 640 kb of D1 6S246. However,
it is important to emphasize that the strong linkage dis-
equilibrium at D1 6S246 in both Moroccan and non-
Moroccan Jews would place MEF close to this marker,
even in the absence of Luria-Delbruck analysis. We are
now constructing a YAC/cosmid contig extending from
D1 6S246 into the FMF candidate region. With the even-
tual identification of the FMF susceptibility gene, it will
be possible to test the validity of Luria-Delbruck dis-
tance estimates in the Moroccan Jewish population.
Acknowledgments
We thank Drs. Norman Doggett, Pu Liu, and Francis S.
Collins for helpful discussions throughout the course of this
work, Mark Daly for extensive discussions and software assis-
tance, and Dr. Sherri Bale for helpful comments on the manu-
script. N.F.-G. is supported by a research award from the
Arthritis Foundation. L.K. is supported by National Institutes
of Health grant HGO0017.
References
Aaltonen J, Bjorses P, Sandkuijl LA, Perheentupa J, Peltonen
L (1994) An autosomal locus causing autoimmune disease:
autoimmune polyglandular disease type I assigned to chro-
mosome 21. Nat Genet 8:83-87
Aksentijevich I, Pras E, Gruberg L, Shen Y, Holman K, Helling
S, Prosen L, et al (1993a) Familial Mediterranean fever
(FMF) in Moroccan Jews: demonstration of a founder effect
by extended haplotype analysis. Am J Hum Genet 53:644-
651
(1993b) Refined mapping of a gene causing familial
Mediterranean fever, by linkage and homozygosity studies.
Am J Hum Genet 53:451-461
Barakat MH, Karnik AM, Majeed HWA, el-Sobki NI, Fenech
FF (1986) Familial Mediterranean fever (recurrent heredi-
tary polyserositis) in Arabs: a study of 175 patients and
review of the literature. Q J Med 60:837-847
Farrall M (1993) Homozygosity mapping: familiarity breeds
debility. Nat Genet 5:107-108
Fischel-Ghodsian N, Bu X, Prezant TR, Oeztas S, Huang Z-
S, Bohlman MC, Rotter JI, et al (1993) Regional mapping
of the gene for familial Mediterranean fever on human chro-
mosome 16pl3. Am J Med Genet 46:689-693
Goodman RM (ed) (1979) Genetic disorders among the Jewish
people. The Johns Hopkins University Press, Baltimore
Haataja L, Schleutker J, Laine A-P, Renlund M, Savontaus M-
L, Dib C, Weissenbach J, et al (1994) The genetic locus for
free sialic acid storage disease maps to the long arm of
chromosome 6. Am J Hum Genet 54:1042-1049
Harris PC, Thomas S, Ratcliffe PJ, Breuning MH, Coto E,
Lopez-Larrea C (1991) Rapid genetic analysis of families
with polycystic kidney disease 1 by means of a microsatellite
marker. Lancet 338:1484-1487
Hastbacka J. de la Chapelle A, Kaitila I, Sistonen P, Weaver A,
Lander E (1992) Linkage disequilibrium mapping in isolated
founder populations: diastrophic dysplasia in Finland. Nat
Genet 2:204-211
Hastbacka J, de la Chapelle A, Mahtani MM, Clines G, Reeve-
Daly MP, Daly M, Hamilton B, et al (1994) The diastrophic
dysplasia gene encodes a novel sulfate transporter: posi-
tional cloning by fine-structure linkage disequilibrium map-
ping. Cell 78:1073-1087
Hill WG (1975) Linkage disequilibrium among multiple neu-
tral alleles produced by mutation in finite population. Theor
Popul Biol 8:117-126
Hill WG, Robertson A (1968) Linkage disequilibrium in finite
populations. Theor Appl Genet 38:226-231
Kaplan NL, Hill WG, Weir BS (1995) Likelihood methods for
locating disease genes in nonequilibrium populations. Am J
Hum Genet 56:18-32
Kaplan NL, Weir BS (1995) Are moment bounds on the recom-
bination fraction between a marker and a disease locus too
good to be true? Allelic association mapping revisited for
simple genetic diseases in the Finnish population. Am J Hum
Genet 57:1486-1498
Kestila M, Mannikko M, Holmberg C, Gyapay G. Weissen-
bach J, Savolainen E-R, Peltonen L, et al (1994) Congenital
nephrotic syndrome of the Finnish type maps to the long
arm of chromosome 19. Am J Hum Genet 54:757-764
Kosambi DD (1944) The estimation of map distances from
recombination values. Ann Eugenics 12:172-175
Kozman HM, Keith TP, Donis-Keller H, White RL, Weissen-
bach J. Dean M, Vergnaud G, et al (1995) The CEPH con-
sortium linkage map of human chromosome 16. Genomics
25:44-58
Kruglyak L, Daly MJ, Lander ES (1995) Rapid multipoint
linkage analysis of recessive traits in nuclear families, includ-
ing homozygosity mapping. Am J Hum Genet 56:519-
527
Lander ES, Botstein D (1987) Homozygosity mapping: a way
to map human recessive traits with the DNA of inbred chil-
dren. Science 236:1567-1570
Lathrop GM, Lalouel J-M, Julier C, Ott J (1984) Strategies
for multilocus linkage analysis in humans. Proc Natl Acad
Sci USA 81:3443-3446
Lehesjoki A-E, Koskiniemi M, Norio R, Tirrito S, Sistonen P,
Lander E, de la Chapelle A (1993) Localization of the EPM1
gene for progressive myoclonus epilepsy on chromosome
21: linkage disequilibrium allows high resolution mapping.
Hum Mol Genet 2:1229-1234
Luria SE, Delbruck M (1943) Mutations of bacteria from virus
sensitivity to virus resistance. Genetics 28:491-511
Mitchison HM, O'Rawe AM, Taschner PEM, Sandkuijl LA,
264
534 Am. J. Hum. Genet. 58:523-534, 1996
Santavuori P, de Vos N, Breuning MH, et al (1995) Batten
disease gene, CLN3: linkage disequilibrium mapping in the
Finnish population, and analysis of European haplotypes.
Am J Hum Genet 56:654-662
Navon R. Proia RL (1991) Tay-Sachs disease in Moroccan
Jews: deletion of a phenylalanine in the a-subunit of 3-
hexosaminidase. Am J Hum Genet 48:412-419
Ozdemir Al, Sokmen C (1969) Familial Mediterranean fever
among the Turkish people. Am J Gastroenterol 51:311-316
Pigg M, Jagell S, Sillen A, Weissenbach J, Gustavson KH,
Wadelius C (1994) The Sjogren-Larsson syndrome gene is
close to D17S805 as determined by linkage analysis and
allelic association. Nat Genet 8:361-364
Pras E, Aksentijevich I, Gruberg L, Balow JE Jr, Prosen L,
Dean M, Steinberg AD, et al (1992) Mapping of a gene
causing familial Mediterranean fever to the short arm of
chromosome 16. N Engl J Med 326:1509-1513
Pras E, Aksentijevich I, Levy E, Gruberg L, Prosen L, Dean
M, Pras M, et al (1994) The gene causing familial Mediterra-
nean fever maps to the short arm of chromosome 16 in
Druze and Moslem Arab families. Hum Genet 94:576-577
Roth C (ed) (1972) Encyclopedia Judaica. Kater, Jerusalem
Schwabe AD, Peters RS (1974) Familial Mediterranean fever
in Armenians: analysis of 100 cases. Medicine (Baltimore)
53:453-462
Shen Y. Holman K, Doggett NA, Callen DF, Sutherland GR,
Richards RI (1993a) Four dinucleotide repeat polymor-
phisms on chromosome 16. Hum Mol Genet 2:1745
(1993b) Three dinucleotide repeat polymorphisms on
chromosome 16p13.11-p13.3. Hum Mol Genet 2:1506
Shohat M, Bu X, Shohat T. Fischel-Ghodsian N, Magal N,
Nakamura Y, Schwabe AD, et al (1992) The gene for famil-
ial Mediterranean fever in both Armenians and non-Ashken-
azi Jews is linked to the a-globin complex on 16p: evidence
for locus homogeneity. Am J Hum Genet 51:1349-1354
Smith CAB (1953) The detection of linkage in human genetics.
J R Stat Soc B 15:153-184
Sohar E, Gafni J, Pras M, Heller H (1967) Familial Mediterra-
nean fever: a survey of 470 cases and review of the literature.
Am J Med 43:227-253
Sulisalo T. Klockars J, Makitie 0, Francomano CA, de la
Chapelle A, Kaitila I, Sistonen P (1994) High-resolution
linkage-disequilibrium mapping of the cartilage-hair hypo-
plasia gene. Am J Hum Genet 55:937-945
Terwilliger JD, Ott J (1994) Handbook of human genetic link-
age. The Johns Hopkins University Press, Baltimore
Weir BS (1990) Genetic data analysis. Sinauer, Sunderland
Weir BS, Cockerham CC (1978) Testing hypotheses about
linkage disequilibrium with multiple alleles. Genetics
88:633-642
Weissenbach J. Gyapay G. Dib C, Vignal A, Morissette J,
Millasseau P. Vaysseix G, et al (1992) A second-generation














Cell, Vol. 90, 797–807, August 22, 1997, Copyright 1997 by Cell Press
Ancient Missense Mutations in a New Member
of the RoRet Gene Family Are Likely to Cause
Familial Mediterranean Fever
The International FMF Consortium* Introduction
The hereditary periodic fever syndromes are a relatively
recently recognized group of inherited inflammatory dis-Summary
orders that are characterized by episodic, self-limited
bouts of fever accompanied by unexplained arthritis,Familial Mediterranean fever (FMF) is a recessively
inherited disorder characterized by dramatic episodes sterile peritonitis, pleurisy, and/or skin rash (reviewed
in Kastner, 1996). To date, three clinical diseases haveof fever and serosal inflammation. This report de-
scribes the cloning of the gene likely to cause FMF been identified in this class: the recessively inherited
familial Mediterranean fever (FMF, MIM249100) andfrom a 115-kb candidate interval on chromosome 16p.
Three different missense mutations were identified in Dutch type periodic fever (MIM260920, also known as
the hyperimmunoglobulinemia D syndrome), and theaffected individuals, but not in normals. Haplotype and
mutational analyses disclosed ancestral relationships dominantly inherited familial Hibernian fever (MIM142680).
In addition, there are a number of other related butamong carrier chromosomes in populations that have
been separated for centuries. The novel gene encodes clinically distinguishable conditions (Gertz et al., 1987;
Karenko et al., 1992) that have been described in casea3.7-kb transcript that is almostexclusively expressed
in granulocytes. The predicted protein, pyrin, is a reports but have not yet been organized into specific
nosologic entities.member of a family of nuclear factors homologous to
the Ro52 autoantigen. The cloning of the FMF gene Of the three well-defined hereditary periodic fever
syndromes, FMF is by far the most common and haspromises to shed light on the regulation of acute in-
flammatory responses. attracted the most investigative interest. FMF is seen
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primarily in individuals of non-Ashkenazi Jewish, Arme- et al., 1995) were found to be unstable. We therefore
established a highly redundant contig comprised ofnian, Arab, and Turkish background. In these popula-
tions, the carrier frequency has been estimated to be small-insert YACs, P1s, PACs, BACs, and cosmids that
completely spans the interval (Sood et al., 1997). Usingas high as 1:5 (Rogers et al., 1989; Daniels et al., 1995;
Yuval et al., 1995), raising speculation that heterozy- an independent panel of non-Ashkenazi Jewish families
and newly developed microsatellites from Généthon, thegotes may have some selective advantage, perhaps
manifested by increased resistance to an as yet uniden- French FMF Consortium (1996) identified markers z600
kb apart defining the MEFV interval by intrafamilial re-tified infectious agent. Depending on poorly defined he-
reditary and environmental factors (Pras et al., 1982), combinants. By comparing FMF carrier chromosomes
in their panel with the ancestral haplotype noted above,homozygotes often develop progressive systemic amy-
loidosis from the deposition of the acute phase reactant the French Consortium found “historical recombinants”
that further narrowed the candidate interval to a z250serum amyloid A (SAA). Prior to prophylactic treatment
with colchicine, FMF amyloidosis was a significant kb YAC. Our own data defined a 285 kb candidate inter-
val by observed intrafamilial recombinants and an z200cause of renal failure and death in the Middle East. In
the absence of an accurate diagnostic test, FMF patients kb minimal region by historical recombinants (Balow et
al., 1997). Both of these sets of data are consistent inin countries where the disease is less prevalent often
experience years of attacks and several exploratory sur- their placement of the FMF gene.
We now report the cloning of the FMF gene fromgeries before the correct diagnosis is made and ade-
quate treatment with colchicine is begun. this 200 kb interval. Our strategy involved developing a
detailed transcript map from this region by a combina-FMF attacks are characterized by a massive influx of
polymorphonuclear leukocytes (PMNs) into the affected tion of exon amplification, direct cDNA selection, single-
pass sequencing of a minimal tiling path of cosmids,anatomic compartment. Inciting factors are unclear,
and, even off treatment, patients can sometimes inexpli- and, for selected areas, finished sequencing. During the
construction of the transcript map, we identified newcably go for long periods without symptoms, only to
relapse into a frequent pattern of attacks at some later microsatellites that permitted further refinement of the
candidate interval to the centromeric-most 115 kb. Us-time. At the biochemical level, patients have variously
been reported to have abnormal levels of a C5a inhibitor ing two trapped exons as probes, we isolated a 3.7 kb
clone from a leukocyte cDNA library. The protein prod-(Matzner and Brzezinski, 1984), neutrophil-stimulatory
dihydroxy fatty acids (Aisen et al., 1985), and dopamine uct is predicted to be 781 amino acids in length and is
a member of a family of proteins that includes the Ro52b-hydroxylase (Barakat et al., 1988), but none of these
findings has led to the identification of the genetic basis autoantigen (Itoh et al., 1991) and RFP (ret finger protein,
the gene encoded by the 59 half of the hybrid ret trans-of FMF.
In the absence of other functional clues, we undertook forming gene; Takahashi et al., 1988). We have identified
three missense mutations in the cloned cDNA, all ofa positional cloning approach to identify the FMF gene
(designated MEFV). Initial linkage studies placed MEFV which encode changes in the same highly conserved
C-terminal domain. None of the three mutations is pres-on chromosome 16p (Pras et al., 1992) in a panel of non-
Ashkenazi Jewish families. Linkage to this region has ent in any of a large panel of normal control chromo-
somes. Two of these mutations are found on FMF carriersubsequently been confirmed and extended to all four
major affected ethnic groups (Shohat et al., 1992; Pras chromosomes in populations that, in some cases, have
been geographically separated for over 2000 years, indi-et al., 1994; French FMF Consortium, 1996), although
differences in severity among subpopulations has sug- cating that most cases of FMF are descended from a
very ancient pool of founders, and suggesting commongested the possibility of allelic heterogeneity (Pras et al.,
1997). Early studies demonstrated a substantial founder origins for several Middle Eastern populations.
effect in the Moroccan Jewish population (Aksentijevich
et al., 1993), and as markers closer to MEFV have been
Resultsidentified, it has become apparent that a high percent-
age of all North African Jewish FMF carrier chromo-
Positional Cloning Strategysomes (93% in our hands) are descended from a com-
Figure 1 depicts schematically the recent steps in ourmon ancestor (French FMF Consortium, 1996; Levy et
positional cloning strategy. Based onearly genetic local-al., 1996; Balow et al., 1997). This same ancestral haplo-
ization data, we established a contig spanning the 1 Mbtype was observed in one third of the Armenian carrier
interval between D16S94 and D16S2622 (Sood et al.,chromosomes we have studied and in about 15% of
1997). Microsatellite markers from this interval definedIraqi Jewish FMF chromosomes.
a critical region of 285 kb (D16S468–D16S3376) basedUsing publicly available polymorphic markers, we nar-
on observed recombinations in a panel of 61 families,rowed the candidate region to an approximately 1 Mb
and a smaller candidate interval of z200 kb (D16S3082–interval lying between the polycystic kidney disease
D16S3373) based on historical recombinants. Tran-(PKD1) and tuberous sclerosis (TSC2) genes on the telo-
scripts were then identified by a combined strategy ofmeric end, and the CREB-binding protein (CREBBP)
exon amplification, direct cDNA selection, and single-gene on the centromeric end (Sood et al., 1996; see
pass sequencing. This led to the isolation of 9 full-lengthFigure 1). The extensive physical maps constructed
cDNA clones (8 of which were previously uncharacter-around these genes (Dackowski et al., 1996; Giles et al.,
ized), including 3 classical zinc finger genes, 2 members1997) did not, however, extend into the MEFV region,
and large insert YACs mapping to this interval (Doggett of the olfactory receptor family, and a novel caspase.
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Figure 1. Schematic Representation of the MEFV Region on Chromosome 16p13.3
(A) z1 Mb region over which a cosmid contig was constructed (Sood et al., 1997). PKD1, polycystic kidney disease 1; TSC2, tuberous sclerosis
2; RSTS, Rubinstein-Taybi syndrome; CREBBP, CREB binding protein gene.
(B) z285 kb candidate interval defined by intrafamilial recombination events in our panel of families (Balow et al., 1997). D16S3405–D16S3373
is the minimal candidate interval defined by historical recombinants in the present study.
(C) Representation of the genomic structure of the v75-1 gene. Shaded boxes represent exons; introns are drawn to scale. Numbers above
the boxes represent the size of the exons, in bp. Numbers below the boxes reflect the order of the exons, with (1) being the most 59.
The furthest centromeric of these 9 cDNAs, clone v75-1, interferon-inducible transcriptional regulator Staf-50
(Tissot and Mechti, 1995), and rpt-1, a mouse down-was isolated by solution hybridization of a leukocyte
cDNA library with biotinylated oligonucleotide probes regulator of IL-2 (Patarca et al., 1988). Homology to the
latter protein is in a domain extending from residuesderived from two exons trapped from PAC 273L24.
In parallel, analyzing finished sequence from z90 kb 385 to 550, while homology to the former two proteins
is particularly high through a domain at the C-terminalin the center of the D16S3082–D16S3373 interval, we
found twonew microsatellites, D16S3404 and D16S3405 end of v75-1 (double-boxed in Figure 2). This domain is
also found in the ret finger protein (RFP) and has been(Figure 1B). In one non-Ashkenazi Jewish family, evi-
dence for a historical recombination event that occurred termed an rfp (Takahashi et al., 1988) or B30.2 domain
(Vernet et al., 1993; Henry et al., 1997). Analysis with thebetween D16S3404 and D16S3405 in the highly con-
served non-Ashkenazi Jewish haplotype (designated SEG algorithm (Wootton, 1994) indicated a high likeli-
hood that this domain assumes a globular conformation.haplotype A) was observed, thereby excluding the re-
gion telomeric of D16S3405 (and four candidate genes Additional analyses of the putative protein product,
termed pyrin to connote its relationship to fever, indicateencoded therein) from further consideration.
that it is very positively charged, with a predicted pI .
8 and with lysine and arginine making up 13% of theCharacterization of cDNA v75-1
The translated v75-1 cDNA sequence is shown in Figure amino acid composition. Moreover, the PSORT algo-
rithm (Nakai and Kanehisa, 1992) detected two overlap-2, and the exon-intron structure deduced from the geno-
mic sequence of two cosmids is depicted in Figure 1C. ping nuclear targeting signals. The first is a four-residue
pattern composed of a histidine and three lysines (start-Although there is an excellent Kozak consensus (Kozak,
1996) at the initial methionine, the reading frame remains ing at residue 419), and the second is a Robbins/Ding-
wall consensus (boxed in Figure 2, residues 420–437;open in the cDNA upstream of this. Nevertheless, there
are no splice-acceptor consensus sequences or in- Robbins et al., 1991). In addition, a PROSITE search
(Bairoch et al., 1997) identified a bZIP transcription fac-frame methionines with good Kozak sequences before
the first stop upstream in genomic DNA, and the tran- tor basic domain (Shuman et al., 1990) at residues 266–
280. The region between residues 375 and 407 (denotedscript size by Northern blot (see below) is 3.7 kb, thus
suggesting that the sequence presented is full-length. by plus signs in Figure 2) contains an arrangement of
cystine and histidine residues with spacing that con-Consistent with the initial analysis of single-pass ge-
nomic sequence from this region, BLASTX (Altschul et forms closely to a B box–type zinc finger domain (Reddy
et al., 1992).al., 1990) demonstrated homologies with a number of
molecules implicated in inflammation. These include the Northern analysis using a probe with unique sequence
from exon 2 of v75-1 showed an abundant z3.7 kb52 kDa Ro/SS-A ribonucleoprotein, against which pa-
tients with systemic lupus erythematosus (SLE) and Sjö- transcript in peripheral blood, but there was no signifi-




Figure 2. The Predicted Protein Sequence Encoded by cDNA v75-1
The boxed segment from aa 266 to 280 is a bZIP transcription factor basic domain; the boxed segment from aa 420 to 437 is a Robbins/
Dingwall consensus nuclear targeting signal. The segment indicated by plus signs between residues 375 and 407 is a potential B-box zinc
finger domain. The region double-boxed from residue 577 to 757 is a rfp, or B30.2, domain. Within this box, the three mutated amino acids
are double-underlined.
spleen and thymus (Figure 3A). Bone marrow and lymph 2080 causing a substitution of valine for methionine
(M694V), was observed in a large number of affectednodes were also negative for v75-1 expression (data not
shown). Among a panel of tumor cells, only the SW480 individuals bearing four apparently distinct disease-
associated haplotypes (see below). The third, a T→Ccolorectal adenocarcinoma cell line showed significant
expression. Expression of v75-1 was absent in HL-60 transition at nt 2177, results in the substitution of alanine
for valine (V726A) and was observed in affected individu-promyelocytic leukemia, K-562 erythroleukemia, and
Burkitt’s lymphoma. Even by RT–PCR, message was als bearing the C haplotype in a Druze family and in
other FMF patients and carriers bearing this haplotype.not detectable in a peritoneal fibroblast cell line, or in
fetal or adult brain (data not shown). Figure 3B demon- When the remaining nine exons of v75-1 were se-
quenced in these haplotypes, no additional mutationsstrates pyrin expression in PMNs, but not in lympho-
cytes. We also found that pyrin is not expressed in were identified.
monocytes purified from peripheral blood (data not
shown). Ancestral Relationships Among FMF
Carrier Haplotypes
Table 1 explores the relationship of v75-1 mutations withMutational Analyses
Direct sequencing of RT–PCR products or amplified ex- specific disease-associated haplotypes in our study
population. Haplotype A is the disease-associated hap-ons from the eight cDNAs telomeric to v75-1 failed to
identify disease-associated mutations. In contrast, three lotype observed in a very high percentage of North Afri-
can Jewish carrier chromosomes, but that is seen lessdifferent missense mutations were identified in exon 10
of v75-1 (Figure 4) after screening a total of 165 individu- frequently in the Armenian and Iraqi Jewish populations.
Haplotypes F and G are additional North African Jewishals from 65 families. The first mutation, a G→C transver-
sion at nt 2040 that results in the substitution of isoleu- disease-associated haplotypes, each observed in a sin-
gle family, that appear by microsatellite analysis to becine for methionine (M680I), was observed in the
homozygous state in the affected offspring of a single different from the A haplotype (Table 1A). Haplotype B
is yet another distinct FMF haplotype observed in theArmenian family. The second, an A→G transition at nt
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Figure 3. Expression Profile of the v75-1
Gene
(A) Results of hybridization of a probe derived
from exon 2 on multiple-tissue Northernblots.
A transcript of 3.7 kb is present in peripheral
blood leukocytes and colorectal adenocarci-
noma SW480. HL-60, promyelocytic leuke-
mia; K-562, erythroleukemia; MOLT4, lym-
phoblastic leukemia; A549, lung carcinoma;
G361, melanoma.
(B) Hybridization of the same exon 2 probe on
Northern blot with mRNA from purified PMNs
and lymphocytes. PMN lanes represent prep-
arations from different individuals. A b-actin
control is shown below.
Iraqi Jewish population, while the C haplotype is seen For any given haplotype, only one mutation was pres-
in patients from several different ethnic groups. The J ent. Altogether, these three mutations accounted for 78
and K haplotypes have only been observed in Armenian carrier chromosomes in our panel. There were several
affected individuals. Table 1A indicates no easily dis- other carrier chromosomes with different microsatellite
cernible relationship among these haplotypes at the haplotypes for which we did not observe any of these
level of microsatellites, except that haplotypes J and K three mutations (these latter carrier chromosomes have
are identical in the region from D16S3403 to D16S2617. thus far only been screened for exon 10 mutations). In
Table 1B summarizes data on 11 single nucleotide four separate families we have observed M694V/V726A
polymorphisms (SNPs) that we have identified from compound heterozygotes. In one such family, the par-
within the v75-1 gene for each of the haplotypes defined ents are of Ashkenazi and Iraqi Jewish ancestry, with
in Table 1A. Nine of these polymorphisms represent the Ashkenazi father carrying the V726A mutation on
synonymous substitutions within exons of this gene, the C haplotype FMF chromosome. This haplotype es-
while the remaining two are seen in introns 4 and 6. The tablishes an ancestral link between Ashkenazi Jews,
A, F, and G haplotypes are identical at all 11 polymor- who have lived in Eastern Europe for the last 1500 years,
phisms, and, although the B haplotype differs from A, F, and the Druze, who have lived in isolated communities
and G at the 59 end of the gene, SNPs for all 4 haplotypes in what is now Israel and Lebanon for the last z1000
converge beginning at exon 3. Similarly, SNPs for the years. The only other Ashkenazi Jewish carrier whom
C, J, and K haplotypes also converge by exon 3. The we have genotyped also has the V726A mutation.
“AFGB” and “CJK” core SNP haplotypes from exon 3
The M680I, M694V, and V726A mutations were not
to 10 were also observed on significant numbers of
present on any of 105 normal chromosomes in our study
ethnically matched normal chromosomes (not shown).
population (defined by haplotype analysis in well-char-Table 1C, which correlates haplotypes with v75-1 mu-
acterized families), nor in almost 200 North Americantations, suggests that ancestral relationships among
control chromosomes. It is also noteworthy that al-these subsets of chromosomes are likely. Thus, the con-
though no A haplotype–bearing noncarrier chromo-vergent A, F, G, and B haplotypes all bear the M694V
somes could be identified, two noncarrier chromosomesmutation, while we have not observed M694V on haplo-
with the B haplotype (both by microsatellites and SNPs)types that do not share the AFGB core SNPs. Similarly,
did not have the M694V mutation, further strengtheningArmenian haplotypes J and K converge within v75-1 and
the connection between the presence of the mutationboth bear the same M680I mutation, while this mutation
and disease. Moreover, 42% of a panel of 24 Middlehas not been observed on haplotypes that do not have
Eastern normal chromosomes bear the AFGB SNP corethe CJK core SNPs. The C haplotype bears the same
haplotype but do not carry M694V, which is further evi-convergent SNP haplotype as J and K, suggesting an





observation of normal chromosomes that bear disease-
associated microsatellite and SNP haplotypes but do
not have the M680I,M694V, or V726Amutations is strong
evidence that these are not just haplotype-specific poly-
morphisms.
While these genetic arguments firmly establish the
identity of v75-1 as the FMF gene, data on v75-1 tissue
distribution are highly consistent with theclinical pheno-
type. Based on the nature of the inflammatory infiltrate
and the anatomic localization of inflammation in FMF,
MEFV gene expression might be predicted to be ob-
served in granulocytes and/or serosal cells. Multiple-
tissue Northern blots demonstrated high levels of ex-
pression in peripheral blood leukocytes, but not in lymph
node, spleen, or thymus, which are comprised largely
of lymphocytes. From this we deduced that pyrin is most
likely expressed primarily in mature granulocytes, an
inference that was subsequently confirmed by direct
observation.
Computational analyses of wild-type and mutant pyrin
molecules suggest a mechanism by which the mutations
identified may cause disease. All three mutations are
clustered within 46 amino acids of one another in the
highly conserved B30.2 (rfp) globular domain at theFigure 4. DNA Sequence Electropherograms Demonstrating the
C-terminal end of the predicted protein, and they proba-M680I, M694V, and V726A Substitutions
bly affect the secondary structure of this domain. BasedFor each mutation, individuals who are homozygous for the normal
on BLASTX homologies and its restriction to granulo-allele are shown at the top, heterozygotes between the normal and
mutant allele are shown in the middle, and homozygotes for the cytes, pyrin is likely to be a nuclear factor that controls
mutation are shown at the bottom. On the pedigree diagram, the the inflammatory response in differentiated PMNs.
heterozygote is shown as an open red symbol, and the homozygote Given that FMF is a disease of excessive inflammation,
for the mutation is shown as a closed red symbol. The control for and that pyrin is homologous to rpt-1, a known down-
the M680I mutation is individual 76-06, the control for M694V is 76-
regulator of inflammation, pyrin may be a negative auto-02, and the control for V726A is 3-01.
regulatory molecule in PMNs. The FMF-associated mu-
tations and resultant pyrin structural changes would
then, after some undefined event that triggers inflamma-Discussion
tion, prevent the normal pyrin-mediated negative feed-
back loop.
In this paper, we describe the molecular cloning of a
None of these three mutations results in a truncated
new cDNA, v75-1, from the familial Mediterranean fever
protein, and the periodic nature of inflammatory attacks
candidate region on chromosome 16p13.3 and present in FMF is consistent with a protein that functions ade-
compelling evidence that this gene is MEFV, the gene quately at steady state but decompensates under
causing FMF. The cornerstone of the argument equating stress. Several other diseases with periodic manifesta-
v75-1 with MEFV is the identification of three different tions follow this paradigm, including sickle cell anemia
v75-1 mutations on FMF carrier chromosomes in multi- (b-globin; Weatherall et al., 1995) and hyperkalemic peri-
ple ethnic groups, mutations that are not seen in a panel odic paralysis (adult skeletal muscle sodium channel;
of almost 300 normal control chromosomes. Ptácek et al., 1991). Both are characterized by missense
It is extremely unlikely that the substitutions we have mutations encoding an abnormal protein with reduced
identified in v75-1 are actually polymorphisms in tight function. Patients experience symptoms when environ-
linkage disequilibrium with “real” mutations on a nearby mental factors (hypoxia or acidosis in the case of sickle
gene. This hypothesis would require that there be three cell, excess consumption of potassium in periodic paral-
such v75-1 polymorphisms on three different haplo- ysis) induce additional conformational changes in the
types, each in perfect linkage disequilibrium with the protein (sickle cell) or destabilize a delicate equilibrium
mutations on the real FMF gene. While not impossible, (periodic paralysis). Similarly, environmental triggers
such a scenario is at the least unnecessarily complex. may play a role in FMF, and the identification of pyrin
It is also unclear where such a closely linked gene would should provide clues regarding the proximal steps in
be located. The historical recombinants at the 59 (centro- the cascade that leads to an attack.
meric) end of v75-1 exclude the interval between Just as protein-truncating mutations in globin pro-
D16S3373 and v75-1. On the telomeric side, the 59 end duce thalassemia and not sickle cell disease, more pro-
of a novel zinc finger gene is located within 10 kb of the found loss-of-function mutations in pyrin may produce
39 end of v75-1, but thorough screening has revealed no a phenotype much different from FMF. It is even conceiv-
mutations in this latter gene (data not shown). Moreover, able that the total lack of pyrin may lead to generalized,
there are no trapped exons, direct-selected cDNAs, or uncontrolled inflammation and may therefore be embry-
expressed sequence tag (EST) hits that map to the inter- onically lethal. Mouse models may shed light on these
questions.val between them. Finally, and most importantly, the
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Table 1. FMF Carrier Haplotypes and cDNA v75-1 Mutations
A. Extended Microsatellite Haplotypes
Microsatellite Markersa
Haplotype Ethnic Grpb S468 S3082 S3403 S3405 S3404 S3370 S2617 ↓ S3373 S3275 S3376
A NAfJ, IrJ, Arm 212 148 1100 165 118, 122 153 104 185 184 211
F NAfJ 204 152 1000 165 118 149 104 187 188 215
G NAfJ 202 150 1000 185 94 141 107 187 184 211
B IrJ 206 138 1000 187 94 141 110 185 186 217
C IrJ, AshJ, Dr, Arm 202 140 1100 165 110 149 107nc 187 186 201
J Arm 202 136 1100 165 118 149 107n 183 188 215
K Arm 202 132 1100 165 118 149 107n 185 196 211
B. cDNA v75-1 Intragenic Haplotypes
Single Nucleotide Polymorphismsd
32.1 32.2 32.3 32.4 33.1 35.1 35.2 35.3 39.1
Haplotype Ethnic Grp 306 414 495 605 901 i4.1e 1422 1428 1530 i6.1f 1764
A NAJ, IrJ, Arm C G A A C A G A T C A
F NAfJ C G A A C A G A T C A
G NAfJ C G A A C A G A T C A
B IrJ T A C G C A G A T C A
C IrJ, AshJ, Dr, Arm T A C G T G A G C T G
J Arm T A C G T G A G C T G
K Arm C G A G T G A G C T G
C. cDNA v75-1 Mutations
Mutation aa Haplotypes Normal Chromosomes
2040 G→C Met680IIe J (1/1) 0/293
K (1/1)




2177 T→C Val726Ala C (8/8) 0/283
aIn each case the “D16” has been omitted at the beginning of the locus designation. The position of MEFV relative to these markers is indicated
by the arrow. Microsatellites are listed telomeric to centromeric, from left to right.
bNAfJ 5 North African Jewish, AshJ 5 Ashkenazi Jewish, IrJ 5 Iraqi Jewish, Arm 5 Armenian, Dr 5 Druze.
cDenotes the presence of a null allele with standard D16S2617 primers, but 107 bp amplicon when an alternative primer pair is used (Balow
et al., in press).
dDesignated by exon or intron; 32.1 indicates the first polymorphism in exon 2. Below each designation is the nucleotide position in the
sequence, with 1 being the adenosine in the ATG initiation codon. Note that the polymorphisms are listed 59 to 39, from left to right, which is
the opposite orientation on the chromosome from that shown in (A).
eIntron 4, nucleotide position 1356 1 43.
FIntron 6, nucleotide position 1610 1 95.
It would appear that at least some of the phenotypic role of pyrin in the homeostatic control of inflammation
is consistent with heterozygotes exhibiting heightenedvariation in FMF may be attributable to the difference
between the M694V and V726A mutations. The M694V responses to a specific pathogen or class of pathogens.
The strikingly high gene frequencies for FMF in moremutation is very common in the populations with the
highest incidence of systemic amyloidosis (especially than one Middle Eastern population could then be ex-
plained by increased heterozygote resistance to suchNorth African Jews), while V726A is seen in populations
in which amyloid is less common (Iraqi and Ashkenazi an organism. Since the gene frequency for FMF is much
lower in the East European Ashkenazi Jewish populationJews, Druze, and Armenians). Nevertheless, M694V-
associated haplotypes can comprise a significant mi- (Yuval et al., 1995), it is possible that such a selective
factor would have been endemic to the Mediterraneannority of carrier chromosomes in populations where se-
vere amyloidosis is exceedingly rare. One possible basin. The identification of pyrin should lead to testable
hypotheses regarding the host inflammatory responseexplanation could be that the “milder” V726A mutation
is “protective” against amyloid, in which case M694V/ in FMF heterozygotes.
Our data indicate that the M694V and V726A muta-M694V homozygotes would be amyloid-prone but
V726A homozygotes and compound heterozygotes tions are very old. Based on the convergence of several
carrier haplotypes, it is likely that all modern M694Vwould not.
Although founder effects clearly have played a role in chromosomes are descended from a common founder.
This mutation is seen on the B FMF haplotype commonlythe population genetics of FMF, selection for heterozy-




Figure 5. Multiple Sequence Alignment of
the C-Terminal End of Human Pyrin
Sequences shown have statistical similarity
as assessed by BLAST (Altschul et al., 1990).
Search cutoffs used to identify homologs
were a Karlin-Altschul score of two aligned
sequences > 70 with a probability < 1023. At
each position, residues occurring in a major-
ity of the sequences are shown in inverse
type. The numbering scheme at the top of the
figure is based on the sequence of pyrin. The
positions of secondary structural elements in
the wild-type pyrin (here, all b sheets) as pre-
dicted by the profile neural network method
PHDsec (Rost and Sander, 1993, 1994) are
shown as bold, horizontal arrows below the
alignment. The residues altered in the three
mutants are indicated by downward-pointed
arrowheads above the alignment. hum-RFP,
RET finger protein (SWISS-PROT P14373);
xla-xnf7, nuclear phosphoprotein xnf7, Xeno-
pus laevis (PIR A43906); pwa-A33, zinc-bind-
ing protein A33, Pleurodeles waltl (SWISS-
PROT Q02084); hum-SS-A/Ro, 52 kDa RO
protein (SWISS-PROT P19474); hum-afp, acid
finger protein (GenBank U09825); hum-BT,
butyrophilin (GenBank U90552); hum-efp, es-
trogen-responsive finger protein (PIR A49656);
hum-B30-2, B30-2 gene, (PRF 2002339); pig-
RFB30, ring finger protein RFB30, Sus scrofa
(EMBL Z97403); hum-Staf-50, transcription
regulator Staf-50 (PIR A57041).
isolated from the rest of the Jewish population from the between these two structural elements is also highly
conserved, suggesting that precise orientation of thetime of the Babylonian captivity (z2500 years ago) until
the formation of the state of Israel. Similarly, the obser- two domains with respect to one another is required for
function. The conservation of the rfp domain (Figure 5)vation of the V726A mutation and C microsatellite haplo-
type in Armenians, Ashkenazi Jews, and Druze FMF in molecules as diverse as butyrophilin (a milk protein
with probable receptor function; Jack and Mather, 1990),patients establishes a historical lower boundary on the
age of this mutation of perhaps 2000 years. Ro52 (a ribonucleoprotein that is autoantigenic in pa-
tients with SLE and Sjögren’s syndrome), A33 (a factorIt is also possible, of course, that the M694V mutation,
and its surrounding SNPs, has been transferred to four that binds polytene chromosomes in the newt; Bellini
et al., 1993),and xnf7 (a factor that binds mitotic chromo-different haplotypes by interchromosomal gene conver-
sion rather than by meiotic recombination events. In that somes in the frog; Reddy et al., 1991) is remarkable; the
sequence identity among these proteins ranges fromcase, the estimation of the age of the original founder
mutation would not be possible. Finally, the possibility 40% to 60%. Scrutiny of B30.2 mutations in pyrin may
provide insights into this evolutionarily conserved butof multiple independent origins of M694V and M680I
cannot be formally excluded, but the concordance of poorly understood domain.
The identification of pyrin mutations as the cause ofthe SNP haplotypes close to the mutation (Table 1B and
1C) renders this possibility rather unlikely. FMF will substantially advance our understanding of this
disorder and will provide a tool to address questionsThe identification of pyrin as the molecule responsible
for FMF also focuses interest on the RoRet family of ranging from population genetics to structural biology.
It represents the first step in the delineation of an impor-proteins, all of which share a B-box zinc finger as well
as a 170 amino acid rfp (B30.2) domain. The spacing tant new pathway in the control of inflammation.
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Experimental Procedures identified by visual inspection and hybridization to DNA fragments
from the FMF critical region, with several exons identified more than
one time.Patients and DNA Samples
Forty-four families of non-Ashkenazi Jewish descent (18 Moroccan,
14 Libyan, 5 Tunisian, 2 Egyptian, and 5 Iraqi) and 5 Arab/Druze cDNA Identification by Solution Hybridization
families were identified and sampled at the Chaim Sheba Medical Solution hybridizations were carried out using the GeneTrapper
Center in Tel-Hashomer, Israel. Twelve Armenian families were re- cDNA Positive Selection System (Life Technologies, Gaithersburg,
cruited from Cedars-Sinai Medical Center in Los Angeles. Details MD). Two trapped exons, v66 and v75, were used as starting mate-
of this panel have been previously described (Balow et al., 1997). rial. PCR screening of Superscript cDNA libraries (Life Technologies,
One additional Ashkenazi/Iraqi Jewish family was also studied. The Gaithersburg, MD) derived from human brain, liver, leukocytes,
diagnosis of FMF in all families was according to established clinical spleen, and testis were used to determine the tissue-specific ex-
criteria (Sohar et al., 1967). Patient consent was obtained from parti- pression of these exons. The leukocyte cDNA library was used in
cipants in the study after approval by the human experimentation further experiments since it showed significant expression of v66
committees at each institution. DNA was extracted from whole blood and v75 exons. GeneTrapper experiments were performed with
or from Epstein-Barr virus–transformed lymphocytes by standard sense and antisense primers from both exons, assuming both orien-
techniques. tations of these exons in the putative transcript. The following oligo-
nucleotides were synthesized and PAGE-purified: v66GT1: AAGCTC
ACT GCC TTC TCC TC; v66GT2: GAG GAG AAG GCA GTG AGCGenotyping
TT; v75GT1: GAC TTG GAA ACA AGT GGG AG; v75GT2: CTC CCAPatients were genotyped as previously described (Balow et al.,
CTT GTT TCC AAG TC. Oligos were biotinylated and hybridized to1997). Additionally, genotyping by PCR was carried out with three
single-stranded DNA from the leukocye cDNA library (one primernew markers that were developed in this study and are described
per reaction), followed by cDNA capture using paramagnetic strep-here (D16S3403, D16S3404, and D16S3405). Sequences of oligonu-
tavidin beads and repair using the corresponding nonbiotinylatedcleotides and PCR conditions used to amplify these markers are
oligos. Colony hybridization of lifts using 32P-dCTP end-labeledavailable from the Genome Database.
oligos was used to identify positive clones. Gel-purified inserts from
these clones were hybridized to cosmid contig blots to distinguishDirect cDNA Selection
cDNA clones mapping to the FMF region from false positive clonesCosmids, BAC, and P1 clones in the FMF candidate region were
due to homologous domains. All positive clones were identified bybiotinylated using BioPrime (Life Technologies, Gaithersburg, MD).
the primers v66GT2 and v75GT2, and no clones were identified bycDNAs were prepared from combined mRNA from fetal brain, fetal
the other set of primers.liver, and human lymph node by reverse transcription and ligation
of an EcoRI/NotI adaptor, which also served as a PCR primer, to
Oligonucleotides for Exon Amplificationsecond-strand cDNAs. cDNAs were directly hybridized to biotinyl-
Oligonucleotides used to amplify pyrin exons were as follows (allated templates that were recovered using streptavidin-labeled mag-
oligo sequences aregiven 59 to 39): exon 1 forward, AACCTGCCTTTTnetic beads. Conditions for blocking, hybridization, binding, and
CTTGCTCA; exon 1 reverse, CACTCAGCACTGGATGAGGA; exon 3elution of cDNAs from magnetic beads (Dynal) were as described
forward, GAACTCGCACATCTCAGGC; exon 3 reverse, AAGGCCCA(Parimoo et al., 1991). After two rounds of selection, eluted cDNAs
GTGTGTCCAAGTGC; exon 4 forward, TTGGCACCAGCTAAAGATwere amplifiedwith CUA-tailedEcoRI/NotI adaptor primers and sub-
GGC; exon 4 reverse, TCTCCCTCTACAGGGATGAGC; exon 5 for-cloned into the pAMP10 vector (Life Technologies, Gaithersburg,
ward, TATCGCCTCCTGCTCTGGAATC; exon 5 reverse, CACTGTGGMD) to yield libraries of selected cDNAs. Recombinant clones were
GTCACCAAGACCAAG; exon 6 forward, TCCAGGAGCCCAGAAGTAarrayed on blots. Clones that hybridized to either repetitive or ribo-
GAG; exon 6 reverse, TTCTCCCTATCAAATCCAGAG; exon 7somal sequences were excluded from further analysis. To confirm
forward, AGAATGTAGTTCATTTCCAGC; exon 7 reverse, CATTTCTGtheir origin, unique clones were individually hybridized to EcoRI
AACGCAGGGTTT; exon 8/9 forward, ACCTAACTCCAGCTTCTCTCdigests of cosmid/BAC/P1 DNAs and DNAs from chromosome 16–
TGC; exon 8/9 reverse, AGTTCTTCTGGAACGTGGTAG; exon 10aspecific human-hamster hybrid lines. Clones were then hybridized
forward, CCAGAAGAACTACCCTGTCCC; exon 10a reverse, AGAGCto each other and were binned into groups. Representative clones
AGCTGGCGAATGTAT; exon 10b forward, GAGGTGGAGGTTGGAGof each group were hybridized to multiple-tissue Northern blots and
ACAA; exon 10b reverse, TCCTCCTCTGAAATCCATGG.sequenced.
Northern Blot AnalysisExon Trapping
To determine transcript size and level of expression in various tis-Exon trapping was performed on PAC clone 273L24 (Sood et al.,
sues, multiple-tissue Northern blots (Clontech) were hybridized with1997) as previously described (Buckler et al., 1991). PAC clone
probes derived from various exons of the gene. These exons were273L24 was partially digested with Sau 3AI. The reaction products
amplified and purified as part of the sequencing protocol for muta-were size-fractionated by agarose gel electrophoresis, and DNA
tion analysis. Larger exons (2, 5, and 10) were labeled by random-fragments 2 kb and larger were isolated from the gel. Partially di-
priming using Stratagene Prime-It Kit and 32P-dCTP (ICN). Hybridiza-gested DNA (50 ng) was ligated with 10 ng of exon-trapping vector
tion and washing of blots were essentially as described in SambrookpSPL3 that had been previously cleaved with BamHI and dephos-
et al. (1989), except using Hybridisol I (Oncor) prepared hybridizationphorylated with calf intestinal alkaline phosphatase (Promega, Madi-
buffer. Hybridization was detected by autoradiography, with 4 hourson, WI). Ligation products were electroporated into E. coli DH12B,
exposures. Northern blots with mRNA from highly purified peripheraland the electroporated cells cultured en mass in LB broth with 200
blood lymphocytes, PMNs, and monocytes were the kind gift of Drs.mg/ml ampicillin for 16 hours at 378C with shaking. DNA prepared
H. Lee Tiffany and Harry Malech.from the culture was used to transfect COS-7 cells (ATCC 30-2002)
using lipofectACE reagent (Life Technologies, Gaithersburg, MD).
Total RNA was isolated from transfected COS-7 cells with Trizol Mutation Detection by Fluorescent Sequencing
Approximately 100 ng of genomic DNA template was used in PCRreagent (Life Technologies) followed by ethanol precipitation. First-
strand cDNAs of transcription products from pSPL3 were primed reactions to amplify exons and flanking intronic sequences ac-
cording to the supplier’s recommendations for AmpliTaq Gold (Per-with the oligonucleotide SA2. Specific amplification of trapped ex-
ons was as follows: PCR primed with oligonucleotides SA2 and SD6 kin Elmer, Branchburg, NJ) and Advantage-GC Genomic PCR Kit
(Clontech, Palo Alto, CA). The PCR primers were tailed with one ofwas performed, followed by digestion of the PCR products with
BstXI. A second PCR reaction using the digestion products was the following sequences: -21M13 forward: GTAAAACGACGGC
CAGT; -28 M13 reverse: CAGGAAACAGCTATGACCAT; -40 M13 for-primed with oligonucleotides dUSD2 and dUSA4. The resulting DNA
fragments were cloned into pAMP10 vector and sequenced. Two ward: GTTTTCCCAGTCACGACG. After amplification, reactions




gel extraction kit (QIAGEN, Santa Clarita, CA) or Microcon/Micro- Gertz, M.A., Petitt, R.M., Perrault, J., and Kyle, R.A. (1987). Autoso-
mal dominant familial Mediterranean fever-like syndrome with amy-pure/Gel Nebulizer system(Amicon, Beverly, MA). Alternatively,PCR
loidosis. Mayo Clin. Proc. 62, 1095–1100.products were column-purified with Microcon-100 (Amicon). Puri-
fied amplicons were sequenced with dye primer chemistry (PE Ap- Giles, R.H., Petrij, F., Dauwerse, H.G., den Hollander, A.I., Lushni-
plied Biosystems, or Amersham, Cleveland, OH). Sequencing reac- kova, T., van Ommen, G.-J.B., Goodman, R.H., Deaven, L.L., Dog-
tions were ethanol-precipitated and run on an ABI 377 automated gett, N.A., Peters, D.J.M., and Breuning, M.H. (1997). Construction
sequencer. Sequence data were analyzedwith eitherAutoassembler of a 1.2 Mb contigsurrounding, and molecular analysis of, the human
1.4 (PE Applied Biosystems, Branchburg, NJ) or Sequencher 3.0 CREB-binding protein (CBP/CREBBP) gene on chromosome
(Gene Codes Inc., Ann Arbor, MI). 16p13.3. Genomics 42, 96–114.
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Abstract Pseudoxanthoma elasticum (PXE) is an inher-
ited disorder of the elastic tissue with characteristic pro-
gressive calcification of elastic fibers in skin, eye, and
the cardiovascular system. Recently mutations in the
ABCC6 gene, encoding a transmembrane transporter
protein, were identified as cause of the disease. Surpris-
ingly, sequence and RFLP analysis for exon 9 with prim-
ers corresponding to flanking intronic sequence in dis-
eased and haplotype negative members from all of our
families and in a control population revealed either a 
homozygous or heterozygous state for the Q378X
(1132C→T) nonsense mutation in all individuals. With
the publication of the genomic structure of the PXE lo-
cus we had identified the starting point of a large genom-
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ic segmental duplication within the locus in the cytoge-
netic interval defined by the Cy19 and Cy185 somatic
cell hybrid breakpoints on chromosome 16p13.1. By
means of somatic cell hybrid mapping we located this
starting point telomeric to exon 10 of ABCC6. The dupli-
cation, however, does not include exon 10, but exons
1–9. These findings suggest that one or several copies of
an ABCC6 pseudogene (ψABCC6) lie within this large
segmental duplication. At least one copy contains exons
1–9 and maps to the chromosomal interval defined by
the Cy163 and Cy11 breakpoints. Either this copy and/or
an additional copy of ψABCC6 within Cy19-Cy183 car-
ries the Q378X mutation that masks the correct identifi-
cation of this nonsense mutation as being causative in
pseudoxanthoma elasticum. Long-range PCR of exon 9
starting from sequence outside the genomic replication
circumvents interference from the ψABCC6 DNA se-
quences and demonstrates that the Q378X mutation in
the ABCC6 gene is associated with PXE in some fami-
lies. These findings lead us to propose that gene conver-
sion mechanisms from ψABCC6 to ABCC6 play a func-
tional role in mutations causing PXE.
Keywords Pseudoxanthoma elasticum · ATP-binding
cassette proteins · ABCC6 · Pseudogene · Gene 
conversion
Abbreviations ABC: ATP-binding cassette · 
PCR: Polymerase chain reaction · PXE: Pseudoxanthoma
elasticum · RFLP: Restriction fragment length 
polymorphism · SNP: Single nucleotide polymorphism ·
BAC: Bacterial artificial chromosome
Introduction
Pseudoxanthoma elasticum (PXE; OMIM 264800), the
classical Mendelian disorder that affects the elastic tis-
sue, is characterized by progressive calcification of elas-
tic fibers in skin, retina, and the cardiovascular system.
While the cutaneous lesions may have mainly cosmetic
implications and diagnostic relevance, it is the ocular
and cardiovascular manifestations that can cause serious
morbidity [1].
The ATP-binding transmembrane transporter (ATP-
binding cassette, ABC) gene ABCC6 was recently identi-
fied to carry causative mutations for PXE [2, 3, 4, 5]. In
an ongoing mutation screen in PXE families [3, 6, 7] we
identified the Q378X (1132C→T) nonsense mutation in
exon 9 of the ABCC6 gene in diseased and haplotype
negative members of our PXE families. Screening 192
chromosomes of a control population revealed that all
these individuals were heterozygous for the Q378X mu-
tation, questioning its disease relevance for pseudoxan-
thoma elasticum.
Here we report the experimental resolution of this ini-
tially enigmatic nonsense mutation. Firstly, somatic cell
hybrid mapping identified one or several copies of an ex-
on 1–9 containing ABCC6 pseudogene, ψABCC6, within
the previously identified large segmental duplication on
chromosome 16p [8] within the immediate vicinity of the
PXE locus [7]. Secondly, DNA sequencing, long-range
polymerase chain reaction (PCR) and restriction frag-
ment length polymorphism (RFLP) analysis, demonstrat-
ed the presence of the Q378X mutation in the ABCC6
gene in certain PXE associated chromosomes and also
identified this Q378X variant at the analogous position in
the ψABCC6 gene in the general population. These find-
ings lead us to propose that the Q378X mutation in the
ABCC6 gene is derived by gene conversion from the si-
lent Q378X variant in the ψABCC6 gene, and therefore
that gene conversion plays a role in at least one mutation
event, which leads to PXE.
Materials and methods
Collection of PXE families and selection of samples for mutation
screen
The establishment of a large repository of 192 affected and 380
nonaffected individuals from a total of 81 families and the tech-
niques to extract DNA from blood samples obtained after appro-
priate informed consent have been previously described [6, 7].
One affected individual per family and four unaffected members
(who carried the reciprocal familial haplotype of their affected sib-
lings) of different families were selected for systematic sequence
analysis of ABCC6.
Sequence and genotype analysis
Fluorescent dideoxyterminator sequencing was carried out on ABI
377, ABI 3100, and ABI 3700 automated sequencing devices, on
appropriate PCR-amplified fragments of ABCC6. Quality score
based sequence comparisons were performed using the Sequench-
er software tool version 4.05 (Gene Codes Corporation, Ann Ar-
bor, Mich., USA). For the Q378X (1132C→T) mutation we devel-
oped two distinct PCR-RFLP screening assays:
(a) The exon 9 1132C→T single nucleotide polymorphism (SNP)
is associated with the loss of a PstI restriction endonuclease recog-
nition site, resulting in major digestion products that differ by
95 bp in length (Fig. 1). Briefly, 20 ng genomic DNA was PCR-
amplified using primer pair E09 (Table 1) and incubated with 5 U
PstI (New England Biolabs) in the appropriate buffer at 37°C
overnight, with a subsequent inactivation at 80°C for 20 min, frac-
tionation by submarine agarose (3.5% LE Agarose BioWhittaker
Molecular Applications) gel electrophoresis and visualization by
Gel Star staining (BioWhittaker Molecular Applications). 
(b) The long range PCR product of exon 9 containing the
1132C→T SNP was amplified with primer pairs E09-LR2
(4165 bp) and/or E09-LR3 (5141 bp) (see also Table 1 and Fig. 1).
Subsequently we performed a simultaneous double digest with
XmnI and PstI. Briefly, at least 100 ng genomic DNA was PCR-
amplified using the above primer pairs (Table 1) and Long and
Accurate (LA) Taq (TAKARA) according to the instructions of the
manufacturer. Of this product 15 µl was then digested in a total
volume of 20 µl with 3 U XmnI and 5 U PSTI (New England Bio-
labs) in buffer 2 with addition of bovine serum albumin at 37°C
overnight, with a subsequent inactivation at 80°C for 20 min, frac-
tionation by submarine agarose (2% LE Agarose, BioWhittaker)
gel electrophoresis and visualization by Gel Star staining. The rel-
evant, major digestion products differ by 135 bp in length.
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Somatic cell hybrid panel analysis
A mouse-human somatic cell hybrid panel for human chromosome
16 was kindly provided by Dr. David Callen [8, 9, 10]. From this
panel five cell lines containing sequential breakpoints informative
for the PXE region, Cy19, Cy185, Cy183, Cy163, Cy11 (ordered
from 16ptel and towards 16qtel) plus one additional clone,
Cy180(D) – deletion Cy180(P), for either verification or exclusion
of additional ψABCC6 copies telomeric to this region, was used
for physical mapping of sequence-tagged sites of exons 1–10 of
Fig. 1 Allelic restriction maps of ABCC6 exon 9 genomic PCR
products generated using primer pairs E09, E09-LR2, and E09-
LR3. Horizontal black lines labeled P PXE alleles; horizontal
green lines labeled N normal alleles; thin vertical lines restriction
enzymes’ cutting sites; numbers in parenthesis restriction frag-
ment size in base pairs (bp)
Table 1 ABCC6 exon sequence-tagged site markers. Primer design and label is based on the sequence and its direction of the BAC
clone CTA-962b4 as provided by GeneBank (accession number U91318) (S sense primer, AS antisense primer)
ABCC6 Allele size Optimal annealing Primer sequence
exon name (bp) temperature (°C)
E01 196 66 S: GGG GGT CTC TCC TCT CCC CAG TAT
AS: CCG AGC AGT CTG CCC AGA GAC TT
E02 296 65 S: CTG TCC CCT GCC TCC CCC GAA CAT
AS: GAG CTG GGG ACC CCT GCC TTG TAC C
E03 280 62 S: GGA GCC TCT TCT CTT CCC CTT GT
AS: CCG CCT ACC AGT TTG CTG TGA C
E04 245 64 S: GCA TGA GCC ACC ATT TTG GTT TC
AS: GGA AGA GAA GAG GCT CCC CTC AG
E05 295 62 S: CTT TTG GTC ACC TGG GGG AGA C
AS: GTC CCC AGA GTG GGC ACT GAC
E06 194 62 S: GGC CAT GGC TGG GAA TCA GAG
AS: TCC TGT CTT CCT ACC CTT GCC ACA T
E07 259 62 S: CGC ACC CGG CCA ATG ATG AG
AS: GCC AGG ATC CTG CAG GGG TGA A
E08 327 64 S: GGC CCT GGA AGG ATG CCA CTA
AS: CCG CTG GCG GCT GAG AGT AT
E09 295 62 S: ACT GCT TTT CCT GGC TGG GAA GAC
AS: TTG GGC AAA GGC AAC ACC CTT AG
E09-LR1 4390 66 S: GGG GTC ACA GCG GAC CTC TTC CAG CCT CTT G
AS: GGC CGA CTG ATC CTC CAC ATC TGG ACT GGT TTG
E09-LR2 4166 64 S: CGT CCA CGG ACA CCA GAT TGA CCA CAT CAC
AS: CCG ACT GAT CCT CCA CAT CTG GAC TGG TTT G
E09-LR3 5141 64 S: TTC CCC CTA AAA TGT TCT CCT CTT GTG TTT TGT G
AS: CGA CTG ATC CTC CAC ATC TGG ACT GGT TTG 
E10 298 64 S: GGG GAA GGA CGA GGG GGA GAA
AS: CCA CCT GGG GCA TCC CTC TG
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ABCC6 (Fig. 2). About 20 ng DNA was used in PCR analyses em-
ploying methods and conditions as described elsewhere [7]. Both
positive (Cy18, contains whole chromosome 16) and negative con-
trols (DNA from the A9 mice strain that had been used to con-
struct the panel, and ddH2O) were included in all experiments.
Results
Genomic evidence of ABCC6 pseudogenes
During the characterization of the PXE locus we identi-
fied a large segmental duplication on chromosome 16p
[8] of potential relevance to the PXE locus. We have pre-
viously shown that the starting point of this genomic rep-
lication occurs within the cytogenetic interval defined by
Cy19 and Cy185 somatic cell hybrid breakpoints and
more precisely to lie within 20,000 bp of bacterial artifi-
cial chromosome (BAC) clone CTA-962b4 (GeneBank
accession number U91318) between base pairs 70,000
and 90,000 [7]. After mutations in one of the candidate
genes within the PXE locus (ABCC6) were found to be
specific for the PXE phenotype [3], it was apparent that
part of the genomic sequence of the ABCC6 gene was lo-
cated within the large replicated region. This conclusion
was based on the alignment of the ABCC6 cDNA with
the genomic sequence of BAC clone CTA-962b4 which
suggested the existence of a partial homologue or an
ABCC6 pseudogene containing exons 1–9 or 1–10. Dis-
tinction between these latter possibilities was dependent
upon further fine-mapping of the region to the exact start
point of the segmental duplication.
Fig. 2A,B Panels are not drawn to scale. A Illustration of approxi-
mate map position and orientation of somatic cell hybrid break-
points on chromosome 16 p. For detailed reference see Callen et
al. [8] and Doggett et al. [10]. Black horizontal arrow Unique part
of ABCC6; green horizontal dotted lines duplicated part of ABCC6
and its homologue with their respective confirmed map positions
in relation to the somatic cell hybrid breakpoint intervals. B Graph
of the partial regional BAC contig of the PXE region and segmen-
tal duplication region centromeric to it. Black arrows Sequenced
BAC clones with confirmed mapping position, orientation„ and
overlap; black lines fully or partially sequenced single or overlap-
ping BAC clones. Their respective relative mapping position is
based on sequence-tagged site mapping or clone-specific compar-
ative sequence analysis with other clones that carry partially iden-
tical sequence-tagged site sequences. The orientation of these
clones is unclear. Red dotted lines Gaps of unknown size; green
dotted lines duplicated part of ABCC6 in Cy19 (attached to the
black arrow symbolizing the unique part of ABCC6) and its homo-
logue in Cy163. Green dotted lines illustrate potentially existing
additional homologous copies of the duplicated part of ABCC6.
Their existence is likely, based on circumstantial evidence, but
cannot currently be proven
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Table 2 Somatic cell hybrids panel sequence-tagged site analysis
Cy180D Cy19 Cy185 Cy183 Cy163 Cy11 Cy18 Chr 16 A9 mouse Human ddH2O
Cy180P DNA
ABCC6-E01 – + + + + – + – + –
ABCC6-E02 – + + + + – + – + –
ABCC6-E03 – + + + + – + – + –
ABCC6-E04 – + + + + – + – + –
ABCC6-E05 – + + + + – + – + –
ABCC6-E06 – + + + + – + – + –
ABCC6-E07 – + + + + – + – + –
ABCC6-E08 – + + + + – + – + –
ABCC6-E09 – + + + + – + – + –
ABCC6-E09LR1 – + + + + – + – + –
ABCC6-E09LR2 – + – – – – + – + –
ABCC6-E09LR3 – + – – – – + – + –
ABCC6-E10 – + – – – – + – + –
In order to clarify the physical map we used the prim-
er pairs designed within flanking intronic or 5′untranslat-
ed region sequence for the PCR amplification of exons
1–10 of ABCC6 (Table 1) to test their PCR amplification
of DNA initially from five clones (Cy19, Cy185, Cy183,
Cy163, Cy11) of the somatic cell hybrid panel. As de-
tailed in Table 2, we identified exons 1–9 to be part of
this large genomic replication. Specifically, exons 1–9
yielded positive PCR results in four of five consecutive-
ly ordered somatic cell hybrid clones, while exon 10 re-
sulted in a positive PCR amplification in 1 (Cy19) of the
five clones, suggesting that Cy163 contains a complete
copy of the first nine exons of ABCC6 (Table 2; Fig. 2).
These results had initially suggested that the starting
point for the genomic sequence replication lies within in-
tron 9. However, PCR amplifying the primer pair E09-
LR1 (the forward-primer lies within intron 10, approxi-
mately 130 bp 3′ prime to exon 10) on DNA templates of
the somatic cell hybrid clones, resulted in positive ampli-
fication for Cy19 through Cy163 (Table 2), suggesting
that part of intron 10 lies within the duplication.
We analyzed the sequence stretch surrounding and
corresponding to the sequence of the forward primer of
the E09-LR1 PCR product with the web-based software
program, RepeatMasker (http://ftp.genome.washing-
ton.edu/cgi-bin/RepeatMasker) and excluded the forward
primer sequence from lying within repetitive sequence
elements. The positive PCR result therefore cannot be
explained as an interspersed repeat sequence PCR arti-
fact.
With primer pair E09-LR2 (the forward-primer corre-
sponds to exon 10 sequence) we tested for segmental du-
plication of exon 10, which was negative in Cy185-Cy11
(Table 2). Utilizing primer pair E09-LR3 (the forward-
primer lies within intron 10, approximately 900 bp 3′
prime of exon 10) we yielded a positive PCR result for
Cy19 only (Table 2). These experiments confirm the ini-
tial result with the exon 10 primer pair (E10) that exon 10
is not part of the large segmental duplication on chromo-
some 16p and additionally show that a part of intron 10
adjacent to exon 10 belongs to the duplication. In addition
to identifying a unique exonic sequence starting point
(E09-LR2), these experiments also identified a unique in-
tron 10 sequence (E09-LR3) suitable for oligonucleotide
design for long-range PCR and subsequent mutation anal-
ysis in the part of ABCC6 that is also duplicated. The fate
of the exon 10 sequence during the process of segmental
duplication within this region remains subject to specula-
tion, as it is possible that it may have been deleted during
nonhomologous recombination events.
The somatic cell hybrid breakpoint intervals Cy19,
Cy185, Cy183 may contain additional complete or partial
copies of the segmentally duplicated block of the first
nine ABCC6 exons. This cannot be excluded or verified
with the mapping method used, as it is based on the se-
quential order and same directional arrangement of the
somatic hybrid cell line clones, from 16pter to 16qter. In
fact, there are new, preliminary sequence and PCR data
(data not shown) that are compatible with the existence
of another segmental duplication of the D16S79 locus ly-
ing between the original D16S79A locus and its other du-
plicate D16S79B (Fig. 2). In analogous terminology to
that used by Callen et al. [8] we named the newly identi-
fied duplication of the D16S79 locus D16S79C. The
D16S79A locus maps into close proximity of the 5′
prime end of ABCC6 [7]. The D16S79B locus maps un-
ambiguously to Cy163 as does one copy of the ψABCC6,
suggesting its immediacy to D16S79B. Therefore it is
likely that the D16S79C locus has in its vicinity an addi-
tional copy of ψABCC6. Neither the D16S79C locus nor
the copy of ψABCC6 close to it can be detected by so-
matic cell hybrid mapping for reasons explained above,
nor by fluorescent in situ hybridization due to insuffi-
cient resolution, since the A and C locus of D16S79 map
too closely to be distinguishable by the latter method.
Although currently the exact mapping position of the
D16S79C locus cannot be precisely determined, prelimi-
nary contig and sequence data (data not shown) suggest
it to map into Cy185. Resolution of the definitive map
will require the complete cloning of this difficult region
that has so far not been achieved by either the public or
private human genome sequencing efforts.
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Table 3 Sequence analysis of allelic variants of SNPs in exon 9 of ABCC6 and ψABCC6
Chromosome PCR Sequencing Phenotype Mutation E09 nt 1077 E09 nt 1132 E09 nt 1141
primer primer
ABCC6 and ψABCC6
Family A E09 E09 PXE A/G T/T C/C
Family B E09 E09 PXE A/G C/T T/C
Family C E09 E09 PXE A/G C/T T/C
Family D E09 E09 PXE A/G C/T T/C
Family E E09 E09 PXE A/G C/T T/C
Controls (50) E09 E09 Unaffected A/G C/T T/C
ABCC6
Family A E09-LR2 E09 Q378X A T C
Q378X A T C
Family B E09-LR2 E09 ? A C T
Q378X A T C
Family C E09-LR2 E09 R1141X A C T
Q378X A T C
Family D E09-LR2 E09 R1164X A C T
Q378X G T C
Family E E09-LR2 E09 R1141X A C T
Q378X A T C
Controls (50) E09-LR2 E09 – A C T
– A C T
Table 4 Somatic cell hybrids panel PSTI RFLP analysis (PXE, 1132T variant=295 bp; normal, 1132C variant=200 bp)
Cy180D Cy19 Cy185 Cy183 Cy163 Cy11 Cy18 A9 Human ddH2O
Cy180P Chr 16 mouse DNA
ABCC6-E09 RFLP – 295 295 295 295 – 295 – 295 –
– 200 295 295 295 – 200 – 200 –
ABCC6-E09LR2 RFLP – 200 – – – – 200 – 200 –
– 200 – – – – 200 – 200 –
To test for additional genomic sequence copies of ex-
ons 1–9 outside the immediate PXE locus towards the te-
lomere of 16p we utilized one additional clone of the so-
matic cell hybrid panel, Cy180(D) – deletion Cy180(P).
The results are shown in Table 2. We have excluded ad-
ditional genomic sequence copies of exons 1–9 telomeric
to the PXE locus based on the primer pairs used. Addi-
tional copies centromeric to the locus are excluded based
on the PCR results on template DNA from the somatic
hybrid cell line Cy11.
Evidence for ABCC6 pseudogenes and disease relevance
of Q378X from mutation analysis data
Genomic sequence screening in our families for muta-
tions in exon 9 using the primer pair E09 identified an
Α→G transition at nucleotide position 1077 (1077A→G),
a C→T transition at nucleotide position 1132 (1132C→T),
and a T→C transition at nucleotide position 1141
(1141T→C) in affected and unaffected members of all
families. Whereas the former and latter are conservative
polymorphisms without amino acid substitution in the
translation product, (1077A→G translates to S359S;
1141T→C translates to L381L) the 1132C→T variant
translates into a predicted premature truncation at amino
acid position 378 (Q378X) of the ABCC6 protein.
This mutation was first encountered in a homozygous
state in two affected individuals (members III:1 and
III:2) of a consanguineous family (Fig. 3A, and upper se-
quence read B) suggesting its potential relevance for the
disease. However, the sequence screen of the unaffected
sibling with a homozygous negative haplotype (Fig. 3A,
member III:3; B, lower sequence read) resulted in an un-
ambiguously heterozygous state for the 1132C→T sub-
stitution, in apparent contradiction to the disease rele-
vance of this mutation. PstI RFLP analysis of the E09
PCR product (Fig. 3C) revealed a much stronger 200-bp
nondisease allele in lane 3 (corresponding to III:3) and
lane 6 (control) than in lane 4 (III:4) and lane 5 (II:1)
(both individuals are haplotypic heterozygous carriers of
one disease allele), in addition to the 295-bp disease al-
lele in all lanes. When this allele-banding pattern is con-
sidered against the background of the PXE-associated
haplotype in this family, these results reveal that the 200-
bp nondisease allele cosegregated in concordance with
the PXE associated haplotype. The 295-bp disease allele,
however, did not cosegregate, suggesting that the true
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Fig. 3 a Haplotype analysis for single sequence length polymor-
phisms on chromosome 16p and for the three SNPs in exon 9 of
ABCC6 depicting the haplotype-mutation-phenotype correlations
in this consanguineous family with PXE. Squares males; circles
females; black symbols diseased individuals; symbols with a dot
genetic disease carrier status. (To protect study subjects’ and their
families’ privacy the pedigree structure has been altered in a way
not affecting the relevant genetic information concerning PXE.)
The estimated (cM) or physical (kb) distances between the single
sequence length polymorphisms used for haplotyping are as fol-
lows: telomere, D16S3079 (0.6 cM), D16S3060 (22 kb), D16S405
(380 kb), D16B9621 (25 kb), D16B9622 (0.7 kb), ABCC6
(0.3 cM), D16S79 (0.4 cM), D16S764 (0.7 cM), FRA 16A
(1.2 cM), D16S3103 (0.1 cM), D16S3017 (0.6 cM), D16S287
(1.1 cM), D16S499 (1.3 cM), D16S3036 (5.0 cM), D16S403. 
b Sequence chromatograms of individuals 01 (upper sequence
chromatogram) and 03 (lower sequence chromatogram) of the
family in a. The identification of a stop codon mutation (Q378X)
in exon 9 of ABCC6 and ψABCC6 is shown, as the sequence was
obtained from the PCR product generated with primer pair E09.
While the diseased individual 01 appears homozygous for the T
allele of 1132C→T substitution in accordance with her disease
phenotype and family haplotype, the PXE unaffected sibling ap-
pears to be heterozygous for this substitution and the Q378X mu-
tation in contradiction to her homozygous negative family haplo-
type and her healthy clinical status with respect to signs and symp-
toms of PXE. C Results of the RFLP screen in family A for the
Q378X mutation (1132C→T). The gel photograph shows restric-
tion fragments of different size created by PSTI digest of PCR




which amplifies both ABCC6 and ψABCC6. Numbers of lanes are
correlated with numbers of individuals in the pedigree/haplotype
rendition in a. The Q378X mutation in ψABCC6 masks the correct
cosegregation of the 1132C→T SNP with the family members’
phenotype and haplotype. Please note that the 295-bp either true
PXE and/or pseudoalleles of ABCC6 is present in all individuals.
Despite its presence, the 200-bp normal alleles are much stronger
in lanes 3 and 6 (corresponding to individual 3 with a negative
haplotype for PXE in this family and a control) than in lanes 4 and
5 that contain DNA of haplotypic heterozygous family members.
This finding implies the correct homozygous cosegregation of the
nondisease allele in these individuals and suggests that the disease
allele is caused by a pseudogene within the genomic duplication
of chromosome 16p. d Results of long-range PCR-RFLP mutation
screening in this family for variant 1132C→T using the ABCC6-
E09LR2 primer pair that does not amplify copies of ψABCC6.
Numbers of lanes are correlated with numbers of individuals in the
pedigree/haplotype rendition in a. Please note the now correct co-
segregation of the 362-bp disease allele and the 227-bp nondisease
allele in concordance with the family members’ individual disease
status and the family haplotype information. Additionally, the con-
trol displays now a homozygous state for the nondisease allele.
These RFLP results were confirmed by sequencing (Table 3)
cosegregation of the disease allele is masked by a pseu-
dodisease allele. Moreover, the RFLP screen in a further
80 PXE families yielded one1 more family in which the
affected individuals showed a homozygous pattern for
the disease allele. All other PXE affected individuals,
carriers, and haplotype-negative individuals from these
families were heterozygous for 1132C→T despite the
presence of other family specific mutations in ABCC6.
In addition, as noted above, the RFLP screen of 192 con-
trol chromosomes showed a heterozygous state for
1132C→T in all of them. The latter two findings further
corroborated the proposal of a pseudodisease allele con-
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sisting of either a pseudogene or an ABCC6 gene homo-
logue that is terminated in exon 9 by a mutation stop co-
don at amino acid position 378.
Long-range PCR of ABCC6 gene exon 9 with primer
pair E09-LR2 excluded exon 9 genomic duplicates from
PCR amplification. The subsequent RFLP analysis of
this PCR product with a double digest with XmnI and
PstI (Fig. 3D; Fig. 1) yielded the correct cosegregation
of the disease (362 bp) and nondisease (227-bp) alleles
in the consanguineous family. Screening of the addition-
al 80 PXE families with this long range PCR-RFLP as-
say uncovered four additional families in which the
1132C→T variant cosegregates in a heterozygous state
with the disease phenotype and family haplotype. This
screen was negative in all controls. These findings con-
firmed the relevance of the Q378X nonsense mutation
for the PXE phenotype in families in which it contributes
in a homozygous or compound heterozygous allelic
state. This is, again, compatible with a loss of function
mutation.
Sequencing of the E09-LR2 PCR product in all mem-
bers of the consanguineous family (Fig. 3 A) showed
that the T allele of the 1132C→T mutation is in linkage
disequilibrium with the C allele of the 1141T→C variant
in the ABCC6 and ψABCC6 genes, while the G allele of
the 1077A→G variant is confined to ψABCC6 (see also
Table 3). In three of the additional four families with the
1132C→T mutation in the functional copy of ABCC6,
the sequence analysis of E09 and of E09-LR2 PCR prod-
ucts showed an identical SNP allele haplotype cosegre-
gation pattern (1077A wild type, 1132T mutation, and
1141C polymorphism). We identified one family, howev-
er, in which the 1132C→T mutation is in linkage dis-
equilibrium not only with 1141C but also with the
1077G allelic variant in ABCC6.
The sequence analysis of the E09 PCR product (am-
plification of exon 9 in ABCC6 and ψABCC6) in 50 con-
trol individuals demonstrated that they are all similarly
heterozygous for the 1077A→G and the 1141T→C poly-
morphisms as well as the 1132C→T mutation. Heterozy-
gosity for the 1132C→T mutation had already been
shown by the previously described RFLP analysis. Se-
quence analysis of the E09-LR2 PCR product (amplifi-
cation of exon 9 in ABCC6, but not in ψABCC6) in the
same controls confirmed their homozygous state for the
respective wild-type alleles (1077A, 1132C and 1141T)
in ABCC6.
In the control population the wild-type alleles of
1077A→G of 1132C→T and of 1141T→C appear solely
in ABCC6 in a homozygous fashion, while the mutant or
variant alleles are confined to ψABCC6. These data sug-
gest linkage disequilibrium among the three wild-type
alleles and between the variant alleles in different posi-
tions on chromosome 16p.
As shown in Table 4, Cy19, Cy18, and the human
control DNA display both 1132C and 1132T products on
E09 RFLP screening, while Cy185, Cy183, and Cy163
show only the 295-bp disease allele (1132T). The E09-
LR2 RFLP screen after long-range PCR on DNA of the
somatic cell hybrid clones resulted in a single 200-bp di-
gest product of Cy19 DNA, Cy18 DNA and human con-
trol DNA. This set of experiments additionally confirms
the normal, 1132C variant in Cy19 and the 1132T variant
in cis-allelic, paralogous position in Cy163.
The five distinct PXE chromosomes identified to car-
ry the mutant allele of the 1132C→T mutation in the
functional ABCC6 gene show two distinct allelic haplo-
type patterns with regard to the three SNPs in exon 9
(Table 3). As noted above, in four of five PXE chromo-
somes the 1132T variant appeared in association with the
1077A wild-type and the 1141C variant, while in one
PXE chromosome it cosegregated together with the
1077G variant and 1141C variant.
These combined observations in the PXE families and
in normal controls suggest that in PXE the 1132C→T
mutation in ABCC6 originates from its pseudogene by
gene conversion. Polymorphism analysis of 1077A→G
in the five 1132C→T associated PXE chromosomes sug-
gests the possibility of two distinct conversion break-
points, one occurring 5′ prime of nucleotide 1077 (in one
PXE chromosome) and the second one occurring 3′
prime to it (in four PXE chromosomes).
Discussion
Gene conversion can bring about a disease-causing mu-
tation in a functional gene when the converted sequence
originates from a pseudogene homologue which carries
the particular mutation in a phenotypically silent manner.
This mechanism has been proposed for some cases of
spinal muscular atrophy (OMIM 253300) in which se-
quences that carry deletions from the survival motor neu-
ron (SMN) gene 2 are converted into SMN1 [11].
In congenital adrenal hyperplasia due to 21-hydroxyl-
ase deficiency (OMIM 201910) Higashi et al. [12] iden-
tified the 21-hydroxylase (CYP21) and an highly homol-
ogous pseudogene (CYP21P) to have a close tandemlike
genomic arrangement on chromosome 6p and suggested
gene conversion as a potential mechanism for the high
incidence of CYP21 deficiency. Collier et al. [13] dem-
onstrated this mechanism for a de novo point mutation in
this disease.
A further example involves the autosomal dominant
polycystic kidney disease gene on chromosome 16p13.3
(PKD1), where the PKD1 homologues map into a seg-
mental duplication adjacent to that containing the PXE
locus [14]. In each of these cases the homologues or
pseudogenes act as a pool of silent variants which can be
incorporated into a functional gene where they can have
pathological consequences.
The results presented here for Pseudoxanthoma elasti-
cum are of significance for several reasons. Firstly, the
PXE locus maps into a region of 16p13.1 that is charac-
terized by an unknown genomic structure of several seg-
mental, potentially rearranged large sequence duplicates
around the fragile site Fra16(A) [7, 8]. The true genomic
representation of this region by cloned DNA has not yet
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been achieved [15, 16, 17]. The existing contigs [7, 18,
19] are likely to have been wrongly assembled [7]. In
fact this region is likely to represent an example of a ge-
nomic sequence gap of the third category according to
the nomenclature suggested by Eichler [20]. The charac-
terization of mutations in ABCC6 that cause the highly
variable PXE phenotype identified a gene whose genom-
ic sequence partially aligned into the large genomic du-
plication. This raised the question of whether the genom-
ic location of the gene and the surrounding genomic
structure have functional implications for the disease and
its phenotype or contribute to mutation mechanisms rele-
vant to the prevalence of this disease. We have presented
data that unambiguously show the existence of at least
one pseudogene copy of the ABCC6 gene that maps to
the cytogenetic interval defined by the consecutive so-
matic cell hybrid breakpoints Cy163 and Cy11. With se-
quence data and PCR data evidence for the existence of a
D16S79C locus that most likely maps to the cytogenetic
interval defined by the consecutive somatic cell hybrid
breakpoints Cy185 and Cy183 this suggests that there are
additional copies of ABCC6 within this large sequence
replication in addition to the one in Cy163. We have also
localized the starting point of the duplication to intron 10
of ABCC6 and refined its mapping position to lie within
900 bp of the intronic sequence. This provides unique se-
quence points for mutation analysis beyond exon 9 to-
wards exon 1 by long-range PCR with subsequent muta-
tion analysis by direct sequencing or other indirect meth-
ods utilizing exon specific nested primers. We have ex-
cluded additional copies of ABCC6 telomeric to the PXE
locus by PCR screening of DNA from the somatic hy-
brid cell line Cy180 [P-deletion Cy180(D)]. The PCR-
based somatic cell hybrid mapping data (with different
primer pairs for exon 10) as well as the sequence analy-
sis of primer sequence corresponding to intron 10 in Re-
peatMasker demonstrates that the duplication starting
point occurs in intron 10; however, exon 10 is not part of
this duplication. A potential, but at this point speculative,
explanation is deletion of exon 10 during the duplication
process as the result of nonhomologous recombination
events.
Secondly, the sequencing screen of exon 9 in the PXE
families revealed two conservative polymorphisms and
the Q378X (1132C→T) nonsense mutation. The 1132C
and 1132T products are both amplified in the general
population. 1132T obviously resides in a pseudogene
copy of ABCC6 in linkage disequilibrium with the vari-
ant alleles of the conservative polymorphisms. Neverthe-
less we have demonstrated that this nonsense mutation is
disease causing in 5 of 81 families either in the com-
pound heterozygous state or apparent homozygous state.
Additionally, we found this mutation in two distinct al-
lelic haplotypes built from the allelic variants of the ge-
nomic SNPs corresponding to nucleotide position 1077,
1132, and 1141 of the cDNA of ABCC6 (counting from
the first ATG). This suggests two distinct conversion
breakpoints in five chromosomes analyzed and points to
gene conversion events from ψABCC6 to ABCC6 as the
most likely mechanism for the occurrence of Q378X in
ABCC6. We are unable to prove such events in our fami-
lies on a de novo basis since the mutation cosegregates
stably in association with a family-specific allelic haplo-
type in all cases. Nevertheless, gene conversion events
could be a relevant mechanism in sporadic PXE if one
disease allele originated from a parental carrier, and the
second disease allele resulted from a parental paralogous
instead of a reciprocal allelic recombination event.
Based on the initial collection criteria for our families
(at least two affected siblings) for the mapping study, it
is clear that such mechanism is unlikely be found in our
families. However, in a sporadic case of PXE who was
seen for genetic counseling (Hans Knoblauch, personal
communication) we identified the Q378X mutation in the
compound heterozygous state with the R1141X mutation.
This could suggest a much higher frequency of the muta-
tion than we have found in our families and among spo-
radic cases. Here we provide the first evidence that
structural genomics of the PXE locus are relevant to
gene function or, in the case of ABCC6, to its loss of
function with potential implications for its disease asso-
ciated phenotype.
A full understanding of the implications of the ge-
nomic structure of the PXE locus onto the disease phe-
notype will require sequence gap closure for this region.
As Eichler states [20], the relevance of these reiterated
genomic regions to human genetic disease renders such
an analysis worthwhile.
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Communicated by Peter Humphries
Pseudoxanthoma elasticum (PXE) is a systemic heritable disorder that affects the elastic tissue in the skin, eye,
and cardiovascular system. Mutations in the ABCC6 gene cause PXE. We performed a mutation screen in ABCC6
using haplotype analysis in conjunction with direct sequencing to achieve a mutation detection rate of 97%. This
screen consisted of 170 PXE chromosomes in 81 families, and detected 59 distinct mutations (32 missense, eight
nonsense, and six likely splice-site point mutations; one small insertion; and seven small and five large deletions).
Forty-three of these mutations are novel variants, which increases the total number of PXE mutations to 121.
While most mutations are rare, three nonsense mutations, a splice donor site mutation, and the large deletion
comprising exons 23–29 (c.2996_4208del) were identified as relatively frequent PXE mutations at 26%, 5%,
3.5%, 3%, and 11%, respectively. Chromosomal haplotyping with two proximal and two distal polymorphic
markers flanking ABCC6 demonstrated that most chromosomes that carry these relatively frequent PXE
mutations have related haplotypes specific for these mutations, which suggests that these chromosomes originate
from single founder mutations. The types of mutations found support loss-of-function as the molecular
mechanism for the PXE phenotype. In 76 of the 81 families, the affected individuals were either homozygous for
the same mutation or compound heterozygous for two mutations. In the remaining five families with one
uncovered mutation, affecteds showed allelic compound heterozygosity for the cosegregating PXE haplotype. This
demonstrates pseudo-dominance as the relevant inheritance mechanism, since disease transmission to the next
generation always requires one mutant allelic variant from each parent. In contrast to other previous clinical and
molecular claims, our results show evidence only for recessive PXE. This has profound consequences for the
genetic counseling of families with PXE. Hum Mutat 26(3), 235–248, 2005. r 2005 Wiley-Liss, Inc.
KEY WORDS: PXE; membrane transporter proteins; ABC cassette proteins; ABCC6; founder mutations; haplotype
analysis.
INTRODUCTION
Pseudoxanthoma elasticum (PXE) (MIM] 264800) is a solely
autosomal recessive genetic disease that primarily affects the skin,
retina, and cardiovascular system [Neldner and Struk, 2002]. This
seems to be in conflict with historic clinical [Pope, 1974a] and
recent molecular claims [Bergen et al., 2000] that PXE is also
dominantly inherited (MIM] 177850). PXE is characterized by
progressive calcification of the elastic fibers in these organ systems
with subsequent destruction of the elastic tissue [Neldner and
Struk, 2002]. The elastic tissue of skin in PXE contains an increased
amount of glycosaminoglycans [Smith et al., 1962, 1964]. The skin
is characterized by yellowish papules and plaques that are diagnostic
of the disorder; however, it is the cardiovascular disease and central
visual field loss that can lead to serious morbidity. Central visual
field loss results from scarring due to bleeding into the fovea from
neoproliferative vessels that grow into the retinal layers from the Published online inWiley InterScience (www.interscience.wiley.com).
DOI10.1002/humu.20206
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choroidea along cracks in Bruch’s membrane. While there is
considerable variability of disease expression among affected
individuals of either the same family or different families, genetic
analysis has revealed a single gene locus for all families.
The gene for PXE was mapped by linkage analysis to 16p13.1
[Struk et al., 1997a, 1997b] and was subsequently located within a
500 kb interval [Cai et al., 2000]. Mutations were recently found
in the ABCC6 (also known as MRP6 or MOAT-E) gene, within
this interval, in patients with PXE [Bergen et al., 2000; Le Saux
et al., 2000; Ringpfeil et al., 2000; Struk et al., 2000].
The ABCC6 gene encodes a member of the ABC family of
transmembrane transporter proteins, several members of which are
known to cause human genetic disease [Klein et al., 1999]
(www.med.rug.nl/mdl/humanabc.htm). The function of ABCC6,
and how perturbation of this function leads to PXE are still unknown.
Here we report the complete scanning of the ABCC6 gene in
affected (and some unaffected) members of 81 families with PXE by
direct sequencing for mutations that cause PXE. In order to
discriminate between different PXE-associated chromosomes within
the PXE families and facilitate the detection of unique mutations, we
established PXE-associated haplotypes with genetic markers imme-
diately flanking the ABCC6 gene. The resultant data are consistent
and indicate that the inheritance of this disorder is exclusively
autosomal recessive, and that all mutations in the ABCC6 gene
associated with PXE appear to lead to loss-of-function of the protein
(Fig. 1). A comparison of the PXE-causing ABCC6 mutations with
mutations in genes encoding other ABC proteins that cause human
genetic diseases, such as cystic fibrosis and Dubin-Johnson syndrome,
reveals some common sites of amino acid mutation.
MATERIALSANDMETHODS
Patient DNACollection
For further information please see Supplementary Materials and
Methods (available online at www.interscience.wiley.com/jpages/
1059-7794/suppmat).
Genotyping and HaplotypeAnalysis
For further information please see Supplementary Materials and
Methods.
PCR Ampli¢cation of ABCC6 Exons
For further information please see Supplementary Materials and
Methods.
FIGURE 1. Predicted transmembraneprotein topology ofABCC6 (GenBankAAH50733.1) and locations ofPXEmutations. Nonsense
andmissensemutations, deletions, and insertions are presented as changes to the protein sequence.Thewild-type protein sequence
at positions of the PXEmutations is shown in a larger font, and a dash points to the protein sequence change caused by a particular
mutationor to the starting and/orendpoint of deletions. Splice-sitemutations arepresented as nucleotide changeswith their respec-
tive starting point. Partial deletions within ABCC6 are indicated; however, complete deletions of ABCC6 are not represented in this
¢gure (see Fig. 2 for illustration).The distribution of mutations shows that the vast majority of mutations lie within cytoplasmic do-
mains. Fifteenmutations occur in intracellular protein loopsupstreamof the nucleotide-binding fold region1 (NBF1),while12 muta-
tions liewithin theNBF1.Thirty-twomutations appearwithin intracellular loops betweenNBF1andNBF2, theNBF2 contains 23 PXE
mutations, andonemutationappears downstreamofNBF2.Theallotmentofmutationswithin intracellulardomains is1:2 comparing
the ¢rst two-thirds of the protein includingNBF1, with the remaining part downstreamofNBF1with a clustering ofmutations around
NBF2. Fourteen mutations appear or start within the transmembrane domain. One splice-site mutation and the large deletions that
start in extracellular loops and also a¡ect the transmembrane and cytoplasmic domains are shown; however, the nucleotide changes
that cause aminoacid substitutions in theextracellulardomains areconsideredpolymorphismsbecause theydonot cosegregatewith
the corresponding familial haplotypes and phenotypes.
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PCR Product Cleanup Prior to Sequencing
For further information please see Supplementary Materials and
Methods.
Subcloning of PCR ProductsWith Suspected Small
Insertions or Deletions
For further information please see Supplementary Materials and
Methods.
SequenceAnalysis
For further information please see Supplementary Materials and
Methods.
Molecular Characterization of the16.5kBDeletion
The ability to PCR amplify all exons except exons 23–29 for
affected individual 63.01 in the manner described above suggested
that this individual was compound heterozygous for a deletion
comprising these exons and a larger deletion (chromosome C in
Fig. 2), as was apparent by the cosegregation of null alleles of
neighboring SSLPs with the larger deletion. Subsequently we
identified the molecular boundary of exons 23–29 comprising the
deletion by PCR intron walking in introns 22 and 29. Eventually
the primer design was chosen close enough to both boundaries of
the deletion that it became possible to PCR amplify the deletion
allele using the primer pair ‘‘delE23-E29’’ (see Supplementary
Table S3). We used this primer pair in addition to the S2-primer to
detect the deletion allele in our set of families. The deletion allele
was characterized by a 400 bp PCR product, while the wild-type
allele generated an 800 bp PCR product across the breakpoint
within intron 22, confirming its integrity.
Consensus Diagram
For further information please see Supplementary Materials and
Methods.
Mutation Detection
At least one affected individual per family and four unaffected
members (who carried the reciprocal familial haplotype of their
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FIGURE 2. Illustration of genetic breakpoint intervals of large deletions occurring in theABCC6 genomic region.The ¢gure is drawn
about to scale.The top panel shows the genomic organization of the regionwith reference to build 34d of the chromosome16 refer-
ence sequence, and depicts the localization of mapping markers in reference to gene locations. Below, approximate physical dis-
tances betweenmarkers are shown inMega bp (Mb). Genes are indicated as arrows and abbreviated with the standard letter code of
databases.The arrow for each gene points from the 50 toward the 30 direction.The deletion chromosomes are illustrated with the
locations of mapping markers.The allelic status for each marker is de¢ned as follows: H: Heterozygous for two informative marker
alleles- the deletionmaps between these two SSLPs. N: Informative null allele-an SSLPallele that cannot bePCR ampli¢ed due
to regional genomic allelic hemizygosity of a¡ecteds carrying a deletion (however, it can be deduced from seemingly inconsistent
cosegregation of either maternal or paternal alleles that are resolved under the assumption of a cosegregating null allele).The dele-
tionexceeds beyond the null allele.U:Uninformative SSLPallele that carries the same allele size for cosegregatingparental alleles to
thenext generation (cis/trans alleles at the same locus).Therefore, the transmissionof thenull allele to the next generation ismasked
and cannot be identi¢ed. h: Hemizygous allelic state of SSLPs.One allele of an SSLPPCR ampli¢es and determines the boundary of
the smaller of two large deletions that compound heterozygously cosegregate with the phenotype and haplotype of an a¡ected indi-
vidual.The deletion lies between the two alleles.The approximate size of the deletions is shown on the right site of each deletion
chromosome with reference to the current reference sequence for chromosome 16 of build 34d. [Color ¢gure can be viewed in the
online issue,which is available at www.interscience.wiley.com.]
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affected siblings) of different families were selected for systematic
sequence analysis of ABCC6. Individuals affected with PXE were
tested first, and when a variation (SNP, deletion, or insertion) was
encountered, the DNA of other family members was tested also by
either direct sequencing or PCR-based RFLP analysis when the
nucleotide variation caused a loss or gain of a restriction site, to
determine with which haplotype it cosegregates. For exons 1–9 of
ABCC6, which lie within a large regional segmental duplication,
exon sequencing was initially performed on PCR products amplified
from primer pairs that were complementary to the neighboring
intronic sequence. The SNPs identified were analyzed first with
respect to their potential changes of the protein sequence of
ABCC6, second to their cosegregation with the disease phenotype in
the original family of SNP identification, and third to their
occurrence in 200 control chromosomes. When it was appropriate
and technically possible, SNPs detected within the duplicated region
were reanalyzed in a second step by PCR amplification of their
exonic or intronic sequences with either a long-range PCR strategy
or with allele specific primers to prevent duplicated sequences from
amplification and to test the SNPs for occurrence within ABCC6.
The exclusion of duplicated sequences from PCR amplification was
tested in a mouse human somatic cell hybrid panel for human
chromosome 16, as previously described [Cai et al., 2001]. The
results are presented in Supplementary Table S4.
Restriction Digests
For further information please see Supplementary Materials and
Methods.
Designation as a Disease-Causing Mutation
We considered sequence variants to be phenotype-modifying by
applying criteria previously used to define a nucleotide sequence
variant as disease-causing [Cotton and Scriver, 1998], as follows: A)
ABCC6 sequence variants resulting in nonsense or splice-site
alterations (i.e., premature stop codons, small or large deletions/
insertions with frameshift, and sequence changes within the genomic
structure of ABCC6 potentially affecting constitutive intron-exon
splicing, respectively) were designated as disease-causing when they
cosegregated with the disease haplotype in affected (but not in
unaffected) members of all PXE families carrying the specific
mutation, and when they were not detected in 200 control alleles of
unrelated and unaffected individuals. B) Nucleotide variations that
resulted in amino acid substitution were deemed disease-causing
when 1) the variant cosegregated with the disease phenotype and
haplotype in all PXE pedigrees carrying it, 2) no other potentially
disease-causing and familial haplotype-specific allelic variant was
identified by complete sequence analysis of ABCC6, 3) the variant
was not found in the panel of 200 control chromosomes, and 4) the
amino acid substitution involved a conserved amino acid.
Conservation of an amino acid was judged in two ways: We
aligned 12 human ABCC proteins, and then separately aligned the
closely related human ABCC1, ABCC3, and ABCC6 with
ABCC6 of mouse, rat, dictyostelium discoideum, dictyostelium
discoideum ABCC1, Drosophila CG6214 gene product, C. elegans
MRP1, and yeast metal resistance protein YCF1P (yeast cadmium
factor I). Conservation was assumed if amino acids were conserved
in several proteins of either alignment.
Exclusion of Disease-Causing SequenceVariants in
Control Chromosomes
For further information please see Supplementary Materials and
Methods.
Mutation Nomenclature
The nomenclature for mutations was chosen according to
previously published recommendations [den Dunnen and Anto-
narakis, 2000, 2001]. The DNA mutation numbering is based on
the ABCC6 cDNA sequence (GenBank accession no.
AF076622.1), and 11 corresponds to the A of the ATG
translation initiation codon of the reference sequence.
RESULTS
Mutational Screening
We performed a mutational screen of ABCC6 in 89 PXE-
affected individuals representing 170 distinct disease chromosomes
from 81 families, as well as in four haplotype-negative individuals
from these families. Sixty-one families (75%) showed the
occurrence of the disease phenotype in only one generation but
in at least two siblings, indicating that these families have an
apparent recessive mode of inheritance. In 11 families (13.5%) we
found the PXE phenotype in only one family member of a single
generation. These cases may therefore represent sporadic PXE. In
some families we also identified the PXE phenotype either in first-
degree cousins (four families) or in two (four families) or three
(one family) generations, suggesting the possibility of a dominant
mode of inheritance. Three of these nine families originated from a
consanguineous genetic background. Therefore, six of 81 families
(7.5%) have the possibility of dominant disease transmission
[Struk et al., 1997a,b]. The clinical and genetic details of the
families are given in Supplementary Table S1.
We determined the likely number of different PXE chromo-
somes among the available PXE families by establishing haplotypes
across the affected (ABCC6) gene. Two telomeric (D16B9621 and
D16B9622) and two centromeric (D16S79 and D16S764)
informative genetic markers were genotyped in the PXE families,
as previously described [Cai et al., 2000]. Phase was established by
transmission, and haplotype was assigned to the PXE chromosome
by cosegregation with the disease. For mutation screening it was
assumed that each distinct PXE haplotype was indicative of a
different ‘‘founder’’ mutation. In this way, representatives of each
PXE haplotype were screened for mutation by direct sequencing.
Where mutations were detected, we substantiated the relationship
between haplotype and mutation by screening all other chromo-
somes with a related haplotype for the presence of the particular
mutation.
Through this approach we identified a total of 59 distinct
mutations (Table 1). Of these, 17 were among the 79 PXE
mutations previously reported by other groups [Ringpfeil et al.,
2000, 2001; Bergen et al., 2000; Le Saux et al., 2000; Pulkkinen
et al., 2001; Meloni et al., 2001; Chassaing et al., 2004; Gheduzzi
et al., 2004] and 42 represent novel mutations, bringing the total
number of known PXE mutations in ABCC6 to 121 (Fig. 1). We
detected eight nonsense mutations, six of which are new variants
or were recently described by our group [Struk et al., 2000; Cai
et al., 2001]. The nonsense mutations account for 13.5% of the
total mutations (59) detected. The majority of mutations
identified in this study are missense mutations (54%). Of the 32
missense mutations identified, 22 represent novel variants. These
missense mutations affected conserved amino acid (aa) residues
(see Materials and Methods), with two exceptions: an asparagine
at aa 370 and an arginine at aa 1164. We encountered six putative
splice-site point mutations (10%), four of which have not
previously been described. We discovered seven small deletions
(11.8%, five of which represent novel variants), a new small
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insertion, and an indel (i.e., a small insertion accompanied by a
deletion). The small deletions cause either in-frame deletions or
frameshift mutations. The two in-frame nucleotide triplet dele-
tions (c.3106delTTT) (c.3141delCTT) eliminate a phenylalanine
in amino acid position 1036 or 1048 (p.F1036del) (p.F1048del) in
exon 23. The previously described single nucleotide deletion
(c.3775delT) (p.G1259fsX1272) in exon 27 was found in two
families (Families 31 and 41; Supplementary Table S1) with a
common haplotype (X-165-165-137), suggesting that both muta-
tions originate from a common founder allele. We uncovered a
single bp deletion in exon 28 (c.3912delG; p.S1305fsX1358). This
deletion affects the Walker A motif of the second nucleotide
binding fold.
The intronic indel (insertion-deletion) (c.3307-3_-38del-3_
-5insAGA) in intron 23 at the boundary to exon 24 involves the
pyrimidine-rich region that comprises the highly conserved
splicing acceptor site, and is therefore predicted to eliminate the
30 splice acceptor signal. This causes exon skipping, which
consequently leads to a truncated protein or possibly to
nonsense-mediated decay of the ABCC6 RNA transcript. The
single nucleotide insertion (c.3769-3770insC) (p.L1259fsX1277)
in exon 27 is responsible for a frameshift mutation and was found
in two families (Families 33 and 44; Supplementary Table 1) with a
common haplotype (323-155-N-133). In addition, we detected
five large, distinct deletions (8%), four of which are new variants
(Fig. 2). More details are given below, and an overview of the
mutations identified is given in Table 1 and Figure 1. Interestingly,
the vast majority of mutations lie within intracellular domains of
ABCC6. We found four missense mutations, three of which are
novel, located in transmembrane domains. An additional four
missense mutations in transmembrane domains were identified in
previous studies, bringing the total number of known missense
mutations in these functional protein domains to eight. Only large
deletions and one splice-site donor mutation (c.99812delTG)
have their starting points in extracellular domains, but these also
affect transmembrane and intracellular domains of ABCC6.
Furthermore, nucleotide variations that cause amino acid
substitutions located in extracellular domains do not cosegregate
with any PXE haplotype, and therefore do not cosegregate with
the PXE phenotype. We identified a total of 21 mutations that
affect 15 distinct arginine residues of the ABCC6 protein. All but
one of these residues are highly conserved.
Rate of Mutation Detection
Likely disease-causing mutations were uncovered in 97% (165/
170) of the disease chromosomes analyzed, which is the highest
mutation detection rate reported so far for this gene. We identified
at least one disease-causing mutation in all (100%) of the 89
affected individuals. In five of these individuals (one in each of five
different families) we were unable to identify the second mutation.
However, all affected members of these families show compound
heterozygosity for the cosegregating familial disease haplotypes
(see Supplementary Fig. S1).
Initial Haplotype-Based Mutation Screening Strategy
for CommonMutations and Deletions
Initially all of the DNA samples were tested for the nonsense
mutation c.3421C4T (p.R1141X) by restriction analysis of PCR
products, since the c.3421C4T mutation causes loss of a Bsl I
restriction site. In samples in which the loss of this restriction site
was detected, the mutation was confirmed by direct sequencing.
From this analysis, c.3421C4T was assigned to a particular
haplotype/chromosome in the families in which it was detected,
and it was found that 26% of the chromosomes (45 out of a total of
170) in this study had the c.3421C4T mutation. This mutation is
therefore the most frequent PXE mutation in ABCC6. Among
these 45 chromosomes, we identified two distinct haplotypes, one
of which appears to be a founder haplotype that occurs in 10
different variations and accounts for 95.5% (43/45) chromosomes
that carry the c.3421C4T mutation. The results indicated that
12.2% (6/49) of disease chromosomes with the founder haplotype
pattern (see below) did not carry the c3421C4T mutation. We
found the most frequent variant of the founder haplotype
(323 bp–139 bp–163 bp–133 bp) (see Supplementary Table S2) in
42.8% (18/42) of the independent PXE chromosomes with the
pattern (323 bp–139 bp–x–x).
During the PXE mutation screen, a deletion that included
exon 24 (the location of the c.3421C4T mutation) was
detected in families that seemed to be transmitting a ‘‘null’’ allele
[Struk et al., 2000]. We were able to independently identify the
extent of this (e23-29del) deletion in a PXE-affected individual
who had both the exons 23–29 deletion (c.2996_4208del;
I1000_S1403delW1404fsX1463) and a more extensive deletion
that comprises all exons of the ABCC6 gene (Family 63;
Supplementary Table S1), and found this deletion to be the same
as that recently reported by Ringpfeil et al. [2001]. By performing
haplotyping and segregation analysis, we assigned the deletion to a
haplotype in each family. Nineteen chromosomes (19/170 5 11%)
from 19 families were found to have this deletion with identical
breakpoints, which makes it the second most frequent PXE
mutation uncovered so far. The deletion chromosomes were
represented by six haplotypes; however, each has the pattern
(323 bp–165 bp–x–x), which suggests that they are related and a
common founder mutation is responsible for all (see Supplemen-
tary Table S2). The 323-165-x-x haplotype pattern was found in
24.7% (42/170) chromosomes. The exon 23-29 deletion was
identified in 45.2% (19/42) chromosomes with this predictive
haplotype pattern. The most common deletion haplotype (323-
165-163-133) occurred in 58% (11/19) of the e23-29 deletion
containing chromosomes. The families that carry it originate from
the UK. The haplotype pattern 323-165-X-X for this deletion is
independent of the geographic origin of the families that carry it,
while specific subhaplotypes may represent a regional origin of that
haplotype (323-165-163-133 5 British/Irish haplotype). The fre-
quency of this deletion among PXE chromosomes of U.S. families
is 14.8% (18/122), compared to 2% (1/48) among PXE chromo-
somes of families that live outside the United States.
The c.4015C4T (p.R1339C) mutation was first identified in a
homozygous allelic state in a consanguineous family from Mexico
[Struk et al., 2000]. By comparing its haplotype (333-169-161-
133) with the haplotypes of all other families in this study, we
found a related haplotype (333-169-153-129) in eight PXE-related
chromosomes that homozygously and compound heterozygously
cosegregated with the PXE phenotype in five South African
families of Dutch descent. Indeed, sequencing confirmed that
these families carried the same mutation as the Mexican family.
This mutation was therefore considered the PXE-founder muta-
tion of the South African Afrikaner or Boer families [Struk et al.,
2000], as was confirmed by a more extensive family analysis by Le
Saux et al. [2002]. The common (333-169-x-x) haplotype among
the Mexican family and the Afrikaner families strongly suggests a
common founder for this mutation. On the other hand, our
finding of a different haplotype (347-139-153-133) for the same
mutation identified by direct sequencing in a family that lives in
Germany, and in the paternal allele carrier of that family that
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originates from Italy, suggests the independent occurrence of this
mutation in different geographic regions.
Further mutations with founder alleles among the family
chromosomes analyzed are the c.4016G4A (p.R1339Q) muta-
tion, the c.1553G4A (p.R518Q) mutation, and the c.27871
1G4T splice donor site mutation (Supplementary Table S2).
The c.3490C4T (p.R1164X) mutation identified in our initial
mutation screen [Struk et al., 2000] cosegregated with the (323-
165-null-137) haplotype. In our current study we identified the
p.R1164X mutation in nine PXE chromosomes, segregating with
five distinct and unrelated haplotypes, which suggests that this
location is more likely a mutational hotspot in ABCC6. However,
among these haplotypes there are founder haplotypes: one
definite, of British descent (x-165-163-x); and one with a potential
for a founder haplotype (x-165-null-137). This mutation ranks as
the third most frequent PXE mutation, and interestingly, in
addition to being both a mutation hot spot and founder mutation,
its wild-type arginine residue is not conserved among the ABCC
proteins.
In our initial mutation screen we identified the c.1132C4T
(p.Q378X) base change in a consanguineous U.S. family originat-
ing from Italy. This mutation is the fourth most frequent PXE
mutation, occurring in 3.5% of all PXE chromosomes analyzed (see
Table 1). The consanguineous family and another U.S. family of
Italian descent share the same haplotype for this mutation,
suggesting an Italian founder allele. However, in six p.Q378X
alleles we identified four distinct haplotypes, suggesting indepen-
dent recurrence of this mutation. This is in accord with the notion
that gene conversion from one of the ABCC6 pseudogenes is the
source of this mutation [Cai et al., 2001].
Search forAdditional Mutations by Direct Sequencing
PXE-affected individuals from the 51 families without muta-
tional assignment for either one or both of the disease
chromosomes were subjected to extensive mutation screening by
sequencing of PCR products from exons 1–31 and the 50UTR and
30UTR of ABCC6.
Search for MutationsWithin theDuplicated Region
(50UTR, exons1^ 9) of ABCC6
In the first round of mutation screening (see Materials and
Methods, and Supplementary Table S5), sequencing of the PCR
products and comparative analysis of the sequencing reads
revealed frequent polymorphisms and potential mutations
(p.A78T, p.E125K, p.A158V, p.R265G, p.K281E, and p.I319V
p.Q378X) (see Tables 1 and 2) that appeared in all families and
initially did not cosegregate with familial haplotypes, which
suggests that they are likely pseudogene polymorphisms. However,
there were also single mutations (p.G129E, p.L248F, p.S317R,
p.L355R, p.T364R, p.N370D, and p.R391G) that did cosegregate
with the disease haplotype in families in which they were observed,
and were absent in 200 control chromosomes. This suggests that
there are ABCC6 mutations in exons 1–9 whose detection is not
hampered by the same mutation or by other polymorphisms that
occur in similar positions of the pseudogenes.
In the second round we were again able to identify the
mutations p.S317R, p.L355R, p.T364R, p.N370D, and p.R391G by
nested sequencing of the long-range PCR products for exons 8 and
9, and to demonstrate their cosegregation with the disease
haplotype. This provided further support for the idea that these
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Although we could not obtain a long-range PCR product for the
approximately 26 kb genomic sequence that included exons 2–9,
we created allele specific long-range PCR primers spanning exons
3 and 4, and allele-specific primers for exon 2 (see Supplementary
Table S3). It was shown that these primers do not amplify the
known ABCC6-pseudogenes when they were tested on a
chromosome 16 somatic hybrid cell panel. DNA was amplified
only from the cytogenetic interval defined by the consecutive
breakpoints Cy 19 and Cy185 containing the functional ABCC6
gene (for reference see Supplementary Table S4 in this paper and
Figure 2 in [Cai et al., 2001]).
For the pseudogene polymorphisms p.A78Tand p.E125K, which
occur at highly conserved amino acid positions of ABCC6, we
could not demonstrate novel gene conversion events in our
families between ABCC6 and its two known pseudogenes;
however, we did unmask a G-to-T nucleotide substitution at
position c.373 that resulted in premature termination of the
protein at amino acid position 125 (p.E125X).
We identified two small deletions in exon 2. One is an in-frame
deletion (p.R60_Y62del) that has since been described [Pulkkinen
et al., 2001], and the other is a single bp deletion of an adenosine
at position c.105 that causes a frameshift (p.S37fsX80).
Within the duplicated part of ABCC6, we identified a total of
15 distinct mutations (including the four large deletions that also
involve this part of the gene). Twelve of these 15 mutations are
novel variants, which increases the total number of PXE mutations
involving this region to 20.
Search forMutations Outside theDuplicated Region of
ABCC6 (Exons10^ 31,30UTR)
Within exons 10–31 we found 25 nucleotide substitutions that
cause missense mutations in the ABCC6 protein. Sixteen of these
represent novel variants, and six of the eight nonsense mutations
identified are contained within the latter 22 exons (see Table 1 for
details).
Predicted Splice-Site Point Mutations
All putative splice-site mutations identified in this study are
located beyond the first nucleotide-binding-fold region toward the
C-terminal end of the protein. The newly identified splice-site
point mutations are located in IVS 24 (c.3507-1G4A), exon 26
(c.3735G4T, E1245D), (c.3735G4A, E1245E), and IVS 27
(c.3883-6G4A). While the first three are predicted to impair
splicing and cause a truncated protein by exon skipping under the
assumption of a stable mutated mRNA, the latter mutation is
predicted to generate a new splice site that leads to aberrant
splicing and, through frameshift, to the generation of an abnormal
and truncated protein.
The splice-site prediction server at the Berkeley Drosophila
Genome Project (BDGP) website predicted, for the wild-type
allele, a score of 0.24 for the splice acceptor site of exon 28. The
c.3883-6A allele creates a new AG splice signal 4 bp upstream of
the wild-type splice site, which has a splice prediction score of
0.54. If splicing occurs at this new site, then four additional bp of
the intronic sequence will be translated into the protein sequence,
inserting an alanine at position 1295 and causing a frameshift
thereafter that results in truncation at position 1321
(p.A1295fsX1321). We propose that this mutation is PXE-causing
on the basis that it cosegregates with the disease phenotype, and
we did not find this mutation in 200 control chromosomes. We are
unable to support this proposal at the cDNA level because fresh
blood samples were not available for isolation of mRNA from the
family carrying this mutation.
The predicted splice-site mutations c.3735G4Tand c.3735G4
A are especially interesting because they occur at the last
nucleotide of exon 26. In addition to causing an amino acid
substitution of glutamic acid to aspartic acid, the c.3735G4T
transversion is also predicted to abolish the splice donor site of
exon 26. While the glutamic acid at this position is highly
conserved among the ABCC proteins, the substitution with
another acidic amino acid may not substantially impair the
protein function. This notion is supported by the discovery of
the allelic variant (c.3735G4A transition), which is a silent
mutation (E1245E). The calculated splice-potential score
[Shapiro and Senapathy, 1987] decreases from 78 for the wild-
type allele to 65, identically for both mutated allelic variants.
In fact, the BDGP splice-site prediction server predicted the
loss of the splice donor site for both mutated alleles. A similar
ABCC6 mutation was previously described [Le Saux et al.,
2001] that affects the last nucleotide in exon 28 and is
also predicted to impair splicing. An ‘‘analogous mutation’’
(Q1291H) in ABCC7 (CFTR) that is responsible for the
development of cystic fibrosis, and for which alteration of
the splice donor site was demonstrated by mRNA studies [Jones
et al., 1992], has also been described.
Genetic Mapping of LargeDeletions
In addition to the Alu-mediated large deletion comprising exons
23–29 of ABCC6, we identified and characterized four additional
large deletion alleles that include ABCC6 partially or completely
in three families (Families 1, 63, and 78) (see also Supplementary
Figure S2). The deletions that completely span ABCC6 also
encompass several neighboring genes. These latter deletions
cosegregate as compound heterozygotes with either a point
mutation or with large deletions that partially contain ABCC6.
So far there has been no description of a family that is homozygous
for the same deletion or is compound heterozygous for large
deletions that comprise ABCC6 completely. The genetic mapping
details of the four new large deletions are depicted in Figure 2. Our
mapping data are at odds with the current human genome
reference sequence for this region, primarily because of the cryptic
genomic duplications discussed above.
ABCC6 and ABCC6-Wx Polymorphisms^Evidence for
Additional Pseudogenes
An overview of the exonic and intronic SNPs identified during
the mutational screen is given in Table 2. Coding sequence SNPs
were considered as neutral (non-disease-causing) when they
resulted in a synonymous amino acid substitution or a nonsynon-
ymous substitution that did not cosegregate with the disease
haplotype and phenotype (p.V614A, p.R724K, p.I742V, p.L946I,
p.R1064W, and p.R1268Q) or did cosegregate with other PXE
mutations in linkage disequilibrium in individual families (p.V514I,
p.H632Q, and p.R1268Q). The exception is the synonymous
c.3735G4A, which is expected to have an effect on splicing
efficiency.
Interestingly, within the duplicated part of ABCC6 (exons 1–9)
we observed SNPs within the coding and noncoding sequence that
occurred in all individuals tested independently of the cosegrega-
tion of the disease phenotype or haplotype when PCR amplifica-
tion was done with primer sequences complementary to
neighboring intronic sequences. Moreover, these polymorphisms
were not detectable when PCR amplification of the duplicated
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region was achieved with a long-range PCR strategy from sequence
points outside the duplication. Some of these polymorphisms
were not detectable by PCR amplification using allele specific
primers (with the exception of gene conversion events [Cai et al.,
2001]) that excluded duplications from amplification. A likely
explanation is that these polymorphisms are not allelic poly-
morphisms within ABCC6 or a neighboring intronic sequence.
Instead, the variant alleles occur within duplicated sequences
that belong to ABCC6 pseudogenes. While some of these
polymorphisms have been identified in recently characterized
ABCC6 pseudogene sequences and neighboring intronic
sequences [Pulkkinen et al., 2001], others (c.345112T4C,
c.474113G4A, c.794136A4C, p.K281E, and p.I319V) were
not found in such sequences. Therefore, these latter polymorph-
isms provide evidence for additional ABCC6 pseudogenes that
have not yet been identified and characterized. This is in







(] of families) Referencea
E 03 c.232G4A p.A78T ABCC6-C2 81 This study, (C,H)
IVS 03 c.345112T4C Intron duplication 81 This study
IVS 03 c.345126C4T Intron 1 This study
IVS 03 c.3466G4A Intron 10 This study, (C)
E 04 c.373G4A p.E125K ABCC6-C1 81 This study, (C)
E 04 c.473C4T p.A158V ABCC6-C2 81 This study, (C)
IVS 04 c.474113 G4A Intron duplication 2 This study
IVS 04 c.474143C4T Intron duplication 80 This study, (C)
IVS 04 c.47576A4C Intron duplication 81 This study
IVS 04 c.47545C4T Intron 3 This study
IVS 04 c.47522T4C Intron duplication 80 This study, (C)
E 05 c.549G4A L183L ABCC6 2 This study, (E)
IVS 05 c.600123C4T Intron 1 This study
E 06 c.645G4A T215T ABCC6 8 This study, (C)
IVS 06 c.662112C4T Intron 1 This study, (C)
E 07 c.793A4G R265G ABCC6-C1 81 This study, (C,H)
IVS 07 c.794136A4C Intron duplication 81 This study, (C)
E 08 c.841A4G K281E ABCC6-Cx 81 This study, (H)
E 08 c.855C4T T285T ABCC6-C1 81 This study, (C)
E 08 c.955A4G I319V ABCC6-Cx 81 This study, (H)
E 09 c.1077A4G S359S ABCC6, ABCC6-C1 1 This study, (C,H)
E 09 c.1132C4T Q378X ABCC6-C1 81 This study, (C,H)
E 09 c.1141T4C L381L ABCC6, ABCC6-C1 81 This study, (C,H)
IVS 09 c.117616C4T No SSM Intron 1 This study
E10 c.1233T4C N411N ABCC6 1 This study, (B,L)
E10 c.1245G4A V415V ABCC6 Frequent This study, (B,L)
IVS10 c.133817C4G Intron Frequent This study
IVS10 c.1338120C4G Intron Frequent This study
IVS10 c.1338162G4C Intron Frequent This study
IVS11 c.143241A4G Intron Frequent This study, (E)
E12 c.1540G4A V514I ABCC6 1 This study
IVS12 c.1635147C4T Intron Frequent This study
E14 c.1841T4C V614A ABCC6 Frequent This study, (B,E)
IVS14 c.186857G4A Intron 3 This study
E15 c.1890C4G T630T ABCC6 Frequent This study, (B,L)
E15 c.1896C4A H632Q ABCC6 Frequent This study, (C,G)
E17 c.2171G4A R724K ABCC6 2 This study
E17 c.2175A4T V725V ABCC6 2 This study
E17 c.2224A4G I742V ABCC6 2 This study
E19 c.2490C4T A830A ABCC6 Frequent This study, (E)
E 22 c.2820T4G R940R ABCC6 1 This study
E 22 c.2835C4T P945P ABCC6 8 This study, (J)
E 22 c.2836C4A L946I ABCC6 3 This study
E 22 c.2904G4A L968L ABCC6 1 This study, (J)
E 23 c.3190C4T R1064W ABCC6 2 This study
IVS 24 c.350716T4C No SSM Intron 4 This study
IVS 24 c.35073C4T No SSM Intron 3 This study
E 27 c.3803G4A R1268Q ABCC6 Frequent This study, (C,M)
IVS 27 c.388324G4A Intron 1 This study
IVS 28 c.4041149C4T Intron Frequent This study, (E)
IVS 28 c.404230C4T Intron Frequent This study
IVS 29 c.420819G4A Intron 2 This study
E 30 c.4305C4T G1435G ABCC6 1 This study
IVS 30 c.440531G4A Intron Frequent This study
30UTR c.4512117G4A UTR 5 This study, (E)
30UTR c.4512138G4A UTR 1 This study
DNA mutation numbering is based on theABCC6 cDNA sequence (GenBank accession no. AF076622.1) and 11 corresponds to the A of the ATG
translation initiation codon of the reference sequence. New polymorphisms are bold.
aReferences: B: Meloni et al. [2001]; C: Le Saux et al. [2001]; E: Le Saux et al. [2000]; G: Struk et al. [2000]; H: Pulkkinen et al. [2001]; J: Hu et al.
[2003b]; K: Ringpfeil et al. [2001]; L:Wang et al. [2001]; M:Germain et al. [2000].
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concordance with our previously published data [Cai et al., 2001].
It also provides an explanation as to why the p.Q378X mutation
could not be identified as a PXE-causing mutation [Pulkkinen
et al., 2001] when an allele-specific PCR approach
was applied that excluded the known pseudogenes from
amplification, but not the unknown pseudogenes (in contrast to
a long-range PCR approach from sequence points outside the
duplication region that excludes both known and uncharacterized
pseudogenes from amplification).
Genotype-Phenotype Observations
We developed a simple clinical grading scale for functional
impairments caused by the natural progression of the disease. We
obtained the necessary information to judge functional impairment
from the patients by taking a detailed clinical history and
performing simple clinical tests. This was done to determine
whether the natural course of the disease is significantly influenced
by the type of mutations responsible. The details of the clinical
grading scale of disease manifestations and their relationship to
genotype are given in Supplementary Table S1.
Analysis of the clinical phenotype over time shows a slowly
progressive degenerative course of the disease, with the frequency of
appearance of all symptoms increasing with patient age. There is clear
variability in the time frame and clinical extent of the individual
appearance of clinical manifestations of the disease. In a limited
number of clinical cases, this variability can be extreme [Nolte, 2000].
On the basis of the analysis described here, there is no clear
relationship between genotype and phenotype in PXE that would
allow prediction of the clinical outcome based on the type of
ABCC6 mutation identified. Rather, the age of the patient
predicts the degree of clinical impairment resulting from PXE more
accurately than the type of mutation.
The types of mutations observed (in-frame termination codons,
small and large deletions, and their homozygous and compound
heterozygous cosegregation with the disease phenotype) suggest a
loss-of-function as the molecular mechanism for PXE. The
proposed transport function of ABCC6 and long-standing
biochemical observations of an increased glycosaminoglycan
content [Smith et al., 1962, 1964] in PXE skin further support
this notion; however, the exact molecular mechanisms by which
the loss of ABCC6 function causes PXE remain elusive. While
different mutations have the potential to affect ABCC6 function
to various extents, any such variation does not appear to be a rate-
limiting factor in phenotypic outcome.
Clinical vs. Molecular InheritanceMechanisms of PXE
At the outset of our studies a dominant mode of inheritance
could not definitely be excluded in six of nine families in which the
PXE phenotype, according to category I diagnostic criteria, was
found in more than one generation or in first-degree cousins.
Genetic-mapping data from all of the families were consistent with
a single genetic locus on chromosome 16p, in agreement with an
earlier proposal that ‘‘recessive’’ and ‘‘dominant’’ forms of PXE
map to the same locus [Struk et al., 1997a,b].
With the completion of the haplotype analysis (in which familial
haplotypes among affected siblings and their unaffected siblings,
when available, were compared), it was apparent that all of the
PXE-affected sib pairs in each family showed a shared maternal
and paternal chromosomal haplotype at the locus, suggesting a
recessive-only molecular mode of inheritance for PXE [Cai et al.,
2000]. Moreover, a comparison of the phenotype and haplotype
data for all individuals made it clear that clinical carriers of the
trait, with a haplotypic heterozygous allelic status for one of the
familial disease alleles, may express a forme fruste of the disease
that can be characterized, in part, by category II diagnostic criteria
[Neldner and Struk, 2002] according to the consensus conference
[Lebwohl et al., 1994]. Such carriers may have a positive skin
biopsy of nonlesional skin and/or show mottled hyperpigmentation
or angioid streaks, but will not exhibit the long-term manifesta-
tions and complications of the disease that are the consequences of
the loss-of-function of both allelic ABCC6 copies.
The current mutational analysis of these families confirms the
previous haplotype-based analysis and conclusions regarding a
recessive-only mode of inheritance in PXE through the identifica-
tion of two mutation alleles in all PXE affecteds that appear in
either consecutive generations or in alternating (first and third)
generations of the same family. This clearly demonstrates that the
phenotypically full expression of the disease requires two defective
(mutant) allelic copies of ABCC6 (a maternal and a paternal
allele), and that pseudo-dominance is the mode of transmission
(i.e., the second parental disease allele ‘‘marries’’ into the family).
The apparent frequency of this mechanism was approximately
7.5% in our family cohort. It is also important to state that in our
families none of the heterozygotes for a large deletion showed any
apparent clinical signs of PXE according to category I diagnostic
criteria. Therefore, while haploinsufficiency does not cause PXE, it
may cause a forme fruste of the disease.
DISCUSSION
Mutation Screening
This study presents the results of systematic screening for PXE
mutations in ABCC6 in the second largest cohort of families
affected by PXE reported so far. We identified a total of 59 distinct
mutations, 72.8% (43/59) of which are novel variants. By applying
a direct sequencing approach in combination with chromosomal
haplotype analysis for mutation screening, we were able to detect
97% of mutations. The mutation detection rate is also influenced
by the concise diagnosis of the disease in each family, and therefore
by the number of families within the cohort that carry a phenocopy
(PXE-like) phenotype or incomplete phenotype (forme fruste of
heterozygous carriers). While other investigators considered family
members without visually detectable skin lesions but with positive
skin biopsies from nonlesional skin as being affected with PXE [Hu
et al., 2003a], we strictly applied the category I diagnostic criteria
for identifying diseased individuals and focused on collecting
families with at least two affected individuals. We were therefore
able to avoid collecting families with an incomplete phenotype or
phenocopy of PXE. Although we made a considerable effort to find
all mutations, we were unable to identify the second mutation in
five of 81 families. We reanalyzed all of the sequence data from
these five families and repeated all ambiguous sequence reads, and
therefore it is not very likely that we missed mutations within the
coding sequence and its surrounding intronic sequence. We may
have missed intron mutations that lie outside the sequence
analyzed, or large deletions that were not detected by noncose-
gregating polymorphisms or promoter mutations, because the
functional promoter may not yet be represented within the human
genome reference sequence for this region due to the unsolved
genomic duplication issues for this region.
PXE Mutations
While most mutations are unique variants that represent the
typical allelic heterogeneity of a recessive disease, we observed five
mutations (p.R1141X [26%], p.I1000_S1403delW1404fsX1463
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[11%], p.R1164X [5.3%], p.Q378X [3.5%], and c.278711G4T
[3%]) at higher frequencies that accounted for almost 50%
(exactly 48.8%) of the PXE mutations. A haplotype analysis of
these mutation alleles shows evidence for common founder alleles.
An exception is the p.R1339C mutation. Its overall high
frequency of 6.5% results from its extremely high frequency due to
a founder effect (8/12 alleles, 66.6%) within the South African PXE
families. Moreover, two additional allelic sequence variants cause
two additional amino acid substitutions (leucine and glutamine) of
the highly conserved arginyl residue at amino acid (aa) position
1339, which makes this location a potential mutation hot spot.
The most frequently observed PXE mutation was p.R1141X.
It occurred in our cohort at a frequency of 26% of all muta-
tion alleles, and 31% in mutation alleles from U.S. families. Hu
et al. [2003a] reported a frequency of 30% within Dutch PXE
families, while Le Saux et al. [2001] observed an overall frequency
of 18% in his family cohort. In this study the mutation was
found at different allele frequencies in European (28.4%) and
American (4.1%) PXE families. While Le Saux et al. [2001]
considered a founder effect for this mutation from the difference
in allele frequencies in different populations, we observed
this mutation in American PXE families at about the same
frequency as reported for European PXE families. However, our
haplotype analysis for this mutation demonstrates two distinct
haplotype patterns, and one of these shows 10 related subhaplo-
types in the United States and in different European countries.
Chassaing et al. [2004] reported a third haplotype pattern (323-
151-x-x) for this mutation. Hu et al. [2003a] reported p.R1141X
in allelic linkage disequilibrium with the c.2490C4G polymorph-
ism in his family cohort. This polymorphism allele was not
observed in our cohort, which indicates a Dutch founder at the
origin for this mutation in the Dutch PXE cohort. This clearly
demonstrates that while the p.R1141X mutation exhibits a founder
effect, it has arisen independently in different population cohorts
at least four times.
The four chromosomes that carry the p.R518Q mutation share a
related haplotype, which suggests a founder mutation that
originates in our cohort from Switzerland. While Le Saux et al.
[2001] identified the mutation in a family from Belgium,
Chassaing et al. [2004] found it in two families (from Morocco
and France) with an identical haplotype that was unrelated to our
haplotype, which suggests that the mutations occurred indepen-
dently of each other.
The p.R1164X mutation occurs at a nonconserved arginyl
residue, and the nine chromosomes carrying this mutation
represent five haplotype groups. Two of these groups represent
two common founder alleles for this mutation, one of which is of
British origin. The additional haplotypes suggest also a founder-
independent occurrence of this mutation, making this location is a
potential mutation hotspot.
Similarly to p.R1164X, the six chromosomes that carry the
p.Q378X mutation represent four independent haplotypes. One
haplotype comprises three identical disease alleles that originate
from Italy; however, the detection of four independent haplotypes
suggests that most of the mutations arose independently in accord
with the proposed mutation mechanism of gene conversion
[Cai et al., 2001].
Distribution of Mutations in ABCC6 and Possible
Mechanisms for Loss of Gene Function
Analysis of the topology of PXE mutations in the ABCC6
protein (Fig. 1) clearly shows a distinct distribution of mutations to
particular protein domains. While nonsense, frameshift, deletion,
and splice-site mutations can occur at any point along the protein,
the majority of missense mutations (28/32 (87.5%) in our study)
occur within the cytoplasmic domains of the protein. The
remaining four missense mutations (4/32, 12.5%) lie within the
transmembrane domains of the protein. To date, no missense
mutations have been identified within the extracellular domains.
For the various mutations that result in a truncated protein, it
has been shown that nonsense-mediated decay is the mechanism
for the loss-of-function of the protein in these cases of PXE
[Bergen et al., 2000; Le Saux et al., 2000, 2001; Ringpfeil et al.,
2001; Hu et al., 2003a,b]. This mechanism appears to be
independent of the position of such mutations within the protein.
A detailed analysis of missense mutations within the cytoplasmic
domains of the ABCC6 protein reveals a distinct clustering of
these mutations within the four cytoplasmic subdomains. Nine
missense mutations occur within the cytoplasmic loops of the first
and second transmembrane domains, not including the NBF1
region. Five missense mutations occur within the nucleotide-
binding-fold region one. Twenty missense mutations lie within the
cytoplasmic loops of the third transmembrane domain, but not
within the NBF2 region. Seventeen missense mutations occur
within the NBF2 region. Therefore, 72.5% (37/51) missense
mutations cluster within the c-terminal one-third of the protein,
and are concentrated within the last cytosolic loop that contains
the NBF2 region. This unequal distribution suggests that the
c-terminal end of the protein, particularly the NBF2 region, is
more critical for the function of the protein. While a distinct
function of the NBF regions in the transport activity of ABCC6
has not yet been demonstrated, functional analyses have been
undertaken for the closely related ABCC1 protein [Gao et al.,
2000; Hou et al., 2000; Nagata et al., 2000]. While mutations
around the NBF1 of ABCC1 resulted in a decrease of transport
activity by approximately 70%, mutations around NBF2 comple-
tely abolished the transport function of the protein. Because
of the close structural relationship between both proteins, such
functional roles are likely for ABCC6, and could explain the
different clustering of missense mutations around different
cytosolic subdomains of ABCC6. It is known that the transmem-
brane domains determine the substrate specificity of ABC
transporters [Higgins, 2001]. Therefore, it is likely that missense
mutations within these domains can change the substrate
specificity of ABCC6 and subsequently cause substrate accumula-
tion, as was shown for glycosaminoglycans in PXE skin [Smith
et al., 1962, 1964]. Alternatively, mutations affecting the
transmembrane domains could change the correct integration of
the protein into the cell membrane, also leading to a loss of
function. Other missense mutations within the cytosolic domains
could either affect substrate specificity through an unidentified
mechanism or disrupt the correct folding of the protein necessary
for its proper function. While the correct folding of ABCC7 has
been proposed to depend on the integrity of the NBF1 region
and its interaction with surrounding domains, particularly the
NBF2 domain [Dalemans et al., 1991; Pollet et al., 2000], a similar
loss-of-function mechanism can be proposed for ABCC6
mutations (L677P and R760W) within or around NBF1 (R807W
and R807Q).
Common AminoAcid Substitutions Among Di¡erent
ABC Proteins in Distinct Human Genetic Diseases
The comparison of PXE-causing ABCC6 mutations with those
in other ABC proteins that cause other human genetic diseases,
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such as cystic fibrosis (ABCC7) and Dubin-Johnson syndrome
(ABCC2), revealed some common amino acid mutations within
highly conserved regions among these proteins. R760W in ABCC6
aligns with R768W in ABCC2, and R765Q in ABCC6 is
comparable with R560T in ABCC7. These mutations lie within
the NBF1 between the Walker C and Walker B motifs. R1030X in
ABCC6, and R1066X in ABCC2 map to conserved arginyl
residues among both genes within the first cytoplasmic loop of the
third transmembrane domain. R1150H in ABCC2 aligns with
R1114H in ABCC6 within the second cytosolic loop of TMD2.
R1066C in ABCC7 matches R1138W, P, or Q in ABCC6, and
R1162X in ABCC7 matches R1235W in ABCC6. Within the
second NBF, R1357W in ABCC6 compares to R1392M in ABCC2.
These common amino acid substitutions among several ABC
transporters provide additional support for the importance of the
domains in which genes are localized, in terms of their function.
Evidence forAdditional ABCC6^ Pseudogenes
The identification of nonallelic polymorphisms within the
duplicated region of ABCC6 that do not belong to the two
known pseudogenes suggests the existence of additional pseudo-
genes within the duplicated region on chromosome 16p13.1 that
have not yet been identified and are not represented within the
human genome reference sequence for this region. The positional
cloning of this genomic region is complex because of these
duplication issues, and is likely to be incomplete. This may hamper
the identification and characterization of as yet unidentified PXE
mutations, such as the exact molecular deletion breakpoints for
some of the large deletions. The occurrence of several distinct
breakpoints for large deletions suggests some instability of the
genomic structure around ABCC6 that may influence disease
manifestation. For example, a role for somatic mutation in PXE
has not been ruled out.
Impact of the Molecular Genetics of PXE on the
Diagnostic Criteria and Clinical Diagnosis
A comparison of the molecular genotype and haplotype data
described here, with the clinical data available for each individual
within and among the families analyzed, demonstrated that sib
pairs that met the category I diagnostic criteria shared a
homozygous or compound heterozygous haplotype. This suggests
that two disease alleles causing a complete loss-of-function of
ABCC6 are necessary for the complete expression of the
phenotype. Family members with an incomplete expression of
the phenotype have no more than one disease allele (that causes
haploinsufficiency in these cases) in common with those siblings
that express a complete phenotype. Because this observation was
consistent across all of our large set of families, these molecular
(haplotype) data enhance and refine the consensus diagnostic
criteria. Currently the category I diagnostic criteria define only
patients who express either a complete phenotype at the time of
diagnosis or develop a complete phenotype in the future as the
result of loss-of-function of ABCC6. Category II diagnostic criteria
characterize disease carriers that express a forme fruste of the
disease as the result of haploinsufficiency, but never as the full
phenotype. These PXE carriers have been ‘‘overdiagnosed’’ with
PXE because a skin biopsy from nonlesional skin showed minimal
changes on a von Kossa stain that were inappropriately considered
diagnostic of PXE. This explains to a large extent the clinical
confusion about extremely heterogeneous disease expression
among the same and different generations within PXE families.
It also explains confusion regarding the mode of inheritance of
PXE [Neldner and Struk, 2002]. While the consensus conference
clearly distinguished between category I and II diagnostic criteria,
in clinical practice this distinction has not been made, with
confusing consequences [Hu et al., 2003a]. This is partly because
more sophisticated methods have been employed to identify
minimal changes in nonlesional skin in an attempt to detect
‘‘PXE’’ more thoroughly and cost-efficiently [Hausser and Anton-
Lamprecht, 1991].
The thorough mutation analysis presented here will influence
the diagnosis of the disease. The combined haplotype and clinical
data are consistent with loss-of-function mutations in ABCC6
being PXE-causative in a homozygous or compound heterozygous
allelic state, in all affecteds, in all PXE families.
NoDominant Form of PXE
The results presented here demonstrate a recessive mode of
inheritance in all of the families studied. For those families that
exhibit PXE in two or more generations, this phenomenon can be
explained by a pseudo-dominant inheritance mechanism. Our
results are in agreement with other studies [Le Saux et al., 2001;
Chassaing et al., 2004]. We found no evidence for a dominantly
inherited PXE, and did not observe any case in which
haploinsufficiency (heterozygotes with a single large deletion
allele) caused the complete PXE phenotype. This clarification will
have a considerable impact on genetic counseling for members of
PXE families, such as in stratifying the risk that relatives of
affected individuals will develop the disease, and, most impor-
tantly, the risk that they will have affected children. Until now,
incomplete mutation screening and inappropriate employment of
diagnostic criteria have increased the potential for an incorrect
diagnosis, with the consequence that genetic counseling has
sometimes been based on inaccurate information.
Genotype-Phenotype Observations
We found no evidence from detailed clinical and molecular
analyses that the variable PXE phenotype was significantly
influenced by different types of mutations in ABCC6. While the
PXE phenotype is mainly the result of a complete loss-of-function
of both ABCC6 gene alleles, the exact molecular pathway from
genotype to phenotype remains elusive at this time. Further
studies are needed to shed light on the pathogenesis of PXE.
ABCC6 is expressed mainly in the kidney and liver [Belinsky and
Kruh, 1999; Kool et al., 1999; Langmann et al., 2003], and both of
these organ systems are responsible for detoxifying the body.
Because the loss-of-function of ABCC6 in these organ systems
and/or in local tissues is likely to cause PXE, the variability of the
phenotype may be considerably influenced by other factors that
are independent of ABCC6. Such factors may be genetically
determined, such as the transport capacity for PXE metabolites by
other, similar transporter systems in the body. Environmental
factors, such as the substances and metabolites transported
through ABCC6, are also likely to influence the progression of
the disease. Since transporter systems play a ubiquitous role in the
homeostasis of the body, they are redundantly present throughout
the membranes of different tissue cells, and the loss of ABCC6
function may in part be compensated for by other transport
systems that may differ among different tissues affected by PXE.
This compensation for ABCC6 transport function may contribute
to the variable phenotype, since it may be determined by the
complex genetic makeup of each individual. Additionally, the
distinct symptoms of PXE disease expression may be influenced
independently of the type of ABCC6 mutation by environmental
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factors such as exposure to or avoidance of metabolites that are
usually transported by ABCC6. Indeed, Neldner [1988] presented
preliminary data indicating that dietary calcium intake influences the
extent of skin lesions, and that the number of pregnancies in women
with PXE may influence the clinical course of the disease. The
occurrence of an acquired PXE-like phenotype in patients with
severe renal failure [Nickoloff et al., 1985; Sapadin et al., 1998]
suggests that the loss of ABCC6-transport function in the kidney
also likely contributes to the hereditary phenotype of PXE. While the
expression of the PXE phenotype may be influenced by an unknown
number of factors that are independent of ABCC6, the genetic basis
for the disease appears to be homogeneous in all families analyzed in
this study, in contrast to previous claims [Pope, 1975, 1974b]. The
current molecular analysis of this family cohort will contribute to our
understanding of the molecular basis of PXE, assist in clinical and
molecular diagnoses, and clarify the clinical variability, genetic locus
homogeneity, and mechanism of inheritance of this disease.
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Chapter 4. Common Chromosomal Fragile Sites: 





Based on a correlation between the location of various common fragile sites on 
chromosomes and known DNA instability and / or ‘cancer genes’, Yunis and Soreng (1984, 
Science, 226, 1199-1204) proposed that common chromosomal fragile sites were predisposed 
to DNA instability in cancer and that the genes perturbed by this instability contributed in some 
way to cancer cell biology.  Experiments at the most readily inducible common fragile site, 
FRA3B, appeared to support this hypothesis in identifying both the region as one of frequent 
instability in cancer and also the FHIT gene spanning the fragile site as one with affected gene 
expression and a functional contribution to cancer.  Despite these findings there was much 
scepticism by both the field in general and by my immediate colleagues as to the generality of 
such a relationship at its contribution (if any) to cancer cell biology.  Therefore, in order to 
assess whether these features were common to other chromosomal fragile site loci I initiated 
studies at the second most readily induced common chromosomal fragile site, FRA16D.  This 
work identified the region of as one where various forms of DNA instability did occur in cancer 
and a gene (FOR or WWOX) that spanned the region and appears to contribute to cancer cell 
biology (refs #45, 46 ).  I established collaborations with Drs Venter and Chenevix-Trench, 
principally in order to obtain tumour samples and cancer cell lines.  The crucial cytogenetics 
experiments were conducted, interpreted and supervised by Elizabeth Baker and her 
colleagues in the Cytogenetics Unit, WCH. 
 
In addition to identifying the FOR (WWOX) gene, our lab addressed several key 
aspects of the mutation mechanism that gives rise to homozygous deletion at the FRA16D 
fragile site in cancer cells. First, the timing of the deletion event in the neoplastic process, as it 
is assumed that early events are more likely to be causal rather than consequential. Secondly, 
the relationship between FRA16D associated deletion and another form of deletion (loss-of-
heterozygosity, LOH) known to occur at high frequency in certain cancers in the 16q23.2 
region. Thirdly, the nature of the deletion endpoints and any identifiable characteristics of the 
sequences at or near these deletion endpoints. Fourthly, the extent of ‘genome-wide’ instability 
that occurs in FRA16D deleted cell lines. Finally, the effect of FRA16D associated deletions on 
the cytogenetic expression of the FRA16D fragile site. This work was published in the journal 
Human Molecular Genetics (ref #48) with a figure appearing on the issue cover. 
 
We have since used a combination of Drosophila genetics and biochemical 
approaches to discover the normal function of the Wwox gene.  Our initial efforts were 
thwarted by difficult to detect background mutations (refs #47, 49), We have subsequently 
found that a significant proportion of Drosophila Wwox interactors identified by proteomics and 
microarray analyses have roles in aerobic metabolism. Functional relationships between 
Wwox and either CG6439/isocitrate dehydrogenase (Idh) or Cu–Zn superoxide dismutase 
(Sod) were confirmed by genetic interactions. In addition, altered levels of Wwox resulted in 
altered levels of endogenous reactive oxygen species. Wwox (like FHIT) contributes to 
pathways involving aerobic metabolism and oxidative stress, providing an explanation for the 
‘non-classical tumour suppressor’ behaviour of WWOX. Fragile sites, and the genes that span 
them, are therefore part of a protective response mechanism to oxidative stress and likely 
contributors to the differences seen in aerobic glycolysis (Warburg effect) in cancer cells. This 
work was also published in the journal Human Molecular Genetics (ref #50). 
 
 Our most recent experiments with Wwox demonstrate an interrelationship with 
metabolism – Wwox is both a regulator of metabolism and is regulated by metabolism (ref 
#51). An insight in to the contribution Wwox plays in cancer was revealed by competition 
experiments that showed a role for Wwox in the elimination of tumourigenic cells (ref #52). 
Furthermore Wwox acts to moderate the mitochondrial respiratory – a likely contribution to the 
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ABSTRACT
It has been proposed that common aphidicolin-inducible fragile sites, in
general, predispose to specific chromosomal breakage associated with
deletion, amplification, and/or translocation in certain forms of cancer.
Although this appears to be the case for the fragile siteFRA3B and may
be the case forFRA7G, it is not yet clear whether this association is a
general property of this class of fragile site. The major aim of the present
study was to determine whether theFRA16D chromosomal fragile site
locus has a role to play in predisposing DNA sequences within and
adjacent to the fragile site to DNA instability (such as deletion or trans-
location), which could lead to or be associated with neoplasia. We report
the localization of FRA16D within a contig of cloned DNA and demon-
strate that this fragile site coincides with a region of homozygous deletion
in a gastric adenocarcinoma cell line and is bracketed by translocation
breakpoints in multiple myeloma, as reported previously (Chesi, M., et al.,
Blood, 91: 4457–4463, 1998). Therefore, given similar findings at the
FRA3B and FRA7G fragile sites, it is likely that common aphidicolin-
inducible fragile sites exhibit the general property of localized DNA
instability in cancer cells.
INTRODUCTION
The idea that fragile site loci might have a role in the chromosomal
instability observed in cancer was originally proposed by Yunis and
Soreng (1) on the basis of a concordance between the physical
locations of chromosomal fragile sites and cancer breakpoints and/or
cancer-associated genes. This proposal was initially supported by a
statistical analysis (2). Examples were subsequently put forward to
disprove the hypothesis (3, 4), whereas other studies revealed the lack
of an association between the presence of a heritable fragile site
within a family and any increased risk of cancer (5). Initially, no
distinction was made between “rare” fragile sites, found in only a
small proportion of the population, and “common” fragile sites, found
in all individuals. Even with such a distinction, further analysis (6)
failed to confirm a statistical association between common fragile
sites and nonrandom chromosome breakpoints in cancer cells. Chro-
mosome breakage is (like fragile sites themselves) a visible cytoge-
netic manifestation of chromosomal instability. Other forms of DNA
instability have more recently become apparent as cryptic (cytogenet-
ically invisible) deletions (7). Such deletions can be detected as LOH4
at polymorphic loci. Chromosomal regions that are deleted in cancer
cells are thought, and in some instances found, to contain tumor
suppressor genes (8, 9).
Recent detailed molecular analysis of the common fragile site
FRA3Bregion revealed a predisposition to localized deletion that is
frequently observed in certain forms of cancer (7, 10). The cancer-
associatedFRA3B deletions can result in inactivation of theFHIT
gene, an event that is thought to have a role in tumor growth (11).
Although the DNA sequence of the region containingFRA3B has
been determined, neither the molecular basis for the cytogenetic
expression of the fragile site nor the cancer-associated instability has
been clearly resolved as yet (12). There has been considerable con-
troversy and conflicting data regarding the role ofFHIT in cancer
(13–15). In one study using neoplastic cells that hadFRA3Bdeletions
and that therefore were deficient in FHIT protein, “replacement” with
stable, overexpressed FHIT protein did not alterin vitro or in vivo
properties of these cells (16). In another study (11), replacement of
FHIT protein in cancer cells suppressed their tumorigenicity. It re-
mains to be assessed whether dysregulation of theFHIT gene, and
therefore, the inappropriate “cell cycle” appearance or cellular com-
partmentalization of FHIT protein is the mechanism for its contribu-
tion to neoplasia.
Another common fragile site,FRA7G,has also been shown to be
located within a;1-Mb region of frequent deletion in breast and
prostate cancer (17, 18), as well as squamous cell carcinomas of the
head and neck, renal cell carcinomas, ovarian adenocarcinomas, and
c lon carcinomas (19). The human caveolin-1 and -2 genes are
located within the same commonly deleted region asFRA7G. Caveo-
lin-1 has been shown to have a role in the anchorage dependant
inhibition of growth in NIH 3T3 cells (20). The caveolins are there-
fore candidates for the tumor suppressor gene that is presumed to be
located in theFRA7Gregion (19).
Fragile sites have been found to act as amplification boundaries (21,
22) in selection experiments; however, a role in cancer-associated
amplification is yet to be demonstrated. It is not yet clear whether the
reported instances of association are due to a predisposition conferred
by the fragile site locus or, alternatively, the selection of an associated
gain and/or loss of gene function.
The long arm of chromosome 16 is of particular interest in cancer
genetics because it exhibits frequent loss in tumor cells (23, 24). It is
also the location of the rare chromosomal fragile siteFRA16Bat
16q22.1 (25) and the common, aphidicolin-inducible fragile sites
FRA16C at 16q22.1 andFRA16D at 16q23.2.FRA16D has been
localized within a large overlapping region of chromosomal instability
in breast and prostate cancer as defined by LOH (23, 24). In addition,
a gene for Wilms’ tumor has been mapped to 16q (26), and a gene for
familial leukemia has been mapped to 16q21–23.2 (27).
We have therefore physically mapped theFRA16Dregion in detail
to provide markers for identifying any possible relationship between
this fragile site and DNA instability in neoplasia. This analysis reveals
the existence of an intimate relationship between the location of
FRA16Dand homozygous deletions in various tumors (this report and
Ref. 28), culminating in the coincidence of two tumor cell DNA
breakpoints with the most likely position of the fragile site.
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Isolation of DNA Probes and YACs in theFRA16D Region. Nine DNA
probes, ACH202 (D16S14), c311F2, c302A6 (D16S1075), c301F10
(D16S373), 16-87 (D16S181), c306D2, 16-08 (D16S162), c307A12, and CRI-
0119 (D16S50), which had been physically mapped into the 16q23 region (29),
were chosen for FISH againstFRA16Dexpressing chromosomes. Four of these
markers mapped within the same somatic cell hybrid breakpoint interval
defined by the cell lines CY113(P) and CY121 (29). One of these, c306D2
mapped proximal toFRA16Dby FISH, whereas the others, c307A12, CRI-
0119, and 16-08 mapped distal toFRA16D. These probes were therefore used
as starting points to isolate a contig of cloned DNA spanningFRA16D.In the
Los Alamos National Laboratory database, a STS sequence from c306D2 was
found within the CEPH YACs My903D9, My912D2, and My933H2, whereas
a STS in c307A12 was found in My891F3 and My972D3. These YACs were
obtained from CEPH and the prepared DNA subjected toPstI digestion,
Southern blotted, and probed with 16-08, 16-87, CRI-0119, c306D2, and
c307A12 in succession to confirm their content. In addition, a search of the
Whitehead Institute database revealed that the two sets of YACs were joined
into a contig by the YACs My801B6, My845D9, and My944D8. Each of these
YACs was used as template DNA to assess STS content (D16S518,
Afma336yg9, WI2755, STSG-10102,andD16S3029) and subjected to FISH to
assess position with respect toFRA16D(Fig. 1B).
Additional Probes, STSs, and BACs from theFRA16D Region. Addi-
tional probes were generated from the YAC 801B6 by subcloningPstI digests
of YAC DNA and screening with total human DNA as probe. These subclones
were digested withHincII to identify and isolate nonrepetitive DNA fragments
as probes. This generated markersH13m, H22s, H23m, H29m,and H40m.
Genome System Inc. BAC library filters were screened with the probes
D16S518, Afma336yg9, WI-2755, STSG-10102, H22s, H29M,andD16S3029
and nine BAC clones, including 379C2, 325M3, and 353B15, were identified.
An additional STS, named 2AS, was established by “bubble” PCR from the
end fragment of BAC 353B15 and was isolated as described by Geczet al.
(30). Briefly, the BAC DNA was digested withAluI and ligated to the annealed
bubble linkers. The final PCR was carried out with a combination ofN tI-A
bubble primer and Sp6-promoter primer as described except that an annealing
temperature of 55°C was used. These STSs and hybridization probes were used
to establish restriction maps of the YAC My801B6 and the BACs (Fig. 2A).
Subcloning and Contig Assembly.The YAC My801B6 and the BAC
325M3 were used as DNA templates for establishing al subclone libraries in
lGEM11 orlGEM12 vectors (Promega) according to the supplier’s protocol.
My801B6 and 325M3 appeared to have intact human DNA inserts, based on
comparative pulsed field gel mapping of the YACs and BACs across the region
(data not shown).
FISH. FRA16D-expressing metaphases were obtained from peripheral
blood lymphocytes by standard methods. Briefly, cultures were grown for 72 h
in Eagle’s minimal essential medium, minus folic acid, supplemented with 5%
FCS. Induction ofFRA16Dwas with 0.5mM aphidicolin (dissolved in 70%
ethanol) added 24 h before harvest (31).
DNA clones were nick translated with biotin-14-dATP, preassociated with
6 mg/ml total human DNA, hybridized at 20 ng/ml to metaphase preparations,
and detected with one or two amplification steps using biotinylated antiavidin
and avidin-FITC as described previously (32). Hybridization signal was visu-
alized using an Olympus AX70 microscope fitted with single pass filters for
49,6-diamindino-2-phenylindole (for chromosome identification), propidium
iodide (as counterstain), and FITC.
FRA16D-expressing chromosomes were scored for signal only when the
width of the fragile site gap was greater than the width of one chromatid, so
that signal was unambiguously proximal or distal to the gap (Fig. 3). Only
fluorescent dots that touched chromatin were scored as signal; the few fluo-
rescent dots that lay within the fragile site gap but did not touch proximal or
distal segments were therefore not scored as signal, because there was a
possibility that they comprised nonspecific background.l clones that gave
very poor FISH results (high nonspecific hybridization to other chromosomes)
were not able to be scored with respect to the fragile site. This is likely to be
due to the large amount of repetitive DNA within these particular clones, as
determined by their DNA sequence.5
Tumor Cell Lines. The tumor cell lines LoVo, HT29, Kato III, SW480,
AGS, MDA-MB436, and LS180 were purchased from the American Type
Culture Collection. LoVo and AGS cells were grown in Ham’s F-12 medium
with 2 mM L-glutamine, 10% FCS in 5% CO2, Kato III cells were grown in
RPMI 1640 with 2 mM L-glutamine, 20% FCS in 5% CO2; HT29 cells were
grown in McCoy’s 5a medium with 1.5 mM L-glutamine, 10% FCS in 5% CO2;
LS180 cells were grown in Eagle’s minimal essential medium with 2 mM
L-glutamine, Earle’s salts, nonessential amino acids, 10% FCS in 5% CO2;
SW480 cells were grown in Leibovitz’s L15 medium with 2 mM L-glutamine
and 10% FCS; and MDA-MB-436 cells were grown in Leibovitz’s L15 with
16 mg/ml glutathione and 0.026 units/ml insulin.
PCR Detection of Homozygous Deletion in Tumor Cell DNAs.PCRs
for the detection of individual STSs from across theFRA16Dregion were
duplexed (33) with control PCRs from the dystrophin gene on the X
chromosome (DMD Pm or DMD49, Ref. 34) or the APRT gene on
chromosome 16 (35). This allowed verification that the PCR was working
in the absence of aFRA16Dregion PCR product (Fig. 4). PCR primers for
Alu29, 17Sp6, Alu20, 178poly, 5.1A6, RD69, and IM7 were as described
by Paige et al. (28). For 504CA, the forward primer was 59-AACA-
CAGCTCTTATCACATCC-39, and the reverse primer was 59-TGGCTG-
TATTTGTCAGAACTG-39. Other primers and their GenBank [or Genome
Data Base (GDB)] accession numbers were as follows:D16S518,Z24645;
Afma336yg9(GDB 1222843);WI2755, G03520; STSG-10102,Z23147;
D16S3029(GDB 605884);WI-17074,G22903;IM9, R05832;D16S3096,
5 K. Ried et al., manuscript in preparation.
Fig. 1. Positional cloning ofFRA16Dand loca-
tion of LOH and translocation in cancer.A, the
locations of LOH regions in breast and prostate
cancer and the approximate location of the
FRA16D fragile site are indicated with respect to
genetic markers (downward arrows) in the 16q23.2
region. Markers in the vicinity ofFRA16D are
shaded. The approximate location as determined by
Chesiet al. (43) of multiple myeloma breakpoints
and the c-MAFgene (bar) are also shown byup-
ward black arrows. Not to scale.B, map of the
contig of YAC subclones across theFRA16D re-
gion with respect to genetic markers andFRA16D.
Open boxes,YACs that map by FISH proximal to
FRA16D; gray boxes,YACs that spanFRA16D;
black boxes,YACs that map distal toFRA16D. Not
to scale.
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Z53592, andD16S516(GDB 200080). PCRs for GenBank accession num-
ber AA368108 (forward, 59-TAATCCTCAGCCTCTAGAATGCCT-39; re-
verse 59-GTATGATGATTTTCAGGGAG-AAAC-39) and GenBank acces-
sion number AA398024 (forward, 59-TGTCCTCAACTGATTCTTACAAAC-3;
reverse, 59-TCAATGGGTTAGGCACAGACC-39) were derived from partial se-
quence analysis of BAC353B15.5 Control PCRs forFRA3B deletions were
D3S1234 (GenBank accession number 186387),D3S1300 (188420), and
D3S1841(254090).
Fig. 2. Positional cloning ofFRA16Dand the extent of heterozygous and homozygous deletion in the AGS tumor cell line.A, pulsed-field gel map of;1 Mb of the right-hand side (RHS)
of YAC My801B6 and the location of BACs, genetic markers, and STS markers (key markers areboxed). Restriction sites between Afma336yg9 and WI2755 are shown inB. The AGS stomach
cancer cell line homozygous deletion is indicated:shaded circles,presence of PCR products for the STS markers;open circles,absence of PCR products for the STS markers. Maximal region
of heterozygous deletion in AGS cell line is indicated by polymorphicD16S518andD16S3029PCR products, indicated as allelesA andB. The two AGS cell line chromosome 16s are indicated
by shaded bars.B, restriction map of the criticalFRA16Dregion (Afma336yg9to D16S3029) showing the location of key members of thel subclone tile path used for FISH in Fig. 3. Clones
designatedl1-n are from 325M3; others are from 801B6.Open boxes,those subclones found to map proximal to the fragile site (on the basis that.85% of their FISH signals were proximal
to FRA16D);gray boxes,those that appear to span the fragile site (,85% on one side or other ofFRA16D);black boxes,those that are distal to the fragile site (on the basis that.85% of their
FISH signals were distal toFRA16D).l clones that gave high background on FISH were not scored. These and otherl clones for which FISH data were not obtained are included asthin boxes.
STS localization of the AGS homozygous breakpoints are indicated by the presence (had d circles) and absence (open circles) of PCR products.
Fig. 3. FISH of l subclones againstFRA16D
expressing chromosomes. Each panel contains two
FRA16D expressing partial metaphases, with and
without FISH signal merged. In each case, the
width of the gap or break at the fragile site is greater
than the width of the chromatid.a, l504 showing
signal proximal (P) to FRA16D;b, l181 showing
signal proximal and distal (D) to FRA16D;c, l191
(top) and l8 (bottom) showing signal distal to
FRA16D. Images of metaphase preparations were
captured by a cooled CCD camera using the Chro-
moScan image collection and enhancement system
(Applied Imaging International Ltd.). FISH signals
and the 49,6-diamindino-2-phenylindole banding
pattern were merged for figure preparation.
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RESULTS
Positional Cloning of FRA16D. A contig of YAC clones was
established in the 16q23.2 region between markersc306D2 and
c307A12,which were found by FISH to map proximal and distal to
FRA16D, respectively (Fig. 1B). The individual YACs from this
contig were also used as hybridization probes to further localize the
fragile site. These experiments identified the YAC 801B6 as spanning
FRA16D, and therefore, this YAC was used as a source of DNA for
subcloning the region to provide shorter DNA fragments for further
refinement of the fragile site position. In addition, BAC clones were
identified from the region to provide redundancy of cloned human
DNA in an effort to avoid potential problems of instability of human
DNA in YACs, as has been noted previously for other fragile site
regions, includingFRAXA(36),FRA10B(37),6 and a Chinese hamster
aphidicolin-inducible fragile site region (38).
A pulsed-field gel restriction map of YAC 801B6 was constructed
by usingHincII restriction fragment subclones of the YAC for use as
hybridization probes (H13m, H22s, H23m, H29m, and H40m; Fig.
2A). The position of the BACs (379C2, 325M3, and 353B15) with
respect to the YAC restriction map was determined by both the
restriction mapping of the BACs and the positioning of common
markers by PCR or hybridization (Fig. 2A). The STS (D16S518,
Afma336yg9, WI2755, STSG-10102,and D16S3029) content of the
YACs and BACs was also determined to assist in map construction.
Subclone libraries of DNA from YAC 801B6 and BAC 325M3
6 O. Handt, personal communication.
Fig. 5. Duplex PCR deletion detection at theFRA16D locus in tumor cell lines. PCR
products from the duplex of STSG-10102 and dystrophin DMD Pm were subjected to agarose
gel electrophoresis and ethidium bromide staining. Template DNAs were seven tumor cell
lines and blood bank and no DNA controls. Markers areHpaII-digested pUC19. The position
of the STSG-10102 and DMD Pm PCR products are indicated by thelarg shaded arrows,
whereas the primer dimer PCR artifact is indicated by thesmall arrow.
Fig. 4. FISH mapping of thel subclone tile path across
FRA16D. The individual clones were scored against
chromosomes in which theFRA16D gap or break was
greater than the chromatid width. Each increment repre-
sents a single FISH signal.n 5 number of chromosomes
scored. Scores were plotted as proximal (p) and distal (d)
with respect toFRA16D. Maximum location forFRA16D
is indicated byarrows. Location of BAC clones 325M3
and 353B15 is also shown. The boxedl contig subclones
indicate those for which FISH signal results with respect
to the FRA16D fragile site were obtained:open boxes,
.85% signal proximal toFRA16D;gray hatched boxes,
spanning (,85% signal on one side or other ofFRA16D);
black boxes,.85% signal distal toFRA16D. Although
this figure is not to scale, the location of thel clones can
be determined from their position in Fig. 2.Thin boxes,l
clones for which FISH data were not obtained.
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were generated using thel vectors lGEM12 andlGEM11 (Pro-
mega), respectively, and assembled into a contig by end-fragment
hybridization and restriction mapping. The integrity of the YAC
restriction map was verified by comparison with that of the BACs
325M3 and 353B15. For the region between the BACs, the integrity
was verified by the use of long-range PCR using human chromosomal
DNA as template (data not shown).
Localization of FRA16Dby FISH. There have been difficulties in
determining the precise localization of common chromosomal fragile
sites using FISH [FRA3B(12, 39–41), FRA7G(17, 18), andFRA7H
(42)]. The FISH data have been interpreted as due to the fragile sites
being spread out over long DNA sequences (e.g.,hundreds of kilo-
bases) or that there are multiple fragile sites at a single locus. An
alternative explanation is that the DNA in the immediate vicinity of
the fragile site is not tightly “packaged” into chromatin. We therefore
chose to score only those chromosomes in which the width of the gap
or break at theFRA16D fragile site was greater than that of one
chromatid (Fig. 3). This approach was intended to reduce the possi-
bility that the “unpackaged fragile site DNA” might be looping back
over the distant side of the fragile site and therefore give a false
“spanning” signal, particularly for probes that are very close to or
within the fragile site region. In addition, although the use of pre-
reassociation in the hybridization process dramatically improved the
signal to noise ratio, it did cause repeat-rich regions to be poor
hybridization probes. This was particularly evident in theFRA16D
region, where there is an abundance of DNA repeat sequences of
various kinds.5
The results of the FISH experiments are plotted in Fig. 4. The
closest clearly proximal probe toFRA16D is l1–44, whereas the
closest unequivocally distal probe isl433. These probes map at a
distance of;200 kb apart. However, this 200-kb region includes
consistent scatter of distal signal aroundl1–38 andl1–27 and the
poor hybridization betweenl181 andl511 (due to repetitive DNA
content). Therefore, this 200-kb region defined by FISH analysis is
likely to be the maximum sequence required to defineFRA16D,rather
than provide any evidence that the fragile site is spread over such a
distance.
Detection of Homozygous Deletion in Tumor Cell Lines.The
FRA3B fragile siteFHIT gene intron 4 region is a frequent site of
deletion in various types of cancer (7). HomozygousFRA3Bdeletions
have been detected in various human adenocarcinoma cell lines,
including (gastric) AGS and Kato III; (breast) MDA-MB436; and
(colon) LoVo, HT29, SW480, and LS180 (7). Because these deletions
are somatic events that presumably occur as a result of exposure of
these cells to certain environmental factors (10), we chose to analyze
tumor cell lines that exhibitFRA3B deletions for the presence of
homozygous deletion at theFRA16Dlocus.
STSs that were either mapped to theFRA16Dregion (Fig. 1)7 or
generated from partial sequence analysis through the region (data
not shown) were used to screen for homozygous deletion in various
tumor cell line DNAs. The STSs were duplexed with a PCR from
the dystrophin locus as an internal control. The results for the
analysis of one of theFRA16D region markers, STSG-10102, is
shown in Fig. 5. Of the seven tumor cell lines tested, the stomach
tumor cell line AGS was found to be homozygously deleted at
STSG-10102 and a series of contiguous markers through the region
(Table 1), thus suggesting the presence of minimal deletions span-
ning the FRA16D region in each chromosome 16 present in the
AGS cell line.
The proximal boundary of the AGS homozygous deletion (Fig. 2B)
falls within the same interval (Alu20–178poly) as that of the HCT116
colon adenocarcinoma cell line homozygous deletion proximal
boundary described by Paigeet al. (28). This is also the most likely
location of FRA16D (Fig. 2). The distal boundary of the AGS ho-
mozygous deletion is within the same interval (IM7–IM9) of the
PEO4 ovarian adenocarcinoma cell line distal boundary (28). This
7 V. Watson, personal communication.
Table 1 PCR results for markers in the FRA16D region in various tumour cell lines
Marker
Cell line
LoVo HT29 Kato III SW480 AGS MDA-MB436 LS180 Positive controla Negative controlb
Control
D3S1234 1c 1 1 1 1 1 1 1 2
D3S1300 2 2 1 2 2 2 2 1 2
D3S1841 1 2 1 2
DMD49 1 1 1 1 1 1 1 1 2
16q
D16S518 1 1 1 1 1 1 1 1 2
Afma336yg9 1 1 1 1 1 1 1 1 2
Alu29 1 1 1 1 1 1 1 1 2
504CA 1 1 1 1 1 1 1 1 2
17Sp6 1 1 1 1 1 1 1 1 2
Alu20 1 1 1 1 1 1 1 1 2
AA368108 1 1 1 1 1 1 1 1 2
AA398024 (IM28) 1 1 1 1 2 1 1 1 2
178poly 1 1 1 1 2 1 1 1 2
WI2755 1 1 1 1 2 1 1 1 2
5.1A6 1 1 1 1 2 1 1 1 2
RD69 1 1 1 1 2 1 1 1 2
STSG-10102 1 1 1 1 2 1 1 1 2
IM7 1 1 1 1 2 1 1 1 2
IM2 1 1 1 1 1 1 1 1 2
IM4 1 1 1 1 1 1 1 1 2
WI-17074 (IM9) 1 1 1 1 1 1 1 1 2
D16S3029 1 1 1 1 1 1 1 1 2
D16S3096 1 1 1 1 1 1 1 1 2
D16S516 1 1 1 1 1 1 1 1 2
APRT 1 1 1 1 1 1 1 1 2
a Peripheral blood leukocyte (blood bank) DNA.
b No added DNA.
c 1, present;2, absent.
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coincidence of breakpoint boundaries suggests the likelihood of a
common mechanism of deletion.
Detection of Heterozygous Deletion in AGS Tumor Cell Line
DNA. The maximal extent of heterozygous deletion in the AGS
tumor cell line in theFRA16Dregion was determined by genotyping
polymorphic markers. The markersD16S518and D16S3029both
gave two alleles indicating proximal and distal outer limits to the
deletion of either chromosome 16 in AGS cells (Fig. 2A). The
markersAfma336yg9and 504CAwere uninformative and therefore
did not aid in delineating the limits of heterozygous deletion.
DISCUSSION
The region in which the chromosomal fragile siteFRA16D is
located has recently been shown to be associated with two types of
chromosomal instability in cancer. In multiple myeloma, translocation
of immunoglobulin loci into the 16q23 region causes the dysregula-
tion of the c-MAFproto-oncogene on the affected allele. Although
these breakpoints are spread over at least 500 kb, they bracket both the
c-MAF gene and theFRA16D fragile site (Ref. 43 and Fig. 1). The
dysregulated expression results in elevated c-MAF mRNA levels,
which is thought to contribute to neoplasia. These translocations were
not identified by conventional cytogenetic analysis. Their detected
frequency in multiple myeloma cell lines suggests an incidence of
;25%.
Using representational difference analysis to identify differences
between the genomes of normal and tumor cells, theFRA16Dregion
has also been shown to be the site of homozygous deletion in three
different types (lung, ovary, and colon) of adenocarcinoma (28). The
commonly deleted region includesFRA16D, with the minimal dele-
tion in colon tumor cell line corresponding almost exactly to the
;200-kb region shown by our FISH studies to span theFRA16D
fragile site. If common aphidicolin fragile sites confer susceptibility to
mutagen induced DNA instability in cancer, then tumor cell lines that
have been shown to have such instability at one fragile site are likely
to exhibit instability at another fragile site. By analyzing tumor cell
lines with knownFRA3Bdeletions, we have found that the AGS cell
line derived from a stomach cancer exhibits homozygous deletion
spanningFRA16D. Heterozygosity of the flanking markersD16S518
and D16S3029indicates that the chromosome 16 deletions are con-
fined to the immediate vicinity ofFRA16D.
Taken together, these deletion data confirm the hypothesis that
FRA16D is associated with specific chromosomal instability in can-
cer. Each of the common aphidicolin chromosomal fragile sites that
have been analyzed in detail (FRA3B, FRA7G,andFRA16D) has been
found to exhibit this association, supporting the hypothesis that this is
a general property of this class of fragile site. There are an additional
75 such fragile sites in the human genome (31), and presumably, these
are also targets for DNA instability in cancer cells. Although found in
all individuals, the different common fragile site loci are found at
different frequencies in metaphase cells, withFRA3Bbeing the most
frequently observed, followed byFRA16D. The molecular basis for
this variation is not yet known. It may be that cytogenetic expression
is an indicator of the relative susceptibility of the region to DNA
instability. Different individuals do exhibit variation in the level of
common fragile site expression, and it will be intriguing to determine
whether the level of cytogenetic expression in an individual correlates
with the likelihood of that individual having DNA instability (such as
deletion, amplification, or rearrangement) at a given common fragile
site.
The mouseFhit gene exhibits instability in mouse tumor cell lines
(44), similar to its human homologue, and it also spans a region
known to contain a common, aphidicolin-inducible fragile site (45).
This apparent conservation of the relationship between theFHIT gene
and a common fragile site during evolution suggests that there may be
a functional association between regions of late DNA replication
(defined by this class of fragile site) and a particular type of gene, the
product of which has a role in coupling DNA replication and cell
division (as has been proposed forFHIT; Refs. 46 and 47).FRA16D
is of the same (common, aphidicolin-inducible) classification as
FRA3BandFRA7G,and therefore, if the DNA instability atFRA3B
andFRA7Greally is a consequence of the sequences that cause this
class of fragile site, then one would expectFRA16Dto behave in a
similar manner.
What, then, are the possible biological consequences ofFRA16D
deletion? Given that the observed deletions are homozygous, they are
therefore likely to represent the loss of a negative function (e.g.,tumor
suppressor) rather than the gain of a tumor promoting function. If the
analogy with theFRA3Blocus holds, then a gene either spanning or
t least partially within theFRA16Dcommonly deleted region may
contribute to neoplasia as a consequence of quantitative and/or qual-
itative effects of the deletion. Alternatively, the proximity of the
FRA16D deletions to the c-MAFgene suggests that they have the
potential to affect c-MAFexpression. TheFRA3B fragile site is
associated with a region of “late” replication (48), as are the rare
fragile sitesFRAXAandFRAXE(49, 50). Assuming that replication
timing is affected by proximity to fragile site loci and given the
coupling of replication with transcription, the deletion of theFRA16D
region may lead to an alteration in the timing, with respect to the cell
cycle, of the expression of genes in the area, including c-MAF.
The present study adds further evidence to the proposal that DNA
instability is a common property of common fragile site loci, and there-
fore, the issue of whether fragile sites have an active or passive role in the
mutation process requires further investigation. For example, it is not
clear whether cytogenetic manifestation of fragile sitesin vivo is neces-
sary to render the DNA in the region sensitive to either somatic or
germ-line mutagenesis. The differential sensitivity of different tissues to
FRA3B-associated deletion led Sozziet al. (10) to suggest that sensitive
tissues may be those at greatest exposure to environmental mutagens.
Germ-line DNA breakage has been found to occur at theFRA11B-rare,
folate-sensitive fragile site (51). Because rare and common fragile sites
appear to be due to different DNA sequences, this breakage would
suggest that chromosome fragility does have a role to play in DNA
instability rather than the instability being simply due to particular DNA
sequences that different classes of fragile sites might have had in com-
mon. The identification of DNA sequences that are necessary and suffi-
cient for common fragile site expression and the molecular mechanism(s)
involved in their cytogenetic appearance will, we hope, lead to a greater
understanding of the mutation process associated with fragile sites and
the role of this process in neoplasia.
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Fluorescence in situ hybridization of a tile path of
DNA subclones has previously enabled the cyto-
genetic definition of the minimal DNA sequence
which spans the FRA16D common chromosomal
fragile site, located at 16q23.2. Homozygous deletion
of the FRA16D locus has been reported in adenocar-
cinomas of stomach, colon, lung and ovary. We have
sequenced the 270 kb containing the FRA16D fragile
site and the minimal homozygously deleted region in
tumour cells. This sequence enabled localization of
some of the tumour cell breakpoints to regions which
contain AT-rich secondary structures similar to
those associated with the FRA10B and FRA16B rare
fragile sites. The FRA16D DNA sequence also led to
the identification of an alternatively spliced gene,
named FOR (fragile site FRA16D oxidoreductase),
exons of which span both the fragile site and the
minimal region of homozygous deletion. In addition,
the complete DNA sequence of the FRA16D-
containing FOR intron reveals no evidence of addi-
tional authentic transcripts. Alternatively spliced
FOR transcripts (FOR I, FOR II and FOR III) encode
proteins which share N-terminal WW domains and
differ at their C-terminus, with FOR III having a trun-
cated oxidoreductase domain. FRA16D-associated
deletions selectively affect the FOR gene transcripts.
Three out of five previously mapped translocation
breakpoints in multiple myeloma are also located
within the FOR gene. FOR is therefore the principle
genetic target for DNA instability at 16q23.2 and
perturbation of FOR function is likely to contribute to
the biological consequences of DNA instability at
FRA16D in cancer cells.
INTRODUCTION
Chromosomal instability is a feature of certain types of cancer.
It is not yet clear whether such instability represents the
outcome of a selection process involving the gain, loss or alter-
ation of specific genetic material or whether certain regions of
the genome are predisposed to instability. Fragile sites are
chromosomal structures which have been proposed to have a
determining role in cancer-associated chromosomal instability
(1). There are in excess of 100 fragile sites in the human
genome (2), of which the fragile site FRA11B is located within
the CBL2 proto-oncogene (3,4) and the FRA3B, FRA7G and
FRA16D sites have been located within or adjacent to regions
of instability in cancer cells (5–11).
There are two distinct forms of chromosomal anomaly
referred to as fragile sites (12). The ‘rare’ form is polymorphic
in the population and is accounted for by the expansion of
repeat DNA sequences beyond a copy number limit. The
‘common’ form is present at many loci in all individuals.
Despite determination of the complete sequence of the
common fragile site FRA3B (13–15) and partial sequence anal-
ysis of the common fragile sites FRA7G (8,9) and FRA7H (16),
the molecular basis for common fragile sites is not yet under-
stood. Fragile sites are also distinguished by the culture condi-
tions required for their induction. Common fragile sites are
(mainly) induced by aphidicolin, whereas the rare fragile sites
are induced by either high or low concentrations of folate, AT-
rich binding chemicals such as distamycin A or by bromo-
deoxyuridine. The role of chromosomal fragile sites in human
genetic disease was thought to be restricted to fragile X
syndrome caused by the FRAXA fragile site; however, a mild
form of mental retardation has been associated with FRAXE
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(17). In addition, the FRA11B fragile site appears to predispose
to 11q breakage leading to some cases of Jacobsen syndrome
(3,4), raising the possibility of other diseases of diverse pheno-
types being associated with other fragile sites.
Recent detailed molecular analysis of fragile site loci has
demonstrated that the common fragile site FRA3B is located
within a region subject to localized deletion and that this dele-
tion is frequently observed in certain forms of cancer (5,6).
FRA3B lies proximal to the major region of loss of heterozy-
gosity (LOH) on chromosome 3p previously shown to be
responsible for deletion of the VHL tumour suppressor (18).
The cancer-associated FRA3B deletions can result in inactiva-
tion of a gene (FHIT for fragile histidine triad) which spans the
fragile site. The FHIT gene product has been shown to have a
role in tumour growth (19); however, there has been a great
deal of controversy over the functional significance of FHIT
loss to the tumorigenic process (20,21).
The sequence of the region containing FRA3B has been
determined; however, neither the molecular basis for expres-
sion of the fragile site nor the cancer-associated instability is
clearly resolved (13–15). The FRA3B region sequence has an
abundance of the L1 type of long interspersed nuclear element
(LINE) DNA repeats. It may be that these elements constitute
the molecular basis for fragile site expression, as the expansion
of repeat elements is the only known cause for ‘rare’ fragile
sites. The L1 elements are frequently found at or near the
boundaries of FRA3B/FHIT deletions in cancer cell DNA
(14,15) and have therefore been proposed to facilitate the dele-
tion process.
Analysis of the common fragile site FRA7G has also demon-
strated that this fragile site is located within a region of
frequent deletion in breast and prostate cancer (8,9). This
region contains two members of the caveolin gene family the
deletion of which may play an important role in tumorigenesis
(7,22). Only a partial sequence for this fragile site is available
and so it is not clear whether other genes may be affected by
FRA7G-associated chromosomal instability. Molecular studies
have also been undertaken at the FRA7H fragile site and the
region around an SV40 integration site at this locus has been
sequenced (16). No genes were identified in this 161 kb
sequence; however, this sequence does not appear to span the
entire fragile site and further analysis may reveal associated
genes.
We have previously localized the minimum region required
for cytogenetic expression of FRA16D by establishing a contig
of subclones across the region and determining their position
with respect to FRA16D by fluorescence in situ hybridization
(10). DNA markers from within this region were used to detect
instability in tumour cell lines that had previously been shown
to exhibit instability at the FRA3B locus. One of these cell
lines, the gastric adenocarcinoma AGS, was shown to have a
homozygously deleted region that spanned the FRA16D fragile
site. Using representational difference and PCR deletion anal-
ysis Paige et al. (11) have identified the FRA16D region as a
site of homozygous deletion in three additional tumours (from
ovary, lung and colon).
We have determined the complete DNA sequence of a
minimal tile path of subclones spanning FRA16D to define the
molecular limits of this common fragile site region. Within this
sequence genetic and/or physical markers have been identified
that delineate the boundaries of the observed DNA instability
in cancer cells. The FRA16D region sequence also allowed
identification of potential genes as expressed sequence tags
(ESTs) as likely candidate targets for instability and found no
evidence for a transcript within the 270 kb containing
FRA16D. Instead, a transcript (FOR for fragile site FRA16D
oxidoreductase) was identified which spans the FRA16D
fragile site, the common minimal region of homozygous dele-
tion found in adenocarcinomas and three out of five transloca-
tion breakpoints in multiple myeloma. Transcripts from the
alternatively spliced FOR gene encode proteins with common
N-terminal WW domains and variable homology to the
oxidoreductase family of proteins. FOR is therefore the most
likely gene to convey any biological consequences of DNA
instability at the FRA16D locus.
RESULTS
DNA sequence spanning FRA16D
The DNA sequence spanning FRA16D was determined by a
combination of approaches. Firstly, a tile path of λ subclones
of YAC My801B6 and BAC 325M3 was restriction mapped
with restriction endonucleases EcoRI, HindIII, BamHI and
SacI in order to provide a reference framework with which to
anchor the DNA sequence (10). Secondly, either whole BAC
DNA preparations of BAC325M3 or BAC353B15 or specific
restriction fragments from the λ subclone tile path were used as
feedstock DNA for construction of random insert plasmid
libraries. Sequences from the region between BAC325M3 and
BAC353B15 [λ subclone tile path λ32–λ191 (10)] were
subjected to long range PCR and restriction digest analysis in
order to verify the integrity of this sequence. Sequenced
subclones were also ordered by hybridization with individual λ
subclones from the minimal tile path. The DNA sequences
were therefore assembled in a directed rather than random
manner. This approach greatly assisted in the assembly of
those regions that were rich in DNA repeats. The 270 kb
contiguous sequence spanning FRA16D, with an average 4-
fold sequence coverage, has been deposited in GenBank
(accession no. AF217490) (Fig. 1).
Relationship between deletion and translocation
breakpoints and FRA16D
PCR analysis of sequence tags across the FRA16D region was
used to refine the location of deletion breakpoints in the AGS
and HCT116 tumour cell lines (Fig. 1 and Table 1). Both cell
lines showed at least two distinct regions of homozygous dele-
tion, indicating a minimum of three deletion events on the two
chromosomes 16 in each cell line. Four regions of the
FRA16D-spanning sequence were particularly difficult to
determine because of their composition (as evident by DNA
polymerase pausing in sequencing). Each of these sequences
coincided with breakpoint regions in HCT116 or AGS tumour
cell lines (Fig. 1, and referred to as ‘pause sites’ in Table 1).
The unstable regions consisted of: (i) a poly(A) homopolymer
region at 144–145 kb of DNA sequence AF217490; (ii) an
imperfect CT repeat of 320 bp at positions 177–178 kb; (iii) an
8 kb region at positions 191–199 kb encompassing a poly(A)
homopolymer region followed by an AT repeat, a poly(T)
homopolymer repeat and two inverted (hairpin-forming)
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repeats; (iv) a TG repeat followed by a homopolymer region
[poly(T)] at 212–213 kb. This fourth sequence is located
within a common breakpoint region for the AGS and HCT116
cell lines at 211.7–219.9 kb of AF217490. PCR across each of
the breakpoint regions in the AGS and HCT116 cell lines using
primers from positive flanking STSs failed to produce prod-
ucts, suggesting that additional cryptic instability (e.g. inver-
sions or amplifications) may also be present.
The locations of three previously identified multiple
myeloma breakpoints (23) were determined by either BLAST
scanning of partial database sequences or by PCR of STSs on
the tile path of λ subclones spanning FRA16D. The location of
MM1 was verified by PCR of λ subclone λ131 (which also
contained the STS IM7). The locations of JJN3 and ANBL6
are based on their presence or absence in the BAC sequences
GenBank accession nos AC027279 and AC009145 and the
relative position of these BAC sequences with respect to the
marker D16S504. The location of the translocation breakpoints
(Fig. 1) is in agreement with that published by Chesi et al. (23).
Repeat elements and DNA flexibility in the FRA16D-
spanning sequence
The DNA sequence spanning FRA16D was analysed for type
and quantity of DNA repeats since DNA repeats are known to
be the molecular basis for the rare fragile sites and have been
proposed to have a role in common fragile site instability (15).
Comparison of the FRA16D-spanning sequence with that of
other common fragile sites, FRA3B and the partially sequenced
FRA7H and FRA6E regions (Fig. 2A), gave a surprising degree
Figure 1. Map of the FOR transcripts and deletion breakpoints in 16q23.2 with respect to FRA16D. (A) Extent of loss of heterozygosity regions in breast (28) and
prostate cancer (29) in relation to the cytogenetic position of the FRA16D fragile site as determined by fluorescence in situ hybridization of a tile path of subclones
(10). (B) Map of YACs which span the FRA16D region showing approximate location of multiple myeloma breakpoints (MM.1, JJN3 and ANBL6) determined by
Chesi et al. (23). Location of homozygously deleted regions in AGS and HCT116 tumour cell lines as determined by STS content. The locations of various partial
BAC sequences (as evidenced by STS content) are indicated. (C) Location of the DNA sequences determined in this study including those spanning FRA16D
(striped boxes with GenBank accession nos) and the respective exons of the alternatively spliced FOR gene transcripts (numbered black boxes). Clusters of EST
sequences representative of each of the alternative mRNA 3′ ends are given.
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of variation in the type and quantity of repeat DNA sequences.
LINE-1 elements, which have been proposed to play a major
role in the DNA instability seen at the FRA3B locus, were
significantly under-represented at the FRA16D locus when
compared with not only the other fragile site loci but also the
human genome in general (Fig. 2A).
Common fragile site DNA sequences have been identified as
containing regions of flexibility as determined by the computer
program FlexStab (16). This program was obtained from the
website of Dr B. Kerem (http://leonardo.ls.huji.ac.il/
departments/genesite/faculty/bkerem.htm ) and was used to
analyse the FRA16D DNA sequence. Six regions of flexibility
Table 1
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were identified (Fig. 2B), two of which (peaks 1 and 4) coin-
cide with breakpoints of homozygously deleted regions in the
HCT116 and AGS cell lines, respectively. A third peak (peak
5) maps in the vicinity of another breakpoint in the AGS cell
line (Fig. 2B).
The alternatively spliced FOR gene spans fragile site
FRA16D
Scanning of the 270 kb sequence spanning FRA16D by
BLAST homology searches revealed a paucity of EST homol-
ogies, almost all of which could be accounted for as illegiti-
Figure 2. Physical properties of the FRA16D-spanning DNA sequence. (A) Comparison of the DNA repeat composition of the FRA16D-spanning sequence with
those of other common fragile sites and regions of the whole genome. Values for various %GC content fractions of the human genome are from Smit (30).
(B) FlexStab analysis of DNA ‘flexibility’ for the FRA16D DNA sequence. The location of FRA16D is indicated as are the six highest peaks of flexibility score.
The position of these peaks with respect to breakpoint locations in the AGS and HCT116 tumour cell lines is also shown. HZD I–IV refer to homozygously deleted
regions. Black bars represent DNA sequences that are present; white bars represent DNA sequences that are absent; grey bars represent DNA sequences that are of
unknown deletion status.
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mate (Table 2). The exceptions were consecutive exons
corresponding to sequences from the EST qg88f04.x1 (Fig. 1).
These exons therefore locate FRA16D within a 260 kb intron.
BLAST searches with the qg88f04.x1 EST sequence revealed
considerable overlap with clusters of ESTs, the longest avail-
able sequence of which was HHCMA56 (U13395). Part of the
HHCMA56 sequence has been mapped previously ~700 kb
distal to FRA16D (11). ESTs qg88f04 and HHCMA56 clearly
have distinct 3′ end sequences and were therefore referred to as
transcripts I and II. Another cluster of ESTs (transcript III) was
found to share 5′ but not 3′ end sequences with transcripts I and
II. A fourth cluster of ESTs (transcript IV) was found to share
sequence homology; however, this overlap is between the 5′
most sequences of transcripts I–III and the 3′ end of the EST
cluster, suggesting that it represents an overlapping gene rather
than another alternatively spliced transcript.
All other ESTs with homology to the FRA16D-spanning
sequence exhibit features which discount them as likely to
represent authentic transcripts. In most cases the homology
between the EST and the chromosomal DNA sequence was
collinear and therefore not interrupted by introns. The excep-
tions (Table 2) were chimeric, having either additional unique
sequences from elsewhere in the genome than 16q23.2 or Alu
sequences of unattributable origin. The 3′ end sequences that
had poly(A) tails also had poly(A) sequences in the chromo-
somal DNA, indicating that the poly(A) sequence in the EST
was not a post-transcriptional addition. In addition, there were
no expected polyadenylation signal sequences (AATAAA)
located ~20 bp upstream of the poly(A) tracts. A single excep-
tion was qz19h11, where the EST has a poly(A) segment while
the genomic DNA does not; however, there is no poly(A)
signal and no intron boundaries are evident. The majority of
the ESTs were singletons indicative of rare events and are most
likely due to rare oligo(dT) priming from a chromosomal DNA
contaminant in the cDNA library preparations. ESTs that are in
the same transcriptional orientation as the FOR gene could
represent 3′ exons of yet additional alternatively spliced forms
of FOR gene transcripts.
The 270 kb FRA16D-spanning sequence was also subjected
to GenScan gene prediction analysis. This analysis revealed
only three likely exons, one of which (at positions 4216–4621)
was exon 8 of the FOR gene. The others (at 8134–7818 and
225 339–225 270) were both in the opposite orientation to the
FOR gene and neither corresponded to any of the EST homol-
ogies that were detected in the BLAST searches. The GenScan
analysis did not identify exon 9 of the FOR I transcript. This is
consistent with this exon (which contains mainly 3′ untrans-
lated region) being a poorly utilized alternative splice pathway
giving rise to the low abundance FOR I mRNA. The remainder
of the FOR I mRNA 3′ untranslated region (consisting of an
AT-rich sequence of only 30 bases) is thought to be encoded
by an additional exon (exon 10) (Fig. 1); however, this exon is
yet to be located in the chromosomal DNA sequence.
5′-RACE experiments using mRNA from normal
(HS578BST) and tumour (T47D) cells were utilized to extend
and confirm the sequences of the clusters of GenBank EST
sequences of transcripts I–IV and to determine the organiza-
tion of the alternatively spliced mRNAs which they represent
(Fig. 3). Transcripts I–III were found to have a common 5′ end,
indicating a common promoter. The exons shared and utilized
in the alternatively spliced mRNAs were identified in BAC
sequences AF217491, AF217492, AC009044, AC009280 and
AC009129 (Fig. 1). The confinement of distribution of EST
sequences amongst exons confirmed that the different tran-
scripts were due to alternative splicing. Transcripts I–III share
Table 2. Location of singleton EST homologies in the FRA16D-spanning
DNA sequence
aSpliced to Alu sequence of unknown origin.
bChimeric, with sequences from other chromosomes.















































qg88f04.x1 AI219858 264 (exon 9 of FOR I)
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a common initiation methionine with an adjacent 5′ Kozak
translation initiation sequence and an upstream in-phase termi-
nation codon. The open reading frames code for proteins of
41.2, 46.7 and 21.5 kDa, respectively. Each of these open
reading frames shares homology with the oxidoreductase
family of proteins and therefore the gene has been named FOR
(fragile site FRA16D oxidoreductase), with the alternatively
spliced transcripts I–III referred to as FOR I, FOR II and FOR
III, respectively.
Northern blot analysis with various FOR exon probes identi-
fied the 2.3 kb FOR II transcript as the predominant and
ubiquitously expressed mRNA, with FOR I and FOR II
mRNAs showing a similar pattern of expression (Fig. 4). A
DNA probe spanning the 5′ exons detected additional RNAs
with a different tissue-specific pattern. A cluster of ESTs (Fig.
1) with homology limited to exon 1 of the FOR gene was found
from a BLAST search of the databases. This suggests that
these transcripts (referred to as FOR IV) might arise from a
different promoter and may well constitute a different gene, the
3′ end of which overlaps with the 5′ end of FOR (Fig. 1). The
3′ end sequences of these ESTs contain a very short open
reading frame (4.1 kDa) which is truncated with respect to that
seen in the FOR transcripts. The complete FOR I–FOR III
mRNA and partial related transcript sequence (FOR IV) were
determined from 5′-RACE and RT–PCR products and depos-
ited in GenBank (accession nos AF227526, AF227527,
AF227528 and AF227529). An mRNA of ~2.7 kb in length of
unknown identity was detected with probe B in the kidney and
three RNAs (~5.5, ~8 and ~11 kb) were found in various
tissues (Fig. 4), indicating that additional alternatively spliced
FOR transcripts are likely. The complete length of the FOR IV
mRNA is yet to be determined and may account for one or
more unidentified transcripts.
FOR mRNA in normal and tumour cells
RT–PCR and 5′-RACE were used to detect the various FOR tran-
scripts in normal and tumour cells. Striking differences between
the presence/absence of FOR I and FOR III transcripts was noted
for the ‘normal’ fibroblast-like cell line HS578BST and various
tumour cell lines (Fig. 5). 5′-RACE and RT–PCR products for
transcript-specific PCR were sequenced to confirm the identity of
the respective products. The sequence of the aberrant RT–PCR
product from cell line MDA-MB-453 generated using a FOR III-
specific primer contains a retroviral element (HERV-H) 5′ of
exons 5 and 6A of FOR (GenBank accession no. AF239665). In
addition, one EST (qz23c04.x1) identified in database BLAST
searches contains exons 1–3 of FOR spliced at the 3′ end to
another retroviral element, LTR13.
Homozygous deletion of FOR I exon 9 detected in AGS
tumour cells suggests that the gain of FOR I transcript will not
be a common event in tumour cells. Similarly, the loss of FOR
III transcript is not common to all tumour cells as FOR III-
specific RT–PCR products were readily detected in both AGS
and HCT116 cells (Fig. 5).
FOR-encoded proteins
The alternatively spliced mRNAs transcribed from the gene each
show homology to the oxidoreductase superfamily of proteins.
The open reading frames of the alternatively spliced FOR gene
mRNAs I–III have a common N-terminus which contains two
WW domains (Fig. 3). The first WW domain is truncated in the
FOR IV open reading frame; however, since this mRNA appears
to originate from a distinct promoter it may well be that an
upstream reading frame is utilized in this mRNA. The open
reading frame from the FOR III transcript retains the WW
domains; however, it is truncated for approximately half the
length of the oxidoreductase homology (Fig. 3).
DISCUSSION
Structure/composition of common fragile sites
A principle aim of the current study was to compare the DNA
sequence spanning the FRA16D fragile site with that of other
common fragile site sequences in order to identify possible shared
sequence elements which might account for common properties.
Given that it is DNA repeat sequences that constitute the molec-
ular basis of rare chromosomal fragile sites, the overall repeat
composition of the FRA16D-spanning DNA sequence was strik-
ingly different to other common fragile site sequences (Fig. 2),
although those from the vicinity of FRA7H and FRA6E have not
been shown to span the fragile site. A further difference was noted
with respect to LINE elements, which have been proposed to play
a role in the DNA instability seen at the FRA3B common fragile
site (15). No consistent association was seen between LINE
elements and the FRA16D breakpoints in AGS and HCT116
tumour cell DNAs, suggesting that LINE elements are not an
essential feature of common fragile site-associated DNA insta-
bility in cancer. Instead, Alu repeats were more common in
FRA16D than LINE elements. These differences suggest that it is
not the broad composition of the region which gives rise to chro-
mosomal fragility and, therefore, it is more likely that localized
sequence elements (such as DNA polymerase pause sites) play the
determining role.
Analysis of the FRA16D sequence using the FlexStab
program supports the proposal that regions of flexibility
contribute to DNA instability in the vicinity of fragile sites (16)
as two peaks of flexibility correspond to homozygous deletion
breakpoints in tumour cells. These DNA sequences contain the
simple AT dinucleotide repeat which is capable of forming
secondary structures. The AT-rich DNA sequences at nucleo-
tide positions 191.6–198.4 kb of AF217490 are also capable of
forming hairpin structures in vitro and are therefore similar to
the AT-rich DNA repeats associated with the FRA10B and
FRA16B rare fragile sites. These DNA polymerase pause sites
coincide with some of the breakpoint locations in AGS and
HCT116 tumour cells. Given that DNA breakage is a form of
chromosome fragility, then the coincidence of cancer cell
breakpoints with these AT-rich secondary structures suggests
that the latter may have a role in cytogenetic expression of the
FRA16D fragile site. While FRA16D is a common fragile site
and is therefore expressed in all individuals, there is a possi-
bility that polyporphism in the vicinity of FRA16D may
contribute to differences in the percentage of metaphases
which exhibit cytogenetic expression of the fragile site.
Fragile site DNA sequences have been found to act as
regions of delayed replication (24–26) and in so doing may
contribute to the coupling of DNA replication with cell divi-
sion. Deletion of fragile site sequences in cancer cells may
therefore confer a selective advantage to the tumour cell in a
manner which is otherwise independent of the gene in which
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the fragile site is located. Alternatively, given the coupling of
replication with transcription, the deletion of a sequence which
normally delays replication may have an effect on the expres-
sion of genes in the vicinity.
Identification of the FOR gene spanning FRA16D
Given the proposed role of the FHIT gene in mediating the
biological consequences of FRA3B-associated DNA instability
in cancer cells we sought to identify the closest gene to
FRA16D which might mediate the biological effects of
FRA16D-associated DNA instability in cancer (10,11).
Sequence analysis of the FRA16D-spanning DNA sequence
revealed the FOR gene as the sole transcript in the immediate
vicinity of the minimal region of homozygous deletion in
cancer cells. Alternative exons of this gene were found to flank
both the FRA16D fragile site and the tumour cell deleted
regions, the alternative exon 9 being deleted in the AGS cell
line. No additional authentic transcripts from within the FOR
Figure 3. Comparison of FOR open reading frames and location of WW and oxidoreductase domains. (A–D) Open reading frames from FOR I–FOR IV mRNAs,
respectively. (E) Comparison of FOR open reading frames and location of WW (white boxes) and oxidoreductase domains (striped boxes). Oxidoreductase
domains were identified by alignment of protochlorophyllide reductase precursor proteins from Arabidopsis thaliana (accession no. P21218), Pisum sativum
(Q01289), barley (P13653) and Avena sativa (P15904), oxidoreductases from Streptomyces antibioticus (Q03326) and Neurospora crassa (Q92247) and FIXR
protein from Bradyrhizobium japonicum (P05406) with the FOR II open reading frame. The three homologous oxidoreductase domains contained: (i) five com-
pletely conserved amino acids over a 28 amino acid sequence; (ii) seven completely conserved amino acids over a 47 amino acid sequence; (iii) five completely
conserved amino acids over a 33 amino acid sequence. (F) Comparison of FOR WW domains with the WW domain consensus sequence.
342
Human Molecular Genetics, 2000, Vol. 9, No. 11 1659
gene intron were evident. In an analogous situation to that seen
at the FRA3B locus, deletions at FRA16D appear to be largely
intronic to the major alternatively spliced transcript (FOR II).
Studies on the FHIT gene spanning FRA3B have given contra-
dictory results in terms of the possible role of FHIT in
neoplasia. Therefore, it will be of interest to determine the
effect of deletions at FRA16D on the FOR gene transcripts and
whether any of the FOR-encoded proteins and their dysfunc-
tion brought about by FRA16D-associated deletion have a role
to play in cancer.
The finding that the FOR gene spans FRA16D represents a
shared feature of ‘common’ fragile sites FRA3B and FRA16D
in that they are both unstable regions located within large
introns of large genes; FHIT (>1 Mb) and FOR (>1 Mb). The
sequences determined at the FRA7G, FRA7H and FRA6E loci
may be of insufficient length to identify the respective span-
ning genes.
Differential expression of alternatively spliced and
aberrant FOR transcripts in normal and tumour cells
RT–PCR and 5′-RACE gave differing patterns of FOR tran-
script expression in various normal and tumour cell lines. It
will be of interest to determine whether there are differences in
the ratio of FOR transcripts which are consistent with the
biological characteristics of various cell types, e.g. neoplastic
state or metastatic potential. It is unlikely that the presence of
FOR I transcripts will be a common property of tumour cells
since at least the AGS cell line is homozygously deleted for
FOR I exon 9. Additional aberrant FOR transcripts, including
sequences fused to retroviral LTRs, were detected in tumour
cells. Extensive studies on the FHIT gene at the FRA3B locus
have yet to resolve the role (if any) of aberrant transcripts of
this gene in neoplasia. It is likely that extensive functional
studies of alternative FOR transcript expression will be needed
in order to determine what contribution (if any) this phenom-
enon contributes to the biological characteristics of the cells
where it is observed.
It may well be that the ratio of the various FOR transcripts is
perturbed by DNA instability in the region and that it is the
resultant alteration in relative abundance of the various FOR-
encoded proteins which mediates the biological consequences
of DNA instability at FRA16D. For example, the homozygous
deletion in AGS cells deletes exon 9 of the FOR I transcript
and may have an effect on the stability of the FOR II transcript;
however, this deletion is unlikely to have any effect on the
FOR III transcript, which terminates well outside the homo-
zygously deleted region.
Figure 4. Northern blots of RNA from various human tissues. Expected FOR mRNAs (I–III) are indicated for the respective DNA probes which span various exons
of the FOR gene. Large arrows indicate FOR mRNAs (FOR I ~1.8 kb, FOR II ~2.2 kb, FOR III ~ 0.74 kb). Other unidentified transcripts (possibly including FOR
IV) are indicated by small arrows. (A) Blots of mRNA from heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas hybridized to probes A, B, C
and D, respectively. (B) Blots of mRNA from spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocytes hybridized to probes B
and C, respectively.
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Possible function of FOR and role in neoplasia
The FOR-encoded proteins show sequence homology to the
oxidoreductase family of proteins and contain WW domains.
Other members of this family of proteins include the YES
proto-oncogene-associated proteins and NEDD ubiquitin
ligases.
The open reading frame from the FOR III transcript retains
the WW domains; however, it is truncated for approximately
half the length of the oxidoreductase/ubiquitin ligase
homology (Fig. 3). The FOR III protein is therefore likely to be
able to bind proteins that recognize the common FOR I and
FOR II WW domains but not be able to perform the enzymatic
function encoded by the FOR I and FOR II proteins (possibly
ubiquitination). Such characteristics make the FOR III protein
a likely competitor of FOR I and/or FOR II. Since ubiquitina-
tion facilitates the process of specific protein turnover, FOR III
could therefore act to prolong the half-life of its substrate by
competing with FOR I and/or FOR II.
WW domains are regions of protein–protein interaction that
bind polyproline-rich motifs (PY domains) in specific partner
proteins. Specificity in this interaction is determined by differ-
ences in particular amino acids in the various WW domains.
Proteins known to bind to WW domains include the YES proto-
oncogene product and p53 binding protein-2 (27). Alteration in
the relative levels of the FOR-encoded proteins as a conse-
quence of FRA16D-associated instability is therefore likely to
influence the biological function of the PY motif-containing
protein(s), which is (are) the normal binding partner that the
FOR proteins share through their WW domain.
The majority of deletions in the 16q23.2 region are hetero-
zygous, with the homozygous deletions being confined and
limited in number (11). Cells which still have the capacity to
produce FOR II protein (from a normal chromosome 16 FOR
allele) might have an elevated level of FOR III (through
FRA16D-associated deletion of the other chromosome 16
allele) and therefore have a selective ‘heterozygote’ advantage.
The finding of aberrant FOR-related transcripts spliced to
retroviral RNA sequences in tumour cells that do not neces-
sarily exhibit FRA16D homozygous deletion (e.g. MDA-MB-
453, Fig. 4) suggests that dysfunction of the pathway involving
the FOR WW domain could be a common event in neoplasia,
perhaps through other forms of FRA16D-related DNA insta-
bility such as DNA insertion or translocation. Three out of five
previously mapped multiple myeloma translocations (23) map
within the FOR gene, suggesting that DNA instability at the
FRA16D locus and aberrant expression of the FOR gene may
have a variety of roles to play in various forms of cancer.
The c-MAF oncogene is also located in the vicinity of
FRA16D (Fig. 1) and has been identified as a target for
multiple myeloma translocations, exhibiting dysregulation of
expression of the translocated allele (23). It is not yet clear
whether deletions in the FRA16D region, such as the LOH
often seen in breast cancer or the homozygous deletions seen in
certain adenocarcinomas, have an effect on c-MAF expression.
The location of the various forms of DNA instability in this
region with respect to the FOR gene suggest that this gene may
also be affected; it is a distinct possibility that both c-MAF and
FOR have a role to play in mediating the biological conse-
quences of FRA16D-associated DNA instability.
It will be of interest to determine whether there is a general
relationship between common chromosomal fragile sites and
DNA instability in cancer. In this regard it is noteworthy that
there are two other common regions of cancer cell LOH on 16q
in addition to that involving FRA16D (28). One of these at
16q24.3 maps near the telomere while the other at 16q22.1
maps near another common fragile site, FRA16C.
MATERIALS AND METHODS
Cell lines
Cell lines AGS, HCT116, HS578BST, HS578T, LS180,
MDA-MB-453 and T47D are from the Department of Cyto-
genetics and Molecular Genetics, WCH collection, and were
originally obtained from the American Type Culture Collec-
tion or the European Collection of Cell Cultures. AGS and
LS180 cells were grown as described previously (10).
HS578BST cells were grown in OPTI-MEM with L-glutamine,
0.01 µg/ml epidermal growth factor, 0.5 µg/ml hydrocortisone,
8% fetal calf serum in 5% CO2. T47D, MDA-MB-453 and
HS578T cells were grown in RPMI 1640 with L-glutamine,
10% fetal calf serum in 5% CO2.
Large-scale sequencing of FRA16D
Sequencing of the 270 kb region spanning FRA16D consisted
of: (i) sonication libraries; (ii) nebulization libraries of BAC
clones 325M3 and 353B15; and (iii) restriction fragments of λ
clones (for sequencing between BAC 325M3 and BAC
353B15).
Construction of sonication libraries. For DNA sonication and
cloning we modified the protocol from the Sanger Centre
(http://www.sanger.ac.uk/Teams/Team53/sonication.shtml ).
Aliquots of 1 µg of each BAC DNA were sonicated in 300 µl
Figure 5. FOR transcripts in normal and tumour cells. Products that were sub-
jected to sequence analysis are indicated by arrowheads. (A) RT–PCR were
either ‘specific’ for the FOR III transcript or ‘general’, being able to detect
FOR I–III mRNAs. (B) 5′-RACE specific for the FOR I, FOR II and FOR III
transcripts in ‘normal’ HS578BST cells and T47D tumour cells.
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H2O and 8 µl 10× mung bean buffer (500 mM Na acetate, 300
mM NaCl, 10 mM ZnSO4, pH 5.0) on ice for 20 s using a Heat
Systems Sonicator W-225 (50% duty, 3.5 power) (Ultrasonic,
Farmingdale, NY). After reducing the volume to 80 µl, blunt
ends were created by adding 40 U of mung bean nucleases
(Biolabs, Beverly, MA) and incubating the mixture at 30°C for
25 min. The products were size fractioned on a 1% agarose gel
and fragments ranging from 0.7 to 2 kb were extracted with the
QiaQuick Gel Extraction kit (Qiagen, Hilden, Germany).
Samples of 1500 ng sonicated DNA (used in 500 ng aliquots)
were ligated into vector pUC18-Sma (Amersham Pharmacia,
Uppsala, Sweden) at 16°C overnight and transformed into
electroporation-competent Sure cells (Stratagene, La Jolla,
CA). Samples of 600 and 1500 clones, respectively, of the
sonication libraries of BAC 325M3 and 353B15 were gridded
on 96-well plates and sequenced in one direction using the
M13-forward primer. Sequences were assembled into contigs
using the Staden Package (MRC, Cambridge, UK) on a UNIX
computer and edited in LASERGENE (Macintosh). For a
selected number of clones additional sequences with the M13-
reverse primer were retrieved and assembled. Additional
sequencing primers were designed and PCR products
sequenced to close the gaps between contigs.
Construction of nebulization libraries. Aliquots of 10 µg of
each BAC DNA were mixed with 200 µl 10× TM buffer
(500 mM Tris–HCl, pH 7.5, 150 mM MgCl2) and 1 ml sterile
glycerol and H2O added to 2 ml. The mixture was pipetted into
an IPI nebulizer and nebulized at 10 p.s.i. for 45 s. The
nebulized DNA was then precipitated, end repaired, size
fractionated and cloned as described for the sonicated DNA.
Samples of 300 and 500 nebulized clones, respectively, of
BAC 325M3 and 353B15 were sequenced as described above
and included in the assemblies. Subclones for sequencing of
BAC 353B15 were picked randomly, whereas BAC 325M3
subclones were selected after hybridization of specific λ clones
of the tile path made from BAC 325M3 (10).
Subcloning of restriction fragments of λ -clones between λ-32
and λ-191 in vector pUC19. Clones were sequenced with
M13-forward and M13-reverse primers as well as with
sequence-specific primers. In some cases subclones derived
from specific restriction fragments were also subject to sonica-
tion, shotgun cloning and sequencing.
Sequencing was performed with the ABI Big Dye Termi-
nator kit from Perkin Elmer (Foster City, CA). In cases where
sequencing with the Big Dye Terminator kit failed, a dRhod-
amine Terminator kit (ABI) was used, as recommended for
GT-rich and homopolymeric regions by the ABI DNA
sequencing guide.
Long range PCRs were performed on ~70 kb of DNA
sequence in the region between BACs 325M3 and 353B15.
Blood bank DNA was used as template. The remaining tile
path of λ subclones (10) was subjected to restriction analysis to
give a redundant restriction map of the FRA16D region.
The final sequence was analysed using BLAST
(http://www.ncbi.nlm.nih.gov/BLAST ), REPEATMASKER
(http://ftp.genome.washington.edu/cgi-bin/RepeatMasker ),





Probes for hybridization on multiple tissue northern blots from
Clontech were: probe A, part of exon 1A (163 bp), positions
298–461 of AF227529; probe B, exons 3–6A (366 bp), posi-
tions 291–657 of AF227528; probe C, exon 7 (186 bp),
positions 690–876 of AF227526; probe D, part of exon 9A
(779 bp), positions 1182–1961 of AF227527.
RNA extraction
RNA was extracted from 1 × 107 cells for each of the cell lines
using the RNeasy Mini Kit from Qiagen. The cells were
disrupted by addition of 600 µl of lysis buffer RLT (supplied
with the kit). The lysed cells were homogenized by passing 5–10
times through a 21G (0.8 × 38 mm) needle attached to a 5 ml
syringe. Aliquots of 600 µl of 70% ethanol were added and the
samples were applied to RNeasy Mini Spin columns. Purifica-
tion and elution of the samples were carried out according to the
kit manual. A total of 35–98 µg of RNA was obtained.
RT–PCR
Reverse transcription was carried out in a 40 µl reaction
volume using 12–33 µg of total RNA from cell lines AGS,
HCT116, MDA.MB.453, LS180, T47D, HS578T and
HS578BST, respectively, according to the product sheet of the
Gibco BRL Superscript RNAse H– Reverse Transcriptase kit
(Gibco BRL, Gaithersburg, MD) except for the addition of
20 U RNase inhibitor (Rnasin; Promega, Madison, WI) to the
mixture.
Aliquots of 100 ng of cDNA were amplified in PCRs using
various cDNA primer combinations under standard PCR
conditions (10 cycles of 94°C for 30 s, 60°C for 30 s, 72°C for
30 s; then 25 cycles of 94°C for 30 s, 55°C for 30 s, 72°C for
30 s).




wb85-F, FOR III-specific; wb85-E12 (TTACTACGCCAAT-
CACACCGAGGA) and wb85-A (TGAATTAGCTCCAGT-
GACCACAAC), common for FORI, FOR II and FOR III.
5′-RACE
Complete 5′ ends of transcripts FOR I, FOR II and FOR III
were determined by 5′-RACE experiments including first
strand cDNA synthesis, purification, TdT tailing of the cDNA,
PCR of dC-tailed cDNA and nested amplification according to
the Gibco BRL instruction manual.
Aliquots of 1 µg of total RNA of cell lines HS578BST
(normal) and T47D (tumour) were taken as templates. First
strand cDNA synthesis was conducted with the following
specific GSP1 primers: FOR I, coxido-R, 5′-TTATTTCAG-
CACTCAGCTCAAAGTCAC-3′; FOR II, HHCMA-B, 5′-
AGCAAAGAGACCTATGCCTAGCCCA-3′; FOR III,
wb85-F, 5′-TTATTCTGCACTTTTCTGGCGGAG-3′.
PCR of the dC-tailed cDNA was carried out with the GSP2
primers: FOR I and FOR II, coxido-32, 5′-ATATCTG-
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TAAATCGATGGGACTCTG-3′; FOR III, wb85-A, 5′-
TGAATTAGCTCCAGTGACCACAAC-3′.
Nested amplification was done with 5 µl of a 1:100 dilution
of GSP2 PCR products and the GSP3 primers: FOR I and FOR
II, coxido-21, 5′-ACATGAAGAGGCACATTCTTGGCCT-
3′; FOR III, wb85-E, 5′-TCCTCGGTGTGATTGGCG-
TAGTAA-3′ in combination with the AUAP primer (Gibco
BRL).
PCR products were extracted with a QiaQuick kit from
agarose gels after electrophoresis and sequenced directly with
GSP3 primers and primer tj96-C (5′-GGAGGCAGCTCGTC-
CTCACTG-3′).
cDNA sequence of FOR IV (GenBank accession no.
AF227529)
The preliminary cDNA sequence of the FOR IV transcript is
incomplete at its 5′ end at this stage. The sequence determined
so far derives from overlapping EST clones qf42f03.x1
(AI149681) and tm79c11.x1 (AI570665). The latter was
sequenced additionally with the internal primer tj96-C (5′-
GGAGGCAGCTCGTCCTCACTG-3′).
Determination of breakpoints in cell lines AGS and
HCT116
Deletions in cell lines AGS and HCT116 were determined in
duplex STS–PCRs as described in Mangelsdorf et al. (10). All
primers are listed 5′→3′ in Table 1.
Four regions of homozygous deletion (referred to as HZD I–
HZD IV) were detected in the AGS cell line. The proximal
breakpoint for HZD I in AGS was narrowed down to 654 bp
between STSs 16D-15/16D-36 (+) and 16D-1/16D-60 (–); the
distal breakpoint of HZD I of 3962 bp is between STS 16D-70
(–) and 16D-47 (+). The proximal breakpoint for HZD II in
AGS was narrowed down to 3030 bp between STSs 16D-57
(+) and 16D-67 (–); the distal breakpoint of HZD II of 1720 bp
is between STS 16D-68 (–) and 16D-54 (+). The proximal
breakpoint for HZD III in AGS was narrowed down to 209 bp
between STSs 16D-51 (+) and 16D-55 (–); the distal break-
point of HZD III of 5690 bp is between STS 16D-202 (–) and
16D-69 (+). The proximal breakpoint for HZD IV in AGS was
narrowed down to 5179 bp between STSs 16D-30/16D-44 (+)
and ETA1 (–); the distal breakpoint of HZD IV of ~1500 bp is
between STS IM7 (–) and 410S1A (+).
Two regions of homozygous deletion (referred to as HZD I
and HZD II) were detected in the HCT116 cell line. The prox-
imal breakpoint for HZD I in HCT116 was narrowed down to
1835 bp between STSs 16D-19 (+) and 16D-61 (–); the distal
breakpoint of HZD I of 1549 bp is between STS 16D-62 (–)
and qz19h11 (+). The proximal breakpoint for HZD II in
HCT116 was narrowed down to 422 bp between STSs 16D-63
(+) and 16D-30 (–); the distal breakpoint of HZD II of 1513 bp
is between STS 16D-66 (–) and 801A (+).
For determining the presence of exon 9 of FOR I (51 bp) in
the AGS cell line a duplex PCR with genomic primers from the
dystrophin gene (DMD) as described in example 1 was carried
out with primers 8040/8041 (Table 1).
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FRA16D common chromosomal fragile site oxido-reductase (FOR/WWOX)
protects against the effects of ionizing radiation in Drosophila
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Fragile sites are chromosomal structures that have been
proposed to have a determining role in cancer-associated
DNA instability. The human WWOX gene spans the
FRA16D chromosomal fragile site, the common minimal
region of homozygous deletion found in adenocarcinomas
and three out of five translocation breakpoints in multiple
myeloma. Transcripts from the alternatively spliced
WWOX gene encode proteins with common N-terminal
WW domains and variable homology to the oxidoreduc-
tase family of proteins. In this study, the Drosophila
orthologue of the WWOX gene was identified and
subjected to mutagenesis via homologous recombination.
The resultant DmWWOX1 mutants were viable but
exhibited an increased sensitivity to ionizing radiation.
This radiation sensitivity was rescued by reintroduction
and expression of either the wild-type Drosophila or
human WWOX genes. Thus, the protective function of
DmWWOX in response to irradiation in Drosophila is
conserved with human WWOX (hWWOX). This is
consistent with a protective role for hWWOX where
aberrant expression, as a result of breakage at the
associated fragile site, could contribute directly to cancer
progression.
Oncogene advance online publication, 20 June 2005;
doi:10.1038/sj.onc.1208806
Keywords: chromosomal fragile site; oxidoreductase;
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At least some of the DNA instability (insertions,
deletions and translocations) observed in cancer is
nonrandom and recurrent. However, it is not clear to
what extent this reflects the selection of certain
instabilities because of the growth advantage they
confer, or whether there are specific regions of the
genome that are predisposed to instability. Common
fragile sites induced on chromosomes in vitro corre-
spond to regions of DNA instability observed in human
cancers in vivo (Richards, 2001). It is not known whether
damage at these sites is merely a consequence of the
environmental stresses to which the cells have been
subjected or whether the instability actually plays a
causal role in determining cellular neoplastic transfor-
mation. The extent to which this fragile site-associated
instability contributes to cancer is likely to depend upon
the relationship between the fragile site and genes in the
vicinity whose function is perturbed.
A clear precedent for an association between a
common chromosomal fragile site and a cancer-related
gene has been demonstrated for the most highly
expressed common fragile site, FRA3B, and the FHIT
gene that spans it (Pekarsky et al., 2002). The product of
the FHIT gene is reduced or absent in many human
cancers and functional studies in a mouse knockout
model have demonstrated that Fhit is able to act as a
tumour suppressor in mice (Zanesi et al., 2001). We have
previously localized the minimum region required for
the cytogenetic expression of the second most highly
expressed common fragile site, FRA16D, and found that
this region is subject to homozygous deletion in certain
forms of cancer (Mangelsdorf et al., 2000; Finnis et al.,
2005). The FRA16D region sequence allowed the
identification of a transcript (Fragile site FRA16D
OxidoReductase – FOR) that spans the FRA16D fragile
site (Ried et al., 2000). Transcripts from the alternatively
spliced FOR gene encode proteins with common
N-terminal WW domains and variable homology to
the oxidoreductase family of proteins. The gene has there-
fore also been named WWOX (Bednarek et al., 2000).
WWOX is the most likely gene to convey any biological
consequences of DNA instability at the FRA16D locus.
The possible processes to which WWOX contributes may
be evident from the roles and arrangement of its con-
served domains in other proteins. WWOX is one of
several proteins that contain a pair of WW domains
separated by an approximately 10 amino-acid linker. In
the yeast splicing factor Prp40, this arrangement leads to
outward facing WW domains that bind to different
proteins and bring them into juxtaposition (Wiesner
et al., 2002). This suggests that WWOX may also act asReceived 28 January 2005; revised 1 April 2005; accepted 3 May 2005
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a bridge between different proteins. In addition to WW
domains, WWOX contains all of the essential sequences
for an oxidoreductase enzyme. Another oxidoreductase,
NAD(P)H:quinone oxido-reductase 1 (NQO1), is known
to be protective in response to increased reactive oxygen
species that can result from ionizing radiation (Nioi and
Hayes, 2004). Thus, WWOX may also play a role in
oxidative stress response following ionizing radiation.
Importantly, the WWOX proteins from different
species are distinct from other oxidoreductases, suggest-
ing that WWOX performs a unique and highly con-
served function.
WWOX has been identified and characterized by
other approaches, also based on a proposed relationship
between this gene and cancer. It was isolated as one of
the genes induced in response to hyaluronidase treat-
ment in mouse and shown to demonstrate both physical
and functional interactions with p53 in vitro (Chang
et al., 2001). WWOX was also identified as a candidate
tumour suppressor gene by virtue of its location within
a region of loss of heterozygosity (LOH) observed in
breast cancer (Bednarek et al., 2000). Cancer-associated
genes found in LOH regions are typically tumour
suppressor genes, the LOH accounting for the loss of
function of one allele, while point mutations or aberrant
methylation usually inactivate the other. Some func-
tional evidence has been produced in favour of the
WWOX gene acting as a tumour suppressor (Bednarek
et al., 2001; Paige et al., 2001). However, the lack of
mutations in the second allele in cancer cells and the
sometimes elevated rather than diminished level of
expression of the gene in cancer cells have led some to
conclude that the WWOX gene does not encode a
‘classical’ tumour suppressor (Watanabe et al., 2003).
While the normal function of WWOX is currently
unknown, its aberrant expression in a variety of cancer
cell types has been extensively reported, also suggesting
a likely association with cancer cell biology (Ried et al.,
2000; Paige et al., 2001; Yakicier et al., 2001; Driouch
et al., 2002; Kuroki et al., 2002; Ishii et al., 2003;
Yendamuri et al., 2003; Aqeilan et al., 2004a; Guler
et al., 2004; Kuroki et al., 2004).
Since its discovery, WWOX has been reported to
interact with a growing set of functionally diverse
proteins including p53 (Chang et al., 2001), JNK1
(Chang et al., 2003), Tau (Sze et al., 2004), SIMPLE
(Ludes-Meyers et al., 2004), p73 (Aqeilan et al., 2004c)
and AP-2g (Aqeilan et al., 2004b). These in vitro
associations have shed some light on the possible func-
tion(s) of WWOX, principally suggesting a role in apop-
tosis. However, the biological significance of these
associations is not yet known. Therefore, despite the
association between the WWOX gene and the DNA
instability seen at the FRA16D fragile site in cancer, the
normal function of the WWOX-encoded proteins and
their possible contribution to cancer cell biology remain
unclear. To address this, we have undertaken an ana-
lysis of the function of WWOX using the genetically
amenable model organism Drosophila to identify the
biological processes and pathways to which the WWOX
proteins contribute.
Database searching identified CG7221 as the ortho-
logue of WWOX in Drosophila. The protein product
of CG7221 shares 49% identity with human WWOX.
Phylogenetic analysis confirmed that DmWWOX
clearly groups with WWOX proteins from other species
onto a distinct branch of oxidoreductases (Figure 1a).
None of the most closely related oxidoreductases
from either human or Drosophila locate within the
WWOX orthologous branch. Having identified CG7221/
DmWWOX as the Drosophila orthologue of WWOX, we
generated a null mutant in DmWWOX by homologous
recombination (we have called this mutant DmWWOX1).
We performed ‘ends-in’ targeting essentially as de-
scribed in Rong et al. (2002). A 5 kb genomic region
of DmWWOX was amplified from wild-type genomic
DNA and site-directed mutagenesis was used to
introduce mutations 24 bp downstream of the start
codon. These mutations encode two premature stop
codons, a þ 1 frame shift and a diagnostic SalI site
(Figure 1b). In addition, an I-SceI site necessary for the
targeting event was introduced into the third intron.
This mutated fragment was cloned into the pTV2 vector
and transformed into wild-type flies to generate donor
lines for gene targeting. A schematic of the targeting
strategy and details of the methods used are described in
the Supplementary information. Briefly, we screened
193 000 flies and obtained five insertion lines, four of
which mapped to the second chromosome (the location
of the endogenous DmWWOX gene). Following reduc-
tion, we screened the white-eyed progeny of multiple
mosaic flies with allele-specific primers to identify those
which had incorporated the desired mutations. Once
we had generated homozygous stocks of these reduced
lines, we used allele-specific primers to confirm that the
DmWWOX1 mutant flies no longer contained any wild-
type sequences (Figure 1b). A PCR product with the
9778/WT primer combination was observed only in
the wild-type sample (Figure 1c, lanes 1 and 3), while
the 9778/MUT primer combination only produced a
product in the DmWWOX1 mutant sample (Figure 1c,
lanes 2 and 4). The 9778 primer lies outside of the
region included in the genomic construct for targeting;
thus, PCR products of the correct size obtained with
9778/MUT primer combination confirmed targeting to
the correct genomic locus. The presence of the diag-
nostic SalI site in DmWWOX1 mutant but not wild type
was confirmed by digestion of the PCR product from
9778/339R (Figure 1d, lanes 1–4). Finally, sequencing
downstream of the start codon confirmed the presence
of the premature termination codons, the þ 1 frame
shift mutation and the SalI site (Figure 1e).
The absence of endogenous protein in these
DmWWOX1 mutants was confirmed by Western analy-
sis using antibodies we generated against a C-terminal
peptide (Figure 2a, anti-C-DmWWOX) and the N-termi-
nal WW-containing region of DmWWOX (Figure
2b, anti-N-DmWWOX). Low levels of endogenous
DmWWOX protein were observed during third instar
larval development with anti-C-DmWWOX (Figure
2a, lane 1, see asterisk) and at 4–8 h of embryogenesis
with anti-N-DmWWOX (Figure 2b, lane 1). These weak
WWOX protection against radiation in Drosophila




bands of expression were absent in the DmWWOX1
mutants (Figure 2a and b, lane 2). Ectopic expression
of DmWWOX in larvae carrying hs-GAL4 and UAS-
DmWWOX constructs (hs>DmWWOX) resulted in a
modest increase in DmWWOX expression (Figure 2a,
lane 3, see asterisk). Embryos carrying daughterless-
GAL4 and UAS-DmWWOX constructs (da>DmW-
WOX) resulted in a significantly increased level of
DmWWOX expression (Figure 2b, lane 3).
We were unable to detect the low level of endogenous
DmWWOX expression above background in whole-
mount embryos. However, in embryos carrying
engrailed-GAL4 and UAS-DmWWOX constructs (en>
DmWWOX), strong alternating stripes of expression
were seen along the length of the embryo (Figure 2c).
DmWWOX was clearly cytoplasmic within these stripes
of expression (Figure 2e, g and i). The same stain-
ing pattern was also observed when human WWOX
Figure 1 Generation of a mutant in DmWWOX, the Drosophila orthologue of WWOX. (a) Phylogenetic analysis revealed that
CG7221/DmWWOX groups with WWOX proteins from other species (top group) rather than the most closely related oxidoreductases
from Drosophila, mouse or human (bottom group). The length of each pair of branches represents the distance between sequence pairs,
while the scale at the bottom of the tree indicates the number of substitution events. Phylogenetic analysis was performed using
‘MegAlign’ from the Lasergene suite of programs from DNASTAR, Inc. (Madison, WI, USA). Accession numbers for FOR/WWOX
sequences used in this analysis are H. sapiens (AAF82054), P. pygmaeus (CAH91445), M. musculus (NP_062519), R. norvegicus
(XP_214696), G. gallus (XP_414161), D. rerio (NP_957207), F. rubripes (FRUP00000070477), C. intestinalis (AK115111.1), D. pseudo-
obscura (EAL33941), A. gambiae (XP_317022) and A. mellifera (XP_395282). (b) A schematic of the 5 kb genomic region of
DmWWOX inserted into the pTV2 targeting vector. Mutations were introduced 24 bp downstream of the start codon. These mutations
encode two premature stop codons, a þ 1 frame shift and a diagnostic SalI site in the first exon (triangle with asterisk), in addition to
an I-SceI site in the third intron (triangle). DmWWOX exons are represented by the shaded boxes. The positions of primers used for
PCR analyses are also shown. (c) PCR analysis using allele-specific primers revealed a 629bp product in wild-type samples, with
9778/WT but not 9778/MUT (lanes 1 and 2). Conversely, in DmWWOX1 samples a 629 bp product was seen with 9778/MUT but
not 9778/WT (lanes 3 and 4). (d) PCR products of the expected size (993 bp) were obtained from wild type and DmWWOX1 using
9778/339R (lanes 1 and 2). However, only the DmWWOX1 product was digested with SalI to give 629 and 364bp products (lanes 3
and 4). (e) Sequencing of PCR products confirmed the introduction of the premature stop codons, þ 1 frame shift and the diagnostic
SalI site into the endogenous DmWWOX gene
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(hWWOX) was ectopically expressed in the same
pattern (en>hWWOX) and stained with an antibody
directed against the N-terminal region of hWWOX
(Figure 2d, f, h and j). These observations are in
agreement with the cytoplasmic staining of hWWOX
observed when ectopically expressed in mammalian
tissue culture cells but do not resolve the conflicting
reports of subcellular localization of WWOX to the
Golgi or mitochondria (Bednarek et al., 2001; Chang
et al., 2001).
Homozygous DmWWOX1 mutant flies were viable
and displayed no obvious phenotype. In addition, the
overexpression of DmWWOX either ubiquitously using
the daughterless promoter or in alternating stripes using
the engrailed promoter resulted in no obvious pheno-
type. It has previously been reported that WWOX is an
essential partner of p53 during TNF-mediated apoptosis
Figure 2 Expression of DmWOXX and hWWOX in Drosophila.
(a) Western analysis of third instar larvae with anti-C-DmWWOX
antibodies revealed a low level of endogenous DmWWOX in wild-
type samples (lane 1, asterisk), which was absent in the DmWWOX1
mutants (lane 2) and moderately increased in larvae ectopically
expressing DmWWOX under heat-shock control (lane 3,
hs>DmWWOX, asterisk). (b) Western analysis of 4–8 h Drosophila
embryos with anti-N-DmWWOX antibodies also showed a low
level of endogenous DmWWOX (lane 1), which was absent in
DmWWOX1 mutant embryos (lane 2) and dramatically increased in
embryos ectopically expressing DmWWOX in all cells (lane 3).
Appropriate loading controls for immunoblots are shown using
anti-tubulin. (c) High levels of ectopic DmWWOX expression were
observed in alternating bands along the length of en>DmWWOX
embryos. (e, g and i) A single band of ectopic DmWWOX staining
at high power revealed the cytoplasmic localization of DmWWOX
(green), which is complementary to the nuclear DNA stain (red) (d,
f, h and j) Similar stripes of expression were observed in embryos
ectopically expressing human WWOX (en>hWWOX), which was
also cytoplasmically localized. For Western analysis, larvae and
dechorionated embryos were homogenized and boiled in SDS load
buffer. Samples run on 10% SDS–PAGE gels were transferred to
nitrocellulose and immunostained. To generate anti-C-DmWWOX
antibody, we used a synthetic peptide coupled with KLH and the
immune sera from rabbits was purified against the GST-
DmWWOX fusion protein and used at 1 : 200. For anti-N-
DmWWOX, the N-terminal 86 amino acids were fused to GST,
purified and cleaved with thrombin. Immune sera from rabbits
were preadsorbed against fixed DmWWOX1 mutant embryos
before being used at 1 : 1000. An anti-Rabbit HRP secondary
antibody was used at 1 : 3000 (Jackson Laboratories). Mouse
monoclonal a-tubulin (Sigma) was used at 1 : 10 000 with an anti-
mouse HRP secondary antibody (Jackson Laboratories) used at
1 : 2000 for larvae and 1 : 9000 for embryos. For whole-mount
immunolocalization studies, dechorionated embryos were fixed in
4% formaldehyde and incubated with either anti-N-DmWWOX
(1 : 100) or anti-N-hWWOX (1 : 100). To generate an anti-N-
hWWOX antibody, the N-terminal 101 amino acids were fused to
GST and immune sera from rabbits were purified against GST-
hWWOX. A biotinylated anti-rabbit secondary antibody (Jackson
Laboratories) was used at 1 : 400 and a tertiary Strepavidin–Alexa
488 (Molecular Probes) was used at 1 : 200. DNA was visualized
with Hoechst 33258 (10 mg/ml, Sigma). Wild-type (w1118), hs-gal4,
da-GAL4 and en-GAL4 stocks were obtained from Bloomington
Drosophila Stock Center (Indiana University, Bloomington, IN,
USA). cDNA clones of DmWWOX (LD03827) were obtained
from Berkeley Drosophila Gene Project and human WWOX
cDNA was isolated by RT–PCR from human RNA. These cDNA
clones were amplified by PCR and cloned into pUAST (Brand and
Perrimon, 1993). Transgenic lines of UAS-DmWWOX and UAS-
hWWOX were generated by standard transformation procedures
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(Chang et al., 2001), although the significance of this
interaction has been challenged (Aqeilan et al., 2004c;
Ludes-Meyers et al., 2004). Mutations generated in the
Drosophila orthologue of p53, Dmp53, also resulted in
viable adult flies with no obvious phenotype (Lee et al.,
2003; Sogame et al., 2003). However, both reports of
Dmp53 mutant animals showed an increased sensitivity
to ionizing radiation. Given this radiation sensitivity
and the possible functional association between WWOX
and p53 (Chang et al., 2001), we assessed the effect
of ionizing radiation on the survival of DmWWOX1
mutants. Third instar wandering larvae were treated to
varying doses of gamma irradiation and assayed for
their survival to adulthood. DmWWOX1 mutants were
more sensitive than wild type, with a decrease in survival
following irradiation in a dose-dependent manner
(Figure 3a). A significant amount of variation in the
percentage survival was observed between experiments
as evident by the large standard deviation at the
different dosages. A similar level of variation in survival
has previously been reported for both wild-type and
Dmp53 mutants following irradiation (Sogame et al.,
2003).
The protective role of WWOX in Drosophila
was confirmed by functional rescue of the radiation
sensitivity of DmWWOX1 mutants. A high level of
ubiquitous expression of DmWWOX was observed
throughout development in flies carrying both da-GAL4
and UAS-DmWWOX constructs (Figure 2b, lane 3,
da>DmWWOX). A marked increase in the percent-
age survival to adulthood following irradiation was obser-
ved in DmWWOX1 mutants carrying these constructs
Figure 3 Radiation sensitivity of DmWWOX1 mutants. (a)
Percentage survival of DmWWOX1 mutant flies to adulthood
following irradiation was reduced compared to wild-type in a dose-
dependent manner. Under the experimental conditions used, 50%
lethality (LD50) for DmWWOX
1 mutants was approx. 15Gy
compared to an LD50 of approx. 25Gy for wild type. Varying
numbers of larvae were tested at each dose (n¼ 1000 for 0Gy,
n¼ 300 for 10Gy, n¼ 150 for 15Gy, n¼ 3725 for 20Gy, n¼ 800
for 25Gy and n¼ 400 for 30Gy) and error bars represent s.d.
between separate experiments. Mitotic cells of wild-type (b) and
DmWWOX1 mutant (c) wing discs in the absence of irradiation
visualized by anti-PH3 staining. Cell cycle arrest is observed 1.5 h
after irradiation at 25Gy in both wild-type (d) and DmWWOX1
mutant (e) wing discs by the absence of mitotic cells. At 5.5 h after
irradiation at 25Gy, cells have re-entered the cell cycle in both wild-
type (f) and DmWWOX1 mutant (g) wing discs. Acridine orange
stains of wild-type (h) and DmWWOX1 mutant (i) wing discs
showed only a few dying cells in the absence of irradiation. A
significant increase in the number of dying cells was observed 4.5 h
after irradiation at 25Gy in both wild-type (j) and DmWWOX1
mutant (k) wing discs. For radiation sensitivity experiments,
wandering third instar larvae were collected and exposed to
varying doses of gamma-irradiation using a CIS Bio-international
IBL 437C machine. The total number of flies eclosed was scored
after 5–6 days at 251C. For staining of mitotic cells, wing discs were
dissected and fixed in 4% formaldehyde in PBS, rabbit anti-PH3
(Upstate Biotechnology) was used at 1 : 300. Secondary antibody
was anti-rabbit Alexa 488 (Molecular Probes) at 1 : 300. For
acridine orange stains, wing discs were dissected in PBS and stained
for 5min in a drop of 1.6 106 M acridine orange in PBS. Discs
were then rinsed and mounted in PBS and the resulting
fluorescence analysed immediately
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(Table 1, DmWWOX rescue). Again there was significant
variation in the percentage survival between experiments;
however, within each experiment there was a definite
trend of decreased survival of DmWWOX1 mutants
compared to wild-type, and a significant increase in
survival in those mutants carrying the rescue constructs.
A similar level of rescue was observed following ectopic
expression of human WWOX in DmWWOX1 mutants
(Table 2, hWWOX rescue). Thus, the protective function
of WWOX in response to ionizing radiation has been
conserved through evolution.
In response to ionizing radiation, checkpoints signal a
cell cycle arrest to allow time for repair of the damaged
DNA, while increased levels of apoptosis act to remove
any cells that are damaged beyond repair (Sogame et al.,
2003; Jaklevic and Su, 2004). We found no significant
effect on either of these responses following irradiation
of the DmWWOX1 mutants. Staining for mitotic cells
with antiphosphohistone H3 (PH3) in the absence of
irradiation showed normal levels of dividing cells in
both wild-type and DmWWOX1 mutant wing discs
(Figure 3b–c). The absence of staining in both wild-type
and DmWWOX1 mutants 1.5 h after 25Gy irradiation
revealed a functional cell cycle arrest (Figure 3d–e). In
addition, some cells in both wild-type and DmWWOX1
mutants had re-entered the cell cycle by 5.5 h after
irradiation (Figure 3f–g). Acridine orange stains re-
vealed very low levels of dying cells in both wild-type
and DmWWOX1 mutant wing discs in the absence of
irradiation (Figure 3h–i). However, in response to 25Gy
irradiation, both wild-type and DmWWOX1 mutants
showed a marked increase in the number of dying cells
(Figure 3j–k). This is in contrast to Dmp53 mutants
where it was reported that dying cells could no longer
be detected by acridine orange following irradiation
(Sogame et al., 2003). Thus, DmWWOX does not
appear to be an essential component of the Dmp53-
dependent cell death response following irradiation
in Drosophila. However, this does not rule out the
possibility of an interaction between DmWWOX and
Dmp53 with a role in apoptosis or other stress response
pathway(s). We have determined that the radiation
sensitivity of DmWWOX1 mutants is probably not due
to a defect in cell cycle arrest or apoptosis. It will be of
interest to determine whether the oxidoreductase acti-
vity of DmWWOX contributes to the observed pro-
tection after ionizing radiation, as has previously been
shown for NQO1 (Nioi and Hayes, 2004).
In vitro functional assays to date have shown a
role for WWOX in various cellular processes. However,
the relative significance of these findings in vivo is yet to
be determined. This is the first report of a knockout of
the WWOX gene allowing the normal biological
function to be assessed. We found that either Drosophila
or human WWOX act in a protective manner against
the effects of ionizing radiation in Drosophila. This
function is consistent with a role for common fragile
site-associated genes in cancer cell biology since loss of
function WWOX mutations could lead to a subsequent
increase in cellular damage.
The function of WWOX in Drosophila may differ
from mouse and human in some minor details, but we
anticipate the major biological functions to be conserved
as evident by the high level of amino-acid conservation
and distinct phylogenetic relationship of WWOX
proteins from other oxidoreductases. The FHIT gene
spanning the FRA3B common fragile site has also been
shown to play a protective role against carcinogen-
induced neoplasia (Zanesi et al., 2001). The finding that
the two most sensitive human chromosomal fragile sites
are both spanned by genes that play protective roles
against environmental challenges could be merely
coincidence. However, it is more likely that there is
a functional relationship of some sort between these
fragile sites and their respective genes resulting in a
contribution to cancer cell biology. This is further
supported by other striking similarities between the
WWOX and FHIT genes. They are both extremely large
(>1Mb in mouse and human), they both are sites of
DNA instability in human cancers and their association
with fragile sites has been conserved in mouse (Glover
et al., 1998; Krummel et al., 2002). These features are
also shared by the Parkin, gene which maps to FRA6E
(Cesari et al., 2003; Denison et al., 2003; Picchio et al.,
2004; Wang et al., 2004) and the ionotropic glutamate
receptor delta 2 (GRID2) gene, which maps to FRA4F
(Bluteau et al., 2002; Rozier et al., 2004). These proper-
ties appear to have been acquired quite independently
during evolution as the genes themselves bear no DNA
sequence similarity nor are their encoded proteins
members of the same protein superfamily. Together,
these data strongly support the proposal that common
chromosomal fragile sites and the genes in their
immediate vicinity constitute part of a protective
Table 1 DmWWOX rescues the radiation sensitivity of DmWWOX1
mutants
I II III IV
Wild-type 53.4 59.0 54.2 54.1
DmWWOX1 mutant 17.8 41.9 23.1 13.6
DmWWOX rescue 50 51.0 44.2 38.7
Percentage survival to adulthood following irradiation at 20Gy
(n¼ 300 for each genotype in experiments I–III and n>200 in
experiment IV). Ectopic expression of DmWWOX in a DmWWOX1
mutant background (DmWWOX rescue) resulted in a marked increase
in survival compared to the DmWWOX1 mutants
Table 2 Human WWOX rescues the radiation sensitivity of
DmWWOX1 mutants
I II III
Wild-type 38.7 56.3 60.8
DmWWOX1 15.4 37.8 29.9
hWWOX rescue (line 1) 30.6 50.3 45.8
hWWOX rescue (line 2) 35.0 49.7 ND
Percentage survival to adulthood following irradiation of larvae at
20Gy (n¼ 300 for each genotype in experiments I and II, n>150 in
experiment III). Ectopic expression of either of two independent lines
of human WWOX in a DmWWOX1 mutant background (hWWOX
rescue) resulted in a marked increase in survival compared to the
DmWWOX1 mutants (ND¼ not determined)
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mechanism that is activated in response to environ-
mental challenges.
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Neither the molecular basis for common fragile site DNA instability nor the contribution of this form of chro-
mosomal instability to cancer is clearly understood. Fragile site FRA16D (16q23.2) is within regions of fre-
quent loss-of-heterozygosity (LOH) in breast and prostate cancers, is associated with homozygous
deletions in various adenocarcinomas and t(14;16) chromosomal translocations in multiple myeloma. The
FOR (WWOX ) gene spans FRA16D and encodes a partner of p53 that also has a role in apoptosis.
Previously untested 53 cancer cell lines were screened for deletions within the FOR/WWOX gene.
Deletions were detected in Co115, KM12C and KM12SM. Homozygous deletions in these and two previously
identified tumour cell lines were intragenic on both alleles, indicating a distinct mutation mechanism from
that causing LOH. Identical FRA16D deletions in two cell lines (one derived from the primary carcinoma
and the other from a secondary metastasis) demonstrate that FRA16D DNA instability can be an early, tran-
sient event. Sequence analysis across one deletion locates one endpoint within a polymorphic AT-dinucleo-
tide repeat and the other adjacent to an AT-rich mini-satellite repeat implicating AT-rich repeats in FRA16D
DNA instability. Another deletion is associated with de novo repetition of the 9 bp AT-rich sequence at one
of the deletion endpoints. FRA16D deleted cells retain cytogenetic fragile site expression indicating that
the deletions are susceptible sites for breakage rather than regions that confer fragility. Most cell lines
with FRA16D homozygous deletions also have FRA3B deletions, therefore common fragile sites represent
highly susceptible genome-wide targets for a distinct form of mutation.
INTRODUCTION
Chromosomal fragile sites are non-staining gaps in metaph-
ase chromosomes that are induced to appear under specific
cell culture conditions (1). There are more than 100 fragile
sites in the human genome, distinguished by their frequency
in the population and chemistry of induction as well as their
physical location. Rare (or inherited) fragile sites are found
in ,5% of individuals and are induced by various chemicals,
some of which perturb nucleotide levels and others that prefer-
entially bind certain DNA sequences. The study of various
rare chromosomal fragile sites has provided insight into the
novel genetic mechanism of repeat expansion termed
dynamic mutation (2). All rare fragile sites characterized to
date are due to the expansion of the longest normal alleles
of a polymorphic DNA repeat beyond a particular copy
number threshold (3). Common (or constitutive) fragile sites
are found in all individuals. Recently trans-acting factors
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ATR, BRCA1, SMC and the Fanconi Anaemia pathway have
been shown to be involved in common fragile site expression
(4–7). These factors and pathways further implicate replica-
tion stalling as the mechanism of cytogenetic expression.
However, the DNA sequence requirements (cis-acting
elements) of common fragile sites are not yet understood.
Increased DNA flexibility at fragile site loci, manifesting as
clustering of ‘FlexStab’ peaks, has been noted using a compu-
ter based algorithm (8,9). Whether the DNA sequences
responsible for FlexStab peaks are necessary and sufficient
for common fragile site expression has not been directly
tested.
On the basis of the observation that common fragile sites
are located at or near structural chromosome defects known
in various cancers, Yunis and Soreng (10) proposed that
fragile sites are susceptible to DNA instability in cancer and
that such instability contributes to neoplasia by virtue of
altered expression of the associated genes. A relationship (if
any) between rare fragile sites and cancer is not clear. In
general, individuals with rare chromosomal fragile sites are
at no greater risk of cancer (11). The folate sensitive fragile
site FRA11B is located within the 50-untranslated region of
the c-CBL proto-oncogene and despite predisposing to the
11q-breakage seen in some cases of Jacobsen syndrome, this
fragile site does not appear to be associated with increased
cancer risk (12,13). On the other hand, higher copy number
alleles of the CCG repeat (that, when expanded, gives rise
to folate sensitive rare fragile sites) are found at higher fre-
quency in individuals with chronic myeloid leukaemia
(CML) (14). Moreover, CML patients with these higher
copy number alleles have a poorer prognosis.
A clearer picture of the role of DNA instability at common
fragile sites in cancer has begun to emerge (1,15). Homozy-
gous deletion at the most readily inducible common fragile
site, FRA3B, is very frequent in cancer cells, particularly in
those from tissues exposed to highest levels of environmental
mutagens (16,17). The FHIT gene spanning FRA3B is usually
inactivated by such deletion resulting in loss of FHIT function.
Mutation of one allele of the Fhit gene in transgenic mice
renders these mice more susceptible to chemical mutagenesis
(18). This susceptibility can be ‘rescued’ by means of Fhit
gene therapy (19). Therefore loss of function of Fhit protein
mediates the increased susceptibility to further mutation,
rather than the alternative possibility that a chromosome-struc-
ture related role for the FRA3B fragile site contributes to
mutagen susceptibility (e.g. via an effect on chromosomal
stability).
Similarly, homozygous deletions at the second most readily
induced common fragile site, FRA16D, at 16q23.2 have been
detected in cell lines derived from adenocarcinomas of the
stomach, lung, breast, ovary and colon (20–22). A gene
(FOR, WWOX, WOX1 ) spanning FRA16D has been identified
(9) and some of its functional characteristics determined
(22–24). In addition, t(14;16) translocations have been
found to map within the 16q23.2 region in 25% of cases
of multiple myeloma and breakpoints for four out of five of
these are located within the FOR gene (20,25,26). FOR gene
expression is reportedly elevated in some breast cancer cell
lines (27) but reduced in breast tumour tissue (28), whereas
the adjacent c-MAF proto-oncogene is increased in expression
in t(14;16) translocated multiple myeloma cells (25). There-
fore multiple genes may be affected by FRA16D associated
DNA instability.
In this report, we address several key aspects of the
mutation mechanism that gives rise to homozygous deletion
at the FRA16D fragile site in cancer cells. First, the timing
of the deletion event in the neoplastic process, as it is
assumed that early events are more likely to be causal rather
than consequential. Secondly, the relationship between
FRA16D associated deletion and another form of deletion
(loss-of-heterozygosity, LOH) known to occur at high fre-
quency in certain cancers in the 16q23.2 region. Thirdly, the
nature of the deletion endpoints and any identifiable character-
istics of the sequences at or near these deletion endpoints.
Fourthly, the extent of ‘genome-wide’ instability that occurs
in FRA16D deleted cell lines. Finally, the effect of FRA16D
associated deletions on the cytogenetic expression of the
FRA16D fragile site.
RESULTS
Timing and stability of FRA16D deletion in tumourigenesis
Various tumour cell lines have previously been identified as
containing FRA16D associated homozygous deletions
(20,21). This included a screen of seven FRA3B containing
cell lines in our laboratory of which one (AGS) had
FRA16D deletions (20) and the HCT116 cell line identified
by others (21). However, the relative frequency and timing
of this form of mutation have not been characterized. There-
fore we have screened an additional 53 tumour cell lines for
FRA16D associated homozygous deletions and detected
three new cell lines with homozygous deletions at FRA16D
(Table 1). Detailed mapping of the FRA16D deletion end-
points in cancer cell lines was conducted using multiplex
PCRs (see Supplementary Material) [refer Ried et al. (9)
and Mangelsdorf et al.(20) for experimental details]. Two of
these cell lines (KM12C and KM12SM) originated from a
Table 1. Tumour cell lines screened for homozygous deletions at fragile site
loci
Cell line Fragile site
FRA3B FRA16D FRAXB FRA7G
(FHIT ) (FOR/WWOX ) (STS )a (D7S522)b
AGS þ þ 2 2
HCT116 2 þ 2 2
Co115 þ þ 2 2
KM12C þ þ 2 2
KM12SM þ þ 2 2
LoVo þ 2 2 2
HT29 þ 2 2 2
KatoIII þ 2 2 2
SW480 þ 2 þc 2
MDA-MB436 þ 2 2 2
LS180 þ 2 2 2
þ indicates homozygous deletion.
aSequence tagged sites SY750, sts-M16505, WI-9247.
bKnown to be within FRA7G locus, but no homozygous deletion yet
detected.
cFrom Arlt et al. (36).
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single patient (KM12) with colorectal cancer of Dukes’ B2
stage (29). The KM12C cell line was derived from the
primary tumour obtained by the injection of the parental
(KM12) cells into the spleen of a nude mouse. The
KM12SM cell line was derived from a spontaneous metastasis
in the liver of the nude mouse. The KM12SM cell line, there-
fore, represents a metastatic derivative and the KM12C cell
line a primary tumour derivative, both originating from the
same primary human carcinoma. Karyotype and isoenzyme
analysis of KM12SM has revealed that this cell line is predo-
minantly tetraploid and has elevated type IV collagenolytic
activity compared with the KM12C cell line (29). No evidence
of ongoing instability at FRA16D was found despite marked
differences in the karyotype of the KM12C and KM12SM
cell lines (Fig. 1). The KM12SM line has at some point under-
gone the duplication of its chromosome complement, yet only
eight chromosomes remain tetraploid, others having increased
or decreased in number, and whereas the KM12C line appears
more stable in terms of chromosome copy number, it has
undergone chromosomal instability distinct from that of
KM12SM, notably a t(2;16) translocation. The identical
extent of FRA16D deletion in the KM12C and KM12SM
cell lines (Fig. 2) demonstrates that this FRA16D fragile site
associated deletion event occurred at an early stage in the pro-
gression of the carcinoma and remained stable in the presence
of other forms of chromosomal instability.
The previously identified AGS and HCT116 cell lines were
found by the analysis of a more detailed set of STS markers
(Fig. 2 and Supplementary Material) to contain the presence
of two or more distinct homozygous deletions (Fig. 2). We
analysed HCT116 cells from three different sources and
found that the homozygous deletion in these cells was identi-
cal; supporting the likelihood that the instability that causes
the deletion is transient (unpublished results). In all FRA16D
deleted cell lines described here, a common region of deletion
was identified that included the previously described Flex-
Stab1 AT peak (9). FlexStab1 is the most flexible (FlexStab
score 18) of six peaks of flexibility clustering in the
FRA16D region, the other peaks having a score of 14,
whereas most human chromosomal DNA scores between
nine and 12 for the FlexStab algorithm (8,9).
Correlations between frequency and extent of cytogenetic
fragility and DNA instability
Chromosomal fragile sites are the in vitro consequences of
culturing cells in the presence of certain chemicals. The
relationship between this in vitro ‘fragility’ and the in vivo
DNA instability observed as homozygous deletion, is as yet
unclear. The common fragile sites are observed with differing
frequencies—FRA3B being most frequently observed fol-
lowed by FRA16D, FRAXB, FRA7G and FRA7H. We there-
fore investigated whether cell lines with known deletion at
one of these fragile sites were also deleted for any of the
other fragile sites for which locations of fragile site DNA
Figure 1. Karyotypes of (A) KM12C and (B) KM12SM. Example karyotypes
of the KM12C and KM12SM colon carcinoma cell lines. The most common
karyotype for each cell line is given. In both cases, variants of these karyo-
types were also observed.
Figure 2. FRA16D associated deletions in tumour cell lines. Schematic (not to
scale) of FRA16D/FOR region in cells with FRA16D deletion (AGS, HCT116,
Co115, KM12C and KM12SM). Approximate lengths of homozygous
deletions are as follows: a ¼ 100 kb, b ¼ 8 kb, c ¼ 116 kb, d ¼ 25 kb,
e ¼ 50 kb, f ¼ 220 kb, g ¼ 46 kb, h ¼ 68 kb, i ¼ 3 kb, j ¼ 221 kb and
k ¼ 221 kb.
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sequences have been determined. The majority (4/5) of
FRA16D deleted cell lines also have FRA3B deletion,
whereas only a minority (4/10) of FRA3B deleted cell lines
have FRA16D deletions (Table 1). Homozygous deletion at
multiple fragile site loci suggests a common molecular mech-
anism with common trans-acting factor(s). The higher fre-
quency of observed in vivo homozygous deletion at FRA3B
compared with that at FRA16D is consistent with the higher
frequency of observed in vitro cytogenetic fragility observed
at FRA3B than at FRA16D, suggesting that there may be a
causal relationship between in vitro fragility and in vivo
DNA instability which is determined, at least in part, by cis-
acting elements, i.e. the primary DNA sequences which con-
stitute the respective fragile site regions of the genome.
Similarly, we sought to determine whether the extent of fra-
gility at a fragile site locus, previously determined by high res-
olution in situ hybridization (20), correlated with the extent of
homozygous deletion in cancer cell lines. Homozygous del-
etions were found as multiple events in three cell lines
(AGS, Co115 and HCT116). In all cases, including those
with multiple deletions, the extent of deletion is confined to
the same 270 kb DNA within which the vast majority
(942/972 of in situ hybridization signals or 97%) of chromo-
some breakage at FRA16D is found to map upon fragile site
induction (20) (Fig. 2).
Relationship between FRA16D homozygous deletion and
16q23.2 LOH
LOH has been identified in the 16q23.2 region in prostate and
breast cancers (30,31) and it was based on this LOH that Bed-
narek et al. (22) identified the WWOX gene also identified by
others (9) as the FOR gene spanning FRA16D or the WOX1
gene induced by hyaluronidase (23). Two polymorphic
markers (D16S518 and D16S504), that define the boundaries
of the prostate and breast cancer regions of heterozygous loss,
were found to be heterozygous in all cancer cells with homozy-
gous FRA16D deletions (Fig. 2). As the D16S518 and D16S504
markers are intragenic to the FOR/WWOX gene, the homozy-
gous deletions are therefore localized events that do not
extend beyond the FOR/WWOX gene in contrast to the LOH
deletions that can extend over very large regions spanning
16q23.2. Therefore, it is unlikely that the FRA16D fragile site
represents a ‘boundary’ of the extensive LOH deletion
events. The LOH and homozygous deletion events are quite dis-
tinct and therefore are likely to have different mutation mech-
anisms and/or genetic/environmental causes.
Deletion endpoints and the role of repeats in fragility
Previously, we have mapped the endpoints of several homozy-
gous deletions by duplex PCR analysis to regions spanning
peaks of DNA ‘flexibility’ (9). The exact position of 20 end-
points in the available cancer cell lines with FRA16D associ-
ated homozygous deletions was determined by detailed duplex
PCR mapping (Fig. 2 and Supplementary Material). In only
one case, it is possible for any two of the deletion endpoints
in unrelated cell lines to coincide, therefore there are
no common endpoints associated with FRA16D associated
homozygous deletion in cancer cells and therefore no apparent
‘hotspots’ for breakage. Long range PCRs were established
across three of these deletions enabling the DNA sequence
spanning the deletion endpoints to be determined. The DNA
endpoints at each end of one of the homozygous deletions in
the HCT116 cell line are either within an AT-dinucleotide
repeat [corresponding to FlexStab 1 in Ried et al. (9)] or adja-
cent to (1 kb away) an AT-rich mini-satellite (Fig. 3). The
sequences giving rise to the FlexStab1 region (9) are either
deleted or present at the endpoint boundary, in all of the
cancer cell lines with FRA16D deletions analysed here. As
the AT-dinucleotide repeat does appear to represent a pre-
ferred target for instability, we undertook PCR analysis of
the repeat in order to determine whether there is variation in
copy number between individuals and whether any such
copy number variation might contribute to variation in cytoge-
netic expression of FRA16D. The PCR analysis of 78 individ-
uals demonstrated an extremely high level of copy number
polymorphism (PCR analysis for 35 individuals is shown in
Fig. 4A) with an observed heterozygosity of 97% in 25 diffe-
rent alleles. This high level of copy number variation
prompted an analysis of the transmission of the repeat
through a CEPH pedigree to ascertain the degree of repeat
instability. Mendelian inheritance was observed with no evi-
dence of copy number instability through the three generations
tested (unpublished results). Therefore, the AT dinucleotide is
stable in germ-line transmission and does not represent a
hyper-mutable sequence. We also looked for a relationship
between the copy number of the repeat in an individual and
the percentage of metaphases expressing the FRA16D fragile
site. No correlation between fragile site expression level and
AT-repeat copy number was observed (Fig. 4B), suggesting
that if the variation in copy number of the AT-dinucleotide
repeat does contribute to fragile site expression levels, then
this contribution is not rate limiting and other factors (e.g.
trans-acting factors) have a greater effect on fragile site
expression levels.
Sequence analysis of the Co115 deletion no. 1 endpoints
(Fig. 3) revealed that a 9 bp sequence located at the proximal
endpoint has been the subject of de novo amplification to give
six additional copies (seven in total) of the 9 bp repeat
TTTCATATG. The molecular process responsible for the
fragile site associated deletion of DNA is therefore able to
facilitate the de novo generation of DNA repeat sequences
upon repair of the damaged DNA.
Cytogenetic FRA16D expression in cells with FRA16D
homozygous deletion
It has been proposed (32) that flexible DNA sequences, such
as the FlexStab1 AT repeat, play a causative role in chromo-
somal fragile site expression. The large homozygous deletions
in the FRA16D region afford the opportunity to assess whether
any or all of the deleted sequences are necessary for the cyto-
genetic expression of the chromosomal fragile site. Therefore,
we analysed those cell lines with homozygous FRA16D
associated deletions that spanned the FlexStab1 AT-dinucleo-
tide repeat deletion for cytogenetic expression of FRA16D. All
of these cell lines still exhibit FRA16D cytogenetically and
in two cell lines, FRA16D was observed on each of the
chromosome 16s present (Fig. 5). These results indicate that
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the FlexStab1 sequences are not necessary for fragile site
expression.
Similarly, those cell lines with FRA3B associated deletions
were still able to express FRA3B (Fig. 5). This suggests that
the deleted sequences are not necessary for cytogenetic
expression and appear to be the most likely ‘high-risk’
targets for breakage when it is going to occur.
DISCUSSION
Cytogenetically distinguishable, aphidicolin inducible
common chromosomal fragile sites are located at .70 sites
around the human genome (1). These sites vary in their sensi-
tivity to induction with FRA3B being the most frequently
observed, followed by FRA16D then FRAXB, FRA7G and
FRA7H. Homozygous deletion is normally a rare event in
the human genome; however, the FRA3B fragile site has
been found to be subjected to frequent homozygous deletion
in cancer. In order to determine whether the events at
FRA3B were generally applicable to other fragile sites in the
‘common’ or ‘constitutive’ category, we have undertaken a
molecular analysis of the FRA16D fragile site and its associ-
ated DNA instability in cancer cells.
Mutation events that occur early in tumourigenesis are
thought more likely to contribute to cancer cell biology than
Figure 3. Sequence analysis across FRA16D associated cancer cell deletions. (A) HCT116 25 kb deletion with one deletion endpoint located within the Flex-
Stab1 AT repeat. (B) Co115 220 kb deletion with de novo amplification of a normally unique 9 bp sequence immediately adjacent to one deletion endpoint.
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Figure 4. Relationship between FlexStab1 AT-repeat copy number and fragile site expression. (A) Polymorphism of FlexStab1 AT-repeat copy number.
M—marker lanes. Copy numbers calculated by comparing mobility of FlexStab1 PCR products against size markers. PCRs from 35 different individuals
were electrophoresed in this gel on the basis of increasing copy number of shorter allele. (B) Percentage FRA16D expression (x-axis) in peripheral
blood lymphocytes of individuals genotyped for FlexStab1 AT-repeat allele copy numbers (y- and z-axis). The expression peaks of two individuals
with either low copy number alleles [37,40] and high FRA16D expression level (59%) or high copy number alleles [44,68] and low FRA16D
expression levels (29%) are arrowed and illustrate inconsistent relationship between FlexStab1 AT-repeat allele copy numbers and relative FRA16D expression
levels.
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later mutation events. Later events may simply be a conse-
quence of genome-wide DNA instability brought about by
loss of DNA repair function. The timing of DNA instability
at common fragile sites in cancer was determined by analysing
FRA16D homozygous deletions in two cancer cell lines
(KM12C and KM12SM) at different stages of cancer
progression but originating from the same primary tumour.
Indeed, the common clonal origin of these cell lines is demon-
strated by their identical deletion endpoint boundaries at
the FRA16D locus. Therefore, the FRA16D deletion in the
KM12 derived cell lines preceded the genetic events that
led to the metastatic KM12SM cell lineage. A great deal of
chromosomal instability is evident in the KM12SM cell
line (Fig. 1), whereas a distinct translocation event, t(2;16),
has taken place in the relatively stable KM12C cell line.
However, no additional mutation at the FRA16D locus
is evident supporting an early role for this form of mutation
and suggesting that once fragile site associated mutation
does occur then the resultant sequences are able to
remain stable even in the presence of other forms of extensive
chromosomal instability. It is likely that the DNA instability is
the result of some sort of environmental factor or stress under
which the cell is temporarily placed and once this is relieved
then no further mutation takes place. Corbin et al. (33) have
found that additional FRA3B mutations have been found in
somatic cell derivatives of cancer cells with FRA3B associated
homozygous deletions. It may well be that such additional
instability is a result of environmental factors associated
with the derivation of these cell lines, or alternatively,
that the higher incidence of FRA3B fragility may render it
prone to substantially more DNA instability than the
FRA16D locus.
If there is a direct causal relationship between chromosomal
fragility and DNA instability at common fragile site loci, it
would be expected that the likelihood of observing fragile
site associated breakage in cancer cells would correlate with
the frequency with which the various fragile sites are observed
cytogenetically. As FRA3B is the most readily observed
fragile site, it would therefore be expected to exhibit the
highest frequency of homozygous deletion. The finding that
FRA16D associated homozygous deletions are found in
some, but not all, cancer cell lines exhibiting FRA3B associ-
ated homozygous deletions is consistent with a causal relation-
ship between cytogenetic fragility and homozygous deletion in
cancer cells.
FRA16D is located in the overlap between frequent LOH
regions identified on 16q23 in breast and prostate cancers.
Indeed Bednarek et al. (22) identified the FOR/WWOX gene
on the basis of its location within the breast cancer 16q23
LOH region. The potential therefore exists that FRA16D acts
as a frequent boundary for the deletions that give rise to
LOH and that the homozygous deletions observed in some
carcinomas are merely the manifestation of overlapping and
more extensive LOH regions. Analysis of polymorphic
markers flanking the FRA16D region demonstrates that in all
the cell lines with a homozygous FRA16 deletion, the adjacent
flanking sequences are still present for both parental chromo-
somes. Therefore, the mechanism giving rise to homozygous
FRA16D deletions appears to be quite distinct from that
giving rise to LOH deletion.
The homozygous deletion of DNA sequences in the
FRA16D region affords the opportunity to assess the contri-
bution of these deleted sequences to cytogenetic expression
of the fragile site. If the deleted sequences either contribute
to or are essential for fragile site expression then their deletion
would be expected to either reduce the frequency of fragile
site expression or abolish it altogether. No evidence of an
impact of deletion on fragile site expression could be found.
In the HCT116 cell line, the two chromosome 16s can be dis-
tinguished by a translocation onto 16p and both the normal
and derivative chromosome 16s express the fragile site. This
observation rules out the trivial explanation that the extent
of deletion is sufficient to obliterate expression of only one
of the two chromosome homologues. Levels of common
fragile site expression vary markedly within the population
and between different cell lines and therefore quantitative
effects are extremely difficult to determine (34,35) [Fig. 4B
which reveals 2-fold variation (29–59%) in the expression
of FRA16D between individuals]. Although a quantitative
effect on the level of expression cannot be ruled out, the fre-
quency of cytogenetic expression in the cell lines was not
remarkably below that observed in cell lines without
FRA16D deletions. The deletions of the FlexStab regions
(FlexStab1 in particular) are therefore noteworthy, because
these regions have been proposed to play a causative role in
fragile site expression (32). Given that chromosome fragility
plays a causal role in the mechanism of homozygous deletion,
then chromosomes with FRA16D deletions will still be able to
undergo further deletion should the necessary environmental
conditions again arise. This may explain the frequent obser-
vation of multiple homozygous deletions in single cancer
cell lines (AGS, HCT116 and Co115), as each deletion
could represent an independent event during the exposure of
the cell to the conditions conducive to homozygous deletion.
Figure 5. Fragile site induction in FRA16D deleted cell lines AGS, HCT116
and Co115. Partial metaphases showing chromosome 16 or chromosome 16
derivatives and chromosome 3 from each cell line, as indicated. a: The
partial metaphase in AGS shows that both chromosome 16s are expressing
FRA16D. b: One of the HCT116 chromosome 16s carries a large translocation
enabling the unique identification of the two chromosome 16s, allowing
FRA16D expression to be observed on both.
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Analysis of the homozygous deletion endpoints reveals a
substantial degree of heterogeneity with only two of the 20
mapped endpoints possibly coinciding. This observation may
be somewhat misleading given that the endpoints actually rep-
resent the outcomes of repair processes rather than the actual
initial sites of breakage. The region spanning the previously
described FlexStab1 region is commonly deleted in each of
the cell lines with FRA16D homozygous deletion suggesting
that this region is prone to instability, however, the relation-
ship between the FlexStab1 AT repeat and this instability is
unclear. No evidence of a causative role could be found.
Indeed, it is noteworthy that despite the conservation of the
relationship between a chromosomal fragile site and the
FOR/WWOX gene between mouse and human, and the high
level of sequence homology found in parts of the respective
exon 8 sequences between mouse and human homologues,
that the mouse does not have the corresponding FlexStab1
sequences conserved. In this regard, the deletion endpoint of
particular note is that in Co115 cells where a sequence of
nine bases is copied six times to give rise to a de novo
repeat. This finding suggests that the mechanism of DNA
instability caused by the presence of a chromosomal fragile
site can actually lead to the formation of a DNA repeat
sequence. This brings into question the relationship between
repeat sequences and fragile sites, as instead of the presence
of repeat sequences causing fragile site expression, it may
well be that the presence of a fragile site can lead to the for-
mation of repeat sequences.
In conclusion, a substantial body of evidence (presented
here and elsewhere) suggests that common fragile sites are
regions of particular sensitivity to DNA instability and that
there is a correlation between the level of in vitro chromoso-
mal fragility and in vivo DNA instability in cancer cells.
The localized multiple-hit nature of the homozygous mutation
together with its subsequent (relative) stability suggests that it
is most likely that an interaction between environmental and
trans-acting factors plays a determining role in the common
fragile site associated mutation mechanism.
MATERIALS AND METHODS
Cell lines
The AGS, HCT116, LoVo, HT29, KatoIII, SW480, MDA-
MB436 and LS180 tumour cell lines were from the collection
of the Centre for Medical Genetics, Women’s and Children’s
Hospital and were grown as previously described (18). Co115,
KM12C and KM12SM and other tumour cell lines (mainly
derived from colon carcinomas) were from the collection of
the Queensland Institute for Medical Research, Royal Bris-
bane Hospital.
PCR and DNA sequence analysis
Duplex PCR was performed on DNA isolated from cultured
cell lines according to the methods of Mangelsdorf et al.
(18) and Ried et al. (21). Primers used in deletion mapping
are indicated in Supplementary Material, Table S1. Most of
the PCR primer oligonucleotide sequences are as reported in
Ried et al. (9). Additional primer sequences may be obtained
upon request. DNA sequence analysis of PCR products was
performed at the Institute of Medical and Veterinary Science
(Adelaide, South Australia) DNA sequencing facility using
Applied Biosystems chemistry and equipment. The software
program Lasergene (DNASTAR Inc., Madison, WI, USA)
was used to analyse DNA sequences. FlexStab1 AT repeat
allele copy numbers were determined by incorporating a32P-
dCTP into the PCR products and then electrophoresis on acryl-
amide gels. Oligodeoxynucleotide primers for FlexStab1 AT-
repeat copy number genotyping were GCATGAGTGGT-
GATGGATGT and GGACAGAACTAACCCAGAGA.
Metaphase preparation and fragile site induction
Metaphases were prepared by standard methods. Briefly, cul-
tures were grown for 72 h in Eagle’s essential medium, minus
folic acid, supplemented with 5% FCS. Induction of FRA16D
was with 0.4 mM aphidicolin dissolved in DMSO added 24 h
before harvest. Fifty metaphases were scored for the percen-
tage of chromosome 16s expressing FRA16D in all but one
individual in whom 100 metaphases were scored.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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The generation and analysis of mutants is central to
studies of gene function in model organisms. Methods
for random mutagenesis in Drosophila melanogaster
have been available for many years, but an alternative
approach – targeted mutagenesis using homologous
recombination – has only recently been developed. This
approach has the advantage of specificity, because
genes of interest can be altered. One might expect with
a gene-targeting approach that the frequency of back-
ground mutations would be minimal. Unfortunately, we
have found that this is not the case. Although the
possibility of background mutations arising during hom-
ologous-recombination-based gene targeting has been
raised in the literature, it is not routinely taken into
account when using this technique. Our experience
suggests that it can be a considerable problem but that
it has a relatively simple solution.
A new generation of mutagenesis in Drosophila
The Human Genome Project has contributed to the
identification of a large number of novel genes of unknown
function, many of which are associated with particular
human diseases. One approach to improve our understand-
ing of the function of specific genes and the pathogenic
pathway(s) by which their mutation leads to disease is
through the use of animal models. Targeted gene mutagen-
esis has enabled analysis of the phenotypic consequences of
specific gene mutations; however, such analysis is based on
the assumption that the model animals have a uniform
genetic background. Recently, some of the concerns associ-
ated with inbred strains of mice and their variable genetic
backgrounds were raised in this journal [1]. Drosophila is
another organism that can provide useful insights into
the function of orthologous genes, and methods have
been established recently to carry out targetedmutagenesis
inDrosophila. Our experience is that although gene target-
ing in Drosophila is effective, it can also result in a signifi-
cant number of background mutations that can either
lead to a phenotype on their own or contribute to the
observed phenotypes.
In the past, mutagenesis of Drosophila involved a
random whole-genome approach, in which a mutagen such
as radiation or DNA-damaging chemicals was applied to
the organism or in which random insertion of transposons
was induced. It is well established that the multiple ‘hits’
generated by these approaches provide background
mutations that can interfere with subsequent phenotypic
analyses. Targeted approaches for mutagenesis have been
available in the mouse and in yeast for many years. The
power of this type of approach lies in the ability to intro-
duce a desired mutation(s) into any gene of interest, with
no reliance on phenotype for identification of the resultant
mutant alleles and no reliance on existing genetic lesions
in the region of interest. Recently, techniques for the
targeted mutagenesis of genes by homologous recombina-
tion (HR) have been developed forDrosophila. Despite this
method having the considerable advantage of specificity,
it does not seem to have been widely embraced by the
Drosophila research community. It is possible that because
HR approaches in Drosophila are time consuming and
involve multiple steps with various genetic rearrange-
ments occurring at unpredictable frequencies (Figure 1),
and because researchers are familiar with more estab-
lished techniques, HR might be the least favoured method
for mutagenesis. However, the benefits of the specificity of
HR-generated mutations can outweigh the investment
required for their generation.
Successful gene targeting using HR in Drosophila was
first reported in 2000 by Rong and Golic [2], and we have
found 29 subsequent reports [3–31]. These reports include
examples of ‘ends-in’ and ‘ends-out’ targeting approaches,
the details of which are outlined in Figure 1. We have
carried out ends-in targeted mutagenesis for the Droso-
phila gene Wwox (also known as CG7221) and found non-
targeted mutation(s), in addition to the desired mutations,
that have significant effects on phenotypic outcomes. In
this Opinion article, we detail our findings, including the
difficulty that we experienced in uncovering the problem of
background mutations, to illustrate the nature of this
issue.
Background nontargeted mutations generated by
HR: some unpleasant surprises
Wecarried out ends-in targeting to introduce twopremature
stop codons and a frameshift mutation at the start of
the endogenous Drosophila gene Wwox. We found that
the resultant mutant flies, which were homozygous for
Wwox1, were viable and fertile but showed an increased
Opinion TRENDS in Genetics Vol.xxx No.x
Corresponding author: Richards, R.I. (robert.richards@adelaide.edu.au).
Available online xxxxxx.
TIGS-537; No of Pages 5
www.sciencedirect.com 0168-9525/$ – see front matter . Crown Copyright  2007 Published by Elsevier Ltd. All rights reserved. doi:10.1016/j.tig.2007.03.007
Please cite this article in press as: O’Keefe, L.V. et al., Know thy fly, Trends Genet. (2007), doi:10.1016/j.tig.2007.03.007
367
sensitivity to ionizing radiation [29] (Figure 2a). Genetic
tools that remove large regions of the genome (i.e. deficiency
strains) were unavailable in the region where the Wwox
gene resides, so the phenotype could not be verified using
trans-heterozygosity with a deficiency allele. However, sen-
sitivity to ionizing radiationwas observed inmultiple homo-
zygous strains generated from independent reduction
events (step 2 of ends-in targeting; Figure 1), and rescue
was achieved by introduction of a transgene encoding either
Drosophila Wwox or human WWOX [29].
Sensitivity to ionizing radiation was subsequently also
observed for an independent allele of Wwox (Wwoxf04545)
that resulted from insertion of a piggyBac transposon into
the second intron of Wwox [32]. However, sensitivity to
ionizing radiationwas not observed in flies that were trans-
heterozygous for both Wwox1 and Wwoxf04545 (Figure 2a),
suggesting, to our surprise, that in homozygous strains for
each of these independent alleles ofWwox the phenotype of
sensitivity to ionizing radiation is independent of the
mutations inDrosophila Wwox. To confirm this, we carried
out four rounds of backcrossing of each of these alleles of
Wwox to the parental (‘wild type’) strain used for the
targeted mutagenesis (i.e. w1118, a strain that has a small
deletion in thewhite eye colour gene but which is otherwise
wild type). In both cases, we found that the resultant
homozygous mutant strains showed a significant decrease
in sensitivity to ionizing radiation after backcrossing to
w1118 (Figure 2a). Therefore, the sensitivity to ionizing
radiation must be independent of mutations induced at
the Wwox locus in these cases. It has been reported that
0.3–0.5% of piggyBac insertion strains contain unlinked
backgroundmutations [32], and these could account for the
radiation sensitivity that we have observed in Wwoxf04545
mutants. Our data, therefore, show that background
mutations can arise during a targeted mutagenesis
approach.
Figure 1. Ends-in and ends-out approaches to targeted mutagenesis in Drosophila melanogaster. (a) Ends-in gene-targeting scheme. The relevant features of the targeting
vector pTV2 [25] containing the mutated genomic region of interest are indicated: FLP recombinase target (FRT) sites (green), white (w)+ selectable marker (white) and I-CreI
recognition site, two exons of a hypothetical gene of interest (red) with the red asterisk representing the introduced mutations(s). The whole construct is contained within P
element ends (black) for transformation. There are two steps involved in this process. Step 1 involves induction of gene expression for FLP recombinase and the
endonuclease I-SceI under the control of a heat shock (hs) promoter. This results in excision and circularization of the genomic region between the two FRT sites, followed
by cleavage at the I-SceI site to facilitate integration into the endogenous target locus (blue). This can produce a tandem duplication of the target locus, with one copy
carrying the introduced mutation(s). Step 2 involves reduction to a single allele and is carried out by heat-shock-induced gene expression of I-CreI (hs::I-CreI), which cleaves
at its recognition sequence. This chromosomal break is enlarged by endogenous exonucleases and repaired by a single-strand annealing mechanism, leaving a single copy
of the target locus. PCR screening with allele-specific primers can then be used to identify the recovered mutant alleles. (b) Ends-out gene-targeting scheme. The ends-out
donor construct contains many of the elements of ends-in donor construct. The w+ selectable marker (white) is inserted into the target locus such that it disrupts the gene of
interest (red). The targeting region is flanked at either end by I-SceI sites and directionally oriented FRT sites. The whole construct is contained within P-element ends (black)
for transformation. There is only one step in this process. Induction of gene expression for FLP recombinase and the endonuclease I-SceI in transgenic flies carrying the
targeting construct results in excision and circularization of the genomic region between the two FRT sites, followed by cleavage at the two I-SceI sites. This results in a
linear DNA molecule with breaks at the end of the region of homology between the targeting construct and the endogenous genomic region. The linear targeting molecule
recombines with the target locus (blue), resulting in a cassette exchange and the generation of a mutant allele.
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Proteomic analysis of HR-generated alleles of Wwox
The observed difference in phenotype – i.e. sensitivity to
ionizing radiation – between HR-generated homozygous
Wwox1 mutants before and after backcrossing to w1118
suggests that there are difference(s) at the genomic level.
Therefore, we used 2Ddifference gel electrophoresis (DIGE)
analysis [33] to compare the protein profiles of homozygous
Wwox1 mutants before and after backcrossing to w1118.
Several changes that were observed in the proteins pro-
duced by homozygousWwox1mutants compared withw1118
– the parental strain used for the mutagenesis – are no
longer present after backcrossing to the same parental
strain (Figure 2b); therefore, we conclude that these
changes were introduced, either directly or indirectly, as
a consequence of the targeting procedures.
Changes in the genetic background following HR
The possibility of generating background nontargeted
mutations has previously been raised in the literature
on HR. However, it has most often been mentioned only
briefly in the ‘Materials and Methods’ section or included
as ‘Online Supplementary Material’ and, therefore, is not
often highlighted. Background nontargeted mutations
affecting viability have been reported following HR muta-
genesis of pug, NLaz [25] and Nap1 [19], whereas back-
ground nontargeted mutations are proposed to contribute
Figure 2. Background mutations following HR mutagenesis at the gene Wwox. (a) Wwox1 mutants are no longer sensitive to ionizing radiation after backcrossing to wild-
type flies (w1118). Radiation sensitivity was determined as percentage survival to adulthood after treatment of wandering third instar larvae (5 days of development) with
30 Gy of ionizing radiation, as previously described [28]. Homozygous strains of HR-generated Wwox1 and piggyback-transposon-generated Wwoxf04545 mutants show
sensitivity to ionizing radiation compared with w1118. Sensitivity to ionizing radiation was significantly decreased in homozygous strains of Wwox1 and Wwoxf04545 after
backcrossing to w1118 and was not observed in flies that were heterozygous for these two alleles of Wwox (Wwox1 and Wwoxf04545). The graph shows the average
percentage and the standard deviation for at least three separate experiments for each genotype, where n = 100 for each experiment. (b) Protein profiles of HR-generated
Wwox1 mutants before and after backcrossing to wild-type flies (w1118). Protein homogenate from w1118 and Wwox1 homozygous mutant embryos (at 2–4 h of
development), before and after backcrossing to w1118, was subjected to DIGE analysis, as described in Gong et al. [33]. The green curve shows the frequency distribution of
the log ratios of proteins from Wwox1 mutants to proteins from w1118. The number of individual protein spots on a DIGE gel showing a twofold or greater increase (blue) or
decrease (red) in abundance in the Wwox1 mutants compared with w1118 was determined. Each spot on the graph represents an individual protein spot on a DIGE gel. A
significant decrease in the proteins that changed in abundance was observed in Wwox1 mutants after backcrossing to w1118 (the wild-type strain used for the mutagenesis).
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to variability in meiotic phenotypes as a consequence of
mutations inErcc1 [5]. We have also identified background
nontargeted mutations resulting in semi-lethality and
sterility of females following HR mutagenesis of Rgk1
and Rgk2, respectively (P. Smibert and R. Saint, unpub-
lished).
The presence of background nontargeted mutations
could also explain differences in stress tolerance tests
observed between strains that are homozygous for a
mutation in the gene desaturase-2 [14]. This was reported
as an unlikely explanation, because the independently
reduced strains (i.e. independent strains following step 2
of ends-in targeting; Figure 1) were assumed to be geneti-
cally identical. Claims of genetic identity, other than at the
target locus, have also beenmade for wild-type flies and for
mutant flies generated by HR procedures to induce
mutations in the Or83b [26] and OdsH [9] loci. Similarly,
the assumption that a particular chromosome remains
isogenic after HR procedures has been reported in studies
of independent targeted mutations of three members of the
metallothionein gene family [3]. As a result of these claims
in the literature, it is possible that the contribution of
background nontargeted mutations is also not fully
appreciated by others. Here, our aim is to highlight the
significant impact that background nontargetedmutations
can have on phenotypic outcomes.
Minimizing the impact of background nontargeted
mutations
The importance of proper control of genetic background
following HR has been discussed recently following conflict-
ing reports of stress tolerance assays of strains that are
homozygous for mutation in desaturase-2 [14,34]. The seg-
regationandreassortmentover timeofalleles obtained from
various strainsused for themutagenesishasbeensuggested
as an explanation for the differences. A proposed strategy to
control for changes ingenetic background is the replacement
of chromosomes, other than that on which the gene of
interest resides, with those from a wild-type strain [35].
However, we proposemultiple rounds of backcrossing to the
parental strain as a preferred approach for the elimination
of potential background nontargeted mutations, because
this will ensure that alleles on all chromosomes will be
replaced by assortment and recombination with those from
the parental strain used for the mutagenesis.
Backcrossing has been reported in five of 29 published
studies of Drosophila with mutations generated by HR.
Multiple rounds of backcrossing to either the parental
strain or another wild-type strain is routinely carried
out before conducting behavioural studies. Backcrossing
was performed before male courtship studies of flies with
HR-generatedmutations in fruitless [6,28]. In addition, ten
rounds of backcrossing were carried out for flies with
mutations generated in Or43b [16], which encodes an
odorant receptor, and an unspecified number of rounds
were carried out for flies with mutations in p53 [20]. In the
case of the cation channel PKD2, a more thorough
approach was undertaken: the chromosomes other than
those carrying the targeted mutation were first replaced
and then ten rounds of backcrossing were carried out
[15]. However, in the remaining 25 reports of mutations
generated by HR, there is no mention of backcrossing to
eliminate potential background nontargeted mutations.
We found that four rounds of backcrossing of Wwox1
mutants to w1118 was sufficient to minimize the effect of
background nontargeted mutations on radiation sensi-
tivity. This is a relatively time-consuming process (one
Drosophila generation is a little less than 2 weeks), requir-
ing at least four generations of backcrossing, in addition to
the crosses required for the generation of homozygous
strains. Together, this process takes in excess of 3 months.
For ends-out targeting approaches, these backcrossing
steps are more straightforward, because the mutations
carry a visible eye colour marker, whereas mutations
generated by an ends-in approach need to be followed by
allele-specific PCR. However, there is no substitute for
using good basic genetics after HR mutagenesis (similar
to any other form of mutagenesis).
Verifying HR-generated alleles
The possibility of background nontargeted mutations
following HR mutagenesis (as for all types of mutagenesis)
necessitates verification that observed phenotypes are
specifically attributable to loss of function of the gene of
interest. Independently derived alleles of the gene of inter-
est that show the same phenotype, both as independent
homozygous strains or in a trans-heterozygous combi-
nation, provide strong support for this attribution, as
discussed by Rong et al. [25]. However, our experience is
that independently reducedHR-generated alleles (i.e. after
step 2 of ends-in mutagenesis; Figure 1) following a single
integration event cannot be treated as truly independent.
This finding suggests that nontargeted mutations can be
introduced during step 1 of ends-in targeting (Figure 1),
and these can then be carried through step 2 to all of the
mutant alleles. In addition, verification of HR-generated
mutant phenotypes can also be carried out by rescue
experiments following either introduction of a construct
bearing the corresponding genomic region or ectopic
expression of the corresponding cDNA [25]. However, these
rescue experiments often involve crossing strategies that
can effectively rescue the phenotypic effects of background
mutations by the introduction of wild-type alleles on other
chromosomes, as we observed in our studies with theWwox
gene. In each of these cases, backcrossing of HR-derived
alleles before commencing any phenotypic and/or rescue
analyses would considerably decrease any confounding
contribution of background nontargeted mutations.
What is the origin of background nontargeted
mutations after HR?
It is reasonable to propose that nontargeted mutations can
arise during HR mutagenesis procedures, because the
enzymes that are used (D2-3 transposase, FLP recombi-
nase and the endonucleases I-SceI and I-CreI) could cleave
at nonspecific sites, especially because they are ectopically
expressed. Alternatively, it is also possible that the back-
ground nontargeted mutations could have been introduced
directly, or indirectly, from the various strains used for
the mutagenesis. Irrespective of the origin of background
nontargeted mutations resulting from HR mutagenesis
procedures, their effects will be minimized following
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multiple rounds of backcrossing to an appropriate
wild-type strain.
What is the extent of the problem?
There is not enough information in the published reports of
HR-generated mutations to know whether any of the pre-
viously reported phenotypes might need to be revised
because background mutations contribute to the pheno-
type. Furthermore, we do not wish to analyse other studies
thatmight have been impaired by suchmutations. Our aim
is specifically to raise awareness of the potential contri-
bution of background nontargeted mutations following HR
mutagenesis.
Concluding remarks
In summary, we have found nontargeted background
mutations following HR mutagenesis in Drosophila.
Although there is nothing new about the appearance of
background nontargeted mutations affecting phenotypic
outcomes following various mutagenic procedures in Dro-
sophila, and indeed in all species, background nontargeted
mutations are rarely reported and are not often given
sufficient focus of attention. The possibility of such
mutations is acknowledged in some reports in the litera-
ture, but steps to minimize the impact of these mutations
are taken only infrequently. We propose that phenotypic
analysis of alleles generated by HR-based gene targeting
ought to be carried out only after efforts have been made to
control for genetic background, by repeated backcrossing to
the parental strain from which the mutants were derived.
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Common chromosomal fragile sites FRA3B and FRA16D are frequent sites of DNA instability in cancer, but
their contribution to cancer cell biology is not yet understood. Genes that span these sites (FHIT and WWOX,
respectively) are often perturbed (either increased or decreased) in cancer cells and both are able to sup-
press tumour growth. While WWOX has some tumour suppressor characteristics, its normal role and func-
tional contribution to cancer has not been fully determined. We find that a significant proportion of
Drosophila Wwox interactors identified by proteomics and microarray analyses have roles in aerobic metab-
olism. Functional relationships between Wwox and either CG6439/isocitrate dehydrogenase (Idh) or Cu–Zn
superoxide dismutase (Sod) were confirmed by genetic interactions. In addition, altered levels of Wwox
resulted in altered levels of endogenous reactive oxygen species. Wwox (like FHIT) contributes to pathways
involving aerobic metabolism and oxidative stress, providing an explanation for the ‘non-classical tumour
suppressor’ behaviour of WWOX. Fragile sites, and the genes that span them, are therefore part of a protec-
tive response mechanism to oxidative stress and likely contributors to the differences seen in aerobic gly-
colysis (Warburg effect) in cancer cells.
INTRODUCTION
Common chromosomal fragile sites have been found to
coincide with the location of various forms of DNA instability
(including homozygous deletions and translocations) in cancer
cells (1–3). Common chromosomal fragile sites are found in all
individuals and appear to be regions of the genome that are par-
ticularly sensitive to environmental damage—they are suscep-
tible to agents in cigarette smoke (4) and their expression
levels in cells are modified by dietary factors such as folate
level and even caffeine and ethanol (1,5). When induced to
appear in cells, .70 different common chromosomal fragile
sites exhibit different frequencies of cytogenetic appearance
such that FRA3B (located on human chromosome 3) is the
most readily observed, followed by FRA16D (on human
chromosome 16) and then others distributed over most of the
human chromosomes at specific locations that are reproducibly
observed (2). The incidence of DNA instability in cancer
follows a similar hierarchy (i.e. FRA3B . FRA16D .
others) suggesting that cytogenetic ‘fragility’ and DNA
instability in cancer are directly related (6,7). Recently, a
screen for small homozygous deletions in 746 cancer cell
lines detected chromosomal fragile sites FRA3B and FRA16D
as the two most frequent sites of this form of mutation (3).
†The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.
∗To whom correspondence should be addressed. Tel: +61 883037541, Email: robert.richards@adelaide.edu.au
# The Author 2010. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License
(http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction
in any medium, provided the original work is properly cited.
Human Molecular Genetics, 2010 1–13
doi:10.1093/hmg/ddq495













Common chromosomal fragile sites themselves appear to
span hundreds of kilobases of DNA and are typically located
within lengthy genes (e.g. FHIT 1.5 Mb, WWOX 1.1 Mb,
parkin 1.36 Mb; 8). In the case of FRA16D, the fragile site
DNA region of 260 kb is completely contained within a
massive 780 kb intron of the WWOX gene (6,9,10). Just why
these genes should be so large (the WWOX spliced mRNA
product is only 1.1 kb) and contain fragile sites that are sus-
ceptible to environmental damage is not known, but is very
likely to reflect functional significance since mouse ortholo-
gues of FHIT and WWOX also span common chromosomal
fragile sites (8). Efforts to find relationships between the
different fragile site genes have been reported, but the func-
tional significance of such associations is unclear (8,11,12).
Attention has, therefore, been focussed on the normal func-
tions of common fragile site genes, as it is the perturbation of
these functions that is most likely to contribute to cancer. Both
FHIT (spanning FRA3B) and WWOX (spanning FRA16D) act
to inhibit tumour growth when introduced into cancer cells
lacking their expression (13,14); however, they do not
exhibit all of the typical characteristics of tumour suppressors.
For example, point mutations are extremely rare in WWOX
and the protein is quite commonly still present in cancer
cells (even sometimes increased in expression; 15–18) indi-
cating absence of the hallmark ‘second-hit’ required to fulfil
the Knudsen hypothesis characteristic of tumour suppressors.
This ‘non-classical’ tumour suppressor function for WWOX
is further evident in analysis of rodent mutants for the
WWOX gene. Some (but not all) lines of loss of function
WWOX mutant mice have higher incidence of tumours,
however tumours from heterozygous mutant mice still
express WWOX (19–23). A spontaneous Wwox mutant rat
has also been described, but it does not exhibit higher inci-
dence of tumours (24,25). Rodent Wwox mutants typically
exhibit early death, which may preclude development of
some tumours, in addition to metabolic disorders, but they
are otherwise surprisingly different in their phenotypes (19–
25). This may reflect the distinct nature of their mutations or
their different genetic backgrounds. While these rodent
studies have provided some insight into the biological role
for WWOX, there is still clearly a need to understand the mol-
ecular processes and pathways in which WWOX participates;
particularly how WWOX contributes to metabolism and how
this altered metabolism can contribute, at least in certain cir-
cumstances, to a greater incidence of cancer.
Genetic studies into the function of Wwox have been initiated
in Drosophila. Drosophila is ideal for this particular purpose as
evident from its unique contributions to understanding human
disease pathogenesis pathways where subtle but significant
roles of cancer genes and intricate signal transduction pathways
have been identified (26,27). We have previously identified the
unique Drosophila WWOX orthologue, Wwox (CG7221; 49%
identity with human WWOX) and disrupted the Wwox gene by
homologous recombination (28). Insertion of stop codons and
an altered reading frame at the beginning of the endogenous
gene was effective in causing loss of Wwox function by render-
ing the resultant mRNA from the mutated gene incapable of
being translated into the Wwox protein (28). Initially, Droso-
phila homozygous for this mutation were reported as being sen-
sitive to ionizing radiation. However, further analysis indicated
that background mutations, rather than the targeted Wwox
mutations, were responsible for this phenotype (29).
The lack of phenotype in Drosophila has precluded direct
genetic analysis of the Wwox function. We have, therefore,
undertaken a distinct approach to understanding the normal
biological functions of Wwox by undertaking genetic and bio-
chemical screens to identify the pathways to which Wwox
contributes. Using the combination of proteomic and microar-
ray screens to identify interactive partners and genetic analysis
to confirm the functionality of such interactions, we have
found that Wwox participates in common pathways with
CG6439/isocitrate dehydrogenase (Idh) and Cu–Zn superox-
ide dismutase (Sod). These interactions indicate a contribution
of Wwox to aerobic metabolism and the regulation of reactive
oxygen species (ROS) levels within cells.
RESULTS
Biochemical responses to altered Wwox levels
Two-dimensional differential in-gel electrophoresis
(2D-DIGE) was used to identify quantitative and qualitative
changes in proteins between Drosophila lines with either
decreased or increased levels of Wwox. To examine the
effect of decreased levels of Wwox, adult flies mutant for
Wwox were compared with wild-type (w1118). We used two
independent alleles of Wwox for these analyses; Wwox1, a
null mutation generated by homologous recombination, and
Wwoxf04545, which carries a pBac insertion in exon 2
(28,29). To investigate the effects of increased levels of
Wwox, the protein profiles of adult flies carrying a
UAS-Wwox transgene together with the da-GAL4 ubiquitous
driver (da . Wwox) were compared with adult flies carrying
the da-GAL4 driver alone (da.+). A common set of 16
protein spots were identified that showed significant changes
in abundance in each of the Wwox mutants, while a further
16 were identified that exhibited significant changes when
Wwox was ectopically over-expressed (summarized in Fig. 1
and Supplementary Material, Table S1). Mass spectrometry
analysis of peptides was successful in identifying 13 of the
16 candidate proteins identified in Wwox mutants in addition
to all of those identified when Wwox was ectopically over-
expressed (Supplementary Material, Table S1).
In a complementary approach, microarray analysis was also
performed on Wwox mutants during early embryonic develop-
ment of Drosophila. Embryos (4–8 h) from each of the two
independent mutant lines were compared with wild-type,
revealing a number of transcripts in common that were
altered in response to decreased Wwox function. The microar-
ray data have been deposited on the NCBI database (GEO
accession number GSE22689). Verification by qPCR showed
seven of these were also significantly altered in adults of
each of the Wwox mutants as well as flies ectopically over-
expressing Wwox (Table 1).
None of the proteins or RNAs detected in these studies, as
altered due to increases or decreases in Wwox, is found
among those that have previously been reported as having phys-
ical interaction with Wwox (reviewed in 30). Indeed none of the
proteins detected has PPxY motifs that might indicate a physical
interaction with Wwox through either of its WW domains.













Therefore, these proteomic and micro-array screens are unlikely
to be comprehensive, however they do reveal novel functional
characteristics of Wwox that are likely to account for its
reported impact on metabolism (19–25).
Candidate Wwox interactors
Proteomic and microarray analyses confirmed an increase in
Wwox protein and transcript levels in da.Wwox flies that ecto-
pically over-express Wwox as well as a decrease in Wwox tran-
script levels in each of the Wwox mutants (Table 1). We have
previously shown the absence of Wwox protein in Wwox1
mutant embryos by western analysis and have now confirmed
the absence of Wwox protein in both Wwox1 and Wwoxf04545
adult flies (28 and Supplementary Material, Fig. S1).
Biochemical analyses of adult flies and embryos with altered
levels of Wwox identified a total of 27 different candidate pro-
teins and/or mRNAs that were altered in response to increased
and/or decreased levels of Wwox (Table 1). Interestingly, a sig-
nificant number of these are known or predicted, based on
sequence similarities (as listed on FlyBase; 31), to participate
in various metabolic pathways. This highlights the impact of
altered Wwox levels on metabolic processes; a common
feature of all the WWOX knockout rodent animals (19–25).
Of significance is the finding that many of these candidates
are either directly or indirectly involved in metabolic pathways
that converge on the tricarboxylic acid (TCA) cycle (Fig. 2).
This is supportive of altered Wwox levels having an impact
on aerobic metabolism in this in vivo model. Two of the candi-
date interactors identified encode proteins with isocitrate dehy-
drogenase (CG6439) and malate dehydrogenase (CG7998)
activities, both of which catalyse enzymatic reactions that are
integral to the TCA cycle. Twelve other interactors are pre-
dicted to be involved in the regulation of metabolism of
various energy sources within cells that ultimately have
effects on the TCA cycle. Several candidates are involved in
regulation of available glucose levels including phosphoglyce-
rate kinase (Pgk)/CG3127, CG7430 which encodes a predicted
dihydrolipoyl dehydrogenase, malic enzyme (Men)/CG10120,
glyceraldehyde-3-phosphate dehydrogenase (Gapdh)/
CG12055, CG10638 which encodes a predicted aldehyde
reductase and CG10924 which encodes a phosphoenolpyruvate
carboxykinase (PEPCK). Four other interactors required for
metabolism of ethanol —alcohol dehydrogenase (Adh)/
CG3481, aldehyde dehydrogenase (Aldh)/CG3752, AcetylCoA
synthase (AcCoAS)/CG9390 and CG31075 which also
encodes an aldehyde dehydrogenase—were also detected. A
further two interactors—fat body protein1 (Fbp1)/CG17285
and glycerol-3-phosphate dehydrogenase (Gpdh)/CG9042—
encode enzymes that are involved in the metabolism of lipids.
Another two of the candidate Wwox interactors, Cu–Zn
superoxide dismutase (Sod)/CG11793 and CG5590, encode
enzymes that are involved in regulation of oxidative pathways.
The formation of ROS is a normal by-product of the electron
transport chain, which is tightly linked to the TCA cycle.
Wwox also encodes an oxidoreductase suggesting that it has
function(s) in similar pathways. CG11089 and CG7470 are
involved in the biosynthesis of inosine monophosphate
(IMP) and proline, respectively. Other interactors identified
are predicted to have various functions as listed in Table 1.
In vivo functional screen for candidate Wwox interactors
The Drosophila genetic model organism enables verification of
functional interaction(s) between Wwox and the various candi-
date Wwox interactors, however a phenotype is required to form
the basis of genetic screening. We have previously determined
that the loss of Wwox function has no phenotype (29), thus the
strategy for our in vivo RNAi screen was first to identify pheno-
types produced by altered levels of any of the candidates on their
own and then to look for modification of these phenotypes by
altered levels of Wwox (Fig. 3A). Candidates were screened
for phenotypes resulting from reduced levels of endogenous
mRNAs via the ectopic expression of specific homologous
RNAi sequences. Given that a significant proportion of the can-
didates encode genes that are involved in aerobic metabolism,
we screened for any effect(s) on survival with ubiquitous
expression of RNAi targeted to these candidates.
The binary GAL4-UAS system was used to ectopically
express various candidate RNAi constructs (32,33) throughout
Drosophila development using the da-GAL4 driver stock. Six
of the candidate RNAi lines tested showed a significant
decrease in viability when expressed ubiquitously, while a
further four were completely lethal (Supplementary Material,
Fig. S2B). These reduced viability phenotypes formed the
basis of genetic screening to identify functional interaction(s)
Figure 1. Proteomic analysis of altered Wwox expression. 2D-DIGE protein
spots that exhibited significant changes in abundance either in both of the inde-
pendent Wwox mutants (Wwox1 and Wwoxf04545) or with ubiquitous ectopic
Wwox expression in 0- to 1-day adult Drosophila (see also Supplementary
Material, Table S1). Spots 19 and 20 are superoxide dismutase (Sod) isoforms.













Table 1. Candidate Wwox interactors identified from proteomic and microarray analyses
Candidate Wwox Interactor Spot
#











Wwox1 Wwoxf04545 da.Wwox Wwox1 Wwoxf04545 da.Wwox
Wwox/CG7221 1 n/d n/d 1.49 22.72 217.38 172 Oxidoreductase activity
AEROBIC METABOLISM
TCA cycle
CG6439 (Idh) 2 21.12 21.19 n/c – – – Isocitrate dehydrogenase (NAD+) activity
CG7998 (Mdh) 3 21.30 21.13 n/c – – – L-malate dehydrogenase activity
Glucose metabolism
Phosphoglycerate kinase (Pgk)/CG3127 4 n/c n/c 1.23 – – – Phosphoglycerate kinase activity
CG7430 5 1.14 1.18 n/c – – – Dihydrolipoyl dehydrogenase activity
Malic enzyme (Men)/CG10120 6 n/c n/c 1.48 – – – Malate dehydrogenase
(oxaloacetate-decarboxylating) (NADP+)
activity
7 n/c n/c 1.43 – – –
Glyceraldehyde-3-phosphate dehydrogenase1
(Gapdh1)/CG12055
8 n/c n/c 1.22 – – – Glyceraldehyde-3-phosphate dehydrogenase
(phosphorylating) activity
CG10638 – – – – 22.15 21.70 2.17 Aldehyde reductase activity
CG10924 (PEPCK) – – – – 5.00 3.77 21.82 Phosphoenolpyruvate carboxykinase (GTP) activity
Ethanol metabolism
Alcohol dehydrogenase (Adh)/CG3481 9 1.53 1.27 n/c – – – Alcohol dehydrogenase (NAD) activity
Aldehyde dehydrogenase (Aldh)/CG3752 10 1.25 1.36 n/c – – – Aldehyde dehydrogenase (NAD) activity
Acetyl Coenzyme A synthase (AcCoAS)/
CG9390
11 n/c n/c 21.57 – – – Acetate-CoA ligase activity
CG31075 12 1.14 1.23 n/c – – – Aldehyde dehydrogenase (NAD) activity




14 1.16 1.21 n/c – – – Glycerol-3-phosphate dehydrogenase (NAD+)
activity
Fat body protein 1 (Fbp1)/CG17285 15 2.70 2.00 n/c – – – Protein transporter activity
16 n/c n/c 3.04 – – –
17 n/c n/c 1.60 – – –
18 n/c n/c 22.20 – – –
Oxidation reduction
Superoxide dismutase (Sod)/CG11793 19 2.15 1.64 21.23 1.33 1.64 21.10 Antioxidant activity; superoxide dismutase activity
20 22.23 21.53 n/c
CG5590 21 n/c n/c 21.37 – – – Oxidoreductase activity, acting on the CH-OH
group of donors
OTHER CATEGORIES
CG7470 22 n/c n/c 21.43 – – – Delta1-pyrroline-5-carboxylate synthetase
Suppressor of Profilin 2 (Sop2)/CG8978 – – – – 21.08 1.13 21.23 Actin binding
Hsp60C/CG7235 23 21.08 21.24 n/c – – – ATPase activity, coupled
CG2852 24 n/c n/c 1.31 – – – Peptidyl-prolyl cis-trans isomerase activity
CG11089 25 1.13 1.21 n/c – – – IMP cyclohydrolase activity
CG14526 26 n/c n/c 21.26 – – – Metalloendopeptidase activity
Bancal (bl)/CG13425 – – – – 1.10 1.01 21.29 mRNA binding; transcription factor binding
Prp19/CG5519 – – – – 1.47 1.78 21.52 Ubiquitin-protein ligase activity
Tudor-SN/CG7008 27 n/c n/c 21.23 – – – Transcription coactivator activity
CG30152 – – – – 1.13 1.23 21.29 Unknown
CG8193 28 n/c n/c 1.22 – – – Monophenol monooxygenase activity
Average fold change ratios of protein abundance for 2D-DIGE spots and transcript abundance for candidates that exhibit significant changes in response to altered levels of Wwox in adult flies. n/d, protein
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with Wwox. The use of the GAL4-UAS system to lower candi-
date gene expression also allowed the simultaneous expression
of constructs either to increase (.Wwox) or decrease (.
WwoxRNAi) Wwox levels, and thereby assess any modification
to the candidate gene phenotype by altered Wwox levels
(Fig. 3A). Altered levels of Wwox transcript in each of these
genotypes (da . WwoxRNAi and da . Wwox) were confirmed
by qPCR analysis (Supplementary Material, Fig. S3) and no
effect was observed on viability when levels of Wwox alone
were increased or decreased via this GAL4-UAS system (Sup-
plementary Material, Fig. S2C); thus any significant altera-
tion(s) in viability observed for each candidate RNAi would
suggest a functional interaction of that candidate with Wwox.
The absence of such an interaction, however, does not necess-
arily rule out a functional interaction between a candidate and
Wwox, but rather suggests that within this assay system any
interaction between the two proteins is not a rate-limiting
requirement for survival of the animal.
Viability assays were thus performed for candidate RNAi
lines alone (da . candidateRNAi) and the percentage survival
to adulthood was compared with that observed when Wwox
levels were either decreased (da . candidateRNAi. WwoxRNAi)
or increased (da . candidateRNAi. Wwox) as summarized in
Supplementary Material, Table S2. A significant amount of vari-
ation was observed in these assays and statistical analyses (as
described in the experimental procedures) were used to identify
any significant modifications resulting from altered levels of
Wwox. Only one of the candidate RNAi lines tested showed a
clear and significant interaction with Wwox. This candidate
RNAi line is directed against CG6439 which encodes an
Figure 2. Metabolic pathways impacted by altered Wwox levels. Alteration of Wwox levels resulted in changes to many enzymes with roles in the TCA cycle,
glucose metabolism, ethanol metabolism, lipid metabolism and oxidation/reduction supportive of a contributing role for Wwox in the maintenance of aerobic
metabolism. Arrows indicate up- or down-regulated Wwox interacting candidates: solid black arrows for those altered following ectopic over-expression of
Wwox and open arrows for those altered in Wwox loss of function mutants. Side arrows indicate that changes were detected in different isoforms of the
protein. Gene abbreviations are listed in Table 1.













enzyme with isocitrate dehydrogenase activity. Knockdown of
endogenous levels of CG6439 transcript following ectopic
expression of this RNAi line was confirmed by qPCR analyses
(Supplementary Material, Fig. S3).
Functional interaction of CG6439/isocitrate
dehydrogenase (Idh) with Wwox
RNAi knockdown of endogenous levels of CG6439/Idh
throughout the development in Drosophila (da . CG6439/
IdhRNAi) resulted in a decrease in viability (Fig. 3B). Droso-
phila with RNAi knockdown of CG6439/Idh as well as
altered (increased or decreased) levels of Wwox were tested
in five separate experiments to determine whether the
observed decrease in viability could be modified by altered
levels of Wwox. A trend was observed across all five exper-
imental replicates, where a further decrease in viability was
observed when Wwox levels were also decreased in these
flies, indicating an enhancement of the CG6439/Idh RNAi
phenotype (Fig. 3B). Conversely, ectopic over-expression of
Wwox in flies with reduced expression of CG6439/Idh
revealed suppression of the decreased viability observed
when CG6439/Idh was knocked down alone (Fig. 3B).
Together, these results are consistent with an in vivo functional
interaction between Wwox and CG6439/Idh.
Independent verification of a genetic interaction between
Wwox and Idh/CG6439 was performed using mutant alleles
for each of these genes. The Idh/CG6439EY00276 mutation
Figure 3. In vivo functional interactions of Wwox with CG6439/Idh. (A) Rationale of the in vivo genetic screens for Wwox functional interactors in Drosophila.
Flies with ubiquitous knockdown of the candidate interactors alone were assayed for any resultant phenotypes that could be modified by either decreased or
increased levels of Wwox. (B) Wwox interacts genetically with CG6439/Idh in viability assays. A deviation from the expected proportion (50%, indicated
by the bold line) of non-TM6B progeny (see Supplementary Material, Fig. S1A) was observed when CG6439/Idh was knocked down ubiquitously (blue), indica-
tive of a decrease in viability. This decrease in viability (blue) was enhanced when Wwox levels were decreased (red) and suppressed when Wwox levels were
increased (green). Chi-square test was performed on each of the five separate experimental replicates and ‘∗’ denotes statistical significance with P , 0.05.
(C) Correlation of WWOX and IDH1 transcript levels in human cancer cell lines. qPCR analyses of WWOX and IDH1 transcript levels were determined for
four different time points/confluencies in each of 15 exponentially growing human cancer cell lines. Regression analysis of WWOX and IDH1 mRNA levels
revealed a positive correlation with a P-value of 2.5E212 (see also Supplementary Material, Figs S2, S3 and Table S2).













consists of a transposon inserted 174 bp upstream of the
initiator ATG codon (and within the reported 5′-UTR) for
Idh/CG6439 (34). Drosophila homozygous for this mutation
are viable and fertile as previously observed for the Wwox1
mutants. However, we were unable to obtain adult flies that
were homozygous for both Idh/CG6439EY00276 and Wwox1,
consistent with the enhanced decrease in viability of da .
Idh/CG6439RNAi observed when Wwox levels were also
decreased by RNAi (Fig. 3B). Although the precise impact
of this insertion mutation is not known, the altered activity
of both Wwox and Idh/CG6439 has a significant effect on
the viability of adult Drosophila, supporting their functional
interaction in normal metabolic pathways during development.
Thus, decreased levels of Wwox were found to significantly
decrease endogenous levels of CG6439/Idh protein in this
model and these changes could account for the functional
interactions observed between Wwox and CG6439/Idh.
Correlation between WWOX and IDH1 mRNA levels in
human cell lines
In order to assess whether WWOX and IDH also exhibit evi-
dence of a functional interaction in human cancer cells, the
steady-state levels of their respective mRNA were assessed.
Fifteen different human cancer cell lines (AGS, Co-115,
HCT116, HeLa, HT29, KATOIII, KM12C, KM12SM,
LOVO, LS180, MCF-7, MDA-MB157, MDA-MB436,
SK-BR-3, U2-OS) were each grown to different levels of
confluence (a factor which affects WWOX mRNA levels,
S. Dayan, unpublished data). Each of these samples was then
assayed for the mRNA level of WWOX as well as the mRNA
levels for isocitrate dehydrogenase family members: IDH1,
IDH2 and IDH3. A significant positive correlation was observed
between endogenous WWOX and IDH1 mRNA levels
(Fig. 3C), consistent with a functional interaction between
their respective encoded proteins. This positive correlation
between WWOX and IDH1 transcripts in these cells is consist-
ent with the relationship observed between Wwox and CG6439/
Idh protein levels in flies. IDH has been found to be altered
specifically in human cancers (35–37). Thus, it is clear that
there is a relationship between endogenous WWOX and IDH1
levels that is consistent with WWOX contributing to metabolic
balance in human cancer cells as well as in the context of the
whole organism of Drosophila.
Cu–Zn superoxide dismutase interacts with Wwox
Proteomic analyses identified two different spots of similar
molecular weight but different isoelectric point corresponding
to Cu–Zn superoxide dismutase (Sod). Spot #19 showed reci-
procal changes in abundance in Wwox mutants and ectopic
over-expression, while spot #20 showed a decrease in Wwox
mutants (Table 1). These results suggest a role for different
isoforms and/or differently modified forms of Sod in response
to altered levels of Wwox. Since it has previously been shown
that Sod mutants are viable but have a decreased lifespan (38),
we determined the ability of altered levels of Wwox to modify
this phenotype.
Missense mutations in Sod (Sodn1 and Sodn64) result in the
expression of mutant forms of the protein, each with decreased
levels of enzyme activity (Sodn1 is also known as Sodn108; 39).
The Sodn1 mutation (G50S) disrupts dimer contact, while the
Sodn64 mutation (G43E) affects metal ion binding. We gener-
ated adult flies that were trans-heterozygous for these two
mutations (Sodn1/Sodn64). This mutant combination showed
no effect on viability of adult flies as the expected percentage
of non-balancer flies was obtained from this cross (Fig. 4A and
Supplementary Material, Fig. S4A). However, the introduction
of homozygous Wwox1 or trans-heterozygous Wwox1/
Wwoxf04545 mutations into this Sod mutant background
resulted in a decrease in viability, where the number of adult
progeny obtained for each of the Wwox;Sod double mutants
was decreased to less than one-third of that expected
(Fig. 4A and Supplementary Material, Fig. S4A). Although
only low numbers of Wwox;Sod double-mutant flies were
able to be collected due to this decreased viability, the effect
of the homozygous Wwox1 mutation on the lifespan of these
Sod mutants was determined. Sodn1/Sodn64 trans-heterozygous
mutants showed a decreased lifespan compared with wild-type
or Wwox mutant flies where the Sod mutants were all dead by
the tenth day of the lifespan assay (Fig. 4B). This decreased
lifespan phenotype was enhanced when the flies were also
homozygous mutant for the Wwox1 mutation as Wwox;Sod
double-mutant flies all died within the first 24 h of the assay.
This was confirmed for Sodn64/Sodn1 trans-heterozygous
mutants where crosses were set up in the opposite direction.
Proteomic analysis showed qualitative changes in endogen-
ous Sod in adult flies both with increased or decreased levels
of Wwox, while qPCR revealed that Sod transcript levels were
increased in Wwox mutants (Table 1). To determine whether
alterations in Sod could similarly affect endogenous Wwox
transcript levels, qPCR analysis was performed on Sod
mutants. Wwox mRNA levels were significantly down-
regulated in Sodn1/Sodn64 mutant third instar larvae
(Fig. 4C). To check whether endogenous Wwox mRNA
levels were directly altered by increased Sod activity, we ubi-
quitously expressed a full-length human SOD1 construct in
Drosophila. Over-expression of SOD1 resulted in an increase
in Wwox transcript showing reciprocal changes in endogenous
Wwox transcript levels in the presence of Sod mutations com-
pared with ectopically over-expressed human SOD1 (Fig. 4C).
We further investigated this relationship in human HEK293
cells and found ectopic expression of human SOD1 also
resulted in an increase in endogenous WWOX mRNA
expression. This increase in endogenous WWOX mRNA
expression was not observed when a G37R mutant form of
SOD1 that is associated with ALS (40) was over-expressed
as an appropriate negative control (Fig. 4D). Together, these
results suggest clear conservation of a functional relationship
between these two genes.
Wwox affects endogenous levels of ROS
We have shown functional interactions between Wwox and
two of the candidate interactors identified: CG6439/Idh and
Sod. Given the known role of CG6439/Idh as an integral
member of the TCA cycle (a known generator of ROS) and
Sod in the direct regulation of ROS levels, we determined
the endogenous level of ROS in Drosophila with altered
levels of Wwox expression. ROS levels were measured













indirectly in dispersed cells from Drosophila by
fluorescence-activated cell sorting. In two independent lines
of Wwox over-expressing larvae, the percentage of cells
with ROS levels above an arbitrary threshold was found to
be higher than for control larvae, while Wwox mutants had
consistently lower levels of ROS compared with their
control larvae (Fig. 5A and B). Thus, these reciprocal results
strongly suggest a role for Wwox in the regulation of ROS.
DISCUSSION
Common chromosomal fragile sites are regions that are predis-
posed to DNA instability in cancer. FRA3B (within the FHIT
gene) and FRA16D (within the WWOX gene) are the most sus-
ceptible sites (3). This DNA instability varies between differ-
ent cells, sometimes comprising multiple events (6) that
together constitute a scar on the genomic landscape that indi-
cates the passage of the damaged cell through some form of
environmental (replicative) stress. The biological conse-
quences of fragile site-mediated DNA instability in cancer
are dependent not only upon the frequency of such instability,
but also upon the perturbation of the normal function of genes
in the vicinity.
Here we report that the highly conserved Drosophila ortho-
logue of WWOX has biologically significant roles in pathways
that control aerobic metabolism and ROS. Alterations were
observed in a number of genes encoding various members of
aerobic metabolic pathways that converge on the TCA cycle
as summarized in Figure 2. A common feature of all of the
rodent WWOX mutants was decreased size and early death
of mutant animals (19–25). These effects could also arise
from Wwox mutations leading to altered regulation of
aerobic metabolism in these mouse models, perhaps via com-
ponents of the TCA cycle. Consistent with this is the reported
hypoglycaemia of the conditional Wwox knockout (23). In the
present study, conserved functional interactions were ident-
ified between Wwox and isocitrate dehydrogenase, an integral
component of the TCA cycle as well as superoxide dismutase,
a known regulator of ROS. Our findings support a protective
role for Wwox under conditions of oxidative stress given the
observed decrease in survival of the Wwox;Sod double
mutants. Significantly, levels of endogenous ROS were
found to correlate both with increased and decreased Wwox
expression. This role for Wwox in regulating ROS levels
could explain previous observations of the biological proper-
ties of WWOX, notably its ability when over-expressed to
inhibit tumour cell growth and the participation of WWOX
in cellular responses to TNF (41), since this pathway is
mediated by ROS (42–44).
ROS are effectors of a vast number and range of essential bio-
chemical pathways although they are also inherently dangerous
chemicals to cells (45). It is, therefore, not surprising that cells
have evolved intricate and integrated strategies to regulate ROS
with cellular metabolism. Perturbations in ROS have previously
been linked to aerobic glycolysis (Warburg effect) in cancer
cells (46,47). Cancer-associated isocitrate dehydrogenase
mutations produce 2-hydroxyglutarate that in turn leads to an
Figure 4. Wwox and Sod interact genetically. (A) A decrease in viability was observed when homozygous Wwox1 or trans-heterozygous Wwox1/Wwoxf04545
mutations were introduced into the Sodn1/Sodn64 mutant background (as indicated by the negative deviation from the expected 33.3% proportion of
non-TM6B progeny, see Supplementary Material, Fig. S2). (B) A decreased lifespan was observed for the trans-heterozygous Sod mutations compared with
wild-type and Wwox mutants. Each of the Wwox;Sod double mutants showed a further decrease in viability. Survival curves for the two Wwox;Sod double
mutants overlap on the graph with all flies dead after 24 h. (C) qPCR showed decreased levels of Wwox transcript in Sodn1/n64 compared with w1118 larvae
(P ¼ 0.003) and increased levels of Wwox transcript in SOD1 overexpressing compared with control GFP overexpressing larvae (P ¼ 0.043). (D) qPCR of
WWOX levels in a HEK293 cells overexpressing SOD1 showed increased levels of endogenous WWOX transcript compared with the control line overexpressing
GFP (P ¼ 0.008, see also Supplementary Material, Fig. S4). No such increase in WWOX transcript was observed when cells were overexpressing a G37R mutant
form of SOD1.













increase in ROS (48,49). Our finding of a direct correlation
between Wwox and ROS levels, together with functional inter-
actions of Wwox with superoxide dismutase and isocitrate
dehydrogenase, uncover perturbation in Wwox levels as
another contributor to the differences seen in aerobic glycolysis
(Warburg effect) between cancer and normal cells.
How could perturbation of WWOX levels (through DNA
instability at FRA16D) contribute to cancer cell biology? A
plausible explanation for the dramatic inhibition of breast
cancer tumour cell growth by WWOX over-expression (14)
is that increased WWOX results in higher ROS in these
cancer cells. Levels of ROS are known to limit the self-
renewal of stem cells (50) which are consistent with mounting
evidence that breast cancer cells derive from stem cells (51)
and are therefore likely to retain some of their properties.
The corollary of this is that decreased WWOX (via FRA16D
DNA deletion) will lead to decreased ROS levels that could
relieve this limitation on self-renewal and therefore promote
tumour cell growth. This latter property of WWOX could
explain its behaviour as a non-conventional tumour suppressor
in both human cancers and mouse models. Reduction of
WWOX levels to 50% may result in a sufficient decrease in
endogenous ROS to cause cellular consequences (i.e. further
knockout of the second WWOX allele is not necessary).
Our studies on the Wwox function in Drosophila reveal a
number of similarities with pathways that involve FHIT ident-
ified in human cancer cells (52,53). Both WWOX and FHIT
are lost in most cancers and their restoration suppresses tumour-
igenicity (13,14). FHIT gene transfer into cancer cells increases
production of ROS, while Wwox over-expression in Droso-
phila larval tissue also leads to increases in ROS. FHIT is
known to functionally interact with ferredoxin reductase and
physically associate with malate dehydrogenase and mitochon-
drial aldehyde dehydrogenase (as well as other proteins; 52). In
addition to Wwox functional interactions with Sod and Idh
described herein, we have also detected Wwox associated
alterations in malate dehydrogenase and mitochondrial alde-
hyde dehydrogenase protein levels in Drosophila by proteomics
(Table 1). These alterations would affect pathways leading to
alterations in aerobic metabolism (Fig. 2), a hallmark of
cancer cells, and give further evidence of the role of Wwox as
a surveyor of the cell’s metabolic status. In addition, WWOX
and FHIT also share Hsp60 as a common interactor (52,53)
with the Drosophila orthologue, Hsp60c, being detected in
the Wwox proteomics analysis (Table 1).
These parallels lead us to propose that there is a functional
basis for the association of the tumour suppressor genes
WWOX and FHIT with the most unstable common chromoso-
mal fragile sites in humans. The presence of these fragile sites
confers the potential for DNA damage within the respective
genes. DNA damage at these sites is an early event in tumour-
igenesis and the variable extent of damage (6) can result in
either decreases or increases in gene expression (15–18).
Those cells with a resultant increase in expression of
Figure 5. Altered Wwox expression affects the levels of ROS in Drosophila larvae. (A) Fluorescence-activated cell sorter (FACS) analysis of ROS levels in cells
from two independent lines over-expressing Wwox (da . Wwox#1 and da . Wwox#2) compared with control (da.+) and two Wwox mutant lines (Wwox1 and
Wwoxf04545) compared with control (w1118) after 1 h incubation with 10 mM CM-H2DCFDA. (B) An arbitrary threshold of fluorescence intensity was set and the
percentage of cells from the total population exhibiting fluorescence above that threshold was measured every 30 min for 3 h.













WWOX and/or FHIT therefore have increased resilience to
further oxidative stress by virtue of increased ROS. We there-
fore propose that the common pathways in which WWOX and
FHIT participate form a network of ‘front-line’ responses to
environmental stresses. These responses include altered meta-
bolic status of cells that impact on their likelihood to proceed
along the path of tumourigenesis.
MATERIALS AND METHODS
Fly lines and crosses
All Drosophila stocks were maintained in vials containing
Fortified (F1) medium and kept at either 18 or 258C. The F1
medium was composed of 1% agar, 18.75% compressed
yeast, 10% polenta, 10% treacle, 1.5% acid mix and 2.5%
tegosept. w1118, da-GAL4, CG6439EY00276, UAS-GFP, Sodn1/
TM3Sb and Sodn64/TM3Sb were all obtained from the Bloo-
mington stock centre. Wwox1, Wwoxf04545 and UAS-Wwox
lines have been previously described, with Wwox1 and
Wwoxf04545 having undergone four rounds of backcrossing to
w1118 (29). UAS-candidateRNAi lines (listed in Supplementary
Material, Table S2) were obtained from the Vienna Drosophila
Research Centre. Multiple transgenic lines of UAS-SOD1 were
generated by standard P-element transformation techniques.
da . Wwox stock was generated by recombination
between da-GAL4 and UAS-Wwox #1 both of which are
located on the third chromosome. The mutant alleles: Sodn1
and Sodn64 were rebalanced and maintained as stocks over
TM6B. The double-mutant stocks: UAS-WwoxRNAi/CyO;da-
GAL4/TM6B, Wwox1/CyO:CG6439EY00276/TM6B, Wwox1/
CyO:Sodn1/TM6B, Wwox1/CyO:Sodn64/TM6B and
Wwoxf04545/CyO:Sodn64/TM6B were all generated by standard
genetic techniques and confirmed by PCR and sequencing (for
Sod alleles using primers from reference 39) or by western
analysis for Wwox alleles.
SOD1 and GFP constructs and expression
SOD1 was amplified from cDNA obtained from HCT116 cells
using primers CACCATGGCGACGAAGGCCGTGT and
CTACAGCTAGCAGGATAACAG and blunt-end cloned
into the pENTR/D-TOPO vector (Invitrogen). The construct
was recombined into either pcDNA 3.2-DEST (Invitrogen)
containing the CMV promoter for expression into human
cells or a pUAST vector containing the Gatewayw ccdb cas-
sette (Invitrogen, from H. Dalton) for expression in
Drosophila (as described in Gateway cloning methods, Invi-
trogen). Human SOD1 ALS mutant G37R was made by the
QuickChange method as described by Stratagene (Quick-
Change Site-Directed Mutagenesis Kit). The forward and
reverse complement primers were designed with a single-base
mutation (underlined), 5′-GTGGGGAAGCATTAAAA
GACTGACTGAAGGCC-3′ and used to PCR pENTR/
D-TOPO-SOD1 plasmid. Parental methylated and hemimethy-
lated DNA was digested with DpnI and the intact SOD1-
mutated plasmids were used for transformation and
subsequent cloning into pcDNA 3.2-DEST vector. GFP was
amplified from pEGFP-N2 (Clontech) using primers CAC
CATGGTGAGCAAGGGCG and TGGCTGATTATGATC
TAGAGTCG and was similarly cloned into pcDNA
3.2-DEST for expression in human cells. Purified plasmids
were used for injecting into Drosophila w1118 embryos or
for transfection using standard protocols for Fugene (Roche).
Cell-line culture
The cancer cell lines: AGS, Co-115, HCT116, HeLa, HT29,
KATOIII, KM12C, KM12SM, LOVO, LS180, MCF-7,
MDA-MB157, MDA-MB436, SK-BR-3 and U2-OS were
obtained from the American Type Culture Collection. Cell
lines AGS and Lovo were grown in F-12K culture media
while Co-115, HCT116, HT29, KatoIII, KM12C, KM12SM,
LS180, MCF-7, MDA-MB157 and SK-BR-3 were grown in
RMPI. HeLa and U2-OS cell lines were grown in DMEM
while MDA-MB436 cells were grown in OPI-MEM. All cell
lines were grown in their respective culture media containing
10% foetal calf serum.
Protein sample preparation and DIGE labelling
Ten 0–1 day male flies were homogenized in sample buffer
(7 M urea, 2 M thiourea, 30 mM Tris, 4% CHAPS) and
protein purification was performed using a Ready PrepTM
2D clean-up kit (BioRad) according to the manufacturer’s pro-
tocol. Protein concentrations were estimated using an EZQ
protein quantitation kit (Molecular Probes). One hundred
micrograms of protein were labelled with 200 pmol of Cy
Dye. An internal standard sample comprised of a protein
pool consisting of 50 mg of each of the adult fly protein
samples was labelled with 2.8 nmol Cy2 dye.
2D-electrophoresis and gel imaging
Cy labelled adult fly sample mixtures were applied to the IPG
strips (24 cm, pH 3–11, GE Healthcare) and isoelectric focus-
ing was performed on an IPGphor II (GE Healthcare) at 208C
using a stepwise gradient. Second-dimension SDS–PAGE was
performed using the EttanTM DALTtwelve Large Vertical
electrophoresis system (GE Healthcare). DIGE gels were
scanned using the Ettan DIGE Imager (GE Healthcare) at
100 mm resolution and image analysis was undertaken using
DeCyder 2D software (version 6.5, GE Healthcare). Each
analytical gel image was processed separately in the differen-
tial in-gel analysis module of DeCyder prior to export to the
biological variation analysis module.
Mass spectrometry
Spots were excised using an EttanTM Spot Picker robot (GE
Healthcare). Excised gel pieces were dehydrated in 100%
acetonitrile then vacuum dried before being rehydrated in
10 ng/ml trypsin in 5 mM ammonium bicarbonate and incu-
bated over night at 378C. Following digestion, peptides were
extracted twice with 50% acetonitrile containing 1% formic
acid, concentrated and reconstituted with FA30 (0.1% formic
acid, 3% acetonitrile) to a final volume of 5 ml. Samples
were then analysed either by LC-ESI-IT-MS where samples
were chromatographed using an Agilent Protein ID Chip
column assembly (40 nl trap column with 0.075 × 43 mm













C-18 analytical column) housed in an Agilent HPLC-Chip
Cube Interface connected to an HCT ultra 3D-Ion-Trap mass
spectrometer (Bruker Daltonics) or by Matrix Assisted Lazer
Desorption Ionisation—Time Of Flight—Mass Spectrometry
(MALDI-TOF-MS) using a Bruker ultraflex III MALDI
TOF/TOF mass spectometer (Bruker Daltonics).
RNA purification
The equivalent of 50 ml of 4–8 h embryos, five third instar
larvae or five 1-day old male flies were used for each biologi-
cal replicate. Samples were frozen in liquid nitrogen and hom-
ogenized in Trizol reagent (Invitrogen). Total RNA was
extracted with chloroform and precipitated with isopropanol.
RNA was further purified using the RNeasy Mini Kit
(Qiagen). For human cell lines, the protocol for total RNA iso-
lation from animal cells as described in Qiagen RNeasy
Minikit was used.
Microarray analyses
RNA from an equivalent volume of 50 ml of 4–8 h embryos
was processed using the One-Cycle Target Labelling and
Control Reagents Kit, as per manufacturer’s instructions
(Affymetrix, Inc). Briefly 2 mg of total RNA was converted
to cDNA (Superscript II, Invitrogen) and an overnight
in vitro transcription reaction performed to generate a pool
of cRNA carrying a biotin tag (MEGAscript T7 Kit,
Ambion, Inc). The Drosophila Genome 2.0 Array was hybri-
dized for 16 h and washed/stained on a FS 450 Fluidics
Station using the Midi euk2 v3 script. Data were acquired
on a 7G GeneChip Scanner 3000 and data extraction per-
formed in GCOS v1.2. Candidates were identified as those
that showed a ‘present’ call in each of three biological repli-
cates. T-tests were performed on raw values to determine
samples that showed a significant difference with a
P-value , 0.05. The microarray data have been deposited on
the NCBI database (GEO accession number GSE22689).
Quantitative real-time PCR (qPCR) assays
The quantitative PCR assays were carried out using protocols
provided by the manufacturers. Superscript III (Invitrogen)
was used to perform reverse transcription on the RNA and
quantitative PCR was carried out using the SYBR Green
mix (Applied Biosystems) in an Applied Biosystem ABI
Prism 7000 Sequence Detection System (Applied Biosys-
tems). The relative standard curve method for quantification
as outlined by Applied Biosystems was used. For Drosophila,
mRNA levels were normalized against the house-keeping gene
ribosomal protein 49 (rp49). Triplicate reactions for each of
three biological replicates were performed for each sample.
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Drosophila crosses (see Supplementary Material, Fig. S2A)
were set up in medium-sized vials containing FI medium
and maintained at 258C. Progeny from the crosses were
scored and only the crosses with a minimum of 30 progeny
carrying the TM6B balancer were included in the analyses.
The ratio of non-TM6B:TM6B progeny was recorded for
each cross and chi-square test analysis using GraphPad
Prism 5 was carried out to determine whether there was a sig-
nificant difference between the ratios when Wwox levels were
increased or decreased compared with the control in each
experiment. The standard value of P , 0.05 was chosen to
indicate significance.
Lifespan assays
Male Drosophila 0 to 1 days old were collected and placed in
a vial containing fly food. Flies were kept at 258C with 70%
humidity. Flies were turned into fresh vials everyday and
deaths recorded at the same time. Statistical analyses and
graphing were done using GraphPad Prism 5.
Reactive oxygen species measurements
Single cells from 10 third instar Drosophila larvae were isolated
using a modification of Singh et al. (54). Larval cuticle was
removed and tissue was digested with 0.5 mg/ml Collagenase
(Sigma) in phosphate buffered saline (PBS: 0.8% NaCl,
0.02% KCl, 0.02% KH2PO4, 0.115% Na2HPO4, pH 7.4) for
1 h at 258C. The digest was filtered through a 100 mM cell strai-
ner and diluted to 1 ml with PBS. Intracellular ROS was
determined using 5-(and-6)-chloromethyl-2′,7′-dichlorodi
hydorfluorescein diacetate (CM-H2DCFDA, Molecular
Probes), a non-fluorescent dye, which upon deacetylation by
cellular esterases and oxidation by ROS becomes fluorescent.
Cells were incubated at 258C for 30 min with 10 mM
CM-H2DCFDA and FACS analysis was performed immedi-
ately and every 30 min for 3 h to allow for dye loading
differences.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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Common Chromosomal Fragile Site FRA16D Tumor
Suppressor WWOX Gene Expression and Metabolic
Reprograming in Cells
Sonia Dayan, Louise V. O’Keefe, Amanda Choo, and Robert I. Richards*
Discipline of Genetics, School of Molecular and Biomedical Sciences and ARCSpecial Research Centre for the Molecular Genetics of
Development,The Universityof Adelaide,Adelaide,SA 5005,Australia
The WWOX gene spans the FRA16D common chromosomal fragile site and is able to suppress tumor growth. FRA16D
is a frequent site of DNA instability in cancer resulting in reduced levels of WWOX expression. Altered levels of WWOX
have been shown to affect metabolism. Whereas metabolic reprograming of cells from oxidative phosphorylation to aero-
bic glycolysis is a major hallmark of tumors, the relationship between common chromosomal fragile site genes and altered
metabolism has been unclear. Here we report that altering metabolism from glycolysis to oxidative phosphorylation causes
stable increase in steady-state levels of transcripts of the WWOX gene. Consistent with this, exposure to hypoxic condi-
tions, in which cells rely on glycolysis, causes a downregulation of WWOX mRNA. The function of WWOX is therefore
intimately integrated with metabolism, as WWOX not only contributes to the metabolic state of cells, its transcript levels
are also linked to intracellular metabolic state. VC 2013 Wiley Periodicals, Inc.
INTRODUCTION
Understanding the causes of cancer and the mo-
lecular steps in the pathways from its initiation to
various clinical outcomes are crucial to early diag-
nosis, prognosis of disease course, and identifica-
tion of targets for intervention. Whereas much
attention has been focused on the role of epige-
netics in the interaction between the genome and
the environment there are other clear and distinct
points of interface. Principal amongst these are
the common chromosomal fragile sites (CFS) that
are found in all individuals. When induced to
appear in human cells, >70 distinct CFSs exhibit
different frequencies of cytogenetic appearance
such that FRA3B (located on chromosome 3) and
FRA16D (located on chromosome 16) are the most
readily observed, followed by others distributed
over most of the human chromosomes, at specific
and reproducible chromosomal locations (Yunis
and Soreng, 1984; Berger et al., 1985; Richards,
2001; Schwartz et al., 2006; Mrasek et al., 2010).
CFS correspond precisely to regions where
genomic DNA rearrangement has been mapped in
human cancer patients. The incidence of this
DNA instability follows a similar hierarchy to CFS
appearance (i.e. FRA3B>FRA16D> others) sug-
gesting that in vitro cytogenetic “fragility” and in
vivo DNA instability in cancer are directly related
(Glover et al., 1986; Casper et al., 2002; Bignell
et al., 2010).
CFS appear on chromosomes in response to spe-
cific chemicals and their cytogenetic appearance is
mediated by replication initiation (Glover et al.
1986). The inducing chemicals include agents typ-
ically found in the diet, e.g., folate, caffeine, and
ethanol (Yunis and Soreng, 1984; Glover et al.,
1986; Demirhan and Tastemir 2008), as well as in
the environment, e.g., chemicals in cigarette
smoke (Stein et al., 2002) and thus are of signifi-
cant interest. CFS are the most sensitive sites in
the genome to these environmental agents, many
of which cause oxidative stress to the cells. Yet the
most readily induced CFS (FRA3B and FRA16D)
are located within genes (FHIT and WWOX,
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respectively) that are able to act as tumor suppres-
sors (Siprashvili et al., 1997; Bednarek et al.,
2001). In several instances the orthologous genes
in other species are also located within CFSs
(Glover et al., 1998; Krummel et al., 2002), giving
rise to the Common CFS paradox: why do some of
the most damage-prone regions of the genome fall
within genes with tumor suppressor activity and
why is this relationship conserved in evolution? In
an effort to resolve this paradox, it has been pro-
posed that CFSs and the genes that span them act
as elements for cells to respond to adverse envi-
ronmental conditions and determinants of cellular
fate decisions in response to DNA damage
(O’Keefe and Richards, 2006).
A major hallmark of cancer cells is an altered
metabolic state. Warburg et al. (1927) showed that
cancer cells were rarely dependent on mitochon-
drial respiration for the production of ATP and
instead relied on glycolysis for the production of
most of their energy, even in the presence of oxy-
gen. Metabolic reprograming, in this way, is now
recognized as one of the most significant pheno-
types in cancer cells and is of particular interest as
it lends itself to therapeutic intervention (Porpor-
ato et al., 2011). The emerging role for WWOX in
altered reactive oxygen species (ROS) metabolism
has recently been reported (O’Keefe et al., 2011)
and its frequent perturbation in cancer cells sug-
gest that the WWOX gene may, at least in part,
contribute to the metabolic reprograming of cancer
cells.
A number of studies have found metabolic
changes in mice and rats knocked-out for WWOX,
the gene spanning the second most highly
expressed common fragile site FRA16D. In both
cases, rodent WWOX mutants had decreased size
and were characterized by early death. WWOX
knock-out mice were reported to have bone meta-
bolic defects as a consequence of low serum cal-
cium levels. These mice were also hypoglycaemic
and had low levels of protein and lipid indicative
of metabolic disease (Aqeilan et al., 2008), as well
as displaying impaired steroidogenesis (Aqeilan
et al., 2009). In another study, conditional WWOX
mutant mice showed metabolic acidosis suggestive
of a role for WWOX in acid/base balance (Ludes-
Meyers et al., 2009). A spontaneously mutated
inbred rat strain carrying a mutation within exon 9
of the WWOX gene was also found to have defects
in steroid metabolism (Suzuki et al., 2009). Addi-
tionally, a strong association between WWOX and
HDL cholesterol and triglyceride levels has been
shown in human populations (Lee et al., 2008).
Supporting a role for WWOX in the regulation of
metabolism, microarray, and proteomic analysis of
Drosophila knocked out or overexpressing WWOX
have also revealed alterations in a number of met-
abolic genes, in particular those involved in mito-
chondrial oxidative phosphorylation (O’Keefe
et al., 2011).
Thus, the associated metabolic changes that
occur in WWOX gene mutant models have led us to
speculate that the metabolic changes in the devel-
opment of cancer may be, at least in part, because
of the perturbed expression of certain fragile site
genes, i.e., those that have previously been reported
to have tumor suppressor activity including WWOX.
We have therefore investigated the effects of alter-
ing metabolism from a glycolytic to an oxidative
phosphorylation pathway in human embryonic kid-
ney cells (HEK293T) on the regulation of WWOX
gene expression. The reciprocal relationship
between the level of oxidative phosphorylation and
glycolysis with WWOX levels, together with the pre-
vious observation that WWOX genotype correlates
with ROS levels and the abundance of metabolites
and enzymes of the citric acid cycle, lead us to
hypothesize that WWOX has a normal role in moni-
toring and maintaining the balance between oxida-
tive phosphorylation and glycolysis in cells.
MATERIALS AND METHODS
Cell Lines and Treatments
The human embryonic cell line HEK293T was
obtained from the American Type Culture Collec-
tion and grown in media as described by Marroquin
et al. (2007). Briefly, cells were either grown in
“Glucose media”: DMEM (Invitrogen, Mulgrave,
Australia Cat# 11995) containing 25 mM glucose
and 1 mM sodium pyruvate and supplemented with
5 mM N-2-hydroxyethylpiperazine-N0-2-ethanesul-
fonic acid (HEPES), 2 mM L-glutamine, 10% FBS
and 500 ug/ml penicillin-streptomycin, or in
“Galactose media”: DMEM containing no glucose
(Invitrogen Cat# 11966-025) and supplemented
with 10 mM galactose, 1 mM sodium pyruvate, 5
mM HEPES, 2 mM L-glutamine, 10% FBS, and
500 ug/ml penicillin-streptomycin. Cells were grown
in a humidified incubator at 37oC and 5% CO2.
For treatment with Dichloroacetate (DCA) or
2-Deoxy-D-Glucose (2DG), cells were plated in
glucose media 24 hrs before treatment and either
50 mM DCA or 5 mM 2DG was added to the
cells. Cells were harvested for RNA extraction 24
hrs later and analyzed for gene expression.
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Hypoxia Induction
For hypoxia experiments, HEK293T cells were
grown in glucose media. Cells were plated and
grown in 10 mm diameter dishes overnight at 37oC
and 5% CO2. Hypoxia was achieved by placing
dishes in a 1.9-l air-tight container together with a
2.5-l Anaerogen sachet (Oxoid) and sealed with
vacuum grease. Cells were incubated at 37oC, 5%
CO2 for the appropriate times, before RNA or pro-
tein extraction. Controls were grown at 37oC in 5%
CO2 for the corresponding times. Hypoxic condi-
tions were confirmed by measuring an increase in
VEGF transcript (White et al. 1995).
Quantitative PCR
For quantitative PCR (qPCR), total RNA was
isolated using Qiagen (Germantown, USA)
RNeasyVR Mini Kit following the manufacturer’s
protocol for RNA isolation from animal cells.
SuperscriptVR III (Invitrogen) was used for first
strand synthesis and qPCR was carried out using
the Power SYBRVR Green PCR Master Mix
(Applied Biosystems, Mulgrave, Australia) using
the primer pairs listed in Table 1. For detection of
WWOX transcripts, a TaqManVR probe with
sequence AACAGGGAGCTGCCAC in combina-
tion with TaqManVR Gene Expression Master Mix
(Applied Biosystems) was used. qPCR was carried
out in an Applied Biosystem ABI Prism 7000
Sequence Detection System (Applied Biosys-
tems). The Relative Standard Curve Method for




Transcript levels were normalized against the in-
ternal control b-ACTIN. Triplicate reactions were
performed for each sample of a set of three biological
replicates. Primers used for qPCR are listed in Table
1 and were designed to span introns using Primer
ExpressTM version 2.0.0 from Applied Biosystems.
Western Blot
Total cell lysates were analyzed for WWOX pro-
tein by washing cells in PBS and lysing them in
RIPA buffer (1% Nonidet (NP40), 1% sodium de-
oxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M
NaPO4 pH 7.2, 2 mM EDTA, 50 mM NaF) con-
taining 1 mM phenylmethylsulfonyl fluoride
(PMSF), 1 mM Na3VO4, and 1X protease inhibitor
cocktail (Complete Mini, EDTA-free, Roche,
Branchburg, USA). Lysates were diluted in 2X
Laemmli buffer (125 mM Tris/HCl pH 6.8, 10%
glycerol, 4% SDS, 0.006% Bromophenol Blue, 2%
2-b-mercaptoethanol) and proteins were resolved
on a 10% SDS-polyacrylamide gel by electropho-
resis and transferred to nitrocellulose membrane.
Western blotting was carried out using a polyclo-
nal rabbit-antihuman-WWOX antibody developed
in the laboratory and mouse monoclonal anti-b-
ACTIN antibody (Abcam ab6276-100).
ROS Measurements
Cells were subjected to different growth condi-
tions and treatments as described above. Cells were
washed with PBS, resuspended in 5 ml phosphate
buffered saline (PBS: 0.8% NaCl, 0.02% KCl, 0.02%
KH2PO4, 0.115% Na2HPO4, pH 7.4) containing
5 mM 5-(and-6)-chloromethyl-20,70-dichlorodihydor-
fluorescein diacetate (CM-H2DCFDA, Molecular
Probes, Mulgrave, Australia) and incubated for 30
min at 37oC, 5% CO2. Cells were washed with PBS,
trypsinized and fluorescence intensity determined
by FACS analysis on a BD FACSCanto.
RESULTS
WWOX Gene Transcript Levels are Upregulated
in Cells Grown in Galactose
HEK293T cells are derived from HEK293 cells
that have been reported to be reliant on glycolysis
TABLE 1. Primers Used for qPCR
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for as much as 30% of their ATP production
(Rodr!ıguez-Enr!ıquez et al., 2008). By growing
HEK293T cells in media deficient in glucose but
containing the poorly metabolized carbon source
galactose, these cells need to switch their metabo-
lism to produce all of their energy from oxidative
phosphorylation for survival (Gohil et al., 2010).
Cells in culture are routinely grown in the pres-
ence of glucose, a condition that is conducive to
aerobic metabolism. The replacement of glucose
with galactose has previously been shown to
induce cells to undergo oxidative phosphorylation
(Gohil et al., 2010). When tested under such con-
ditions, the resultant reprograming of HEK293T
cells to oxidative phosphorylation was accompa-
nied by a two-fold increase in the level of WWOX
mRNA (Fig. 1A). To test whether this response
was a universal effect on genes that are involved
in mitochondrial respiration, the levels of tran-
scripts of a number of genes involved in oxidative
phosphorylation were tested. These included
three isocitrate dehydrogenase (IDH) isoforms,
malate dehydrogenase-2 (MDH2) and superoxide
dismutase-1 (SOD1). Only IDH2 mRNA level was
increased to the same extent as that of the WWOX
gene (Fig. 1A), whereas IDH1, IDH3, and SOD1
were unchanged under such conditions, indicating
specificity of the WWOX gene response and the
selective metabolic reprograming of these cells. A
similar response of WWOX transcript levels to met-
abolic reprograming was found in Hela cells (Sup-
porting Information Fig. S1). Increases in other
fragile site gene mRNAs were also found to
respond to metabolic reprograming (Supporting
Information Fig. S2).
To test whether protein levels correlated with
the gene mRNA levels, WWOX protein levels were
assessed after growing cells in galactose for 48 h.
WWOX protein levels were also increased (by
approximately 30%) in these cells (Fig. 1B). The
western blot from which these levels were quanti-
fied in shown in Supporting Information Figure S3.
Upregulation of WWOX Gene Expression in
Galactose is Reversible
In order to test whether the relationship
between WWOX gene expression and metabolism
is dynamic, cells growing in glucose were split into
two lots and transferred and maintained in galac-
tose over a month with passaging. Cells were har-
vested at the end of this period and analyzed for
WWOX gene transcript levels. Transcripts were
found to be stably upregulated in both populations
originating from glucose growing cells (Fig. 2).
These cells were then transferred back to glucose
media and analyzed for WWOX gene transcript lev-
els after three days. Interestingly, WWOX gene
transcript levels had decreased albeit not com-
pletely, when compared with those observed in
the original glucose growing population (Fig. 2).
Thus, the changes occurring in the shift to oxida-
tive phosphorylation maintain high levels of
WWOX gene transcripts, but these effects are, at
least to some extent, reversed when cells are
grown under conditions that favor glycolysis once
more. Data for duplicate samples and various
times of growth in galactose are given in Support-
ing Information Figure S4.
Inhibition of Glycolysis by DCA or 2DG Causes
Upregulation of WWOX Gene Transcripts
DCA is a well-characterized inhibitor of pyru-
vate dehydrogenase kinase (PDK), a kinase essen-
tial for shunting pyruvate into the glycolytic
pathway, rather than into the TCA cycle. This
drug has been used in diseases such as lactic aci-
dosis to shift metabolism from glycolysis and lactic
acid production, to oxidation of glucose via the
Figure 1. Glycolysis vs oxidative phosphorylation in HEK293T
Cells. (A) Galactose forces cells to undergo mitochondrial respiration
significantly inducing the expression of the WWOX gene as well as
IDH2 and MDH2, two mitochondrial enzymes involved in oxidative
phosphorylation. (B) WWOX protein levels are concomitantly elevated
under oxidative phosphorylation. Quantification of protein levels meas-
ured using Image J software.
4 DAYAN ETAL.
Genes, Chromosomes & Cancer DOI 10.1002/gcc
390
mitochondria. DCA has been shown to increase
glucose oxidation via the mitochondria with a con-
comitant decrease in glycolysis (Bonnet et al.,
2007) and has been explored as a candidate anti-
cancer drug (Michelakis et al., 2010). To confirm
that the increase in WWOX gene expression was
not because of nonspecific effects of growing cells
in galactose, DCA was used to promote oxidative
phosphorylation. Treatment of HEK293T cells
growing in glucose media with DCA for 24 hrs
increased the levels of WWOX mRNA by a factor
similar to that observed when cells were grown in
galactose (Fig. 3), suggesting a similar mechanism
is responsible for these effects.
The metabolic reprograming (Warburg effect)
that occurs in cancer cells has been exploited med-
ically to detect abnormally growing cells using the
radioactive fluoride derivative of 2DG, 2-18F-flu-
oro-2DG. 2DG is rapidly taken up by cancer cells
that rely on glycolysis for ATP production, but is
not further metabolized and has been shown to in-
hibit glycolysis (Gambhir, 2002). This compound
was therefore used to divert metabolism to oxida-
tive phosphorylation. Again, WWOX gene tran-
script levels were increased in the presence of
2DG (Fig. 3), suggesting that the mechanisms
involved in the activation of the alternative path-
way for ATP production in HEK293T cells is re-
sponsible for the observed effects.
In both cases (DCA and 2-DG) a response was
only seen above a particular concentration, rather
than as a dose-response (Supporting Information
Figs. S5 and S6), probably indicating a threshold
shift in metabolism is required in order to induce
altered WWOX transcript levels.
WWOX Gene Transcript Levels Decrease in Cells
Exposed to Hypoxia
Early tumor environments usually have reduced
oxygen levels because of the lack of blood irriga-
tion to the internal mass. Cells in these tumors
metabolize glucose to lactic acid to produce suffi-
cient ATP for cell proliferation. To investigate the
effects of conditions of reduced oxygen and hence
induced glycolysis on WWOX transcript levels,
HEK293T cells were exposed to hypoxic condi-
tions for 24 hrs. Hypoxia was confirmed by an
increase in VEGF, a transcript known to be upregu-
lated in low oxygen environments (White et al.,
1995) (Fig. 4A). Under the conditions used, VEGF
transcript levels were increased by approximately
five folds, whereas WWOX transcript levels were
significantly downregulated by seven folds, when
compared with cells grown under normoxic condi-
tions (Fig. 4B). To test whether this effect was evi-
dent at the protein level, cells were exposed to
similar hypoxic conditions for 24 hrs as well as 48
hrs. Hypoxia resulted in decreased WWOX protein
levels after 24 hrs of treatment and this was more
pronounced after 48 hrs (Fig. 4C and repeated
experiment in Supporting Information Fig. S3).
Level of ROS Correlate with the Upregulation of
the WWOX Gene
As glycolysis and oxidative phosphorylation
were having opposite effects on WWOX gene
Figure 2. Reversion to normal WWOX gene transcript levels in
glucose media after prolonged growth in galactose media. HEK293T
cells exposed to galactose media for prolonged periods maintain high
WWOX gene expression. However, replacement of galactose media
with glucose media rapidly restores WWOX gene expression to levels
closer to those of cells grown in glucose.
Figure 3. Two chemicals known to induce oxidative phosphoryla-
tion cause an upregulation of WWOX gene transcript. Dichloroace-
tate, shown to inhibit glycolysis, causes a similar increase in the
expression of fragile site genes as does growing cells in galactose
media. 2DG, another inhibitor of gylcolysis, also induces expression of
the WWOX gene. (Numbers above bars represent fold changes)
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expression, we hypothesized that ROS might par-
ticipate in, and perhaps mediate, this relationship.
This hypothesis is based on our findings in Dro-
sophila that ROS levels are dependent upon
WWOX genotype, with reduced WWOX levels
leading to decreased ROS, whereas elevated
WWOX results in increased ROS in the whole or-
ganism (O’Keefe et al., 2011). Although the gener-
ation of ROS, under hypoxic conditions, has been
contentious, it is well established that a byproduct
of mitochondrial respiration is ROS generated by
leaky electron transport chain (Chance and Hol-
lunger, 1961). To confirm that ROS levels were
altered under the conditions used here, we meas-
ured the levels of ROS produced by cells grown in
glucose versus galactose media as well as in those
cells grown in glucose in the presence of DCA or
2DG. In all cases high ROS levels paralleled the
increase in WWOX gene expression observed for
each growth condition (Fig. 5) consistent with a
role for ROS as an intermediary in the relationship
between WWOX gene activity and metabolic state
of the cell.
DISCUSSION
Environmental DNA damage and uncontrolled
cellular proliferation are typical early events in the
initiation of cancer. The consequences of high
proliferation rate for solid tumors are changes to
the microenvironment that include diminished nu-
trient supply and oxygen availability to the cell. In
order for such cells to survive, they must adapt to
this flux in energy and an increasingly hypoxic
environment. The evolutionarily conserved unsta-
ble DNA regions that constitute common CFS
have been proposed to be the front-line respond-
ers to adverse environmental changes (O’Keefe
and Richards, 2006). For example active smokers
exhibit a significantly higher frequency of com-
mon chromosomal fragile site expression (Stein
et al., 2002). These regions are found within large
genes whose expression is often altered in cancer
cells. Alteration of fragile site genes in animal
models has clear consequences on metabolism and
can result in decreased size and/or early death of
the organism (Palacino et al., 2004; Aqeilan et al.,
2008; Suzuki et al., 2009).
The functional contribution of WWOX to cancer
cell biology is evident from the profound differ-
ence in survival for individuals with colon cancers
with high compared to low WWOX gene expres-
sion (Zelazowski et al, 2011). Cancers that are defi-
cient in WWOX have a markedly poorer prognosis
indicating that WWOX has a determining role in
cancer cell progression.
Perturbations in the WWOX gene (that spans
the second most readily expressed fragile site
FRA16D in humans) have been shown to affect
levels of several genes within, and leading into,
the TCA cycle (O’Keefe et al., 2011). The
Figure 4. Effect of hypoxia on fragile-site gene transcripts. An
increase in VEGF levels (A) shows hypoxic conditions have been
reached, whereas WWOX transcript levels (B) as well as protein levels
quantified using Image J software are significantly decreased (C).
Figure 5. Fluorescence-activated cell sorter (FACS) analysis of
HEK293T cells labelled with CM-H2DCFDA grown under conditions
favoring oxidative phosphorylation (galactose, dichloroacetate, or
2DG) or glucose. Fluorescence intensity is proportional to the levels
of ROS per cell. The percentage of cells above an arbitrary threshold
of fluorescence is plotted for each growth condition.
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relationship between the FRA16D-associated per-
turbation of the WWOX gene and changes that also
occur in the transformation of a cell to a cancerous
phenotype, i.e., from mitochondrial oxidative
phosphorylation to a glycolytic form of ATP pro-
duction, are consistent with causal roles for the
WWOX gene in cellular transformation. A plausible
contribution would be that the DNA instability at
fragile site FRA16D in cancer, and consequent
perturbation of WWOX gene mRNAs, gives rise to
a lack of normal feedback control of metabolism in
cancer cells.
While the WWOX gene acts to inhibit growth of
tumor cells it does not act as classical tumor sup-
pressor and its alternative splicing renders the
relationship between common fragile site DNA
instability and its biological consequences quite
complex. For example, mice that are heterozygous
for WWOX loss-of-function mutation develop
tumors that still express WWOX indicating that a
“second-hit” and complete loss-of-function of
WWOX is not required (Aqeilan et al., 2007). Fur-
thermore, FRA16D deletions in cancers can be
completely intragenic with respect to the WWOX
gene and therefore alter the ratio of alternative
splice forms of the gene transcript (Driouch et al.,
2002; Finnis et al., 2005). Indeed, the significance
and complexity of the relationship between com-
mon fragile site DNA instability and gene expres-
sion has recently been highlighted by the report of
a patient with an inherited heterozygous 767kb
intragenic WWOX gene deletion and a disorder of
sex development (White et al., 2011). Premalig-
nant germ cells were identified in this patient’s go-
nadal tissue. The deletion spans the region known
to contain FRA16D (Ried et al., 2000) and removes
exons 6–8 of the WWOX gene, with maintenance
of the reading frame through the exon 5–9 junc-
tion. In this case the resultant truncated protein
presumably acts as a dominant negative competi-
tor for the normal protein in order to elicit the
observed phenotype.
The results presented herein demonstrate that
cells growing under various conditions that induce
oxidative phosphorylation by increasing the rate of
consumption of oxygen and decreasing the rate of
glycolysis (Gohil et al., 2010), respond by increas-
ing the levels of mRNAs for the WWOX (FRA16D)
CFS gene (Fig. 6). Furthermore, this increase is
not transient but is maintained for long periods
under conditions where cells are reliant on oxida-
tive phosphorylation as a sole source of ATP pro-
duction. Interestingly, WWOX has pro-apoptotic
activity, yet more than two-fold increase in the
mRNA levels of this gene and a substantial eleva-
tion in its protein level are not sufficient to induce
cell death.
Two drugs with potential therapeutic value
because of their known effects on the glycolytic
pathway have also important effects on the expres-
sion of the WWOX gene. Both DCA, a drug shown
to block glycolysis and induce mitochondrial oxi-
dation of glucose in cancer cells by inhibiting
PDK (Bonnet et al., 2007), and 2DG, which is rap-
idly taken up by and accumulates in the cell inhib-
iting glycolysis, cause an increase in WWOX gene
transcription. Interestingly, 2DG has also been
shown to have antimetastatic properties in vivo
and to inhibit cell migration and invasion in vitro
(Sottnik et al., 2011). This decrease in aggressive-
ness is associated with an increase in oxidative
phosphorylation.
Conversely, but consistently, cells that are grown
under hypoxic conditions that lead to increased
Figure 6. Model for the role of the WWOX Gene and ROS in the
balance between oxidative phosphorylation and glycolysis. Approxi-
mately 30% of ATP in HEK293 is derived from glycolysis. The levels of
WWOX mRNA are proportional to the amount of oxidative phospho-
rylation and inversely proportional to the level of glycolysis. ROS levels
parallel the increase in WWOX gene expression and could be an inter-
mediary in the relationship between WWOX gene expression and
metabolic state. Altering the ratio of glycolysis to oxidative phospho-
rylation in HEK293T cells alters the expression of the WWOX gene.
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glycolysis exhibit marked reduction in WWOX
mRNA levels (Fig. 6). Thus, a reciprocal relation-
ship exists between the metabolic state of cells
and the steady state level of WWOX mRNAs with
these levels being proportional to the amount of
oxidative phosphorylation and inversely propor-
tional to the level of glycolysis. Similar fluctuations
in ROS levels with metabolic state were also
observed. Whereas it is unclear whether these
changes in ROS levels are a cause or consequence
of changes in WWOX gene activity they clearly
have the potential to mediate the relationship
between metabolic state within the cell and
WWOX gene expression, and vice versa. As WWOX
has been shown to be a determinant of ROS levels
(O’Keefe et al., 2011), a model for this relationship
with a causal role for WWOX function in maintain-
ing the balance between oxidative phosphorylation
and glycolysis, mediated by ROS levels, is pro-
posed in Figure 6.
Distinguishing cause from consequence in can-
cer cells can be problematic. Although first discov-
ered over 80 years ago by Otto Warburg (Warburg
et al. 1927), altered metabolism has only been
recently added to the list of recognized hallmarks
of cancer (Hanahan and Weinberg, 2011). Warburg
et al. (1927) revealed that cancer cells favor ATP
production via rapid consumption of glucose and
formation of lactic acid rather than via the more
efficient mitochondrial respiration, even when ox-
ygen is available. Although this change in metabo-
lism has been exploited in the development of
drugs for cancer therapy (Porporato et al., 2011), it
has been unclear what causal cellular changes
bring about this phenotype.
“Genome instability and mutation” is another
hallmark of cancer (Hanahan and Weinberg,
2011). DNA damage in cells can either cause acti-
vation of apoptosis resulting in cell death or in
repair of the damaged DNA, with or without alter-
ation of the site of DNA lesion. Recurrent DNA
changes in cancer typically identify loci that make
causal contributions to cancer. Common CFS and
the genes that span them provide a link between
the hallmarks of altered metabolism and DNA
instability. Common CFSs are the most sensitive
sites in the genome to environmental agents that
bring about replicative stress. DNA damage at
common CFSs in vivo in cancer follows a similar
hierarchy to the in vitro induction of their cytoge-
netic appearance. The FRA3B and FRA16D loci
are two of the most frequent sites of homozygous
deletion in human cancers (Bignell et al., 2010).
Paradoxically, the conservation during evolution of
the physical relationship between these fragile
sites and the genes that span them indicates that
this relationship is biologically advantageous.
Common chromosomal fragile site genes including
WWOX have previously been show to make func-
tional contributions to the regulation of cellular
metabolism and, recently, to cancer cell fate (Zela-
zowski et al., 2011). Here we show that the WWOX
gene normally responds to external factors that
affect the metabolic state of the cell, i.e. the
WWOX gene not only regulates cellular metabo-
lism, it is also responsive to factors affecting cellu-
lar metabolism. In cells with DNA damage at the
FRA16D common chromosomal fragile site this
relationship with metabolism will be altered irre-
versibly, as the perturbed WWOX gene will no lon-
ger be able to respond in the normal manner (Fig.
6). This nexus therefore identifies the WWOX gene
as a primary candidate for a causal contribution to
the altered metabolism seen in cancer cells.
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Abstract
WWOX is a >1Mb gene spanning FRA16D Common Chromosomal Fragile Site, a region of
DNA instability in cancer. Consequently, alteredWWOX levels have been observed in a
wide variety of cancers. In vitro studies have identified a large number and variety of poten-
tial roles for WWOX. Although its normal role in vivo and functional contribution to cancer
have not been fully defined, WWOX does have an integral role in metabolism and can sup-
press tumor growth. Using Drosophila melanogaster as an in vivomodel system, we find
that WWOX is a modulator of TNF!/Egr-mediated cell death. We found that altered levels of
WWOX can modify phenotypes generated by low level ectopic expression of TNF!/Egr and
this corresponds to altered levels of Caspase 3 activity. These results demonstrate an in
vivo role for WWOX in promoting cell death. This form of cell death is accompanied by an
increase in levels of reactive oxygen species, the regulation of which we have previously
shown can also be modified by altered WWOX activity. We now hypothesise that, through
regulation of reactive oxygen species, WWOX constitutes a link between alterations in cel-
lular metabolism observed in cancer cells and their ability to evade normal cell death path-
ways. We have further shown that WWOX activity is required for the efficient removal of
tumorigenic cells from a developing epithelial tissue. Together these results provide a
molecular basis for the tumor suppressor functions of WWOX and the better prognosis
observed in cancer patients with higher levels of WWOX activity. Understanding the con-
served cellular pathways to which WWOX contributes provides novel possibilities for the
development of therapeutic approaches to restore WWOX function in cancer.
Introduction
Evasion of cell death and altered metabolism are recognized as hallmarks of cancer cells, whilst
DNA instability is one of the enabling characteristics [1]. The FRA16D Common Chromo-
somal Fragile Site (CCFS) spanning gene,WW domain containing oxidoreductase (WWOX),
participates in each of these phenomena and therefore its perturbation in cancer cells presents
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multiple possible avenues for contributing to cancer cell biology. CCFS are specific regions of
chromosomes that can be induced to break in vitro by inhibitors of DNA polymerase and are
affected by certain dietary or environmental factors [2–3]. More than 70 common fragile sites
have been identified in the human genome and it has been observed that there is a hierarchy of
sensitivity in vitro that is matched by the frequency with which these sites show in vivo DNA
instability in various cancers [4]. Of these fragile sites, FRA3B and FRA16D have been shown
to be the most frequent regions of recurrent homozygous deletion in cancer cell lines [5]. CCFS
are typically located within extremely large genes (i.e. FRA3B in 1.5 Mb FHIT gene, FRA16D in
1.1 MbWWOX gene), a relationship that is conserved in mice and suggestive of biological sig-
nificance [4, 6]. DNA instability at these sites, resulting in deletion(s) and / or localised rear-
rangements, is associated with alterations to CCFS-associated gene expression [7–8].
Altered expression ofWWOX has been reported for many different cancer cell types
(reviewed in [9–11]). In addition, low expression alleles ofWWOX were found at a higher fre-
quency in patients with lung cancer [12] or glioma [13], consistent with decreasedWWOX as a
predisposing factor for tumorigenesis.WWOX hypomorphic mice showed an increased inci-
dence of B-cell lymphoma [14] and mice heterozygous forWWOX exhibit higher rates of
tumor growth [15], however the tumor cells still express WWOX protein indicating a lack of
the typical ‘second-hit’ somatic mutation that is characteristic of classical tumor suppressors.
Thus it appears that a reduced level of WWOX activity is sufficient for contribution to cancer
progression. Conversely, ectopically expressed WWOX has been shown to function as a sup-
pressor of tumor growth since restoration of WWOX activity in cancer cells inhibits their
growth in vivo [16–20]. Correlation of higher WWOX expression with better prognosis has
also been reported for various types of cancer including colon, breast and bladder [21–23].
Therefore the pathways that WWOX normally participates in, and the nature of this participa-
tion, are of considerable interest for their likely causal and therapeutically targetable contribu-
tion to cancer cell biology.
WWOX encodes an enzyme with short-chain dehydrogenase/reductase (SDR) activity in
addition to twoWW domains that facilitate protein-protein interactions. WWOX has been
implicated in a diverse range of cellular pathways and processes in mammalian studies by vir-
tue of its physical and / or functional interactions with other proteins or pathways (reviewed in
[24–26]). Whilst various functions for WWOX have been revealed in vitro, it is difficult to
assess their relative significance and contribution to cancer in vivo. A role for WWOX in
metabolism has been established through the analysis of knockout models in mouse, rat and D.
melanogaster [14–15,27–30]. The protein encoded byWWOX has been found not only to con-
tribute to cellular metabolism but also is, in turn, regulated by the relative level of glycolysis
versus oxidative phosphorylation [31]. WWOX has also been widely reported to play a role in
apoptotic pathways, principally through interactions with the tumor suppressor p53 (reviewed
in [24–32]). A pro-apoptotic role for WWOX in vitro has previously been reported for many
different cancer cell types; multiple myeloma [33], colon [34], gall bladder [35], cervical [36],
leukaemic [37], glioblastoma [38–39], hepatoma [40], lung [17], pancreatic [18] and squamous
epithelia [41]. However the molecular mechanism(s) by which WWOX contributes to cell
death pathways in vivo has not been determined. The genetically tractable system of D.melano-
gaster is an effective system in which to dissect various aspects of the contribution of WWOX
to cellular pathways. Herein we determine the role of WWOX in modulating TNF!-mediated
cell death through regulation of Caspase 3 activity. In addition we are able to demonstrate a
requirement for WWOX in the elimination of tumorigenic cells, thus supporting a requirement
for WWOX function early in the tumorigenic process for the removal of abnormal cells.
WWOX and the Elimination of Tumorigenic Cells
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Results
Altered WWOXmodulates ectopic Egr/TNF! eye phenotypes
Ectopically expressed WWOX has been shown to enhance the in vitro cytotoxicity of TNF! in
various tissue culture cell lines [42], yet the contribution of WWOX to TNF!-mediated cell
death in vivo has not been determined. D.melanogaster has a single ortholog to TNF! encoded
by the EDA-like cell death trigger or Eiger (Egr) gene [43–44]. Genetic modification analyses
have previously revealed a number of metabolic genes that are rate-limiting in their contribu-
tion to Egr/TNF!-induced cell death phenotypes in the D.melanogaster eye [45]. TheWWOX
gene has been identified as participating in aerobic metabolism in D.melanogaster [30] and
thus also represents a candidate for contributing to Egr/TNF!-mediated cell death. Ectopic
over-expression of a low level expression construct for Egr/TNF! in the eye during its develop-
ment results in a phenotype characterised by disruption to the precise patterning of repeated
ommatidial units on the external surface of the eye as well as a decrease in overall size (Fig 1A
and [46]) when compared to a control eye (Fig 2D). This Egr/TNF! phenotype was completely
suppressed by RNAi-mediated knockdown of wengen, a gene that encodes the D.melanogaster
TNF receptor (TNFR) thus confirming the specificity of the ectopic Egr/TNF!-mediated phe-
notype (Fig 1B and [47–48]). Introduction of aWWOX knockdown construct (WWOX-IR#1)
resulted in suppression of the Egr/TNF!-mediated rough eye phenotype evident as restoration
of ommatidial patterning across the surface of the eye as well as an increase in eye size (Fig 1C
and 1D). A similar suppression of eye size was observed with an independentWWOX knock-
down construct as well as in flies heterozygous forWWOX loss-of-function mutant alleles (S1
Fig). This indicates that WWOX can contribute to low level Egr/TNF!-mediated cell death.
Ectopic expression ofWWOX alone does not result in any obvious cell death-induced pheno-
type in the biological context of theD.melanogaster eye (S1 Fig). Ectopic over-expression of
WWOX cDNA showed enhancement of the Egr/TNF!mediated mild rough eye phenotype evi-
dent as further disruption to ommatidial patterning and a significant decrease in eye size (Fig 1E
and 1F). A decrease in adult eye size was also observed with ectopic over-expression of an open
reading frame (ORF) encodingWWOX although these results were more variable despite compa-
rable levels of expression ofWWOX (Fig 1F and S1 Fig). Notably, ectopic expression of WWOX
together with Egr/TNF! did not result in any further increase inWWOX levels (S1 Fig). Together
these data demonstrate that WWOX contributes to Egr/TNF!-mediated cell death phenotype.
To determine whether the interaction between WWOX and Egr/TNF! was specific we also
tested the contribution of WWOX with other inducers of cell death. Given the significant anal-
ysis of WWOX function together with p53 in the literature, we also tested for any modification
of ectopic p53 phenotypes with altered levels of WWOX. However, we were unable to detect
any alteration to the much more severe eye phenotypes generated by ectopic expression of
either p53 or Hid (head involution defective), another of the cell death promoting proteins
identified in D.melanogaster (S2 Fig).
Egr/TNF!-mediated cell death phenotypes are mediated by increased
ROS
Reactive oxygen species (ROS) are known to be principle effector molecules of Egr/TNF!-
mediated cell death [45]. We were able to confirm this in larval wing discs expressing Egr/
TNF! in the posterior region by increased staining for CellRox compared to low levels
observed in the anterior control region for each disc (Fig 2A–2C). We also determined whether
the Egr/TNF!-mediated rough eye phenotypes can be modified by enzymes known to modify
ROS levels. Superoxide dismutase (SOD) activity is required for conversion of superoxide to
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Fig 1. AlteredWWOXmodifies ectopic Egr/TNF!-mediated eye phenotype. (A) Ectopic expression of
Egr/TNF! (GMR>egr+w>empty vector (EV)) results in a decrease in eye size and disruption to ommatidial
patterning. (B) The ectopic Egr/TNF! phenotype is completely suppressed by decreased levels of TNFR
(GMR>egr+w>wengen/TNFR-IR). (C) Decreased expression of WWOX by RNAi knockdown
(GMR>egr+w>WWOX-IR#1) results in suppression of the rough eye phenotype. (D)Quantification of
increased eye size with independent WWOX knockdown constructs (GMR>egr+w>WWOX-IR#1 and
GMR>egr+w>WWOX-IR#2). (E) Increased expression of WWOX by ectopic expression of theWWOX cDNA
(GMR>egr+w>WWOX-cDNA) resulted in an enhancement of the Eiger/TNF! phenotype. (F)Quantification of
decreased eye size with independent ectopic expression constructs for WWOX (GMR>egr+w>WWOX-ORF
and GMR>egr+w>WWOX-cDNA). Significance indicated by **** = p <0.0001, * = p<0.05 and ns = not
significant.
doi:10.1371/journal.pone.0136356.g001
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hydrogen peroxide as an intermediary in the detoxification process. There are different SOD
enzymes found within the cell; SOD1 (CuZn) is located in cytoplasm whilst SOD2 (Mn) is
found in the mitochondria. Ectopic expression of either SOD1 or SOD2 gave no phenotype on
their own (Fig 2D–2F) but were able to obviously suppress the Egr/TNF! eye (Fig 2G–2I). This
suppression of the Egr/TNF! small eye phenotype was consistently observed in all progeny
and supports a role for ROS in these Egr/TNF!-mediated phenotypes.
WWOX remains cytoplasmically localised in response to ectopic Egr/
TNF! expression
Nuclear localisation of WWOX has been reported to be necessary for the cell death promoting
functions of WWOX in mammalian cells [42]. Although endogenous levels of WWOX are too
Fig 2. Ectopic expression of Egr/TNF! gives increased ROS and is suppressed by increased SOD
activity. (A) Ectopic expression of GFP and Egr/TNF! with hh-GAL4 in the posterior portion of wing discs of
wandering third instar larvae, GFP shows the region of ectopic expression (outlined by dotted line). (B)
Punctate CellRox staining revealed increased ROS levels at posterior edge of disc. (C)Merged image with
GFP in green and CellRox in red. (D) Control eye phenotype (GMR>EV) showing regular ordered arrays of
ommatidial units on the surface of the adult eye (E-F) Ectopic expression of SOD1 or SOD2 alone has no
effect. (G). Ectopic expression of Egr/TNF! in the eye (GMR>egr+w>EV) results in a decrease in eye size and
disruption to ommatidial patterning. (H-I) The ectopic Egr/TNF! phenotype is obviously suppressed by
increased levels of SOD1 or SOD2.
doi:10.1371/journal.pone.0136356.g002
WWOX and the Elimination of Tumorigenic Cells
PLOS ONE | DOI:10.1371/journal.pone.0136356 August 24, 2015 5 / 19
401
low to be detected in D.melanogaster, we have previously shown cytoplasmic localization of
ectopically expressed WWOX during embryonic development [49]. Here, we also determined
the localisation of ectopically expressed WWOX in differentiated cells of the developing eye
disc. GMR-GAL4 was used to ectopically express WWOX in all cells posterior to the morpho-
genetic furrow. WWOX expression can be visualised in cytoplasmic regions surrounding the
DAPI stained clusters of nuclei from photoreceptor cells (S3 Fig). A similar pattern of cyto-
plasmic WWOX expression was observed in the presence of ectopic Egr/TNF! expression (S3
Fig). Thus we observed no alteration to ectopic WWOX localisation in response to Egr/TNF!
in vivo. Given the small size and complex organisation of cells in the developing eye disc, the
effect of ectopic Egr/TNF! expression on the localisation of WWOX was also determined in
cells in the posterior compartment of the wing disc using hh-GAL4. Co-expression of GFP
allowed for the positive identification of cells in the region of ectopic expression. Ectopic
WWOX alone resulted in cytoplasmic staining with WWOX detected in regions surrounding
the DAPI stained nuclei throughout the posterior half of the disc (Fig 3A–3D). In the presence
of ectopic Egr/TNF! expression, the wing discs are smaller and there is significant disruption
to the region of the disc marked by GFP expression (Fig 3E). Closer examination of cells
located in the posterior region of the disc showed that ectopic WWOX remains clearly cyto-
plasmic as staining was observed complementary to the DAPI stained nuclei (Fig 3F–3H).
Thus there was no evidence in vivo for nuclear localisation of detectable levels of ectopic
WWOX in response to Egr/TNF! expression in eye or wing imaginal discs.
Ectopic Egr/TNF! alone promotes apoptosis and disrupts cellular
patterning in wing discs
Ectopic expression of Egr/TNF! alone in the posterior region of wing discs resulted in a signifi-
cant decrease in tissue size and disruption to compartment boundaries as visualised by GFP
expression (Fig 4E). In particular there is posterior GFP expression extending into the central
wing pouch region of the disc (Fig 4E’). In order to determine the identity of these cells, Cubitis
interruptus (Ci) staining was used as a marker of cells specific to the anterior portion of the
wing disc. In control discs the region corresponding to Ci staining is complementary to the
GFP expression pattern in the posterior region under control of hh-GAL4 thus defining the
boundary of these distinct cell types (Fig 4B). However, in response to ectopic Egr/TNF!
expression in the posterior region, there is now a region of Ci positive anterior cells overlapping
with the GFP positive posterior cells in the central wing pouch region (Fig 4F and 4F’). Thus
ectopic expression of Egr/TNF! has resulted in disruption to normal patterning of the wing
disc cells such that there is no longer a clear distinction between cells from the Ci staining por-
tion of the disc (i.e. the wild-type cells from the anterior region) and GFP positive cells from
the posterior part of the disc (i.e. cells ectopically expressing Egr/TNF!).
Furthermore, the GFP expression observed in this region of overlap was punctate in appear-
ance suggestive of increased cell death (Fig 4E’). To assess the cell death we examined immu-
nostaining for cleaved Caspase 3 [50]. Whilst negligible levels of Caspase 3 staining were
observed in control discs (Fig 4C), increased levels were observed in the central wing pouch
region of discs ectopically expressing Egr/TNF! (Fig 4G and 4G’). In addition, Caspase 3 stain-
ing was found to extend beyond the GFP region of the wing pouch in two distinct regions (Fig
4G’, asterisks). Similar localisation of Caspase 3 staining to these two regions has previously
been reported following ectopic expression of Hid or Src64B, together with the apoptosis inhib-
itor P35 in the posterior region of developing wing discs [51–52]. The extremities of these
regions have previously been shown to contain cells undergoing a process of Apoptosis-
induced Apoptosis (AiA) with Egr/TNF! shown to be required for the death signal [52]. Closer
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examination of Cell Rox staining (Fig 2B) also revealed increased ROS corresponding to these
two distinct regions. These results confirm that over-expression of a low level of Egr/TNF! in
the posterior compartment is sufficient to induce ROS and cell death in anterior regions, con-
sistent with a key role of Egr /TNF! as an activating signal for AiA.
WWOXmodifies Caspase 3 staining in response to ectopic Egr/TNF!
Since WWOX has been shown to modify adult eye phenotypes resulting from ectopic over-
expression of Egr/TNF!, we determined whether WWOX was also able to regulate the
increased region of Caspase 3 staining and consequent disruption to the patterning induced by
ectopic expression of Egr/TNF! in wing discs. Decreased WWOX activity together with
ectopic expression of Egr/TNF! in the posterior portion of the disc resulted in a decrease in the
relative area of Caspase 3 staining (Fig 5C, 5D and 5G). Conversely, increased WWOX
Fig 3. Ectopic Egr/TNF! has no obvious effect on cytoplasmically localizedWWOX. (A) Ectopic
expression of GFP andWWOX in the posterior portion of wing discs of wandering third instar larvae
(hh>GFP>WWOX), GFP shows the region of ectopic expression. (B)WWOX staining reveals expression
localized to areas complementary to the DAPI stained nuclei shown in (C) with the merged image shown in
(D). (E-H) Ectopic expression of WWOX in the presence of ectopic Egr/TNF! (hh>GFP>WWOX>egr+w) also
results in cytoplasmic localisation of WWOX. Nuclei/DAPI staining shown in blue andWWOX staining in
magenta. Boxed regions shown in A and E correspond to regions that are enlarged in B-D and F-H
respectively.
doi:10.1371/journal.pone.0136356.g003
WWOX and the Elimination of Tumorigenic Cells
PLOS ONE | DOI:10.1371/journal.pone.0136356 August 24, 2015 7 / 19
403
expression increased the relative area of Caspase 3 staining (Fig 5E–5G). Thus we have shown
that WWOX activity is required for, and can contribute to, cell death in Egr/TNF! expressing
cells via regulation of Caspase 3 activity. The outcome of this interaction at the interface
between wild-type cells in the anterior and the posterior Egr/TNF! expressing cells is sugges-
tive of competitive interactions between these two cell types.
Requirement for WWOX tumor suppressor activity in vivo
Competition occurs between cell types that are genetically distinct such that one has a competi-
tive advantage over the other. In order to determine whether decreased WWOX impacts on
Fig 4. Qualitative effects of ectopic Egr/TNF! and increased apoptosis in the larval imaginal wing
disc. (A) Control disc showing ectopic expression in the posterior region of wing discs using hh-GAL4
visualized by co-expression of GFP. (B) Ci staining of control discs show staining of the anterior compartment
and is complementary to the region of GFP expression. (C) Caspase 3 staining revealed low levels of
apoptosis in control imaginal wing discs. (D)Merged image where GFP is green, Caspase 3 staining is
magenta and Ci is yellow. (E-E’) Ectopic expression of Eiger/TNF! resulted in a significant decrease in disc
size and disruption to the pattern of GFP expression with punctate staining in the central wing pouch region.
(F-F’) Staining of the anterior compartment with Ci reveals expression beyond the boundary and overlapping
with the region of GFP expression. (G-G’) Caspase 3 staining reveals high levels of staining in the central
wing pouch region and in two distinct regions extending towards to anterior portion of the disc (indicated with
the red asterisks). (H-H’)Merged image (GFP is green, Caspase 3 is magenta and Ci is yellow). In all images
the dotted line outlines the regions of GFP expression corresponding to the posterior region of the discs. Red
boxes indicate the regions that are enlarged in E’-H’.
doi:10.1371/journal.pone.0136356.g004
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the ability of tumorigenic cells to compete with non-tumorigenic / normal cells we utilized the
well characterised system of mitotic clones of the cell polarity regulator Scribbled (Scrib). Epi-
thelial tissues in D.melanogaster where all cells are mutant for Scrib will overgrow and give rise
to tumours [53]. However tumorigenic clones of Scribmutant cells that are surrounded by
wild-type cells will be eliminated [46, 54]. Clones of Scribmutant cells generated in this way
using theMosaic Analysis with a Repressible CellMarker (MARCM) system are positively
labelled with GFP expression [55]. Many cells of the randomly generated mutant clones are
eliminated however this process is not complete and some remain and can be visualized by
patches of GFP positive cells in developing eye discs (Fig 6A and 6A’). These cells also corre-
spond to regions of disruption to the normal pattern of differentiation as visualised by Elav
staining during larval development (Fig 6B, 6B’, 6C and 6C’). When WWOX levels were
Fig 5. WWOXmodifies Caspase3 staining in wing pouch in response to ectopic Egr/TNF!. (A) Ectopic
expression of GFP and Eiger/TNF!with hh-GAL4 in the posterior portion of wing discs of wandering third
instar larvae, GFP showing the regions of ectopic expression. (B) Caspase 3 staining reveals high levels of
apoptosis in the central wing pouch region as well as in two distinct regions extending towards the anterior.
(C) DecreasedWWOX expression results in a decrease in area of GFP expression. (D) DecreasedWWOX
expression results in a decreased region of Caspase 3 staining. (E) IncreasedWWOX expression results in
an increase in area of GFP expression. (F) IncreasedWWOX expression results in a increased region of
Caspase 3 staining. (G)Quantification of the area of Caspase 3 staining as a proportion of the area of the
whole disc for individual wing discs of each genotype. Significance indicated by * = p<0.05, ** = p<0.005.
doi:10.1371/journal.pone.0136356.g005
WWOX and the Elimination of Tumorigenic Cells
PLOS ONE | DOI:10.1371/journal.pone.0136356 August 24, 2015 9 / 19
405
reduced within these tumorigenic clones, an increase in the proportion of disc area with GFP
positive cells was observed despite no change to overall disc size (Fig 6D, 6D’, 6G and 6H).
These GFP positive cells were also found to correspond to regions disrupted in their differenti-
ation as visualised with Elav (Fig 6E, 6E’, 6F and 6F’). Thus a decrease of WWOX within the
clones of tumorigenic cells results in a mild but significant increase in their ability to compete,
observed as a decrease in their effective elimination during this larval stage.
These tumorigenic Scrib clones persist throughout development and differentiation of eye
tissue and result in mild adult eye phenotypes characterised by patches of roughness and disrup-
tion to ommatidial patterning (Fig 6I). This phenotype is enhanced whenWWOX is decreased
by RNAi knockdown within cells of the Scribmutant clones where eyes consistently showed a
significant decrease in size, as well as an increase in the frequency of black necrotic lesions of
increased size on the surface of the adult eye (Fig 6J–6L). This enhanced phenotype also corre-
sponds to an observed decrease in overall viability with flies with decreased WWOX expression
in Scribmutant clones showing a survival rate of 31.9% of that expected compared to 74.1% for
flies with the Scribmutant clones alone (!!p = 0.0016). A decrease in adult viability (or increase
in pupal lethality) has previously been reported as an indication of reduced elimination of Scrib
mutant clones in other genetic backgrounds [45–46, 56]. Thus we have demonstrated a cell
autonomous contribution fromWWOX for the elimination of tumorigenic cells in a whole ani-
mal model system. Similar effects on adult eye development were obtained when Scribmutant
clones were generated in eye discs where the whole animal had reducedWWOX function (het-
erozygous for either of two independent alleles ofWWOX) or where WWOX function is
completely removed (trans-heterozygous for independentWWOX alleles) (S4 Fig). Together
these findings confirm that there is a decrease in the effectiveness of the process whereby tumor-
igenic Scribmutant clones are eliminated whenWWOX activity is reduced either exclusively
within cells comprising the mutant clones or whenWWOX activity is reduced or completely
removed from all cells of the animal. Although mild effects were observed during developmental
stages they resulted in more significant outcomes at the end of differentiation.
Discussion
TheWWOX gene spanning FRA16D has previously been shown to have a variety of in vitro
contributions to known cell death pathways in different mammalian cell lines, however it is
unclear how these translate into a role in vivo, particularly in relation to the ability of WWOX
to act as a tumor suppressor. We have therefore utilized a well-characterized D.melanogaster
model of cell-cell competition to investigate an in vivo role for WWOX in the process of elimi-
nation of cancerous cells.
Significantly we determined an in vivo contribution byWWOX to the process whereby
clones of epithelial cells carrying tumorigenic mutations are eliminated by the surrounding
wild-type cells. The outcomes of competitive cell interactions in this way are essential contribut-
ing factors to the development of tumors in vivo [57]. We report here that reduction, or absence,
of WWOX activity specifically in the tumorigenic cells decreased the effectiveness of this elimi-
nation process. Although this cell autonomous requirement forWWOX activity resulted in rela-
tively mild effects on GFP expressing mutant cells in the eye imaginal discs, much more striking
effects were evident at later stages. Generation of Scribmutant clones in this way is analogous to
the accumulation of mutations in cells that can gain a competitive advantage over the surround-
ing wild-type (non-mutant) cells and ultimately give rise to human cancers. Thus, our results
show that endogenous WWOX plays a significant in vivo role in the process whereby mutation-
bearing cells are eliminated. Together these results represent a plausible mechanism for low
WWOX levels contributing to poor prognosis in various cancers [21–23,58].
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Fig 6. WWOX is required for elimination of Scribbled (Scrib)mutant clones. (A-A’) Clones of cells mutant for Scrib generated in the eye using the
MARCM system are positively labelled with GFP. (B-B’) Elav staining reveals absence of differentiated photoreceptors within a portion of Scribmutant
clones. (C-C’)Merged image showing GFP in green and Elav in magenta. (D-D’)GFP expressing Scribmutant clones with decreasedWWOX expression
(Scrib1;WWOX-IR). (E-E’) Elav staining reveals absence of differentiated photoreceptors within a portion of the Scrib1;WWOX-IRmutant clones. (F-F’)
Merged image showing GFP in green and Elav in magenta. Red boxes indicate the regions that are enlarged in D’-F’. (G)Quantification of the proportion of
GFP expressing cells showed a significant increase whenWWOX expression was decreased in the Scribmutant clonal tissue compared to the Scribmutant
clones alone. (H)Quantification of total area of the eye disc containing Scrib clones with and without WWOX knockdown revealed no significant difference. (I)
Clones of cells mutant for Scrib generated in the eye using the MARCM system result in a mild adult rough eye phenotype. (J) DecreasedWWOX expression
in the Scribmutant clones gave a stronger phenotype with a decreased eye size, significant disruption to ommatidial patterning and the presence of necrotic
lesions. (K)Quantification of the overall size of the adult eyes showed a significant decrease whenWWOX levels were knocked down in Scribmutant clones.
(L)Quantification of percentage of adult fly eye showing necrotic spots of different sizes: Small (550–3000 pixels), Medium (3000–5500 pixels) or Large
(>5500 pixels). Genotypes used in these experiments: Scrib1 = (ey-FLP1, UAS-mCD8-GFP;;tub-GAL4 FRT82B tub-GAL80/ FRT82B, Scrib1), Scrib1;
WWOX-IR = (ey-FLP1, UAS-mCD8-GFP; UAS-WWOX-IR#2/+;tub-GAL4 FRT82B tub-GAL80/ FRT82B, Scrib1). Significance indicated by * = p<0.05 and **
= p<0.005, ns = not significant.
doi:10.1371/journal.pone.0136356.g006
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We have also utilised D.melanogastermodels to dissect the cell death pathways to which
WWOX contributes in vivo. In mouse L929 cells, an ectopic increase in WWOX was found to
enhance TNF!-mediated cell death [42]. Consistent with this observation, altered WWOX lev-
els modulate the phenotype obtained from ectopic expression of Egr/TNF! in the eye of D.
melanogaster. WWOX was also previously shown to be an essential component of p53-medi-
ated apoptosis in NIH3T3 cells [42], however no impact of altered WWOX levels was observed
on the D.melanogaster eye phenotype from ectopic expression of p53. Similarly, no WWOX-
mediated alteration of the D.melanogaster eye phenotype from ectopic expression of hid was
observed herein, although others have reported a mild effect with further reduced WWOX lev-
els on ectopic hid expression in the D.melanogaster eye [59]. Together these data are consistent
with WWOX having a conserved, biologically significant role to play in the cell death mediated
by Egr/TNF!.
In vitro nuclear localisation of pro-apoptotic WWOX was reported in L929 cells [42] as well
as in MC7 cells in response to DNA damage [60]. However, we found no in vivo evidence for
nuclear localization of ectopic WWOX in the presence of ectopic TNF! expression, indicating
that the tumor suppressive functions may not be at the level of detection or alternatively they
may be mediated through cytoplasmic WWOX functions. Conflicting reports appear in the lit-
erature for the location of WWOX protein to various cytoplasmically localised organelles
including Golgi and mitochondria [16, 49]. Thus the localisation of WWOXmay vary in differ-
ent cell types and in response to different cellular stressors.
We observed no phenotypic effect with ectopic expression of WWOX alone, thus the cell
death promoting effects of WWOX may require that WWOX be activated or modified in some
way (e.g. phosphorylation) and may only become effective in vivo once cells are under some
type of stress. Reactive oxygen species (ROS) are known to be principle effector molecules of
TNF!-mediated cell death [45]. We have previously shown ectopic expression of WWOX
gives high levels of ROS whilst reduced levels of WWOX show decreased ROS in developing D.
melanogaster larvae [30]. Therefore, a likely mechanism by which WWOX contributes to the
Egr/TNF!-mediated cell death pathway is via its regulation of ROS (Fig 7). At least to some
extent, this occurs through regulation of the subset of ROS that are also responsive to enzymes
of the superoxide dismutase (SOD) family and we have previously shown alterations in iso-
forms of SOD1 in WWOXmutant flies as well as genetic interactions between WWOX and
SOD1 [30]. However the role for WWOX in the regulation of ROS levels may occur in a con-
text dependent manner given the opposing effects reported for altered ROS in response to
modified WWOX expression [61–62]. In addition, alterations to ROS levels would occur as a
consequence of cancer cells shifting their metabolism from oxidative phosphorylation to a
more glycolytic Warburg-based metabolism and we have previously shown that WWOX is
both responsive to, and contributes to aerobic metabolism [30–31]. The protein products of
other Common Fragile Site-associated genes; Fragile histidine triad (FHIT) at FRA3B and Par-
kin at FRA6E have also previously been shown to act as regulators of ROS [63–65]. Thus these
genes may act together to maintain genome integrity under conditions of heightened oxidative
stress, potentially arising from alterations to cellular aerobic metabolism known to be associ-
ated with cancer.
Materials and Methods
Fly lines and crosses
w1118, UAS-Dmp53 [66], GMR-GAL4, GMR-hid [67], hh-GAL4 [68–69], UAS-SOD1 and
UAS-SOD2 [70] were provided by Bloomington Stock Centre. UAS-TNFR-IR (v9152),
UAS-WWOX-IR#1 (v22536), and UAS-WWOX-IR#2 (v108350) were obtained from Vienna
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Drosophila RNAi Center. Successful knockdown of WWOXmRNA in each of these lines has
previously been shown to be effective by quantitative real-time PCR (30, 61). Ectopic Eiger/
TNF! expression stock (UAS-egr+w) was kindly provided by Professor Miura [46].WWOX1,
WWOX2, UAS-WWOX ORF#1 and UAS-WWOX cDNA#1 have previously been described [49
and 61]. MARCMIII and FRT82B, Scrib1 stocks were kindly provided by Helena Richardson.
D.melanogaster stocks were maintained on fortified (F1) medium composed of 1% agar, 1%
glucose, 6% fresh yeast, 9.3% molasses, 8.4% coarse semolina, 0.9% acid mix and 1.7% tegosept.
All crosses were carried out at 25°C unless otherwise stated.
Analyses of Adult Eyes
Photographs of exterior adult female D.melanogaster eyes were taken using an Olympus SZX7
microscope fitted with a SZX-AS aperture diaphragm unit. Images were captured using an
Olympus ColourView IIIU Soft Imaging System camera and AnalysisRuler image acquisition
software. Images prepared using Adobe Photoshop CS version 8.0. The anterior of eye is posi-
tioned to the left of all images. For determination of adult eye sizes the outline of ten different
randomly selected eye photos were traced using ImageJ and total area (in pixels) for each
image was measured. Results for each experiment were graphed as scatterplot and statistical
analyses (T-test analyses and One Way ANOVA) performed in GraphPad Prism.
Clonal analyses
Mitotic clones were generated for analyses using the MARCM III system, by crossing ey-FLP1,
UAS-mCD8-GFP;;tub-GAL4 FRT82B tub-GAL80/TM6B flies to those carrying either aWWOX
mutant allele orWWOXRNAi transgene together with FRT82B, Scrib1. Timed lays were carried
out for all eye disc analyses. Third instar wandering larvae were dissected in PBS and fixed with
4% formaldehyde before mounting in glycerol to visualise GFP expression (GFP indicative of
Fig 7. Model for the conserved role of WWOX in TNF!-mediated apoptosis in vivo inD.melanogaster.
The function of WWOX in promoting cell death in response to Egr/TNF! signalling (throughWengen/TNFR)
is mediated by ROS and Caspase 3. This can be modulated though expression of SOD enzymes that act to
limit cellular levels of ROS and is also responsive to the metabolic status of cells.
doi:10.1371/journal.pone.0136356.g007
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clones and a minimum n = 20 eye discs were analysed per genotype). Significant disruption to
eye disc morphology was observed in 13/52 pairs of the Scrib1 clones and 31/50 pairs Scrib1;
WWOX-IR clones and these were not included in these analyses. The size of the whole eye disc
and area of GFP clones were quantified using Image J. The clonal area was calculated as a per-
centage of the total size of the eye imaginal disc and the averaged results were graphed as a scat-
terplot. T-test analyses were performed using GraphPad Prism. For determination of necrotic
spots, the area of the black regions on the surface of the adult eyes were measured using ImageJ
and divided into/scored as different categories based on size; small (550–3000 pixels), medium
(3000–5500 pixels) or large (>5500 pixels). The percentage of eyes in each category was calcu-
lated and graphed using Microsoft Excel. For the viability assays, the overall number of adult
progeny that eclosed from pupae were scored and the ratio of non TM6B:TM6B progeny were
recorded for each cross, as described previously (30). The survival rate is presented as a per-
centage of the expected ratio of progeny. Statistical analyses were performed using the chi-
square test with p = 0.05 as cut off value for significance using GraphPad Prism.
Western blot analyses
30 female adult flies (0–1 day old) per sample were collected and Western blot analyses were
performed as previously described (49). Primary antibodies used were anti-C-DmWWOX
antibody (1:1000) (49) and mouse monoclonal anti-"-tubulin antibody (1:2000, Sigma). Sec-
ondary antibodies used were Anti-Rabbit DyLight 649 antibody (1:2500, Vector Laboratories)
and anti-mouse-Cy3antibody (1:200, Jackson Laboratories).
Immunohistochemistry
Wing discs or eye imaginal discs were dissected from late third instar larvae in 1x phosphate buff-
ered saline (PBS) and fixed in 3.7% formaldehyde for 20 minutes. Discs were then washed three
times with PBST (1xPBS + 0.3% Triton-X-100) for 20 minutes and blocked with PBSTF (1xPBS
containing 5% fetal calf serum) for 90 minutes, followed by incubation of primary antibody over-
night at 4°C. Anti-C-DmWWOX antibody (1:100 (52), anti-cleaved Caspase 3 antibody (1:100,
Cell Signaling), anti-Elav 9F8A9 (1:10, Developmental Studies Hybridoma Bank) and anti-Ci 2A1
(1:100, Developmental Studies Hybridoma Bank) were used as primary antibodies. Discs were
washed with PBST three times for 20 minutes and blocked with PBSTF for 30 minutes, followed
by incubation of secondary antibody in the dark at room temperature for 2 hours. Secondary anti-
bodies used were Anti-Rabbit DyLight 649 antibody (1:100, Vector Laboratories) and Anti-Rat
rhodamine antibody (1:100). Discs were then washed three times with PBST for 20 minutes before
incubation of DAPI (1:1000) for five minutes at room temperature and mounting in 80% glycerol.
Relative areas of Caspase 3 staining were quantified in Image J and analysed in GraphPad Prism.
Cell ROS Assay
Reactive oxygen species (ROS) in third instar wing disc were detected using the fluorogenic
probe CellRox (Life Technologies) as described previously [70].
Supporting Information
S1 Fig. Altered WWOXmodifies ectopic Egr/TNF!-mediated eye phenotype. (A) Ectopic
expression of Egr/TNF! (GMR>egr+w>+) results in a decrease in eye size and disruption to
ommatidial patterning. (B) Decreased expression of WWOX by RNAi knockdown (GMR>
egr+w>WWOX-IR#2) resulted in suppression of the rough eye phenotype. (C) Decreased
expression of WWOX by heterozygous null allele (GMR>egr+w>WWOX1/+) resulted in
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suppression of the rough eye phenotype. (D) Decreased expression of WWOX by heterozygous
insertion mutation allele (GMR>egr+w>WWOX2/+) resulted in suppression of the rough eye
phenotype. (E) Increased expression of WWOX (GMR>egr+w>WWOX-ORF) resulted an
enhancement of the Egr/TNF! phenotype. (F)Quantification of increased eye size with indepen-
dent heterozygousWWOX alleles (GMR>egr+w>WWOX1/+ and GMR>egr+w>WWOX2/+).
(G) Increased expression of WWOX alone by ectopic expression of the ORF for WWOX
(GMR>WWOX-ORF) resulted in no effect on development of the adult eye. (H)Western blot
analysis and (I) quantification of the relative levels of WWOX protein expressed in each of the
ectopic expression lines compared to a "-Tubulin control. (J)Western blot analysis and (K)
quantification of WWOX protein expressed alone and together with Egr/TNF! compared to a
"-Tubulin control.
(TIF)
S2 Fig. Altered WWOX has no effect on ectopic p53 or Hid eye phenotypes. (A) Ectopic
expression of Dmp53 in the developing eye (GMR>DmP53>EV) at 18°C in the adult eye
results in a phenotype characterized by decrease in eye size and significant disruption to
ommatidial patterning accompanied by loss of pigment and the presence of small necrotic
lesions. (B) Decreased expression of WWOX by RNAi (GMR>DmP53>WWOX-IR#1) resulted
in no significant modification. (C) Increased expression of WWOX (GMR>DmP53>WWOX-
cDNA) also resulted in no significant modification. (D) Ectopic expression of head involution
defective in the adult eye (GMR>GMR-Hid>EV) results in a very strong rough eye phenotype
with reduction in eye size and almost complete loss of ommatidial structures. (E) Decreased
expression of WWOX by RNAi (GMR>GMR-Hid>WWOX-IR#1) resulted in no significant
modification. (F) Increased expression of WWOX (GMR>GMR-Hid>WWOX-cDNA) also
resulted in no significant modification.
(TIF)
S3 Fig. Ectopic Egr/TNF! has no effect on the cytoplasmic localization of WWOX in the
eye imaginal disc. (A-D) Ectopic expression of WWOX alone with GMR-gal4 results in
WWOX localisation to areas complementary to the DAPI stained nuclei of eye-imaginal discs
of wandering third instar larvae. (E-H) Ectopic expression of WWOX with GMR-gal4 in the
presence of ectopic Egr/TNF! expression also results in WWOX localisation to areas comple-
mentary to the DAPI stained nuclei of eye-imaginal discs of wandering third instar larvae.
(TIF)
S4 Fig. WWOX is required for elimination of Scribbled (Scrib)mutant clones in adult eyes.
(A) Clones of cells mutant for Scrib generated in the eye using the MARCM system result in a
mild adult rough eye phenotype. (B) Decreased WWOX expression throughout the whole ani-
mal (Scrib1;WWOX1/+) resulted in a stronger phenotype with a decreased eye size, significant
disruption to ommatidial patterning and the presence of some necrotic lesions. (C) Complete
absence of WWOX throughout the whole animal (Scrib1;WWOX1/ WWOX2) resulted in a
phenotype with a decreased eye size, significant disruption to ommatidial patterning and the
presence of large necrotic lesions. Genotypes used: Scrib1 (ey-FLP1, UAS-mCD8-GFP; +/+;tub-
GAL4 FRT82B tub-GAL80/ FRT82B scrib1), Scrib1;WWOX-/+(ey-FLP1, UAS-mCD8-GFP;
WWOX1/+;tub-GAL4 FRT82B tub-GAL80/ FRT82B scrib1), Scrib1;WWOX-/- = (ey-FLP1,
UAS-mCD8-GFP; WWOX1/ WWOX2;tub-GAL4 FRT82B tub-GAL80/ FRT82B scrib1). Adults
carryingWWOXmutations were generated by crossing ey-FLP1, UAS-mCD8-GFP;;tub-GAL4
FRT82B tub-GAL80/TM6B flies carrying either aWWOXmutant allele or wild-type second
chromosome together with FRT82B, Scrib1 carrying aWWOXmutant allele.
(TIF)
WWOX and the Elimination of Tumorigenic Cells
PLOS ONE | DOI:10.1371/journal.pone.0136356 August 24, 2015 15 / 19
411
Acknowledgments
The authors wish to thank Dr. Stephen Gregory, Dr. Donna Denton and Dani Fornarino for
their comments during preparation of this manuscript. We thank Bloomington stock centre
and Vienna Drosophila Resource Centre for providing stocks and the Australian Drosophila
Biomedical Research Support Facility (OzDros) for their ongoing support of D.melanogaster
research.
Author Contributions
Conceived and designed the experiments: LVO CSL AC RIR. Performed the experiments: LVO
CSL AC. Analyzed the data: LVO CSL AC RIR. Contributed reagents/materials/analysis tools:
LVO CSL AC. Wrote the paper: LVO CSL AC RIR.
References
1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646–674. doi:
10.1016/j.cell.2011.02.013 PMID: 21376230
2. Yunis JJ, Soreng AL. Constitutive fragile sites and cancer. Science. 1984; 226: 1199–1204. PMID:
6239375
3. Glover TW, Arit MF, Casper AM, Durkin SG. Mechanisms of common fragile site instability. HumMol
Genet. 2005; 14 Spec No. 2, R197–205. PMID: 16244318
4. O'Keefe LV, Richards RI. Common chromosomal fragile sites and cancer: focus on FRA16D. Cancer
Lett. 2006; 232: 37–47. PMID: 16242840
5. Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S, Andrews JM, et al. Signatures of mutation
and selection in the cancer genome. Nature. 2010; 463: 893–898. doi: 10.1038/nature08768 PMID:
20164919
6. Gao G, Smith DI. Very large common fragile site genes and their potential role in cancer development.
Cell Mol Life Sci. 2014; 71: 4601–4615. doi: 10.1007/s00018-014-1753-6 PMID: 25300511
7. Mangelsdorf M, Reid K, Woollatt E, Dayan S, Eyre H, Finnis M, et al. Chromosomal fragile site FRA16D
and DNA instability in cancer. Cancer Res. 2000; 60:1683–1689. PMID: 10749140
8. Ried K, Finnis M, Hobson L, Mangelsdorf M, Dayan S, Nancarrow JK, et al. Common chromosomal
fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous
deletions and translocation breakpoints in cancer cells. HumMol Genet. 2000; 9:1651–1663. PMID:
10861292
9. Schrock MS, Huebner K. WWOX: A fragile tumor suppressor. Exp Biol Med. (Maywood) 2014; pii:
1535370214561590.
10. Gardenswartz A, Aqeilan RI. WW domain-containing oxidoreductase's role in myriad cancers: clinical
significance and future implications. Exp Biol Med (Maywood). 2014; 239: 253–263.
11. Bary!a I, Styczen-Binkowska E, Bednarek AK. Alteration of WWOX in human cancer, a clinical view.
Experimental Biology and Medicine. 2015; 0: 1–10. doi: 10.1177/1535370214561953
12. Yang L, Liu B, Huang B, Deng J, Li H, Yu B, et al. A functional copy number variation in the WWOX
gene is associated with lung cancer risk in Chinese. HumMol Genet. 2013; 22: 1886–1894. doi: 10.
1093/hmg/ddt019 PMID: 23339925
13. Yu K, Fan J, Ding X, Li C, Wang J, Xiang Y, et al. Association study of a functional copy number varia-
tion in theWWOX gene with risk of gliomas among Chinese people. Int J Cancer. 2014; doi: 10.1002/
ijc.28815
14. Ludes-Meyers J H, Kil H, Nuñez MI, Conti CJ, Parker-Thornburg J, Bedford MT, et al. WWOX hypo-
morphic mice display a higher incidence of B-cell lymphomas and develop testicular atrophy. Genes
Chromosomes Cancer. 2007; 46: 1129–1136. PMID: 17823927
15. Aqeilan RI, Trapasso F, Hussain S, Costinean S, Marshall D, Pekarsky Y, et al. Targeted deletion of
WWOX reveals a tumor suppressor function. Proc Natl Acad Sci. USA 2007; 104: 3949–3954. PMID:
17360458
16. Bednarek AK, Keck-Waggoner CL, Daniel RL, Laflin KJ, Bergsagel PL, Kiguchi K, et al. WWOX, the
FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res. 2001; 61: 8068–8073. PMID:
11719429
WWOX and the Elimination of Tumorigenic Cells
PLOS ONE | DOI:10.1371/journal.pone.0136356 August 24, 2015 16 / 19
412
17. Fabbri M, Iliopoulos D, Trapasso F, Aqeilan RI, Cimmino A, Zanesi N, et al. WWOX gene restoration
prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci U S A. 2005; 102: 15611–15616.
PMID: 16223882
18. Nakayama S, Semba S, Maeda N, Aqeilan RI Huebner K, Yokozaki H. Role of the WWOX gene,
encompassing fragile region FRA16D, in suppression of pancreatic carcinoma cells. Cancer Sci. 2008;
99: 1370–1376. doi: 10.1111/j.1349-7006.2008.00841.x PMID: 18460020
19. Iliopoulos D, Fabbri M, Druck T, Qin HR, Han SY, Huebner K. Inhibition of breast cancer cell growth in
vitro and in vivo: effect of restoration of WWOX expression. Clin Cancer Res. 2007; 13: 268–274.
PMID: 17200365
20. Qin HR, Iliopoulos D, Semba S, Fabbri M, Druck T, Volinia S, et al. A role for the WWOX gene in pros-
tate cancer. Cancer Res. 2006; 66: 6477–6481. PMID: 16818616
21. Pluciennik E, Kusinska R, Potemski P, Kubiak R, Kordek R, Bednarek AK. WWOX—the FRA16D can-
cer gene: expression correlation with breast cancer progression and prognosis. Eur J Surg Oncol.
2006; 32: 153–157 PMID: 16360296
22. Zelazowski MJ, Pluciennik E, Pasz-Walczak G, Potemski P, Kordek R, Bednarek AK. WWOX expres-
sion in colorectal cancer—a real-time quantitative RT-PCR study. Tumour Biol 2011; 32: 551–560. doi:
10.1007/s13277-010-0150-5 PMID: 21347750
23. Lin JT, Tzai TS, Liao CY, Wang JS, Wu TT, Wang HY, et al. WWOX protein expression varies among
RCC histotypes and downregulation of WWOX protein correlates with less-favorable prognosis in clear
RCC. Ann Surg Oncol. 2013; 20: 193–199. doi: 10.1245/s10434-012-2371-x PMID: 22555346
24. Chang JY, He RY, Lin HP, Hsu LJ, Lai FJ, Hong Q, et al. Signaling frommembrane receptors to tumor
suppressor WW domain-containing oxidoreductase. Exp Biol Med (Maywood). 2010; 235: 796–804.
25. Salah Z, Aqeilan R, Huebner K. WWOX gene and gene product: tumor suppression through specific
protein interactions. Future Oncol. 2010 6:249–59. doi: 10.2217/fon.09.152 PMID: 20146584
26. Richards R, Choo A, Lee CS, Dayan S, O'Keefe L. WWOX, the chromosomal fragile site FRA16D
spanning gene: its role in metabolism and contribution to cancer. Exp Biol & Med (Maywood). 2015; pii:
1535370214565990.
27. Aqeilan RI, Hagan JP, Aqeilan HA, Pichiorri F, Fong LY, Croce CM. Inactivation of theWWOX gene
accelerates forestomach tumor progression in vivo. Cancer Res. 2007; 67: 5606–5610. PMID:
17575124
28. Ludes-Meyers JH, Kil H, Parker-Thornburg J, Kusewitt DF, Bedford MT, Aldaz CM. Generation and
characterization of mice carrying a conditional allele of theWWOX tumor suppressor gene. PLoS ONE.
2009; 4: e7775. doi: 10.1371/journal.pone.0007775 PMID: 19936220
29. Suzuki H, Katayama K, Takenaka M, Amakasu K, Saito K, Suzuki K. A spontaneous mutation of the
WWOX gene and audiogenic seizures in rats with lethal dwarfism and epilepsy. Genes Brain Behav.
2009; 8: 650–660. doi: 10.1111/j.1601-183X.2009.00502.x PMID: 19500159
30. O'Keefe LV, Colella A, Dayan S, Chen Q, Choo A, Jacob R, et al. Drosophila orthologue of WWOX, the
chromosomal fragile site FRA16D tumor suppressor gene, functions in aerobic metabolism and regu-
lates reactive oxygen species. HumMol Genet 2011; 20: 497–509. doi: 10.1093/hmg/ddq495 PMID:
21075834
31. Dayan S, O’Keefe LV, Choo A, Richards RI. Common chromosomal fragile site FRA16D tumor sup-
pressor WWOX gene expression and metabolic reprogramming in cells. Gene Chromosomes Cancer.
2013; 52: 823–831.
32. Lo JY, Chou YT, Lai FJ, Hsu LJ. Regulation of cell signaling and apoptosis by tumor suppressor
WWOX. Exp Biol Med (Maywood). 2015; pii: 1535370214566747.
33. Zhang H, Kong L, Cui Z, DuW, He Y, Yang Z, et al. The WWOX gene inhibits the growth of U266 multi-
ple myeloma cells by triggering the intrinsic apoptotic pathway. Int J Mol Med. 2014; 34: 804–809. doi:
10.3892/ijmm.2014.1824 PMID: 24968878
34. Nowakowska M, Pospiech K, Lewandowska U, Piastowska-Ciesielska AW, Bednarek AK. Diverse
effect of WWOX overexpression in HT29 and SW480 colon cancer cell lines. Tumor Biol. 2014; 35:
9291–9301.
35. Wei D, Zhang X, Zou H, Wang L, Fu B, Wu X, et al. WW domain containing oxidoreductase induces
apoptosis in gallbladder-derived malignant cell by upregulating expression of P73 and PUMA. Tumor
Biol. 2014; 35: 1539–1550.
36. Qu J, LuW, Li B, Lu C, Wan X. WWOX induces apoptosis and inhibits proliferation in cervical cancer
and cell lines. Int J Mol Med. 2013; 31: 1139–1147. doi: 10.3892/ijmm.2013.1314 PMID: 23525362
37. Cui Z, Lin D, Cheng F, Luo L, Kong L, Xu J, et al. The role of theWWOX gene in leukemia and its mech-
anisms of action. Oncol Rep. 2013; 29: 2154–2162. doi: 10.3892/or.2013.2361 PMID: 23525648
WWOX and the Elimination of Tumorigenic Cells
PLOS ONE | DOI:10.1371/journal.pone.0136356 August 24, 2015 17 / 19
413
38. Chiang MF, Yeh ST, Liao HF, Chang NS, Chen YJ. Overexpression of WW domain-containing oxidore-
ductaseWOX1 preferentially induces apoptosis in human glioblastoma cells harboring mutant p53.
Biomed Pharmacother. 2012; 66: 433–438. doi: 10.1016/j.biopha.2012.03.003 PMID: 22898080
39. Kosla K, Pluciennik E, Kurzyk A, Jesionek-Kupnicka D, Kordek R, Potemski P, et al. Molecular analysis
of WWOX expression correlation with proliferation and apoptosis in glioblastoma multiforme. J. Neu-
rooncol. 2011; 101: 207–213. doi: 10.1007/s11060-010-0254-1 PMID: 20535528
40. Hu BS, Tan JW, Zhu GH,Wang DF, Zhou X, Sun ZQ. WWOX induces apoptosis and inhibits prolifera-
tion of human hepatoma cell line SMMC-7721. World J Gastroenterol. 2012; 18: 3020–3026. doi: 10.
3748/wjg.v18.i23.3020 PMID: 22736928
41. Lai FJ, Cheng CL, Chen ST, Wu CH, Hsu LJ, Lee JY, et al. WOX1 is essential for UVB irradiation-
induced apoptosis and down-regulated via translational blockade in UVB-induced cutaneous squa-
mous cell carcinoma in vivo. Clin Cancer Res. 2005; 11: 5769–5777. PMID: 16115915
42. Chang NS, Pratt N, Heath J, Schultz L, Sleve D, Carey GB, et al. Hyaluronidase induction of a WW
domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol. Chem.
2001; 276: 3361–3370. PMID: 11058590
43. Igaki T, Kanda H, Yamamoto-Goto Y, Kanuka H, Kuranaga E, Aigaki T, et al. Eiger, a TNF superfamily
ligand that triggers the Drosophila JNK pathway. EMBO J. 2002; 21: 3009–3018. PMID: 12065414
44. Moreno E, Yan M, Basler K. Evolution of TNF signaling mechanisms: JNK-dependent apoptosis trig-
gered by Eiger, the Drosophila homolog of the TNF superfamily. Curr Biol. 2002; 12: 1263–1268.
PMID: 12176339
45. Kanda H, Igaki T, Okano H, Miura M. Conserved metabolic energy production pathways govern Eiger/
TNF-induced nonapoptotic cell death. Proc Natl Acad Sci U S A. 2011; 108: 18977–18982. doi: 10.
1073/pnas.1103242108 PMID: 22065747
46. Igaki T, Pastor-Pareja JC, Aonuma H, Miura M, Xu T. Intrinsic tumor suppression and epithelial mainte-
nance by endocytic activation of Eiger/TNF signaling in Drosophila. Dev Cell. 2009; 16: 458–465. doi:
10.1016/j.devcel.2009.01.002 PMID: 19289090
47. Kauppila S, Maaty WSA, Chen P, Tomar RS, Eby MT, Chapo J, et al. Eiger and its receptor, Wengen,
comprise a TNF-like system in Drosophila. Oncogene. 2003; 22: 4860–4867. PMID: 12894227
48. Kanda H, Igaki T, Kanuka H, Yagi T, Miura M. Wengen, a member of the Drosophila tumor necrosis fac-
tor receptor superfamily, is required for Eiger signaling. J Biol Chem. 2002; 277: 28372–28375. PMID:
12084706
49. O'Keefe LV, Liu Y, Perkins A, Dayan S, Saint R, Richards RI. FRA16D common chromosomal fragile
site oxido-reductase (FOR/WWOX) protects against the effects of ionizing radiation in Drosophila.
Oncogene. 2005; 24: 6590–6596. PMID: 16007179
50. Denton D, Kumar S. Immunostaining using an antibody against active caspase-3 to detect apoptotic
cells in Drosophila. Spring Harb Protoc. 2015; doi: 10.1101/pdb.prot086215
51. Pérez-Garijo A, Fuchs Y, Steller H. Apoptotic cells can induce non-autonomous apoptosis through the
TNF pathway. Elife. 2013; 2:e01004. doi: 10.7554/eLife.01004 PMID: 24066226
52. Fernández BG, Jezowska B, Janody F. Drosophila actin-Capping protein limits JNK activation by the
Src proto-oncogene. Oncogene. 2014; 33: 2027–2039 doi: 10.1038/onc.2013.155 PMID: 23644660
53. Bilder D Epithelial polarity and proliferation control: links from the Drosophila neoplastic tumor suppres-
sors. Genes Dev. 18. 2004; 1909–1925. PMID: 15314019
54. Ohsawa S, Sugimura K, Takino K, Xu T, Miyawaki A, Igaki T. Elimination of oncogenic neighbors by
JNK-mediated engulfment in Drosophila. Dev Cell. 2011; 20: 315–328. doi: 10.1016/j.devcel.2011.02.
007 PMID: 21397843
55. Lee T, Luo L. Mosaic analysis with a repressible cell marker (MARCM) for Drosophila neural develop-
ment. Trends Neurosci. 2001; 24: 251–254. PMID: 11311363
56. Brumby AM, Richardson HE. Scribbled mutants cooperate with oncogenic Ras and Notch to cause
neoplastic overgrowth in Drosophila. EMBO J. 2003; 22: 5769–5779. PMID: 14592975
57. Wagstaff L, Kolahgar G, Piddini E. Competitive cell interactions in cancer: a cellular tug of war. Trends
Cell Biol. 2013; 23: 160–167. doi: 10.1016/j.tcb.2012.11.002 PMID: 23219382
58. Park SW, Ludes-Meyer J, Zimonjic DB, Durkin ME, Popescu NC, Aldaz CM. Frequent downregulation
and loss of WWOX gene expression in human hepatocellular carcinoma. Br J Cancer. 2004; 91: 753–
759. PMID: 15266310
59. Schoenherr JA, Drennan JM, Martinez JS, Chikka MR, Hall MC, Chang HC, et al. Drosophila Activated
Cdc42 Kinase Has an Anti-Apoptotic Function. PLoS Genet. 2012; 8(5): e1002725. PMID: 22615583
WWOX and the Elimination of Tumorigenic Cells
PLOS ONE | DOI:10.1371/journal.pone.0136356 August 24, 2015 18 / 19
414
60. Abu-Odeh M, Salah Z, Herbel C, Hofmann TG, Aqeilan RI. WWOX, the common fragile site FRA16D
gene product, regulates ATM activation and the DNA damage response. Proc Natl Acad Sci U S A.
2014. 111:E4716–25. doi: 10.1073/pnas.1409252111 PMID: 25331887
61. Choo A, O’Keefe LV, Lee CS, Gregory SL, Shaukat Z, Lee CA, et al. Tumour suppressorWWOXmod-
erates the mitochondrial respiratory complex.Genes, Chromosomes and Cancer (in press).
62. Shaukat Z, Liu D, Choo A, Hussain R, O’Keefe L, Richards R, et al. Chromosomal instability causes
sensitivity to metabolic stress. Oncogene. 2014; doi: 10.1038/onc.2014.344
63. Trapasso F, Pichiorri F, Gaspari M, Palumbo T, Aqeilan RI, Gaudio E, et al. Fhit interaction with ferre-
doxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cells. J Biol
Chem. 2008; 283: 13736–13744. doi: 10.1074/jbc.M709062200 PMID: 18319262
64. Karras JR, Paisie CA, Huebner K. Replicative stress and the FHIT gene: roles in tumor suppression,
genome stability and prevention of carcinogenesis. Cancers. 2014; 6:1208–1219. doi: 10.3390/
cancers6021208 PMID: 24901304
65. Palacino JJ, SAgi D, Goldberg MS, Krauss S, Motz C, Wacker M, et al. Mitochondrial dysfunction and
oxidative damage in parkin-deficient mice. J Biol Chem 2004; 279: 18614–18622. PMID: 14985362
66. Ollmann M, Young LM, Di Como CJ, Karim F, Belvin M, Robertson S, et al. Drosophila p53 is a struc-
tural and functional homolog of the tumor suppressor p53. Cell. 2000; 101: 91–101. PMID: 10778859
67. Grether ME, Abrams JM, Agapite J, White K, Steller H. The head involution defective gene of Drosoph-
ila melanogaster functions in programmed cell death. Genes Dev. 1995; 9: 1694–1708. PMID:
7622034
68. Evans CJ, Olson JM, Ngo KT, Kim E, Lee NE, Kuoy E, et al. G-TRACE: rapid Gal4-based cell lineage
analysis in Drosophila. Nat Methods. 2009; 6: 603–605. doi: 10.1038/nmeth.1356 PMID: 19633663
69. Ibrahim DM, Biehs B, Kornberg TB, Kiebes A. Microarray comparison of anterior and posterior Dro-
sophila wing imaginal disc cells identifies novel wing disc. G3 (Bethesda). 2013; 3: 1353–1362.
70. Anderson PR, Kirby K, Orr WC, Hilliker AJ, Phillips JP. Hydrogen peroxide scavenging resuces frataxin
deficiency in a Drosophila model of Friedreich’s ataxia. Proc Natl Acad Sci U S A. 2008; 105: 611–616.
doi: 10.1073/pnas.0709691105 PMID: 18184803
WWOX and the Elimination of Tumorigenic Cells






Tumor Suppressor WWOX Moderates the
Mitochondrial Respiratory Complex
Amanda Choo, Louise V. O’Keefe, Cheng Shoou Lee, Stephen L. Gregory, Zeeshan Shaukat,
Alexander Colella, Kristie Lee, Donna Denton, and Robert I. Richards*
Departmentof Genetics and Evolution and Centre for Molecular Pathology,School of Biological Sciences,The Universityof
Adelaide,Adelaide,SA 5005,Australia
Fragile site FRA16D exhibits DNA instability in cancer, resulting in diminished levels of protein from the WWOX gene that
spans it. WWOX suppresses tumor growth by an undefined mechanism. WWOX participates in pathways involving aero-
bic metabolism and reactive oxygen species. WWOX comprises two WW domains as well as a short-chain dehydrogen-
ase/reductase enzyme. Herein is described an in vivo genetic analysis in Drosophila melanogaster to identify functional
interactions between WWOX and metabolic pathways. Altered WWOX levels modulate variable cellular outgrowths
caused by genetic deficiencies of components of the mitochondrial respiratory complexes. This modulation requires the
enzyme active site of WWOX, and the defective respiratory complex-induced cellular outgrowths are mediated by reac-
tive oxygen species, dependent upon the Akt pathway and sensitive to levels of autophagy and hypoxia-inducible factor.
WWOX is known to contribute to homeostasis by regulating the balance between oxidative phosphorylation and glycoly-
sis. Reduction of WWOX levels results in diminished ability to respond to metabolic perturbation of normal cell growth.
Thus, the ability of WWOX to facilitate escape from mitochondrial damage-induced glycolysis (Warburg effect) is, there-
fore, a plausible mechanism for its tumor suppressor activity. VC 2015 Wiley Periodicals, Inc.
INTRODUCTION
Common fragile sites (CFS) are specific regions
of chromosomes found in all individuals that have
been observed to correspond to regions of DNA
instability in various types of cancers (Richards,
2001). More than 200 different fragile sites have
been induced to appear in human cells in vitro, and
among them is the FRA16D CFS on chromosome
16 (Mrasek et al., 2010). Several CFS, including
FRA16D have been identified as frequent sites of
small homozygous deletions in cancer, consistent
with a correlation between chromosomal fragility
observed in vitro and in vivo DNA instability in
cancer (Bignell et al., 2010). Numerous CFS are
located within genes, leading to the suggestion that
CFS-mediated perturbation of the function of these
genes could have a role in cancer cell biology
(Gao and Smith, 2014).
The FRA16D CFS is located within the WW
domain containing oxidoreductase (WWOX) gene (Bed-
narek et al., 2000; Ried et al., 2000). Phylogenetic
analyses have revealed that a WWOX ortholog is
found in organisms as evolutionarily distinct as
humans and sea sponge, indicating that WWOX
likely performs a unique and primary biological
function (Richards et al., 2015). Reduced levels of
full-length WWOX have been reported in multiple
types of cancers (Paige et al., 2001; Lewandowska
et al., 2009; Gardenswartz and Aqeilan, 2014;
Schrock and Huebner, 2014) and correlate with
poorer prognosis (Pluciennik et al., 2006; Zelazow-
ski et al., 2011). Evidence of individuals with low
WWOX levels being more predisposed to develop-
ing lung cancers and gliomas also support a role for
WWOX in tumorigenesis (Yang et al., 2013; Yu
et al., 2014). Aberrant WWOX transcripts are often
observed in tumors with reduced levels of full-
length WWOX (Paige et al., 2001; Driouch et al.,
2002; Ishii et al., 2003; Mahajan et al., 2005;
Pluciennik et al., 2006). These transcripts mostly
lack part, if not all, of the exons that encode
its short-chain dehydrogenase/reductase (SDR)
enzyme, with several of these transcripts shown to
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be translated into truncated protein products that
lack the complete SDR enzyme (Ishii et al., 2003;
Mahajan et al., 2005). These findings support the
conclusion that loss of the SDR enzymatic activity
of WWOX has a significant contribution to tumori-
genesis. In efforts to define the pathway(s) in which
WWOX participates, many studies have been
directed at identifying protein-binding partners of
the WW domains of WWOX. Many such partners
and candidate pathways have been identified; how-
ever, the manner in which the SDR enzyme of
WWOX contributes to such pathways is unclear as
the SDR enzyme function has not been defined.
Neither the enzymatic product of WWOX nor its
endogenous substrate(s) have been identified.
WWOX has been shown to have tumor suppres-
sor activity (Bednarek et al., 2001), although it
does not seem to act as a highly penetrant classical
tumor suppressor (Aldaz et al., 2014). Low levels
of WWOX, rather than complete absence of
WWOX, are often observed in tumors, indicating
that the tumor suppressor function of WWOX
does not fit Knudson’s two hit hypothesis of
tumorigenesis. An increase in incidence of tumor
formation was reported in a WWOX knockout
mouse model (Aqeilan et al., 2007). However, as
of yet, there are no reports of neoplasia in a differ-
ent null mutant mouse model (Ludes-Meyers
et al., 2009; Ferguson et al., 2012), spontaneous
null mutant rats (Suzuki et al., 2009), Drosophila
null mutants (O’Keefe et al., 2005), or humans
with nonsense mutations of WWOX resulting in
epilepsy and mental retardation (Abdel-Salam
et al., 2014; Mallaret et al., 2014). The mutant
rodents, however, were all found to have meta-
bolic disorders, including bone metabolic disor-
ders, impaired steroidogenesis, and metabolic
acidosis (Aqeilan et al., 2008, 2009; Ludes-Meyers
et al., 2009; Suzuki et al., 2009). A metabolic role
for WWOX is also supported by genome-wide
association studies that showed associations
between WWOX and triglyceride and high density-
lipoprotein cholesterol levels in humans (Saez
et al., 2010; Iatan et al., 2014).
Evidence of WWOX having a contribution to
metabolism has also been reported in Drosophila
melanogaster (O’Keefe et al., 2011). Although loss
of WWOX has no obvious effect on the viability
and lifespan of Drosophila, microarray and proteo-
mic analyses of flies with altered levels of WWOX
revealed qualitative and quantitative alterations in
various metabolic mRNAs and/or proteins, particu-
larly those involved in oxidative phosphorylation.
Genetic analyses confirmed that WWOX has an
important role in aerobic metabolism, through
contributions to biological processes that require
isocitrate dehydrogenase as well as superoxide dis-
mutase (SOD). Alterations in WWOX levels also
resulted in altered endogenous levels of reactive
oxygen species (ROS). A recent study in WWOX
knockout mouse embryonic fibroblasts has pro-
vided further support for WWOX having a role in
aerobic metabolism, with loss of WWOX promot-
ing aerobic glycolysis through a physical interac-
tion between its WW domain and the hypoxia-
inducible factor (HIF)21/ (Abu-Remaileh and
Aqeilan, 2014). In addition, experiments in human
cells have demonstrated that the WWOX gene
responds to external factors that affect the meta-
bolic state of cells (Dayan et al., 2013). Increased
WWOX mRNA was observed under conditions
that promote oxidative phosphorylation, whereas
decreased levels were seen when cells are in a gly-
colytic and hypoxic state. Hence, it is not only the
function of WWOX but also its regulation that is
intrinsically integrated with the metabolic state of
cells. Together, those results define WWOX as a
major participant in pathways regulating metabo-
lism and oxidative stress.
Altered metabolism is now recognized as one of
the hallmarks of cancer cells (Hanahan and Wein-
berg, 2011) and is the focus of therapeutic targets
for cancer treatment (Porporato et al., 2011). The
molecular basis for this has not been defined; how-
ever, mutations identified in tumors include those
affecting the tricarboxylic acid (TCA) cycle as
well as the mitochondrial respiratory chain (Carew
and Huang, 2002; Kroemer and Pouyssegur, 2008;
Wallace, 2012). The identification of WWOX hav-
ing a role in aerobic metabolism suggests that loss
of WWOX is a contributor to the metabolic
reprogramming of cells that accompanies tumori-
genesis. Herein, we describe a genetic study
aimed at detecting novel functional interactions
between WWOX and components of metabolic
pathways. Through this study, we have identified
a novel functional contribution for WWOX in a
mitochondrial-mediated pathway that is depend-
ent upon its SDR enzyme function.
MATERIALS AND METHODS
Drosophila Husbandry
Drosophila stocks were maintained on fortified
medium (1% agar, 1% glucose, 6% fresh yeast,
9.3% molasses, 8.4% coarse semolina, 0.9% acid
mix, and 1.7% tegosept). Crosses were carried out
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at 258C. The w1118, ey-GAL4, UAS-SOD1, UAS-
SOD2, UAS-Catalase, and UAS-Foxo stocks were
obtained from Bloomington Drosophila Stock Center
(Indiana University, Bloomington, IN). The WWOX
lines have previously been described (O’Keefe
et al., 2005, 2011). RNAi lines were obtained from
Bloomington and the Vienna Drosophila Resource
Centre (VDRC, Vienna, Austria).
Site-Directed Mutagenesis of WWOX
In vitro site-directed mutagenesis was used to
introduce the different amino acid substitutions into
the Drosophila WWOX open reading frame in
pENTR/D-TOPO vector (Life Technologies, Pleas-
anton, CA). Constructs carrying the desired mutation
were subcloned into the Drosophila transformation
vector (Gateway pTW-attB, obtained from the
Drosophila Genomics Resource Centre, Indiana Uni-
versity) by LR clonase recombination according to
manufacturer’s guidelines (Life Technologies).
Constructs were then microinjected into the ZH-68E
line (FBst0328401) by standard methods to obtain
germline transformants. The constructs were
inserted into the same site in the Drosophila genome
to minimize insertional effects and to ensure that any
observed differences are due to the particular muta-
tion. Mutations in the transformed Drosophila lines
were verified using sequence analyses conducted by
Australian Genome Research Facility Ltd. (AGRF),
Adelaide, Australia.
Primers used for the mutagenesis reactions were












Western blot analyses were performed on adult
flies (n5 5 per sample) as previously described
(O’Keefe et al., 2011), with the following modifica-
tions: secondary antibody Anti-Rabbit DyLight
649 (1:2,500, Vector Laboratories, Burlingame,
CA), mouse monoclonal anti-a-tubulin (1:2,000,
Sigma, St. Louis, MO), and mouse anti-Cy3
(1:200, Jackson Laboratories, West Grove, PA).
Antibody Staining
Eye imaginal discs were dissected from late third
instar larvae in 13 phosphate-buffered saline (PBS)
and fixed in 4% formaldehyde for 20 min. Three
10-min washes were performed in PBST (13
PBS1 0.3% Triton-X-100). Discs were incubated
with PBST containing 5% fetal calf serum for 1 h
before incubation with primary antibody overnight
at 48C, followed by three 20-min washes with
PBST and 2 h incubation with second antibody at
room temperature in the dark before another round
of three 20-min washes with PBST. Primary anti-
bodies used were mouse anti-Elav-9F8A9 (1:10,
Developmental Studies Hybridoma Bank, Univer-
sity of Iowa, Iowa City, IA), rabbit anti-phospho-
histone H3 (S10) (1:1,500, Cell Signaling, Danvers,
MA), and rabbit anti-phospho-Akt (Ser473) (1:100,
Cell Signaling). Secondary antibodies were anti-
mouse Cy3 (1:200, Jackson Laboratories) and anti-
rabbit-Dylight 649 (1:200, Vector Laboratories).
Discs were mounted in 80% glycerol, and fluores-
cence was visualized using a Zeiss Axioplan 2
microscope. Images were compiled using Axiovi-
sion (Carl Zeiss) and Adobe Photoshop software.
Detection of ROS
CellROXVR Deep Red Reagent (Life Technologies)
was used to detect presence of ROS in live cells as a
measure of oxidative stress. Eye imaginal discs were
dissected from wandering third instar larvae in D22
media (insect culture media, pH6.8) and incubated in
5 lmCellROXVR in D22 media for 15 min (in the dark
at room temperature). The discs were then subjected
to two quick washes with 13 PBS, fixed with 3.7%
formaldehyde for 5 min, and then mounted in 80%
glycerol for fluorescence visualization. The absorption/
emission maxima of the dye is !644/665 nm. Images
were taken using the 203 PlanApo objective.
Light Microscopy
Photographs of exterior adult Drosophila eyes
were taken using an Olympus SZX7 microscope fit-
ted with a SZX-AS aperture diaphragm unit. Images
were captured using an Olympus ColourView IIIU
Soft Imaging System camera and AnalysisRuler
image acquisition software. Images were prepared
using Adobe Photoshop CS version 8.0. Anterior of
the eye is positioned on the right of all images.
Phenotypic Quantification
Adult eyes were grouped into different phenotypic
categories depending on analysis. Representative
WWOX’S DEHYDROGENASE/REDUCTASE ENZYME FUNCTION 3
Genes, Chromosomes & Cancer DOI 10.1002/gcc
419
images of each phenotypic category are presented in
Supporting Information Figure S1. Eyes were scored
from multiple independent crosses under identical
conditions, and counts were pooled to obtain the final
tally per genotype, with a minimum of 120 eyes
scored per genotype. In the analyses performed to
determine the effect of reduced WWOX levels, the
adult eyes were grouped into three different catego-
ries based on the severity of the phenotype: “mild/
normal”—normal or mild disorganization in the pat-
terning of the ommatidia; “moderate”—disruption in
the patterning of the ommatidia with the loss of pho-
toreceptor cells; and “severe”—significant disruption
in the gross structure and development of the eye
(e.g., tissue outgrowth, presence of ectopic structures
in the eye, or significant loss of cells resulting in
decreased eye size). Chi-square test analyses were
performed to compare the differences in the three
categories. Analyses were also performed using Fish-
er’s exact test to compare two categories—“severe”
vs. combined “moderate1mild/normal” in order to
determine whether reduced WWOX levels specifi-
cally affect the proportion of severe phenotypes. In
the analyses performed to determine the suppressive
effect of increased WWOX levels, eyes with any sig-
nificant tissue disruption (“phenotype”) were com-
pared with eyes with no considerable tissue
disruption (“no phenotype”), and Fisher’s exact test
analyses were performed to determine significance.
Phenotypic scoring of the different WWOX over-
expression mutant lines was performed in a blinded
manner. For the larval phenotype, eye discs were
examined for the presence or absence of an out-
growth with a minimum of 50 eye discs scored per
genotype. Statistical significance was determined
using Fisher’s exact test, with P5 0.05 as the cut-off
value for significance. All statistical analyses were
performed using GraphPad Prism. Percentages of
eyes or eye discs in each category were plotted for
visual representation using Microsoft Excel. Appro-
priate controls were used in all experiments: an
empty vector (EV) control was used for experiments
with over-expression of genes, whereas a nonspecific
RNAi (lacZRNAi) control was used for the experi-
ments with RNAi lines to account for any effects due
to nonspecific activation of the RNAi machinery.
Quantitative Real-Time polymerase chain
reaction Assay
The quantitative polymerase chain reaction
assays were performed using the protocols previ-
ously described by O’Keefe et al. (2011). For the
assay done with Drosophila heads, 50 adult heads
were used per sample, whereas for the assay with
whole flies, five adult flies were used per sample.
For all assays, three biological replicates were
used for each genotype and triplicate reactions
were performed for each biological replicate.
mRNA levels were normalized against the Dro-
sophila house-keeping gene ribosomal protein 49
(rp49). t-test analyses were performed using
Microsoft Excel to determine significance, with
P5 0.05 as the cut-off value for significance.
The quantitative real-time polymerase chain







Screening Metabolic Pathways for Visible
Cellular Dysfunction in Drosophila
Our previous study in Drosophila has shown that
WWOX has an impact on metabolic pathways
such as the TCA cycle and redox homeostasis
(O’Keefe et al., 2011). To gain a better under-
standing of the role of WWOX in these metabolic
pathways, an in vivo RNAi screen was conducted
to identify novel functional interactions between
WWOX and genes involved specifically in the
TCA cycle and related oxidative processes. As
altered WWOX expression does not result in any
visible phenotype in Drosophila and a phenotype
is required for the genetic dissection of pathway
interactions, the approach taken was to induce cel-
lular dysfunction (which would result in a pheno-
type) by targeting metabolic genes and to test
whether WWOX is able to modify those pheno-
types. Modification of the phenotype by WWOX
would indicate that WWOX is able to functionally
interact with those metabolic genes and would
identify the types of cellular dysfunction that
WWOX is able to affect.
Drosophila is a good model for such genetic
interaction assays because of the capability of
expressing multiple transgenes using the binary
GAL4-UAS system (Brand and Perrimon, 1993)
and the availability of various RNAi lines to
reduce expression of candidate genes (Dietzl
et al., 2007). This analysis was performed in the
Drosophila eye, which has long been used as a
model system to dissect biological pathways.
RNAi constructs targeting metabolic genes were
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expressed in the developing eye using the ey-
GAL4 promoter together with binary GAL4-UAS
system. Out of the 56 genes tested, reduction in
expression of 10 genes resulted in a visible disrup-
tion to eye morphology, indicative of cellular dys-
function (Supporting Information Table S1).
Reduced Expression of Mitochondrial Respiratory
Genes Result in Significant Cellular Dysfunction
Out of the 10 genes that, when reduced in
expression, produced a characteristic eye pheno-
type, altered WWOX activity was able to modu-
late the cellular dysfunction caused by six of those
genes (Supporting Information Table S1). The six
genes (ND23, ND42, ND75, CG7580, CoVa, and
CoVb) all encode components of the mitochondrial
respiratory chain. Although some flies displayed
mild or no disruption in eye tissue (Fig. 1A), a sub-
stantial percentage of flies exhibited a phenotype
where there is loss of cells, resulting in a cavity in
the surface of the adult eye (Fig. 1B). More severe
eye phenotypes were observed in a small percent-
age of flies (Figs. 1C and 1C00), where there was
outgrowth of eye tissue (Fig. 1C), presence of
ectopic cuticle structures within the eye field (Fig.
1C0), or substantial loss of cells resulting in an
overall decrease in eye size (Fig. 1C00). These phe-
notypes indicate that there is significant cellular
dysfunction caused by decreased expression of
mitochondrial respiratory complex genes. Target-
ing of ND42 and CoVa by different RNAi lines
has previously been shown to result in defects in
mitochondrial activity in Drosophila eye discs
(Ambrus et al., 2013), and we have also previously
shown that the use of our RNAi line to target
ND42 results in significant loss of mitochondrial
membrane potential (Shaukat et al., 2014). The
production of the same phenotypes by independ-
ent RNAi targeting of six different genes of the
mitochondrial respiratory complexes strongly sup-
port that the phenotypes are caused by loss of
mitochondrial respiratory chain function.
Loss of WWOX Exacerbates Cellular Dysfunction
Caused by Mitochondrial Defects
A phenotype scoring system was established to
determine whether altered WWOX levels could
significantly modulate the cellular dysfunction
produced by reduced expression of these mito-
chondrial respiratory complex genes. Eyes were
scored individually for a phenotype and grouped
into different categories according to severity
(mild/normal, moderate, and severe or phenotype
and no phenotype; Supporting Information Fig.
S1A). Reduced WWOX expression was found to
enhance the mitochondrial-mediated cellular dys-
function, with significantly higher proportions of
adult eyes exhibiting the severe phenotypes (tis-
sue outgrowth, presence of ectopic structures, or
reduced eye size). This was observed when
WWOX expression was reduced by RNAi target-
ing, together with decreased expression of any one
of the six mitochondrial respiratory complex genes
(Fig. 2A and Supporting Information Figs. S1B
and S1C) (P" 0.01, Supporting Information Table
S2). Independent verification was obtained using a
different RNAi line targeting WWOX as well as
with loss of one functional copy of the WWOX
gene in a heterozygous WWOX loss-of-function
mutant (WWOX1/1), together with decreased
expression of the three different Complex I genes
(Supporting Information Fig. S2 and Supporting
Information Table S2). These results indicate that
reduced WWOX expression contributes to the
Figure 1. Adult eye phenotypes indicative of cellular dysfunction
caused by reduced expression of mitochondrial respiratory complex
genes. Decreased expression of ND23, ND42, ND75, CG7580, CoVa,
and CoVb all results in a range of phenotypes: (A) mild or no disrup-
tion to the patterning of ommatidia; (B) absence of photoreceptor cells
within the eye field forming a cavity in the eye; or phenotypes indica-
tive of defects in development, which include (C) outgrowth of the eye
tissue, (C0) presence of ectopic structures within the eye field, and
(C00) significant loss of cells resulting in an overall decrease in eye size.
[Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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Figure 2. Decreased WWOX expression exacerbates the cellular dys-
function caused by reduced expression of mitochondrial respiratory com-
plex genes. (A) Reduced WWOX levels result in higher proportions of
adult eye phenotypes indicative of cellular dysfunction. Adult eyes were
scored based on severity of phenotype (severe, moderate, and mild/nor-
mal). *P< 0.01 and ***P" 0.001, compared with respective controls, deter-
mined by v2 test. P-values and further statistical analyses are presented in
Supporting Information Table S2. n# 150 eyes per genotype. (B) Out-
growth phenotype in larval eye discs. The protrusion is characterized as an
increased region of differentiated cells (neuronal cells stained with anti-elav,
green) behind the morphogenetic furrow (MF, indicated by white arrow).
Differentiation occurs in a sequential manner from posterior (P) to anterior
(A) of the disc with mitotic cells (stained with anti-phospho-histone H3
(pH3), red) normally observed anterior of the MF. In discs with the out-
growth phenotype, mitotic cells are observed posterior of the MF at the tip
of the protrusion. (C) Reduced WWOX levels result in higher proportions
of larval eye discs with the outgrowth phenotype. **P" 0.01 and
***P" 0.001 compared with control determined by Fisher’s exact test (Sup-
porting Information Table S2). n# 50 discs per genotype. [Color figure can
be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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dysfunction caused by loss of these mitochondrial
respiratory complex genes.
Similar enhancement of cellular dysfunction by
decreased WWOX levels was observed in third
instar larval eye imaginal discs, which are the
developmental precursors to the Drosophila adult
eye (Figs. 2B and 2C). An outgrowth phenotype,
characterized as a protrusion from the eye disc,
was seen in a small proportion of larvae when
mitochondrial dysfunction was induced and is
indicative of defects in cellular differentiation and
proliferation (Fig. 2B). The abnormal protrusion
appears to be an extension of the eye tissue and is
comprised of an increased region of both differen-
tiated cells (detected by elav, a marker of differen-
tiated neurons) and mitotic cells that are
abnormally distributed (as stained by anti-
phospho-histone H3, Fig. 2B). In the larval eye
disc, differentiation of eye cells occurs in a
sequential manner from the posterior to the ante-
rior side of the disc, following the movement of
the morphogenetic furrow (MF). Mitotic cells are
usually observed anterior of the MF where cells
are yet to differentiate. In the eye discs with the
outgrowth phenotype, mitotic cells were observed
posterior of the MF at the distal tip of the protru-
sion, suggesting that there is proliferation of cells
driving the outgrowth of tissue. A significantly
higher proportion of this outgrowth phenotype was
observed in larvae with reduced expression of
both WWOX and the Complex I gene (Fig. 2C).
These data further support the conclusion that
reduced WWOX expression contributes to
mitochondrial-mediated cellular dysfunction.
Increased WWOX Levels Suppress the Tissue
Disruption Caused by Mitochondrial Defects
Given that decreased WWOX is able to exacer-
bate the tissue disruption caused by mitochondrial
respiratory complex defects, WWOX cDNA was
over-expressed together with reduced expression
of the mitochondrial respiratory complex genes to
determine whether increased WWOX is able to
suppress the phenotype. The phenotypes at the
adult stage were examined to ascertain whether
increasing WWOX levels had any significant last-
ing effect throughout cellular development. The
proportions of adult eyes displaying any consider-
able tissue disruption were compared with the pro-
portions of normal eyes. It was observed that for
the three Complex I genes and two Complex IV
genes, increased WWOX expression resulted in
significantly higher proportions of normal eyes and
lower proportions of eyes with any considerable
tissue disruption (Fig. 3A) (P< 0.001, Supporting
Information Table S3). This demonstrates that
increased WWOX expression is able to suppress
some of the cellular dysfunction caused by mito-
chondrial defects. In the case of the highly pene-
trant Complex III gene phenotype, however,
increased WWOX expression was unable to signif-
icantly rescue the tissue disruption, suggesting
that there may be a particular threshold of cellular
dysfunction that increased WWOX is unable to
overcome. Nevertheless, the data altogether illus-
trates that WWOX is involved in the maintenance
of cellular homeostasis in response to mitochon-
drial defects, with low WWOX levels resulting in
further perturbation of cellular dysfunction,
whereas elevation of WWOX levels is able to
restore homeostasis in some cells, thus leading to a
suppression of the phenotypes (Fig. 3B).
The SDR Catalytic Active Site of WWOX Is
Required for Its Functional Interaction with the
Mitochondrial Complex Genes
The WWOX protein contains distinct functional
elements that are well conserved across species.
These conserved regions include two WW
domains and essential components of an SDR
enzyme. The WW domains have been shown to
physically interact with various proteins with a
PPxY and LPxY motif (Aqeilan et al., 2004; Hu
et al., 2004; Abu-Odeh et al., 2014a), and phospho-
rylation of the first tyrosine residue (Tyr33) in the
first WW domain is required for WWOX-mediated
apoptosis in the nucleus (Chang et al., 2003). Not
much is currently known about the endogenous
function of the SDR enzyme. It is classified as a
SDR enzyme based on amino acid sequence
homology, which includes the presence of a puta-
tive NAD(H) or NADP(H) co-factor binding motif
(TGxxxGxG) as well as a catalytic active site motif
(YxxxK), characteristic of the classical SDR family
of enzymes.
To determine which functional elements of
WWOX are essential for the observed modulation
of cellular dysfunction caused by mitochondrial
defects, mutations were generated in amino acids
that have previously been shown or are predicted
to be critical for WWOX function (Figs. 4A and
4B and Supporting Information Table S4). The
mutagenesis targeting was based on studies
that have demonstrated that such mutations are
able to abolish or decrease the activity of WWOX
or other similar proteins (Oppermann et al., 1997;
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Nakajin et al., 1998; Koepf et al., 1999; Filling
et al., 2002; Aqeilan et al., 2004; Cancemi et al.,
2011). Transgenes containing these specific muta-
tions were expressed in Drosophila to test for their
ability to suppress the tissue disruption caused by
decreased expression of a Complex I gene, ND23.
Comparable levels of WWOX protein were
observed in Drosophila ubiquitously expressing the
wildtype and mutant forms of WWOX except for
the mutant form that contains a mutation in the co-
factor binding site in the SDR region (T127A) (Fig.
4C), which suggests that the mutation results in a
significant reduction in stability of the WWOX
protein. The same mutation in another SDR
enzyme has previously been shown to alter co-
factor binding preference and abolish some (but
not all) of its enzymatic activity (Oppermann et al.,
1997; Filling et al., 2002). It was thought that this
threonine residue in the cofactor-binding motif
does not bind to the cofactor itself but is involved
in stabilizing the framework for cofactor position-
ing. Hence, it is possible that although this muta-
tion may not necessarily abolish all enzymatic SDR
activity, it is able to affect protein folding and, thus,
overall stability of the WWOX protein, resulting in
lower levels of protein being produced.
Figure 3. Increased WWOX expression rescues some of the cellu-
lar dysfunction caused by reduced expression of mitochondrial respira-
tory complex genes. (A) Over-expression of WWOX cDNA results in
higher proportion of normal eyes when expressed together with
decreased levels of ND23, ND42, ND75, CoVa, and CoVb. Eyes
scored based on the presence or absence of a phenotype. ***P" 0.001
compared with respective controls determined by Fisher’s exact test
(Supporting Information Table S3), n.s. indicates nonsignificance.
n# 150 eyes per genotype. (B) Model for the moderation of mito-
chondrial complexes by WWOX. Endogenous WWOX is both a regu-
lator of metabolism and responsive to changes in metabolism. It
normally acts over a range of endogenous levels (*) in the maintenance
of cellular homeostasis. Reduction in WWOX levels below this range
limits its ability to contribute to the maintenance of homeostasis,
resulting in an increased frequency of the cell growth phenotype (due
to mitochondrial dysfunction). Elevation in WWOX levels above this
range, on the other hand, restores homeostasis and rescues cells from
the cellular dysfunction produced by deficiencies in the mitochondrial
complexes.
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As previously seen, over-expression of the wild-
type WWOX protein was able to suppress the tis-
sue disruption caused by decreased expression of
ND23 as demonstrated by the higher proportion of
eyes displaying no considerable tissue disruption.
Similar suppression was evident with over-
expression of four mutant forms of WWOX (Y29R,
W58F, T127A, and P277A), indicating that these
specific amino acid residues are not required for
this suppressive function of WWOX. The Y288F
mutant, however, was unable to rescue the tissue
disruption (Fig. 4D and Supporting Information
Table S5); rather the disruption seems to be
slightly stronger in this mutant. The lack of
suppression due to this Y288F mutation was also
observed when tested with two other Complex I
genes, ND42 and ND75 (Supporting Information
Fig. S3 and Supporting Information Table S6). The
Y288F mutant contains a mutation in the catalytic
active site in the SDR region—such a mutation has
previously been shown to completely abolish enzy-
matic activity of other SDR proteins (Nakajin et al.,
1998; Filling et al., 2002). Comparable levels of pro-
tein were observed for the wildtype and Y288F
mutant form of WWOX (Fig. 4C), indicating that
the lack of suppression by the Y288F mutant was
not due to insufficient WWOX protein being
expressed. Thus, this demonstrates that the SDR
enzymatic activity of WWOX is required for its
cellular response to mitochondrial defects.
Figure 4. Catalytic active site in the SDR region of WWOX
required in its suppression of tissue disruption caused by mitochondrial
defects. (A) Critical amino acid residues mutated in the different func-
tional elements of WWOX. (B) Sequencing results of nucleotide sub-
stitutions giving rise to the different amino acid mutations. (C)
Comparable levels of WWOX protein detected by Western blot analy-
sis in WWOX mutant lines compared with the wildtype control
(WWOX), except for lower levels observed in the cofactor binding
mutant (T127A). Alpha tubulin used as a loading control. Only endoge-
nous WWOX is present in the empty vector (EV) control, which was
too low to be detected in this analysis. A lane was removed from the
gel image between the W58F and T127A samples during processing of
the image (as indicated with the black line delineating the boundary
between the samples); however, this does not affect the data that are
presented. (D) Different WWOX mutant lines tested for their ability
to suppress the tissue disruption caused by decreased ND23 expres-
sion. Proportion of eyes with presence or absence of phenotype
compared with EV control. *P" 0.05, **P" 0.01, and ***P" 0.001,
indicative of suppression compared with EV control determined by
Fisher’s exact test. P-values and further statistical analyses are pre-
sented in Supporting Information Table S5. n# 250 eyes per genotype.
WWOX’S DEHYDROGENASE/REDUCTASE ENZYME FUNCTION 9
Genes, Chromosomes & Cancer DOI 10.1002/gcc
425
Reactive Oxygen Species Are Effectors of the
Mitochondrial-Mediated Cellular Dysfunction
Mitochondrial respiratory complex dysfunction
has been shown to promote tumor progression
through the production of high levels of ROS
(Sharma et al., 2011). We have previously shown
that decreased expression of ND42, a component
of the mitochondrial respiratory Complex I, in the
Drosophila wing disc produces an increased level
of ROS that is detectable by CellRoxVR staining
(Shaukat et al., 2014). Similar CellRoxVR stains
were performed on the larval eye discs with the
mitochondrial-induced outgrowth phenotype.
Punctate staining corresponding to presence of
ROS was detected in the outgrowth region of the
eye discs (Fig. 5A), which demonstrates that the
mitochondrial dysfunction can result in increased
levels of ROS. Over-expression of antioxidant
enzymes catalase, SOD1, or SOD2 was able to sig-
nificantly reduce the proportion of larval eye discs
with the outgrowth phenotype (Fig. 5B and Sup-
porting Information Table S7). Conversely,
decreased expression of SOD1 or SOD2 signifi-
cantly increased the proportion of the outgrowth
phenotype (Fig. 5C and Supporting Information
Table S7). These results indicate that ROS gener-
ated by mitochondrial dysfunction are effectors of
the outgrowth phenotype.
Requirement of Akt and Foxo in the
Mechanism of Cellular Dysfunction Caused by
WWOX-Associated Mitochondrial Defects
Because mitochondrial complex deficiencies
have been associated with tumorigenesis, the
mitochondrial dysfunction-mediated cellular dys-
morphology is of particular interest. Other genes
that are known to be commonly involved in
tumorigenesis were tested to identify potential
common pathways involved in this model. Several
recent studies, in particular, have shown that inhi-
bition of the mitochondrial respiratory complex
results in increased phosphorylation of the v-AKT
murine thymoma viral oncogene (AKT) and sub-
sequently activation of AKT-mediated signaling
pathways, leading to malignancy (Pelicano et al.,
2006; Sharma et al., 2011; Santidrian et al., 2013).
Aberrant AKT activation has been reported in
numerous cancers and has been described as one
of the most common molecular changes in tumor
cells (Bellacosa et al., 2005). Furthermore, WWOX
has been shown to regulate AKT activation (Hu
et al., 2014). Although there are three known AKT
proteins in humans, there is only one identified
AKT ortholog (Akt) in Drosophila. Detectable
staining using a monoclonal antibody specific for
phosphorylated Akt (pAkt) was observed in the
positive control Dp110-overexpressing discs
around individual ommatidia (Fig. 6A, second row
panels) compared with the weaker staining in
wildtype eye discs corresponding to low levels of
endogenous pAkt (Fig. 6A, first row panels). pAkt
staining was also detectable in the mitochondrial
dysfunction discs (Fig. 6A, third row panels), sug-
gesting that there is elevated Akt activation in the
eye discs that have mitochondrial dysfunction.
Reduction of Akt levels using a RNAi line, which
has previously been shown to strongly reduce Akt
protein levels as well as pAkt function (Ye et al.,
2012), significantly suppressed the outgrowth phe-
notype caused by decreased expression of ND42,
with a lower proportion of eye discs exhibiting the
phenotype compared with the corresponding con-
trol (Fig. 6B and Supporting Information Table
S7). This result identifies Akt signaling as the
pathway that mediates the outgrowth phenotype.
A well-known target of AKT signaling is the fork-
head box O (FOXO) transcription factor (J!unger
et al., 2003; Kramer et al., 2003; Greer and Brunet,
2005; Calnan and Brunet, 2008), which can function
as a tumor suppressor by upregulating various target
genes involved in detoxification of ROS, cell cycle
arrest, DNA damage repair as well as autophagy
(Calnan and Brunet, 2008). Activated AKT signaling
results in phosphorylation of FOXO in response to
cellular stimuli, such as oxidative stress (Vurusaner
et al., 2012), and causes it to be retained in the cyto-
plasm instead of translocating into the nucleus to
activate transcription of its target genes, thus inhibi-
ting its tumor suppressive function. AKT-mediated
inhibition of FOXO activity has been reported in
various cancers and has been thought to be a con-
tributing factor to tumor progression (Greer and
Brunet, 2005). Drosophila has only one FOXO gene,
which contains conserved Akt phosphorylation sites
and has been shown to be a critical target of Dro-
sophila Akt (J!unger et al., 2003; Kramer et al., 2003;
Puig et al., 2003). Overexpression of Foxo in larval
eye discs with decreased levels of ND42 was able
to suppress the larval eye disc outgrowth pheno-
type, with a lower proportion of eye discs displaying
that phenotype (Fig. 6C and Supporting Informa-
tion Table S7). Thus, it seems that Foxo activity is
able to reduce or prevent the mitochondrial defect-
mediated cellular dysfunction, demonstrating that
Foxo has either a protective or compensatory role in
cells with mitochondrial dysfunction.
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Participation of HIF-1/ and Autophagy in the
Mitochondrial-Mediated Cellular Dysfunction
Recent studies have shown a reciprocal regula-
tory relationship between the HIF-1/ and WWOX
(Abu-Remaileh and Aqeilan, 2014); hence, it was of
interest to examine whether HIF-1/ has any con-
tribution to the larval eye disc outgrowth pheno-
type. HIF-1/ has been shown to have contrasting
Figure 5. Reactive oxygen species (ROS) are effectors of the larval
eye disc outgrowth phenotype. (A) Presence of ROS detected by
CellRoxVR staining in the outgrowth region of the affected larval eye
discs. Punctuate staining is observed in the outgrowth region of
affected discs (A0) but not in wildtype discs (A). (B, C) Changes in the
levels of antioxidant enzymes modify the proportion of the outgrowth
phenotype caused by decreased expression of ND42. A recombinant
ey, ND42RNAi fly line that has a stronger phenotype was used for the
modification analyses. The WWOXRNAi line was used as a positive
control for the experiment. *P< 0.01, **P< 0.05, and ***P" 0.001
compared with respective controls determined by Fisher’s exact test.
Exact values are presented in Supporting Information Table S7. n5 50
discs per genotype for both experiments. Expression of the different
antioxidant enzyme lines by themselves has no effect on the morphol-
ogy of the eye disc. (B) Overexpression of antioxidant enzymes, such
as catalase, SOD1, and SOD2, result in significantly lower proportion
of the outgrowth phenotype compared with the control (which has
overexpression of an empty vector, EV). (C) Decreased expression of
SOD1 and SOD2 result in significantly higher proportion of the out-
growth compared with the control (which is expressing a nonspecific
RNAi, lacZRNAi). [Color figure can be viewed in the online issue, which
is available at wileyonlinelibrary.com.]
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Figure 6. Requirement for Akt and Foxo in the larval eye disc out-
growth phenotype induced by mitochondrial dysfunction. (A) Detec-
tion of increased pAkt staining in third instar larval eye imaginal discs.
Low levels of pAkt staining was present in the wildtype eye disc,
although stronger pAkt staining was observed in discs with the out-
growth phenotype. Eye discs with ectopic expression of Drosophila
phosphoinositide 3-kinase (Dp110) driven by the ey-GAL4 promoter
were used as a positive control for pAkt staining. Panels on the right
were taken at 203 PlanApo objective, whereas panels on the left
were taken using the 633 PlanApo objective. The 633 images were
taken of the area highlighted with the red boxes in the 203 images.
(B) Decreased Akt expression by RNAi targeting results in suppression
of the outgrowth phenotype, with significantly lower proportion of eye
discs showing the phenotype (4%) compared with the lacZRNAi control
(34%) (***P5 0.0004). n5 50 eyes per genotype. (C) Increased expres-
sion of Foxo is able to suppress the mitochondrial-mediated larval eye
disc outgrowth phenotype, with a lower proportion of the phenotype
(4%) observed compared with the EV control (34%) (***P5 0.0002).
n5 50 eyes per genotype. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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roles in tumorigenesis. Although most studies are
indicative of activated HIF-1/ having a protumori-
genic function (Semenza, 2002), there are some
studies that suggest that HIF-1/ is able to nega-
tively regulate tumor growth through induction of
apoptosis and/or autophagy (Sowter et al., 2001;
Rankin and Giaccia, 2008; Chiavarina et al., 2010).
Indeed, the Drosophila ortholog of HIF-1/, Similar
(Sima), has been shown to be a negative regulator
of cell growth (Romero et al., 2007). Decreased
expression of Sima/HIF-1/ was found to result in a
significant increase in the proportion of the out-
growth phenotype (Fig. 7A and Supporting Infor-
mation Table S7), consistent with its role as a
negative regulator of cell growth. The result
obtained with decreased Sima/HIF-1/ expression
was parallel to that with decreased expression of
WWOX, suggesting that the regulatory relationship
between WWOX and HIF-1/ in this context could
be a control mechanism to cope with the perturba-
tion of cellular homeostasis (Dayan et al., 2013).
Sima/HIF-1/ has been shown to have an effect
on autophagy in Drosophila, with RNAi targeting
of Sima resulting in the inhibition of compensa-
tory autophagy (L!ow et al., 2013). Autophagy was
previously found to be a protective mechanism for
restricting metastatic growth caused by mitochon-
drial Complex I defects in cancer cells (Santidrian
et al., 2013); thus, it is possible that autophagy
could also be a normal cellular mechanism used to
restrict the larval eye disc outgrowth caused by
mitochondrial defects in this model. In addition,
Drosophila Foxo has also been demonstrated to be
required for maintaining expression of an essential
autophagy gene, Atg18 (Omata et al., 2014). Thus,
expression of Atg18 was decreased by RNAi
targeting to determine any contribution to the
mitochondrial defect phenotype. Decreased Atg18
expression resulted in an enhancement of the
larval eye disc outgrowth phenotype, with higher
proportions of the phenotype compared with the
corresponding control (Fig. 7B and Supporting
Figure 7. The mitochondrial-mediated cellular outgrowth is affected
by Sima/HIF-1a levels as well as autophagy. (A) Decreased expression
of Sima/HIF-1a by RNAi targeting results in higher proportion of the
outgrowth phenotype (66%) compared with the lacZRNAi control
(42%) (*P5 0.0268). The result obtained with decreased Sima is paral-
lel with that obtained with decreased Wwox. n5 50 eyes per geno-
type. (B) Decreasing expression of an autophagy gene, Atg18, results in
enhancement of the cellular dysfunction caused by mitochondrial
defects. A significantly higher proportion of larval eye disc outgrowth
phenotype (56%) was observed compared with the lacZRNAi control
(32%), *P5 0.0262. n5 50 eye discs per genotype.
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Information Table S7), indicating that the normal
level of autophagy is able to restrict the cellular
dysfunction caused by mitochondrial defects.
Genetic dissection herein, of the molecular
pathway by which mitochondrial dysfunction leads
to cellular dysmorphology, has revealed a mecha-
nism that is not only sensitive to the level of
WWOX enzyme activity but also mediated by
ROS and AKT and influenced by the levels of
HIF-1/ and autophagy (Fig. 8).
DISCUSSION
The study herein utilized D. melanogaster to
genetically dissect pathways in which WWOX par-
ticipates. In previous studies, WWOX has been
shown to have a role in metabolism, and therefore,
an RNAi screen was performed to identify those
components of metabolism that give rise to a phe-
notype, which could then be modified by altering
levels of WWOX to below and/or above endoge-
nous levels. WWOX has a functional relationship
with IDH, a component of the TCA cycle and
SOD1, a regulator of ROS; therefore, genes
involved in the TCA cycle and oxidative processes
emanating from the TCA cycle were examined to
identify other novel functional interactions. Out of
the 56 genes tested in the developing eye of Dro-
sophila, 10 were found to result in cellular dysmor-
phology. WWOX was able to modulate the
cellular dysmorphology seen with six of these
genes, all of which are components of the mito-
chondrial respiratory chain. Reduction in endoge-
nous levels of WWOX exacerbated the cellular
dysfunction, resulting in a higher proportion of
eyes displaying severe dysmorphology phenotypes
in adults and outgrowth of tissue in the larval eye
imaginal discs. These severe adult eye dysmor-
phology phenotypes (which include tissue out-
growths, presence of ectopic structures, and
reduced eye size) as well as the larval eye disc out-
growth are evidence of defects in growth control,
differentiation, and survival, all of which are proc-
esses that have been associated with tumorigene-
sis. This demonstrates that loss of WWOX
together with these mitochondrial complex genes
contributes to cellular properties often exhibited
by cancer cells.
Defects in mitochondrial respiratory complexes
have been reported in cancer, with these defects
shown to promote the tumorigenic potential of
cancer cells (Santidrian et al., 2013). One of the
major effects of mitochondrial dysfunction is the
production of high ROS levels, which promote
tumor progression and metastasis (Sharma et al.,
2011; Taddei et al., 2012). Indeed, the larval eye
disc outgrowth phenotype produced by defects in
mitochondrial function was shown to correlate
with high levels of ROS. WWOX has been found
to have an effect on ROS levels, although the
resultant effect appears to be context dependent
(O’Keefe et al., 2011; Shaukat et al., 2014). We
have previously shown that decreasing WWOX
levels in cells with chromosomal instability results
in high levels of ROS and DNA damage (Shaukat
et al., 2014); hence, there is a precedent for loss of
WWOX contributing to cellular dysfunction that is
mediated by high ROS levels. Loss of WWOX by
itself has now also been associated with impaired
DNA damage response, potentially driving
genomic instability (Abu-Odeh et al., 2014b, Aqei-
lan et al., 2014); thus, it is likely that this is
through the modulation of ROS levels.
Significantly, increased WWOX expression above
endogenous levels was able to suppress the tissue
disruption caused by Complex I and IV genes. This
indicates that increased WWOX levels are able to
provide a more favorable outcome for cells that
have mitochondrial dysfunction. Evidence pointing
toward reduced mitochondrial respiration has
recently been shown in WWOX-deficient mice
(Abu-Remaileh and Aqeilan, 2014), suggesting that
WWOX may be able to affect mitochondrial func-
tion. There are also other studies that observed
up-regulation of WWOX expression in damaged
mitochondria of mice with retinal defects (Chen
et al., 2005) and that increasing WWOX expression
can induce mitochondrial-mediated apoptosis in var-
ious cancer cells (Qin et al., 2006; Iliopoulos et al.,
2007; Zhang et al., 2012; Cui et al., 2013). These
Figure 8. Mechanism for the contribution of WWOX to cellular
homeostasis. Deficiencies in the mitochondrial respiratory complexes
results in cellular dysfunction through increased production of ROS
and activation of the Akt signaling pathway, with the effects moderated
by Foxo and HIF-1/ levels as well as autophagy. WWOX has been
shown to maintain cellular homeostasis caused by such mitochondrial
respiratory complex deficiencies. It is proposed that WWOX acts to
moderate excesses in metabolism and facilitate the transition between
glycolysis and oxidative phosphorylation through regulation of ROS and
reciprocal interactions with HIF-1/. [Color figure can be viewed in
the online issue, which is available at wileyonlinelibrary.com.]
14 CHOO ETAL.
Genes, Chromosomes & Cancer DOI 10.1002/gcc
430
studies are consistent with a requirement for mito-
chondrial WWOX function. The observation that
increasing WWOX above endogenous levels is able
to suppress the disruption caused by mitochondrial
defects in this model indicates that WWOX is able
to moderate the effect of mitochondrial dysfunction
in cells.
Structure–function analyses were carried out to
identify the amino acid residues required for the role
of WWOX in moderating mitochondrial dysfunction.
The ability of WWOX to suppress the tissue disrup-
tion caused by mitochondrial defects was abolished
when a mutation was introduced specifically into the
active site of its SDR enzyme. Such mutations have
been shown to result in complete abolishment of
enzymatic activity of SDR enzymes (Nakajin et al.,
1998; Filling et al., 2002). This demonstrates that the
modulation of mitochondrial-mediated cellular dys-
function by WWOX is dependent upon its ability to
carry out its SDR enzymatic activity. Indeed,
WWOX has been shown to be able to translocate
into the mitochondria under stress conditions, and a
mitochondrial localization signal has been identified
in its SDR region (Chang et al., 2001). Although the
exact enzymatic reaction(s) catalyzed by the SDR
region of WWOX is currently unknown, SDR
enzymes have been reported to have essential roles
in metabolism and cellular NAD(P)(H) redox sensor
systems (Kavanagh et al., 2008). Changes in the lev-
els of nicotinamide adenine dinucleotide (NADH)
and nicotinamide adenine dinucleotide phosphate
(NADPH) in WWOX-deficient mice with reduced
mitochondrial respiration have been reported in a
recent study (Abu-Remaileh and Aqeilan, 2014).
The results described herein report a novel role
for the SDR region of WWOX in maintaining cel-
lular homeostasis, specifically in response to mito-
chondrial dysfunction. This has physiological
relevance for human diseases, both in cancer and
also the neuronal dysfunction observed in patients
with WWOX mutations, as mitochondrial dysfunc-
tion and the resultant oxidative stress have been
shown to have pathological contributions to tumor-
igenesis (Sharma et al., 2011; Ma et al., 2013;
Santidrian et al., 2013) and neurodegeneration
(Koutnikova et al., 1997; Zeviani and Carelli,
2007). In cancer, mitochondrial dysfunction has
been proposed to have a role in tumor develop-
ment, progression and metastasis, with emerging
evidence that deficiencies in mitochondrial respi-
ratory complexes are able to promote tumor pro-
gression and metastasis (Sharma et al., 2011; Ma
et al., 2013; Santidrian et al., 2013). Genetic analy-
ses of the molecular pathways involved in the
cellular dysmorphology caused by mitochondrial
dysfunction have identified ROS, AKT, HIF-1/,
and autophagy as key players in this model, with
Sima/HIF-1/ and autophagy appearing to act in
feedback mechanisms to restrict the cellular dam-
age. Altered levels or activity of these key players
are noted to be characteristic of cancer cells.
Indeed, dysfunction of mitochondrial respiratory
Complex I has been found to result in high levels
of ROS and promote tumorigenesis through AKT
activation in human cell lines (Sharma et al.,
2011). WWOX has previously been shown to block
activation of AKT in cancer cell lines through an
unknown mechanism (Hu et al., 2014); thus, it is
likely that reduced WWOX levels lead to AKT
activation and contribute to the cellular dysmor-
phology possibly through modulation of specific
ROS levels and/or their compartmentalization.
Reduced levels of WWOX, rather than complete
absence, are often observed in tumors and contrib-
ute to both cancer initiation and progression. The
identified role for WWOX in moderating cellular
homeostasis in a pathway mediated by ROS and
AKT thus provides a mechanism for how reduced
WWOX levels can contribute to tumor growth.
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Inventory of Supplementary Information 
 
Table S1 summarises the overall results from the RNAi screen of metabolic genes  
 
Figure S1 shows representative images of the different phenotypic categories for the 
adult eye phenotypes and the qPCR results confirming successful RNAi targeting for 
WWOX and ND42 (related to Figure 1). 
 
Figure S2 shows independent verification that reduced WWOX expression 
exacerbates the cellular dysfunction caused by mitochondrial defects (related to 
Figure 2). 
 
Table S2 provides statistical analyses supporting that reduced WWOX expression 
exacerbates the cellular dysfunction (related to Figure 2 and Figure S2). 
 
Table S3 provides statistical analyses supporting that increased WWOX expression 
suppresses the cellular dysfunction (related to Figure 3). 
 
Table S4 provides details regarding the mutations generated in the different domains 
of WWOX (related to Figure 4). 
 
Table S5 provides statistical analyses supporting that the SDR active site of WWOX 
is required for its suppression of cellular dysfunction (related to Figure 4) 
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Figure S3 shows additional verification that the SDR catalytic active site of WWOX 
is required for the suppressive effect on mitochondrial mediated-cellular dysfunction 
(related to Figure 4).  
 
Table S6 provides statistical analyses for the additional verification of the role of the 
WWOX SDR catalytic active site (related to Figure S3). 
 
Table S7 provides statistical analyses supporting that alterations in the level of 





Table S1. Summary of the RNAi screen testing for cellular dysfunction that is modulated by WWOX in the developing eye of Drosophila. 
  
Eye phenotype caused by eye-specific 
knockdown of gene expression using 
RNAi 
  








(control)  BL35785 - No phenotype No phenotype 
TCA cycle (includes processes converging in and out of the TCA cycle) 
1 CG15400  v7261 Glucose-6-phosphatase activity No phenotype  No phenotype 
2 CG1516  v105936 Pyruvate carboxylase activity No phenotype No phenotype 
3 CG7070 Pyruvate kinase (Pyk) v35165 Pyruvate kinase activity No phenotype No phenotype 
4 CG17725 Phosphoenolpyruvate carboxykinase (Pepck) v20529 
Phosphoenolpyruvate carboxykinase 
(GTP) activity No phenotype  No phenotype 
v110081 No phenotype No phenotype 5 CG3127 Phosphoglycerate kinase (Pgk) v33797 
Phosphoglycerate kinase activity 
No phenotype No phenotype 
6 CG7010/ l(1)G0334  v107209 
Pyruvate dehydrogenase (acetyl-
transferring) activity No phenotype No phenotype 
7 CG7430  v106126 Dihydrolipoyl dehydrogenase activity No phenotype No phenotype 






transferring) kinase activity No phenotype No phenotype 









oxidase at 57D distal 
(Acox57D-d) 
v106733 Acyl-CoA oxidase activity No phenotype No phenotype 
12 CG11198 Acetyl-CoA carboxylase (ACC) BL34885 Acetyl-CoA carboxylase activity  No phenotype No phenotype 
13 CG9390 Acetyl Coenzyme A synthase (AcCoAS) v100281 Acetate-CoA ligase activity No phenotype No phenotype 
v26301 No phenotype No phenotype 14 CG3861 Knockdown(kdn)  v107642 Citrate (Si)-synthase activity No phenotype No phenotype 
BL34028 No phenotype No phenotype 15 CG9244 Aconitase(Acon) v103809 Aconitate hydratase activity No phenotype No phenotype 
16 CG6439   v14443 Isocitrate dehydrogenase (NAD+) activity No phenotype No phenotype 
17 CG5028   v103834 Isocitrate dehydrogenase (NAD+) activity No phenotype No phenotype 
18 CG11661 Neural conserved at 733F BL33686 
Oxoglutarate dehydrogenase (succinyl-
transferring) activity No phenotype No phenotype 
19 CG1065 
Succinyl coenzyme A 
synthetase a subunit 
(Scsa) 
v107164 Succinate-CoA ligase (GDP-forming) activity 
Loss of cells at 
the posterior end 
of the eye 
No modification 
20 CG11963 skpA associated protein (skap) v105350 
Succinate-CoA ligase (ADP-forming) 
activity No phenotype No phenotype 
21 CG10622 Succinate-CoA ligase (Sucb) v101554 
Succinate-CoA ligase (GDP-forming) 






Succinate dehydrogenase (ubiquinone) 
activity; Mitochondrial electron transport 
(Complex II) 






Succinate dehydrogenase activity; 
Mitochondrial electron transport (Complex 
II) 
No phenotype No phenotype 
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24 CG10219   v101739 
Succinate dehydrogenase (ubiquinone) 
activity; Mitochondrial electron transport 
(Complex II) 
No phenotype No phenotype 
25 CG4094/ l(1)G0255   v105680 Fumarate hydratase activity 
Mild disruption to 
the patterning of 
ommatidia  
No modification 
26 CG7998 Malate dehydrogenase 2 (Mdh2) v101551 Malate dehydrogenase activity No phenotype No phenotype 
BL35486 
Extremely mild 
disruption in the 
patterning of 
ommatidia 
No modification 27 CG5889 Malic enzyme b (Men-b) 
v100812 
Malate dehydrogenase (oxaloacetate-
decarboxylating) (NADP+) activity 
No phenotype No phenotype 
28 CG10120 Malic enzyme (men/ME3) v104016 
Malate dehydrogenase (oxaloacetate-
decarboxylating) (NADP+) activity No phenotype No phenotype 
BL28930 No phenotype No phenotype 29 CG3523   
BL35775 
Fatty acid synthase 
No phenotype No phenotype 
30 CG5009   v103761 Palmitoyl-CoA oxidase activity No phenotype No phenotype 
31 CG8036   BL32884 Transketolase activity No phenotype No phenotype 
32 CG4389 
Mitochondrial 
trifunctional protein α 
subunit (Mtp α) 
v100021 Fatty acid beta-oxidation No phenotype No phenotype 
Oxidative phosphorylation/Cell redox homeostasis  
v31551 No phenotype No phenotype 
v31552 No phenotype No phenotype 
v108307 No phenotype No phenotype 






Removal of superoxide radicals; located in 
the cytoplasm 






v110547 Removal of superoxide radicals; located in the mitochondria No phenotype No phenotype 
v103591 No phenotype No phenotype 35 CG6871 Catalase v6283 Response to hydrogen peroxide No phenotype No phenotype 
36 CG8913 Immune-regulated catalase v101098 Response to oxidative stress No phenotype No phenotype 















v109255 glutathione transferase activity No phenotype No phenotype 
41 CG12529 Zwischenferment (Zw)  v101507 glucose-6-phosphate dehydrogenase activity No phenotype No phenotype 
42 CG3896/ CG34399 
NADPH oxidase 
(Nox) v102559 
Oxidoreductase activity; calcium ion 







NADH dehydrogenase (ubiquinone) 
activity; Mitochondrial electron transport 
(Complex 1 of ETC) 
Disruption of 
ommatidia, with a 













NADH dehydrogenase (ubiquinone) 
activity; Mitochondrial electron transport 
(Complex 1 of ETC) 
Disruption of 
ommatidia, with a 












NADH dehydrogenase (ubiquinone) 
activity; Mitochondrial electron transport 
(Complex 1 of ETC) 
Disruption of 
ommatidia, with a 





increased Wwox  
46 CG2014   v108457 
NADH dehydrogenase (ubiquinone) 
activity; Mitochondrial electron transport 
(Complex 1) 







NADH dehydrogenase (ubiquinone) 
activity; Mitochondrial electron transport 
(Complex 1) 







v15508 Electron-transferring-flavoprotein dehydrogenase activity No phenotype No phenotype 
49 CG7580 Ubiquinol-cytochrome c reductase subunit 8 v101371 
Ubiquinol-cytochrome-c reductase 
activity; Mitochondrial electron transport 
(Complex III) 
Disruption of 
ommatidia, with a 






cytochrome c oxidase 
subunit I (Cox1) 
v109391 Cytochrome-c oxidase activity (Complex IV) No phenotype No phenotype 
51 CG34069 Mitochondrial v109278 Cytochrome-c oxidase activity; No phenotype No phenotype 
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cytochrome c oxidase 
subunit II (Cox2) 
Mitochondrial electron transport (Complex 
IV) 
52 CG14724  Cytochrome c oxidase subunit V (CoVa) v44490 Cytochrome-c oxidase activity 
Disruption of 
ommatidia, with a 





increased Wwox  
53  CG11015 Cytochrome c oxidase subunit V (CoVb) v30892 Cytochrome-c oxidase activity 
Disruption of 
ommatidia, with a 





increased Wwox  
54 CG5818 Mitochondrial ribosomal protein L4 v40608 Translation No phenotype No phenotype 
55 CG16944 Stress-sensitive B (sesB) v104576 ATP:ADP antiporter activity 
Loss of cells at 
the posterior end 
of the eye 
No modification 
56 CG10523 Parkin (park) v104363 
ubiquitin-protein ligase activity, response 
to oxidative stress, positive regulator of 
mitochondrial fission 




Figure S1. RNAi targeting of mitochondrial complex genes with WWOX and its 
effects. (A) Categories of eye phenotype severity used to quantify the effects of 
altered WWOX levels together with knockdown of genes encoding components of the 
mitochondrial respiratory chain. Eyes were grouped into three different categories: 
“mild/normal” – normal organisation or mild disruption in the patterning of the 
ommatidia; “moderate” –the loss of photoreceptor cells in the eye field forming a 
cavity in the eye; “severe” – significant disruption in the structure and development of 
the eye (tissue outgrowth, presence of ectopic structures in the eye or substantial loss 
of cells resulting in overall decreased eye size). (B) Successful RNAi targeting for 
WWOX and ND42 in Drosophila heads. ND42 and WWOX mRNA levels were 
measured in Drosophila heads with eye-specific RNAi knockdown of those genes. 
Significant reduction in WWOX and ND42 levels were observed in flies expressing 
either the WWOX RNAi, ND42 RNAi or both RNAi lines together. ***p≤0.001, ** 
p≤0.01, * p≤0.05 compared to the respective control. (C) Comparing the knockdown 
efficiency of WWOX by ubiquitious targeting between two independent WWOX 
RNAi constructs. Higher level of knockdown was observed in WWOX RNAi #1 
compared to WWOX RNAi #2 and this result corresponds to the level of 
enhancement by the two different lines (WWOX RNAi #1 has a stronger effect than 





Figure S2. Independent verification that reduced WWOX expression exacerbates 
the cellular dysfunction caused by decreased expression of three different 
mitochondrial Complex I genes (ND23, ND42 and ND75). Decreased WWOX 
expression using two other independent lines (different RNAi line v22536, WWOX1/+ 
is heterozygous for a WWOX null mutation) increases the proportion of eye 
phenotypes indicative of cellular dysfunction. Eyes were scored based on severity of 
the phenotype (severe, moderate or mild/normal) for each genotype. Chi-square test 
analyses were performed using GraphPad Prism. ***p≤0.001 when comparing to the 
respective controls, exact p values as well as further statistical analyses are provided 












Table S2. Statistical analyses of the severity of eye phenotypes exhibited by flies 
with reduced WWOX expression together with reduced expression of six 
different mitochondrial complex genes.  
 
For the adult eye phenotypes, chi-square test analyses were firstly performed to 
compare all three categories of phenotype between the different genotypes. Further 
analysis using Fisher’s exact test were also carried out as comparisons of the severe 
phenotypes with the other phenotypes (combined moderate and mild/normal 
categories). For the larval eye outgrowth phenotype, Fisher’s exact test was using to 
determine significance when comparing presence and absence of the outgrowth 
phenotype. All analyses were performed with GraphPad Prism. The different WWOX 
lines used were v108350 (WWOXRNAi 1), v22536 (WWOXRNAi 2) and a heterozygous 
WWOX null mutation (WWOX1/+). 
 
 
Adult eye phenotypes 
Control vs WWOXRNAi 1 n>150 eyes 
per 
genotype 
Chi-square test comparing all 
three categories (severe, moderate 
and mild/normal) 
Fisher’s exact test comparing 
severe phenotypes with the other 
phenotypes 
ND23RNAi  Enhancement (p<0.0001 ***) Enhancement (p<0.0001 ***) 
ND42RNAi Enhancement (p<0.0001 ***) Enhancement (p<0.0001 ***) 
ND75RNAi Enhancement (p<0.0001 ***) Enhancement (p<0.0001 ***) 
CG7580RNAi Enhancement (p<0.0001 ***) Enhancement (p<0.0001 ***) 
CoVaRNAi Enhancement (p<0.0001 ***) Enhancement (p=0.0003 ***) 
CoVbRNAi Enhancement (p=0.0107 *)   Enhancement (p=0.0073 **)  
 
Control vs WWOXRNAi 2 Control vs WWOX1/+ n>130 eyes 
per 
genotype 
Chi-square test  Fisher’s exact 
test  
Chi-square test  Fisher’s exact 
test  
























     
Larval eye disc outgrowth phenotype 
n≥50 eye discs per genotype Control vs WWOXRNAi 1 (Fisher’s exact test) 
ND23RNAi  Enhancement (p<0.0001 ***) 
ND42RNAi Enhancement (p=0.0034 **) 
ND75RNAi Enhancement (p<0.0001 ***) 
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Table S3. Statistical analyses of the presence or absence of eye phenotypes 
exhibited by flies with increased WWOX expression together with reduced 












Fisher’s exact test analyses were performed using GraphPad Prism to compare the 
proportion of flies exhibiting considerable tissue disruption (“phenotype”) to the 
proportion of flies with no considerable tissue disruption (“no phenotype”).   
 
n>150 eyes per genotype Control vs WWOXcDNA 
ND23RNAi  Suppression (p<0.0001 ***) 
ND42RNAi Suppression (p<0.0001 ***) 
ND75RNAi Suppression (p<0.0001 ***)  
CG7580RNAi No change    (p=0.2767 n.s.)  
CoVaRNAi Suppression (p<0.0001 ***)  
CoVbRNAi Suppression (p<0.0001 ***)  
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Table S4. Mutations generated to target amino acids that are known or predicted 
to be crucial for WWOX function. 
Mutations generated to 
replace predicted functional 
amino acid residues in 
Drosophila 
Predicted functional 










Y29 TAT  CGT Y29R Corresponding Y33R 
mutation in mammalian 
systems abolished 
binding of partner 
proteins to the WW 
domain and resulted in 
reduced apoptotic 




W58 TGG  TTC  W58F Substitution of tryptophan 
residues (to 
phenylalanine) in WW 
domain proteins could 
either affect their function 
or result in structural 
changes in the protein 




T127 ACG  
GCG 
T127A TA substitution in the 
cofactor binding motif 
resulted in changes in 
cofactor binding 
preference and abolished 
some enzymatic activities 
of another SDR protein 
(Oppermann et al., 2997; 
Filling et al., 2002).  
Identified risk 
polymorphism  
P277 CCG  
GCG 
P277A Corresponding variant 
A282 in humans 
associated with increased 
risk of thyroid cancer 




Y288 TAC  TTC Y288F Y F substitution in the 
active site completely 
abolished enzymatic 
activity of other SDR 
proteins (Nakajin et al., 
1998; Filling et al., 2002).  
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Table S5. Statistical analyses of the modification of eye phenotypes by increased 
WWOX expression for all WWOX over-expression mutant lines together with 
reduced expression of ND23.  
 
 
Fisher’s exact test analyses were performed using GraphPad Prism to compare the 
proportion of flies exhibiting considerable tissue disruption (“phenotype”) to the 
proportion of flies with no considerable tissue disruption (“no phenotype”).   
# The significant difference detected for the Y288F mutant line compared to EV 
control is due to a enhancement with the Y288F mutant line, not a suppression; the 
significance was not included in Figure 4 as the significance shown in that figure was 
to demonstrate suppressive effects. 
Comparisons were also made between the wildtype and mutant WWOX lines to 
demonstrate that the Y288F mutant is the only line that shows any significant 





n>250 eyes per 
genotype 
Compared to EV control Compared to wildtype WWOX 
Wildtype 
WWOX 
Suppression (p=0.001 **) - 
Y29R Suppression (p<0.0001 ***) No difference (p=0.4285 n.s) 
W58F Suppression (p=0.0002 ***) No difference  (p=0.5888 n.s.) 
T127A Suppression (p=0.0154 *) No difference  (p=0.1669 n.s.) 
P277A Suppression (p<0.0001 ***) No difference  (p=0.1217 n.s.) 
Y288F Enhancement# (p=0.0223 *) Difference       (p<0.0001 ***) 
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Figure S3. Additional analyses supporting that the SDR catalytic active site is 
required for the suppressive function of Wwox on mitochondrial defect-mediated 
tissue disruption. Both ectopic wildtype Wwox and Y288F form of Wwox (mutation 
in the SDR active site) were tested for their ability to suppress tissue disruption 
caused by decreased expression of different mitochondrial complex genes – (A) 
ND23, (B) ND42 and (C) ND75 in the Drosophila eye. Whilst expression of the 
ectopic wildtype Wwox consistently resulted in suppression of the tissue disruption, 
expression of the Y288F mutant form was unable to suppress the tissue disruption 
caused by defects in all three genes. The lines tested in these experiments were all 
inserted into the 68E1 chromosomal location. The lines have previously been tested 
with ND23 (Figure 4). In this experiment, the lines were again tested with ND23 as 
well as with the two other genes (ND42 and ND75). *** p≤0.0001 indicative of 
suppression compared to the empty vector (EV) control as determined by Fisher’s 
exact test, p values and further statistical analyses in Table S6. 
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Table S6. Statistical analyses of the additional experiments testing the 
suppressive function of the Y288F mutant compared to wildtype WWOX on 
mitochondrial defect-mediated tissue disruption in the Drosophila eye.  
n>250 eyes per 
genotype 
Compared to EV Control Compared to 
wildtype WWOX 
Wildtype 
WWOX Suppression (p<0.0001 ***) - 
ND23 
Y288F mutant  No change (p=0.3077 n.s.) Difference  (p=0.0004 ***) 
Wildtype 
WWOX Suppression (p<0.0001 ***) - 
ND42 
Y288F mutant  No change (p=0.2045 n.s.) Difference (p<0.0001 ***) 
Wildtype 
WWOX Suppression (p<0.0001 ***) - 
ND75 
Y288F mutant  No change (p=0.0643 n.s.) Difference (p<0.0001 ***) 
 
Fisher’s exact test analyses were performed using GraphPad Prism to compare the 
proportion of flies exhibiting considerable tissue disruption (“phenotype”) to the 
proportion of flies with no considerable tissue disruption (“no phenotype”). The 





Table S7. Statistical analyses of the modification of the larval eye disc outgrowth 
phenotype by altered levels of candidate genes. 
 
Overexpression of candidate genes 
n= 50 eye discs per genotype Compared to control (ey, ND42RNAi, EV) 
WWOXRNAi Enhancement (p=0.0439 *) 
UAS-Catalase Suppression (p<0.0001 ***) 
UAS-SOD1 Suppression (p=0.0008 ***) 
UAS-SOD2 Suppression (p=0.0338 *) 
UAS-Foxo Suppression (p=0.0002 ***) 
 
Decreased expression of candidate genes 
n= 50 eye discs per genotype Compared to control (ey, ND42RNAi, lacZRNAi) 
WWOXRNAi Enhancement (p=0.0001 ***) 
SOD1RNAi Enhancement (p=0.0052 **) 
SOD2RNAi Enhancement (p= 0.0025 **) 
AktRNAi Suppression (p=0.0004 ***) 
AtgRNAi Enhancement (p=0.0262*) 
 
WWOXRNAi Enhancement (p=0.0085 **) 
SimaRNAi Enhancement (p=0.0268 *) 
 
Fisher’s exact test analyses were performed using GraphPad Prism to compare the 
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Figure S1. Related to Figure 1, Western analysis of Wwox protein levels in 
Wwox1 and Wwoxf04545 homozygous adult flies. 
(A) Anti-Wwox antibody detects a band corresponding to Wwox (*), as 
previously determined (28), that is absent in Wwox1 as well as in Wwoxf04545 
adult mutant flies.  
(B) Alpha Tubulin loading control.   
Westerns were performed using anti-N-terminal Wwox antibody as previously 
described (28) with the following modifications: anti-Rabbit Cy5 secondary 
antibody was used at 1:500 (Rockland) and amplification of the signal was 
achieved using SignalBoostTM Immunoreaction Enhancer Kit (Calbiochem). 
Alpha Tubulin was detected using anti-alpha tubulin at 1:2000  (Sigma) and 
anti-mouse Alexa 488 at 1:2000 (Molecular Probes). Protein size markers are 
shown in kDaltons (kDa). 
453
Table S1. MS Identification of proteins in spots that exhibited significant 
changes in abundance as identified by DIGE.  Related to Figure 1.  











Observed mol. mass 
(Da)/pI 
          
w1118 vs Wwox1 adults  
15 2.70 0.011 gi|24664081 Fat body protein 1 630 (35) 18 (9) 20% 119,666 / 6.39 ~47,000 / 5.9 
19 2.15 0.001 gi|8647 Cu-Zn superoxide 
dismutase 
94 (35) 2 (2) 20% 15,974 / 5.67 ~15,000 / 5.5 
9 1.53 0.004 gi|8282 Alcohol dehydrogenase 114 (35) 4 (1) 19% 27,858 / 7.74 ~28,000 / 6.2 
10 1.25 0.034 gi|20129399 Aldehyde 
dehydrogenase 
212 (35) 8 (2) 16% 57,325 / 6.37 ~54,000 / 5.4 
14^ 1.16 0.006 gi|157561 Glycerol-3-phosphate 
dehydrogenase 
80(60) 7(0) 6% 35,351 / 8.42 ~37,000 / 6.1 
5 1.14 0.006 gi|21358499 CG7430 72(31) 4(1) 7% 53,565 / 6.41 ~54,000 / 5.65 
12 1.14 0.006 gi|24650465 CG31075 315(35) 8(4) 18% 52,607 / 6.64 ~54,000 / 5.55 
25 1.13 0.017 gi|24649832 CG11089 380 (35) 9 (7) 16% 63,797 / 7.97 ~65,000 / 7.65 
13 1.10 0.003 gi|24650465 CG31075 311(35) 9(5) 22% 52,607 / 6.64 ~54,000 / 5.85 
23 -1.08 0.003 gi|45550132 Hsp60C 88 (35) 3 (1) 6% 61,890 / 6.75 ~60,000 / 5.1 
2 -1.12 0.003 gi|24648872 CG6439 / Isocitrate 
dehydrogenase 
83(31) 4(1) 10% 40,382 / 8.74 ~40,000 / 6.65 
3 -1.30 0.006 gi|24647881 CG7998 138(35) 6(1) 26% 35,524 / 9.2 ~35,000 / 7.5 
20 -2.23 0.001 gi|8647 Cu-Zn superoxide 
dismutase 
63 (24) 1 (1) 9% 15,974 / 5.67 ~15,000 / 5.9 
w1118; da>GAL4 vs w1118; da>Wwox adults 
  
16^ 3.04 0.002 gi|24664081 Fat body protein 1 483 (60) 40 (6) 33% 119,350 / 5.82 ~46,000 / 6.45 
17 1.60 0.001 gi|7961 Fat body protein 1 273 (34) 6(4) 6% 119,350 / 5.82 ~47,000 / 5.65 
1 1.49 0.001 gi|20129347 Wwox 101 (35) 2 (2) 8% 47052 / 7.19 ~35,000 / 6.10 
6^ 1.48 0.006 gi|7248650 Malic enzyme 128 (36) 4(1) 9% 84,368 / 7.23 ~60,000 / 5.8 
7 1.43 0.019 gi|7248650 Malic enzyme 192 (35) 9(4) 19% 84,368 / 7.23 ~60,000 / 5.65 
24 1.31 0.021 gi|20130249 CG2852 45 (32) 1 (1) 9% 22,185 / 8.69 ~20,000 / 6.75 
4 1.23 0.042 gi|17136394 Phosphoglycerate 
kinase 
144 (32) 4 (1) 9% 44,119 / 7.01 ~45,000 / 6.45 
28 1.22 0.006 gi|19921864 CG8193 79 (35) 3 (1) 4% 79,520 / 6.49 ~80,000 / 6.35 
8^ 1.22 0.004 gi|157476 Glyceraldehyde-3-
phosphate 
dehydrogenase 
72 (60) 7 (0) 19% 35,351 / 8.42 ~35,000 / 6.4 
27 -1.23 0.047 gi|20130403 Tudor-SN 593 (35) 14 (8) 18% 103,436 / 8.14 ~100,000 / 6.5 
19 -1.23 0.035 gi|8647 Cu-Zn Superoxide 
dismutase 
94 (35) 2(2) 20% 15,988 / 5.85 ~15,000 / 5.45 
26 -1.26 0.013 gi|21358001 CG14526 60 (35) 3 (1) 5% 79,172 / 5.69 ~80,000 / 5.7 
21 -1.37 0.046 gi|21357673 CG5590 57 (32) 2 (1) 5% 44,611 / 8.11 ~46,000 / 7.15 
22 -1.43 0.001 gi|21357643 CG7470 308 (34) 7 (4) 13% 84,093 / 6.71 ~85,000 / 5.7 
11 -1.57 0.031 gi|1079042 Acetyl Coenzyme A 
synthase 
60 (33) 2 (1) 4% 75,946 / 5.44 ~75,000 / 5.45 
18 -2.20 0.004 gi|24664081 Fat body protein 1 575 (43) 14 (8) 16% 119,350 / 5.82 ~47,000 / 5.95 
# Numbers in parentheses represents the peptide ‘identity’ threshold score 
* Numbers in parentheses represents number of queries over the peptide ‘identity’ threshold score 




Figure S2. Related to Figure 2, effect of knocking down expression of Wwox candidate interactors and altering Wwox expression on viability in 
Drosophila.  
(A) Crosses were set up for ubiquitous RNAi knockdown of the candidate gene either with normal levels of WWOX (i) or with altered (ii – decreased, 
iii – increased) levels of WWOX. The da-GAL4 driver was used to drive ubiquitous expression of the UAS constructs using the binary UAS-GAL4 
system. From each cross, progeny of two different genotypes could be obtained at a 1:1 ratio, in accordance with Mendel’s law of segregation. The 
two types of progeny obtained were those that carried a copy of the UAS-candidate RNAi construct with either the da-GAL4 driver (non-TM6B 
progeny, in which the candidate gene is ubiquitously knocked down) or the TM6B balancer (TM6B progeny, in which there is no knockdown of the 
candidate gene). Crosses with a minimum of 30 TM6B progeny were analysed and the ratio of non-TM6B: TM6B progeny were compared from (i), 
(ii) and (iii).  
(B) Viability of Drosophila expressing candidate RNAi lines ubiquitously with the da-GAL4 driver. The percentage of non-TM6B progeny was scored 
for each RNAi line. The mean percentage for each RNAi line was compared to the expected percentage (50%, as indicated with the bold line) and 
error bars represent standard deviation of experimental replicates when the experiment has been replicated. Any negative deviation from the 
expected percentage was taken as an indication of reduced viability and “*” denotes statistical significance (p<0.05) determined by t-test analysis. 
(C) No significant difference in viability (0.90≥p>0.10) was observed when Wwox levels were increased (da>Wwox) or decreased (da>WwoxRNAi) 
compared to the wildtype control (da>+).  
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Table S2: Summary of results from the viability screen testing the effect of 







Effect on viability with 
da>WwoxRNAi
 
Effect on viability with da>Wwox 
 
Reduced viability with da-GAL4   
   
#1 ↓       P=0.256 #1 ↑       P=0.757 
#2 ↓       P=0.768 #2 ↑       P=0.072 
#3 ↓       P<0.001 ** #3 ↑       P=0.016 ** 
#4 ↓       P=0.002 ** #4 ↑       P<0.001 ** 
CG6439 14443^ 
 
#5 ↓       P=0.405 #5 ↑       P<0.001 ** 
#1 ↓       P=0.185 #1 ↓       P=0.238 CG11089 31421 
#2 ↓       P=0.007 ** #2 ↑       P=0.471 
#1 ↓       P=0.052 #1 ↓       P=0.413 
#2 ↓       P<0.001 ** #2 ↓       P=0.003 ** 
#3 No change #3 ↑       P=0.197 
Bancal/CG13425‡ 2912 
#4 No change #4 ↑       P=0.158 
#1 ↑       P=0.198 #1 ↓       P=0.102 47138 
#2 ↑       P=0.036 ** #2 ↓       P=0.005** 
#1 ↑       P=0.565 #1 ↑       P=0.096 47139 
 #2 ↓       P=0.529 #2 ↑       P=0.933 
#1 ↓       P=0.897 #1 ↑       P=0.090 
CG14526 
39838^ 
#2 ↑       P=0.207 #2 ↑       P=0.483 
#1 ↓       P=0.425 #1 ↓       P=0.685 Fat body protein 
1(Fbp1)/CG17285 
37881  
 #2 ↑       P=0.613 #2 ↑       P=0.215 
#1 ↑       P=0.520 #1 ↑       P=0.132 CG30152 38848 
#2 ↓       P=0.033 ** #2 ↑       P=0.663 
 
Lethal with da-GAL4 
   
#1 No rescue of lethality #1 No rescue of lethality Prp19/CG5519 22147 
#2 No rescue of lethality #2 No rescue of lethality 
#1 No rescue of lethality #1 No rescue of lethality CG5590 42040 
#2 No rescue of lethality #2 No rescue of lethality 
CG7430 28011 #1 No rescue of lethality #1 No rescue of lethality 
#1 No rescue of lethality #1 No rescue of lethality Sop2/CG8978 42171 
#2 No rescue of lethality #2 No rescue of lethality 
 
Related to Figure 2. 10 of the candidate genes identified by proteomic or microarray analysis 
were tested in this screen. For CG14526, line 47138 was the original line tested and included in 
Figure S1; lines 47139 and 39838 were later tested as two other independent lines for that 
gene. Numbers #1-5 refer to the number of experimental replicates tested for that particular 
RNAi line. The arrows indicate the direction in which altering WWOX levels affects the viability 
of the genotype. The p-values highlighted in grey indicate statistical significance (p<0.05) 
determined by chi-square test analysis. 
   ^These RNAi lines have 1 reported off target (http://stockcenter.vdrc.at). 
‡For candidate gene Bancal/CG13425, ubiquitously expressing the RNAi construct in 
Drosophila resulted in reduced viability in two experiments (#1 and #2) but complete lethality in 
two other replicates (#3 and #4). In experiments #3 and #4, decreasing WWOX levels in 
Drosophila expressing the Bancal RNAi construct also resulted in lethality, hence the results are 





‘Figure S3. Related to Figure 2, qPCR analysis of Wwox and CG6439 transcript 
levels in 3rd instar larvae. 
(A) Ubiquitous expression of RNAi directed against Wwox (da>WwoxRNAi) 
resulted in knockdown of endogenous Wwox transcript levels compared to the 
control with the ubiquitous driver alone (da>+).  
(B) Ubiquitous ectopic expression of Wwox open reading frame (ORF) under the 
daughterless promoter (da>WwoxORF) results in increased levels of Wwox 
transcript compared to the control (da>+). 
(C) Knockdown of endogenous CG6439/Idh transcripts was observed following 




Figure S4. Related to Figure 3, crosses set up to test the effect of the Wwox mutations on the viability of Drosophila trans-
heterozygous for the Sodn1/Sodn64 mutations. 
(A) In order to generate Drosophila that are trans-heterozygous for the Sodn1/Sodn64 mutations, Sodn1 flies that are 
balanced over a TM6B balancer were crossed to Sodn64 flies balanced over a TM6B balancer. In accordance to Mendel’s 
law of segregation, progeny of 4 different genotypes could be obtained at a 1:1:1:1 ratio. However, as having two copies of 
TM6B balancer results in lethality, only progeny of the 3 other genotypes were obtained and it was expected that 33.3% of 
the total progeny would be of the desired Sodn1/Sodn64 genotype. 
(B) & (C) Crosses set up to test the effect of the Wwox mutations on the viability of Drosophila trans-heterozygous for the 
Sodn1/Sodn64 mutations. The percentage of progeny being Wwox;Sod double mutants out of the total progeny was 
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Fragile sites are nonrandomly located gaps or breaks 
in chromosomes that are induced to appear by specific
culture conditions. They are classified according to their
chemistry of induction and by their frequency in the
population (Box 1). Rare (or heritable) fragile sites 
are found on the chromosomes of less than 5% of
individuals, whereas common (or constitutive) fragile
sites are found in all individuals. Rare folate-sensitive
fragile sites are associated with FRAXA and FRAXE
mental retardation, whereas the FRA11B site
predisposes to 11q breakage giving rise to some cases 
of Jacobsen syndrome (see Ref. 1 for review). Since the
culture conditions used for the cytogenetic observation
of fragile sites are artificial there had been concern 
that they merely represent a cell culture artefact. The
FRA11B breakage provided the first evidence that
fragile sites can break in vivo and are not just an in vitro
tissue-culture artifact2. There is, as yet, no direct
evidence that other rare fragile sites are associated with
disease – indeed, some individuals have been identified
as homozygous for rare fragile-site-expressing
autosomes (FRA16B and FRA10B) (Refs 3,4).
Expanded repeats form at least part of the
molecular basis for rare fragile sites. All known folate-
sensitive rare sites are associated with CCG repeats,
while AT-rich minisatellite repeats are found at the
non-folate-sensitive FRA10B and FRA16B fragile site
loci (see Ref. 1 for review). Several common fragile
sites have been completely [FRA3B (Refs 5–7) and
FRA16D] or partially [FRA7G (Refs 8,9) and FRA7H
(Ref. 10)] sequenced. However, it is not yet clear what
the necessary and sufficient conditions are for
common fragile site expression.
Yunis and Soreng11 put forward the hypothesis that
common fragile sites predispose to DNA instability
frequently observed in certain forms of cancer. This
proposal was based on the observation that common
fragile sites are located at or near structural defects
known in various cancers. Statistically, this
association was found to be highly significant. An
association between common fragile sites and cancer
genes, although mentioned, was not clear. However,
Yunis and Soreng went so far as to suggest that their
‘remarkable proximity’might enable fragile sites ‘to 
be used as valuable markers in the search for and
analysis of protooncogenes’. The question raised by
this proposal was whether the cytogenetic breakpoints
(fragile sites) actually correspond to translocation
breakpoints (and associated cancer genes) or might
simply be close to them? Common fragile sites are
found on the chromosomes of all individuals and
cancer is a common disease; therefore, demonstrating
a causal relationship between the two has not been
straightforward.
Aphidicolin (an inhibitor of DNA polymerase-α) 
is an inducer of the majority of common fragile sites
(Figs 1,2). The different common fragile sites are 
found at quite variable frequencies in metaphases,
suggesting that they exhibit differing sensitivities to
Cancer cells commonly exhibit various forms of genetic instability, such as
changes in chromosome copy number, translocations and point mutations in
particular genes. Although transmissible change seems to be an essential part
of the neoplastic process, the extent to which DNA instability is a cause rather
than a consequence of cancer is unclear. Chromosomal fragile sites have been
proposed to be not only susceptible to DNA instability in cancer cells, but also
associated with genes that contribute to the neoplastic process. Mutation at
fragile site loci might therefore have a causative role in cancer. Recent studies
on one class of human chromosomal fragile sites show that instability at fragile
site loci can functionally contribute to tumor cell biology.
Fragile and unstable chromosomes in
cancer: causes and consequences
Robert I. Richards
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the induction mechanism. Prolonged exposure to, or
higher levels of, aphidicolin causes such widespread
chromosomal fragmentation that the chromosomes are
no longer cytogenetically identifiable (Fig. 2). Variation
in the level of expression of particular common fragile
sites between individuals has been noted12,13 and high
levels of common fragile site expression have been
associated with cancer14. The wide variation in
cytogenetic expression levels within an individual
undermines the utility of expression levels for
predicting risk. Environmental and/or dietary factors
might well contribute to fluctuations in expression
levels in a given individual as common fragile sites are
known to be sensitive to a range of chemicals, including
ingested substances (caffeine and ethanol) (Box 2).
Understanding the molecular basis of common fragile
sites might reveal a correlation between the molecular
determinants of expression levels and sensitivity to
mutagens, and therefore allow development of a useful
predictive assay for cancer risk.
Studies on two of the most frequently observed
common fragile site loci, FRA3B and FRA16D, have
now provided compelling evidence that these regions
are indeed prone to DNA instability (deletions and
translocations) in cancer cells. In addition the genes
spanning these two sites have been identified15,16 and
experimental evidence indicates that both have a role
in neoplasia17–19.
Where do fragile sites fit in the spectrum of
chromosomal instability in cancer?
The most frequently observed chromosomal
instability in cancer cells is aneuploidy – change from
the normal number of chromosomes, which usually
involves several chromosomes. Aneuploidy has been
proposed as necessary for (at least certain forms of)
cancer20. Certainly, cell transformation by some
cancer-associated single genes, such as those
encoding T antigen or cyclin D, can lead to dramatic
changes in chromosome copy number20,21. The
simplest outcome of such chromosomal changes
would be the altered expression of genes that promote
or suppress cancer due to changes in gene dosage.
Amplification or nonrandom partial chromosomal
copy number increases have frequently been
observed in cancer. Fragile sites have been proposed
to be the boundaries of amplified DNA regions.
Evidence has been presented for fragile sites acting
as the end points for the breakage–fusion–bridge
mechanism of DNA amplification22. Coquelle et al.23
have found that hypoxia can induce fragile-site-
associated rearrangement. Furthermore, they
showed that repeated induction of fragile sites
generates large marker chromosomes containing
tandemly amplified genes (Fig. 3).
The validated24 ‘two hit’hypothesis of Knudsen
provides a basis for the nonrandom deletion of
chromosomal DNA observed in tumor cells. Where two
mutations are required in certain genes for neoplasia
these can occur successively – the first ‘hit’ is usually a
point mutation, followed by extensive deletion of DNA
encompassing the second allele. Tumor suppressor
genes are therefore thought to reside within the
smallest region of overlap (SRO) between the
commonly deleted regions of cancer patients. The
deletions are observed as loss of heterozygosity (LOH)
of informative genetic markers when normal and
tumor DNAs from individual cancer patients are
compared. A compilation of LOH data published for
breast cancer suggests that there are as many as
24 recurrent SROs across the human genome25.
Several common fragile site loci have been mapped
within such LOH regions. However, a functional
relationship between breakage at fragile site loci 
and LOH deletion has yet to be demonstrated. One
possible way of doing so would be to examine the
extent of heterozygosity around fragile-site-
associated deletions. This analysis has been
performed at the FRA16D locus for one cell line
(Mangelsdorf et al.26) and suggests that the fragile
site homozygous deletion is distinct from the 16q23.2
LOH seen in breast and prostate cancers. However,
further studies are needed for conclusive results.
Recurrent chromosomal translocations tend to be
hallmarks of particular kinds of cancer. The molecular
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Common fragile sites (found in all individuals)
Aphidicolin (n = 76)
Aphidicolin is an inhibitor of certain DNA polymerases. Ethanol is
synergistic in fragile site induction. The addition of caffeine 6 h before
harvest increases the proportion of metaphases expressing fragile sites.
Aphidicolin is added 24 h before chromosome harvest.
5-Azacytidine (n = 4)
This must be added ~8 h before chromosome harvest – earlier or later
addition is ineffective for fragile site expression.
5-Bromodeoxyuridine (BrdU) (n = 7)
This gives maximum induction 4–6 h before harvest.
Rare fragile sites (found in less than 5% of the population)
Folic acid (n = 22)
This acts as a cofactor for the conversion of uridine monophosphate to
thymidylate. These fragile sites are induced by conditions that give rise to a
relative deficiency of dCTP or dTTP during DNA synthesis.
Distamycin A (n = 5, two of these also inducible by BrdU)
This is an oligopeptide antibiotic that binds to the minor groove of AT-rich
DNA in a sequence-specific manner. These sites are also induced by berenil
and netropsin.
BrdU (n = 2)
Incorporated into DNA in place of thymidine. This is not the case for BrdU
common fragile sites. Also inhibits expression of folate-sensitive fragile sites.
*(n = number of known human loci)
Box 1. Different classes of chromosomal fragile sites and their inducing
agents* 
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basis of this is most likely that a specific fusion gene
product is required for that particular cancer to
develop. Recently, however, evidence has emerged 
that at least certain translocations are more frequent
because of the physical proximity between the
relevant sites of translocation within the nucleus of
the particular cell type27. Chromosomal fragile site
regions have been seen to interact in metaphase
spreads after induction28. Such interaction might
facilitate the chromosomal translocation process. 
The FRA3B fragile site has been found to be the site 
of the chromosome 3 breakpoint in the familial clear
cell renal carcinoma t(3;8) translocation29 and in 
both chromosome 3 homologs in esophageal
adenocarcinoma30, whereas the FRA16D fragile site is
the location of the chromosome 16 breakpoint in four
out of five t(14;16) translocations that are observed in
about 25% of cases of multiple myeloma26,31–33.
Common fragile site loci have been found to be
preferential sites of viral integration. Cervical
carcinomas frequently exhibit human papillomavirus
(HPV) integration in association with acquiring
malignant phenotype. Thorland et al.34 have
demonstrated that at least some HPV-16 integrations
occur within common fragile sites.
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Fig. 1. Ideogram of human chromosomes showing the location of
cytogenetically discernible aphidicolin-induced common fragile site
loci. Data from Glover et al.48 and Sutherland et al.49 G-banded
ideograms were modified from those created by Tim Knight, FHCRC
Image Analysis Lab (http://www.fhcrc.org/shared_resources/image/)
and obtained from the Primate Cytogenetics Network
(http://www.selu.com/bio/cyto/human/).
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Do the genes that span fragile sites have roles to play in
cancer cell biology?
Role of FHIT/FRA3B in cancer
A wide variety of tumor types have FRA3B
deletions. Many of these are adenocarcinomas of 
the tissues exposed to the environment, for example
gastrointestinal tract and lung. On this basis it has
been proposed that common fragile site loci are
particularly sensitive to environmental mutagens35.
The FHIT gene was found to span the FRA3B 
fragile site15. Since its discovery over 200 articles
concerning the FHIT gene and/or protein have 
been published, including controversy over whether
FHIT has a functional role in cancer. The FHIT 
gene is huge (>1 Mb) with some homozygous
deletions located solely within a single large 
intron. Deletions frequently give rise to aberrant
transcripts; however, FRA3B-deleted cancer cells
are marked by an absence of the encoded FHIT
protein, indicating that loss of function is the most
likely consequence of deletion36. Verification of a
functional role for FHIT by gene rescue in FRA3B-
deleted tumor cells has been problematic37. This
might be because tumor cells that have FHIT
deletions are also deleted at additional loci and the
loss of gene function at these ‘unrescued’ deletions
also contributes to neoplasia.
The FHIT protein is a member of the histidine
triad family of enzymes and has been shown to have
diadenosine 5 ′,5′′′- P(1),P(3)-triphosphate (Ap3A)
hydrolase activity38. Despite known roles for Ap3A-
related nucleotides in controlling cell division39,
elimination of an amino acid crucial for Ap3A
hydrolysis does not affect the ability of the FHIT gene
to rescue phenotype in at least certain cancer cells40.
In functional studies FHIT has been found to have 
a role in apoptosis; this rule appears to be distinct
from the well-characterized caspase pathways41.
Transgenic mice heterozygous for knockout of 
the Fhit gene have increased susceptibility to
mutagenesis42. The resultant tumors mimic
Muir–Torre syndrome. Remarkably, the mouse Fhit
gene has been found to contain also a common fragile
site43, and presumably this fragile site provides the
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Fig. 2. GTL-banded metaphases showing (a) minimal (FRA3B, FRA16D),
(b) moderate and (c) severe aphidicolin-induced chromosome
breakage. Photograph kindly supplied by Elizabeth Baker.
Fig. 3. Fragile-site-associated amplification. Tandem duplication of
genes on a marker chromosome after repeated fragile site induction.
Chromosomes hybridized with probes for mdr1 (green) and ampd2
(red). Figure reproduced, with permission, from Ref. 23.
In vitroa
Inhibitors of DNA replication
Caffeine and ethanol (enhance rather than cause breakage)
In vivoa,b
Hypoxia
Breakage affected by dietary intake of certain agents
References
a Yunis, J.J. and Soreng, A.L. (1987) Constitutive fragile sites and cancer. Science
226, 1199–1204
b Coquelle, A. et al. (1998) A new role for hypoxia in tumour progression: Induction of
fragile site triggering genomic rearrangements and formation of complex Dms and
HSRs. Mol. Cell 2, 259–265
Box 2. Causes of DNA breakage at chromosomal fragile site loci
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susceptible target for the second hit in the
heterozygous knockout mice. The contribution of
reduced FHIT protein to the mutagen sensitivity of
the transgenic mice overcomes the issue of whether
FRA3B deletion alone contributes to neoplasia by
some means independent of FHIT, such as loss of
possible DNA replication control elements associated
with the fragile site. The phenotype of homozygous
Fhit knockout mice has not yet been reported and it
will be of interest to see whether mutations at loci in
addition to Fhit are necessary for tumor formation.
Fhit gene therapy protects Fhit+/− mice from
sensitivity to mutagens44, further supporting an
early role for FRA3B/FHIT deletion in
carcinogenesis (Box 3).
Role of FOR (WWOX, WOX1)/FRA16D in cancer
The alternatively spliced FOR gene (also known as
WWOX and WOX1) of >1 Mb in length, which spans
FRA16D, has been independently identified by three
laboratories12,15,42. The open reading frames of these
transcripts all code for N-terminal WW domains and 
for varying extents of oxidoreductase (OR) domains.
Multiple myeloma t(14;16) translocation breakpoints
described by Chesi et al.31 were subsequently found to
map mainly within the FOR gene12,31. Chesi et al. found
that the protooncogene MAF, located in the region, has
increased expression in cells with t(14;16) translocation;
they have proposed that dysregulated MAF expression
contributes to multiple myeloma pathogenesis.
Bednarek et al.45 identified the FORII transcript (which
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• Hydrolase of Ap3A (also able to hydrolyse Ap4A) (Ref. a), a signal in the timing of cell divisionb.
• FRA3B-associated deletions result mainly in FHIT loss of functionc.
• Gene transfer able to rescue ‘normal’ phenotype from tumor cells with FRA3B/FHIT deletionsd (deletion of amino
acids essential for diadenosine 5′,5′′′ -P(1),P(3)-triphosphate (Ap3A) hydrolase activity does not affect rescue).
• FHIT-rescued tumor cells exhibit increased apoptosis and G0/G1 arreste (apoptosis independent of p53 and
Bcl2/BclX/Bax pathways).
• Transgenic mice heterozygous for Fhit loss-of-function mutations are more susceptible to mutagen-induced
tumor formationf.
• Rescue from mutagen sensitivity of Fhit knockout transgenic mice with ‘gene therapy’ – adenovirus vectors
expressing Fhit (Ref. g).
References
a Barnes, L.D. et al. (1996) FHIT, a putative tumour suppressor in humans, is a dinucleotide 5′,5′′′-P1,P3-triphosphate hydrolase.
Biochemistry 35, 11529–11535
b Nishimura, A. (1998) The timing of cell division: Ap4A as a signal. Trends Biochem. Sci. 23, 157–159
c Huebner, K. et al. (1998) The role of the FHIT/FRA3B locus in cancer. Annu. Rev. Genet. 32, 7–31
d Siprashvili, Z. et al. (1997) Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc. Natl. Acad. Sci. U. S. A.
94, 13771–13776
e Sard, L. et al. (1999) The tumour-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc. Natl.
Acad. Sci. U. S. A. 96, 8489–8492
f Fong, L.Y.Y. et al. (2000) Muir–Torre-like syndrome in Fhit-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 97, 4742–4747
g Dumon, K.R. et al. (2001) FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 
98, 3346–3351
Box 3. Function of FHIT and possible roles in cancer
• Gene induced by hyaluronidase, protein located mainly in mitochondria.
• Permeabilization of mitochondria – e.g. by tumor necrosis factor (TNF) – leads to translocation of FOR to nucleus.
• TNF-mediated FOR translocation occurs after and independent of NF-κB.
• FOR enhances: (1) TNF cytotoxicity via WW and oxidoreductase domains; and (2) TNF-receptor-associated
death domain (TRADD)-mediated cell death. 
• Lowering FOR raises TNF resistance.
• FOR downregulates Bcl2 and BclxL, and upregulates p53 via the OR domain.
• The OR domain of FOR is able to mediate apoptosis.
• WW domains do not modulate p53, Bcl2 or BclxL proteins, but sensitize cells to TNF killing and cause
caspase-independent apoptosis.
• Coexpression of FOR and p53 causes apoptosis synergistically.
• FOR colocalizes with p53 in the cytosol (p53 polyPro binds FOR WW).
• Blocking FOR synthesis abolishes p53 apoptosis. FOR is a mitochondrial apoptogenic protein and an
essential partner of p53 in cell death.
Reference
a Chang, N.S. et al. Hyaluronidase induction of a novel WW domain-containing oxidoreductase that enhances tumour necrosis factor
cytotoxicity. J. Biol. Chem. (in press)
Box 4. Function of FOR/WOX1/WWOX and possible roles in cancera
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they named WWOX) when looking for genes in 16q23.2,
one of three frequent sites of LOH on the q arm of human
chromosome 16 in breast cancer. This transcript was
found to be increased in expression in cancer cell lines
compared to normal cells. No ‘second hit’mutations were
detected suggesting that the gene does not act as a
typical tumor suppressor. Ried et al.16 identified exons of
the FOR I transcript at either end of the DNA sequence
spanning the FRA16D fragile site. A variety of tumor
types have FRA16D deletions, although not at such a
high frequency as FRA3B. At least one cell line (AGS)
known to have FRA3B deletion was also shown to have
FRA16D deletion. Some homozygous deletions are solely
intragenic, mainly within the huge intron (~800 kb) of
the FORII exons 8 and 9A. Like FRA3B, deletion gives
rise to aberrant transcripts.
Chang et al.19 identified the mouse ForII transcript
through functional studies and have described FORII
(which they refer to as WOX1) as a mitochondrial
apoptogenic protein that is an essential partner of p53 in
cell death. FORII and p53 were found to bind to each other
through their respective WW and polyproline domains.
However, the nature and extent of the FORII–p53
interaction requires further exploration. Similarly, the
effect of FRA16D deletions and translocations on FOR
function is yet to be determined. These functional
studies at least suggest a molecular basis for this
FRA16D-spanning gene in cancer cell biology.
Given the proposed role for MAF in multiple
myeloma it might be that multiple genes, affected by
FRA16D-associated DNA instability, contribute to
neoplasia (Box 4).
Other common fragile sites?
Common fragile sites might be regions of particular
sensitivity to environmental mutagens. The extent of
this sensitivity appears to correlate with the frequency
of fragile site expression. FRA3B is the most frequently
expressed, followed by a group of moderately expressed
sites (FRA2G, FRA6E, FRA7H, FRA16D and FRAXB)
and in excess of 70 infrequently expressed, identifiable
fragile site loci (Fig. 1). FRA3B is more frequently
deleted than FRA16D and, although homozygous
deletions are yet to be reported at other fragile sites,
several of them are located within regions of frequent
LOH (Ref. 43). The distinction between cytogenetically
distinguishable fragile sites, such as FRA3B and
FRA16D, and a host of other sites in the genome is 
the degree of sensitivity to inducing agents and,
presumably, to mutagens (Figs 1,2). Therefore, cancer
cells that develop after environmental mutagenesis
are quite likely to have deletions at multiple fragile
site loci and therefore multiple affected fragile-site-
spanning genes. The redundancy in vital cellular
pathways such as apoptosis might account for
inconsistencies in functional studies: rescuing one
pathway might not overcome deficits in others. Given
a relationship between the extent of fragile site
expression and sensitivity to mutagens, it also follows
that individuals in the population with higher levels 
of common fragile expression are at higher risk of
mutation at these loci. The greater sensitivity of 
the heterozygous Fhit knockout transgenic mouse
supports the notion that individuals with higher levels
of fragile site expression would appear to be more
sensitive to environmental mutagenesis and therefore
at greater risk of any associated forms of cancer. A
considerable degree of variability within and between
individuals in common fragile site expression has 
been observed, suggesting that environmental and/or
metabolic factors might contribute to fragile site
expression and sensitivity to mutagenesis.
More questions
The recent findings at the FRA3B and FRA16D loci
raise many questions regarding the relationship
between chromosomal fragile sites and the genes 
in their vicinity and cancer (Box 5). The mechanisms
and extent to which genes such as FHIT and FOR
contribute to the neoplastic process are still unclear.
Both appear to be involved in apoptotic pathways.
The conserved location of a fragile site in the mouse
Fhit gene is intriguing and suggests an important
functional relationship between fragile sites and 
the genes that span them. Toledo et al.46 have
demonstrated an association between fragile sites
and DNA replication origins. Given the role of FHIT
in cell cycle regulation, intragenic fragile site loci
could therefore act to couple DNA replication with 
the expression of genes involved in cell cycle control.
Although rare fragile sites have been dismissed as
having a role in cancer predisposition, Auer et al.47
have recently shown that the same CCG repeats that
cause folate-sensitive rare fragile sites are located at
the 11q deletion breakpoints in chronic lymphocytic
leukemia (CLL) patients. Higher copy number alleles
of one of these CCG repeats are more frequently found
on the chromosomes of CLL patients with deletions
spanning the region. Furthermore, they have shown
that the presence of the larger allele is indicative of a
poor prognosis for patients with CLL. It might be that
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• Are fragile-site-associated deletions and translocations early (and
therefore determining) events in neoplasia?
• What are the necessary and sufficient conditions for in vitro or
cytogenetic expression of a chromosomal fragile site?
• What conditions/chemicals bring about in vivo breakage at fragile sites?
• What is the relationship between cytogenetic 'fragility'observed in vitro
and DNA breakage in vivo in cancer cells?
• What is the relationship between homozygous deletion at fragile site loci
and loss-of-heterozygosity deletions seen in cancer cells?
• Do all common fragile sites exhibit DNA instability in cancer, and where
they do exhibit breakage does this instability interfere with gene function
and in so doing contribute to neoplasia?
• What is the relationship between fragile site loci and the loss-of-
heterozygosity regions within which they are, at least occasionally, located?
• What DNA sequences are found at deletion/translocation breakpoints?
Box 5. Questions still to be addressed
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the requirements for repeat sequences to manifest as
a cytogenetically visible fragile site in vitro exceed
those that are necessary for increased fragility in vivo.
Conclusions
A substantial body of evidence now supports the
proposal that at least some common chromosomal
fragile sites predispose to DNA instability in cancer
cells. Although the nature and extent of the
contribution of this instability to cancer cell biology
remains unclear, functional studies have provided
some evidence supporting a role in neoplasia for 
the genes spanning (or near) at least two of these
sites (FRA3B and FRA16D). It might be
inappropriate to assume that what we know about
some fragile sites can be applied to all others.
Perhaps variation in chromosomal fragile site
structure, expression and location will mean that
the Yunis and Soreng hypothesis is correct for some
fragile site loci but not all.
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Abstract
A growing body of experimental evidence supports the view that certain human chromosomal fragile sites have roles to play
in cancer. The principle lines of evidence are at the level of mutation mechanism and gene function. Most research in this area
has previously focussed on the FRA3B common fragile site and the FHIT gene that spans this site. Here we review recent
progress in characterising the second most readily observed common fragile site, FRA16D, and the WWOX gene that spans it.
Comparative analyses of FRA3B/FHIT and FRA16D/WWOX reveal some striking similarities suggesting that these sites and
their associated genes may play a part in a normal protective response of cells to environmental stress.
q 2005 Published by Elsevier Ireland Ltd.
Keywords: Common chromosomal fragile site; In vitro fragility/in vivo instability; Protective gene function
1. What are common fragile sites and how do they
relate to cancer?
Common fragile sites are observed as non-staining
gaps, or breaks, in metaphase chromosomes of cells
cultured under conditions of replicative stress. More
than 70 common fragile sites have been described.
They are located at specific positions on chromo-
somes from all individuals and are most readily
observed after treatment of cells in culture with low
doses of aphidicolin, an inhibitor of DNA polymerase
[1]. These reproducible non-random ‘fragile’ regions
of chromosomes observed in vitro correspond to
regions where specific DNA instability has been
observed in vivo in various human cancers,
suggesting there may be a direct correlation between
chromosomal fragility and DNA instability [2]. There
has been some controversy over such a relationship
due to the large number of fragile sites and the high
prevalence of DNA instability in cancer [3,4].
However, recent evidence now supports a clear
relationship between a number of common fragile
sites and regions where DNA instability is observed in
certain forms of cancer [5–8]. In addition, functional
studies suggest that disruption of the FHIT gene at
FRA3B [9] and the WWOX gene at FRA16D [10]
could contribute directly to cancer progression. These
results are supportive of a causative role for fragile
site associated DNA instability in cancer, rather than
simply being a consequence of widespread genomic
instability after the initiation of tumour progression.
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2. What factors contribute to breakage at common
chromosomal fragile sites?
Common fragile sites show a consistent hierarchy
in their relative frequency of expression with FRA3B
being most frequently observed, followed by
FRA16DOFRA6EOFRA7GOFRAXBOothers [11].
Limited progress has been made in the identification
of intrinsic (cis-acting) features of these common
fragile site loci that specifically render them suscep-
tible to breakage. In contrast, several trans-acting
factors have been identified that regulate stability at
these loci.
2.1. Cis-acting sequences required for breakage
at common fragile site loci
It is not yet clear which cis-acting DNA sequences
are required for breakage at common fragile sites.
This situation is distinct to that of rare fragile sites,
which are associated with an inherited form of DNA
repeat instability and are observed in !5% of the
population (reviewed in Ref. [12]). Expanded CCG
repeats account for folate sensitive rare fragile sites,
while different repeat sequences are responsible for
those that are induced by other agents. For example,
rare fragile sites FRA10B and FRA16B are due to
expansions of AT-rich mini-satellite repeat
sequences.
Sequencing has revealed that common fragile site
regions are predominantly characterised by the
presence of various AT-rich DNA sequences some
of which comprise simple tandem repeats (Table 1).
In some cases, these sequences manifest as regions of
high flexibility and low stability (referred to as
FlexStab peaks) [13]. It has been proposed that
these AT-rich flexible sequences could be responsible
for DNA instability and that the resultant fragility
observed at common fragile sites could have a similar
molecular basis to rare fragile sites [14]. However, in
contradiction to such a proposal, a correlation was not
observed between AT-repeat (FlexStab1) copy num-
ber and the frequency of FRA16D common fragile site
expression in various individuals [5].
Are the AT-rich flexible regions necessary for
breakage at common fragile sites? Chromosomes
carrying homozygous deletions that remove the
characterised FlexStab and AT-rich sequences of
FRA16D are still able to break after treatment with
aphidicolin [5]. Similarly, chromosomes carrying
homozygous deletions in FRA3B that remove most
of this fragile region are also still able to break
cytogenetically [6]. On the other hand, deletions of the
complete fragile region of FRAXB rendered cells
unable to break at this fragile site [8]. Thus, it is
possible to localise the DNA sequences required for
breakage. These results suggest that for the FRA16D
and FRA3B deleted chromosomes, sufficient AT-rich
flexible (or indeed other) sequences were still present
either within or adjacent to the fragile site region to
enable breakage.
2.2. Trans-acting factors affecting breakage
at common fragile sites
There have been some clear examples of trans-
acting factors reported to regulate common fragile site
expression. Inhibition of the checkpoint kinase ATR
resulted in an increased frequency of breaks at
common fragile sites, even in the absence of
aphidicolin treatment [11]. ATR is an essential gene
required for the cellular response to DNA damage and
replicative stress. BRCA1 has also been shown to be
required for maintaining fragile site stability [15].
BRCA1 acts downstream of ATR, and the G2/M
checkpoint function of BRCA1 were shown to be
necessary to ensure stability at common fragile sites.
In addition, the Fanconi anaemia (FA) pathway has
also been implicated [16]. In response to DNA
damage, FA proteins associate with BRCA1 and
another repair protein RAD51, and are activated
during S-phase. Finally, the structural maintenance of
chromosomes (SMC) proteins Smc1 and Smc3, which
are part of the cohesin complex that holds sister
chromatids together, are also involved in repair of
double strand breaks (DSBs) and have been shown to
regulate fragile site stability in an ATR dependent
manner [17]. Thus, it is clear that factors normally
required to ensure a functional replication checkpoint
are also critical for maintaining stability at fragile
sites and thus preventing genomic instability.
A relationship of some sort between fragile sites
and replication timing has been known for some
time. Fragile sites FRA3B, FRA16D and FRA7H
have all been shown to be late replicating regions of
the genome [18–21]. It has been proposed that
L.V. O’Keefe, R.I. Richards / Cancer Letters xx (2005) 1–112
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FRAXB 500 Kb 57.7 31 n.d. GS1 105 Kb Deletions [8]
STS 146 Kb
TLR5a 28.6 Kb













FRA7I 2 Mb n.d. n.d. 17 PIP* 7.7 Kb Amplification [29]
FRA7H 161 Kb 58 32.6 4 No ORFs Viral integration [13]
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n.d. [14]
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the AT-rich sequences at common fragile sites
contribute to stalling of replication forks during
S-phase. Further delay in replication (in response to
aphidicolin in vitro or other stresses in vivo) could
then result in non-replicated or ‘fragile’ regions that
escape the normal replication checkpoint and thus are
prone to breakage.
Environmental and dietary factors are also known
to play a role in the cytogenetic manifestation of
common fragile sites. Caffeine and ethanol enhance
cytogenetic breakage at common fragile sites [2].
Fragile sites were also observed in response to
hypoxia [22] and various mutagens and carcinogens
[23]. In addition, a direct link has been shown
between tobacco smoking and instability at FRA3B
in lung cancer [24]. These results suggest that
common fragile sites manifest in response to a variety
of environmental insults. It is therefore likely that
fragile site associated DNA instability will occur
in vivo under these various environmental conditions.
3. Mutation mechanism in cancer cells
Various forms of DNA instability have been
associated with common fragile sites. They corre-
spond to positions of sister chromatid exchange and
recombination [25,26] plasmid and DNA viral
integration [27,28] and form boundaries of amplified
regions of the genome [29,30]. All of these
chromosomal rearrangements would require for-
mation of DSBs as an initiating event and therefore
DSBs appear to be a typical feature of common
fragile site loci. Aberrant repair of these fragile
site-associated DSBs could then give rise to deletions
such as those that have been observed at common
fragile sites in various cancers.
Furthermore, the relative frequency of the cytoge-
netic appearance of common fragile sites in vitro
corresponds to the relative frequency of deletions
observed in cancer cell lines in vivo [5,8]. Thus,
strongly suggesting that the in vitro cytogenetic
observations (i.e. FRA3BOFRA16DOFRA6EO
FRA7GOFRAXBOothers) are indicative of the
level of susceptibility to DNA instability in vivo.
What is the relationship between homozygous
deletions in cancer cells and common fragile sites? It
has been shown that the DNA instability at FRA16D
can arise from various discrete homozygous deletions
within the 270 Kb region where most fragile site
breakage locates (Fig. 1). This would suggest that
these homozygous deletions arise via a mechanism
that is distinct from the more extensive 16q23.2 LOH
identified in prostate [31] and breast cancer [32].
Common fragile site-associated homozygous
deletions have been shown to be stable and arise as
an early event in tumorigenesis. Deletion analysis of
cell lines derived from a primary carcinoma (KM12C)
and from a secondary metastasis of this same
carcinoma (KM12SM) revealed precisely the same
deletion endpoints in the region of FRA16D, despite
instabilities in other regions of the genome [5].
Furthermore, it has been shown that loss of expression
of FHIT (the gene spanning FRA3B) occurs as an
early event in breast and other cancers [33,34]. These
results are supportive of an early and therefore
causative role for these homozygous deletions in
cancer, rather than simply being a consequence of
widespread genomic instability after the initiation of
tumour progression.
The identification of homozygous deletions
presents a novel mechanism for gene inactivation in
cancer in the absence of mutations within the coding
sequence. Epigenetic control of gene expression in
cancer is already well established, predominantly as
silencing of tumor suppressor genes via methylation
of CpG islands in promoter regions. Hypermethyla-
tion of WWOX and FHIT has been reported in various
cancers and thus contributes to the silencing of these
genes in some cancers [35,36].
Alteration of the expression of other genes in the
vicinity of the common fragile sites may also
contribute to cancer cell biology (Table 1). Both the
MAF oncogene and the WWOX gene are affected by
translocations at FRA16D [37,38]. There are also
numerous genes in the vicinity of some common
fragile sites. At some of these fragile sites, the altered
expression of a number of these genes is observed in
various tumor cells.
4. Functional studies of genes at fragile sites
What is the normal function of genes located at
common fragile sites and how might the altered
expression of these genes be contributing to cancer
L.V. O’Keefe, R.I. Richards / Cancer Letters xx (2005) 1–114
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cell biology? Some of these genes have been shown to
have tumor suppressor functions (e.g. FHIT), strongly
supporting the hypothesis that loss of gene expression
through breakage at fragile sites could have a causal
role to play in cancer. For others, a tumor suppressor
function is yet to be determined, however, in most
cases they do show homozygous deletions or other
forms of genomic instability (Table 1) and/or altered
expression in various cancers both of which are
supportive of such a role.
4.1. FRA3B/FHIT
FRA3B has been reported to extend over a region
greater than 4 Mb within which five genes are located,
including Fragile Histidine Triad (FHIT) [39]. The
FHIT gene, spanning the majority of FRA3B
cytogenetic breakpoints, has been extensively
characterised with more than 500 publications
reported in the literature. The FHIT gene encodes a
diadenosine polyphosphate (Ap3A) hydrolase and
altered expression has been reported in numerous
human cancers (reviewed in Ref. [7]). Homozygous
deletions and translocation breakpoints map to a
region of approximately 300 Kb spanning exon 5 and
introns either side [6].
Analysis of a mouse knockout model has provided
valuable information on normal Fhit function. Fhit
can act as a tumor suppressor, as FhitK/K mice
displayed an increased rate of both spontaneous and
carcinogen-induced tumor formation [40,41]. The
cellular basis of Fhit function as a tumor suppressor
has been shown to involve inhibition of cell growth
and increased levels of apoptosis [42].
FhitK/K cells from mouse and human are more
resistant than FhitC/C cells to various cellular
stresses including ionizing radiation [43], mitomycin
Fig. 1. FRA16D associated DNA instability in cancer and the WWOX (FOR) gene. Diagram represents the cytogenetic location of FRA16D [45]
and the corresponding locations of loss-of-heterozygosity regions mapped in prostate [31] and breast [32] cancers; translocation breakpoints in
multiple myeloma [38] and homozygous deletions in adenocarcinomas [5,45,46,57]. The location of the WWOX (FOR) gene including its
780 Kb intron is also depicted.
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C and ultraviolet light [44]. Decreased levels of
apoptosis were observed in FhitK/K cells after
exposure and the surviving cells showed an increased
frequency of mutations. FhitK/K cells were shown to
have an overactive ATR/CHK1 pathway in response to
ionising radiation [43]. Hence, loss of Fhit function
enables cells to evade the normal checks that would
limit their growth following genomic insult.
4.2. FRA16D/WWOX(FOR)
The WWOX gene spanning the FRA16D fragile site
encodes a protein with tandem WW domains, a nuclear
localization signal and homology to an oxido-
reductase enzyme [45]. Some of the translocation
breakpoints in multiple myeloma and homozygous
deletions in various cancers map to, or near, a 270 Kb
region of FRA16D even though breakage over a 1 Mb
region has been reported (Fig. 1) [46,47]. In addition,
aberrant expression of WWOX has been reported in
various cancer cell types including breast, ovarian,
prostate, gastric, hematopoietic, esophageal, hepatic,
bladder and lung [34,35,45,48–61]. There is some
evidence for suppression of tumor growth following
ectopic expression of WWOX [62]. However, as with
FHIT at FRA3B, WWOX does not seem to be acting as
a classical tumor suppressor in that expression is not
always absent in tumors and mutations or deletions in
the coding region appear to be lacking [63].
WWOX was identified by a variety of approaches.
Firstly, as FRA16D oxido-reductase (FOR), based on
its direct association with this fragile site [45].
Secondly, it was identified as a candidate tumor
suppressor based on its location within a region of
LOH at 16q23 [64]. Finally, WWOX was identified as
a gene whose activity was increased after treatment
with hyaluronidase [65]. Functional studies have
shown that WWOX interacts synergistically with
p53 during TNF-mediated apoptosis [65]. This pro-
apoptotic role for WWOX is negatively regulated by
interaction with JNK [66]. WWOX has also been
reported to associate with p73 [67], Tau [68],
SIMPLE [69] and AP-2g [70] but the biological
significance of these interactions in vivo is yet to be
determined.
Recently, a Drosophila model has been developed
for the investigation of WWOX function in vivo [10].
Drosophila is well established as a model organism
for the identification of various pathways involved in
human cancers (reviewed in Ref. [71]). The Droso-
phila DmWWOX orthologue shares 49% identity
with human WWOX and has a conserved domain
structure of tandem WW domains and oxidoreductase
homology. DmWWOX null mutants are viable and
fertile with no obvious phenotype, however, they do
show an increased sensitivity to ionising radiation
[10]. Protection from radiation can be restored by re-
introduction of either Drosophila or human WWOX.
This highlights the evolutionarily conserved function
of WWOX and the utility of this model system for
genetic dissection of the normal pathways of WWOX
function. These results are also consistent with a
protective role for WWOX in response to environ-
mental challenges. The radiation sensitivity pheno-
type is similar to that previously observed for
Drosophila mutants in p53 [72,73]. The in vivo
significance of the reported interaction between
WWOX and p53 can therefore be investigated using
the Drosophila system. These studies will also allow
the identification of additional pathway(s) in which
DmWWOX normally participates and testing of the
various reported in vitro interactions for their in vivo
significance.
4.3. Other characterised fragile site loci and their
associated genes
A number of other common fragile site loci have
now been characterised (summarised in Table 1). In
each case, the extent of chromosome breakage spans a
large genomic region, from 161 Kb (FRA7H) up to
9.8 Mb (FRA9E). Sequence analysis of most of these
fragile regions revealed they were AT-rich. In some
cases, the proportion of specific AT-rich repetitive
sequences and/or the number of FlexStab peaks were
determined. In addition, a number of these loci have
been shown to be sites of various forms of genomic
instability. Together, these data are consistent with
cis-acting elements playing a causative role in the
observed instability at common fragile site loci.
Genes associated with these loci were also
identified. In some cases single (very large) genes
have been found, however, in many cases there were a
number of associated genes. Some of these genes
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show abnormalities in various cancers or have been
shown to suppress tumorigenicity. However, for many
of them, a clear role in cancer initiation and/or
progression is yet to be determined. In the case of
FRA7H, there have not been any genes identified
within the 161 Kb region of fragility [13]. This raises
the possibility that there could be a very large gene
spanning this fragile region that is yet to be
determined.
5. Features shared by some genes at common
chromosomal fragile sites
A typical feature of numerous common fragile site
associated genes is their large size (Table 1). This is
particularly remarkable in the cases of FHIT
(FRA3B), WWOX (FRA16D), Parkin (FRA6E) and
GRID2 (FRA4F). These genes span genomic regions
of 1.5, 1.1, 1.49 and 0.6 Mb, respectively, however,
their mRNAs are relatively small (1.1–3.0 Kb).
This association between common fragile sites and
extremely large genes is known to be conserved
between mouse and human for FRA3B/FHIT [74],
FRA16D/WWOX [75] and FRA4F/GRID2 [76]. It is
normally assumed that a conserved relationship such
as this is indicative of functional significance where
some benefit is conserved, i.e. selective advantage to
the organism.
Similarities have also been observed in the
expression of two of these large genes, WWOX and
FHIT. Loss of expression of both WWOX and FHIT
has been reported in gastric [51] and breast [52]
carcinomas. In addition, FHIT and WWOX both show
decreased expression in tumors of the lung, breast and
bladder, dependent on their methylation status [35].
They have also both been shown to be down regulated
in response to various carcinogens [77], UV exposure
[78] and E2F-1 treatment [79]. Thus, it is possible that
their expression could be coordinately regulated in
response to environmental challenges.
6. Common fragile sites and cancer
Is it possible that breakage at fragile sites could, at
least initially, be protective against cancer? Since
common fragile sites are found on chromosomes of all
individuals and thus constitute a normal part of
chromosome biology, could they actually form part of
a protective mechanism against cancer? Could it be
that the fragility at these sites somehow provides a
sensor mechanism that, coupled with altered
expression of the associated genes, can mount a
cellular response to environmental conditions? Such a
protective role for common fragile sites is supported
by recent findings that the DNA damage pathway is
activated early in the tumorigenic process [80,81].
Following replicative stress in cells, the resultant
DSBs led to activation of the ATM/ATR checkpoint
kinase. Analysis of common fragile site loci under
these conditions showed LOH. Thus, the inherent
sensitivity to breakage of these fragile regions of
chromosomes could perform a key role in activation
of the DNA damage surveillance mechanism to
ensure genomic integrity following environmental
insult [80,81].
Further to this, we propose that the purpose of the
large regions of unstable DNA, in some cases located
largely within their associated genes, could be to
enable the accumulation of recurrent deletions that
initially have a positive effect on expression of fragile
site associated genes. However, once the accumu-
lation of damage is too great, following continuous
exposure to replicative stress then altered or loss of
gene expression eventuates. Such an initial beneficial
role in prevention against environmental insult during
normal cell divisions could explain the potential cost
of contributing to cancer.
7. Conclusions
A clear relationship has been established between
chromosomal breakage at common fragile sites
observed in vitro and DNA instability observed
in vivo in human cancers. What are the functional
consequences of such a relationship? Most intrigu-
ingly, how can it be that regions of chromosomes that
are the most sensitive to breakage under stressful
conditions are the very same regions where genes are
located whose function is protective against cancer? Is
there a benefit to be had in such a relationship? In
order to better understand these questions we need to
ask what are the normal pathways to which these
genes contribute, perhaps then we can gain a clear
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picture of the contribution that these genes and their
associated fragile sites make to cancer cell biology.
Acknowledgements
This work was supported by grant (207809) from
the National Health and Medical Research Council
(NHMRC) of Australia, the Australian Research
Council (ARC) Special Research Centre for the
Molecular Genetics of Development and
the ARC/NHMRC Research Network in Genes and
the Environment in Development. LVO is the
recipient of a Peter Doherty Post-doctoral Research
Fellowship (207830) from the National Health and
Medical Research Council, Australia. Apologies to all
those whose work we could not include due to space
limitations. Thanks to Donna Crack, Sonia Dayan,
Blair Hopwood and Yinghong Liu for helpful
comments on drafts of this work.
References
[1] T.W. Glover, C. Berger, J. Coyle, B. Echo, DNA polymerase
alpha inhibition by aphidicolin induces gaps and breaks at
common fragile sites in human chromosomes, Hum Genet 67
(1984) 136–142.
[2] J.J. Yunis, A.L. Soreng, Constitutive fragile sites and cancer,
Science 226 (1984) 1199–1204.
[3] G.R. Sutherland, R.N. Simmers, No statistical association
between common fragile sites and nonrandom chromosome
breakpoints in cancer cells, Cancer Genet Cytogenet 31 (1988)
9–15.
[4] M. Le Beau, H. Drabkin, T. Glover, R. Gemmill, F. Rassool,
T. McKeithan, D. Smith, An FHIT tumor suppressor gene?,
Genes Chromosomes Cancer 21 (1998) 281–289.
[5] M. Finnis, S. Dayan, L. Hobson, G. Chenevix-Trench,
K. Friend, K. Ried, et al., Common chromosomal fragile site
FRA16D mutation in cancer cells, Hum Mol Genet 14 (2005)
1341–1349.
[6] S. Corbin, M.E. Neilly, R. Espinosa 3rd, E.M. Davis,
T.W. McKeithan, M.M. Le Beau, Identification of unstable
sequences within the common fragile site at 3p14.2:
implications for the mechanism of deletions within fragile
histidine triad gene/common fragile site at 3p14.2 in tumors,
Cancer Res 62 (2002) 3477–3484.
[7] K. Huebner, C.M. Croce, Cancer and the FRA3B/FHIT fragile
locus: it’s a HIT, Br J Cancer 88 (2003) 1501–1506.
[8] M.F. Arlt, D.E. Miller, D.G. Beer, T.W. Glover, Molecular
characterization of FRAXB and comparative common fragile
site instability in cancer cells, Genes Chromosomes Cancer 33
(2002) 82–92.
[9] K. Huebner, C.M. Croce, FRA3B and other common fragile
sites: the weakest links, Nat Rev Cancer 1 (2001) 214–221.
[10] L.V. O’Keefe, Y. Liu, A. Perkins, S. Dayan, R. Saint,
R.I. Richards, FRA16D common chromosomal fragile site
oxido-reductase (FOR/WWOX) protects against the effects of
ionizing radiation in Drosophila, Oncogene 24 (2005)
6590–6596.
[11] A.M. Casper, P. Nghiem, M.F. Arlt, T.W. Glover, ATR
regulates fragile site stability, Cell 111 (2002) 779–789.
[12] R.I. Richards, Dynamic mutations: a decade of unstable
expanded repeats in human genetic disease, Hum Mol Genet
10 (2001) 2187–2194.
[13] D. Mishmar, A. Rahat, S.W. Scherer, G. Nyakatura,
B. Hinzmann, Y. Kohwi, et al., Molecular characterization
of a common fragile site (FRA7H) on human chromosome 7
by the cloning of a simian virus 40 integration site, Proc Natl
Acad Sci USA 95 (1998) 8141–8146.
[14] E. Zlotorynski, A. Rahat, J. Skaug, N. Ben-Porat, E. Ozeri,
R. Hershberg, et al., Molecular basis for expression of
common and rare fragile sites, Mol Cell Biol 23 (2003)
7143–7151.
[15] M.F. Arlt, B. Xu, S.G. Durkin, A.M. Casper, M.B. Kastan,
T.W. Glover, BRCA1 is required for common-fragile-site
stability via its G2/M checkpoint function, Mol Cell Biol 24
(2004) 6701–6709.
[16] N.G. Howlett, T. Taniguchi, S.G. Durkin, A.D. D’Andrea,
T.W. Glover, The Fanconi anemia pathway is required for
the DNA replication stress response and for the regulation
of common fragile site stability, Hum Mol Genet 14
(2005) 693–701.
[17] A. Musio, C. Montagna, T. Mariani, M. Tilenni,
M.L. Focarelli, L. Brait, et al., SMC1 involvement in fragile
site expression, Hum Mol Genet 14 (2005) 525–533.
[18] M.M. Le Beau, F.V. Rassool, M.E. Neilly, R. Espinosa
3rd, T.W. Glover, D.I. Smith, T.W. McKeithan, Replica-
tion of a common fragile site, FRA3B, occurs late in S
phase and is delayed further upon induction: implications
for the mechanism of fragile site induction, Hum Mol
Genet 7 (1998) 755–761.
[19] L. Wang, J. Darling, J.S. Zhang, H. Huang, W. Liu,
D.I. Smith, Allele-specific late replication and fragility of
the most active common fragile site, FRA3B, Hum Mol
Genet 8 (1999) 431–437.
[20] A. Palakodeti, Y. Han, Y. Jiang, M.M. Le Beau, The role of
late/slow replication of the FRA16D in common fragile site
induction, Genes Chromosomes Cancer 39 (2004) 71–76.
[21] A. Hellman, A. Rahat, S.W. Scherer, A. Darvasi, L.C. Tsui,
B. Kerem, Replication delay along FRA7H, a common fragile
site on human chromosome 7, leads to chromosomal
instability, Mol Cell Biol 20 (2000) 4420–4427.
[22] A. Coquelle, L. Rozier, B. Dutrillaux, M. Debatisse, Induction
of multiple double-strand breaks within an hsr by
L.V. O’Keefe, R.I. Richards / Cancer Letters xx (2005) 1–118
DTD 5 ARTICLE IN PRESS 476
meganucleaseI-SceI expression or fragile site activation leads
to formation of double minutes and other chromosomal
rearrangements, Oncogene 21 (2002) 7671–7679.
[23] J.J. Yunis, A.L. Soreng, A.E. Bowe, Fragile sites are targets of
diverse mutagens and carcinogens, Oncogene 1 (1987) 59–69.
[24] C.K. Stein, T.W. Glover, J.L. Palmer, B.S. Glisson, Direct
correlation between FRA3B expression and cigarette smoking,
Genes Chromosomes Cancer 34 (2002) 333–340.
[25] T.W. Glover, C.K. Stein, Induction of sister chromatid
exchanges at common fragile sites, Am J Hum Genet 41
(1987) 882–890.
[26] T.W. Glover, C.K. Stein, Chromosome breakage and
recombination at fragile sites, Am J Hum Genet 43 (1988)
265–273.
[27] F.V. Rassool, T.W. McKeithan, M.E. Neilly, E. van Melle,
R. Espinosa, M.M. Le Beau, Preferential integration of marker
DNA into the chromosomal fragile site at 3p14: an approach to
cloning fragile sites, Proc Natl Acad Sci USA 88 (1991) 6657–
6661.
[28] E.C. Thorland, S.L. Myers, D.H. Persing, G. Sarkar,
R.M. McGovern, B.S. Gostout, D.I. Smith, Human papillo-
mavirus type 16 integrations in cervical tumors frequently
occur in common fragile sites, Cancer Res 60 (2000) 5916–
5921.
[29] M. Ciullo, M.A. Debily, L. Rozier, M. Autiero, A. Billault,
V. Mayau, et al., Initiation of the breakage-fusion-bridge
mechanism through common fragile site activation in human
breast cancer cells: the model of PIP gene duplication from a
break at FRA7I, Hum Mol Genet 11 (2002) 2887–2894.
[30] A. Hellman, E. Zlotorynski, S.W. Scherer, J. Cheung,
J.B. Vincent, D.I. Smith, et al., A role for common fragile
site induction in amplification of human oncogenes, Cancer
Cell 1 (2002) 89–97.
[31] A. Latil, O. Cussenot, G. Fournier, K. Driouch, R. Lidereau,
Loss of heterozygosity at chromosome 16q in prostate
adenocarcinoma: identification of three independent regions,
Cancer Res 57 (1997) 1058–1062.
[32] T. Chen, A. Sahin, C.M. Aldaz, Deletion map of chromosome
16q in ductal carcinoma in situ of the breast: refining a putative
tumor suppressor gene region, Cancer Res 56 (1996) 5605–
5609.
[33] H. Ishii, K. Ozawa, Y. Furukawa, Alteration of the fragile
histidine triad gene early in carcinogenesis: an update, J Exp
Ther Oncol 3 (2003) 291–296.
[34] G. Guler, A. Uner, N. Guler, S.Y. Han, D. Iliopoulos,
P. McCue, K. Huebner, Concordant loss of fragile gene
expression early in breast cancer development, Pathol Int 55
(2005) 471–478.
[35] D. Iliopoulos, G. Guler, S.Y. Han, D. Johnston, T. Druck,
K.A. McCorkell, et al., Fragile genes as biomarkers:
epigenetic control of WWOX and FHIT in lung, breast and
bladder cancer, Oncogene 24 (2005) 1625–1633.
[36] H. Ishii, A. Vecchione, Y. Furukawa, K. Sutheesophon,
S.Y. Han, T. Druck, et al., Expression of FRA16D/WWOX
and FRA3B/FHIT genes in hematopoietic malignancies, Mol
Cancer Res 1 (2003) 940–947.
[37] R.V. Jamieson, R. Perveen, B. Kerr, M. Carette, J. Yardley,
E. Heon, et al., Domain disruption and mutation of the bZIP
transcription factor, MAF, associated with cataract, ocular
anterior segment dysgenesis and coloboma, Hum Mol Genet
11 (2002) 33–42.
[38] M. Chesi, P.L. Bergsagel, O.O. Shonukan, M.L. Martelli,
L.A. Brents, T. Chen, et al., Frequent dysregulation of the
c-maf proto-oncogene at 16q23 by translocation to an Ig locus
in multiple myeloma, Blood 91 (1998) 4457–4463.
[39] N.A. Becker, E.C. Thorland, S.R. Denison, L.A. Phillips,
D.I. Smith, Evidence that instability within the FRA3B region
extends four megabases, Oncogene 21 (2002) 8713–8722.
[40] L.Y. Fong, V. Fidanza, N. Zanesi, L.F. Lock, L.D. Siracusa,
R. Mancini, et al., Muir-Torre-like syndrome in Fhit-deficient
mice, Proc Natl Acad Sci USA 97 (2000) 4742–4747.
[41] N. Zanesi, V. Fidanza, L.Y. Fong, R. Mancini, T. Druck,
M. Valtieri, et al., The tumor spectrum in FHIT-deficient mice,
Proc Natl Acad Sci USA 98 (2001) 10250–10255.
[42] L. Sard, P. Accornero, S. Tornielli, D. Delia, G. Bunone,
M. Campiglio, et al., The tumor-suppressor gene FHIT is
involved in the regulation of apoptosis and in cell cycle
control, Proc Natl Acad Sci USA 96 (1999) 8489–8492.
[43] B. Hu, S.Y. Han, X. Wang, M. Ottey, M.B. Potoczek,
A. Dicker, et al., Involvement of the Fhit gene in the ionizing
radiation-activated ATR/CHK1 pathway, J Cell Physiol 202
(2005) 518–523.
[44] M. Ottey, S.Y. Han, T. Druck, B.L. Barnoski, K.A. McCorkell,
C.M. Croce, et al., Fhit-deficient normal and cancer cells are
mitomycin C and UVC resistant, Br J Cancer 91 (2004) 1669–
1677.
[45] K. Ried, M. Finnis, L. Hobson, M. Mangelsdorf, S. Dayan,
J.K. Nancarrow, et al., Common chromosomal fragile site
FRA16D sequence: identification of the FOR gene spanning
FRA16D and homozygous deletions and translocation break-
points in cancer cells, Hum Mol Genet 9 (2000) 1651–1663.
[46] M. Mangelsdorf, K. Ried, E. Woollatt, S. Dayan, H. Eyre,
M. Finnis, et al., Chromosomal fragile site FRA16D and DNA
instability in cancer, Cancer Res 60 (2000) 1683–1689.
[47] K.A. Krummel, L.R. Roberts, M. Kawakami, T.W. Glover,
D.I. Smith, The characterization of the common fragile site
FRA16D and its involvement in multiple myeloma transloca-
tions, Genomics 69 (2000) 37–46.
[48] H. Ishii, Y. Furukawa, Alterations of common chromosome
fragile sites in hematopoietic malignancies, Int J Hematol 79
(2004) 238–242.
[49] R.I. Aqeilan, T. Kuroki, Y. Pekarsky, O. Albagha, F. Trapasso,
R. Baffa, et al., Loss of WWOX expression in gastric
carcinoma, Clin Cancer Res 10 (2004) 3053–3058.
[50] K. Driouch, H. Prydz, R. Monese, H. Johansen, R. Lidereau,
E. Frengen, Alternative transcripts of the candidate tumor
suppressor gene, WWOX, are expressed at high levels in
human breast tumors, Oncogene 21 (2002) 1832–1840.
[51] C. Gourley, A.J. Paige, K.J. Taylor, D. Scott, N.J. Francis,
R. Rush, et al., WWOX mRNA expression profile in epithelial
ovarian cancer supports the role of WWOX variant 1 as a
tumour suppressor, although the role of variant 4 remains
unclear, Int J Oncol 26 (2005) 1681–1689.
L.V. O’Keefe, R.I. Richards / Cancer Letters xx (2005) 1–11 9
DTD 5 ARTICLE IN PRESS 477
[52] G. Guler, A. Uner, N. Guler, S.Y. Han, D. Iliopoulos,
W.W. Hauck, et al., The fragile genes FHIT and WWOX
are inactivated coordinately in invasive breast carcinoma,
Cancer 100 (2004) 1605–1614.
[53] T. Kuroki, F. Trapasso, T. Shiraishi, H. Alder, K. Mimori,
M. Mori, C.M. Croce, Genetic alterations of the tumor
suppressor gene WWOX in esophageal squamous cell
carcinoma, Cancer Res 62 (2002) 2258–2260.
[54] T. Kuroki, S. Yendamuri, F. Trapasso, A. Matsuyama,
R.I. Aqeilan, H. Alder, et al., The tumor suppressor gene
WWOX at FRA16D is involved in pancreatic carcinogenesis,
Clin Cancer Res 10 (2004) 2459–2465.
[55] M.I. Nunez, J. Ludes-Meyers, M.C. Abba, H. Kil,
N.W. Abbey, R.E. Page, et al., Frequent loss of WWOX
expression in breast cancer: correlation with estrogen receptor
status, Breast Cancer Res Treat 89 (2005) 99–105.
[56] M.I. Nunez, D.G. Rosen, J.H. Ludes-Meyers, M.C. Abba,
H. Kil, R. Page, et al., WWOX protein expression varies
among ovarian carcinoma histotypes and correlates with less
favorable outcome, BMC Cancer 5 (2005) 64.
[57] A.J. Paige, K.J. Taylor, C. Taylor, S.G. Hillier, S. Farrington,
D. Scott, et al., WWOX: a candidate tumor suppressor gene
involved in multiple tumor types, Proc Natl Acad Sci USA 98
(2001) 11417–11422.
[58] S.W. Park, J. Ludes-Meyers, D.B. Zimonjic, M.E. Durkin,
N.C. Popescu, C.M. Aldaz, Frequent downregulation and loss
of WWOX gene expression in human hepatocellular carci-
noma, Br J Cancer 91 (2004) 753–759.
[59] M.C. Yakicier, P. Legoix, C. Vaury, L. Gressin, E. Tubacher,
F. Capron, et al., Identification of homozygous deletions at
chromosome 16q23 in aflatoxin B1 exposed hepatocellular
carcinoma, Oncogene 20 (2001) 5232–5238.
[60] S. Yendamuri, T. Kuroki, F. Trapasso, A.C. Henry,
K.R. Dumon, K. Huebner, et al., containing oxidoreductase
gene expression is altered in non-small cell lung cancer,
Cancer Res 63 (2003) 878–881.
[61] J.E. Watson, N.A. Doggett, D.G. Albertson, A. Andaya,
A. Chinnaiyan, H. van Dekken, et al., Integration of high-
resolution array comparative genomic hybridization analysis
of chromosome 16q with expression array data refines
common regions of loss at 16q23-qter and identifies
underlying candidate tumor suppressor genes in prostate
cancer, Oncogene 23 (2004) 3487–3494.
[62] A.K. Bednarek, C.L. Keck-Waggoner, R.L. Daniel,
K.J. Laflin, P.L. Bergsagel, K. Kiguchi, et al., WWOX, the
FRA16D gene, behaves as a suppressor of tumor growth,
Cancer Res 61 (2001) 8068–8073.
[63] A. Watanabe, Y. Hippo, H. Taniguchi, H. Iwanari, M. Yashiro,
K. Hirakawa, et al., An opposing view on WWOX protein
function as a tumor suppressor, Cancer Res 63 (2003) 8629–
8633.
[64] A.K. Bednarek, K.J. Laflin, R.L. Daniel, Q. Liao,
K.A. Hawkins, C.M. Aldaz, WWOX, a novel WW domain-
containing protein mapping to human chromosome 16q23.3-
24.1, a region frequently affected in breast cancer, Cancer Res
60 (2000) 2140–2145.
[65] N.S. Chang, N. Pratt, J. Heath, L. Schultz, D. Sleve,
G.B. Carey, N. Zevotek, Hyaluronidase induction of a WW
domain-containing oxidoreductase that enhances tumor
necrosis factor cytotoxicity, J Biol Chem 276 (2001) 3361–
3370.
[66] N.S. Chang, J. Doherty, A. Ensign, JNK1 physically interacts
with WW domain-containing oxidoreductase (WOX1) and
inhibits WOX1-mediated apoptosis, J Biol Chem 278 (2003)
9195–9202.
[67] R.I. Aqeilan, Y. Pekarsky, J.J. Herrero, A. Palamarchuk,
J. Letofsky, T. Druck, et al., Functional association between
Wwox tumor suppressor protein and p73, a p53 homolog, Proc
Natl Acad Sci USA 101 (2004) 4401–4406.
[68] C.I. Sze, M. Su, S. Pugazhenthi, P. Jambal, L.J. Hsu, J. Heath,
et al., Down-regulation of WW domain-containing oxido-
reductase induces Tau phosphorylation in vitro. A potential
role in Alzheimer’s disease, J Biol Chem 279 (2004) 30498–
30506.
[69] J.H. Ludes-Meyers, H. Kil, A.K. Bednarek, J. Drake,
M.T. Bedford, C.M. Aldaz, WWOX binds the specific
proline-rich ligand PPXY: identification of candidate inter-
acting proteins, Oncogene 23 (2004) 5049–5055.
[70] R.I. Aqeilan, A. Palamarchuk, R.J. Weigel, J.J. Herrero,
Y. Pekarsky, C.M. Croce, Physical and functional interactions
between the Wwox tumor suppressor protein and the AP-
2gamma transcription factor, Cancer Res 64 (2004) 8256–
8261.
[71] A.M. Brumby, H.E. Richardson, Using Drosophila melano-
gaster to map human cancer pathways, Nat Rev Cancer 5
(2005) 626–639.
[72] N. Sogame, M. Kim, J.M. Abrams, Drosophila p53 preserves
genomic stability by regulating cell death, Proc Natl Acad Sci
USA 100 (2003) 4696–4701.
[73] J.H. Lee, E. Lee, J. Park, E. Kim, J. Kim, J. Chung, In
vivo p53 function is indispensable for DNA damage-
induced apoptotic signaling in Drosophila, FEBS Lett 550
(2003) 5–10.
[74] T.W. Glover, A.W. Hoge, D.E. Miller, J.E. Ascara-Wilke,
A.N. Adam, S.L. Dagenais, et al., The murine Fhit gene is
highly similar to its human orthologue and maps to a common
fragile site region, Cancer Res 58 (1998) 3409–3414.
[75] K.A. Krummel, S.R. Denison, E. Calhoun, L.A. Phillips,
D.I. Smith, The common fragile site FRA16D and its
associated gene WWOX are highly conserved in the mouse
at Fra8E1, Genes Chromosomes Cancer 34 (2002) 154–167.
[76] L. Rozier, E. El-Achkar, F. Apiou, M. Debatisse, Character-
ization of a conserved aphidicolin-sensitive common fragile
site at human 4q22 and mouse 6C1: possible association with
an inherited disease and cancer, Oncogene 23 (2004)
6872–6880.
[77] M. Iida, C.H. Anna, W.M. Holliday, J.B. Collins,
M.L. Cunningham, R.C. Sills, T.R. Devereux, Unique patterns
of gene expression changes in liver after treatment of mice for
2 weeks with different known carcinogens and non-carcino-
gens, Carcinogenesis 26 (2005) 689–699.
[78] H. Ishii, K. Mimori, T. Inageta, Y. Murakumo, A. Vecchione,
M. Mori, Y. Furukawa, Components of DNA damage checkpoint
L.V. O’Keefe, R.I. Richards / Cancer Letters xx (2005) 1–1110
DTD 5 ARTICLE IN PRESS 478
pathway regulate UV exposure-dependent alterations of gene
expression of FHIT and WWOX at chromosome fragile sites,
Mol Cancer Res 3 (2005) 130–138.
[79] H. Ishii, K. Mimori, A. Vecchione, K. Sutheesophon,
T. Fujiwara, M. Mori, Y. Furukawa, Effect of exogenous
E2F-1 on the expression of common chromosome fragile site
genes, FHIT and WWOX, Biochem Biophys Res Commun
316 (2004) 1088–1093.
[80] J. Bartkova, Z. Horejsi, K. Koed, A. Kramer, F. Tort,
K. Zieger, et al., DNA damage response as a candidate anti-
cancer barrier in early human tumorigenesis, Nature 434
(2005) 864–870.
[81] V.G. Gorgoulis, L.V. Vassiliou, P. Karakaidos, P. Zacharatos,
A. Kotsinas, T. Liloglou, et al., Activation of the DNA damage
checkpoint and genomic instability in human precancerous
lesions, Nature 434 (2005) 907–913.
[82] J. Fang, M. Arlt, A. Burgess, S. Dagenais, D. Beer, T. Glover,
Translocation breakpoints in FHIT and FRA3B in both
homologs of chromosome 3 in an esophageal adenocarcinoma,
Genes Chromosomes Cancer 30 (2001) 292–298.
[83] T. Glover, J. Coyle-Morris, F. Li, R. Brown, C. Berger,
R. Gemmill, F. Hecht, Translocation t(3;8)(p14.2;q24.1) in
renal cell carcinoma affects expression of the common fragile
site at 3p14(FRA3B) in lymphocytes, Cancer Genet Cytogenet
31 (1988) 69–73.
[84] K. Mimori, T. Druck, H. Inoue, H. Alder, L. Berk, M. Mori,
et al., Cancer-specific chromosome alterations in the con-
stitutive fragile region FRA3B, Proc Natl Acad Sci USA 96
(1999) 7456–7461.
[85] S.R. Denison, F. Wang, N.A. Becker, B. Schule, N. Kock,
L.A. Phillips, et al., Alterations in the common fragile site
gene Parkin in ovarian and other cancers, Oncogene 22 (2003)
8370–8378.
[86] S.R. Denison, G. Callahan, N.A. Becker, L.A. Phillips,
D.I. Smith, Characterization of FRA6E and its potential role
in autosomal recessive juvenile parkinsonism and ovarian
cancer, Genes Chromosomes Cancer 38 (2003) 40–52.
[87] F. Wang, S. Denison, J.P. Lai, L.A. Philips, D. Montoya,
N. Kock, et al., Parkin gene alterations in hepatocellular
carcinoma, Genes Chromosomes Cancer 40 (2004) 85–96.
[88] M.C. Picchio, E.S. Martin, R. Cesari, G.A. Calin,
S. Yendamuri, T. Kuroki, et al., Alterations of the tumor
suppressor gene Parkin in non-small cell lung cancer, Clin
Cancer Res 10 (2004) 2720–2724.
[89] R. Cesari, E.S. Martin, G.A. Calin, F. Pentimalli, R. Bichi,
H. McAdams, et al., Parkin, a gene implicated in autosomal
recessive juvenile parkinsonism, is a candidate tumor
suppressor gene on chromosome 6q25-q27, Proc Natl Acad
Sci USA 100 (2003) 5956–5961.
[90] O. Bluteau, J.C. Beaudoin, P. Pasturaud, J. Belghiti,
D. Franco, P. Bioulac-Sage, et al., Specific association
between alcohol intake, high grade of differentiation and
4q34-q35 deletions in hepatocellular carcinomas identified
by high resolution allelotyping, Oncogene 21 (2002)
1225–1232.
[91] K.O. Robinson, A.M. Petersen, S.N. Morrison, C.M. Elso,
L. Stubbs, Two reciprocal translocations provide new clues to
the high mutability of the Grid2 locus, Mamm Genome 16
(2005) 32–40.
[92] H. Huang, J. Qian, J. Proffit, K. Wilber, R. Jenkins, D.I. Smith,
FRA7G extends over a broad region: coincidence of human
endogenous retroviral sequences (HERV-H) and small
polydispersed circular DNAs (spcDNA) and fragile sites,
Oncogene 16 (1998) 2311–2319.
[93] C. Tatarelli, A. Linnenbach, K. Mimori, C.M. Croce,
Characterization of the human TESTIN gene localized in the
FRA7G region at 7q31.2, Genomics 68 (2000) 1–12.
[94] M.Z. Limongi, F. Pelliccia, A. Rocchi, Characterization of the
human common fragile site FRA2G, Genomics 81 (2003)
93–97.
[95] G. Callahan, S.R. Denison, L.A. Phillips, V. Shridhar,
D.I. Smith, Characterization of the common fragile site
FRA9E and its potential role in ovarian cancer, Oncogene
22 (2003) 590–601.
[96] C. Morelli, E. Karayianni, C. Magnanini, A.J. Mungall,
E. Thorland, M. Negrini, et al., Cloning and characterization
of the common fragile site FRA6F harboring a replicative
senescence gene and frequently deleted in human tumors,
Oncogene 21 (2002) 7266–7276.
L.V. O’Keefe, R.I. Richards / Cancer Letters xx (2005) 1–11 11





WWOX, the chromosomal fragile site FRA16D spanning gene: Its
role in metabolism and contribution to cancer
Robert I Richards, Amanda Choo, Cheng Shoou Lee, Sonia Dayan and Louise O’Keefe
Discipline of Genetics and Centre for Molecular Pathology, School of Molecular and Biomedical Sciences, The University of Adelaide,
Adelaide, SA 5000, Australia
Corresponding author: Robert I Richards. Email: robert.richards@adelaide.edu.au
Abstract
The WWOX gene spans the common chromosomal fragile site FRA16D that is located within a massive (780 kb) intron. The WWOX
gene is very long, at 1.1 Mb, which may contribute to the very low abundance of the full-length 1.4 kb mRNA. Alternative splicing
also accounts for a variety of aberrant transcripts, most of which are devoid of C-terminal sequences required for WWOX to act as
an oxidoreductase. The mouse WWOX gene also spans a chromosomal fragile site implying some sort of functional relationship
that confers a selective advantage. The encoded protein domains of WWOX are conserved through evolution (between humans
and Drosophila melanogaster) and include WW domains, an NAD -binding site, short-chain dehydrogenase/reductase enzyme
and nuclear compartmentalization signals. This homology has enabled functional analyses in D. melanogaster that demonstrate
roles for WWOX in reactive oxygen species regulation and metabolism. Indeed the human WWOX gene is also responsive to
altered metabolism. Cancer cells typically exhibit altered metabolism (Warburg effect). Many cancers exhibit FRA16D DNA
instability that results in aberrant WWOX expression and is associated with poor prognosis for these cancers. It is therefore
thought that aberrant WWOX expression contributes to the altered metabolism in cancer. In addition, others have found that a
specific (low-expression) allele of WWOX genotype contributes to cancer predisposition.
Keywords: Chromosomal fragile site, FRA16D, oxidoreductase, altered metabolism
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Introduction
WWOX gene spans the common chromosomal
fragile site, FRA16D
Chromosomal fragile sites are enigmatic regions of human
chromosomes that are of particular interest because of their
contribution to human disease (Figure 1). Fragile sites are
distinguished by their frequency – rare fragile sites are
found in only a minority of the population and are inher-
ited, while common fragile sites are found in all individuals.
Common fragile sites are also distinguished by the chem-
icals that cause their cytogenetic appearance. The inducing
chemicals include agents typically found in the diet (e.g.
folate, caffeine, and ethanol1,2), as well as in the environ-
ment (e.g. chemicals in cigarette smoke3). The major group
of rare fragile sites are induced by folic acid, while the
majority of common fragile sites are induced in vitro by
aphidicolin, an inhibitor of DNA polymerase. It is this
group of common, aphidicolin-inducible fragile sites that
are associated with stress during replication and conse-
quent DNA instability. Common fragile sites are also note-
worthy because of their frequent colocation with regions of
chromosomal instability in cancer.1,44 There is a hierarchy in
the cytogenetic appearance of fragile sites in vitro in
response to chemical induction and that is matched by
their DNA instability observed in vivo in various cancers –
indicating a direct relationship between cytogenetic appear-
ance and DNA breakage in cancer. This DNA instability
appears to be an early event in carcinogenesis occurring
as a result of exposure to environmental agents such as
the chemicals in cigarette smoke.3 The two fragile sites,
FRA3B and FRA16D, that are the most readily induced
in vitro are also those that most frequently exhibit DNA
instability in vivo in cancer.2,4,5 Common fragile sites and
the genes in their vicinity that are affected by their DNA
instability in cancer are therefore of interest for their causal
contribution to neoplasia.
WWOX is a protein encoded by a common fragile site
gene (Figure 2). The WWOX gene spans FRA16D that is
located within a very large, 780 kb intron of this alterna-
tively spliced, massive gene of 1.1 Mb in length.4,45 The
time taken for transcription of such a length of DNA
makes it likely that just one or a few full-length spliced
transcripts are produced per cell cycle. As has been found
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for several common fragile site genes, the relationship
between the WWOX gene and a common fragile site is con-
served between mouse and human, implying a functional
relationship with a selective advantage of some sort. The
alternative splicing of the WWOX gene transcript leads to
an abundance of aberrant transcripts incapable of encoding
the full-length WWOX protein.4 While these appear to be
the subject of nonsense-mediated decay, some truncated
proteins are produced that may act as dominant negative
competitors for the full-length protein.7 Some of these alter-
native splice RNA products are conserved between mouse
and human, also implying functional significance.
A genetic variant of the WWOX locus, that has lower
levels of WWOX, has been found to be associated with
cancer predisposition. Specifically, carriers of loss variant
(CNV-67048) genotypes have been found to have signifi-
cantly increased risk of lung cancer, in a dose-dependant
manner.8 Recently, a similar association has been found
between the CNV-67048 genetic variant and risk of gliomas.9
Characteristics of the WWOX protein sequence
The WWOX protein itself comprises multiple distinct func-
tional domains as well as sequences encoding a small chain
dehydrogenase/reductase (SDR) enzyme. Phylogenetic
analysis (Figure 3) of the WWOX amino acid sequence indi-
cates evolutionary conservation of WWOX as a discrete
ortholog, from species as diverse as humans and insects.10
The functionally important sequences in WWOX, including
the WW domains and the SDR enzyme sequences, are evi-
dent as more highly conserved regions of the WWOX
sequence (Figure 4). SDR enzymes typically have their spe-
cific substrate-binding sequences located C-terminal to the
catalytic region. The WWOX orthologs exhibit sequence
homology in this WWOX-specific domain that is as high
as that for the enzyme co-factor and catalytic regions, con-
sistent with these sequences being the region where WWOXFigure 2 Summary box 2 – WWOX in cancer initiation and progression
Figure 1 Summary box 1 – common chromosomal fragile sites and their
genes.43
Figure 3 Phylogenetic tree of WWOX orthologs from various species and other oxidoreductases in Drosophila melanogaster. Distinct sequence relationships through
evolution of WWOX orthologs in various species are evident when compared to other oxidoreductases (in this case from Drosophila). Note: all species have a single
WWOX ortholog except Caenorhabditis elegans with two, neither of which has WW domains. Figure modified from that of O’Keefe et al.10
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binds to its specific (as yet unknown) substrate. Each of the
SDR enzymes contains an nicotinamide adenine dinucleo-
tide (oxidized form) (NADþ)/nicotinamide adenine dinu-
cleotide phosphate (NADPþ) co-factor-binding site as well
as characteristic sequences required for the catalytic active
site. The in vivo substrate and reaction product for the SDR
enzyme activity of WWOX are unknown, although several
in vitro targets have been identified11 and ablation of
WWOX in mice leads to impaired steroidogenesis.12
Steroids are therefore likely suspects although impaired
steroidogenesis is not evident in the Drosophila melanogaster
WWOX mutants.
It is noteworthy that the closest organism that does not
have a complete WWOX ortholog, Caenorhabditis elegans,
has two genes with homology to WWOX but both are
devoid of the two N-terminal WW domains (Figure 3).
However, both have sequence homology to the putative
‘‘WWOX substrate binding region,’’ suggesting that these
enzymes act on the same substrate/substrates and that this
is independent of the WW domain interactions seen in, and
presumably needed for, WWOX activity in other species.
The link between the WWOX substrate binding domain
and SDR enzyme function appears evident in Opisthokonts
(Casaspora owczarzaki) and C. elegans orthologs not having
WW domains but sharing substrate-binding domain hom-
ology. The addition of WW domains to WWOX is an ancient
event, albeit of unknown biological significance, with the sea
sponge (Amphimedon queenslandica) WWOX protein having
both WW domains and all other WWOX domains, including
substrate-binding domain homology (not shown).
WW domains are known to act as protein–protein recog-
nition and binding domains, pairing up with proteins
through proline-containing motifs (PPXY or similar). WW-
mediated protein interactions are thought to be a physical
mechanism that causes a functional relationship between
the partner proteins. The identity of the WW-binding
motif partners of WWOX has therefore been sought in
order to gain insight into the function of WWOX. WW
domains have been classified into subgroups with specifi-
city in their interacting motifs, e.g. the WW1 motif of
WWOX is expected to interact with PPXY or LPXY motifs.
Mass spectrometry and phage display techniques have
been used in an effort to identify the specific PPXY-contain-
ing WWOX-interacting proteins.13 This analysis revealed
that the WW1 domain of WWOX is capable of binding to
many different proteins, although the significance of most
of these interactions to the function of WWOX is yet to be
determined.
Figure 4 Homology between orthologs WWOX protein sequences. Alignment of WWOX protein sequences from human, chicken, Drosophila melanogaster, zeb-
rafish, and mouse. Majority sequence is indicated with color coding for identity between 6, 5, 4, 3, and 2 sequences. The two WW domains are indicated by blue
shading. Sequences comprising the SDR enzyme are indicated by red shading, and the putative ‘‘WWOX substrate binding site’’ is shaded in green. (A color version of
this figure is available in the online journal.)
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In addition to the WW domains, the WWOX protein con-
tains compartmentalization signals for localization to the
nucleus and the mitochondria, although the latter is not
well defined.14,15 The SDR-related sequences define
WWOX as a member of this family of enzymes. These
enzymes are NAD(P)(H)-dependent oxidoreductases that
catalyze diverse small molecule reactions including those
involving lipids, amino acids, carbohydrate, and steroids.16
NAD(P)(H) binding is not only for the role of this co-factor
in catalysis but also as a means for SDR enzymes to act as
metabolic sensors of NADþ/nicotinamide adenine dinu-
cleotide (reduced form) (NADH)/NADPþ/NADP levels
and in so doing contribute to the regulation of metabolism,
transcription, and signal transduction. The typical small
molecule substrates and products of SDRs contribute to
their designation as a ‘‘druggable’’ enzyme class, suitable
for targeting with potential pharmaceuticals.
WWOX is able to act as a ‘‘non-classical’’ tumor
suppressor
When cancer cells exhibit DNA instability at the FRA16D
site, this is typically associated with a reduction in full-
length WWOX mRNA and an increase in either normal
incomplete splice forms and/or the appearance of novel
aberrant transcripts. While the resultant cancer cells there-
fore have lower levels of WWOX, they do not exhibit second
allele loss typical of Knudsen’s two-hit hypothesis and
therefore retain some level of WWOX protein. Even so the
transfer of intact WWOX gene back into tumor cells that are
deficient in this protein, does reduce the ability of these
WWOX-replenished cells to form tumours6 and therefore
WWOX is regarded as a tumor suppressor, albeit a ‘‘non-
classical’’ one – i.e. a reduction in WWOX level, rather than
its absence, appears sufficient for its functional contribution
to cancer. The mechanism by which WWOX might act in
this capacity is unclear although some possibilities have
been put forward on the basis of the proteins with
which WWOX physically interacts. For example, the WW
domains of WWOX may serve as negatively regulating,
competitor-binding sites for proteins such as ErbB-4,
thereby competing with these proteins for their ability to
physically and functionally interact with other WW
domain-containing proteins, in particular yes-associated
protein (YAP).17 Reduction in WWOX levels below a thresh-
old may therefore facilitate the activation by YAP of tumor-
promoting pathways mediated by ErbB-4 and perhaps
other proteins.
Consistent with its role as a tumor suppressor, patients
with tumors who exhibit diminished levels of WWOX, have
a poorer prognosis than those with normal levels of the
protein. Nunez et al.18 reported that WWOX protein expres-
sion varies among ovarian carcinoma histotypes and correl-
ates with less-favorable outcome. In addition, Pluciennik
et al.19 found that WWOX expression correlated with
breast cancer progression and prognosis. Furthermore,
Aqeilan et al.20 and Wang et al.21 reported the prognostic
significance of WWOX expression levels in patients with
breast cancer and its association with the basal-like pheno-
type. The reduction in WWOX levels, by DNA instability at
one allele, appears to be sufficient to enable a functional
contribution of some sort to cancer cell biology. The
normal biological function of WWOX is therefore of par-
ticular interest as it represents a target for improving the
prospects of individuals with WWOX deficient cancers.
FRA16D/WWOX damage is an early event
in a population of precancerous cells
A clear illustration of the mechanism through which envir-
onmental factors are thought to trigger cancer through
effects on common fragile sites, is the contribution of cigar-
ette smoke to fragile site DNA instability in lung cancer.3
Much greater levels of cytogenetic fragile site expression are
well documented in the ‘‘normal’’ cells of young cigarette
smokers, well before the onset of lung cancer.22 There is a
direct correlation between in vitro-induced cytogenetic fra-
gile site expression and DNA instability observed as a con-
sequence of events in vivo.2,23 The influence of tobacco
smoke chemical exposure on fragile site expression is fol-
lowed by chromosome breakage and/or rearrangement
that, in turn, contributes to carcinogenesis. The deleterious
‘‘hit’’ related to small cell lung cancer may occur at any time
during tobacco exposure, but, given that carcinogenesis is a
stepwise process, the actual tumor may not arise for several
years after the individual stops smoking.3 Such ‘‘fragile site
damaged’’ cells will not exist in isolation but as a popula-
tion of similarly ‘‘damaged’’ cells. Cigarette smoke chem-
icals preferentially affect the most readily induced common
fragile sites (FRA3B and FRA16D) and, therefore, common
fragile site genes (FHIT and WWOX). Any one of these
FRA16D/WWOX damaged cells has the potential to act as
a cancer stem cell (CSC), particularly after additional
damage in genes that also contribute to cancer initiation.
We have found that common fragile site damage at
FRA16D is an early event in cancer cell progression.23
Two cancer cell lines developed from a primary carcinoma
(KM12C) and secondary metastasis (KM12SM) have iden-
tical FRA16D deletions despite having drastic differences in
their karyotype.
The normal biological function/functions of WWOX
The biological function of WWOX has been explored by
genetic approaches, both by targeted mutagenesis and by
the identification and characterization of spontaneous
WWOX mutations in a rat, and more recently, in humans.
A ‘‘non-classical’’ tumor suppressor function for WWOX is
evident in the analysis of rodent mutants for the WWOX
gene. Some (but not all) lines of loss-of-function WWOX
mutant mice have higher incidence of tumors, however
tumors from heterozygous mutant mice still express
WWOX.24–27 A spontaneous WWOX mutant rat does not
exhibit higher incidence of tumors.28,29 Rodent WWOX
mutants typically exhibit metabolic disorders leading to
early death (which may preclude development of some
tumors) limiting the utility of rodent models in understand-
ing WWOX protein function.24–29 While these rodent stu-
dies have provided some insight into the biological role for
WWOX, there is still clearly a need to understand the
molecular processes and pathways in which WWOX
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participates; particularly how WWOX contributes to metab-
olism and how this altered metabolism can contribute, at
least in certain circumstances, to cancer.
Three reports detail clinical consequences in humans
due to inherited mutations in WWOX. The first of these30
involves a disorder of sex development due to a deletion, in
one allele of the WWOX gene, removing exons 6–8, with
exon 5 being spliced on to exon 9. The resultant encoded
protein would have intact WW domains, but absence of the
SDR catalytic domain. Only one allele is affected and is
therefore acting in a dominant manner. While haploinsuffi-
ciency is possible, another explanation is that the mutant
WWOX-truncated protein is acting in a dominant negative
manner. Two recent reports31,32 detail recessive epilepsy
and other symptoms due to loss of function mutations in
both alleles of the WWOX gene. Three different homozy-
gous WWOX mutations were identified in three consan-
guineous families. The neurological symptoms in each of
the affected individuals are similar to those observed for the
spontaneous rat WWOX mutation indicating likely
common pathogenic pathway for these symptoms. The
human and rat WWOX mutations also share a lack of
noted increase in spontaneous tumours28,29,31,32 as has
been reported for mouse WWOX mutations.24–27
Insights into the role of WWOX in metabolism
Given the phenotypic consequences of homozygous loss-of-
function WWOX mutations in mammals, it is somewhat
surprising that loss-of-function WWOX mutations in the
D. melanogaster ortholog of WWOX do not exhibit a pheno-
type.33 The D. melanogaster ortholog has 49% amino acid
sequence identity with its human counterpart, with all of
the functional domains and SDR enzyme-related sequences
retained (Figures 3 and 4). The function of WWOX protein
in D. melanogaster has become evident from the conduct of
genetic and biochemical analyses in WWOX-deficient flies.
Microarray and proteomic experiments identified quantita-
tive and qualitative changes in other proteins consistent
with a role for WWOX in metabolism. An advantage of
the D. melanogaster system is the ability to undertake genetic
analyses of function and this revealed a role for WWOX in
pathways that included the proteins superoxide dismutase
(SOD1) and isocitrate dehydrogenase (IDH).33 SOD1 has a
role in the control of reactive oxygen species (ROS) in cells,
while IDH is an integral component of the citric acid cycle.
Both the viability and life span of SOD1 mutant D. melano-
gaster were impacted by altered WWOX levels, while both
D. melanogaster and human cancer cells showed a correl-
ation between SOD1 and WWOX mRNA levels.33
Reducing IDH levels in D. melanogaster impacts on viability
and this impact is exacerbated by also reducing WWOX
levels and relieved by increasing WWOX levels.33
Furthermore, WWOX and IDH mRNA levels correlate in
cancer cells.33 Roles for WWOX in regulation of ROS and
metabolism are both intriguing, in terms of the possible
mechanism of WWOX contributing to cancer. ROS levels
are lower in at least certain types of CSCs than correspond-
ing nontumourigenic cells.34 These lower ROS levels in
CSCs are associated with increased free radical scavenging
and decreased sensitivity to ionizing radiation. In this set-
ting, the lower level of ROS brought about by reduced
WWOX could therefore contribute to tumor radioresis-
tance, and therefore poorer prognosis for patients with
WWOX-depleted cancers.
Altered cellular metabolism in cancer cells was first dis-
covered over 80 years ago by Warburg,35 but has only
recently been added to the list of recognized hallmarks of
cancer.36 Warburg revealed that cancer cells favor adeno-
sine triphosphate (ATP) production via rapid consumption
of glucose and formation of lactic acid rather than via the
more efficient mitochondrial respiration, even when
oxygen is available.35 There are clear instances of altered
metabolism playing causal roles in the development of
cancer e.g. mitochondrial DNA mutations in cancers of
the head and neck37 and the recent finding of very specific
leukemia-associated IDH1 and IDH2 mutations lead to neo-
morphic enzyme activity, converting alpha-ketoglutarate to
the ‘‘oncometabolite’’ 2-hydroxyglutarate.38 Although this
change in metabolism has been exploited in the develop-
ment of drugs for cancer therapy,39 until very recently, it has
been unclear what causal cellular changes bring about this
phenotype. Therefore with few exceptions, therapeutics
have not yet specifically targeted the causal changes in
cancer cells that are responsible for altered cellular metab-
olism. There is, however, growing recognition that because
of this distinction between normal and cancer cells, altered
metabolism has the potential for such exploitation.40,41 Thus
the molecular cause/causes of altered metabolism in cancer
cells need/needs to be defined in order to enable the iden-
tification of therapeutic leads.
WWOX not only contributes to metabolic regulation, its
expression is also responsive to changes in metabolism.42
Altering metabolism from glycolysis to oxidative phosphor-
ylation causes an increase in the steady-state levels of
WWOX mRNA, whereas hypoxic conditions, in which
cells rely on glycolysis, cause a decrease in WWOX
mRNA. Both the WWOX gene and its encoded protein are
therefore monitors of and contributors to the metabolic state
of cells.
Perturbation of WWOX in cancer cells is therefore a clear
candidate for contributing to the altered metabolism
(Warburg effect35) seen in these cells and associated with
poor prognosis, and therefore an ideal target for therapeutic
intervention.
Conclusions/future directions
The presence of a distinct WWOX protein, in species as
diverse and distant in evolution as sea sponge and
humans, would suggest that it serves a fundamental func-
tion in biology. Indeed the protein has normal roles in
metabolism. The level of WWOX protein is affected by
DNA instability within its gene in human cancers.
Reduced WWOX level appears to facilitate cancer progres-
sion, rather than act as a classical tumor suppressor. Lower
levels of WWOX, due to genetic variation, contribute to the
risk of carriers to increased cancer incidence. Lower levels
of WWOX in cancers correlate with poorer prognosis.
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Clearly in both cases, mutations in other genes are required
to both initiate and establish cancer.
The altered metabolism of cancer cells is an intriguing
possibility for the contribution of WWOX to cancer cell biol-
ogy. Identifying the role of WWOX in metabolism and tar-
geting this role in cancers found to be deficient in WWOX
may lead to better therapeutic interventions.
The WW domains of WWOX have been the focus of
attention as the identity of their partner proteins can give
insight into the pathways to which WWOX contributes.
However, the role of WWOX in metabolism is more likely
to be mediated by the enzyme function of WWOX, as SDR
enzymes are known monitors of NADþ/NADPþ through
their co-factor binding sites.16 Indeed the C. elegans ortho-
logs of WWOX do not contain WW domains. The substrate
and product of WWOX are therefore of particular interest.
Protein homology searches indicate that the likely ‘‘sub-
strate-binding domain’’ indicated by amino acid sequence
homology C-terminal to the enzyme catalytic site (Figure 4)
appears to be unique to WWOX orthologs (including those
of C. elegans) and therefore likely to have a unique substrate.
Either the accumulation of substrate or the reduced level of
product of the WWOX enzyme, present potential targets to
compensate for the contribution that lower WWOX levels,
which lead to increased cancer risk and/or poorer cancer
prognosis.
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Chapter 5. ‘Dynamic’ Mutations:  
  Rare Chromosomal Fragile Sites, Mechanism of Repeat Expansion   
 




  In addition to contributing to the Human Genome Project another reason why I was 
attracted to working at the Adelaide Children’s Hospital was because of the work that Grant 
Sutherland and Liz Baker had previously done on Fragile X Syndrome.  This project involved 
the positional cloning of the mutation causing this disease based on its physical location on a 
chromosome (rather than its genetic position).  I was responsible for oversight and conduct of 
the Molecular Genetics component of this mainly ‘internal’ collaboration.  Liz Baker and her 
colleagues in the Cytogenetics Unit conducted the cytogenetics (fluorescence in situ 
hybridisation) component of the project. In 1991 this research resulted in the identification of 
an expanded CGG repeat as the mutation causing of Fragile X Syndrome. This work was the 
subject of two publications in the journal Science (refs #58, 60). Subsequently a series of 
publications ensued reporting the various properties of the unstable repeat and how they 
account for the unusual genetics of this disease (refs #63 – 67).  Coupled with similar findings 
for other diseases caused by expanded repeats, I coined the term ‘Dynamic Mutation’ in order 
to distinguish this form of mutation from other (static) mutations (refs #84, 86, 91, 95). This 
term is now in wide usage in Genetics, including in textbooks and an encyclopedia. 
 
 I then conducted a comparative analysis of different chromosomal fragile sites in order to 
identify their common and distinguishing features and relate these to their biological 
properties.  Folate sensitive rare fragile sites were found to all be due to expanded CGG 
repeats (irrespective of whether they were located on the X-chromosome) and were not 
normal sites of DNA imprinting. The work by PhD student Julie Nancarrow on FRA16A was 
published in the journal Science (ref #68). Work on the FRA11B folate sensitive fragile site 
was a collaboration with Chris Jones and colleagues in the UK and succeeded in 
demonstrating for the first time that chromosomes could break in vivo at fragile site loci and 
that this breakage could be responsible for a proportion of cases of a chromosomal breakage 
disorder – in this case Jacobsen Syndrome. This work was published in the journal Nature (ref 
#72).  Other non-folate sensitive rare chromosomal fragile sites FRA10B and FRA16B were 
found to be also due to expanded DNA repeats, but of considerably greater length and AT-rich 
composition (possibly accounting for their distinct induction chemistry). This work was 
published in the journals Molecular Cell and Cell, respectively (refs #74, 76). 
 
 While the identification of expanded repeats has lead to definitive diagnostic tests for their 
respective diseases, there has been a low uptake of such tests by at-risk, pre-symptomatic 
individuals in affected families for certain of these diseases (e.g. Huntington’s Disease) 
because nothing can be done for individuals with a positive test result. For this reason, I 
moved MY lab to the University of Adelaide in 2001 for the specific purpose of utilizing the 
model organisms Drosophila and zebrafish to both model and genetically dissect the 
molecular pathways from the expanded repeat mutation to the clinical symptoms of these 
diseases.  These studies have enabled the testing of various hypotheses including the role of 
RNA in the pathogenic process for the dominantly inherited neurodegenerative diseases.  
They have also enabled the analysis of the normal function of the genes responsible for these 
diseases with a view to understanding how the perturbation of these normal roles might 
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Fragile X Syndrome: Diagnosis Using Highly Polymorphic
Microsatellite Markers
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Summary
We describe two highly polymorphic microsatellite AC repeat sequences, VK23AC and VK14AC, which are
closely linked to the fragile X at Xq27.3. Both VK23AC (DXS297) and VK14AC (DXS292) are proximal
to the fragile site. Two-point linkage analysis in 31 fragile X families gave (a) a recombination frequency of
1% (range 0.00%-4%) with a maximum lod score of 32.04 for DXS297 and (b) a recombination frequency
of 7% (range of 3%-15%) with a maximum lod score of 12.87 for DXS292. Both of these polymorphisms
are applicable to diagnosis by linkage in families with fragile X syndrome. A multipoint linkage map of
genetic markers at Xq27.3 was constructed from genotyping these polymorphisms in the CEPH pedigrees.
The DXS292 marker is in the DXS98-DXS297 interval and is 3 cM proximal to DXS297.
Introduction
The rare fragile site at Xq27.3 (FRAXA) is associated
with the most common familial form of mental retar-
dation (Sutherland and Hecht 1985). Prenatal diagno-
sis and carrier detection can be performed cytogeneti-
cally; however, incomplete penetrance of the fragile
site renders this technology, in isolation, inaccurate.
Diagnosis for individuals who do not express the frag-
ile site therefore relies on polymorphic DNA markers
closely linked to it (Sutherland and Mulley 1990).
The majority of DNA polymorphisms currently
used for risk estimation are detected by Southern blot
analysis of RFLPs (Suthers et al. 1991a). These mark-
ers are less common on the X than on the autosomes
(Hofker et al. 1986), and laboratory analysis is labor
intensive. In addition, the majority have only two al-
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leles and therefore a maximum heterozygosity -and,
in the case of X-linked markers, PIC-of 50%.
Recently, two laboratories have described polymor-
phisms associated with length variation in dinucleo-
tide microsatellite repeats (Litt and Luty 1989; Weber
and May 1989). These polymorphisms can be rapidly
typed and are usually highly informative (compared
with RFLPs). They are quite common; there are about
50,000 copies of the (AC)n repeat in the mammalian
genome-i.e., approximately one every 50 kbp, if one
assumes uniform distribution.
We have screened cloned DNA from the vicinity of
Xq27.3 for dinucleotide microsatellite sequences to
identify polymorphisms useful for linkage analysis
near FRAXA. The established physical order for
markers proximal to FRAXA is DXS98 (4D-8)-
DXS292 (VK14)-DXS369(RN1 )-DXS297(VK23 )-
FRAXA (Suthers et al. 1990). Two polymorphisms,
VK23AC and VK14AC, are described, together with
both their genetic mapping in the Centre d'Etude du
Polymorphisme Humain (CEPH) pedigrees and the
results of their application to 31 fragile X syndrome
pedigrees.
Material and Methods




tively labeled with alpha-32P-dCTP in a random-
primed reaction (Multiprime; Amersham). AC re-
peat-containing DNA sequences were identified by
hybridization to this probe in 0.5 M sodium phos-
phate pH 7.0,7% SDS (without carrier DNA) at 65 0C
for 16 h and by washing at 650C for 1 h in 2 x SSC.
Clones tested constituted the VK series which had
been mapped to Xq26-qter (Hyland et al. 1989).
DNA from positive lambda clones was digested
with Sau3A and was subcloned into BamHI-cut M13
mpl 8 for sequence analysis. Synthetic oligodeoxyri-
bonucleotide primers suitable for PCR were designed
from apparently unique sequences flanking the micro-
satellite AC repeats. Length polymorphism of the AC
repeats was typed in a PCR using the reaction condi-
tions of Kogan et al. (1987), except for the addition
of the 1 pCi of alpha-32P-dCTP to each reaction. These
PCR conditions were used because they have been suc-
cessfully applied to multiplex PCR (Chamberlain et
al. 1988, Richards et al., submitted).
PCR incubations were performed in 10-gl volumes
in a Perkin Elmer-Cetus thermal cycler for 10 cycles
at 940C for 60 s, at 600C for 90 s, and at 721C for
90 s, followed by 25 cycles at 941C for 60 s, at 551C
for 90 s, and at 72° C for 90 s. The volume was ad-
justed to 40 pl with formamide loading buffer (95%
formamide, 1 mM EDTA, 0.01% bromophenol blue,
0.01 % xylene cyanol). After denaturation at 900C for
3 min, 2.5-pl aliquots of each reaction mixture were
subjected to electrophoresis in 6% polyacrylamide de-
naturing (7 M urea) gels. Genotypes were determined
after autoradiography for 18-48 h.
Linkage analysis were based on 31 kindreds. Five
small kindreds with isolated cases of fragile X were
excluded from the analysis because of uncertainty
about relative mutation rates in males and females.
Parameters used were as given elsewhere (Suthers et
al. 1991a), except for allele frequencies of the marker
loci, VK23AC and VK14AC, frequencies which were
determined from unrelated individuals in the informa-
tive fragile X families and are given in table 1.
Modification of the phenotypic coding of family
members was made in those cases in which closely
linked flanking markers clearly indicated carrier status
different from that determined by the conventional
definition of phenotype. In previous studies the pheno-
type has been defined only by cytogenetic expression
of the fragile X and by mental retardation. Now that
there are many markers closely linked on either side
of FRAXA (Suthers et al. 1991a), the definition of
phenotype for the purposes of the present study was
Table I
Alleles, Allele Frequency, and Heterozygosity for
VK23AC and VK14AC In Fragile X Pedigrees
No. of
Marker and Allele Chromosomes Frequency Heterozygosity
VK23AC: 65 (60) .74 (.67)
+4 .......... .00 (.02)
+2 .......... .08 (.03)
0 .......... .34 (.53)
-2 .......... .32 (.13)
-4 .......... .11 (.17)
-6 .......... .15 (.12)
-12 .......... .00 (.02)
VK14AC: 44 (60) .53 (.58)
+ 6 ......... .00 (.02)
+4 ......... .00 (.05)
+2 ......... .02 (.13)
0 ......... .64 (.62)
-2 ......... .23 (.08)
-4 ......... .11 (.10)
NOTE. -Data in parentheses refer to CEPH pedigrees.
extended to include the genotypes of closely linked
surrounding markers. If a cytogenetically negative
nonretarded individual has marker alleles both proxi-
mal and distal to FRAXA, clearly demonstrating that
the individual carries the fragile X chromosome (if the
possibility of double crossover is disregarded), then
that individual will contribute more information to a
linkage analysis if he or she is coded as a carrier than if
he or she is coded as unaffected in a defined penetrance
class. Conversely, if it could be demonstrated that
such an individual does not carry the fragile X chromo-
some (if the possibility of double crossover is disre-
garded), then that individual also will contribute more
information to a linkage analysis if he or she could be
coded as a definite noncarrier. Determination of such
carrier status by DNA markers does not rely on map
distances estimated in the present study by using
VK23AC and VK14AC. The genetic map distances
on which carrier status is based were previously estab-
lished in an independent analysis of linkage data (Suth-
ers et al. 1991a). For the present study, first the un-
affected individuals of either sex were coded as if they
were affected, when closely linked informative mark-
ers flanking the fragile X demonstrated that they were
carriers. Second, a penetrance class of 100% was as-
signed to unaffected individuals of either sex in whom
closely linked informative markers flanking the fragile
X demonstrated that they were not carriers. This both
removed the option, available under incomplete pene-
1052
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VK 14 AC
V K 14 F
GATCANNNNC TCATACCATA CTGTATGATG ATTTTGTTTC CTG'I'GNAAAT GGAATGCTTT
ATATGTGTGT GTGTGTGTGT GTGTGTGTGT GTGTGTGTGT ACAIAGACAC (;TATGCAGTG
<--- VK14R 100
CTATGCAGGA GCTAGTTCTT AATT(TTCAT GACACAT(C1' TI(IA'IT1I('1' CTAACT(TAC
ATTCATATTG GTAGCTTGAG ACTGGCCATG TTGAGAAIAC A1ITA X1A 1AlTATAI XCIA
200
TGAAGATCGC AGGTGAAAT1' C(CAGTATTC GTCCACG(;GC TCCC('TC'I'C
VK18AC
VK18F --->
GATCACCCTC TCATATCCGT GAAATCTGAC TGCTGACGCA TAAACACACA GCATTCACAC
_VK18R




GATCGCACCC GCAAGCCCCCC TGAACATGGG GATCTTTCTG GAAGAAGAAG (;ACTAAGAC
VK23F --->
TGTAAATCTT CACTGGGTCT CCAGCCTCCT GACCCACCCT GCAGATTTTC CACTTCCCAA
100
GCCTCCACAA TAATGAAAAC TAATTTCTTA AAATGAAACA ATCTCTCTCT CTCTGTCTCT
GTCTCTCTCT CTCTCATGGG TGTGTGTGTG TGTGTGTGTC TGCTGTGTGTC TGTGTCTGTG
200 <--- VK23R
TATACTGTGG TTCTGATTTT CTAGAGAACT CTGACAAATA CACTGCACAG ACTCAGAAAT
300
GAGCAGACCA GCAGACCTGG GAACTAGTGC CCAGTG
VK37AC
GATCCAAGAT GTATATGTGT GTGTGCCTCT GTGTGTGTGT GTGCCTCTGC' (;TG'I'G1'GTGT
GCCTCTGTGT GTGTGTGTGT GTGTGTGTGT GTATGTGTAT GTTCAGAACA (;GGATC
100
Figure I AC/GT repeat sequences determined from VK14,
VK18, VK23, and VK37. Nucleotide sequences containing AC.GT
repeats from each of the markers near Xq27.3 are shown. Sequences
used to design primers for genotyping polymorphism of repeat
length are underlined. PCR products are shown in boldface.
trance, that they might carry the fragile X and allowed
full utilization of data from these individuals.
Twenty-seven and 14 of the 31 fragile X families
were at least partially informative for VK23AC and
VK14AC, respectively. One additional family was in-
formative for the VK23B HindIII RFLP but not for
VK23AC. The analysis of fragile X families was car-
ried out by using the LINKAGE (version 5.04) pack-
age of computer programs and incorporated the data
from the HindIlI RFLP of VK23B from the earlier
study of Suthers et al. (1991a). Confidence intervals
were obtained by the lod - 1 method (Conneally et al.
1985). Multipoint analysis was based on 40 normal
families from CEPH (Dausset et al. 1990). Analyses
of the CEPH families were carried out by using the
LINKAGE (version 4.9) package for use with CEPH
three-generation families.
Results
Identification of (AC.GT) in Repeats at Xq27.3
Nineteen human genomic DNA clones (lambda
VK7, 9-11, 14, 16-18, 21, 23-25, 29, 34, 37, 40,
41, 44, and 47) which map to the interval Xq26-qter
(Hyland et al. 1989) were screened for the presence of
AC-repeat microsatellite sequences, and nine of these
were positive. The four positive clones VK14, VK1 8,
VK23, and VK37, which physically map closest to
FRAXA (Suthers et al. 1990) were sequenced to deter-
mine both the length of AC repeats and the composi-
tion of unique flanking sequences. The relevant se-
quences from each of these regions are shown in figure
1, as are the location and sequences of PCR primers
designed from them to type the AC-repeat-length poly-
morphism. No primers could be designed from the
VK37 sequence, because of the close proximity be-
tween the Sau3AI cloning sites and the AC repeat.
Characterization of AC-Repeat Microsatellite Polymorphism
Primers were specifically designed at distances
sufficient to allow simultaneous typing of both
VK23AC and VK14AC. Twenty unrelated individu-
als were typed for length variation of the AC repeats
attheVK14, VK18, andVK23 loci. TheVK18 repeat
showed no polymorphism and was therefore not ana-
lyzed further. Both the VK14 and VK23 AC repeats
revealed length variation inherited in a Mendelian
fashion (fig. 2) in fragile X families and had heterozy-
gosities greater than 50% (table 1). Key carriers from
all available fragile X-linked mental retardation pedi-
grees were genotyped, and informative families were
completed. Heterozygosities for unrelated individuals
in the fragile X pedigrees were 53% VK14, and 74%
VK23, compared with the 58% VK14 and 67% VK23
for unrelated individuals from unaffected (CEPH)
pedigrees.
Two-Point Linkage Analysis
Genotypes of AC-repeat length at the DXS297 and
DXS292 loci were used to calculate genetic distance
from FRAXA (table 2). DXS292 was found to have a
peak lod score of 12.87 at a recombination fraction of
.07 (confidence interval .03-.15), and DXS297 had a
peak lod score of 32.04 at a recombination fraction of
.01 (confidence interval .00-.04).
The lod score for the FRAXA:DXS297 comparison
remains positive at a recombination fraction of zero,
despite the observation of a recombinant between
FRAXA and DXS297 in a definite carrier female. This
result presumably arises from the incorporation of
mutation into the analysis: there is a small chance
that the apparent "recombinant" is instead a second
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Figure 2 Genotype analysis of VK14AC and VK23AC repeats in a fragile X syndrome pedigree. Right, Fragile X syndrome pedigree
with DXS297 (AC) and DXS292 (AC) genotypes. E and ® = transmitter based on pedigree and/or DNA results; f and * = affected
individual with cytogenetically characterized fragile X; E = affected individual without cytogenetic analysis; ( ) = genotype inferred.
Carrier status was determined in conjunction with analysis of the distal flanking marker Stl4. Below, Autoradiograph of DXS297 (AC)
and DXS292 (AC) genotypes. Individuals in the affected pedigree are as follows: lane 1, II-1; lane 2, II-2; lane 3, IV-1; lane 4, IV-2; lane
5, 111-3; lane 6, III-4; lane 7, IV-3; lane 8, IV-4; lane 9, IV-5; lane 10, IV-6; lane 11, IV-7; lane 12, III-5; lane 13, 11-3; lane 14, 11-4; lane
15, III-6; lane 16, III-7; lane 17, III-8; lane 18, IV-8; lane 19, III-9; lane 20, II-5; lane 21, II-6; lane 22, III-11; lane 23, III-12; lane 24,
11-7; and lane 25, 11-8.
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Table 2
Two-Point Lod Scores for Fragile X Kindreds
MAXIMUM MAXIMUMLOD SCORE AT RECOMBINATION FRACTION OF MATION LODRECOMBINATION LOD
LINKAGE COMPARISON .0 .01 .05 .1 .2 .3 .4 FRACTION SCORE
FRAXA:DXS297.......... 31.45 32.04 30.36 27.73 21.38 14.35 6.91 .01 (.00-.04) 32.04
FRAXA:DXS292 .. 9.95 12.70 12.72 10.67 7.51 3.81 .07 (.03-.15) 12.87
DXS297:DXS292 ......... ... 7.82 11.57 12.06 10.48 7.52 3.85 .09 (.04-.17) 12.08
X. In contrast, the lod score for the FRAXA:DXS292
comparison approaches minus infinity at a recombina-
tion fraction of zero, because the two recombinants
involve unaffected individuals who have been diag-
nosed as carriers by closely linked flanking markers.
Recombination events within the DXS292-DXS297-
FRAXA linkage group were consistent with the estab-
lished order derived from physical mapping. Only one
recombination event was observed between DXS297
and FRAXA, in a female unambiguously expressing
the fragile X. Since recombination was observed be-
tween DXS292 and FRAXA in the same individual,
DXS297 and DXS292 are on the same side of FRAXA.
In other pedigrees, a noncarrier female and a male
transmitter (as determined by closely linked informa-
tive markers flanking FRAXA) demonstrated recom-
bination between DXS292 and FRAXA but not be-
tween DXS297 and FRAXA. Hence, of the two
markers, DXS297 is confirmed as being closer to
FRAXA. Two additional individuals, both carrier fe-
males, were recombinants between DXS292 and
FRAXA. They were uninformative for recombination
between DXS297 and FRAXA.
Figure 2 demonstrates Mendelian inheritance of
both AC-repeat polymorphisms. Some of the diffi-
culties in this large affected pedigree were resolved
through the analysis of the AC-repeat markers, which
were both partially informative. A recombinant be-
tween FRAXA and DXS292 was detected between
individuals 11-2 and III-2. Male transmitter status for
1-2 and 111-9 was based on informative flanking mark-
ers VK23AC and St14, and III-8 and IV-8 are likely
carriers.
The degree of linkage disequilibrium between
VK23AC, the VK23B HindIII RFLP, and the VK23B
XmnI RFLP was not quantified. Only one family not
informative for VK23AC was found to be informative
for the HindIII RFLP, suggesting that the RFLP does
not significantly increase informativeness in families
already typed for VK23AC. Very few families have
been typed for the XmnI RFLP, so the extent to which
this RFLP might increase informativeness in families
already typed for VK23AC is not known.
Multipoint Linkage Analysis
The result of multipoint analysis of VK23AC and
VK14AC in CEPH families is given in figure 3. This
shows the two-point lod scores and the multipoint
recombination frequencies. The new marker DXS292
(VK14AC) is placed 3% proximal to DXS297 in the
interval between DXS297 and DXS98. This confirms
the established physical order and is consistent with
anecdotal evidence for the order derived above from
the fragile X families.
Discussion
The mutation responsible for fragile X syndrome
has not yet been identified and characterized at the
molecular level. DNA diagnosis relies on analysis of
flanking genetic markers (Suthers et al. 1991a). The
utility of markers is governed by their distance from
the mutation and by their information content. In the
present work, we have characterized two additional
markers, both highly polymorphic and closely linked
to FRAXA. The AC-repeat microsatellites identified
at the DXS297 and DXS292 loci were applied to the
36 fragile X families available to our laboratory.
Multipoint recombination frequencies between
markers near FRAXA were previously estimated from
CEPH pedigrees (Suthers et al. 1991b); they are
DXS98 (12.3%) DXS369 (0%) DXS297 (5.7%)
DXS296 (0%) IDS (1%) DXS304 (12%) DXSS2 (re-
combination frequency is shown in parentheses be-
tween the respective markers). FRAXA was located
3.7% distal to DXS297 and 2% proximal to DXS296
(Suthers et al. 1991a). In the present study the addition
of DXS297 (VK23AC) and DXS292 (VK14AC) data
from the CEPH families had little effect on the
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Figure 3 Partial multipoint map of region near FRAXA,
based on CEPH analysis. FRAXA is located between DXS297 and
DXS296. The order of loci was derived from physical mapping and
confirmed by the odds, as shown, against inverting adjacent loci.
Numbers above the marker intervals are two-point lod scores, and
numbers below the marker intervals are multipoint recombination
fractions.
markers (fig. 2). The suggested recombination fre-
quency for diagnosis using VK23AC therefore re-
mains at 4%; however, when considered in light of
subsequent data from the fragile X families them-
selves, as determined in the present study, this may be
an overestimate (table 2). The previous report of 4%
was based only on the VK23B HindIII RFLP typed in
a subset of the Adelaide families. The data presented
in table 2 were based on all the Adelaide families and
used the more informative VK23AC marker. When
data are available from additional markers currently
being characterized near the fragile X, the FRAXA
locus may be repositioned onto the background map,
as previously described by Suthers et al. (199la).
DXS292 has now been placed on the multipoint
background map by using CEPH pedigrees. Since it is
3 cM proximal to DXS297 on the background map,
the suggested recombination frequency for diagnosis
of fragile X syndrome is 7%. This corresponds exactly
with the most likely recombination frequency derived
from fragile X families by using two-point analysis
(table 2). When it is used for diagnosis, DXS292
should be used in conjunction with an informative
marker distal to FRAXA.
The availability of numerous closely linked markers
(Suthers et al. 1991a) can have considerable impact
on the precision of linkage analysis. In the present
study, sets of closely linked informative markers
flanking FRAXA facilitated the identification with vir-
tual certainty of male transmitters and carrier females.
Although it has been shown that recombination values
are insensitive to variation of the penetrance parame-
ters used in linkage analysis (Oberle et al. 1986), the
exact coding of carrier status, wherever possible, had
substantial impact on both the magnitude of lod scores
and the associated lod- 1 confidence intervals.
Three mentally retarded individuals (not expressing
the fragile X) within our set of fragile X families were
shown (with a probability greater than 99%) not to
have inherited the chromosomal segment containing
FRAXA. This excluded the diagnosis of fragile X-
linked mental retardation. The diagnosis of five nonre-
tarded individuals expressing the "fragile X" in 1%-
2% of cells was also clarified. None of these individu-
als had inherited the chromosomal segment containing
the fragile X, implying that the detection of the com-
mon fragile site (Sutherland and Baker 1990) can lead
to misdiagnosis of carrier status. In two cases this con-
firmed the conclusion tentatively made earlier when
only loosely linked flanking markers were available
(Mulley et al. 1988). The availability of numerous
flanking markers can be invaluable for accurate diag-
nosis of some mentally retarded individuals and of
individuals with low rates of expression of the "fragile
X." These clarifications can have considerable impact
on the determination of the potential carrier status of
other family members in some sections of a pedigree.
Finally, the simultaneous detection of highly poly-
morphic VK23AC and VK14AC markers as described
above now allows determination of at least one infor-
mative marker on the proximal side of FRAXA -
within 3 d, in most families. Because these markers
are highly polymorphic, they facilitate detection of
both nonpaternity and sample error and often permit
inference of missing parental marker genotypes when
this cannot be achieved with the less informative dial-
lelic RFLPs. The present experimental approach's fail-
ure to secure polymorphic markers from VK18 and
VK37 necessitates either screening additional se-
quences distal to FRAXA as they become available or
walking from the existing loci (e.g., with yeast artifi-
cial chromosomes), in order to identify polymorphic
dinucleotide repeats. The characterization of these
markers distal to FRAXA will enable a comprehensive
approach to genetic linkage, an approach that will
supersede present RFLP analysis.
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Summary
To identify the sequences involved in the expression of the fragile X and to characterize the molecular basis
of the genetic lesion, we have constructed yeast artificial chromosomes (YACs) containing human DNA and
have screened them with cloned DNA probes which map close to the fragile site at Xq27.3. We have isolated
and partly characterized a YAC containing approximately 270 kb of human DNA from an X chromosome
which expresses the fragile X. This sequence in a yeast artificial ring chromosome, XTY26, hybridizes to the
two closest DNA markers, VK16 and Do33, which flank the fragile site. The human DNA sequence in
XTY26 also spans the fragile site on chromosome in situ hybridization. When a restriction map of XTY26,
derived by using infrequently cutting restriction enzymes, is compared with similar YAC maps derived from
non-fragile-X patients, no large-scale differences are observed. This YAC, XTY26, may enable (a) the fragile
site to be fully characterized at the molecular level and (b) the pathogenetic basis of the fragile-X syndrome
to be determined.
Introduction
Fragile-X syndrome is the most common form of fa-
milial mental retardation, affecting 1 in 2,500 children
(Davies 1989). A reasonably constant manifestation
is the presence of a cytogenetically detectable fragile
site in band q27.2 of the X chromosome, a fragile
site which, if not the cause of the disorder, is closely
associated with it (Sutherland and Hecht 1985). Its
mode of inheritance is very unusual for an X-linked
trait, with incomplete penetrance in both males and
females. Recent evidence by Vincent et al. (1991) has
suggested a differential DNA methylation in the
FRAXA region, supporting the hypothesis of Laird
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(1987; Laird et al. 1990) that the fragile site and the
fragile-X syndrome are due to local failure ofX reacti-
vation mediated through DNA methylation. Other
hypotheses include sequence rearrangement or dupli-
cation during meiotic recombination (Pembrey et al.
1985; Ledbetter et al. 1986). In the present paper we
describe the isolation of a ring yeast artificial chromo-
some (YAC) which contains the fragile-X region from
a fragile-X syndrome patient, and we compare its re-
striction map with the restriction-enzyme pattern of
DNA of this region from normal individuals (Vincent
et al. 1991).
Material and Methods
Construction of YAC Library
The YAC library was constructed by the procedure
of Reithman et al. (1989) and was designed to rescue
telomeres by complementation. The procedure was
modified to employ digestion of the vector pTYAC1
with BamHI and either EcoRI or ClaI, to accommo-
date inserts of DNA digested with either EcoRI or
TaqI. The library was made from DNA from the hu-
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man/hamster somatic cell hybrid X3000.11 (Nuss-
baum et al. 1986), which contains an X chromosome
from band q24 to qter-which in turn expresses the
fragile X-translocated onto a hamster chromosome.
This DNA was digested with TaqI, ligated to pTYAC1,
and transformed into yeast which were grown on se-
lective media. The details of library construction and
characterization will be described elsewhere, but, in
brief, the collection includes clones with sequences
from a number of locations in Xq24-Xqter.
In Situ Hybridization
The DNA probes VK16 (Suthers et al. 1990),
2-34, and Do33 (Rousseau et al. 1991) and totalDNA
extracted from yeast cultures containing XTY26 were
fluorescently labeled (Kievits et al. 1990) and used as
probes for in situ hybridization to metaphase chromo-
somes expressing the fragile X. The fragile X was in-
duced in blood lymphocytes from a fragile-X male
(Sutherland 1979), and metaphase spreads were pre-
pared using standard methods. The in situ hybridiza-
tion and signal detection were as described elsewhere
(Callen et al. 1990; Kievits et al. 1990). Probes were
nick-translated with biotin-14-dATP and hybridized
in the presence of 125 x excess sonicated human pla-
cental DNA. A plasmid containing human repetitive
sequences hybridizing at high stringency to the peri-
centromeric alphoid sequences of the X chromosome
(Choo et al. 1987) was added to the hybridization
solution immediately prior to hybridization, to un-
equivocally identify the X chromosomes (fig. lb-i).
Detection and amplification of the target sequences
were with avidin-FITC and biotinylated goat anti-
avidin. Propidium iodide was used as a counterstain.
The metaphases were examined and photographed us-
ing a Leitz incident light fluorescence microscope;
there was no computerized enhancement of the im-
ages.
Restriction Map of XTY26
The map of the yeast artificial ring-chromosome,
XTY26, was derived by pulsed-field gel electrophore-
sis of single and double digests of the restriction en-
zymes shown and by hybridization ofthe blottedDNA
Figure I Partial metaphases showing in situ hybridization results for various probes to fragile-X chromosome. a, Metaphase showing
VK16 (whole lambda clone) proximal to fragile site and general level of background. b and c, VK16 showing signal proximal to fragile




fragments with probes derived from pUC19 (vector),
2-34 (DXS463), Do33 (DXS465), and two subclones
(A3 and B3) of VK16 (DXS293) (fig. 2). Restriction
enzymes were used according to the suppliers' proto-
cols. The yeast clone XTY26 was encapsulated in
agarose beads as described elsewhere (Overhauser and
Radic 1989). The DNA samples were usually digested
for 12-16 h.
Pulsed-Field Gel Electrophoresis
Pulsed-field gel electrophoresis of Sf1 digests of both
XTY26 and normal human DNA was undertaken.
DNA was isolated from the lymphocytes of a normal
human female and from yeast containing XTY26 and
was cleaved with the restriction enzyme SfiI and elec-
trophoresed to resolve fragments in the 50-300-kb
size range. The DNA was transferred to a nylon mem-
brane (Hybond N+) and hybridized with 32P-labeled
VK16A3 (DXS2 93) probe.
Results and Discussion
There are a number of DNA probes closely linked
to the fragile X (Suthers et al. 1991); but the fragile
site itself has not been cloned, and nothing is known of
its molecular nature. In order to identify the sequences
Figure 2 Restriction map of XTY26. Complete map sites in
human insert DNA are shown only for Sall, Sfil, NruI, RsrI, and
SacII. Each of the other enzymes may have one or more additional
sites. Multiple additional NaeI sites within the vector sequences are
not shown.
involved in the expression of the fragile site and to
characterize the molecular basis of the genetic lesion,
we have constructed YACs containing human DNA
and screened them with cloned DNA probes which
map close to the fragile site at Xq27.3 (Suthers et al.
1990; Rousseau et al. 1991). One of these constructs,
XTY26, was isolated by hybridization with a unique
subclone (VK16B3) of the DXS2 93 locus which is one
of the DNA probes closest to the fragile site. It was
not known whether DXS293 was proximal or distal
to the fragile site. The method of construction of the
telomere complementation YAC library, involving te-
lomere rescue, selects for clones which acquire or no
longer need an additional telomere. A few clones con-
tain sequences that hybridize to the human telomere
repeat probe (ttaggg)n; others contain segments from
nontelomeric regions; yet others are circular chromo-
somes, maintained as such in yeast (Hieter et al. 1985),
which also satisfy the selection. Insertion of human
DNA sequences into the ClaI site was verified by se-
quence analysis of a subclone of XTY26, a subclone
containing the vector-insert junction fragment (data
not shown). The telomere complementation YAC li-
brary, as well as the library with human inserts in
pYAC4 (Abidi et al. 1990), were screened with the
pVK16B3 probe (DXS293) as described. Only one
clone, XTY26, from the telomere library was found
to be positive.
Because of the close proximity of XTY26 to the
fragile site, we investigated by means of in situ hybrid-
ization the possibility that the human DNA sequences
it contained might span the fragile site. The results in
table 1 demonstrate that the majority of the fluores-
cent signal is distal to the fragile site, whereas the
probe (VK16) used to isolate the YAC was proximal
to it on in situ hybridization (fig. lb).
The integrity of the human DNA in XTY26 was
established by hybridization to additional flanking
DNA probes known to map close to the fragile site.
Both Do33 (DXS46S) and 2-34 (DXS463) (Rousseau
et al. 1991) were found to be present in XTY26, and
their maps for the restriction enzymes BamHI,
HindIII, and TaqI were identical in both XTY26 and
human chromosomal DNA (data not shown). Linkage
mapping has shown that Do33 and 2-34 are distal
and proximal, respectively (Rousseau et al. 1991).
Subsequently Do33 was shown to map distal to the
fragile site (fig. lb and i)- and 2-34 was shown to
map proximal to it-by fluorescence in situ hybridiza-
tion.
Restriction mapping of XTY26 by using infre-
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Table I
Location of Signal for Various Probes, in Relation
to Fragile Site at Xq27.3
POSITION OF SIGNAL
(in relation to fragile site)
Proximal
PROBE Proximal Central Distal and Distal
XTY26.... 11 10 39 8
VK16 ..... 10 2 0 0
2-34 ..... 9 3 0 0
Do33 ..... 0 0 10 0
NOTE. - Sequential metaphase spreads from two fragile-X males
were examined until at least 10 X chromosomes expressing the
fragile site and exhibiting signal from probe hybridization had been
scored. The position of the signal was scored as proximal, central
(i.e., overlying the gap in the chromosome), or distal to the fragile
site. Sensitivity and specificity was such that 35%-90% of all meta-
phases (depending on the probe) had yellow fluorescent dots on the
end of at least one chromatid of the X chromosome, with virtually
no background signal (fig. 1).
quently cutting enzymes revealed that this construct
was indeed a ring (fig. 2). The evidence for this comes
from several restriction digests which are only compat-
ible with a circular map. The first is SalI, which cuts
XTY26 only once yet maps within DXS293, which in
turn, according to other digests (e.g., NaeI), maps
toward the middle ofthe humanDNA sequence. Com-
pared with undigested DNA, the Sall digest gives only
a minimal alteration in the size of XTY26, a finding
which presumably reflects the difference between the
mobility of the circular DNA and that of linear DNAs.
Second, DXS293 mapped onto the same NruI frag-
ment (140 kb) as did 2-34 but onto a different SfiI
fragment (DXS293, 120 kb; 2-34, 160 kb). The two
Sfi1 fragments equaled the total length ofXTY26. This
is only possible in a circular map which has two Sf1l
sites (rather than in a linear map with one SfiI site). In
addition, 2-34 mapped to within 60 kb of one end of
the humanDNA insert on a NaeI digest and to a 50-kb
ClaI fragment, yet the vector sequences which map to
the same 60-kb NaeI fragment are found on an 80-kb
ClaI fragment. The ClaI sites at map positions 5 kb, 55
kb, and 205 kb indicate the origin of these fragments.
Most of the restriction endonucleases used to gener-
ate the pulsed-field gel map of XTY26 contain CpG
dinucleotides in their recognition sequences. While
this contributes to their underrepresentation in the ge-
nome and therefore to their utility in long-range re-
striction mapping, the methylation of mammalian
DNA at these sites rendered a direct comparison be-
tween the XTY26 map and human chromosomal
DNA all but useless. A fortunate exception was Sfi,
which does not contain CpG and generates a 120-kb
Sfil fragment from XTY26, which in turn contains
DXS293 and most of the DNA between this locus and
Do33 (approximately 150 kb). The same 120-kb Sfil
fragment was detected in human lymphocyte DNA
from a normal individual (fig. 3), confirming the integ-
rity of at least a portion of the human DNA sequence
in XTY26. The integrity of the human insert is further
supported by evidence from restriction maps of YACs
in this area (Vincent et al. 1991) that show the probes
2-34 and Do33 to be approximately 210 kb apart.
We had previously estimated, on the basis of our
pulsed-field gels, that these probes are 230-260 kb
apart in XTY26. This discrepancy is probably due
to different pulsed-field gel electrophoresis conditions
and not to a rearrangement of either YAC. Vincent
et al. (1991) have suggested that methylation affects
12 3 4 5 6
120 kb
Figure 3 Sfi digests of XTY26 and normal human DNA
probed with VK16A3. Lanes 1 and 4, Approximately 5 pg human
DNA. Lanes 2 and 5, Approximately 25 jig human DNA. Lanes 3
and 6, Approximately 1 gg total yeast DNA including XTY26.
Lanes 1-3 show results after 16 h autoradiography, and lanes
4-6 show results for the same filter after exposure for 72 h. The
slight differences in mobility of the 120-kb fragment (e.g., between
lanes 2 and 4) occur because of the different amounts ofDNA loaded
in these lanes, as demonstrated by ethidium bromide staining (not
shown). The additional approximately 200-kb band in lanes 1, 2,
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cleavage of the restriction-endonuclease BssHII and
SacII sites at or near the FRAXA region in affected
lymphoblastoid cell lines or leukocyte DNA samples
of fragile-X patients. The location of these sites is con-
served in fragile-X (XTY26) and normal (Heitz et al.
1991) DNAs. The conservation of these sites suggests
that the observed differences in the mobility of BssHII
and SacII restriction fragments from this region (a) are
not due to large amplification or rearrangement in
fragile-X affected individuals and (b) support a role
for methylation. The clustering of CpG-containing re-
striction-endonuclease recognition sequences at posi-
tion 130 kb (fig. 1) is indicative of the promoter region
of a gene and suggests that the observed methylation
differences may effect expression of such a gene.
The screening of the human insert in XTY26 for
AC repeat microsatellite sequence (Weber and May
1989) should provide additional highly polymorphic
DNA markers for carrier detection and prenatal diag-
nosis of the fragile X (Richards et al. 1991). Identifi-
cation of the DNA sequences for fragile-X expression
should now be possible, and the identification of tran-
scribed sequences may allow the gene(s) responsible
for the fragile-X syndrome to be characterized. The
CpG-rich region delineates a logical position at which
to commence the search for such a gene.
Acknowledgments
We thank Fatima Abidi for preliminary characterization
of the telomere library, and we thank Sandy Johnson for
screening the YAC libraries. This work was supported by
grants from the National Health and Medical Research
Council of Australia and from The Adelaide Children's Hos-
pital Research Foundation.
References
Abidi FE, Wada M, Little RD, Schlessinger D (1990) Yeast
artificial chromosomes containing human Xq24-Xq28
DNA: library construction and representation of probe
sequences. Genomics 7:363-376
Callen DF, Baker E, Eyre HJ, Lane SA (1990) An expanded
mouse-human hybrid cell panel for mapping human chro-
mosome 16. Ann Genet 33:190-195
Choo HK, Brown R, Webb G, Craig 1W, Filby RG (1987)
Genomic organization of human centromeric alpha satel-
lite DNA: characterization of a chromosome 17 alpha
satellite sequence. DNA 6:297-305
Davies KE (1989) The fragile X syndrome. Oxford Univer-
sity Press, Oxford
Heitz D, Rousseau F, Devys D, Abderrahim H, Paslier D,
Cohen D, Vincent A, et al (1991) Isolation of sequences
that span the fragile X and identification of a fragile X
related CpG island. Science 251:1236-1239
Hieter P, Mann C, Snyder M, Davis RW (1985) Mitotic
stability of yeast chromosomes: a colony color assay that
measures nondisjunction and chromosome loss. Cell 40:
381-392
Kievits T, Dauwerse JG, Wiegant J, Devilee P, Breuning
MH, Cornelisse CJ, van Ommen GJB, et al (1990) Rapid
subchromosomal localization of cosmids by nonradioac-
tive in situ hybridization. Cytogenet Cell Genet 53:134-
136
Laird CD (1987) Proposed mechanism of inheritance and
expression of the human fragile-X syndrome of mental
retardation. Genetics 117:587-599
Laird CD, Lamb MM, Thorne JL (1990) Two progenitor
cells for human oogonia inferred from pedigree data and
the X-inactivation imprinting model of the fragile-X syn-
drome. Am J Hum Genet 46:696-719
Ledbetter DH, Ledbetter SA, Nussbaum RL (1986) Implica-
tions of fragileX expression in normal males for the nature
of the mutation. Nature 324:161-163
Nussbaum RL, Airhart SD, Ledbetter DH (1986) A rodent-
human hybrid containing Xq24-qter translocated to a
hamster chromosome expresses the Xq27 folate-sensitive
fragile site. Am J Med Genet 23:457-466
Overhauser J, Radic M (1989) Encapsulation of cells in
agarose beads for use with pulsed-field gel electrophoresis.
Focus 9:8-9
Pembrey ME, Winter RM, Davies KE (1985) A premuta-
tion that generates a defect at crossing over explains the
inheritance of fragile X mental retardation. Am J Med
Genet 21:709-717
Reithman HC, Moyzis RK, MeyneJ, Burke DT, Olson MV
(1989) Cloning human telomeric DNA fragments into
Saccharomyces cerevisiae using a yeast-artificial-chro-
mosome vector. Proc Natl Acad Sci USA 86:6240-6244
Richards RI, Shen Y, Holman K, Kozman H, Hyland VJ,
Mulley JC, Sutherland GR (1991) Fragile X syndrome:
diagnosis using highly polymorphic microsatellite mark-
ers. Am J Hum Genet 48:1051-1057
Rousseau F, Vincent A, Rivella S, Heitz D, Triboli C, Mae-
strini E, Warren ST, et al (1991) Four chromosomal
breakpoints and four new probes mark out a 10-cM re-
gion encompassing the fragile-X locus (FRAXA). Am J
Hum Genet 48:108-116
Sutherland GR (1979) Heritable fragile sites on human chro-
mosomes. I. Factors affecting expression in lymphocyte
culture. Am J Hum Genet 31:125-135
Sutherland GR, Hecht F (1985) Fragile sites on human chro-
mosomes. Oxford University Press, New York
Suthers GK, Hyland VJ, Callen DF, Oberle I, Rocchi M,
Thomas NS, Morris CP, et al (1990) Physical mapping of
new DNA probes near the fragile X (FRAXA) by using a
panel of cell lines. Am J Hum Genet 47:187-195
518
Cloning the Fragile X 661
Suthers GK, Mulley JC, Voelckel MA, Dahl N, Vaisanen
ML, Steinbach P, Glass IA, et al (1991) Genetic mapping
of new DNA probes at Xq27 defines a strategy for DNA
studies in the fragile X syndrome. Am J Hum Genet 48:
460-467
Vincent A, Heitz D, Petit C, Kretz C, Oberle I, Mandel JL
(1991) Abnormal pattern detected in fragile X patients by
pulsed field gel electrophoresis. Nature 349:624-626
Weber JL, May PE ( 1989) Abundant class of human DNA
polymorphisms which can be typed using the polymerase




Hereditary unstable DNA: a new explanation for
some old genetic questions?
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Fragile X syndrome, associated with the fragile X
chromosome, is the most common cause of familial
mental retardation. The condition is characterised by
a heritable DNA sequence that consists of an
abnormal number of CCG repeats, and which is
unstable in both mitosis and meiosis. We suggest
that such heritable unstable DNA sequences could
be present in other parts of the genome and that
these might explain a number of genetic events that
are not well understood in terms of classic genetic
mechanisms. Such poorly explained observations
include anticipation, incomplete penetrance, variable
expression, and possibly imprinting, variegation, and
multifactorial inheritance.
Although the inheritance patterns of many genetic
diseases are straightforward, there are a number of genetic
events for which the molecular basis is either unknown or
poorly understood. These include, anticipation, penetrance,
variable expression, imprinting, variegation, and
multifactorial inheritance.
Fragile X syndrome is the most common familial form of
mental handicap, and has recently been found to be
associated with a novel genetic element-a heritable
unstable DNA sequence.12 We suggest that such sequences
may not be unique and could offer explanations for some or
all of the genetic processes listed above.
Fragile X syndrome
The fragile X syndrome is characterised by mental
retardation and mild dysmorphism. Males are commonly
more severely affected than females. About 1 in 2000
children are affected by this disorder. In males, features
include a typical facies with high forehead, prominent lower
jaw, and large ears with a mild connective tissue abnormality
that leads to fine skin, hyperextensible joints, flat feet, and
mitral valve prolapse. Macro-orchidism in adult males is a
striking feature. Behavioural difficulties are common and
many fragile X boys have been labelled as autistic,
hyperactive, or psychotic. These behavioural disturbances
usually improve after puberty. The degree of mental
retardation ranges from borderline to profound, but the
abilities of most males are in the moderately to severely
retarded range.
About one-third of females who carry the fragile X have
mental retardation but are often less severely affected than
males. Affected females may show the same craniofacial and





The syndrome is associated with a rare folate-sensitive
fragile site in band Xq27.3. This abnormality is not found in
all cells and is seen only if cells are cultured under specific
conditions before chromosome preparation. Most mentally
retarded individuals with the syndrome show the fragile X
chromosome. This cytogenetic defect is rarely seen in
normal carrier males but is present in some normal carrier
females.
Genetics
The fragile X syndrome has unusual genetics. The
disorder is clearly X-linked with a single locus of major
effect mapping to the end of the long arm (band q27.3). One
of the most unusual features of the genetics, for an X-linked
disorder, is the existence of normal carrier males. These
were originally identified as obligate carriers at the top of
pedigrees, and were intellectually normal males who had
daughters with mentally retarded children; these carriers
became known as transmitting males. Such males are
phenotypically normal and do not express the fragile site at
Xq27.3.
A second unusual feature is that the risk of a fragile X
carrier female having a retarded child depends on her own
phenotype. The children of women with no signs of the
fragile X phenotype, but who inherit the fragile X
chromosome, have different risks of intellectual handicap
(boys 76 %, girls 35%). Moreover, if the carrier mother has
signs of the fragile X syndrome, notably mental impairment,
these risks become 100% for boys and 55% for girls.
Fragile X syndrome shows anticipation; this observation
is exemplified by the Sherman paradox. The frequency of
intellectual handicap in the offspring of carrier women who
are mothers of transmitting males is much less than in the
carrier daughters of such males. The proportion of
members of fragile X families with retardation increases in
successive generations.
Molecular genetics
Recent studies have shown that the fragile X contains a
DNA sequence that is unstable in both families and
individuals.12 The sequence maps to a trinucleotide repeat
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(CCG) that is at the fragile site and is either greatly amplified
or allows the insertion of other unknown DNA sequences.4
For simplicity we refer to this process as amplification.
Normal X chromosomes have about 40 copies of the
trinucleotide and in normal families these sequences are
stable and transmitted like any other genetic polymorphism.
Both male and female fragile X carriers have 70-200 copies
of the trinucleotide (unpublished observations). When these
elements are transmitted by female carriers they can remain
stable but usually increase and differ in size in each child.
Daughters of male carriers usually have a repeat sequence
that is either the same size or smaller than their father’s,
although the sequence does not usually return to the size
found in normal X chromosomes.
Once this sequence is amplified beyond a certain size
(probably beyond 200 copies) it becomes unstable and can
Unstable sequences associated with the fragile X genotype.
Southern blot of Pst I digested DNA probed with pfxa3 Molecular
weights in kilobases (kb) are shown A normal male (lane 1 ) shows a 1 0
kb band Transmitting males (lanes 2 and 3) show loss of the normal band
but a band of increased size up to about 1 6 kb Fragile X syndrome males
(lanes 4 {3) also lack the normal 1 kb band and have either a single band
greater than about 1 kb in size (lane 4) or multiple bands of decreased
intensity which approach a "smear" (lanes 5 and 6)
be seen as a smear of DNA fragments in Southern blots
(figure). We interpret this result to mean that different cells
within the same tissue, and possibly different tissues in the
same individual, have a different genetic constitution as far
as the degree of amplification of the repeat sequence is
concerned.
How this unstable sequence might lead to either the
clinical disorder or fragile site expression in vitro remains
unclear. Expression of the fragile site and the syndrome
seem more likely as the size of the amplification increases.
For instance, if the sequence is close to an expressed gene,
possibly in an intron or a control region, then as the
sequence becomes larger it might either intefere with
transcription or lead to further deviation of the gene product
from normal.
Anticipation
Anticipation describes the increase in severity and
progressively earlier age of onset of a genetic disease in
successive generations. No biological mechanism has been
suggested to explain this observation. Dystrophia
myotonica (DM) is the only human genetic disease in which
anticipation has been invoked.s However, although the
condition is known to result from a mutation of a gene on the
long arm of chromosome 19, the molecular basis of this
defect remains unknown.
In DM families, expression of the disease begins at an
earlier age and is more disabling in successive generations.s
Furthermore, the severe congenital form of the disease is
confined to the offspring of affected women. An
unidentified maternal factor may be responsible for the
severe congenital phenotype. 6
An unstable DNA sequence close to or within the DM
gene and which increased in size in successive generations,
as the fragile X sequence can when transmitted by women,
could, if it progressively interfered with the DM gene
product, be a biological mechanism for anticipation. An
unstable sequence of the type found in fragile X could be one
example; Howeler et at5 suggested that " ... it might be that
the mutation itself changes from generation to generation".
The sensitivity of certain cell types to both the effects of
the DM gene and the instability of potentially unstable
DNA sequences could determine the variable features of the
disorder. In early generations of DM families, the main
feature of the disease is the presence of senile cataracts
suggesting, perhaps, that the lens is especially susceptible
whereas muscle is more resistant.
In fragile X genotypes, the sequence usually increases in
size when transmitted by women rather than by men but
this may be because the sequence is on the X chromosome.
An unstable autosomal sequence might be expected to
increase in size when transmitted by both men and women.
However, if the pattern of instability of the fragile X
sequence is related to the different mechanisms of meiosis in
males and females rather than the number of X
chromosomes present, it may be that female meiosis has a
greater potential for amplifying sequences. It is primarily
women with DM who have children with the severe
congenital form of the disease.
Not all those with the fragile X genotype express the
fragile site, yet they do have the unstable sequences.
Unstable sequences could exist without expressing fragile
sites cytogenetically. For instance, the lack of a fragile site
mapping to the location of the DM gene does not mean that




Many genetic diseases, especially those that follow
autosomal dominant inheritance, show both incomplete
penetrance and striking differences in expression.
Penetrance refers to the proportion of individuals with a
disease gene who show clinical evidence of its presence.
Some carriers of a gene defect may have clinical disease
while other family members, who apparently have the same
genetic mutation, have little or no clinical evidence of a
disease gene; some may have only minor difficulties in
adulthood whereas others experience severe disease during
childhood.
Adult polycystic kidney disease can present in infancy
with enlarged polycystic kidneys that have only limited
function, while other individuals in the same family may still
be symptom-free in old age and have only a small number of
cysts detectable by ultrasound.7 A further example is
Waardenburg syndrome (type 1), which includes cochlear
deafness, mild facial dysmorphism, and pigmentary
disturbances such as heterochromia irides and white
forelock.8 Some family members will have full expression of
the disorder including severe bilateral deafness, whereas
others may have only premature greying of the hair or
heterochromia.
Incomplete penetrance and variable expression have been
suggested to occur as a result either of differences in the
genetic background of different individuals with the same
gene,9 or of variation in the non-pathologically-mutated
allele on the chromosome not carrying the mutant allele. to A
hereditary unstable DNA sequence provides an alternative
and testable explanation. Such a sequence could produce
different phenotypic effects if it varied in size as it was
transmitted. This variation may take place because of
different degrees of interference with the action of one or
more genes. An unstable sequence in vivo could readily
explain why different individuals exhibit different
phenotypic components of a syndrome. Similarly,
differences in age of onset of a disorder could be explained
by differences in rate of change of size of an unstable
sequence as cell lineages that are involved in the disorder
age.
Multifactorial inheritance, a term that describes the
familial occurrence of disease with no obvious
environmental cause or inheritance pattern, could be an
extreme example of incomplete penetrance of dominant
genes. These two inheritance patterns can be difficult to
distinguish from each other. If incomplete penetrance is
associated with heritable unstable DNA sequences, then
perhaps multifactorial inheritance is as well.
Imprinting
Imprinting has been suggested as a mechanism to explain
both unusual patterns of inheritance" and parental-origin-
specific effects of small chromosomal deletions.12 For those
instances in which imprinting seems to involve a single gene,
for instance hereditary glomus tumours,13 the "malignant"
state of the gene "switches" on and off as it moves through a
family depending on the sex of the transmitting parent. No
such mechanism has been observed or suggested for DM.
A hypothesis explaining the inheritance patterns of fragile
X, which involves imprinting, has been suggested. 14
Although this theory is plausible, it has no molecular basis
other than that it could predict increased DNA methylation
patterns around the fragile site. Such patterns have been
observed and correlate with phenotype but not genotype.15
Laird’s hypothesis therefore remains unproven, but it may
not be invalidated by the finding that fragile X is
characterised by an unstable DNA sequence. This unstable
sequence could provide a mechanism for imprinting.
However, there still remains no satisfactory explanation
for imprinting. DNA methylation has been suggested but it
is not a complete explanation on its own. Sex differences in
the behaviour of unstable sequences could be involved. The
fragile X unstable sequence may be associated with
methylation changes to DNA adjacent to the unstable
sequence.2,15,16
Variegation
In several genetic diseases, there is obvious tissue
mosaicism that is visible as skin variegation. In X-linked
disorders, such as incontinentia pigmenti, the explanation
has always been X inactivation. In dominant disorders such
as tuberous sclerosis and neurofibromatosis, there is no such
simple explanation. However, a DNA sequence that affects
gene action and which is unstable in vivo could offer a
mechanism for this observation.
Fragile sites
The characterisation of the fragile X genotype as having a
hereditary unstable DNA sequence is recent and, at present,
represents a unique genetic element. The fragile X itself is
unique since it is the only fragile site that is associated with a
genetic disease. However, over one hundred fragile sites, of
several different types, are now known in the human
genome. The fragile X is a rare folate-sensitive fragile site;
there are 19 others of this type alone in the human
genome.17,18 Other folate-sensitive fragile sites may be
associated with unstable DNA sequences similar to that in
the fragile X syndrome, and other types of fragile sites might
also be accounted for by this type of sequence.
Long cherished notions of the stability of the genome
were shattered both by the discovery of transposable
elements and by the recognition that genome
rearrangements were an essential part of immunoglobulin
production. Fragile X is another example of what seems to
be genome instability and is characterised by a novel
mechanism of mutation. This mechanism provides a
possible biological explanation for several genetic events that
are currently poorly understood. Could fragile X syndrome
be the first of many disorders due to hereditary unstable
DNA sequences?
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CLINICAL PRACTICE
High fecundity of amenorrhoeic women in embryo-
transfer programmes
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There is uncertainty over whether the steady decline
in human fertility with increasing maternal age is due
to quality of the oocyte or of the endometrium. To
clarify the issue age-related implantation and
pregnancy rates in two embryo-transfer programmes
were examined in relation to embryo quality and type
of menstrual cycle. In both the UK and the US
programmes rates were higher in previously
amenorrhoeic (acyclic) women than in eugonadal
women, irrespective of age and number of embryos
replaced. Oocyte quality, as determined by age of
oocyte donor, in-vitro growth of embryo, and
proportion of defective embryos in culture, did not
contribute to the difference, nor did type of cycle
during therapy. If a uterus that has not been
subjected to regular menstrual cycles is a favourable
factor, a period of induced amenorrhoea might be
beneficial for infertile women.
Introduction
In women the decline in fertility with age might be due to
poor quality of the oocyte or of the endometrium. To find
out whether either of these factors affects fertility in the older
woman we have examined pregnancy rates among women in
two embryo-transfer programmes-that in Cambridge,
UK, which used frozen embryos, and that in Irvine,
California, USA, which used fresh embryos. To assess
effect of oocyte quality pregnancy and implantation rates in
women of different age-groups were examined in relation to
embryo growth in vitro, frequency of defective embryos
in vitro, and age of oocyte donor. To assess effect of
endometrium, pregnancy and implantation rates were
assessed in relation to type of menstrual cycle.
Patients and methods
UK patients
More than 300 embryo transfers were done in Cambridge.
Women who had regular cycles received embryos obtained from
previous stimulated cycles and frozen with propanediol.l,2 Embryos
were cultured for 24 h after thawing and replaced 3 days after the
onset of the luteinising hormone surge during the natural menstrual
cycle or on the 3rd day of progesterone therapy during an artificial
cycle. Artificial cycles were established by down-regulating the
pituitary gland with luteinising hormone releasing hormone
(LH-RH) agonists for 7 days or longer until gonadotropins reached
basal levels3 then giving oral oestradiol valerate to prime the uterus
and adding progesterone 15 days later to establish a secretory
endometruum 4 Amenorrhoeic women, many of whom were
agonadal, received donated oocytes that had been fertilised in vitro
by their husbands’ spermatozoa; the resulting embryos had been
stored for 3 months for clearance of human immunodeficiency
virus.
US patients
Fresh embryos were transferred into more than 200 patients.
Women with regular cycles were down-regulated with LH-RH
agonists for 7 days or longer, then stimulated with human
menopausal gonadotropins (HMG) and human chorionic
gonadotropin (HCG).5 Embryos were replaced 2-5 days after
oocyte collection. The second group of women were agonadal and
artificial cycles were established in them in the same manner as for
the Cambridge patients. Embryos formed from donated oocytes
and the patient’s husband’s spermatozoa were replaced on the 3rd
day of progesterone therapy.
Monitoring of pregnancy
The growth of the embryos, and assays of oestradiol-170,
progesterone, LH, and HCG(3 during the follicular and luteal
phases and during pregnancy, were monitored. On day 35 after the
onset of the natural or artificial luteal phase, the uterus was scanned
by ultrasound and the state of the pregnancy was classified as the
presence of a living or dead fetus, of a blighted ovum (gestational sac
with no fetus), or of an ectopic pregnancy. The absence of a
gestational sac after transient rises in plasma HCG(3 was taken as
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Fragile X syndrome: genetic localisation by linkage
mapping of two microsatellite repeats FRAXACJ
and FRAXAC2 which immediately flank the fragile
site
R I Richards, K Holman, H Kozman, E Kremer, M Lynch, M Pritchard, S Yu, J Mulley,
G R Sutherland
Abstract
We report the genetic localisation of the fra-
gile site at Xq27.3 associated with fragile X
syndrome. The position of the fragile site
within the multipoint linkage map was deter-
mined using two polymorphic microsatellite
AC repeat markers FRAXACl and FRAXAC2.
These markers were physically located within
10 kilobases and on either side of the p(CCG).
repeat responsible for the fragile site.
FRAXACI has five alleles with heterozygosity
of44% and is in strong linkage disequilibrium
with FRAXAC2 which has eight alleles and a
heterozygosity of 71%. No recombination was
observed either between these markers in 40
normal CEPH pedigrees or with the fragile X
in affected pedigrees. These markers provide
the means for accurate diagnosis of the fragile
X genotype in families by rapid polymerase
chain reaction analysis and were used to posi-
tion the fragile X within the multipoint map of
the X chromosome to a position 3-7 cM distal
to DXS297 and 1P2 cM proximal to DXS296.
Fragile X syndrome is the most common familial
form of mental retardation. It is associated with the
expression under certain specific culture conditions
of a fragile site at Xq27.3. This cytogenetic associ-
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ation has been used diagnostically; however, incom-
plete penetrance and the bizarre segregation pattern
of the disorder have necessitated the use of linkage
analysis to determine accurately carrier status using
restriction fragment length polymorphism (RFLP)
markers.'2 The discovery of length polymorphism of
AC repeat microsatellites,3 which are in general
more informative than RFLPs, has enabled the
recent characterisation and application of these
markers to fragile X diagnosis.4 AC repeats were
identified in the DNA sequences which define the
DXS292 and DXS297 loci, which are 7 cM and
4 cM, respectively, proximal to the fragile X.
Recently, cloned DNA sequences which span the
fragile site at Xq27.3 have been isolated' and an
unstable region of DNA which segregates with the
fragile X genotype has been identified.6 A DNA
probe, pfxa3, adjacent to the unstable p(CCG).
repeat, is able to detect the fragile X genotype
directly in fragile X syndrome pedigrees.67 A cor-
relation between the length of the unstable sequence
and phenotype is evident permitting reliable and
accurate prenatal diagnosis of fragile X phenotype
by Southern analysis.8
The exceptionally high GC content of this ele-
ment and its flanking DNA sequences has prohib-
ited the development of a simple PCR based dia-
gnostic test for amplification of the p(CCG)n repeat.
The Southern blot hybridisation using pfxa3, while
accurate in determining genotype, is a relatively
slow procedure, particularly for prenatal diagnosis.
Genotype can be determined just as accurately by
linkage analysis using PCR based markers which
show no recombination with the disease locus and
which can be determined much more rapidly. Half
of the at risk pregnancies will be negative for fragile
X genotype and PCR based diagnosis will quickly
alleviate parental anxiety in those cases.
We have therefore undertaken characterisation of
two AC repeat sequences in the immediate vicinity
81
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of the fragile X site p(CCG). unstable element.
These markers allow rapid exclusion of the fragile X
genotype and, in conjunction with the pfxa3 analy-
sis, may be incorporated into a rational diagnostic
strategy for fragile X syndrome prenatal diagnosis.
The remaining pregnancies, positive for fragile X
genotype, must undergo diagnosis for phenotype
using pfxa3.68
Materials and methods
The yeast artificial chromosome XTY26 containing
275 kb ofhumanDNA has previously been shown to
span the fragile site at Xq27.3 which segregates with
fragile X syndrome.5 A saturation library of 108
lambda subclones was derived from XTY26 and a
contig of overlapping DNA sequences established
between the closest known proximal (VK-16) and
distal (Alu2) markers to the fragile X site.6
Synthetic poly (AC.GT) (Pharmacia) was
radioactively labelled with a-32P-dCTP in a random
primed reaction (Multiprime, Amersham). AC re-
peat containing DNA clones was identified by
hybridisation to this probe in 05 mol/l sodium
phosphate, pH 7 0, 7% SDS (without carrier DNA)
at 65°C for 16 hours and by washing at 65°C for one
hour in 2 x SSC. Clones tested constituted the 108
lambda subclones of the yeast artificial chromosome,
XTY26.'6
DNA from positive clones was digested with
either HaeIII, Sau3AI, HinPI, HpaII, RsaI, HinfI,
or TaqI, electrophoresed on 1 4% agarose gels,
blotted onto nylon membranes (GeneScreen Plus,
NEN-Dupont), and probed with 32P-poly (AC.GT)
as above. Digests which gave a hybridising fragment
of less than 600 base pairs were chosen for subclon-
ing into M13mp18 for sequence analysis. Synthetic
oligodeoxyribonucleotide primers suitable for PCR
were designed from apparently unique sequences
flanking the microsatellite AC repeats. Length poly-
morphism of the AC repeats was typed in a PCR
using the reaction conditions previously described,49
except for the addition of 10 gCi of ac-2PdCTP to
each reaction.
PCR incubations were performed in 10 jIl
volumes in a Perkin Elmer-Cetus thermal cycler for
10 cycles at 94°C for 60 seconds, at 60°C for 90
seconds, and at 72°C for 90 seconds, followed by 25
cycles at 94°C for 60 seconds, at 55°C for 90 seconds,
and at 72°C for 90 seconds. The volume was
adjusted to 40 jl with formamide loading buffer
(95% formamide, 1 mmol/l EDTA, 0 01% bromo-
phenol blue, 0-01% xylene cyanol). After denatura-
tion at 90°C for three minutes, 2-5 p1 aliquots of each
reaction mixture were subjected to electrophoresis
in 6% polyacrylamide denaturing (7 mol/l urea) gels.
Genotypes were determined after autoradiography
for 18 hours.
Multipoint analysis was based on genotypes of
each marker in the 40 large kindred pedigrees of the
Centre d'Etude du Polymorphisme Humain
(CEPH) and was carried out by using the LIN-
KAGE (version 4.9) package for use with CEPH
three generation families.
Results
IDENTIFICATION OF AC REPEATS AT FRAXA
The library of XTY26 subclones was screened for
the presence of AC repeats by hybridisation to 32P
labelled synthetic poly (AC.GT). Ten positive
clones were assigned to each of three groups by
virtue of their position in the XTY26 contig (table
1). That each group contained unique AC repeats
was determined by the size of their HaeIII and
Sau3AI restriction fragments which hybridised to
32P-poly (AC.GT) (not shown).
DNA from one member of each group was
digested with a four base pair enzyme which gave a
32P-poly (AC.GT) hybridising restriction fragment
< 600 base pairs, suitable for subcloning and
sequencing in M13. For lambda 12 this digest was
with Sau3AI which gave an approximately 280 base
pair hybridising fragment (table 2A). For lambda 25
a HaeIII digest gave an approximately 600 base pair
hybridising fragment, part of the sequence of which
is shown in table 2B. The initial sequence deter-
mined from the universal sequencing primer
allowed accurate reading up to and including the AC
repeat, but not beyond, to allow for reverse PCR
primer design and synthesis. To obtain sequence
from this side of the repeat the forward PCR primer
was used to prime the sequencing reaction. For
lambda 26 an RsaI digest gave a 200 base pair
hybridising fragment, the sequence of which is
shown in table 2C.
The derived sequences were then used to design
synthetic oligodeoxyribonucleotide primers suitable
for PCR analysis of length variation in the AC repeat
sequences. Sequences were chosen on the basis of
their apparent uniqueness, their 50% GC composi-
tion, and their lack of consecutive G residues, which
appear to interfere with chemical synthesis of oligo-
deoxyribonucleotides (unpublished observations).
Table 1 Groups ofAC repeat containing lambda clones
derivedfrom the fragile X containing YAC, XTY26.
Group
I II III
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Table 2 AC/GT repeat sequences determinedfrom lambda 12 (A), lambda 25 (B), and lambda 26 (C). Sequence
recognition sites for the enzymes used to isolate the respective fragments are inferred. Sequences used to design primers for














































































PHYSICAL LOCATION OF FRAXA AC REPEATS
Each of the three AC repeats was shown to represent
each of the three groups of lambda subclones of
XTY26 DNA by using the synthetic oligodeoxy-
ribonucleotides to prime PCR reactions with each of
the lambda DNAs as template. In each case, product
of the expected size was synthesised (data not
shown).
The location of the group I and group II AC
repeats was determined, relative to the unstable
element p(CCG). which characterises the fragile
site, by probing EcoRI digests of these clones with
32P labelled poly (AC.GT). The position of the
hybridising fragments is indicated in fig 1.
The markers from each microsatellite were subse-
quently termed FRAXACI (from lambda 12),
FRAXAC2 (from lambda 25), and FRAXAC3
(from lambda 26).
X27
POLYMORPHISM OF FRAXA AC REPEATS
The observed heterozygosity of FRAXAC3 in 18
unrelated females was only 16% and so the charac-
terisation of this marker was not pursued further.
The observed heterozygosities of FRAXACI and
FRAXAC2 were found to be 45% and 80%, re-
spectively, in 40 unrelated females. However, none
of the unrelated females who were homozygous for
FRAXAC2 was heterozygous for FRAXACI and
so the combined observed heterozygosity was also
80%. This indicates linkage disequilibrium between
the two markers. Expected heterozygosities, based
on observed allele frequencies, were 44% and 71%
for FRAXACI and FRAXAC2 respectively (table
3). Apart from diagnosis, FRAXAC2 will be useful
as a marker for construction of the index map of the
X chromosome which will be based on markers with
minimum heterozygosity of 70%. Codominant men-
1 kb
X5





Figure 1 Location ofAC repeat sequences relative to the fragile site. Lambda clones from the XTY26 contig across the
fragile site6 are shown as is the location of the fragile site p(CCG)n repeat (pfxa), the exact position of which was
previously determined by Kremer et al.5 The length in kilobases of EcoRIfragments across the contig are indicated and those
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Table 3 Allele frequencies ofAC repeat markers at FRAXA.
% heterozygosity
Allele
Marker Allele (AC)n frequency Observed Expected*













'Based on observed allele frequencies.
delian inheritance was observed in each pedigree
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FRAXA LOCUS IN FRAGILE X PEDIGREES
EJ O O Fragile X affected pedigrees, which had previously
been shown to have recombinants in the vicinity of
the fragile site, were genotyped with FRAXAC2.
One subject in each of three pedigrees was a recom-
binant with IDS and another in a fourth pedigree
was a recombinant with DXS297 (VK23AC). Three
*,, of these pedigrees were informative with
* FRAXAC2 and no recombination was found
between this marker and the fragile X genotype (as
us " determined by pfxa3 hybridisation). Analysis with
FRAXACIwas not undertaken because of the high
degree of linkage disequilibrium between the two
markers. Pedigrees informative for FRAXAC2 are
) C A C shown in fig 3.
.B-
A lwaf_t
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Figure 2 AC repeat genotypes for FRAXACI in CEPH
pedigree 1420 (top) and FRAXAC2 in CEPH number 12
(bottom). The position of the major bandfor each allele is
indicated alongside the autoradiograph. Allele designations
are indicated below each lane.
MULTIPOINT LINKAGE ANALYSIS
In order to place FRAXA onto the background
genetic map of the X chromosome, the FRAXACI
and FRAXAC2 markers were genotyped from the
40 CEPH pedigrees. The location of FRAXA
(FRAXACI-FRAXAC2) within the multipoint
linkage map is given in table 4.
When genotype analysis of the informative CEPH
pedigrees was completed, only one female who was
homozygous for FRAXAC2 was found to be hetero-
zygous for FRAXACI, confirming a high degree of
linkage disequilibrium.
Discussion
Suthers et aP established a background map of
genetic markers using the CEPH families. Within
the interval of 6 cM on the background map between
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OCytogenetically positive for fragile site, phenotypically
normal
Cytogenetically negative, phenotypically normal, obligate
carrier
Figure 3 Fragile X pedigrees which had previously been
shown to exhibit recombination between the fragile X and
the flanking marker at IDS. In each pedigree the
FRAXAC2 marker cosegregates with the fragile site. The
member of each pedigree which shows recombination is
arrowed (R). Brackets indicate that the genotype was
inferred.
aP positioned the FRAXA locus 2 cM proximal to
DXS296 using the location score method applied to
fragile X families. This location relative to the
flanking markers has subsequently been applied to
the estimation of risk in fragile X syndrome when
diagnosis has been carried out using linked markers.
The location of FRAXA has now been indepen-
dently located within the DXS296 and DXS297
interval using the CEPH families. This localisation
used additional marker data, the AC repeats at
DXS292 and DXS297,4 and was carried out in-
directly from the CEPH database using FRAXACI
and FRAXAC2, which define the position of
FRAXA. The new position for FRAXA is 1-2 cM
proximal to DXS296, compared with the 2 cM
determined by Suthers et al.2
The mutation responsible for fragile X syndrome
has now been identified and characterised at the
molecular level. An unstable element p(CCG)n,
which is present at from 15 to 65 copies in normal
subjects,7 is amplified in both carriers and affected
subjects, phenotypic status being determined by the
size of the amplification. This direct correlation
between size of amplification (which is detected by
the DNA probe pfxa3) and phenotype allows for
accurate carrier detection and prenatal diagnosis.8
The limitation of the pfxa3 probe is that it is
restricted to Southern blot based hybridisation, a
relatively slow technology.
An alternative approach to rapid diagnostic analy-
sis would be tightly linked, highly informative gen-
etic markers which show no recombination with
FRAXA. The microsatellite AC repeats would ap-
pear to fulfil both these criteria since they are located
on average every 50 kilobases or so throughout the
genome, they have generally high PIC values, and
they can be rapidly genotyped by PCR. We there-
fore sought to characterise such sequences in the
vicinity of the fragile X site in the hope of identify-
ing any which might make suitable markers for
fragile X pedigree analysis. The markers
FRAXACI and FRAXAC2, with observed hetero-
zygosities of 45% and 80% respectively, fulfil these
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within 10 kilobases of the fragile X site, make them
ideal genetic markers for fragile X genotyping since
recombination between either marker and the fragile
site ought to be exceptionally rare. The high degree
of linkage disequilibrium between the two markers
indicates this but makes the less informative of the
two (FRAXAC1) redundant for linkage analysis.
Initial attempts to multiplex the two markers were
therefore abandoned. The high level of linkage dis-
equilibrium between these two markers which flank
the fragile site confirms that the fragile site is not an
area of high meiotic recombination. Verkerk et al'
have recently reported the characterisation of an
additional AC repeat marker (DXS548) 150kb
proximal to FRAXA, with an observed heterozygo-
sity of >80% in fragile X families. Given that
DXS548 and FRAXAC2 do not exhibit linkage
disequilibrium then a multiplex reaction of these
two markers will enable application of linkage analy-
sis to virtually all fragile X pedigrees.
Together with the pfxa3 hybridisation probe, the
FRAXAC2 marker can now be incorporated into a
rational approach to prenatal diagnosis in fragile X
pedigrees. This involves analysis of chorionic villus
sample (CVS) DNA with the AC repeat marker at
Xq27.3 to determine the FRAXA genotype, fol-
lowed by Southern blots with pfxa3 as probe to
detect amplification of the p(CCG). repeat in preg-
nancies positive for fragile X genotype. The initial
microsatellite results will allow rapid exclusion in
half of the at risk pregnancies whereas the prediction
of phenotype for subjects with the FRAXA geno-
type will be subsequently determined by the size of
pfxa3 hybridising fragments.68
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Summary
The fragile site at Xq27.3 is an unstable microsatellite repeat, p(CCG)n. In fragile-X syndrome pedigrees, this
sequence exhibits variable amplification, the length of which correlates with fragile-site expression. There
is a direct relationship between increased p(CCG)n copy number and propensity for instability: individuals
having large amplifications exhibit somatic variation due to increased instability. The instability of the
p(CCG)n repeat, when transmitted through affected pedigrees, explains the unusual segregation patterns of
fragile-X phenotype, referred to as the Sherman paradox. All individuals of fragile-X genotype were found
(where testing was possible) to have a parent with amplified p(CCG)n repeat, indicating that few, if any, cases
of fragile-X syndrome are not familial.
Introduction
Fragile-X syndrome, associated with a rare fragile site
at Xq27.3, is the most common familial form of men-
tal retardation (Sutherland 1985). Its segregation pat-
tern is unique (Sherman et al. 1984, 1985); its cytoge-
netic detection can be difficult (Sutherland et al. 1985);
and its molecular basis is only now beginning to be
elucidated. Recently it has been demonstrated that
fragile-X genotype is characterized by an unstable re-
gion of DNA (Oberle et al. 1991; Yu et al. 1991)-a
trinucleotide repeat p(CCG)n of variable copy number
(Kremer et al. 1991; Verkerk et al. 1991). In situ hy-
bridization showed that the sequences flanking the
p(CCG)n repeat also flank the fragile site (Kremer et
al. 1991 ). The p(CCG)n repeat is embedded within the
FMR-1 gene whose function is yet unknown (Verkerk
et al. 1991). The FMR-1 gene is not expressed in frag-
ile-X syndrome (Pieretti et al. 1991). Thus, all avail-
able experimental evidence leads to the conclusion
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that the unstable p(CCG). repeat is the molecular basis
of the fragile site, that cytogenetic expression of the
fragile site is a reflection of increased repeat copy num-
ber, and that manifestation of fragile-X syndrome
might be related to modulation of expression of a sin-
gle gene.
Fragile-X genotype is defined by the extent of ampli-
fication of the trinucleotide repeat, and we and others
therefore hypothesized (Oberle et al. 1 991; Sutherland
et al. 1991b; Yu et al. 1991) that the length of the
unstable sequence might correlate with phenotype,
which is known to be variable. DNA from several
fragile-X individuals was previously reported to ex-
hibit multiple bands when probed with pfxa3, possi-
bly because of somatic instability of the unstable ele-
ment (Yu et al. 1991). In addition, methylation of
restriction-endonuclease recognition sites in the vicin-
ity of the p(CCG)n repeat is associated with fragile-X
phenotype (Bell et al. 1991; Vincent et al. 1991), al-
though the relationship of methylation to genotype is
not clear. In order to examine instability of the tri-
nucleotide repeat during transmission from generation
to generation and to assess possible correlations of the
fragile-X genotype with phenotype, the genotypes of




Fragile-X Syndrome Unstable Element
Material and Methods
Fragile X-affected Pedigrees
Fragile-X pedigrees assessed in this study have been
described elsewhere (Richards et al. 1991a, 1991b).
Index-case diagnosis was by cytogenetic detection of
the fragile X. All consenting members of affected fami-
lies were assessed clinically. The distinction between
normal transmitting and affected males was made on
the basis of assessment for mental retardation prior to
DNA analysis ofunstable-element band size. Chromo-
somal DNA was isolated by the method of Wyman
and White (1980), from whole blood samples taken
from members of affected families. Risk analysis was
carried out using linked DNA markers according to
a method described elsewhere (Mulley et al. 1987;
Richards et al. 1991a, 1991b; Suthers et al. 1991a,
1991b). Fragile-X genotypes were confirmed by link-
age analysis, with >95% probability, except for iso-
lated cases where familial inheritance could only be
demonstrated by using the pfxa3 probe.
Detection of the Fragile-X Unstable Element with pfxa3
Chromosomal DNA was digested to completion
with PstI. Samples were separated by electrophoresis
on a .8% agarose gel and transferred to hybond N+
(Amersham) blotting membrane. The probe pfxa3 (On-
cor) is a 536-bp sequence located immediately distal
to the unstable element, p(CCG)n repeat, which is
thought to constitute the fragileX (Kremer et al. 1991;
Yu et al. 1991). The probe pS8 is an 800-bp PstI frag-
ment from a yeast artificial chromosome isolated using
VK21 (DXS296) as probe. pS8 was used as an intern-
al positive control for hybridization with pfxa3.
The probes were radioactively labeled with alpha-
32PdCTP by using a Multiprime labeling kit (Amer-
sham) and were hybridized overnight at 421C in 5
x SSPE (pH 7.4), 1% SDS, 50% formamide, 10%
dextran sulfate, and 100 jg salmon sperm DNA/ml.
Membranes were washed in 0.1 % SDS, 0.1 x SSC at
70°C for at least 30 min prior to exposure to X-Omat,
XK-1 film (Kodak) for 16-72 h at - 800C in the pres-
ence of two intensifying screens. The amount, in kilo-
base size, by which the unstable element was amplified
relative to the normal 1.0-kb PstI fragment was mea-
sured as A, adopting the nomenclature of Oberle et
al. (1991). For higher resolution of unstable-element
band length, chromosomal DNA was digested to com-
pletion with Sau3AI prior to electrophoresis on 1.3%
agarose gels and was probed with pfxa3 alone.
Cytogenetic Detection of the Fragile-X Site
The fragile-X site was detected in lymphocytes by
culture in folic acid-free medium or by induction with
300 mg thymidine/liter or 0.05 mg FUdR/liter (Suth-
erland and Baker 1990).
Methylation at the Fragile-X Locus
Methylation at the fragile-X locus was detected by
the resistance of the methylation-sensitive SacIl re-
striction site to digestion. To limit methylation detec-
tion to the single SacII site in the CpG island immedi-
ately proximal to the fragile X p(CCG)n repeat, the
chromosomal DNA was also cleaved with EcoRI. The
double-digested (SaclI and EcoRI)DNA was subjected
to electrophoresis on 0.8% agarose gels and was
probed with pfxa3 as described above. The increase
in SacMI-Ecoll band length conferred by amplification
of the fragile-X unstable element allowed distinction
between the normal and fragile-X chromosomes in
females. The percentage methylation was estimated
by visual comparison of the relative intensity of the
hybridization bands, approximated to the nearest 5%
or 10%.
PCR Across the p(CCG)n Repeat
PCR across the p(CCG)n repeat was accomplished
using a modification of the reaction conditions of Ko-
gan et al. (1987). Because of the exceptionally high
GC content of this region, 7-deaza-dGTP was used in
place of dGTP. The reactions were performed in a
volume of 10 pl with 5 gCi of alpha-32PdCTP and
were visualized by autoradiography for 72 h after elec-
trophoresis on 6% polyacrylamide-urea gels. Ther-
mal cycle conditions were as described elsewhere
(Richards et al. 1991a, 1991b) and consisted of 10
cycles of 940C for 60 s, 60°C for 90 s, and 720C for
90 s, followed by 25 cycles of 940C for 60 s, 550C for
90 s, and 720C for 90 s and a final extension at 720C
for 10 min. Primers utilized were 203 and 213 of
Kremer et al. (1991). The electrophoretic mobility of
the p(CCG)n-containing sequence (in certain instances
of known length) was inconsistent with the mobility
ofDNA size markers on both acrylamide and agarose
gels, presumably as a consequence of the unusual base
composition. This is evident (in fig. 6B) by the large
discrepancy between the dystrophin PCR markers
(388 bp, 360 bp, and 331 bp) and the 203/213 PCR
products when pfxa2 (Kremer et al. 1991) is used
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Figure I A, Distribution of unstable element length in fragile-X males indicating relationship to phenotype. H = Transmitting male;
and f = affected male. B, Correlation between unstable-element length in fragile-X males and the percentage of cells that express the fragile
site in culture. C, Correlation between unstable-element length in fragile-X females and the percentage of cells that express the fragile site
in culture. For the individuals with multiple bands, only the site of the largest detected band was scored.
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Figure 2 Correlation between unstable-element length in fragile X-carrier mothers and that in their fragile X-genotype offspring.
The change in length of the pfxa3 Pstl fragment in mothers is indicated beneath each column, and the change in length of the pfxa3 PstI
fragment in their offspring is plotted above. The number of mothers with each element length is indicated in parentheses. Females are
denoted by unblackened circles; male carriers are denoted by unblackened squares; and affected males are denoted by blackened squares.
taining sequences must therefore be considered ap-
proximations.
Results
Correlation between Size of the Amplified Element
and Phenotype
The fragile-X genotype is characterized by an unsta-
ble DNA element manifested as either a single band
or multiple bands of increased size on Southern blot
analysis. The properties of the segregation of this
novel DNA element (referred to as an amplification
here) were examined using the pfxa3 probe to detect
the amplified region. The 49 fragile-X syndrome-
affected pedigrees analyzed consisted of 120 normal
and 85 fragile X-genotype males and 90 normal and
125 fragile X-genotype females. The normal 1-kb PstI
band (for simplicity, referred to as A = 0 kb) was
replaced by one or more bands of increased but vari-
able size in all males with fragile-X genotype. The
variable bands seen in the affected individuals (fig.
1A) are larger than A = 0.6 kb, while in 16 transmit-
ting males they are smaller than or equal to A = 0.6
kb (fig. 1A). It would thus appear that, in males, small
amplification of the unstable element is tolerable as
far as the functions of the target tissue are concerned,
but once the amplification reaches a certain size, either
it fails to generate enough gene product, or variation
in the gene product results in failure of its function.
Correlation for both sexes was found between cytoge-
netic expression and size of the amplified region (fig.
1B and C). Among female carriers, those with small
amplifications (A < 0.6 kb) were not mentally im-
paired and often did not express the fragile site cytoge-
netically; those with larger amplifications usually had
cytogenetic expression of the fragile site and could
be either normal carriers or mentally affected. This
observation implies that factors other than amplifica-
tion, such as methylation of this region of the X chro-
mosome and/or nonrandom X inactivation in cells
of the target tissues, may contribute to the pheno-
type, especially to intellectual status, in female hetero-
zygotes.
Segregation Patterns
Fragile-X syndrome has an unusual and characteris-















the unique phenomenon of an X-linked disorder with
phenotypically normal carrier males (male transmit-
ters) and also to the different frequency of affected
males in different generations within a pedigree (the
Sherman paradox). Analysis of the transmission of the
unstable element through affected pedigrees usually
revealed marked amplification when transmitted by
carrier females (small decrease was observed in two
cases) but revealed only small or no amplification
when transmitted by males. In addition, the risk of a
female carrier having an affected son increased with
the length of her amplified sequence. Figure 2 shows
that female carriers with A = 0.1 kb (".70 copies of
CCG) usually produce only small increases up to A
= 0.3 kb (<140 copies) in the successive generation;
those with A = 0.2 kb ('v110 copies of CCG) may
have small (<0.6 kb; <200 copies) or large (A > 0.6;
>200 copies) increases in length. By comparison,
those carrier females with A = 0.3 kb-0.5 kb ("'140-
210 copies of CCG) usually had offspring with large
increases. As a result, when the fragile X was passed
on by carrier women with small amplifications (i.e.,
A <- 0.2 kb), they had either transmitting or affected
sons, while those with larger amplifications (i.e., A >
0.2 kb) had only affected sons. Therefore, the size of
the unstable element in carrier women is significant
for genetic counseling.
The pattern of transmission of the unstable element
explains the Sherman paradox, in which the pene-
trance of the mutation, as measured by intellectual
status, was greater in the offspring of daughters of
transmitting males than in the offspring of the mothers
of transmitting males. The mothers and daughters of
transmitting males, who were assumed to be of identi-
cal genotype, should have a similar ratio of affected
and unaffected offspring, but this was not the case.
The study of the transmission of the unstable element
indicates that mothers and daughters of transmitting
males are at different stages ofprogression of the muta-
tion. The DNA element is less stable when transmitted
by females than when transmitted by males. Since the
instability correlates with length of the p(CCG)n re-
peat, and since the amplification is usually observed
to increase progressively through fragile-X pedigrees,
the daughters of transmitting males, who will usually
have larger amplifications than the mothers of trans-
mitting males, are at greater risk of having affected
sons.
Methylation
Methylation of the SacIl site, adjacent to the
p(CCG)n repeat, was examined in fragile-X pedigrees








Figure 3 Methylation at the fragile X site. A, Methylation
at the SacII site in the CpG island adjacent to the fragile-X site,
determined by cleavage ofchromosomal DNA with EcoRI and SacII
and by probing the electrophoresed DNA with pfxa3. Lane 1, Nor-
mal male DNA cleaved with EcoRI only, to show the normal size
of the pfxa3 hybridizing fragment (5.0 kb). Lanes 2, 3, and 5,
SacIM-EcoRI-cut genomic DNA of three carrier females with dif-
ferent-size amplifications. Varying degrees of methylation of the
fragile-X and normalX chromosomes (constant 2.8-kb band is from
the normal X chromosome) are apparent. Lane 4, SaclI-EcoRI-cut
genomicDNA of an affected male showing almost total methylation
of the SacII site. Shown are the position of the normal methylated
(unblackened arrowhead) and the position of the unmethylated
(blackened arrowhead) pfxa3 hybridizing bands. B, Correlation of
methylation with length of p(CCG)n sequence in fragile X-pedigree
males. Normal transmitting males are denoted by unblackened
squares; and affected males are denoted by blackened squares. As-
terisks indicate affected males with multiple bands, exhibiting meth-
ylation in only those bands above A = 0.3 kb. Numbers above
symbols indicate the number of individuals at the same position. C,
Degree of methylation in females of the fragile-X and normal X
chromosomes, plotted against length of the fragile-X unstable ele-
ment. The degree of methylation was judged visually.
in order to determine the utility of methylation status
for phenotype prediction in carrier females and for
prenatal diagnosis. Genomic DNA was cleaved with
EcoRI and with EcoRI plus SacII and was probed with
pfxa3 after Southern blotting. If the SacII site was
methylated, then the normal X gave a band of nv5.2 kb
for both restriction-endonuclease digests when pfxa3
was used as probe. If the SacII site was not methylated,
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Figure 4 Somatic variation at the fragile-X site. Southern
blot analysis of PstI-digested chromosomal DNA from various cell
types that was probed with pfxa3. The probe pS8, which hybridizes
to a unique 800-bp PstI fragment on the X chromosome, was used
as a positive control. A, DNAs from a fragile X-carrier female (KO
from family 5). B, DNAs from a fragile X-affected male (AM from
family 4).
bridizing band of 2.8 kb. Fragile X-genotype chromo-
somal DNA gave fragments that increased from these
sizes by the length of the amplification. These could
be readily distinguished from the normal X chromo-
some in carrier females (fig. 3C). Figure 3A shows
a clear correlation of methylation with length of the
unstable element in males. The methylation status of
the SacII sites on the normal and fragile-X chromo-
somes in carrier females was analyzed. As shown in
figure 3B, the normal X chromosome usually exhib-
ited <50% methylation, while the fragile-X chromo-
some showed <50% methylation (if the amplification
A 0.6 kb) or >50% methylation (if the amplification
A > 0.6 kb). This indicates again a correlation be-
tween methylation and unstable-element length.
Somatic Variation
To test the hypothesis that the multiple bands fre-
quently observed from fragile X-affected individuals
were due to somatic instability of the unstable ele-
ment, DNA was isolated from lymphocytes and from
cultured fibroblasts and/or Epstein-Barr virus-trans-
formed lymphoblast cell lines from 23 individuals (in-
cluding affected males, carrier females, and normals)
in nine fragile X-syndrome pedigrees. Figure 4 dem-
onstrates the results obtained for a female carrier and
an affected male. In all 11 affected males, regardless
of whether instability was observed in the lymphocyte
DNA, one or more bands of different length were ob-
served in cultured cell lines. The results of the analysis
of the somatic variation between the different tissues
are shown in table 1. No somatic variation was de-
tected in eight normal individuals (four male and four
female). Among four carrier females, the three carriers
with small amplification (A = 0.1-0.2 kb) showed
no somatic variation, while the carrier with a slightly
larger amplification (A = 0.7 kb) exhibited obvious
somatic variation between different tissues (table 1).
All the individuals for whom somatic variation has
been observed were positive for cytogenetic expression
of the fragile X.
Mutation
No evidence of new mutation was detected in the
42 initial pedigrees analyzed, which included three
isolated cases, three pedigrees in which the earliest
female carrier could have been a new mutant, and
the four-generation pedigree shown in figure 5. In an
attempt to identify instances ofnew mutation, the ped-
igrees of an additional seven apparently isolated cases
of fragile X (G. Turner, unpublished data) were ana-
lyzed. In all 10 apparently isolated cases (eight affected
males and two affected females), the pfxa3 probe dem-
onstrated that the mother carried the fragile-X geno-
type; and, where DNA was available (in two families),
it was found that one of the relevant grandparents
was also a carrier. In another pedigree, several distant
relatives of the affected girl were found to be carriers
by pfxa3, indicating that one of the great-grand-
parents of the affected girl was an obligate carrier. All
affected individuals were found to have both a parent
who had a fragile-X genotype and (where testing was
possible) a grandparent who had a fragile-X genotype.
In all 14 affected pedigrees, in which it was possible
to observe a new mutation (because of availability of
material), no such new mutation was observed.
It is clear that the mutation of the fragile X proceeds
from a predisposed state, itself a minor amplification,
which leads in subsequent generations to a major am-
plification. In different individuals, the relative size of
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Change in size of Pstl fragment detected by pfxa3.
b Less than half of dosage.
the unstable element detected by either Southern blot
or PCR was identical (fig. 6), confirming the localiza-
tion of the unstable region to the p(CCG). repeat and
clearly demonstrating the wide range of lengths of this
sequence in normal individuals. Each PCR product
gave a cluster of four bands for each allele; while this
is a common property for PCR products from microsat-
ellite repeats, its molecular basis is not clear. While
PCR was able to amplify across the repeat sequence of
some fragile-X carriers, no products were obtained
from carriers or from affected individuals with large
unstable-element sequences (data not shown). Fur-
thermore, in carrier females there was preferential am-
plification of the normal (shorter) allele (fig. 6, lanes 4
and 7), indicating the limitations ofPCR for fragile-X
diagnosis. Application of PCR to diagnosis is further
complicated by somatic variation, which may result
in an affected individual having one or more bands in
the normal range. The risk of false-negative results in
such instances would appear substantial.
The exact repeat length at which phenotype is










Figure 5 Inheritance of the fragile-X unstable element in a
four-generation lineage from a large affected pedigree. Chromo-
somal DNA was digested with PstI and was probed with pfxa3. The
control probe pS8 was included in the hybridization. Dot in square
indicates normal carrier male; dot in circle indicates normal carrier
female not expressing the fragile X; half-blackened circle indicates
normal carrier female expressing the fragile X; blackened square
indicates affected fragile X syndrome male expressing the fragile X;
and unblackened circle indicates normal female. All carriers are
obligate carriers.
cation corresponding to more than "'240 copies of the
repeat are affected, whereas those with fewer than this
number were transmitting males. The exact length at
which a random individual ought be considered an
asymptomatic carrier is also not clear. The variation
in length observed from high-resolution Southern
blots in the normal population corresponds to 15-65
copies of the p(CCG)n repeat. The smallest amplifica-
tion observed in apparently asymptomatic carriers
(corresponding to "'70 copies of p(CCG)n) is very
close to the biggest band observed in the normal popu-
lation (fig. 6). Since the data suggest that instability is
related to repeat length, individuals with longer re-
peats would be at greater risk of transmitting an even
longer p(CCG)n repeat to their offspring, and yet they
would only be scored as carriers if this probability had
been realized. Mutation in the fragile X would appear
to be a continuous process rather than a simple one-
or two-step process involving a premutation followed
by a full mutation. Isolated affected individuals who
have the amplified unstable element should therefore
be considered as familial, rather than as possible new
mutations.
Discussion
The instability associated with the fragile X has
been localized to a trinucleotide repeat p(CCG)n
(Kremer et al. 1991; Yu et al. 1991), where in normal
individuals n has been approximated to the range of
40 + 25 (by Southern blots; Kremer et al. 1991) or
30 + 24 (by PCR; Fu et al. 1991). The molecular basis
for the instability could be either insertion or increase
in repeat copy number (as instability is most frequently
characterized by an increase in fragment length). The
most parsimonious view of the molecular basis is vari-
ation in repeat copy number, since oligonucleotide
repeat sequences of this type frequently exhibit such
variation. Although the possibility of insertion of for-
eign sequences has not been excluded, such a mecha-
nism is difficult to reconcile with the observed proper-
ties of the unstable sequence.
Several reports have shown that differences in meth-
ylation in the vicinity of the fragile-X site exist between
normal and affected members of fragile X-syndrome
pedigrees (Bell et al. 1991; Oberle et al. 1991; Vincent
et al. 1991). In addition, DNA from chorionic villi
of an affected male fetus (Sutherland et al. 1991a)
exhibited no SacII methylation, which was uncharac-
teristic of its 2.4-kb PstI fragment (A = 1.4 kb). Fur-
thermore, no methylation was detected in this DNA
at the NruI, BssHII, or EagI sites common to the SacII
CpG island (data not shown). Tissues from the termi-
nated fetus, other than fetal chorionic villi, exhibited
both the 2.4-kb PstI fragment (A = 1.4 kb) and vary-
ing degrees of methylation of the SacII site. Methyla-
tion status does not provide additional information on
fragile-X phenotype and may, in certain tissues such
as chorionic villi, be misleading (Oberle et al. 1991;
Sutherland et al. 1991a). Methylation is therefore
likely to be a consequence of the fragile-X mutation
(p(CCG)n amplification), and its progression through
development may differ from one tissue to the next.
Whether methylation has any causative role in fragile
X-syndrome phenotype is yet to be established.
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Figure 6 Variation in unstable-element length. A, Genomic
DNA from normal and fragile-X individuals that was digested with
Sau3AI and probed with pfxa3 to give accurate sizing and discrimi-
nation of unstable-element length. The normal male DNAs were
chosen to represent the range including the maximum (lane 6),
corresponding to ,.,60 copies of the p(CCG). repeat, and minimum
(lane 1), corresponding to "'15 copies of the p(CCG)n repeat,
Laird (1987) has postulated a role for genetic im-
printing in the transmission pattern of the fragile X.
In this hypothesis, the passage of the X chromosomes
through a female predicts a different pattern ofmethyl-
ation on the inactiveX compared with its active homo-
logue. If the mutated X is methylated, the son of such
a carrier female will be affected; if the mutated X is
not methylated, then the son will be unaffected. Fur-
thermore, according to Laird's X-inactivation im-
printing model, once imprinted (methylation in frag-
ile-X syndrome) the fragile-X chromosome remains
stably imprinted when transmitted through the mother.
However, four methylation-sensitive restriction-enzyme
recognition sites in the vicinity of the fragile X-CpG
island were unmethylated in chorionic villus, even
though the SaclI site was methylated to different de-
grees in other tissues of the fetus tested (Sutherland et
al. 1991a). In addition, in two affected males with
multiple bands, methylation was detected in bands
with A > 0.6 kb, whereas bands below this size were
completely unmethylated (fig. 3B). These results fail
to provide experimental evidence in support of the
imprinting hypothesis. The correlation between the
length ofthe unstable element and phenotype in males,
and the observation that methylation correlates with
length, suggest that methylation may be a consequence
of amplification and that maternal X inactivation need
not have a role in determining the phenotype of the
offspring.
Since the amplified sequence p(CCG). contains
many additional targets for methylation, we propose
that increased methylation is a function of amplifica-
tion. Indeed, in fetal tissues, amplification has been
observed in the absence of methylation (Oberle et al.
1991; Sutherland et al. 1991a). Methylation may have
a role in the phenotypic manifestations of the disorder,
but it does not appear to be involved in determining
the transmission of the phenotype.
In the normal population, the p(CCG). repeat is
highly polymorphic although stable within pedigrees
(Kremer et al. 1991). Variation in copy number of
unstable-element lengths detected in >100 unrelated normal indi-
viduals tested. The three fragile-X carriers shown have the smallest
fragile-X unstable elements (corresponding to "'70-80 copies of the
p(CCG). repeat) detected in >200 fragile X-genotype individuals.
Size markers are indicated in kilobases. B, PCR performed on the
same chromosomal DNA samples as in A. Size markers were PCR
products from the dystrophin locus (Chamberlain et al. 1988) and
the 203/213 reaction using pfxa2 DNA (Kremer et al. 1991) as
template. Arrows indicate the position of faint products of the




polymorphic oligonucleotide repeats is a common
property of such sequences (Weber and May 1989).
Extent of polymorphism is directly proportional to
repeat length, suggesting that longer repeat sequences
have a higher rate of new mutation. This rate is nor-
mally relatively low, as the majority of AC repeats
(whose copy number is always <40) exhibit normal
Mendelian inheritance. Instances of new mutation at
AC repeats have been noted (Dracopoli et al. 1991).
In addition to dinucleotide repeats, the microsatellite
sequences also include trinucleotide and tetranucleo-
tide repeats. The p(CCG). repeat identified at the frag-
ile X is therefore a member of the microsatellite repeat
class of sequences and ought therefore to have proper-
ties in common with the well-characterized repeats,
most notably the property that mutability is propor-
tional to length. In fragile-X pedigrees, all affected
individuals have a parent with a copy number above
the normal range. The instability is almost always re-
flected by an increase in repeat copy number, although
decreases have been seen in three independent pedi-
grees. The preponderance of increases probably re-
flects bias of ascertainment, in favor of the genotype
that is responsible for fragile-X syndrome.
The relationship between repeat copy number and
instability extends further than the differences seen
between generations in affected pedigrees. In fragile
X-genotype individuals with large pfxa3 hybridizing
bands (corresponding to repeat copy numbers >230),
somatic variation is evident. The mutation rate of the
repeat sequence is now so high as to result in variation
between somatic cell lineages. In these instances, the
further instability is often characterized by reduction
in repeat copy number, giving rise to multiple bands
in DNA samples from the one affected individual-
and even in DNA samples from a single tissue. This
somatic variation does complicate the correlation be-
tween repeat length and phenotype, although all males
who exhibit this variation are affected. It is possible
that such instability may lead to deletion of the re-
peat-down to the range permissive of gene function
in the tissues which produce the fragile-X phenotype-
and that the individual therefore would be unaffected.
The mechanism of amplification is in itself puzzling.
Linkage analysis using informative and closely linked
flanking markers demonstrates that amplification does
not occur as a result of meiotic recombination. The
haplotype incorporating the affected allele is transmit-
ted through affected pedigrees with rates of recombi-
nation consonant with map distances (Richards et al.
1991a, 1991 b; Suthers et al. 1991a, 1991 b). Amplifi-
cation occurs in the pedigree in the absence ofrecombi-
nation between flanking markers.
The trinucleotide p(CCG)n repeat has been found in
several other locations in the human genome. Poly-
morphism of the p(CCG)n sequence in the ribosomal
RNA genes on chromosome 21p has been reported
(Gonzalez et al. 1985). This repeat is present at the
breakpoint of a t(X;21) (p21;p12) translocation in a
female with Duchenne muscular dystrophy (Bodrug et
al. 1987) and in the 5' untranslated region of the BCR
gene, which undergoes translocation with the ABL
gene in the genesis of the t(9;22) Philadelphia chromo-
some (Zhu et al. 1990). The difficulties encountered
in cloning the sequences containing the repeat, as well
as the frequent deletion of these sequences during clon-
ing, suggest that none of the reported DNA sequences,
which have all been derived from cloned DNA, repre-
sent the true length of p(CCG). repeats in the human
chromosome, although the sequences of 20 and 30
copies obtained by Oberle et al. (1991) and Verkerk
et al. (1991), respectively, are in the normal range.
PCR across these sequences, while successful in nor-
mal individuals and in carriers with small amplifica-
tions, has been problematic in affected individuals.
Genomic sequencing, if technically feasible, may pro-
vide the only means of establishing the true in vivo
length of p(CCG)n repeats and of confirming that am-
plification, rather than insertion, is involved in length
variation in affected individuals.
Mutation at the fragile X does not manifest at the
molecular level in the same way we normally view
insertions, substitutions, and deletions. The normal
genotype consists of a range of copy numbers of the
repeat, and an increase in copy number merely predis-
poses to further increases (or decreases). The correla-
tion of repeat length and phenotype does imply a direct
role for variation of the repeat copy number as the
mechanism of mutation of the disease, although no
functional data are yet available to support this. The
40 + 25 (or 30 + 24) copies of the repeat in normal
individuals, which is uncommonly high for this type
of repeat, suggests that this sequence may itself have
a function.
Index cases with rare autosomal folate-sensitive frag-
ile sites (the same type of fragile site as the fragile
X) always appear to inherit the fragile site from their
mothers. In the study by Sherman and Sutherland
(1986), 17 of 19 index cases had maternally derived
fragile sites; the other two had an obligate carrier par-
ent in whom the fragile site was not detected. In the
same study it was shown that fragile sites were fully
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penetrant when transmitted by women but were only
50% penetrant when transmitted by men. Although
the fragile X is the only one of these sites for which
there is an associated phenotype, it should be noted
that none of the other folate-sensitive fragile sites
(which are all on autosomes) has ever been seen in a
homozygous state. These segregation patterns suggest
that a similar unstable element may be involved (Suth-
erland et al. 1991).
Verkerk et al. (1991) have recently reported the
partial sequence of a cDNA (FMR-1) from the
fragile-X locus, which includes the p(CCG). repeat
and sequences 3' to it. An open reading frame was
observed, suggesting that the p(CCG)n repeat may be
translated as well as transcribed. A consensus peptide
sequence for nuclear translocation was identified, and
the authors suggest that the FMR-1 gene might encode
a nuclear protein. However, an ATG which conforms
to the eukaryote consensus for initiation of translation
is found 69 bases 3' to the p(CCG)n repeat, suggesting
that the repeat may be located in the 5' untranslated
region. Indeed, this methionine residue is followed by
13 of 20 hydrophobic amino acids, which is character-
istic of an extracellular signal peptide. The compart-
mentalization and function of the FMR-1 protein
product, as well as the translation of the p(CCG)n
repeat, need to be clarified. It is clear that (a) the char-
acterization of a gene, either FMR-1 or some other
transcript, which is responsible for manifesting the
fragile-X phenotype and (b) the characterization of
other folate-sensitive fragile sites constitute important
further approaches to understanding the molecular
basis of fragile-X syndrome.
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The trlnucleotlde repeat sequences which become unstable In fragile X syndrome and myotontc dystrophy are
located In the untranslated regions of their respective genes, FMR1 and DM1. This Implies that a functional
constraint other than coding capacity maintains the presence of the repeats. In the case of fragile X syndrome,
sequences adjacent to the repeat are methylated In affected Individuals and the FMR1 gene Is transcriptlonally
Inactive. We demonstrate that the fragile X p(CCG)n repeat Itself Is methylated In vivo and that methylation of
this repeat Is able to Inhibit In vitro binding of a novel, specific nuclear p(CCG)n binding protein (CCG-BP1) —
one of at least 10 distinct simple tandem repeat sequence binding proteins (STR-BPs). We describe additional,
apparently distinct, binding activities both for the methylated form of the p(CCG)n repeat and for each of the
single strands of the repeat.
INTRODUCTION
Simple tmnVm repeat sequences are widely distributed throughout
mammalian genomes and frequently exhibit polymorphism due
to variation in repeat copy number (1). The variation in copy
number is in some way related to stability such that higher copy
number sequences are more likely to mutate. Therefore the
mutability of a product of mutation is different from that of its
precursor. This nwhnniam has been termed dynamic mutation
(2, 3). When located within a gene the dynamic mutation can
lead to a disease phenotype with unusual inheritance
characteristics, most notably anticipation (4) — increasing severity
of the disorder with successive generations — due to increasing
instability of the repeat sequence. In such cases the repeat
sequence has been referred to as a heritable unstable element (2).
Heritable unstable sequences characterized to date consist of
triplet repeat sequences; p(CCG)n for fragile X syndrome (5),
p(AGC)n for myotonic dystrophy (6), spinal and bulbar muscular
atrophy (Kennedy disease) (7) and Huntington disease (8). In the
case of fragile X syndrome (9, 10) and myotonic dystrophy (6)
these repeat sequences are located in the untranslated regions of
the genes (FMR1 and DM1 respectively) in which they are
transcribed. In addition, the FMR1 p(CCG)n repeat demonstrates
conservation in position throughout mammalian evolution
although the distribution in number of repeats varies between
species (11). Therefore in diseases caused by dynamic mutation
some function other than translation into the encoded protein is
affected by the amplification of the heritable unstable repeat
sequences. For fragile X syndrome the transcription of the FMR1
gene is terminated and flanking sequences hypermethylated after
amplification of the p(CCG)n repeat (12).
p(CCG)n repeat sequences are located in the 5' untranslated
regions of a number of other human genes (3, 13). in the case
of the BCR gene this sequence has been characterized as the
binding site for a nuclear protein (14). We have therefore
searched for nuclear binding proteins for simple tandem repeat
sequences. Each of the dinucleotide and trinucleotide simple
tandem repeat sequences binds one or more nuclear proteins all
of which demonstrate at least some degree of sequence specificity.
The fragile X p(CCG)n binding proteins were characterized with
respect to the properties of&cFMRl repeat in vivo and possible
roles in the molecular pathway from fragile X syndrome genotype
to phenotype.
RESULTS
Methylation of the fragile X syndrome p(CCG)n repeat
Oberle" et al. (IS) have previously demonstrated a correlation
between fragile X syndrome phenotype and methylation of a CpG
island adjacent to the fragile X heritable unstable element, later
shown to be a p(CCG)n repeat (5). Methylation of the CpG island
was identified by inhibition of restriction cleavage of a number
of methylation sensitive restriction enzymes with CpG in their
recognition site. These enzymes are usually referred to as 'rare-
cutters' and their recognition sites are frequently clustered in CpG
islands adjacent to genes. The fragile X p(CCG)n repeat itself
* To whom thoulri be
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Figure 1. Methylatlon of the p(CCG)n repeat in a fimgOe X affected male. A. Location of methytabo
dependent!
Pno4HI ekes in and around the fragile X p(CCG)n
thylatlon and the location of the ffsa3 probe uaedrepeat. The location of the previously characterized CpG island anodated with fragile X i>
in Southern blot analysis. B. Southern blot, probed with pfm3, of DNA from normal male (M), and fragile X syndrome male (FXM). DNAs were digested with
Fno4HI, PstI or both enzymes as H r i
contains a site for methylation. The restriction enzyme Fno4HI
with its restriction cleavage site CGNCG is able to cleave the
p(CCG)n repeat bat only in the absence of methylation.
Figure 1A shows the location of Fnu4HI restriction sites in and
around the fragile X p(CCG)n repeat (S, 16) and also the location
of thepfxa3 (17) probe sequences used to detect Fnu4HI digest
fragments on Southern blots of DNA from a normal and a fragile
X affected male. (Figure IB). If there were no or few sites of
methylation of the p(CCG)n repeat then there would be no
difference in the Fno4HI restriction fragments detected by pfxa3
between a normal and an affected individual. Clearly the
methylation is preventing cleavage both within the p(CCG)n
repeat and even more distant to it in die DNA sample from die
affected individual, since the 390 bp fragment is absent in Fnu4HI
digests. Methylation in the fragile X region therefore includes
the p(CCG)n repeat itself.
While it is difficult to draw accurate conclusions from lane
to lane comparisons of Southern blots (due to variation in transfer
efficiency and membrane binding capacity) it appears as though
the reduced signal in die FXM lane may reflect a smearing of
die hybridisation signal and therefore incomplete methylation.
The absence of any detectable 390 base pair fragment in the FXM
Fnu4HI digest suggests that partially (or totally) unmedrylated
DNA sequences (if present at all) represent only a small
proportion of die total.
Hansen etal (18) have recently reported similar findings using
bom Fnu4HI and Acil to probe methylation in die vicinity of
the FMR-1 p(CCG)n repeat. Their more detailed analysis
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Hgve 3. p(CCG)n.p(COG>i repot copy amber required far C0G.BP1 binding.
Synthetic doable-itnmded 30 men far either the p(CCG)n repeat alone (10 copies)
or the p(CCG)n repeat and FMR-1 flanking sequences (with either copy number
of 4, 5 or 6) were radiolabelled and uaed to may for CCG.BPl binding activity
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F1|DR 2. A. Specificity of CCG.BPl binding teaed by couaiajtiou with DNA
Mmitiig gfeef for known mmcriptioo fiKton. The M"Hing of ^P4abeDed
p(CCG)lo.p(COG),o to a HeLa cell nuclear protein was challenged by
i with excess cuucemiaiiom of a variety of unhbriled DNAi. The
no HCXJI fffi Ĥ yî r̂ ̂ tjucti wnflc "̂̂  positive cootroi
QO ̂ nii)K^Mor DNA. All other lines hive 50 pmote of the imlibeDed
Bi Specificity of CCG.BPl HiiMtipff tf ttpo by C4HiiiTrt K ton
with di- and tri-uudeotide simple tandem repeat irqucnrrs. The same reagenti
and conditkns as in A. were used J*L*JJ4 dM the
syndietic 30 men of each of die unlabefled co




demonstrated a similar pattern of CpG methylation for both
inactive X female and fragile X (affected male) chromosomes
although the degree of methylation appeared more extensive in
the latter.
Nuclear DNA binding proteins and simple tandem repeats
The p(CCG)n repeat in the 5' untranslated region of the human
BCR gene has previously been shown to be the binding site for
a nuclear protein (14). We therefore sought to characterize this
protein in terms of its identity (whether it was a previously
characterized transcription factor) and its specificity for p(CCG)n
as opposed to a relatively non-specific simple tandem repeat
binding protein. HeLa cells were chosen as a source of nuclear
proteins because the FMR1 gene was found by reverse
transcriptase PCR assay to be transcriptionalry active in these
cells. (K.H. and R.I.R., unpublished observations). Figure 2A
demonstrates that p(CCG)n binding by HeLa cell nuclear protein
is not competed off by consensus binding she oligos for a number
of well characterized nuclear transcription factors. Thep(CCG)n
repeat is very similar in sequence to the consensus binding sites
for Spl and AP2 yet neither of the synthetic sequences for these
transcription factors competes for p(CCG)n binding. In addition
(Figure 2B) none of the other simple tandem repeats is able to
compete for p(CCG)n binding. We therefore designated this
binding protein CCG-BP1.
The p(CCO)n repeat in FMR1 associated with fragile X
syndrome is polymorphic in the normal population. The normal
copy number ranges upward from 6 copies (16). This lower limit
of copy number may represent a minimum functional requirement
for protein binding to the p(CCG)n repeat. We tested this
hypothesis by the synthesis of double-stranded DNAs of 30 base
pairs in length representing the FMR1 repeat and flanking
sequences (16) for bandshift assays. Sequences corresponding
to four, five and six copies of the repeat were tested. Only the
DNA containing six copies of the repeat gave comparable CCG-
BP1 binding to the p(CCG)lo.p(CXjG)1o — corresponding to ten
copies of the repeat (Figure 3B). The ten copy, p(CCG)n, repeat
was able to compete for CCG.BPl binding with its six copy
(FMR1) counterpart (data not shown) confirming the identity of
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in the pretence (+) and absence ( - ) of HeLa cell noclev extract.
idem repeat Synthetic double ided 30 men for etch di- and tri-node epeit' :
 MP labelled and incubated
die bandshift signals. It tiierefore appears that the minimum
normal human copy number corresponds to the minimum copy
number requirement for CCG.BPl binding and (presumably)
function. In addition this experiment demonstrates fast CCG.BPl
is able to bind in vitro to the p(CCG)n repeat sequence in the
context of FMR1 flanking sequences. Preliminary DNAse I
protection (footprint) experiments using the FMR1 promoter
region and HeLa nuclear proteins are consistent witfi the bandshift
experiments (K.H. and R.I.R., unpublished results).
Since the p(AGQn repeat associated with myotonic dystrophy
also appears to be located in the untranslated region of a gene,
DM1 we tested this and die other simple tandem repeats for their
ability to bind nuclear proteins. In this assay it can be seen
(Figure 4) that all die repeats tested were capable of binding by
nuclear proteins. In several instances multiple band shifts were
present indicating that either multiple proteins were binding a
single repeat or that die band shifts of slower mobility were due
to the formation of complexes which included the higher mobility
band shift protein. Variation in die intensity of these bands
between experiments (data not shown) suggested that the multiple
bands were more likely to be due to die formation of complexes.
Competition experiments (summarised in Table 1) established
that repeats of the composition polypurine/polypyrimidine (i.e.
p(AG)n, p(AAG)n and p(AGG)n are able to compete for the same
nuclear protein. Each of the other repeats bound a unique binding
protein almough eidier die low abundance in HeLa cells or die
low affinity of die p(ACG)n and p(AGQn binding proteins, under
die conditions tested, rendered their characterization problematic.
These binding proteins, as a group, have therefore been termed
simple tandem repeat-binding proteins (STR-BPs).
Effect of methyiatton on CCG-BP binding
Since dw fragile X p(CCG)n repeat is methylated in affected
individuals and this methylation is associated with inactivation
of me FMR1 gene we sought to assess die effect of p(CCG)n
methylation on CCG-BP 1 binding. The synthetic
o.pCCGG^o oligodeoxyribonucleotides were metiiylated
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in vitro using CpG methylase. The memylated p(CCG)n repeat
was used in band-shift assays in eidier radiolabelled (Idnased),
low concentration form or as a high concentration, cold
competitor. In radiolabelled, low concentration form die extent
of mttfaylation was monitored by the degree of protection against
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monomer Labelled Oligo CCG/CGG
MeCPl?
CCG.BP1
Figure 5. The effect of methylabon on CCG.BPL binding. A. Amy of the in vitro methylation of the synthetic double stranded p(CCG).p(COG) 30 mer by M.Sal
msthylaie. ^P labelled 30 men were subjected to direction with Fnu4HI before ( - ) md after (+) methylation. Samples before ( - ) and after (+) Pnu4HI digestion
were subjected to electrophoresis on 20% potyacrylamide-urea gels. Undigested (or protected) 30 mer if shown at the top of the gel, digestion products in the
bottom section of the gd. B. Methylatkn p(CCG)10.p(COO)10 is unable to compete with
 nP labelled unmethylated p(CCG)10.p(COG)10 for CCO.BPl binding.
While an excess of imirfmnii CCG/CGG 30 mer is able to fwprtr for CCO.BPl binding, the methylated repeat is a much poorer competitor. Digestion of either
methylated or mMnHiiyi«tm) p(CCO)jQ.p(COO)jQ with Fnu4Hl ^""'"*1** the nnn*Hiiyij*Fri repeat from both and thus renders itfillifj effective competitors. 10 pmolr
of each unlabelled oligonucleotide was used as cold competitor. C. Binding proteins for methylated p(CCG)10.p((CGG)10. Both unmetfaylated ( - ) and methylated
(+) repeat oligos were ^P radiolibeUcd and "wuh**^ in tbe presence (+) and MT^***" (—) of HeLa cell •*<rl**r extract. The normal mobility of CCO.BPl is
these "*n"^"*n gels is
digestion by the restriction enzyme Fnu4HI (Figure SA). In the
high concentration, cold competitor band-shift experiments
Fnu4HI digestion was used to eliminate partial or unmethylated
sequences (Figure SB).
Figure 5C demonstrates clear inhibition of CCG.BP1 binding
as a consequence of methylatkn. Instead the methylated p(CCG)n
is bound by a higher molecular weight protein (or complex).
Methylated, radiolabclled p(ACG)n (the only other trinucleotide
repeat able to be CpG methylated) gave a band-shift of similar
molecular weight (data not shown) suggesting that this protein
may be a non-sequence specific methyl-CpG binding protein. A
protein which could act in this manner is the previously
characterized MeCPl (19), although this protein is thought to
require more than the ten methyl CpG pairs present in either of
the oligodeoxyribonucleotides tested. Confirmation of the identity
of this protein will require further analysis.
Since the total amount of radiolabelled p(CCG)n bound to
protein in Figure 5C is not greatly affected by methylation and
the unbound radiolabelled p(CCG)n is «rfll in vast excess (of either
binding protein) then it would appear that the effect of methylation
is to directly inhibit CCG.BP1 binding rather than facilitate the
binding of a higher affinity competitor. The binding of the
methylated p(CCG)n binding protein therefore appears to be
independent of CCG.BP1 binding. This view is supported by the
observation that excess methylated p(CCG)n is unable to
effectively compete for CCG.BP1 binding (Figure 5B). All
competition is ffiiminatnH by Fnu4HI digestion demonstrating that
it is unmethylated p(CCG)n sequences that were responsible for
the weak competition observed.
The origin of the faint bands in Figures 3 and 5B is at this
stage unknown. These bands were not reproducible (see Figure 2)
and most of them could not be competed for by unlabelled
oligonucleotides (lane 3, Figure SB), therefore, if they do
represent DNA binding proteins they appear to be not sequence
specific.
Single-strand p(CCG)n and p(CGG)n binding proteins
Single strand simple repeat sequences are able to adopt unusual
structures (20) which may affect normal cellular processes such
as replication and transcription. For this reason we assayed
nuclear extracts for the presence of single strand simple repeat
sequence binding proteins which might stabilize eiher the unusual
structure itself or the complimentary strand facilitating unusual
structure formation. Apparently distinct binding proteins were
detected for each strand of the p(CCG)n repeat (Figure 6) and
several other STRs (data not shown). Binding proteins for single-
stranded pyrimidine-rich DNA sequences have recently been
identified (21 and references therein). The most thoroughly
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Single-drnided p(CCG)jn end P(CGG)IQ binding piotrira. Each tingle
^rmyi of the "Hff"C- X reped WM ^ P iwtioiMnf UPO sod iocubNboG in the presence
( + ) md absence ( - ) of Hell cefl nuclear extract. The normal mobility of the
double Branded binding piutelu, CCG.BP1, if m
characterised of these is a protein (p70) isolated from mouse
tumor cells which binds to the single-stranded repeat p(CCT)n
(21). Competition bandshift assays demonstrated that neither of
the proteins binding to single-stranded forms of the p(CCG)n
repeat is the human homologue of the mouse p70 protein as
unlabelled p(CCG)10 or p(CGG)10 were unable to compete for
labelled p(CCT)10 binding (data not shown).
DISCUSSION
Despite the identification of the mutation responsible for fragile
X syndrome (IS, 17) and the characterization of the affected gene
(10, 22) comparatively little is known about the molecular
pathway from genotype to phenotype in this disease. The fragile
X mutation, along with those for myotonk dystrophy, spinal and
bulbar muscular atrophy and Huntington disease constitute a
unique form of simple tandem repeat sequence amplification
referred to as dynamic mutation (2, 3). For fragile X syndrome
the amplification of the repeat is associated with inactivation of
the gene (FMRI) in which the repeat is transcribed and with
concomitant methylation of the adjacent CpG island (12, 23).
Although a clear relationship between inhibition of transcription
and methylation exists it is not yet dear whether methylation is
a cause or a consequence of transcription inhibition.
Simple tandem repeat sequences have already become popular
as a source of polymorphic markers with which to establish
genetic linkage maps of mammalian genomes (1). The properties
they exhibit that support such utility are variation in copy number
(resulting in polymorphism), frequency and dispersion throughout
the genome. The function of such sequences, in their own right,
is unknown and it has only been in those imamv^s where then-
physical location within a gene is associated with a disease
phenotype that some insight into their function has been gained.
In this study we therefore chose to search for nuclear binding
proteins for each of die four dinucleotide and ten trinucleotide
repeats.
The finding mat the repeats of composition polypurine/poly-
pyrimidine are all able to compete for binding to the same nuclear
protein is of particular interest since sequences of this composition
have been shown to adopt non-B-DNA conformations (19). One
of these conformations, nodule DNA, forms from a triple helix
and it may be that die binding protein for tiiese repeats is binding
to a specific structure rather than a specific sequence. The non-
sequence specific polypurine/pdypyrimidine double-stranded
DNA binding protein described in this study is clearly distinct
from die single-stranded, sequence specific p(CCT)n binding
protein (p70) identified by Muraiso et al. (21).
The fragile X unstable element in either its double or single
strand form binds a number of nuclear proteins. This multiplicity
will necessitate cloning of die individual binding protein cDNAs
in order to assign function in either die normal expression of die
FMRI gene or a role in die molecular pathway from fragile X
syndrome genotype to phenotype. The single stranded binding
proteins are of particular interest in relation to die mechanism
of mutation and expression of die fragile site since it has long
been thought that induction of die fragile site could be a
manifestation of under-replication of fragile site DNA sequences
(24). Binding proteins which might interfere with replication or
stabilize alternative conformations of die repeat may facilitate
slippage mffHiatf-H amplification at die replication forks (25).
The finding of multiple nuclear proteins for simple tnnArn
repeats further supports die hypothesis of a role for these
sequences. Since STRs are abundant and dispersed and at least
on occasion located in transcribed regions of die genome these
elements conform remarkably well to the postulated control
elements of Davidson a aL who suggested that dispersed,
moderately repeated sequences (identified by hybridization
reassociation assays — CJL curves) might play a role in die
coordinated regulation of eukaryote genes (26). Such a role in
die FMRI and other p(CCG)n containing genes awaits functional
analysis of tiiese sequences. Deletion analysis of die p(CCG)n
repeat (and additional sequences) from promoter constructs of
UK BCR gene (14) suggests that the repeat sequence does not
have a major role in basal level transcription, however tiiese
experiments did not address Die role of die repeat in isolation.
Gain-of-function experiments to assess a role for nrnplificH repeat
sequences in FMRI transcription have been problematic due to
the instability of p(CCG)n copy numbers of n>50 in E.coli
(unpublished observations). In addition die possibility exists that
instead of a role in die level of transcription per se that die repeats
are normally involved in coupling FMRI transcription to some
other cellular process, such as replication. The existence of strand
specific single-stranded binding proteins may be indicative of such
a role.
A causal role (if any) of methylation in die phenotypic
manifestation of die fragile X genotype has been difficult to
ascertain since die distinction between cause or consequence is
not yet clear. The finding that methylation specifically interferes
wim the binding of CCG.BP1 and allows the binding of a different
protein (possibly the non-sequence specific MeCPl) suggests a
molecular pathway which can account for the coupling of
methylation to lack of FMRI expression. Amplification of die
repeat may hinder transcription (since the repeat sequences are
able to form unusual structures) in turn causing at least partial
methylation of die repeat. The partially methylated repeat then
brcorro a lower affinity binding site for CCG.BP1 and a higher
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affinity site for the methyl-p(CCG)n binding protein. If this
protein is MeCPl then its binding would further suppress FMR1
transcription since MeCPl is a known repressor of transcription.
In this scenario CCG.BP1 need not take an active role in
transcription but merely be a facilitator of the process, perhaps
by protecting the p(CCG)n repeat from methylation. Whatever
the identity of the methyl-p(CCG)n binding protein its role in
the pathway from fragile X genotype to phenotype warrants
further investigation.
It is of interest that all STR.BPs exhibit at least some degree
of specificity. Since at least two of the repeats, p(CCG)n and
p(AGC)n, are associated with important human genetic (tisfflfffl
any relationship between their respective binding proteins is
intriguing. While apparently distinct, the finding of specific
binding proteins for the fragile X and myotonic dystrophy
unstable elements increases the number of common properties
exhibited by these disorders. Other properties characterized to
date include the phenomenon of anticipation (4, 6) — referred
to as the Sherman paradox for fragile X syndrome, and the
observation of founder chromosomes (27, 28) for both disorders.
METHODS
SoutoBH boot VHUJTHB
Chromosomal DNA wu i>
10 p& subjected to rettrictia
feted from peripiK
Ktonucle dip
nl blood lymphocytes (29) tnd
itioo prior to gel electropborcds
(oo 1.5% agarose), and blotting onto nylon membranes. The mtiiiN'mci were
probed with a- 32NCTP random labelled pfta3 (16) (Mukiprime, Amenbam).
After washing fflten were «wpn««H to autondiograpby for 16 noun at —70°C.
Otigodeoxyribonucleotides, of 30 baaei in length, were chemically synthesized
on an Applied Biotyctemt Inc. model 391 PCR-Mate EP DNA synthesizer.
Trinuckodde repeats all contained 10 copies of the repeat, HhmrbnriiU repeats,
13 copies. The FMR1 30 men were:-
(CCG)4 - forward, 5'-GCGGCAOCaCQOCGGCOGCOGCTaOGCCrC-3',
reverse, 5'<jAGGCCCAO<XGCCOCCXKXC3COCTOCCaC-3';
(CCG)j - forward, 5'-GGCAGCGCGGCGGCGGCGGCOOCTGOGCCT-3',
reverse, 5^ACKXXX>QCCCKX»CCGCCOCCGCOCrGCX:-3';
((XGJj - forward, 5'-aCAGCGCGGCGGCOOaXXX3G(XX3CrOGOC-3',
reverse, 5'<KXXA<KXXKXOCX»CCOCCOCCGCOCrGC-3'
AD odieroligodeoxvribomickotMw (for known traitiJtiUuu factor binding sites)
were purchased from Promega.
Bandsadft
The Bandririft assay wn based on die Promega gel drift assay kk. Otigonudeotides
were end-labelled with gamma-BP-ATP (Amenbam) using T4 porynucleotide
kinase (Bresatec). IS pg HeLa nuclear extract and 10-30 pmote of unlabelled
ouuipetiiui or non-competitor DNA was incubated at room temperature for 10
mm in binding buffer (20% gtycerol, 5 mm Mgdj, 2.3 mm EDTA. 2.3 mm
DTT, 230 mm Nad, 30 mm Tris-Hd pH 7.3 and 0.3 ag/al poly dLdC). 33
ftp"** rf\tk<rf)rA nlign » f thfTI ««MnH «"H fiirthor
for 20 mm. Reactions, were stopped with lOx gd loading buffer (230 mm
Tris-Hd pH 7 5,0.2% bromophenol blue 0.2% xyiene cyanoi and 40% giycerol)
andnman4%noo^lenaliiringporjracrylamidegds(lJmmdiick, 80:1 aaytamide
to bis-acryiamide) at 120 V at room temperature in OJx TBE. The gels were
dried and autondiographed at -70*C overnight
/ • rkn methrtation of DNA
The CpO methykse ( M M ) was purchased from New England Bioiabs and used
according to die manufacturer! directions. Fifty units of enzyme were used for
each microgram of <knir4f jtrarMifd otiyxlffYgvr^innnr^fw*^^ After in
at 37*C for 1 hour an ««Miiimni aliquot of S-adenotyi metfnonme was added
tirf nytinatiori *̂*N*̂ *ff̂  nsr Mm îî t* IM^H t 37 C
The methylated DNA w u radiotabeDed with gamma-^P-ATP and T4
1̂  ŷ M'̂ ^^ kmase (as above) and an ***F^^ subjected to FOSOTKOOD endooudcase
t^t^ftiitui widi Fnu4Hl (New Fjiglin<l Bioiabs). Rctikui products were separated
by electropboresis on a 20% poiyacrylamide-urea • ^ p " * * ^ t^ which was then
autondiographed at -70 'C.
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Fragile X syndrome, one of the most com- 
mon human genetic diseases, is character- 
ized by a unique genetic mechanism which 
involves dynamic mutation in a heritable 
unstable DNA sequence, a p(CCG)n repeat, 
in the FRAXA locus. It has recently been 
suggested that a few founder chromosomes 
are responsible for most fragile X mutations 
in the Caucasian population. In order to in- 
vestigate the origin of the fragile X muta- 
tions in the Japanese population, we ana- 
lyzed haplotypes of the FRAXA locus in 40 
unrelated fragile X chromosomes and 142 
normal X chromosomes in Japanese males, 
by using two polymorphic AC repeats, 
FRAXACl and FRAXAC2, which flank the 
fragile site. This analysis provided evidence 
for founder fragile X chromosomes in the 
Japanese population, similar to that in Cau- 
casians, although different haplotypes are 
involved. The distribution of normal allele 
size of the p(CCG)n repeat among the X 
chromosomes in the Japanese population is 
very similar to that reported for Caucasians, 
except that the most frequent copy number 
(n = 28) is one copy less than that in Cau- 
casians and that there is an additional peak 
at 35 copies. There is significant correlation 
between FRAXAC alleles and the p(CCG)n 
repeat copy number in non-fragile X chro- 
mosomes, however, alleles with more than 
31 copies of the p(CCG)n repeat do not seg- 
regate with either of the fragile X common 
FRAXAC haplotypes. 0 1994 WiIey-Liss, Inc. 
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INTRODUCTION 
The fragile X syndrome is one of the most common 
genetic disorders and is the most common form of fa- 
milial mental handicap. This syndrome is known to be 
associated with the cytogenetic marker of a folate-sen- 
sitive fragile site on the long arm of chromosome X at 
Xq27.3 (FRAXA), but has a very unusual mode of in- 
heritance [Richards and Sutherland, 1992aJ. I t  has re- 
cently been characterized as  involving a dynamic mu- 
tation because of a heritable unstable DNA sequence, 
p(CCG)n/p(CGG)n, at the FRAXA locus [Yu et al., 1991; 
Kremer et al., 1991; Fu et al., 1991; Oberle et al., 19911. 
Recent studies have shown that the fragile X mutation 
results from expansion of the p(CCG)n repeat in the 5‘ 
untranslated region of the FMRl gene a t  the FRAXA 
locus [Verkerk et al., 19911. The size of the restriction 
fragment containing the p(CCG)n repeat increased dra- 
matically in fragile X affected patients (full mutation, n 
> 230). A smaller increase in size was also detected in 
phenotypically normal carriers (premutation, n = 
-50-230), although the p(CCG)n repeat copy number 
varied among normal individuals (n = 5-50). The full 
mutation is associated with methylation in the CpG is- 
land and failure of expression of the FMR-1 gene 
[Pieretti et al., 19911. In general, the p(CCG)n repeat in 
the fragile X chromosome usually increases in size 
when transmitted by female carriers, while there is lit- 
tle alteration or reduction in size when transmitted 
through a male [Rousseau et al., 1991; Hori et al., 
19931. There is no evidence for any de novo mutation, 
all probands having parents who themselves have a 
premutation or full mutation [Yu et al., 1992; Rousseau 
et al., 1991; Smits et al., 19931. 
The increasing size of the unstable repeat through an 
unaffected pedigree is, therefore, accompanied by an 
increase in the percentage of individuals expressing the 
560
Haplotype Analysis on Japanese FRAXA 413 
Hecht, 1985; Hori et al., 19881 and by DNA analysis us- 
ing pPCRfxl as a probe [Yamauchi et al., 1992; Hori et 
al., 1993; Suzumori et al., 1993; Yamauchi et al., 19931. 
FRAXAC1-FRAXACS Haplotype Analysis 
PCR analysis of length variation in the AC repeat 
markers was performed using the oligonucleotide 
primers described by Richards et al. r19911. Alleles 
were identified by electrophoresis of multiple internal 
standards [Richards et al., 1991,19921. 
Determination of p(CCG)n Copy Number 
The copy number of p(CCG)n was determined by 
PCR amplification using the oligonucleotide primers 
203 and 213 described by Kremer et al. [1991] and con- 
ditions described by Yu et al. [1992]. Each allele exhib- 
ited a set of bands of varying intensity, the strongest of 
which was scored as the number of p(CCG)n repeats 
[Richards et al., 19921. Size standards were according 
to  the copy number reported for CEPH pedigree 1408 
by Fu et al. [19911. 
RESULTS AND DISCUSSION 
FRAXAC1-FRAXACS Haplotype Analysis 
Table I summarises the allele frequencies at 
FRAXACl and FRAXAC2 in the Japanese population 
and compares them with the results in Caucasian pop- 
ulations reported by Richards et al. r19921. There were 
distinct differences in the allele frequencies between 
Japanese and Caucasians, both in normal and fragile X 
affected individuals. The fragile X and normal X chro- 
mosomes showed only two different alleles (C and D) 
at the FRAXACl locus and 7 different alleles a t  the 
FRAXAC2 locus in the Japanese population. The most 
frequent allele found at  FRAXACl locus in normal X 
chromosomes was D (69%) and C (77%) in Japanese 
and Caucasians, respectively. The A (50%) and F (25%) 
alleles a t  the FRAXAC2 locus were common in Japan- 
ese, while the E (48%) and D (18%) were more frequent 
than others in Caucasians. 
Two polymorphic AC repeat markers, FRAXACl and 
FRAXAC2, which flank the fragile X p(CCG)n repeat, 
were reported t o  show no recombination with the frag- 
ile X mutation and are in strong linkage disequilibrium 
with one another. Thus, they are able t o  identify the 
DNA (including FRAXA locus) between them as a hap- 
lotype. In normal Japanese X chromosomes, two major 
haplotypes for FRAXAC1-FRAXAC2 were DA (50%) 
and CF (25%), whereas they were CE (48%) and CD 
(17%) in Caucasians. Two haplotypes, CF (43%) and DB 
(20%), were more frequent on Japanese fragile X chro- 
mosomes than on normal chromosomes (x2, corrected = 
7.07, P < 0.008)) while DA haplotype (15%) is clearly 
under-represented in Japanese fragile X chromosomes. 
In Caucasians, Richards et al. [1992] suggested a few 
founder mutations which differ in their contribution to  
each cohort from Australia, South Carolina, and New 
York are responsible for the majority of fragile X cases. 
For example, three haplotypes (AF, DD, and DB) which 
account for only 15% of the normal Caucasian popula- 
tion are found in 58% of fragile X chromosomes (see 
Table I). In agreement with the findings by Richards et 
phenotype. This increase in penetrance of the mutation 
is referred t o  as the Sherman paradox and is equivalent 
to anticipation-the increase in severity and/or earlier 
age-at-onset seen in several other dominant genetic 
disorders. The most notable of these is myotonic dys- 
trophy which was postulated-then found-to have a 
similar molecular mechanism based on the observed 
common genetic properties of DM and fragile X syn- 
drome [Richards and Sutherland, 1992bl. 
Linkage analysis of markers in the vicinity of the mu- 
tation responsible for myotonic dystrophy has shown 
that all mutant chromosomes, even from apparently 
distinct European and Japanese populations, segregate 
with a particular allele of a polymorphic marker [Yam- 
agata et al., 19921, indicating that the initial mutation 
is very rare, possibly a single event. This extremely low 
mutation rate for the DM mutation was seemingly at 
odds with the apparent high mutation rate for fragile X 
syndrome, given their similar mutation mechanism. 
This apparent paradox was resolved by the demonstra- 
tion of linkage disequilibrium at  the fragile X locus 
with particular haplotypes [Richards et al., 19921. 
These haplotypes were themselves in linkage disequi- 
librium in the normal population with fragile X repeat 
copy numbers at the high end of the normal range. Be- 
cause of a relationship between repeat copy number 
and instability the higher repeat copy numbers are at 
greater risk of increasing into the “premutation” range 
(n = -50-230) where they are then subject to  a much 
higher risk of amplification into the affected range. 
The linkage disequilibrium at the fragile X locus has 
been confirmed in several populations of European ori- 
gin; Richards et al. 119921; Oudet et al. [1993]; Jacobs 
et al. [1993]; Hirst et al. [1993]. Within these different 
cohorts distinct haplotypes were preferentially associ- 
ated with the fragile X mutation. Together these re- 
ports suggest that certain founder chromosomes may 
have carried a larger number of p(CCG)n repeats from 
which recurrent dynamic mutations have arisen in pop- 
ulations of European origin. 
In order to examine the origin of the fragile X muta- 
tions in the Japanese population, we have performed 
haplotype analysis of the FRAXA locus in normal and 
fragile X chromosomes, by using two polymorphic 
AC repeat markers, FRAXACl and FRAXAC2, which 
flank, and are within 10 kb of, the FRAXA p(CCG)n re- 
peat. Analysis of the allele frequencies for FRAXACl 
and FRAXAC2 showed that there are distinct differ- 
ences between Japanese and Caucasians at  this locus 
both in normal and fragile X affected individuals. 
Therefore, there is evidence for founder fragile X chro- 
mosomes in the Japanese population similar to that in 
Caucasians, although different haplotypes are involved. 
MATERIALS AND METHODS 
Fragile X Patients and Normal Subjects 
Typing of the allele of two AC repeat markers, 
FRAXACl and FRAXAC2, was made on 40 unrelated 
fragile X affected males and 142 normal males, includ- 
ing fathers of fragile X patients. Diagnosis of fragile X 
syndrome was made by standard cytogenetic methods 
in thymidylate-stress conditions [Sutherland and 
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TABLE I. Haplotype Frequencies for Normal and Fragile X Chromosomes in Japanese and Caucasian Populations 










































































































































































































"Normal Caucasian males (N = 202). 
bFRAX 1, Australia (N = 47); FRAX 2, South Carolina (N = 61); FRAX 3, New York (N = 26) [Richards et  al., 19921. 
'"orma1 Japanese males iN = 142). 
dFRAX Japanese males IN ~ 4 0 ) .  
al. 119921, Oudet et al. r19931 have reported significant 
differences between normal and fragile X chromosomes 
in the distribution of alleles or  haplotypes a t  DXS548 
and FRAXAC2 loci. They also suggested that a limited 
number of primary mutations may be the origin of most 
present-day fragile X syndrome in Caucasian popula- 
tions of France and Spain. 
The Copy Number of the p(CCG)n Repeat 
The copy number of the p(CCG)n repeat was deter- 
mined by PCR analysis in a total of 125 unrelated X 
chromosomes from normal Japanese males. The fre- 
quency distribution of p(CCG)n copy number is shown 
in Figure 1. The copy numbers range from 13 to 39. 
There is a major peak between 28 and 30, and a minor 
peak at 35 repeats. The distribution of p(CCG)n copy 
number among normal X chromosomes in Japanese 
males is very similar to that reported for Caucasians by 
Fu et al. [19911 and Jacobs et al. 119931, except that the 
most frequent copy number (n = 28,35% of the X chro- 
mosomes examined) in Japanese is one copy less than 
that in Caucasians and there is an  additional peak a t  
35 repeats. Caucasian populations have a major peak 
between 28 and 31 with 22.5-30% of their X chromo- 
somes having 29 repeats and bimodal minor peak be- 
tween 19 and 23. The distribution of the copy number 
of p(CCG)n repeats in normal populations appears to be 
quite similar in all ethnic groups studied to date, al- 
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A:  Jacobs et al. !1993; N=309 
a: Present stl ldy N = 1 2 5  
C :  FU et al. (1994, N=492  
30 40 50' 6C 
3f Repeats  
Fig. 1. Frequency distributions of (CCC)n repeats in unrelated non-fragile X chromosomes. 
though there might be minor deviations. This is in con- 
trast to observations made in myotonic dystrophy and 
Kennedy's disease in which there are marked ethnic 
variations in the distribution of copy numbers in the 
trinucleotide repeats [Davies e t  al., 1992; Edwards 
et al., 19921. 
It has been suggested that the founder chromosomes 
may have carried a copy number of p(CCG)n repeats of 
much greater than average normal copy number, from 
which dynamic mutation has occurred [Richards et al., 
1992; Oudet et al., 1993; Jacobs et  al., 19931. Table I1 
summarises the frequencies of 3 major haplotypes de- 
tected in the Japanese population and the distribution 
of the copy number of p(CCG)n repeats in normal males 
with these haplotypes. The CF and DB haplotypes are 
significantly more frequent in fragile X chromosomes 
than in normal X chromosomes, while the DA haplo- 
type is clearly under-represented in fragile X chromo- 
somes. In contrast to findings in Caucasians, there is no 
significant correlation between founder haplotypes and 
the higher copy numbers of the p(CCG)n repeat in non- 
fragile X chromosomes in the Japanese population. Of 
the 33 unrelated normal CF haplotype individuals, only 
2 (6.170) had a p(CCG)n copy number of 35 which con- 
stitutes a minor peak (17.5%) in the frequency distri- 
bution of p(CCG)n copy number of non-fragile X chro- 
mosomes. However, both of the founder haplotypes 
exhibit striking linkage disequilibrium with p(CCG)n 
repeat copy numbers in the normal range-80% of nor- 
mal DB haplotype chromosomes have a p(CCG)n copy 
number of n = 28, whereas 63% of normal CF haplo- 
types have n = 29. These results do not support a no- 
tion that founder chromosomes may have carried a 
number of p(CCG)n repeats in the upper-normal range. 
This might be due to the fact that the Japanese popu- 
lation has a rather uniform genetic background (evi- 
TABLE 11. Frequencies of Three Major Haplotypes and Distribution of dCCG)n Cow Number 
Frequency in Copy No. of p(CCG)n repeat in normal males (70) 
Major haplotype Normal X Fragile X 28 29 30 35 [31-391 N 
C F  
D B  
D A  
Total 
0.25 0.43 0 21 (63.6) 6 (18.2) 2 (6.1) 2 (6.1) 33 
0.13 0.20 8 (80.0) 0 0 1C10.0) 2 (20.0) 10 
0.88 0.78 40 25 6 19 [231 95 
0.50 0.15 32 (61.5) 4 (7.7) 0 16 (30.8) 19 (36.5) 52 
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dent by the p(CCG)n copy number distribution com- 
pared to Caucasians, Fig. 1) or that the fragile X muta- 
tions are occurring on haplotypes more frequent in the 
Japanese population than the comparable at-risk hap- 
lotype frequencies in normal Caucasians. Therefore, our 
results may not exclude a possibility that the individu- 
als carrying the p(CCG)n of more than 31 copies have a 
risk for the multistep expansion of p(CCG)n repeats in 
subsequent generations. Alternatively, length alone 
may be an inappropriate measure of propensity for in- 
stability. Weber 119901 has shown that polymorphism 
for AC repeats is proportional to  perfect repeat copy 
number. Single base substitutions have been noted in 
normal alleles of the fragile X p(CCG)n repeat. It may 
well be that mutation of these substitutions back to the 
perfect repeat or amplification of perfect repeat se- 
quence alone-from a compound repeat-forms the ba- 
sis of the founder mutations observed by linkage dise- 
quilibrium of flanking markers at the fragile X locus 
[Richards and Sutherland, 1992133. 
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Autosomal fragile sites, unlike their X-llnked counterparts, are not known to be associated with disease. However,
one case report has highlighted a possible relationship between the Inheritance of a rare folate-sensitive fragile
site in band 11q23.3 (FRA11B) and the chromosome 11q23-qter deletion in Jacobsen (11q-) syndrome. The
mother and brother of the reported Jacobsen syndrome child are FRA11B carriers, suggesting that In vivo breakage
at the fragile site during early development could have given rise to the chromosome deletion. We have tested
this hypothesis by high resolution physical mapping of FRA11B and of the deletion chromosome breakpoint in
the Jacobsen syndrome patient. A detailed restriction map of 600 kb of human chromosome band 11q23.3 has
been assembled which covers the PBGD, CBL2 and THY1 genes. FISH experiments with YACs and cosmlds from
this region have localised FRA 11B to an interval of approximately 100 kb containing the 5' end of the CBL2 gene,
which includes a CCG trinucieotide repeat. This class of repeat is expanded In the four cloned examples of fragile
site and therefore the CBL2 repeat is a candidate for the location of FRA11B. Further, it is shown that the
chromosomal deletion breakpoint of the Jacobsen syndrome child maps within the same interval as the fragile
site. The breakpoint has apparently been repaired and stabilised by the de novo addition of a telomere. These
data are consistent with a role for an inherited fragile site in the aetiology of a chromosome deletion syndrome.
INTRODUCTION
Fragile sites are specific inherited chromosomal aberrations that
appear as a constriction in the chromosome and render it
susceptible to breakage under specific experimental conditions
(1). However, although chromosomal breakage at fragile sites
can be induced in vitro, there is no direct evidence of breakage
occurring in vivo in carriers of fragile sites.
Fragile sites can be divided into two major categories, rare
or common, according to their frequency within the population.
Rare fragile sites are sub-classified according to the conditions
under which they are expressed. The majority of rare fragile sites
are expressed when cells are grown in folic acid-deficient culture
medium, whereas others are induced by the addition of distamycin
A, BrdU, or related compounds, to the culture medium. In
contrast, common fragile sites are weakly induced by folate
deficiency, more strongly by aphidicolin and most effectively by
both of these conditions together (1).
The only fragile site with which a clinical phenotype has been
unequivocally linked is the rare folate-sensitive fragile site at
Xq27.3 (FRAXA) (2) which causes fragile X syndrome (3,4), the
most common form of inherited mental retardation (5). Recently,
a gene associated with FRAXA (FMR1) has been identified (6)
and shown to contain specific molecular anomalies in affected
individuals (7—10). In the majority of cases, the molecular basis
of fragile X syndrome has been found to be the extensive
expansion of a CCG-trinucleotide repeat in the 5' untranslated
region of FMR1 (6,11,12), associated methylation of an adjacent
CpG island (8,9) and reduction in the transcription of FMR1
(13,14).
Despite the lack of an obvious clinical phenotype in carriers
of other fragile sites, there is some statistical evidence that the
incidence of nine autosomal fragile sites is higher in mentally
retarded individuals than in the general population (15). In
addition, there are case reports suggesting links between fragile
sites and other phenotypes such as breast cancer (16), multiple
spontaneous abortions (17,18) and autosomal deletion syndromes
(19). Since FRA16A is the only autosomal fragile site to have
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574
2124 Human Molecular Genetics, 1994, Vol. 3, No. 12
Table 1. Location of YAC and cosmid probes in relation to FRAUB, as determined by FISH
Probe Proximal
Position of signal (in relation to fragile site)













Sequential metaphases were examined until at least 13 chromosomes 11 expressing the fragile site and exhibiting
signal from probe hybridisation had been scored. The position of the signal was scored as proximal, central (ie
overlying the gap in the chromosome), or distal to the fragile site. Specificity and sensitivity was such that 60-100%
of all metaphases (depending on the probe) had signal on the end of at least one chromatid with little or no background.
been defined to date (20), the precise relationship between disease
and fragile site expression has yet to be resolved.
Jacobsen syndrome (or l l q - syndrome) is the clinical
presentation of the loss of part of the long arm of chromosome
11, typically from band Ilq23 —qter, and is recognised by
specific dysmorphic features and severe mental retardation
(21,22). Voullaire et al. (19) reported a case in which a child
who had a deletion del(ll)(q23) of one chromosome 11
homologue, and who had signs of Jacobsen syndrome, was born
to a mother who expressed FRA11B. A second child in this family
was also reported to express the fragile site. FRA11B has
previously been shown to map to band Ilq23.3 (23), hence it
is possible that the chromosomal deletion in this Jacobsen patient
was due to inheritance of the mother's FRA11B chromosome and
its subsequent breakage at an early stage in development. If this
were the case, autosomal fragile sites may have more important
clinical implications than previously believed. To test this
hypothesis, we are attempting to characterise both FRA11B and
the deletion breakpoint in the llq— case reported by Voullaire
et al. (19). In this study we have mapped the location of both
FRA11B and the l l q - breakpoint to a region of Ilq23.3 of
approximately 100 kb and we have identified a likely candidate
for the molecular basis of fragility at Ilq23.3.
RESULTS
Using standard banding techniques, FRA11B has previously been
assigned to chromosome band Ilq23.3 (23). However, the
precise location of the fragile site within Ilq23.3 has not been
deduced. To date, three folate-sensitive fragile sites have been
characterised at the molecular level (FRAXA, FRAXE, and
FRA16A) and have all been found to be due to the expansion
of CCG-trinucleotide repeats (6,11,12,20,24). The proto-
oncogene CBL2 maps to 1 Iq23.3 (25,26) between the PBGD and
THY1 genes (26) and has a CCG-repeat in its 5' untranslated
region (27), which is therefore a candidate for the location of
FRAUB. YACs containing the 3' end of the CBL2 gene (y323El)
and the PBGD gene (yl5E5) were used in preliminary FISH
experiments with F/t477B-expressing cells and were shown to
flank the fragile site (see Table 1). Therefore, we decided to
restriction map these clones in order to position them with respect
to a genomic map of the interval (26) and hence to more
accurately position FRAUB.
Restriction map of YACs containing the PBGD, CBL2 and
THY1 genes
The YACs containing the CBL2 gene (y323El) and the PBGD
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Figure 1. Autoradiographs of YAC restriction digests hybridised with various
probes. YACs yl5E5 and y323El were digested with the restriction enzymes
Sail, Notl and Nrul and restriction fragments separated by PFGE and transferred
to nylon membranes as described in Materials and Methods. Autoradiographs
of various hybridisations (on a single Southern blot for each YAC) are aligned
to demonstrate the same, or different restriction fragments identified with groups
of probes. Uncut YAC in most lanes indicates partial digestion of both YACs
with these enzymes. Arrows indicate the positions and sizes in kilobases (kb)
of bacteriophage X markers (left) and of the uncut YACs (right). (A) Restriction
digests of yl5E5 hybridised with the YAC-left, PBGD and P2 probes.
(B) Restriction digests of y323El hybridised with the YAC-left, vCBL (CBL2)
and THY1 probes.
using conventional pulsed field gel electrophoresis (PFGE) and
Southern blotting technology. Details of probes used in
hybridisation experiments are given in Materials and Methods.
Hybridisation of y 15E5 with a YAC-specific probe identifies a
single band of approximately 125 kb. Digestion of yl5E5 with
SaR yields a 60 kb fragment that is recognised by both the YAC-
left probe and the PBGD probe (Fig. 1A). However, the PBGD
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Figure 2. Summary of the mapping information interpreted from restriction enzyme and Southern analysis of cosmids and YACs, and FISH analysis of FRA11B
and Jacobsen ( l l q - ) chromosomes. (A) Restriction map of YACs yl5E5 and y323El, showing the relative positions of FRAHB and the PBGD, CBL2 and THY1
genes and (dark shaded boxes; arrows denote the known orientation of genes), probes mentioned in the text (lightly shaded boxes) and cosmids from this region.
(B) The long range restriction map of this region as previously reported by Tunnacliffe and McGuire (26). Restriction sites mapped in this study are aligned with
those identified by Tunnacliffe and McGuire as described in the text. N, Noil; Nr, Nrul; S, Sail; (S), possible additional Sail sites; c and y prefixes denote cosmid
and YAC respectively; Circled R and L denote right and left YAC arms respectively.
probe does not hybridise to the 50 kb Notl fragment recognised
by the YAC-left probe (see Fig. 1A) but to the adjacent 35 kb
Notl fragment (data not shown, see Fig. 2A). Hence this localises
the PBGD gene to the intervening 10 kb Sail-Noil fragment
(Fig. 2A). Similarly the P2 probe, which is a genomic fragment
located 15 kb distal to PBGD, hybridises to the 50 kb left-arm
Notl fragment, but not to the 25 kb left-arm Nrul fragment (Fig.
1A). This localises the P2 probe to the intervening 25 kb
Notl—Nrul fragment (Fig. 2A). Other fragments were identified
(data not shown) to produce the map shown in Figure 2A. The
positions of the P2 probe and the PBGD gene with respect to
the restriction sites described is in agreement with the map of
a previously described cosmid (cPl) containing these probes (26).
However, cPl was shown to contain an extra Notl site compared
to our map of yl5E5, which may not be seen in yl5E5 due to
partial digestion with this enzyme.
Hybridisation of y323El with a YAC-specific probe identifies
a single band of approximately 395 kb (size accurately determined
from PFGE not shown). A probe for the 5' end of the CBL2
gene (CBL2-5') which includes the CCG-trinucleotide repeat,
does not hybridise to y323El, indicating that the whole gene is
not contained within this YAC. However, probes representing
more 3' sequences of CBL2 do hybridise to y323El. For
example, digestion of y323El with Sail, Notl and Nrul yields
70, 95 and 230 kb fragments respectively that are each recognised
by the YAC-left probe and also by the vCBL probe (Fig. IB;
some data not shown), thus localising the vCBL sequence to the
70 kb Sail left-end-fragment of y323El (Fig. 2A). It is clear that
y323El also contains the THY1 gene, since hybridisation with
a THY1 probe identifies the 230 kb Nrul left-end-fragment and
a 245 kb Notl fragment that co-hybridises with the YAC-right
probe (Fig. IB, some data not shown), thus localising THY1 to
the intervening 80 kb Notl-Nrul fragment (Fig. 2A).
The centromeric boundary of sequences recognised by the
vCBL probe is identified in the long range restriction map (26)
by Notl and Nrul sites between PBGD and CBL2 (Fig. 2B) and
are the same sites as those telomeric to PBGD in yl5E5 (Fig.
2A). The telomeric boundary of sequences recognised by the
vCBL probe in the long range restriction map is identified by
Sail and Notl sites between CBL2 and THY1 (Fig. 2B). These
sites are in the same orientation and of very similar spacing to
the sites that mark the telomeric boundary of the vCBL probe
in y323El (Fig. 2A). The long range restriction map estimates
the boundaries of vCBL to be 250 kb apart (Fig. 2B), so
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Figure 3. Fluorescence in situ hybridisation of the FRA11B cell line JE, with cosmid probes. (A) DAPI stained metaphase spread showing normal chromosome
11 (blue arrow) and FRA11B chromosome (red arrow). (B) The same metaphase spread as in (A) but with the hybridisation signals of cCO617 (red fluorescence)
and cA0734 (green fluorescence). On the FRA11B chromosome, the proximal signal (cC0617) is indicated with a red arrow and the distal signal (cA0734) is indicated
with a green arrow.
alignment of the two physical maps allows us to estimate the
physical distance between the ends of yl5E5 and y323El as
approximately 100 kb (Fig. 2A). Therefore according to the
preliminary FISH results using these YACs, FRA11B must lie
in this 100 kb interval. This was confirmed in FISH experiments
using cosmids corresponding to the approximate boundaries of
this interval.
Isolation of cosmids containing PBGD and CBL2 sequences
Initial attempts to clone the region between yl5E5 and y323El
in YACs were unsuccessful, so in order to link yl5E5 and
y323El to form one continuous contig and also to identify the
position of the trinucleotide repeat of the CBL2 gene, we
attempted to clone this region in cosmids. We used probes made
from a previously described PBGD cosmid, cPl (P2 and P7HR)
(26) and the CBL2 gene (CBL2-5', vCBL and CBL-RI) to isolate
several cosmids from the ICRF chromosome 11 gridded cosmid
library (28). These cosmids were aligned with each other and
with YACs yl5E5 and y323El by restriction and Southern
analyses (data not shown; Fig. 2A). Only one cosmid, cA0353,
hybridises to the CBL2-5' probe (data not shown; Fig. 2A) and
the presence of the CCG-trinucleotide repeat was confirmed by
sequence analysis of part of this cosmid (data not shown). cA0353
was found neither to overlap with the small cosmid contigs
identified, nor with the YACs y 15E5 or y323El (data not shown;
Fig. 2A). Therefore this cosmid is predicted to lie in the gap
between these two YACs and CBL2 must be transcribed in a
telomeric direction (Fig. 2A). Knowing the direction of the CBL2
gene has allowed us to orientate cosmids that span this region
(Fig. 2A) and to estimate that the CBL2 gene covers over 100 kb.
Cosmids containing the PBGD and CBL2 genes flank the
fragile site FRA11B
To localise the position of the fragile site FRA11B, we performed
FISH on a lymphoblastoid cell line (JE) derived from an
individual that expresses the fragile site, using cosmids cC0617
and either cA0734 or cEO 182 as probes. The region between these
cosmids must contain the CCG-trinucleotide repeat of the CBL2
gene, a candidate for the molecular basis of fragility at 1 Iq23.3.
Expression of the fragile site was induced by growing cells
in medium deficient in folic acid. Biotin-labelled cosmid cC0617
(red fluorescence) and digoxigenin-labelled cosmid cA0734
(green fluorescence) were co-hybridised to metaphase spreads
prepared from the fragile site-induced cells and detected using
standard procedures (see Materials and Methods). Figure 3A
shows part of a DAPI-stained metaphase spread with the normal
11 (blue arrow) and FRA11B chromosome (red arrow) labelled.
Figure 3B shows the same image as Figure 3A, but with the
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Figure 4. Fluorescence in situ hybridisation of the Jacobsen ( l l q - ) cell line C262, with cosmid probes. (A) DAPI stained metaphase spread showing normal chromosome
11 (blue arrow) and Jacobsen (1 l q - ) chromosome (red arrow). (B) The same metaphase spread as in (A) but with die hybridisation signals of cC0617 (red fluorescence)
and CA0734 (green fluorescence).
Figure 5. Fluorescence in situ hybridisation of the Jacobsen ( l l q - ) cell line C262, with a telomeric probe. (A) DAPI stained metaphase spread showing normal
chromosome 11 (blue arrow) and Jacobsen (1 l q - ) chromosome (red arrow). (B) The same metaphase spread as in (A) but with the hybridisation signal of the
telomeric probe (yellow fluorescence).
fluorescent labels of the hybridised probes superimposed. Both
cC0617 (red) and cA0734 (green) hybridise to the normal
chromosome 11 at band q23.3 (blue arrow) as had been predicted
by the mapping information described above. Following
hybridisation with cC0617 (red), a clear signal is seen on the
FRA11B chromosome centromeric to the fragile site (red arrow),
whereas hybridisation with cA0734 (green) produces a clear
signal telomeric to the fragile site (green arrow). The result using
cA0734 is confirmed by FISH with the overlapping clone,
cE0182, and the results of FISH with this and cC0617 are shown
in Table 1. This localises the fragile site FRA11B to the 100 kb
region between these two cosmids (Fig. 2), which includes the
CCG-trinucleotide repeat at the 5' end of the CBL2 gene and
confirms the preliminary FISH experiments with YAC probes.
Since expansion of similar repeats has been shown to be the
cause of fragility at other chromosomal loci, the CBL2 repeat
would now appear to be a strong candidate for the location of
FRA11B. FISH experiments with the cosmid cA0353, which lies
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within this interval and contains the CCG-trinucleotide repeat,
were unsuccessful (data not shown). Preliminary mapping
information suggests that this cosmid consists mainly of high copy
repeat sequences that may be difficult to suppress (data
not shown).
The breakpoint of an l l q - chromosome maps to the FRA11B
region
Voullaire et al. (19) reported a case in which a child with apparent
Jacobsen syndrome and a deletion del(ll)(q23) was born to a
mother who expressed FRA11B. To investigate whether the
breakpoint on the 1 lq— chromosome of this child coincides with
the position of the fragile site FRA11B, we performed FISH upon
metaphase spreads from a fibroblast cell line (C262) derived from
this patient, with cosmids flanking FRA11B.
Digoxigenin-labelled cosmid cC0617 (red fluorescence) and
biotin-labelled cosmid cA0734 (green fluorescence) were co-
hybridised to metaphase spreads prepared from the C262 cell
line and detected using standard procedures (see Materials and
Methods). Figure 4A shows part of a DAPI-stained metaphase
spread of C262 with the normal 11 (blue arrow) and the 1 lq —
chromosome (red arrow) labelled. Figure 4B shows the same
image, but with the fluorescent labels of the hybridised probes
superimposed. Both cC0617 (red) and cA0734 (green) gave clear
signals on the long arm of the normal chromosome 11 (blue
arrow). In contrast only cC0617 (red), the more centromeric
cosmid, gave a signal on the llq— chromosome (red arrow).
This demonstrates that the breakpoint of the 1 l q - chromosome
is between these two cosmids and is therefore localised to the
same 100 kb region containing the fragile site FRA11B.
The truncated q-arm of the l l q - chromosome contains a
telomere
A previous report has analysed the breakpoint of a terminal
truncation of the p-arm of chromosome 16 and demonstrated that
a tandem repeat of the telomeric sequence (TTAGGG)n was
added directly to the site of the break (29). The truncated
chromosome was stably inherited, demonstrating that telomeric
DNA alone is able to stabilise a broken chromosome in the
absence of subtelomeric telomere-associated sequences (29). We
were therefore interested to determine whether the 1 lq—
chromosome had also been stabilised by the addition of a telomere
subsequent to its breakage. To this end, we performed FISH on
metaphase spreads from the C262 cell line using a probe to the
telomeric repeat sequence.
A digoxigenin-labelled telomere (TTAGGG)n probe (yellow
fluorescence) was hybridised to metaphase spreads prepared from
the C262 cell line and detected using standard procedures (see
Materials and Methods). Figure 5A shows a DAPI-stained
metaphase spread of C262 with the normal 11 (blue arrow) and
l l q - (red arrow) chromosomes labelled. Figure 5B shows the
same image, but with the fluorescent label of the hybridised probe
superimposed. The telomere probe (yellow) gives clear signals
at the ends of most chromosomes, including the long arm of both
the normal 11 (blue arrow) and the l l q - chromosomes (red
arrow; Fig. 5B). Of 15 metaphase spreads from C262 that were
analysed, all demonstrated a specific signal with the telomere
probe at the deleted long arm of chromosome 11. This
demonstrates that the 1 l q - chromosome has been stabilised by
the addition of a telomere or telomere-like sequences.
DISCUSSION
The significance of the co-localisation of FRA11B and an 1 l q -
breakpoint to the same 100 kb region of band 1 Iq23.3 is enhanced
by examination of the family of the Jacobsen patient. The patient's
mother is FRA11B positive and has apparendy transmitted the
FRA11B chromosome to her second child (19). The patient was
apparently mosaic for del(ll)(q23) with three out of 463
lymphocytes having a normal karyotype. It is therefore tempting
to speculate that the affected child also inherited the FRA11B
chromosome and that this suffered a deletion at the fragile site
at an early stage of development. Haplotype analysis of this family
would allow us to determine that the deleted chromosome was
the ^7t477fl-expressing maternal homologue, but insufficient
family members are currently available for this analysis to be
performed.
Penny et al. (30) have located the breakpoints of 18 other
Jacobsen patients and show that eight of these are clustered
between DUS1341 and D11S924, which is consistent with the
map position of the Jacobsen case studied here. Hence it seems
likely that the localisation of a Jacobsen syndrome chromosome
deletion breakpoint to the FRA11B region of 1 Iq23.3 as described
in this study may not be a unique event. Cytogenetic analysis
of the parents of the Jacobsen cases described by Penny et al.
(30) may reveal other individuals expressing FRA11B. In
addition, molecular analysis following characterisation of the
fragile site will allow the identification of individuals who are
FRA11B carriers, but are otherwise cytogenetically normal.
Carriers of FRAXA are found to have a premutation of the FMR1
p(CCG)n repeat that does not cause expression of the fragile site
in that individual, but which predisposes to further expansion
in future generations (11,31).
Although many chromosomes expressing fragile sites are
known to break under specific cell culture conditions (hence their
name), there is currently no direct evidence that chromosome
breakage occurs in vivo in other fragile site carriers. For example,
chromosome deletion syndromes associated with the inheritance
of fragile sites on the X chromosome have not been described.
Such deletions may be lethal however, and it is likely that partial
aneusomy is only viable for certain regions of the genome.
Therefore we might predict, based on our data, that a subset of
fragile sites will have associated chromosomal deletion
syndromes. In addition, a pathological role of fragile sites might
also be invoked in cases of early pregnancy loss resulting from
chromosomal aberrations that are, in contrast, not sustainable.
Molecular cloning of FRA11B and Jacobsen syndrome
breakpoints will allow us to further test the possible link between
fragile sites and chromosome breakage. Should this link be
demonstrated, it would be necessary to re-evaluate the role of
fragile sites in the aetiology of chromosomal abnormalities.
MATERIALS AND METHODS
Probes
vCBL is a 400 bp EcoVl-PsA fragment from the vCBL cDNA (32). CBL2-5'
is a 175 bp BamHl—Sacl fragment from a pUC clone of part of the human CBL2
cDNA (pUC-hCBL) (27) and contains the first 171 bp of the CflUcDNA, which
includes the CCG-trinudeodde repeat. CBL-RI is a 2.3 kb £ooRI fragment isolated
from pUC-hCBL and contains CBL2 sequences from the internal EcoRI site at
position 578 bp to the stop codon (27). PBGD is an 800 bp BamHI-£coRI
fragment from the porphobilinogen deaminase (PBGD) cDNA. P2 is a 700 bp
Xho\—No& fragment subcloned from a cosmid, cPl, isolated using the PBGD
probe (26). P7HR is a 800 bp Hindm-EcoKL fragment also subcloned from
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cPl (26). THY1 is a 1 kb Bamm-Pstl fragment isolated from the THY1 cDNA
(33). Probes specific for the left and right arms of pYAC4 were generated from
vector DNA by PCR using appropriate primers (34): for the right end, YACRP
5'-ATCATCGTCGCGCTCCAGCGA and YACRR3 5'-CTCGCCACTT-
CGCCGTCA, which generates a 265 bp fragment; for the left end, YACLR1
5-GTGTGGTCGCCATGATCGCG and YACLP 5'-ATGCTGTAGTTTATCA-
CAGTTAA, which generates a 330 bp fragment. All of the above probe fragmerHs
were separated by electrophoresis on low-melting point agarose gels and excised
fragments treated with /3-agarase (Sigma) and purified using the Wizard DNA
clean-up system (Promega). All of the above probes were radio-labelled with
[or-32P]dCTP (Amersham) using a previously described oligo-labelling protocol
(35). The telomere probe is a multimer of the telomeric repeat sequence (TTA-
GGG)0, generated by PCR (36).
YAC isolation
YACs yl5E5 and y323El were isolated from the CEPH Mid library by PCR
screening of primary pools in Cambridge, secondary screening by CEPH in Paris
and final colony purification in Cambridge. yl5E5 was isolated using a PBGD
STS and y323El using a THY1 STS (37).
Cosmtd isolation and purification
Nylon membranes containing DNA from the ICRF chromosome 11-specific
Lawrist 4 cosmid library no. 107 (L4/FS11, ICRF Reference library) (28) were
screened by hybridisation with the single copy probes CBL-RI, vCBL, CBL2-5',
P2, P7 and PBGD (see above for details). DNA from positive clones was prepared
from bacteria grown in Terrific broth supplemented with kanamycin at 25 /ig/ml,
using a standard alkaline lysis protocol (38) followed by a multiple precipitation
procedure. Briefly, following precipitation of the bacterial lysate with isopropanol,
excess protein was removed by precipitation with 2.5 M ammonium acetate (DNA
precipitated with 2.5 vols ethanol) and RNA was removed by treatment with 0.2
mg/ml RNase (DNA precipitated with 7.5% PEG/1.5 M NaCl). Following
treatment with 1 mg/ml proteinase K, DNA was cleaned by extraction with
phenol/chloroform and precipitated with ethanol.
Pulsed field gel electrophoresis and Southern analysis
High molecular weight YAC DNA was prepared in low-melting point-agarose
plugs using a previously described method (39). Restriction digestions of YAC-
plug DNA were performed with at least 100 U of enzyme in a 250 /d volume
(including plug volume) overnight. DNA was electrophoresed on 1 % agarose
gels using the CHEF DR-H apparatus (Bio-Rad) at 200 V in 0.5 XTBE for 20
h, with the switch time linearly ramped from 1 to 30 s. Size markers were a
bacteriophage X oligomeric ladder and bacteriophage X HindUl digest (New
England Biolabs). DNA was blotted from pulsed field gels onto Zeta-probe GT
nylon membranes (Bio-Rad) by alkaline capillary transfer using standard techniques
(38). Pre-hybridisation (with 0.5 mg/ml sonicated salmon sperm DNA) and
hybridisation with specific probe were performed in a standard dextran-
sulphate/Demhardt's hybridisation buffer (38) at 65°C for 2 h and 16 h
respectively. Filters were washed for 30 min in 2xSSC/0.1% SDS at room
temperature, followed by washing for 30 min in0.2xSSC/0.1% SDS at 65 "C,
before exposure to X-OMAT AR X-Ray film (Kodak).
Cell culture
C262 is a human skin fibroblast cell line derived from the Jacobsen patient
(del 11 [q23]) described by Voullaire et al (19) and was a gift from Dr L.Voullaire.
C262 was maintained in RPMI 1640 medium (Gibco-BRL) supplemented with
10% foetal bovine serum. JE is an Epstein-Barr virus-(EBV)-transformed
lymphoblastoid cell line derived from a patient expressing FRA11B. JE was
maintained in RPMI with 15% foetal bovine serum and fragile she expression
was induced by growing cells for 24 h in Eagles MEM with Earl's salts, deficient
in folk: acid (Gibco-BRL special order) with 2% foetal bovine serum.
Fluorescence in situ hybridisation (FISH)
Metaphase spreads were prepared using standard techniques. Probe cC0617 was
labelled with digoxygenin-11-dUTP and probe cA0734 was labelled with
bkxin-16-dUTP using a nick-translation kit (all Boehringer Mannheim). 100 ng
labelled probe DNA was pre-annealed with 2 ng COT1 DNA (Gibco-BRL) at
37°C for 60 min in a hybridisation solution (2xSSC; 50% formamide; 10%
dextran sulphate; 0.5 mM Tris-HCl pH 7.6; 0.1 mM EDTA; 0.1 /ig//J sonicated
salmon sperm DNA). Metaphase spreads were denatured in 70%
formamide/2xSSC at 70°C for 2 min and preannealed probe was hybridised
in a moist chamber at 42 °C overnight.
Detection of probes hybridised to the C262 (1 lq—) cell line was achieved using
either FITC-conjugated avidin (Vector Laboratories) for bkxinylated probes; or
Texas red-conjugated anrj-digoxygenin (Sigma) for digoxygenin labelled probes.
Detection of probes hybridised to the JE (FRAUB) cell line was achieved using
either Texas red-conjugated avidin (Sigma) for biotinylated probes; or anti-
digoxygenin/anti-mouse FITC antibodies (Sigma) for digoxygenin labelled probes.
Slides were mounted in antifadant solution (AF1; Citifluor) containing DAPI
(4,6-diamino-2-phenyl-inole; 10 j»g/ml). Staining and hybridisation signals were
analysed under a computer-controlled Nikon epifluorescence microscope equipped
with a cooled charge-coupled device (CCD) camera. Computer images were
merged and Q-banding (generated by DAPI staining) converted to G-banding,
using IP Lab Spectrum software (Digital Scientific).
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Rare, folate-sensitive fragile sites are the result of the unstable expansion of trinucleotide p(CCG)n repeats,
which are normally polymorphic in copy number. Differences in the number and frequency of alleles of the
fragile site FRA16A p(CCG)n repeat were observed between different ethnic populations suggesting that
certain alleles might be predisposed to instability. Sequence analysis demonstrated that the longer and more
variable alleles were associated with loss of repeat interruption. Perfect repeat configuration therefore appears
to be a necessary precondition for the instability associated with fragile site genesis.
INTRODUCTION
The rare folate-sensitive fragile site FRA16A has been charac-
terized (1), and in common with the other cloned fragile sites
FRAXA (2-7) and FRAXE (8), is associated with an unstable
p(CCG)n trinucleotide repeat locus which is polymorphic
in the normal population. A common mechanism (dynamic
mutation) (9), may be responsible for the instability of tri-
nucleotide repeat sequences associated with fragile sites and
a number of human genetic diseases. The common properties
exhibited by these unstable sequences reveal features of the
molecular basis of the mutation process. For example, haplo-
type analysis with markers flanking the fragile X (10), myotonic
dystrophy (11) and Huntington's disease (12) loci have indi-
cated that the expanded trinucleotide repeats causing these
genetic diseases are more often associated with certain genetic
backgrounds. Haplotypes most commonly found on fragile X
chromosomes are those associated with alleles in which the
number of CCG repeats is at the upper end of the normal
range, the larger normal alleles may therefore be the ancestors
of fragile X chromosomes (10).
Studies of other simple tandem repeats (p(AC)n repeats)
have shown that relatively long, uninterrupted tracts of repeats
are more frequently highly polymorphic than those containing
repeat imperfections (13). This finding suggests that interrup-
tions confer a relative stability when the repetitive DNA is
replicated, resulting in a lower mutation rate, than for perfect
repeats of similar copy number. Sequence analysis of the
p(AGC)n repeat associated with spinocerebellar ataxia (SCA1)
has shown that the vast majority of repeats in unaffected
individuals contain interruptions (i.e. they are imperfect
repeats). By contrast, all unstable repeat arrays were uninter-
rupted (perfect) repeats, indicating that loss of the interruption
may predispose the repeat to expansion (14). Recently (15,16),
analysis of repeat interruptions in the FRAXA p(CCG)n repeat
has provided supportive evidence for loss of interruption of
the longer repeats being the essential step (founder mutation)
in predisposing particular alleles to instability (9).
The FRA16A p(CCG)n repeat is also interrupted, yet highly
polymorphic in the European population (1). The purpose of
the present study was to determine features in common between
the FRAXA and FRA16A repeats in the hope of gaining further
understanding of the molecular basis for repeat instability and
the consequent genesis of folate sensitive fragile sites.
RESULTS
Frequency of alleles at the FRA16A locus in different
populations
Initial analysis of the allele distribution of the FRAJ6A
p(CCG)n in the European population revealed a broader
distribution of alleles than has been evident at other fragile
site loci. For this reason other populations (of Japanese and
Indian origin) were assessed for the distribution of FRA16A
p(CCG)n alleles. The results obtained from this study are
shown in Figure 1. Twenty-one alleles were found in the
European population, 17 of which appeared to be absent
from the Japanese population samples and rare in the Indian
population samples. As a control for population sampling the
p(CCG)n repeat at the FRAXE locus was typed and found to
give greater similarity of allele distributions and frequencies
for all three populations (Fig. 1). Therefore, the difference in
*To whom correspondence should be addressed
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FRA16A allele frequencies appeared to be specific for the
locus, and not due to sampling within relatively isolated groups
in the Japanese and Indian populations.
To test for the statistical significance of the results an
arbitrary cut-off length of PCR product >168 bp was chosen.
The frequency of alleles above and below this length was
significantly different between the European and Japanese
populations tested, x(l (Yate's correction) = 103.714
(P<0.0001). A similar analysis between all three populations
gave XiZ = 49.82 (P<0.0001).
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Figure 1. Allele frequency distributions of the FRAI6A (a-c) and FRAXE
(d-f) p(CCG)n repeats in European (a,d), Japanese (b,e) and Indian (c,f)
populations. Number of chromosomes scored were a (160), b (114), c (64), d
(68), e (76) and f (78). FRA16A alleles are given as length of PCR product
(in base pairs) due to the complex nature of the repeat.
Figure 2. Sequence analysis of six FRA16A p(CCG)n repeat alleles. Sequences
are I, 159 bp allele (configuration B); 2, 183 bp allele (configuration C); 3,
171 bp allele (configuration C); 4, 159 bp allele (configuration B); 5, 186 bp
allele (configuration C); 6, 162 bp allele (configuration B). Slight differences
in the mobility of sequences is due to staggered loading of the sequencing
gel. For sequence number 6 the regions (I —IV) of repeat polymorphism are
bracketted and the CTG repeat interruption is arrowed.
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The increased variation evident in the European population
suggested that certain alleles may be inherently unstable (albeit
over many generations). To test whether FRA16A alleles may
be frequently meiotically unstable, six CEPH pedigrees with
10 large FRA16A alleles (PCR products of more than 168 bp
in length) were typed; however, no evidence of instability was
found in 47 meioses. Two individuals from the CEPH pedigrees
Human Molecular Genetics, 1995, Vol. 4, No. 3 369
were found to have three alleles; however, the extra alleles
were probably due to somatic instability in cell culture as they
were not transmitted to the next generation (data not shown).
Sequence analysis of FRA16A alleles
A total of 75 normal FRA16A p(CCG)n alleles (46 European,
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Figure 3. Structure and frequency of FRAI6A p(CCG)n repeat configurations (A-D). Location and variation of the polymorphic repeat regions (I-IV) is
shown. The number of FRA16A p(CCG)n alleles in each configuration and the percentage of each configuration in the European, Japanese and Indian populations
studied is given.
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(Table 1) and from this the individual allele frequencies were
deduced. This analysis demonstrated that the FRA16A repeat
is a complex polymorphism in the normal population with
four distinct simple tandem repeat regions (I—IV) contributing
variously to the polymorphism (Fig. 2). Four configurations
(A—D) of the repeat can be distinguished by differences in
the various repeat regions. Repeat region III which is a
p(CCG)n repeat (interrupted by a single CTG trinucleotide in
configurations A and B) was found to be the greatest source
of variation.
Sequence analysis (Table 1) of the most common alleles of
153, 159 and 162 bp found them to be of identical configuration
(B) in all populations with region III (CCG)mCTG(CCG)n
polymorphism of m = 6, n = 6 (153); m = 6, n = 8 (159)
and m = 9, n = 6 (162) respectively. All alleles of > 168 bp
contained an uninterrupted region III sequence of 19 or more
CCG repeats (configuration C). One of these alleles contained
25 uninterrupted CCG repeats and a direct duplication of the
CCTCCA sequence (region IV). The majority of alleles with
an uninterrupted region III p(CCG)n repeat also had a single
copy of the region II p(CCT)n repeat suggesting that all of
these (configuration C) alleles might have a common origin.
DISCUSSION
Polymorphism at the FRA16A locus
The rare folate-sensitive fragile site FRA16A has a similar
structure to that reported for the X-linked fragile sites FRAXA
and FRAXE. At the locations of these fragile sites in the
genome is a normally polymorphic p(CCG)n repeat adjacent
to a CpG island, with individuals expressing the fragile site
having expansion of the repeat and methylation of the CpG
island. Characterization of FRA16A demonstrated that fragile
sites could arise in the genome at sites that are apparently not
associated with any methylation imprinting, such as that
occurring with X inactivation. The FRA16A repeat expansion
is larger (3.0-5.7 kb amplification), and more somatically
stable than that of the other characterized fragile sites, as it is
usually found as a discrete single band on Southern analysis.
A common FRA16A normal allele (from a non-fragile site
expressing chromosome) contained 20 copies of the CCG
trinucleotide repeat, with an interrupting sequence or base
substitution occurring at a minimum of six repeat intervals
(1). Polymerase chain reaction (PCR) analysis across the
FRA16A p(CCG)n repeat in unrelated individuals demonstrated
a high level of variability. The presence of alleles with high
numbers of uninterrupted repeats that may become amplified
in some individuals is a feature that the FRA16A locus shares
with the other two cloned fragile sites and five other loci at
which an unstable p(AGC)n repeat is responsible for a genetic
disease (17).
In this study we compared the polymorphism of the FRA16A
locus in normal populations of European, Japanese and Indian
origin. The results shown in Table 1 indicate that the distribu-
tion and frequency of the p(CCG)n repeat alleles at this locus
is very different between the European and other populations.
The European population has a high heterozygosity of 91%,
compared with the Japanese (66.7%), and Indian (59%) popula-
tions. The normal range of allele sizes were 141-216 bp (21
alleles) for the European population, 153-168 bp (four alleles)
for the Japanese population and 141-198 bp (seven alleles)
for the Indian population. Fu et al. (6) have previously found
no significant difference for the pattern of distribution of
FRAXA p(CCG)n alleles in normal populations of European,
African, Hispanic and Asian origin.
Molecular basis for instability at the FRA16A locus
Sequence analysis demonstrated that the FRA16A repeat is
a complex polymorphism in the normal (non-fragile site
expressing) population. Different regions of polymorphism
allow the distinction of four configurations of the locus. Each
of these configurations can be related by a single mutation
event (deletion or duplication) to another configuration,
although there is no experimental evidence to support these
pathways nor the fact that one configuration (i.e. D) is
necessarily the intermediary between other configurations (B
and C). The benefit of grouping the alleles into the four
configurations, however, is that the basis of the relationship
between instability and repeat composition becomes more
obvious.
Configurations A and B are distinguishable from configura-
tions C and D by virtue of an interruption (CTG) to the region
III p(CCG)n repeat. Configuration C represents approximately
25% of European chromosomes yet accounts for about three-
quarters of the different alleles and is therefore relatively
unstable compared with configuration B which represents
about 70% of European chromosomes in only five alleles. In
addition all Japanese alleles and 97% of Indian alleles com-
prised this configuration. Indeed, this analysis cannot exclude
the possibility that the single Indian configuration C allele is
actually of European origin. Propensity for unstable alleles to
increase in length is evident from the observation that all
alleles of > 168 bp are configuration C [with a single exception
(C)] and this increase in length is due solely to region III
perfect repeat copy number polymorphism.
While the vast majority of variation was observed in the
region III p(CCG)n repeat, sequences flanking this region also
exhibited variation as did the p(CCG)n repeats either side of
the repeat interruption in region III (Fig. 3). The polarity of
repeat polymorphism observed at the FRAXA p(CCG)n repeat
(15,16) is not clearly evident at the FRAI6A locus and may
not be an obligatory component of the mutation process.
Polarity of repeat sequence mutation could vary from one
locus to the next dependent upon additional m-acting factors,
such as distance from origin(s) of replication.
In addition to the absence of repeat region III interruption,
configuration C alleles also differ from configuration B alleles
by virtue of a single copy of the region II CCT repeat. It could
be argued that the single CCT repeat allows the binding of a
protein which somehow destabilizes the repeat independent of
repeat composition. Such a proposal has been put forward to
explain allele specific instability of a minisatellite repeat (18).
While this argument cannot be refuted on experimental grounds
the absence of such a predisposing polymorphism at the
FRAXA locus in association with unstable haplotypes suggests
that the CCT at the FRA16A locus is merely a flanking
polymorphism in linkage disequilibrium with the mutation
which brought about loss of CTG interruption in the region
III p(CCG) repeat.
The fragile site, FRA16A, is rare in the European population
and has not been observed in other populations. Insufficient
data exist on which to base estimates of population frequency
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for this (or any other autosomal folate sensitive) fragile site
(19). If alleles with a high copy number perfect repeat are the
unstable precursors of fragile sites (10,15,16) a higher incidence
of FRA16A in Europeans compared with Indians and Japanese
would be consistent with the observed differences in allele
frequency and distribution.
CONCLUSIONS
Each of the human loci which are known sites of dynamic
mutation exhibit a normal range of repeat copy number
polymorphism in normal individuals. The incidence of mutation
to the extent observed as cytogenetic expression of a fragile
site and/or phenotypic manifestation of a disease varies from
one locus to the next and may well be dependent upon the
probability to mutate determined by the repeat length and
composition. The founder effects observed for fragile X
syndrome, myotonic dystrophy and Huntington disease prob-
ably represent a pool of higher risk alleles. The disorders for
which no such effects have yet been observed (e.g. Kennedy
disease, Richards et al, unpublished results) may well reflect
the rarity with which such predisposed alleles appear in the
population coupled with their inevitable transition to an infertile
phenotype and therefore loss from the gene pool. No phenotype
has yet been ascribed to the FRA16A fragile site, although
none of the autosomal folate sensitive fragile sites has ever
been observed in a homozygous state. The incidence of
FRA16A may therefore not be constrained by phenotype.
The striking similarity in the molecular basis for instability
at the FRA16A locus with observations at the SCA1 (14) and
FRAXA (15,16) loci suggests that a common mechanism is
responsible. The composition of a repeat together with its
normal range in copy number—manifest as degree of poly-
morphism in a given population—may be a useful indicator
of whether the repeat is prone to extensive amplification
characteristic of fragile sites and certain genetic disorders. The
extent and incidence of such amplification may well depend
upon the location of the repeat and its effect (if any) upon the
product of the gene in which it is transcribed. The results
presented here on the molecular basis for instability of the
FRA16A p(CCG)n repeat provide support for the view that
instability (manifest as polymorphism) is directly related to
perfect repeat copy number. This view of simple tandem repeat
mutation as first described for dinucleotide repeats (13) would
see an increased probability of mutation related to increase in
perfect repeat copy number rather than an all-or-none threshold
below which transmission is always stable and above which
it is always unstable.
MATERIALS AND METHODS
DNA samples
Indian DNA samples were from the region south of Bombay. The majority
were from the state of Tamil Nadu with no known European ancestry in any
individual. Japanese DNA samples were those previously used as normal
controls in FRAXA studies (20). The Japanese samples were all collected from
three of the main islands of Japan and the Okinawa islands. European
DNA samples constituted the parental generation of the Centre d'Etude
Polymorphisme Humain (CEPH) pedigrees.
Genotyping the FRA16A and FRAXE p(CCG)n repeat polymorphism
Genotyping of the repeat copy number polymorphism at the FRA16A locus
was undertaken using the previously described a and b PCR primers (1) and
utilized the PCR conditions of Yu et al. (7). PCR products were resolved by
denaturing 5% acrylamide gel electrophoresis. Alleles were determined on
the basis of length rather than repeat copy number because of the complexity
of the repeat polymorphism.
Sequence analysis of FRA16A alleles
Alleles subjected to sequence analysis were selected on the basis of their
ability to resolve from one another. Alleles from homozygous individuals
were sequenced in order to overcome problems in the resolution, and therefore
purification, of alleles. In general the FRA16A p(CCG)n locus was PCR
amplified with Tag polymerase and 7-deaza-dGTP (7) using the set of primers
a and d which flank the FRA16A repeat (1). PCR products from this initial
step were purified by electrophoresis through denaturing acrylamide gels.
These PCR products were then used as templates for further amplification
using Pfu polymerase and the primers a and e (1). PCR products were purified
directly using a Prep-a-gene Kit (BioRad) and sequenced using an Exo(-)
Pfu Cyclist DNA Sequencing Kit (Stratagene).
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Human Chromosomal Fragile Site
FRA16B Is an Amplified
AT-Rich Minisatellite Repeat
Sui Yu,* Marie Mangelsdorf,* Duncan Hewett,* (Jones et al., 1995). This association provided clear evi-
dence that fragile sites can cause instability in vivo andLynne Hobson,* Elizabeth Baker,* Helen J. Eyre,*
lead to chromosomal breakage. The common aphidi-Naras Lapsys,*‖ Denis Le Paslier,†
colin-induced fragile site, FRA3B, is located in the vicin-Norman A. Doggett,‡ Grant R. Sutherland,*
ity of a translocation breakpoint associated with renaland Robert I. Richards*§
carcinoma (Wilke et al., 1996). The molecular basis for*Centre for Medical Genetics
fragility at FRA3B is not yet known. However, the FHITDepartment of Cytogenetics and Molecular Genetics
gene, which spans FRA3B, was recently found to haveWomen’s and Children’s Hospital
aberrant transcripts in 50% of gastrointestinal cancersNorth Adelaide, South Australia 5006
(Ohta et al., 1996) and 80% of small-cell and 40% ofAustralia
non–small-cell cancers of the lung (Sozzi et al., 1996).†Fondation Jean Dausset–CEPH
No known phenotype has been associated with the otherCentre d’Etude Polymorphisme Humain
characterized folate-sensitive fragile sites, FRAXF andParis
FRA16A (Nancarrow et al., 1994; Parrish et al., 1994).France
Despite the molecular characterization of five fragile‡Life Sciences Division
sites, the relationship between the chemistry of fragileLos Alamos National Laboratory
site induction and their DNA sequence composition isLos Alamos, New Mexico 87545
not yet clear. All fragile sites that have been described§Department of Genetics
at the molecular level are of the folate-sensitive type,The University of Adelaide
and all have the same DNA sequence composition, theSouth Australia 5000
trinucleotide p(CCG)n repeat (Kremer et al., 1991; OberleAustralia
et al., 1991; Verkerk et al., 1991; Yu et al., 1991; Knight
et al., 1993; Nancarrow et al., 1994; Parrish et al., 1994;
Jones et al., 1995; Sutherland and Richards, 1995a).
Summary These fragile sites arise by the unstable expansion of
p(CCG)n repeats, which normally exhibit repeat–copyFragile sites are nonstaining gaps in chromosomes number polymorphism and methylation of both the ex-
induced by specific tissue culture conditions. They panded p(CCG)n repeats and the adjacent CpG islandsvary both in population frequency and in the culture (Pieretti et al., 1991; Vincent et al., 1991).
conditions required for induction. Folate-sensitive Expansion of the trinucleotide repeat p(AGC)n is asso-
fragile sites are due to expansion of p(CCG)n trinucleo- ciated with several neurological disorders (Sutherland
tide repeats; however, the relationship between se- and Richards, 1995b). In myotonic dystrophy, the
quence composition and the chemistry of induction of p(AGC)n repeat expansion can extend for thousands of
fragile sites is unclear. To clarify this relationship, the copies; however, no visible chromosomal anomaly is
distamycin A–sensitive fragile site FRA16B was iso- associated with this expansion, despite attempts to in-
lated by positional cloning and found to be an ex- duce fragile sites on DM chromosomes with a variety
panded 33 bp AT-rich minisatellite repeat, p(ATATA of agents (Jalal et al., 1993). Recently, expansion of a
TTATATATTATATCTAATAATATATC/ATA)n (consistent p(AAG)n repeat in the first intron of the gene FRDA has
with DNA sequence binding preferences of chemicals been demonstrated to be the overwhelmingly predomi-
that induce its cytogenetic expression). Therefore the nant mutation in the autosomal recessive disorder
mutation mechanism associated with trinucleotide re- Friedreich’s ataxia (Campuzano et al., 1996). Although
peats is also a property of minisatellite repeats (vari- expansion of trinucleotide repeats of various composi-
able number tandem repeats). tion has been noted previously (Lindblad et al., 1994),
until this finding, only p(CCG)n and p(AGC)n had been
associated with disease. To date, only p(CCG)n ex-Introduction
panded repeats have been shown to be inducible sites
of chromosome fragility.Some fragile sites are known to be associated with ge-
The finding that fragile sites are associated with innetic disease (Sutherland and Richards, 1995a). The
vivo chromosome breakage (Joneset al., 1995) presentsrare, folate-sensitive fragile site FRAXA is associated
the need to understand the mechanisms by which suchwith the most common familial form of mental retarda-
breakage is likely to occur. In an effort to gain a greatertion, fragile X syndrome (Kremer et al., 1991; Oberle et
understanding of the relationship between the chemistryal., 1991; Verkerk et al., 1991; Yu et al., 1991). FRAXE
of induction of fragile sites and their DNA sequencegives rise to a milder and considerably rarer form of
composition, we have characterized the first non–folate-mental retardation (Knight et al., 1993). The fragile site
sensitive rare fragile site: FRA16B. FRA16B is locatedFRA11B is located in the CBL2 proto-oncogene and is
at 16q22.1 and is present on about 1 in 40 chromosomesassociated with Jacobsen (11q2) deletion syndrome
in European persons (Sutherland et al., 1984; Schmid
et al., 1986). It is induced by chemicals such as dista-
mycin A and berenil, which are known to bind AT-rich‖ Present address: Garvan Institute, Darlinghurst, New South Wales,
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likely to act by substituting for thymine in the DNA se- had been used on the basis that fragile sites might repre-
sent pseudotelomere sequences; however, all telomerequence. Since this fragile site is present in some individ-
repeat positive clones mapped proximal to the fragileuals and not others, it would be anticipated that the
site. An overlap was established between the proximalDNA sequence that gives rise to it is AT-rich and poly-
and distal walks when several minute plaque lambdamorphic. By analogy with the folate-sensitive fragile
subclones (including l961 and l962) were identified insites, we would predict this polymorphism to consist of
the immediate vicinity of FRA16B. A unique probe (18–variation in repeat copy number.
10) from the proximal side of the contig was able to
detect the FRA16B-associated amplification on Eco-
Results O109I digests comparing normal and FRA16B chromo-
somes (Figure 2).
Positional Cloning of FRA16B
and Detection of Instability Characterization of
The region of chromosome 16 encompassing the FRA16B-Associated Amplification
FRA16B fragile site was isolated by positional cloning. A combination of polymerase chain reaction (PCR) anal-
DNA markers were mapped to the FRA16B physical ysis and Southern blot analysis was used to localize the
interval defined by chromosome 16 breakpoint hybrids region of amplification associated with FRA16B (Figure
(Figure 1). The relative position of these markers (Dog- 1). The sequence of the expanded region was composed
gett et al., 1995) was determined first by fluorescence almost entirely of AT-rich DNA and has several types
in situ hybridization and then by order on yeast artificial of repeated sequence, including minisatellites with 32,
chromosomes (YACs) isolated from the Centre d’Etudes 33, and 37 bp repeat motifs. The 37 bp repeat with
du Polymorphisme Humain (CEPH) library. Attempts the consensus motif of CACAA/GTATAC/TTGTA/GTATTGTA
were made to link by pulsed-field gel electrophoresis TA/TT/AACTATATACAAT/AA and 32 bp repeat with the per-
the two closest flanking markers (16–10 and 16–53), fect motif of [GACTATAGTATATATACTATATATACTAT
but these attempts were unsuccessful with all of the ATA] were eliminated as candidates for FRA16B by PCR
restriction enzymes used. When 16–53 was used as a amplification using primers 22 and 23 and primers 24
probe on blots of normal and FRA16B chromosome SalI and 28 respectively (Figure 1G). Normal size 22/23 and
restriction digests separated by pulsed-field gel electro- 24/28 products were generated when using template
phoresis, bands of decreased mobility were found asso- DNA from the cell line CY1, which contains a single
ciated with the FRA16B chromosomes (Figure 2). The FRA16B chromosome, or from the individual N.S., who
increase in size, as measured by a decrease in electro- is homozygous for FRA16B chromosomes. In contrast,
phoretic mobility, corresponded to z15 to z70 kb, dif- no PCR products (null alleles) were produced from either
fering between families but of similar size within families CY1 or N.S. DNA templates with primers that flank the
(Figure 2 and unpublished data). 33 bp repeat (primers 27 and 29, Figure 1G), localizing
The megaYACs My821G9 and My837F9 were both the additional sequences associated with FRA16B to the
found by fluorescence in situ hybridization to span PCR product containing the 33 bp repeat. The FRA16B
FRA16B. My837F9 was used as a source of human DNA fragile site was found to cosegregate in families with
to construct a detailed restriction map of the region and the null allele of the 33 bp repeat PCR. The sequence
a library of subclones in the vector lGEM-11 (Promega). composition of one normal allele of the 33 bp repeat
A walk was initiated out from the marker 16–53, with (Figure 3A) reveals a complex minisatellite with seven
direction being determined with respect to the restric- copies of a repeat unit varying in length from 26 to 33
tion map. The 16–53 walk ended abruptly in the immedi- bp, with all copies conforming to a 33 bp consensus
ate vicinity of the fragile site at l109, 11 different l except for a single base substitution at position 31 and
subclones terminating within a region of less than 250 deletions of varying extent toward one end of the repeat
bp. Concurrently, a walk was initiated from the closest motif. PCR across the 33 bp repeat demonstrated that
proximal lambda subclones (Figure 1). The proximal- this repeat was polymorphic in the European (CEPH)
walk start-site sequences were identified by hybridiza- population: 13 alleles were observed in 58 chromo-
somes with a heterozygosity of 52%. The repeat copytion to the telomere repeat p(TTAGGG)n. This sequence
Figure 1. Molecular Cloning and Identification of FRA16B
(A) Somatic hybrid (mouse–human) cell lines that contain single human chromosome derivative 16s with breakpoints in the vicinity of FRA16B.
CEN, centromere; TEL, telomere.
(B) Map of markers and STSs used in screening the YAC libraries and their positions relative to the somatic cell hybrid breakpoints.
(C) YAC contig: compiled map of CEPH YACs and megaYACs isolated with markers from the FRA16B region (Doggett et al., 1995).
(D) PFGE restriction map of megaYAC MY837F9 around the marker 16–53.
(E) Lambda contig and fluorescence in situ hybridization (FISH) analysis: the location with respect to the FRA16B fragile site of a contig of
lambda subclones of the human sequences that span the fragile site.
(F) Restriction map of lambda subclones spanning FRA16B and Southern blot mapping of FRA16B instability. Restriction fragments were
identified as unstable or stable through use of the probes 16–53 and 18–10.
(G) PCR map of instability. PCR of DNA from an individual homozygous for FRA16B and cell line CY1, which contains a single human
chromosome 16 that expresses FRA16B, was used to localize the FRA16B-specific unstable sequences. The presence of products for all
other PCRs and the absence of products for the 29–27 PCR (which were present for control DNAs, including FRA16B heterozygotes)




Figure 2. Southern Blot Analysis of the
FRA16B Locus
(A) Pulsed-field gel electrophoresis of SalI re-
striction digests of chromosomal DNAs from
individuals with no (open symbols), one (half-
closed symbols), or two (closed symbol)
FRA16B chromosomes probed with 16–53.
(B) Southern blot of EcoO109I-digested chro-
mosomal DNAs and megaYACs probed with
proximal probe 18–10. Open arrow, the mobil-
ity of the normal restriction fragment; shaded
arrow, the mobility of the FRA16B-associated
restriction fragments.
number varies from 7 to 12 copies (based on differences smallest detectable FRA16B-containing DNA restriction
fragment greater than 20 kb, running within the zone ofin mobility), with some alleles differing by less than a
whole repeat unit, indicating a complex polymorphism. compaction on ordinary agarose gels. Pulsed-field gel
electrophoresis of some families (Figure 2A) showedThese polymorphic 33 bp repeats were found to be
coincident with instability of the lambda clones in E. coli, apparent stability of the amplified allele; however,
changes of even several kilobases would have not beensuggesting that this region is one of inherent genomic
instability. resolved under these conditions. Every unrelated FRA-
16B individual has an expanded band of different mobil-To confirm the identity of the 33 bp repeat as the
basis for FRA16B, PCR primer pairs consisting of either ity and therefore copy number. One individual in family
C (Figure 4) with only a very faint ladder of bands hasstrand of one copy of the repeat were used in conjunc-
tion with unique proximal or distal flanking primers to below the threshold of cytogenetic expression (2%)
used to distinguish fragile site from normal chromo-generate a ladder of bands from an amplification of the
repeat. While normal chromosomes usually gave rise to somes. This individual has a haplotype consistent with
inheritance of the FRA16B chromosome and is thereforemultiple products, none of these was as extensive as the
ladder of bands generated from FRA16B chromosomes mosaic for the expanded repeat, indicating somatic in-
stability at the FRA16B locus. Germline instability at the(Figure 3). PCR analysis in FRA16B pedigrees demon-
strated cosegregation of these ladders with the fragile FRA16B locus is apparent in a family in which the father
expresses FRA16B and one of his children has a t(1;16)site (Figure 4). Ladders of bands were generated from
both ends of the repeat (Figure 3), thereby confirming translocation, the chromosome 16 breakpoint of which
maps to the FRA16B region (Garcia-Sagredo et al., 1983the location of FRA16B at the 33 bp repeat. This result
demonstrates that the fragile site is composed of an and unpublished data).
amplification of the existing 33 bp repeat. The amplifica-
tion gives rise to a perfect repeat of up to 2000 copies. Discussion
Attempts to demonstrate instability of the amplified
repeat within FRA16B families were unsuccessful be- When compared to the folate-sensitive fragile sites, the
distinguishing features of FRA16B are the length andcause of the extremely large size of the amplification
(the smallest is z15 kb). This property rendered the composition of its repeat motif. Basic local alignment
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Figure 3. Sequence of the 33 bp Repeat Motif and PCR Analysis in Normal and FRA16B Chromosomes
(A) Sequence of a normal allele of the 33 bp repeat with 7 copies of the repeat unit, varying in length from 26 to 33 copies. Variation in length
is confined to one end of the repeat motif. Only one base substitution variation from the repeat motif is found at position 31 of the first repeat
unit.
(B) The 33-mer repeat was shown to be the molecular basis of FRA16B by using either strand of the repeat motif as a PCR primer (3303 or
3309) in conjunction with a flanking unique primer (29 or 38). Proximal PCR was performed with primers 29 and 3303; distal PCR was performed
with primers 38 and 3309.
search tool (Altschul et al., 1990) searches of the tandem repeats and VNTRs. Analysis of repeat–copy
number changes at the DM p(AGC)n repeat implicatedFRA16B repeat motif revealed striking homology with
the polymorphic variable number tandem repeat (VNTR) gene conversion in microsatellite repeat–copy number
mutation (O’Hoy et al., 1993). Recently the demonstra-at the COL2A1 collagen gene locus (Berg and Olaisen,
1993). Many alleles of this locus have been sequenced, tion that the genotype of thenormal allele of MJD individ-
uals has an affect on the instability of the expandedand comparison of these sequences reveals that the
copy number variation at this locus occurs in the most allele (Igarashi et al., 1996) again implicated a gene con-
version–like mechanism. The hypermutable minisatellitehighly homologous copies of the repeat toward the mid-
dle of the VNTR. The variation in COL2A1 VNTR repeat MS32 has been found to have certain alleles that are
predisposed to higher frequency of mutation, and thosecopy number therefore exhibits a striking parallel to the
simple tandem repeat–copy number polymorphisms alleles are associated with a point mutation in the flank-
ing DNA sequence (Jeffreys et al., 1994; Monckton etthat are dependent on perfect-repeat composition (Berg
and Olaisen, 1993). Highly homologous copies of the al., 1994). These MS32 mutations that occur by gene
conversion are small changes in repeat copy number,VNTR repeat predispose to repeat–copy- number insta-
bility, suggesting that the mutation mechanism involves by comparison with those in FRA16B. It is possible that
distinct mechanismsof repeat expansion mutation exist:events similar to those thought to characterize simple
tandem repeat mutation. On this basis we propose that gene conversion (possibly mediated by trans-acting fac-
tors), giving relatively small changes in copy number,FRA16B is due to theexpansion of perfect-repeat copies
of the 33 bp motif located at the site of repeat–copy and slippage (which is dependent on the composition
of the VNTR itself), giving very large increases in copynumber polymorphism in the normal population.
Gene conversion has been implicated as the molecu- number. The finding that FRA16B consists of a greatly




Figure 4. Cosegregation of 33 bp PCR Ladder and FRA16B Fragile Site in Families
The proximal (29–3303) 33-mer repeat assay in three FRA16B families, demonstrating segregation of the expansion with cytogenetic expression
of the FRA16B fragile site (half-closed symbols). One individual (half-shaded symbol) with a faint ladder of bands (downward arrow) has less
than 2% of metaphases expressing FRA16B and therefore has below the threshold level used as the criteria for expression of the fragile site.
This individual has a haplotype consistent with inheritance of the FRA16B chromosome and may be mosaic for the expanded repeat and
therefore have a very low level of chromosomes capable of expressing the fragile site.
sequence–copy number mutation can proceed by simi- B9-DNA. This is of relevance to the mechanics of fragile
site induction, since as a general rule sequence-specificlar mechanisms regardless of the length of the repeat
motif. binding proteins bind to the major groove while non–
sequence-specific proteins bind to the minor groove.Recently, two VNTRs have been associated with hu-
man disease: the H-ras VNTR with increased risk of Unlike the folate (and thymidine)–sensitive fragile sites,
the induction chemistry of FRA16B is obviously consis-cancer (Krontiris et al., 1993) and the insulin gene VNTR
with insulin-dependent diabetes mellitus (Bennet et al., tent with its AT-rich composition. Identification of the
sequence composition of FRA16B will allow in vitro anal-1995; Kennedy et al., 1995). Rare alleles of the H-ras
VNTR act as modifiers of genetic risk to cancer (Krontiris ysis of the affect of inducing agents on the ability of the
FRA16B repeat to bind proteins and determination ofet al., 1993; Phelan et al., 1996). Individualswith a BRCA1
mutation are at much higher risk of developing ovarian whether there might be common components for the
fragile site induction process for the different classescancer if they also have a rare H-ras VNTR allele than
are individuals with a BRCA1 mutation and a common of chromosomal fragile site.
Unstable repeat sequence mutation is also referredH-ras VNTR allele. It has been proposed that the rare
alleles indicate predisposition of the repeat to instability to as dynamic mutation (Richards and Sutherland, 1992)
and has generally been associated with the increase(Phelan et al., 1996). The molecular basis for FRA16B
and the COL2A1 VNTR support the view that for some in copy number of trinucleotide repeats. The common
properties of this form of mutation appear equally appli-VNTRs prone to copy number instability, the composi-
tion of the repeat is the predisposing factor. cable to dinucleotide repeats, polymorphism being re-
latedto copy number and repeat interruptions stabilizingThe sequence of FRA16B is of particular significance
to understanding the relationship between the chemistry the repeat (Weber, 1990). Various trinucleotide repeats
have been demonstrated to undergo amplification in theof induction and the sequence composition of fragile
sites. The cytogenetic expression of FRA16B is sensitive human genome (Lindblad et al., 1994). The finding that
FRA16B is due to the amplification of a 33 bp repeatto chemicals that bind to AT-rich regions of DNA. These
include the antiviral and antitumor drugs distamycin A demonstrates that dynamic mutation is a property com-
mon to repeats, not only of various composition (Kremerand netropsin. Distamycin A and netropsin bind to AT-
rich runs of 3 or 4 (or more) bp, provided there are no et al., 1991; Oberle et al., 1991; Verkerk et al., 1991; Yu
et al., 1991; Knight et al., 1993; Lindblad et al., 1994;59-TpA-39 steps (Klevit et al., 1986). Distamycin A does
not bind to normal B-DNA; it only fits into narrow-groove Nancarrow et al., 1994; Parrish et al., 1994; Jones et al.,
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vicinity of FRA16B. The PCR primers used in this mapping are as1995; Sutherland and Richards, 1995b) but also with
follows: primer 4, 59-TTGGGAACTGTGCACCATGT-39; primer 22,various lengths of repeat motif. This common mecha-
59-CTATAGTTTAGTATGTATAGTATATC-39; primer 23, 59-GCTCCATnism for changes in repeat copy number suggests that
GATTTATTTCTACATGT-39; primer 24, 59-GATATACTATACATACTA
minisatellite sequences (such as the H-ras VNTR) might AACTATAG-39; primer 27, 59-CATAGTATATACTATAGTATATAG-39;
be subject to similar repeat instability, as seen at simple primer 28, 59-CTGTATAATATAGTATAGTATAGTACA-39; primer 29,
59-GTACTATACTATACTATATTATACAG-39; primer 38, 59-GTATTATtandem repeat loci in various forms of cancer as a con-
ATATTATCTAATTATATCTTATATATGAATATTAC-39; and primer 39,sequence of defects in replication error repair (Fishel
59-GTAATATTCATATATAAGATATAATTAG-39. Either strand of theand Kolodner, 1995). Similarly, genetic diseases that
33-mer repeat was used as a PCR primer in conjunction with aexhibit anticipation may be due to expansion of unstable
flanking unique primer (29 or 38) to amplify the FRA16B minisatellite
repeats other than trinucleotides. repeat. The PCR conditions were as follows: 30 cycles of 888C for
30 s, 458C for 30 s, and 588C for 3 min. Products were electropho-
Experimental Procedures resed on a 5% acrylamide gel, which was dried and subjected to
autoradiography.
Construction of YAC Contig Proximal PCR was performed with primers 29 and 3303: 59-ATATA
Sequence-tagged site (STS) sequences (16–10, 16–53, and 16–101) TTATATATTATATCTAATAATATATC/ATA-39. Distal PCR was per-
from within the CY125-CY130 interval were used to screen the CEPH formed with primers 38 and 3309: 59-TAG/TATATATTATTAGATATA
YAC library. Positive YACs were used as templates for Alu-PCR to ATATATAATATAT-39.
generate products for screening the Los Alamos human chromo-
some 16–specific cosmid library. Positive cosmids (306C5, 60H5, Acknowledgments
and 328F12) were subject to sequence analysis to generate addi-
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Fluorescence In Situ Hybridization Mapping
Lambda DNA clones and total DNA extracted from yeast cultures
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containing YACs were used as probes for fluorescence in situ hy-
bridization to metaphase chromosomes expressing FRA16B.
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Summary Introduction
A number of genes have been found to be mutated inThe identification of genes responsible for the rare cases of
leukemia, largely through the cloning of somatic translo-familial leukemia may afford insight into the mechanism
cation breakpoints and the screening of known tumorunderlying the more common sporadic occurrences. Here
suppressor genes, oncogenes, and other genes with cellu-we test a single family with 11 relevant meioses transmitting
lar regulatory function (Sachs 1996). However, theautosomal dominant acute myelogenous leukemia (AML)
pathogenic mutations that initiate the multistep evolu-and myelodysplasia for linkage to three potential candidate
tion of leukemia have been more difficult to elucidateloci. In a different family with inherited AML, linkage to
(Fialkow et al. 1991; Busque and Gilliland 1993). Rarechromosome 21q22.1-22.2 was recently reported; we ex-
autosomal dominant cancer families provide an oppor-clude linkage to 21q22.1-22.2, demonstrating that familial
tunity to study genes involved in the earliest phases ofAML is a heterogeneous disease. After reviewing familial
malignancy (Knudson 1993).leukemia and observing anticipation in the form of a declin-
Familial leukemia is exceptionally rare; we are awareing age of onset with each generation, we had proposed
of only three extant pedigrees that have been adequately9p21-22 and 16q22 as additional candidate loci. Whereas
sampled (Ho et al. 1996; Horwitz et al. 1996b; Olopadelinkage to 9p21-22 can be excluded, the finding of a maxi-
et al. 1996). The difficulty of ascertaining large leukemiamum two-point LOD score of 2.82 with the microsatellite
families with multiple available affected members limitsmarker D16S522 at a recombination fractionuÅ 0 provides
the power of a genomewide survey for linkage andevidence supporting linkage to 16q22. Haplotype analysis
makes evaluation of candidate loci a more feasible ap-reveals a 23.5-cM (17.9-Mb) commonly inherited region
proach. In previous reviews of the clinical features ofamong all affected family members extending from
familial leukemia (Horwitz et al. 1996a; Horwitz 1997),D16S451 to D16S289. In order to extract maximum linkage
we observed anticipation, in the form of a declining ageinformation with missing individuals, incomplete informa-
at onset with each passing generation, and proposedtiveness with individual markers in this interval, and possible
potential candidate regions: In a family inheriting au-deviance from strict autosomal dominant inheritance, we
tosomal dominant myelodysplasia and acute myeloge-performed nonparametric linkage analysis (NPL) and found
nous leukemia (AML) of multiple subtypes, which servesa maximum NPL statistic corresponding to a P-value of
as the subject of the current study, we found that two.00098, close to the maximum conditional probability of
affected individuals shared a constitutional cytogeneticlinkage expected for a pedigree with this structure. Muta-
euchromatic banding variation at chromosome 9p21-22tional analysis in this region specifically excludes expansion
(Horwitz et al. 1996b), suggesting potential linkage toof the AT-rich minisatellite repeat FRA16B fragile site and
this region. Evidence supporting a chromosome 21 locusthe CAG trinucleotide repeat in the E2F-4 transcription fac-
includes the finding of linkage for a platelet disordertor. The ‘‘repeat expansion detection’’ method, capable of
and propensity to develop AML to 21q22.1-22.2 in onedetecting dynamic mutation associated with anticipation,
family (Ho et al. 1996), an increased incidence of leuke-
more generally excludes large CAG repeat expansion as a mia in Down syndrome (Epstein 1995), and frequent
cause of leukemia in this family. somatic translocation in leukemia involving the CBFA
gene on 21q22.3. We proposed 16q22 as a potential
familial leukemia candidate region (Horwitz et al.
1996a; Horwitz 1997), in part because of a report of aReceived May 6, 1997; accepted for publication July 23, 1997.
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The family that we have described (Horwitz et al. fected, at-risk individuals, including obligate heterozy-
gotes II-1, II-5, and III-5, consented to clinical and bone1996b) may be particularly valuable in the study of leu-
kemia genesis because affected family members have de- marrow examination; therefore, the sample available for
linkage testing, for which clinical phenotype was avail-veloped myelodysplasia or AML of differing subtypes,
indicating that the responsible gene operates at a primi- able, consisted solely of affected individuals.
tive and signal step in myeloid differentiation. In the
Linkage Analysiscurrent article, we evaluate linkage of disease in this
family to these proposed candidate loci and report provi- Since all individuals at risk for leukemia included in
the linkage analysis were either affected or obligate het-sional evidence for assignment of the disease to chromo-
some 16q21-23.2. In addition, we conduct preliminary erozygotes, and the overall incidence of AML (Ho et al.
1996) is low (.0001), it was possible to use an autosomalmutational analysis of repetitive sequence elements in
this region, because familial leukemia displays anticipa- dominant model of inheritance that is essentially inde-
pendent of penetrance. This avoids the consideration oftion (Horwitz et al. 1996a). The only known mechanism
of anticipation results from the instability of repeat se- anticipation and age-dependent penetrance. The data
were initially examined under this single conservativequences (La Spada et al. 1994; Sutherland and Richards
1995), although we have also proposed a model of antic- model with gene frequency set to .0001, fixed prior to
obtaining genotypes.ipation in familial cancer based on polygenic inheritance
of multiple de novo mutations secondary to a loss of a Genotype information was generated with PCR am-
plification of microsatellite repeat polymorphisms. PCRmajor gene regulating DNA replication fidelity (Horwitz
1997). was employed with end-labeled primers or in the pres-
ence of [a32P]dCTP, using protocols published in the
Genome Database (Fasman et al. 1996), and the prod-Subjects and Methods
ucts were analyzed by 6% denaturing PAGE and autora-
Clinical Description and DNA Sources diography.
Two-point LOD scores were calculated using theRelevant individuals in the pedigree are shown in fig-
ure 1. Diagnostic criteria were previously established, MLINK subroutine of the LINKAGE software package,
version 5.1 (Lathrop et al. 1984), and maximum likeli-and a full clinical description has been reported (Hor-
witz et al. 1996b). All affected individuals had frank hood estimate of u was performed with the ILINK sub-
routine. Nonparametric linkage analysis was performedhematopoietic maturation defects documented by bone
marrow examination interpreted by at least one hemato- with GENEHUNTER software, version 1.1 (Kruglyak
et al. 1996). Allele frequencies for markers were takenpathologist unaware of the family history. The proband
is individual IV-1, who had M7 megakaryoblastic AML. from the Genome Database, except for the chromosome
21 marker UT7582 and D16S398, for which informa-Individuals II-3 and II-1 had M2 AML. Patients III-3
and III-4 had myelodysplastic syndrome terminating in tion is not published. Allele frequencies for UT7582
were determined by genotyping 32 chromosomes fromAML. Because of limited clinical information, it was not
possible to determine leukemia subtype on patient II-3. unrelated individuals in CEPH families (M. F. Leppert,
unpublished data). Allele frequencies for D16S398 wereIndividual IV-3 had myelodysplasia with monosomy of
chromosome 7 in bone marrow cells. Patients II-4 and derived using family-based allele frequency estimation
(Boehnke 1991); LOD scores were determined usingIV-2 had bone marrow abnormalities consistent with
incipient myelodysplasia; in addition, a rare opportunis- ILINK to estimate iteratively allele frequencies jointly
with maximum likelihood estimation of u (Terwilligertic mycobacterial infection contributed to the death of
patient II-4. and Ott 1994, pp. 185–87), starting with the allele fre-
quencies observed in the three genotyped founders, II-DNA was obtained from various preparations as fol-
lows: buffy coat from peripheral blood from individuals 6, III-6, and IV-3. The LOD scores for the other chromo-
some 16 markers were separately evaluated using thisIV-1 and IV-2; Epstein-Barr virus–transformed poly-
clonal lymphoblastoid cell lines derived from peripheral method, to assess the influence of allele frequencies in
this family in which genotypes of several founders areblood from individuals II-1, II-5, II-6, III-1, III-5, III-6,
and IV-3; paraffin blocks of autopsy-derived liver on absent.
patient II-3, biopsied lymph nodes on patient II-4, bone
Mutational Analysismarrow biopsy on patient III-2, skeletal muscle on pa-
tient III-3; and air-dried microscope slides of bone mar- PCR quantification of the AT-rich FRA16B minisatel-
lite repeat (Yu et al. 1997) was performed in 16.5 mMrow aspirate on patient III-4. Archival DNA was ex-
tracted by the QIAGEN QIAamp tissue kit and was used (NH4)2SO4, 4.5 mM MgCl2, 67 mM Tris-HCl (pH 8.8),
0.65 mM EDTA, 0.17 mg/ml BSA, 10% (v/v) dimethylaccording to the manufacturer’s instructions. Archival
material was not used for linkage analysis on chromo- sulfoxide (DMSO), 1.42 mM b-mercaptoethanol, 1.5
mM each of the four dNTPs, 5 mCi [a32P]dATP, 50 ngsomes 9p21-22 and 21q22.1-22.2. No apparently unaf-
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Figure 1 Pedigree and haplotype analysis for chromosome 16q21-23.2. Solid symbols denote affected individuals. The common haplotype
is denoted in black. Dashes (-) indicate not tested or a failure to detect a PCR amplification product. Inferred genotypes are given in parentheses.
(Inferred genotypes were not used in the linkage analysis.)
of DNA sample, 37.5 ng of each primer (5-TGTAAA- step of 94C for 5 min; and products were analyzed by
7% denaturing PAGE with autoradiography.ACGACGGCCCAGTGTACTATACTATACTATATT-
ATACAG-3 and 5-CAGGAAACAGCTATGACCGTA-
TTATATATTATCTAATTATATCTTATATATTGA- Results
ATATTAC-3), and 2.5 U Taq polymerase for 10 cycles
Exclusion of Linkage to 9p21-22 and 21q22.1-22.2of 88C at 30 s, 45C at 30 s, and 58C at 3 min and
20 cycles of 88C at 30 s, 50C at 30 s, and 58C at 3 In the initial clinical evaluation of this family (Horwitz
et al. 1996b), we observed a constitutional euchromaticmin. Products were analyzed by denaturing PAGE and
autoradiography. banding variation of chromosome 9p21-22 in patient
IV-3 and in a grandson of patient II-3 (implying its pres-PCR amplification of the E2F-4 CAG repeat was per-
formed as described by Ginsberg et al. (1994). PCR ence in patient II-3, who died before the era of routine
cytogenetic testing in leukemia). One candidate gene inamplification of the AF9 CAG repeat was performed as
described by Walker et al. (1994). this region is AF9, which is the frequent site of reciprocal
translocation with the MLL gene on chromosome 11 inRepeat expansion detection (RED) analysis was per-
formed as described by Bleyl et al. (1995) with the fol- recurrent t(9;11)(p22;q23) associated with AML (Na-
kamura et al. 1993). Furthermore, AF9 has a polymor-lowing modifications: the (CTG)15 oligonucleotide was
purified by 19% nondenaturing PAGE after [g32P]ATP phic polyserine-encoding CAG repeat (Walker et al.
1994) that is of interest in view of the observation ofphosphorylation; 396 cycles of 94C for 10 s and 80C
for 30 s were performed after an initial denaturation anticipation in familial leukemia (Horwitz et al. 1996a).
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Linkage analysis with the markers D9S126 on 9p21 and by two affected second cousins (IV-1 and IV-3)
prompted further investigation of linkage to this region.IFNA on 9p22 (table 1) effectively excludes linkage to
this region. In addition, karyotypes of individuals III-2 Results of linkage analysis to multiple flanking mark-
and IV-1 failed to reveal the cytogenetic variation, and ers in 16q21-23.2 are shown in table 2. A maximum
PCR amplification of the CAG repeat in AF9 demon- two-point LOD score of 2.82 occurs with the marker
strated that all individuals in this family were homozy- D16S522 at uÅ 0. All affected individuals share a haplo-
gous for the most common allele of 42 repeats (not type without recombination extending 23.5 cM (or 17.9
shown). Mb, as determined from the chromosome 16 physical
map [Doggett et al. 1995]) from D16S451 to D16S289In a large family inheriting platelet granule defects
and a predisposition to AML, linkage to a 15.2-cM in- (fig. 1).
terval on chromosome 21q22.1-22.2 has been deter- Linkage analysis in this family is limited by missing
mined (Ho et al. 1996). That family differs from the individuals and is therefore a function of the estimated
subject family here by the presence in the prior family population allele frequencies. To gauge the effect of this
of platelet granule and aggregation defects, constitutive potential bias, we also calculated LOD scores with a
thrombocytopenia, an evident risk for solid tumors, and family-based approach to estimate allele frequency
an apparently lower penetrance of AML that may occur (Boehnke 1991). Since the allele segregating with leuke-
after solid tumor treatment with chemotherapy (Dow- mia for several of the markers is not observed in the
ton et al. 1985). However, this locus is an obvious candi- unrelated founders, we conclude the reported LOD
date for other leukemia families, especially in light of scores to be conservative. For example, when this ap-
the fact that it is the site for recurrent t(8;21)(q22;q22) proach is used for D16S522 or D16S265, Zmax inflates
of the CBFA gene in many cases of sporadic AML and to Ç3.00.
the association of Down syndrome with leukemia (Ep- Linkage analysis in this family is further limited by a
stein 1988). Two-point linkage analysis of six markers lack of informativeness for all markers with each meiosis
spanning an Ç12.4-cM interval excludes linkage of dis- and the potential for model misspecification due to pos-
ease in our family to 21q22.1-22.2 (table 1). sible complex inheritance (Horwitz 1997). In order to
extract maximum linkage information under these re-
strictions, we evaluated the genotype data utilizing non-Evidence Supporting Linkage to 16q21-23.2
parametric linkage analysis (NPL; Kruglyak et al. 1996)It has been proposed that inherited fragile sites might
as shown in figure 3. The maximum NPL statistic in thisbe involved in familial cancers (LeBeau and Rowley
interval of 10.13 corresponds to an exact P value of1984; Richards and Yu 1996). The observation of a
.00098 that the observed marker segregation would oc-fragile site on 16q22 in one small leukemia family (Ferro
cur under the null hypothesis of no linkage.et al. 1994) suggested that this region may contain a
locus for familial leukemia (Horwitz et al. 1996a; Hor-
Preliminary Mutational Analysiswitz 1997). Therefore, we evaluated the distamycin-sen-
sitive FRA16B site resulting from amplification of an A possible explanation for the observation of antici-
pation in familial leukemia (Horwitz et al. 1996a) isAT-rich minisatellite sequence at the 16q21-22.1 bound-
ary (Yu et al. 1997). Pathological expansion of the mini- dynamic mutation of repetitive DNA sequences. The
E2F-4 transcription factor interacts with the RB homo-satellite to lengths productive of a fragile site was not
detected in individuals in two branches of the family logue p107 and is implicated in control of the cell cycle
(Ginsberg et al. 1994); it has been mapped to 16q22.1(fig. 2). However, the finding that allele 5 is coinherited
Table 1
Pairwise LOD Scores between Familial Leukemia and Chromosomes 9p21-22 and 21q22.1-22.2
LOD SCORE AT u Å
Marker .001 .01 .05 .1 .2 .3 .4 Zmax umax
D9S126 01.67 0.69 0.08 .11 .20 .16 .09 .20 .21
IFNA 04.46 02.50 01.16 0.63 0.18 0.01 .04 .04 .40
UT7582 0 05.10 03.02 02.13 01.23 0.69 0.30 0 .5
D21S263 02.21 01.22 0.57 0.33 0.14 0.06 0.03 0 .5
IFNAR 04.43 02.46 01.14 0.64 0.23 0.07 0.01 0 .5
D21S65 05.20 03.20 01.83 01.26 0.71 0.40 0.18 0 .5
D21S167 04.57 02.61 01.28 0.77 0.34 0.15 0.06 0 .5
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expansions of repetitive DNA sequences (Schalling et al.
1993). There is no evidence for the presence of a large
CAG repeat in individuals in this family. Note, however,
that this does not completely exclude the possibility of
pathological expansion of a short CAG repeat below the
limit of RED detection, such as occurs in spinocerebellar
ataxia (SCA) type 6 (Zhuchenko et al. 1997).
Discussion
Of the three candidate loci for leukemia in this family
that we have proposed, we have excluded 9p21-22 and
21q22.1-22.2 by linkage analysis. We are unable to ex-
clude 16q21-23.2 and, in fact, find evidence supporting
linkage to this region. The highest two-point LOD score
of 2.82 with D16S522 at u Å 0 is below the generally
accepted linkage criterion of a LOD score §3.0. Never-
theless, we believe that this result is important for the
following two reasons. First, linkage analysis here is
vulnerable to a loss of information from missing individ-
uals, incompletely informative markers, and the possi-
bility of model misspecification resulting from complex
Figure 2 PCR analysis of FRA16B minisatellite repeat. Allele inheritance (Horwitz 1997). To extract linkage informa-
numbering is relative to additional alleles that have been identified in tion maximally, we examined the genotype data using
a CEPH control population (not shown). nonparametric linkage analysis (Kruglyak et al. 1996).
NPL is a computationally tractable method based on
multipoint analysis of genotypic identity by descent. It
has the advantages of greater power to detect significantand contains a polymorphic polyserine-encoding CAG
repeat (Ginsberg et al. 1994). All individuals in this fam- linkage with incomplete pedigree data and is indepen-
dent of inheritance model. The P value correspondingily appear to be homozygous for the most common allele
of 13 repeats (not shown), excluding expansion of this to the maximum NPL statistic is .00098. Notably, this
is less than the conditional probability of linkage of .001repeat as a cause of leukemia here.
Since this family displays apparent autosomal domi- defined by the two-point LOD score standard of 3.0 and
is nearly equal to the conditional probability of linkagenant inheritance and, so far, all the repeat expansions
with dominant inheritance are CAG triplets (La Spada et (1003.01) corresponding to the theoretical maximum
LOD score of Ç3.01 that can be generated from thisal. 1994; Sutherland and Richards 1995), we conducted
RED analysis (fig. 3) to determine whether this family pedigree structure of 11 meioses with missing individu-
als (as approximated from a two-point simulation studywas transmitting an expanded CAG repeat (anywhere
in the genome). The RED method is a general procedure with a fully informative marker and nearly infinitely rare
and polymorphic alleles). Second, familial leukemia isbased on the ligase chain reaction for detecting large
Table 2
Pairwise LOD Scores between Familial Leukemia and Chromosome 16q21-23.2
LOD SCORE AT u Å
Marker 0 .01 .05 .1 .2 .3 .4 Zmax umax
D16S451 03.00 01.29 0.52 0.19 .06 .12 .08 .12 .30
D16S265 2.66 2.61 2.41 2.14 1.56 .94 .36 2.66 0
D16S186 .97 .96 .89 .79 .59 .38 .18 .97 0
D16S398 1.81 1.77 1.62 1.44 1.05 .66 .29 1.81 0
D16S301 .99 .98 .93 .86 .68 .48 .25 .99 0
D16S522 2.82 2.77 2.55 2.28 1.69 1.04 .41 2.82 0
D16S395 1.42 1.38 1.23 1.04 .68 .36 .13 1.42 0
D16S289 02.79 0.51 .09 .26 .31 .25 .14 .32 .18
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Figure 3 Nonparametric linkage analysis. Shown is the output of the GENEHUNTER program with NPL score (thick line) on the left
ordinate and the information content (thin line) on the right ordinate. The NPLmax occurs at a map position of 5.99 cM with a corresponding
P value of .00098. The indicated intermarker distances from the corresponding genetic maps (Shen et al. 1994; Kozman et al. 1995) were used
in the analysis.
exceedingly rare, and the families are generally small family (Gunz et al. 1978), HLA types differed among
affected individuals. Three siblings developing CLL hadand ascertained after most affected individuals have died
(Horwitz et al. 1996a; Horwitz 1997), limiting opportu- a constitutional deletion of the short arm of chromo-
some 22 (Fitzgerald and Hamer 1969). Two brothersnities for further sampling. Definitive linkage results may
not be obtainable in a single study. The identification with childhood myelodysplasia with monosomy 7, a dis-
order that appears to be autosomal recessive (Horwitzof reasonable candidate regions will facilitate the study
of additional small families that are ascertained in the 1997), had constitutional inversion of chromosome
1p22q23 (Paul et al. 1987). And, as noted, a father-future.
There are clinical differences between some of the re- daughter pair with AML and ALL apparently coinher-
ited a 16q22 fragile site (Ferro et al. 1994).ported leukemia families (Horwitz 1997). The exclusion
of linkage to 21q22.1-22.2, a locus to which inherited We were led to test for instability of repetitive DNA
sequence tracts, because we had previously observed an-AML is mapped in another family (Ho et al. 1996),
demonstrates that familial leukemia is a genetically het- ticipation in the form of a declining intergenerational
age at onset in the inheritance of familial leukemia (Hor-erogeneous disease. Evidence for other loci for familial
leukemia is limited. Two brothers (Blattner et al. 1978) witz et al. 1996a). A preliminary mutational analysis
excludes minisatellite repeat amplification at thewith acute lymphocytic leukemia (ALL) shared two
HLA haplotypes, and, in a different family (Kato et al. FRA16B fragile site and CAG trinucleotide repeat am-
plification in the polyserine coding region of the E2F-41983), two first cousins (whose parents were half sib-
lings of one another) with ALL shared a common HLA transcription factor as responsible for leukemia in this
family. Negative RED analysis further excludes largehaplotype, thereby suggesting the possibility of linkage
to chromosome 6p. However, in a family with multiple CAG repeat expansion as causative. Dynamic mutation
of repetitive sequence elements is the only documentedsiblings with chronic lymphocytic leukemia (CLL)
(Schweitzer et al. 1973) and a multigenerational AML molecular mechanism for anticipation in inherited neu-
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mice with targeted interruption of CBFB includes CNS
bleeding (Castilla et al. 1996; Wang et al. 1996); in
the presently studied family, three individuals in three
generations died of hemorrhagic stroke at young ages
(Horwitz et al. 1996b). It is interesting that a gene en-
coding another subunit of the hematopoietic CBF tran-
scriptional complex, CBFA, maps to the region on
21q22.1-22.2 (Speck and Stacy 1995), to which the
other family with AML predisposition has been linked
(Ho et al. 1996), although, thus far, there is no evidence
of mutation of CBFA in that family (Legare et al. 1995).
Moreover, the two known CBFA homologues, AML2
and AML3, map to 1p and 6p, respectively (Levanon et
al. 1994; Wijmenga et al. 1995), where, as discussed
above, there is suggestive support for localization of fa-
milial myelodysplasia and familial ALL. Third, SCA4
has been mapped to 16q22.1 (Flanigan et al. 1996). Like
the other spinocerebellar ataxias, SCA4 also demon-
strates anticipation (Flanigan et al. 1996). It is clinically
differentiated from the other types, however, by the ad-
ditional presence of an axonal neuropathy, and the diag-
nosis can be clinically confused with Friedreich ataxia
(Flanigan et al. 1996). Of note, the grandson of patient
II-3 carries the diagnosis of Friedreich ataxia (Horwitz
et al. 1996b), but the results of molecular genetic testing
for this disorder have not been available for confirma-
tion. The possibility that this family may also transmit
SCA4, then, could be a significant observation, espe-
cially in light of the overlap of spinocerebellar ataxia
and leukemia in yet another family (Li et al. 1981).
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FRA10B Structure Reveals Common
Elements in Repeat Expansion and
Chromosomal Fragile Site Genesis
Richards, 1995). They are manifested as areas of chro-
matin that fail to compact during mitosis. There are two
main types of fragile sites: common and rare. Common
fragile sites are expressed in all individuals. In contrast,
rare fragile sites are present in less than 5% of the
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Rare fragile sites have been classified into threeDepartment of Cytogenetics and Molecular
classes according to the chemistry of their induction:Genetics
Group 1, folate-sensitive; Group 2, distamycin A–induc-Women’s and Children’s Hospital
ible; and Group 3, BrdU-requiring (Sutherland and Rich-North Adelaide, SA 5006
ards, 1995). Several fragile sites have been character-Australia
ized at the molecular level. Most of these are members2Department of Medical Genetics
of the folate-sensitive class of rare fragile site. TheyLudwig-Maximilians-Universität München
are: the X-linked FRAXA at Xq27.3 (Kremer et al., 1991;80539 München
Oberle et al., 1991; Verkerk et al., 1991; Yu et al., 1991),Germany
FRAXE at Xq28 (Knight et al., 1993), and FRAXF at3Department of Human Genetics and Molecular
Xq28 (Parrish et al., 1994), and the autosomal FRA16ABiology
at 16p13.11 (Nancarrow et al., 1994) and FRA11B atCollaborative Research Inc. Division
11q23.3 (Jones et al., 1995). All of these fragile sitesGenome Therapeutics Corporation
have been shown to share their molecular basis inWaltham, Massachusetts 02254
expansion of the trinucleotide p(CCG)n repeat. The ob-4Department of Genetics
servation of linkage disequilibrium at the FRAXA locusThe University of Adelaide
suggests that expanded alleles arise from a pool ofAdelaide, SA 5000
predisposed normal haplotypes (Richards et al., 1992).Australia
Sequence analysishas demonstrated that these “at risk”
haplotypes are those containing 24 or more perfect re-
peats (Kunst and Warren, 1994).Summary
Some of the rare fragile sites are disease related.
FRAXA is associated with the fragile X syndrome, theA common mechanism for chromosomal fragile site
most common heritable form of mental retardation (Hag-
genesis is not yet apparent. Folate-sensitive fragile
erman and Silverman, 1991). A milder form of mental
sites are expanded p(CCG)n repeats that arise from
retardation is found in FRAXE-expressing individuals
longer normal alleles. Distamycin A orbromodeoxyuri-
(Knight et al., 1993). FRA11B is located in the 59 untrans-
dine-inducible fragile site FRA16B is an expanded AT- lated region of the CBL2 proto-oncogene and is associ-
rich z33 bp repeat; however, the relationship between ated with chromosome breakage in a proportion of pa-
normal and fragile site alleles is not known. Here, we tients with Jacobsen (11q-) syndrome (Jones et al.,
report that bromodeoxyuridine-inducible, distamycin 1995).
A–insensitive fragile site FRA10B is composed of ex- Pathological trinucleotide repeat expansion (but not
panded z42 bp repeats. Differences in repeat motif fragile site expression) has been noted in an increasing
length or composition between different FRA10B fami- number of X-linked and autosomal dominant neurologi-
lies indicate multiple independent expansion events. cal disorders (see Richards and Sutherland, 1997 for
Some FRA10B alleles comprise a mixture of different review). Instability of p(AGC)n repeats has been seen
expanded repeat motifs. FRA10B fragile site and long in SBMA, DM, HD, SCA-1, DRPLA/HRS, MJD/SCA3,
normal alleles share flanking polymorphisms. Somatic SCA-2, SCA-6, and SCA7. In addition, expansion of a
and intergenerational FRA10B repeat instability analo- third type of trinucleotide repeat, p(AAG)n, was demon-
gous to that found in expanded trinucleotide repeats strated in the autosomal recessive disorder Friedreich
supports dynamic mutation as a common mechanism ataxia (FRDA) (Campuzano et al., 1996). Despite its dif-
for repeat expansion. ferent mode of inheritance, FRDA exhibits many fea-
tures, such as premutations and founder effects, seen
in other dynamic mutations (Cossee et al., 1997; Monter-
Introduction mini et al., 1997).
Recently, the molecular basis for the first non–folate-
Fragile sites are defined as specific chromosomal re- sensitive fragile site was determined. The distamycin
gions that show nonrandom gaps or breaks when ex- A–inducible FRA16B at 16q22.1 was shown to be due
posed to particular culture conditions (Sutherland and to an expanded AT-rich minisatellite repeat (Yu et al.,
1997). The very large size of the expanded FRA16B al-
leles, however, meant that it was not possible to investi-5 To whom correspondence should be addressed.
gate other properties that are typical of dynamic muta-6 These authors contributed equally to this work.
tion—instability that is related to repeat copy number7 Present address: Department of Pathology, University of Cam-




“pool” of long normal alleles indicating predisposition
to expansion. In fact, it could be argued that all FRA16B
chromosomes are due to a few cataclysmic events unre-
lated to the dynamic mutation process responsible for
the instability seen at trinucleotide repeats.
The fragile site FRA16B is sensitive not only to “AT–
minor groove binders” (including distamycin A, berenil,
and netropsin) but also to bromodeoxyuridine, which
may act by incorporating itself into the DNA sequence.
The fragile site, FRA10B, is only induced by bromodeox-
yuridine or bromodeoxycytidine (Sutherland et al., 1980;
Sutherland, 1981, 1982). Analysis of the molecular basis
of FRA10B has therefore been undertaken to determine
structural features that FRA10B and FRA16B might
share. Such common features may allow for a clearer
understanding of the mechanism of fragile site genesis.
The characterization of FRA10B has also enabled a thor-
ough analysis of minisatellite repeat expansion and
demonstrated hallmarks of the dynamic mutation pro-
cess (Richards and Sutherland, 1992, 1997).
Results
Detection of Expansion at the FRA10B Locus
FRA10B (located at 10q25.2) was isolated by positional
cloning (Figure 1).The YAC 944H7was shown by fluores-
cence in situ hybridization (FISH) to span the fragile site.
This YAC was subcloned, and unique markers flanking
FRA10B were identified by FISH. A contig of overlapping
subclones was generated by walking between these
Figure 1. Positional Cloning of the FRA10B Regionflanking markers (Figure 1D). The distal and proximal
(A) Genetic map of polymorphic markers in the FRA10B region.lambda walks were joined to form a contig by l1002.
(B) YAC contig including the markers D10S597 and D10S88. The
l1002 gave FISH signal on both sides of FRA10B. location of other markers used to map the extent of each YAC is
Unique probes from l1002 recognized the variable indicated.
expansion of genomic DNA in both SacI- and PstI- (C) Restriction map of the distal ends of YACs 944H7 and 941C4.
(D) Tile path of lambda subclones from YAC 944H7 and their locationdigested DNA from FRA10B heterozygotes (Figure 2).
(by FISH) with respect to the FRA10B fragile site. Open bars indicateDiscrete bands of increased size ranging from z5 to
FISH signal proximal to the fragile site; shaded bars indicate distalz20 kb were found in 7 out of 11 FRA10B carriers. Other
signal. Subclones with open and shaded bars gave at least one
FRA10B carriers had only a single “normal” size band, signal on both sides of the fragile site.
which we interpret as the result of somatic mutation (E) Restriction map of lambda subclones (numbered) in the immedi-
leading to the presence of a smear of amplified bands ate vicinity of FRA10B and the position of these subclones and their
restriction fragments with respect to the fragile site as determined(similar to some cases of FRAXA expansion). Alterna-
by FISH. Open bars indicate FISH signal proximal to the fragile site;tively, the DNA may have been sheared during prepara-
shaded bars indicate distal signal.tion, rendering very large expansions undetectable as
(F) Restriction fragments used on Southern blots of FRA10B carriersdiscrete entities. Further Southern blot analysis (Figures
indicating their ability to detect the instability associated with fragile
1F and 2B) narrowed the region of amplification to a 1.9 site chromosomes. Open bars indicate constant-sized restriction
kb PstI fragment. An individual homozygous for FRA10B fragments; hatched bars indicate variable, larger bands in FRA10B
individuals.chromosomes was found tohave no bands in the normal
(G) Structure of the 1.9 kb PstI restriction fragment showing instabil-size range (Figure 2B).
ity in FRA10B chromosomes. Arrows indicate the location of various
AT-rich repeats of 16–52 bases in length that were amplified using
primers F1 or F2 and R.Sequence Composition of the FRA10B Region
Sequence analysis of the 1.9 kb PstI fragment from a
normal allele of the FRA10B locus revealed a variety of 5 and 9 kb), and these, together with some of the various
repeats between 16 and 52 bp in length throughout the normal alleles, were subsequently sequenced (Figures
extremely (91%) AT-rich central 1 kb (Figure 1). PCR 4 and 5). The repeat motif sequences within these alleles
primers were designed todetermine the molecular basis exhibit varying degrees of relatedness to one another
for expansion (Figure 3). PCR across the central AT-rich and were categorized accordingly as TspI (T), proximal
repeat sequence (using primers F2 and R, Figure 1G) (P), expanded (e/E), SnaBI (S), or distal (D) derivate re-
demonstrated that this region is highly variable in length peats (Figures 4 and 5). Repeat motifs were categorized
with more than 16 different alleles detected (Figure 3). in an effort to minimize the number of differences be-
PCR products could be generated from the smallest of tween motifs so as to illustrate their relationship with
one another.the FRA10B-expressing alleles (between approximately
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Figure 2. Southern Blot Detection of Expansion at FRA10B
(A) Expansion associated with FRA10B chromosomes. Southern blot
Figure 3. Length Polymorphism of the FRA10B AT-Rich Region Re-of SacI-digested DNA from FRA10B individuals probed with the 4 kb
vealed by PCREcoRI fragment from subclone l1002. Circles indicate the position of
PCR amplification across the FRA10B-associated unstable regionrestriction fragments carrying fragile-site-associated amplification.
revealed length variation among normal and fragile site alleles. AtBracket indicates normal-sized hybridizing restriction fragments.
least fifteen non–fragile site alleles—distinguishable by lengthSize markers are indicated in kilobase pairs.
alone—were detected and are indicated by numbered arrows. Allele(B) Expansion in a FRA10B homozygote. Southern blot of PstI-
#16 is the smallest allele that gives rise to cytogenetic expressiondigested DNA from two FRA10B heterozygous parents (half-shaded
of FRA10B. DNA size markers are indicated in kilobases. Allelessymbol) and their FRA10B homozygous offspring (fully-shaded sym-
have been grouped into short normal (SN), intermediate (INT), longbol) probed with the 1.9 kb PstI fragment from subclone l1002.
normal (LN), and FRA10B (EXP) on the basis of size and ability to
express the FRA10B fragile site. Allele frequencies for each group
are indicated as percentages and were determined by analysis of
Sequence Comparison of “Normal” 170 chromosomes. Artifactual bands (e.g., between allele 12 and
and FRA10B Alleles 13) were occasionally found in some PCR products and were not
Sequence analysis of variousnormal and FRA10B alleles reproducible.
revealed differences in repeat copy number as the pri-
mary basis for length polymorphism (Figure 5A). Alleles
could be grouped into four categories: small normal (SN, and FRA10B alleles in more than one copy shares 26
identical bases with the 33 bp repeat that gives rise tocomprising z66% of alleles), intermediate (INT, z33%),
large normal (LN, ,1%), and FRA10B-expressing (z1%) FRA16B (Figure 5B). This identity includes a continuous
sequence of 12 nucleotides at the beginning of the re-(Figure 3). Alleles #1–#4 are representative of the SN
group and are distinguished from other alleles by a dis- peat motif and copies of a 9 bp repeat of which there
are three copies in the FRA16B repeat motif. It remainstinct set of proximal derivative repeats (P1, [P3]2, P4)
and only four or five copies of the expanded derivative to be determined whether these sequence elements
might have any functional significance.repeats (E1, [E2]2–3, E4) (Figure 5A). Similarly, the inter-
mediate INT (#6–#8, #11, and #12) alleles have certain
unique flanking repeat motifs, e.g., P2 and D2. The LN Intergenerational and Somatic Instability
of FRA10B Alleles(#14 and #15) and FRA10B alleles share a subset of
flanking repeats (e.g., P1, P6, P7, P8, S4, and [S9]2), Long-range PCR across the FRA10B AT-rich repeat in
some families carrying the fragile site allowed the stabil-suggesting that the FRA10B alleles have been derived
from the LN alleles. The LN alleles, in turn, share more ity of the repeat during transmission to be assessed.
Changes in the size of PCR products reveal intergenera-flanking polymorphisms with INT alleles than SN alleles.
Sequence analysis of alleles that give rise to the fragile tional instability of those alleles that give rise to the
fragile site in virtually every transmission (Figure 6). Insite FRA10B demonstrated that each had at least four
uninterrupted E repeats (Figure 5A). For one allele (17), most cases, this involved increase in size. In addition,
the presence of two large PCR products in one FRA10B-the E19 42mer was shown to be present at both ends
of the expanded region.These results lead to the conclu- carrying individual is evidence for somatic instability of
the FRA10B repeat (Figure 6A, lane 2). In contrast, thesion that FRA10B alleles are caused by expansion in
copy number of certain E repeat motifs. It is of interest long normal allele (LN#14) exhibited minimal changes in
length upon transmission (Figure 6B). Individuals withthat the FRA10B alleles #17–#19, which are from mem-
bers of different kindreds, show different expanded re- LN#14 do not express theFRA10B fragile site cytogenet-
ically; although nine copies of the E19 repeat have beenpeat motifs (Figure 5A). In some cases, the expanded
allele from multiple members of the same family was determined for allele #15, the same repeat motif was
observed in the EXP allele #17. Therefore, the LN#14sequenced; however, no differences in either the flank-
ing sequence or the compositionof the expanded repeat allele appears to be below a critical copy number for
fragile site expression. Assuming a repeat motif lengthmotif were found (data not shown). Repeat E19 was
observed in both LN alleles and FRA10B allele #17. A of 42 bp, the z5 kb length of the PCR product from the




FRA10B Repeat Motif Length and Composition
Ladder PCR (Yu et al., 1997) was used to assess the
repeat composition of the expanded alleles. This in-
volved PCR between a redundant primer (Exp-19F1),
derived from the E19 repeat motif, and a unique primer
(R) from thenonrepetitive region flanking the repeat (Fig-
ure 1). Comparison of the spacing of the ladder in two
unrelated FRA10B individuals (Figure 7A) indicated that
different length repeat motifs were giving rise to these
two FRA10B alleles. Due to the similarity of most E
repeats, the ladder primer used was not specific for a
single repeat motif. This result indicates that while lad-
der PCR is effective in demonstrating the presence of
expanded repeats, it is not specific enough to identify
the repeat motif sequence. The basis for differences in
the intensity of ladder PCR bands is not known; how-
ever, it could be due to minor sequence differences
between repeat motifs affecting the efficiency of hybrid-
ization to the repeat motif PCR primer used in the ladder
PCR. As a consequence, the exact sequence of the
FRA16B repeat motif (which was deduced by ladder
PCR) is now in question, although to date all FRA16B
alleles give ladders of equal spacing (Yu et al., 1997 and
M. M., unpublished data).
Repeat composition of FRA10B-expanded and nor-
mal alleles was therefore also analyzed by restriction
endonuclease digestion. The enzyme NdeI has a recog-
nition site in some of the expanded allele repeat motifs
(E11–E13) (Figure 5A). Cleavage of PCR products from
FRA10B individuals showed that some but not all ex-
panded alleles were sensitive to NdeI (Figure 7). In the
related individuals in which the NdeI-containing repeat
motif was present (individuals [B] and [C], Figure 7B),
only part of the PCR product was digested. The ex-
panded FRA10B alleles are therefore composed of dif-
ferent repeats, and, in one instance, the expanded allele
consists of two (or more) repeats of different composi-
tion (Figure 7). Changes in electrophoretic mobility of
the NdeI-digested DNAs indicate an increase in the copy
number of the NdeI-site-containing repeat and a de-Figure 4. Various Repeat Motifs in the FRA10B Unstable Region
crease in the non-NdeI repeat in the transmission fromSequence analysis of normal and FRA10B alleles revealed a variety
of repeats that could be divided into distinct groups by virtue of their (B) to (C). Therefore, both NdeI-containing and non–
relatedness to one another. The TspI derivate repeats (T), proximal NdeI-containing repeats contribute to the instability of
derivate repeats (P), expanded derivate repeats ([e] and [E]), SnaBI this allele (Figure 7C).
derivate repeats (S), and distal derivate repeats (D) are aligned to
maximize identity within and between groups. (e) and (E) are related
but distinct repeats—all expanded repeats belonging to the (E)
Discussiongroup. Sequences that give rise to common restriction enzyme sites
(TspI, SnaBI, and NdeI) are boxed.
Dynamic mutation, the mechanism of repeat expansion,
has been the subject of intense investigation since its
discovery as the molecular basis for fragile X syndromefragile site is observed corresponds to an apparent
threshold of about 75 copies of the FRA10B repeat. (Kremer et al., 1991; Oberle et al., 1991; Verkerk et al.,
1991; Yu et al., 1991) and spino-bulbar muscular atrophyLong-range PCR in theCEPH panelof familiesdemon-
strated the segregation of a null allele (no product due (La Spada et al., 1991). The fundamental distinction be-
tween dynamic and other forms of mutation is that dy-to the expansion length exceeding PCR limits) in family
#104. Cytogenetic analysis of the CEPH 104 family re- namic mutation is a process rather than a single event.
It is this process involving a relationship between perfectvealed that individuals with PCR null alleles expressed
FRA10B, while Southern blot analysis showed FRA10B repeat copy number and instability that accounts for
the phenomenon of anticipation (the increasing diseasealleles of $100 kb (data not shown). The ability to predict
the presence of the FRA10B fragile site by virtue of the incidence and/or severity) seen in families carrying a
dynamic mutation disease. Until recently, all of the disor-length of the expansion reveals a relationship between
repeat copy number and fragile site expression. ders caused by dynamic mutation involved expansion
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Figure 5. Repeat Motif Composition of Various FRA10B Alleles and Sequence Comparison of FRA10B and FRA16B Expanded Repeat Motifs
(A) Sequence analysis of various “normal” FRA10B locus alleles. Partial sequences were determined for eleven of the alleles in Figure 3 (#1–#4,
#6–#8, #11, #12, #14, and #15), the shortest FRA10B allele (#17), and two additional FRA10B individuals (#18 and #19). Sequences were
aligned to maximize identity within and between groups. The LN alleles (#14 and #15) and the FRA10B alleles (#17–#19) are from unrelated
individuals. The regions of proximal and distal flanking sequence identity limited to FRA10B and LN alleles are boxed. FRA10B alleles are
shaded. Question marks indicate undetermined sequence, and dashes represent gaps introduced to maximize alignment. Multiple copies of
certain repeats are indicated by brackets, e.g., (T1)3 5 T1T1T1. NR indicates nonrepetitive sequence. Relative position and orientation of PCR
primers F1, F2, and R are identified by arrows.
(B) Comparison of the FRA16B and FRA10B expanded repeat motifs. A consensus sequence was derived from E repeats found in multiple
copies at the extremities of sequencing into the LN and FRA10B alleles. The FRA16B 33mer and the FRA10B 42mer are aligned to demonstrate
26 bases of homology including a 9 bp repeat (black arrows common to all motifs and grey arrows found in some motifs). Hairpin structure
can be formed based on the inverted copies of the 9 bp repeat. An identical 12 base sequence at the start of each repeat motif is shaded.
(w) indicates that the base can be either A or T.
of either p(CCG)n or p(AGC)n—only two of the possible it was not possible to observe changes in copy number
between generations. The composition of sequencesten trinucleotide repeats. On this basis, it had been pos-
tulated (Gacy et al., 1995) that since p(CCG)n and flanking FRA16B rendered conventional PCR analysis
and sequencing problematic, and therefore, the expan-p(AGC)n were the only trinucleotides thought capable
of forming hairpin structures, this was a necessary con- sion of the minisatellite repeat sequence was deter-
mined by ladder PCR (Yu et al., 1997). Consequently,dition for repeat expansion. Expansion of other tri-
nucleotide repeats has however been noted (Lindblad there are important unanswered questions in regard to
the instability of expanded minisatellites in families (andet al., 1994), and expansion of one of these, p(AAG)n,
has been found to be the predominant mutation leading individuals) as well as the relationship between the ex-
panded and normal alleles.to Friedreich ataxia (Campuzano et al., 1996).
Repeat expansion has recently been demonstrated Some of these questions have been addressed by
the analysis of the FRA10B chromosomal fragile sitenot to be limited to trinucleotide repeats. Minisatellite
repeats have been found to undergo expansion that is because it has been possible to generate PCR products
from the shorter of the fragile site–expressing alleles.manifested as either the fragile site, FRA16B (Yu et al.,
1997), or the geneticdisease myoclonic epilepsy (EPM1) Characterization of FRA10B has revealed that the repeat
expansion causing this fragile site bears the hallmarks(Lalioti et al., 1997a; Virtaneva et al., 1997). This common
property calls into question whether there might be a of the dynamic mutation process as it has been de-
scribed for trinucleotide repeats. First, FRA10B exhibitssingle, common mechanism for repeat instability, irre-
spective of repeat motif length (Buard and Jeffreys, instability of the expanded alleles, both upon transmis-
sion and somatically (Figures 6 and 7). Second, the ex-1997).
While the positional cloning of the fragile site FRA16B panded FRA10B alleles share flanking sequence poly-
morphisms with the longest normal (LN) alleles. Theserevealed that its molecular basis is an expanded AT-
rich minisatellite, analysis of the properties of this repeat LN alleles are more closely related to the intermediate
(INT) sized alleles than short normal (SN) alleles. A likelywas limited. The very large size of restriction fragments




Figure 7. FRA10B Repeat Motif Length and Composition
(A) Ladder PCR of two unrelated FRA10B individuals. A section
of an autoradiograph is shown to indicate differences in ladder
spacing—7 bands of a longer repeat in one individual span the same
distance as 8 repeats in another.
(B) Digestion of FRA10B PCR products with NdeI. Lanes A and D
are unrelated individuals; lanes B and C are related, as shown in
Figure 6A, lanes 2 and 3. (2) and (1) indicate without and with NdeI
digestion, respectively. Arrows indicate NdeI-sensitive FRA10B al-
leles before (black) and after (white) digestion.
Figure 6. Intergenerational and Somatic Instability of the Expanded (C) A likely model to explain the observed differences in E repeat
FRA10B Allele composition of the FRA10B allele transmitted between individuals
PCR across the smallest of the FRA10B fragile site alleles in families, (B) and (C). Shaded arrows represent repeats containing the NdeI
showing increase in size upon intergenerational transmission and recognition site; open arrows are deficient in this site. Gaps indicate
a doublet-expanded band in one individual indicative of somatic an unknown number of additional repeats common to each allele.
instability ([A], lane 2). Inset boxes show the relevant section of the The exact number of copies by which each allele differs is unknown.
agarose gel after prolonged electrophoresis. PCR products were Somatic instability in individual (B) is due to differences in NdeI-
stained with ethidium bromide. Size markers are given in kilobase resistant repeat copy number. The FRA10B allele in individual (C)
pairs. In (B), black arrows indicate FRA10B alleles, open arrows has fewer NdeI-resistant repeats and a greater number of NdeI-
LN14 alleles. In the pedigrees, half shading indicates the presence sensitive repeats than either of the FRA10B alleles seen in individ-
of a single FRA10B chromosome. Size ranges for small normal (SN), ual (B).
intermediate (INT), long normal (LN), and expanded (EXP) alleles are
indicated.
provided by analysis of the EPM1 repeat expansion (Lali-
oti et al., 1997a; Virtaneva et al., 1997). Premutations,
typically alleles at the high end of the normal repeatINT → LN → FRA10B. Increase in repeat copy number
is accompanied by greater instability—in common with copy number range, are another characteristic of the
dynamic mutation process. Unstable transmission of 12the expansion of trinucleotide repeats (Imbert et al.,
1993; Kunst and Warren, 1994; Nancarrow et al., 1995; and 13 copy number alleles of the EPM1 dodecamer
repeat have been observed, whereas the common 2 andCossee et al., 1997; Montermini et al., 1997). Finally,
expanded repeat motifs differ in length and/or composi- 3 copy number alleles exhibit only stable transmission
(Lalioti et al., 1997a).tion between different FRA10B families, indicating multi-
ple independent expansion events. Therefore, repeats Analysis of germline mutation at other minisatellite
repeat loci has shown this to be an exceptionally com-of diverse composition and length exhibit common
properties indicative of a common dynamic mutation plex process (Armour et al., 1993; Buard and Vergnaud,
1994; Jeffreys et al., 1994; Monckton et al., 1994).mechanism.
Further support for a common mechanism has been Changes are biased toward gains in copy number and,
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like trinucleotide repeat expansion, tend to occur at one bp repeat demonstrating that this form of mutation is not
restricted to trinucleotide repeats. The z42 bp repeatend of the repeat (Kunst and Warren, 1994). Since mini-
satellite repeats can differ slightly from one copy to the causing FRA10B further erodes the trinucleotide re-
quirement. A 24 bprepeat within the prion protein codingnext, it is possible to identify, at least in certain cases,
the origin of the incoming sequences. A variety of mech- sequence may also undergo a similar form of repeat
expansion (Goldfarb et al., 1996).anisms is implicated, including gene conversion and
slippage as well as changes in copy number of unknown Identification of the common properties of sequences
that undergo dynamic mutation may eventually enableorigin (Buard and Vergnaud, 1994; Jeffreys et al., 1994).
Differences in mutation mechanism may be locus and/ the prediction of those sequences elsewhere in the ge-
nome that have the capacity for expansion.or sequence specific. Hypermutation at the CEB1 locus
appears to be independent of high internal homology,
whereas polymorphism at the COL2A1 locus is largely Experimental Procedures
due to changes in copy number of a single repeat unit
(Berg and Olaisen, 1993; Buard and Vergnaud, 1994). Positional Cloning
Initially, the fragile site was positioned in FRA10B families relative toWhile these processes appear to be unique to the longer
chromosome 10 markers from the Genethon first generation humanminisatellite repeats, the simple repetitive nature of tri-
linkage map (Gyapay et al., 1994). Yeast artificial chromosomesnucleotide repeats could well mask such multiple com-
(YACs) positive for markers in the area of 10q25 were located relative
plex mutation processes and render them cryptic. to the fragile site by fluorescence in situ hybridization (FISH). FISH
The sequences of the expanded repeat motifs that was performed on metaphase spreads of FRA10B heterozygotes
give rise to FRA10B and FRA16B exhibit striking similar- after fragile site induction. These first results localized FRA10B be-
tween markers D10S597 (on the proximal side) and D10S554 (onity. This similarity extends to the COL2A1 minisatellite
the distal side) (Hewett et al., 1996), a region of no recombinationrepeat (Berg and Olaisen, 1993). While there have, as
on the original Genethon linkage map (Gyapay et al., 1994).yet, beenno reports of a fragile site at the COL2A1 locus,
A more detailed genetic map of the region (Figure 1A) was made
the similar sequence compositions of these repeats may by scoring meiotic recombination between D10S597, D10S554, and
reflect predisposition to repeat expansion. The hypothe- other new markers in the area, in all 40 CEPH pedigrees. Further
sis (Gacy et al., 1995) that hairpin structures area prereq- FISH analysis using YACs in the region localized FRA10B to between
D10S597 (on the proximal side) and AFM078xa9 (on the distal side).uisite for repeat expansion receives substantial support
An existing contig of CEPH MegaYACs extended from D10S597from the current finding that the repeats responsible for
(Figure 1B), but the direction of this contig was initially ambiguous.the FRA10B and FRA16B fragile sites share the ability of
Two of these YACs (y944H7 and y941C4) gave FISH signal spanning
forming inverted hairpin repeat structures. Such hairpin FRA10B. y944H7 and y941C4 were the only YACs of this contig
structures may contribute to the instability and ultimate positive for marker D10S88. D10S88 was positioned in the genetic
expansion of the repeat via the formation of nuclease- map between D10S597 and AFM078xa9. This assignment gave the
YAC contig an orientation (Figure 1).resistant “flaps” at the end of Okazaki fragments (Gorde-
Partial MboI digests of YAC944H7 were cloned into the Lambdanin et al., 1997). While it is possible that such structures
Gem-11 vector (Promega). Lambda subclones positive for D10S88are essential for the formation of a chromosomal fragile
were shown to lie proximal to FRA10B by FISH. Rare cutter restric-
site (since these sequences have been selected on the tion mapping of y944H7 and y941C4, and positioning of D10S88
basis of this ability), it is noteworthy that expanded positive lambda on this map, showed FRA10B to reside within the
p(AGC)n repeats at the myotonic dystrophy locus have terminal 450 kb MluI fragment of y944H7. Lambda grids were pre-
pared and screened with this 450 kb MluI fragment as a hybridizationnot been found to give rise to fragile sites (Jalal et al.,
probe. Lambda DNAs were purified using the Wizard Lambda Preps1993), even though p(AGC)n repeats are thought to be
DNA Purification System (Promega) and were utilized as probesable to form hairpin structures (Gacy et al., 1995). Hairpin
against filters containing BssHII-, NotI-, SacII-, and MluI-digested
formation may be a necessary and sufficient condition YAC 941C4 and 944H7 DNAs. Those lambda DNAs showing a signal
for repeat expansion (Gacy et al., 1995; Mitas, 1997); for the 450 kb MluI fragment were (a) used as probes in FISH to
however, it appears insufficient for cytogenetic manifes- determine whether they were proximal and/or distal to FRA10B, and
(b) fingerprinted to establish a lambda contig across the FRA10Btation as a chromosomal fragile site. The striking similar-
region. Most lambda subclones gave FISH signals clearly distality between the FRA10B and FRA16B repeat motifs sug-
or proximal to the fragile site; however, two clones gave signalgests that there may be certain requirements for repeat
inconsistent with their physical locations, suggesting the presence
expansion and/or fragile site expression that these se- of low copy number repeat sequences. End fragments of the most
quences meet. For example, the mechanism of BrdU proximal and most distal lambda DNAs were used as probes against
induction of fragile site expression, shared by FRA10B the lambda grids to walk toward the fragile site, and l1002 was
found to span FRA10B.and FRA16B, may have a specific DNA sequence re-
quirement.
All FRA10B and FRA16B fragile site–expressing al- Fluorescence In Situ Hybridization
Fluorescence in situ hybridization mapping was essentially per-leles are above a certain length (z75 copies of the E
formed as described by Yu et al. (1997). FRA10B was induced inrepeat), which suggests that, like rare, folate-sensitive
blood lymphocytes by the addition of BrdU (Sutherland et al., 1980).fragile sites, there is a threshold for cytogenetic expres-
sion—although the size threshold differs for these two
Pulsed-Field Gel Electrophoresis and Southern Blotclasses of fragile sites.
Mapping of FRA10B ChromosomesDynamic mutations have previously been referred to
Genomic DNA from normal and FRA10B individuals was prepared
as trinucleotide repeat mutations because all of the early in 1% agarose blocks. The DNA was digested with EcoRI, PstI, SacI,
observed expansions had taken place in trinucleotide BamHI, or XbaI; agarose plugs containing YAC 941C4 and 944H7
repeats. The molecular basis for FRA16B is an expanded DNA were digested with rare-cutter restriction nucleases BssHII,




1% agarose gel using horizontal PFGE (CHEF Mapper system, Bio- Berg, E.S., and Olaisen, B. (1993). Characterisation of the COL2A1
VNTR polymorphism. Genomics 16, 350–354.Rad) andsubsequently transferred to Hybond N1 blotting membrane
(Amersham). Various subclones or restriction fragments of lambda Buard, J., and Vergnaud, G. (1994). Complex recombination events
DNAs were used as probes against FRA10B family blots (Figure 1F). at the hypermutable minisatellite CEB1 (D2S90). EMBO J. 13, 3202–
3210.
Sequence Analysis Buard, J., and Jeffreys, A. (1997). Big, bad minisatellites. Nat. Genet.
A 4 kb EcoRI fragment of l1002 was subcloned into smaller EcoRI/ 15, 327–328.
PstI, PstI, NlaIII, and Tsp509I fragments, and these subclones were
Campuzano, V., Montermini, L., Molto, M.D., Pianese, L., Cossee,sequenced with dye terminator or dye primer cycle sequencing.
M., Cavalcanti, F., Monros, E., Rodius, F., Duclos, F., Monticelli,Sequence analysis concentrated on a 1.9 kb PstI fragment that
A., et al. (1996). Friedreich’s ataxia: autosomal recessive disease
showed instability in FRA10B individuals when utilized as a hybrid-
caused by an intronic GAA triplet repeat expansion. Science 271,
ization probe against Southern blots. Gaps in the sequence were
1423–1427.
closed by using the 4 kb EcoRI fragment as a template in a PCR
Cossee, M., Schmitt, M., Campuzano, V., Reutenaur, L., Moutou,reaction across the gap and subsequent sequencing of the PCR
C., Mandel, J.-L., and Koenig, M. (1997). Evolution of the Friedreich’sproduct.
ataxia trinucleotide repeat expansion: founder effect and premuta-
tions. Proc. Natl. Acad. Sci. USA 94, 7452–7457.PCR across FRA10B Alleles
Gacy, M.A., Goellner, G., Juranic, N., Macura, S., and McMurray,Sequence of PCR Products of Normal
C.T. (1995). Trinucleotide repeats that expand in human diseaseand FRA10B Alleles
form hairpin structures in vitro. Cell 81, 533–540.DNA was amplified in a DNA Thermal Cycler 480 (Applied Biosys-
tems) using the Taq Plus Long PCR System (Stratagene). Reaction Goldfarb, L.G., Cervenakova, L., Brown, P., and Gajdusek, D.C.
(1996). Genotype-phenotype correlations in familial spongiform en-conditions typically were: 13 high salt buffer (20 mM Tris–HCl [pH
cephalopathies associated with insert mutations. In Transmissible9.2], 60 mM KCl, 2 mM MgCl2), 0.8 mM each dNTP, additional 2 mM
Subacute Spongiform Encephalopathies: Prion Diseases. L. CourtMgCl2, 7 pmol of each primer: F1, 59-TGTAAAACGACGGCCAGTGGA
and B. Dodet, eds. (Paris: Elsevier).AGTCCAGGTATAAGGGAC-39, F2, 59-TGTAAAACGACGGCCAGTGT
ATATTATATAATATACACATATAT CAT-39, and R, 59-CAGGAAACAG Gordenin, D.A., Kunkel, T.A., and Resnick, M.A. (1997). Repeat
CTATGACCGTCTTGATTATATACATATGCTTAG- 39 (underlined are expansion—all in a flap? Nat. Genet. 16, 116–118.
the M13-ends), 0.5 U of Taq Plus Pol, and 100 ng of template DNA Gyapay, G., Morissette, J., Vignal, A., Dib, C., Fizames, C., Millas-
per 10 ml reaction volume. The cycling conditions were: 45 s at 928C, seau, P., Marc, S., Bernardi, G., Lathrop, M., and Weissenbach, J.
1 min at 568C, 20 min 1 10 s automatic extension at 628C for 5 (1994). The 1993–94 Genethon human genetic linkage map. Nat.
cycles and 45 s at 928C, 25 min 1 10 s automatic extension at 628C Genet. 7, 246–339.
for 25 cycles. To achieve a better separation of normal-sized alleles,
Hagerman, R.J., and Silverman, A.C. (1991). Fragile X syndrome:a “hot” PCR was performed adding 0.5 ml of [a-32P]dATP (10 mCi/
diagnosis, treatment and research (Baltimore, MD: The Johns Hop-
ml), and the products were run on a 3.5% wedge-shaped denaturing
kins University Press).polyacrylamide gel. For sequencing reactions, products from 210
Hewett, D.R., Handt, O., Mulley, J.C., Eyre, H., Mao, J., Le Paslier,ml PCRs were separated on a preparative 0.8% agarose gel, the
D., Sutherland, G.R., and Richards, R.I. (1996). Construction of abands were cut out, and the DNA was electroeluted (Sambrook et
genetic and physical map spanning the bromodeoxyuridine-induc-al., 1989). Dye terminator sequencing was carried out using M13
ible fragile site on human chromosome 10q25.2. Am. J. Hum. Genet.forward and reverse primers.
59, A304 (abstract #1764).
Imbert, G., Kretz, C., Johnson, K., and Mandel, J.-L. (1993). OriginLadder PCR
of the expansion mutation in myotonic dystrophy. Nat. Genet. 4,FRA10B ladder PCR was performed essentially as previously de-
72–76.scribed (Yu et al., 1997) except for the use of Clontech Advan-
tage Genomic Polymerase Mix. PCR primers were R and Exp-19F1 Jalal, S.M., Lindor, N.M., Michels, V.V., Buckley, D.D., Hoppe, D.A.,
59-TGTAAAACGACGGCCAGTTATATTATATATGATATATTATATAT Sarkar, G., and Dewald, G.W. (1993). Absence of chromosome fragil-
GAT -39. Cycle conditions were 958C for 3 min, then 5 cycles of ity at 19q13.3 in patients with myotonic dystrophy. Am. J. Med.
928C, 30 s; 528C, 30 s; 628C, 8 min, then 25 cycles of 928C, 45 s; Genet. 46, 441–443.
628C, 8 min. Jeffreys, A., Tamaki, K., MacLeod, A., Monckton, D.G., Neil, D.L., and
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Abstract Mutations in the brain specific P/Q type Ca2+
channel alpha1 subunit gene, CACNA1A, have been iden-
tified in three clinically distinct disorders, viz. episodic
ataxia type2 (EA-2), familial hemiplegic migraine (FHM)
and spinocerebellar ataxia6 (SCA6). For individuals with
EA-2, the mutations described thus far are presumed to
result in a truncated protein product. Several different
missense mutations have been identified in patients with
FHM. At least two of these mutations have been identi-
fied on two different chromosome 19p13 haplotypes and
thus represent recurrent mutations. In the present study,
we have screened several individuals for mutations in all
47 exons in the CACNA1A gene by single-strand confor-
mation analysis. We have characterised a novel missense
mutation, G5260A, in exon32 in a family segregating for
EA-2. The consequence of this mutation is an amino acid
substitution at a highly conserved position within the
CACNA1A gene. This represents the first point mutation
not resulting in a proposed truncated protein. Further-
more, this mutation has been detected in a family member
with mild clinical signs including only migraine. Addi-
tionally, a second previously identified recurrent muta-
tion, C2272T, in exon16 has been discovered in a patient
with FHM.
Introduction
Episodic ataxia type2 (EA-2) is characterised by variable
symptoms, including acute periodic attacks of unsteadi-
ness, gait ataxia and dysarthria. Some patients also expe-
rience episodes of vertigo and nausea. Attacks of symp-
toms can last from several minutes to a few hours or even
days. The frequency of attacks varies greatly among pa-
tients and attacks are often precipitated by emotional or
physical stress, coffee or alcohol. Clinical onset is gener-
ally during childhood, with a few cases being described in
which onset is after 40years. In the majority of patients
with EA-2, oral administration of acetazolamide prevents
or dramatically lessens attacks (Farrher and Mustian
1963; White 1969; Griggs et al. 1978).
Familial hemiplegic migraine (FHM) is a distinctive
form of dominantly inherited migraine in which patients
have hemiparesis in addition to other aura symptoms,
such as hemianopic blurring of vision, unilateral parethe-
sia, numbness and dysphagia. Aural symptoms persist for
30–60minutes followed by migraine lasting from a few
hours to days (Bradshaw and Parsons 1965; Heyk 1973;
Whitty 1986). At least three loci are known to exist for
FHM: one at 19p13 (Joutel et al. 1993; Ophoff et al.
1994), one at 1q21-q23 (Ducros et al. 1997; Gardner et al.
1997) and one at a third as yet unidentified locus (Ducros
et al. 1997).
Mutations in the brain specific P/Q type Ca2+ channel
α1-subunit gene, CACNA1A, have been identified in fam-
ilies consistent with a 19p localisation of FHM and EA-2.
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To date, four different missense mutations have been
characterised for FHM. For patients with EA-2, three mu-
tations distinct from those identified in individuals with
FHM have been described (Ophoff et al. 1996; Yue et al.
1998). Mutations in the CACNA1A gene have also been
shown to be responsible for a third clinically distinct dis-
order, spinocerebellar ataxia6 (SCA6). The most common
disease-causing mutation for SCA6 is an expansion of an
(AGC)n repeat located within the 3’ region of the gene
(Matsuyama et al. 1997; Riess et al. 1997; Zhuchenko 
et al. 1997). Additionally, a base substitution in the
CACNA1A gene has been identified in a family with pro-
gressive ataxia (Yue et al. 1997) and affected individuals
from a family segregating for EA-2 have been reported 
to have a small expansion of the (AGC)n repeat (Jodice et
al. 1997). It remains to be determined whether all cases 
of EA-2 and FHM are the result of mutations in the
CACNA1A gene or whether there are multiple genes re-
sponsible for the phenotypic heterogeneity in these disor-
ders. If the variability of symptoms is attributable to dif-
ferent mutations in one gene, then the characterisation of
these mutations may allow a correlation between geno-
type and phenotype (Terwindt et al. 1998).
We have screened several patients with FHM and indi-
viduals from a family segregating for EA-2 for possible
mutations in the CACNA1A gene. A novel missense muta-
tion in exon32 in a family with EA-2 has been identified.
This mutation has not been detected in 252 normal blood
bank control samples and does not disrupt the reading
frame of the protein. A second mutation has been detected
in an individual from a small nuclear family segregating
for FHM. The mutation identified in this patient is shown
to be the same as that previously described by Ophoff et
al. (1996) and subsequently described in a large number
of patients with FHM and associated permanent cerebellar
symptoms (Ducros et al. 1999). Furthermore, two new
polymorphisms have been characterised during this study.
Materials and methods
Patients
A family of 14 individuals segregating for EA-2 was screened in
this study. The family was consistent for the chromosome 19p lo-
calisation (see below) and affected family members were shown to
be responsive to acetazolamide, thus making it a good candidate
for screening for mutations in the CACNA1A gene.
We also studied four individuals from a small FHM pedigree
spanning two generations. From the age of eleven, the proband has
had migraine with aura associated with right side hemiparesis,
hemianopia and aphasia. Interictally, he has horizontal nystagmus
but no other focal neurological signs. Magnetic resonance imaging
of the brain showed vermian cerebellar atrophy. Two sporadic
cases of hemiplegic migraine of unknown etiology were also in-
cluded in the screening.
DNA samples and polymerase chain reaction
Informed consent was obtained from individuals who gave blood
samples. DNA was extracted from blood lymphocytes according
to a standard protocol. Polymerase chain reaction (PCR) analysis
was undertaken under the following conditions in a total volume of
10µl containing 100ng DNA, 75ng of each forward and reverse
primer, 0.1U Taq polymerase (Perkin Elmer), 1.5mM MgCl2.
PCR products for sequencing reactions were generated in 100µl
reactions. For reactions that were analysed on single-strand con-
formation analysis (SSCA) gels, 0.2µCi [32P] dCTP was added to
each reaction. Cycling was performed at 94°C for 1min, 60°C for
30s and 72°C for 30s (10 cycles), 94°C for 1min, 55°C for 30s
and 72°C for 30s (25 cycles), followed by 10min at 72°C in a Hy-
baid PCR express thermalcycler.
Mutation analysis
All 47 exons and adjacent intron sequences of the CACNA1A gene
were amplified by PCR with previously described primers (Ophoff
et al. 1996). SSCA was the same as that described by Orita et al.
(1989) with a few modifications. The gel systems were composed of
MDE TM gel (mutation detection enhancement, FMC Bioproducts)
made to the manufacturer’s specifications and 5% and 10% non-de-
naturing polyacrylamide gel (49:1 acrylamide:bisacrylamide with
5% glycerol added). All gels were run at room temperature. Exons of
altered mobility were sequenced. An analysis of (AGC)n copynum-
ber in exon47 of the CACNA1A gene was also undertaken.
Sequence analysis
PCR products were sequenced with both the reverse and forward
primer with a DYE terminator kit (Perkin Elmer). Sequences gen-
erated were compared with the published sequence (GenBank no.
X99897) by using Lasergene software (DNA star).
Results
Linkage analysis
Family1, indicated as having EA-2, was analysed for mi-
crosatellite markers at and flanking the known localisation
for EA-2at 19p13.1. Two-point linkage analysis was per-
formed by the linkage 5.1 package (Lathrop and Lalouel
1984) under the assumption of autosomal dominant inheri-
tance and a disease frequency of 1:10,000. The allele fre-
quencies were assumed to be equal for each marker and
penetrance was set at 1.00. The highest LOD score of 1.36
(θ=0.0) was attained at several fully informative mi-
crosatellite markers, both flanking and within the
CACNA1A localisation. This was consistent with linkage to
the 19p13.1 localisation. Furthermore, the (AGC)n repeat
(normal alleles, n=4–16) known to be within exon47 at the
3’ end of the CACNA1A gene and the microsatellite marker
D19S1150 within intron7 of the CACNA1A gene segre-
gated with the disease phenotype in the family (Fig.1). No
expansion at the (AGC)n repeat was detected in the family.
Individual III.7 was chosen for initial screening by SSCA
and, after observation of an aberrant band and subsequent
mutation identification, all individuals from the pedigree
were screened to confirm the presence of the mutation as-
sociated with the disease phenotype.
Mutation screening
During the screening by SSCA, two previously unpub-
lished polymorphisms were detected in both patient sam-
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ples and the normal blood bank controls used in the analy-
sis (Table1). Bandshifts in patient material were detected
for exon16 (FHM patient) and exon32 (EA-2 individual).
No bandshifts were detected for any other exon of the
CACNA1A gene in family1 (EA-2). In the EA-2 individ-
ual, sequence analysis of the exon32 bandshift revealed a
G5260A transition resulting in an Arg1666His amino acid
substitution. This amino acid substitution occurred in a
highly conserved region of the protein (Fig.2). Further-
more, this bandshift was analysed in other available fam-
ily members (affected and unaffected) and cosegregated
only with the disease phenotype (Fig.3). One individual
(Fig.3, lane1) who had inherited both the mutation and
the affected haplotype had no clinical evidence of cere-
bellar dysfunction. On examination, he had no signs of
nystagmus on lateral gaze and his balance and cerebellar
examination were well within normal limits. This individ-
ual however does experience migraine.
Sequence analysis revealed that the base change in
exon16 detected in the family with FHM was the same
mutation as that previously reported by Ophoff et al.
(1996). The C-to-T transition at nucleotide (nt)2272 re-
sults in a Thr666Met amino acid substitution.
Sequence comparison
The nucleotide sequence from exon32 (nt5237–5267) of
the human CACNA1A gene was compared with the
BLASTn database. The altered base (G at nt5260) was
found to be conserved both within the same species for
different calcium channel gene members and also across
species (data not shown). Analysis of the protein se-
quence for similarity by using the BLASTp algorithm in-
dicated that the residue that is altered in the affected indi-
viduals is conserved over many species, including Mus
musculus, Oryctolagus cuniculus, Discopyge ommata and
Caenorhabditis elegans. Results from BLASTp also re-
vealed that this same residue was conserved for several
members of the calcium channel gene family, including
N-type calcium channel genes.
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Fig. 1 Haplotype analysis of microsatellite markers flanking and
intragenic to the CACNA1A gene. Linkage is consistent with a 19p
localisation. Bandshift change C detected in exon32 cosegregates
with the disease status
Table1 Two previously unpublished polymorphisms in the
CACNA1A gene were detected in normal unrelated blood bank
samples. Heterozygosities calculated were based on results from
50 samples (nt nucleotide)
Intron Nucleotide Substitution Hetero-
position zygosity
Intron15 2192–39nt g–a 0.2
Intron43 6471–94nt c–a 0.24
Fig. 2 Protein similarity alignment with BLASTp algorithm. The
human sequence (X99897) from exon32 of the CACNA1A gene
was used for the search. This region was found to be highly con-
served across species, particularly the substituted arginine residue,
Arg1666His (boxed), in affected individuals in family1. This




Prior to this study, three mutations leading to disruption of
the reading frame had been described in patients with EA-
2. Two of these mutations, a deletion mutation and a splice
site mutation, are both postulated to result in a truncated
protein product (Ophoff et al. 1996). Similarly, a de novo
mutation in exon6 of the CACNA1A gene leading to a pre-
sumed premature stop codon has been identified in a pa-
tient with sporadic EA-2 (Yue et al. 1998). Furthermore, in
one family with symptoms of EA-2 rather than SCA6, an
expanded (AGC)n repeat has been identified (Jodice et al.
1997). It was speculated in that study that the expanded
(AGC) repeat might affect mRNA stability, splicing effi-
ciency or processes at the transcriptional/translational
level. In general, the mutations described to date for EA-2
are predicted to result in truncated protein product.
Thus, the identification of a novel missense mutation re-
sulting in a proposed altered protein of normal size is of
considerable significance, since it is the first missense mu-
tation identified as causing EA-2. The mutation identified
in these individuals is an G5260A transition (giving rise to
an Arg1666His amino acid substitution) in exon32 of the
CACNA1A gene. No other bandshifts for all the other 46
known exons of the CACNA1A gene have been identified
in this family. Furthermore, there is no apparent expansion
at the (AGC)n repeat located in the 3’ portion of the gene.
The region of the CACNA1A gene in which the muta-
tion has been detected is the IVS4 region of the calcium
channel. S4 domains are considered to be the voltage sen-
sors of calcium channels and have an unusual, highly con-
served pattern of an arginine residue at every third or
fourth position. These arginine residues are interleaved
with hydrophobic residues (Tanabe et al. 1987; Stea et al.
1995) The Arg1666His substitution alters this highly con-
served region; thus, this mutation possibly alters the abil-
ity of the voltage sensor to function efficiently. Previ-
ously, a similar mutation affecting the IS4 domain has
been shown to be responsible for FHM (Ophoff et al.
1996). Given the high degree of species homology, the
importance of an arginine residue at every third or fourth
position in S4 domains, the presence of a similar mutation
in an IS4 domain in FHM and the failure to detect this
mutation in a large number of normal control chromo-
somes, it is proposed that this is the disease-causing mu-
tation. It is of considerable interest that one individual
from this pedigree (III.1) is clinically normal with no evi-
dent signs of episodic ataxia but does experience mi-
graine. Therefore, the missense mutation detected in this
individual may only manifest itself as migraine. However,
although no bandshifts have been detected in the addi-
tional 46 exons of the CACNA1A gene tested, the sensi-
tivity of SSCA is not 100% and an additional mutation
may have been unidentified (Orita et al. 1989; Sheffield et
al. 1993; Ranvik-Glavac et al. 1994; Jordanova et al.
1997). Another possible explanation is that the detected
mutation is a rare polymorphism.
The mutation detected in the individual with FHM,
cerebellar atrophy and nystagmus is the same as that orig-
inally detected in the study by Ophoff et al. (1996). Fur-
ther studies have also identified this same mutation in ap-
proximately 50% of families with FHM and permanent
cerebellar ataxia. The mutation described in all these pa-
tients is a C-to-T transition at nt2272 in the IIS6 domain
in exon16 of the CACNA1A gene and results in a
Thr666Met change. The normal sequence at the mutated
site is CCTGA(C)GGG. The cytosine C in parentheses is
mutated to thymidine. The dinucleotide CpG is a known
hotspot for mutations in the human genome (Cooper and
Krawczak 1993). Approximately one third of human
point mutations occur at these sites (Ollila 1996). Thus,
the mutation described for the FHM patients is probably
the result of similar mutational mechanism and may rep-
resent a commonly occurring recurrent mutation in the
CACNA1A gene.
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Fig. 3 SSCA analysis of exon
32 of the CACNA1A gene in
family1 (EA-2). All affected
individuals inherited the aber-
rant bandshift, including indi-
vidual in lane 1. (Numbers
(1–13) beside symbols indicate
lane numbers)
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We present data that suggest that a novel missense mu-
tation in the IVS4 domain of the CACNA1A gene pro-
duces a variable phenotype, including both migraine and
EA-2. This finding supports the notion that phenotypic
variability may be attributable to one or more modifying
loci rather than multiple disease-causing loci. This muta-
tion represents the first missense mutation that does not
lead to a premature stop codon and possible subsequent
truncated protein described in EA-2. The characterisation
of further mutations in the CACNA1A gene may enable us
to obtain a better understanding of the phenotype/geno-
type correlation and may provide additional information
enabling greater comprehension of the action of the
CACNA1A gene in families with both FHM and EA-2.
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with the SCA15 locus
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Abstract—Background: Most patients with pure nonprogressive congenital cerebellar ataxia have a sporadic form of
unknown heredity and etiology. Several small families have been reported with a dominantly inherited nonprogressive
congenital ataxia (NPCA). Methods: The authors ascertained and clinically characterized a four-generation pedigree
segregating an autosomal dominant type of congenital nonprogressive cerebellar ataxia associated with cognitive impair-
ment. Following the exclusion of several SCA localizations (SCA-1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 17, IOSCA, and DRPLA), a
genome-wide linkage study was performed. Results: Examination of the family showed that all affected members had gait
ataxia and cognitive disability with variable features of dysarthria, dysmetria, dysdiadochokinesia, nystagmus, dystonic
movements, and cerebellar hypoplasia on imaging. Clinical signs of pyramidal tract dysfunction and sensory changes were
absent. A genome-wide search in this family detected linkage to chromosome 3p with a maximum two-point lod score of
4.26 at D3S3630. This localization to the pter is distal to D3S1304, as defined by a recombination event. This overlaps
with the SCA15 locus, with the critical overlapping region between the microsatellite markers, D3S1304 and D3S1620
(approximately 8 cM). Conclusion: Autosomal dominant congenital nonprogressive cerebellar ataxia with or without
cerebellar hypoplasia overlaps with the SCA15 locus on chromosome 3pter.
NEUROLOGY 2004;63:2288–2292
The pure cerebellar congenital ataxias include all
nonprogressive encephalopathies showing typical
features of cerebellar dysfunction in the absence of
pyramidal tract dysfunction or dysmorphic features.
This group can be further subdivided according to
morphologic features into pure nonprogressive cere-
bellar ataxia (NPCA) with or without cerebellar hyp-
oplasia, pure cerebellar ataxia with other posterior
fossa malformations, non-hereditary, and pure cere-
bellar ataxia with supratentorial malformation, non-
hereditary.1 We report a four-generation family with
autosomal dominant, pure NPCA with or without
cerebellar hypoplasia.
Patients and methods. Patients. Twenty-five family mem-
bers of Caucasian ancestry were available for examination. Seven
family members agreed to have a cerebral MRI, ophthalmologic
review, and nerve conduction studies. Nine agreed to neuropsy-
chological evaluation. Blood was collected for DNA extraction from
25 family members and two spouses after written informed
consent.
Mutation and linkage analyses. Repeat expansions at SCA1,
SCA2, SCA3, SCA7, SCA8, SCA10, SCA12, SCA17, and DRPLA
were investigated by PCR. Linkage analysis at SCA1 to 8, SCA10,
SCA12, SCA17, DRPLA, and IOSCA loci was undertaken to ex-
clude an allelic mutation at one of these genes. After excluding
known SCA localizations, a semi-automated genome-wide search
for the disease locus was performed. The average distance be-
tween markers was 20 cM. Once localized, further manual
genotyping was carried out in order to refine the localization.
Two-point lod scores were based on the pedigree (figure 1) using
Linkage 5.2.2 Autosomal dominant inheritance and a disease fre-
quency of 1:10,000 was assumed. Given that age at onset is early,
penetrance was set at 1.00.
Results. Clinical features of the family. The proband
(IV-2), age 3, walked unsupported at 2.5 years. Her par-
ents had noted poor balance and coordination since a few
months of age. Language was delayed, and at age 3 she
used only single words. On examination, she had a wide-
based ataxic gait. Examination of cranial nerves, tone,
power, sensory testing, deep-tendon reflexes, and hearing
revealed no abnormalities. She had no nystagmus. Optic
fundi, visual acuity, and color vision were normal. Her
head circumference was 42 cm (10th–25th centile). A cra-
nial MRI was normal. A Griffith developmental assess-
ment placed the child at the 2-year level with a general
quotient of 61 (mildly retarded range). The proband has a
Additional material related to this article can be found on the Neurology
Web site. Go to www.neurology.org and scroll down the Table of Con-
tents for the December 28 issue to find the title link for this article.
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clinically unaffected brother (IV-1) who reached his devel-
opmental milestones on time and had a formal develop-
mental assessment within the normal range. The
proband’s mother (III-6), age 34 years, walked without
support at 18 months and was slow to speak. She was
assessed by a pediatric neurologist at age 10 and was
reported to have an ataxic gait, intention tremor, and cer-
ebellar dysarthria. She attended a class for the mildly
intellectually handicapped and left school at age 15. Sport
was avoided because of poor balance and coordination. On
examination, her head circumference was 56 cm. She had
a scanning type cerebellar dysarthria and a bilateral in-
tention tremor accompanied by a wide-based gait and diffi-
culty with heel-toe walking. Cerebral MRI examination
revealed atrophic changes of the vermis of the cerebellum
(figure 2). III-6 has a clinically unaffected sibling of normal
intelligence.
Other family members (see figure 1) were examined and
20 were classified as affected based on the presence of gait
ataxia. The minimum criterion for gait ataxia was the
complete inability to tandem walk (table 1). The mean age
at time of examination was 82 years in generation I, 51
years in generation II, 25 years in generation III, and 4
years in generation IV. All affected individuals had an
observed congenital onset of ataxia or had a history of
delayed walking and a wide-based gait as a young child
with an unremarkable perinatal history. In addition, they
all gave a history of learning difficulties at school and
members of the younger generations were placed in special
learning classes. The presence of other cerebellar signs,
including dysarthria, dysmetria, dysdiadochokinesia, and
nystagmus, varied between affected family members. Clin-
ical signs of pyramidal tract dysfunction and sensory
changes were absent. One individual (III-13) developed
dystonic movements in the second decade. Only three of
the seven family members who agreed to further investiga-
tions, including neuropsychological testing, showed atro-
phic changes of the cerebellar vermis on MRI, and there
appeared to be no association between the presence of cer-
ebellar hypoplasia and the degree of ataxia or cognitive
Figure 1. Haplotype analysis of chromosome 3 microsatellite markers in a family with congenital ataxia. Affected dis-
ease haplotype is boxed. Recombinant events in individuals III-11 and IV-3 indicate that the disease gene lies distal to
D3S1304. Individual II-8 inherits the affected haplotype. This individual sustained hip injuries in a car accident, thus
clinical assessment of this individual is unclear. For two-point linkage analysis, this individual was coded as unknown
affection status.
Figure 2. Cranial MRI of proband’s mother (III-6) show-
ing cerebellar vermal hypoplasia.
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impairment. The possibility of postnatal cerebellar atrophy
cannot be excluded as serial MRIs were not performed.
Five family members reported a slight improvement in
coordination with increasing age. Neuropsychological ex-
amination of nine adults revealed cognitive impairment
(table E-1 available on the Neurology Web site at www.
neurology.org). Eight individuals performed adequately (z
scores  2.0) on tests of new learning and memory.
While there was considerable scatter of performance on
tests of executive and adaptive functioning, no individual
performed adequately on all such tests and six performed
poorly (z scores  2.0) on more than one. The vertical
mode of inheritance is consistent with autosomal dominant
inheritance.
Exclusion of known loci. Linkage analysis revealed
that the gene segregating in this family with congenital
ataxia was not at several of the already identified loci
(SCA-1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 17, and IOSCA and
DRPLA) (tables E-2 and E-3), excluding the possibility of a
different type of mutation in these genes. Repeat expan-
sion analysis revealed that there was no expansion in af-
fected members of this family for those genes known to
have expansions associated with SCA (SCA1, SCA2, SCA3,
SCA7, SCA8, SCA10, SCA12, SCA17, and DRPLA).
Genome-wide screen. Analysis of the genotype data
from the genome screen revealed several regions of poten-
tial interest, including chromosomes 3, 13, and 21. Linkage
data from the genome screen did not reveal linkage to any
of the other known SCA localizations (SCA11, SCA13–24).
Analysis of additional markers from these regions revealed
linkage at chromosome 3p (table 2) with regions on chro-
mosomes 21 and 13 excluded (data not shown). A maxi-
mum lod score of 4.26 (  0.00) for the microsatellite
marker D3S3630 demonstrated linkage. Results from hap-
lotype analysis (see figure 1) indicate the disease gene lies
distal to D3S1304 in the pter region of chromosome 3.
Discussion. The characteristic clinical features of
NPCA include congenital ataxia, which is persistent
but nonprogressive, and cognitive impairment.3
There is wide clinical variability of other neurologic
features such as nystagmus, dystonia, and epilepsy.
Cerebellar hypoplasia on imaging is present in less
than 50% of children, and cannot be used to predict
the degree of ataxia, cognitive impairment, or epilep-
sy.3 The presence or absence of cerebellar hypoplasia
on MRI was discordant in two previously reported
Table 1 Clinical features in affected family members
I-2 II-2 II-3 II-6 II-9 II-12 II-13 II-15 II-16 III-6
Age, y 82 58 56 58 50 49 38 53 49 34
Learning problems          
Dysarthria          
Dysdiadochokinesia Left         
Nystagmus          
Gait ataxia N/A         
Unable to tandem walk *         
Limb ataxia          






Eye review N/A N/A N/A N/A N/A N/A N N N N
Nerve conduction studies N/A N/A N/A N/A N/A N/A N N N N
* Unable to assess due to hip injury.
N/A  not applicable; N  no abnormality on testing.
Table 2 Pairwise lod scores between AD NPCA and microsatellite markers near 3pter
Marker
Lod score at recombination fraction of:
Z max  max0.0 0.01 0.05 0.1 0.2 0.3 0.4
D3S1307 3.01 2.96 2.77 2.51 1.94 1.31 0.61 3.01 0.0
D3S1297 3.87 3.02 2.85 2.68 1.85 1.35 0.73 3.87 0.0
D3S3630 4.26 4.19 3.89 3.49 2.65 1.72 0.74 4.26 0.0
D3S1304 infinity 1.14 2.22 2.41 2.12 1.51 0.75
D3S1263 infinity 0.41 1.53 1.77 1.60 1.13 0.54
D3S2338 infinity 0.86 0.94 1.45 1.52 1.14 0.57
AD NPCA  autosomal dominant nonprogressive cerebellar ataxia.
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sib pairs, confirming suggestions that NPCA with or
without cerebellar hypoplasia has the same origin.3
The vast majority of patients with pure nonsyn-
dromic NPCA with or without cerebellar hypoplasia
have an apparently sporadic form of unknown heredity
and etiology; however, families exhibiting autosomal
recessive,3-14 autosomal dominant inheritance,15-20 and
sex-linked recessive21-23 have been reported. In the pre-
viously reported small families with autosomal domi-
nant NPCA,15-20 mild to moderate early-onset
nonprogressive ataxia, delayed motor milestones, and
cerebellar vermal hypoplasia on imaging are consistent
features. Although cognitive impairment is described
as a characteristic feature of NPCA,3 only half of the
previously reported families with autosomal dominant
NPCA had cognitive impairment in addition to the
ataxia. There was variability within and between fam-
ilies with respect to cerebellar dysarthria, nystagmus,
dysmetria, and brisk tendon reflexes. One family15 dif-
fered from other reported cases by the presence of up-
beat nystagmus. Two families19,20 also report a
moderate, slowly progressive improvement of coordina-
tion and ataxia with increasing age. The main differ-
ence between our family and previously reported
families with autosomal dominant NPCA is that
ataxia, associated with mild cognitive impairment, was
clinically apparent with or without cerebellar hypopla-
sia on MRI.
Cognitive impairment of varying degree, rather
than ataxia, was the major disability affecting mem-
bers of our family. Evidence of cerebellar involve-
ment in certain cognitive and language functions is
well documented.24 A review of clinical features and
long-term development of 34 patients with congeni-
tal NPCA3 concluded that the degree of cognitive
impairment, rather than ataxia, was the limiting
factor for independent living. MRI showed mild to
moderate degrees of cerebellar hypoplasia in 41%. As
in our family, the presence of cerebellar hypoplasia
was not associated with the degree of cerebellar
ataxia or cognitive impairment; and the degree of
cognitive impairment was not related to the degree
of ataxia and motor deficit.25
The literature suggests that autosomal dominant
NPCA with or without cerebellar hypoplasia has a
variable phenotype within and between families that
may result from variable penetrance; however, the
interfamily variability also raises the possibility that
autosomal dominant NPCA may be a genetically het-
erogeneous disorder. Exclusion of the known SCA
gene expansions or linkage to known SCA loci was
not undertaken in previously reported families.
The family in this study has been localized to
chromosome 3pter. The critical region identified lies
distal to D3S1304, and encompasses a genetic dis-
tance of 18.9 cM.26 Screening of the coding regions of
the CALL gene by single stranded conformation
analysis failed to identify any mutations (data not
shown). It is speculated that mutation screening of
ITPR1 and PANG may result in the identification of
the disease causing mutation in this and possibly
other families with NPCA.
Spinocerebellar ataxia type 15, recently linked to
3p24.2–3pter, was characterized clinically as a dom-
inantly inherited pure slowly progressive cerebellar
ataxia with onset ranging from mid-childhood to
middle age.27 The main clinical features suggesting
distinction from SCA15 in our family are congential
onset, no progression of ataxia, and cognitive impair-
ment. Two Japanese families with a similar, al-
though not identical, spinocerebellar ataxia
phenotype to SCA15 were localized to 3p26.1–25.3.28
Comparison of linkage data from both these publica-
tions indicates that the localization of NPCA, as de-
termined in our family, is overlapping. The critical
overlapping region for these localizations lies be-
tween the microsatellite markers, D3S1304 and
D3S1620 (approximately 8 cM). Despite their differ-
ing phenotypes, it is possible that future gene identi-
fication may show that spinocerebellar ataxia type
15, the Japanese SCA localization, and autosomal
dominant NPCA are allelic conditions.
Table 1 Continued
III-7 III-9 III-11 III-13 III-17 III-20 IV-2 IV-4 IV-5 IV-6
28 25 18 20 23 31 3 2 6 4
       N/A  
      N/A N/A  
 Left        
    Lateral gaze     
         
      N/A N/A  




N/A N/A N/A N/A N/A N N/A N/A N/A
N N/A N/A N/A N/A N/A N N/A N/A N/A
N N/A N/A N/A N/A N/A N/A N/A N/A N/A
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It is not possible to distinguish apparently spo-
radic congenital NPCA from the inherited forms on
the basis of clinical features or neuroimaging. There-
fore, it is important to examine family members, in-
cluding parents, when evaluating a patient with
pure congenital ataxia.
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Invited Editorial: Anticipation Legitimized:
Unstable DNA to the Rescue
Grant R. Sutherland and Robert 1. Richards
Department of Cytogenetics and Molecular Genetics, Adelaide Children's Hospital, Adelaide
The discovery and recognition of new mechanisms of
genome organization and function are not common
events. Furthermore, they are usually the result of the
gradual accumulation of evidence rather than sudden
revelation. Genome properties that are contrary to
existing dogma find particular difficulties in being ac-
cepted. Transposable elements and introns were be-
yond most of our imaginations until they had been
convincingly demonstrated.
In this issue, Harper et al. (1992) revive and give
legitimacy to an old and generally discredited genetic
phenomenon, anticipation. Anticipation denotes the
increasing severity or earlier age at onset of a genetic
disease in successive generations. While clinicians,
since early this century, have been impressed by antici-
pation in myotonic dystrophy (DM), the concept had
not found favor with geneticists, for two main rea-
sons. As Harper et al. point out, the concept was asso-
ciated with "degeneration," and such a concept was
not acceptable to the strongly anti-eugenic and highly
influential geneticist Lionel Penrose, who ascribed an-
ticipation to no more than ascertainment bias (Penrose
1948). Furthermore, the genome was considered to be
stable, and there was no known mechanism by which
this virtually Lamarckian entity could operate.
The cloning of the fragile X (OberlM et al. 1991; Yu
et al. 1991) provided a mechanism for anticipation
(Fu et al. 1991; Sutherland et al. 1991; Yu et al. 1992).
Since the detailed segregation studies by Sherman et
al. (1984, 1985), this disorder had been recognized
as having unusual genetic properties. These studies
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confirmed that this X-linked disorder could have
asymptomatic male carriers of the mutation, and they
also showed that the penetrance ofmental impairment
in children depended on the phenotype of their
mother. The disorder manifested a form of anticipa-
tion that became known as the "Sherman Paradox."
This paradox was that the mothers and daughters of
asymptomatic males who carried the fragile-X muta-
tion had very different risks of having mentally handi-
capped offspring, yet these two groups ofwomen were
supposed to be genetically identical at the fragile-X
locus- after all, they both had the same part of the
same X chromosome.
The fragile X was rapidly confirmed to be due to
a heritable unstable DNA sequence (Nakahori et al.
1991; Verkerk et al. 1991). This instability was due
to changes in copy number of a trinucleotide repeat
p(CCG)n (Kremer et al. 1991) that appears to be in
the 5'-untranslated region of a gene (Yu et al. 1992),
FMR-1 (Verkerk et al. 1991), whose transcription is
blocked in fragile-X syndrome (Pieretti et al. 1991).
One fascinating property of the unstable sequence
is that the repeat copy number usually increases when
it is transmitted by women (decreases have been seen,
however), whereas it usually remains the same size or
decreases when transmitted by men. This means that
no two individuals in a fragile-X family need be geneti-
cally identical at this locus. Furthermore, at high copy
numbers, the sequence is somatically unstable, such
that different cells in a single tissue, as well as different
tissues, are also genetically different at this locus. We
postulated that such an unstable sequence could ac-
count for a number of ill-understood genetic phenom-
ena, including anticipation in DM (Sutherland et al.
1991). Both the isolation of the DM gene (DM-1)
(Brook et al. 1992; Fu et al. 1992; Mahadevan et al.
1992) and the recognition that it contains an unstable
DNA sequence (Aslanidis et al. 1992; Buxton et al.
1992; Harley et al. 1992) provided the mechanism for
anticipation that this disorder manifests so strikingly;
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and it gave comfort to the clinicians who had observed
the anticipation, only to be told by their geneticist
colleagues that it was only a mirage.
The unstable sequence in DM-1 is also a trinucleo-
tide repeat p(AGC)n of composition identical to that
amplified in the androgen-receptor gene of individuals
with Kennedy disease (La Spada et al. 1991). In DM
it has been observed only to increase in size when
transmitted. The copy number of the trinucleotide
correlates well with the severity of the disease, al-
though the birth of children with congenital DM only
to women with the disease is yet to be accounted for.
The repeat is transcribed but appears to be in the 3'-un-
translated region of a gene whose product is predicted
to be a member of the protein kinase family (Fu et al.
1992).
The recognition that unstable DNA has a different
mechanism of mutation requires a reconsideration of
what mutation is. Mutations of all types previously
recognized were static mutations; that is, the product
of a mutation was no more likely to undergo further
change than was the original DNA sequence. Unstable
DNA can be considered to be the result of dynamic
mutation (Pirsig 1991; Richards and Sutherland 1992),
where the initial change to a DNA sequence alters the
chance of further changes to it.
The concept that only one type of mutation can
account for all disease-gene segregation patterns nec-
essarily colors attempts to make observations fit
dogma. When a good fit is not found, the validity of
the observations can be doubted, or, traditionally, in
genetics, some modifying agent is invoked, and terms
such as "incomplete penetrance," "variable expres-
sion," "different genetic background," "multifactorial
effects," etc., are spawned. While some of these terms
undoubtedly describe observations, they all reveal that
something else is happening and that we do not know
what it is. Now that molecular analysis of DM and
fragile-X syndrome has revealed unstable DNA as the
basis of their mutational mechanism, it may be time
to abandon terminology that indicates ignorance and
to refer to these as disorders due to unstable DNA and
a dynamic mutation mechanism.
In the immediate future it will be of interest to deter-
mine which genetic characteristics- e.g. anticipation,
incomplete penetrance, variable expression, etc. - are
common to all disorders that have a heritable unstable
element as their molecular basis. For this reason there
has been some reluctance to include Kennedy disease
in the category of disorders caused by dynamic muta-
tion. It should be pointed out, however, that the ap-
parently "normal" genetics in this disorder is still in
keeping with the behavior of the unstable element,
since, in Kennedy disease, the copy number of the
repeat has not yet been observed to amplify to the
lengths that accord instability in fragile-X syndrome
and DM. It may well be that such amplification either
is lethal or causes a substantially different phenotype
that as yet is not associated with the androgen-
receptor gene. It is worth noting that, in Kennedy dis-
ease, the repeat, located in the androgen receptor gene
is within the coding region, and that amplification,
therefore, has a qualitative effect on the encoded pro-
tein-that is, it affects function. The repeats in
DM-1 - and probably those in FMR-1 - are located in
untranslated regions and therefore only have quantita-
tive effects on the gene product. This is exemplified in
the case of fragile-X syndrome, where the majority of
fragile-X males have no FMR-1 mRNA (Pieretti et al.
1991).
The discovery of unstable DNA sequences means
that genetic concepts that reflect the rules obeyed by
static mutations may no longer be appropriate. There
are messages in the resurrection of anticipation, for
both the laboratory geneticist and the clinical geneti-
cist. Clinical observations are important. The fact that
they may be ideologically unpopular or that there is
no known mechanism to explain them should not be
used as reason to deny their validity.
Many genetic diseases are relatively rare. Because
fragile-X syndrome and DM are common, however,
they were recognized to have unusual features to their
inheritance, and many families were available for
study. How many of the less common diseases have
similar properties? How many others that do not fit
with classical Mendelian inheritance may provide
clues to other unstable sequences in the genome or
other mechanisms that we have not yet even imagined
to exist?
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Dynamic Mutations: 
A New Class of Mutations 
Causing Human Disease 
Robert I. Richards and Grant Ft. Sutherland 
Department of Cytogenetics and Molecular Genetics 
Adelaide Children’s Hospital 
North Adelaide SA 5006 
Australia 
The rate of mutation in the human genome varies widely. 
Unique gene sequences, even of nonessential function 
(e.g., fibrinogen peptides), appear to change very slowly 
at a rate of about 1 aa (out of 400) per 200,000 years 
(Alberts et al., 1983). Such mutations are static, in that the 
mutant has the same rate of mutation as its predecessor. 
Repeated sequences associated with heterochromatin 
are, on the other hand, in an apparently constant state of 
flux. While these sequences may be involved in fundamen- 
tal processes, their mutation does not usually manifest a 
gross phenotypic change. This is apparently due to their 
remoteness from sequences encoding genes, which are 
more or less confined to euchromatin. 
Interspersed repeated DNA sequences, however, are 
distributed widely throughout the genome. Among this 
group are the microsatellites or simple tandem repeated 
sequences. The distribution of interspersed repeats close 
to and even within genes has brought the mechanism of 
their mutation into the arena of human molecular genetics. 
These sequences have a unique form of mutation: varia- 
tion in copy number. The rate of the mutation is related 
to the copy number, and therefore, the mutability of the 
product of a change in copy number is different from that 
of its predecessor. For this reason, we have termed this 
mechanism dynamic mutation (Richards et al., 1992, and 
references therein). 
Dynamic mutation is responsible for at least two (and 
possibly three) important human genetic diseases. In the 
case of fragile X syndrome, amplification of a trinucleotide 
p(CCG), repeat is involved (Kremer et al., 1991) while for 
myotonic dystrophy and Kennedy’s disease, the amplified 
repeat is the trinucleotide p(AGC). (Brook et al., 1992; Fu 
et al., 1992; Mahadevan et al., 1992; La Spada et al., 
1991). These repeated sequences, which are inherited in 
fragile X and myotonic dystrophy pedigrees, change in 
copy number at virtually every meiosis; hence the term 
heritable unstable elements has been coined. Because 
copy number is also polymorphic in unaffected individuals, 
“normal” copy number constitutes a range rather than a 
single definitive sequence. The unique properties of dy- 
namic mutation account for the unusual geneticcharacter- 
istics of fragile X syndrome and myotonic dystrophy. 
Heritable Unstable DNA Sequences in Human 
Genetic Disease 
Fragile X syndrome, a human genetic disease associated 
with mental retardation and minor dysmorphic features, is 
so called because most affected individuals exhibit cyto- 
genetically a fragile site at the locus of this disease on the 
X chromosome. 
Minireview 
The mutation responsible for fragile X syndrome was 
first characterized by a correlation of phenotype with the 
length of an unstable sequence-all affected individuals 
have one or more unstable bands at least 600 bp greater 
than normal length (Vu et al., 1991; Oberle et al., 1991). 
The instability is due to variation in copy number of a tri- 
nucleotide repeat p(CCG), (Kremer et al., 1991; Fu et al., 
1991). Sequences that flank the repeated sequence also 
flank the fragile site. Therefore, the fragile site appears to 
consist solely of repeated sequence. 
The heritable unstable sequence explains two unusual 
genetic properties of fragile X syndrome (Fu et al., 1991; 
Sutherland et al., 1991; Yu et al., 1992). While the disorder 
is clearly X linked, phenotypically normal males identified 
as obligate carriers by their position in the pedigree are 
common. Analysis of the fragile X unstable element 
showed that these transmitting males have - 60-200 cop- 
ies of the repeat; normal individuals have usually 6-60 
copies. The higher copy number in transmitting males pre- 
disposes to further amplification in subsequent genera- 
tions. Amplification mostly occurs when the sequence is 
transmitted by females-to the extent that transmission 
through a female is essential to generate a copy number 
that will manifest the disorder. 
The increasing copy number of the unstable sequence 
with subsequent generations accounts for the second un- 
usual genetic property-anticipation-usually referred to 
in fragile X syndrome as the Sherman paradox. Since 
there is a relationship between copy number and pheno- 
type (and the copy number increases with successive gen- 
erations), the penetrance of the disorder increases in 
successive generations of affected pedigrees (Sutherland 
et al., 1991; Fu et al., 1991; Yu et al., 1992). 
Instability can be meiotic and mitotic (Oberle et al., 1991; 
Fu et al., 1991; Yu et al., 1991, 1992). Meiotic instability, 
seen as a change in copy number between parent and 
offspring, has been observed for copy numbers of 54 or 
greater (Fu et al., 1991). Mitotic instability, which gives 
rise to somatic variation, is more frequent when the copy 
number exceeds 200. In cases of mitotic instability, differ- 
ent sized or multiple bands in DNA arise in tissues or cell 
lines from an individual, reflecting a change in copy num- 
ber in some cells, even within a single tissue or cell line 
(Vu et al., 1992). Owing to both forms of instability, fragile X 
genotype individuals within a family are usually genetically 
different at the fragile X locus. 
Kennedy’s disease is a rare X-linked disorder resulting in 
spinal and bulbar muscular atrophy. This disease involves 
mutation of the same trinucleotide as that in myotonic dys- 
trophy, p(AGC), (La Spada et al., 1991). The situation in 
this case is a little different from that of myotonic dystrophy 
and fragile X syndrome. The repeat is transcribed and 
translated as CAG within the coding sequence of the an- 
drogen receptor gene. Some DNA instability has been ob- 
served (Biancalana et al., 1992). Amplification is limited in 




als have 39-60 copies. This may explain the absence of 
the unusual genetic characteristics (normal transmitting 
males and anticipation) that might otherwise be expected 
of dynamic mutation. 
Myotonic dystrophy is an autosomal dominant neuro- 
muscular disease. With an incidence of at least 1 in 6000, 
it is the most common form of muscular dystrophy in 
adults. The myotonic dystrophy mutation is associated 
with unstable DNA (Harley et al., 1992) and isolation of 
the gene (Brook et al., 1992; Fu et al., 1992; Mahadevan 
et al., 1992) reveals that the unstable DNA is a p(AGC), 
trinucleotide in the 3’ untranslated region of a gene known 
as DM, which encodes a putative myotonin protein kinase 
(Figure 1). The repeat, transcribed as CUG, is normally 
present in 5-27 copies, while carriers have >50 copies. 
There is an association between copy numbers and phe- 
notype, and the copy number increases with subsequent 
generations through affected pedigrees, again accounting 
for the phenomenon of anticipation (Harper et al., 1992). 
Somatic (mitotic) instability of high copy number repeats 
has also been observed. 
Trinucleotide Repeats in Human Genes: Inclusion 
by Chance or Necessity 
Given the deleterious consequences of including poten- 
tially unstable trinucleotide repeats within agene, it seems 
logical to conclude that the presence of unstable repeats 
in genes must have functional significance. Repeats in 
FMR-1 - Fragile X Syndrome 
AR - Kennedy’s Disease 
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Figure 1. Location and Copy Number of Trinucleotide Repeated Se- 
quences in Human Genetic Disorders 
The location of the p(CCG). repeat with respect to the FM?-7 coding 
region is not yet clear (Verkerk et al., 1991). 
coding sequences may be necessary if the function of the 
encoded protein requires a particular homopolymer. In this 
case, there would seem to be pressure to select for wobble 
mutations, so that the DNA sequence would lose its repeti- 
tive nature yet maintain the homopolymer-coding capac- 
ity. The high mobility group protein of trout appears to 
have such wobble mutations: its p(ACG), repeat frequently 
mutates to p(ATG), yet conserves the coding capacity 
(GAUIC) of its mRNA. 
A number of previously characterized genes are candi- 
dates for similar unstable elements. A search of Genl3ank 
has revealed more than 30 sequences (most of which are 
genes) with five or more copies of one of the only ten 
possible trinucleotide repeats. (The most common normal 
copy number of the myotonic dystrophy repeat is five.) 
Human genes containing p(CCG), repeats mostly have the 
repeat in their 5’ untranslated region (Table 1). 
The finding of repeated sequences in untranslated re- 
gions suggests that a functional constraint other than cod- 
ing capacity maintains the presence of the repeats. The 
trinucleotide repeat p(CCG), in the 5’ untranslated region 
of BCR mRNA is the binding site for a nuclear protein (Zhu 
et al., 1990). If the nuclear protein were a transcription 
factor, changing the copy number of the repeat could 
change the number of sites for the factor and therefore 
affect transcriptional activity of the gene. 
At a certain copy number, the function of the sequence 
is lost, perhaps in favor of a different function that is not 
consistent with normal biosynthesis of the encoded pro- 
tein. In the case of fragile X syndrome, this may be medi- 
ated by methylation; the CpG island adjacent to FMR-7 is 
methylated when the fragile X syndrome p(CCG), copy 
number exceeds - 200 (coincident with abolition of FMR-7 
transcription). However, it is not yet clear whether methyla- 
tion is a cause or a consequence of FMR-7 transcription 
activity (Oberle et al., 1991; Pieretti et al., 1991). CpG 
islands frequently occur in promoters, and their methyla- 
tion status is usually linked to expression of the adjacent 
gene. The 5’ end of the FMR-1 gene is yet to be mapped, 
and so it is not known whether the adjacent CpG island 
acts in this capacity. 
Common Properties of Disorders Caused 
by Dynamic Mutation 
Unifying concepts help to limit descriptive aspects of phe- 
nomena. For dynamic mutation to be useful as a new 
mechanism of heritable unstable DNA sequence muta- 
tion, it must exhibit at least some properties that are com- 
mon and therefore predictable. Fortunately this has 
already occurred. The atypical segregation patterns of 
fragile X syndrome and myotonic dystrophy (referred to 
as the Sherman paradox and anticipation, respectively) 
allowed the prediction that a heritable unstable element 
similar to that in fragile X syndrome might underlie the 
molecular basis for myotonic dystrophy (Sutherland et al., 
1991). 
Similarly, Harley et al. (1992) predicted that, since myo- 
tonic dystrophy exhibits a founder chromosome (linkage 
disequilibrium) effect, fragile X syndrome might also ex- 
hibit such a phenomenon. This was indeed found to be the 




Table 1. p(CCG), Repeats in Human Genes 
Gene or Encoded Protein 
znf6 (zinc finger transcription factor) 
CENP-B (centromere autoantigen) 
c-cbl (proto-oncogene) 
Small subunit of calcium-activated neutral protease 
CAM/// (calmodulin) 
BCR (breakpoint cluster region) 
Ferritin H chain 
Transcription elongation factor SII 
Early growth response 2 protein 
Androgen receptor 
GenBank Symbol Copy Number 











5’ Untranslated region 
5’ Untranslated region 
5’ Untranslated region 
Coding region (N-terminal) 
5’ Untranslated region 
5’ Untranslated region 
5’ Untranslated region 
5’ Untranslated region 
Coding region (central) 
Coding region (central) 
mutations can account for the majority of fragile X syn- 
drome cases. 
Another similarity of fragile X syndrome and myotonic 
dystrophy is that, despite their variable phenotypes, they 
exhibit a remarkable degree of homogeneity in the site of 
their mutation. Many human genetic disorders have an 
array of insertions, deletions, and point mutations as their 
molecular basis and exhibit a variable phenotype as a 
consequence. Variable phenotype in fragile X syndrome 
and myotonic dystrophy does not (in the vast majority of 
cases) arise from the degree to which different types of 
mutation affects the function of the gene, but from the 
degree of amplification of a single site of mutation (the 
trinucleotide repeat). 
In fragile X syndrome, the amplification blocks transcrip- 
tion of the FM/%7 gene (Pieretti et al., 1991). There does 
not appear to be an abnormal gene product. The location 
of the repeat in DM in the 3’ untranslated region suggests 
that a similar quantitative (rather than qualitative) defect 
forms the molecular basis for the pathway from genotype 
to phenotype. 
Founder Chromosomes 
The recent finding that fragile X syndrome, like myotonic 
dystrophy, has founder chromosomes raises a fundamen- 
tal question about the molecular events involved in dy- 
namic mutation. Two models of founder mutations are 
shown in Figure 2. In one model, mutation of a sequence 
unrelated to the trinucleotide repeat in some way predis- 
poses the repeat to greater instability. For example, the 
acquisition of a DNA binding site for a protein involved in 
DNA mechanics may confer a greater rate of subsequent 
copy number variation than is normally accorded these 
sequences. 
Alternatively, an increase in copy number beyond a cer- 
tain length may occur rarely, but once beyond this length, 
subsequent mutation is relatively frequent. Simple tandem 
repeated sequences are often interrupted by an imperfec- 
tion in the repeated motif that appears to limit their muta- 
bility. For example, polymorphism of AC repeats is pro- 
portional to perfect repeat length (Weber, 1990). Such 
interruptions have been observed in the fragile X syn- 
drome p(CCG), repeat (Oberle et al., 1991; Kremer et al., 
1991; Verkerk et al., 1991). Therefore, the founder muta- 
tion could be either a rare increase in copy number of only 
perfectly repeated sequence or a mutation of an imperfect 
interruption back to the normal motif, which establishes a 
perfect repeat of unstable length. 
Analysis of normal individuals with one of the haplotypes 
common to fragile X individuals reveals a high incidence 
of high (normal) copy number (n > 39) (Richards et al., 
1992). This suggests that there might be a pool of individu- 
als whose descendants are at risk of subsequent mutation 
due to the relationship between copy number and muta- 
bility. 
While it is clearly established that a repeated sequence 
capable of amplification is a necessary condition for dy- 
namic mutation disease, it is not clear whether this se- 
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Figure 2. Models of Unstable Element Founder Mutation 
(A) Acquisition of a DNA binding site for an activity that destabilizes 
the repeated sequence, resulting in different rates of mutation for the 
founder and normal chromosomes. 
(B) Acquisition of increased instability due to a rare increase in perfect 
repeat copy number. The founder mutation is indicated by the large 
arrow; subsequent increases in copy number are indicated by multiple 
small arrows. The shape of the curve relating instability and copy 




quence alone is sufficient. There is no experimental 
evidence to suggest the involvement of nonrepeated se- 
quences (from analysis of flanking sequences of normal 
and affected individuals). However, the resolution of this 
issue is essential in determining how widespread a role 
dynamic mutation of repeated sequences might have in 
human genetic variation. Do heritable unstable elements 
consist of simple tandem repeated sequence alone or is 
another sequence essential to confer copy number insta- 
bility on the repeat? 
Yu, S., Mulley, J., Loesch. D., Turner, G., Donnelly, A., Gedeon, A., 
Hillen, D., Kremer, E., Lynch, M., Pritchard, M., Sutherland, G. R., and 
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Dynamic mutations on the move
Grant R Sutherland, Robert I Richards
It is only a short time since the isolation and
characterisation of the fragile X syndrome mu-
tation'-3 uncovered a new genetic element and
mechanism of mutation. The genetic element
was an unstable DNA sequence resulting from
amplification of a naturally occurring poly-
morphic trinucleotide repeat, p(CCG)n. The
mechanism of mutation, which we have
termed dynamic mutation,4 is the change (in-
crease or decrease) in copy number of the
trinucleotide repeat with the rate of change
related to the number of copies present at any
time. This process, in which an initial change
to a DNA sequence alters the chance of further
changes to it, contrasts with classical or static
mutation in which the product of a mutation is
no more likely to undergo further changes than
was the initial DNA sequence.
The instability of the amplified p(CCG)n
repeat in fragile X syndrome is such that
different cells in different tissues, and even
different cells in the same tissue, can have
different numbers of copies of the repeat. Fur-
thermore, when the repeat is transmitted from
parent to offspring the number of copies can
change markedly. Hence different subjects in a
single family who carry the mutation can have
it in different forms. Normal X chromosomes
have six to about 50 copies of the repeat. The
mutation appears to begin as a small increase
in copy number out of the normal range. This
is transmitted unstably over a few generations,
gradually increasing when transmitted by
women but with little change in size when
transmitted by males. Subjects with small size
increases (up to about 200 copies) are clinically
normal and said to carry premutations at this
locus.
The properties of this new genetic element
provided possible mechanisms for a variety of
phenomena which were poorly understood.'
These included incomplete penetrance, vari-
able expression, other fragile sites, and anti-
cipation. The prediction that anticipation, es-
pecially as shown by myotonic dystrophy
(DM), was the result of an unstable sequence
was soon confirmed.`-5 In this disease the tri-
nucleotide was p(AGC)n. This finding of a
dynamic mutation in DM allowed the recogni-
tion that anticipation was a legitimate clinical
observation,9"" now with an acceptable genetic
mechanism, and not an artefact resulting from
biased ascertainment."
The number of disorders resulting from
unstable amplification of trinucleotide se-
quences is rapidly increasing (table). These
include another fragile site (FRAXE) that may
be associated with mild mental retardation.'2
This fragile site has turned out to be similar in
structure to the fragile X (FRAXA), involving
the same trinucleotide p(CCG)n and being
close to a CpG island which is hypermethy-
lated when the copy number exceeds approx-
imately 200.*
The dynamic mutations characterised to
date fall into two categories probably deter-
mined by whether the trinucleotide repeat is in
a translated or untranslated region of a gene.
The mutations in known or presumed
untranslated regions, FRAXA, FRAXE, and
DM, appear to have little constraint on the
number of repeats, which can range up to
several thousand copies. When the mutation is
in a presumptively translated region of the
gene (SBMA, HD, SCAI) the amplification is
restrained and rarely exceeds 100 copies of the
repeat. The molecular basis for this limit will
hopefully become clearer after more detailed
analysis of the biology of the respective
encoded proteins.
When compared to other types of single
gene defect the properties of dynamic muta-
tion diseases afford distinct advantages and
disadvantages for diagnosis. The mutations
seen in most single gene defects are character-
istically variable and numerous, occasionally a
single mutation may predominate (as does
AF508 in cystic fibrosis), but it still remains
one of many at that locus. The dynamic muta-
tion disorders are remarkably homogeneous.
Apart from fragile X syndrome where a few
deletions and a point mutation in the gene
(FMR1) have been described, no other muta-
tions in the genes involved in dynamic muta-
tion disorders have been recorded. This is a
great advantage for the diagnostic laboratory
where the primary diagnosis of these disorders
can now be made with confidence. The major
*Xoienc/lature. 'I'here arc only 10 possiblc diffcrcnt trinucle,o-
tides which can be produced from the four primary bases from
which DNA is constructed. Only two of thcse have becn
identified in dynamic mutations and thesc are p(CCG)n and
p(AGC)n. Confusion is rampant in published reports because
there is no consistent nomenclature for these sequences. TIhe
p(CCG)n rcpcat associatcd wvith fragile sites on the X chromo-
some has bccn cxpresscd as p(CGG)n, p(C CG)n, and
p(GCC)n. The convention proposed bv the gene mappingw,vorkshops for polymorphic oligonucleotidc rcpeats is that the
bases be written in alphabctical order from 5' to 3, thus
p(AGC)n and not p(CTG)n for the DM repcat. We arc of the
Vicw that adhering to this convention will make the body of
publications much more intclligible to those readers who wish















Dynamic mutations on the move
disadvantages relate to uncertainty over the
relationship between genotype and phenotype.
Somatic variation can mean that copy number,
determined from peripheral blood lympho-
cytes, is not an accurate determination of the
size of the repeat in the affected tissue(s). In
addition (perhaps as a consequence) there can
be overlap in copy number for the different
phenotypic categories (table). For example, in
HD there is a very small area of overlap in the
copy number distributions of normal and mu-
tant chromosomes. About 2% of mutant chro-
mosomes have copy numbers at the top of the
normal range.'3 In practice, the vast majority
of direct diagnoses of dynamic mutation dis-
eases based upon repeat copy number are
reliable.
Parent of origin effects are marked in trans-
mission of dynamic mutations. In fragile X
syndrome the premutation only progresses to a
full mutation and becomes clinically signific-
ant when it is transmitted by a female. In DM,
the congenital form of the disease only occurs
when a child receives the mutation from its
mother. In HD, and possibly spinocerebellar
ataxia, juvenile onset of the disease is pater-
nally determined. The instability of the re-
peats would appear to be different in germline
and somatic tissues. In fragile X only small
changes, within the premutation range, are
apparently transmitted through sperm and
possibly also through ova.'4 The large expan-
sions seen in somatic tissues occur postzygoti-
cally but, by some imprinting mechanism,
these expansions only occur on the maternally
transmitted chromosome. The p(AGC)n re-
peat in HD sperm is particularly unstable and
may be the reason why there are greater dif-
ferences in copy number between fathers and
their children than mothers and their chil-
dren. '5
The parental bias of congenital DM trans-
mission appears to be because of constraints on
the size of the repeat which can be transmitted
by males; these constraints are not apparent in
maternal transmission.'6 17 In particular, the
copy number of the p(AGC)n repeat may
increase when it is transmitted by either par-
ent, but once males have about 600 to 700
copies little further increase occurs and de-
creases in size are seen. Females can, however,
have children with up to approximately 4000
copies of the repeat. Studies on sperm from
DM males are yet to be reported.
The basis for the sex differences, including
the imprinting associated with the fragile X,
are unknown. Whether they reflect the dif-
ferences in the mechanisms of gamete forma-
tion or some other property of the sequences
themselves remains unclear. There is evidence
in fragile X syndrome that the increases in
repeat copy number occur early in develop-
ment after which time the sequence is stabi-
lised and copy number changes no longer
occur in somatic tissues. Jansen et al'8 reported
findings that suggest imprinting does not con-
tribute to the manifestation of DM.
Effect of repeat copy number
In some of the dynamic mutation disorders
there is a relationship between copy number
and age of onset of disease. This is most clearly
seen in spinocerebellar ataxia where there is a
clear curvilinear relationship with only little
scatter.'9 In DM there is a general relationship
with the congenital form of the disease having
the largest number of repeats, but for any
given copy number there is a wide range of
ages of onset.202' A similar situation exists for
Huntington's disease; high copy numbers are
associated with juvenile onset but there ap-
pears to be little relation between age of onset
and copy number where there are fewer than
50 repeats. Andrew et aP22 report that 50% of
the variation in age of onset in Huntington's
disease can be attributed to repeat copy
number. In Kennedy disease there is general
decreasing age of onset with increasing copy
number.23
In fragile X, generally, when n exceeds
about 200, transcription of the FMR1 gene
stops (in lymphocytes), the p(CCG)n repeat
and adjacent CpG island become hypermethy-
Features of dynamic mutations.
Spinocerebellar FRAXE
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lated, and the syndrome is apparent. Below
200 copies (the premutation) there is little
clinical effect. The general situation is,
however, occasionally disturbed by two forms
of tissue mosaicism, repeat copy number and
degree of methylation of the CpG island adjac-
ent to the repeat (and possibly of the repeat
itself). This situation will probably not be
clarified until it is known in which tissue(s)
abnormal expression of the FMR1 gene is
critical for the various components of the syn-
drome and whether the inactivation of FMR1
expression in lymphocytes in which the CpG
island is methylated also applies to other
tissues.
Founder chromosomes
The conventional interpretation of the finding
of linkage disequilibrium between a mutation
and polymorphic DNA sequences adjacent to
it (haplotype) is that the mutation arose only
once on each haplotype on which it is present.
Hence such disequilibrium is evidence of
founder mutations and a very low mutation
rate. The fragile X shows marked linkage
disequilibrium24 and DM shows complete dis-
equilibrium with a diallelic RFLP.25 Hunt-
ington's disease also shows a similar effect.26
How can these data be interpreted for dyna-
mic mutations? Some of the fragile X mutant
haplotypes which do not carry the mutation
have repeat copy numbers at the top of the
normal range.24 Since the rate of mutation of
simple repeat sequences is proportional to
copy number, there may be a group of normal
alleles with high copy number which are
predisposed to mutate. Alternatively, since
there can be imperfections in the repeat on
normal alleles, and since mutation may be
proportional to the length of perfect repeat,
some normal alleles without imperfections
may also be predisposed to mutation. The
linkage disequilibrium studies may therefore
not be evidence of rare ancestral mutation but
of a small number of normal alleles which have
much higher rates of copy number increase,
and thus mutation, than other normal alleles.
Genotype to phenotype
The mechanisms by which dynamic mutations
produce their phenotypic effects are not clear.
In fragile X syndrome the full mutation results
in inactivation of the FMR1 gene (for a puta-
tive RNA binding protein) with cessation of
transcription in lymphocytes. In DM there
are conflicting reports of decreased27 and
increased28 steady state mRNA levels. In the
fragile sites and DM the repeat is in a non-
coding part of the gene. The functional role of
these sequences is therefore unrelated to the
encoded protein. One possibility is that they
are recognition sites for RNA or DNA binding
proteins. Nuclear binding proteins for each of
the di- and trinucleotide repeats (including
various forms of the fragile X p(CCG)n repeat)
have been reported.29 In the other disorders,
where the repeat codes for polyglutamine, the
expansion may confer some gain of function to
the protein involved.
The finding30 that FMR 1 is a member of the
KH domain family of RNA binding proteins is
intriguing given the known roles of other
members of this family. One of these, the yeast
protein MERI, is a splicing regulator of the
RNA transcript of another gene, MER2. The
function of MER1 is crucial for meiosis.3'
FMR1 appears to be essential for sperm viabi-
lity (all X bearing sperm of fragile X affected
males have a p(CCG)n copy number permissive
for FMR1 expression) and therefore a role in
male meiosis would be consistent with both
these in vivo observations of FMR1 and the
function of its yeast relative MER1. Assessment
of spermatogenesis in males with deletion or
point mutation in FMR1 would be of interest.
Unstable repeat sequences in other
diseases
Two additional instances of changes in repeat
copy number associated with disease warrant
discussion. The first of these is in hereditary
non-polyposis colon cancer (HNPCC). In this
disorder tumour tissue exhibits genome wide
instability of simple tandem repeat se-
quences.32 This instability is associated with
genetic predisposition to HNPCC which maps
to chromosome 2.3 At this stage it is not clear
whether the chromosome 2 gene is a cause of,
or an 'at risk' target for, this instability. In-
stability appears to be restricted to the malig-
nant cells of affected subjects in either sporadic
or familial HNPCC.
The second instance of repeat copy number
associated disease involves a 24 base pair re-
peat coding for an octapeptide in the prion
protein (PrP) gene.34 A variety of mutations in
this gene cause Creutzfeldt-Jakob disease and
Gerstnann-Straussler-Scheinker syndrome. The
repeat copy number is normally four with
insertions of four copies or deletions of one
copy having no phenotypic effect; however,
insertions of five or more extra copies of the
repeat result in neurological disease of variable
severity. No instability of the repeats has been
noted within affected pedigrees although the
sample size at this stage is very small.
While it might be premature to include the
phenomena observed in HNPCC and in the
PrP gene under the heading of dynamic muta-
tion, it is important to be open to the possi-
bility that this mutation mechanism is not
restricted to just trinucleotide repeats.
How common are dynamic mutations?
There are now enough dynamic mutations for
a number of general properties of this type of
mutation to have become apparent. (1) The
severity of the disease, which includes age of
onset, can be related to the number of copies
of the repeat and is highly variable. (2) De-
partures from mendelian inheritance are com-
mon. (3) Founder chromosomes which reflect
either very low rates of mutation or haplotypes
which are predisposed to mutation are seen.
Certainly, new mutations are very rare. (4)
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Dynamic mutations on the move
The diseases are virtually or completely muta-
tionally homogeneous. (5) Parent of origin
effects are common.
The six known dynamic mutations have all
been recognised within the last three years.
The common properties of these mutations,
especially the departures from mendelian in-
heritance and the highly variable phenotypes
with wide ranging ages of onset, may give some
clues to other diseases which have similar
mutational mechanisms. Because anticipation
as a legitimate form of inheritance was so
effectively discredited by Penrose," it has rar-
ely been mentioned in genetic publications
since. A careful study, especially of clinically
variable diseases, perhaps concentrating on
those with a neurological abnormality since all
the dynamic mutations so far have been in this
region, looking for anticipation may give
further clues. Care will need to be taken in
such studies not to ignore Penrose com-
pletely," since ascertainment bias may in some
instances mimic anticipation. Similarly envir-
onmental effects which could possibly produce
anticipation, especially in psychiatric dis-
orders, will need to be taken into account. The
discovery of dynamic mutation should now
give rise to careful segregation analyses which
in turn should provide new disorders which
are candidates for dynamic mutation.
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The molecular basis of fragile sites 
in human chromosomes 
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Fragile sites on chromosomes have been classified into a number of groups 
according to their frequency and the conditions required to induce them. A 
number of the rare folate-sensitive fragile sites have been characterized and 
shown to be amplified methylated CCG trinucleotide repeats. One common 
fragile site has been partly characterized and appears to be a region of fragility, 
rather than a single site. 
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Introduction 
Fragile sites on chromosomes are loci that show an in- 
creased frequency of  gaps and breaks when the cells from 
which the chromosomes are prepared are exposed to spe- 
cific conditions of  tissue culture or chemical agents [1]. 
The most important fragile site clinically is the fragile 
X (FRAXA) associated with fragile X syndrome, the 
most common form of  familial mental retardation. The 
physical basis of  fragile sites is largely unknown, but they 
appear to be an area ofchromatin which fails to compact 
for mitosis. It was thought originally that the molecu- 
lar characterization of  the DNA sequences at fragile sites 
would reveal the mechanism(s) for this failure of  com- 
paction. All the fragile sites that have been cloned are 
members of  one particular class of  fragile site: the rare 
folate-sensitive group [2]. These have all been shown to 
be dynamic mutations of  naturally occurring CCG trin- 
ucleotide repeat sequences, but this knowledge has not 
revealed the mechanism leading to failure of  chromatin 
compaction and thus cytogenetic manifestation as a frag- 
ile site. In this review, we outline briefly the cytogenetics 
of  fragile sites and the tissue culture conditions required 
for their demonstration, and we discuss the molecular 
bases of  the fragile sites that have been cloned. 
Types of fragile site 
A knowledge of  the different types of  fragile sites is 
necessary before any discussion of  their molecular ba- 
sis can be meaningful. They are firstly divided into 
rare and common ones. Any common one is proba- 
bly present on all chromosomes, that is it is part of  
normal chromosome structure; however, the proportion 
of  metaphases in which any common fragile site is ex- 
pressed cytogenetically can vary from person to person. 
The rare ones range in frequency from 1 in 40 chromo- 
somes for FRA16B in the German population [3] and 1 
in 80 chromosomes for FRA10B in the Australian pop- 
ulation [4] to those such as FRA1M at lp21.3 which are 
the subject of  only a single report [5]. Some of  the rare 
ones have been seen only in the Japanese [6]. 
Both the rare and common types of  fragile site are fur- 
ther subdivided according to the conditions of  tissue 
culture required to induce their cytogenetic expression. 
Most fragile sites are not expressed spontaneously, but 
instead require induction by manipulation of  tissue cul- 
ture conditions under which the cells being prepared for 
chromosome harvest are grown. A classification of  fragile 
sites is shown in Table 1. 
Cytogenetics 
Fragile sites are seen as discontinuities of  chromatin in 
metaphase chromosomes. The chromosome can break 
at these discontinuities, and breakage followed by non- 
disjunction of  acentric fragments in tissue culture can 
give rise to a variety of  unusual chromosomal con- 
figurations. Similarly, culturing somatic cells containing 
human chromosomes with fragile sites under conditions 
which induce their cytogenetic expression can give rise 
to rearrangements with breakpoints at the fragile sites 
[7,8]. Whether such rearrangements occur in vivo has 
been the subject of considerable controversy. Evidence 
now exists that on very infrequent occasions at least, 
breakage near the rare fragile site at 11q23.3 (FRAllB)  
in humans can give rise to a constitutional chromosome 
deletion (11q-) resulting in Jacobsen syndrome [9,10]. 
The phenomenon of  double ascertainment, the finding 
of  more than one rare fragile site in a single individual, is 
(as yet) unexplained. It is worth noting that one fragile 
site, FRA12D, has been seen only in individuals who also 
have another rare folate-sensitive fragile site [11]. Many 
other examples are known of  individuals with more than 
one rare fragile site, either having two of  the same type 
or having fragile sites of  different types. 
Tissue culture requirements 
Although some fragile sites are sometimes expressed 
spontaneously in chromosomes prepared from standard 
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Table 1. Classification of fragile sites, with examples of each. 
Type of fragile sile Examples 
Rare 
Group (n =21) 
(folate sensitive) 
Group 2 (n=5) 
(distamycin A inducible) 
Group 3 (n=2) 
(bromodeoxyuridine requiring) 
Common 
















FRA16D (1 6Q23.2) 
FRAXD (Xq27.2) 
Group 5 (n=4) FRA1J (lq12) 
(5-azacytidine inducible) FRA19A (19ql 3) 
Group 6 (n = 7) 
(bromodeoxyuridine inducible) 
FRA6D (6ql 3) 
FRA10C (10q21) 
Each example is given as the gene symbol with the chromosome band 
in parentheses. *These fragile sites fall into two subgroups (subgroup b 
has been reported in the Japanese only [6]). 
lymphocyte cultures, almost all require some manipula- 
tion of  the culture conditions to allow for or to greatly 
enhance expression [12]. The common aphidicolin- 
inducible fragile sites can be expressed without in- 
duction, but only in vanishingly small numbers of  
metaphases. Exposure to aphidicolin enhances expres- 
sion in a concentration-dependent manner until at high 
concentration, chronmsome pulverization occurs [13]. It 
is of  interest to note that the proportion ofmetaphases in 
which the common fragile sites are seen can vary fronl 
person to person and occasional individuals will be en- 
countered who have high (up to 30% ofmetaphases) lev- 
els of  expression of  one of  these fragile sites. 
For the other common fragile sites, the timing of  ex- 
posure to the inducing agents is critical to fragile site 
expression, maxinmm induction being seen after 6-12 
hours exposure, but nmch longer (24 hours) or very brief 
exposure not resulting in fragile site expression [14]. 
The rare folate-sensitive fragile sites require low lev- 
els of  either dTTP or dCTP at the time of DNA 
synthesis before chromosome preparation. This can be 
achieved by omitting folic acid (hence folate-sensitive) 
and thymidine from normal culture media, by adding 
inhibitors of  folate metabolism such as methotrexate, 
inhibitors of  thymidylate synthesis (e.g. fluorodeoxyuri- 
dine) or high concentrations of  thymidine which inhibit 
ribonucleotide reductase and thus give low dCTP con- 
centrations. The group 2 rare fragile sites can be induced 
by bromodeoxyuridine (except for group 2B) and the 
group 3 fragile sites are induced by distamycin A and 
a series of  related compounds which bind in the major 
groove of  AT-rich DNA. 
Unfortunately, none of  this knowledge sheds much light 
on the mechanism(s) of  fragile site expression. Because 
the folate-sensitive group members are expressed when 
an immediate component of  DNA (dTTP or dCTP) is 
in limiting concentration, it was considered originally 
that the fragile site nfight have a sequence of  composition 
which did not allow completion of  DNA synthesis at the 
same time as the remainder of the genome, the fragile 
site therefore being single-stranded DNA that could not 
package for mitosis. 
Molecular structure 
The only fragile sites to have been cloned and had 
their structures determined are in the rare folate-sen- 
sitive group (Table 2). At these fragile site loci are 
found normally occurring polymorphic CCG repeat 
sequences. These repeat sequences undergo increases 
in copy number by postulated mechanisms of  dynamic 
mutation [15,16]. These involve initially small increases 
in copy number because of  failure of mismatch repair 
(or possibly unequal crossing over) and then larger in- 
creases by slippage. A premutation phase exists in which 
the copy number is above the normal range but does not 
lead to expression of  a fragile site. Once the copy number 
is in the premutation range, the CCG repeat becomes 
unstable when transmitted to offspring, who may have 
a longer or shorter stretch of the repeat sequence than 
the parent. As the sequence increases in copy number, 
it passes a critical limit or threshold o f - 2 3 0  copies, 
above which it becomes a full mutation and gives rise 
to a fragile site (and, in fragile X syndrome, the disease 
is apparent). 
Table 2. Cloned rare folate-sensitive fragile sites. 
Symbol Normal copy Premutation Full mutation References 
(location) number copy number copy number 
FRA16A (16p13.1) 16-50 50-200? 1000-20007 [25 eel 
FRAXA (Xq27.3) 6-55 55-230 > 230 [17,34] 
FRAXE (Xq28) 6-25 50-200? > 130? [37 e] 
FRAXF (Xq28) 6-29 .,' 300-500 [39°,40] 
Methylation of  the CpG residues m the repeat appears to 
be a requirement for fragile site expression. Full nmta- 
tions (in terms of  copy number) are normally completely 
methylated [17]. In women with prenmtations (at least of 
FRAXA which has been most studied), some fragile site 
expression is seen and this is likely to be associated with 
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methylation o f  the CCG repeat as part of  the X-inacti- 
vation process. Hence, in terms of fragile site expression, 
the important feature is an expanded CCG repeat which 
is methylated, the reason for the methylation appearing 
to be unimportant. 
Common aphidicolin-inducible fragile sites 
The only other fragile site to have been isolated, but not 
yet fully characterized, is the common aphidicolin-sen- 
sitive one at 3p14.2 (FRA3B). Glover and Stein [8] used 
aphidicolin induction of  breakage and rearrangement of  
FRA3B in somatic cell hybrids to generate cell lines in 
which there were human/hamster translocations with 
breakpoints at, or close to, FRA3B. Subsequent stud- 
ies [18,19] have shown that although the breakpoints in 
these hybrids cluster, they do so over a region of  up to 
100kb. This suggests that FRA3B may represent a re- 
gion of  fragility, rather than a single site. Evidence also 
exists that this region contains a site for the preferential 
integration of  the SV2neo vector [20]. Paradee et al. [21] 
isolated a 4.5 kb fragment of  DNA which spanned one 
of  the areas of  fragility in this region. Analysis of  the 
nucleotide sequence of  this fragment did not reveal any 
striking features, such as a trinucleotide repeat, which 
could explain the fragility. 
What controls fragile site expression? 
Expression of  the rare folate-sensitive fragile sites has at 
least two requirements: an expanded methylated CCG 
and limiting concentration of  either dTTP or dCTP 
at the time o f  DNA synthesis. It appears that at least 
one other requirement awaits discovery. For example, 
if lymphocytes from an individual with a full muta- 
tion, showing no somatic heterogeneity in CCG repeat 
size, are cultured under the most rigorous conditions, the 
fragile site may be seen in at most 30% of  metaphases. 
No amount of  manipulation of  culture conditions can 
significantly increase the fragile site expression, which, 
if only the two conditions mentioned above were re- 
quired, should be seen in close to 100% of  metaphases. 
The only fragile site seen in close to 100% ofmetaphases 
is FILA16B, when induced with berenil, and then only 
in some carriers. Perhaps for this fragile site the require- 
ments for expression are an extreme form of  whatever 
the mutation might be and a high-affinity DNA-bind-  
ing agent. 
Proteins have been identified that bind specifically to the 
methylated and unmethylated forms of the CGG re- 
peat (and other simple sequence repeats) [22]. Hence, 
although the tissue culture requirements point to a 
DNA problem in chromatin compaction as a basis for 
fragile site expression, it is possible that the expanded 
methylated repeat sequence either destroys or creates 
protein binding sites which interfere with chromatin 
compaction. 
Fragile site genesis 
The molecular origins of  fragile sites have recently be- 
come clearer. Previously, a working hypothesis (which 
attracted a great deal of  attention for many years) sug- 
gested that the mutation which caused fragile X syn- 
drome was a result of  the failure to erase the normal 
X-inactivation imprint [23]. The finding ofmethylation 
associated with the fragile X mutation was taken initially 
as evidence in support of  this hypothesis given the role 
of  methylation in the normal process of  X-inactivation. 
Unfortunately, this did not account for the segregation 
pattern exhibited by the fragile X mutation whereby far 
fewer than the expected 50% of  male offspring of  fe- 
male (premutation) carriers exhibit symptoms. Instead, 
a good correlation between the copy number of  the 
FRAXA p(CCG)n repeat and affection status was ob- 
served, with affected individuals usually having copy 
numbers of  >230. Repeats above this length are usu- 
ally methylated and expression of  the FMR1 gene ex- 
tinguished. 
Subsequent characterization of  an individual with a point 
mutation in the F M R  1 gene has demonstrated that frag- 
ile X syndrome is a single gene disorder caused by loss 
of  F M R  1 function [24]. Together, these data suggest that 
the methylation associated with FRAXA might well be 
a consequence of  the repeat expansion and, although 
perhaps necessary for extinction of  FMR1 expression 
and the fragile X syndrome phenotype, methylation 
was not part of  the mutation process. Support for this 
view has come from the analysis of  the autosomal frag- 
ile site FRA16A. Like FRAXA, this is a folate-sensitive 
fragile site and is caused by a similar molecular mech- 
a n i s m - a n  unstable p(CCG)n repeat which is methy- 
lated in fragile site expressing individuals [25"]. Unlike 
FILAXA, however, no evidence was found of  methyla- 
tion of  the p(CCG)n repeat on non-fragile site expressing 
chromosomes-- this  is not a normal site of  methylation 
imprinting. The methylation associated with FILA16A 
is clearly a consequence of  repeat expansion and not a 
cause of  it. The unusual genetics associated with fragile 
site expression appears, therefore, to be largely a mani- 
festation of  properties of  the unstable repeat sequence. 
An intriguing aspect of  fragile X syndronm is the mu- 
tation rate for this disorder. It was calculated originally 
to be the highest ever at a single locus [26]. Follow- 
ing molecular characterization of  the fragile X, it has 
been observed that all patients with the syndrome have 
a mother with at least a premutation, and this prenm- 
tation is inevitably familial. The estimation of the high 
nmtation rate was presumably incorporating the change 
from pre- to full mutation. 
The rarity of new nmtations was confounded further by 
the observation of linkage disequilibrium at the FR.AXA 
locus with flanking markers [27]. Such disequilibrium 
suggested that a pool of (founder) chromosomes exists 
from which the majority of  FRAXA sites arise. In 
molecular terms, this meant that there were sequences 
in the vicinity of  the F1LAXA repeat which affect the 
stability of  the repeat. Either a sequence adjacent to 
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the repeat could confer such instability (e.g. an acquired 
binding site for a protein involved in DNA stability) or 
sequences within the repeat could affect repeat stability. 
Evidence for the latter has come from several quarters. 
The FRAXA repeat had been found previously to con- 
tain sequence imperfections. Such imperfections were 
known to have an effect on the copy number polymor- 
phism of  the dinucleotide repeats [28]. 
Analysis ofa p(AGC) n repeat associated with spino-cere- 
bellar ataxia (SCA1) showed that all expanded disease al- 
leles were uninterrupted repeats, whereas 98% of normal 
alleles had repeat interruptions. Recently, sequence anal- 
ysis of  both the FRAXA [29"-32 °] and FRA16A [33 °] 
p(CCG)n repeats has shown a similar lack of  repeat in- 
terruption in those alleles which exhibit greatest instabil- 
ity. A requirement for folate-sensitive fragile sites is likely 
to be a site of  p(CCG)n copy number polymorphism at 
which the repeat is uninterrupted. 
F r a g i l e  s i tes  a n d  g e n e s  
The normal function (if any) of  the unstable repeat se- 
quences is still an issue of  conjecture. Once it became 
clear that the FRAXA repeat was located in the 5' un- 
translated region of  the FMR1 gene, then a role for these 
sequences in normal protein function could be excluded 
[34,35]. Database searches [15,36] revealed that the vast 
majority of  human genes containing CCG repeats have 
them located in their 5' untranslated regions and almost 
always in the same orientation (the CGG strand is in the 
mR.NA transcript). The FRAXE fragile site is associated 
with a mild form of  mental retardation, suggesting that 
the affected gene (FMR2) will contain this CCG repeat 
[37°,38]. These observations, together with the conser- 
vation of the CCG repeat in the FMR I gene of  various 
mammalian species, suggests that some function is served 
by the repeat. Although nuclear DNA-binding proteins 
have been described for each of  the simple tandem repeat 
sequences [22], a function for these sequences at either 
the R.NA or DNA level is yet to be determined. 
C o n c l u s i o n s  
The molecular basis for fragile sites is just beginning to 
be understood. We have an incomplete picture of  the 
molecular mechanism involved in the expression of  the 
rare folate-sensitive g r o u p -  amplified methylated CCG 
repeat and specific conditions of  tissue culture are re- 
quirements for cytogenetic expression, but other factors 
may be involved. Only two fragile sites, FR_AXA and 
F1LAXE, are of  proven clinical significance, in that they 
are the cytogenetic manifestations of  the full dynamic 
mutations which result in either fragile X syndrome 
(FRAXA) or mild mental retardation (FRAXE). An au- 
tosomal fragile site (FRA11B) has been implicated in the 
genesis of  a chromosomal deletion syndrome (Jacobsen 
syndrome). 
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INTRODUCTION 
Tandem-arrayed, simple repeat sequences have 
been found to be associated with, and in some 
cases to cause, human inherited and somatic dis- 
ease. Both the DNA repeat sequences themselves 
(Sutherland and Richards, 1995a) and the proteins 
involved in their replication (Nystrom-Lahti et 
al., 1994) can have roles in repeat copy number 
mutation. In this review we discuss the various 
components of the mutation mechanism and describe 
current thoughts on the pathways by which repeat 
DNA sequence mutations lead to disease. 
CIS-ACTING ELEMENTS: PROPERTIES OF 
REPEATS ASSOCIATED WITH MUTATION 
OR DISEASE 
The term “cis-acting elements” is used here to 
refer to those properties of the DNA repeat se- 
quence itself that affect its mutation or a resultant 
phenotype. Some insight into the relationship be- 
tween the physical and genetic properties of DNA 
repeat sequences can be gleaned from observing 
what characteristics different repeats have in com- 
mon. 
The large-scale characterisation of simple repeat 
sequences in the human genome came about as 
a consequence of their use as highly informative 
genetic markers. Their ease of typing by PCR, 
frequency, and relatively uniform distribution 
throughout the genome make them well suited to 
the construction of genetic linkage maps, diagnosis 
by linkage analysis, and loss-of-heterozygosity stud- 
ies. For example, the high-resolution genetic link- 
age map of the human genome consists mainly of 
dinucleotide (AC repeat) markers (Gyapay, 1994). 
In assessing the general properties of AC repeats, 
Weber (1990) observed that perfect repeats were 
generally more informative than repeats that had 
one or more interruptions to the recurring repeat 
motif. Furthermore, the information content (a 
measure of the instability of the repeat) was pro- 
portional to the perfect repeat copy number. This 
relationship between perfect repeat copy number 
and instability appears to be a general characteristic 
of simple tandem repeats (Fisch et al., 1995; Lee- 
flang et al., 1995). The general function (if any) of 
the simple tandem repeat sequences scattered 
throughout the genome remains elusive. Of the 
possible 10 different trinucleotide repeat motifs, 
until recently, only p(CCG)n and p(AGC)n have 
been associated with human genetic disease. 
p(CCG)n Repeats 
Database searches reveal that p(CCG)n repeats 
are not uncommon in the human genome and are 
mostly located within the 5’ untranslated regions 
of genes (Richards and Sutherland, 1992). The 
first evidence that such a repeat could mutate and 
lead to disease came from the cloning of the fragile 
site (FRAXA) on the X chromosome associated 
with Fragile X syndrome (Kremer et al., 1991; 
Oberle et al., 1991; Ververk et al., 1991; Yu et al., 
1991). Here the mutational process, which we 
term “dynamic mutation,” is an increase in the 
number of copies of the repeat beyond its normal 
polymorphic range of copy numbers (6--55), 
through a clinically inocuous premutation range 
(-55--230) to a full mutation (> -230) (Fu et 
al., 1991; Yu et al., 1992). 
Subsequently, four other fragile sites, all of the 
same type as FRAXA, have been cloned and all are 
dynamic mutations of p(CCG)n repeats (Table 1). 
Whereas all appear as though they are in the 5’ 
untranslated regions of genes, only the gene in 
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TABLE 1: Charaderised Fragile Sites 
Copy number 
Symbol normal pre-mutation' full mutationb Gene References 
FRAl 1 8  7-32 ? (-85) ? (>230) CBL2 Jones et al.. 1995 
FRAl6A 16-50 ? (-100) ? (>230) ? Nancarrow et al., 1994 
Nancarrow et al.. 1995 
FRAXA 6-55 55-230 >230 EMRl Yu et al., 1991 
Oberle et al.. 1991 
Verkerk et al., 1991 
Kremer et al., 1991 
Fu et al., 1991 
Yu et al.. 1992 
FRAXE 6-25 ? ? (>230) ? Knight et al., 1993 
FRAXF 6-29 ? ? (>230) ? Parrish et al., 1994 
Ritchie et al., 1994 
"Where the premutation range is not known, the sizes of documented premutations are given. 
bCopy number for all full mutations is >230, but only the FRAXA locus has sufficient number of alleles to define the range. 
which FRAf f B is located has been identified. In- 
deed, this gene was identified after database 
searches revealed that a p(CCG)n repeat in the 
CBU proto-oncogene was at the same chromo- 
somal location as the fragile site (Jones et al., 
1995). 
A common property of large p(CCG)n expan- 
sions (full mutations) is that the repeat sequence 
and adjacent CpG residues become the subject of 
cytosine methylation. At least in the case of 
FRAXA, this is associated with the transcriptional 
silencing of the gene FMRl , in which the repeat is 
located (Pieretti et al., 1991). Hence the molec- 
ular mechanism by which Fragile X syndrome is 
produced is the lack of mRNA and thus protein 
from the FMRf gene. Even when the area of DNA 
around the repeat is not methylated, the expanded 
FRAXA repeat greatly inhibits translation of the 
mRNA containing it (Feng et al., 1995). 
For both FRAXA (Kunst and Warren, 1994) 
and FRAf6A (Nancarrow et al., 1995), there is 
now compelling evidence that repeat interruptions 
stabilize the repeat or, conversely, that long per- 
fect repeats are associated with increased instabil- 
ity. For FRAXE, FRAXF, and FRAf f B, the situ- 
ation is not so clear; 75% of alleles at the FRAl1B 
locus have a copy number of just 11 repeats with 
no interruptions in this sequence. Therefore, it 
appears that fragile site genesis can begin from a 
rare increase in copy number of a relatively short 
perfect repeat. 
What is the normal function of the repeat? The 
occurrence of potentially unstable repeats within 
the 5' untranslated regions of genes suggests that 
they could have some particular function. Deletion 
analysis of the FMRf promoter (Hwu et al., 1993) 
failed to demonstrate a role for the p(CCG)n re- 
peat at the DNA level, suggesting that a normal 
function for the pr:CCG)n repeat is more likely to 
be at the RNA lewel. This remains to be explored. 
Characterisation of FRAf f B has provided the 
first evidence of in vivo breakage at a fragile site. 
Jacobsen (1 lq-) syndrome, a rare chromosome de- 
letion disorder, was found in the offspring of two 
female carriers of the FRAf f B chromosome (Fig. 
1). The l l q -  breakpoint was found by detailed flu- 
orescence in situ hybridisation mapping to be 
within 2Okb of the fragile site (Jones et al., 1995). 
These observations are likely to rekindle an old 
debate about the relationship between fragile sites 
and specific chromosomal breakage associated with 
various forms of cancer. Other genes that contain 
p(CCG)n repeats in their 5' untranslated regions 
include the BCR and CBFB genes, which are both 
associated with specific chromosome transloca- 
tions in particular forms of leukemia (Zhu et al., 
1990; Liu et al., 1995). These associations suggests 
that a careful re-evaluation of a role in predispos- 
ing the locus to bIeakage may be in order. 
p(AGC)n Repeats 
The p(AGC)n repeats in the genes causing 
Huntington disease (Jou and Myers, 1995; Schill- 
ing et al., 1995; Trottier et al., 1995), spinocere- 
bellar ataxia (type 1) (Servadio et al., 1995), and 
dentatorubral pallidoluysian atrophy (Yazawa et 
al., 1995) have recently been shown to code [as 
p(CAG)n] for polyglutamine tracts in the affected 
genes confirming that these proteins, such as the 
androgen receptor for spinobulbar muscular atro- 
phy, undergo a common likely gain of function 
(Housman, 1995). The open reading frame of the 
MJD gene also has the expanded p(AGC)n repeat 
coding for polyglutamine (Kawaguchi et al., 
1994). Disorders where the repeat is translated 
have a similar affected copy number range, yet no 
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Founder mutation a t  p(CCG)n repeat 
[loss of repeat interuption or rare increase in copy number1 
V 
Premutation copy number of p(CCG)n repeats 
v 
Increase in p(CCG)n copy number by slippage to unstable number 
[Full mutation ~ fragile site expression] 
? V ?  
Chromosome susceptible to breakage in the vicinity of fragile site 
v 
Chromosome breakage syndrome 
FIGURE 1. CIS-acting unstable DNA induced chromosome 
breakage. 
other reported protein sequence similarities. Each 
is associated with a neurological disorder, although 
the genes appear to be widely expressed-perhaps 
the tissue specificity of the mutation is dictated by 
cell-specific protein-protein interactions (Hous- 
man, 1995). 
The similar molecular, genetic, and clinical fea- 
tures of these diseases probably reflect a common 
molecular pathway from genotype to phenotype. 
In this light, the SCAl transgenic mice of Burright 
et al. (1995) provide several important insights 
into this mechanism. This transgene had its ex- 
pression targeted to the Purkinje cells, and it was 
these cells that were affected, indicating a cell- 
autonomous mechanism. The disease phenotype 
was observed in the absence of repeat instability 
indicating that instability is not an essential com- 
ponent of the pathogenic process. Whereas these 
diseases only have been observed in humans, other 
species are susceptible; therefore, even though 
other proteins may be involved (such as those in- 
teracting with the polyglutamine tract), these are 
not unique to humans. 
Only myotonic dystrophy has the p(AGC)n re- 
peat in the untranslated region-at the 3’ end of 
the myotonin protein kinase (M-PK) gene, tran- 
scribed as p(CUG)n. The expanded repeat has 
been shown (Wang et al., 1994) to be a preferen- 
tial site of nucleosome assembly in vitro; however, 
the in vivo significance of this observation has 
been questioned based on functional studies of the 
M-PK gene, which detect no effect of repeat am- 
plification on transcription, but an effect on RNA 
stability and/or processing (Krahe et al., 1995). 
Other experiments (Kang et al., 1995) have shown 
that the instability of the p(AGC)n repeat is ori- 
entation dependent in Escherichia cob and may be 
affected by the distance from the origin of replica- 
tion. 
Repeat interruption plays a role in the instabil- 
ity of the SCAl locus where all of the expanded 
alleles are perfect p(AGC)n repeats, whereas 98% 
of the normal alleles are interrupted (Chung et al., 
1993). No interruptions have been reported in sev- 
eral of the disease locus repeats, whereas those in 
the h4JD repeat are found in both normal and ex- 
panded repeats. 
These disorders, as do all those involving trinu- 
cleotide repeats, exhibit parent-of-origin biases. In 
FRAXA, full mutations only occur after female 
transmission of the repeat. In myotonic dystrophy, 
the size of the repeat appears to be unconstrained on 
female transmission, but upon male transmission 
large repeats tend to regress in size. For the trans- 
lated AGC repeats, the phenomenon of paternal 
anticipation has been noted. This means that in- 
dividuals who inherit their repeat from their father 
usually have it increased in size and thus develop the 
disease at an earlier age than did their father. 
Other Repeats 
Talbot et al. (1995) have found a tetranucle- 
otide p(AAAG)n repeat (D21S1245) that demon- 
strates hypermutability in germline and somatic 
cells. Therefore, this form of mutation is not re- 
stricted to trinucleotide repeats, although the like- 
lihood of trinucleotide repeats resulting in disease 
may be greater because of their higher prevalence 
within the coding regions of genes. In common 
with trinucleotide repeats, the p(AAAG)n repeat 
instability is copy number dependent. 
Minisatellite Repeats and Human Disease 
Minisatellite sequences are a popular form of 
genetic marker and are frequently used for individ- 
ual identification. The mechanism of their muta- 
tion has been the subject of intense analysis at the 
MS32 minisatellite where variation in mutation 
rate has been correlated with a flanking sequence 
polymorphism. Just how this polymorphic site 
might predispose to mutation or whether the poly- 
morphism is in linkage disequilibrium with a par- 
ticularly unstable repeat configuration is not yet 
clear (Monckton et a!., 1994). The MS32 locus is 
not associated with any disease, but certain alleles 
of the HRASl minisatellite are associated with a 
higher risk of cancer. These high-risk alleles may 
be deficient in variant copies of the repeat that act 
as transcription factor binding sites. The HRAS1 
minisatellite binds at least four members of the 
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reVINF-KB family of transcription factors; alter- 
ation in the minisatellite repeat has been proposed 
to alter the ratio of rel binding and consequently 
alter HRAS 1 expression and predispose to cancer 
(Krontiris et al., 1993). 
A remarkably similar set of findings has demon- 
strated an apparent association between certain 
alleles of the polymorphic minisatellite 5’ of the 
insulin gene with insulin-dependent diabetes mel- 
litus (Bennet et al., 1995a; Kennedy et al., 1995). 
The precise nature and extent of this association is 
still under question (Bennet et al., 199513; McGin- 
nis and Spielman, 1995). Variants within the re- 
peat motif modulate the ability of a transcription 
factor, Pur-1, to activate transcription. This vari- 
ation has been proposed to account for the associ- 
ation of certain short minisatellite alleles with in- 
sulin-dependent diabetes mellitus. 
A 24-base pair repeat coding for an octapeptide 
in the prion protein (PrP) gene is associated with 
some cases of Creutzfeldt-Jacob disease and Gerst- 
mann-Straussler-Scheinker syndrome (Palmer and 
Collinge, 1993). The normal repeat copy number 
is four copies with minor variation (plus/minus one 
copy) having no phenotypic effect. Addition of 
five or more extra copies, however, causes neuro- 
logical disease of variable severity. The molecular 
basis for this association is not yet known, and no 
instance of repeat instability within a family has 
been reported. 
TRANSACTING FACTORS: PROPERTIES OF 
THE REPLICATION MACHINERY THAT 
AFFECT MUTATION 
The term “trans-acting factors” is used here to 
refer to any cellular component not linked to the 
repeat sequence, which in some way or other af- 
fects the stability of the repeat sequence and there- 
fore the mutation process. 
One of the more curious aspects of the finding 
that several (perhaps many) important human dis- 
eases are associated with repeat sequence mutation 
is that this form of mutation had not previously 
been reported in experimental organisms. One 
possibility is that the replication machinery re- 
sponsible for the fidelity in transmission of repeat 
sequences is for some reason less faithful in humans 
than other species. Evidence that this may indeed 
by the case comes from various quarters. Rubin- 
sztein et al. (1995a,b) conducted a survey of a 
variety of different repeat loci scattered throughout 
the human genome comparing the copy number of 
these repeats in humans and closely related pri- 
mates. A significant general trend was found for 
Mutation in mismatch repair genes (Inherited) 
e.g. MLHl and MSH2 genes 
[somatic: mutation of normal allelel 
v 
Defective mismatch repair enzymes 
v 
Genome-wide instabnlity of simple tandem repeats (Somatic) 
v 
Mutation of target STR containing genes 
[“turnour suppressor” gene] 
eg. type I1 TGF-P receptor 
v 
Loss of function by frameshift mutation 
w 
l’urnour progression 
FIGURE 2. M s - a c t i n g  pathway of STR mutation in 
HNPCC 
repeat loci to be longer in the human genome. 
Given the relationship between copy number and 
instability, it would appear much more likely for 
repeat sequence mutation to occur in humans. 
Transgenic mice harbouring 45 copies of the 
p( AGC)n repeat in a human androgen receptor 
(AR) gene are notable for the stability of the re- 
peat (Bingham et al., 1995). The normal AR gene 
contains 11-33 repeats, whereas the disease caus- 
ing AR gene has 38-66 repeats, which exhibit 
instability upon tr:msmission. Similarly, there was 
no observed repeat instability in the SCAl trans- 
genic mice carrying 83 copies of the repeat (Bur- 
right et al., 1995). The stability of these expanded 
repeats in mice might go some way to explaining 
why the only examples of this form of mutation 
have been found in humans. 
These observations suggest that trans-acting fac- 
tors (the replication machinery responsible for fi- 
delity of repeat transmission) may be particularly 
prone to errors in humans. 
Repeat Instability in Cancer 
The genomewide instability of simple tandem 
repeat sequences in certain forms of cancer has 
been associated with defects in specific mismatch 
repair proteins (Aaltonen et al., 1993; Ionov et 
al., 1993; Peltomaki et al., 1993; Thibodeau et al., 
1993). Evidence has now been presented (Marko- 
witz et al., 1995) that this phenomenon has a caus- 
ative role in tumour progression (Fig. 2). 
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In tumour tissue from patients with hereditary 
nonpolyposis colon cancer (HNPCC), there is in- 
stability of many simple tandem repeats with the 
presence of novel alleles resulting from increases 
and decreases in copy number. This instability is 
evident when the copy number of repeat sequences 
in malignant tissue is compared with that of nor- 
mal tissue in affected individuals. 
The more common HNPCC loci map by link- 
age analysis to chromosomes 2 and 3 (Nystrom- 
Lahti et al., 1994). Mutations in yeast MLHl and 
MSH2 genes (homologues of the bacterial mutL or 
mutS genes that are normally involved in DNA 
mismatch repair) severely affect instability of re- 
peat sequences (Strand et al., 1993). By positional 
cloning, the HNPCC gene on chromosome 2 was 
found to be hMSH2, the human homologue of 
mutS (Fischel et al., 1993; Leach et al., 1993). As 
a consequence of this information, the chromo- 
some 3 gene was identified as hMLHI , the human 
homologue of mutL (Bronner et al., 1994; Papa- 
dopoulos et al., 1994). 
At least one simple repeat-sequence-containing 
gene, that coding for the type I1 TGF-f3 receptor 
(RII) gene, is a specific target for this form of mu- 
tation (Markowitz et al., 1995). TGF-P inhibits 
the growth of multiple epithelial cell types, and 
loss of this negative regulation is thought to con- 
tribute to tumour development. The RII receptor 
is one of two receptors that transduce the TGF-p 
signal and is commonly inactivated in tumour cells 
exhibiting microsatellite instability. The simple re- 
peat sequences (GT), and (A)lo in the RII gene 
are targets for copy number mutation-the frame- 
shift caused by these mutations resulting in loss of 
RII function. Mutations in the RII receptor there- 
fore link DNA repair defects with tumour progres- 
sion. Interestingly, Msh2 and Pms2 knockout mice 
(Baker et al., 1995; de Wind et al., 1995; Reitmar 
et al., 1995) do not exhibit early onset colon can- 
cer but instead develop lymphoid tumours, suggest- 
ing that a broader role for mismatch repair in can- 
cer may exist. 
Conclusions 
Repeat sequence “polymorphism” appears to ac- 
count for a significant amount of variation in the 
human genome and may be an important source of 
human variation at the phenotypic level. Complex 
traits and diseases may have simple molecular bases 
in normally variable simple sequences. It would 
appear essential to understand the normal func- 
tion(s) of repeat sequences and their copy number 
polymorphism in order to account for the existence 
of what appears to be a high-risk target for disease- 
causing mutation. Repeat sequences themselves 
and the proteins responsible for the fidelity of their 
replication can both play a role in copy number 
mutation. 
The characterisation of the FRAl I B fragile site 
has shown that chromosomal instability can lead 
to in vivo breakage, yet it is not clear under what 
circumstances and at what frequency this is likely 
to occur. Somatic instability as a result of the mu- 
tator mutations in certain forms of cancer renders 
repeat containing genes “high-risk” targets for mu- 
tation, and therefore inactivation. This phenom- 
enon might account for some of the pleiotropic 
effects of mutator mutations -is TGF-RII the only 
target? 
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NOTE ADDED IN PROOF 
The FHlT gene which spans the FRA3B fragile 
site gives rise to aberrant transcripts in a variety of 
cancers (Ohta et al., 1996; Sozzi et al., 1996). A 
gene has been isolated at the FRAXE locus which 
has homologies to AF-4 [which is fused with the 
MLL gene in ALL patients with t(4;11)] and 
LAF-4, a lymphoid nuclear protein with transac- 
tivation potential (Chakrabarti et al., 1996; Gecz 
et al., 1996; Gu et al., 1996). These observations 
strengthen the association between (at least cer- 
tain) fragile sites and chromosome instability in 
cancer. An expanded p(AAG)n repeat in the first 
intron of the FRDA gene constitutes the majority 
of mutations leading to Friedreich‘s ataxia (Cam- 
puzano et al., 1996). Therefore dynamic mutations 
can involve repeats other than the trinucleotides 
p(AGC)n and p(CCG)n and can lead to autoso- 
ma1 recessive disorders. 
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Fragile Sites—Cytogenetic Similarity with Molecular Diversity
Grant R. Sutherland and Robert I. Richards
Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital, Adelaide, Australia
When examined in metaphase chromosome prepara-
tions, all fragile sites appear as a gap or discontinuity
in chromosome structure. These gaps, which are induced
by several specific treatments of cultured cells, are of
variable width and promote chromosome breakage with
variable efficiency. Within a single metaphase, it is not
possible to distinguish between a fragile site and random
chromosomal damage. Only the statistically significant
recurrence of a lesion at the same locus and under the
same culture conditions delineates fragile sites. Several
classes of fragile sites have now been characterized at
the molecular level. The “rare” fragile sites contain tan-
demly repeated sequences of varying complexity, which
undergo expansions or, occasionally, contractions. The
common fragile sites remain as enigmatic at the molec-
ular level as the rare ones once were at the genetic level
(Sutherland 1985).
The cytogenetic expression of a fragile site is but one
manifestation of genomic instability that is generated by
the DNA sequences at fragile-site loci. For instance, the
rare folate-sensitive fragile sites are associated with tran-
scriptional silencing of genes, and some of the common
fragile sites may also affect gene expression by creating
local regions of chromosomal instability. The current
challenge is to understand the mechanisms of this insta-
bility and its biological significance.
Fragile sites are classified according to their frequency
and the conditions or agents that induce their expression
(Sutherland et al. 1996). Common fragile sites appear
to be part of normal chromosomal structure and are
probably present at all common fragile-site loci in all
individuals. Rare fragile sites vary in frequency from
only a handful of case reports up to 1 in 40 chromo-
somes. A classification of fragile sites and some details
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of their cytogenetic and molecular properties are given
in table 1.
Fragile sites are identifiable as gaps or chromosomal
breaks in only a fraction of metaphase spreads from a
given individual. At one extreme is FRA16B, which,
when induced by berenil, may be found in 190% of
metaphases (Schmid et al. 1986). At the opposite end of
the spectrum are the common aphidicolin fragile sites.
Even the most conspicuous of these, FRA3B, is rarely
seen in 110% of metaphases (Smeets et al. 1986), and
many of the other common fragile sites are seen in !5%
of metaphases. Whatever the mechanisms are that result
in fragile-site expression, they usually operate success-
fully in only a minority of cells.
Most of the treatments that induce fragile sites (e.g.,
perturbed nucleotide pools and aphidicolin) result in
slowing DNA replication, particularly at fragile-site loci
(Hansen et al. 1997; Le Beau et al. 1998). It is thus
possible that the common fragile sites, and perhaps the
rare ones, arise because of incompletely replicated DNA
sequences that do not package completely for mitosis.
Whereas such packaging is completed in most cells, in
a varying, often small proportion of cells it may not be
completed before the end of G2, and it is in these cells
that fragile sites manifest themselves as gaps or breaks.
Sequences of Fragile Sites
Only three of the different classes of rare fragile sites
have been studied at the molecular level. Most is known
about the rare folate-sensitive fragile sites, of which five
members have been cloned. This group includes
FRAXA, the site of the molecular lesion in the fragile
X syndrome gene FMR1, which underlies the most com-
mon familial form of mental retardation.
The normal alleles at the FRAXA locus vary in size
from ∼6–55 CCG repeats, mostly with interspersed CCT
units after every 9–10 CCG units (Hirst et al. 1994),
although there is variation in this pattern, with some
alleles having no or only one CCT unit. In Tunisian Jews,
there is an increased incidence of normal alleles without
CCT units, and this is likely to be the basis of an ap-
parently high incidence of fragile X syndrome in this
ethnic group (Falik-Zaccai et al. 1997). The increased
length of premutation and mutation alleles appears to
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1. Folate sensitive Low folate and thymidine, FUdR, MTX, high thymidine 23 5 CCG
2. Distamycin A inducible a. Distamycin A, other minor groove-binding oligopeptide
antibiotics, and BrdU 2 1 33 bp AT-rich
b. As above, but not BrdU (recorded only in the
Japanese) 3 0 )
3. BrdU inducible BrdU or BrdC 2 1 ∼42 bp variable AT-rich
Common:
4. Aphidicolin inducible Aphidicolin for at least 24 h 76 3 None obvious
5. 5-Azacytidine inducible 5-Azacytidine for no more than 8 h 4 0 )
6. BrdU inducible BrdU for no more than 8 h 6 0 )
7. Adenovirus 12
inducible
Adenovirus 12 in U1 small nuclear RNA genes in
p53-expressing cells 4 0 )
be due to increased numbers of CCG units alone. Fur-
thermore, the alleles that expand to give pre- and full
mutations are in linkage disequilibrium with microsat-
ellite (Richards et al. 1992) and single nucleotide poly-
morphisms (SNPs; Gunter et al. 1998) within the gene
or close to its 5′ end. The presence of one of these SNPs,
ATL1, can be used to predict which alleles are likely to
proceed to expansion (Gunter et al. 1998), although it
is unlikely that the ATL1 polymorphism, in the first in-
tron of FMR1, has functional significance in relation to
expansion. More likely, it is in linkage disequilibrium
with some CCG repeat structure that promotes expan-
sion.
The only other folate-sensitive fragile site for which
there is information on allele structure is FRA16A (Nan-
carrow et al. 1995). As with FRAXA, some of the longer
alleles that lack CCT interruption might be expected to
undergo expansion more readily than interrupted alleles.
However, too few expanded alleles are available for
study to test this prediction rigorously.
The cloning of FRA16B showed that repeat sequences
other than trinucleotides could undergo expansion and
result in a fragile site (Yu et al. 1997). At this locus, a
33-bp AT-rich repeat, which is highly polymorphic on
normal chromosomes, expands up to several thousand
copies to yield a fragile site. Such large expansions can
be viewed only on pulse-field gels, where variation in
size by a relatively small number of copies would not
be resolved. Hence, although the expansions in different
families with FRA16B are clearly distinct, neither size
variation within families nor somatic instability in car-
riers of this fragile site has been observed.
Fragile site FRA10B differs from FRA16B in that,
whereas the former is induced only by nucleotide ana-
logues such as BrdU or BrdC, the latter is also (indeed,
more strongly) induced by DNA minor groove-binding
agents such as distamycin A and berenil. FRA10B is the
most complex fragile site yet studied. It is an expansion
of 5–100 kb, consisting of an AT-rich minisatellite repeat
unit of ∼42 bp in length, which varies in size and com-
position between families (Hewett et al. 1998). The ex-
panded sequence shows both somatic and intergenera-
tional instability.
Three common fragile sites (FRA3B, FRA7G, and
FRA7H) have also been studied in some detail (Mishmar
et al. 1998). In contrast to the rare fragile sites, here the
fragility occurs over a region of tens to hundreds of
kilobases rather than at a single point. Sequence analysis
of these regions reveals no striking features that could
account for the fragile site, although there are regions
of decreased stability and increased flexibility of the
DNA that might be significant (Mishmar et al. 1998;
Palin et al. 1998). FRA3B occurs within the FHIT gene,
but the other two fragile sites are not known to be within
genes. These common fragile sites are late-replicating
regions, and it is of interest that aphidicolin, which in-
duces these fragile sites, further delays their replication
(Le Beau et al. 1998). This finding supports the model
that these fragile sites may simply represent very
late–replicating regions of DNA, which, in a minority
of cells, fail to complete replication before mitosis begins
and, for this reason, do not package well into chro-
mosomes.
A common aphidicolin type fragile site in the Chinese
hamster has been cloned on the basis of its increased
sensitivity for the incorporation of a linearized plasmid
containing a selectable drug-resistance marker. Sequence
analysis showed the region of the fragile site to be AT-
rich, with a number of other features, including ho-
mologies to yeast autonomous replicating sequences and
a consensus sequence for replication origins (Palin et al.
1998). Fragile sites inducible by adenovirus 12 occur in
727
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Figure 1 CCG repeat instability and methylation at the FRAXA locus during male and female development. FRAXA is the best-studied
such site, but some of the observations depicted here probably apply at other fragile sites as well.
the small nuclear RNA gene clusters but only in cells
expressing p53. It has been postulated that a viral pro-
tein causes p53 to undergo a gain of function, leading
either to perturbed transcription by RNA polymerase II
or to inefficient chromatin condensation. As Li et al.
(1998) note, continued replication or transcription be-
yond G2 might be expected to interfere with chromatin
compaction.
The Induction of Instability at Fragile Sites
Although fragile sites are themselves visual manifes-
tations of genome instability, there is considerable evi-
dence that genome instability at these loci occurs at other
levels. Because most or all of the rare fragile sites are
prone to intergenerational and somatic repeat expan-
sion, it is worth considering how this instability comes
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about. In the case of FRAXA, the best-known example,
certain normal alleles can increase in size from within
the normal range of copy numbers into the premutation
range. Mechanisms to account for instability include un-
equal crossing over, gene conversion, and replication
slippage (see Sinden 1999 [in this issue]). These events
are apparently rare, and the rate at which they occur is
probably little different from the mutation rate of other
simple tandem repeats (∼1023 per locus/generation).
Once the number of uninterrupted repeats exceeds ∼80,
the length of an Okazaki fragment, replication slippage
is likely to be the predominant mechanism by which
increasingly larger size changes occur, the process of dy-
namic mutation (Richards and Sutherland 1994; Suth-
erland et al. 1998). This model has recently received
experimental support (Freudenreich et al. 1998; Sarkar
et al. 1998).
Superimposed on this process are a number of factors
such as the age and sex of the individual in which the
changes occur. The most likely series of events in the
genesis of an individual with a FRAXA full mutation is
shown in figure 1. An ovum with a full mutation is
produced (by either a pre- or a full mutation carrier)
and fertilized. This full mutation is unmethylated (Mal-
ter et al. 1997), and it remains so throughout early em-
bryogenesis. The unmethylated mutation is somatically
unstable and gives rise to cell lineages with different
numbers of copies of the repeating unit. Most of these
are probably breakdown products with fewer copies of
the repeat than are found in the ovum, but some may
contain additional copies. Once the expanded repeat un-
dergoes CpG methylation, further changes in repeat
copy number are rare. Methylation is probably not com-
plete until 12–14 weeks of gestation. At least in the case
of the FMR1 gene, methylation also leads to transcrip-
tional silencing of the allele on the fragile X chromo-
some. In the male fetus, there is premeiotic selection
against germ cells that contain the full mutation in favor
of cells with a premutation (Ashley-Koch et al. 1998).
Eventually spermatogenesis results in sperm with pre-
mutations only. However, no selection occurs in the
ovary of a female fetus, so full mutations persist in the
female germline. During oogenesis, when CpG methyl-
ation is erased, instability is restored to the CCG repeat,
and ova with different-sized mutations are generated.
Finally, as individuals age, there is very slow selection
against somatic cells with the largest alleles (Ashley-
Koch et al. 1998). In females, there is slow selection
against cells in which the fragile site is on the active X
chromosome (Rousseau et al. 1991). It is likely that this
series of events is also applicable to FRAXE but not
entirely to the autosomal sites. Thus, full mutations in
FRA16A do not appear to be subject to selection in male
germ cells (Nancarrow et al. 1994).
Although intergenerational and somatic instability
can occur at FRA10B and probably also at FRA16B,
the rates at which these changes occur are much lower
than at folate-sensitive fragile sites, perhaps because rep-
lication slippage is less likely with longer-repeat motifs.
Other mechanisms, such as gene conversion, may ac-
count for changes in allele size at FRA10B and FRA16B
(Jeffreys et al. 1994). Genomic instability at the common
fragile sites has been documented extensively for FRA3B
and to a lesser extent for FRA7G (Huang et al. 1998).
Instability at FRA3B occurs by recombination between
long L1 sequences (Inoue et al. 1997) and generates de-
letions in the FHIT gene in a range of solid tumors.
FRA7G is within an area of instability in prostate can-
cers, but the mechanism of its instability has not been
determined.
Other manifestations of genomic instability at FRA3B
include its function as a target for viral integration, spe-
cifically of HPV16. There is also evidence for the com-
mon fragile sites being involved in gene amplification by
being points of breakage in a breakage-fusion bridge
mechanism (Coquelle et al. 1998).
The Biological Significance of Fragile Sites
The biological significance of chromosomal fragility
is not easily generalized among fragile loci. Two of the
rare fragile sites on the X chromosome are manifesta-
tions of disease (mental retardation)–producing dynamic
mutations, whereas the third rare fragile site on this
chromosome, FRAXF, is not found within any known
gene and does not lead to any obvious phenotypic ab-
normality. The autosomal fragile sites of this type may
be associated with transcriptional silencing of genes in
which they might be located. Breakage at fragile sites
may be capable of producing chromosomal deletion syn-
dromes, as perhaps occurs when FRA11B breakage leads
to Jacobsen syndrome (Jones et al. 1995). It is of interest
that none of the rare folate-sensitive fragile sites has been
identified in species other than humans, yet repeats that
are potentially capable of expansion to fragile sites have
been identified in other species.
Fragile sites are probably all associated with localized
genomic instability; although this instability might lead
only to the “gap” seen in cytogenetic preparations, it is
also possible that the consequences are more significant.
There is growing evidence that some common fragile
sites predispose their surrounding region to the localized
chromosomal instability seen in certain cancers. FRA3B
is one such region of instability, and abnormal tran-
scripts of the FHIT gene in which it is located are found
in a range of tumor and normal cell types (Siprashvili
et al. 1997; Carapeti et al. 1998; Otterson et al. 1998).
The human caveolin genes CAV1 and CAV2 are located
in the vicinity of FRA7G, which is frequently deleted in
human cancers (Engelman et al. 1998b). Caveolin-1 has
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been shown to have a role in the anchorage-dependent
inhibition of growth in NIH 3T3 cells (Galbiati et al.
1998). The caveolins are therefore candidates for the
tumor-suppressor gene presumed to be located in the
FRA7G region (Engelman et al. 1998a). By similar
mechanisms, fragile sites may also lead to gene ampli-
fication in tumors. The noncompacted state of the DNA
at fragile sites may also facilitate the integration of vi-
ruses into the genome.
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CLASSIFICATION OF FRAGILE SITES
Fragile sites are specific, inherited chromosome
loci that appear as gaps or breaks in chromosomes of
cells which are exposed to certain cell culture condi-
tions (1). They were first described in 1965 (2) and
have been found on every chromosome with the ex-
ception of chromosome 21 (3).
On the basis of frequency, fragile sites have been
grouped into common and rare fragile sites. The
common ones are part of the normal chromosome
structure, although the proportion of metaphases
showing cytogenetic expression varies between indi-
viduals. Common fragile sites are further classified
into three groups according to their induction chem-
istry by either bromodeoxyuridine (BrdU), 5-azacy-
tidine, or aphidicolin, an inhibitor of DNA polymer-
ase a.
The most prevalent rare fragile site is FRA16B,
with an occurrence of 1 in 40 chromosomes in the
German population (4); some rare fragile sites have
been reported only once (5). Just as for the common
fragile sites, the mode of chemical induction pro-
vides the basis for classification of the rare fragile
sites into three groups: (1) folate sensitive, (2) dis-
tamycin A inducible, and (3) BrdU-requiring. Induc-
tion of folate sensitive fragile sites is caused by
omitting folic acid and thymidine from culture me-
dia and hence by lowering the levels of either dTTP
or dCTP at the time of DNA replication. The dista-
mycin A inducible group contains fragile sites that
can be induced by distamycin A, berenil, netropsin,
Hoechst 33258, and BrdU (6–8). Distamycin A, ne-
tropsin, and Hoechst 33258 bind DNA with a high
affinity to AT-rich sequences. The BrdU-requiring
fragile sites, on the contrary, can only be induced by
(BrdU) or bromodeoxycytidine (BrdC). BrdU gets
incorporated into the DNA in substitution for thy-
midine (9) and may also affect the pyrimidine path-
ways. Both distamycin A inducible and BrdU-re-
quiring fragile sites show spontaneous expression in
vitro, the first frequently, the latter rarely (8). The
addition of distamycin A and BrdU increases the
fragile site expression.
The molecular basis for the cytogenetic expression
of chromosomal fragile sites is not yet completely
understood. The different classes of fragile site have
allowed the opportunity to compare the molecular
anatomy of chromosomal fragile sites with the aim
of identifying features that are common to all classes
and that might constitute the essential require-
ments for fragile site expression. Conversely, ele-
ments unique to a particular fragile site class might
account for the specific induction chemistry of each
class.
MOLECULAR CHARACTERIZATION OF
RARE FOLATE SENSITIVE FRAGILE
SITES
From a clinical point of view the rare folate sen-
sitive fragile site FRAXA is the most important frag-
ile site. It causes the fragile X syndrome, a familial
form of mental retardation. The prevalence of the
fragile X syndrome is estimated to be about 1 in
1 To whom correspondence should be addressed. Fax: 161 8
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4000 males and 1 in 6000 females (10) and it is the
second most common chromosome abnormality
causing mental retardation after trisomy 21. The
rare folate sensitive fragile site FRAXE is associated
with a mild form of mental retardation (11). No
other phenotypic effects have been observed in indi-
viduals expressing different fragile sites on one or
even both chromosomes (7,12,13). Therefore, it is not
surprising that FRAXA was the first fragile site for
which the DNA sequence was determined. It was
shown that it is caused by a novel mutation mecha-
nism referred to as “dynamic mutation.” A polymor-
phic CCG trinucleotide repeat, which has up to 55
copies in normal alleles, was expanded beyond 230
copies in fragile site expressing alleles (14). The
expanded CCG repeat inactivates the FMR1 gene
(15). Other trinucleotide repeat expansions have
since then been found in a number of hereditary
neurodegenerative disorders which include Hun-
tington’s disease, Friedreich ataxia, and various
types of spinocerebellar ataxia (for references see
Table 1).
Every other rare folate sensitive fragile site that
has been positionally cloned also showed expansion
of the CCG trinucleotide repeat (24–28). Most short
nonfragile site expressing alleles have imperfect re-
peat stretches at all these loci which are believed to
have a stabilizing effect, whereas fragile site alleles
do not usually show interruptions of the expanded
repeats. Alleles with long stretches of uninterrupted
repeats are at high risk of further repeat expansion.
This has not only been shown for the CCG repeat
(29) but also for the Friedreich ataxia GAA triplet
repeat (30) and for the CAG repeat expanded in




It was hoped that the characterization and com-
parison of members of all three classes of rare fragile
sites on the DNA sequence level would reveal the
molecular mechanism causing the gaps and breaks
in chromosomes. The first non-folate-sensitive rare
fragile site that was characterized by positional
cloning was the distamycin A-inducible rare fragile
site located at 16q22.1 (31). Analogous to the rare
folate sensitive fragile sites, the fragility at FRA16B
is caused by repeat expansion. However, in this in-
stance it was found that a 33-bp AT-rich minisatel-
lite repeat was expanded on the fragile chromo-
somes. Minisatellite or variable number of tandem
repeats (VNTR) range from 10 bp to more than 100
bp in length. The finding of an expanded AT-rich
minisatellite repeat was in agreement with the
knowledge that most chemicals inducing FRA16B
bind to AT-rich DNA sequences. The sequence at the
fragile site locus was composed of various AT-rich
minisatellite repeat motifs of which the 33-bp repeat
was shown to be expanded to up to 2000 copies in
FRA16B alleles (31). The DNA consensus sequence
for the FRA16B repeat is presented in Fig. 1.
As the expanded FRA16B alleles were very large
(;15 to 70 kb) it was not feasible to carry out an
amplification across the expanded repeats by poly-
merase chain reaction (PCR). It was therefore not
possible to study features like intergenerational in-
stability, to determine and compare the sequences of
different FRA16B alleles, or to check whether long
normal alleles are predisposed to expansion.
MOLECULAR CHARACTERIZATION
OF THE BrdU REQUIRING RARE
FRAGILE SITE FRA10B
The BrdU requiring rare fragile site FRA10B is
located at chromosome band 10q25.2. It can be in-
duced by BrdU or BrdC and is present in about 1 in
40 of the Australian population (12,32,33). The mo-
lecular basis for this fragile site was recently deter-
mined (34). Sequence analysis revealed a highly AT-
rich region (91%) in the center, which contained a
variety of minisatellite repeats, and nonrepetitive
flanking regions of ;58% AT content (Fig. 2A). PCR
across this region showed that it is very polymorphic
in length, with alleles in sizes between ;0.8 kb up to
more than 5 kb. Individuals heterozygous for
FRA10B showed amplification of one fragment less
TABLE 1




Spinocerebellar ataxia type 1 16 poly CAG
Spino-bulbar muscular atrophy 17 poly CAG
Dentatorubral and pallidoluysian
atrophy 18 poly CAG
Huntington disease 19 poly CAG
Myotonic dystrophy 20 poly CAG
Fragile X syndrome 21 poly CCG
Friedreich ataxia 22 poly AAG
SCA3/Machado–Joseph disease 23 poly CAG
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than 5 kb in size as well as either a large fragment
(.5 kb) or a null allele (no amplification product).
On the basis of their lengths, amplification products
could be divided into four groups: small normal (SN),
intermediate (INT), large normal (LN), and
FRA10B-expressing (EXP). Sequence analysis dem-
onstrated that the length polymorphism was mainly
due to differences in repeat copy number. SN, INT,
LN, and EXP alleles showed distinct sets of flanking
repeat motifs (Fig. 2B). Analysis of these flanking
haplotypes revealed that FRA10B-expressing alleles
are derived from LN alleles, and that these are
derivatives from INT alleles which are in turn
formed from SN alleles (Fig. 2B). Such founder ef-
fects have also been observed for a number of trinu-
cleotide repeat disorders (Table 1) and therefore
seem to be a common property of the dynamic mu-
tation mechanism which gives rise to the expansion
of both mini- and microsatellite repeats.
At the FRA10B locus the LN and EXP haplotypes
were closely related. Surprising was the small size
difference between the largest LN alleles which do
not express FRA10B (;4.5 kb) and the shortest
FRA10B-expressing alleles (;5 kb). This suggests
that there is a threshold in repeat copy number that
has to be exceeded for cytogenetic expression of the
fragile site. Similar thresholds have also been de-
scribed at the FRAXA and FRAXE loci (35). Hence
this is another feature shared by mini- and micro-
satellites.
The long-range PCR amplification across the
FRA10B locus allowed the assessment of mitotic and
meiotic instability. One heterozygous FRA10B-ex-
pressing individual repeatedly showed one short as
well as two large amplification products which were
interpreted as proof of somatic (mitotic) instability
(34). A number of pedigrees revealed meiotic insta-
bility: e.g., a decrease or increase in repeat copy
number from parent to offspring which resulted in a
shift in the size of PCR products between related
individuals. Mitotic and meiotic instability have also
been described at trinucleotide repeats (reviewed in
36) and are hence a third property shared between
mini- and microsatellite repeats.
COMPARISON OF DISTAMYCIN A
INDUCIBLE AND BrdU REQUIRING RARE
FRAGILE SITES
One question arising from the fact that FRA16B is
sensitive to distamycin A and BrdU, whereas
FRA10B can only be induced by BrdU, is whether
FRA16B and FRA10B share structural features.
Both fragile site loci revealed expansion of AT-rich
minisatellite repeats; their close relationship be-
comes obvious in Fig. 1. The FRA10B and FRA16B
FIG. 1. Comparison of the FRA10B and FRA16B consensus
sequences. Identical bases between the two repeats are marked
with I, asterisks point to differences that are either due to differ-
ent nucleotides or to the shorter sequences of the FRA16B repeat.
The 11-bp repeat element is presented in capital letters for the
forward sequence and in lowercase letters for the reverse se-
quence.
FIG. 2. Representation of the AT-rich minisatellite region at
the FRA10B locus. (A) Illustration of one FRA10B allele demon-
strating the differences in percentages of AT/GC-values across
FRA10B. The central region (91% AT) contains numerous mini-
satellite repeats that are depicted in different patterns. The
flanking regions consist of nonrepetitive sequences that still have
quite a high AT content (58%). (B) Simplified illustration of the
FRA10B minisatellite repeat region. Presented are three groups
of repeat motifs that were termed proximal (triangle), expanded
(diamond), and SnaBI (hexagon). Variation in the sequences is
shown as different shading or patterns. Stars point out identical
repeat motifs between short normal (SN), intermediate (INT),
long normal (LN), or FRA10B-expressing alleles. Only SN alleles
were sequenced over the full length; question marks represent
gaps in the sequences and dashes depict absence of a repeat motif.




consensus sequences share—depending on the se-
quence alignment—up to 31 identical bases (Fig. 1).
The 59-ends of the repeats reveal the highest homol-
ogy with 12 identical base pairs. This includes an
11-bp sequence that is present in its inverse form
further 39 of the repeat motif. The FRA10B and
FRA16B repeats both contain three copies each of
these 11-bp sequence elements (Fig. 1). The inverted
repeats are able to form hairpin structures (Fig. 3).
Similar AT-rich repeats are, for example, present
at the ApoB locus (37), the COL2A1 minisatellite
region (38), and in the human minisatellite MSY1
(39). This widespread occurrence suggests that
AT-rich minisatellite repeats might be of functional
significance.
A possible biological role for AT-rich minisatellite
repeats is that they might function as matrix attach-
ment regions (MAR), which are DNA sequences that
are attached to the nuclear matrix (reviewed in 40).
They are on average 500 bp long, occur about every
30 kb, and may play a role in DNA replication and
transcription. The AT-rich class of MARs are often
enriched in inverted repeats which is also the case
for the FRA10B and FRA16B minisatellite repeats.
The chemicals that induce the cytogenetic expres-
sion of FRA16B are known to preferentially bind to
AT-rich DNA sequences. This is in agreement with
the ascertainment of an expanded AT-rich minisat-
ellite repeat at the fragile site. But despite this
consistency and the fact that members of all classes
of rare fragile sites have now been characterized at
the molecular level, the relation between sequence
composition and induction chemistry of fragile sites
is still unclear.
COMMON FRAGILE SITES
It has been hypothesized that fragile sites predis-
pose to chromosome breakage at the fragile site loci
and that they may lead to cancer (41). A number of
common fragile sites have been positionally cloned
in recent years (42–46) but although there is evi-
dence for tumor suppressor genes at these loci, the
results are as yet not conclusive. Common fragile
sites seem to represent regions of fragility, rather
than specific loci. No repeat expansion has been
found at any of the common fragile sites studied.
Nevertheless, they seem to be regions of the genome
that attract interspersed repeats and are targets for
viral integration. Future research will show
whether the fragility at common fragile sites is in
fact associated with cancer and whether it is caused
by the formation of unusual secondary structures or
a clustering of high flexibility regions as proposed by
Mishmar et al. (45,47).
MINISATELLITES AND DISEASE
Minisatellites have repeatedly been correlated
with human disease. In some cases the VNTR do-
mains have been found to act as transcriptional
regulators. Examples for this are first, that genetic
susceptibility to insulin dependent diabetes mellitus
type 2 (IDDM2) is encoded by the number of mini-
satellite repeats located 600 bp upstream of the in-
sulin gene (48,49) and second, that the majority of
patients with progressive myoclonus epilepsy of the
Unverricht–Lundborg type (EPM1) have expansions
to more than 40 copies of a dodecamer repeat which
is located upstream of the 59-transcription start site
of the cystatin B gene, as compared to 2–3 repeat
copies in normal alleles (50). There is more and more
evidence that minisatellite repeats could be involved
in disease epidemiology. For example, the minisat-
ellite repeat at the 39 end of the human apolipopro-
tein B gene is likely to play a role in coronary dis-
orders (51). Ogilvie et al. (52) proposed that a
polymorphism in the serotonin transporter gene is
associated with susceptibility to depression in more
than 10% of affected individuals. Another illustra-
tion for the influence of VNTR elements on the sus-
FIG. 3. Examples for the ability of AT-rich minisatellite re-
peats to form hairpins. Similar secondary structures have been
described for Apo B VNTR dimeric repeats (36).
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ceptibility of disease was recently given by Deckert
et al. (53): a repeat polymorphism in the promoter of
the monoamine oxidase A gene was shown to be
associated with panic disorder. It is likely that other
VNTR polymorphisms afford susceptibility to addi-
tional diseases. These findings give only a glimpse
into this exciting research area and reveal that the
copy number of minisatellite repeats can not only
determine the genetic stability of a chromosome lo-
cus, as in the case of fragile sites, but it can also
influence the level of gene expression if the repeat is
located within or close to a gene. This underlines the
importance of understanding the molecular mecha-
nism causing minisatellite instability.
MECHANISMS GENERATING INSTABILITY
AT REPEAT LOCI
Whereas microsatellites, which comprise trinucle-
otide repeats, seem to mutate primarily by strand
slippage during DNA replication (54), instability
present at minisatellites is thought to be due to
recombinational processes. Bois and Jeffreys (55)
differentiate between mutation processes at GC-rich
and AT-rich minisatellite repeats. Although insta-
bility at GC-rich minisatellite repeats is well stud-
ied, the processes causing it are still poorly under-
stood. It is likely that meiotic instability of GC-rich
minisatellites involves gene conversion-like events,
whereas mitotic instability is caused by unequal
sister chromatid exchange and intramolecular re-
combination, although replication slippage can not
be excluded (reviewed in 55). Even less is known
about mechanisms causing instability at AT-rich
minisatellite repeats. Only the minisatellite present
at the 39 end of the human apolipoprotein B gene has
been studied in some detail. It consists of a dimeric
AT-rich core repeat of 30 bp (56,57). Linkage dis-
equilibrium between flanking polymorphisms and
Apo B minisatellite alleles was observed (37), which
is in agreement with intrallelic mutation events like
replication slippage and/or unequal sister chromatid
exchange. Ellsworth et al. (37) proposed that insta-
bility of repeat arrays depends on the DNA sequence
and their ability to form secondary structures. This
accords with the fact that AT-rich minisatellite re-
peats like the ones detected at the FRA10B and
FRA16B loci consist of shorter inverted repeats and
are able to form hairpin structures (Fig. 3). Debrau-
were et al. stated in a recent review that no general
rule can explain the instability at micro- and mini-
satellites because it is controlled by their sequence
environment and biological activities (58). Under-
standing of mutation mechanisms causing the insta-
bility of minisatellite repeat arrays might therefore
involve the detailed analysis of each single VNTR
locus—a task that is not feasible with current tech-
nology.
EXPECTATIONS FOR THE FUTURE
With increasing DNA sequencing information be-
coming publicly available, it emerges that finishing
the sequencing of the human genome is on no ac-
count the end of all activities but only the closure of
the first chapter in the book of understanding hu-
man molecular genetics. Many more chapters are to
follow and one of them will certainly be dealing with
the biological roles that repeat sequences play—not
only in the formation of fragile sites on chromosomes
but also in the regulation of gene expression and
possibly as matrix attachment regions. Sequencing
of repeat arrays has proven to be cumbersome and
time consuming. Advances in technology will hope-
fully open up faster ways of determining the exact
composition of repeat tracts which will consequently
enable us to gain a better understanding of not only
the mutation mechanisms generating instability at
fragile site loci but also of how the repeat number
influences gene expression.
ACKNOWLEDGMENTS
The authors are supported by funds from the National Health
and Medical Research Council of Australia, the WCH Research
Foundation, and the Anti-Cancer Foundation of South Australia.
REFERENCES
1. Sutherland GR. Heritable fragile sites on human chromo-
somes. I. Factors affecting expression in lymphocyte culture.
Am J Hum Genet 31:125–135, 1979.
2. Decaban A. Persisting clone of cells with an abnormal chro-
mosome on a woman previously irradiated. J Nucl Med
6:740–746, 1965.
3. Sutherland GR, Mattei JF. Report of the committee on cy-
togenetic markers. Cytogenet Cell Genet 46:316–324, 1987.
4. Schmid M, Feichtinger W, Jeßberger A, Köhler J, Lange R.
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Chapter 6. Pathogenic pathways from expanded repeat mutation to disease: 
  ‘Non-self’ Mutations and the autoinflammatory mechanism of  





These manuscripts detail our efforts to model expanded repeat diseases in Drosophila 
and zebrafish. The overall aim was to utilize these models to discover the responsible 
pathogenic pathways and thereby identify targets for therapeutic invention in the human 
diseases. Experiments in zebrafish were able to assess the consequences on development of 
reduced protein levels of either FMRP (ref #97) or huntingtin (refs #98, 99). 
 
In the Drosophila model we tested the idea that expanded repeat RNA in one form or 
other might by the common proximal pathogenic agent in the dominantly inherited expanded 
repeat diseases that exhibit the common pathology of neurodegeneration (refs #96, 100-102, 
104, 105). This idea was based on the observation that all expanded repeat loci are 
transcribed (typically off both strands) but not all expanded repeats encoded proteins – or 
even when aberrantly translated the resultant polypeptides were unrelated. The experimental 
data led to the hypothesis that the dominantly inherited expanded repeat diseases are due to 
an autoinflammatory disease mechanism whereby the expanded repeat encoded double-
stranded RNA synthesized from bi-directional transcription, is no longer correctly modified and 
is therefore recognized as ‘non-self’ even when it is produced endogenously (refs #106-108). 
This recognition elicits the anti-viral RNA pathway that typically recognizes long double strand 
viral RNA and includes cell death as a normal containment strategy for exogenous RNA (such 




96.  The pathogenic agent in Drosophila models of ‘polyglutamine’ diseases. 
 Human Molecular Genetics (2005) 14: 1041-1048. 
 McLeod, C., O’Keefe, L. and Richards, R.I.      
  
This work forms the core of Catherine McLeod’s PhD thesis.  I proposed the hypothesis that 
was being tested, I supervised the project, analysed and interpreted the data and had a minor 
role in writing of the manuscript.        Citations 41 
 
97. Contribution of mGluR and Fmr1 Functional Pathways to Neurite Morphogenesis, 
Craniofacial Development and Fragile X Syndrome. 
Human Molecular Genetics (2006) 15: 3446-3458.  
Tucker, B., Richards, R.I., and Lardelli, M.     
 
This work forms the core of Ben Tucker’s PhD thesis.  I jointly supervised Ben with Michael 
Lardelli.  Ben wrote the first draft of the manuscript and subsequent revisions with my and 
Michael’s input.  While I instigated the project Ben took up the challenge to make it work 
experimentally and it is Ben’s model in this paper that also graces the cover of the journal 
issue in which it was published.        Citations 115 
 
98. Huntingtin deficient zebrafish exhibit defects in iron utilization and development. 
Human Molecular Genetics (2007) 16: 1905-1920 
Lumsden, A.L., Henshall, T., Dayan, S., Lardelli, M., and Richards, R.I. 
 
This work forms the core of Amanda Lumsden’s PhD thesis.  I was Amanda’s major supervisor 
and instigated this project.  Amanda identified and experimentally validated the significant role 
of huntingtin in iron metabolism.  Amanda wrote the first draft and subsequent revisions after 






99. Selective neuronal requirement for Huntingtin in the developing zebrafish.  
Human Molecular Genetics (2009) 18: 4830-4842. 
Henshall, T.L., Tucker, B., Lumsden, A.L., Nornes, S., Lardelli, M.T and Richards, R.I 
 
This work forms the core of Tanya Henshall’s PhD thesis.  I was Tanya’s major supervisor and 
instigated this project.  Tanya identified and experimentally validated the significant role of 
huntingtin in early nervous system development.  Tanya wrote the first draft and subsequent 




100. Perturbation of the Akt/Gsk3-β signalling pathway is common to Drosophila 
expressing expanded untranslated CAG, CUG and AUUCU repeat RNAs. 
Human Molecular Genetics (2011) 20: 2783-2794. 
van Eyk, C.L., O’Keefe, L.V., Lawlor, K.T., Samaraweera, S.E., McLeod, C.J., Price, G.R., 
Venter, D.J., and. Richards R.I.  
  
This work forms the core of Clare van Eyk’s PhD thesis.  I was Clare’s major supervisor and 
instigated this project and the collaboration, with Deon Venter, required to complete it.  Clare 
wrote the first draft and subsequent revisions after input from myself and the other co-authors.
           Citations 29 
 
 
101. Double stranded RNA is pathogenic in Drosophila models of expanded repeat  
neurodegenerative diseases 
Human Molecular Genetics (2011) 20: 3757–3768. 
Lawlor, K.T., O’Keefe, L.V., Samaraweera, S., van Eyk, C., McLeod, C.J., Maloney, C., 
Dang, T., Suter C. and Richards, R.I. 
 
This work contains key components of the PhD theses of Kynan Lawlor and Saumya 
Samaweera.  Along with Louise O’Keefe I was supervisor for both and instigated this project. 
and the collaboration, with Cath Suter, required to complete it.  I wrote the first draft and 
subsequent revisions after input from the other co-authors.   Citations 48 
 
 
102. Ubiquitous Expression of CUG or CAG Trinucleotide Repeat RNA Causes Common  
Morphological Defects in a Drosophila Model of RNA-Mediated Pathology.                     
PLoS ONE (2012) 7(6): e38516. doi:10.1371/journal.pone.0038516 
Lawlor, K.T., O’Keefe, L.V., Samaraweera, S.E., van Eyk, C.L., Richards, R.I.  
 
This work contains key components of the PhD thesis of Kynan Lawlor.  Along with Louise 
O’Keefe I was supervisor and instigated this project.  Kynan Lawlor wrote the first draft and I 
rewrote subsequent revisions after input from the other co-authors.  
           Citations 10 
 
 
103. Comparative Toxicity of Polyglutamine, Polyalanine and Polyleucine Tracts in 
Drosophila Models of expanded repeat disease  
Human Molecular Genetics (2012) 21: 536-547.  
van Eyk, C.L., McLeod, C.J., O’Keefe, L.V., and Richards, R.I.  
 
Clare van Eyk undertook these studies as a post-doctoral fellow under my and Louise 
O’Keefe’s supervision. Clare wrote the first draft and I rewrote subsequent revisions after input 








104. Distinct roles for Toll and autophagy pathways in double-stranded RNA toxicity in 
a Drosophila model of expanded repeat neurodegenerative diseases.                        
Human Molecular Genetics (2013) 22: 2811-2819. PMID: 23719916 
Samaraweera, S.E., O’Keefe, L.V., Price, G.R., Venter D.J. and Richards, R. I.       
 
This work contains the major components of the PhD theses of Saumya Samaweera. Along 
with Louise O’Keefe I was supervisor and instigated this project.  Saumya and I wrote the first 
draft and I rewrote subsequent revisions after input from the other co-authors.   Citations 16 
 
 
105. Non-self Mutation: Double-stranded RNA elicits antiviral cell death response in a 
Drosophila model of expanded CAG repeat neurodegenerative diseases    
Human Molecular Genetics (2019) doi/10.1093/hmg/ddz096/5487598 
van Eyk, C.L., Samaraweera, S.E., Scott, A., Webber, D.L., Harvey, D.P., O’Keefe, L.V., 
Cropley, J.E., Young, P., Ho, J., Suter C., and Richards R.I.  
 
This work contains the major components of the PhD theses of Andrew Scott and Saumya 
Samaweera. Along with Louise O’Keefe I was supervisor and instigated this project.  I wrote 




REVIEWS and HYPOTHESES 
 
Dynamic mutations: where are they now? 
Chapter in ‘Tandem Repeats and Dynamic Mutations Leading to Neurological Disorders’ (A, 
Hannan, ed) Adv Exp Med Biol. 2012; 769: 55-77.   
van Eyk, C.L. and Richards, R.I. (2012)           
 
Modeling and Analysis of Repeat RNA Toxicity in Drosophila  
Methods Mol Biol.(2013) 1017: 173-192. doi: 10.1007/978-1-62703-438-8_13.  
Samaraweera, S.E., O’Keefe, L.V., van Eyk, C.L., Lawlor, K.T., Humphreys D.T., Suter, C.M. 
and Richards, R.I.                    
 
106. RNA pathogenesis via Toll-like receptor-activated inflammation in expanded repeat 
neurodegenerative diseases  
Frontiers in Molecular Neuroscience (2013) 6: 25 doi: 10.3389/fnmol.2013.00025. 
Richards, R.I., Samaraweera, S.E., van Eyk, C.L., O’Keefe, L.V., Suter C.M. 
 
I wrote this manuscript with numerous consultations with my colleagues. I wrote the revised 
and resubmitted version.                     Citations 10 
 
“Dynamic Mutations (Revised)” In Brenner's Online Encyclopedia of Genetics 3e (2016)  
 Richards, R.I.                  Encyclopedia 
 
107. The Enemy Within: Innate Surveillance-mediated Cell Death, the common 
mechanism of neurodegenerative disease.  
Front. Neurosci. (2016) Doi: 10.3389/fnins.2016.00193  
Richards, R.I., Robertson, S.A., O’Keefe, L.V., Fornarino, D., Scott, A., Lardelli, M, Baune, BT 
 
I formulated the central hypothesis put forward. I wrote this manuscript after numerous 
consultations with my colleagues. I wrote the revised and resubmitted version. Citations 24 
 
Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy (3rd edition) 
Autophagy, (2016)  12(1): 1-222.  







108. Neurodegenerative diseases have genetic hallmarks of autoinflammatory disease  
Human Molecular Genetics (2018) 27(R2):R108-R118. doi: 10.1093/hmg/ddy139. 
Richards, R.I., Robertson, S.A., Kastner, D.L.  
 
I formulated the central hypothesis put forward. I wrote this manuscript after numerous 
consultations with my colleagues. I wrote the revised and resubmitted version. Citations 3 
 
751
The pathogenic agent in Drosophila models of
‘polyglutamine’ diseases
Catherine J. McLeod1, Louise V. O’Keefe1 and Robert I. Richards1,2,*
1ARC Special Research Centre for the Molecular Genetics of Development and 2ARC/NHMRC Research Network in
Genes and Environment in Development, School of Molecular and Biomedical Sciences, The University of Adelaide,
Adelaide 5005, South Australia
Received January 19, 2005; Revised February 18, 2005; Accepted February 28, 2005
A substantial body of evidence supports the identity of polyglutamine as the pathogenic agent in a variety of
human neurodegenerative disorders where the mutation is an expanded CAG repeat. However, in apparent
contradiction to this, there are several human neurodegenerative diseases (some of which are clinically
indistinguishable from the ‘polyglutamine’ diseases) that are due to expanded repeats that cannot encode
polyglutamine. As polyglutamine cannot be the pathogenic agent in these diseases, either the different dis-
orders have distinct pathogenic pathways or some other common agent is toxic in all of the expanded repeat
diseases. Recently, evidence has been presented in support of RNA as the pathogenic agent in Fragile
X-associated tremor/ataxia syndrome (FXTAS), caused by expanded CGG repeats at the FRAXA locus. A
Drosophila model of FXTAS, in which 90 copies of the CGG repeat are expressed in an untranslated
region of RNA, exhibits both neurodegeneration and similar molecular pathology to the ‘polyglutamine’ dis-
eases. We have, therefore, explored the identity of the pathogenic agent, and specifically the role of RNA, in a
Drosophila model of the polyglutamine diseases by the expression of various repeat constructs. These
include expanded CAA and CAG repeats and an untranslated CAG repeat. Our data support the identity of
polyglutamine as the pathogenic agent in the Drosophila models of expanded CAG repeat neurodegenerative
diseases.
INTRODUCTION
Mutation of the androgen receptor leading to Kennedy disease
was identified 13 years ago as the first neurodegenerative
disease caused by the expansion of a CAG repeat within a
coding region (1). Since then, numerous human neurodegenera-
tive diseases have been identified with an identical mutation
mechanism, but with the CAG repeat expansions occurring
in quite distinct genes. Presumably, a similar pathogenic
pathway is involved, as each of the expanded CAG repeats
encodes polyglutamine and the pathogenic threshold for
disease is roughly the same, at around 40 copies of the repeat.
The role of a toxic gain of function for the polyglutamine-
containing protein in these diseases has been supported by a
variety of experimental and pathological observations. For
example, mutation of a specific amino acid in Ataxin1 that
lies outside the repeat region severely diminishes pathology
in a mouse model of SCA1 (2). In a Drosophila model of
Kennedy disease, testosterone (which activates the androgen
receptor and translocates it to the nucleus) is necessary to
observe pathology (3). In addition, analysis of mouse models
of SCA7 suggest that polyglutamine–based association
between the SCA7 protein containing expanded polyglutamine
and the transcription factor CRX results in transcription inter-
ference that is a predominant factor in SCA7 cone-rod dystro-
phy retinal degeneration (4).
A prominent feature of polyglutamine diseases is the pre-
sence of intranuclear inclusions formed by aggregation of the
expanded polyglutamine protein. These inclusions are
observed in brain tissue of patients with neurodegenerative dis-
eases and contain cellular components such as ubiquitin, the
proteasome, Hsp70 and transcription factors (5). Similar
inclusions are also observed in Drosophila models of the dis-
eases, where disruption of the inclusions is associated with a
dramatic reduction in pathology (6). On the other hand, the
role of nuclear inclusions in the pathology of neurodegenera-
tive diseases has been controversial almost because their dis-
covery with disagreement as to whether the inclusions are an
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integral component of the pathology. Rather, some studies have
suggested that they may instead play a protective role (7,8).
In addition to the earlier mentioned diseases, a series of
expanded repeat diseases have been described, some of which
demonstrate clinically indistinguishable phenotypes from the
‘polyglutamine’ disorders, but in each case, the repeat cannot
encode polyglutamine. In several cases, such as SCA8 (9) and
SCA12 (10), the repeat is located in the untranslated region of
a transcript. In HDL2, which shows marked similarity to
Huntington’s disease, the repeat occurs in a variably spliced
exon and is either in an untranslated region or encodes polyleu-
cine or polyalanine (11). Furthermore, SCA10 is due to the expan-
sion of a 5 bp repeat in an intron of another unrelated gene (12). In
these disorders, polyglutamine cannot be the pathogenic agent.
Taken together, these data suggest that a different pathogenic
pathway is responsible for the consequences of repeat expansion
in these diseases. Alternatively, polyglutamine is not respon-
sible for the ‘polyglutamine’ diseases and some other agent is
the toxin in a common pathogenic pathway for all of the neuro-
degenerative diseases caused by expanded repeats.
If the toxic agent in ‘polyglutamine’ diseases is not polyglu-
tamine, what else could be responsible? One alternative agent
that has been proposed to play a role is polyalanine, which
expands to cause pathogenesis in the degenerative disorder
oculopharyngeal muscular dystrophy (13). Investigation into
a role for polyalanine in Machado–Joseph disease, a ‘polyglu-
tamine’ disorder, revealed that the nuclear inclusions contain-
ing expanded polyglutamine also show immunostaining with
anti-polyalanine antibodies (14). This study also demonstrated
using cultured cells that frameshifting during transcription or
translation of expanded CAG repeats occurs in a length-
dependent matter, leading to the suggestion that polyalanine
contributes to nuclear toxicity in the polyglutamine diseases
by virtue of frame-shifted translation of the expanded CAG
repeat (14). Although toxic polyalanine may also account for
the HDL2 phenotype, as this transcript can potentially encode
polyalanine, it fails to provide a common mechanism for all
of the expanded repeat diseases, as some of the repeat tran-
scripts implicated in the diseases, such as the pentanculeotide
repeat responsible for SCA10, cannot encode polyalanine.
Another toxic agent already implicated in expanded repeat-
induced pathogenesis is RNA. In the case of myotonic dystro-
phy, there are two genetically distinct forms, DM1 and
DM2, caused by CTG or CCTG repeat expansions in unrelated
genes (15,16). In both forms, RNA containing the repeat
expansion is central to pathogenesis (reviewed in 17). The
ability of the repeat-containing RNA to form a stable hairpin
secondary structure appears to be involved in pathology: in
DM1, this double stranded structure binds to the splicing
factor Muscleblind in vitro (18) and co-localizes with it in
vivo (19), suggesting that Muscleblind is sequestered by the
double stranded CUG repeat. In addition, levels of another
splicing factor CUG-binding protein (CUG-BP) are altered
in DM1 (20), and perturbation of normal splicing is observed,
suggesting that pathogenesis is caused by the expanded
CUG repeat-containing RNA inducing these alterations in
splicing via Muscleblind and CUG-BP (21,22). As in DM1,
the repeat-containing transcript present in DM2 affects the
levels of CUG-BP and Muscleblind resulting in altered spli-
cing (23,24). This RNA-based model of pathogenesis accounts
for the remarkably similar multisystemic phenotypes seen in
DM1 and DM2, despite the causative mutations occurring in
unrelated genes.
In addition to myotonic dystrophy, a role for RNA in
disease characterized by neurodegeneration has recently
been revealed by a study using Drosophila. Fragile
X-associated tremor/ataxia syndrome (FXTAS) is a late
onset ataxia observed in some male carriers of the FRAXA
expanded CGG ‘premutation’ (copy numbers of 55 to 230
repeats) (25). RNA has been implicated in a Drosophila
model of this repeat expansion, where both neurodegeneration
and the presence of nuclear inclusions are observed (26). This
study demonstrates the ability of expanded repeat-containing
RNA to induce neurodegeneration.
In the ‘polyglutamine’ diseases, protein pathogenesis has
been assumed, but this assumption has not been tested
directly. A possible ‘mechanistic overlap’ between neuro-
degenerative diseases mediated by RNA and those thought
to be mediated by polyglutamine has recently been suggested
(27). Others have suggested that RNA-mediated mechanisms
in Huntington’s disease pathogenesis may act in parallel
with polyglutamine toxicity to promote cell death (28). This
suggestion was based on evidence that expanded CAG
repeats in the Huntington’s disease transcript cause the acti-
vation of PKR, a double stranded RNA binding protein that
is involved in inducing apoptosis (28). More recently, the
possibility that CAG repeat-containing RNA could act as a
pathogenic agent based on its secondary structure has been
investigated. Examination of CAG repeat-containing RNA
generated in vitro has revealed that CAG repeats in RNA
can form a double stranded hairpin structure (29). Further-
more, examination of the secondary structure of RNA tran-
scripts implicated in the ‘polyglutamine’ diseases has
demonstrated that the CAG repeats form hairpin structures
in the context of these full-length disease transcripts (30).
These observations have lead us to test the hypothesis that it
is RNA that causes pathogenesis in the ‘polyglutamine’ dis-
eases, as has been found to be the case in myotonic dystrophy
and FXTAS.
We have, therefore, addressed the possibility that RNA is
the toxic agent using a Drosophila model of ‘polyglutamine’
disease. The Drosophila system has been previously estab-
lished and validated as a useful model of polyglutamine
diseases (31–33) and also exhibits neurodegeneration
mediated by RNA containing expanded repeats (26). To
examine the RNA hypothesis, we have expressed various
repeat constructs in the Drosophila eye, comparing the
effect of expanded CAG and CAA repeats and an untranslated
CAG repeat. By comparing the effects of expressing these
various repeats, we have been able to rule out a role for
RNA in pathogenesis. Instead, our results suggest that toxicity
does occur at the protein level, at least in this model system.
RESULTS
Expression of trinucleotide repeat transgenes in the
Drosophila eye
Drosophila has previously been utilized to investigate the
mechanisms of polyglutamine toxicity. The expression of an
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expanded CAG repeat was found to cause neuronal degener-
ation in a length-dependent manner (33). The relevant con-
struct encoded a polyglutamine tract flanked by short amino
acid sequences (six on the N-terminal and four on the
C-terminal side) and a myc/flag epitope tag of 26 amino acids
at the C-terminus. These sequences were placed downstream
of an upstream activator sequence (UAS), which allows
tissue-specific expression when flies containing the transgene
are crossed to a driver strain expressing GAL4 (34) (Fig. 1A).
We have assembled several versions of this construct containing
various repeat tracts (Fig. 1B–D) in a P-element transformation
vector and used them to generate multiple lines of transgenic
Drosophila. These transgenic lines were then crossed to the
driver strain GMR-GAL4, resulting in expression of the repeat
transgene in all cells of the developing eye behind the morpho-
genetic furrow and on into adulthood (35).
Expression of either expanded CAG or CAA causes
neurodegeneration
Previously, only polyglutamine repeats encoded by CAG
have been expressed using this system (Fig. 1A). To determine
whether hairpin-containing RNA and/or some sequence
specific attribute of CAG has a role in pathogenesis, we
expressed polyglutamine encoded by CAA repeats. When
present in RNA, this repeat is not predicted to form a hairpin
secondary structure, as the complementary C–G base pairs
required for this are lacking. However, the CAA repeat con-
struct encodes an identical protein to that encoded by the
CAG repeat. Thus, comparison of the effects of expression of
these two constructs will allow us to determine whether RNA
sequence composition or structure has a role in pathogenesis.
If this is the case, we would expect a milder or even no pheno-
type to result from the expression of expanded CAA repeats.
Repeat lengths below and above the human pathogenic
threshold (of !40 repeats) were generated for both CAA
and CAG (Fig. 1B and C) and expressed in the Drosophila
eye. Expression of repeats below the pathogenic threshold
had no apparent effect on the external morphology of the
eye when compared with a fly carrying GMR-GAL4 alone
(Fig. 2E), as expected, for either (CAG)30 (Fig. 2A) or
(CAA)20 (Fig. 2B). In contrast, expression of the expanded
(CAG)99 transgene caused a dramatic phenotype with dis-
organization of the ommatidia, loss of pigment cells and a
collapsed eye (Fig. 2C). This is in agreement with the previous
description of the phenotype resulting from the expression of
this construct in the Drosophila eye (33). Expression of
expanded (CAA)94 driven by GMR-GAL4 resulted in a pheno-
type which is indistinguishable from the expanded CAG phe-
notype. Again, a dramatic phenotype was observed with
disorganization of the ommatidia, loss of pigment cells and
collapse of the eye structure (Fig. 2D). For both the expanded
CAG and the expanded CAA constructs, phenotypes ranging
in severity from wild-type to lethality resulted when indepen-
dently generated transgenic lines were crossed to GMR-GAL4
(Table 1). Presumably, this is due to positional effects, where
varying levels of expression between independent lines are
caused by differences in the site of integration (36).
However, the same range of phenotypes was seen for
expanded CAG and CAA, indicating that the expression of
these different constructs has the same effect on the
Drosophila eye.
Expanded CAG and CAA-induced pathology involves
protein aggregation
The observation that the expression of expanded CAA and
CAG repeats in the Drosophila eye has the same effect
suggests that pathogenesis is independent of RNA sequence
and secondary structure and that it is indeed polyglutamine-
containing protein which is the pathogenic agent. We deter-
mined the distribution of the polyglutamine protein in the
eye of these flies by examining horizontal sections of the
eye stained with anti-myc antibody, which recognizes the
myc epitope tag on the C-terminus of the polyglutamine
protein. In flies expressing polyglutamine encoded by either
CAG or CAA repeats that are below the pathogenic threshold,
the polyglutamine protein appeared to be diffusely distributed
throughout the eye (Fig. 3A and B). However, when the
repeats are expanded to !100 copies, the protein forms aggre-
gates in the eye, a result that has been reported previously for
polyglutamine encoded by CAG repeats (37). We observed
such aggregation for expanded polyglutamine proteins
encoded by both CAG repeats (Fig. 3C) and CAA repeats
(Fig. 3D). This suggests that the behaviour of the encoded pro-
teins is a major determinant of the phenotypes observed in this
Drosophila model of the CAG repeat expansion diseases.
Untranslated CAG repeats do not induce pathology in
Drosophila
The results described earlier suggest that pathogenesis occurs
at the protein level. However, it is possible that the pathogen-
esis observed in this Drosophila model involves multiple
Figure 1. Schematic representation of repeat constructs. (A) All repeat con-
structs were inserted downstream of UAS sites to allow expression under
the control of GMR-GAL4. The repeats are flanked by six amino acids on
the N-terminal side and four on the C-terminal, and a myc/flag epitope tag
is downstream. (B) Constructs containing polyglutamines encoded by
(CAG)30, (CAG)52 and (CAG)99 were generated. (C) These were compared
to constructs containing polyglutamine encoded by (CAA)20 or (CAA)94.
(D) A variation of this construct was generated, where a termination codon
is inserted immediately upstream of (CAG)93, effectively moving the repeat
into the 30 untranslated region. This is referred to as term(CAG)93.
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pathways and that both RNA and the encoded polyglutamine
both contribute to pathogenesis via independent pathways.
This possibility can be addressed by expressing a transcript
containing expanded repeats in a non-coding region: if RNA
has a role in pathogenesis, we would expect to observe a
phenotype in the Drosophila eye. Therefore, a construct was
generated in which a premature termination codon is inserted
before the expanded CAG repeat, referred to as ‘term(CAG)93’.
This has the effect of moving the CAG repeats into the
30-untranslated region of the transcript (Fig. 1D). When the
expression of this transgene was driven in the eye using
GMR-GAL4, no phenotype was observed (Fig. 2F), with the
resulting eye having an appearance identical to the eyes of
control flies expressing GAL4 alone (Fig. 2E). This confirms
that it is indeed the encoded polyglutamine that is the patho-
genic agent and rules out a role for RNA containing expanded
repeats in this Drosophila model of expanded CAG repeat
diseases.
The untranslated CAG repeat transcript is expressed
To determine whether the untranslated CAG repeat construct
was expressed at a sufficiently high level to induce toxicity,
quantitative (real time) PCR was performed. This was necess-
ary as the lack of phenotype observed upon expression of this
transgene could possibly be due to a difference in the stability
of the mRNA. In particular, the introduced (premature) ter-
mination codon could cause the transcript to be recognized
as nonsense and degraded via the nonsense mediated decay
mechanism (38). Two independently generated lines carrying
the term(CAG)93 transgene were crossed to GMR-GAL4, and
the level of expression of the repeat transcript relative to the
GAL4 transcript was compared to two lines expressing trans-
lated (CAG)99. One of these (CAG)99 lines caused a moderate
phenotype when expressed in the eye driven by GMR-GAL4,
and one caused no phenotype, presumably owing to diffe-
rences in expression of the transgene caused by variation in
the site of integration. Real-time PCR demonstrated that
the expression of the (CAG)99 transcript was higher in the
line showing a phenotype, whereas the line showing no pheno-
type demonstrated a lower level of expression (Fig. 4A and B).
Furthermore, the two lines expressing the untranslated CAG
repeat did so at a higher level than the translated (CAG)99
transcripts (Fig. 4). Thus, the steady state levels of these trans-
gene mRNAs are comparable to and actually exceed those
sufficient to induce toxicity. The lack of phenotype observed
can, therefore, be interpreted to mean that untranslated CAG
repeats are not pathogenic in this Drosophila model.
Figure 2. Effect of expressing various repeat constructs on the external
appearance of the Drosophila eye. All repeats are downstream of UAS sites,
and expression is driven by GMR-GAL4. (A) No alteration from the wild-
type eye phenotype is observed in flies expressing polyglutamine encoded
by (CAG)30. (B) Expression of polyglutamine encoded by (CAA)20 also has
no effect on the external appearance of the eye. (C) Expanded polyglutamine
encoded by (CAG)99 causes degeneration of the eye, seen here as a lack of
pigmentation and collapsed eye structure. (D) Expression of expanded poly-
glutamine encoded by (CAA)94 repeats also causes degeneration, with a phe-
notype indistinguishable from that caused by (CAG)99. (E) Control fly,
expressing only GAL4 in the eye. (F) Expression of an untranslated CAG
repeat encoded by term(CAG)93 has no effect on the appearance of the eye.
Table 1. Effect of expressing expanded repeats in the Drosophila eye driven by
GMR-GAL4 varies between lines
Eye phenotype None Mild Moderate Severe Lethal Total
(CAG)99 2
a 5 1a 2 1 11
(CAA)94 1 2 3 6 1 13
Term(CAG)94 16
a 0 0 0 0 16
For each repeat construct, the total number of independently generated
lines is indicated, as well as the number of lines showing no eye pheno-
type, a mild, moderate or severe phenotype, or lethality, upon expression
in the eye. Examples of these phenotypic categories are shown, which do
not correspond to any of the particular lines.
aLines that were analysed for transgene RNA expression levels by
RT–PCR.
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Expanded polyalanine does not make a major contribution
to the observed neurodegeneration
In addition to examining the pathogenic RNA hypothesis,
these experiments address another question relating to poly-
glutamine pathogenesis. An alternative model has been pro-
posed whereby the expanded CAG repeat undergoes a
frameshift during transcription and/or translation, resulting
in the expression of protein encoded by the alternative
reading frame GCA (14). These alternative proteins contain
a polyalanine repeat, which is suggested to be more toxic
than the polyglutamine repeat, and therefore to contribute
towards pathogenesis in the ‘polyglutamine’ diseases. This
frameshifting has been shown to occur in vivo in a patient
with Machado–Joseph disease and also in transfected COS-7
cells in a length-dependent manner (14). This mechanism
could account for the observation that either polyglutamine
(encoded by CAG) or polyalanine are the expanded amino
acid repeats found in a growing number of human genetic
diseases.
Expression of a polyglutamine protein encoded by CAA
repeats in Drosophila also indirectly addressed this hypo-
thesis, as CAA is unable to code for polyalanine in any
alternative frame. If polyalanine proteins are contributing to
the phenotype observed when expanded CAG repeats are
expressed, a milder (or no) phenotype would be expected
when CAA repeats are expressed, as the contribution made
by polyalanine would be lacking. However, both CAG and
CAA repeats cause a phenotype when expressed in the Droso-
phila eye (Fig. 2C and D). Furthermore, no obvious difference
in severity was observed between the CAG and CAA flies, as
we saw the same range of phenotypes for each type of repeat.
This suggests that polyalanine is not making a major contri-
bution to the pathogenesis observed. Thus, although we
cannot rule out a role for polyalanine in the human polygluta-
mine disorders or the suggestion that it may contribute in a
minor way to pathogenesis in Drosophila, it certainly does
not appear to play a principle role in pathogenesis in the
Drosophila system.
DISCUSSION
The expanded repeat disorders are a group of diseases caused
by the expansion of a repeat above a roughly common
pathogenic threshold and characterized by late-onset neurode-
generation. It seems parsimonious that, considering the
common features shared by the disorders, they would share
a common pathogenic agent or at least a common pathogenic
pathway. A good candidate for a common toxic agent in these
diseases is RNA, as it has previously been implicated in
expanded repeat disorders including a recent Drosophila
model of FXTAS that is characterized by neurodegeneration.
Figure 3. Distribution of polyglutamine proteins in the Drosophila eye.
Expression of the UAS repeat constructs is driven by GMR-GAL4. Horizontal
cryosections are stained with Hoechst (blue) to show DNA and Myc antibody
(green), which recognizes the Myc epitope tag on the C-terminus of the poly-
glutamine protein. Short polyglutamine proteins encoded by (CAG)30 (A) or
(CAA)20 (B) show a diffuse distribution. Polyglutamine proteins above the
pathogenic threshold form tight aggregates, whether the polyglutamine is
encoded by (CAG)99 (C) or by (CAA)94 (D).
Figure 4. Expression levels of translated and untranslated CAG repeat tran-
scripts. GMR-GAL4 is used to drive expression of UAS repeat constructs.
Quantitative (real time) PCR was performed to determine levels of repeat tran-
scripts in the following flies: (CAG)99 showing a phenotype (A) in light grey,
(CAG)99 showing no phenotype (B) in white and two independent lines of
term(CAG)93 shown in dark grey. The expression level of the repeat tran-
scripts are normalized to the level of the GAL4 transcript, and the expression
level of each line is expressed as the fold difference relative to the (CAG)99
line that shows a phenotype (A), which is set at one.








niversity of Adelaide user on 04 July 2019
756
Furthermore, the disease-causing repeats are always located
within the transcriptional unit of the gene, and therefore
each repeat is present in an RNA sequence. However, in this
study, we have demonstrated that the pathogenic agent in
‘polyglutamine’ disease is indeed polyglutamine-containing
protein, ruling out a role for RNA in the Drosophila model.
Expanded polyalanine is another candidate previously
suggested to act as a pathogenic agent in the polyglutamine
diseases and may also be implicated in HDL-2. However,
our results also suggest that polyalanine does not play a
major role in polyglutamine disease in the Drosophila
system. Thus, it appears that there may be at least two
major pathways of pathogenesis in the expanded repeat dis-
orders, one caused by protein containing expanded polygluta-
mine and a separate pathway, possibly still involving RNA, in
those disorders where polyglutamine is not present.
Prior to this study, the question of a role for RNA in the
polyglutamine disorders had not been directly addressed.
Evidence from transgenic mouse models suggested that
protein is required to mediate pathogenesis, but this evidence
was not entirely conclusive. An early mouse model expressing
the human Huntington’s disease transcript containing 44 CAG
repeats, which failed to produce any protein, also failed to
demonstrate a disease phenotype (39). However, this may
simply be due to the fact that 44 copies of the repeat is insuffi-
cient to induce a phenotype in the mouse, an explanation
which has been suggested previously (28) and is supported
by the failure of repeats of similar length to cause a phenotype
in other mouse models, despite translation of the mRNA (40).
Further evidence of a role for protein in pathogenesis comes
from a SCA1 mouse model in which mutation of the nuclear
localization signal in Ataxin1 resulted in mice that did not
display the disease phenotype, an observation difficult to
explain if pathology is RNA-based (41). However, these
results are contradicted by an earlier report from the same
group describing five lines of SCA1 mutant transgenic mice
in which Ataxin1 mRNA but not protein could be detected,
and which displayed the disease phenotype (42). The possi-
bility that the mutation of the nuclear localization signal
(41) also had some effect on the structure or localization of
the mRNA cannot be ruled out. Therefore, it is difficult to con-
clusively rule out a role for expanded repeat-containing RNA
in polyglutamine pathogenesis from these studies.
We have utilized a Drosophila model of polyglutamine
disease, which has previously been well characterized. The
neurodegeneration caused by the expression of expanded
CAG repeats in this model system is late onset and progressive
(33), as are the human disorders. However, in the Drosophila
model, expanded polyglutamine proteins are expressed at a
high level driven by GMR-GAL4 which does not necessarily
reflect the human disease state. Thus, it is possible that this
level of expression causes degeneration in Drosophila via a
mechanism which is not involved in the human diseases or
which plays a minor role. In addition, the fly has a much
shorter lifespan, and the expanded repeat disorders generally
do not occur in humans until later in life. Therefore, care
must be taken when extrapolating results from Drosophila to
human.
In contrast with our results, two groups have recently
reported RNA-mediated neurodegeneration in Drosophila.
As discussed earlier, a Drosophila model of FXTAS has
been generated, in which rCGG repeats mediate neurodegen-
eration. A surprising aspect of this model is the presence of
aggregates containing Hsp70 and the ability of Hsp70 over-
expression to decrease severity (26). A similar decrease in
severity is also seen when Hsp70 is overexpressed in a
Drosophila model of polyglutamine disease (43). As Hsp70
is a molecular chaperone, with a central function in protein
folding (44), this decrease in severity was suggested to
imply that misfolding of the polyglutamine-containing
protein is central to pathogenesis. However, in FXTAS, no
altered protein sequence or expanded polyglutamine is
present, making the role of Hsp70 unclear. Nonetheless, it
does provide a possible link between polyglutamine disease
and RNA-mediated neurodegeneration, as Hsp70 can clearly
modulate pathogenesis in both cases, but whether this modu-
lation implies a specific role in pathogenesis, and therefore a
common pathway shared by both types of disorders, remains
to be determined.
In addition to these results, a Drosophila model of SCA8
has also been recently generated. SCA8 is caused by the
expansion of a CTG repeat, and it is unique in that the
repeat occurs in a predicted non-coding RNA. When the
SCA8 RNA containing 112 CUG repeats was expressed in
the Drosophila eye, progressive neurodegeneration was
observed (45). Similar neurodegeneration was observed
when the SCA8 transcript contained nine CUG repeats, in
the normal range, making it difficult to determine whether
the degeneration is due to the repeats or rather some property
of the SCA8 transcript itself. However, when the
SCA8(CTG)112 phenotype was used to conduct a screen for
genetic interactions, genes were identified which exhibited
length-dependent interactions with SCA8(CTG)112 and
SCA8(CTG)9 (45). One of these interactors was Muscleblind,
which is implicated in myotonic dystrophy pathogenesis and
has been shown to bind to CUG or CCUG repeats in the
DM1 and DM2 transcripts. This finding demonstrates that
there are apparent parallels between myotonic dystrophy,
which is RNA-mediated, and SCA8, further strengthening
the case for RNA-mediated SCA8 pathogenesis. Furthermore,
this SCA8 model and the FXTAS Drosophila model demon-
strate that the pathways involved in RNA-mediated neuro-
degeneration are present in Drosophila. Therefore, the lack
of phenotype we observed upon the expression of rCAG
repeats is not due to the Drosophila system missing some com-
ponents of the pathways involved in RNA-mediated degener-
ation, but instead suggests that rCAG repeats are not toxic in
the manner that rCGG and possibly rCUG repeats appear to
be. This may be due to an intrinsic property of the repeat
itself, although it is able to form a hairpin secondary structure
(29) like the CUG repeat (18), or alternatively it could be due
to the context in which the repeat occurs, with surrounding
RNA sequences necessary for toxicity in some way.
In conclusion, it seems likely that the true pathogenic agent
in polyglutamine disorders is indeed polyglutamine, an
assumption which had largely been accepted, but until now
remained unproved. However, it also seems likely that RNA
will be uncovered as the pathogenic agent in a growing
number of diseases including those caused by the expansion
of untranslated repeats. It will be interesting to see whether
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there is a point of convergence between the otherwise distinct
mechanisms of pathogenesis in these two closely related
groups of disorders.
MATERIALS AND METHODS
Generation of repeat constructs
Repeats were generated by ligating together shorter repeat
oligonucleotides and expanded using PCR-based techniques
(46). These were subcloned into the Drosophila transform-
ation vector pUAST (34), which had been modified to
contain the amino acid sequence surrounding the repeat,
including the myc and flag epitope tags, which has been
described previously (33).
Fly stocks and crosses
The length and integrity of repeat constructs were confirmed
by DNA sequencing and then microinjected into a w1118
strain by standard methods to obtain germ line transformants.
Multiple transgenic lines were obtained for each construct, and
the repeat length from each line was confirmed by PCR and
sequencing. The GMR-GAL4 line used in this study was
obtained from the Bloomington Drosophila stock centre
(Indiana University, Indiana, PA, USA). For all figures, the
expression of UAS repeat constructs is driven by GMR-
GAL4, represented by GMR . repeat. Flies were maintained
on cornmeal medium and all crosses were performed at
258. For light microscopy and cryosectioning, all flies were
24–48 h old.
Cryosectioning and antibody staining
Cryosections 10 mm thick of whole Drosophila heads were cut
using a Leipzig 1500 cryostat. They were fixed in 4% formal-
dehyde and stained using a 9E10 monoclonal anti-myc
antibody (47) obtained from Dr David Lawrence, IMVS,
Adelaide, Australia at 1:250 dilution. The secondary antibody
used was goat anti-mouse IgG conjugated with Alexa488
(Rockland), at 1:300 dilution. Hoechst 33258 (Sigma) was
used at 10 mg/ml to stain DNA.
Quantitative PCR
To test the expression levels of transgenes, heads of flies
0–24 h old were collected. Trizol (Invitrogen) and the RN
easy mini kit (Qiagen) was used to isolate total RNA, which
was then treated with DNAse I (Invitrogen) and reverse-tran-
scribed with oligo(dT)12–18 and SuperScript II (Invitrogen).
Real-time PCR was carried out in a LightCycler (Roche Mol-
ecular Biochemicals) using primers specific for the repeat-
containing transcript and GAL4-specific primers (forward:
50-CACTGACCCCGTCTGCTTTG-30, and reverse: 50-
GGTTCGGACCGTTGCTACTG-30). The transgene expres-
sion level was quantified using the standard curve method
for relative quantitation and expressed relative to the level
of GAL4 transcript. The expression level of the GMR-GAL4;
UAS(CAG)99 line which shows an eye phenotype was
arbitrarily set at 1, and levels of other lines examined are
expressed as the fold difference relative to this line.
ACKNOWLEDGEMENTS
L.V.O. is the recipient of a Peter Doherty Post-doctoral
Research Fellowship (207830) from the National Health and
Medical Research Council, Australia. C.J.M. is the recipient
of an Australian Postgraduate Award. The authors would
like to thank V. Evci for technical assistance and members
of the Richards lab for their constructive comments on
drafts of this manuscript. This work was supported by a B3
grant from the Faculty of Health Sciences, Adelaide
University, Australia to R.I.R. and by infrastructure support
from the ARC Special Research Centre for the Molecular
Genetics of Development.
REFERENCES
1. La Spada, A.R., Wilson, E.M., Lubahn, D.B., Harding, A.E. and
Fischbeck, K.H. (1991) Androgen receptor gene mutations in X-linked
spinal and bulbar muscular atrophy. Nature, 352, 77–79.
2. Emamian, E.S., Kaytor, M.D., Duvick, L.A., Zu, T., Tousey, S.K.,
Zoghbi, H.Y., Clark, H.B. and Orr, H.T. (2003) Serine 776 of ataxin-1 is
critical for polyglutamine-induced disease in SCA1 transgenic mice.
Neuron, 38, 375–387.
3. Takeyama, K., Ito, S., Yamamoto, A., Tanimoto, H., Furutani, T.,
Kanuka, H., Miura, M., Tabata, T. and Kato, S. (2002)
Androgen-dependent neurodegeneration by polyglutamine-expanded
human androgen receptor in Drosophila. Neuron, 35, 855–864.
4. La Spada, A.R., Fu, Y.H., Sopher, B.L., Libby, R.T., Wang, X., Li, L.Y.,
Einum, D.D., Huang, J., Possin, D.E., Smith, A.C. et al. (2001)
Polyglutamine-expanded ataxin-7 antagonizes CRX function and induces
cone-rod dystrophy in a mouse model of SCA7. Neuron, 31, 913–927.
5. Michalik, A. and Van Broeckhoven, C. (2003) Pathogenesis of
polyglutamine disorders: aggregation revisited. Hum. Mol. Genet., 12,
R173–R186.
6. Kazantsev, A., Walker, H.A., Slepko, N., Bear, J.E., Preisinger, E.,
Steffan, J.S., Zhu, Y.Z., Gertler, F.B., Housman, D.E., Marsh, J.L. et al.
(2002) A bivalent Huntingtin binding peptide suppresses polyglutamine
aggregation and pathogenesis in Drosophila. Nat. Genet., 30, 367–376.
7. Ravikumar, B., Vacher, C., Berger, Z., Davies, J.E., Luo, S., Oroz, L.G.,
Scaravilli, F., Easton, D.F., Duden, R., O’Kane, C.J. et al. (2004)
Inhibition of mTOR induces autophagy and reduces toxicity of
polyglutamine expansions in fly and mouse models of Huntington disease.
Nat. Genet., 36, 585–595.
8. Bowman, A.B., Yoo, S.Y., Dantuma, N.P. and Zoghbi, H.Y. (2005)
Neuronal dysfunction in a polyglutamine disease model occurs in the
absence of ubiquitin–proteasome system impairment and inversely
correlates with the degree of nuclear inclusion formation. Hum. Mol.
Genet., 14, 679–691.
9. Koob, M.D., Moseley, M.L., Schut, L.J., Benzow, K.A., Bird, T.D., Day,
J.W. and Ranum, L.P. (1999) An untranslated CTG expansion causes a
novel form of spinocerebellar ataxia (SCA8). Nat. Genet., 21, 379–384.
10. Holmes, S.E., O’Hearn, E.E., McInnis, M.G., Gorelick-Feldman, D.A.,
Kleiderlein, J.J., Callahan, C., Kwak, N.G., Ingersoll-Ashworth, R.G.,
Sherr, M., Sumner, A.J. et al. (1999) Expansion of a novel CAG
trinucleotide repeat in the 50 region of PPP2R2B is associated with
SCA12. Nat. Genet., 23, 391–392.
11. Holmes, S.E., O’Hearn, E., Rosenblatt, A., Callahan, C., Hwang, H.S.,
Ingersoll-Ashworth, R.G., Fleisher, A., Stevanin, G., Brice, A.,
Potter, N.T. et al. (2001) A repeat expansion in the gene encoding
junctophilin-3 is associated with Huntington disease-like 2. Nat. Genet.,
29, 377–378.
12. Matsuura, T., Yamagata, T., Burgess, D.L., Rasmussen, A., Grewal, R.P.,
Watase, K., Khajavi, M., McCall, A.E., Davis, C.F., Zu, L. et al. (2000)
Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar
ataxia type 10. Nat. Genet., 26, 191–194.








niversity of Adelaide user on 04 July 2019
758
13. Brais, B., Bouchard, J.P., Xie, Y.G., Rochefort, D.L., Chretien, N.,
Tome, F.M., Lafreniere, R.G., Rommens, J.M., Uyama, E., Nohira, O.
et al. (1998) Short GCG expansions in the PABP2 gene cause
oculopharyngeal muscular dystrophy. Nat. Genet., 18, 164–167.
14. Gaspar, C., Jannatipour, M., Dion, P., Laganiere, J., Sequeiros, J.,
Brais, B. and Rouleau, G.A. (2000) CAG tract of MJD-1 may be prone
to frameshifts causing polyalanine accumulation. Hum. Mol. Genet., 9,
1957–1966.
15. Brook, J.D., McCurrach, M.E., Harley, H.G., Buckler, A.J., Church, D.,
Aburatani, H., Hunter, K., Snell, R.G., Rundel, S., Crow, S. et al. (1992)
Molecular basis of myotonic dystrophy: expansion of a trinucleotide
(CTG) repeat at the 30 end of a transcript encoding a protein kinase family
member. Cell, 68, 799–808.
16. Liquori, C.L., Ricker, K., Moseley, M.L., Jacobsen, J.F., Kress, W.,
Naylor, S.L., Day, J.W. and Ranum, L.P. (2001) Myotonic dystrophy type
2 caused by a CCTG expansion in intron 1 of ZNF9. Science, 293,
864–867.
17. Ranum, L.P. and Day, J.W. (2004) Myotonic dystrophy: RNA
pathogenesis comes into focus. Am. J. Hum. Genet., 74, 793–804.
18. Michalowski, S., Miller, J.W., Urbinati, C.R., Paliouras, M., Swanson,
M.S. and Griffith, J. (1999) Visualization of double-stranded RNAs from
the myotonic dystrophy protein kinase gene and interactions with
CUG-binding protein. Nucleic Acids Res., 27, 3534–3542.
19. Miller, J.W., Urbinati, C.R., Teng Umnuay, P., Stenberg, M.G.,
Byrne, B.J., Thornton, C.A. and Swanson, M.S. (2000) Recruitment of
human muscleblind proteins to (CUG)(n ) expansions associated with
myotonic dystrophy. EMBO J., 19, 4439–4448.
20. Timchenko, N.A., Cai, Z.J., Welm, A.L., Reddy, S., Ashizawa, T. and
Timchenko, L.T. (2001) RNA CUG repeats sequester CUGBP1 and alter
protein levels and activity of CUGBP1. J. Biol. Chem., 276, 7820–7826.
21. Jiang, H., Mankodi, A., Swanson, M.S., Moxley, R.T. and Thornton, C.A.
(2004) Myotonic dystrophy type 1 is associated with nuclear foci of
mutant RNA, sequestration of muscleblind proteins and deregulated
alternative splicing in neurons. Hum. Mol. Genet., 13, 3079–3088.
22. Charlet, B.N., Savkur, R.S., Singh, G., Philips, A.V., Grice, E.A. and
Cooper, T.A. (2002) Loss of the muscle-specific chloride channel in
type 1 myotonic dystrophy due to misregulated alternative splicing. Mol.
Cell, 10, 45–53.
23. Mankodi, A., Urbinati, C.R., Yuan, Q.P., Moxley, R.T., Sansone, V.,
Krym, M., Henderson, D., Schalling, M., Swanson, M.S. and
Thornton, C.A. (2001) Muscleblind localizes to nuclear foci of aberrant
RNA in myotonic dystrophy types 1 and 2. Hum. Mol. Genet., 10,
2165–2170.
24. Savkur, R.S., Philips, A.V., Cooper, T.A., Dalton, J.C., Moseley, M.L.,
Ranum, L.P. and Day, J.W. (2004) Insulin receptor splicing alteration in
myotonic dystrophy type 2. Am. J. Hum. Genet., 74, 1309–1313.
25. Hagerman, R.J., Leehey, M., Heinrichs, W., Tassone, F., Wilson, R.,
Hills, J., Grigsby, J., Gage, B. and Hagerman, P.J. (2001) Intention tremor,
parkinsonism, and generalized brain atrophy in male carriers of fragile
X. Neurology, 57, 127–130.
26. Jin, P., Zarnescu, D.C., Zhang, F., Pearson, C.E., Lucchesi, J.C.,
Moses, K. and Warren, S.T. (2003) RNA-mediated neurodegeneration
caused by the fragile X premutation rCGG repeats in Drosophila. Neuron,
39, 739–747.
27. Orr, H.T. (2004) RNA gains a new function: a mediator of
neurodegeneration. Trends Neurosci., 27, 233–234.
28. Peel, A.L., Rao, R.V., Cottrell, B.A., Hayden, M.R., Ellerby, L.M. and
Bredesen, D.E. (2001) Double-stranded RNA-dependent protein kinase,
PKR, binds preferentially to Huntington’s disease (HD) transcripts and is
activated in HD tissue. Hum. Mol. Genet., 10, 1531–1538.
29. Sobczak, K., de Mezer, M., Michlewski, G., Krol, J. and Krzyzosiak, W.J.
(2003) RNA structure of trinucleotide repeats associated with human
neurological diseases. Nucleic Acids Res., 31, 5469–5482.
30. Michlewski, G. and Krzyzosiak, W.J. (2004) Molecular architecture of
CAG repeats in human disease related transcripts. J. Mol. Biol., 340,
665–679.
31. Warrick, J.M., Paulson, H.L., Gray Board, G.L., Bui, Q.T.,
Fischbeck, K.H., Pittman, R.N. and Bonini, N.M. (1998) Expanded
polyglutamine protein forms nuclear inclusions and causes neural
degeneration in Drosophila. Cell, 93, 939–949.
32. Jackson, G.R., Salecker, I., Dong, X., Yao, X., Arnheim, N., Faber, P.W.,
MacDonald, M.E. and Zipursky, S.L. (1998) Polyglutamine-expanded
human huntingtin transgenes induce degeneration of Drosophila
photoreceptor neurons. Neuron, 21, 633–642.
33. Marsh, J.L., Walker, H., Theisen, H., Zhu, Y.Z., Fielder, T., Purcell, J. and
Thompson, L.M. (2000) Expanded polyglutamine peptides alone are
intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum.
Mol. Genet., 9, 13–25.
34. Brand, A.H. and Perrimon, N. (1993) Targeted gene expression as a
means of altering cell fates and generating dominant phenotypes.
Development, 118, 401–415.
35. Ellis, M.C., O’Neill, E.M. and Rubin, G.M. (1993) Expression of
Drosophila glass protein and evidence for negative regulation of its
activity in non-neuronal cells by another DNA-binding protein.
Development, 119, 855–865.
36. Spradling, A.C. and Rubin, G.M. (1983) The effect of chromosomal
position on the expression of the Drosophila xanthine dehydrogenase
gene. Cell, 34, 47–57.
37. Kazemi-Esfarjani, P. and Benzer, S. (2000) Genetic suppression of
polyglutamine toxicity in Drosophila. Science, 287, 1837–1840.
38. Valencia-Sanchez, M.A. and Maquat, L.E. (2004) An enemy within: fly
reconnaissance deploys an endonuclease to destroy nonsense-containing
mRNA. Trends Cell Biol., 14, 594–597.
39. Goldberg, Y.P., Kalchman, M.A., Metzler, M., Nasir, J., Zeisler, J.,
Graham, R., Koide, H.B., O’Kusky, J., Sharp, A.H., Ross, C.A., et al.
(1996) Absence of disease phenotype and intergenerational stability of the
CAG repeat in transgenic mice expressing the human Huntington disease
transcript. Hum. Mol. Genet., 5, 177–185.
40. Bingham, P.M., Scott, M.O., Wang, S., McPhaul, M.J., Wilson, E.M.,
Garbern, J.Y., Merry, D.E. and Fischbeck, K.H. (1995) Stability of an
expanded trinucleotide repeat in the androgen receptor gene in transgenic
mice. Nat. Genet., 9, 191–196.
41. Klement, I.A., Skinner, P.J., Kaytor, M.D., Yi, H., Hersch, S.M., Clark,
H.B., Zoghbi, H.Y. and Orr, H.T. (1998) Ataxin-1 nuclear localization and
aggregation: role in polyglutamine-induced disease in SCA1 transgenic
mice. Cell, 95, 41–53.
42. Burright, E.N., Clark, H.B., Servadio, A., Matilla, T., Feddersen, R.M.,
Yunis, W.S., Duvick, L.A., Zoghbi, H.Y. and Orr, H.T. (1995) SCA1
transgenic mice: a model for neurodegeneration caused by an expanded
CAG trinucleotide repeat. Cell, 82, 937–948.
43. Warrick, J.M., Chan, H.Y., Gray Board, G.L., Chai, Y., Paulson, H.L. and
Bonini, N.M. (1999) Suppression of polyglutamine-mediated
neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat.
Genet., 23, 425–428.
44. Muchowski, P.J. and Wacker, J.L. (2005) Modulation of
neurodegeneration by molecular chaperones. Nat. Rev. Neurosci., 6,
11–22.
45. Mutsuddi, M., Marshall, C.M., Benzow, K.A., Koob, M.D. and Rebay, I.
(2004) The spinocerebellar ataxia 8 noncoding RNA causes
neurodegeneration and associates with staufen in Drosophila. Curr. Biol.,
14, 302–308.
46. Takahashi, N., Sasagawa, N., Suzuki, K. and Ishiura, S. (1999) Synthesis
of long trinucleotide repeats in vitro. Neurosci. Lett., 262, 45–48.
47. Evan, G.I., Lewis, G.K., Ramsay, G. and Bishop, J.M. (1985) Isolation of
monoclonal antibodies specific for human c-myc proto-oncogene product.
Mol. Cell Biol., 5, 3610–3616.








niversity of Adelaide user on 04 July 2019
759
Contribution of mGluR and Fmr1 functional
pathways to neurite morphogenesis, craniofacial
development and fragile X syndrome
Ben Tucker*, Robert I. Richards and Michael Lardelli
ARC Special Research Center for the Molecular Genetics of Development and Discipline of Genetics, School of
Molecular and Biomedical Science, The University of Adelaide, South Australia 5005, Australia
Received August 30, 2006; Revised and Accepted October 23, 2006
Fragile X Syndrome is a leading heritable cause of mental retardation that results from the loss of FMR1 gene
function. Studies in mouse and Drosophila model organisms have been critical in understanding many
aspects of the loss of function of the FMR1 gene in the human syndrome. Here, we establish that the zebra-
fish is a useful model organism for the study of the human fragile X syndrome and can be used to examine
phenotypes that are difficult or inaccessible to observation in other model organisms. Using morpholino
knockdown of the fmr1 gene, we observed abnormal axonal branching of Rohon–Beard and trigeminal
ganglion neurons and guidance and defasciculation defects in the lateral longitudinal fasciculus. We demon-
strate that this axonal branching defect can be rescued by treatment with MPEP [2-methyl-6-(phenylethynyl)
pyridine]. This is consistent with an interaction between mGluR signalling and fmr1 function in neurite mor-
phogenesis. We also describe novel findings of abnormalities in the abundance of trigeminal ganglion neur-
ons and of craniofacial abnormalities apparently due to dysmorphic cartilage formation. These abnormalities
may be related to a role for fmr1 in neural crest cell specification and possibly in migration.
INTRODUCTION
Fragile X syndrome is the most common form of inherited
mental retardation. The degree of mental retardation is moder-
ate to severe and tends to be worse in males. Behavioural
abnormalities of fragile X syndrome include developmental
delays, hyperactivity, anxiety and autistic behaviours (1,2).
Craniofacial abnormalities in adolescent and adult patients
include a long thin face with prominent ears, facial asymme-
try, a large head circumference and a prominent forehead
and jaw. Common peripheral symptoms include heightened
sensitivity to tactile irritation.
Fragile X syndrome is caused by the absence of the RNA
binding protein fragile X mental retardation protein (FMRP)
(3). Loss of the FMRP is due to a trinucleotide repeat expan-
sion in the 50-UTR of the FMR1 gene. FMR1 is involved in the
control of protein synthesis and FMRP shuttles from the
nucleus to the cytoplasm as an mRNP particle (4). It appears
that FMRP represses translation of its target mRNAs (5–7),
and it may be alleviation of this repression by FMRP loss
that leads to the syndrome. FMRP target mRNAs include
those of microtubule-associated protein 1B (MAP1B), the
FMR1 message itself, FMR1-related genes, FXR1 and FXR2,
as well as a number of other mRNAs involved in neuronal
development, plasticity/maturation of synapses and calcium
regulation (8–11).
Although fragile X syndrome is not associated with specific
brain malformations or neurodegeneration, a subtle neuronal
defect has been found in dendritic spines which exhibit a
long, spindly ‘immature’ morphology in pyramidal cells of
the cortex of fragile X syndrome patients (12,13). This pheno-
type has been recapitulated in a mouse model (14), along with
enhanced long-term depression (LTD) in the hippocampus.
LTD is a result of increased activity of the metabotropic glu-
tamate receptor (mGluR) group I type 5 (15). This receptor
alters FMRP levels at the synapse and is associated with a
protein-synthesis-dependent lengthening of dendritic spines
(16,17).
Dendritic spines are actin-rich structures. It has been
suggested that an interaction between the FMRP and the
Rac1 pathway, which is known to regulate actin dynamics,
may be related to FMR1 loss-of-function synaptic defects
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(18,19). The Rac1 pathway has been linked to FMRP in a
study of higher order neurite morphogenesis (20) through
knockdown of the Drosophila dfmr1 (dfxr) gene. Lee et al.
(20) described an increased level of dendritic branching in
Drosophila dendritic arborizing neurons lacking dFmrp.
These neurons branch more frequently than normal, whereas
overexpression of dfmr1 leads to a reduction in the level of
branching. Furthermore, they demonstrated that overexpres-
sion of Rac1 causes an increase in branching and this can
rescue the effects of dfmr1 overexpression (20).
Mouse models have been generated, which recapitulate
several behavioural and physical characteristics of fragile X
syndrome, including hyperactivity and macroorchidisim
(21,22). There has been no report of neurite branching
abnormalities in fragile X syndrome patients or in a mouse
model, and it has been suggested that such effects may be
masked in vertebrates by redundant function from the pre-
sence of FMRP-related proteins, FXR1 and FXR2 (19,23).
The zebrafish fmr1 gene family has been identified and its
expression pattern described (24–26). The zebrafish has ortho-
logues of all three FMR1-related genes, suggesting that any
masking or redundancy of FMRP function by related proteins
in mouse or human will be replicated in a fish model of the
syndrome. Studies in zebrafish may thus be more relevant to
understanding the human syndrome than those in Drosophila.
The enhanced mGluR activity in the brains of Fmr1 knock-
out mice, as well as the connection between mGluR signalling
and human/mouse fragile X syndrome-related behavioural
phenotypes, suggests that inappropriate mGluR signalling is
the cause of at least part of the disease phenotype (27).
Pharmacological treatment with an mGluR5-specific antagon-
ist MPEP [2-methyl-6-(phenylethynyl)pyridine] has recently
been shown to rescue some behavioural defects in knockout
mice (28). It can rescue behavioural and mushroom body
defects in Drosophila lacking dfmr1 activity.
In this study, we establish the zebrafish embryo as a model
for fmr1 loss-of-function analysis. Morpholino antisense oli-
gonucleotide repression of fmr1 mRNA translation in zebra-
fish embryos is observed to produce changes in neurons and
in neurite branching in the central and peripheral nervous
systems that are not masked by the partially redundant activi-
ties of fxr1 and fxr2. Modulation of mGluR signalling can
rescue these neurite branching defects. We propose a model
for the interaction of Fmr1 and mGluR in control of axonal
branching, guidance and fasciculation that has implications
for the synaptic morphology component of fragile X syn-
drome. We also show the effects of fmr1 expression on trigem-
inal neuron number and craniofacial pattern, which suggest a




Zebrafish were bred and maintained under standard conditions
at 28.58C (29). Morphological features were used to determine
the stage of the embryos in hours (hpf) or days (dpf) post-
fertilization according to Kimmel et al. (30).
Morpholinos
For transient knockdown of gene expression, morpholino anti-
sense oligomers (morpholinos, MO; GeneTools, LLC) were
prepared to target and inhibit the translation of fmr1 mRNA.
Two non-overlapping morpholinos were designed targeting
endogenous fmr1 transcript, fmr1MOA (50-agctcgtccatgacg
ccagtaattt-30) and fmr1MOB (50-cgcgctttctatttcacgcagcggt-30).
A standard control morpholino (ControlMO; GeneTools,
LLC) was used to control for morpholino injection-specific
effects. All morpholinos were diluted in E3 solution (29).
In initial experiments, fmr1MOA and fmr1MOB were
injected individually and were compared with embryos
injected with a standard control morpholino (ControlMO).
An initial titration of the anti-fmr1MOs was conducted,
based on observed gross morphological defects and mortality.
These experiments suggested an appropriate fmr1MOA to
fmr1MOB ratio, based on their relative optimal concentration.
Both morpholinos were then co-injected at this ratio and
titrated again to find the optimal injection protocol. The con-
centration used for complete knockdown was equal part of
0.5 mM fmr1MOA and 0.6 mM fmr1MOB (final concentration
0.25 mM fmr1MOA and 0.3 mM fmr1MOB) and embryos were
injected with a total of !5 nl/embryo. Standard control mor-
pholino was injected as a control at a concentration of
0.55 mM. The rationale is that reduction of individual morpho-
lino concentration as much as possible while retaining com-
plete knockdown is preferable to injection of higher
concentrations of a single morpholino. Efficacy may be
improved by having multiple sites on a particular mRNA
recognized by morpholinos as opposed to a single site.
Secondly, low concentrations of morpholinos with non-
overlapping sequences should have less sequence-related
non-specific defects than injection of a single sequence mor-
pholino at higher concentrations. As individual injections of
fmr1MOA at 0.25 mM and of fmr1MOB at 0.3 mM are not dis-
tinguishable from normal or ControlMO injection, it can be
inferred that non-specific defects (if any) are not morpholino
sequence specific.
As fmr1 mRNA has previously been found to be maternally
expressed, all morpholino injections were performed at
one-cell stage, and injections into later cell stages resulted in
incomplete knockdown (data not shown).
MPEP treatment
After injection, MPEP-treated embryos were developed in
250 ng/ml MPEP dissolved in E3 embryo medium (29).
Western blot
For western blot analyses, 10 dechorionated embryos for each
condition (24 hpf) were directly homogenized in SDS lysis
buffer (63 mM Tris–HCl, pH 6.8, 10% glycerol, 5%
b-mercaptoethanol, 3.5% sodium dodecyl sulphate) and sub-
jected to SDS–PAGE (29). Lysate was probed against a poly-
clonal mouse anti-Fmrp antibody (Abnova). The membrane
was then stripped and probed with b-tubulin as a loading
control (Fig. 1A). The final concentrations used were
fmr1MO 0.25 mM A/0.3 mM B.
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For comparison, also shown are extracts from embryos
co-injected with either of !5 nl/embryo fmr1MO 0.125 mM
A/0.15 mM B or fmr1MO 0.05 mM A/0.06 mM B. A graphical
representation of the ratio of Fmr1 to b-tubulin signal is also
shown (Fig. 1B).
mRNA and bilateral injections
Rescue of fmr1 activity by fmr1 mRNA injection is discussed
here. Full-length fmr1 cDNA lacking morpholino complemen-
tarity was subcloned into the PCS2þ vector (26). Capped
mRNA was synthesized from the construct using mMES-
SAGE mMACHINE (Ambion) according to the manufac-
turer’s instructions. The synthesized mRNA and fmr1MOs
were simultaneously injected into the one-cell stage
embryos. This resulted in rescue of abnormalities caused by
fmr1MO injection. In order to demonstrate the rescue with
an internal control, bilateral injections were conducted.
Embryos injected with fmr1MO at one-cell stage were sub-
sequently co-injected with fmr1 mRNA and high molecular
weight tetramethylrhodamine dextran (Molecular Probes) to
mark cell lineage into one-cell of a two-cell stage embryo.
fmr1MO and fmr1 mRNA injections were separated by
approximately half an hour. All embryos were then stained
for dlx-2a or fgfr1 marker genes to illustrate bilateral differ-
ences, and these embryos were photographed in 80% glycerol
using a Fujix HC-1000 camera attached to a Zeiss Axiophot
microscope.
Whole-mount in situ hybridization
Whole-mount in situ transcript hybridization was performed as
described by Jowett (31) using single-stranded RNA probes
labelled with digoxigenin-UTP (Roche Ltd, Basel, Switzer-
land) according to the manufacturers’ protocols. Probes
against axial, dlx-1a, dlx-2a, dlx-4a, emx1, emx3, fgfr1, hlx1,
lim1, otx2, pax6 and wnt1 transcripts were synthesized from
cDNA clones using T7 or T3 RNA polymerase as appropriate.
Stained embryos were photographed in 80% glycerol follow-
ing fixation using a Fujix HC-1000 camera attached to a
Zeiss Axiophot microscope.
Antibody stains
For whole-mount immunohistochemistry, embryos were fixed
in 4% formaldehyde overnight, incubated at 658C in FST sol-
ution overnight (50% formamide, 2 " SSC, 0.1% Tween-20),
washed in PBT, blocked in ABS (PBS containing 2% DMSO,
0.1% IGEPAL, 2% horse serum, 2% BSA, 0.1% Tween) and
incubated overnight in the monoclonal antibody ZN-12
(1:200; Zebrafish International Resource Center, Eugene,
OR, USA) or anti-acetylated a-tubulin (1:1500; Sigma,
St Louis, MO, USA). Primary antibody was washed off in
ABS, and embryos were incubated overnight in donkey anti-
mouse secondary antibody conjugated to Alexa-488 (4 mg/
ml; Molecular Probes, Eugene, OR, USA). Embryos were
imaged with a Leica SP5 spectral scanning confocal micro-
scope and Leica LAS AF software, or with a Zeiss Axioplan
2 microscope with a Zeiss ApoTome attachment. Images
were taken with a Zeiss AxioCamMR camera and analysed
with Zeiss AxioVision V4.5 software. Image analysis was
conducted using the NeuronJ plugin (32) through National
Institutes of Health (NIH) ImageJ software.
Whole-mount Alcian blue skeletal stainings
Alcian blue-stained cartilage preparations were prepared
according to Neuhauss et al. (33) and were imaged in 80%
glycerol. Images taken with a Fujix HC-1000 camera attached
to a Zeiss Axiophot microscope and were analysed with Zeiss
AxioVision V4.5 software.
RESULTS
Anti-fmr1 morpholino design, validation and initial
characterization
Fragile X syndrome is caused by expansion of a 50-UTR trinu-
cleotide repeat sequence in the FMR1 gene that silences gene
transcription, resulting in the loss of FMRP. To model this in
zebrafish embryos, we inhibited translation of the mRNA of
the zebrafish FMR1 orthologue, fmr1 (GenBank accession
no. AF305882), by injection of morpholino antisense oligonu-
cleotides (MO). Two non-overlapping morpholinos were
synthesized with binding sites spanning a region of the fmr1
50-UTR and the start codon ( fmr1MOA and fmr1MOB). To
confirm the specificity and efficacy of the morpholinos, a
number of control experiments were conducted (see also
Materials and Methods; Supplementary Material, Fig. S1).
The morpholinos were injected at various concentrations
either individually or in combination. A mixture of 0.25 mM
fmr1MOA and 0.3 mM fmr1MOB was found to be the
minimum concentration at which zebrafish Fmr1 protein
Figure 1. Injection of a combination of anti-fmr1MOs greatly reduces protein
level of Fmr1. A minimal concentration (0.25A/0.3B) of fmr1MO was used to
achieve significant knockdown. (A) Western blot analysis of whole zebrafish
extract (24 hpf). Fmr1 detected by a mouse anti-Fmrp antibody and b-tubulin
antibody. Embryos were co-injected with a combination of two non-
overlapping anti-fmr1MOs ( fmr1MOA and fmr1MOB). For comparison,
also shown are extracts from embryos co-injected with 0.125A/0.15B and
0.05A/0.06B. (B) Ratio of anti-Fmr1 signal to anti-b-tubulin signal, expressed
graphically.
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expression was completely suppressed (Fig. 1) as assayed by
western blotting using a mouse antibody against human
FMRP (Abnova). This concentration was subsequently used
throughout this study and is henceforth referred to as an
‘fmr1MO’ injection.
Gross morphological phenotypes resulting from fmr1MO
injection were analysed (Fig. 2). fmr1MO causes morphological
changes in the midbrain/hindbrain boundary (47/60; MHB) and a
distinctive lack of organization in the brain (Fig. 2A and B). By
24 hpf, the anterior extension of the head appears incomplete in
some embryos (13/60; Fig. 2E and F). At 48 hpf, some
embryos display expanded brain ventricles and/or pericardial
oedema (6/60). This is generally subtle in nature (Fig. 2C and D).
At the molecular level, fmr1MO injection causes an altered
pattern of transcription of the ventral telencephalon/dience-
phalon marker dlx-2a (17/30; Fig. 3B and D) relative to
those injected with controlMO (0/30; Fig. 3A and C).
Expression of the MHB marker fgfr1 is also perturbed (11/
30; Fig. 3G) relative to controlMO-injected embryos (0/30;
Fig. 3F). Whole-mount in situ hybridization with axial
reveals an occasional axial defect (3/30; Fig. 2E and F).
To confirm that the neural defects caused by fmr1MO injection
result specifically from suppression of fmr1 activity, we
attempted the rescue of the defects by co-injection with an fmr1
mRNA modified to lack fmr1MO binding sites. Co-injection of
modified fmr1mRNA and fmr1MO at the one-cell stage results
in phenotypically normal embryos (dlx-2a 28/30; fgfr1 30/30).
This rescue was confirmed by injection of embryos first at the
one-cell stage with fmr1MO and subsequently unilaterally at
the two-cell stage with a mixture of modified fmr1 mRNA and
the lineage tracer tetramethyl-rhodamine dextran (MW
2 000 000). Unilateral injection of mRNA into one-cell of the
two-cell stage embryo allows for one side of the embryo to
display the mRNA rescue and for the other side of the embryo
to act as an internal control for this rescue. Whole-mount in
situ transcript hybridization was then used to reveal expression
of dlx-2a and fgfr1 (Fig. 3). dlx-2a expression appeared normal
in the mRNA-injected half but was reduced in the half lacking
modified fmr1 mRNA (13/30; Fig. 3E). In the MHB, fgfr1 is per-
turbed in fmr1MO-injected embryos (11/30; Fig. 3G) compared
with normal/controlMO-injected embryos (0/30; Fig. 3F).
Neurite morphology is altered by the loss of fmr1 and
can be returned to normal by MPEP
A number of reports have demonstrated a link between neurite
morphogenesis or synaptogenesis and the function of FMRP in
mouse, humans (14,34,35) and Drosophila (19,20,35–40).
Many of these studies focus on the role of FMRP in post-
synaptic sites and dendritic spines.
Recent findings have been made in Drosophila regarding
neurite growth/branching defects. Lee et al. (20), Michel
et al. (37), Morales et al. (38) and Pan et al (39). reported
the possibility of different functions of Drosophila dFmrp in
different neurons. Recently, suppression of mouse
FMRP-related behavioural phenotypes (28,41) and Drosophila
synaptic/mushroom body fusion defects (41) has been
achieved through use of the mGluR antagonist, MPEP.
These studies suggest that fragile X syndrome is a conse-
quence of exaggerated response to mGluR activation
(27,28,41). Here, we examine whether the loss of fmr1 func-
tion affects neurite morphogenesis, whether this can be
rescued in vertebrates using MPEP and whether the effects
of MPEP alone are equivalent to ectopic expression of fmr1
mRNA.
To determine whether change in fmr1 expression affects
neurite morphogenesis, we stained 24 hpf embryos with the
monoclonal antibody zn12, which marks a subset of neurons
including Rohon–Beard (RB) primary sensory neurons in
the developing spinal cord and neurons of the trigeminal
ganglion (Fig. 4). In embryos with reduced Fmr1 protein
expression due to fmr1MO injection, we found a highly
Figure 2. Description of gross morphological defects associated with fmr1MO injection. (A–F) Gross morphological defects resulting from co-injection
of fmr1MOs compared with control-injected embryos. (A–F) Lateral view, dorsal is to the top, anterior to left. (A and B) MHB (arrow) is disrupted in
fmr1MO-injected embryos (47/60) compared with control-injected embryos (2/60). The forebrain and hindbrain ventricle also appears disrupted in these
embryos (arrowheads), 24 hpf. (C and D) At stages from 36 hpf onwards, hydrocephaly (arrow) is occasionally observed in some fmr1MO-injected embryos, as
is pericardial oedema (arrowhead), 36 hpf. (E and F) Whole-mount in situ hybridization for axial gene transcription in 24 hpf zebrafish embryos. Uncommon axis
defects (black arrowhead; n ¼ 3/30) and incomplete extension (white arrows) tend to manifest in severely effected fmr1MO-injected embryos. Yolk extension
defects have also been observed (black arrows). Scale bars (A and B), 200 mM; (C and D), 200 mM; (E and F), 200 mM.
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statistically significant 2-fold increase in neurite branching in
RB neurons (Fig. 4C; P , 0.001) and a similar increase in
neurite branch terminations, suggesting that branches are gen-
erally shorter (42). An 8-fold increase in rare axon-guidance
defects was also observed ( fmr1MO-injected embryos: 0.16
guidance defects/mm neurite length; controlMO-injected
embryos: 0.02 guidance defects/mm neurite length).
Having established a clear and measurable neurite morpho-
logical phenotype, we then attempted to rescue this mor-
phology by antagonizing mGluR function with MPEP
(Fig. 4B). Treatment of fmr1MO-injected embryos with
MPEP resulted in a normal/controlMO phenotype
(P , 0.751), suggesting that mGluR function is responsible
for branching defects in the absence of Fmr1.
To examine the relationship between mGluR and Fmr1
further, we examined the effect on neurite morphogenesis of
MPEP treatment alone and of ectopic/overexpression of
Fmr1 following mRNA injection (Fig. 4D and E). Both
these treatments resulted in simplification of neurite branching
(P , 0.001; P , 0.001) and reduction in branch termination.
This suggests that Fmr1 function influences neurite morpho-
genesis by facilitating mGluR signalling.
Extending our analysis to cells of the PNS, we examined the
elaborately arborizing axons of the trigeminal ganglion neurons
that make up part of the facial motor and sensory system
(Fig. 4H–N). The effects of reduction or overexpression of
fmr1 and of MPEP treatment were similar to those seen for
RB neurons (Fig. 4A–G), suggesting that fmr1 function is con-
sistent between, at least, these two neuronal populations.
Guidance defects were difficult to examine in neurites of
the trigeminal ganglia, although such defects were identified
in neurites projecting from the RB neurons. A search for
other axon-guidance morphological defects resulted in the
identification of a role for fmr1 in neurons in the placode
that gives rise to the lateral longitudinal fasciculus (Fig. 5).
To examine functions of fmr1 in the lateral longitudinal fas-
ciculus, we stained injected embryos with antibodies against
a-acetylated tubulin at 5 dpf. In fmr1MO-injected embryos,
we occasionally observed a dramatic axon defect (3/30;
Fig. 5E). A more frequent phenotype of apparent axon defas-
ciculation was also found (13/30; controlMO-injected 0/30;
Fig. 5C, D and F). This appears initially as a termination of
the lateral longitudinal fasciculus anterior to its normal termin-
ation site in the posterior of the tail generally before this
reaches the posterior limit of the yolk extension. In contrast,
in normal or control embryos, termination of the lateral longi-
tudinal fasciculus occurs in the extreme posterior tail (Fig. 5A
and B). Examination of the site of termination of the lateral
longitudinal fasciculus leads to the identification of individual
axons separating from the fasciculus (Fig. 5F).
A role for fmr1 in cranial neural crest specification and
possibly migration
In addition to mental retardation, the characteristic phenotype
of fragile X syndrome includes mild craniofacial anomalies
such as a long face and prominent jaws (2). Observation of
fmr1MO-injected fish has revealed defects in the craniofacial
structure possibly related to those described in the syndrome
(9/15; controlMO-injected 0/15; Fig. 6A and B). The defect
is not prominent until 5 dpf when cartilage has formed. We
performed an Alcian blue staining for cartilage (43,44) and
found that Meckels’ cartilage was specifically affected.
Meckels’ cartilage is both shorter (AP; P , 0.001;
Fig. 6E–H) and wider (laterally; P , 0.05; Fig. 6F and G)
in fmr1MO embryos than in normal/controlMO-injected
Figure 3. Defects associated with injection of fmr1MO can be rescued by injection of fmr1 mRNA and can largely be rescued unilaterally in accordance with
unilateral injection of fmr1 mRNA. (A–E) Whole-mount in situ hybridization for dlx-2a. (A and B) Lateral view, anterior to left, dorsal to top. (C–E) Dorsal
view, anterior to left. (A and B) Expression of dlx-2a in ventral telencephalon and ventral diencephalon is disrupted by injection of fmr1MO compared with
controlMO-injected embryos. (C–E) Dorsal view of dlx-2a expression in telencephalon/diencephalon. (E) Unilateral injection of modified fmr1 mRNA and
a high molecular weight rhodamine dextran marker (at two-cell stage) into fmr1MO-injected embryos. mRNA-injected side is marked here with an asterix.
dlx-2a expression in the telencephalon/diencephalon is unilaterally rescued. (E0) Cartoon illustrating unilateral asymmetry in (E). fmr1MO side ventral telence-
phalon (green) is abnormal compared with fmr1MO and fmr1mRNA-injected side ventral telencephalon (red). Injection of fmr1 mRNA at one-cell stage resulted
in the rescue of dlx-2a expression (data not shown). Scale bars (A and B), 200 mM; (C–E), 100 mM.
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Figure 4. Neurites of RB and trigeminal ganglion neurons tend to branch and terminate more frequently in embryos injected with fmr1MO than in
controlMO-injected embryos and less frequently in embryos injected with fmr1 mRNA or treated with MPEP. The phenotype caused by injection with
fmr1MO can be rescued with MPEP. (A–E) Lateral view, anterior to left, dorsal to top. (H–L) Dorsal view, anterior to left. Fluorescence imaging of RB
and trigeminal ganglion neurons and neurites in embryos stained with the zn12 antibody at 24 hpf. All measurements were taken from the same area of neurites:
(A–E) covering the yolk extension, at the posterior end of the yolk extension and (H–L) covering the region immediately anterior to the trigeminal ganglion.
Red box indicates 90 " 90 mM2 working area represented in (A0 –E0) or 100 " 100 mM2 working area represented in (H0 –L0). (A, A0, H and H0)
ControlMO-injected embryos. (B, B0, I and I0) fmr1MO-injected embryos rescued by the application of MPEP. (C, C0, J and J0) fmr1MO-injected embryos.
(D, D0, K and K0) ControlMO-injected embryos exposed to MPEP. (E, E0, L and L0) fmr1 mRNA-injected embryos. No significant differences in the number
of RB neurons were found between treatments, but significant variations were found in the number of trigeminal neurons between treatments (Fig. 7). (A0 –
E0 and H0 –L0) Tracings of neurites in the working area. Tracings were made using the NeuronJ plugin (32) for National Institutes of Health (NIH) ImageJ soft-
ware. (F and M) Branching frequencies per unit length neurite expressed graphically. (G and N) Termination frequencies per unit length neurite expressed
graphically. (F, G, M and N) Significance analysed using Student’s t-test for unpaired samples. # denotes significance at P , 0.05, ## denotes significance at
P , 0.01 and ### denotes significance at P , 0.001. Error shown is the SEM. (n ¼ 10 for each treatment; scale bars 50 mM).
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embryos. A minority of embryos were more severely affected as
far posterior as the ceratobranchial arches (2/60; Fig. 6J).
Two very consistent abnormalities are found in the angles
between individual cartilage components in fmr1MO-injected
embryos. First, the angle between ceratobranchial/ceratohyal
arch cartilage and basibranchial/hyal cartilage tends to be
less acute in fmr1MO-injected embryos than in normal/
controlMO-injected embryos. (Fig. 6F and G). Secondly, the
angle that Meckels’ cartilage makes with the rostrocaudal
axis (Fig. 6C and D) is also less acute in fmr1MO-injected
embryos than in normal/controlMO-injected embryos
(P , 0.001). This phenotype is subtle compared with many
other craniofacial defects found in fish (33,45–49).
Figure 6. Craniofacial defects in fmr1MO-injected embryos and in embryos
treated with MPEP appear to be connected with perturbation of underlying
cartilage. This is connected to a variety of non-specific effects that contribute
to an overall abnormal morphology that is difficult to measure, possibly reca-
pitulating ‘syndromic appearance’ of fragile X patients. (A–E, I and J) Lateral
view, anterior to left, dorsal to top. (F–H) Ventral view, anterior to left. (A
and B) Nomarski optics. (C–H) Brightfield; Alcian blue-labelled. (I and J)
Fluorescent analysis of injected embryos stained with antibodies against
a-acetylated tubulin. (A and B) Embryos treated with fmr1MO and MPEP
exhibit distinct craniofacial abnormalities, appearing in both conditions as
shortening of the length of the head and variation in ventral morphology. A
number of non-specific abnormalities are common. fmr1MO-treated
embryos tend to be more severely affected. (C–H) This variation in mor-
phology appears to be related consistently to alteration in the morphology
of Meckles’ cartilage (anterior limit denoted by arrowhead) and also to the
angle Meckels’ cartilage makes with the AP axis. (C–E) Frequency of
reduction in the anterior extension of Meckle’s cartilage is quite consistent
in fmr1MO-injected embryos (12/15; ControlMO-injected 0/15; length differ-
ence fmr1MO/ControlMO P , 0.0001), but is also found to a lesser extent and
greater variation in MPEP-treated embryos (8/15; length difference MPEP/
ControlMO P , 0.05). (F–H) Width (lateral extension) of Meckels’ cartilage
is consistently greater in fmr1MO-injected embryos than either MPEP-treated
(0/15; width difference fmr1MO/MPEP P , 0.05) or ControlMO- injected (9/
15; width difference fmr1MO/ControlMO P , 0.001) embryos. Length and
width of Meckels’ cartilage are indicated by parallel lines. (H) Rarely, very
severely affected embryos may exhibit variations in cartilage as far posterior
as the fifth ceratobranchial arch (2/30). (I and J) Craniofacial abnormalities
also appear to be linked to a reduction in innervation of the face by cranial
nerves (arrow). cb, ceratobranchial; ch, ceratohyal; hs, hyosymplectic; m,
Meckel’s; pq, palatoquadrate cartilage (46). Scale bar 200 mM.
Figure 5. The lateral longitudinal fasciculus is affected by injection of
fmr1MO. Axons contributing to the fasciculus often defasciculate at a much
anterior location compared with ControlMO-injected embryos. A canonical
axon-guidance defect is also observed. (A–F) Fluorescent analysis of Con-
trolMO or fmr1MO-injected embryos stained with antibodies against
a-acetylated tubulin at 5 dpf. Lateral view, anterior to left, dorsal to top. (A
and C) ControlMO-injected embryos. (B and D–F) fmr1MO-injected
embryos. (A and B) View of the full-length embryo. (C) In
ControlMO-injected embryos at 5dpf, the lateral longitudinal fasciculus gener-
ally extends to the extreme posterior of the tail. (D) In fmr1MO-injected
embryos at 5dpf, the lateral longitudinal fasciculus often (13/30;
ControlMO-injected 0/30) defasciculates before it extends beyond the pos-
terior extent of the yolk extension. (E) More rarely (3/30; ControlMO-injected
0/30), the lateral longitudinal fasciculus in fmr1MO-injected embryos demon-
strates canonical axon-guidance defects. (F) Axon tracing of the lateral longi-
tudinal fasciculus in (D) using NeuronJ (32) in ImageJ, illustrating
defasciculation of the lateral longitudinal fasciculus. (A, B, D and F) are com-
posite images. Arrowheads indicate posterior extent of the lateral longitudinal
fasciculus. Scale bars (A and B), 200 mM; (C–F), 100 mM.
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Meckel’s cartilage is shorter and wider than normal in
fmrMO-injected embryos. However, interpretation of this
result is complicated by our ignorance of the long-term
(.2 days) efficacy of the injected morpholinos. Unexpectedly,
a much less extreme and more variable, short rostrocaudal
extension phenotype is also found in embryos treated with
MPEP (P , 0.001, Fig. 6E). Meckels’ cartilage width in
MPEP-treated embryos is not significantly different from
normal or control embryos. Treatment of fmr1MO-injected
embryos with MPEP returns the length and width of
Meckels’ cartilage to close to normal.
Consistent with the neurite morphology phenotypes
reported earlier, we also found a reduced level of innervation
of the facial region by the cranial nerves (Fig. 6I and J).
The cranial ganglia and Meckels’ cartilage share a common
origin in the neural crest. This suggested that problems in
cranial ganglia and cartilage formation might be due to defec-
tive neural crest specification, migration or differentiation. To
support this, we examined other neural crest-derived structures
and found defects in the trigeminal ganglion.
In fmr1MO-injected embryos, we observed that the number
of trigeminal neurons was significantly reduced relative to
normal/controlMO-injected levels (Fig. 7). Upon examination
of MPEP-treated and fmr1mRNA-injected embryos, we found
a significant increase in the average number of trigeminal
neurons in the ganglion (MPEP-treated P , 0.01; fmr1
mRNA-injected P , 0.05). Furthermore, these treatments
increased the number of neurons beyond the maximum
observed in normal/controlMO-injected embryos. The trigem-
inal neurons and Meckels’ cartilage are derivatives of the
neural crest cell stream that populates the first branchial arch
(50).
To confirm a role of fmr1 in the cranial neural crest, we
directly examined the cranial neural crest in 26-somite stage
embryos using whole-mount in situ transcript hybridization
to reveal the expression of dlx-2a (Supplementary Material,
Fig. S2). dlx-2a was reduced in fmr1MO-injected embryos,
indicating that the loss of fmr1 does indeed have an effect
on neural crest specification (Supplementary Material,
Fig. S2A and B). Unilateral rescue experiments demonstrated
differences in the location of neural crest streams between
fmr1MO and controlMO-injected embryos (Supplementary
Material, Fig. S2C and D). This suggests that fmr1 has a
role in specification and possibly migration of a subset of
neural crest cells and that the distinctive syndromic craniofa-
cial abnormalities found in patients with fragile X syndrome
may be due to defects in the neural crest.
DISCUSSION
Zebrafish is a suitable model system of fragile X
syndrome
In the current study, we used a range of experimental
approaches to look at various morphological defects related
to the loss of Fmr1 and to the human syndrome connected
to the loss of FMRP. Our first aim was to determine
whether zebrafish was a suitable model organism in which
to model aspects of human fragile X syndrome. We have
demonstrated that the zebrafish is an entirely appropriate and
easily manipulated fragile X syndrome model in which to
examine multiple aspects of the syndrome. Furthermore, we
extended our study to demonstrate that the drug MPEP,
previously demonstrated to rescue murine Fmr1-knockout
behavioural phenotypes, also rescues more basic neuro-
physiological abnormalities and appears to have a role in
alleviating craniofacial defects associated with the loss of
zebrafish Fmr1.
The zebrafish will prove an important model organism in
the study of fragile X syndrome and associated neural abnorm-
alities, as it appears to recapitulate human craniofacial defects
as well as providing a stereotypical pattern of neurons that are
simple to image with fluorescent probes in whole embryos.
The zebrafish also has a full complement of genes orthologous
to the human FMR1 gene family, as well as fmr1 interacting
proteins that will be crucial to understanding the context-
dependent activities of the transcript and protein. The zebra-
fish may also be an appropriate model in which to study the
RNA-related phenotypes associated with FMR1 premutations
(51).
Loss of Fmr1 recapitulates phenotypes found in other
model organisms and in the human syndrome
Given that the primary syndromic phenotype of fragile X syn-
drome is mental retardation, most work using model organ-
isms to study effects of the loss of FMR1 has focused on
some aspect of the neuronal or brain phenotypes. A great
deal of work has addressed the role of FMR1 in synaptic
defects, LTD, and dendritic spine defects. This is appropriate
considering the altered dendritic spine morphology identified
abnormality in the brains of fragile X syndrome patients.
Neurite morphogenesis defects due to dfmr1 loss has been
Figure 7. The average number of trigeminal neurons decreases significantly in
the absence of Fmr1 and increases in ectopic fmr1 mRNA-expressing embryos
and in embryos treated with MPEP. MPEP rescues the decrease in neurons in
fmr1MO-injected embryos. # denotes significance at P , 0.05, ## denotes
significance at P , 0.01 and ### denotes significance at P , 0.001. Inner
error bars shown denote the SEM and solid circles denote the range of
values for each condition. Note that the maximum number of neurons in
MPEP or fmr1 mRNA-treated embryos exceeds the maximum number
found in ControlMO-treated embryos and in normal (max ¼ 30) as reported
in the literature.
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found in Drosophila (20,39), implicating dfmr1 in branching
and neuronal elaboration. However, dfmr1 function has also
previously been indirectly connected to both fasciculation
and guidance defects through its interaction with CYFIP in
both CNS and PNS (19). It appears likely that the behavioural
or cognitive defects associated with fragile X syndrome are
due, in part, to both synaptic and neurite abnormalities. Fur-
thermore, identifying the mechanisms controlling neurite mor-
phology is important to our understanding of nervous system
development in general.
In this study, we have shown that, similar to invertebrates,
the loss of FMRP in a vertebrate is connected with neurite
branching defects. These defects and other neuritic abnormal-
ities (defasciculation and errors in axon guidance) occur in the
context of the full, vertebrate FMR1 gene family. Thus, it is
unlikely that partially redundant function provided by FXR1
and FXR2 is masking axonal, fasciculation or guidance
defects in fragile X syndrome. Our work also suggests that
these various neurite morphological defects may result from
a common molecular mechanism causing different morpho-
logical outcomes depending on the cellular developmental
context. We have also demonstrated that craniofacial abnorm-
alities resulting from the loss of fmr1 activity in zebrafish may
be consistent with defects found in fragile X syndrome
patients (2). The defect in the width of Meckles’ cartilage at
5 dpf may reflect the human syndromic phenotype of head cir-
cumference greater than the 50th percentile, dental overcrowd-
ing and jaw defects. Furthermore, it appears that trigeminal
innervation of the face in 5 dpf zebrafish larvae is affected
by fmr1 knockdown. We speculate that this may be related
to the characteristic ‘syndromic appearance’ of patients with
fragile X syndrome, as well as to some behaviours identified
in the syndrome, such as childhood vomiting or gagging.
fmr1 appears to affect the fate of the neural crest
Cranial cartilage develops in the pharyngeal arches from
mesenchyme of neural crest origin. The fate of neural crest
cells is specified largely by their position on the rostrocaudal
axis prior to the onset of migration (52). The first arch (man-
dibular arch) is populated by neural crest cells from midbrain,
rhombomeres 1 and 2, the second arch (hyoid arch) is popu-
lated by cells from rhombomere 4 and the third arch by
cells from rhombomeres 6 and 7 (53).
Both Meckels’ cartilage and the trigeminal ganglion are
derived from the mandibular arch. Meckels’ cartilage, in par-
ticular, is derived specifically from the neural crest cells orig-
inating in the posterior midbrain (50), whereas the trigeminal
ganglion (or cranial nerve V) is derived partially from ectoder-
mal placodal cells and partially from neural crest (54,55) orig-
inating between the posterior midbrain and the second
rhombomere.
In this study, we have demonstrated that both of Meckels’
cartilage and the trigeminal ganglion are affected by the loss
of fmr1 activity. Furthermore, both Meckels’ cartilage
defects and trigeminal ganglion neuron number are rescued
to normal by MPEP treatment. Furthermore, we have found
that dlx-2a expression in migrating neural crest is significantly
altered in fmr1MO-injected embryos. These results suggest
that fmr1 has a role in neural crest specification and possibly
migration and that fmr1 and mGluR signalling affect these
processes through the same pathway.
A close association between fmr1 and mGluR
signalling influences various aspects of neuronal
architecture and function
In individuals with fragile X syndrome, dendritic spines that
form synapses are abnormally long and appear to be immature
(12,34). This has led to the theory that FMRP is involved in
synaptic maturation or morphogenesis. Long-term potentiation
and LTD are mechanisms of synaptic plasticity in the dendritic
spines. These mechanisms are indirectly triggered by local
protein synthesis. FMR1 appears to be one of the transcripts
that is translated at the synapse in response to mGluR stimu-
lation (17). In Fmr1 knockout mice, mGluR-dependent
activity is increased, leading to increased LTD (mGluR-LTD)
(15,56), and this, along with a number of other features of
FMR1-related functions, has lead to the development of an
‘mGluR theory of fragile X mental retardation’ (27), which
suggests that a significant portion of the disease phenotypes
is due to mGluR misregulation.
MPEP is a potent and specific non-competitive antagonist of
mGluR receptors. MPEP has been used to rescue behavioural
abnormalities in Fmr1 knockout mice (28) and courtship and
mushroom body defects in Drosophila dfmr1 loss-of-function
mutants (41).
Our ability to rescue fmr1 loss-of-function neurite branching
abnormalities in vertebrate embryos with MPEP gives further
support to the mGluR theory of fragile X syndrome. In addition,
we demonstrated that overexpression of fmr1 in normal
embryos has a similar effect on neurite branching to that of
MPEP treatment. This indicates that the effect of mGluR and
Fmr1 on neurite architecture is closely linked and extends
beyond mutual regulation in synapses. There is also a connec-
tion between mGluR signalling and fmr1 function in specifica-
tion of trigeminal ganglion neurons. Both overexpression of
fmr1 and treatment with MPEP significantly raise the mean
and the maximum number of neurons above that normally seen.
Zebrafish embryos are highly amenable to drug screening.
In particular, drugs applied to their growth medium are not
metabolized by an intervening placenta. This simplifies
interpretation of their effects on developing embryos. Our
development of a zebrafish model for the analysis of human
FMR1 loss-of-function phenotypes and our demonstration of
the efficacy of MPEP in alleviating these phenotypes support
the use of this model in screens for additional drugs that can
modulate FMR1 activity and FMRP function.
We have incorporated the findings presented here with those
in the literature to construct a model of the role of FMR1 path-
ways in neurite morphogenesis. This model integrates FMR1
function with mGluR signalling.
A model integrating mechanisms of neurite
morphogenesis affected by fmr1 knockdown,
overexpression and pharmacological rescue
The experiments reported here demonstrate a close similarity
in neurite phenotype caused by fmr1 overexpression and
mGluR antagonism. This suggests that both fmr1 activity and
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mGluR signalling directly affect the same pathway(s) control-
ling neurite morphogenesis. Furthermore, fmr1 function is
involved in not only neurite branching but also axon guidance
and defasciculation. It is plausible that there is a common
mechanistic link between these phenotypes.
Here, we propose a model that describes how neurite mor-
phologies (branching, guidance and fasciculation) might be
dependent on the modulating influences and balance of fmr1,
Fmr1 and mGluR (Fig. 8). Our model is based on a compu-
tational model of neurite outgrowth and branching described
by Hely et al. (57) and Kiddie et al. (58). One of the predic-
tions of that model is that an increase in intracellular
calcium leads to an increased likelihood of neurite branching.
This is due to the destabilization of structural microtubules
and proliferation of path-finding F-actin filaments. Our obser-
vations are consistent with this prediction since, if fmr1 affects
neurite morphogenesis through modulation of intracellular
calcium, then this provides a mechanism through which
fmr1 may affect other aspects of neurite morphogenesis.
Microtubule assembly and bundling are regulated by
microtubule-associated proteins (MAPs). MAP2 functions by
binding to microtubules and stabilizing them. This promotes
microtubule assembly and bundling into a rigid cytoskeleton.
The ability to stabilize microtubules depends on the phos-
phorylation state of MAP2. Dephosphorylated MAP2
favours elongation by promoting microtubule polymerization
and bundling. In contrast, phosphorylated MAP2 tends to sep-
arate microtubules, leading to their destabilization. This delays
elongation of the neurite and encourages branching (59–61).
The ratio of phosphorylated to dephosphorylated MAP2 is
determined by the activity of calmodulin-dependent protein
kinase II (CaMKII). CaMKII activity is regulated by intra-
cellular calcium levels (57,58).
In this study, we observed a number of defasciculation and
axon-guidance phenotypes in zebrafish embryos lacking fmr1
activity. These phenotypes have been well established, as
resulting from changes in the activity of calcium-dependent
processes (62–65). Loss of FMRP regulation may lead to per-
turbed distribution of calcium. This would lead to differential
MAP2 phosphorylation and thus differential microtubule
assembly.
mGluR signalling and its role in rescuing the fmr1 morphant
phenotypes is consistent with the model described in Figure 8.
mGluR is known to control the release of calcium from
internal stores and has been associated with the lengthening
of dendritic spines (66).
A number of targets of FMRP have previously been shown
to be related to the regulation of intracellular calcium levels.
Loss of FMRP has been connected to the upregulation of
L-type Ca2þ channel subunits aB3 and a1D (9,10; Fig. 8,
Pathway 1).
FMRP interacts with (but does not appear to regulate) Cal-
reticulin, a low-affinity but high-capacity Ca2þ binding protein
(10). Calreticulin is a resident endoplasmic reticulum protein
that may be transported via FMRP into intracellular stores in
neurites to regulate calcium stores (67; Fig. 8, Pathway 2).
It has previously been established that FMRP negatively
regulates CaMKIIa (68) and NAP-22 (neuronal axonal mem-
brane protein) (9,11; Fig. 8, Pathway 3). CaMKIIa is a Ca2þ–
calmodulin-dependent protein kinase, which is known to
phosphorylate MAP2 (69). NAP-22 is a Ca2þ dependent–
calmodulin-binding protein present in neurites, which possibly
facilitates sensitivity to calcium (70). CaMKII a has also been
found to localize to growth cones in the FMRP granule (71)
and has previously been established to have roles in phos-
phorylation of MAP2 and neurite branching (52).
A pathway has also been identified by which FMRP can
directly regulate the phosphatase Pp2Ac (protein phosphatase
2A, catalytic subunit c) (18; Fig. 8, Pathway 4) that has an
established involvement in the dephosphorylation of
CaMKIIa (72). Inhibition of Pp2Ac has also been shown to
increase the phosphorylation of MAP1B and MAP2 and
inhibit their microtubule binding activity (73). Pp2Ac is also
a phosphatase of phospho-ADF/cofilin (P-cofilin), a major
mediator of Rac1 signalling. A link between FMRP and
Rac1 through CYFIP has previously been demonstrated and
provides a mechanism through which FMRP may interact
with actin cytoskeleton remodelling (18,19). The role of
fmr1 in neurite morphogenesis as described in the present
study, and morphogenesis attributed to interactions between
Rac1 and actin, may therefore be one and the same. Indeed,
Lee et al. (20). have previously described that Rac1 overex-
pression in dendritic arborization neurons also leads to
increased dendritic branching in Drosophila. Furthermore, it
is reported that decreased dendritic branching caused by over-
expression of dfmr1 can be partially rescued by co-expression
of Rac1. This suggests that Rac1 may be affecting neurite
morphogenesis through CaMKIIa and MAP2 signalling.
As described earlier, there is considerable evidence con-
necting fmr1, mGluR signalling and calcium levels. As
mGluR is known to control the release of calcium from
internal stores, antagonism of this activity with MPEP would
clearly reduce the levels of calcium released (Fig. 8,
Pathway 5). In fmr1 knockdown cells, this may rescue abnor-
mal neurite branching caused by abnormal calcium regulation.
This model is also consistent with the established theory that
the absence of FMRP leads to misregulation of protein syn-
thesis at the synapse in response to mGluR activity. Treatment
of mGluR activity with antagonists should again reverse these
defects attributable to the loss of FMRP function (15,27). The
model may also explain the synaptic defects associated with
the loss of fmr1, as a large rise in intracellular calcium is per-
missive for LTD in synaptic morphology, and LTD of the
synapse is an identified result of the loss of FMR1 (15).
In conclusion, we have demonstrated that the zebrafish is an
appropriate model organism for studies of the genetic basis of
fragile X syndrome. It is a vertebrate with single orthologues of
all the human FMR1-related genes. It is simple to knockdown
fmr1 activity in zebrafish embryos using morpholino antisense
olignucleotides, and this suggests that zebrafish embryos would
be an ideal system in which to study combinatorial interactions
between the FMR1-related genes through simultaneous knock-
down. We have described the first identified fmr1-related cranio-
facial abnormalities in a model of the human syndrome, and we
have discovered a new effect of fmr1 loss on the abundance of
neurons in the trigeminal ganglion. These phenotypes may be
connected by a role for fmr1 in the specification and, possibly,
the migration of neural crest cells (Supplementary Material,
Fig. S2). We have also described effects of the loss of fmr1
function on neurite morphogenesis in a genetic background
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Figure 8. A proposed mechanism explaining and unifying the neurite morphological abnormalities associated with fmr1MO knockdown (branching, fascicula-
tion and guidance) and MPEP antagonism of mGluR. fmr1 and MPEP might regulate calcium signalling pathways and influence neurite morphology through
modulation of MAP2 phosphorylation. FMRP (yellow hexagon) is translocated into the nucleus (via its NLS) where it forms a messenger ribonucleoprotein
(mRNP) complex. The complex is exported into the cytoplasm (via its NES). The Fmrp/mRNP complex can associate with ribosomes and is known to regulate
(positively and negatively) a number of transcripts. FMRP can form an mRNA granule that can translocate into F-actin-rich compartments, such as filopodia,
spines and growth cones (74–76), likely through an association with MAP1B (MAP1B appears to be negatively regulated by FMRP). It has been speculated that
this translocation of the FMRP granule is a form of mRNA and protein transport. In post-synaptic sites, and perhaps in growth cones, the FMRP granule is
disassembled or translated in response to stimulation (occurring post-synaptically via mGluR signalling). Alternatively, granule formation might act to
repress the translation of a pool of interacting mRNAs (8,16,71,77). These FMRP mechanics have been used to suggest models effectively illustrating the
origins of post-synaptic morphological defects (27,78,79). These models have also connected FMRP to the activity of mGluR (inset) (15). Stimulation of
mGluRs increases transport of FMRP-containing granules to the neurites and exaggerates granule disassembly (8,74). mGluR stimulation also increases the
levels of many post-synaptic mRNAs, including FMR1 mRNA and mRNAs downregulated by FMRP. A reduction in the level of FMRP at synapses has
been speculated to reflect the process of granule disassembly (3). This has lead to a theory that fragile X syndrome is a consequence of exaggerated response
to mGluR activation (27).
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possessing other, partially redundant FMR1-related genes.
We have observed whole or partial rescue of these phenotypes
using the mGluR antagonist MPEP and have shown that both
treatment with MPEP and fmr1 overexpression lead to similar
phenotypes. From these observations and the known functions
of FMR1, we have proposed a model that connects FMRP,
neurite and synaptic morphogenesis and mGluR signalling to a
common pathway.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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Huntington’s disease (HD) is one of nine neurodegenerative disorders caused by expansion of CAG repeats
encoding polyglutamine in their respective, otherwise apparently unrelated proteins. Despite these proteins
having widespread and overlapping expression patterns in the brain, a specific and unique subset of neurons
exhibits particular vulnerability in each disease. It has been hypothesized that perturbation of normal protein
function contributes to the specificity of neuronal vulnerability; however, the normal biological functions of
many of these proteins including the HD gene product, Huntingtin (Htt), are unclear. To explore the roles of
Htt, we have used antisense morpholino oligonucleotides to observe the effects of Htt deficiency in early zeb-
rafish development. Knockdown of Htt expression resulted in a variety of developmental defects. Most nota-
bly, Htt-deficient zebrafish had hypochromic blood due to decreased hemoglobin production, despite the
presence of iron within blood cells. Furthermore, transferrin receptor 1 transcripts were increased,
suggesting cellular iron starvation. Provision of iron to the cytoplasm in a bio-available form restored hemo-
globin production in Htt-deficient embryos. Since erythroid cells acquire iron via receptor-mediated endocy-
tosis of transferrin, these results suggest a role for Htt in making endocytosed iron accessible for cellular
utilization. Iron is required for oxidative energy production, and defects in iron homeostasis and energy
metabolism are features of HD pathogenesis that are most pronounced in the major region of neurodegen-
eration. It is therefore plausible that perturbation of Htt’s normal role in the iron pathway (by polyglutamine
tract expansion) contributes to HD pathology, and particularly to its neuronal specificity.
INTRODUCTION
Huntington’s disease (HD) is a dominant, progressive neuro-
degenerative disorder characterized by cognitive deficits,
choreic involuntary movements, mood disturbances and
weight loss, despite adequate dietary intake. HD is caused
by the expansion of an unstable CAG trinucleotide repeat
within the coding region of the HD gene (also known as
IT15), resulting in an expanded polyglutamine tract in the
encoded protein, Huntingtin (Htt). HD is one of nine diseases
caused by expansion of polyglutamine tracts in different
proteins, the others being spinobulbar muscular atrophy
(SBMA), dentatorubral pallidoluysian atrophy and spinocere-
bellar ataxias (SCAs) 1, 2, 3, 6, 7 and 17. Features common to
these disorders include delayed onset neurodegeneration and
dominant inheritance. Furthermore, the age of onset of clini-
cal symptoms decreases with increasing repeat copy number.
Largely due to the dominant inheritance of these diseases, it is
generally believed that the expanded polyglutamine tract
confers a toxic gain-of-function upon each affected protein.
This notion has been supported by findings that expression
of disease-length polyglutamine tracts within truncated Htt
fragments or in isolation causes cellular dysfunction and/or
cell death in a variety of model systems, including mouse
(1), nematode (2), zebrafish (3,4), Drosophila (5,6), Sacchar-
omyces (7) and cultured neurons (8).
However, in the human polyglutamine diseases, despite the
proteins having widespread and overlapping patterns of endo-
genous expression, only a subset of neurons is most prone to
degeneration. Furthermore, a different subset of neurons
degenerates from one disease to the next, as reflected in vari-
able clinical features. It is likely that the unique specificities of
neuronal vulnerability in each of these diseases are mediated
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somehow by the different protein contexts in which the poly-
glutamine tracts reside. There is increasing evidence that
unique attributes of the affected proteins, outside of the poly-
glutamine tract, are critical for neurodegeneration. For
example, in SCA1, neurodegeneration is dependent upon the
phosphorylation of a serine residue within the mutant
protein, ataxin-1 (9). In SBMA, nuclear translocation of the
mutant androgen receptor upon binding of its ligand, testoster-
one, is required for neurodegeneration (10). In SCA6, the
polyglutamine expansion perturbs the normal function of the
calcium channel subunit in which it resides (11,12) leading
to symptoms that resemble those of other channelopathies
unrelated to polyglutamine (13). Currently, the normal func-
tions of many of the proteins affected in polyglutamine dis-
eases (including Htt) are unclear. Further understanding of
their normal functions and the biological processes in which
they are involved is likely to provide further insight into the
molecular pathway(s) underlying pathology in these diseases.
In HD, although the expanded Htt allele (like wild-type Htt)
is expressed throughout the brain, a hierarchy of neuronal vul-
nerability to degeneration exists. Characteristically, HD neuro-
pathology is most striking in the striatum, where medium spiny
g-aminobutyric acid (GABA)-utilizing neurons that project to
the substantia nigra and globus pallidus are gradually, and
selectively, lost (14,15). Neurons in the deeper layers of the
cerebral cortex are also vulnerable, and pathology has been
observed to a lesser extent in other regions of the brain, while
some areas, also expressing the mutant protein, seem relatively
unaffected. What determines this hierarchy of sensitivity to
expanded mutant Htt has not yet been established.
In the HD striatum, decreased glucose metabolism is
observed prior to the bulk of cell loss (and clinical symptoms)
(16–18), supporting the notion that cellular dysfunction pre-
cedes cell death. Signs of decreased oxidative respiration are
evident in this region, including a reduction in activities of
the citric acid cycle enzyme, aconitase (19), and mitochondrial
respiratory complexes II–IV (20,21). Consistent with these
findings, decreased striatal oxygen consumption (22) and
increased lactate concentrations in the basal ganglia and occi-
pital cortex have also been reported (23,24). Other abnormal-
ities observed in the HD striatum include increased
excitotoxicity (25), accumulation of iron (26–29) and
markers of oxidative stress (30). The underlying mechanism
by which expanded mutant Htt triggers these effects and
why the striatum is most vulnerable is unknown.
Htt is a relatively large protein (!350 kDa) that has a wide-
spread distribution throughout the human body suggesting that
it plays a ubiquitous role that is not limited to neurons. Within
the cell Htt is mostly found in the cytoplasm where it is con-
centrated in the perinuclear region (31,32), although it has also
been detected in dendrites and nerve endings (33,34) and
within the nucleus (35–38). Htt associates with a variety of
cellular structures and organelles including the plasma mem-
brane, clathrin-coated and non-coated vesicles, endosomes,
endoplasmic reticulum, Golgi complex, mitochondria and
microtubules (31,33,39–44). This wide variety of associations
and lack of distinct compartmentalization has not made the
role of Htt immediately clear.
Since the identification of the HD gene 14 years ago (45),
Htt has been implicated in a large variety of cellular processes
including apoptosis, endocytosis, vesicle trafficking, transcrip-
tional regulation and dendrite formation (reviewed in 46,47).
Studies in mouse have revealed a dose-dependent response
to Htt depletion. While a single active allele of the mouse
orthologue (Hdh) is sufficient for healthy development (48–
50), a hypomorphic Hdh allele resulting in a reduction of
Htt levels to one-third of wild-type levels produces severe
cranial and brain abnormalities leading to lethality around
the time of birth (51). Homozygous inactivation of the Hdh
gene leads to early embryonic lethality (48–50) associated
with increased apoptosis (48) and disrupted transport of
maternal nutrients into the fetus (52). In a conditional mouse
model, postnatal Hdh inactivation in the forebrain and testes
results in cellular dysfunction and cell death in those regions
(53). These findings indicate that Htt plays a vital role and
is critical for cellular viability.
Past investigations of Htt function in vivo have been some-
what limited by the lack of a viable mouse model of Htt
deficiency. Here a novel approach is taken by using antisense
methodology [morpholino oligonucleotides (MOs)] to transi-
ently ‘knock down’ hd gene function in early zebrafish devel-
opment. A major advantage of using the zebrafish/MO system
is that zebrafish produce optically transparent embryos that
develop externally, allowing the morphological effects of Htt
knockdown to be observed in live embryos, non-invasively,
under the microscope. Furthermore, the MO method of gene
knockdown enables the extent of inhibition to be adjusted
by modifying the dose of MOs administered, thus allowing
the effects of partial Htt depletion to be investigated. This
study investigates the effects of Htt-deficiency in zebrafish,
in the hope that characterization of the resulting phenotypes
might provide further insight into the normal biological role
of Htt, and provide some insight into whether perturbation
of this normal function is capable of contributing to the speci-
ficity of neuronal vulnerability seen in HD. Our findings reveal
a requirement for Htt in cellular iron utilization.
RESULTS
Expression pattern of the hd gene in early
zebrafish development
The Htt protein encoded by the zebrafish orthologue of the
HD gene (hd ) has been detected at high levels in late embryo-
nic development (54). To visualize the expression pattern of
the hd gene in early zebrafish development, whole-mount
in situ hybridization was performed on embryos of various
stages from 1-cell to 48 h post-fertilization (hpf; Fig. 1A–F).
Zebrafish hd transcript was detected at the 1-cell stage, prior
to the onset of zygotic expression [which starts between 2.3
and 5.3 hpf (55)] and is therefore maternally deposited. Distri-
bution of the hd transcripts was uniform throughout the
embryo during gastrulation (Fig. 1B), but as development
progressed, expression decreased in non-neural tissues and
was strongest in the head. This pattern of zebrafish hd
mRNA distribution is consistent with the early uniformity
(49,52,56) and subsequent down-regulation in non-neuronal
tissues (56) of Hdh mRNA expression in rodent development.
It is also similar to that of many ‘housekeeping’ genes (57),
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normally associated with the maintenance of a basal cellular
function (58).
Knockdown of zebrafish Htt function
Given the early expression of hd in zebrafish, and that Hdh
knockout mice die during embryonic development (48–50),
it was hypothesized that depleting, rather than eliminating,
Htt protein in zebrafish embryos using antisense translation
inhibitors (MOs) would have a detrimental, yet diminished,
effect on zebrafish development and produce phenotypes that
would provide insight into the normal role of Htt. Two non-
overlapping MOs (hdMO1 and hdMO2) were designed to
specifically target the hd translation initiation codon and
50-UTR. As negative controls, either a standard negative
control morpholino (cMO), or a mispair control morpholino
(hdMO1 with 5 base modifications out of 25; mcMO1) were
used. Neither of the control MOs produced any morphological
consequences upon injection at the 1-cell stage zebrafish
embryos, at the concentrations used in this study.
To test the effectiveness of the hdMOs at binding the hd
transcript and blocking downstream translation, an EGFP
reporter construct (hd(1.2):EGFP) driven by 1.2 kb of hd 50
sequence (encompassing the hdMO target region) was gener-
ated. Injection of hd(1.2):EGFP (0.2 ng) at the 1-cell stage,
resulted in strong fluorescence at 10 hpf due to mosaic
EGFP expression (100%, n ¼ 45; Fig. 2A). Co-injection of
cMO (21 ng) with hd(1.2):EGFP did not affect EGFP
expression (100%, n ¼ 28; Fig. 2B), but co-injection of a
mixture of hd(1.2):EGFP and either hdMO1 or hdMO2
(21 ng) inhibited EGFP expression (hdMO1: 0%, n ¼ 39;
hdMO2: 0%, n ¼ 27; Fig. 2C and D). These results showed
that both hdMO1 and hdMO2 were each able to bind their
hd-specific target sequence and prevent translation.
In addition, antibodies raised against the N-terminus of zeb-
rafish Htt were used to confirm a reduction in endogenous Htt
levels. Embryos were injected at the 1-cell stage with cMO or
hdMO1 (21 ng) and extracts were prepared from these and
wild-type uninjected embryos after 48 hpf. Western blot
analysis with the antisera showed that Htt expression was
greatly reduced in embryos injected with hdMO1 compared
with uninjected or cMO-injected embryos (Fig. 2E).
Developmental consequences of Htt depletion
in zebrafish
To investigate the normal role of Htt in development, hdMO1
or hdMO2 (21 ng) was injected into 1-cell embryos and
examined during early development. The same spectrum of
phenotypes was produced using either hdMO1 or hdMO2,
indicating specificity of Htt knockdown. Early in develop-
ment, throughout gastrulation, somitogenesis and early neuru-
lation (formation of the neural plate, neural keel and
notochord), Htt-deficient embryos appeared similar to
cMO-injected embryos. By 18 hpf, Htt-deficient embryos
often exhibited slight growth delay. Brain necrosis was seen
at this time, and persisted at 24 hpf when it was also evident
that the brain ventricles had not enlarged as they had in
control embryos (Fig. F–H). At 26 hpf (Fig. 2I–K) the yolk
extension (YE) was notably thinner than in control embryos
and had disappeared in the majority of hdMO-injected
embryos by 48 hpf (Fig. 2L–P). At this stage, Htt-deficient
embryos were shorter, and had delayed or paler
pigmentation of melanophores, small head and eyes and pale
or colorless blood. In more severely affected embryos, the
tail was often twisted and/or truncated (Fig. 2N and P). By
96 hpf, the melanophores had developed in color, but their pat-
terning along the length of the body was obviously disrupted
(Fig. 2Q–U). The body was also thinner than control
embryos, and appeared necrotic. At this stage, the hdMO-
injected embryos appeared to have poorly formed jaw and
branchial arch structures and the swim bladder had not inflated
as it had in cMO-injected embryos by this time. These pheno-
types were often accompanied by pericardial edema (Fig. 2R).
Since Htt deficiency had such a global effect on zebrafish
development it was difficult to ascertain which aspects of
the morphant phenotype were primary effects of Htt depletion
and which were secondary consequences. To address this
issue, a lower morpholino dose (8.5 ng/embryo) was used.
Injection of hdMO1 or hdMO2 at this lower dose produced
milder effects in comparison to the higher dose (21 ng),
indicating a dose-response to the hdMOs. When the lower
dose was injected, pericardial edema, brain necrosis and tail
curvature were very rarely observed among morphant
embryos. While decreased eye size and disrupted pigment
alignment were frequently seen at later stages (72–96 hpf)
Figure 1. Whole-mount in situ hybridization of hd mRNA (stained purple) in
early zebrafish development. (A) Zebrafish hd transcript was detected at the
1-cell stage, prior to the onset of zygotic expression, and is therefore mater-
nally deposited. (B) Distribution of hd transcript was found to be uniform
throughout gastrulation (10 hpf shown). (C–F) From 18 to 48 hpf expression
was detected more strongly in the head, with weaker signal in the trunk/tail. In
images (E) and (F), dark brown melanophores are visible.
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(Fig. 3L compared with H), the most common morphological
defects among embryos injected with the lower morpholino
dose were the thin YE (for example, Fig. 3H compared
with I) and blood hypochromia (Fig. 3B compared with A).
The hypochromic appearance of the blood was not due to a
lack of red blood cells since similar cell numbers were seen
circulating in Htt-deficient and wild-type embryos (Fig. 3C
and D). Rather, the blood cells were lacking red pigment
(Fig. 3B). All further morpholino experiments were performed
using this lower dose (8.5 ng/embryo).
The various characteristics of the Htt morphant phenotype
were compared with those of zebrafish genetic mutant pheno-
types listed on the Zebrafish Information Network database
(www.zfin.org). Aspects of the Htt morphant phenotype such
as brain (or CNS) necrosis, pericardial edema, small head
and eyes and thin YE were found to occur frequently among
zebrafish genetic mutant strains with defects in housekeeping
genes, and thus did not reveal any obvious hints as to Htt func-
tion. The blood hypochromia, however, is observed in mutants
with deficits in hemoglobin (Hb) production (59,60) and is
often caused by a disruption in iron metabolism (61–63).
This phenotype of Htt morphant embryos was intriguing
since wild-type Htt has been previously implicated in iron
homeostasis and hematopoiesis in cultured cells (64,65), and
also in the transport of nutrients such as iron across the visc-
eral endoderm from maternal to embryonic tissues in the
mouse fetus (52). Furthermore, expression of b globin
(embryonic bH-1 and adult b) has been shown to be increased
in hematopoietic cells derived from an Hdh knockout mouse
model (64), suggesting that the hypochromia phenotype in
Figure 2. Specific knockdown of an EGFP reporter or endogenous Htt by
hd-targeted morpholinos and the phenotype of Htt-deficient zebrafish. To
test the effectiveness of the MOs at binding the transcript and blocking down-
stream translation, an EGFP reporter construct driven by DNA sequence
upstream from the zebrafish hd coding region (hd(1.2):EGFP, encompassing
the hdMO target region) was used. (A) Injection of hd(1.2):EGFP at the
1-cell stage, resulted in strong fluorescence at 10 hpf due to mosaic EGFP
expression. (B) This expression was unaffected when hd(1.2):EGFP was
co-injected with 21 ng of cMO. Co-injection of hd(1.2):EGFP with 21 ng of
hdMO1 (C) or hdMO2 (D) inhibited EGFP expression. (E) To confirm a
reduction in endogenous Htt levels, antibodies raised against the N-terminus
of zebrafish Htt were used. Western blot analysis of Htt expression in
lysates prepared from 48 hpf embryos shows that Htt is markedly reduced
in embryos injected with 21 ng hdMO1 in comparison with uninjected, or
21 ng cMO-injected embryos. Actin loading control also shown. Zebrafish
embryos injected at the 1-cell stage with 21 ng of either cMO (F, I, L, Q),
hdMO1 (G, J, M, N, R, S) or hdMO2 (H, K, O, P, T, U) were examined
at 24 hpf (F–H), 26 hpf (I–K), 48 hpf (L–P) and 96 hpf (Q–U). The
cMO-injected embryos show normal embryonic development (F, I, L, Q).
At 24 hpf embryos treated with hdMO1 or hdMO2 exhibit brain necrosis
(G, H; arrowhead) and failure to enlarge ventricles (G, H; arrows) compared
with cMO embryos (F). Visible regions of the brain are labeled in (F): cb, cer-
ebellum; hv, hindbrain ventricle; fv, forebrain ventricle; me, mesencephalon;
mv, midbrain ventricle; nc, neural crest; op, olfactory placode; ret, retina; te,
telencephalon. At 26 hpf, the YE is pronounced in the control embryos (I) but
thinner in Htt-deficient embryos (J, K). At 48 hpf, Htt-deficient embryos lack
the YE and have delayed pigmentation and small eyes (M–P) in comparison
with control embryos (L). The more strongly affected embryos exhibit tail
abnormalities such as curling (N) or truncation (P). By 96 hpf, Htt-deficient
embryos have small heads and eyes, and the normal alignment of melano-
phores along the trunk (Q, arrows) is disrupted (R–U). Pericardial edema is
often seen (for example, R, arrowhead). The more severely affected
embryos are shorter and ventrally curved (S, U). Images (F–H) are dorsal
views of live embryos within their chorion. Images (I–U) are lateral views
of live embryos that were manually dechorionated.
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Htt-deficient zebrafish was unlikely to be caused by a defect in
globin expression. Htt-deficient zebrafish also showed no evi-
dence of porphyric blood photosensitivity or blood autofluor-
escence characteristic of zebrafish with mutations affecting
enzymes downstream of the initial Alas2-catalyzed step in
mitochondrial heme biosynthesis (66,67).
Expression of hd mRNA in zebrafish erythroid tissue
Zebrafish embryos hybridized with hd mRNA probe were
examined to see if hd is normally expressed in erythroid
cells that manufacture Hb, as this would be consistent with
Htt having a role in these cells. Zebrafish hematopoiesis
occurs in two successive waves, ‘primitive’ and ‘definitive’
as it does in other vertebrates (68). The primitive wave of
hematopoiesis produces predominantly erythroid cells that
begin to circulate at 24–26 hpf. It is this period of zebrafish
hematopoiesis that was examined in the current study. The
site of primitive zebrafish erythropoiesis is the intermediate
cell mass (ICM), which is analogous to extraembryonic yolk
sac blood islands of mammals and birds.
hd mRNA was detected ubiquitously throughout the tail,
including the ICM at 22 hpf, prior to the onset of circulation
of erythroid cells (Fig. 3F). Expression is shown in compari-
son to notch2 expression, which is detected in somites but is
notably absent in the ICM (Fig. 3E). At 36 hpf hd mRNA
was also detected in the posterior ICM (Fig. 3G) more strongly
than the basal expression in the rest of the tail. By this time,
the majority of circulating cells are of the erythroid lineage,
although hematopoietic activity in the ICM tissue is not exclu-
sively erythroid (68). Expression of hd mRNA in the ICM is
consistent with Hdh gene products having also been detected
in a range of mouse hematopoietic tissues (64).
Transient knockdown of hemoglobin production
While the color of embryonic erythroid cells gives a general
indication of Hb levels, o-dianisidine staining is a more
sensitive and definitive method for detecting Hb. The basis
of this assay is that Hb catalyzes the H2O2-mediated oxidation
of o-dianisidine, producing a dark red stain in Hb-positive
cells. To assess Hb levels in Htt morphant zebrafish,
embryos were injected with 8.5 ng of hdMO1 or cMO, and
were collected at 33 or 72 hpf for o-dianisidine staining. At
33 hpf, a marked reduction in Hb production was observed
in the blood cells of Htt-deficient embryos (Fig. 3L and M)
Figure 3. hd mRNA is expressed in erythroid tissue, and Htt knockdown leads to blood hypochromia in early development due to transient suppression of hemo-
globin production. (A and B) Blood flowing through the heart (he) of hdMO1-injected embryos (72 hpf) is pale (B), in comparison with wild-type blood (A).
Lateral view shown, rostral to the left. (C and D) Similar numbers of blood cells are visible circulating across the yolk of wild-type uninjected embryos (C) and
embryos treated with 8.5 ng hdMO1 (D), at 36 hpf. Boxed area in the insets indicates the magnified region. Arrows indicate an example of a single blood cell in
each image. (E–G) In comparison with notch2 mRNA expression that is not detected in the ICM at 22 hpf (E), hd mRNA is expressed in the ICM (and through-
out the tail) at 22 hpf (F). At 36 hpf hd mRNA expression is increased in the posterior ICM above basal expression throughout the rest of the tail (G). (H–O), Hb
was detected by o-dianisidine staining in zebrafish embryos injected with 8.5 ng of cMO (H–K) or hdMO1 (L–O). At 33 hpf, Hb production was suppressed in
hdMO1-injected embryos [lateral (L) and ventral (M) views of a representative embryo] in comparison with cMO-injected embryos (H, I). By 72 hpf, Hb levels
in hdMO1-injected embryos (N, O) returned to a level similar to cMO-injected control embryos (J, K).
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when compared with control embryos (Fig. 3H and I). Very
weak staining was detectable in the blood cells of the Htt mor-
phants at this stage, however, confirming that the general low
level of staining was not due to an absence of these cells. By
72 hpf, all morphant zebrafish exhibited strong o-dianisidine
staining in the blood, similar to control embryos (Fig. 3J
and K, compared with N and O), indicating that suppression
of Hb production was transient.
Iron staining in whole embryos and isolated
blood cells
In the zebrafish embryo, iron is absorbed from maternally
derived stores in the yolk (63) and erythroid cells endocytose
iron from the plasma as transferrin (Tf) via the Tf receptor
(TfR) (61). To investigate the possibility that the decrease in
Hb levels could be due to a disruption in iron transport,
DAB-enhanced Prussian blue staining was used to detect the
presence of ferric iron in morphant and control embryos (52,
also see Materials and Methods) in order to assess any differ-
ences in iron distribution.
At 36 hpf, ferric iron was detected throughout the animal
(non-yolk) part of Htt-deficient embryos at a level at least the
same, and in many cases higher, than in wild-type embryos
(Fig. 4A and B). In wild-type embryos, ferric iron was also
present in the peripheral layer that surrounds the yolk sac, pre-
sumably representing the yolk iron stores (100%, n ¼ 52/52;
Fig. 4A, arrow). Embryos injected with hdMO1 frequently
lacked staining in this region (Fig. 4B, arrow), with only 54%
staining positively in the yolk syncytial layer (n ¼ 32/59). All
hdMO1-injected embryos that lacked iron staining in the yolk
also had a thin YE. These results suggested that more iron
was being absorbed from the maternally derived yolk stores
in Htt morphant embryos, and indicated that hypochromia
was not due to impaired uptake of iron from the yolk.
Blood cells visible in the ventral tail region of morphant
embryos (predominantly of the erythroid lineage at this
stage) stained positively for ferric iron suggesting that iron
was able to enter the Htt-deficient blood cells (Fig. 4C–F).
To examine blood iron staining more closely, embryos were
injected with hdMO1 or mcMO1 (mispair control MO), and
blood cells were extracted at 33 hpf, for DAB-enhanced Prus-
sian blue staining. The Prussian blue staining procedure
detects ferric iron (Fe3þ) which is the stable state of iron in
most of its biological complexes (including when it is bound
to Tf). Hb, however, utilizes ferrous iron, so Prussian blue
staining ought not detect iron in Hb. Ferric iron was detected
both in control and Htt-deficient blood cells, and staining
did not appear to be decreased in Htt-deficient cells (Fig. 4G
and H). Since erythrocytes acquire iron for Hb exclusively
via TfR-mediated endocytosis of Tf (61), this placed the
disruption of Hb production downstream of TfR-mediated
endocytosis of iron in the Htt-deficient blood cells. This is
consistent with the previous finding that Htt is not required
for the endocytosis of TfR and Tf (65).
Rescue of hypochromia and thin YE phenotypes
by provision of iron to the cytoplasm
Following the detection of iron within the blood cells of
Htt-deficient embryos, it was hypothesized that Htt may be
required for rendering this intracellular iron available for cel-
lular use (perhaps by facilitating iron release from the endocy-
tic compartment). If this were the case, then provision of
bio-available iron to the cytoplasm ought to bypass the need
for Htt, and thereby rescue the hypochromic phenotype of
Htt-deficient embryos.
A ‘targeted rescue’ experiment was therefore performed,
based on a technique used to rescue the hypochromic pheno-
type of chianti genetic mutant zebrafish (61). In zebrafish,
gene duplication has given rise to two isoforms of TfR1: an
erythroid specific isoform encoded by tfr1a and a ubiquitously
expressed isoform encoded by tfr1b. In chianti mutants, hypo-
chromia is caused by a mutation in the blood specific tfr1a
gene resulting in the inability of blood cells to absorb iron
(as Tf) from the plasma (61). Hb production is restored in
these embryos by injection of iron-dextran into the cytoplasm
at the 1-cell stage such that all cells of the developing chianti
embryos contain bio-available iron in the cytoplasm, hence
circumventing the need for trf1a function (61).
To test whether provision of bio-available iron to the cyto-
plasm would restore Hb production in Htt-deficient embryos,
iron-dextran was co-injected with hdMO1 (8.5 ng) at the
1-cell stage. Uninjected control embryos, hdMO-injected
embryos, and embryos co-injected with hdMO1 and 100 ng
iron-dextran were stained with o-dianisidine at 33 hpf
(Fig. 5A–F) and were scored with regards to Hb production
and YE status (Fig. 5G, Experiment 1). All wild-type
embryos (n ¼ 20/20) had a normal YE and exhibited robust
Hb staining. The number of embryos with normal Hb levels
was reduced to 14% (n ¼ 3/22) in hdMO1-injected embryos,
and co-injection of iron-dextran rescued to 62% (n ¼ 13/21).
Interestingly, iron supplementation also rescued the YE phe-
notype from 5% normal YE in morphants (n ¼ 1/22) to 71%
normal YE (n ¼ 15/21) in the rescue group (Fig. 5F).
Similar results were achieved in a second rescue experiment
(Fig. 5G, Experiment 2), this time using greater population
numbers, and using mcMO1-injected embryos as the control
group. The MO dose was the same as the previous experiment
(8.5 ng); however, the dose of iron-dextran used for the rescue
was halved (50 ng). All control embryos (mcMO1-injected)
had a normal YE and robust Hb staining (n ¼ 47/47). The
number of embryos with normal Hb levels was reduced to
20% (n ¼ 10/49) in hdMO1-injected embryos, and
co-injection of iron-dextran rescued to 66% (n ¼ 29/44).
Only 6% of hdMO1-injected embryos had a normal YE
(n ¼ 3/49), and iron supplementation was able to increase
the number of embryos with a normal YE to 48% in the
rescue group (n ¼ 21/44). The ability of the addition of cyto-
plasmic iron to restore Hb production and rescue the thin YE
phenotype supports the hypothesis that Htt knockdown causes
cellular iron deficiency.
Morpholino effectiveness is not diminished by
iron-dextran treatment
To ensure that iron-dextran did not decrease hdMO1 function,
the hd(1.2):EGFP reporter construct (used earlier to demon-
strate hdMO-mediated translation knockdown) was
co-injected with 8.5 ng of either cMO, hdMO1 or both
hdMO1 and iron-dextran (200 ng). All cMOþ hd(1.2):EGFP
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Figure 4. Histochemical staining for ferric iron, detected by DAB-enhanced Prussian blue staining (reddish brown). Histochemical ferric iron staining was exam-
ined in 36 hpf wild-type embryos (A, C, D0, D00) and embryos injected with 8.5 ng of hdMO1 (B, E, F0, F00). Ferric iron was detected throughout wild-type
(A) and Htt-deficient (B) embryos. Ferric iron present in the yolk syncytial layer in wild-type embryos (A, arrow) was frequently absent in hdMO1-injected
embryos (B, arrow). Blood cells visible in the ventral tail region of hdMO1-injected embryos (E, arrowheads) appeared to stain more strongly for ferric iron
than blood cells in wild-type embryos (C). At higher magnification, round basophilic blood cells identified by Nomarski optics (D0 and F0, arrowheads)
stained positively for ferric iron, as viewed using bright-field optics (D00, F00, arrowheads). Blood cells extracted at 33 hpf from embryos injected with 8.5 ng
of hdMO1 (H) appeared to contain at least as much ferric iron as blood cells from mcMO1-injected control embryos (G). Scalebars represent 10 mM.
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embryos exhibited mosaic EGFP expression at 10 hpf (n ¼ 29/
29). No fluorescence was observed in either the hdMO1þ
hd(1.2):EGFP embryos (n ¼ 0/20) or hdMO1þ hd(1.2):
EGFPþ iron-dextran embryos (0/18), indicating that the
ability of hdMO1 to bind the hd target sequence and prevent
translation was not inhibited by the presence of iron-dextran
(data not shown).
Htt-deficiency leads to an increase in TfR1 mRNAs
The results presented so far suggest that although iron is
detected within the blood cells of Htt-deficient embryos,
insufficient iron is available for cellular use, hence the
decrease in Hb production. To further validate this model,
quantitative real-time PCR (qPCR) methodology was used
to examine the levels of TfR1 mRNA transcripts in
Htt-deficient and control embryos. Since cells typically
respond to iron starvation by up-regulating expression of
TfR1 (69), it was predicted that levels of TfR1 mRNAs
would be increased in Htt-deficient embryos. Levels of tran-
scripts from both zebrafish paralogues of the TfR1 gene,
tfr1a (erythroid specific) and tfr1b (ubiquitous) were each
examined in embryos injected with 8.5 ng of hdMO1 or
mcMO1 (mispair control MO), and wild-type uninjected
control embryos, at 33 hpf. Levels of tfr1a and tfr1b tran-
scripts were normalized to transcript levels of acta1
(GenBank accession no. NM_131591), encoding actin alpha 1.
Normalized tfr1a and tfr1b triplicate values from three indepen-
dent experiments are represented graphically in Figure 6. One
hdMO1/tfr1b value was considered to be an obvious outlier
(indicated in Fig. 6B), and was excluded from further statistical
analyses.
Increased levels of TfR1 transcripts were observed in
hdMO1-treated embryos in each of the experiments. Statistical
analyses were performed on the collated normalized data.
Analysis of variance (ANOVA) revealed a significant effect
(P , 0.001) due to different embryo treatments. Subsequent
Student’s t-tests indicated that in hdMO1-injected embryos,
the level of erythroid specific tfr1a transcript was significantly
increased in comparison to mcMO1-injected (P , 0.0002) and
uninjected (P , 0.002) embryos. Furthermore, the level of
ubiquitous tfr1b transcript was also significantly increased in
hdMO1-injected embryos in comparison to mcMO1-injected
(P ¼ 0.032) and uninjected (P , 0.008) embryos, thus indicat-
ing that the role of Htt in intracellular iron homeostasis is not
limited to erythroid cells. These findings offer strong support
for cellular iron starvation in Htt knockdown embryos, and
provide in vivo validation of a previous report that embryonic
stem (ES) cells lacking Htt [derived from a homozygous
knockout mouse model (49)] have increased TfR1 protein
levels (65).
DISCUSSION
HD and eight other late-onset neurodegenerative disorders are
caused by the abnormal expansion of a polyglutamine repeat
within their respective, otherwise unrelated disease proteins.
A different subset of neurons is vulnerable in each disease
despite mostly widespread and overlapping patterns of
protein expression. It is suspected that the unique properties
of the host proteins mediate the specificity of neuropathology
in these diseases. In HD, the primary site of neurodegeneration
is the striatum, even though Htt is expressed throughout the
Figure 5. Provision of iron to the cytoplasm rescues hypochromia and reduced
YE phenotypes in Htt-deficient embryos. Detection of Hb (by o-dianisidine) in
33 hpf embryos that were either uninjected (control) (A, ventral; B, lateral),
injected with 8.5 ng of hdMO1 (knockdown) (C and D) or both hdMO1 and iron-
dextran (Fe; rescue) (E and F). Representative embryos are shown. The thin YE
of Htt-deficient embryos (D) is restored to normal size in iron-supplemented
embryos (F). (G) Raw data from iron rescue experiments. In both experiments,
hdMO1 dose was 8.5 ng. In Experiment 1, control embryos were uninjected; and
100 ng of iron-dextran was co-injected with hdMO1 in the rescue group. In
Experiment 2, control embryos were injected with 8.5 ng of mcMO1, and
50 ng of iron-dextran was co-injected with hdMO1 in the rescue group.
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brain. Within the striatum, medium-sized spiny projection
neurons are selectively lost. As yet, studies into Htt function
have not revealed an explanation for the specificity and domi-
nant inheritance of HD pathology.
To gain a new perspective into the normal function of Htt,
we have examined the effects of Htt depletion in early zebra-
fish development. Knockdown of Htt produced symptoms of
cellular iron deficiency, including decreased hemoglobin in
the blood, increased erythroid and ubiquitous transferrin
receptor transcript levels and exhausted maternal iron stores
in the yolk. These findings implicate Htt in cellular iron acqui-
sition, and since blood cells from Htt morphants stained posi-
tively for ferric iron, Htt is likely to act downstream of
TfR-mediated endocytosis. Consistent with a role for Htt in
cellular iron acquisition, wild-type ES cells have been
shown previously to up-regulate Htt levels in response to
iron chelation (65).
Provision of iron in a bio-available form to the cytoplasm
restored hemoglobin production in Htt-deficient zebrafish
embryos and also rescued the thin YE phenotype. The thin
YE is a characteristic of previously described genetic mutant
zebrafish lines that have defects in housekeeping genes, such
as those encoding polymerases, ribosomal proteins, RNA
processing factors and translation initiating factors (70) and
is therefore likely to be a consequence of general cellular dys-
function. It is interesting to note, however, that while genetic
mutation of the erythroid specific tfr1a gene in chianti zebra-
fish results in hypochromic blood, morpholino-mediated
knockdown of the ubiquitous tfr1b isoform in zebrafish
embryos causes phenotypes including thin YE, small head
and eyes, CNS necrosis and an overall morphology that is
similar to Htt morphants, indicating that these phenotypes
can result from cellular iron deficiency.
Further studies are required in order to elucidate the exact
role of Htt in making iron accessible for cellular use.
However, since erythroid cells acquire iron for Hb production
solely by TfR-mediated endocytosis (61), a plausible expla-
nation for intracellular iron not being available for Hb pro-
duction in Htt-deficient cells is that this iron has not been
released from endocytic vesicles (Fig. 7). It could therefore
be envisioned that Htt might play a role in the targeting, trans-
port and/or fusion of iron-containing endocytic vesicles to
acidic early endosomes for iron release into the cytosol.
Recently, Htt has been shown to interact with the small
Figure 6. Levels of tfr1a and tfr1b transcripts are increased in response to Htt knockdown. Quantitative PCR was used to compare the levels of tfr1a (A and C)
and tfr1b (B and D) transcripts in zebrafish embryos injected with either mcMO1 or hdMO1, and uninjected embryos. Levels of tfr1a and tfr1b transcripts were
normalized to the level of acta1 transcript. Normalized triplicate values from three independent experiments are graphically represented for tfr1a transcript levels
(A) and tfr1b transcript levels (B). A data point that was considered an outlier is indicated (B). In (C and D), the same data shown in (A and B), excluding the
outlier, is represented in box-plot format. The ‘box’ contains the middle 50% of the data (with the upper and lower edges representing the 75th and 25th per-
centiles, respectively), the ‘horizontal line’ within the box represents the median value. The dotted lines, or ‘whiskers’, indicate minimum and maximum data
values for each embryo class, unless data points extend further than 1.5 times the inter-quartile range, in which case these values are represented as individual
points, as in (C).
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GTPase Rab5 on early endosomes, via Htt binding partner,
HAP40 (71). Interestingly, Rab5 is a key regulator of the tar-
geting and fusion of endocytic vesicles to early endosomes,
and the attachment of endosomes to, and transport along
microtubules (72), thus supporting a role for Htt in these
processes.
Other known interactions and properties of Htt support a
role for Htt in endocytic vesicle/endosome dynamics; Htt
associates with clathrin-coated and non-coated vesicles, endo-
somes (32,33,40–42,71), and co-fractionates with TfR in
density gradient studies (40,42). Many proteins that interact
with Htt are involved in clathrin-mediated endocytosis, such
as HIP1 (73,74), a-adaptin C (75), SH3GL3 (76), PACSIN1
(77) and HIP14 (78) and Htt also interacts with the plasma
membrane directly, via a lipid-binding domain located
within the N-terminus (43). Htt associates with micro-
tubules (31,33,39) and is concentrated in the perinuclear
region of cells (31,32). These findings are consistent with
Htt having a role in the microtubule-dependent transport of
vesicles and endosomes through the recycling pathway.
Furthermore, Htt has been implicated in microtubule-
mediated vesicle transport due to an interaction of Htt with
dynactin subunit p150Glued, via HAP1 (79,80). Both HAP1
and Htt are transported in neurons (41). A role for Htt in
vesicle transport is also supported by findings that over-
expression of wild-type Htt enhances microtubule-mediated
trafficking of vesicles containing brain-derived neurotrophic
factor (BDNF) (81) and RNAi knockdown of Drosophila
Htt reportedly disrupts vesicle trafficking in Drosophila
nerve axons (82).
Figure 7. Schematic model illustrating how disruption of hemoglobin production in Htt-deficient zebrafish blood cells is rescued by provision of bio-available
iron (iron-dextran) to the cytoplasm. In normal cells, binding of iron-loaded transferrin (Tf) to the transferrin receptor (TfR) on the plasma membrane initiates
clathrin-mediated endocytosis of the receptor/ligand complex into endocytic vesicles that then lose their clathrin coat and fuse to early endosomes (115). The
decreased internal pH of the early endosome causes iron to disassociate from apo-Tf/TfR, facilitating its release into the cytoplasm via divalent metal transporter,
DMT1 (116). Once released, iron enters the mitochondria where it is incorporated into haem (and iron–sulfur clusters). In erythroid cells, most haem is utilized
(in conjunction with globin) as hemoglobin (Hb). When Htt levels are depleted by morpholino knockdown, the availability of iron endocytosed by the Tf/TfR
pathway (for utilization in Hb) is compromised. Supplementing the cytoplasm with bio-available iron (iron-dextran) restored Hb production, suggesting a role for
Htt in the release of iron from endocytic compartments.
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How could perturbation of Htt function contribute
to dominant, iron-related phenotypes in HD?
Various signs of disrupted iron homeostasis have been
observed in HD patients. Levels of serum ferritin are
decreased (83,84), which is a common indication of iron
deficiency reflecting a reduction in body iron stores (85).
Also, reduced Hb levels have been observed in male HD
patients (83). The activities of many iron-requiring enzymes
are decreased in HD patients, including aconitase and mito-
chondrial complexes I–IV, each of which plays a key role
in oxidative energy production (86,87). Decreased activities
of aconitase (19) and complexes II–IV (19–21) have been
observed selectively in HD-affected brain regions, and
decreased complex I activity has been recorded in muscle
samples (88). A number of studies have reported accumulation
of iron specifically in the striatum of post-mortem HD
brain samples (26,28,29) and a significant increase in ferritin
iron has been detected in the striatum (and associated globus
pallidus) of live HD patients, even in early symptomatic
stages of disease (27,89).
How could a disruption of Htt’s role in cellular iron utiliza-
tion be connected to these dominant iron-related phenotypes in
HD? HD does not appear to be caused by a simple loss of
function of the affected allele (i.e. haploinsufficiency), since
mice in which one Hdh allele is completely inactivated
(Hdhþ/2), and a human subject with a translocation interrupt-
ing one normal HD allele, do not develop HD symptoms
(48,49,90). Furthermore, HD patients who are homozygous
for an expanded disease allele do not exhibit the embryonic
lethality of Hdh knockout mice, but instead survive birth
and develop essentially as normal until the onset of symptoms
(91,92). Therefore, in order for a disruption of Htt function to
be responsible for the defects in iron homeostasis observed in
HD, the expanded polyglutamine tract would have to alter Htt
function in a manner that causes dominant, detrimental conse-
quences in the Tf/TfR pathway. While it is unclear whether
the embryonic lethality of Hdh knockout (Hdh2/2) mice is
solely attributable to disruption of cellular iron utilization,
demonstrations that a single allele expressing expanded
Htt is functionally sufficient to rescue Hdh2/2 mice from
embryonic lethality (51,93,94), and the fact that HD is a
late-onset disease, suggest that the polyglutamine expansion
allows expanded Htt to retain at least some of its normal func-
tion, presumably including its role in cellular iron utilization.
In HD, the expanded polyglutamine tract could disrupt
the Tf/TfR pathway by altering the affinities of Htt for its
normal binding partners and/or by facilitating novel inter-
actions that have detrimental consequences on the Tf/TfR
pathway. The interactions of Htt with many binding partners
involved in endocytic and vesicle trafficking pathways are
modulated by polyglutamine expansion. For example, inter-
actions of Htt with endocytic proteins HIP1 (74) and
a-adaptin-C (75) are decreased by polyglutamine expansion,
and the interaction of Htt with vesicle trafficking protein
HAP1 is increased (95). Furthermore, the association of Htt
with microtubules via HAP1 and p150Glued is reduced in
the presence of expanded Htt (81), as is the efficiency of
vesicle trafficking (71,81,82,96,97). Additionally, HAP40 is
up-regulated in HD, leading to striking co-localization of
Htt, HAP40 and Rab5 on early endosomes, an interaction
that favors the binding of endosomes to actin rather than
microtubules (71). Based on the evidence for interrupted
vesicle transport in the presence of expanded Htt, it is appeal-
ing to speculate that the release of iron from endocytic com-
partments could be impaired in HD.
Support for the possibility that Htt’s role in the iron pathway
is altered in HD is provided by previous findings of increased
TfR levels and altered intracellular distribution of TfR and Tf
in cultured striatal cell lines (STHdhQ111/Q111 and
STHdhQ111/Q7) established from a knock-in mouse model of
HD (98,99). Notably, the fact that these defects in the Tf/
TfR cycle were observed in heterozygous STHdhQ111/Q7
cells indicates that they are dominant effects of expanded
Htt (99).
HD is one of a growing list of neurodegenerative disorders
associated with iron accumulation in the respective regions of
pathology. Others include neuroferritinopathy, Friedreich’s
ataxia, neurodegeneration with brain iron accumulation
(NBIA; formerly Hallervorden–Spatz syndrome), Parkinson’s
disease and Alzheimer’s disease (100). Neuroferritinopathy
and Friedreich’s ataxia are examples of monogenic diseases
in which the affected protein has a known role in iron
homeostasis.
Neuroferritinopathy is a rare, adult-onset neurodegenerative
disorder that presents similar to HD but is caused by dominant
negative mutations in ferritin L, one of the two ferritin sub-
units (101,102). Like HD, neuroferritinopathy is associated
with low serum ferritin levels, accumulation of iron and ferri-
tin in the basal ganglia, oxidative stress and signs of mitochon-
drial dysfunction (103).
Friedreich’s ataxia is a relatively common autosomal reces-
sive neurodegenerative disorder (affecting spinal cord and
peripheral neurons) that is associated with mitochondrial
accumulation of iron and oxidative stress (104). Friedreich’s
ataxia is caused by the expansion of a GAA trinucleotide
repeat (within the first intron of the FRDA gene) that
impairs transcription, leading to reduced expression of frataxin
protein. Frataxin is a mitochondrial protein involved in ISC
formation and accordingly, reduced activities of ISC
enzymes (respiratory complexes I, II and III, and aconitase)
have been observed in affected patient tissues (105), as they
have in HD.
Further advancements in understanding of the sequence of
events leading to pathology in these and other iron-related
neurodegenerative disorders, may offer insight into HD path-
ology, and vice versa.
Conclusion
In this study, the zebrafish model organism has been used to
examine the effects of Htt deficiency in early development,
in order to gain new insight into the normal function of Htt.
The most significant outcome of this work is the finding that
Htt knockdown leads to signs of cellular iron deficiency,
despite the presence of iron in the cell. Htt appears to act
downstream of TfR-mediated endocytosis of iron, thus impli-
cating Htt in the release of iron from endocytic compartments
into the cytosol.
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Iron is vital for the function of a variety of cellular proteins
and enzymes, many of which play important roles in energy
metabolism. Since defects in iron homeostasis (26–
29,83,84,89) and energy metabolism (reviewed in 106) are
features of HD pathogenesis, the results of the current study
raise the possibility that these defects are dominant effects
of a perturbation (by the expanded polyglutamine tract) of
Htt’s normal role in the iron pathway. Furthermore, since
iron accumulation and defects in energy metabolism are
most pronounced in the primary site of HD neurodegeneration
(19–21,26–29,89), these findings provide a novel link
between perturbation of normal Htt function, and the speci-
ficity of neuronal vulnerability in HD.
The hypothesis has been put forward that the normal func-
tion of Htt (and for that matter, each of the polyglutamine-
containing disease proteins) is such that when perturbed this
dysfunction contributes, in some way, to the specificity of
the neurodegeneration seen in HD (and each of the other poly-
glutamine disorders). In order for this hypothesis to remain
plausible, the normal function(s) of Htt need to be consistent
with some process that is able to account for such specificity
of pathogenesis. We have found a clear role for Htt in cellular
iron utilization—a process that is entirely consistent with the
specificity of HD neurodegeneration in the striatum.
MATERIALS AND METHODS
Zebrafish maintenance and staging
Zebrafish were maintained at 28.58C under standard con-
ditions as described (107). Developmental stages were deter-
mined by using both hours post fertilization (hpf) and
morphological features (108).
Whole-mount in situ hybridization
The template used to make the probe for in situ hybridization
of hd mRNA corresponds to the first 1503 bp of zebrafish hd
open-reading frame (ORF). This region was amplified from
total cDNA from 72 hpf embryos using primers ZHD.F7þ
EcoRI (50-CTGATGAATTCCATGGCCACCATGGAGAAG
CTAA-30, start codon underlined) and ZHD.R7þ XbaI
(50-GACTGTCTAGATGACATCTGGTTGGCATCGGTT-30),
and cloned into the eukaryotic expression vector pCS2þ (109)
as an EcoRI/XbaI fragment. For synthesis of labeled antisense
RNA probe, vector template was linearized at the 50 ClaI site
and transcribed with T7 RNA polymerase in the presence of
digoxigenin-labeled dUTP. notch2 (previously known as
notch6) probe was prepared as described (110). Whole-mount
in situ hybridization was performed as described (111). Pro-
teinase K was used at a concentration of 10 mg/ml in PBST
(0.1% Triton-X in PBS), to further permeabilize embryos
aged 36 hpf (5 min) and 48 hpf (10 min). Following hybridiza-
tion of the probe, alkaline phosphatase-conjugated anti-
digoxigenin antibody and BCIP/NBT substrate were used for
probe detection, as described (111). Embryos were stored in
80% glycerol for microscopy and photography.
Morpholino design
All MOs were designed and synthesized by Gene-Tools, LLC
Ore. and were solubilized in water to create 2 mM stocks. Prior
to microinjection, MO stock samples were diluted to the
required concentration, in water. MO sequences antisense
to the hd mRNA transcript were as follows: hdMO1,
50-GCCATTTTAACAGAAGCTGTGATGA-30 (þ5 to –20
with respect to the start of the hd ORF, first codon underlined)
and hdMO2, 50-GATATAATCTGATCGGAGATAGGGT-30
(222 to 246). Two negative control MOs were used; a stan-
dard MO with no known target in zebrafish, cMO, 50-CCT
CTTACCTCAGTTACAATTTATA-30, and a mispair control
MO representing hdMO1 with five base alterations (lower
case), mcMO1, 50-GCgATTTcAACAcAAcCTGTcATGA-30.
Generation of hd(1.2):EGFP reporter construct
The published zebrafish hd cDNA sequence (54) (GenBank
accession no AF052603) was used to perform a BLAST
search of the Sanger Centre Zebrafish Sequencing Project
genomic DNA database in order to obtain additional 50
sequence. A region of DNA sequence spanning !1.25 kb 50
to, and including, the first 15 nucleotides of the hd ORF was
amplified from zebrafish genomic DNA using primers
ZHD.F8þ SphI (50-GATGCATGCTGACCTACCATCCCAT
CTGAGA-30) and ZHD.R8þ SacII (50-GTACCGCGGCTCC
ATGGTGGCCATTTTAACAGAAG-30) and was ligated into
the bacterial cloning vector pGem-T (Promega). The EGFP
ORF and SV40 polyadenylation signal were amplified from
expression vector pIRES2-EGFP (Clontech) using primers
pI2EGFP.F2 (50-TGGCCACAACCATGGTGAGCAA-30) and
pI2EGFP.R2þ NcoI (50-GTCCATGGACAAACCACAACTA
GAATGCA-30), and ligated in frame as a NcoI fragment
downstream of the hd sequence, utilizing the NcoI sites span-
ning both the fourth codon of the hd ORF and the start meth-
ionine of EGFP. The resulting vector (hd(1.2):EGFP) was
linearized (XmnI) and purified using the QIAquickw PCR Puri-
fication Kit (QIAGEN) prior to injection.
Embryo microinjections
In preparation for experiments involving the injection of DNA,
vector DNA was linearized (XmnI) and purified using the QIA-
quick PCR Purification Kit. For iron-rescue experiments, Ferro-
ject iron-dextran injectable solution (Swift and Company Ltd)
(referred to here as iron-dextran) was co-injected with MOs,
as indicated. For all experiments involving microinjection, a
sample volume of 2 or 5 nl was injected into the cytoplasm of
zebrafish embryos at the 1-cell stage, using an MPPI-2 Pressure
Injector (Applied Scientific Instrumentation Inc.). Sample
doses are indicated in nanograms in the text.
Generation of polyclonal antibodies against the
N-terminus of zebrafish Htt
Polyclonal antibodies were raised in rabbit against a synthetic
peptide (Auspep) representing the first 17 amino acids of the
zebrafish Htt protein (MATMEKLMKAFESLKSF), conju-
gated to keyhole limpet hemocyanin via a C-terminal cysteine
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residue. This sequence differs from the conserved N-terminal
of mammalian Htt by only one amino acid, the fourth residue
being lysine in mammals.
Western blot analysis
Dechorionated and deyolked embryos (48 hpf) were lysed in
2 " SDS sample buffer (107) at a concentration of 1 ml per
embryo and homogenized with a pestle, on ice. Lysates were
boiled for 5 min and centrifuged at 55 000g for 20 min at 48C
in a TL-100 Ultracentrifuge (Beckman). The supernatant was
removed and stored at 2808C. Equal quantities of protein
were separated by electrophoresis on a 4–12% Bis–Tris
acrylamide gel (Invitrogen) at 200 V, and transferred to a nitro-
cellulose membrane in transfer buffer (25 mM Tris, 192 mM
glycine). Transfer was carried out in a mini-PROTEAN 3
apparatus (Bio-Rad), at 30 V overnight (48C). The membrane
was blocked for 3 h at room temperature with blocking buffer
[5% skim milk powder in 1 " TBS-T (10 mM Tris pH 7.5,
100 mM NaCl, 0.1% Tween-20)] prior to overnight incubation
at 48C with polyclonal anti-Htt antibodies (described earlier)
diluted in the same buffer. After three 15-min washes in block-
ing buffer, the membrane was incubated for 1 h with horse-
radish peroxidase-conjugated donkey anti-rabbit IgG secondary
antibody (Rockland). The membrane was then washed three
times in 1 " TBS-T before detection of the Htt band by chemi-
luminescence using Super Signal West Dura ECL Substrate
(Pierce). Immediately following Htt detection, b-actin was
detected on the same membrane, as a protein loading control,
using the same western blot method as described earlier. Anti-
beta Actin (Abcam) primary antibody and horseradish
peroxidase-conjugated donkey anti-mouse IgG secondary anti-
body (Rockland) were used.
Histochemical staining for hemoglobin
Hb activity was detected in whole embryos by performing
o-dianisidine staining using methods previously described
(112). The basis of this assay is that Hb catalyzes the H2O2-
mediated oxidation of o-dianisidine, producing a dark red
color in Hb-positive cells. Embryos were post-fixed in 4%
formaldehyde (in PBS) overnight at 48C and stored in 80%
glycerol for microscopy.
Histochemical staining for ferric iron
For detection of ferric iron in whole zebrafish embryos, a
3,3-diaminobenzidine (DAB)-enhanced Prussian blue staining
method was used, as follows. Fixed embryos were immersed
in a freshly prepared working solution containing 2.5% potass-
ium ferrocyanide and 0.25 M HCl, for 30 min at room tempe-
rature, then rinsed three times in PBST. Potassium
ferrocyanide reacts with ferric ions in the embryo, producing
ferric ferrocyanide (Prussian blue). In preparation for stain
enhancement, endogenous peroxidase activity was quenched
by incubating the embryos in 0.3% H2O2 (in methanol) for
20 min at room temperature. Following two rinses in PBST,
embryos were incubated for 7 min in DAB substrate using
PBS-dissolved SigmaFast DAB/urea (H2O2) tablets (Sigma-
Aldrich). Ferric ferrocyanide catalyses the H2O2-mediated
oxidation of DAB, producing a reddish brown color. Finally,
embryos were rinsed three times in PBST, and stored in
80% glycerol for microscopy.
To obtain blood cells, live embryos (33 hpf) were placed in
a solution of PBS, containing tricaine. Blood cells were
released by cardiac puncture onto a poly-L-lysine-coated
slide. Embryo debris was removed and blood cells were
allowed to settle and adhere to the slide for 30 min. The
cells were then fixed in 4% formaldehyde (in PBS) for 30 min.
Ferric iron was detected using a DAB-enhanced Prussian
blue staining method similar to that used for whole embryos
described earlier, with a few modifications, as follows. Cells
were incubated in a working solution of 0.5% potassium ferro-
cyanide and 0.75% HCl (conditions previously described for
staining blood cells [113)] for 30 min. The cells were then
rinsed three times in PBST. Endogenous peroxidase activity
was quenched by incubating the cells in 0.3% H2O2 (in metha-
nol) for 20 min. Following two rinses in PBST, embryos were
incubated for 4 min in DAB substrate using PBS-dissolved
SigmaFast DAB/urea (H2O2) tablets (Sigma-Aldrich).
Finally, cells were rinsed three times in PBST, and air-dried
before being covered with 80% glycerol and a coverslip for
microscopy.
Quantitative PCR
Total RNA was extracted from zebrafish embryos (!30
embryos per sample) using the RNeasy mini kit (QIAGEN).
From this RNA, cDNA was synthesized using Superscript II
RNase H-Reverse Transcriptase (Invitrogen). Quantitative
real-time PCR (qPCR) was performed on an ABI 7000 sequ-
ence detection system (Applied Biosciences), using the rela-
tive standard curve method for quantification (as set out by
the manufacturers) to generate raw values representing arbi-
trary units of RNA transcript. The experiment was performed
on three independent occasions. In every experiment, each
embryo sample was run in triplicate. Triplicate values for
acta1 were averaged, and each triplicate tfr1a and tfr1b
value was then normalized to the average acta1 value for
that sample. One hdMO1/tfr1b value was omitted from stati-
stical analyses as it was .2.5 standard deviations from the
mean value observed for that embryo class and was therefore
considered an outlier. Statistical analyses on normalized data
were performed using R software (114) and included
ANOVA and Student’s t-tests. The following primers were
used: tfr1a (fwd: AATCGCATTATGAGGGTGGAA and rev:
GGGAGACACGTATGGAGAGAGC); tfr1b (fwd: AAGAA-
TAGTGACCTGGAAGACATGG and rev: AATGAGACG-
TAAGGAGAGAGGAAATT); and acta1 (fwd: TGCCCAGA
GGCCCTGTT and rev: ACCGCAAGATTCCATACCCA).
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Huntington’s disease shares a common molecular basis with eight other neurodegenerative diseases, expan-
sion of an existing polyglutamine tract. In each case, this repeat tract occurs within otherwise unrelated pro-
teins. These proteins show widespread and overlapping patterns of expression in the brain and yet the
diseases are distinguished by neurodegeneration in a specific subset of neurons that are most sensitive
to the mutation. It has therefore been proposed that expansion of the polyglutamine region in these genes
may result in perturbation of the normal function of the respective proteins, and that this perturbation in
some way contributes to the neuronal specificity of these diseases. The normal functions of these proteins
have therefore become a focus for investigation as potential pathogenic pathways. We have used synthetic
antisense morpholinos to inhibit the translation of huntingtin mRNA during early zebrafish development and
have previously reported the effects of huntingtin reduction on iron transport and homeostasis. Here we
report an analysis of the effects of huntingtin loss-of-function on the developing nervous system, observing
distinct defects in morphology of neuromasts, olfactory placode and branchial arches. The potential common
origins of these defects were explored, revealing impaired formation of the anterior-most region of the neural
plate as indicated by reduced pre-placodal and telencephalic gene expression with no effect on mid- or hind-
brain formation. These investigations demonstrate a specific ‘rate-limiting’ role for huntingtin in formation of
the telencephalon and the pre-placodal region, and differing levels of requirement for huntingtin function in
specific nerve cell types.
INTRODUCTION
Huntingtin (htt) is a large 350 kDa protein that while ubiqui-
tously expressed is more abundant in the brain. Expansion
of the polyglutamine-coding region in the amino terminus of
htt results in a devastating neurodegenerative disease,
Huntington’s disease (HD). HD is associated with progressive
and debilitating motor, cognitive and psychological symptoms
(1,2). Presently, there is no treatment or cure for this disease,
which is fatal usually 15–20 years after onset.
The primary pathology of HD involves gradual and selective
death of medium spiny g-aminobutyric acid (GABA)-utilizing
neurons of the striatum, and neurons in the deeper layers of the
cerebral cortex. It is currently not known how the expansion of
the polyglutamine-containing region within htt gives rise to this
pathology (3,4). The dominant inheritance characteristic of the
disease suggests that the polyglutamine expansion may confer a
toxic gain-of-function upon htt. Interestingly, the same polyglu-
tamine expansion mechanism is found to be the same basis for
eight other neurodegenerative diseases, albeit in eight distinct
and unrelated proteins. Each disease shows a distinct neuronal
pattern of vulnerability to pathology. These distinctions have
been proposed to indicate that the loss or alteration of the
unique normal functions of these proteins contribute in some
way to the specificity of neuronal cell death (5). In order for
this to be the case, different neuronal cell types must therefore
have different needs for htt function for their survival. Analysis
of the normal role of htt may therefore provide some under-
standing of the molecular and cellular basis of the pathology
associated with HD.
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Since its identification over a decade ago, some insight has
been gained into the biological functions of htt. Analysis of its
structure and the dozens of binding partners provide clues to
htt’s function in a variety of processes including cell survival,
endocytosis, axonal transport and neuronal transcription
(reviewed in 6). Of particular interest is htt’s ability to regulate
the expression and transport of neurotrophin BDNF, which
plays an important role in neuronal survival and differentiation
(7–10). Expansion of the polyglutamine repeat region in htt
impairs both production and transport of BDNF (8,10,11).
Knock-out of the mouse orthologue, Hdh, demonstrated that
htt is required for development. Investigation of very early
Hdh2/2 mouse embryos, prior to embryonic lethality,
suggests a role for htt in embryonic organization, patterning,
cell survival and nutrient transfer between the embryo and
the extra-embryonic tissue (12–17). Limited information can
be gained from these Hdh2/2 mouse embryos with complete
absence of htt due to the early age of lethality and highly dis-
organized structure of the embryo.
In the current study, we have carried out an investigation of
the functions of htt in vivo, using an alternative animal model
system, Danio rerio. We have used morpholino oligonucleo-
tides to inhibit translation of the htt protein from the one
cell stage of development. One major advantage of using
this system is that we are able to partially reduce the level
of htt expression in order to gain a milder phenotype than
achieved with Hdh2/2 mice. Our previous analysis using
this model has demonstrated dramatic effects on embryogen-
esis upon reduction of htt expression (18). This investigation
revealed a role for htt in iron homeostasis and transport in zeb-
rafish (18). Using the same model system, htt was also shown
to be required for differentiation of cartilage of the pharyngeal
arches, a process which was shown to involve BDNF signaling
(19). Here we show that htt plays a role in formation of the
anterior most region of the neural plate, specifically in for-
mation of telencephalic progenitor cells and the pre-placodal
tissue. Subsequent inhibition of formation of sensory
neurons arising from the placodal tissue is rescued by addition
of exogenous BDNF.
By using morpholinos to reduce htt levels in the developing
zebrafish, we have demonstrated that neuronal cells have dif-
fering requirements for htt function. Given that perturbation of
normal htt function is a component of HD pathogenesis, this
differing requirement of particular neurons for htt function
provides a mechanism that can account for the specificity of
neuropathology in HD brains despite the widespread
expression of htt in the brain.
RESULTS
Htt signaling is required for normal peripheral sensory
neuron development in zebrafish
In this study, the zebrafish model system was used to deter-
mine the effects of reduced htt expression on early develop-
ment. The aim of these experiments was to determine
whether the normal functions of htt would be rate-limiting
for particular developmental processes involving the nervous
system and therefore indicate specificity of neuronal require-
ment for htt function.
Previous studies have suggested that htt may play a role in
the prevention of apoptosis (20). We therefore decided to look
at the general pattern of apoptosis within the whole embryo at
various stages of development, after injection of a morpholino
targeted to the zebrafish htt mRNA at the one cell stage. This
validated zebrafish model of htt function has been previously
described by our laboratory (18) and has also recently been
utilized by others (19,21).
Acridine orange was used to view cell death throughout
development in the whole hdMO1 embryo. As cell death is
a normal part of development, the pattern of cell death in
hdMO1 embryos was compared with that of two control
groups, wild-type (uninjected) and cMO injected embryos.
Very similar results were obtained for wild-type and control
morpholino injected embryos (cMO or mcMO1) in all exper-
iments in this manuscript. For simplicity, only one control
group image is shown, and as injection of a control morpho-
lino is a more stringent test of morpholino specificity, these
images are shown.
When analyzing the level of apoptosis with acridine orange,
of particular note was the reduction in cell death within the
olfactory placode (Fig. 1A and B) and within the lateral line
neuromasts (result appears similar to Fig. 1E and F described
below) of hdMO1 embryos (Fig. 1B and F) compared with
either of the control groups (Fig. 1A and E). Cell death is a
normal and continuous process within both the olfactory and
lateral line sensory systems to allow constant replenishing of
sensory neurons from the basal support cell population (22–
24). The absence of cell death in these regions suggests
either that these sensory neurons are not able to undergo cell
death in hdMO1 embryos, or that these sensory neurons are
not present with the olfactory or lateral line placodes. In
order to further investigate this phenotype, two dyes were
used which are specifically taken up by olfactory sensory
neurons and lateral line neuromasts. DiI is a lipophillic dye
used previously to visualize mature olfactory sensory
neurons in zebrafish (25). Staining embryos in this dye
revealed an absence of mature olfactory sensory neurons in
the olfactory placode of hdMO1 embryos at 96 hpf (Fig. 1D)
unlike the control (mcMO1) injected embryos (Fig. 1C). Simi-
larly, quantitative PCR (qPCR) analysis of olfactory marker
protein 2 (zOMP), expressed by mature olfactory sensory
neurons (26), is significantly reduced in hdMO1 embryos com-
pared with mcMO1 embryos (Table 1).
Like DiI, DASPEI staining is used to visualize sensory
neurons; however, DASPEI is specifically taken up by hair
cells within the lateral line neuromasts (27). In the wild-type
embryo, the number and pattern of lateral line neuromasts is
well characterized (28). DASPEI staining showed that
hdMO1 embryos have fewer lateral line neuromasts compared
with wild-type and mcMO1 injected embryos (Fig. 1E and F).
Quantification of the total number of neuromasts in each
embryo shows that this reduction occurs as a dose-dependent
response to hdMO1 injection (Fig. 1G).
Htt has a rate-limiting role in anterior neural
plate formation
Both the olfactory and lateral line sensory systems arise
from specialized regions of embryonic ectoderm termed the
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Figure 1. Htt is required for development of the olfactory and lateral line sensory systems of zebrafish. (A and B) hdMO1 embryos show reduced level of apop-
tosis in the olfactory placode visualized by staining with acridine orange. (C and D) Mature olfactory sensory neurons are absent in olfactory placode of hdMO1
embryos unlike in cMO embryos as revealed by staining with DiI. (E and F) DASPEI staining revealed hdMO1 embryos have a reduced number of lateral line
neuromasts compared with wt or mcMO1 embryos. (G) Reduction of htt expression significantly affects the number of neuromasts in a dose dependent manner.
!!!Significance is determined by P-value ¼ ,0.001. P-values were determined by a Student’s t-test comparison of each group to wt. Wt versus mcMO1 com-
parison showed no evidence of a significant effect due to mcMO1 injection. P-values ¼ 17 ng mcMO1, 0.10637499; 4.25 ng hdMO1, 1.83991E208; 8.5 ng
hdMO1 5.16023E221; 8.5 ng hdMO2, 2.82275E223; 17 ng hdMO2, 5.56472E221. (A–D) 8.5 ng of morpholino injected per embryo; (E and F) 17 ng
hdMO1 injected per embryo. (A–D) Ventral views of embryos at 72 hpf. (E and F) Lateral views of embryos at 96 hpf, anterior to the left. Numbers of
embryos displaying the described phenotypes were (A and B) cMO1 0/53, hdMO1 26/37. Representative embryos shown; (A, C and E) cMO1 injected
embryos, (B, D and F) hdMO1 injected embryos. Scale bar ¼ 25 mm.
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olfactory and lateral line placode, respectively. These are
among a number of placodal tissues that originate from a
common precursor region, the pre-placodal region, early in
gastrulation of all vertebrates (reviewed in 29–34). Given
this common origin, we speculate that htt may be important
in formation of the pre-placodal region. Six1, orthologue of
Drosophila sine oculis, encodes a homeodomain transcription
factor expressed throughout the pre-placodal region and in all
cranial placodes throughout development (35). We analysed
the mRNA expression pattern of six1 at 12 hpf in an attempt
to visualize the pre-placodal region in the developing zebra-
fish. In situ hybridization analysis revealed a clear reduction
in the level of six1 expression in the pre-placodal region of
hdMO1 embryos (Fig. 2A and B). At this time in normal
development, placodal cells have formed at the anterior end
of the neural plate and some of the placodal cells (the lateral
line and otic placodes) have broken away and are migrating
posteriorly toward their final destination. Six1 expression
appears to be reduced in both areas in hdMO1 embryos
(Fig. 2B). Quantitation of the overall level of six1 mRNA
expression by qPCR analysis shows that six1 expression was
significantly reduced in hdMO1 zebrafish embryos (Table 1).
In support of this result, expression of a second marker of pre-
placodal cells which are more specifically expressed within the
olfactory precursor cells, Drosophila distal-less orthologue,
dlx3b was also shown to be significantly reduced in hdMO1
embryos (Table 1) (36). This reduction in six1 and dlx3b
expression suggests that htt has a rate-limiting role during
development in the formation of the pre-placodal region.
Fate and expression mapping (36–39) has been carried out
for cells of the zebrafish anterior neural plate. Figure 2C
demonstrates the position of pre-placodal tissue expressing
six1 and dlx3b at the anterior ridge of the neural plate.
Immediately adjacent to this, telencephalic precursor cells at
the neural plate margin express emx3 (green) (40–42).
qPCR analysis of hdMO1 embryos revealed reduced
expression levels of emx3 (Table 1) suggesting that htt is
also required for formation of neural-fated ectoderm, not
only the pre-placodal region. This result correlates with
reduced expression of dlx2 within the subpallial telencephalon
and diencephalon later in the development (Fig. 2D and E).
Interestingly, anterior neural plate expression of otx2 (slightly
more posterior to emx3) was not significantly reduced in
hdMO1 embryos by qPCR (Table 1) and in situ hybridization
analysis, with no change in the pattern of expression (Fig. 2F
and G).
In an effort to identify the cellular location and develop-
mental process(es) in the neural plate for which htt activity
was rate-limiting, we examined the expression of a number
of genes, which are markers for known regions of the neural
plate, neural plate derivative tissues and also for notochord
formation. First, we selected genes that are expressed at
specific locations along the neural plate from the forebrain
to the hindbrain. As visualized by in situ hybridization,
expression of krox20 and hoxd4a genes within the hindbrain
(expressed in rhombomere 3 and 5, and rhombomere 7þ,
respectively) were not altered in hdMO1 embryos (Fig. 3A
and B). In addition, expression of neural crest cell marker
dlx2 at 19 hpf demonstrated that in hdMO1 embryos, cranial
neural crest cells form in the same three-group pattern in the
hindbrain as seen in both mcMO1 and wild-type embryos
(Fig. 3C and D).
In 2005, Woda et al. (15) showed that Hdh2/2 mouse
embryos at e6.5 had reduced neuroectoderm formation, and
lack a morphological node. This was suggested to be caused
by a deficiency in formation of the anterior primitive streak
(anterior blastopore; anterior blastoderm margin in zebrafish
(43)). The blastoderm margin is required for the formation
of the germ layers. To investigate whether a deficiency in
the anterior blastoderm margin gives rise to the anterior
neural plate deficiency phenotype observed here, we examined
mesoderm formation in hdMO1 embryos. In situ hybridization
Table 1. Quantitative PCR analysis of various genes within the neural plate and derivative tissue, the olfactory receptor neurons
Plot order Gene Treat Estimate Log10-Fold change SE T-Stat DF Adjusted P-value Significance
hdMo1 versus mcMo1
1 dlx3b hdMo1 versus mcMo1 21.17221 214.867 0.1684 26.959 66 8.94E209 !!!
2 emx3 hdMo1 versus mcMo1 21.20867 216.169 0.1257 29.613 53 4.60E212 !!!
3 ntl hdMo1 versus mcMo1 20.00583 21.014 0.0610 20.096 80 0.9238
4 zOMP hdMo1 versus mcMo1 20.30378 22.013 0.1105 22.749 47 2.96E202 !!!
5 otx2 hdMo1 versus mcMo1 20.25161 21.785 0.1213 22.075 50 0.1007
6 six1 hdMo1 versus mcMo1 21.07600 211.912 0.1437 27.491 53 5.12E209 !!!
7 val hdMo1 versus mcMo1 20.15320 21.423 0.0736 22.081 51 0.1007
wt versus mcMo1
1 dlx3b wt versus mcMo1 20.19321 21.560 0.1667 21.159 66 0.3900
2 emx3 wt versus mcMo1 20.12011 21.319 0.1257 20.955 53 0.4815
3 ntl wt versus mcMo1 0.11289 1.297 0.0604 1.870 80 0.1303
4 zOMP wt versus mcMo1 20.13956 21.379 0.1105 21.263 47 0.3724
5 otx2 wt versus mcMo1 20.04433 21.107 0.1193 20.372 50 0.8153
6 six1 wt versus mcMo1 0.04467 1.108 0.1437 0.311 53 0.8153
7 val wt versus mcMo1 20.02317 21.055 0.0723 20.320 51 0.8153
‘Estimate’ column shows raw values representing arbitrary units of RNA transcript as determined by the standard curve showing expression of each gene relative
to expression of the control gene, elongation factor (ef-1a) (78). !!! Significance is determined by P-value # 0.001. For hdMO1 versus mcMO1, dlx3b, emx3,
zOMP and six1 all show statistically significant evidence of differential regulation with P # 0.001. ntl, otx2 and val do not show statistically significant evidence of
differential regulation. None of the wt versus mcMO1 comparisons show any evidence of a significant effect due to mcMO1 injection. 8.5 ng of morpholino
injected per embryo. All embryos were analysed at 12 hpf except zOMP which was analysed at 48 hpf. Abbreviations: DF, degrees of freedom; se, standard error.
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of mesodermal marker, no tail (ntl) in hdMO1 embryos
showed no change in pattern of expression in the notochord
compared to control embryos, however lower expression
within the tailbud was observed (Fig. 3E–H and Table 1)
(44). The tailbud is important for the formation of posterior
structures of the developing embryo, both axial and non-axial
structures such as the notochord and the tail, respectively
(45,46). With high doses of morpholino, hdMO1 embryos
appear to have a curled tail (18) which suggests deficiency
in the non-axial mesoderm. Importantly, within the tail bud,
hdMO1 embryos still form the Kupffer’s vesicle, the zebrafish
structure equivalent to the mouse node and required for left–
right patterning (47). These investigations demonstrate that
hdMO1 embryos are deficient only in the very anterior
margin of the neural plate and suggest a possible role for htt
in the formation of this region. Appropriate formation of the
notochord suggests that this is not due to deficiency in the
anterior blastoderm margin. These results also show that htt
does not play a rate-limiting role in the formation of the mid-
brain or hindbrain, or in anterior–posterior patterning of the
neural plate at this reduced level of htt expression.
To further elucidate the mechanism of anterior ectoderm
deficiency in hdMO1 embryos, investigation into embryonic
tissues required for formation of this region was carried out.
In zebrafish, the yolk syncytial layer (YSL) plays an important
role in the formation of the anterior neuroectoderm in a similar
manner to the anterior visceral endoderm in mouse (48). At
30% epiboly (4.7 hpf), sox32 is expressed by cells of the
YSL and presumptive endoderm. By in situ hybridization
analysis, there appears to be no change in the abundance or
pattern of cells in the YSL in hdMO1 embryos (Fig. 3L) com-
pared with the control embryos (Fig. 3I). This suggests that the
reduction in htt levels to this experimental level does not alter
the formation of the YSL and therefore that this is not a cause
of the reduction in anterior ectoderm derivatives seen in
hdMO1.
Like the node in mouse and chick, the zebrafish shield has
an essential role in the induction of anterior neural tissue
(reviewed in 49). We analyzed the expression of the gene,
goosecoid (gsc), that is normally expressed within the zebra-
fish organizer at shield stage (6 hpf) and plays an essential
role in dorso-ventral patterning and formation of forebrain
development (50). We found that injection of hdMO1 did
not affect the pattern or level of gsc expression in the organi-
zer (Fig. 3M and N) suggesting that perturbation in organizer
activity does not play a role in the hdMO1 phenotype
described herein.
Htt is important for neural crest cell differentiation
into cartilage
Gross analysis of the morphology of hdMO1 embryos revealed
disruption in tissues of the mouth. This was especially evident
after staining with acridine orange (Fig. 1A and B) with no
increase in cell death seen in this region. However, the acri-
dine orange staining provided some contrast within the trans-
parent embryo, exposing the external pharyngeal morphology.
As the structure of the branchial region lies over the cartilage
Figure 2. RNA in situ hybridization and qPCR reveal htt is required specifi-
cally for the formation of the anterior neural plate. (A and B) hdMO1 embryos
show reduced expression of six1 in the pre-placodal region (arrow head) com-
pared with mcMO1 embryos. Asterisk shows lateral line and otic placode cells
migrating toward the posterior in (A) which are also reduced in hdMO1
embryos (B). (C) Schematic drawings showing expression and fate maps of
the zebrafish anterior neural plate and pre-placodal field at the end of gastrula-
tion (32,36,39). The location of particular cell fates in the anterior neural plate
and pre-placodal field correlate to gene expression patterns. All placodal
tissues express six1 (32), and in addition express one (or a number of) other
genes as listed; adenohypophysis precursor cells (pituitary) express dlx3b
and pitx3. Lens precursors express pitx3 or pitx3 and dlx3b. Olfactory precur-
sors express dlx3b and pitx3, or only dlx3b. Anterior neural plate tissues,
which are not derived from the pre-placodal region include: telencephalic pre-
cursor cells (expressing emx3, or emx3 and zic1) and retinal precursors
(expressing zic1). The otx2 expression domain in the anterior neural plate is
shown in grey. Dorsal view, anterior to top. (D and E) At 19 hpf, hdMO1
embryos have reduced expression of dlx2, particularly in the subpallial tele-
ncephalon (te), but also in the diencephalon (di). Expression of anterior
neural plate marker otx2 is only slightly reduced in hdMO1 embryos by
in situ hybridization (F and G). (A and B) 20 hpf, (D and E) 19 hpf, (F and
G) 10 hpf. (A, B, D and E) Lateral view, anterior to the left, (F, G) dorsal
view, anterior to the top. Numbers of embryos displaying the described phe-
notypes were (A and B) wt, 7/22, mcMO1 3/45, 8.5 ng hdMO1 25/46, 17 ng
hdMO1 34/40, results combined from two independent experiments; and (D
and E) wt, 0/12, mcMO1 1/18, 17 ng hdMO1 15/18. Representative
embryos shown. Abbreviations: te, telencephalic dlx2 streak; di, diencephalic
dlx2 streak. Scale bars represent (A, B) 200 mm and (D, E) 100 mm.
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skeleton, it seemed likely that hdMO1 embryos would have an
altered cranioskeletal structure. Alcian blue was used to stain
the cartilage of hdMO1 embryos in order to visualize this
disruption (Fig. 4A–C). At a moderate dose of morpholino
(8.5 ng), hdMO1 embryos (Fig. 4B) have fully formed pharyn-
geal arch 1 (p1; or Meckel’s cartilage) and p2 (or ceratohyal)
cartilages. In 25% of embryos, the p2 is pointing in a caudal
rather than rostral direction. An example of this is shown in
Figure 4B. Approximately 70% of all hdMO1 embryos show
partial or complete loss of p3–p7 cartilages. During prep-
aration of this manuscript, a similar phenotype was described
using this model (19).
In an effort to investigate further, the cause of this pheno-
type, in situ hybridization analysis of dlx2 expression was
used to visualize the undifferentiated cartilage forming cells,
the cranial neural crest, throughout their development. As
shown earlier, the cranial neural crest cells form in the hind-
brain in the correct pattern (Fig. 3B), then by 33 hpf they
have migrated from the hindbrain into the pharyngeal arches
in hdMO1 embryos in a similar manner to cMO1 embryos
(Fig. 4D and E). The arches, containing neural crest cells,
are separated from each other by pharyngeal endoderm (non-
staining tissue between the arches). At this time, arches p1–
p6 are divided by the endoderm, but p6 and p7 have not yet
been divided, as seen in Fig. 4D. However, in hdMO1
embryos, arches p5–p6 have not yet finished dividing
(Fig. 4E, arrow) suggesting a slight developmental delay of
craniofacial formation.
In wild-type embryos, the pharyngeal neural crest cells con-
tinue to express dlx2 until they differentiate into cartilage. The
process of differentiation begins at approximately 48 hpf.
In situ hybridization of dlx2 shows that at 56 hpf, well after
onset of differentiation, some dlx2 is still expressed by neural
crest cells of cMO embryos (Fig. 4F and G). dlx2 is also
expressed by neural crest cells of hdMO1 embryos. This
demonstrates that in hdMO1 embryos, cartilage precursors
have survived beyond the onset of differentiation and it is there-
fore unlikely that the pharyngeal disruption in hdMO1 embryos
is due to early apoptosis of pharyngeal neural crest cells. It is
Figure 3. Further characterization of the hd MO1 neural plate phenotype.
(A–D) Reduction in Htt expression does not alter anterior–posterior brain pat-
terning. (A and B) In situ hybridization analyses of krox-20 (red) and hoxd4a
(purple) show the segmental nature of the zebrafish hindbrain into rhombo-
meres. The hindbrain of hdMO1 (B) is unaltered when compared with
cMO1 (A). (C and D) In situ hybridization of dlx2 shows that neural crest
cells arise at the lateral edge of the neural plate in the correct pattern. Htt
does not affect formation of the notochord, however hdMO1 embryos (F)
have a noticeably smaller tailbud compared with cMO1 embryos (E;
compare distance between arrows in each image. Also compare length of
bars in dorsal view; G, H). (I and J) The YSL of hdMO1embryos is indistin-
guishable from that of mcMO1 embryos by in situ hybridization of sox32.
(M and N) Reduction in htt expression does not alter formation of the node
shown here by expression of gsc. (A–D) Dorsal views of embryos at
19 hpf, anterior to the left; (E and F) lateral views of embryos at 12 hpf,
anterior to the left; (G and H) dorsal views of embryos at 12 hpf; (I and J)
dorsal views of embryos at 30% epiboly; (K and L) lateral views of
embryos at 30% epiboly, dorsal to the top; (M and N) lateral views of
embryos at 60% epiboly, dorsal to the top. Numbers of embryos displaying
the described phenotypes were (G and H) cMO1 8/47, hdMO1 27/35. Repre-
sentative embryos shown. Abbreviations: r3-r7þ, rhombomere 3 to rhombo-
mere 7 onward; ov, otic vesicle; m, mandibular group; h, hyoid group; b,
basihyal group; kv, kupffler’s vesicle; tb, tailbud; cnc, cranial neural crest.
All scale bars represent 200 mm. All embryos in left column except (A) and
(C) have been injected with mcMO1, (A) and (C) are cMO embryos. All
embryos in right hand column are hdMO1 embryos. All embryos were injected
with 17 ng of morpholino, except (C) and (D) injected with 8.5 ng morpholino.
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possible, however, that reduced htt expression impairs
differentiation of neural crest into cartilage.
To investigate the differentiation of pharyngeal cartilage, we
analyzed the expression pattern of col2a1, a gene expressed by
and required for neural crest cells during differentiation into
cartilage. At 56 hpf, the most anterior pharyngeal cartilage is
differentiating in cMO1 embryos including the epiphyseal
plate (ep), palatoquadrate (pq), p2 and p3 cartilages (Fig. 3G
and H). Differentiation has also begun in hdMO1 embryos;
however, col2a1 is reduced in the pq and p2 cartilages, and
absent in p3. This result suggests that the absence of many or
all of the ceratobranchial cartilage elements is likely to be due
to impaired differentiation of these cartilage elements in
hdMO1 embryos. Injection of a higher dose of hdMO1 morpho-
lino still does not affect differentiation of the p1 or p2 cartilage,
suggesting that htt at this low level is not a rate-limiting step in
p1 and p2 cartilage differentiation, although they are grossly
malformed. Initially, it was thought that the caudal pointing
p2 cartilage in Figure 4B was due to fusion of this bone to the
basihyal (bh) or p3 during development. However, the caudal
pointing p1 and p2 cartilages in Figure 4C suggests the cause
of this malformation may be lack of development of the under-
lying endoderm.
BDNF rescues the hdMO1 peripheral sensory
neuron phenotype
Growth factor, BDNF has been shown previously to play a
major role in neural development including formation, survi-
val and differentiation of neurons. htt has been shown to regu-
late the production and transport of BDNF (7–10) and
recently, Diekmann et al. (19) showed that exogenous
BDNF is able to rescue partially a craniofacial phenotype
(in hdMO1 embryos) similar to that described earlier. It was
Figure 4. Htt has a role in differentiation of neural crest cells into pharyngeal cartilage. (A) Alcian blue shows the normal pattern of cartilage in the pharyngeal
region of cMO1 embryos. hdMO1 embryos have a disrupted craniofacial cartilage structure. (B) Some, more severe hdMO1 embryos show a malformed p2
(ceratohyal) cartilage, which is pointing in a caudal rather than rostral direction. (C) Injection of a higher concentration of hdMO1 results in a more severe
phenotype; however, p1 and p2 are still present. (D–G) In situ hybridization of dlx2, shows undifferentiated cartilage precursor cells are present within the
pharyngeal arch endoderm of cMO and hdMO1-injected embryos at 33 hpf (D and E) and at 56 hpf (F and G), well after onset of neural crest differentiation
into pharyngeal cartilage. The reduced level of col2a1 expression within some cartilage elements, however, suggests that the reduction in htt expression inhibits
differentiation of pharyngeal arch cartilage (H and I). (A–C) 7 hpf, (D and E) 33 hpf (20 somites), (F–I) 56 hpf. All scale bars represent 200 mm except (D and
E) which equals 100 mm. (A–C) Ventral view, anterior to left. (D–I) Lateral views, anterior to the left. 8.5 ng morpholino injected per embryo, except in (C)
where 17 ng morpholino was injected. Representative embryos shown. Numbers of embryos displaying the described phenotypes were: (A and B) 0/33 wt, 1/51
cMO, 40/47 hdMO1; (H and I) 0/17 cMO, 11/12 hdMO1. Abbreviations: bh, basihyal; hs, hyosymplectic; p, pharyngeal arch; p3–p7, pharyngeal arch 3–7; pq,
palatoquadrate.
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therefore hypothesized that altered BDNF may contribute to
the hdMO1 sensory neuron phenotypes described in this
paper. The number of lateral line neuromasts in zebrafish
embryos is well characterized and highly consistent (28).
We used DASPEI staining of lateral line neuromasts to deter-
mine whether adding BDNF to the embryo medium during
development was able to rescue the reduction in neuromast
number seen in hdMO1 embryos. Exogenous BDNF protein
was added to the embryo medium immediately following
hdMO1 injection. Embryos were allowed to develop in
embryo medium with or without BDNF until 120 hpf.
Similar to the results shown in Figure 1G, hdMO1 embryos
had a reduced number of neuromasts than wild-type
embryos at 120 hpf, P ¼ ,0.001 (average neuromast
numbers were WT, 26.83+ 0.38, n ¼ 42; hdMO1, 20.53+
3.75, n ¼ 49). BDNF was able to restore partially the
number of lateral line neuromasts, shown by a shift in the
mean number of lateral line neuromasts toward WT levels
(hdMO1 versus hdMO1þBDNF P ¼ ,0.005; average neuro-
mast number was hdMO1þBDNF, 22.73+ 2.95, n ¼ 45).
This result showed a partial but statistically significant
rescue of the number of lateral line neuromasts toward wild-
type levels, supporting that BDNF plays a role in the
sensory neuron phenotype in hdMO1 embryos. Currently, it
is not known at which stage BDNF may play a role in the
sensory neuron phenotype caused by reduced htt levels.
However, this result highlights the important role of BDNF
in htt signaling and development.
DISCUSSION
Htt is a large 350 kDa protein that is ubiquitously expressed
throughout development. Expansion of a polyglutamine
repeat region in the amino terminus of htt is responsible for
the devastating neurodegenerative condition, HD. Although
it is widely accepted that the presence of the polyglutamine
repeat beyond a threshold number imparts a toxic
gain-of-function property to this protein, there is some com-
pelling evidence to suggest that a loss of the normal function
of htt contributes to HD pathology, especially its neuronal
specificity (reviewed in 6).
Presently, the normal functions of htt are unclear. The many
binding partners and biological processes described to date
suggest that the cellular functions of htt are numerous, includ-
ing transcriptional regulation, vesicle trafficking, iron homeo-
stasis and cell survival (reviewed in 6). It has been unclear
which, if any, of these functions might be rate-limiting in
neurons and therefore candidates for perturbation in HD.
Animal model systems are useful to identify the functions of
htt in the complex developing organism. Previously, analysis
of htt functions in the mouse model has been difficult due to
the early embryonic lethality of homozygous knockout
animals and the apparent lack of phenotype in heterozygous
animals (12,16,17). Embryonic lethality in these embryos
demonstrates that htt plays a critical role in early embryonic
development; however, it also makes analysis of the conse-
quences of htt knockout in older embryos difficult.
In the present work, we describe the effects of
morpholino-induced inhibition of htt translation in zebrafish
embryos. Morpholinos are short strands of non-degradable,
synthetic antisense oligonucleotides injected at the one cell
stage to block the translation of htt mRNA into protein. The
benefit of this approach is that the extent of inhibition of htt
expression can be varied as can the resulting phenotype by
adjusting the dosage of morpholino injected. We have
described the use of this model system previously (18) and
have used a moderate level of morpholino so as to investigate
the effects of a partial reduction of htt expression. With partial
htt reduction, hdMO1 embryos have impaired formation of the
anterior region of the early neural plate as evidenced by
reduced expression of genes characteristically present within
the pre-placode and anterior neural plate including: six1,
dlx3b and emx3. The reduction in anterior neural plate precur-
sor cells later results in a dose-dependent reduction in the
number of lateral line neuromasts and also reduction in olfac-
tory sensory neurons and forebrain regions such as the subpal-
lium and diencephalon.
Placodal tissue is a homogeneous layer of embryonic ecto-
derm that becomes specified early in development to form a
number of different tissues. The olfactory and lateral line
systems are among a number of placodal tissues that originate
from this common precursor region, others include adenohy-
pophyseal, trigeminal, profundal, lens, otic and a series of epi-
branchial and hypobranchial placodes. It is hypothesized that
reduction of the pre-placodal domain will affect all tissues
derived from these placodes; including the anterior lobe of
the pituitary gland, ganglia of the trigeminal and profundal
nerves, lens, otic vesicle and the sensory neurons of the
distal ganglia of the face, respectively (32). The downstream
effects of disruption in placode formation alone are wide
ranging and, in addition to the loss of telencephalic precursor
cells, have devastating consequences on embryo development.
While a significant reduction was observed in the level of
anterior gene expression (for six1, dlx3b and emx3), no signifi-
cant change was observed in the slightly more posterior
marker otx2. There was also no significant change in
markers of mid- and hindbrain tissue (valentino, krox20 and
hoxd4a), or the hindbrain-derived tissue, the cranial neural
crest (dlx2b). It therefore appears that the consequences of
htt deficiency in hdMO1 embryos are restricted to the most
anterior regions of the neural plate and pre-placodal region,
and do not affect anteroposterior patterning of the neural plate.
The anterior neural plate, along with the cranial dorsolateral
endomesoderm, is important for the induction of the pre-
placodal region (51). Given this, it is possible that the
reduction in pre-placodal tissue occurs as a result of deficiency
in the anterior neural plate emx3 expressing cells, located at
the anterior neural plate border region. Therefore, we hypoth-
esize that htt is specifically required for the formation or sur-
vival or the anterior neural plate margin, including emx3
expressing telencephalic precursor cells.
Investigation of the possible cause of anterior neural plate
deficiency showed no change in two structures known to be
important in the formation of the anterior neural plate, the
shield (expressing gsc) and the YSL (expressing sox32).
This result is in contrast to that observed by White et al.
(14), and Woda et al. (15), where Hdh2/2 mice did not
form a morphological node. The difference between hdMO1
and Hdh2/2 mice is likely to be due to the small amount of
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htt present in hdMO1 embryos as a result of the incomplete
reduction of htt translation by hdMO1, and pre-injection
translation of maternally deposited htt mRNA in 1-cell
hdMO1 embryos (18). This small level of htt expression is
likely to be sufficient to allow formation of the node in
hdMO1 embryos and supports that the anterior deficiency is
not a result of perturbation in node formation.
During the preparation of this manuscript, another descrip-
tion of brain morphology and apoptosis in zebrafish with
reduced htt expression was published (19). In this paper, it
was stated that their hdMO1 embryos had similar brain mor-
phology to that described earlier in our lab (18). Diekmann
et al. (19) noted apoptosis within the midbrain and hindbrain
of their hdMO1 embryos. Our analysis did not reveal the
same pattern in apoptosis within the midbrain or hindbrain
at anytime during development. However, we observed a sig-
nificant increase in apoptosis within the optic tectum at 36–
48 hpf (data not shown). This result may complement
another observation of Diekmann et al. (19), showing signifi-
cantly reduced axonal innervation of this region by retinal
axons. At approximately 36–48 hpf, retinal axons are required
to make contact with the optic tectum. Any neurons in the
optic tectum that are not contacted by retinal axons undergo
apoptosis (22). Although retinal precursors form within the
anterior region of the neural plate, the anterior neural plate
deficiency in hdMO1 embryos is not necessarily the cause of
this retinal axon phenotype. Retinal precursor cells express
zic1. This gene is expressed largely within the otx2-expressing
domain as shown in Figure 2C. As hdMO1 embryos do not
appear to be deficient in the otx2 expressing cells, it is unlikely
that this phenotype is due to reduction of retinal precursor cell
number. It is possible, however, that htt may play a role in
retinal development after retinal cell formation, such as in sur-
vival, differentiation or axon guidance of the retinal cells. This
possibility is supported by a Drosophila htt knockout model in
which absence of htt leads to retinal degeneration in adult flies
(52). The observed neurodegeneration is similar to that caused
by overexpression of htt with an expanded polyglutamine
region (52). Retinal degeneration is also seen in HD transgenic
mouse model R6/2 (53,54) and a human HD patient compared
with age-matched control, although only one HD patient was
studied (55). This evidence suggests a role for htt in survival
of retinal cells, and for perturbation of htt function in the
pathogenesis of HD.
Clinical observations of HD patients also reveal some evi-
dence of olfactory impairment. HD patients have been
shown to have impaired olfactory detection (56–58), olfactory
memory (56,57,59), identification (57,58,60,61) and discrimi-
nation of quality and intensity of odors (58). This dysfunction
may occur by either of two mechanisms. First, neurodegenera-
tion within brain regions which are important for processing
olfactory information is likely to be the cause of impaired
olfactory memory, identification and discrimination (59),
while impaired odor detection is likely to be due to dysfunc-
tion of olfactory neurons. Because of htt’s role in anterior
neural plate formation shown here, it is possible that either
of these mechanisms results from perturbation of normal htt
function. These findings therefore suggest that loss of
normal functions of htt contributes to the impaired olfactory
function seen in HD patients.
A number of functions have been proposed for htt, which
may affect brain formation and patterning contributing to
a deficiency in anterior neural plate formation. Such functions
include promotion of cell survival, differentiation and for-
mation of progenitor cells. Neurotrophins, such as BDNF,
are important in mammalian neurons for survival and differen-
tiation. Htt is known to play an important role in regulating the
production of BDNF (7–9) and in the transport of BDNF
along microtubules (10). Adding exogenous recombinant
BDNF to the embryo medium was able to rescue partially
the number of lateral line neuromasts toward wild-type
levels, suggesting that alteration in the production or supply
of BDNF is responsible in part for the loss of lateral line neu-
romasts. It is currently not clear which step in the formation of
lateral line neuromasts is rescued by BDNF—whether in the
formation of the anterior neural ectoderm, in its survival or
in differentiation of the sensory neurons, a known function
of BDNF (62). The significant, yet incomplete, rescue of neu-
romast number upon addition of BDNF to hdMO1 embryos
suggests that other distinct (still to be identified) htt interacting
pathways may play a role in neuromast development.
A role for htt in brain development is suggested by the high
level of htt expression in the brain early in development;
however, its precise function at this stage is not clear. Htt
has a known important role in neuronal survival, and has
been shown to be required for the formation or survival of
neurons in specific regions of the brain. A conditional knock-
out system in mouse has previously shown that htt is required
for survival of neurons within the postnatal forebrain (63).
More specifically, Hdh2/2 ES cells injected into a wild-type
blastocyst showed that htt expression was required for neur-
onal survival within the striatum, cortex, hippocampus and
Purkinje cells of the cerebellum (13). These results are comp-
lementary to that seen in our zebrafish model of
morpholino-induced htt knockdown, highlighting a role for
htt in formation or survival of anterior neural tissues.
A search of the literature did not reveal any report of a
mutant or morphant zebrafish exhibiting the same constella-
tion of phenotypes brought about by reduction in htt. There-
fore, the identity of other participants in these pathways that
might be revealed by such mutants awaits more thorough
mutation analysis of zebrafish.
In summary, the data presented here demonstrates a role for
htt in the formation of the anterior most region of the neural
plate using a zebrafish model system of htt knockdown. The
advantages of this system enable analysis of htt function at
the earliest stages of development, a difficult task in mouse
Hdh knockout models. Our data show that despite the homo-
geneous expression of htt in the brain, htt functions specifi-
cally within the forebrain to enable formation of precursors
of the telencephlon and pre-placodal cells. The downstream
effect of this includes loss of placode-derived tissue including
olfactory and lateral line sensory neurons, and reduction in tel-
encephalic tissue. The observed sensory neuron requirement
for htt in the zebrafish htt depletion model described here is
consistent with the observation that HD patients show
impaired olfactory function (64–69). This suggests that the
loss of normal function of htt contributes to at least some of
the symptoms of HD pathology. We have also demonstrated
that the htt-dependant reduction in peripheral sensory
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neurons is rescued partially by BDNF, further highlighting the
important developmental role for htt in regulation of BDNF
signaling, and the likely participation of BDNF in HD pathol-
ogy.
MATERIALS AND METHODS
Zebrafish maintenance and staging
Zebrafish were maintained at 28.58C under standard con-
ditions as described (70). Embryo medium (71) was used to
develop fish for all experiments. Developmental stages were
determined by using both timing (hours post fertilization,
hpf) and morphological features according to Kimmel et al.
(71). For in situ hybridization analysis after 20 hpf, embryos
were raised in 40 mM 1-phenyl-2-thiourea (PTU) from gas-
trula stage (5.5 hpf) to inhibit pigment formation.
Morpholino design
All morpholinos (MOs) used were designed and synthesized
by Gene-Tools, LLC Ore and were of the same antisense
sequence as described previously (18). hdMO1, hdMO2,
cMO and mcMO1 morpholinos were prepared and injected
in the manner described in ref. (18).
Acridine orange staining
Apoptosis in whole embryos was assessed by staining with the
vital dye, acridine orange (AO; Sigma-Aldrich) (72). The acri-
dine orange protocol was adapted from Li and Dowling (73).
A stock solution was made up to 1 mg/ml in water. Embryos
were dechorionated and placed in 1/1000 dilution of the acri-
dine orange stock solution in embryo medium for 30 min.
After washing in embryo medium, the embryos were placed
into tricaine anesthetic solution (3-amino benzoic acid ethyl
ester; Sigma-Aldrich) (70) and viewed immediately using a
green fluorescence filter.
Alcian blue
Alcian blue cartilage stain was used to visualize the structure
of the craniofacial skeleton of zebrafish. Five- to 8-day-old
larvae were fixed in 4% formaldehyde in 1 $ phosphate buf-
fered saline (PBS) overnight at 48C. Embryos were bleached
in 0.5 ml 30% hydrogen peroxide for about 2 h. Twenty-five
microlitres of 2 M potassium hydroxide was added to
enhance the bleaching process. When eyes appeared suffi-
ciently translucent, embryos were stained overnight in a fil-
tered alcian blue solution (1% concentrated hydrochloric
acid, 70% ethanol, 0.1% alcian blue (AnaSpec)). Embryos
were cleared in acidic ethanol (5% concentrated hydrochloric
acid, 70% ethanol) for 4 h, rehydrated in a graded ethanol
series (50%, 25% then PBS), then stored in 80% glycerol at
2208C. Craniofacial cartilage was visualized under a Zeiss
Axiophot light microscope and photographed using a 10$
objective.
DiI staining
DiI was used to label mature olfactory sensory neurons in live
zebrafish embryos (25). DiIC18(3) powder (Invitrogen) was
made up to a 5% stock solution in dimethylformamide
(DMF). To stain the embryos, 1 ml of DiI stock was added
to 5 ml DMF and 4 ml 70% glycerol. The 10 ml working
stock of DiI solution was added to 96 hpf zebrafish embryos
in 4 ml of embryo medium for 15 min. For viewing, fish
were anesthetized in tricaine then mounted in 3% methylcellu-
lose with tricaine. DiI stained olfactory receptor neurons were
initially viewed on a dissecting microscope using a rhodamine
cube or filter suitable for 550 nm emission 2565 nm exci-
tation. Images were captured on a Leica SP5 spectral scanning
confocal microscope.
DASPEI staining
DASPEI specifically stains hair cells within lateral line neuro-
masts (27) of live zebrafish embryos. The staining procedure
was carried out as described in ref. (74). One hundred and
twenty hours post fertilization live zebrafish embryos were
immersed in 1 mM DASPEI in embryo medium for 5 min
(supernatant only). The embryos were then rinsed thoroughly
in embryo medium before anesthetizing and viewing as
described above for DiI. For quantitation, presence or
absence of each lateral line neuromast was recorded with
reference to the previously described pattern along the
lateral side of the embryo (28). Statistical analysis was per-
formed using a Student’s t-test.
For BDNF rescue experiments, human recombinant BDNF
(100 ng/ml; Millipore) was dissolved in water and added to
the embryo medium 10 h after morpholino injection.
Embryo medium with or without BDNF was replaced with
Table 2. Primers used for quantative PCR
Gene Upstream primer (50 to 30) Downstream primer (50 to 30) Product (bp)
dlx3b GAGGGCTGAGAACACGAACC TCACCATTCTAATGACCGCT 51
ef1a CCAACTTCAACGCTCAGGTCA CAAACTTGCAGGCGATGTGA 105
emx3 GATATCTGGGACACCGGTTTCA AGCAGGTTTTCAGGGCTACTGT 52
ntl CACACCACAAACACTACCTCCAAC TGACCACAGACTTGGGTACTGACT 51
zOMP GAACCCACCGGACTCTTCTG TTGGCCAGCTCTGCTATCCT 101
otx2 CCCTCCGTTGGATACCCAGT TCGTCTCTGCTTTCGAGGAGTC 51
six1 CTACCACACAAGTGAGCAACTGG AGCGCCCGTGTTGTTGTT 99
val CAGCTTGTGACCATGTCCGT TGAAGCCCCGCAGGTGT 52
All primers span introns where possible (exceptions are zOMP and val).
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fresh medium every 24 h. Each experiment was carried out on
three separate occasions by a blinded investigator. Seventeen
nanogram hdMO1 was injected per embryo.
Whole-mount in situ hybridization
In situ hybridization was carried out according to the protocols
published by Jowett (75) with minor changes, described as
follows. To allow chromogenic detection, alkaline phospha-
tase conjugated antibody was added at 1:4000 dilution in
PBS with 0.1% Tween-20 and 1% BSA for 1 h at 48C. For
two color in situ hybridization, NBT/BCIP was used to
detect the first (and weakest) probe, prior to detection of the
second probe with Vector red. Digoxygenin and fluorescein-
labelled antisense probes were synthesized from cDNAs of
krox 20 (64), gsc (65), otx2 (66), six1 (35), ntl (44), dlx2
(67), dlx3b (67), col2a1 (68), sox32 (69), val (76) and
hoxd4a (77).
Quantitative PCR
Total RNA was extracted from zebrafish embryos (!30
embryos per sample) and quantitative PCR carried out as
described in ref. (18) on an ABI 7000 sequence detection
system (Applied Biosciences), where possible primers were
designed to span an intron. Exceptions were the genes
zOMP and val. The relative standard curve method was used
for quantification (as described by the manufacturer) to gener-
ate raw values representing arbitrary units of RNA transcript.
Each experiment was performed on three independent
occasions except for val, which was performed twice. In
every experiment, each embryo sample was run in triplicate.
The experimental gene value was then normalized to the
average ef1-a value for that sample. Statistical analyses on
normalized data were performed using ANOVA and Student’s
t-tests. Raw P-values were adjusted using the false discovery
rate method. All primers used are shown in Table 2.
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Recent evidence supports a role for RNA as a common pathogenic agent in both the ‘polyglutamine’ and
‘untranslated’ dominant expanded repeat disorders. One feature of all repeat sequences currently associated
with disease is their predicted ability to form a hairpin secondary structure at the RNA level. In order to inves-
tigate mechanisms by which hairpin-forming repeat RNAs could induce neurodegeneration, we have looked
for alterations in gene transcript levels as hallmarks of the cellular response to toxic hairpin repeat RNAs.
Three disease-associated repeat sequences—CAG, CUG and AUUCU—were specifically expressed in the
neurons of Drosophila and resultant common transcriptional changes assessed by microarray analyses.
Transcripts that encode several components of the Akt/Gsk3-b signalling pathway were altered as a conse-
quence of expression of these repeat RNAs, indicating that this pathway is a component of the neuronal
response to these pathogenic RNAs and may represent an important common therapeutic target in this
class of diseases.
INTRODUCTION
Despite the identification of expanded repeat sequences as
disease-causing mutations two decades ago (1,2), the mechan-
isms by which this class of mutations exert their pathogenic
effect still remain unclear. Repeat expansions that cause domi-
nantly inherited diseases have been classified into two distinct
groups of diseases, based upon the location of the expanded
repeat tract within the gene. One group is the result of the expan-
sion of trinucleotide repeat tracts within the coding regions of a
number of unrelated genes. The most common such expansion
is of a CAG repeat encoding glutamine, resulting in the ‘poly-
glutamine diseases’ which include Huntington’s disease (HD),
spinal bulbar muscular atrophy, dentatorubral-pallidoluysian
atrophy and spinocerebellar ataxia (SCA) types 1, 2, 3, 6, 7
and 17 (Fig. 1). The polyglutamine diseases do not appear to
be the result of a simple loss-of-function mechanism, since
they show dominant inheritance and share a number of clinical
features. This phenotypic overlap suggests that there are likely
to be pathogenic mechanisms involved which are not gene-
specific (3). There is a large amount of evidence to support a
role for the polyglutamine peptides themselves in pathogenesis,
including the demonstrated intrinsic toxicity of polyglutamine
peptides in transfected cells (4–6) and Drosophila models (7,8).
There are another nine dominantly inherited expanded
repeat diseases that are caused by the expansion of repeat
tracts within the non-coding regions of genes (the ‘untrans-
lated repeat’ diseases, Fig. 1). To date, expansions of tri-,
tetra- and penta-nucleotide repeats of this class have been
identified as the mutations causing myotonic dystrophy
(DM) types 1 and 2 (DM1 and 2), HD like-2 (HDL-2),
fragile X tremor ataxia syndrome (FXTAS) and spinocerebel-
lar ataxia types 8, 10 and 12. Despite the apparent inability of
these expanded repeat sequences to code for polyglutamine, in
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several cases there is significant phenotypic overlap with the
polyglutamine diseases, suggesting that a common pathogenic
mechanism may play a role in both classes of disease. Further-
more, given that there are diseases caused by the expansion of
repeat sequences of differing sequence composition and that
the expansions reside in functionally distinct genes, it seems
likely that some common property of the expanded repeat
tracts may be a component of pathogenesis in both sets of
diseases.
One common property of disease-causing expanded repeat
sequences is the predicted ability of their RNA transcripts to
form strong hairpin secondary structures. In the case of CNG
repeats, this structure is formed through binding between C
and G residues, with a mismatch every third base (9,10). Tri-
nucleotide repeats of this type account for the majority of the
expanded repeat diseases, including all of the polyglutamine
diseases. Expanded CCTG repeats, the mutation responsible
for DM2, have been predicted to form a similar structure to
CUG repeats in vivo (9), while the penta-nucleotide AUUCU
repeat which is expanded in SCA10 is predicted to form an
unusual anti-parallel hairpin structure, with a C-C mismatch
every fifth base and an equal ratio of A-U/U-U mismatches (11).
A central role for hairpin RNA-mediated pathogenesis was
first suggested in DM1 and 2. In both cases, the expanded
repeat tract binds and sequesters the splicing factor
muscleblind-like (MBNL) (12). Sequestration of MBNL is
thought to be pathogenic via both the loss of MBNL-splicing
activity and the associated mis-regulation of splicing by the
antagonistic splicing factor CUG-binding protein (CUG-BP),
since over-expression of human CUG-BP is sufficient to reca-
pitulate a number of features of DM in a mouse model (13). A
number of MBNL-splicing targets, including chloride channel
1, troponin T type 3 and insulin receptor, are mis-spliced in
both DM1 and 2 individuals as a result of the inappropriate
interaction of the expanded repeat-containing RNA and
endogenous RNA-binding proteins (14,15).
A similar mechanism of pathogenesis has also been
suggested for FXTAS, which is caused by a CGG expansion
in the 5′UTR of the Fragile X mental retardation 1 (FMR1)
gene within the pre-mutation range (55–200 repeats) for
fragile X syndrome. Individuals with FXTAS also show
inclusions which contain MBNL along with several intermedi-
ate filament proteins, including lamins A/C and internexin, and
heterogeneous nuclear ribonucleoprotein A2 (hnRNP A2)
(16). In cells from SCA10 individuals and transgenic mice
ectopically expressing the expanded intronic AUUCU repeat
tract, inclusions containing both the expanded repeat RNA
and the RNA-binding protein hnRNP K have been identified.
The sequestration of hnRNP K within these aggregates is
suggested to result in an increase in translocation of PKCd
to the mitochondria, resulting in induction of apoptosis (17).
The localization of this repeat sequence with MBNL has not
been demonstrated to date.
Recent evidence also supports a role for RNA-mediated
pathogenesis in the polyglutamine diseases. In a Drosophila
model of SCA3 (18), altering expression levels of the
Drosophila muscleblind (Mbl) splicing factor was found to
modify phenotypes associated with expression of a pure CAG
repeat tract, but not a mixed CAG/CAA repeat. This result
suggests that an interaction between CAG repeats and Mbl is
occurring at the RNA level and that the secondary structure of
the RNA species is important for this interaction. Nevertheless,
binding of MBNL to expanded CAG repeats has been shown not
to elicit the same splicing defects as binding to CUG repeats in
transfected cells and therefore the biological outcome of this
interaction remains unclear (19). It does, however, suggest a
pathogenic role for expanded repeat-containing RNA in the
polyglutamine diseases. There is therefore mounting evidence
of a role for expanded repeat-containing RNA species in patho-
genesis of both the untranslated expanded repeat diseases and
the polyglutamine diseases.
Drosophila is well established as a model for polyglutamine
disease (7,20–22) and has also been demonstrated to exhibit
neurodegenerative phenotypes resulting from expression of
expanded repeat RNAs (18,23–25). In this study, we have
used a Drosophila model of expanded repeat pathogenesis to
investigate common transcriptional changes in neurons result-
ing from expression of different disease-associated RNA
repeat sequences with the aim of identifying common cellular
changes resulting from the intrinsic toxicity of repeat RNAs.
The repeat sequences investigated—CAG, CUG and
AUUCU—represent the mutations responsible for the majority
of the dominant expanded repeat diseases, including all of the
polyglutamine diseases as well as the untranslated repeat dis-
eases DM1, HDL-2, SCA8, 10 and 12.
There are several unique components to the analyses per-
formed in this study. First, it describes the only direct com-
parison of the transcriptional outcomes of expression of
CAG and CUG expanded repeat RNAs. Furthermore, it is
also the only study thus far to examine the general transcrip-
tional response to neuronal expression of CUG repeat RNA.
Since neuronal toxicity resulting from CUG repeat expansion
is a feature of DM1 and may also play a role in HDL-2, defin-
ing the pathways involved in CUG repeat-mediated neuronal
toxicity is of great importance. Similarly, while toxicity of
CAG repeat RNA has now been described in several model
systems (18,26,27), the cellular basis of this toxicity has not
yet been extensively explored. Additionally, this is also the
first report of the effects of expression of the
SCA10-associated expansion in a Drosophila model.
Figure 1. Schematic representation of the mutations currently known to cause
dominant expanded repeat diseases. Expansions can occur either within the
coding region of the gene, such as the CAG repeat expansions resulting in
the ‘polyglutamine’ diseases (above), or within non-coding regions, resulting
in the ‘untranslated’ repeat diseases (below). Expansions of tri-, tetra- and
penta-nucleotide repeat sequences have been identified as pathogenic
mutations in these diseases. While SCA8 has typically been considered an
‘untranslated’ repeat disease, polyglutamine aggregates have also been
detected in both a mouse model and human autopsy tissue (51). DM, myotonic
dystrophy; DRPLA, dentatorubral-pallidoluysian atrophy; FXTAS, fragile X
tremor ataxia syndrome; HD, Huntington’s disease; HDL-2, Huntington’s
disease like-2; SBMA, spinal bulbar muscular atrophy; SCA, spinocerebellar
ataxia.
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RESULTS
We have previously reported a Drosophila expanded repeat
disease model utilizing the UAS-GAL4 system to drive
expression of different expanded repeat sequences in a tissue-
specific manner (8). In this model, repeats are expressed in the
context of a short peptide sequence (7) which is unrelated to
the context in any of the expanded repeat diseases (Fig. 2A).
In contrast to most other models described in the literature,
this model therefore allows investigation of the intrinsic tox-
icity of expanded repeat sequences, which is likely to
account for common features observed in these diseases.
This Drosophila model was previously used to investigate the
contribution of hairpin-forming RNA to toxicity of polygluta-
mine tracts (8) by comparing the phenotypes seen when CAG
repeats, which encode polyglutamine and are able to form an
RNA hairpin secondary structure, or CAA repeats, which
encode polyglutamine but are unstructured at the RNA level,
are expressed in the Drosophila eye. The results obtained in
this investigation suggested that the majority of the phenotype
seen in flies expressing polyglutamine is likely to be the result
of the polyglutamine peptide itself and not the repeat-containing
RNA. However, subtle cellular changes resulting from
expression of RNA species, which may result in cell death
over an extended period of time, were not further investigated
(Fig. 2K). In this study, we look specifically at cellular
changes resulting from neuronal expression of disease-causing
untranslated expanded repeat sequences.
Expression of expanded, untranslated CAG, CAA, CUG
and AUUCU repeat RNAs in Drosophila
In order to investigate the intrinsic toxicity of different
disease-associated expanded repeat RNA sequences, a set of
constructs were generated in which a termination codon is
inserted ahead of the repeat sequence such that the repeat
tract is effectively shifted into the 3′UTR of the transcript in
each case (Fig. 2F). Expression of this construct containing
a hairpin-forming CAG repeat RNA (rCAG) does not result
in a phenotype when expressed in the Drosophila eye, as pre-
viously reported (8). Similarly, expression of untranslated
hairpin-forming CUG repeat RNA (rCUG) or unstructured
CAA repeat RNA (rCAA) does not alter the appearance of
the Drosophila eye.
An identical construct was also generated with an insertion
of 65 interrupted repeats of the penta-nucleotide AUUCU
sequence responsible for the rare spinocerebellar ataxia,
SCA10. The sequence of the repeat tract in this construct is
(ATTCT)20 ACTCT (ATTCT)23 ATTCC (ATTCT)15
ATTTT (ATTCT)7, surrounded by 141 bp of sequence from
the region of intron 9 of human ataxin-10. Although the
repeat number in this construct is lower than in the CAG,
CUG and CAA repeat constructs, in each case the total size
of the repeat tract is #300 bp and therefore, in the cases
where a secondary structure is predicted, the resulting
hairpin RNAs will be of similar size.
In order to increase the expression level of expanded repeat
RNA, Drosophila lines carrying four independent insertions of
each of these repeat constructs were subsequently generated.
Expression of four independent insertions of untranslated
CAG, CUG, CAA or AUUCU repeat RNAs in the Drosophila
eye does not result in any external phenotype (Fig. 2G–J).
This is in contrast to the phenotypes observed when a single
Figure 2. Schematic representation of repeat constructs and effect of
expression of translated and untranslated expanded repeat constructs on the
external appearance of the Drosophila eye. (A) Translated repeat constructs:
similarly sized expanded repeat tracts are inserted downstream of UAS sites
to allow expression under the control of a GAL4 driver. The repeats are
flanked by six amino acids on the N-terminal side and four on the C-terminal,
and a myc/flag epitope tag is located downstream. Repeat sequences are CAA
and CAG, both of which encode polyglutamine, and CUG which encodes
polyleucine. CAG and CUG repeat RNAs are predicted to form a hairpin sec-
ondary structure, while the CAA repeat RNA is not. (B) Expression of UAS
sequences alone results in an eye of wild-type appearance. (C and D)
Expression of polyglutamine encoded by either a CAG or CAA repeat tract
results in an indistinguishable loss of pigment phenotype in the Drosophila
eye (8). (E) Expression of polyleucine encoded by a CUG repeat tract
results in a mild disruption to the patterning of the eye. (F) Untranslated
repeat constructs: constructs in which the repeat tract is not translated were
generated by insertion of a stop codon upstream of the repeat tract. (G–J)
Expression of four transgene insertions of any of the untranslated expanded
repeat sequences does not cause a visible disruption to the external patterning
of the Drosophila eye. (K) Proposed mechanism of RNA-mediated pathogen-
esis in the expanded repeat diseases. Expression of expanded, untranslated
CAG, CUG or AUUCU repeat-containing RNAs, all of which are predicted
to form a hairpin secondary structure, results in cellular dysfunction which,
over an extended period of time, leads to apoptosis and neurodegeneration.
The expanded rCAA repeat RNA used in this study is not able to form a
hairpin secondary structure and therefore should not induce cellular dysfunc-
tion in this manner.
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transgene insertion of a translated CAG or CAA repeat tract,
both of which encode polyglutamine, or a translated CUG
repeat tract, encoding polyleucine, are expressed in the Droso-
phila eye (Fig. 2B–E). Similarly, no obvious defects were
observed in newly eclosed flies when any of the untranslated
repeat RNA constructs were expressed pan-neuronally.
Detection of neuronal transcriptional changes resulting
from expression of expanded repeat RNA
While no phenotype was observed when rCAG, rCUG or
rAUUCU repeat RNAs were expressed in the nervous system
of newly eclosed flies, the presence of expanded repeat tran-
scripts was detected in all cases (Supplementary Material,
Fig. S1A and C). To investigate the transcriptional effects of
expression of different expanded repeat sequences in the
neurons of Drosophila, microarray analyses were performed
using Affymetrix Drosophila Genome 2.0 arrays. A summary
of lines used in this analysis can be found in Supplementary
Material, Figure S1 and a summary of analyses performed can
be found in Figure 3A and B. For flies expressing rCUG and
rCAG repeat sequences, separate microarray experiments
were performed using two alternative elav-GAL4 driver lines
(depicted in Supplementary Material, Fig. S1B) in order to
increase the robustness of these analyses. Multiple independent
lines carrying either two (experiment 1) or four (experiment 2)
transgene insertions of the repeat constructs were also tested, in
order to minimize any transcriptional effects related to the inser-
tion sites or expression levels of the transgenes. A single
four-transgene-insertion line was also included in experiment
2 for the rAUUCU repeat RNA.
For flies expressing each hairpin repeat sequence, transcript
ratios were calculated compared with flies expressing rCAA
repeat RNA, which cannot form a hairpin secondary structure,
as well as to flies heterozygous for the elav-GAL4 driver, but
not expressing any repeat construct. Flies heterozygous for
elav-GAL4 were used as a control for genetic background.
However, since GAL4 has been reported to be toxic in
Drosophila neurons (28), flies expressing rCAA repeat RNA
were included as an additional control. These flies carry the
same number of transgene insertions as the rCAG, rCUG and
rAUUCU repeat expressing flies, thus minimizing the contri-
bution of GAL4 toxicity to the transcriptional read-out. The
inclusion of flies carrying elav-GAL4 alone should also identify
any effects resulting from expression of CAA repeat RNA,
which are therefore not the result of secondary structure of the
RNA species.
Some variation in expression levels of expanded repeat
sequences was observed, both between independent lines for
the same repeat and different repeat sequences. The most strik-
ing difference was seen in flies expressing the rCAA repeat,
which showed consistently low steady-state levels compared
with other repeat sequences, possibly as a result of the inability
of this sequence to form a stable secondary structure. These
lines were included in analysis primarily as a control for
GAL4 toxicity. Additionally, with the exception of the
rAUUCU repeat, several independent lines were analysed for
each repeat sequence so as to minimize the impact of variation
in repeat expression levels on the transcriptional outcome.
In this way, candidate genes were identified which were sig-
nificantly altered (two-tailed t-test value of P , 0.05) in flies
expressing rCAG and rCUG expanded repeat sequences com-
pared with either flies carrying elav-GAL4 alone or expressing
rCAA repeat RNA for each experiment. The total number of
genes identified in each comparison is shown in
Figure 3C. Genes found to be significantly altered in more
than one comparison are also listed in Supplementary
Material, Table S1, while select candidates identified in both
experiments 1 and 2 are shown in Figure 3D. In experiment
2, a remarkably high overlap in transcriptional changes
between flies expressing rCAG or rCUG repeats and those
expressing rAUUCU repeats was observed (between 40.7
and 71.4%, Fig. 3E), suggesting that there is a considerable
common component to cellular perturbation in flies expressing
each of these repeat sequences. Select candidates identified in
experiment 2, which included the rAUUCU repeat expressing
flies, are also listed in Figure 3F.
Genetic validation of effects of expanded repeat expression
Disruptions to the ordered patterning of ommatidia in the
Drosophila eye can be readily observed in adult flies and for
this reason have been frequently used as a basis for genetic
screens. This approach has also been successfully used to
identify mechanisms of toxicity in models of expanded
repeat disease (24,29–33). We have tested candidate genes
identified by microarray analysis for their ability to alter the
patterning of the Drosophila eye. While expression of untrans-
lated expanded repeat RNAs does not result in a phenotype in
the eye (Fig. 2G–J), expression of expanded repeats encoding
polyglutamine or polyleucine causes an easily visualized per-
turbation to the exterior patterning of the eye (Fig. 2B–E) and
therefore these phenotypes were initially used as a screening
tool. Flies expressing a translated CAG repeat tract express
both polyglutamine peptide and hairpin-forming RNA, while
flies expressing a translated CAA repeat express polygluta-
mine peptide in the absence of any hairpin-forming RNA.
Similarly, flies expressing the translated CUG repeat construct
express both polyleucine peptide and hairpin-forming RNA.
Therefore, the ability of candidate genes to alter either the
polyglutamine or polyleucine phenotype in a manner that
was dependent upon the sequence composition of their encod-
ing RNAs would be indicative of this functional interaction
occurring at the RNA level. A similar methodology has been
used recently to identify Drosophila mblA as important in
pathogenesis in a model of SCA3 (18). In this study, the
authors demonstrate the ability of mblA to modify phenotypes
in flies expressing truncated Ataxin-3 containing a pure CAG
repeat but not a mixed CAG/CAA repeat, suggesting that this
interaction is occurring at the RNA level.
Using this approach, two genes which were able to induce
toxicity in flies expressing untranslated expanded repeats
were identified (Fig. 4). One of these genes, mef2, showed a
significant interaction with translated CUG repeats, but
no interaction with translated CAG or CAA repeats
(Fig. 4D–F). This may suggest that Mef2 is a unique modifier
of either polyleucine or CUG repeat RNA pathogenesis (or
both), or that a critical pathogenic threshold was not reached
in the flies expressing expanded CAG repeats. The other








niversity of Adelaide user on 04 July 2019
807
gene, mod(mdg4), demonstrated an interaction with both trans-
lated CAG and CUG repeats (Fig. 4G and I). In flies expres-
sing polyglutamine encoded by expanded CAG, reduction in
expression of mod(mdg4) by RNAi resulted in nearly com-
plete lethality, with the small number of flies that did eclose
showing a significant enhancement of the eye phenotype com-
pared with flies expressing the CAG repeat alone (Fig. 4G). In
contrast, flies expressing polyglutamine encoded by expanded
CAA with reduction in levels of mod(mdg4) showed only a
mild enhancement of the loss of pigment eye phenotype
(Fig. 4H). It is likely that the observed lethality in flies expres-
sing CAG repeats with reduced mod(mdg4) is the result of the
expression of both the expanded repeat and the mod(mdg4)
RNAi construct in tissues other than the eye, as has been pre-
viously reported for the GMR-GAL4 driver (7).
Different RNA repeat sequences demonstrate distinct
interactions with candidate genes in our Drosophila model
While expression of rCAG, rCUG or rAUUCU repeats in the
Drosophila eye does not result in a phenotype, reducing
Figure 3. Experimental design of microarray experiments. (A) Experiment 1: microarray analyses were performed on flies expressing two insertions of the
rCAG, rCUG and rCAA repeat sequences driven by the pan-neuronal elavc155 –GAL4 driver and flies heterozygous for the elavc155 –GAL4 driver
(elav.+). For each repeat sequence, three lines with independent insertion sites were tested and candidates were selected which showed altered transcription
in all three lines. Microarray analysis of elavc155 –GAL4 heterozygotes was performed in duplicate. Comparisons were performed between elav.rCAG or elav.
rCUG and each of the controls, which were elav.+ and elav.rCAA. (B) Experiment 2: microarray analysis was performed on flies expressing four insertions
of the rCAG, rCUG, rCAA and rAUUCU repeat sequences driven by the pan-neuronal elavII–GAL4 driver and flies heterozygous for the elavII–GAL4 driver
(elav.+). For rCUG, rCAG and rCAA, two lines with independent insertion sites were tested. A single four-transgene-insertion rAUUCU line was tested.
Microarray analysis of elavII –GAL4 heterozygotes was performed in duplicate. Comparisons were performed between elav.rCAG, elav.rCUG or elav.
rAUUCU and each of the controls, which were elav.+ and elav.rCAA. (C) Number of transcripts significantly altered in flies expressing rCAG and
rCUG repeats compared with flies expressing rCAA repeats or heterozygous for the driver line. In each case, transcripts were selected which met the criteria:
log2(ratio).0.5 or ,20.5, where the ratio was calculated using an average of all independent lines tested, with a two-tailed t-test value of P , 0.05. Transcripts
common to more than one comparison are listed in Supplementary Material, Table S1. (D) Select genes which were detected as altered in flies expressing rCAG
or rCUG in both microarray experiments. (E) Percent of genes altered in experiment 2 for rCAG and rCUG repeat expressing flies which were also altered in flies
expressing the rAUUCU repeat construct. These transcripts are listed in Supplementary Material, Table S2. (F) Number of transcripts significantly altered in
experiment 2, selected for log2(ratio).0.5 or ,20.5, where the ratio was calculated using an average of all independent lines tested, with a two-tailed
t-test value of P , 0.05 for flies expressing rCAG or rCUG. T-tests were not performed for rAUUCU repeat expressing flies, since a single
four-transgene-insertion line was available for this repeat. Genes of particular interest are listed.
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expression of genes that are components of pathogenic path-
ways involved in RNA-mediated toxicity may result in the
appearance of a phenotype, through pushing cells beyond a
critical pathogenic threshold. Therefore, candidates identified
by microarray analysis were also directly assayed for func-
tional interaction at the RNA level with untranslated expanded
repeat RNAs.
Co-expression of RNAi constructs targeting mef2 or
mod(mdg4) with expanded rCUG repeats in the Drosophila
eye resulted in a marked disruption of the pigmentation and
patterning of the eye (Fig. 4R and W) supporting a role for
these candidates in CUG repeat pathogenesis. No disruption
to the eye was observed when these RNAi constructs were
co-expressed with any other repeat sequence, supporting the
conclusion that these candidates may either be unique to
CUG repeat pathogenesis in this model, or that a critical
threshold of toxicity has not been reached in flies expressing
the other expanded repeat sequences.
Common perturbation of downstream effectors of
Akt/Sgg signalling
A number of candidate genes identified in these microarray
analyses of different disease-associated expanded repeat
sequences were downstream effectors or regulators of the
Drosophila Gsk-3b (Sgg) signalling pathway (Fig. 5). There-
fore, we also investigated a role for this pathway in RNA-
mediated pathogenesis. Investigation of genetic interaction
between expanded translated repeat sequences revealed a reci-
procal effect of over-expressing or reducing Sgg expression in
flies expressing translated CUG repeats (Fig. 6C, G, K). The
effect was less clear for CAG and CAA repeat-encoded poly-
glutamine expressing flies. While there was a clear enhance-
ment when Sgg was over-expressed with either CAG or
CAA (Fig. 6A, B, I, J), there was little effect in either case
when Sgg expression levels were reduced (Fig. 6A, B, E, F).
Furthermore, no difference in the strength of interaction with
Sgg was observed between flies expressing CAG or CAA,
and therefore it was not possible to determine whether there
was any contribution of the hairpin-forming repeat RNA to
this interaction.
To further investigate a role for this pathway in RNA-
mediated pathogenesis, we over-expressed Sgg in the presence
of each of the different untranslated repeat sequences. Over-
expression of Sgg in the presence of rCAG, rAUUCU or
rCAA expanded repeat sequences resulted in a decrease in
the amount of pigmentation in the eye compared with over-
expression of Sgg in flies carrying four transgene insertions
in the absence of a repeat sequence (Fig. 6R–U compared
with Q). However, there was a marked increase in the
degree of roughness of the surface of the eye in flies expres-
sing the rCAG or rAUUCU repeat sequences compared with
those expressing the rCAA repeat (Fig. 6R and U compared
with S). Since the steady-state levels of rCAA RNA are
Figure 4. Altering levels of Mef2 and Mod(mdg4) can modify the effect of expression of expanded repeat RNAs in the Drosophila eye. (A–C) Eye phenotypes
resulting from expression of expanded translated CAG, CAA and CUG repeats, as shown in Figure 2. (D and E) Co-expression of an RNAi construct targeting
mef2 with polyglutamine encoded by either a CAG or CAA repeat tract does not alter the appearance of the eye. (F) Reducing expression of mef2 in the eye of
flies expressing a translated CUG repeat causes an enhancement of the polyleucine eye phenotype, resulting in flies with smaller eyes which have a glazed
appearance and necrotic patches. (G) Reducing expression of mod(mdg4) in flies expressing polyglutamine encoded by a CAG repeat results in an enhancement
of the eye phenotype and a reduction in viability of the flies. (H) Expression of this same RNAi construct with polyglutamine encoded by a CAA repeat results in
a milder enhancement of the loss of pigment phenotype and no reduction in viability. (I) An enhancement of the polyleucine phenotype was also observed with
this RNAi construct. (J–N) Expression of four insertions of any of the untranslated repeat constructs alone does not cause an alteration to the appearance of the
Drosophila eye, as described in Figure 2; however co-expression of either the RNAi construct targeting mef2 or mod(mdg4) with four insertions of the rCUG
repeat construct was able to induce a strong eye phenotype (R and W). This effect was not seen with any of the other untranslated repeat constructs (O–Q, S,
T–V, X).
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consistently lower than the other repeats (Supplementary
Material, Fig. S1), it is not possible to determine whether
there is generally a stronger interaction between Sgg and
hairpin-forming RNA repeats. However, there does appear to
be a degree of sequence-dependence to the interaction with
Sgg, since the rAUUCU repeat RNA is expressed at similar
levels to rCUG, while the rCAG repeat RNA is expressed at
much higher levels than rCUG and yet there is a weaker inter-
action observed with Sgg in both cases. Co-expression of
rCUG repeat RNA with Sgg was completely lethal at 258C.
When flies were grown at 238C to reduce expression levels
of the UAS constructs, a severe phenotype involving loss of
pigment, necrotic patches and a loss of ommatidial organiz-
ation of the eye was observed, indicating a strong interaction
between this repeat sequence and Sgg (Fig. 6T). Therefore,
while there appears to be a mild interaction between all
Figure 5. Alteration to activity of the Akt/GSK3-b signalling pathway can
explain a number of the changes observed in microarray analysis of flies
expressing rCAG, rCUG and rAUUCU repeats in the nervous system.
Genes for which a Drosophila orthologue showed altered transcript levels in
microarray analysis of flies expressing at least one of the untranslated repeat
constructs are shown in red. Activation of Akt can be regulated by a
number of different signals, including glutamate (52) or neurotrophic
(53,54) signals and Ca2+ signalling (55). Activated Akt is in turn involved
in down-regulation of GSK3-b activity which is involved in regulation of a
number of transcription factors, including MEF2 (56) and CREB (57),
which is an orthologue of Drosophila Nej. Both CREB and MEF2 have
been demonstrated to play a role in the regulation of expression of the
nuclear receptor NUR77, an orthologue of Drosophila Hr38, in a calcium-
dependent manner (58). Activation of NUR77 can also be regulated directly
by Akt (59). The Akt/GSK3-b signalling pathway is therefore able to have
broad downstream transcriptional effects. A number of links between Akt
activity and expanded repeat-containing proteins themselves have also been
demonstrated. Akt phosphorylates HTT, ataxin-1 and the androgen receptor
(AR) (stars), altering their interactions with other proteins (60–62). Phos-
phorylation of ataxin 3 by GSK3-b (star) has also been recently demonstrated
to regulate nuclear entry and therefore may play a role in SCA3 (63).
Expression of expanded CUG repeats has also been demonstrated to alter acti-
vation of the Akt/Gsk3-b pathway in PC12 cells (64).
Figure 6. Altering expression of GSK3-b can modify the effect of expression of
expanded repeat RNAs in the Drosophila eye. (A–C) Phenotypes resulting from
expression of translated CAG, CAA and CUG repeat expression, as shown in
Figure 2. (D) Expression of RNAi construct targeting Drosophila sgg does not
alter the exterior appearance of the eye. (E and F) Co-expression of an RNAi
construct targeting sgg with polyglutamine encoded by either CAG or CAA
does not dramatically alter the exterior appearance of the eye. (G) Co-expression
of the sgg RNAi with polyleucine results in eyes of wild-type appearance. (H)
Ectopic expression of Sgg in the eye results in a severe rough eye phenotype
with a dramatic reduction in the size of the eye and the amount of pigmentation.
(I and J) Co-expression of polyglutamine encoded by either a CAG or CAA
repeat with ectopically expressed Sgg results in an increase in the size of the
eye compared with ectopic expression of Sgg alone. There appears to be a
reduction in the amount of pigment in the eye and in most cases there are necrotic
patches and nearly complete loss of the ommatidial array structure. (K) Ectopic
expression of Sgg in the eye of flies co-expressing polyleucine is completely
lethal. (L–P) Expression of four insertions of any of the untranslated expanded
repeats alone does not result in a visible phenotype in the eye, as shown in
Figure 2. (Q) Driving expression of four insertions of the UAS portion of the
transgene without the remainder of the construct in flies ectopically expressing
sgg in the eye results in a milder rough eye phenotype than expression of sgg
alone. (S) Co-expression of four transgene insertions of the rCAA construct
with the Sgg overexpression construct does not significantly alter the organiz-
ation of the eye compared with co-expressing the UAS sites alone. (R and T)
Co-expression of the rCAG or rAUUCU repeat constructs with the Sgg overex-
pression construct results in eyes which are consistently rougher than those of
flies co-expressing either rCAA or the UAS construct with Sgg. (U)
Co-expression of rCUG with the Sgg overexpression construct results in com-
plete lethality at 258C. At 238C, the few flies which survive to eclosion have a
strong loss of pigment phenotype, with the loss of ommatidial structures and
the appearance of necrotic patches.
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expanded repeat sequences tested and Sgg in this model, the
strength of this interaction is affected by the sequence of the
repeat.
DISCUSSION
Identification of the molecular pathway(s) from mutation to
clinical symptoms in the dominantly inherited neurodegenera-
tive diseases has proved extremely difficult. A contributing
factor to this is that the sensitive cells of affected individuals
are lost in the course of the disease. Animal models therefore
afford the opportunity to access cells in which the pathogenic
pathways are active and also to explore alternative hypotheses
as to the nature of the pathogenic agent(s) responsible for these
diseases. RNA is such a potential pathogen in the dominantly
inherited expanded repeat neurodegenerative diseases. The use
of animal models such as Drosophila enables the identification
of pathways through which such potential pathogens act and
the identification of biomarkers of the responsible pathways.
These biomarkers can subsequently be tested in the respective
human diseases to validate the role of the pathway and its con-
tribution to the disease. Using this approach, we have mod-
elled repeat RNA pathology in Drosophila and have
identified common pathways perturbed by the expression of
expanded repeat RNAs.
Analyses of transcriptional changes in a number of models
of expanded repeat disease have previously been reported
(34–40). These studies have largely modelled toxicity of poly-
glutamine, which induces severe, early phenotypes in both
mouse and Drosophila models, and therefore transcriptional
changes are likely to partially reflect downstream effects of
cell death. More recently, evidence for a role of RNA-
mediated pathogenesis in the polyglutamine diseases has
been reported (18). Since expression of each of the repeat
sequences as untranslated RNA either in the Drosophila eye
or throughout the nervous system does not result in gross
developmental or degenerative phenotypes, this model can
be used to investigate markers of cellular dysfunction attribu-
table to these repeat sequence RNAs which precede cell death
and are therefore more likely to represent causative changes in
disease progression.
Given the ability of all of the disease-associated repeat
sequences to form hairpin secondary structures at the RNA
level and the phenotypic overlap seen in the expanded
repeat diseases, despite the presence of the repeat tracts
within unrelated genes, we predicted that there are likely to
be common, intrinsic, sequence-independent cellular effects
of expression of expanded repeat sequences. In support of
this prediction, pan-neuronal expression of rCAG, rCUG and
rAUUCU expanded repeat RNAs was found to elicit a
number of common transcriptional changes. Strikingly, a com-
parison of transcripts showing altered expression in flies
expressing rAUUCU repeat RNA revealed a minimum of
40.7% and maximum of 71.4% overlap with genes altered in
flies expressing either rCAG or rCUG repeats (Fig. 3E).
This result is strongly suggestive of common mechanisms of
toxicity of expanded repeat RNAs.
In the untranslated expanded repeat diseases where there is
no toxic peptide expressed, RNA-mediated pathogenesis is
presumably sufficient to induce all of the cellular changes
leading to neurodegeneration and disease progression. This
Drosophila model of RNA repeat pathogenesis investigates
some components of pathogenesis in these diseases, but
there are also likely to be specific effects of expression of
the repeat-containing transcript in each disease which are
dependent on the context of the repeat tract. Nevertheless, at
least one candidate which showed a strong interaction with
context-independent repeat RNAs used in this study,
mod(mdg4), has been previously identified as transcriptionally
altered in another Drosophila model which used repeats within
the context of the SCA8 transcript (24).
In addition, changes identified in these microarray analyses
support a role for more generalized transcriptional dysregula-
tion in toxicity of expanded repeat RNAs. In particular, altered
transcript levels of histones (H3 and H1), histone acetylating
enzymes (msl-2 and Atac1), chromatin modifiers
(mod(mdg4)), a number of transcription factors (including
mef2, lola, cut, hr38, a member of the SP1/SP3-like transcrip-
tion factor family and a Drosophila orthologue of PAX5) and
transcriptional co-regulators (tna and med24) were detected in
flies expressing more than one of the repeat sequences (Sup-
plementary Material, Tables S1 and S2). This is consistent
with observations in several models of polyglutamine patho-
genesis in which wide-spread transcriptional dysregulation
has been reported (35,40,41) and suggests that this sort of
effect may be an intrinsic property of expanded repeat
sequences.
Examination of common transcriptional changes detected in
this model also revealed changes to a number of other com-
ponents of the cell that have been previously implicated in
polyglutamine pathogenesis, including several cellular trans-
port and cytoskeletal components. For example, the actin-
binding proteins hu li tai shao, which is an orthologue of
mammalian Adducin 1, and cut up, a component of the
dynein complex, both showed altered expression in flies
expressing more than one of the expanded repeat sequences
(Fig. 3F). Hu li tai shao has been previously demonstrated
to suppress a phenotype associated with expression of an
expanded N-terminal fragment of Huntingtin in the
Drosophila eye (29), while cut up and its human orthologue,
DYNLL1, showed altered expression in a comparison of
Drosophila and human cell culture models of polyglutamine
pathogenesis (37). We therefore predict that some of the
pathogenic pathways previously identified in models of
expanded repeat disease may be common to both polygluta-
mine and untranslated repeat diseases and therefore some of
these effects may be at least partially mediated through
RNA pathogenesis.
Recently published data (42) demonstrate that expanded
CAG repeat alleles are able to be translated internally in all
three reading frames, irrespective of whether or not they are
located in coding regions and without requiring an initiation
AUG, through a mechanism known as repeat-associated
non-ATG translation (RAN translation). It is thought that the
hairpin structure formed by the expanded repeat RNAs is
acting as an Internal Ribosome Entry Site (IRES). In our
model, expression of up to four transgene insertions of
untranslated CAG and CUG repeat sequences does not result
in a phenotype, while expression of a single polyglutamine
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or polyleucine-encoding transgene is sufficient to induce a
visible phenotype in the Drosophila eye (Fig. 2; 8). Therefore,
RAN translation does not appear to play a major role in RNA
toxicity in this model. However, as a consequence of these
recent findings, homopolymeric amino acid sequences have
emerged as a potential mediator of repeat RNA toxicity in
the ‘untranslated’ repeat diseases.
Altered transcription of components of the Akt/GSK3-b
regulatory pathway was consistently observed in flies expres-
sing rCAG, rCUG and rAUUCU repeat RNAs by microarray
analysis, suggesting that this is a key component of cellular
dysfunction in this Drosophila model of untranslated repeat
disease pathogenesis. While the ability of CUG repeat RNA
to disrupt Akt/GSK3-b signalling has been described, this is
the first evidence that expression of other hairpin-forming
RNA species can also influence activity of this pathway.
The initial stimulus resulting in the disruption of Akt/
GSK3-b signalling in this model is unclear; however, there
is precedent for similar effects in fragile X syndrome where
increased levels of stimulation of the mGluR5 receptor have
been demonstrated to increase GSK3-b activity (43). A disrup-
tion to mGluR5 signalling has also been described in a pre-
symptomatic model of HD (44), and in other HD models
alterations to N-methyl-D-aspartate receptor (45), brain-
derived neurotrophic factor (46,47) and nerve growth factor
(48) signalling, all of which are associated with activation of
the Akt/GSK3-b pathway, have also been observed. Our
observations indicate that expression of expanded repeat
RNA is sufficient to cause transcriptional changes to the
Akt/GSK3-b pathway, and therefore that the hairpin RNAs
expressed in the disease situation might also interact with
components of this pathway to disrupt normal signalling.
MATERIALS AND METHODS
Drosophila strains and husbandry
CAG and CUG repeats were generated by ligating together
shorter repeat oligonucleotides and expanded using polymerase
chain reaction (PCR)-based techniques as described previously
(8). The AUUCU repeat construct was generated from a PCR
product containing the region in intron 9 of human ataxin-10 con-
taining the AUUCU repeat, plus 141 bp of surrounding sequence
which was amplified from HeLa cell DNA. This repeat tract was
expanded from an original size of 13 repeats by a PCR-based
method, based on a previously outlined protocol (49).
Each repeat sequence was subcloned into the Drosophila
transformation vector pUAST, which had been modified to
contain the amino acid sequence surrounding the repeat,
including the MYC and FLAG epitope tags. For the untrans-
lated repeat constructs, a stop codon was inserted in front of
the repeat tract by PCR mutagenesis as described previously
(8). The length and integrity of repeat constructs were con-
firmed by DNA sequencing and then each construct was
microinjected into the w1118 strain (Stock #3605) by standard
methods to obtain germline transformants. Multiple transgenic
lines were obtained for each construct, and the repeat length
from each line was confirmed by PCR and sequencing.
The GMR-GAL4 (Stock #9146), elavc155-GAL4 (Stock
#458) and P{GAL4-elav.L}2 (designated elavII) (Stock
#8765) strains used in this study were obtained from the
Bloomington Drosophila stock centre (Indiana University,
Indiana, PA, USA). GMR-GAL4 drives expression of UAS
constructs in all cells posterior of the morphogenetic furrow
in the developing eye. Both elav-GAL4 insertions drive
expression of UAS constructs throughout the central and per-
ipheral nervous system.
RNAi strains tested for genetic interaction with expanded
repeats were obtained from the Vienna Drosophila RNAi
centre (50). VDRC strains shown in figures are: Stock
#15550 (mef2), 52268 (mod(mdg4)) and 101538 (Sgg).
UAS-Sgg was obtained from the Bloomington Drosophila
stock centre (Stock #5361). All Drosophila stocks were main-
tained in vials containing Fortified (F1) medium and kept at
either 18 or 258C. The F1 medium was composed of 1%
agar, 18.75% compressed yeast, 10% polenta, 10% treacle,
1.5% acid mix and 2.5% tegosept. Crosses were performed
at 258C unless otherwise indicated.
RNA extraction and purification
Approximately 100 male Drosophila heads from newly
eclosed flies were collected and snap frozen for each genotype,
before homogenization in Trizol (Invitrogen). Total RNA was
extracted using chloroform and precipitated with isopropanol,
and then further purified using the RNeasy mini kit (Qiagen).
RNA to be used for microarrays was precipitated in sodium
acetate and ethanol and shipped under ethanol on ice.
Quantitative real-time PCR
One microgram of total RNA per sample was treated with
DNAse I (Invitrogen) and reverse-transcribed with
oligo(dT)18 and SuperScript III (Invitrogen). Quantitative
real-time PCR was performed in a LightCycler (Roche
Molecular Biochemicals) using Power SYBR green mix
(Applied Biosystems) and either GAL4-specific primers
(forward: 5′-CACTGACCCCGTCTGCTTTG-3′, and reverse:
5′-GGTTCGGACCGTTGCTACTG-3′) or primers specific
for the repeat-containing transcript. The transgene expression
level was quantified using the DCt method for relative quanti-
tation and expressed relative to the level of GAL4 transcript
for each line.
Microarrays
Total RNA was processed using the One-Cycle Target Label-
ling and Control Reagents Kit, as per manufacturer’s instruc-
tions (Affymetrix Inc.). Briefly, 2 mg of total RNA was
converted to cDNA (Superscript II, Invitrogen) and an over-
night in vitro transcription reaction performed to generate a
pool of cRNA carrying a biotin tag (MEGAscript T7 Kit,
Ambion, Inc). The Drosophila Genome 2.0 Array was hybri-
dized for 16 h and washed/stained on a FS 450 Fluidics
Station using the Midi euk2 v3 script. Data were acquired
on a 7G GeneChip Scanner 3000 and data extraction per-
formed in GCOS v1.2. Candidates were selected from the
pool of transcripts which showed a ‘present’ call in either all
independent lines for a particular repeat sequence, or in all
samples for the elav-GAL4/+ control in that experiment.
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Where possible, two-tailed Student’s t-tests were performed
on raw values to identify significantly altered transcripts
(P-value , 0.05). The microarray data have been deposited
on the NCBI database (GEO accession number GSE27178).
Microscopy
Image preparation was performed using Adobe Photoshop 6.0.
Light photos were taken with an Olympus SZX7 dissection
microscope fitted with an SZX-AS aperture. Images were cap-
tured with a Colorview IIIu camera and AnalysisRuler image
acquisition software. In all cases, anterior is to the left. Flies
were photographed at 24–48 h post-eclosion.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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The pathogenic agent responsible for the expanded repeat diseases, a group of neurodegenerative diseases
that includes Huntington’s disease is not yet fully understood. Expanded polyglutamine (polyQ) is thought to
be the toxic agent in certain cases, however, not all expanded repeat disease genes can encode a polyQ
sequence. Since a repeat-containing RNA intermediary is common to all of these diseases, hairpin-forming
single-stranded RNA has been investigated as a potential common pathogenic agent. More recently, it has
become apparent that most of the expanded repeat disease loci have transcription occurring from both
strands, raising the possibility that the complementary repeat RNAs could form a double-stranded structure.
In our investigation using Drosophila models of these diseases, we identified a fortuitous integration event
that models bidirectional repeat RNA transcription with the resultant flies exhibiting inducible pathology. We
therefore established further lines of Drosophila expressing independent complementary repeat RNAs and
found that these are toxic. The Dicer pathway is essential for this toxicity and in neuronal cells accounts
for metabolism of the high copy number (CAG.CUG)100 double-stranded RNAs down to (CAG)7 single-
stranded small RNAs. We also observe significant changes to the microRNA profile in neurons. These
data identify a novel pathway through which double-stranded repeat RNA is toxic and capable of eliciting
symptoms common to neurodegenerative human diseases resulting from dominantly inherited expanded
repeats.
INTRODUCTION
There are "20 inherited neurodegenerative diseases caused by
expanded repeat sequences, including Huntington’s disease
(HD) and a series of related movement disorders termed spino-
cerebellar ataxias (SCAs) that are usually late-onset and pro-
gressive, leading to death after 15–20 years (1,2). The
various repeat expansions that give rise to human genetic
disease exhibit a number of common properties. Each arises
from a repeat that exhibits polymorphism in the human popu-
lation and the disease alleles arise from increases in copy
number of the longest of these to beyond a critical threshold.
The repeat composition varies, but most are trinucleotide
repeats. In some diseases, the repeat expands to the point
where gene expression is either substantially reduced or lost
altogether, resulting in loss-of-function of the gene in which
they are located. Typically such diseases are inherited in a
recessive manner. Many of these repeats, however, give rise
to dominantly inherited diseases in a manner that is not gene-
dose dependent, suggesting a gain-of-function mechanism
rather than haploinsufficiency. Where expanded repeats are
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translated, the repeat RNA generally codes for polyglutamine,
however, the proteins in which they are located are all unre-
lated in the remainder of their amino acid sequence. These
‘polyglutamine’ diseases typically manifest as neurodegenera-
tive and/or muscular diseases, some with a high degree of
overlap despite affecting distinct proteins. Therefore much
attention has been focused on expanded polyglutamine as
the common basis of pathology. Another group of expanded
repeat diseases, the ‘untranslated’ repeat diseases, have
repeat expansions located within untranslated RNAs that
cannot encode polyglutamine yet exhibit similar phenotypes
(1,3,4). The polyglutamine and ‘untranslated’ diseases also
have similar disease allele copy number repeat pathogenic
thresholds (HD CAG .36, SCA17 CAG .47, HD-like-2
CUG .44) suggesting shared pathways of pathogenesis.
Since expanded repeat-containing RNA is present in all of
these dominant neurodegenerative diseases we, and others,
have pursued the notion that RNA is a common pathogenic
agent and that expanded repeat RNAs gain some common
function that is toxic to cells (5–7). Precedence for this
comes from the DM1 and DM2 repeat expansions that
both give rise to myotonic dystrophy (8). The repeat expan-
sions are similar but, importantly, not identical (CUG and
CCUG) and are located in untranslated regions (3′UTR or
intron) of two otherwise unrelated genes (DMPK and
ZNF9). Expanded allele RNAs from both repeats are able
to bind and sequester alternative splicing factors (MBNL1
and CUG-BP) and in so doing, perturb the normal splicing
pathways of proteins for which alternative splicing is a
necessary step for their complete range of functions (9).
The consequent loss of these functions is thought responsible
for at least some of the common symptoms exhibited in
DM1 and DM2 patients. RNA as a pathogenic agent has
subsequently been implicated in a number of the expanded
repeat diseases (8).
Single-stranded CAG RNA repeat pathogenesis has pre-
viously been investigated in the Drosophila model system
(5–7) and evidence has been reported for the ability of
CAG containing expanded repeat RNAs to induce neuronal
toxicity (6). However, recently it has become clear that
expanded repeat disease loci are typically transcribed from
both strands raising the possibility that double-stranded
RNAs are produced from these loci and account for toxicity
(10–13). Yu et al. (14) have recently reported modelling
of double-stranded RNA toxicity in flies. They established
a Drosophila model for myotonic dystrophy (DM1) and
tested the role of interactions between expanded CUG tran-
scripts and expanded CAG repeat transcripts. This revealed
toxicity in flies co-expressing CUG and CAG expanded
repeats. The transient expression of the two transcripts led
to the generation of Dicer-2 and Argonaute-2-dependent
21-mer triplet repeat-derived siRNAs. These findings raise
the possibility that triplet repeat-derived siRNAs may play
a role in the pathogenesis of human repeat expansion neuro-
degenerative diseases.
Using the Drosophila model system, we report evidence of
double-strand repeat RNA toxicity in the nervous system that
is dependent upon the activity of Dicer. Toxicity is evident as
neurodegeneration and a movement disorder. The almost
exclusive de novo appearance of (CAG)7mers [and absence
of (CUG)7mers] has been identified as a signature of this
pathway along with an altered endogenous miRNA profile.
RESULTS
Bidirectional expression of repeat RNA from a transgenic
insertion within cheerio leads to dominant degenerative
phenotypes
Drosophila is well-established as a model system for the
study of human neurodegenerative diseases (15). The devel-
oping fly eye has been successfully used to study the path-
ology associated with expanded repeat neurodegenerative
diseases through the ectopic expression of various human
disease genes or their causative expanded repeat sequences
(16–22). We and others have previously used Drosophila
models to test the hypothesis that hairpin structures formed
by rCAG"100 single-strand RNA could be a common patho-
genic agent in the untranslated repeat RNA disease SCA
type 12 and each of the polyQ translated expanded repeat
neurodegenerative diseases (5–7). We did not observe
rCAG"100 single-stranded RNA-specific pathology in any
but one of our lines [line C]. Ectopic expression of
rCAG"100 [line C] in all cells of the eye (using
GMR-GAL4) (23) resulted in a consistent mild disruption
to the precise patterning of ommatidia on the exterior
surface of the eye when compared to control lines
(Fig. 1A–C). Neurodegeneration associated with this pheno-
type was confirmed in sections of aged adult eyes, where the
number of rhabdomeres in each ommatidial unit decreased
significantly from the normal number of seven observed in
controls (Fig. 1E–G). A decrease in lifespan was observed
in flies ectopically expressing rCAG"100 [line C] under the
control of a ubiquitous promoter, daughterless-GAL4 (24)
(Fig. 1H), while an increase in the proportion of flies that
failed to climb was observed when this insertion was
expressed throughout the nervous system (Fig. 1I) using
elavc155-GAL4 (25). Flies expressing rCAG"100 [line C]
throughout the nervous system also showed a movement dis-
order involving a sudden loss of coordination in which flies
would fall on their backs, followed by a brief period of
uncoordinated movement in which they could not right
themselves (Supplementary Material, Movie S1). This be-
haviour could also be induced by knocking flies to the
bottom of the vial, and therefore may contribute to the
observed failure to climb phenotype (Fig. 1I). This effect
was quantified at a higher temperature (378C) where
increased incidence of the phenotype was observed com-
pared with controls (Fig. 1J).
Inverse PCR of the rCAG"100 [line C] transgene revealed its
insertion into the endogenous cheerio gene and the presence of a
rCUG"100 repeat-containing cheerio transcript was confirmed
by RT–PCR (Fig. 1K and L and Supplementary Material,
Fig. S1). The phenotypes observed after ectopic expression of
rCAG"100 [line C] were not due to disruption of cheerio by
transgene insertion, since the removal of one copy of cheerio
had no effect on patterning of the eye (Fig. 1D and G). In
addition, each of the observed phenotypes was dependent on
GAL4-driven expression of the repeat sequence (Fig. 1A–J)
and quantitative PCR indicated that in this situation cheerio
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transcript levels are increased, rather than decreased (Sup-
plementary Material, Fig. S1). Our results, as well as previous
studies, indicate that overexpression of cheerio is not respon-
sible for the observed phenotypes (26,27) (Fig. 1I). Thus the
rCAG"100 [line C] transgene acts in a GAL4-dependent, domi-
nant manner and the ensuing pathology relies on the expression
of both of the complementary repeat-containing transcripts.
Expression of complementary repeat RNA leads to
Dicer-2-dependent neurodegeneration
Numerous expanded repeat human disease gene loci have been
found to be bi-directionally transcribed across the repeats
(10–13). This raises the question of whether complementary
repeat-containing RNAs bind to each other to form perfect
double-stranded RNA structures and thereby contribute to
Figure 1. Expression of complementary repeat RNA from rCAG"100 [line C] leads to dominant phenotypes. (A) rCAG"100 [line C] heterozygotes and (B)
GMR-GAL4 heterozygotes show a regular array of ommatidia forming the structure of the eye, which is disrupted when, (C) rCAG"100 [line C] is ectopically
expressed via GMR-GAL4. (D) Heterozygous deletion of cheerio via deficiency allele Df(3R)Exel6176 in the presence of GMR-GAL4 does not cause disruption.
(E) Tangential sections show the underlying structure of the eye, with seven rhabdomeres present in each ommatidium of an age matched control. (F) Ectopic
expression of rCAG"100 [line C] causes degeneration, with one or more rhabdomeres missing from some ommatidia after ageing. (G) Degeneration was quantified
by scoring the number of rhabdomeres in each ommatidium (as a proportion of the total, n ≥ 20 ommatidia per image, mean+1 standard deviation for n ≥ 4 images
shown). Compared with GMR-GAL4 alone, GMR-GAL4 . rCAG"100 [line C] eyes have significantly less ommatidia with the normal seven rhabdomeres (P ¼
0.004) and significantly more with six (P ¼ 0.0033) and five (P ¼ 0.039). Two-tailed Student’s t-test, ∗∗P , 0.01, ∗P , 0.05. This effect is not seen with
rCAG"100 [line C] alone, or with GMR-GAL4 and the Df(3R)Exel6176 cheerio deficiency. (H) Survival of flies ubiquitously expressing rCAG"100 [line C] via
da-GAL4 (n ¼ 97) is significantly reduced compared with rCAG"100 [line C] alone (n ¼ 113, P , 0.0001) or da-GAL4 alone (n ¼ 76, P , 0.0001, log-rank
test). (I) Pan-neuronal expression of rCAG"100 [line C] via elav
c155-GAL4 (n ¼ 58) leads to an increase in the percentage of flies that fail in a climbing assay com-
pared with elavc155-GAL4/+ (n ¼ 55, P ¼ 0.001), rCAG"100 [line C ]/+ (n ¼ 54, P ¼ 0.0023) and a cheerio overexpression line elavc155-GAL4 . cheerioEP(3)3715
(n ¼ 55, P ¼ 0.0002), two-tailed Student’s t-test , ∗∗P , 0.01 ∗∗∗P , 0.001, error bars show s.d. All flies were 14 days old, raised at 298C. (J) Movement disorder
was quantified as the proportion of flies that spent more than 1 s on their back during a 60 s period (see Methods), elavc155-GAL4 . rCAG"100 [line C] (n ¼ 20) flies
show a significantly higher proportion than rCAG"100 [line C]/+ (n ¼ 19, P ¼ 0.0012) or elavc155-GAL4/+ (N ¼ 32, P , 0.0001). Fisher’s exact test, ∗∗P , 0.01
∗∗∗P , 0.001, error bars show 95% confidence interval, in this case rCAG"100 [line C]/+ progeny also contain a second rCAG"100 insertion at another site within the
genome that is not expressed. All flies 0–3 days old, raised at 298C. (K) Bidirectional repeat transcription from the rCAG"100 [line C] insertion locus. Expression of
rCAG RNA is driven by the UAS sequence while the complementary rCUG repeat is transcribed as part of the cheerio transcript. RT–PCR primers (A and B) used to
confirm the rCUG repeat-containing cheerio transcript are shown. (L) RT–PCR products using indicated primers and cDNA template from rCAG"100 [line C]/
Df(3R)Exel6176 flies (+RT indicates addition of reverse transcriptase, both gels trimmed at the 2.0 and 0.1 kb marker band).
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pathology in these diseases. We therefore hypothesized that
the phenotypes observed in the rCAG"100 [line C] could be
due to bidirectional transcription (Fig. 1K). However, the
level of repeat-containing double-stranded RNA and the resul-
tant pathology would be limited by the endogenous expression
level and tissue specificity of the cheerio gene. In order to
model the pathogenic effects of complementary RNA repeat
sequences independently of the cheerio gene, both
rCAG"100 and rCUG"100 from randomly inserted transgenes
were co-expressed (i.e. in trans) under the control of the
UAS/GAL4 ectopic expression system. Ectopic expression of
four transgenes encoding either rCAG"100 or rCUG"100
single-stranded RNA repeat sequences alone did not result in
any effect on patterning of the Drosophila eye compared
with negative controls (Fig. 2D, E and G; 7) despite compar-
able levels of expression as determined by qRT–PCR (Sup-
plementary Material, Fig. S2). However, ectopic expression
of two transgenes each of both rCAG"100 and rCUG"100
(referred to henceforth as rCAG.rCUG"100 or dsRNA)
together resulted in a rough eye phenotype (Fig. 2F and H).
In this case, the co-expression of these complementary
repeats would be expected to form a perfect double-stranded
repeat-containing RNA (Fig. 2C), in contrast to the mis-
matches predicted in hairpin structures for either of the
single-strand repeat-containing RNA sequences alone
(Fig. 2A and B). A range of phenotypes was observed in inde-
pendent lines of rCAG.rCUG"100 that were designated strong
(S1–3) and medium (M1–5) based on their severity (Sup-
plementary Material, Fig. S3).
To gain insight into the molecular pathways involved in this
novel form of pathogenesis, we then tested the ability of well-
characterized double-stranded RNA processing pathways
(28,29) to modify the observed phenotype. The double-
stranded RNA (rCAG.rCUG"100) rough eye phenotype was
found to be dependent upon Dicer-2 activity, since reduction
of endogenous Dicer-2 expression resulted in suppression of
the rough eye phenotype (Fig. 2H–I and Supplementary
Material, Fig. S4). In addition, the overall disruption observed
in patterning of the internal structure of the eye was signifi-
cantly reduced with decreased Dicer-2 dosage as revealed by
sections through adult eyes (Fig. 2J–L). Conversely, increas-
ing Dicer-2 levels resulted in lethality when co-expressed
with rCAG.rCUG"100 double-stranded repeat RNA. At the
lower temperature of 188C (with decreased levels of transgene
expression), ectopic expression of either rCAG.rCUG"100 or
Dicer-2 alone did not result in a phenotype, but together
they resulted in a loss of pigment phenotype (Fig. 2M–O),
indicating a dose-dependent pathogenic effect due to increased
processing of the double-stranded repeat-containing RNA.
Although double-stranded RNAs are well-known substrates
for Dicer-2/RNA-induced silencing complex (RISC) proces-
sing, there is also evidence for Dicer processing of rCAG
and rCUG single-stranded RNAs that are predicted to form
hairpin structures (28). Thus the effects of Dicer-2 activity
Figure 2. Modification of rCAG.rCUG"100 double-stranded RNA repeat phe-
notypes as a result of altered Dicer-2 activity. (A–C) Schematic representation
of RNA transcripts ectopically expressed and predicted mismatch hairpin (A and
B) and perfect double-strand (C) secondary structures. (D–F) External eye phe-
notypes with ectopic expression of (D) 4xrCAG"100
#1, (E) 4xrCUG"100
#1 and
(F) 2xrCAG"100 together with 2xrCUG"100. (G–O), Modification of
rCAG.rCUG"100 rough eye phenotype by Dicer-2. External eye phenotype of
(G), control (H), rCAG.rCUG"100 (I), rCAG.rCUG"100 with heterozygous
mutation in dcr2L811fsx/+, (J–L) eye sections showing internal ommatidial pat-
terning of (J), normal eye section (K), rCAG.rCUG"100 shows severe disruption
to this patterning which is suppressed with (L), dcr2L811fsx/+. (M–O), External
eye phenotypes with ectopic Dicer-2 expression. (M) rCAG.rCUG"100 shows no
phenotype at 188C. (N) UAS-dcr2 also shows no phenotype at 188C but (O),
rCAG.rCUG"100 expressed together with ectopic Dicer-2 shows a loss of
pigment eye phenotype. GMR-GAL4 is used for all ectopic expression.
rCAG.rCUG"100 lines used in this figure are S1 (F), S2 (H, I, M and O) and
M5 (K and L). All flies are 1 day old and raised at 258C (D–L) or 188C (M–
O). Control (G and J) is 4xUAS.
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on single-stranded RNA repeat sequences were also examined.
Ectopic expression of single-stranded rCAG"100 or rCUG"100
repeat RNA in the eye does not affect patterning (Fig. 2D and
E) and this was not affected with ectopic expression of Dicer-2
(Supplementary Material, Fig. S5) suggesting different levels
of toxicity and/or distinct processing pathways compared
with rCAG.rCUG"100 double-stranded RNA repeat sequences.
We have genetic evidence of a role for Dicer-2/RISC pro-
cessing in our model for rCAG.rCUG"100 pathogenicity in dif-
ferentiating cells of the adult eye (Fig. 2G–O). Since the
expanded repeat diseases are characterized by neurodegenera-
tion, we determined the effects of ectopic expression of
double-stranded repeat RNA specifically in neuronal cells of
Drosophila. Ectopic expression of rCAG.rCUG"100 using pan-
neuronal driver elavc155-GAL4 (25) resulted in a significant
level of male lethality, while the females showed a mild phe-
notype in the adult eye (Fig. 3A and B). A significant enhance-
ment of this phenotype was observed with ectopic Dicer-2
expression, indicating that Dicer-2/RISC processing of
double-stranded repeat RNA occurs in neuronal cells
(Fig. 3C and D). Ectopic expression of rCAG.rCUG"100
driven by an independent pan-neuronal driver (elav II-GAL4)
(30) showed no effects on viability or defects in adult eyes.
However, flies did show an age-dependent movement disorder
(failure-to-climb phenotype) compared with the negative
control and to flies expressing either of the single-stranded
RNAs (Fig. 3E). Thus ectopic expression of rCAG.rCUG"100
double-stranded RNA is also pathogenic in neuronal cells.
Complementary repeat expression leads to the formation
of (CAG)7 21mers and altered endogenous miRNA profiles
in neurons
To investigate more specifically the contribution of Dicer pro-
cessing to this neuron-specific pathogenicity, the pool of
steady-state small RNAs from heads of these adult flies
was sequenced. Using the SOLiD platform, we obtained
between 1.5 and 2.6 million reads that mapped uniquely to
the Drosophila genome. The raw colour-space data were
also separately screened for the presence of CAG or CUG
repeat-containing sequences. A large number of processed
CAG repeats, predominantly the 21mer (CAG)7, in addition
to a single CUG containing repeat were found in the
rCAG.rCUG"100 double-stranded RNA sample that were
absent from the negative control where no repeat RNA is
expressed (Fig. 3F and Supplementary Material, Table S1).
In contrast, only a few processed repeats were detected
when either of the single-stranded RNA repeats were
expressed. These data support the hypothesis that the comp-
lementary rCAG"100 and rCUG"100 sequences form aFigure 3. rCAG.rCUG"100 double-stranded repeat RNA is pathogenic in neur-
onal cells and processed to (CAG)7. (A–D) External eye phenotypes of
1-day-old flies with elavc155-GAL4 neuronal ectopic expression stock. (A)
Flies expressing 4xUAS alone or (C) ectopic Dicer-2 alone have no pheno-
type. (B) rCAG.rCUG"100 alone shows a mild eye phenotype which is signifi-
cantly enhanced with (D), ectopic Dicer-2. (E) Climbing assays of flies
expressing single-stranded rCAG"100 or rCUG"100ectopically expressed
with elavII-GAL4 show normal climbing compared to control flies at week
0 and week 4. At week 0 the flies expressing the rCAG.rCUG"100 double-
strand RNA with elavII-GAL4 show normal climbing compared with control
(elavII.+) flies. However, at week 4, the rCAG.rCUG"100 flies show an
increase in the percentage of flies failing to climb (n ¼ 70, P ¼ 7.6 × 1028,
two-tailed Student’s t-test) compared with controls (n ¼ 70). ∗∗∗ P , 0.001,
error bars show s.d. At week 0 n ≥ 74 and at week 4 n ≥ 47. (F) Sequence
reads of small RNAs containing frames of CAG repeats in heads of
1-day-old flies expressing rCAG.rCUG"100 with elavII-GAL4. A high abun-
dance of reads containing 21 nt small RNA CAG repeats was observed. All
flies used were males except in the case of (B) and (D) where the males
showed significant lethality. rCAG"100 #1 and rCUG"100 #1 were used in
(E). rCAG.rCUG"100 S1 line was used for all experiments.
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rCAG.rCUG"100 double-stranded RNA structure that is
subsequently processed to normal constituent lengths for
Dicer/RISC complexes (28), with a clear preference for
loading, and therefore stabilization, of the CAG strand of the
hybrid RNA. Precedents in the literature suggest that either
(CAG)7 21mers or perturbed Dicer function are responsible
Table 1. Expression levels of CUG or CAG repeat-containing transcripts
Biological replicates Mean SD P-value
1 2 3
CUG containing transcripts
CG31845 Experiment 1 Control 1.447 1.281 1.362 1.364 0.083 0.006
dsRNA 1.113 1.073 1.004 1.063 0.055
Experiment 2 Control 1.045 0.837 0.940 0.940 0.104 0.131
dsRNA 1.117 1.001 1.103 1.074 0.063
Experiment 3 Control 0.972 0.871 0.912 0.918 0.051 0.257
dsRNA 0.889 0.893 0.830 0.871 0.035
CG42347 Experiment 1 Control 1.362 1.437 1.458 1.419 0.050 0.004
dsRNA 1.046 0.933 1.136 1.038 0.101
Experiment 2 Control 0.935 0.975 1.034 0.981 0.050 0.741
dsRNA 0.973 0.792 1.084 0.950 0.148
Experiment 3 Control 0.960 1.054 1.099 1.038 0.071 0.106
dsRNA 1.011 0.739 0.762 0.837 0.151
Futsch Experiment 1 Control 1.008 0.935 0.935 0.959 0.042 0.050
dsRNA 1.017 1.115 1.058 1.063 0.049
Experiment 2 Control 1.081 1.013 1.007 1.034 0.041 0.221
dsRNA 1.065 1.063 1.218 1.116 0.089
Experiment 3 Control 0.839 0.795 0.787 0.807 0.028 0.044
dsRNA 0.771 0.724 0.739 0.745 0.024
CG11462 Experiment 1 Control 0.994 1.306 1.048 1.116 0.167 0.426
dsRNA 1.065 0.973 1.045 1.028 0.048
Experiment 2 Control 0.871 0.815 0.858 0.848 0.029 0.122
dsRNA 0.830 0.787 0.732 0.783 0.049
Proc R Experiment 1 Control 0.864 0.801 0.918 0.861 0.059 0.168
dsRNA 1.098 0.850 1.058 1.002 0.133
CG11380 Experiment 1 Control 0.960 1.063 1.360 1.128 0.207 0.877
dsRNA 1.235 1.059 1.153 1.149 0.088
CAG containing transcripts
NcKX30C Experiment 1 Control 1.059 0.983 1.009 1.017 0.038 0.009
dsRNA 0.813 0.900 0.860 0.858 0.044
Experiment 2 Control 1.140 0.958 1.108 1.068 0.097 0.051
dsRNA 1.199 1.230 1.292 1.240 0.047
Dunce Experiment 1 Control 1.109 1.040 1.095 1.081 0.036 0.013
dsRNA 0.826 0.964 0.860 0.883 0.072
Experiment 2 Control 1.023 0.868 0.986 0.959 0.081 0.037
dsRNA 1.082 1.136 1.209 1.142 0.064
Roadkill Experiment 1 Control 0.718 0.658 0.771 0.716 0.056 0.003
dsRNA 1.021 1.062 0.944 1.009 0.060
Experiment 2 Control 0.986 0.904 0.980 0.957 0.046 0.085
dsRNA 1.160 1.056 1.422 1.213 0.189
Ataxin-2 Experiment 1 Control 1.378 0.906 1.005 1.096 0.249 0.541
dsRNA 1.052 1.250 1.316 1.206 0.137
Bruno-2 Experiment 1 Control 1.158 1.019 1.233 1.136 0.108 0.678
dsRNA 1.147 1.117 1.055 1.106 0.047
CG9850 Experiment 1 Control 0.691 0.786 0.719 0.732 0.049 0.879
dsRNA 0.699 0.606 0.942 0.749 0.173
Darkener of apricot Experiment 1 Control 0.678 0.674 0.702 0.685 0.016 0.085
dsRNA 0.779 0.796 1.026 0.867 0.138
Pumilio Experiment 1 Control 1.132 1.019 1.006 1.053 0.069 0.616
dsRNA 1.025 1.101 1.112 1.079 0.047
Rutabaga Experiment 1 Control 1.207 1.067 1.020 1.098 0.097 0.920
dsRNA 1.054 1.139 1.082 1.092 0.044
Sema1b Experiment 1 Control 1.052 0.951 0.886 0.963 0.084 0.505
dsRNA 0.712 0.847 1.074 0.878 0.183
Vein Experiment 1 Control 0.692 0.870 0.877 0.813 0.105 0.726
dsRNA 0.755 0.723 0.875 0.784 0.080
X11Lbeta Experiment 1 Control 1.193 1.064 1.101 1.120 0.066 0.228
dsRNA 1.104 0.993 1.049 1.049 0.055
Expression levels of repeat-containing transcripts in flies expressing dsRNA with elavII-GAL4 as analysed by qRT–PCR and normalized to rp49. Each experiment
included three biological replicates for each sample. Standard deviations for the three replicates are shown in SD. P-values were calculated with a two-tailed
Student’s t-test using the mean value of the biological replicates. Control is 4xUAS and dsRNA refers to rCAG.rCUG"100 S1.
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for the next step in pathogenesis (31). The (CAG)7 21mers
could act to target endogenous CUG repeat-containing
mRNAs essential for cell survival. However, we have quanti-
fied six Drosophila mRNAs containing eight or more CUG
repeats and find no reproducible changes (P , 0.05) over
and above biological variation (Table 1). In addition, no
changes were observed in 12 transcripts containing eight or
more CAG repeats (Table 1). Alternatively, the normal func-
tion(s) of the Dicer processing pathway could be reduced by
increased levels of dsRNA processing in our model.
Removal of Dicer activity in specific neuronal cell types has
been shown to result in neurodegenerative phenotypes
(32,33). Consistent with this second prospective pathway,
miRNA sequence analysis revealed ten different miRNAs
(.1000 reads) that showed more than a 2-fold change in
expression levels (miR-7, miR-8, miR-11, miR-12, miR-34,
miR-100, miR-307, miR-317, miR-932 and miR-988)
(Table 2).
DISCUSSION
Identification of the molecular pathways linking mutation to
clinical symptoms in the dominantly inherited neurodegenera-
tive diseases has proved extremely difficult. However, a
common pathogenic pathway is clearly possible given the
common molecular basis of their mutation and overlapping
clinical symptoms of these diseases. Animal models afford
the opportunity to explore alternative hypotheses on the
nature of the pathogenic agents responsible for these diseases.
The data presented herein demonstrate that ectopic
co-expression of complementary rCAG"100 and rCUG"100
repeat RNA sequences is toxic in Drosophila. These double-
stranded expanded repeat RNAs are significantly more toxic
than either of the single-stranded RNA sequences alone and
the pathogenic effects are elicited via a distinct pathway. In
addition, Dicer processing of the double-stranded RNA
repeats is essential for the observed pathology. Co-expression
of rCAG"100 and rCUG"100 RNAs in neuronal cells resulted
in an abundance of (CAG)7 sequences, indicating specificity
in Dicer processing. These data identify a novel mechanism
through which double-stranded repeat-containing RNAs
cause neurodegeneration (Fig. 4). Together with the obser-
vation of bidirectional transcription across expanded repeat
disease loci, this implicates double-stranded repeat RNA as
a potential pathogenic agent contributing to clinical symptoms
common to the dominantly inherited expanded repeat neurode-
generative diseases. In support of this, perturbed Dicer activity
and altered miRNA levels have been reported in other models
of HD or polyQ diseases (34,35).
Recently published data (26) demonstrate that expanded
CAG and CUG repeat alleles are able to be translated intern-
ally in all three reading frames, through a mechanism known
as repeat-associated non-ATG translation (RAN translation).
It is thought that the predicted hairpin is acting as an Internal
Ribosome Entry Site (IRES). In addition, RAN translation is
copy number-dependent as 20 CAG repeats are insufficient,
whereas 42 CAG repeats are sufficient for RAN translation.
Table 2. List of Drosophila miRs showing significant changes
miR Control dsRNA log2 (ratio)
dsRNA versus control
miR-932 4732.415 317.347 23.898
miR-307 118788.915 13787.176 23.107
miR-7 17414.671 2742.788 22.667
miR-34 1153.333 238.882 22.271
miR-11 12161.822 2822.997 22.107
miR-988 3894.429 1272.877 21.613
miR-317 4897.807 1802.952 21.442
miR-100 10042.600 4238.855 21.244
miR-8 15573.307 7551.822 21.044
miR-12 1365.035 3405.382 1.319
miR reads are normalized to account for variation in total number of miR reads
between the samples. Significance was determined as a minimum of log2
(ratio) dsRNAvs control . +1 or , 21 (2-fold change) and a minimum of
1000 reads in at least one of the samples.
Figure 4. Toxicity of double-stranded repeat-containing RNA from bidirec-
tional transcription of expanded repeat disease genes. Results from this
study support a novel pathogenic pathway whereby an expanded repeat tract
within a disease associated gene is bidirectionally transcribed. The two result-
ing RNA transcripts contain complementary expanded repeats that are able to
form a perfect double-stranded RNA (dsRNA). Results indicate that this struc-
ture is processed by Dicer pathways to form 21mers with a strong preference
for (CAG)7 production. Neurodegeneration may then occur either via (CAG)7
targeting of complementary endogenous transcripts that are important to neur-
onal survival and function or by perturbation of normal Dicer processing path-
ways, as indicated by the observed mis-regulation of endogenous miRNA
levels.
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In our model, expression of four transgene insertions of
expanded untranslated CAG or CUG repeat sequences does
not result in a phenotype (7), while bi-directional expression
of the single-copy CAG transgene within the cheerio gene
or two copies each of CAG and CUG transgenes are sufficient
to induce a visible phenotype in the Drosophila eye (Figs 1
and 2). Our data also reveal Dicer processing of double-
stranded rCAG.rCUG"100 RNA to CAG7 21mers, well
below the repeat copy number required for RAN translation.
Therefore, RAN translation does not appear to play a major
role in RNA toxicity in the double-strand RNA model.
However, as a consequence of the recent findings of Zu
et al. (36), homopolymeric amino acid sequences have
emerged as a potential mediator of single-strand repeat RNA
toxicity in the ‘untranslated’ repeat diseases.
While this manuscript was in preparation, toxicity of
CAG.CUG repeat-containing RNA was reported by Yu et al.
(14), where ectopic expression of dsRNA in the eye also
caused toxicity that was dependent on endogenous Dicer-2
activity. Our studies and those of Yu et al. (14) are generally
consistent, however, there are some important and noteworthy
distinctions. First, we report an endogenous gene model of
bidirectional transcription of an expanded CAG.CUG repeat
locus and its phenotypic consequences. We fortuitously ident-
ified an insertion of our CAG repeat transgene into the cheerio
gene of Drosophila, giving rise to CAG repeat-containing
transcripts from one strand and CUG repeat-containing tran-
scripts from the other, thus modelling the reported bidirec-
tional transcription across the expanded repeat disease loci.
Secondly, we find evidence of progressive neurodegenerative
phenotypes and a movement disorder. Different promoter
regions were used to drive expression of the dsRNA in each
of the studies: we report persistent neuronal expression, result-
ing in neurodegeneration, whereas Yu et al. (14) use the ‘heat-
shock’ promoter to induce transient pathogenic RNA
expression. The phenotypes we see for both the repeat-
containing cheerio allele and flies expressing double-stranded
CAG.CUG RNA are degenerative (i.e. lifespan of the bidirec-
tional cheerio line [line C] is shortened and the ability of
CAG.CUG repeat flies to climb decreases with age).
Thirdly, we observe specificity of Dicer double-stranded
CAG.CUG RNA processing evident by the presence of CAG
21mer but not CUG 21mer. This almost total bias for CAG
21mers demonstrates distinction between the Dicer-2 proces-
sing of persistent neuronally specific versus transient ectopic
expression of double-stranded CAG.CUG RNA as Yu et al.
(14) observe similar levels of CAG and CUG repeat 21mers.
We also quantified a series of CUG (and CAG) repeat-
containing endogenous mRNAs to assess their targeted degra-
dation by CAG 21mer (or CUG 21mer) loaded RISC and see
no reproducible changes in steady-state mRNA levels
(Table 1). Finally, our RNA deep sequencing data revealed
changes in small RNA species with a significant and
.2-fold change in 10 different miRNAs (Table 2). Identifi-
cation of the mRNA targets for these miRNAs and their con-
sequent alteration in abundance and/or translation will be
necessary to demonstrate whether these account for the role
of Dicer in double-stranded CAG.CUG RNA pathogenesis.
In contrast to the findings reported here and by Yu et al.
(14), Sofola et al. (20) find that co-expression in Drosophila
of both CGG and CCG RNAs suppresses the toxicity
evident from expressing either of these RNAs alone. This sup-
pression was also found to be Dicer-dependent implicating the
formation of double-stranded RNA. It would therefore appear
that there are distinct differences between mechanisms of
CAG.CUG and CGG.CCG RNA toxicity, however, further
experimentation will be required to verify this and establish
its molecular basis.
Whatever the precise molecular pathway of Dicer-mediated
pathogenesis, these observed molecular characteristics consti-
tute a ‘biomarker’ fingerprint indicative of the activity of this
double-stranded repeat-containing RNA pathogenic pathway.
The identification of the presence of these biomarkers in
affected tissues will enable demonstration of the activity of
this pathway in human disease.
MATERIALS AND METHODS
Fly stocks
w1118, GMR-GAL4 (Bloomington stock #1104), da-GAL4
(#8641), UAS-dcr2 (#24650), elavc155-GAL4 (#458), elavc155-
GAL4;UAS-dcr2 (#25750), P{GAL4-elav.L}2/CyO (#8765
referred to as elavII-GAL4) and Df(3R)Exel6176(#7655) were
obtained from the Bloomington stock centre. cherEP(3)3715
was obtained from the Szeged stock centre. dcr2L811fsX was
obtained from Prof. Richard Carthew (29). GMR, dcr2L811fsX/
CyO stock was generated and verified by sequencing.
GMR-GAL4, UAS-dcr2/CyO was generated by recombination.
Constructs
The UAS-rCAG"100 construct and single-copy transgenic
lines used in this study have previously been described (5).
In brief, repeat-containing oligos (CAG10 and CTG10) were
annealed and cloned to generate repeat-containing constructs
with the longest repeat length obtained being "30 repeats.
These constructs were then expanded using PCR-based
methods to obtain repeat lengths of "100 perfect CAG
repeats. Clones obtained in the opposite orientation correspond
to the UAS-rCUG"100 constructs used in this study.
UAS-rCUG"100 constructs were transformed into w
1118 and
multiple transgenic lines (named alphabetically) were gener-
ated and mapped. Transgenic lines were checked for the size
and composition of repeat sequences by PCR and sequencing
of genomic DNA.
Multiple transgene insertion repeat lines
Multiple recombinant stocks were generated with two inser-
tions of each repeat construct on either chromosome II and
III (except rCAG ‘J, K’ which is on the X chromosome). Stan-
dard genetic crosses were used to generate four copy lines in
the various combinations; 4xrCAG, 4xrCUG and
2xrCAG.2xrCUG. A control line was also generated using
the UAS plasmid without any insert (UAS) which is an appro-
priate control for titration of free GAL4 by each of the four
copy UAS repeat constructs. This was generated separately
in the attB system (37) with inserts at genomic locations
22A, 58A, 68E and 96E which were then recombined
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and flies carrying recombinant chromosomes were then
crossed together to give the control line ‘UAS’. The repeat-
containing constructs were kept in separate stocks from the
GAL4 ectopic expression lines throughout the analyses.
Expression levels of repeat sequences with the various
ectopic expression drivers were determined by quantitative
real-time PCR (Supplementary Material, Fig. S2).
Single- and double-stranded RNA transgenic combinations
used in this study
Control.
UAS (22A,58A; 68E,96E)
Single-stranded RNA (rCUG"100 or rCAG"100).
rCAG"100 #1 (A,E; G,I)
rCAG"100 #2 (J,K; D,H)
rCUG"100 #1 (C,D; E,F)
rCUG"100 #2 (H,I; J,G)
Double-stranded RNA (rCUG.rCAG"100).
#S1 - rCUG"100 (H,I); rCAG"100 (G,I)
#S2 - rCAG"100 (A,E); rCUG"100 (E,F)
#S3 - rCUG"100 (C,D); rCAG"100 (G,I)
#M1 - rCAG"100 (A,E); rCUG"100 (J,G)
#M2 - rCAG"100 (J,K); rCUG"100 (J,G)
#M3 - rCAG"100 (J,K); rCUG"100 (E,F)
#M4 - rCUG"100 (H,I); rCAG"100 (D,H)
#M5 - rCUG"100 (C,D); rCAG"100 (D,H)
RNA purification
Five 1-day-old whole flies or 50 heads from 1-day-old adult
females were used in each sample for quantitative real-time
PCR (qRT-PCR). One hundred heads from 1-day-old adult
males were used for RNA sequencing. The samples were
frozen in liquid nitrogen and homogenized using Trizol (Invi-
trogen). Total RNA was extracted using chloroform and iso-
propanol precipitation. RNA for qRT-PCR was further
purified using the RNeasy Mini Kit (Qiagen). RNA for
sequencing was further purified by precipitation in sodium
acetate and ice cold 100% ethanol.
Quantitative real-time PCR
RNA was DNAse (Invitrogen) treated and reverse transcribed
using Superscript III (Invitrogen) and random hexamers.
Power SYBRw Green mix (Applied Biosystems) was used
to carry out qRT-PCR in triplicate in an Applied Biosystems
ABI Prism 7000 Sequence Detection System (Applied Biosys-
tems) and quantified using the Relative Standard Curve
Method as outlined by Applied Biosystems. Expression
levels were normalized to the house-keeping gene ribosomal
protein 49 (rp49). The experiments were performed using
three independent RNA preparations for each sample.



































vein : ATCAAGCATGGAAAGAAGCTGC/CG TTGCGA
TTGATGGACTT







Inverse PCR was performed using standard methods (38), with
enzyme MspI and primers, 5′ P element : CGCACACAAC
CTTTCCTC/ATGAACCACTCGGAACCA, 3′ P element :
CCTTAGCATGTCCGTGG/AGTGGATGTCTCTTGCCG.
cheerio RT–PCR
RNA from five 1-day-old adult males was purified and reverse
transcribed as described discussed earlier. Primers used to
amplify the repeat-containing cheerio transcript were (letters
correspond to Fig. 1K and L):
AF - ATCCGAATGCCGGTGATC and AR- ACAGGACC
TAACGCACAG
BF- TGAGAGTCAGCAGTAGCC and BR – CAGCGTT
GTTACTCGAGC.
The identity of products was confirmed by sequencing.
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Photography of eyes
Light microscopy was performed on an Olympus SZX7 micro-
scope fitted with a SZX-AS aperture. Images were captured
using an Olympus ColourView IIIU Soft Imaging System
camera and AnalysisRuler image acquisition software. Photo-
shop 6.0 and Aperture 2.1.2 was used for image preparation.
Anterior is to the left in all eye photos.
Eye sections and counting
Eyes were aged for "35 days and tissue was dissected, fixed
and sectioned following standard protocols (38). Photographs
were taken at 100x using a ZeissAxioplan 2 microscope and
adjusted using Axiovision LE 4.8.1 to ensure rhabdomeres
were clearly visible. Ommatidia within each image were
scored for the number of rhabdomeres present, with a possible
range of 1–8. At least five images, each representing individ-
ual animals, were analysed per genotype with each image con-
taining at least 20 ommatidia. For each genotype, a mean of
the frequency of each category across all animals was calcu-
lated. Values for each category were then compared with the
corresponding control value using a Student’s t-test in Graph-
Pad Prism 5.0a.
Survival assays
Adult male flies were collected within 5 days post-eclosion
and separated into populations no greater than 20 per vial.
Flies were transferred to fresh food every 2 days at 258C
and any deaths or escapes recorded. Survival analysis and
log-rank tests were performed using Graphpad Prism 5.0a
for Mac OS X (GraphPad Software, San Diego, CA, USA,
www.graphpad.com). Escaping flies were entered as
censored data.
Quantification of movement disorder
0–3-day-old male flies raised at 298C were separated into
individual vials then allowed to recover for 30 min. Vials
were placed at 378C in a humid box for "60 min, then each
vial was knocked and filmed for 60 s using a standard home
video camera. Films were reviewed in Apple iMovie to deter-
mine the time that each fly spent on its back in the 60 s after
the vial was knocked. Proportions were determined, and 95%
confidence intervals calculated using a binomial distribution.
Climbing assays
Flies were collected and maintained as for survival assays,
with each genotype separated into multiple sets with at most
25 animals per set. Climbing assays were performed by trans-
ferring flies to a 500 ml measuring cylinder (diameter 48 mm)
sealed at the top with Parafilm. Multiple identical cylinders
were used so that all genotypes could be tested in the same
session. Tests were conducted by gently tapping the cylinder
on the benchtop to knock flies to the bottom, then scoring
the number of flies that remained below the 50 ml mark
(height 27 mm) after 25 s. Five consecutive trials were con-
ducted per set of flies, with an approximate 3 min rest
between trials. Scores from age matched sets were combined
for corresponding trial number to give a total score for each
genotype. Total scores were then averaged across all trials
(n ¼ 5) to determine the mean for each genotype. Genotypes
were compared with the control using a 2-tailed Student’s
t-test in GraphPad Prism with a cut off of P ¼ 0.05 for deter-
mining significance.
Small RNA library generation and sequencing
Libraries for deep sequencing were prepared from total RNA
using the Small RNA Expression Kit (SREK; Ambion, as
per the Applied Biosystems protocol). Briefly, total RNA
(300 ng) was ligated to SOLiD P1 and P2 adaptors. The result-
ing ligated RNAs were reverse transcribed followed by 15–18
cycles of PCR. The primers used in this PCR included a
unique six nucleotide barcode for each sample. The products
were resolved on an 8% polyacrylamide gel and the 105–
150 base pair fraction (corresponding to small RNAs 16–61
nucleotides in length) was excised from the gel. The amplified
PCR products were purified to yield a SOLiD small RNA
library for emulsion PCR to generate clonally templated
beads. A single emulsion PCR reaction was used to couple
the barcoded libraries to P1-coated beads as per the standard
Applied Biosystems protocol. After emulsion PCR, templated
beads were enriched in a glycerol gradient and deposited onto
the surface of a glass slides for SOLiD sequencing. Sequen-
cing was performed using 35 bp chemistry on a Version 3.0
SOLiD machine.
Sequence analysis
For determining the number of trinucleotide repeat-containing
reads, only exact matches were accepted. For example, the
number of CAG repeat reads of length 21 can be determined
via:
grep T21231231231231231231233302010303131 bc5.fasta |
wc | head | less
For other small RNA analyses, the SOLiDTM System
Analysis Pipeline Tool (Corona Lite) (http://solidsoftwa
retools.com/gf/project/corona/) was used to remove adapter
dimers (25 seed, maximum 2 colour space mismatches) and
subsequently to map reads to miRNA precursors (miRBase
version 14) and the D. melanogaster genome (BDGP5.0;
April 2006) with the following parameters (seed length.maxi-
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Only reads which did not map at step n were included in step
n + 1. If a read mapped to multiple locations, the longest
alignment was selected; reads with multiple maximally long
alignments were discarded. Reads mapping to microRNA pre-
cursors in miRBase were considered further if they matched
the mature miR sequence or reported (or predicted) star
sequence. To allow for isomiRs we accepted the match if it
occurred within +3 nt at either the 5′ or 3′ ends. Reads
mapping to the precursor that could be considered neither
mature nor star (e.g. including the loop sequence) were dis-
carded from further analyses. RNA deep sequencing data is
deposited at NCBI’s Sequencing Read Archive (http://www.
ncbi.nlm.nih.gov/sra)
SUPPLEMENTARY MATERIAL
Supplementary material is available at HMG online.
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Abstract
Expanded DNA repeat sequences are known to cause over 20 diseases, including Huntington’s disease, several types of
spinocerebellar ataxia and myotonic dystrophy type 1 and 2. A shared genetic basis, and overlapping clinical features for
some of these diseases, indicate that common pathways may contribute to pathology. Multiple mechanisms, mediated by
both expanded homopolymeric proteins and expanded repeat RNA, have been identified by the use of model systems, that
may account for shared pathology. The use of such animal models enables identification of distinct pathways and their
‘molecular hallmarks’ that can be used to determine the contribution of each pathway in human pathology. Here we
characterise a tergite disruption phenotype in adult flies, caused by ubiquitous expression of either untranslated CUG or
CAG expanded repeat RNA. Using the tergite phenotype as a quantitative trait we define a new genetic system in which to
examine ‘hairpin’ repeat RNA-mediated cellular perturbation. Further experiments use this system to examine whether
pathways involving Muscleblind sequestration or Dicer processing, which have been shown to mediate repeat RNA-
mediated pathology in other model systems, contribute to cellular perturbation in this model.
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Introduction
The expansion of polymorphic repeat sequences (dynamic
mutation) is responsible for over 20 human diseases, including
Huntington’s disease (HD), myotonic dystrophy and several types
of spinocerebellar ataxia (SCA) [1–3]. In all cases affected
individuals inherit a repeat number that exceeds a pathogenic
threshold. Increased disease severity and earlier age-of-onset are
correlated with repeat length expansion, which occurs within
successive generations [1–3]. Expansion is associated with loss of
repeat-containing gene function and recessive inheritance in a few
cases [4,5], however the majority of diseases appear to be caused
by dominant, repeat-mediated mechanisms. As well as a shared
genetic basis, many diseases show similar clinical features,
including late onset neurodegeneration and movement disorder,
highlighting the possibility that common pathways contribute to
pathology in most, if not all cases of dominantly inherited dynamic
mutation [1–3,6].
In diseases including HD and some types of SCA, expanded
CAG trinucleotide repeats are found within a coding region,
producing an expanded polyglutamine tract within the final
protein [2]. Polyglutamine is able to cause pathology through
multiple possible pathways, including gain-of-function interactions
inherent to the expanded protein tract and alterations to normal
protein function [3,7,8]. Nevertheless, polyglutamine protein-
mediated pathology is not able to account for diseases where
repeats are unable to encode polyglutamine, due to the repeat
sequence composition and/or presence of the repeat tract within
non-coding regions of the associated gene. This class of
‘untranslated’ repeat diseases share similar repeat sequences,
pathogenic thresholds and clinical features with the ‘polygluta-
mine’ diseases and includes myotonic dystrophy type 1 (DM1) and
2 (DM2), Huntington’s disease-like-2 (HDL-2), fragile X tremor/
ataxia syndrome (FXTAS) and SCA8, 10 and 12. In these
diseases, gain-of-function properties of the expanded repeat RNA
transcript appear to be responsible for dominant pathology [9–11].
Since repeat-containing RNA is present whether repeats are
coding or non-coding, it may also represent a common contributor
to all the dominant expanded repeat diseases. Studies have
reported the ability of repeat RNA to cause pathology in animal
and cellular model systems, via multiple, and likely distinct
pathways [12–21].
Pathology due to expanded repeat RNA was first attributed in
DM1, caused by a non-coding CUG repeat within the 39UTR of
the dystrophia myotonica-protein kinase (DMPK) gene, and DM2, caused
by a non-coding CCUG repeat within an intron of ZNF9 (now
called CNBP) [22,23]. Expanded repeat RNA transcripts form a
‘hairpin’ secondary structure, which is able to bind and sequester
specific RNA-binding proteins [24–26]. The most extensively
characterised of these is Muscleblind-like 1 (MBNL-1), which is
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38516
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involved in the regulation of alternative splicing [27,28]. Seques-
tration of MBNL-1 leads to mis-splicing of certain transcripts and
subsequent disease [29]. Pathology is associated with the formation
of nuclear RNA foci that co-localise with MBNL-1 and may
therefore be sites at which sequestration occurs [24,30–32]. A
number of other proteins have been identified that are bound or
mis-regulated by repeat RNA, including CUG-binding protein
(CUG-BP) [14,33], Pur-alpha [34] and some heterogeneous
nuclear ribonucleoproteins (hnRNPs) [35,36], indicating a com-
plex set of both common and repeat sequence specific interactions.
The presence of RNA foci, co-localisation of MBNL-1 with foci
and dysregulation of alternative splicing have also been observed
in either human tissue or animal models of the untranslated repeat
diseases, DM1, DM2 [29], FXTAS [37,38], SCA8 [39,40], HDL-
2 [41] and SCA10 [36]. Based on these hallmarks it is proposed
that the sequestration of MBNL-1 and dysregulation of splicing
may be a common contributor to pathology. Furthermore, RNA
foci that co-localise with MBNL-1 have been observed in human
HD cells [42], supporting a role for this pathway in the
polyglutamine diseases, however evidence for perturbation of this
pathway in human patients is limited.
Recent studies have identified other mechanisms, distinct from
RNA-binding protein sequestration, through which repeat RNA
may contribute to common pathology. We and others have
reported evidence supporting a pathogenic role for bi-directional
transcription, producing complementary repeat transcripts that
hybridise to form double-stranded RNA [19,20]. Pathology is
modified by altering Dicer-2 levels and is associated with the
formation of 21nt repeat RNAs, highlighting a role for small RNA
processing pathways in disease [20]. Bi-directional transcription
has been identified in a number of diseases and therefore this
pathway may be a common contributor to dominant pathology
[43–48].
Evidence for a repeat-mediated mechanism of non-ATG
initiated translation, occurring in all three reading frames,
highlights another alternative mechanism that may account for
common pathology [49]. Combined with bi-directional repeat
transcription this mechanism may produce multiple homopoly-
meric protein tracts that can contribute to pathology [49,50]. The
increasing number of pathogenic agents and pathways identified
highlights the need for model systems in which to better define the
contributors to pathology in each case.
Expanded repeat disease involves late onset neurodegeneration
and loss of affected tissue, making access to samples and the
detection of early changes that underlie pathology difficult.
Human studies are therefore limited and animal models have
been essential in investigating pathology. Drosophila is well
established as a model for expanded repeat disease and a number
of key pathways are conserved and have been identified or
characterised in this system [7,8,13–15,17,19,20,39,50,51]. Re-
peats can be ectopically expressed in non-essential tissues such as
the eye, allowing phenotypes involving cellular perturbation to be
examined in an otherwise viable organism [52]. The Drosophila
system is also amenable to the powerful approach of examining
modifier genes, thus identifying genetic pathways required for
pathology that will inform further studies in vertebrate models and
human tissue.
We recently reported phenotypes, due to co-expression in the
Drosophila eye or neurons, of complementary repeat transcripts that
form double-stranded repeat RNA [20]. However, no consistent
phenotypes were observed in the eye or neurons when each repeat
sequence was ectopically expressed in the absence of a comple-
mentary transcript, thus acting only as a single-stranded ‘hairpin’
RNA [17,20]. Here we characterise a morphological phenotype
caused by ubiquitous expression of CUG or CAG repeat RNA-
containing transgenes in Drosophila identifying a new system,
independent of the Drosophila eye, in which to study common
‘hairpin’ repeat RNA-mediated pathology. Ubiquitous expression
of either CUG or CAG repeat RNA disrupts the adult Drosophila
dorsal abdominal tergites, possibly through an effect on the
developing histoblast cells. Results indicate that the tergite
phenotype is quantitative and dependent on repeat-transgene
expression, providing a biological read-out of ‘hairpin’ RNA
mediated pathology in this model system.
Further experiments examine whether pathways known to
contribute to repeat RNA-mediated pathology are rate limiting for
tergite disruption. Reducing levels of Mbl, the Drosophila ortholog
of MBNL-1, does not enhance pathology and only modifies CUG-
mediated phenotypes.
In contrast to recently reported double-stranded repeat RNA-
mediated pathology [20], reducing Dicer-2 (Dcr-2) levels was not
rate limiting for ‘hairpin’ RNA-mediated tergite disruption.
However, reducing Dicer-1 (Dcr-1) levels gave opposing results
for phenotypes caused by CAG compared to CUG repeat RNA,
highlighting the possibility of a sequence-dependent role for this
pathway. Finally, examining RNA localisation identified specific
RNA foci formed due to CUG, but not CAG, RNA expression.
Thus, in this system ‘hairpin’ RNA may contribute to pathology
through multiple interactions.
Results
Ubiquitous CAG or CUG Repeat RNA Expression Perturbs
Abdominal Developmental in Drosophila
We previously reported a system to ectopically express ‘hairpin’-
forming CUG or CAG repeat RNA transcripts under UAS control
in Drosophila [8,17,20]. Co-expression of both CUG and CAG
complementary repeat-containing transgenes gave Dcr-2 depen-
dent eye phenotypes, behavioural phenotypes, and changes in the
miRNA profile [20]. In contrast, expression of either one of CUG
or CAG repeat-containing transgenes, in the absence of a
complementary transcript, gave transcriptional changes indicative
of cellular perturbation, but no observable phenotypes with
ectopic expression in the neurons or eye [17,20]. The absence of
an observable phenotype limits the ability to genetically examine
the basis of cellular perturbation caused by CUG or CAG repeat
‘hairpin’ RNA.
In this study we therefore set out to identify morphological
phenotypes caused by ectopic expression of either CUG or CAG
expanded repeat RNA in Drosophila. Ectopic expression of CUG or
CAG expanded repeat RNA was compared to an empty vector
(EV) negative control as well as ectopic expression of expanded
CAA repeat RNA, which unlike CAG or CUG, is not predicted to
form a stable secondary structure [53]. Experiments were
undertaken using the system that we have previously reported,
whereby different untranslated repeat RNA sequences are
expressed within the 39 untranslated region of an RNA encoding
a short, non-functional peptide [8,17]. Independent transgenic
lines were examined for each repeat sequence, with each line
carrying four independent insertions of the transgene to generate
high steady state levels of RNA [20]. Multiple independent
transgenic insertions were initially generated for each construct
(rCUG,100, rCAG,100 or rCAA,100, named alphabetically, ‘A’
through to ‘K’) and used to create lines carrying sets of 4
independent transgene insertions (4xrCAG,100, 4xrCUG,100 or
4xrCAA,100, named numerically, ‘line 1’ onwards) [20]. We have
previously shown that, in the case of CUG or CAG expression,
these lines give comparable levels of transgene expression, so that
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phenotypic outcomes can be compared in each case [17,20]. CAA
expression transgenes appear to be present at a lower steady state
level [17], possibly due to their inability to form stable secondary
structures. Since it is possible that greater steady state RNA levels
may be an outcome, rather than a cause, of pathogenic RNA-
protein interactions, these lines were included nonetheless, along
with other controls to ensure that robust comparisons were made
in each case.
Expanded repeat RNA transgenes, under UAS control, were
expressed ubiquitously using the da-GAL4 driver [54]. Progeny
expressing expanded CUG (4xrCUG,100), or CAG (4xrCAG,100)
repeat RNA showed a variable reduction in adult viability
compared to each of the controls. At the standard culture
temperature of 25uC, a significant reduction was observed in one
of two independent 4xrCUG,100 expressing lines compared to
those expressing 4xrCAA,100 and the EV control (Table S1A). One
of two independent 4xrCAG,100 expressing lines showed a
significant reduction compared to 4xrCAA,100 expressing progeny,
but not the EV control (Table S1A). When grown at 29uC, giving
increased GAL4 activity and hence increased repeat expression
levels, complete lethality was observed in 4xrCUG,100 and
4xrCAG,100 expressing progeny but not in either 4xrCAA,100
expressing progeny or EV controls (Table S1B). These results
therefore demonstrate that ubiquitous expression of expanded
CUG or CAG repeat RNA leads to pathology in this Drosophila
model.
Closer physical examination of adult flies revealed a phenotype
in viable progeny expressing expanded CUG or CAG repeat RNA
at 25uC whereby the tergites of the dorsal abdomen were not
correctly formed. In wild-type adults, the abdomen contains a
series of regularly arranged tergites (Figure 1A), while in repeat
expressing flies one or more of the tergite bands is split down the
midline so that the two sides do not meet at all, or meet only
partially (Figure 1B).
A strong phenotype was observed in both independent lines
expressing 4xrCAG,100, with semi-lethality and the strongest
phenotype in 4xrCAG,100 [line 1], and a moderate to strong
phenotype in 4xrCAG,100 [line 2]. Both independent 4xrCUG,100
lines gave a more moderate phenotype. This phenotype was not
observed with expression of independent 4xrCAA,100 lines, the EV
control line, or in flies carrying each set of transgenes, in the
absence of a GAL4 driver. Repeat expression via an independent
ubiquitous driver, Actin5C-GAL4, gave an almost identical pheno-
type. In this case, the most severe phenotypes were observed in the
same lines which gave the strongest da-GAL4 phenotype (Table
S2). Thus, ubiquitous expression of CUG or CAG repeat RNA
gives rise to a specific morphological disrupted tergite phenotype.
To further confirm and characterise the disrupted tergite
phenotype in each repeat expression line, a method was
established to quantify phenotype severity. Newly eclosed adult
female flies were individually scored and placed into one of four
categories based on the severity of disruption and the number of
tergites affected (See Methods) (Figure 1C). To give an overall
measure of phenotype severity for each genotype, data was tallied
to determine the proportion of progeny within each phenotype
category (Figure 1D, E, F, G). Using this method, control progeny
expressing either EV or each of two independent 4xrCAA,100
transgenes were scored as having a phenotype at a frequency of
only 0–2% (Figure 1D, E and Table S3). Similarly those carrying
da-GAL4 alone, or each UAS construct in the absence of GAL4
driver expression, were scored as having a phenotype in less than
1% of progeny (Table S3). Progeny expressing 4xrCAG,100 had
the most severe phenotype with independent transgenic lines
showing at least 89% of progeny with a phenotype (Figure 1G and
Figure 1. Tergite phenotype caused by ubiquitous expression
of CAG or CUG repeat RNA in Drosophila. A, wild-type flies show a
regular arrangement of tergite bands along the dorsal abdomen
(arrows). B, An example of the disrupted phenotype, whereby tergites
do not fuse at all (white arrowheads), or fuse only partially (grey
arrowheads). C, Phenotype severity was scored on a scale of 1–4,
images show typical examples from each category, where category 1 is
like wildtype; category 2, tergites disrupted but not split; category 3,
one tergite split; and category 4, two or more tergites split. D-E, Graphs
showing the proportion of progeny within each scoring category. D,
da-GAL4 driven expression of the EV control line (n = 161) and, E, da-
GAL4 driven expression of 4xrCAA,100 [line 1] (n = 148) gives no
phenotype with almost all progeny like wild-type. F, da-GAL4 driven
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Figure S1). Independent lines expressing 4xrCUG,100 showed a
less severe phenotype, with at most 78% of progeny with a
phenotype and a greater proportion within the mildest category,
compared to 4xrCAG,100 expression (Figure 1F and Figure S1).
Decreased dosage of rCAG,100, with ectopic expression from lines
carrying two transgene copies, gave a more mild tergite phenotype
than expression from the corresponding four transgene copy line
(Figure S1). Thus, the phenotype is dependent on the number of
transgene insertions being expressed, suggesting that increasing the
dosage of available repeat-containing transcripts increases pheno-
type severity. Together, these results confirm that similar tergite
disruption phenotypes are caused by the expression of CUG or
CAG repeat-containing transcripts.
Although repeat RNA is ubiquitously expressed in this system,
specific tergite disruption is observed, indicating that particular
cells, or processes, may be sensitive to repeat RNA-mediated
perturbation. The adult tergites are formed from the histoblast
cells, a small population that is specified during early development
and is located symmetrically, either side of the larvae [55]. During
pupation these cells proliferate and migrate towards the midline,
eventually giving rise to the tergite bands [56] (Figure 1H). We
hypothesised that histoblast cells may be specifically perturbed by
repeat expression, leading to the observed phenotype. To examine
this possibility, repeats were expressed within histoblasts using the
T155-GAL4 driver [57,58]. Expression from 4xrCAG,100 [line 1]
gave a mild phenotype with T155-GAL4, while line 2 gave a
phenotype in a very small, but significant proportion of progeny
(Figure 1I&J and Figure S2). 4xrCUG,100 expression with T155-
GAL4 did not give a significant phenotype in either independent
transgenic line (Figure S2). The milder CAG phenotype, and
absence of CUG phenotype, observed with this driver may be due
to a lower level of expression than da-GAL4, or a requirement for
repeat expression in neighbouring cell types to give a strong
phenotype. Nonetheless, these results indicate that expression
within histoblast cells is sufficient to cause tergite disruption,
supporting the conclusion that cell specific perturbation is
responsible for the phenotype.
Tergite Disruption is not Enhanced by Reducing
Muscleblind Levels
Expanded CUG or CAG repeat RNA expression in this
Drosophila model leads to common perturbation of specific cells,
giving a tergite disruption phenotype. This provides a quantitative
biological read-out, and hence a model system to investigate
whether genetically altering specific pathways modifies the
observed repeat-mediated tergite phenotype. Using this approach,
experiments examined whether pathways known to contribute to
other forms of repeat RNA-mediated pathology also contribute to
the disrupted tergite phenotype.
Muscleblind (mbl), the Drosophila orthologue of MBNL-1, was
chosen as an initial candidate, as previous studies in Drosophila have
found that altering this gene can modify repeat RNA-mediated
pathology in the eye [14,15,51]. To determine whether reducing
mbl levels modifies tergite pathology, repeats were expressed with
da-GAL4 in progeny carrying one copy of the mblE27 mutant allele
[27]. We hypothesized that if Mbl protein sequestration contrib-
utes to the phenotype, a further reduction in Mbl, in progeny
heterozygous for the mutant allele, would lead to an enhanced
phenotype.
The severity of the disrupted tergite phenotype was compared
to determine whether repeat-mediated phenotypes were modified
in progeny carrying one copy of mblE27, compared to those with
two wild-type mbl alleles (Figure 2A, B, C, D, S3 and Table S4).
The proportion of progeny showing any phenotype (defined by
progeny in all three phenotype categories) and the proportion
showing a strong phenotype only (defined by progeny in the two
most severe categories), were compared between genotypes
(Figure 2E, F and Table S7). Statistical analysis revealed a
significant (Fisher’s exact test) decrease in the proportion that show
any phenotype with expression from two independent 4xrCUG,100
lines in the presence of mblE27 (Figure 2E and S3). However, no
change was observed when comparing the proportion within the
strongest two categories only, perhaps indicating that only those
with the weakest phenotype are suppressed (Figure 2E and S3).
Expression of 4xrCAG,100 in the presence of mbl
E27 led to no
significant change in phenotype proportion compared to expres-
sion of 4xrCAG,100 alone (Figure 2F and S3). Thus reducing Mbl
levels did not enhance the tergite phenotype caused by either
CUG or CAG repeat expression in this Drosophila system. Instead,
suppression was observed that appeared to be specific to the
phenotype caused by CUG expression only. Flies homozygous for
mblE27 were not viable and thus it was not possible to examine the
effect of complete Mbl loss-of-function in this system. However,
these results do not support a role for Mbl sequestration as a
common contributor to CUG or CAG RNA-mediated tergite
phenotypes.
Reduced Dicer-2 Processing is not Rate Limiting for the
Tergite Phenotype
Previously we reported that co-expression of complementary
CAG and CUG repeat RNA transcripts leads to pathology that is
suppressed by reducing Dcr-2 levels [20]. Based on this evidence,
and the presence of 21nt repeat RNAs, it is proposed that
complementary repeats form double-stranded repeat RNA that is
processed by Dicer enzymes [20]. Pathology is associated with
altered miRNA profiles, indicating that double-stranded repeat
RNA may perturb normal Dicer processing pathways [20]. Single-
stranded ‘hairpin’ RNA has also been reported to be a substrate
for Dicer processing, and therefore could potentially perturb Dicer
processing pathways in a similar manner [59]. Ectopic expression
of CUG or CAG repeat transgenes separately does not lead to a
phenotype in the eye, such that modification by reducing Dicer
processing could not be tested [20,17]. However, as ubiquituous
expression of each transgene gives tergite disruption, this
phenotype can be used to genetically examine the role of Dicer
processing in cellular perturbation caused by single-stranded CUG
or CAG ‘hairpin’ repeat RNA, in the absence of a complementary
transcript.
Experiments first examined whether reducing Dcr-2 levels can
modify the tergite phenotype. Each of the expanded repeat RNA
expression lines, 4xrCAG,100, 4xrCUG,100 and 4xrCAA,100, were
ubiquitously expressed via da-GAL4 in the presence of one copy
of the Dcr-2L811fsX loss-of-function mutant allele (Figure 3A, B, C,
D, S4 and Table S5). If Dcr-2 function is rate limiting for the
phenotype then this reduction in Dcr-2 levels would be expected
to result in suppression, as was previously observed with
complementary repeat RNA expression [20]. In independent
lines, 4xrCUG,100 and 4xrCAG,100 expression in the presence of
expression of 4xrCUG,100 [line 1] (n = 271) or G, 4xrCAG,100 [line 2]
(n = 343) gives a tergite disruption phenotype. H, Schematic (not to
scale) showing the location of histoblast cells (black). Histoblasts
proliferate and migrate to form the tergite bands (arrows). I, Expression
within the histoblasts using T155-GAL4 gives wild-type tergites in EV
control progeny (n = 56). J, T155-GAL4 expression of 4xrCAG,100 [line 1]
(n = 25) gives a mild tergite phenotype, ***p,0.001 comparing the
proportion with a phenotype in I and J.
doi:10.1371/journal.pone.0038516.g001
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the Dcr-2L811fsX mutant allele did not give a significantly different
phenotype severity compared to repeat RNA expression in a
wild-type Dcr-2 background (Figure 3E, F, S4 and Table S7).
Thus, a reduction in Dcr-2 levels is not rate limiting for CAG or
CUG repeat RNA-mediated tergite disruption. These results
support tergite disruption being caused by a mechanism that is
distinct to that responsible for Dcr-2 dependent double-stranded
repeat RNA pathology.
Reduced Dicer-1 Processing can have Opposing Effects
on CUG or CAG RNA-mediated Tergite Phenotypes
In Drosophila, Dcr-1 and Dcr-2 have distinct roles in small RNA
biogenesis and therefore may have different preferences for
hairpin-forming repeat RNA [60]. Thus, the ability of reduced
Dcr-1 levels to modify tergite pathology was also examined.
Repeat constructs were ubiquitously expressed using da-GAL4 in
the presence of one copy of the Dcr-1Q1147X mutant allele and
phenotype severity examined (Figure 4A-D, S5 and Table S6). In
Figure 2. Reducing Mbl levels does not enhance the tergite phenotype. A-D, Proportion of progeny within each phenotype category when
repeat expression is driven by da-GAL4 alone (left column), or in the presence of the mblE27 mutant allele such that Mbl levels are reduced (right
column). A, Wild-type control, B, 4xrCAA,100 [line 1], C, 4xrCUG,100 [line 1], D, 4xrCAG,100 [line 2]. E, F, Total proportion for each genotype that shows
any phenotype (‘any phenotype’ - category 2, 3 and 4) and the proportion with a strong phenotype (‘strong phenotype’ – category 3 and 4). E,
4xrCUG,100 [line 1] shows a reduction in the proportion with any phenotype, but no change in the proportion with a strong phenotype with reduced
Mbl levels. F, No significant effect was observed with 4xrCAG,100 [line 2]. Comparisons were made using Fisher’s exact test, with significant results
indicated above the proportion, where *p,0.05.
doi:10.1371/journal.pone.0038516.g002
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one of two lines expressing 4xrCUG,100 in the presence of Dcr-
1Q1147X the proportion of progeny with any phenotype, and those
with a strong phenotype, was significantly reduced (Figure 4E, S5
and Table S7). A second 4xrCUG,100 line gave a reduction in the
proportion of progeny with any phenotype, however this was not
statistically significant (Figure S5, Table S7). In contrast, one of
two 4xrCAG,100 lines showed a more severe phenotype in the
presence of Dcr-1Q1147X than when the repeat was expressed alone,
with both the proportion showing any phenotype, and a strong
phenotype, significantly increased (Figure 4F and S5). It was not
possible to confirm this finding in an independent line, as the
second four transgene copy expression line already showed a
strong phenotype and reduction in viability, giving insufficient
progeny for analysis (Table S6). Results indicate that reducing
Dcr-1 levels may have opposing effects on CUG or CAG mediated
phenotypes in this system. A further reduction in Dcr-1 function
may cause stronger effects, providing further evidence for this
effect, however, flies homozygous for the Dcr-1Q1147X allele are not
viable and the involvement of this protein in small RNA
processing limits the feasibility of using RNAi methods. Nonethe-
Figure 3. Reducing Dcr-2 levels is not rate limiting for the tergite phenotype. A-D, Proportion of progeny within each phenotype category
when repeat expression is driven by da-GAL4 alone (left column), or in the presence of the Dcr-2L811fsX mutant allele such that Dicer-2 levels are
reduced (right column). A, Wild-type control, B, 4xrCAA,100 [line 1], C, 4xrCUG,100 [line 1], D, 4xrCAG,100 [line 2]. E, F, Total proportion for each
genotype that shows any phenotype (‘any phenotype’ - category 2, 3 and 4) and the proportion with a strong phenotype (‘strong phenotype’ –
category 3 and 4). E, 4xrCUG,100 [line 1], F, 4xrCAG,100 [line 2]. None of the observed changes were statistically significant (Fisher’s exact test).
doi:10.1371/journal.pone.0038516.g003
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less, our results do not support a simple model whereby Dcr-1
processing is rate-limiting for the common pathway leading to
tergite disruption.
Ubiquitous CUG, but not CAG, Repeat RNA Expression
Gives Nuclear RNA Foci in Specific Cells
A hallmark of pathology associated with ‘hairpin’ repeat RNA is
the formation of nuclear repeat RNA foci [61]. Thus RNA
localisation was examined to determine whether each of the
repeat-containing transgenes being expressed in our system is able
to form nuclear RNA foci. Expanded repeat RNA was visualised
in cryo-sections of whole larvae by in situ hybridisation with a
fluorescently labelled probe complementary to the repeat sequence
(Figure 5). With da-GAL4 driven 4xrCUG,100 expression, many
nuclei contained up to four sites of RNA accumulation, possibly
related to the sites of transcription for each transgene (data not
Figure 4. Reduced Dicer-1 processing can have opposing effects on CUG or CAG RNA-mediated tergite phenotypes. A-D, Proportion
of progeny within each phenotype category for expression with da-GAL4 alone (left column), or in the presence of the Dcr-1Q1147X mutant allele such
that Dcr-1 levels are reduced (right column). A, wildtype control, B, 4xrCAA,100 [line 1], C, 4xrCUG,100 [line 1], D, 4xrCAG,100 [line 2]. E, F, Total
proportion for each genotype that shows any phenotype (‘any phenotype’ - category 2, 3 and 4) and the proportion with a strong phenotype (‘strong
phenotype’ – category 3 and 4). E, 4xrCUG,100 [line 1] shows a suppression for both measures. F, 4xrCAG,100 [line 2] shows an enhancement for both
measures. Comparisons were made between the populations using Fisher’s exact test, with significant results indicated above the proportion, where
*p,0.05, **p,0.01 and ***p,0.001.
doi:10.1371/journal.pone.0038516.g004
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shown). However, in a specific subset of cells, identified by
morphology as larval muscle cells, multiple speckled foci were
observed throughout the nucleus (Figure 5C). Identical staining
was observed in independent samples and in independent
transgenic lines (Figure S6). Furthermore, no signal was observed
in lines carrying the repeat expression transgene but no GAL4
driver, confirming that RNA foci are dependent on transgene
expression (Figure S6). 4xrCAG,100 expression from independent
transgenic lines gave up to four sites of RNA accumulation in all
cell types, with multiple speckled foci not observed in muscle cells
(Figure 5D, S7). Unexpectedly 4xrCAA,100 expression gave a
staining pattern almost identical to that observed with 4xrCAG,100.
Up to four sites of RNA accumulation were observed in both
muscle and non-muscle nuclei from independent transgenic lines
expressing 4xrCAA,100, suggesting that sites of RNA accumulation
are not ‘hairpin’-specific (Figure 5E, S8). These sites may be the
sites of transcription, or processing, of the repeat containing
transgenes, as the one to four sites observed correlate with the four
transgenes being expressed. In each case, no staining was observed
in nuclei carrying the transgene, but no GAL4 driver, suggesting
that the observations are dependent on the transgene being
transcribed (Figure S6, S7, S8).
RNA localisation results were confirmed by expressing each
expanded repeat RNA sequence within the 59UTR of the
transcript encoding green fluorescent protein (GFP). In this case
a probe complementary to the GFP sequence was used (Figure 5F),
eliminating any effects specific to the binding dynamics of each
repeat sequence. Lines carrying four transgenes were generated for
each expanded repeat sequence: 4xrCUG,100-GFP, 4xrCAG,100-
GFP and 4xrCAA,100-GFP. Identical results were obtained to those
observed initially, with 4xrCUG,100-GFP expression giving mul-
tiple foci within muscle cells (Figure 5H). However, 4xrCAG,100-
GFP and 4xrCAA,100-GFP expression within a GFP encoding
transcript gave only one to four sites of RNA concentration in all
cell types (Figure 5I, J). Although each of the lines carried four
independent transgene insertions, the number of sites of RNA
concentration observed was between one and four for each cell. It
is possible that the variation in this number is dependent on the
focal plane observed for any given cell. In order to confirm this, a
control line expressing a single GFP transgene, with no repeat
sequence was examined. In this case nuclei showed a single site of
RNA concentration in all cells, indicating that these RNA
localisation experiments are detecting sites of transgene expression
(Figure 5K).
In this model, ubiquitously expressed CUG, but not CAG or
CAA-containing transcripts are able to undergo interactions
sufficient to result in the formation of nuclear foci in specific cells.
Thus, the mechanism that gives rise to cell-specific foci appears to
be specific to CUG, but not CAG repeat RNA ‘hairpins’ in this
system.
Discussion
Recent evidence suggests that repeat RNA transcripts may
contribute to dominantly inherited human pathology through
multiple pathways [19,20]. However, the specific mechanisms
involved, particularly the way in which different repeat sequences
give rise to similar pathology, is not fully understood. In this study
we characterise a new system in which to study common CUG or
CAG repeat RNA-mediated pathology. Reduced viability and a
disrupted tergite phenotype were observed with ubiquitous
expression of ‘hairpin’-forming CUG or CAG repeat RNA in
this Drosophila model. Expression of either ‘hairpin’ repeat
sequence gives similar tergite disruption, likely involving the same
cell type, suggesting that a common pathway is responsible for
cellular perturbation. In contrast, co-expressing both complemen-
tary repeat sequences in the same Drosophila system, to give double-
stranded repeat RNA led to complete lethality [20]. Thus, single-
stranded hairpin RNA may make a milder, more specific
contribution to pathology, perturbing a particular pathway or
cellular process and giving rise to susceptibility in certain cell types
only. In support of this, expression of repeat RNA transcripts in
histoblast cells was sufficient to cause mild tergite pathology.
Repeat RNA expression phenotypes observed in this study are
not expected to mirror human pathology, but rather provide a
tissue specific biological read-out of repeat-mediated cellular
perturbation. The Drosophila eye has been used in a similar
manner to show that key disease mechanisms identified in
vertebrates appear to be conserved in flies [7,8,13–15]. The
tergite phenotype provides an independent system in which to
explore repeat RNA-mediated pathology. As distinct cell types,
and biological processes, are predominant in each model tissue, an
independent system may extend our knowledge of the genetic
pathways that may contribute to pathology in human disease. The
nature of the tergite phenotype itself suggests that processes
involving cytoskeletal regulation, required for histoblast migration
and intercalation, may be candidate pathogenic pathways [56].
The cytoskeleton is important for neuronal function and
transcriptional changes in genes involved in cytoskeletal regulation
were previously identified in microarray studies of neuronal repeat
RNA expression in Drosophila [17]. While perturbation in neurons
likely gives a different cell biological outcome than in histoblasts,
the molecular pathways involved may be the same in each case.
Thus, this Drosophila system provides a way to study these pathways
using a quantitative morphological read-out, that would likely not
be observed with neuronal perturbation. Furthermore, the tergite
phenotype appears to perturb cells that are proliferating and
migrating, and thus such processes that are not occurring in the
Drosophila eye could be specifically examined in this system.
In our study, a modifier gene approach was used to examine
whether pathways shown to alter repeat RNA-mediated pathology
in the eye [14,20] could also modify the tergite phenotype. Initially
we examined whether perturbation of Mbl, a known target of
repeat RNA-mediated sequestration and contributor to pathology,
contributes to the tergite disruption phenotype. If the phenotype
was caused by Mbl sequestration, a further reduction in Mbl
would be expected to enhance pathology, however, this was not
observed with either CUG or CAG expression phenotypes. Thus,
Mbl sequestration does not appear to be a major contributor to the
common pathway that leads to similar CUG or CAG-mediated
tergite disruption. Interestingly, in both CUG expressing lines, the
proportion of progeny showing a milder phenotype was reduced
when Mbl levels were reduced, while the proportion with a
stronger phenotype was not significantly changed. Pathways
involving Mbl sequestration may therefore make a mild, or
indirect, contribution to CUG specific pathology, perhaps through
the role of Mbl in RNA processing and stability [15,62]. Structural
studies show that each repeat sequence has distinct binding
abilities that may account for the CUG specificity in this case [63].
We previously reported that co-expression of complementary
CAG and CUG repeat RNA expression transgenes in the eye gives
a strong phenotype, that is suppressed by reducing Dcr-2 levels
[20]. However, expression of either CAG or CUG repeat RNA
transgenes alone, in the absence of a complementary transcript
and thus acting as a single-stranded ‘hairpin’ RNA only, gives no
eye phenotype [20]. The tergite phenotype therefore enabled us,
for the first time, to examine whether single-stranded ‘hairpin’
RNA-mediated cellular perturbation is also suppressed by
CUG and CAG Repeat RNA Pathogenesis in Drosophila
PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e38516
835
Figure 5. Ubiquitous CUG and CAG RNA repeat expression leads to distinct localisation in muscle nuclei. Images from cryosections
hybridised with fluorescent probes to detect repeat RNA. Images are representative of observations from multiple animals and independent
transgenic lines for each repeat. A, Schematic of the repeat expression construct, indicating the location of the repeat and probe. B-E, Repeat
transcripts detected with a complementary repeat probe. B, Progeny carrying the da-GAL4 driver alone show no signal in the nucleus. C, Expression
of 4xrCUG,100 [line 2] leads to multiple foci throughout the nucleus. D, E, Expression of 4xrCAG,100 [line 1], or 4xrCAA,100 [line 1] leads to between
one and four sites of RNA concentration (arrowheads). F, Schematic of the construct giving repeat expression within the context of the GFP
transcript, in this case RNA is detected using a probe against the GFP sequence.G-K, Repeat RNA localisation when expressed within a GFP transcript.
G, No signal is observed using the GFP complementary probe against control EV progeny. H, 4xrCUG,100-GFP expression leads to a similar pattern of
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reducing Dcr-2. In contrast to double-stranded repeat RNA
mediated pathology, reduced Dcr-2 levels were not rate limiting
for either CUG or CAG-mediated tergite phenotypes [20]. This
result suggests that mechanisms responsible for ‘hairpin’ RNA-
mediated tergite pathology are not identical to those involved in
double-stranded repeat RNA mediate pathology. For technical
reasons it was not possible to examine progeny homozygous for
the Dcr-2 loss of function allele, and the participation of this
enzyme in RNAi processing limits the feasability of reducing Dcr-2
function via this targeted RNAi approach. Thus, we cannot
exclude the possibility that some level of Dcr-2 processing, of CUG
or CAG ‘hairpin’ RNA, may be necessary for the phenotype.
However, our results suggest that even if Dcr-2 is required in both
double-stranded and ‘hairpin’-mediated pathology, different dy-
namics must be involved. Further studies will be necessary to
dissect the mechanisms involved in each case.
We further examined whether Dcr-1 processing is rate limiting
for the tergite phenotype. Reduced Dcr-1 levels gave opposing
effects, with a suppression observed with CUG transgene
expression and an enhancement with CAG transgene expression.
If pathology occurs through a mechanism dependent on the
processing of ‘hairpin’ repeats by Dcr-1, it would be expected that
a reduction in processing would give a similar effect in each case.
In contrast, the ability to induce opposing effects is suggestive of a
more complex interaction. It is unclear how this may occur,
however these results highlight the need to further investigate Dcr-
1 processing as a candidate pathogenic pathway. Future studies
examining other small RNA processing components, such as the
Argonaut proteins, may be necessary to understand how this
pathway may differentially interact with CUG or CAG repeat-
mediated pathology. We have previously reported that double-
stranded repeat RNA may cause pathology through the alteration
of endogenous miRNA levels [20]. Thus, a possible interaction of
‘hairpin’ RNA with Dcr-1 processing pathways, known to regulate
miRNA processing, may provide a candidate pathway that is a
common downstream target of ‘hairpin’ and double-stranded
RNA-mediated pathology.
Finally, we examined the localisation of ‘hairpin’ repeat RNA in
our system, as the formation of nuclear foci has previously been
shown to be a hallmark of ‘hairpin’ RNA pathology [61]. Results
indicate, that in our model system, CUG expression is sufficient to
produce certain, specific RNA foci, while CAG expression is not.
Expression of non-hairpin-forming CAA repeat RNA led to
identical nuclear staining as with CAG expression. Thus, the
ability to form a ‘hairpin’ structure is not sufficient to enable
interactions required for the formation of cell specific foci observed
with CUG RNA expression. CAG RNA foci have been previously
observed in Drosophila, mouse and human cells, indicating that
CAG expression may induce specific foci under some conditions
[15,18,42]. These different observations may be due to charac-
teristics of the transgenic expression system. Examining RNA
localisation in histoblast cells was not possible for technical
reasons, and thus we could not determine whether foci are formed
specifically in cells that are perturbed by repeat RNA expression.
Nonetheless, CAG transcripts in our system, that did not form
specific foci, gave a strong tergite phenotype, and thus are able to
undergo as yet undefined interactions necessary to induce
pathology. These results, together with our observations of
sequence specific modification with Mbl and Dcr-1, are consistent
with the possibily that ‘hairpin’ repeat RNA may undergo multiple
interactions that contribute to pathology.
The tergite phenotype should be considered in the context of
recent findings that non-coding repeat RNA sequences may
undergo translation through a repeat-mediated mechanism known
as repeat-associated non-ATG (RAN) translation, producing
transcripts in all possible reading frames [49]. This process is yet
to be observed in Drosophila, however, it is possible that
homopolymeric peptides are produced at some frequency from
our repeat RNA expression constructs including polyglutamine
and polyalanine proteins that are known to be pathogenic
[8,49,50]. Indeed, we previously reported a tergite phenotype
due to the expression of a single copy of a transgene encoding a
translated GCA repeat, producing a polyalanine peptide [50].
This phenotype may potentially be caused by either the repeat-
containing GCA RNA, which is structurally identical to CAG
repeat RNA, the presence of polyalanine protein, or a combina-
tion of the two. Ubiquitous expression of a polyglutamine
encoding CAG repeat is lethal in this system, preventing the
analysis of adult tergites [50]. However, expression of a single
translated CUG repeat-encoding transgene did not lead to a
tergite phenotype [50], perhaps consistent with the weaker CUG
phenotypes observed in this current study. As positively confirming
the presence of homopolymeric peptides in multiple reading
frames is technically complex, further analysis will be required to
determine the relative contribution of RNA and homopolymeric
protein to the tergite phenotype.
Recent findings suggest that multiple pathways, mediated by
‘hairpin’ and double-stranded repeat RNA, as well as homopol-
ymeric protein tracts, are able to independently cause pathology in
Drosophila models of expanded repeat disease. Here we characterise
a Drosophila tergite disruption phenotype caused by CUG or CAG
‘hairpin’ repeat RNA, providing a new, independent system in
which to study common pathways that lead to pathology.
Drosophila models such as this will enable the genetic pathways
contributing to each type of repeat-mediated pathology to be
defined. Identifying conserved pathways will provide candidates
for future studies in vertebrate models, as well as defining
‘molecular hallmarks’ that may be used to verify the contribution
of specific pathways modelled in Drosophila to human disease.
Materials and Methods
Drosophila Stocks
Stocks were obtained from the Bloomington Drosophila Stock
Centre (Bloomington, IN, USA) unless otherwise noted. Nomen-
clature used for Drosophila genotypes is as used on Flybase (www.
flybase.org). da-GAL4 (Bloomington stock #8641) was originally
described in [54]. Act5c-GAL4 (Bloomington stock #4414) was
originally described in [64]. T155-GAL4 (Bloomington stock
#5076) was originally described by [57]. Dcr-1Q1147X and Dcr-
2L811fsX were obtained from Professor Richard Carthew and are
described in [60]. mblE27 (Bloomington stock #7318) is caused by
imprecise excision of a P-element, removing exon 1 and 2 [27].
Repeat Expression Lines
Generation of repeat constructs has been previously described
[8,17]. Generation of rCAG,100 and rCUG,100 four transgene
copy lines, and nomenclature is described in [20]. Identical
methods were used to generate 4xrCAA,100. To generate GFP-
foci as in C. I, J, Expression of 4xrCAG,100-GFP or 4xrCAA,100-GFP leads to a similar pattern as in D and E. K, Expression of a single copy of GFP, not
containing a repeat, leads to the formation of a single similar site of RNA concentration.
doi:10.1371/journal.pone.0038516.g005
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repeat expression lines previously described expanded CAG,100,
CTG,100 and CAA,100 constructs were subcloned into pBKS+
vector (GenBank/EMBL accession number X52327) and subse-
quently inserted into pBD1010 (kindly donated by Professor Barry
Dickson) upstream of GFP using EcoRI and XhoI restriction sites.
The expanded repeat together with GFP was then cloned into
pUAST-attB [65] using EcoRI and XbaI restriction sites. The
length of the repeats and the integrity of GFP were confirmed by
DNA sequencing.
Quantification of Tergite Disruption
Newly eclosed adult females were scored for tergite disruption
by examining the dorsal abdomen under a standard dissecting
microscope. The phenotype was categorised on the scale: 1, like
wild-type; 2, tergites mildly disrupted but not split; 3, at least one
tergite split; 4, two or more tergites split. Counts from multiple
crosses scored under identical conditions were pooled to give a
final tally for each genotype. To compare the effect of modifiers on
the tergite phenotype categories were pooled into 2 groups, those
in category one or two, and those in category three or four. This
represents those with a mild, or no phenotype, and those with a
strong phenotype, and appeared to be the most robust way to
determine if modification was significant. Statistical significance
was determined using Fisher’s exact test (GraphPad Prism). This
enabled direct comparison of different sized populations, and
determined the probability that the distribution of progeny within
categories differ between genotypes by chance alone. p= 0.05 was
used as a cut off for significance.
Images of the adult abdomen were taken using an Olympus
SZX7 microscope fitted with a SZX-AS aperture. Images were
captured using an Olympus ColourView IIIU Soft Imaging
System camera and AnalysisRuler image acquisition software.
Adobe Photoshop CS was used for image preparation.
In situ Hybridisation of Frozen Sections
Whole wandering third instar larvae were frozen in Tissue-TekH
O.C.T.TM freezing medium and a Leica CM1900 cryostat was
used to cut 10 mm sections. For each genotype multiple larvae
were frozen per mould such that each section contained multiple
animals. Prior to hybridisation sections were fixed 15 minutes in
ice cold 4% paraformaldehyde in PBS, washed 3615 minutes in
room temperature PBS and quickly rinsed in 100% ethanol. Slides
were dried and hybridised for 2 hours, or overnight at 37uC in a
humid chamber with 0.5 ng/ul fluorescent oligonucleotide probe
in hybridisation buffer (46SSC, 0.2 g/mL dextran sulphate, 50%
formamide, 0.25 mg/mL poly(A) RNA, 0.25mg/mL single
stranded DNA, 0.1 M DTT, 0.56 Denhardt’s reagent). Slides
were washed 2615 minutes in 26SSC, 2615 minutes in 0.5xSSC
at 37uC, air-dried and mounted in VectashieldTM (Vector labs)
with 1 ng/mL DAPI to visualise nuclei. Fluorescent microscopy
for in situ hybridisation experiments was performed using a Zeiss
Axioplan 2 microscope with 636PlanApo objective. Images were
captured using Axiovision 4.5 software with an Axiocam MRm
camera. Further preparation of images was done using Axiovision,
or Adobe Photoshop CS. Multiple nuclei from multiple sections,
each containing multiple animals (n<10) were examined per
genotype. Independent transgenic lines were examined for each
repeat construct.










Figure S1 Graphs show the proportion of progeny
within each category for all genotypes. Proportion (0.0 to
1.0) is shown on the y-axis while each category (1–4) is shown on
the x-axis. Total population size, n, is indicated above each graph.
A – K, phenotype when each line is ubiquitously expressed with
da-GAL4. A’ – H’, phenotype when the same lines are crossed to
w1118 to give progeny with all four repeat transgenes, in the
absence of GAL4 driven expression. A, A’ w1118 wild-type lines. B,
B’ 4xUAS control line. C, C’ 4xrCAA,100 [line 1] and D, D’
4xrCAA,100 [line 2]. E, E’ 4xrCUG,100 [line 1] and F, F’
4xrCUG,100 [line 2]. G, G’ 4xrCAG,100 [line 1] and H, H’
4xrCAG,100 [line 2]. I, 2xrCAG,100 [line 1A] and J, 2xrCAG,100 [line
1B], the two transgene copy lines that were used to create
4xrCAG,100 [line 1]. When each of the two copies is expressed via
da-GAL4, I, J, the resultant phenotype is weaker than in the 4 copy
line, G.
(TIF)
Figure S2 Complete data sets showing proportion of
progeny within each tergite phenotype category when
repeat constructs were expressed in histoblasts with
T155–GAL4. Population size, n, is shown above each graph.
Significance indicated is based on comparing each repeat
expression line to the EV control, using Fisher’s exact test to
compare the distribution of progeny between those with any
phenotype (category 2, 3 and 4) and those like wild-type (category
1). *p,0.05 and ***p,0.001. Only 4xrCAG,100 expression in, F,
G, gives a significant phenotype.
(TIF)
Figure S3 Effect of reducing Mbl levels on the tergite
phenotype. Each repeat line was expressed ubiquitously via da-
GAL4 and via da-GAL4 in the presence of one copy of the mblE27
allele. A, B, C, expression of independent lines for each repeat
construct, either in a Mbl wild-type background (left column), or in
the presence of one copy of the mblE27 allele (right column). A,
w1118 control, and two independent 4xrCAA,100 lines, B, two
independent 4xrCUG,100 lines and C, two independent
4xrCAG,100 lines. D–G, statistical comparison (Fisher’s exact test)
of the proportion of progeny with any phenotype (category 2, 3, 4)
and a strong phenotype (category 3, 4) for D, 4xrCUG,100 [line 1],
E, 4xrCUG,100 [line 2], F, 4xrCAG,100 [line 1] and G, 4xrCAG,100
[line 2]. *p,0.05, **p,0.01, ***p,0.001.
(TIF)
Figure S4 Effect of reducing Dcr-2 levels on the tergite
phenotype. Each repeat line was expressed ubiquitously via da-
GAL4 and via da-GAL4 in the presence of one copy of the
dcr2L811fsX allele. A, B, C, expression of independent lines for each
repeat construct, either in a Mbl wild-type background (left
column), or in the presence of one copy of the mblE27 allele (right
column). A, w1118 control, and two independent 4xrCAA,100 lines,
B, two independent 4xrCUG,100 lines and C, two independent
4xrCAG,100 lines. D–G, statistical comparison (Fisher’s exact test)
of the proportion of progeny with any phenotype (category 2, 3, 4)
and a strong phenotype (category 3, 4) for D, 4xrCUG,100 [line 1],
E, 4xrCUG,100 [line 2], F, 4xrCAG,100 [line 1] and G, 4xrCAG,100
[line 2]. *p,0.05, **p,0.01, ***p,0.001.
(TIF)
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Figure S5 Effect of reducing Dcr-1 levels on the tergite
phenotype. Each repeat line was expressed ubiquitously via da-
GAL4 and via da-GAL4 in the presence of one copy of the
dcr1Q1147X allele. A, B, C, expression of independent lines for
each repeat construct, either in a Mbl wild-type background (left
column), or in the presence of one copy of the mblE27 allele (right
column). A, w1118 control, and two independent 4xrCAA,100
lines, B, two independent 4xrCUG,100 lines and C, two
independent 4xrCAG,100 lines. D–G, statistical comparison
(Fisher’s exact test) of the proportion of progeny with any
phenotype (category 2, 3, 4) and a strong phenotype (category 3,
4) for D, 4xrCUG,100 [line 1], E, 4xrCUG,100 [line 2], F,
4xrCAG,100 [line 1] and G, 4xrCAG,100 [line 2]. *p,0.05,
**p,0.01, ***p,0.001.
(TIF)
Figure S6 Cellular localization of the rCUG,100 tran-
script. A, Schematic of the rCUG,100 transcript (not to scale). A
short non-functional peptide (black) is encoded upstream of the
repeat (blue) which is within the 39UTR (dotted line). Probes were
designed to be complementary to the repeat, in this case a Cy3-
CAG10 probe targets the CUG,100 repeat. B-F, Microscope
images (63x) of larval muscle cells probed with the Cy3-CAG10
probe. Left panel shows the Cy3 signal alone, right panel shows a
merge of the Cy3 signal (red) and DAPI (blue) to label nuclei. B,
da-GAL4/+ larvae show no Cy3 signal. C, +/4xrCUG,100 [line 1]
progeny with four transgenes but no GAL4 driver show no Cy3
signal. D, da-GAL4 driven expression of 4xrCUG,100 [line 1] leads
to many foci throughout the nucleus. E, +/4xrCUG,100 [line 2]
progeny with no GAL4 driven expression show no signal, while, F,
expression of 4xrCUG,100 [line 2] via da-GAL4 leads to multiple
nuclear foci.
(TIF)
Figure S7 Cellular localization of the rCAG,100 tran-
script. A, Schematic of the rCAG,100 transcript (not to scale). A
short non-functional peptide (black) is encoded upstream of the
repeat (blue) which is within the 39UTR (dotted line). Probes were
designed to be complementary to the repeat, in this case a Cy3-
CTG10 probe targets the rCAG,100 repeat. B–F, Microscope
images (63x) of larval muscle cells probed with the Cy3-CTG10
probe. Left panel shows the Cy3 signal alone, right panel shows a
merge of the Cy3 signal (red) and DAPI (blue) to label nuclei. B,
da-GAL4/+ larvae show a weak Cy3 signal due to background
staining (asterisk). C, +/4xrCAG,100 [line 1] progeny with four
transgenes but no GAL4 driver show only weak background
staining. D, da-GAL4 driven expression of 4xrCAG,100 [line 1] leads
to only one to four foci (arrowheads) throughout the nucleus. E, +/
4xrCAG,100 [line 2] progeny with no GAL4 driven expression show
only weak background staining, while, F, expression of
4xrCAG,100 [line 2] via da-GAL4 leads to only a small number of
foci (arrowheads).
(TIF)
Figure S8 Cellular localization of the rCAA,100 tran-
script. A, Schematic of the rCAA,100 transcript (not to scale). A
short non-functional peptide (black) is encoded upstream of the
repeat (blue) which is within the 39UTR (dotted line). Probes were
designed to be complementary to the repeat, in this case a Cy3-
TTG10 probe targets the CAA,100 repeat. B-F, Microscope
images (63x) of larval muscle cells probed with the Cy3-TTG10
probe. Left panel shows the Cy3 signal alone, right panel shows a
merge of the Cy3 signal (red) and DAPI (blue) to label nuclei. B,
da-GAL4/+ larvae show only weak background staining. C, +/
4xrCAA,100 [line 1] progeny carrying four transgenes but no GAL4
driver show only weak background staining (asterisk). D, da-GAL4
driven expression of 4xrCAA,100 [line 1] leads to one to four foci
(arrowheads) throughout the nucleus. E, +/4xrCAA,100 [line 2]
progeny with no GAL4 driven expression show only weak
background staining, while, F, expression of 4xrCAA,100 [line 2]
via da-GAL4 leads to one to four foci (arrowheads).
(TIF)
Table S1 Viability when each repeat is expressed via
da-GAL4 A at 256C and B at 296C. For each genotype total
population size (n) is shown along with number of progeny that
express four copies of the transgene, and number that inherit the
compound balancer chromosome. Proportion with four copies of
the transgene, and 95% confidence interval (based on a binomial
distribution) for the particular proportion are shown. P values are
given for Fisher’s exact test using the raw values comparing the
number of 4x transgene, and balancer progeny for each genotype
to either the 4xUAS control, or 4xrCAA,100 [line 1].
(TIF)
Table S2 Tergite phenotypes with the ubiquitous Act5c-
GAL4 driver. Analysis of tergite phenotypes when repeat lines
are driven with the ubiquitous Act5c-GAL4 driver. Phenotype
strength is based on a qualitative scale (mild, moderate, severe)
where severe represents the worst phenotype observed of all lines,
and cannot be compared directly to da-GAL4 quantitative results.
Relative severities appear to be approximately comparable
between drivers where rCAG,100 [line 1] gave the most severe
tergite phenotype with both da-GAL4 and Act5c-GAL4. Similarly, as
for da-GAL4, rCAG,100 [line 1] and rCUG,100 [line 2] showed
reduced viability.
(TIF)
Table S3 Distribution of progeny between phenotype
categories in all repeat lines with and without da-GAL4
driver. Proportion of total progeny (n) for each genotype that fall
within each phenotype scoring category.
(TIF)
Table S4 Effect on distribution of progeny between
categories with and without mblE27. Each repeat line was
expressed ubiquitously via da-GAL4 and via da-GAL4 in the
presence of one copy of the mblE27 allele. Table shows the total
number of flies scored for each genotype (n), and the proportion of
the total represented by each phenotype category where 0.000 is
no progeny in that category and 1.000 is all progeny in that
category.
(TIF)
Table S5 Effect on distribution of progeny between
categories with and without Dcr-2L811fsX. Each repeat line
was expressed ubiquitously via da-GAL4 and via da-GAL4 in the
presence of one copy of the Dcr-2L811fsX allele. Table shows the
total number of flies scored for each genotype (n), and the
proportion of the total represented by each phenotype category
where 0.000 is no progeny in that category and 1.000 is all
progeny in that category.
(TIF)
Table S6 Effect on distribution of progeny between
categories with and without Dcr-1Q1147X. Each repeat line
was expressed ubiquitously via da-GAL4 and via da-GAL4 in the
presence of one copy of the Dcr-1Q1147X allele. Table shows the
total number of flies scored for each genotype (n), and the
proportion of the total represented by each phenotype category
where 0.000 is no progeny in that category and 1.000 is all
progeny in that category.
(TIF)
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Table S7 Statistical comparison of tergite severity when
different mutations are introduced. Tables shows p values
from Fisher’s exact test comparing genotypes for the distribution
between progeny with any phenotype (category 2, 3 and 4) and
others, or between progeny with a strong phenotype (category 3
and 4) and others. In each case comparisons are made to the
population expressing each repeat with da-GAL4 alone.
(TIF)
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Homopolymeric amino acid repeat sequences in proteins are of particular interest due to the discovery that
expanded copy numbers of these repeats are the molecular basis for a growing list of human genetic dis-
eases. Repeat copy numbers above a typical normal range of polyglutamine repeats have been found to
be the principal pathogenic agents in a number of these diseases, including Huntington’s disease. There
is emerging evidence that expansions of amino acids encoded by other reading frames of CAG/CUG repeats,
including polyalanine and polyleucine, could contribute to toxicity in the ‘polyglutamine’ diseases. We have
therefore used the Drosophila model system to investigate effects of ectopic expression of polyglutamine,
polyleucine and polyalanine repeats in vivo to assess their relative toxicities and the common and distinct
characteristics of the pathogenesis that they cause. We find that these homopolymeric sequences all exhibit
toxicity and are able to form aggregates in Drosophila, although there are marked differences in the degree of
toxicity dependent upon the tissue in which they are expressed.
INTRODUCTION
It has been 20 years since the discovery that the expansion of
repeats in the human genome can lead to disease (1,2). There
are now at least 22 diseases involving neurological or neuro-
muscular degeneration attributed to repeat expansion (3).
Despite the fact that the causative mutations and the genes
in which they reside have been identified, the mechanisms
by which the mutations lead to degeneration remain unclear.
The expanded repeat diseases can be divided into two main
groups, defined by the location of the expanded repeat
sequence. Nine are caused by the expansion of CAG repeats
in the coding region of different genes, resulting in an
expanded polyglutamine tract in the encoded protein, and
are thus referred to as ‘polyglutamine’ diseases. These
include Huntington’s disease and six forms of spinocerebellar
ataxia (SCA). Dysfunction and eventual loss of neurons in the
cerebellum are observed in each disease, with aggregates of
expanded polyglutamine protein observed in the brain, as
well as in animal models. The role of these aggregates as a
pathogenic agent, a protective mechanism or an innocent
bystander in disease is unresolved (4,5), although several
studies suggest that soluble monomeric conformers and insol-
uble oligomers of polyglutamine formed during the aggrega-
tion process may be more toxic than the aggregates
themselves (6–8). While the intrinsic toxicity of expanded
polyglutamine peptides has been demonstrated both in trans-
fected cells (9–11) and in Drosophila (12,13), there is also
growing evidence supporting a role for expanded CAG repeat-
containing RNA in pathogenesis (14–16). It appears that cel-
lular dysfunction in the polyglutamine diseases likely results
from a complex interplay of these pathogenic pathways,
although the contribution of each is not yet clear.
In addition to the polyglutamine diseases, there are another
11 repeat expansion diseases involving neurological and/or
neuromuscular degeneration which have been attributed to
expansion of untranslated repeats (17,18). Three of these are
loss-of-function, recessively inherited diseases and therefore
unlikely to share a common pathogenic mechanism with the
remaining untranslated repeat diseases, which are dominantly
inherited. Four more untranslated repeat diseases are SCAs,
which show pathology and clinical features similar to the
†The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.
∗To whom correspondence should be addressed at: Molecular Life Sciences Building, The University of Adelaide, Adelaide, South Australia 5005,
Australia. Tel: +61 883037541; Fax: +61 883037534; Email: robert.richards@adelaide.edu.au
# The Author 2011. Published by Oxford University Press. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
Human Molecular Genetics, 2012, Vol. 21, No. 3 536–547
doi:10.1093/hmg/ddr487








niversity of Adelaide user on 04 July 2019
842
SCAs caused by polyglutamine expansion, but are caused by
repeats located in a 5′ untranslated region (UTR), a non-
coding RNA or an intron (18–22). A further three diseases, in-
cluding myotonic dystrophy, have been ascribed to toxicity of
an expanded repeat present in the mature transcript of the
affected gene (23).
Two more expanded repeat diseases share similarities with
the diseases described above, but to date defy categorization
into the ‘polyglutamine’ or ‘untranslated repeat’ groups;
these are Huntington’s disease like 2 (HDL-2) and oculophar-
yngeal muscular dystrophy (OPMD). In the case of HDL-2,
which can be clinically indistinguishable from Huntington’s
disease, the repeat expansion has been mapped to the gene
junctophilin-3 (JPH3), which encodes a protein involved in
the formation of junctional membrane structures. The repeated
triplet is CTG, located in a variably spliced exon, and expands
from 14–19 copies to 51–57 copies in the disease state. Alter-
native transcripts either containing the repeat located in the 3′
UTR or encoding a polyalanine or polyleucine tract have been
detected (24). No transcripts encoding polyglutamine have yet
been detected in patient tissue; however, a recently published
mouse model expressing an HDL-2 BAC shows bi-directional
transcription of the HDL-2 locus, resulting in the production
of a transcript from the opposite strand to JPH3 encoding an
expanded polyglutamine tract (25). Additionally, CUG repeat-
containing RNA foci which co-localize with muscleblind-like
protein 1 have been detected both in the frontal cortex from
HDL-2 individuals (26) and in the HDL-2 BAC mouse
model (25), suggesting that RNA-mediated pathogenesis
may also contribute to phenotypes. Therefore, the relative con-
tribution of repeat-containing RNA and homopolymeric amino
acid sequences (including polyglutamine, polyalanine and
polyleucine) to pathogenesis in HDL-2 remains unresolved.
The second of these diseases, OPMD, is caused by a GCG
expansion encoding polyalanine. There are nine known dis-
eases caused by expanded polyalanine repeats, but eight of
these expansions occur in transcription factors that play im-
portant roles during development, and the resulting pheno-
types are congenital malformation syndromes (27). In these
cases, the same phenotypes can arise from different mutations
in the affected gene, suggesting that they are due to loss of
function of the encoded transcription factor (28). However,
this is not the case for OPMD, which instead shares some clin-
ical similarities with the other expanded repeat diseases.
OPMD is a late-onset, progressive disease characterized by
muscle weakness. The phenotype is caused by expansion of
a (GCG)6 repeat in nuclear poly(A)-binding protein 1
(PABPN1) to 8–13 copies (29). In OPMD, aggregates of
PABPN1 containing the alanine expansion are observed in
muscle cells, the major site of pathology. These polyalanine
aggregates contain ubiquitin and components of the prote-
asome, which are also found in polyglutamine aggregates (30).
Based on the presence of polyalanine aggregates in OPMD
and the fact that much shorter alanine tracts can give rise to
disease compared with polyglutamine, a novel pathogenic
mechanism for the polyglutamine disorders involving polyala-
nine was proposed (31). Peptides composed of polyalanine
tracts have been shown to be more toxic and more prone to ag-
gregation than polyglutamine when they are expressed in cul-
tured cells (32). Therefore, it was suggested that
frame-shifting to the GCA frame occurring during the transcrip-
tion of expanded CAG results in the production of polyalanine-
containing proteins that are more toxic than polyglutamine, thus
contributing to pathogenesis (31). Indeed, an antibody raised
against the C-terminal sequence of Ataxin-3 predicted to
result from polyalanine-producing frame-shifts showed accu-
mulation of such frame-shift products in the polyglutamine
aggregates of an SCA3 patient brain (31). Furthermore, in a
cell culture model, frame-shifts were shown to occur in a
CAG length-dependent manner and to be harmful to cells,
with the addition of a ribosome-interacting drug that reduces
frame-shifting able to decrease the toxicity of expanded poly-
glutamine (33). Frame-shift products containing polyalanine
have also been detected in postmortem Huntington’s patients
brains (34). These findings support the possibility that polyala-
nine toxicity might contribute to polyglutamine pathogenesis.
In addition to evidence that transcripts encoding polyalanine
and/or polyleucine may play a role in HDL-2 and OPMD
pathogenesis, recently published data demonstrate that both
CAG- and CUG-expanded repeat sequences are also able to
be translated in the absence of an AUG initiation codon
through a mechanism known as repeat-associated non-AUG
translation (RAN translation), potentially resulting in the pro-
duction of homopolymeric peptides in all three reading frames
of each repeat sequence (35). It is thought that the hairpin
structure formed by the expanded repeat RNAs is acting as
an internal ribosome entry site. As a consequence of these
findings, homopolymeric amino acid sequences have also
emerged as a potential mediator of RNA repeat toxicity in
the ‘untranslated’ repeat diseases. Furthermore, a contribution
of repeat peptides encoded by alternate frames must also be
considered in the ‘translated’ repeat diseases. Thus, investiga-
tion of the outcomes of expression of each of the possible
repeat peptides encoded by CAG/CTG repeats is important
to provide information about the role of each of these potential
toxic entities in disease pathogenesis.
Polyalanine toxicity has been previously modelled in
Drosophila using two different approaches: expressing
PABPN1 with an expanded polyalanine repeat (A17) in the fly
(36), or expressing expanded polyalanine (A37) tagged with
GFP (37). Polyalanine repeats of both lengths, in the context
of PABPN1 or tagged with GFP, formed aggregates and exhib-
ited toxicity in Drosophila, which manifested as an eye pheno-
type upon expression in the eye, or as muscle degeneration
reminiscent of OPMD upon expression in muscle. The toxicity
of polyleucine has not been examined in a model organism to
date. Furthermore, the degree of toxicity of polyglutamine and
polyalanine has not been directly compared in a model organ-
ism. In this study, we therefore sought to determine the relative
toxicities and characterize pathogenic effects of polyglutamine,
polyalanine and polyleucine peptides of comparable length
using a Drosophila model of expanded repeat expression.
RESULTS
Generation of transgenic Drosophila carrying expanded
repeats
We have previously described an approach to express
expanded repeats, independent of gene context, in Drosophila
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under the control of the bipartite upstream activator sequence
(UAS)-GAL4 system (13). We utilized this system again to
generate CAG, GCA and CTG repeats of roughly equal
copy number, encoding polyglutamine, polyalanine and poly-
leucine, respectively, in order to compare their relative toxici-
ties. In addition, a (CAG)52 repeat tract was also generated,
since longer polyglutamine tracts have previously been
demonstrated to be highly toxic in this context (13). In order
to verify that any differences in phenotypes observed when
repeat sequences were expressed in Drosophila are not the
result of differences in expression level or insertion site, con-
structs were generated containing attB recognition sites to
allow site-specific integration of the expanded repeats into
the Drosophila genome by phiC31 integrase. This technique
has been previously described (38) and allows the expression
of the different repeat sequences from the same genomic
location.
Each of the homopolymeric repeats are located in a short
peptide tagged on the C-terminal end with MYC and FLAG
epitopes for detection with antibodies and are placed under
the control of a UAS to allow tissue-specific expression
using different promoters (39) (Fig. 1). The polyglutamine
and polyleucine constructs were generated by sub-cloning
from constructs described previously (13,40) into a Drosophila
transformation vector containing the attB recognition sites
necessary for site-specific integration. In the case of the poly-
alanine construct, a frame-shift of the CAG repeat and sur-
rounding sequence was generated by insertion of a single
nucleotide before the repeat tract and deletion of a single
nucleotide following the repeat tract, such that the MYC and
FLAG epitopes are maintained in-frame (Fig. 1C).
The (CAG)99-polyglutamine, (CAG)52-polyglutamine,
(GCA)99-polyalanine and (CTG)86-polyleucine constructs
were each inserted into the 3L-68E genomic location (41)
and at least two independent Drosophila lines were generated
for each repeat sequence. Final repeat sizes in transgenic lines
were checked by sequencing of genomic DNA and found to be
91 repeats and 55 repeats for polyglutamine (polyQ91 and
polyQ55), 90 repeats for polyalanine (polyA90) and 84
repeats for polyleucine (polyL84). Expression of each con-
struct was verified by quantitative real-time polymerase
chain reaction (PCR) (Supplementary Material, Fig. S1).
Figure 1. Effect of expression of expanded repeat sequences on the Drosophila
eye. (A–C) Schematic representation of repeat constructs. Each repeat se-
quence was inserted downstream of UAS sites to allow expression using the
UAS-GAL4 system. The repeats are flanked by six (or seven for polyalanine)
amino acids on the N-terminal side and four on the C-terminus, with a C-
terminal MYC/FLAG epitope. (A) (CAG)99 or (CAG)52 repeats encoding
polyglutamine. (B) (CTG)86 repeat encoding polyleucine. (C) CAG repeat
altered to the –1 frame by inserting one (G:C) base pair before the repeat
and deleting one (G:C) following the repeat so that it becomes GCA, which
encodes polyalanine. The resulting minor alteration to the surrounding
protein sequence is shown in yellow. (D–H) Effect of expression of expanded
repeat sequences on the exterior appearance of the Drosophila eye. Additional
photographs are included in Supplementary Material, Fig. S2. (D′ –H′)
Tangential sections of the Drosophila eye stained with toluidine blue to
reveal the underlying structure of the eye. Additional photographs are included
in Supplementary Material, Fig. S3. (D and D′) Control fly, expressing empty
vector. Both the exterior and the interior of the eye have an ordered structure.
(E, E′, F and F′) Expression of polyglutamine encoded by either (CAG)91 or
(CAG)55 causes an eye phenotype characterized by varying degrees of
pigment loss, as well as internal collapse of the eye structure. (G and G′) Ex-
pression of polyleucine encoded by (CTG)84 induces a mild rough eye pheno-
type, with significant disorganization in the underlying structure of the eye.
(H) Expression of polyalanine encoded by (GCA)90 has no effect on the exter-
nal appearance of the eye. (H′) Mild disruption of the underlying structure of
the eye is evident from sections. (I–M) Expanded repeat eye phenotypes are
dose-dependent. (I) Introducing a second insertion of the empty vector alone
does not alter the appearance of the eye. (J and K) Expression of two insertions
of (CAG)91 or (CAG)55 results in an enhancement of the loss of pigment eye
phenotype. (L) Expression of two insertions of (CTG)84 results in a decrease in
size and loss of the ordered structure of the surface of the eye. (M) Expression
of two insertions of (GCA)90 results in a rough eye phenotype with some loss
of pigmentation.
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Analysis of expression was performed relative to both GAL4
(Supplementary Material, Fig. S1B), which is expressed only
in cells which are also expressing the repeat transgene, as
well as to the endogenous ribosomal protein 49 (RP49) tran-
script (Supplementary Material, Fig. S1A), which is expressed
ubiquitously.
Expression of expanded repeat sequences in the
Drosophila eye
External phenotypes resulting from expression of each of the
repeat sequences in the Drosophila eye were examined. Ex-
pression of polyQ91 with the eye-specific GMR-GAL4 driver
results in a severe phenotype in which pigment is lost and
the surface of the eye is disordered and collapsed (Fig. 1E
and Supplementary Material, Fig. S2D–I). This phenotype is
indistinguishable from those we have previously reported in
flies expressing randomly inserted polyQ99 repeats (13). In con-
trast, expression of the shorter repeat, polyQ55, resulted in mild
loss of pigment localized mostly to the posterior of the eye
(Fig. 1F and Supplementary Material, Fig. S2J–O). Both of
these phenotypes appear to be dose-dependent, since expression
of two insertions of either construct results in an increase in the
severity of the phenotype (Fig. 1J and K). In contrast, expres-
sion of two insertions of the UAS portion of the construct
alone results in eyes of wild-type appearance (Fig. 1I).
Using this same approach, we also expressed the polyala-
nine and polyleucine constructs in the Drosophila eye. Expres-
sion of a single insertion of polyL84 was sufficient to cause a
very mild disorganization of the ordered arrays of the eye
(Fig. 1G and Supplementary Material, Fig. S2P–U). This
phenotype is distinct from both the strong phenotype observed
when polyQ91 is expressed in the eye (Fig. 1E) and the milder
phenotype observed when polyQ55 is expressed in the eye
(Fig. 1F), since it does not involve any loss of pigment. Ex-
pression of two insertions of polyL84 results in a near complete
loss of eye tissue, with the remaining tissue having a glazed
appearance (Fig. 1L).
In contrast, expression of a single insertion of the polyA90
construct did not result in any phenotype in the eye (Fig. 1H
and Supplementary Material, Fig. S2V–Z′). This differs from
a previous report of the effect of expressing a GFP-tagged poly-
alanine tract containing 37 repeats in the Drosophila eye, which
resulted in an eye phenotype characterized by abnormal shape,
small size and rough surface (37). This difference could be the
result of variations in expression level or stability of the trans-
gene products in each case. This possibility is supported by
the observation that expression of two transgene insertions of
the polyA90 construct results in a rough eye phenotype with a de-
crease in size (Fig. 1M). Therefore, polyalanine toxicity appears
to be dose-dependent in this model.
Polyglutamine, polyleucine and polyalanine peptides cause
disorganization in the underlying structure of the
Drosophila eye
In order to investigate the cellular specificity of toxicity of
each of the repeat sequences, the underlying structure of the
Drosophila eye was examined by tangential sectioning and
staining with toluidine blue to reveal the organization of the
ommatidial arrays. The ommatidial units should be arranged
in an array, with seven photoreceptors visible in each unit, sur-
rounded by pigment granules (Fig. 1D′ and Supplementary
Material, Fig. S3A–C). Expression of either polyQ91 or
polyQ55 resulted in a severe disruption to the organization of
the eye, with no photoreceptors evident in the polyQ91 eye
(Fig. 1E′ and Supplementary Material, Fig. S3D–F) and
very few evident in the polyQ55 eye (Fig. 1F
′ and Supplemen-
tary Material, Fig. S3G–I).
In contrast, expression of either the polyleucine or polyala-
nine peptide results in milder defects in the eye structure.
Polyleucine-expressing flies show deviation from the normal
seven photoreceptors per ommatidial unit and severe structural
disorganization (Fig. 1G′ and Supplementary Material, Fig.
S3J–L). Despite the absence of an external phenotype in
flies expressing a single insertion of the polyalanine construct,
there is a mild defect in the organization of the underlying
structure of the eye, with some alterations in photoreceptor
number, as well as a mild disorganization of pigment granules
surrounding the ommatidial units (Fig. 1H′ and Supplementary
Material, Fig. S3M–O).
Expanded polyleucine and polyalanine tracts form
distinctive aggregates in the Drosophila eye
In order to examine the localization of the different repeat pep-
tides in the eye, horizontal sections of heads expressing each
of the repeat constructs under the control of the GMR-GAL4
driver were stained with an antibody raised against the MYC
epitope tag. In the control fly, staining with the anti-MYC anti-
body resulted in a low level, ubiquitous pattern of staining
(Fig. 2A′′ and Supplementary Material, Fig. S4A–C). In con-
trast, flies expressing polyglutamine show large aggregates in
the eye (Fig. 2B′′ and Supplementary Material, Fig. S4D–F),
as previously reported for expression of polyglutamine when
the construct is randomly inserted in the Drosophila genome
(13).
Examination of sections from flies expressing polyleucine
revealed tiny aggregates or speckles throughout the eye upon
anti-MYC staining, as well as some diffuse staining
(Fig. 2C′′ and Supplementary Material, Fig. S4G–I). These
speckles were not seen in control flies, suggesting that they
correspond to the polyleucine protein. In support of this con-
clusion, polyleucine proteins have been reported to form
small aggregates described as speckles when expressed in cul-
tured cells (32). These aggregates differ markedly in appear-
ance from the polyglutamine aggregates, which are much
larger. In the Drosophila eye, it appears that polyglutamine
aggregates are exclusively apically localized, whereas poly-
leucine aggregates are found throughout the retina.
In contrast, staining of sections from flies expressing a single
polyalanine transgene, which do not have an external phenotype
in the eye, resulted in diffuse staining similar to the control, sug-
gesting that either aggregates are not formed or are not detect-
able in the Drosophila eye (Fig. 2D′′ and Supplementary
Material, Fig. S4J–L). Increasing expression of polyalanine
peptide by introducing a second transgene insertion resulted in
the appearance of variably sized aggregates in the eye, which
is consistent with dose-dependent toxicity of this peptide in
Drosophila (Fig. 2E′′ and Supplementary Material, Fig. S4M–
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O). As was observed with polyleucine (Fig. 2C′′), there is also
diffuse staining throughout the retina in these eyes.
Polyglutamine, polyalanine and polyleucine peptides show
distinct cellular localization
In order to further investigate the cellular localization of each
of the homopolymeric peptides, third instar larvae expressing
each of the expanded repeat sequences ubiquitously under the
control of the da-GAL4 driver were collected and cryosec-
tioned for staining with the anti-MYC antibody. Distinctly dif-
ferent patterns of staining were seen for each peptide:
polyglutamine was found to be predominantly present in
nuclear aggregates (Fig. 3B′), polyleucine appeared to be ex-
clusively cytoplasmic and more diffuse, with a small number
of aggregates apparent in some cells (Fig. 3C′, arrows),
Figure 2. Localization of expanded repeat proteins in the Drosophila eye. Horizontal cryosections of the heads of Drosophila expressing each of the UAS-repeat
constructs under the control of GMR-GAL4 were stained with DAPI to show DNA and the anti-MYC antibody, which recognizes the MYC epitope tag on the
C-terminus of the proteins. Additional photographs for all genotypes are included in Supplementary Material, Fig. S4. Boxed regions in (A′)–(E′) are shown at
increased size in (A′′)–(E′′). (A–A′ ′′) Stained section from a control fly expressing empty vector to determine the level of background staining. (B–B′ ′′) Section
from a fly expressing polyglutamine peptide. Apically localized, large aggregates are evident, with an absence of MYC-staining in the retina. The structure of the
lamina appears to be disorganized. (C–C′ ′′) Section from a fly expressing polyleucine peptide in the eye. Small speckles are observed, as well as diffuse staining
throughout the retina. The localization of nuclei in the eye also appears to be disrupted, with a wider band of DAPI staining than was observed in control flies.
(D–D′ ′′) Section from a fly expressing one polyalanine transgene in the eye. No aggregates were detected, with low-level diffuse staining evident. (E–E′ ′′)
Co-expression of a second polyalanine transgene results in the appearance of a large number of variably sized aggregates in the eye, although staining is
still more diffuse than was observed in flies expressing polyglutamine. The structure of the lamina also appears to be disrupted. (F–J) Inverted images (A–
E) showing DAPI staining: A, apical surface; R, retina; L, lamina.
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whereas polyalanine localized to both the nucleus and the
cytoplasm, but appeared to form predominantly cytoplasmic
aggregates (Fig. 3D′).
On further observation of the progeny of each of these crosses,
expression of polyglutamine encoded by either polyQ91 or
polyQ55 was found to result in complete lethality prior to pupar-
iation. In contrast, adult flies expressing either polyL84 or
polyA90 were viable. While adult flies expressing polyleucine
appear morphologically normal (Fig. 3G and Supplementary
Material, Fig. S5I–N), a severe defect in the patterning on the
abdomen of the fly was observed when polyalanine was
expressed. Normally, the abdomen should consist of a series
of regular bands known as tergites (Fig. 3F, white arrows).
However, when polyalanine was expressed, the tergites were
frequently split at the midline (Fig. 3H, black arrows and Sup-
plementary Material, Fig. S5A–H), suggesting that this
peptide is toxic in a specific subset of cells. Although exact
mechanisms of tergite development are not fully understood,
the difference in effect between polyleucine and polyalanine
suggests differences in specificity of their toxicity.
Figure 3. Effect of ubiquitous expression of expanded repeats in Drosophila. (A–D) Horizontal cryosections of third instar larvae expressing each of the UAS-
repeat constructs under the control of daughterless-GAL4 were stained with DAPI to show DNA and the anti-MYC antibody, which recognizes the MYC epitope
tag on the C-terminus of each of the repeat peptides. (A–A′′) Very little background MYC staining is observed in larvae expressing empty vector alone. (B–B′′)
Polyglutamine protein can be detected in aggregates which are localized to the nucleus. These aggregates are indistinguishable in larvae expressing polyQ91 or
polyQ55. (C) Polyleucine peptide is mostly diffuse and localized to the cytoplasm. In some cases, a few punctuate aggregates were observed (arrowheads). (D)
Polyalanine protein shows a distinct localization pattern, with both nuclear and cytoplasmic staining observed. Small aggregates were observed, predominantly
localized to the nucleus, along with some diffuse staining, suggesting that not all of the MYC-tagged protein is aggregated. (E–H) Patterning of the tergites (dark
bands) on the back of the abdomen of adult flies expressing each of the expanded repeat peptides. In each case, flies are female. (E) Flies expressing empty vector
alone (control) show normal patterning, with five dark tergite bands evident (white arrows show three of the tergites). (F) Ubiquitous expression of either polyQ91
or polyQ55 is lethal prior to pupariation. (G) Flies expressing polyleucine are indistinguishable from control flies. (H) Flies expressing polyalanine protein show a
strong disruption to the patterning of the tergite bands, where the tergite bands frequently appear to be split at the midline. This phenotype is consistent and fully
penetrant. Additional photographs are included in Supplementary Material, Fig. S5.
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Polyglutamine, polyalanine and polyleucine peptide
expression causes neuronal defects
Each of the repeat constructs was also expressed pan-
neuronally using the elavc155-GAL4 driver, which consists of
an insertion in the promoter region of the endogenous elav
gene, resulting in expression of GAL4 in a pan-neuronal
pattern (42). Flies expressing either the polyQ55 or polyQ91
constructs under the control of this driver died prior to pupar-
iation, suggesting that this peptide is highly toxic in Drosoph-
ila neurons. Flies expressing either polyleucine or polyalanine
were viable and therefore were further tested for neuronal
defects using a climbing assay (Fig. 4A).
In this assay, flies are placed in a plastic measuring cylinder
and tapped down. Normally, flies respond to this stimulus by
immediately climbing vertically up the side of the cylinder.
In the control group (elav . UAS), #90% of flies climbed
to above the higher mark on the cylinder (170 mm) within
25 s of the stimulus, with all flies tested climbing to above
the lower mark (27 mm) in this time. In contrast, flies expres-
sing polyleucine show a climbing defect, with #69% of flies
failing to climb to the lowest mark within this time and a
further 25% unable to climb to beyond the higher mark.
Flies expressing polyalanine show a milder defect, with
#9% of flies failing to climb to the lower mark on the cylinder
and a further 25% of flies unable to climb to the higher mark
within the given time.
Localization of repeat peptides in the Drosophila brain
Since expression of polyglutamine was completely lethal
when driven by elavc155-GAL4, we also expressed each of
the repeat constructs under the control of the pan-neuronal
P{GAL4-elav.L}2 driver, which consists of an insertion of a
construct containing the elav promoter region controlling
GAL4 expression into a genomic location on the second
chromosome (described previously in 40). Adult flies expres-
sing the polyQ55 construct driven by this promoter were
viable, however expression of polyQ91 was still lethal. Hori-
zontal cryosections of heads from flies carrying a UAS inser-
tion alone and flies expressing each of polyQ55, polyL84 and
polyA90 were stained with the anti-MYC antibody in order
to visualize the localization of each of the repeat peptides
in the adult brain (Fig. 4B–I and Supplementary Material,
Fig. S6).
Viewing the whole brain at low magnification (10× object-
ive) revealed the overall localization pattern of each of the
repeat peptides in the brain (Fig. 4B–E). Expression of the
UAS construct alone resulted in very little background stain-
ing (Fig. 4B and B′). Flies expressing either polyglutamine
or polyleucine showed a large number of aggregates of MYC-
tagged protein (Fig. 4C and C′ and D and D′). In both cases,
these aggregates appear to be localized to the neuronal cell
bodies and are found in the central brain (C), the optic lobes
(OL) and the antennae (A) in both cases. In contrast, flies
expressing polyalanine show no evidence of aggregates at
this magnification (Fig. 4E and E′).
Further examination of a region within the optic lobe at
higher magnification (63× objective) revealed the cellular lo-
calization pattern of each of the repeat peptides (Fig. 4F–I).
Where aggregation was observed, polyglutamine peptide con-
sistently formed a single aggregate per nucleus (Fig. 4G and
G′). In contrast, polyleucine aggregates were less uniform,
with more variation in aggregate size and some aggregates
present outside of the nucleus (Fig. 4H and H′). Some more
diffuse staining was also observed in this case. Although
aggregates were not observed at lower magnification in flies
expressing polyalanine, a few small aggregates, along with
some diffuse staining, were evident in these flies at higher
magnification (Fig. 4I and I′). This staining is likely to corres-
pond to polyalanine peptide, since aggregates were not
observed in flies expressing the empty vector alone (Fig. 4F
and F′).
DISCUSSION
This study describes the first direct comparison of the intrinsic
toxicity of expanded polyglutamine, polyleucine and polyala-
nine peptides. Since intrinsic properties of expanded repeat
peptides such as translation rate, stability and the rate of accu-
mulation contribute to their relative toxicity, this is an import-
ant comparison which has implications for the role of each of
these potential pathogenic agents in the expanded repeat dis-
eases. It is also the first study to investigate the toxicity of
polyleucine in an animal model. The data presented here dem-
onstrate differences in toxicity between these repeat
sequences, perhaps resulting from differences in the physical
properties of each of the amino acids. For example, expression
of each repeat sequence in the Drosophila eye results in mark-
edly different effects, with polyglutamine expression causing a
strong loss of pigment phenotype, while polyleucine expres-
sion causes dose-dependent disruption to the patterning of
the ommatidial arrays. In contrast, expression of polyalanine
was able to induce a rough eye phenotype in the eye only
with an increased dosage, suggesting that it is either less
toxic or turned over more quickly in this tissue than the
other repeat peptides.
Interestingly, ubiquitous expression of each of the peptides
resulted in variable toxicity which does not entirely correlate
with what was observed in the eye. Like in the eye, polyglu-
tamine is also most toxic when expressed ubiquitously, with
the longer polyQ91 repeat being completely lethal prior to
pupariation. However, polyleucine appears to be least toxic,
with no phenotype observed in adult flies, whereas flies
expressing the polyalanine peptide show a strong, completely
penetrant defect in tergite patterning. Therefore, toxicity of
polyalanine and polyleucine peptides appears to differ
between cell types.
In addition, although all three homopolymeric peptides
demonstrate the ability to aggregate, there appear to be differ-
ences both in cellular specificity, localization and appearance
of these aggregates. Aggregates of polyglutamine were
observed in all tissues examined and appeared to be consist-
ently localized to the nucleus. Aggregates formed by polyleu-
cine were more variable, with sectioning of third instar larvae
ubiquitously expressing polyleucine-revealing cytoplasmic,
diffuse localization. In contrast, when polyleucine was
expressed in either the eye or the nervous system, punctate
aggregates were observed. Expression of polyleucine in
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Figure 4. Effect of pan-neuronal expression of expanded repeats in Drosophila. (A) Climbing assay of flies expressing empty vector, polyA90 or polyL84 under
the control of the pan-neuronal elavc155-GAL4 driver. Expression of either polyQ91 or polyQ55 using this driver results in lethality and therefore these flies were
not tested. Briefly, 3 sets of 20 newly eclosed male flies were collected for each genotype over a 3 day period. By days 9–12, some flies had died so that final
numbers for sets of flies tested for each genotype were as follows: elav . UAS n ¼ 18, 18 and15; elav . (GCA)90 n ¼ 19, 18 and 18; elav . (CTG)84 n ¼ 19, 19
and 20. At this time, flies were scored for their ability to climb beyond two set points (27 and 170 mm) on a plastic cylinder within a period of 25 s after being
tapped to the bottom. Each set of flies was tested three times each (three trials) and the results from all flies in a particular genotype were pooled. Error bars are
standard deviation across the three trials for flies of each genotype. Flies expressing polyL84 show a severe climbing defect, with nearly 70% of flies failing to
climb to above the 27 mm mark within the given time (significantly different from the control group, P ¼ 4.14 × 10– 6). Flies expressing polyA90 show a milder
climbing defect, with nearly 10% of flies failing to climb to at least 27 mm within 25 s (significantly different to control group, P ¼ 0.007). (B–E) Inverted
images showing DAPI staining. White arrows show basic structures: A, antenna; C, central brain; OL, optic lobe. (B′, B′′ –E′ and E′′) Horizontal cryosections
of heads from adult flies expressing empty vector, polyQ55, polyA90 or polyL84 under the control of the pan-neuronal P{GAL4-elav.L}2 driver were stained with
DAPI to show DNA and (B′ –E′) the anti-MYC antibody, which recognizes the MYC epitope tag on the C-terminus of each of the repeat peptides. (B′′ –E′′)
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these tissues also resulted in phenotypes: a roughening of the
surface and perturbation of underlying patterning when
expressed in the eye and a climbing defect when expressed
pan-neuronally. Polyalanine peptide formed fewer aggregates
in the brain and eye and was also notably less toxic in these
tissues; however, ubiquitous expression resulted in aggrega-
tion both in the nucleus and in the cytoplasm of cells.
Therefore, toxicity appears to be associated with the formation
of aggregates in each case; however, it remains unclear
whether the aggregates themselves are protective or
pernicious.
The observed differences between toxicity of polyalanine
and polyleucine are particularly intriguing, since these amino
acids have similar properties: they are both small, hydrophobic
amino acids. It would be expected that if toxicity were directly
related to the hydrophobicity of the peptide chain, polyleucine
would be consistently more toxic than polyalanine. Instead,
there appear to be differences in the degree of toxicity of
these sequences, dependent upon the tissue in which they
are expressed. Furthermore, although proteins containing
polyalanine and polyleucine tracts have been previously
found to be more toxic than polyglutamine (32), our study sug-
gests that expression of polyglutamine is more toxic in various
Drosophila tissues. This may be the result of the context in
which these repeat peptides are expressed, or may represent
a real biological difference in this Drosophila model. It
should be noted that other studies which have directly com-
pared toxicity and cellular localization of homopolymeric
amino acid sequences have been performed in cell culture
systems (32,43) and therefore have not examined toxicity
resulting from expression in the context of a whole organism.
Although we have detected expression of the MYC-tagged
reading frames encoding glutamine, leucine and alanine in
our Drosophila model, we cannot rule out a contribution of
RAN-translated peptides from other frames to the observed
phenotypes. The situation is likely to be even more complex
in the expanded repeat diseases, since the context and expres-
sion pattern of the repeat-containing gene in each case could
result in bias for the production of particular alternate
reading frame products. Additionally, there is evidence that
a number of the disease-associated expanded repeat-
containing genes are transcribed in a bi-directional manner
(25,44–47), resulting in the production of transcripts contain-
ing a complementary repeat sequence which may also be able
to undergo RAN translation. Sensitivity of specific cells to ex-
pression of some of the alternate reading frames of the CAG/
CTG repeat, as well as the ratios of transcripts from each
strand, may contribute to variability in phenotypes seen in dis-
eases caused by these repeat expansions. The possibility of a
similar mechanism playing a role in diseases caused by
other hairpin-forming repeat sequences must also now be con-
sidered. Further investigation of toxicity of the repeat peptides
encoded by the other reading frames of this repeat, as well as
those encoded by other disease-causing expanded repeat
sequences, will be necessary in order to gain further insight
into the contribution of each of these potential pathogenic
agents to disease.
MATERIALS AND METHODS
Drosophila strains and husbandry
Expanded repeat sequences were generated by ligation of
shorter CAG and CTG repeat oligonucleotides, which were
then expanded using PCR-based techniques as described pre-
viously (13). These expanded repeats were then sub-cloned
into pENTR/D-TOPO (Invitrogen), which had been modified
to contain the amino acid sequence surrounding the repeat, in-
cluding the MYC and FLAG epitope tags, which has been
described previously (12). Selection of repeats inserted into
this vector in opposite orientations gave the CAG and CTG
constructs. In the case of the GCA construct, the same
expanded repeat fragment was sub-cloned into an alternative
modified pENTR/D-TOPO vector containing the amino acid
sequence surrounding the repeat, but this time with a single
extra nucleotide inserted immediately before the repeat tract
and a deletion of a single nucleotide following the repeat
tract. Therefore, insertion of the expanded repeat into this
vector results in a 21 frameshift of the CAG repeat to give
a GCA repeat, while maintaining the MYC and FLAG epi-
topes in-frame. Finally, each repeat construct (including the
surrounding amino acid sequence and the MYC/FLAG tag)
was recombined into the Drosophila transformation vector
pTW-attB—generated by insertion of the Gateway cassette
from pTW [obtained from the Drosophila Genomics Resource
Centre (DGRC), Indiana University, PA, USA] into
pUAST-attB (41) by S. Gregory, University of Adelaide,
Australia—using the LR clonase enzyme (Invitrogen) accord-
ing to the manufacturer’s instructions.
The length and integrity of repeat constructs were confirmed
by DNA sequencing, and constructs were then microinjected
into the ZH-attP-68E line (FBst0328401, described in 41) by
standard methods to obtain germline transformants. Multiple
transgenic lines were obtained for each construct, and the
repeat length from each line was confirmed by PCR and se-
quencing. The GMR-GAL4 (Stock #9146), P{da-GAL4.w[-]}3
(Stock #8641), P{GAL4-elav.L}2 (Stock #8765) and elavc155-
GAL4 (Stock #458) strains used in this study were obtained
Merged images of DAPI and MYC staining for each genotype. Images of whole brains were viewed with a 10× objective lens to determine the overall local-
ization of each of the repeat peptides in the Drosophila brain. Additional images are included in Supplementary Material, Fig. S6. (B′ and B′′) Very little back-
ground MYC staining is observed in flies expressing empty vector. White arrows show basic structures: A, antenna; C, central brain; OL, optic lobe. White box
shows an example of a region in the optic lobe selected for examination at higher magnification (F–I). (C′ –C′′) Expression of polyglutamine peptide in the brain
results in aggregates throughout the central body, optic lobes and antennae. (D′ and D′′) Flies expressing polyleucine show a similar pattern of aggregates
throughout the brain and in the antennae. (E′ –E′′) Flies expressing polyalanine show no aggregates in the brain at low magnification. (F–I) Higher magnification
(63× objective) showing localization of repeat peptides in a region of the optic lobe for each genotype. (F) Very low levels of background MYC staining were
observed in flies expressing empty vector. (G) Polyglutamine peptide forms aggregates that appear to be completely nuclear, with a single large aggregate
observed per nucleus. (H) Polyleucine protein aggregates are more variable in size and are not exclusively nuclear. Some diffuse staining is also observed.
(I) A small number of aggregates of MYC-tagged polyalanine are evident in some brains at higher magnification, with some diffuse staining also evident.
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from the Bloomington Drosophila Stock Center (Indiana
University, Indiana, PA, USA). Flies were maintained on for-
tified medium containing 1% agar, 10% molasses, 1% glucose,
6% fresh yeast, 8.4% coarse semolina, 1.5% acid mix and
2.5% tegosept. All crosses were performed at 258C.
Tangential sectioning
Heads from 24–48-h-old flies were dissected and the probos-
cis removed before being cut in half. These were then fixed
overnight in 2.5% glutaraldehyde, 0.1 M sodium phosphate
(pH 7.2), post-fixed in 2% osmium tetroxide, washed in
water and dehydrated in acetone. Samples were then
mounted in epoxy resin and sectioned at 1 mm using an
RMC Mt7 ultra-microtome, mounted onto slides and stained
with toluidine blue.
Reverse transcription and quantitative real-time PCR
For each genotype, five 0–48-h-old flies were collected on dry
ice, and TRIzol (Invitrogen) and the RNeasy Mini Kit
(Qiagen) were used to isolate total RNA. One microgram
per sample was treated with DNAse I (Invitrogen) and reverse-
transcribed with oligo(dT)12–18 and SuperScript III
(Invitrogen). Quantitative real-time PCR was performed in a
LightCycler (Roche Molecular Biochemicals) using GAL4-
specific primers (forward: 5′-CACTGACCCCGTCTGCTT
TG-3′, and reverse: 5′-GGTTCGGACCGTTGCTACTG-3′)
and primers specific for the repeat-containing transcript. The
transgene expression level was quantified using the DCt
method for relative quantitation and expressed relative to the
level of GAL4 transcript for each line. For each line, RNA
samples for three biological replicates were reverse-
transcribed and subjected to quantitative PCR.
Cryosectioning and antibody staining
Ten micrometer cryosections of whole Drosophila heads or
third instar larvae were cut on a Leica CM1900 cryostat,
fixed in 4% formaldehyde and stained using 9E10 monoclonal
anti-MYC antibody obtained from Dr David Lawrence
(IMVS, Adelaide, Australia) at 1:250 dilution and
anti-mouse-Cy3 (Rockland) at 1:200 dilution. Sections were
then mounted in Vectashieldw fluorescence mounting
medium (Vector Laboratories) supplemented with 1 ng/ml
4′,6-diamidino-2-phenylindole (DAPI, Sigma) to stain DNA.
Microscopy
Image preparation was performed using Adobe Photoshop 6.0.
Photos of the exterior of the Drosophila eye and abdomens
of adult Drosophila were taken with an Olympus SZX7 dis-
section microscope fitted with an SZX-AS aperture. Images
were captured with a Colorview IIIu camera and the Analysis-
Ruler image acquisition software. In all cases, anterior is to the
left. Flies were photographed at 24–48 h post-eclosion. For
each genotype, a number of flies (.10) were visually exam-
ined to check for consistency of phenotype. Light photos are
representative, with typically three to four flies photographed
per genotype.
Photos of tangential sections and fluorescent images were
taken using a Zeiss Axioplan 2 upright microscope with a
63× PlanApo objective unless otherwise stated. Images
were captured with an Axiocam MRm camera and the AxioVi-
sion 4.5 image acquisition software. For tangential sectioning,
a minimum of five eyes were sectioned and photographed per
genotype. For immunofluorescence performed on adult eyes,
adult heads and larval sections, between 7 and 10 animals
were sectioned for each genotype. A minimum of 7 photos
(typically more than 10) were taken for each genotype.
Photos shown are representative.
Climbing assays
Climbing assays were performed on flies expressing either
empty vector, polyL84 or polyA90 under the control of the pan-
neuronal elavc155-GAL4 driver. Three sets of 20 newly eclosed
male flies were collected for each genotype and kept on forti-
fied medium at 258C until the assay was performed. Flies were
all between 9 and 12 days old when assayed and at this time
each set contained a minimum of 15 flies, with the total
number of flies for each genotype being at least 51. Each set
of flies was transferred to a 500 ml measuring cylinder (diam-
eter 48 mm) sealed at the top with parafilm, without anaesthe-
tization. Tests were conducted by tapping the cylinder to
knock flies to the bottom, then scoring the number of flies
that remained below the 50 ml mark (27 mm), those that
climbed to between the 50 and 300 ml mark (27–170 mm)
and those that climbed to above the 300 ml mark (170 mm)
in 25 s. Three consecutive trials were performed on each set
of flies, with at least a 5 min rest between trials. Scores for
the three sets of flies for each genotype were pooled for
each trial to give a total score. This total score was then aver-
aged across the three consecutive trials for each genotype to
give a mean value. The distribution of flies across the three
categories (,27, 27–170 and .170 mm) for each genotype
was then compared with the control (elav . UAS) using a
two-tailed Student’s t-test, with a cut-off of P , 0.05 to deter-
mine significance.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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Dominantly inherited expanded repeat neurodegenerative diseases are caused by the expansion of variable
copy number tandem repeat sequences in otherwise unrelated genes. Some repeats encode polyglutamine
that is thought to be toxic; however, other repeats do not encode polyglutamine indicating either multiple
pathogenic pathways or an alternative common toxic agent. As these diseases share numerous clinical fea-
tures and expanded repeat RNA is a common intermediary, RNA-based pathogenesis has been proposed,
based on its toxicity in animal models. In Drosophila, double-stranded (rCAG.rCUG∼100) RNA toxicity is
Dicer dependent and generates single-stranded (rCAG)7, an entity also detected in affected Huntington’s
Disease (HD) brains. We demonstrate that Drosophila rCAG.rCUG∼100 RNA toxicity perturbs several path-
ways including innate immunity, consistent with the observation in HD that immune activation precedes
neuronal toxicity. Our results show that Drosophila rCAG.rCUG∼100 RNA toxicity is dependent upon Toll
signaling and sensitive to autophagy, further implicating innate immune activation. In exhibiting molecular
and cellular hallmarks of HD, double-stranded RNA-mediated activation of innate immunity is, therefore, a
candidate pathway for this group of human genetic diseases.
INTRODUCTION
The expansion of repeat sequences beyond a pathogenic
threshold is the causative mutation mechanism in over 20
dominantly inherited neurodegenerative diseases including
Huntington’s disease (HD) and several spinocerebellar
ataxias (SCAs) (1,2). The genes that carry repeat sequences
in each of these diseases are otherwise unrelated but give
rise to similar late-onset progressive neurodegeneration and
disease severity correlates with the length of the expanded
repeat. A number of these diseases are caused by the expan-
sion of CAGn trinucleotide repeats within the coding region
of affected genes. Such expansions result in the production
of a protein containing an expanded polyglutamine tract that
is thought to be the causative agent for neuronal dysfunction
and atrophy in specific regions of the brain.
In addition to these translated repeat sequences encoding poly-
glutamine, expansion of repeat sequences can also be found in un-
translated regions of genes. The expansion of untranslated tri-,
tetra-, penta- or hexanucleotide repeats has been identified as
the mutations leading to the dominantly inherited myotonic dys-
trophy type 1 and 2 (DM1 and DM2), HD-like-2 (HDL-2), fragile
X tremor ataxia syndrome (FXTAS) and SCA 8, 10, 12, 31 and 36
(3–5). Furthermore, an expanded hexanucleotide repeat has re-
cently been characterized to lead to a substantial proportion of
cases of frontotemporal dementia and amyotrophic lateral scler-
osis (6,7). The striking similarity of phenotypic outcomes in
several instances between translated and untranslated repeat dis-
eases and typical features of late-onset dominant inheritance
suggest the possibility of a common pathogenic mechanism (Sup-
plementary Material, Fig. S1). Expanded repeat-containing RNA
is common to each of these diseases and has therefore been
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hypothesized as a common pathogenic agent (8–13). Various
experimental approaches have been undertaken in animal
models to define the physical properties of the RNA which are ne-
cessary and sufficient for toxicity and the downstream pathways
that contribute to pathogenesis. A number of distinct mechanisms
by which RNA can cause pathogenesis have been described.
First, expanded repeat-containing single-stranded RNAs
form RNA secondary structures that recruit and sequester RNA-
binding proteins such as Muscleblind, resulting in the loss of
function of these proteins, and in doing so contribute to patho-
genesis (14). Second, a recent study demonstrates that hairpin
repeat RNA can act as an internal ribosomal entry site to
enable repeat-associated non-ATG (RAN) initiated translation
of expanded repeat-containing RNA (15). Therefore, toxicity
of translated homopolymeric peptides must be considered
(16). Third, recent reports demonstrate that expanded repeat-
containing genes are often transcribed from both strands, a phe-
nomenon termed bidirectional transcription. The products of
this transcription are predicted to form perfectly paired double-
stranded RNA (17–20). This double-stranded RNA has, in turn,
been shown to be capable of toxicity via various mechanisms in-
cluding recruitment of histone modifiers and/or perturbation of
transcriptional regulation through effects on CTCF-binding
sites that flank the repeat sequences (17,21), or a Dicer-
dependent mechanism (11,12).
We have previously described Drosophila models of
expanded repeat diseases that specifically investigate the intrin-
sic toxicity of both translated and untranslated expanded repeat
sequences (9,10,13,16). Bidirectional transcription was
modeled by co-expression of expanded rCAG"100 together
with rCUG"100 (rCAG.rCUG"100 or dsRNA) to produce repeat-
containing double-stranded RNA (11). Flies expressing dsRNA
showed Dicer-dependent toxicity. Additionally dsRNA expres-
sion throughout the nervous system caused an age-dependent
neurodegenerative phenotype. An abundance of rCAG7 also
implicated specific Dicer processing of the rCAG.rCUG"100
as a pathogenic pathway in this model (11). Similar findings
have also been reported in an independent Drosophila model
(12). Furthermore, an altered endogenous miRNA profile was
observed. Examination of HD patient samples revealed the pres-
ence of similar rCAG7 (22) providing evidence in support of the
activity of this pathway in HD pathogenesis.
In an effort to identify further components of expanded repeat
RNA pathogenesis in Drosophila, we have undertaken micro-
array analysis of Drosophila expressing rCAG.rCUG"100
repeat RNAs. Changes in transcription profiles reveal candidate
pathways for mediating resultant pathogenesis. Alterations in
transcripts common to several pathways were detected, includ-
ing components of innate immunity. Hallmarks of immune ac-
tivation appear prior to clinical symptoms of dominantly
inherited expanded repeat human diseases (23,24). Therefore,
we have used a Drosophila model to test two key elements of
immune activation; the Toll and autophagy pathways for their
contribution to expanded repeat RNA pathogenesis. We have
identified that the Toll signaling pathway is essential for double-
stranded RNA pathogenesis, and that autophagy reduces tox-
icity in this model.
RESULTS
Identification of candidate pathways contributing to
rCAG.rCUG∼100 repeat RNA pathogenesis in Drosophila
Microarray analysis was performed using Affymetrix Dros-
ophila 2.0 arrays. RNA was extracted from heads of 1-day
old male Drosophila expressing double-stranded RNA with




analyzed to identify robust changes caused by the expression
of dsRNA and minimize any changes simply due to site of
transgene insertion effects. These changes were compared
with a control with no repeat expression (4xUAS). Each geno-
type was analyzed with triplicate samples to account for bio-
logical variation. The repeat expression levels of each
dsRNA line used in this experiment were analyzed by a quan-
titative PCR (Supplementary Material, Fig. S2). Repeat ex-
pression in the rCAG.rCUG"100
S2 triplicates was lower than
that of rCAG.rCUG"100
S1 and is consistent with the phenotypic
severity observed in the eye (11).
Two approaches were utilized to identify possible pathways
contributing to dsRNA pathogenesis. The first was to identify
transcripts exhibiting the most significant quantitative changes
as a result of rCAG.rCUG"100 repeat RNA expression. In
order to determine expression changes caused by double-
stranded RNA, genes that showed a significant change in each
of the dsRNA lines (rCAG.rCUG"100
S1 or rCAG.rCUG"100
S2 )
compared with the control (4xUAS) (P , 0.05) but were un-
changed between each other (P ≥ 0.05) were examined.
Altered transcripts were further filtered for those that gave a
log2 of the expression ratio—defined as log2 (ratio)—of
.+1 or ,21, that is the genes with a greater than +2-fold
change in expression (Supplementary Material, Table S1).
The altered transcripts were grouped into particular pathways
based on their function and potential role in pathogenesis
(Fig. 1).
Second, the data generated from this microarray analysis
was searched for genes which contain a CUG or CAG repeat
tract (complementary to repeat-derived CAG or CUG small
RNA respectively) and thus are potential targets of
rCAG.rCUG"100 Dicer cleavage products. Transcripts that
showed a significant change in abundance (P , 0.05)
between both rCAG.rCUG"100 lines and the 4xUAS control
were obtained. In this case the data was not filtered for a
minimum fold change difference (log2 (ratio)) in expression.
None of the transcripts with a significant change in abundance
contained a CUG repeat tract. On the other hand, 13 transcripts
containing seven or more tandem CAG repeats show a signifi-
cant change in expression in the presence of rCAG.rCUG"100
(Supplementary Material, Table S2).
Several of the transcripts that were significantly altered
were involved in various components of innate immunity. Evi-
dence in the literature of elevated cytokine levels and micro-
glia activation in dominant expanded repeat diseases (23,24),
together with the significant alteration of the Drosophila
NFkB ortholog, dorsal, led to further investigation of the
Toll pathway in double-stranded RNA-mediated pathogenesis.
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Double-stranded RNA-mediated toxicity is dependent
on activation of the Toll pathway
The external surface of the Drosophila eye consists of precise-
ly patterned ommatidia. Ectopic expression of expanded
repeat sequences in the eye using the GAL4/UAS expression
system has been used to study expanded repeat disease patho-
genesis (26–31). Expression of rCAG.rCUG"100 in differen-
tiated cells of the eye using the GMR-GAL4 driver (32)
causes disruption to ommatidial patterning and some loss of
pigmentation (see Fig. 2A versus A′). A modification of the
dsRNA phenotype was indicative of a functional interaction
between the candidate protein and double-stranded RNA.
The expression levels were altered using conditional gene in-
activation in the Drosophila eye by RNAi knockdown of each
individual gene (33,34). The RNAi lines used in this experi-
ment have no predicted off-target effects, are expressed from
specific insertion sites in the Drosophila genome (to prevent
variable expression) and are flanked by gypsy insulator
sequences to increase the level of expression (34). Expression
of control dsRNA (LacZRNAi) (35) in the eye gave no pheno-
type (Supplementary Material, Fig. S3).
Nine Toll receptors are present in Drosophila. Of these,
seven Toll receptors: Tl, 18-wheeler (18W), MstProx, Toll-4,
Toll-7, Tollo and Toll-9, were individually reduced in the
Drosophila eye by RNAi using GMR-GAL4 (32). In each
case of RNAi knockdown of Toll receptors alone, no effect
on ommatidial patterning was observed and eyes appeared
similar to the expression of the control mCherryRNAi, which
does not have an endogenous target (Fig. 2A–H). Knockdown
of Tl in flies also expressing rCAG.rCUG"100 has a mild effect
on pigmentation (Fig. 2B′ versus A′), whereas knockdown of
18W, MstProx, Toll-4, Toll-7, Tollo and Toll-9 significantly
suppressed the rCAG.rCUG"100 double-stranded RNA repeat
induced rough eye and loss of pigmentation phenotype
observed in the mCherry control (Fig. 2C′ –H′ versus A′).
These findings suggest that various receptors of Toll signaling
contribute to rCAG.rCUG"100 double-stranded RNA toxicity.
In addition, several different protein components of the Toll
pathway (Supplementary Material, Fig. S4) were also indi-
vidually decreased by RNAi to further assess the participation
of this pathway in double-stranded RNA toxicity. Knockdown
of spatzle (spz), the receptor ligand, resulted in significant sup-
pression of the rCAG.rCUG"100 phenotype seen with expres-
sion of mCherryRNAi control (Fig. 3B′ versus A′). Knockdown
of pelle (pll) caused a mild effect with reduced black necrotic
regions and disruption to patterning (Fig. 3C′). The knock-
down of cactus (cact) had no detectable effect on the
rCAG.rCUG"100 phenotype (Fig. 3D
′). Due to the negative
regulatory role of cactus in the Toll pathway, reduced levels
of cactus were expected to enhance the rCAG.rCUG"100
phenotype. The lack of an enhancement may be attributed to
a threshold, in which reducing cactus levels does not activate
the Toll pathway more than that caused by degradation of en-
dogenous cactus. Knockdown of dorsal (dl), however, resulted
in significant suppression of the rCAG.rCUG"100 phenotype
(Fig. 3E′). In each case, knockdown of each gene alone did
not cause any phenotype in the eye (Fig. 3A–E).
These experiments provide evidence that reduction of Toll
pathway proteins suppresses rCAG.rCUG"100 double-stranded
RNA toxicity, indicating that inhibition of a Toll-mediated re-
sponse reduces pathogenesis. This demonstrates that repeat-
containing double-stranded RNA toxicity is dependent on
the activation of the Toll pathway.
The Toll pathway is activated in the presence of
repeat-containing double-stranded RNA in Drosophila
Drosomycin is a classic antimicrobial peptide activated by Toll
signaling and is widely used as a functional readout of this
pathway (36). The expression level of Drosomycin was assessed
to determine if a Toll-mediated response was activated in this
dsRNA model. A quantitative PCR was performed to determine
the transcript levels in flies that pan-neuronally (elavII-GAL4
(ref 25)) express rCAG.rCUG"100. These flies showed a
1.7-fold increase (P ¼ 0.0034) in Drosomycin expression
levels compared with control flies expressing no expanded
repeats (Fig. 4A). A similar elevation of Drosomycin has previ-
ously been observed with induction of an immune response via
the Toll pathway (37–39). The initiation of an inflammatory re-
sponse was determined by measuring the transcript levels of the
Drosophila TNF homologue, Eiger (40). A quantitative PCR of
flies expressing rCAG.rCUG"100 in neurons (elavII-GAL4
25)
showed a 1.4-fold increase (P ¼ 0.0043) in Eiger expression
levels compared with control flies (Fig. 4B).
These findings demonstrate the activation of the Toll
pathway in response to ectopic expression of repeat-containing
double-stranded RNA. Furthermore, expression of double-
Figure 1. Gene ontology analysis of significantly altered genes in flies expres-
sing rCAG.rCUG"100 dsRNA in all neurons. Genes that show a significant
(P , 0.05) change between each of the dsRNA lines and the control, but
were unaltered (P ≥ 0.05) between each other and show a log2 (ratio) .+1
or ,21 were selected. The number of genes in each category and the percent-
age are indicated. Genes that do not have a function that fits into the listed cat-
egories are represented as ‘other’. Those with no known function are listed as
‘unknown’.
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stranded RNA activates innate immunity, suggesting that
rCAG.rCUG"100 causes an immune response similar to that
observed in neurodegenerative disease.
Double-stranded RNA toxicity in glial cells leads to
neurodegeneration
Toxicity in glial cells, the immune cells of the nervous system,
has previously been shown to lead to neurotoxicity (41–45).
Double-stranded RNA was expressed in glial cells to determine
its contribution to neuronal dysfunction in this model. Glial ex-
pression of rCAG.rCUG"100 with repo-GAL4 (46) was highly
toxic and led to lethality in strong expression lines. Therefore,
two weaker rCAG.rCUG"100 lines, rCAG.rCUG"100
W1 and
rCAG.rCUG"100
W2 , containing 1xrCAG"100 and 1xrCUG"100
were used. Substantial lethality was also observed with these
lines and hence, only a small sample size was used for the
experiment. The climbing ability of flies expressing these
weak rCAG.rCUG"100 lines was scored to determine neuronal
function, using the method described previously (11).
An average of 53.34 and 42% of flies expressing
rCAG.rCUG"100
W1 and rCAG.rCUG"100
W2 showed ‘failure to
climb’ at week 1 compared with 8.57% control flies, demon-
strating a significant climbing defect (P , 0.0001 in each
case) (Fig. 5). The same flies aged for another week showed
further exacerbation of the climbing defect. At week 2, an
average of 96 and 76.25% of flies expressing rCAG.rCUG"100
W1
and rCAG.rCUG"100
W2 showed a ‘failure to climb’ compared
with 21.54% control flies (P , 0.0001 in each case) (Fig. 5).
Statistical analysis also demonstrated a significant effect on
the climbing ability of flies expressing rCAG.rCUG"100
W1 and
rCAG.rCUG"100
W2 between weeks 1 and 2 demonstrating age-
dependent progressive deterioration of (P , 0.001 in each
case) neuronal function due to toxicity in glial cells. An
age-dependent effect was not observed in the control flies
(P ¼ 0.1227).
The neuronal dysfunction observed with glial expression
of rCAG.rCUG"100 indicates the potential for human
neurodegenerative disease phenotypes to be caused by toxicity
that is not cell-autonomous, given that the relevant human
disease genes are usually not restricted in their expression to
specific cell types.
Autophagy restricts double-stranded RNA toxicity
Autophagy activation is a key element of the inflammatory re-
sponse (47). To investigate the role of autophagy in repeat-
containing double-stranded RNA toxicity, the level of two
autophagy specific genes (Atg) was reduced by RNAi in the
Drosophila eye. Knockdown of Atg1 or Atg18 alone had no
effect on the Drosophila eye (Fig. 6B and C). These eyes
appeared similar to a control with the GMR-GAL4 driving a
UAS construct with no RNAi (Fig. 6A). Knockdown of
either Atg1 or Atg18 in flies also expressing rCAG.rCUG"100
caused an enhancement of the dsRNA phenotype (Fig. 6B′ and
C′). These eyes showed an increase in the rough eye pheno-
type and also showed some necrosis compared with the
rCAG.rCUG"100 alone (Fig. 6A
′). These results indicate that
autophagy is necessary for clearing the toxicity caused by
the double-stranded RNA and is therefore restrictive of tox-
icity.
DISCUSSION
The specific mechanism(s) through which dynamic mutations
lead to pathogenesis in the dominantly inherited, expanded
repeat diseases is/are not fully understood. The degeneration
and loss of susceptible tissues and cells in affected individuals
have made the study of pathogenic mechanisms in primary
tissues extremely difficult, since these somatic targets are no
longer available in those whose death occurs in the latter
stages of the disease. The use of model organisms such as
Drosophila circumvents this problem. Specifically in the
case of Drosophila, expanded repeat toxicity can be
modeled in a tissue specific manner with the GAL4/UAS
Figure 2. Knockdown of Drosophila Toll receptors reduces dsRNA toxicity. (A–H) External phenotype of eyes with GMR-GAL4 expression of RNAi stock.
Flies expressing (A) mCherryRNAi, (B) TlRNAi, (C) 18WRNAi, (D) MstProxRNAi, (E) Toll-4RNAi, (F) Toll-7RNAi, (G) TolloRNAi and (H) Toll-9RNAi have no obvious
phenotype. (A′ –H′) Modification of the rCAG.rCUG"100 phenotype with RNAi knockdown of Toll receptors. (A
′) GMR-GAL4-driven expression of
rCAG.rCUG"100 together with mCherry
RNAi causes disruption to ommatidial patterning and loss of pigmentation. (B′) Expression of TlRNAi has a minimal
effect on the rCAG.rCUG"100 phenotype, whereas (C
′) 18WRNAi, (D′) MstProxRNAi, (E′) Toll-4RNAi, (F′) Toll-7RNAi, (G′) TolloRNAi and (H′) Toll-9RNAi signifi-
cantly suppress the dsRNA phenotype and show return of external patterning and pigmentation. Experiments were performed at 258C. rCAG.rCUG"100 refers to
rCAG.rCUG"100
M3 .
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system. This permits the analysis and dissection of potential
pathogenic mechanisms without affecting the rest of the or-
ganism. We have used this system to model complementary
double-stranded RNA toxicity as a potential pathogenic
pathway in these diseases.
In this study, we identify activation of the innate immune
system as a component of double-stranded RNA-mediated
toxicity. The data presented herein showed that the Toll
pathway is activated in the presence of repeat-containing
double-stranded RNA and toxicity is dependent on this
pathway. Normally, endogenous RNAs are shielded from
Toll pathway activation as part of the mechanism to distin-
guish ‘self’ from ‘non-self’ RNAs (48). This typically involves
post-transcriptional modification or editing of the RNA.
Therefore, it is likely that rCAG.rCUG"100 repeat-containing
double-stranded RNA has some property that interferes with
this mechanism.
Interestingly, several miRNAs altered in this Drosophila
double-stranded RNA model (11) are known to influence
Drosophila immunity, including the Toll pathway (49). Further-
more double-stranded RNA toxicity in glial cells causes neuro-
degeneration, suggesting that non-autonomous toxicity is
sufficient for neuronal dysfunction. In addition, we have also
uncovered a protective role for autophagy in double-stranded
RNA toxicity. This restrictive effect of autophagy on toxicity
is consistent with previous findings in polyglutamine disease
models (50–52). These findings suggest that the homeostatic
balance between the activation of the Toll pathway by double-
stranded RNA and induction of autophagy as a defence response
may be critical to pathogenic progression. Together, these data
identify a novel mechanism through which repeat-containing
double-stranded RNAs cause pathogenesis (Fig. 7).
The Toll pathway induces immune responses necessary for
clearance of pathogenic agents. One such immune effector is
autophagy. Autophagy is a cellular process primarily involved
in recycling cellular organelles in response to starvation but is
also involved in the clearance of toxic aggregates and patho-
gens. A number of TLRs, namely TLR-4, TLR-7 and TLR-8,
have been found to induce autophagy as a means of
eliminating toxicity (53,54). In Drosophila, virus recognition
by Toll-7 activates autophagy (55). Furthermore, autophagy
acts as a negative regulator of TLR-mediated inflammatory
responses (56) and demonstrates crosstalk between these two
pathways. Autophagy is implicated in several pathological
conditions, including neurodegenerative diseases. Specifically,
induction of autophagy was found to reduce toxicity in models
of dominant expanded repeat diseases (50–52), suggesting a
protective role for autophagy in this context. Recently,
nucleic acids have also been found to mediate the role of
autophagy in heart inflammation and failure (57). Oka et al.
(57) showed that mitochondrial DNA that escapes from autop-
hagy leads to TLR-9-mediated inflammatory responses in car-
diomyocytes and is capable of inducing myocarditis and
dilated cardiomyopathy. Thus, a growing body of evidence
suggests that perturbation in the metabolism of endogenous
nucleic acids can initiate pathways with pathogenic conse-
quences.
An increase in inflammatory factors, altered microglial cell
activity and deregulation of Toll-like receptors (TLR) are all
observed in healthy aging brains (58). However, further perturb-
ation of these inflammatory factors occurs in neurodegenerative
diseases, including HD (58,59). Elevation of interleukin-6
(IL-6), a cytokine regulated by the Toll pathway, has been
observed in preclinical HD mutant gene carriers, suggesting
that abnormal immune activation may precede clinical path-
ology (23). The observation of an increase in IL-10 in FXTAS
preclinical individuals and a correlation between immune acti-
vation and repeat copy number further demonstrate the import-
ance of immune activation in pathogenesis (24). Additionally
increased activation of microglia adjacent to degenerating
neurons and upregulation of inflammatory cytokines have also
been observed in post-mortem HD samples (60,61). Despite
these observations, the role of neuroinflammation in pathogen-
esis is not fully understood. A simple explanation would be that
neuroinflammation is a response to the neuronal toxicity caused
by the mutant expanded repeats. Yet the elevated levels of IL-6
observed in preclinical HD individuals (23) and IL-10 observed
in preclinical FXTAS individuals (24) suggest that immune
Figure 3. Double-stranded RNA toxicity is dependent on the Toll pathway. (A–E) External phenotype of eyes with GMR-GAL4 expression of RNAi stock. Flies
expressing (A) mCherryRNAi, (B) spzRNAi, (C) pllRNAi, (D) cactRNAi and (E) dlRNAi have no obvious phenotype. (A′ –E′) Knockdown of components of the Toll
pathway restricts the rCAG.rCUG"100 pathogenesis. (A
′) GMR-GAL4-driven expression of rCAG.rCUG"100 together with mCherry
RNAi causes disruption to
ommatidial patterning, loss of pigmentation and some necrosis. (B′) spzRNAi, (C′) pllRNAi and (E′) dlRNAi suppress the rCAG.rCUG"100 phenotype, whereas
(D′) cactRNAi has no effect. Experiments were performed at 258C. rCAG.rCUG"100 refers to rCAG.rCUG"100
M3 .
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activation precedes neuronal pathology. This implies that
immune activation may be causative in pathogenesis rather
than a consequence. Furthermore the level of immune activation
has also been identified as an early indicator of prognosis. Spe-
cifically, heightened microglia activation has been correlated
with a greater 5-year disease severity of preclinical HD patients
(62,63). These findings collectively suggest that the expanded
repeat mutations induce an immune response, which may in
turn contribute to the resulting pathogenesis. The findings in
this study propose that repeat-containing double-stranded
RNA toxicity in glial cells is sufficient to cause non-autonomous
toxicity leading to neurodegeneration.
In summary, we have utilized Drosophila to model the
human expanded repeat neurodegenerative diseases that
include HD and found that rCAG.rCUG"100 RNA toxicity is
dependent upon Toll signaling and is sensitive to autophagy.
Since decreasing the activity of the Toll pathway reduces the
observed toxicity, this pathway is an attractive target for po-
tential therapeutic intervention. Double-stranded RNA exhi-
bits the molecular and cellular hallmarks of HD-affected
brain specific (CAG)7 mer RNA and HD-mediated activation
of innate immunity, and is, therefore, an ideal candidate patho-
genic pathway for this group of human genetic diseases.
MATERIALS AND METHODS
Fly stocks
GMR-GAL4 (Bloomington stock #1104), P{GAL4-elav.L}2/
CyO (#8765 referred to as elavII-GAL4), repo-GAL4 (#7415),
mCherryRNAi (#35785), TlRNAi (#35628), 18WRNAi (#30498),
MstProxRNAi (#28526), Toll-4RNAi (#28543), Toll-7RNAi (#30
488), TolloRNAi (#28519), Toll-9RNAi (#30535), spzRNAi (#285
38), pllRNAi (#34733), cactRNAi (#34775) and dlRNAi (#27650)
were obtained from the Bloomington stock center. Atg1RNAi
(v16133) and Atg18RNAi (v22646) were obtained from the
Vienna Drosophila RNAi Center. LacZRNAi was obtained
from Richard Carthew (35).
Transgenic fly lines
The generation of transgenic lines used in this study has previous-
ly been described (10,11). 4xUAS was generated in the attB
system (64) and contains four independent insertions of the
UAS construct with no repeats. 2xUAS contains two independent
insertions of the UAS construct at the 22A and 58A loci. UAS con-
tains a single insertion of the UAS construct at the 68E locus. The
double-stranded RNA line rCAG.rCUG"100
S1 was used for a quan-
titative PCR. For microarray analysis rCAG.rCUG"100
S1 and
rCAG.rCUG"100
S2 crossed to elavII-GAL4 were used. For
genetic screening in the eye, the rCAG.rCUG"100
M3 line was
crossed to GMR-GAL4 driver flies to generate male flies carrying
both the driver and rCAG.rCUG"100
M3 . These flies were then
crossed to each of the candidate RNAi lines to obtain the
desired female progeny. rCAG.rCUG"100
W1 and rCAG.rCUG"100
W2
were used for climbing assays and contain independent inserts
of 1xrCAG"100 and 1xrCUG"100. rCAG.rCUG"100
W1 comprises
rCAG"100 [line E]; rCUG"100 [line J] and rCAG.rCUG"100
W2 com-
prises rCUG"100 [line D]; rCAG"100 [line G] (10,11).
RNA purification and quantitative PCR
RNA from 50 heads from 1-day-old adult females was used in
each sample for a quantitative PCR. RNA extraction and quan-
titative PCR were performed as described previously (11). Ex-
pression levels were normalized to ribosomal protein 49
Figure 4. The Toll pathway is activated by rCAG.rCUG"100. Expression
levels were measured in flies expressing rCAG.rCUG"100 in neurons (elavII-
GAL4). (A) Drosomycin transcript levels are significantly increased (P ¼
0.0034) in flies expressing dsRNA compared with controls. (B) Eiger tran-
script levels are significantly increased (P ¼ 0.0043) in flies expressing
dsRNA compared with controls. dsRNA refers to rCAG.rCUG"100
S1 and
control refers to 4×UAS. Expression levels are normalized to Rp49.
Figure 5. Expression of double-stranded RNA in glial cells results in a neuro-
degenerative phenotype. Repo-GAL4-driven expression of rCAG.rCUG"100
W1
and rCAG.rCUG"100
W2 shows a significant increase in the percentage of flies
that fail to climb at week 1 (n ¼ 18, P , 0.0001 and n ¼ 20, P , 0.0001, re-
spectively) compared with the control (n ¼ 14). This phenotype in enhanced at
week 2 (n ¼ 10, P , 0.0001 and n ¼ 16, P , 0.0001 respectively) compared
with the control (n ¼ 13). Statistical analysis performed by two-way ANOVA
and Bonferroni’s multiple comparison tests. ∗∗∗P , 0.0001, error bars show
s.d. Control is 2×UAS.
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(Rp49). The experiments were performed with three independ-
ent RNA samples for each genotype.










The elavII-GAL4 pan-neuronal driver was used for this experi-
ment. RNA was purified from heads of 1-day-old adult male




4xUAS). Microarray analysis was performed using Affymetrix
Drosophila 2.0 GeneChipw arrays and the quality of the RNA
samples was verified by the Affymetrix Expression ConsoleTM
Software. Sample preparation, hybridization and detection
were performed according to manufacturer’s guidelines.
Genes that showed a significant change in each of the double-
stranded RNA lines (rCAG.rCUG"100
S1 or rCAG.rCUG"100
S2 )
compared with the control (4xUAS) (P , 0.05) but were un-
changed between each other (P ≥ 0.05) were examined. The
significance of each comparison was determined by a two-
tailed Student’s t-test. The microarray data generated in
these experiments are deposited in the GEO repository
(NCBI) with accession number GSE42910.
Climbing assays
Climbing assays were performed as described previously (11).
Due to significant lethality of double-stranded RNA lines with
repo-GAL4, only one replicate of flies was used for each geno-
type. Five trials were performed for each genotype at each
time point (n ¼ 5). Two-way analysis of variance (ANOVA)
and Bonferroni‘s multiple comparisons tests were performed
(GraphPad Prism version 6.01 for Windows, GraphPad Soft-
ware, La Jolla California, USA, www.graphpad.com) to
compare the climbing ability of each genotype with the
control and to determine the effect of aging. The significance
threshold was set at P , 0.05.
Photography of eyes
At least 15 eyes of 1-day-old adult females were scored for
each genotype and representative eyes were imaged using an
Olympus SZX7 microscope fitted with a SZX-AS aperture
along with an Olympus ColourView IIIU Soft Imaging
System camera and AnalysisRuler image acquisition
Figure 6. Autophagy restricts double-stranded RNA toxicity. (A–C) External
phenotype of eyes with GMR-GAL4 expression of constructs. Flies expressing
(A) UAS construct with no insert, (B) Atg1RNAi and (C) Atg18RNAi have no
phenotype in the eye. (A′ –C′) Knockdown of autophagy specific genes
increases toxicity. (A′) GMR-GAL4-driven expression of rCAG.rCUG"100 to-
gether with UAS causes mild disruption to ommatidial patterning and some
loss of pigmentation. (B′) Atg1RNAi and (C′) Atg18RNAi enhance the
rCAG.rCUG"100 phenotype. Experiments were performed at 258C.
rCAG.rCUG"100 refers to rCAG.rCUG"100
M3 .
Figure 7. Model of toxicity caused by repeat-containing double-stranded RNA
in Drosophila. Bidirectional transcription of expanded repeat disease genes pro-
duces repeat-containing rCAG.rCUG"100 double-stranded RNA (dsRNA).
These dsRNA are cleaved by Dicer to small (rCAG)7 (11,12,22). In addition,
an altered miRNA profile is observed. These small RNAs may activate the
Toll pathway leading to an innate immune response. Increased toxicity in glial
cells may cause glial cell death and eventual neurodegeneration. Results in
this study indicate that pathogenesis is dependent on activation of the Toll
pathway and toxicity in glial cells is sufficient to cause neurodegeneration. In
addition, autophagy, an effector of the Toll pathway, plays a role in reducing
pathogenesis by ‘mopping-up’ toxicity.
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software.Photoshop 6.0 and Aperture 2.1.2 was used for image
preparation. Anterior is to the left in all eye photos.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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Abstract
Inflammation is activated prior to symptoms in neurodegenerative diseases, providing a plausible pathogenic mechanism.
Indeed, genetic and pharmacological ablation studies in animal models of several neurodegenerative diseases demonstrate
that inflammation is required for pathology. However, while there is growing evidence that inflammation-mediated
pathology may be the common mechanism underlying neurodegenerative diseases, including those due to dominantly
inherited expanded repeats, the proximal causal agent is unknown. Expanded CAG.CUG repeat double-stranded RNA causes
inflammation-mediated pathology when expressed in Drosophila. Repeat dsRNA is recognized by Dicer-2 as a foreign or
‘non-self’ molecule triggering both antiviral RNA and RNAi pathways. Neither of the RNAi pathway cofactors R2D2 nor
loquacious are necessary, indicating antiviral RNA activation. RNA modification enables avoidance of recognition as ‘non-self’
by the innate inflammatory surveillance system. Human ADAR1 edits RNA conferring ‘self’ status and when co-expressed
with expanded CAG.CUG dsRNA in Drosophila the pathology is lost. Cricket Paralysis Virus protein CrPV-1A is a known
antagonist of Argonaute-2 in Drosophila antiviral defense. CrPV-1A co-expression also rescues pathogenesis, confirming
anti-viral-RNA response. Repeat expansion mutation therefore confers ‘non-self’ recognition of endogenous RNA, thereby
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Introduction
Dynamic mutation is the common mechanism of expansion for
existing repeat sequences that accounts for about 30 inherited
diseases. In some cases the repeat expansion causes loss of
gene function, and the resultant phenotype can be attributed to
loss of function of the protein normally encoded by the affected
gene (1). About 20 expanded repeat diseases are dominantly
inherited and occur in otherwise unrelated genes, therefore they
must gain some type of common attribute that causes diseases
(2–4). These diseases share neurodegeneration as a common
symptom, yet are typically distinguished by the neurons first
affected and therefore the symptoms that lead to their initial
clinical presentation and differential diagnosis. As the diseases
progress their pathology tends to spread and so their symptoms
converge, as overlapping neurons are affected (5).
Despite their identification more than two decades ago,
the mechanism(s) by which these dominant mutations cause
symptoms is/are as yet unclear. While most of these diseases
only have an expanded repeat as their single mutation
mechanism, the recent identification of repeat expansion in
the C9orf72 gene has been a particularly notable addition (6,7).
Repeat expansion in the C9orf72 gene is but one of numerous
genetic causes of amyotrophic lateral sclerosis and/or fronto-
temporal dementia (ALS/FTD). ALS/FTD causing mutations
in other genes are not expanded repeats and in some cases
involve the loss of protein function. Commonalities in the lost
functions of the different ALS/FTD genes are therefore likely
indicators of common pathways of pathogenesis. It is therefore
noteworthy that several of these proteins have functions in
RNA Stress Granule metabolism (TDP43, FUS, VCP, CHMP2B)
(8–11) and innate inflammatory pathways (sequestosome 1
(p62), progranulin, optineurin, TBK1) (12–15).
Late age-at-onset neurodegenerative diseases are increas-
ingly being found associated with activation of inflammation
(16–22). In the past this association has been dismissed on the
basis that the inflammatory machinery was just coming in to
clean up after the proximal cause. However, where timing has
been assessed the inflammatory activation precedes neuronal
pathology. Presymptomatic Huntington’s Disease (HD) gene
mutation carriers have elevated circulating levels of cytokines
(16,17). Mouse models of prion disease and Alzheimer’s disease
reveal in both cases that microglial cell activation precedes nerve
cell pathology (23,24). The molecular mechanism for triggering
inflammatory activation thereby causing neurodegeneration
has not been clear.
Inflammation is the front line cellular defense mechanism
that responds to a diverse variety of danger signals (25). Some
of these danger signals or trigger molecules are components of
pathogens, including RNA (22). In such cases the inflammatory
surveillance relies on the molecular architecture to distinguish
these ‘non-self’ molecules from the endogenous molecules in
the cell. In addition, cells have resident, endogenous trigger
molecules that are normally kept below levels required for
inflammatory activation by one or other degradative processes
or are masked by ligation to inhibitors. A recently reported
example of such an endogenous trigger molecule is double-
stranded (ds) Alu RNA, which is recognized by the IFIH1 pattern
recognition receptor unless modified by the ADAR1 editing
enzyme (26–28). Pathogens can therefore also be detected
when their presence results in the increase and/or activation
of such endogenous trigger molecules. Upon activation the
inflammatory response has an early acute phase during which
trigger molecules (that threaten the organism) are degraded
in order to contain the pathogen and destroy its ability to
replicate. If the threat is not eliminated, then a chronic phase
is activated in order to alarm neighboring cells and prime their
response. Chronic inflammation can include the programmed
death of cell foci that are activated during the acute phase. While
inflammation is effective in restricting exogenous pathogens,
this mechanism is the cause of pathology when mutations lead
to the perpetual synthesis of endogenous trigger molecules
that lack ‘self’ architecture, such as repeat RNA. Mutations
that impair the cell’s degradative capacity or cause constitutive
activation of pattern recognition pathways, such as those
which increase receptor sensitivity (29), can also give rise to
autoinflammatory disease (25).
Cells recognize the presence of viral RNA by means of
either the absence of ‘self’ recognition patterns or the presence
of ‘non-self’ patterns, or both, and in so doing distinguish
potentially dangerous RNAs from endogenous RNAs. Specific
pattern recognition receptors for RNA include the RIG-I-
like receptors (RLRs) (30). The RLRs are members of a larger
family of proteins that include Dicer, RIG-I and IFIH1 (MDA-5)
(Supplementary Material, Fig. S1). Drosophila has two members
of the RLR family—Dicer-1 and Dicer-2—with Dicer-2 having been
found to act as both a component of the RNAi machinery and a
pattern recognition receptor for antiviral RNA response (31). The
antiviral RNA response in Drosophila is heavily dependent upon
Argonaute-2 (32,33), but independent of R2D2, a co-factor in the
RNAi pathway (31).
Previously, we and the others explored the hypothesis that
one or other forms of expanded repeat RNA are pathogenic and
have found that (CAG.CUG)100 dsRNA is able to cause pathol-
ogy when expressed in the Drosophila eye (34,35). Furthermore,
this pathology is both dependent upon components of innate
surveillance (TLRs and TLR signaling) and also activates the
inflammatory response (as indicated by elevated drosomycin and
TNF/eiger) (36). Pathology was found to be dependent upon Dicer
and Argonaute proteins, and the (CAG.CUG)100 RNA was cleaved
down to 21mers of (CAG.CUG)7. This latter finding appeared to
indicate the participation of the RNAi machinery (34,35); how-
ever, herein we tested this hypothesis and found that key com-
ponents of RNAi processing (R2D2 and loquacious) are not only
unnecessary for (CAG.CUG)100 dsRNA pathology, but also appear
to constitute an alternative pathology avoidance pathway. We
have therefore pursued the hypothesis that (CAG.CUG)100 dsRNA
is recognized as ‘non-self’ RNA in the manner typical of viral
RNA sequences. The human ADAR1 RNA-editing enzyme con-
trols innate immune responses to RNA and when ectopically
expressed in Drosophila rescues (CAG.CUG)100 dsRNA pathology.
Ectopic expression of cricket paralysis virus protein CrPV-1A,
which facilitates viral infection by suppressing the antiviral cell
death response (37–39), rescues (CAG.CUG)100 dsRNA pathology
in Drosophila.
Results
RNAi co-factors R2D2 and loquacious not required for
dsRNA pathology
The requirement for (CAG.CUG)100 dsRNA pathology on certain
components of the RNAi machinery (specifically Dicer-1, Dicer-
2, Argonaute-2) has previously been reported (34–36). Given the
ability of Drosophila Dicer proteins to also act as pattern recog-
nition receptors (32,33,40–46) we assessed the need for other
components of the Drosophila RNAi machinery in (CAG.CUG)100
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pathway in Drosophila along with Dicer-2 and Argonaute-2 (47,48),
therefore the role of R2D2 in (CAG.CUG)100 dsRNA pathology
was assessed by its heterozygous deletion or Gal4/UAS over-
expression.
RNAi has become a widely used experimental tool in
Drosophila, as a means to investigate gene function in a particular
pathway, by lowering levels of targeted RNAs. There is, however,
substantial overlap between the RNAi pathway and the antiviral
response mechanism in Drosophila (31,49). The common roles
in these pathways played by Dicer-2 and Argonaute-2, render the
RNAi targeted reduction of candidate modifiers of the antiviral
response problematic. The studies herein have therefore been
restricted to the analyses of loss-of-function mutations (as
heterozygotes) or Gal4-UAS directed ectopic over-expression
of the relevant protein.
While Drosophila carrying a loss-of-function mutation in
Dicer-1 have reduced (CAG.CUG)100 dsRNA pathology, those
with loss of R2D2 have enhanced pathology (Fig. 1A’–D’;
Supplementary Material, Fig. S2). Furthermore, over-expression
of R2D2 rescues the (CAG.CUG)100 dsRNA pathology (Fig. 1I’ and J’;
Supplementary Material, Fig. S2). The reciprocal effects of a
more severe phenotype caused by reduction in R2D2 and
rescued phenotype with R2D2 over-expression suggest that
the pathway in which R2D2 participates is actually in compe-
tition with that which causes (CAG.CUG)100 dsRNA pathology.
Loquacious also acts as an RNAi co-factor. Loquacious protein
function is complicated by alternative splicing that gives rise
to isoforms with distinct roles in the processing of different
small RNA populations. Loquacious mutations can therefore dif-
ferentially affect isoform functions (50,51). Nevertheless, neither
of two independent loquacious mutations (loqsKO and loqsf00791)
exacerbated expanded CAG.CUG repeat pathology (Fig. 1E’
and F’), consistent with RNAi pathways being not required for
dsRNA pathology but instead being a competing pathway to
that which causes the pathology. Furthermore, miRNA sequence
profiles were assessed in (CAG.CUG)100 dsRNA expressing
Drosophila to determine whether small RNA processing is
altered. This analysis revealed minimal differences (+/− 1.2-fold
change) in a small number of miRNAs, between flies expressing
(CAG.CUG)100 dsRNA versus control (Supplementary Material,
Table S1). Those miRNAs (miR-184, miR-263b, miR-274, miR-932,
miR-1017) showing altered levels were tested for the ability of
increased or decreased levels of these miRNAs to alter pathology
in Drosophila lines also expressing (CAG.CUG)100 dsRNA and none
were found to impact eye phenotype (Supplementary Material,
Fig. S3).
Since both Dicer and Argonaute proteins are required for
(CAG.CUG)100 dsRNA pathology (Supplementary Material, Fig. S4)
this suggests that these proteins work in concert to recognize
(CAG.CUG)100 dsRNA as a viral RNA and give rise to the resultant
pathology through pattern recognition pathway instigated
antiviral RNA response rather than the RNAi pathway in which
R2D2 and loquacious normally participate.
Human ADAR1 (but not human ADAR2) editing rescues
dsRNA pathology
RNA modification is a major form of distinguishing ‘self’ from
‘non-self’ RNAs. RNA modifying enzymes typically recognize
distinct sequence and/or structural features in the RNA. The
expanded CAG repeat contains the normal recognition sequence
of adenosine deaminase of RNA (ADAR) enzymes. These
enzymes are also typically affected by the secondary structure
of the RNA. The ds structure of (CAG.CUG)100 dsRNA therefore
represents a normal target for ADARs. The ADAR enzymes are
also of great interest for their relationship with known RNA-
binding pattern recognition receptors (IFIH1 in humans). Loss-
of-function mutations in IFIH1 are able to rescue the phenotype
caused by loss of ADAR1 in mice (51,52). Furthermore, loss-of-
function mutation in human ADAR1 is found to be one genetic
cause of the congenital neurodegenerative disease Aicardi-
Goutieres Syndrome (AGS) (53). Gain-of-function mutations
in the IFIH1 pattern recognition receptor are another cause
of AGS (29), strongly implicating RNA modification in AGS
pathogenesis.
ADAR1 mutations in some individuals give rise to bilateral
striatal necrosis (54), an intriguing link to HD given that this
brain region is typically the first to exhibit pathology in HD.
Based on the finding that mutations in ADAR1 cause AGS and the
substrate specificity of the ADAR enzymes it has been proposed
that ADAR1 may limit the cytoplasmic accumulation of the
dsRNA generated from genomic repetitive elements (55). The
finding (56) of interferon-stimulated gene expression signatures
in the heterozygous ADAR1 mutation carrier parents of affected
offspring with both ADAR1 alleles mutated, suggests that ADAR1
is a rate-limiting determinant of interferon induction and innate
inflammatory response. Therefore, given the role of ADAR1 in
human pathology and CAG RNA sequence specificity of ADAR
proteins, human and Drosophila ADAR enzymes were assessed
herein for their impact on Drosophila (CAG.CUG)100 dsRNA
pathology.
RNAseq analysis of CAG7mer from Drosophila expressing
(CAG.CUG)100 dsRNA alone revealed the activity of endogenous
Drosophila ADAR on ∼6% of CAG7mer RNAs, with most having a
single edited A>I in the final CAG repeat (Fig. 2E). Thus, while
CAG.CUG is a substrate for Drosophila ADAR this low level of
editing suggests that it is either a poor substrate or the level of
endogenous enzyme is rate-limiting. The Drosophila genome has
a single ADAR gene, while three human genes encode ADAR
proteins. Human ADAR1 and ADAR2 are well characterized
and expressed, whereas ADAR3 is not known to have catalytic
function (57). Human ADAR1 is differentially expressed with
alternative splicing giving rise to constitutive (hADAR1c) and
interferon-induced (hADAR1i) forms (58). We therefore tested the
ability of both human hADAR1c and hADAR1i as well as hADAR2
and the Drosophila isoform dADAR to affect the (CAG.CUG)100
dsRNA pathology.
Co-expression with either human hADAR1c or hADAR1i along
with (CAG.CUG)100 dsRNA saw a complete rescue of pathology
(Fig. 2B’ and C’). Little effect was seen with human ADAR2
(Fig. 2F’), while alteration in Drosophila ADAR levels also had
minimal impact (Fig. 2G’), consistent with dADAR being more
closely related to hADAR2 than hADAR1 (59). Co-expression of
Dicer-2 with (CAG.CUG)100 dsRNA causes lethality in the S1 line;
however, lethality and eye phenotype were completely rescued
by co-expression of hADAR1i (Supplementary Material, Fig. S5).
Steady state levels of (CAG.CUG)100 dsRNA were determined
by quantitative RT-PCR on triplicate RNA samples from flies
expressing (CAG.CUG)100 dsRNA and either human ADAR1 or
ADAR2 or Drosophila ADAR (Supplementary Material, Fig. S6).
While all gave lower levels than flies expressing (CAG.CUG)100
dsRNA alone, the comparable level for flies also expressing
hADAR1, hADAR2 or dADAR indicates that lower steady-state
RNA levels alone do not account for phenotype rescue seen with
hADAR1, as hADAR2 and dADAR have no phenotype rescue.
ADAR1 is therefore specifically capable of masking ‘non-self’
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Figure 1. R2D2 is not required for the dsRNA phenotype in the Drosophila melanogaster eye. In each case the GMR-GAL4 driver is used to express the control or candidate
alone (A–L) and together with rCAG.rCUG∼100 M3 dsRNA line (A’–L’). (A) GMR-GAL4 does not have an obvious phenotype alone. (A’) Expression of rCAG.rCUG∼100
dsRNA results in disruption to ommatidial patterning and loss of pigmentation. (B) Reducing Dicer-1 levels using Dcr1Q1147X/+ does not alter the phenotype of the eye.
(B’) Reducing Dicer-1 levels while co-expressing dsRNA results in a suppression of the dsRNA rough eye phenotype (when compared to A’). (C and D) Reducing r2d2
levels using r2d21 or r2d2s165fsx do not alter the phenotype of the eye. (C’ and D’) Heterozygous loss-of-function mutants r2d21 or r2d2s165fsx flies with GMR-GAL4 driven
expression of rCAG.rCUG∼100 dsRNA results in an enhanced eye phenotype with increased regions of necrosis (when compared to A’). (E and F) Heterozygous loqsKO
and loqsf00791 have no eye phenotype alone. (E’ and F’) The dsRNA phenotype is enhanced by each of the loqs mutants (when compared to A’). (G) GMR-GAL4 does not
have an obvious phenotype alone. (G’) Expression of rCAG.rCUG∼100 dsRNA results in disruption to ommatidial patterning and loss of pigmentation. (H) GMR-GAL4
driven expression of UAS-Dcr-1 has no eye phenotype alone but (H’) enhances rCAG.rCUG∼100 dsRNA eye phenotype (when compared to G’). (I and J) Over-expression
of r2d2 with either of two independent UAS-r2d2 lines (II or III) does not affect the normal patterning of the eye. (I’ & J’) Co-expression of either these UAS-r2d2 over-
expression constructs together with dsRNA rCAG.rCUG∼100 suppresses the dsRNA phenotype, restoring both regular patterning and pigmentation to the eye (when
compared to G’).
Copy number requirement for expanded repeat
(CAG.CUG) dsRNA pathology
The antiviral RNA defense mechanism involves the binding of
multiple RIG-I-like pattern recognition receptors along single
molecules of RNA to form a filament structure that is then bound
by mitochondrial antiviral signaling protein (MAVS) (60,61). A
length requirement for the RNA molecule appears related to
the need for such filaments to exceed a threshold for MAVS
binding and/or activation (61,62). Therefore, experiments were
undertaken to assess the length dependence of the expanded
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Figure 2. ds RNA pathology is dependent on editing by ADAR. GMR-GAL4 was used to express constructs in the eye or ELAV(II)-GAL4 to drive expression in all
neurons. Ectopic-expression of either hADAR1-c or hADAR1-i reduce the rCAG.rCUG∼100 dsRNA eye phenotype. (A) GMR-GAL4 driven expression of 4xUAS with no
repeat construct has no phenotype. (A’) GMR-GAL4 driven expression of rCAG.rCUG∼100 causes disruption to patterning of the eye and loss of pigmentation (line S1).
(B and C) GMR-GAL4 driven expression ectopic-expression of either constitutive (hADAR1-c) or interferon inducible (hADAR1-i) human ADAR1 isoforms does not disrupt
the patterning of the eye. (B’ and C’) GMR-GAL4 driven co-expression of either hADAR1-c or hADAR1-i together with rCAG.rCUG∼100 rescues the rCAG.rCUG∼100 eye
phenotype (when compared to A’). (D) RNAseq of hADAR1 rescued eyes/neurons (GMR/Elav). CAG cleavage products (CAG7mer) are detected following GAL4 driven
expression of rCAG.rCUG∼100 in the either the eye (GMR) or in all neurons (pan neuronal, Elav). CAG7mer abundance is significantly reduced in either tissue following
GAL4 driven co-expression of hADAR1-i with rCAG.rCUG∼100. (E) RNAseq of CAG7mer showing editing of final A in 6% RNAs. CAG7mer is A>I edited in 6% of RNAs
predominantly at position 20 (the last CAG). In the minority of CAG cleavage products that are not 21mers that are edited, it is usually the most 3’ A residue that is edited,
suggesting endogenous dADAR editing is targeted to the last A in the sequence. (F and G) Rescue is specific to hADAR1. GMR-GAL4-driven expression ectopic-expression
of either human hADAR2 or Drosophila dADAR-3/4 does not disrupt the patterning of the eye. (F’and G’) GMR-GAL4 driven expression ectopic-expression of either human
hADAR2 or Drosophila dADAR-3/4 does not reduce the eye phenotype caused by co-expression of rCAG.rCUG∼100 (when compared to A’).
The Drosophila model of expanded CAG repeat disease uti-
lized herein has previously been found to exhibit expanded
dsRNA pathology for 100 copies of the repeat (34). Using a similar
Drosophila model, Yu et al. (35) have also found that (CAG)250
and (CUG)250 RNAs cause pathology when co-expressed in the
eye, whereas the (CAG)34.(CUG)19 combination of RNAs (below
the human disease threshold) do not. Therefore, the ability of
shorter length (CAG.CUG) repeats of 50 copies to cause pathology
was assessed. This copy number is well below the putative
disease threshold (∼100 copies) (63) but above the DNA insta-
bility threshold (∼36 copies) for HD and related expanded CAG
repeat diseases. Fifty CAG.CUG repeats (150 bases) is also well
above that required for RNAi processing, as a ds repeat length
of 19–29 base pairs is sufficient for Dicer-mediated cleavage (64).
Multiple lines of Drosophila were established that express four
UAS-transgenes, two encoding (CAG)50 RNA and the other two
(CUG)50 RNA. None of these (CAG.CUG)50 expressing lines exhib-
ited pathology even though comparable levels of (CAG.CUG)
RNA were expressed (Fig. 3). The (CAG.CUG)100 lines exhibited
much greater pathology when Drosophila Dicer proteins were
also ectopically over-expressed (25), so Dicer-2 was also ectopi-
cally over-expressed in (CAG.CUG)50 lines. Even in the pres-
ence of excess Dicer-2 in no case was pathology observed for
(CAG.CUG)50, in clear contrast to Dicer-2 increasing pathology
in (CAG.CUG)100 lines (Fig. 3B’–E’). Therefore, the dsRNA pathol-
ogy that we have observed in this Drosophila model exhibits
length dependence typical of that required for the antiviral RNA
response, as well as copy number dependence consistent with
that in the human expanded CAG.CUG repeat diseases (63).
Cricket paralysis virus CrPV-1A suppressor of Argonaute
2 rescues (CAG.CUG)100 dsRNA pathology
Length dependence for expanded repeat dsRNA pathology is
consistent with the antiviral recognition mechanism where mul-
tiple pattern recognition receptor molecules bind to long ds RNA
molecules, forming a filament structure. This filament assembly
takes place in RNA stress granules and if unresolved (by granu-
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Figure 3. Fifty copies of CAG.CUG are insufficient to cause pathology, even in the presence of increased levels of Dicer-2/ ds RNA pathology is length dependent. In each
case the GMR-GAL4 driver is used to express the UAS constructs in the eye. (A) Expression of 4xUAS with no repeat construct has no obvious phenotype. (A’) Ectopic
over-expression of Dicer-2 also has no phenotype in the eye. (B–D) Three independent lines expressing rCAG.rCUG∼50 dsRNA do not affect the patterning of the eye
(when compared to A). Line #1 – rCAG∼50 [M1,M7]; rCUG∼50 [M5,M9], line #2 – rCUG∼50 [M4,M8]; rCAG∼50 [M2,M4] and line #3 – rCAG∼50 [M3,M9]; rCUG∼50 [M2,M3].
(B’–D’) Co-expression of Dicer-2 together with each of the three independent lines of rCAG.rCUG∼50 dsRNA also does not affect the patterning of the eye (when compared
to A’). (E) Expression of a mild line of rCAG.rCUG∼100 (M5) results in loss of patterning and pigmentation. (E’) Co-expression of Dicer-2 together with rCAG.rCUG∼100
(line M5), results in lethality indicating an enhancement of the phenotype. (F) qRT-PCR levels of GMR-GAL4 driven expression of repeat RNA transcripts in independent
rCAG.rCUG∼50 lines compared to rCAG.rCUG∼100 (M5 line). Steady-state rCAG.rCUG repeat RNA levels measured relative to Rp49. PCR primers sequences are given in
Supplementary Material, Table S2.
including cell death. The hypothesis that the antiviral cell death
mechanism is responsible for expanded repeat dsRNA pathology
was therefore tested by co-expression with a viral protein that
inhibits this mechanism (38).
Insect viruses have evolved an effective ablation of the
host antiviral defense mechanism. RNA silencing endonuclease
Argonaute-2 mediates specific antiviral immunity in Drosophila
melanogaster (32). CrPV escapes the antiviral response by
encoding an inhibitor of Argonaute-2. The CrPV suppressor (CrPV-
1A) interacts with the endonuclease Argonaute-2 and inhibits its
activity without affecting microRNA (miRNA)-Ago1-mediated
silencing (37). We therefore crossed two independent lines of
flies ectopically expressing CrPV-1A with fly lines expressing
(CAG.CUG)100 dsRNA—one exhibiting moderate (M3) and two
exhibiting strong (S1 and S2) eye phenotype. In each case
(CAG.CUG)100 dsRNA pathology was completely rescued (Fig. 4;
Supplementary Material, Fig. S7) consistent with the antiviral
RNA functions of Argonaute-2 (and Dicer-2) being required for
(CAG.CUG)100 dsRNA pathology.
Discussion
The pathogenic mechanism by which expansion of existing
DNA repeat sequences brings about dominantly inherited neu-
rodegenerative diseases has been elusive. Indeed, it has been
unclear whether there are multiple such pathways, distinct for
each expanded repeat and its cognate gene, or whether there
is a common mechanism that the different diseases share in
a common chain of causality. These expanded repeat diseases
have diverse repeat motifs located in unrelated genes. However,
in all cases the repeat is transcribed, therefore RNA could be a
common causal agent.
Expanded repeat RNA pathology has been modeled in
Drosophila and ds expanded repeat RNA has indeed been found
to induce pathology (34,35). For all expanded repeat disease
loci tested, transcription is found on both strands, raising the
possibility that ds expanded repeat RNA could be the culprit in
these diseases (65). Indeed, human cells normally contain dsRNA
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Figure 4. Cricket paralysis viral protein (CrPV-1A) antagonist of Argonaute ablates rCAG.rCUG∼100 dsRNA pathology when co-expressed in the Drosophila eye. In each case
the GMR-GAL4 driver is used to express the constructs in the eye. (A) Expression of 4xUAS with no repeat construct has no obvious phenotype. (A’) Ectopic expression
of CrPV-1A alone has no phenotype in the eye. (B–D) Lines of Drosophila expressing rCAG.rCUG∼100 dsRNA exhibit variable eye phenotype with one mild (B line M3)
and two strong lines of flies (C, line S1; D, line S2) chosen to assess CrVP-1A impact. (B’–D’) in all three lines expressing rCAG.rCUG∼100 dsRNA, together with the
co-expression of CrVP-1A exhibit complete inhibition of rough eye phenotype.
Furthermore, cytoplasmic ds expanded repeat RNAs have been
detected in the brains of individuals affected with C9ORF72
repeat expansion caused ALS/FTD (67).
Dicer and Argonaute proteins are necessary for Drosophila
expanded repeat dsRNA pathology (34,35) (Fig. 1; Supplementary
Material, Fig. S4). These observations together with cleavage of
long RNAs down to (CAG.CUG)7 21mers, have been interpreted
as the RNAi pathway being responsible and the 21mers the
causal agent. This hypothesis is tested herein by assessing the
requirement for further components of the RNAi pathway, R2D2
and loquacious. In both cases reduction of these co-factors led
to an increase in pathology. Indeed, not only does reduction of
R2D2 increase pathology, but also an increase of R2D2 reduces
pathology. These relationships are consistent with the RNAi
pathway and cleavage of the (CAG.CUG)100 RNA to 21mers being
in competition with the responsible pathogenic pathway. Since
the Dicer and Argonaute proteins are also required for antiviral
RNA-mediated cell death we hypothesize that this pathway is
the one responsible for (CAG.CUG)100 RNA pathology.
Both the activation of, and requirement for, the innate
inflammatory surveillance system, have been reported in
this Drosophila model of expanded repeat dsRNA pathology
(36). Inflammatory activation correlates with various neu-
rodegenerative diseases but has been typically thought of
as a consequence of cell death—coming in to clean up the
mess that something else has started. There is, however,
increasing evidence that inflammatory activation precedes
neurodegeneration, consistent with a causal role both in the
human diseases (16,17) and in experimental animal disease
models (23,24).
Nucleic acids are the common means of encoding genetic
information for both hosts and pathogens, therefore innate host
defense requires a mechanism to distinguish harmless endoge-
nous nucleic acids from those that are foreign and potentially
harmful. A large number and variety of modification reactions
alter specific nucleotides in host nucleic acids to essentially ‘bar-
code’ those that are ‘self’ and allow their distinction from those
that are ‘non-self’ or foreign. RNA editing is a form of modi-
fication in which the coding potential of the target nucleotide
is changed, most notably the sequence specific conversion of
adenosine to inosine in RNA sequences, catalyzed by adeno-
sine deaminase of RNA (ADAR). Editing of endogenous RNAs by
ADAR1 is required to prevent activation of the cytosolic innate
immune system (51–54,68).
In the expanded CAG repeat diseases, ADAR editing is of
particular interest as the recognition motif/modification site
is contained in the expanded CAG repeat. Furthermore, ADAR
enzymes have a general preference for dsRNA. Therefore,
expanded CAG.CUG dsRNA is an ideal target for ADAR editing.
The ability of human ADAR1, but neither human ADAR2 nor
Drosophila ADAR, to confer ‘self’ status on expanded CAG.CUG
dsRNA is noteworthy as ADAR1 is a known component of
inflammatory activation (51–54,68). The human ADAR1 gene has
two promoters, one for constitutive expression and the other
interferon-inducible (69). The acute inflammatory response
produces a pulse of interferon signaling as one of its ‘feed-
forward’ responses aimed at resolving the trigger molecules/
danger signals that activate inflammation. Interferon-induced
increase in ADAR1 levels therefore enables the editing of RNAs,
thereby reducing the level of ‘non-self’ RNA signal. Together with
induced increases in RNA turnover processes, this mechanism
can degrade RNA trigger molecule/danger signal threats.
ADAR1 also has a functional relationship with the RIG-I-like
pattern recognition receptor IFIH1 (MDA5), a member of the same
family of proteins as Dicer (51,52). Loss-of-function mutations
in ADAR1 cause early lethality in mice that can be rescued
by deletion of IFIH1. ADAR1 is responsible for the editing of
endogenous RNAs to enable their recognition as ‘self’ (27,28,70).
Absence of ADAR1 sees the ‘non-self’ forms of these RNAs
recognized by IFIH1 that then activates inflammation (26,28).
The endogenous RNAs recognized by IFIH1 include not only
Alu dsRNA but also products of the unfolded protein response
(UPR) pathway. One of the UPR response proteins, IRE-1, cleaves
RNAs in a manner that renders them inducers of IFIH1. Loss-of-
function mutations in ADAR1 and gain-of-function mutations
in IFIH1 are both causes of AGS, a congenital disorder that
includes neurodegeneration, with affected newborns having the
appearance of being subjected to in utero inflammatory injury
(53,71). The gain-of-function mutations in IFIH1 that cause AGS
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The sensitivity to ADAR1 editing of the pathology caused by
(CAG.CUG)100 dsRNA in this Drosophila model is therefore con-
sistent with the recognition of the product of repeat expansion
mutation as a ‘non-self’ RNA trigger molecule/danger signal
that then activates inflammation. ‘Non-self’ driven antiviral
RNA recognition is an important process for virus removal as
evident by the finding that HIV evades this process by recruiting
the RNA 2′-O-methyltransferase FTSJ3 to avoid innate immune
sensing (72).
A growing body of evidence is consistent with there being a
distinction between repeat instability threshold and a greater
copy number threshold for pathology (1,63,73–80). Genetic
variations in mismatch repair enzymes have been shown to
be major modifiers of age-at-onset of Huntington’s Disease (75)
and other polyglutamne diseases (76), as well as mouse models
of these diseases (74,77–80). These enzymes control the rate of
increase by somatic mutation from its inherited (germ-line) copy
number and imply the existence of a higher copy number disease
threshold of approximately 100 copies (63). Copy numbers above
36 are unstable, with the shorter unstable repeats (e.g. 40 copies)
taking longer to reach the disease threshold than inherited
80 copy alleles (typically associated with juvenile HD) (1,63).
Such a mechanism explains genetic anticipation: the inverse
relationship between inherited repeat copy number and age-
at-onset of disease symptoms (1,81). The expanded (CAG.CUG)
dsRNA pathology in this Drosophila model exhibits length depen-
dence consistent with the antiviral RNA response mechanism
being responsible. In addition, the observed copy number
dependence is consistent with distinct thresholds for DNA
instability and pathology in the human expanded CAG repeat
diseases (63).
In order to be infectious, viruses must evade detection and/or
response mechanisms of the innate surveillance system. This
response can include the programmed death of cells if the viral
threat is not degraded. Cell death is orchestrated in both the
cell in which the threat is detected and in adjacent sensitized
cells to give a focal ‘scorched earth’ response that denies the
virus both the opportunity to replicate and to infect adjacent
cells. CrPV has evolved a mechanism of specific interference
with the anti-viral RNA response. The CrPV-1A protein is a
specific inhibitor of Argonaute and RNA stress granule formation
(37,39). Stress granules are the location of filament formation
between viral RNA and the RIG-I-like receptors. In vertebrates
these filaments are then bound by the protein MAVS on the
mitochondrial outer surface that in turn activates the antivi-
ral response (60,61). Co-expression of CrPV-1A with expanded
CAG.CUG repeat dsRNA completely rescues the pathology other-
wise caused by this dsRNA. Therefore, the same cellular defense
pathway of cell death that is normally utilized against viruses
(and evaded by CrPV) is responsible for the pathology caused
by the presence of expanded CAG.CUG repeat dsRNA, indicating
its recognition by the cell as a viral ‘non-self’ RNA, a gain-of-
function that accounts for dominant inheritance.
Inflammatory activation, with increased circulating cytokines
(16) and microglial activation (17) precedes neuronal pathology
in premanifest HD carriers. Inflammatory genes are activated in
cells that are destined to undergo neurodegeneration. These
include the induction of interferon-regulated genes in the
cataracts of patients with myotonic dystrophy due to expansion
of either CUG (DM1) or CCUG (DM2) (18). Increased inflammatory
gene expression is evident in HD brain (19) and inflammatory
gene signatures found in ALS motor neurons (20). Inflammation
is activated at the right time and place to be the causal
mechanism of disease.
In addition to the requirement for inflammatory activation in
the expanded CAG.CUG model described herein (36), other ani-
mal models of dominantly inherited neurodegenerative diseases
caused by the expansion of various repeat motifs have shown
dependence on components of inflammation for pathology. Loss
of MyD88 attenuates early Purkinje cell loss in a spinocerebellar
ataxia type-6 mouse model (82), while p62 plays a protective
role in polyglutamine disease model flies (83). Furthermore, defi-
ciency of toll-like receptors 2, 3 or 4 extends life expectancy in
HD mice (84). Genetic ablation of inflammation typically results
in rescue of disease phenotypes—indicating that inflammatory
activation is required for pathogenesis. While the agent causing
inflammatory activation has not been identified in these latter
cases, a zebrafish model for C9orf72 ALS/FTD reveals RNA as a
pathogenic agent (85). In addition, many of the genes mutated
in non-repeat expanded cases of ALS have roles in inflamma-
tory activation pathways and RNA metabolism. Furthermore,
their mutation typically leads to an increase in inflammatory
activation (12,15).
Repeat expansions are therefore ‘non-self’ mutations that
convert expanded repeat RNA from a harmless molecule when
in low copy number to a nucleic acid that lacks the molecu-
lar architecture to be distinguished as ‘self’. Expanded repeat
RNA that exceeds a copy-number threshold is a persistent trig-
ger of pattern recognition receptor signaling and inflamma-
tory responses. Preventing the detection of the proximal repeat
RNA trigger by either masking the ‘non-self’ RNA (with over-
expression of human ADAR1) or blocking viral-detection path-
ways (with co-expression of a viral antagonist) both prevent
pathology. Elongated repeat sequences are conducive to multi-
merisation of repeat structures that are known to trigger chronic
inflammatory activation. These characteristics not only account
for autoinflammatory cell death being the pathogenic mecha-
nism for neurodegeneration, they are also consistent with the
age-related somatic mutation of inherited (but sub-pathogenic)
unstable copy numbers being the rate-limiting determinant of
disease onset.
While studies herein describe the acquisition ‘non-self’
recognition by RNA, this principle can also apply to other gene
products. For example, structures adopted by prion proteins
activate inflammation (23) and glycated forms of proteins are
preferential activators of the RAGE pattern recognition receptor
(86). ‘Non-self’ mutation can include alteration in structure or
post-translational modification that confers pattern receptor
recognition. ‘Non-self’ mutation therefore provides a specific
mechanism for pathogenic activation of inflammation that can
account for numerous neurodegenerative diseases.
Materials and Methods
Fly husbandry
All crosses were performed at 25◦C with 70% humidity unless
otherwise indicated. Drosophila melanogaster stocks were main-
tained on fortified (F1) medium composed of 1% (w/v) agar,
18.75% compressed yeast, 10% treacle, 10% polenta, 1.5% acid
mix (47% propionic acid, 4.7% orthophosphoric acid) and 2.5%
tegosept (10% para-hydroxybenzoate in ethanol).
Fly stocks
Controls stocks used were 4xUAS (empty vector) as we have
previously described (34), UAS-LacZRNAi was kindly provided by
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Bloomington Drosophila Stock Centre (BDSC). Driver lines used
were GMR-GAL4 (76) and P{GAL4-elav.L}2/CyO (referred to as
elavII-GAL4) (88). Pathogenic dsRNA rCAG∼100.rCUG100∼100 lines
used are as previously described (34). Dcr-1Q1147X and Dcr-2L811fsx
(89) as well as UAS-Dcr1, UAS-Dcr2 and UAS-r2d2 (90) were kindly
provided by Richard Carthew, as were UAS-AGO2 (II) and UAS-
AGO2 (III) (90) lines. AGO2414 (91) was obtained from the Kyoto
stock centre. AGO2V966M (92) was obtained from the BDSC. r2d21
(47), r2d2s165fsx (93) and loqsf00791 (94) were obtained from BDSC.
loqsKO was kindly provided by Qinghua Liu and Dennis McKearin
(95). UAS-miR-184 and ∆miR-184 were kindly provided by Ulrike
Gaul (96). UAS-miR-263b and ∆miR-263b were kindly provided
by Stephen Cohen (97). UAS-miR-1017 was kindly provided by
Eric Lai (98). Df(3L)BSC577 (including miR-274) and Df(3L)BSC577
(including miR-932) were obtained from BDSC. UAS-hADAR-1c,
UAS-hADAR1i and UAS-hADAR2 (99) and UAS-dADAR (100) were
kindly provided by Liam Keegan. ADAR1F1 was kindly provided
by Michael Palladino (101). CrPV1A lines (39) were obtained from
Christophe Antoniewski. Genotypes of fly lines were confirmed
by PCR (Supplementary Materials, Fig. S8 and Table S2 of oligo
PCR primers).
Generation of untranslated CAG∼50 and CUG∼50 repeat
constructs
Generation of (rCAG.rCUG)100 lines is described in Lawlor et al.
(34). CAG∼50 repeats were digested from pBluescript CAG∼50 (102)
using flanking Hind III. This fragment was then ligated into the
Hind III site of pENTR/D-TOPO IVM2 MYC FLAG. The presence
of the insert was confirmed by restriction digestion with Acc65I
and XbaI. Plasmids were also sequenced and screened for insert
orientation and integrity. Constructs containing either CAG∼50 or
CTG∼50 were subcloned into pDEST-UAST by LR clonase recom-
bination. Constructs were confirmed by digestions with the
restriction enzymes BsrG I and BamH I and by sequencing.
Generation of transgenic lines
Microinjections to generate transgenic lines were performed by
BestGene Inc., Chino Hills, CA, USA. Transformants were mapped
to determine the chromosome of insertion and balanced stocks
were generated by standard genetic crosses. Single insertion
lines for either the CAG∼50 or CTG∼50 constructs were labeled
rCAG∼50 M1-10 and rCUG∼50 M1-10.
Generating recombinant lines
Recombinants carrying two independent insertions of the same
transgene (either rCAG∼50 or rCTG∼50) on the same chromosome
were generated by crossing trans-heterozygous virgin females to
male w1118 flies. Standard genetic crosses were then performed
to generate three lines each carrying four transgenes, i.e. two
expressing rCAG.2 and two expressing rCUG∼50, as follows:
rCAG.rCUG∼50#1 – rCAG∼50 [M1,M7]; rCUG∼50 [M5,M9]
rCAG.rCUG∼50#2 – rCUG∼50 [M4,M8]; rCAG∼50 [M2,M4]
rCAG.rCUG∼50#3 – rCAG∼50 [M3,M9]; rCUG∼50 [M2,M3].
RNA isolation and quantitative real-time PCR
Expression in the fly eye enables qualitative assessment of the
phenotypic consequences of transgene expression, however the
GMR promoter only drives RNA expression in a small proportion
of cells (even though some of these are nerve cells) with the
majority of non-expressing cells of the fly head effectively
diluting out responses. Therefore, as in previous studies in
this model (34,36), RNA was isolated from the whole heads of
either GMR-Gal4 (eye) or ElavII-Gal4 (pan-neuronal) expressing
fly lines of various UAS-transgene genotypes and subjected
to quantitative reverse transcriptase real-time PCR (qRT-PCR)
as described (34,36). Approximately 100 male Drosophila heads
from newly eclosed flies were collected and snap frozen for
each genotype, before homogenization in Trizol (Invitrogen).
Total RNA was extracted using chloroform and precipitated
with isopropanol, then further purified using the RNeasy mini
kit (Qiagen). RNA to be used for RNAseq was precipitated in
sodium acetate and ethanol and shipped under ethanol on
ice. 1 µg of total RNA per sample was treated with DNAse
I (Invitrogen) and reverse-transcribed with oligo(dT)18 and
SuperScript III (Invitrogen). Quantitative real-time PCR was
performed in a LightCycler (Roche Molecular Biochemicals)
using Power SYBR green mix (Applied Biosystems) and either
GAL4-specific primers (forward: 5′-CACTGACCCCGTCTGCTTTG-
3′, and reverse: 5′-GGTTCGGACCGTTGCTACTG-3′) or primers
specific for the repeat-containing transcript. The transgene
expression level was quantified using the delta Ct method for
relative quantification and expressed relative to the level of
GAL4 transcript for each line.
The quantity of amplified cDNA product for each primer pair
was normalized to the quantity of product with primers for the
housekeeping gene, ribosomal protein 49 (Rp49), for the same
sample. The average of triplicate reactions for each sample was
obtained and the standard deviation of the mean was calculated.
The significance between samples was determined by using a
two-tailed Student’s t-test. The significance threshold was set at
P < 0.05.
RNAseq identification of CAG 21-mer repeat editing and
changes in miRNA profiles
RNAseq was as previously described in Samaraweera et al. (36).
Barcoded small RNA libraries were prepared from 1 µg total
RNA isolated from neurons and eyes using the NEBnext Small
RNA Library Prep set for Illumina (NEB). 2S RNA was depleted
at the RT primer hybridization step using a terminator oligo
blocking strategy, as described in http://www.ncbi.nlm.nih.
gov/pmc/articles/PMC4077022/. Libraries were sequenced on
an Illumina HiSeq 2500 in Rapid Run mode. Fastq files were
trimmed with Cutadapt (v1.6) to lengths of 18–35 nt, with 10%
adapter sequence error allowed. CAG repeats were identified
in the sequencing data by searching for exact matches to
18–35 nt strings of CAG repeating units. Edited repeats were
identified by allowing replacement of any to all CAG units
with CGG.
Eye photos
Eyes of at least 15 flies were viewed and representative eyes
imaged. Flies were photographed at 24–48 h post-eclosion. Light
photos were taken with an Olympus SZX7 dissection microscope
fitted with an SZX-AS aperture. Images were captured with
a Colorview IIIu camera and AnalysisRuler image acquisition
software. In all cases, anterior is to the left. Image preparation
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Supplementary Data:  
 




S1 - Homology between Dicer proteins and other members of the RIG-I family (IFIH1 and RIG-I). 
Homology identified using Clustal alignment in MegAlign Pro program from DNASTAR (Lasergene). 
 
S2 - Variable severity eye phenotype Drosophila rCAG.rCUG~100 lines (Weak, Medium and Strong) 
expressed with altered levels of RNAi co-factor R2D2 at 25°C.  [relates to Fig. 1] 
 
S3 - Altered miRNAs have a minimal effect on double stranded meditated toxicity [relates to Fig. 1] 
 
S4 - Argonaute-2 is a rate-limiting factor in double-stranded RNA mediated toxicity [relates to Fig. 1] 
 
S5 - hADAR-1 function overrides that of dicer2 in the rCAG.rCUG~100 dsRNA phenotype in the 
Drosophila melanogaster eye. [relates to Fig. 2] 
 
S6 - qRT-PCR levels of uncleaved repeat transcripts in rCAG.rCUG~100 dsRNA flies with co-over-
expression of Drosophila or human ADAR proteins. [relates to Fig. 3] 
 
S7 – A: Ectopic expression of CrPV1A completely rescues dsRNA-mediated pathology.  
        B: Sequence alignment of Cricket Paralysis Virus 1A coding sequences. [relate to Fig. 4] 
 
S8 - Verification of genotypes of Drosophila lines by PCR 
 
S9 - Graphical Abstract of ‘Non-Self’ Mutation and Experiments in the Drosophila model of expanded 






S1 - Drosophila miRNAs changes with rCAG.rCUG~100 dsRNA expression [relates to Fig. 1] 
 
S2 - Oligodeoxynucleotide primers utilized for verification of genotypes of Drosophila lines.  
       [relates to Fig. S8] 
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Figure S1 –  
 
Homology between Dicer proteins and other members of the RIG-I family (IFIH1 and RIG-I) 
 
- Homology determined using Clustal alignment in MegAlign Pro program from DNASTAR 
(Lasergene) 
 
 A – overview alignment (human IFIH1, RIG-I, Dicer, Drosophila Dicer1, Dicer2)
 
 
B – sequence homology alignment (consensus, human IFIH1, RIG-I, Dicer, Drosophila Dicer1, Dicer2, logo) 
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Figure S2 – [relates to Figure 1] 
 
Variable severity eye phenotype Drosophila rCAG.rCUG~100 lines (Weak, Medium and Strong) 
expressed with altered levels of RNAi co-factor R2D2 at 25°C.   
 
A, E and I) EV51C is the empty vector control exhibiting no eye phenotype when crossed with GMR-
Gal4. 
B) Weak, C) Medium and D) Strong rCAG.rCUG~100 lines eye phenotypes exhibited when crossed 
with GMR-Gal4.  
E – H) When crossed in to heterozygous loss-of-function r2d21 mutation line, increased severity of 
eye phenotype is evident in the Medium rCAG.rCUG~100 line (G) and lethality for the Strong 
rCAG.rCUG~100 line (H).  
I – L) When additional r2d2 was ectopically co-expressed from the UAS-r2d2 transgene, reduction in 
the severity of the Medium (K) and Severe (L) lines is evident. 
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Figure S3 [relates to Figure 1] 
Altered miRNAs have a minimal effect on double stranded meditated toxicity  
In each case the GMR-GAL4 driver is used to express the constructs in the eye. A) The GMR-GAL4 driver alone 
has no phenotype in the eye. A’) Expression of dsRNA causes disruption to patterning of the eye and loss of 
pigmentation. Heterozygous mutation of B) miR-184 using the miR-184Δ allele, C) miR-263b using the miR-
263bΔ allele D) miR-274 using the deficiency Df(3L)BSC577 and E) miR-932 using the deficiency 
Df(3L)BSC577 does not affect the patterning of the eye alone and B’-E’) does not have a significant effect on 
the dsRNA phenotype.  F) GMR-GAL4 driven expression of a UAS construct alone has no phenotype in the eye. 
F’) Expression of the dsRNA together with UAS alone causes mild disruption to patterning and loss of 
pigmentation. G) UAS-miR-184 causes a significant phenotype alone showing disruption to patterning, loss of 
pigmentation and necrotic spots and G’) is lethal when expressed together with dsRNA. H) Expression of UAS-
miR-263b alone causes a change in the pigmentation of the eye that is H’) also seen together with dsRNA. I) 
Expression of UAS-miR-1017 does not have a phenotype alone and I’) does not have a significant effect together 
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Figure S4 - [relates to Figure 1] 
 
Argonaute-2 is a rate-limiting factor in double-stranded RNA mediated toxicity.  
 
In each case the GMR-GAL4 driver is used to express the constructs in the eye.  The M3 line of 
rCAG.rCUG~100 dsRNA Drosophila is utilized. This experiment was performed at 25 C.  
A) GMR-GAL4 does not have an obvious phenotype alone.  
B & C) Heterozygous AGO2414 and AGO2V966M mutants have no effect on the patterning of the eye.  
A’) Expression of dsRNA results in disruption to ommatidial patterning and loss of pigmentation.  
B’ & C’) Expression of the dsRNA together with these Argonaute-2 mutants suppresses the rough eye 
and loss of pigmentation of dsRNA toxicity.  
D) GMR- GAL4 driving a single UAS transgene with no insert does not show a phenotype.  
E & F) Over-expression of Argonaute-2 with two independent UAS-AGO2 lines does not have a 
phenotype alone.  
D’) Expression of rCAG.rCUG~100 dsRNA causes loss of ommatidial patterning and pigment loss.  
E’ & F’) Expression of these UAS-AGO2 contructs along with dsRNA has no effect.  
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Figure S5 – [relates to Fig 2] 
 
hADAR-1 function overrides that of dicer2 in the rCAG.rCUG~100 dsRNA phenotype in the 
Drosophila melanogaster eye.  
 
rCAG.rCUG~100 toxicity in the eye is not restored by over-expressing dicer2 in flies also over-
expressing hADAR1 FL. The GMR-GAL4 driver was used to express all constructs.  
A)  Ectopic expression of dicer2 (together with empty UAS vector) has no phenotype in the eye.  
A’) Co-expression of dicer2 and rCAG.rCUG~100 dsRNA is lethal in the S1 line.  
B)  Co-expression of dicer2 together with hADAR1-i does not affect the patterning of the eye.    
B’) hADAR1-i rescues lethality and eye phenotype in S1 flies co-expressing rCAG.rCUG~100 dsRNA 
and dicer2 in the eye. 
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Figure S6 [relates to Fig 3] 
 
qRT-PCR levels of uncleaved repeat transcripts in rCAG.rCUG~100 dsRNA flies with co-over-
expression of Drosophila or human ADAR proteins.  
 
qRT-PCR levels of GMR-GAL4 driven expression levels of repeat transcript in (A) three independent 
rCAG.rCUG~100 dsRNA lines compared to rCAG.rCUG~100 dsRNA lines co-expressing either (B) 
Drosophila dADAR-3/4 or (C) human hADAR1-i or (D) hADAR2 (samples as per Figure 2 A’, C’, F’ 
and G’). Repeat expression is measured relative to Rp49. 
 
    A                      B              C             D 
 
 
   
883
van Eyk et al  ‘Non-self’ Mutation in Expanded Repeat Neurodegenerative Diseases 8 




Figure S7A: Ectopic expression of CrPV1A completely rescues dsRNA-mediated pathology. 
In each case the GMR-GAL4 driver is used to express the constructs in the eye. A) Expression of a single 
UAS transgene with no insert as a control eye. B-C) Expression of two independent full-length (FL) UAS-
CrPV1A constructs alone. D-E) Expression of two independent truncated UAS-CrPV1A mutant constructs 
alone. A’) Co-expression of repeat dsRNA together with a single UAS transgene. B’-C’) Co-expression of 
repeat dsRNA together with two independent full-length (FL) UAS-CrPV1A constructs. D’-E’) Co-
expression of repeat dsRNA together with two independent truncated UAS-CrPV1A mutant constructs. The 
full length CrPV1A encodes a 148 amino acid long protein. The truncated CrPV1A encodes a 108 amino 
acid long protein. The experiment was performed at 25°C using the CAG.CUG~100M3 dsRNA line.  
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Figure S7B – Sequence alignment of Cricket Paralysis Virus 1A coding sequences  
 
Alignment of the PCR generated sequence from the constructs encoding full length 148 amino acid 




NC_003924.1      TCCCTTTGATGTGAGCTAATAAGGAGTAACCGATTCTTACAATGTGATCATGTCTTTTCA 
BB17F_G05        CCCCCT--------------------------------------TCACCATGTCTTTTCA 
BB20F_G07        CCCCCT--------------------------------------TCACCATGTCTTTTCA 
                  *** *                                      * * ************ 
 
NC_003924.1      ACAAACAAACAACAACGCAACCAACAACATCAACTCCCTTGAGGAGCTTGCTGCTCAAGA 
BB17F_G05        ACAAACAAACAACAACGCAACCAACAACATCAACTCCCTTGAGGAGCTTGCTGCTCAAGA 
BB20F_G07        ACAAACAAACAACAACGCAACCAACAACATCAACTCCCTTGAGGAGCTTGCTGCTCAAGA 
                 ************************************************************ 
 
NC_003924.1      ACTAATAGCAGCACAATTTGAAGGAAATCTTGATGGTTTCTTTTGCACTTTTTATGTGCA 
BB17F_G05        ACTAATAGCAGCACAATTTGAAGGAAATCTTGATGGTTTCTTTTGCACTTTTTATGTGCA 
BB20F_G07        ACTAATAGCAGCACAATTTGAAGGAAATCTTGATGGTTTCTTTTGCACTTTTTATGTGCA 
                 ************************************************************ 
 
NC_003924.1      GTCCAAACCACAACTATTGGACTTAGAGAGTGAATGTTATTGTATGGATGATTTTGATTG 
BB17F_G05        GTCCAAACCACAACTATTGGACTTAGAGAGTGAATGTTATTGTATGGATGATTTTGATTG 
BB20F_G07        GTCCAAACCACAACTATTGGACTTAGAGAGTGAATGTTATTGTATGGATGATTTTGATTG 
                 ************************************************************ 
 
NC_003924.1      TGGGTGTGATAGGATCAAGAGAGAAGAAGAATTACGTAAACTGATTTTCTTAACATCGGA 
BB17F_G05        TGGGTGTGATAGGATCAAGAGAGAAGAAGAATTACGTAAACTGATTTTCTTAACATCGGA 
BB20F_G07        TGGGTGTGATAGGATCAAGAGAGAAGAAGAATTACGTAAACTGATTTTCTTAACATCGGA 
                 ************************************************************ 
 
NC_003924.1      CGTTTATGGATATAACTTTGAAGAGTGGAAAGGATTAGTTTGGAAATTTGTTCAAAATTA 
BB17F_G05        CGTTTATGGATATAACTTTGAAGAGTGGAAAGGATTAGTTTGGAAATTTGTTCAAAATTA 
BB20F_G07        CGTTTATGGATATAACTTTGAAGAGTGGAAAGGATTAGTTTGGAAATTTGTTCAAAATTA 
                 ************************************************************ 
 
NC_003924.1      TTGCCCAGAACATCGATATGGATCAACTTTTGGTAATGGATTATTAATTGTGAGTCCCCG 
BB17F_G05        TTGCCCAGAACATCGATATGGATCAACTTTTGGTAATGGATTATTAATTGTGAGTCCCCG 
BB20F_G07        TTGCCCAGAACAT----------------------------------------------- 
                 *************                                                
 
NC_003924.1      TTTCTTTATGGATCATCTTGACTGGTTTCAGCAATGGAAACTTGTTTCAAGTAATGATGA 
BB17F_G05        TTTCTTTATGGATCATCTTGACTGGTTTCAGCAATGGAAACTTGTTTCAAGTAATGATGA 
BB20F_G07        ------------------------------------------------------------ 
                                                                              
 
NC_003924.1      ATGCAGAGCCTTCTTGAGAAAGAGAACGCAACTTTTGATGAGTGGTGATGTCGAATCTAA 
BB17F_G05        ATGCAGAGCCTTC------------------------AAGGGTGG--------------- 
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Figure S8 – Verification of genotypes of Drosophila lines by PCR 
 
Gel electrophoresis of PCR products using oligodeoxynucleotide primers specific for the genes 
indicated (see Table S2 for oligodeoxynucleotide sequences). All PCR products (indicated by vertical 
red arrows) are of the anticipated size as predicted by the distance apart of oligodeoxynucleotide 
primers. 
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Figure S9 – Graphical Abstract of ‘Non-Self’ Mutation and Experiments in the Drosophila 
model of expanded CAG repeat diseases. 
 
          
 
Abbreviations 
RLR-PRRs  = RNA binding RIG-I-like pattern recognition receptors 
Dicer, Ago = components of RNAi and antiviral RNA recognition and defense pathways 
R2D2, loqs = components of RNAi pathway 
21mers = RNA comprised of 7 copies of the CAG repeat (typical RNAi product) 
ADAR1  = human adenosine deaminase of RNA 
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log2 (ratio)        
dsRNA vs control 
Experiment 1 elavII-GAL4 
miR-932  4732.415 317.347 -3.898 
miR-7  17414.671 2742.788 -2.667 
miR-34  1153.333 238.882 -2.271 
miR-988  3894.429 1272.877 -1.613 
miR-317  4897.807 1802.952 -1.442 
miR-100  10042.600 4238.855 -1.244 
miR-8  15573.307 7551.822 -1.044 
miR-125  4245.060 2476.007 -0.778 
miR-184  4963.964 3145.576 -0.658 
miR-274  3391.638 2174.353 -0.641 
miR-34*  1503.964 985.172 -0.610 
miR-279  26039.310 17696.478 -0.557 
let-7  4099.515 2915.411 -0.492 
miR-133  1874.442 1340.880 -0.483 
bantam  36736.862 27408.704 -0.423 
miR-970  8893.677 7046.159 -0.336 
miR-263b  2059.681 1644.278 -0.325 
miR-263a  9436.163 11567.488 0.294 
pre-miR-34 14594.186 19869.087 0.445 
pre-miR-193 6538.495 9705.251 0.570 
pre-miR-263a  793.881 1332.162 0.747 
miR-1017  2002.345 3658.214 0.869 
Experiment 2 elavc155-GAL4 
miR-184 48388.914 9845.824 -2.297 
miR-274 5763.316 2064.591 -1.481 
pre-miR-34 16768.186 9640.060 -0.799 
miR-957 4220.718 2613.293 -0.692 
miR-278 4210.636 3063.587 -0.459 
miR-263b 2973.029 2317.074 -0.360 
miR-995 1406.486 1111.321 -0.340 
pre-miR-193 5060.073 3998.965 -0.340 
miR-932 2283.649 1820.061 -0.327 
miR-285 12319.355 10111.228 -0.285 
miR-1003 7356.325 6058.586 -0.280 
miR-193 3916.988 3247.482 -0.270 
miR-1017 917.493 1204.759 0.393 
miR-987 986.809 1305.156 0.403 
miR-87 1616.955 2585.461 0.677 
miR-317 9278.270 15641.987 0.753 
miR-133 1305.663 2667.965 1.031 
let-7 12081.160 26889.387 1.154 
pre-miR-210 142.413 1010.924 2.828 
pre-miR-284 148.714 1475.134 3.310 
miR-210 1192.236 22028.601 4.208 
bantam 520.501 15582.345 4.904 
miR-34 37.809 14031.665 8.536 
 
The miRNA with common changes in both experiments are shown in bold. ie. Those with a ±1.2 fold change, between dsRNA and the 
control sample, and a minimum of 1000 reads per million in at least one of the samples (control or dsRNA within an experiment).  
 Control= 4xUAS, dsRNA in Experiment 1= rCAG.rCUG~100S1, dsRNA in Experiment 2= rCAG.rCUG~100S2.  
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Methods for Table S1  
Alterations of miRNA profiles were analysed using the data sets generated by deep sequencing of flies 
expressing expanded repeats throughout the nervous system.  Briefly, in Experiment 1 the elavII-GAL4 
driver was used to express rCAG.rCUG~100S1 (dsRNAS1), rCAG~100#1 and rCUG~100#1 whereas in 
Experiment 2, rCAG.rCUG~100S2 (dsRNAS2) was expressed using the elavC155-GAL4 driver. In each 
experiment the small RNA population was sequenced in each of the repeat expressing samples using 
Illumina small RNA sequencing and was compared to each driver with no repeat expression (4xUAS-
control). Independent pan-neuronal drivers together with independent rCAG.rCUG~100 lines were used 
with the expectation of identifying miRNA changes that can be replicated using different genetic 
backgrounds to exclude biological and experimental artefacts in order to obtain robust changes caused 
by dsRNA.  
 
The sequencing analysis produced between 1.5-2.6 million reads that were uniquely mapped to the 
Drosophila genome (BDGP 5.0, 2006). These reads were then mapped to the annotated miRNA 
precursors (D.melanogaster miRBase version 14).  Reads mapping to multiple precursors (pre-miR) 
were further analysed to identify the ‘best match’ based on the longest alignment. These reads were 
further matched to the annotated mature miRNA sequence or predicted star sequence (miRNA*). 
Reads that did not map to miRNA precursors were removed from the analysis. The total number of 
reads mapping to miRBase was normalised across the samples to allow comparison.  
 
Significant changes in miRNA abundance were identified based on two parameters. Firstly the 
complete list was filtered to include miRNAs that recorded a minimum of 1000 reads in at least one of 
the samples (control or dsRNA within an experiment). This list was then filtered based on fold change 
between the samples. Additionally, in Experiment 1 miRNAs that were significantly changed in either 
rCAG~100#1 or rCUG~100#1 compared to the control were excluded, in order to generate a list of altered 
miRNAs that are unique to double-stranded RNA expression.  
 
In order to identify common changes to the miRNA profile between the two experiments, these 
analyses were expanded to include miRNAs with a log2 (ratio) of >+0.26 or <-0.26; that is a ±1.2 fold 
change, between dsRNA and the control sample, and a minimum of 1000 reads in at least one of the 
samples (control or dsRNA within an experiment) was included. This generated a list of 22 and 23 
miRNAs with a significant change in abundance in the two experiments respectively. miR-184, miR-
263b, miR-274 and miR-932 are decreased and miR-1017 is increased in dsRNA compared to the 
control in both Experiment 1 and 2, indicating the potential for a functionally relevant effect, 
independent of the different genetic backgrounds used in the two experiments.  
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Table S2 
Oligodeoxynucleotide primers utilized for verification of genotypes of Drosophila lines.  
A common (pUAST forward) primer was used for each PCR in conjunction with a unique reverse 
primer as indicated. 
 
Primer name Sequence (5’-3’) 
pUAST forward GAAGAGAACTCTGAATAGGG 
R2D2 reverse GGACGCAGTAGTCACGCAG 
hADAR1 reverse GCCATTGTAATGAACAGGTGGTT 
hADAR2 reverse CCCACGTAAAAGGGAGGCTC 
dADAR reverse AGAACTGCTCCATCCTTAAACTG 
pUASp forward GGCAAGGGTCGAGTCGATAG 
pUASp reverse AGGTTTAACCAGGGGATGCT 
pUASp sequencing forward  CAAGGGTCGAGTCGATAG 
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Previously, we hypothesized that an RNA-based pathogenic pathway has a causal role in the
dominantly inherited unstable expanded repeat neurodegenerative diseases. In support of
this hypothesis we, and others, have characterized rCAG.rCUG100 repeat double-strand
RNA (dsRNA) as a previously unidentified agent capable of causing pathogenesis in a
Drosophila model of neurodegenerative disease. Dicer,Toll, and autophagy pathways have
distinct roles in this Drosophila dsRNA pathology. Dicer dependence is accompanied by
cleavage of rCAG.rCUG100 repeat dsRNA down to r(CAG)7 21-mers. Among the “molecular
hallmarks” of this pathway that have been identified in Drosophila, some [i.e., r(CAG)7
and elevated tumor necrosis factor] correlate with observations in affected people (e.g.,
Huntington’s disease and amyotrophic lateral sclerosis) or in related animal models (i.e.,
autophagy). The Toll pathway is activated in the presence of repeat-containing dsRNA and
toxicity is also dependent on this pathway. How might the endogenously expressed dsRNA
mediateToll -dependent toxicity in neuronal cells? Endogenous RNAs are normally shielded
fromToll pathway activation as part of the mechanism to distinguish “self” from “non-self”
RNAs. This typically involves post-transcriptional modification of the RNA. Therefore, it is
likely that rCAG.rCUG100 repeat dsRNA has a characteristic property that interferes with
or evades this normal mechanism of shielding. We predict that repeat expansion leads
to an alteration in RNA structure and/or form that perturbs RNA modification, causing
the unshielded repeat RNA (in the form of its Dicer -cleaved products) to be recognized
by Toll -like receptors (TLRs), with consequent activation of the Toll pathway leading to
loss of cell function and then ultimately cell death. We hypothesize that the proximal
cause of expanded repeat neurodegenerative diseases is theTLR recognition (and resultant
innate inflammatory response) of repeat RNA as “non-self” due to their paucity of “self”
modification.
Keywords: RNA pathogenesis, Toll-like receptor, innate inflammation, expanded repeat diseases, neuro-
degeneration
INTRODUCTION
Since the first discovery of trinucleotide repeat expansion as the
basis for many important human genetic diseases (Kremer et al.,
1991; La Spada et al., 1991; Yu et al., 1991; Richards and Suther-
land, 1992), there has been a vast amount of research in this
area (PubMed search “trinucleotide repeat disorders” gives >3,700
results). Much of this research is aimed at identifying the mech-
anism of pathogenesis underlying diseases caused by this form
of mutation. Individual diseases can follow either dominant or
recessive mode of inheritance indicating distinct pathogenic path-
ways. Repeat sequences that are expanded in copy number are
the basis for ∼20 dominantly inherited neurodegenerative dis-
eases, including Huntington’s disease (HD). Despite some of the
responsible genes being identified as long as 20 years ago, the iden-
tity and nature of the disease-causing pathogenic pathway remains
a gap in knowledge for these diseases, i.e., no definitive molecu-
lar pathway from the mutation to the clinical symptoms has yet
been identified. For at-risk individuals in families affected with
dominantly inherited late-onset neurodegenerative diseases due
to expanded repeats, the majority opt not to have the definitive
pre-symptomatic diagnostic test. Their preference is to live with
the uncertainty of not knowing, than the certainty of getting the
disease, as no treatments are yet available. Therefore, determin-
ing the pathogenic pathway and identifying therapeutic targets for
intervention is an urgent priority for reducing the impact of these
devastating diseases. This understanding is essential for rational
approaches to delay onset, slow progression, or ultimately effect
cure.
MOLECULAR PATHWAY FROM REPEAT EXPANSION TO
DISEASE
There are common properties exhibited by the various repeat
expansions that give rise to human disease. The vast majority
of these diseases originate from an existing repeat sequence that
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exhibits copy number variation in the human population. In each
case, the disease alleles arise when copy number increases beyond
a critical threshold. The repeat composition varies, but most are
trinucleotide repeats. In some diseases, the repeat expands to
the point where gene expression at the expanded repeat locus is
either substantially reduced or lost altogether, resulting in loss-
of-function of the repeat-harboring gene. Typically such diseases
are inherited in a recessive manner. Many repeat loci, however,
give rise to dominantly inherited diseases in a manner that is
not gene-dose dependent (i.e., two mutant alleles are no worse,
and may be even better than one – see Carroll et al., 2013). This
suggests that gain-of-function is the mechanism rather than hap-
loinsufficiency. Repeat copy number in many cases is a major
determinant of age at onset of clinical symptoms (referred to as
“anticipation”) indicating that the repeat itself is a rate-limiting
determinant of the pathogenic pathway. However, since pathology
typically involves cell death and there are many ways in which cells
die, identification of the disease-causing “toxic agent” has been
problematic.
IS THERE A COMMON PATHOGENIC AGENT?
The unstable expanded repeat diseases (Figure 1) typically man-
ifest as neurodegenerative and/or muscular diseases, some with
a high degree of clinical overlap, despite affecting distinct pro-
teins and unrelated loci. Where expanded repeats are translated,
they generally code for polyglutamine; however, the proteins
in which they are located are all unrelated in the remainder
of their amino-acid sequence. Therefore, much attention has
been focused on expanded polyglutamine as the common basis
of pathology (McLeod et al., 2005; van Eyk et al., 2011, 2012).
Some of these diseases, however, have repeat expansions located
within untranslated RNAs and/or arise from repeat sequences
that cannot encode polyglutamine (Figure 1; Richards, 2001; La
Spada and Taylor, 2010). Despite these significant differences in
the location of the repeat in this family of diseases they exhibit
overlapping symptoms resulting from neuronal loss of function
and/or neurodegeneration. In addition, in most cases the polyglu-
tamine and “untranslated” diseases have similar disease allele copy
number repeat thresholds (HD CAG > 36, SCA17 CAG > 47,
FXTAS CGG > 55, HDL2 CUG > 44, DM1 CUG > 50, SCA12
CAG > 66). This suggests that there may be a common pathogenic
agent or agents in the translated and untranslated repeat diseases.
RNA MAY BE PATHOGENIC IN TRANSLATED REPEAT
DISEASES
While there is growing consensus that RNA plays a causal role in
“non-coding repeat expansion disorders,” its contribution when
the repeat is located in coding regions (specifically polyglutamine
disorders) is more controversial (Fiszer and Krzyzosiak, 2013). Yet
even here there is evidence that RNA is key. For example, inter-
mediate copy number CAG alleles of SCA2 that are below the
threshold required to encode aggregate forming polyglutamine,
increase the risk of amyotrophic lateral sclerosis (ALS; Elden et al.,
2010). Furthermore, interruption of CAG repeat with CAA dra-
matically mitigates polyglutamine toxicity in a Drosophila model
of SCA3 (Li et al., 2008).
It is possible that multiple pathways (at least one of which
is RNA mediated) contribute to progression of expanded repeat
neurodegenerative diseases. In support of this possibility, ALS
and SCA7 both appear to involve two cell types (nerve cells
and glial cells; Furrer et al., 2011; Polymenidou and Cleveland,
2011). Astrocytes and glial cells have both been shown to affect
their neighboring neurons in individuals with repeat expan-
sions, leading Ilieva et al. (2009) to hypothesize that the onset
of the disease is determined in the nerve cell, and the progres-
sion of the disease determined in adjacent glial(-like) cells. But
FIGURE 1 | Location of expanded repeats in disease genes. SCA, spinocerebellar ataxia (multiple loci numbered); FXTAS, fragile X tremor ataxia syndrome;
ALS, amyotrophic lateral sclerosis; FTLD, frontotemporal lobar dementia; SBMA, spinobulbar muscular atrophy; DRPLA, dentatorubral-pallidoluysian atrophy.
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importantly, there is consistent evidence implicating RNA as of
principle importance as the originating causal event that initiates
pathology.
MECHANISMS OF RNA-INITIATED PATHOLOGY
What precedents and potential mechanisms are there for RNA to
initiate pathogenesis in human diseases? See Figure 2.
SINGLE-STRANDED RNA TOXICITY
Precedence for expanded repeat RNA being a disease-causing
entity in its own right first came from the DM1 and DM2 repeat
expansions that both give rise to myotonic dystrophy (Ranum and
Day, 2004). The repeat expansions in these diseases are similar,
but importantly, not identical (CUG vs. CCUG) and are located in
untranslated regions (3′UTR or intron) of two otherwise unrelated
genes (DMPK and ZNF9). In muscle cells, RNAs from expanded
alleles of either repeat are able to bind and sequester alternative
splicing factors (muscleblind and CUG-BP) and in so doing, per-
turb the splicing pathways of proteins for which alternative splicing
is a necessary step for their complete range of functions (Mankodi
et al., 2002; Ranum and Day, 2004). It is now generally accepted
that RNA is the common pathogenic agent in these diseases most
likely through its impact on alternative splicing, although this
has recently been challenged with evidence that GSK3β mediates
at least some aspects of the RNA-based pathology in myotonic
dystrophy (Jones et al., 2012) and in a Drosophila model (van Eyk
et al., 2011).
Evidence for a more widespread role for RNA in neurodegener-
ative diseases has been steadily accumulating. SCA31 and SCA36
are due to large expansions of de novo 5 bp TGGAA repeat and an
existing 6 bp GGCCTG repeat, respectively – both located within
introns of different genes (Sato et al., 2009; Kobayashi et al., 2011).
An expanded GGGGCC repeat has recently been found to cause a
substantial proportion of cases of ALS and frontotemporal lobar
dementia (FTLD; DeJesus-Hernandez et al., 2011; Renton et al.,
2011). As indicated by others (Orr, 2011) “The location of this
repeat within an intron of the C9ORF72 gene along with some
evidence for alternative splicing of C9ORF72 transcripts brings
in to play a prominent aspect of non-coding repeat expansion
disorders – the role of RNA metabolism in pathogenesis.”
REPEAT ASSOCIATED NON-AUG TRANSLATION
The hairpin structure of expanded repeat RNA is such that it can
enable the initiation of translation in the absence of the normal
requirement of an AUG start codon (Zu et al., 2011). Although
this mechanism involves conversion of the RNA into peptides,
thereby rendering the RNA no longer “untranslated,” the phe-
nomenon can occur to RNA sequences that do not normally
appear in protein-coding sequences, i.e., RNA from introns or
5′ or 3′ untranslated regions of mRNAs. The resultant translated
FIGURE 2 | Competing hypotheses of expanded repeat disease
pathogenic pathways involving RNA. (1) RNA sequestration – via
alternative splicing (Mankodi et al., 2002; Ranum and Day, 2004) or
Akt/GSK3β pathway (van Eyk et al., 2011; Jones et al., 2012; Lawlor et al.,
2012). (2) RAN (repeat associated non-AUG) Translation (Zu et al., 2011;
Ash et al., 2013; Mori et al., 2013; Todd et al., 2013). (3) Toll “self”
RNA recognition (Lawlor et al., 2011; Yu et al., 2011; Samaraweera et al.,
(2013)).
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polypeptides can initiate from within the repeat sequence and in
any reading frame, therefore, a single strand containing repeat
RNA sequence can encode three different polypeptide sequences.
Since expanded repeat sequences are typically located in regions of
bi-directional transcription (Batra et al., 2010), the resultant tran-
scripts from both strands potentially enable the production of six
different peptide sequences, any of which may be toxic to the cell.
Such polypeptides have now been detected in pathology specimens
from individuals affected with a number of different expanded
repeat diseases including DM1, fragile X syndrome (FRAXA) and
ALS/FTLD (Zu et al., 2011; Ash et al., 2013; Mori et al., 2013; Todd
et al., 2013). Of particular note, two recent publications (Ash et al.,
2013; Mori et al., 2013) have identified repeat associated non-AUG
(RAN)-translation of the GGGGCC expanded repeats that cause
ALS/FTLD into polypeptides that also form aggregates in affected
tissues. However, these aggregates are confined to nerve cells and
are absent from adjacent glial cells that are also involved in the
pathology. On the other hand, the absence of visible aggregates
does not prove the absence of toxic peptides.
These RAN translation results have suggested that an aggre-
gate polypeptide analogous to polyglutamine could be neurotoxic
in diseases where the causative repeat expansion cannot encode
polyglutamine. However, this is doubtful in the cases of ALS and
FTLD because of the observations that mutations in either of two
RNA-binding proteins, FUS and TDP-43, can also cause disease
(Rutherford et al., 2008; Van Langenhove et al., 2010). In individu-
als affected due to these mutations, no such expanded polyGly-Pro
polypeptide is evident, therefore while polyGly-Pro may lead to
subtle differences in pathology (Ash et al., 2013; Mori et al., 2013),
it appears to play a modifying role at most.
Furthermore, inhibition of an RNA lariat debranching enzyme
has recently been shown to suppress TDP-43 toxicity in ALS dis-
ease models (Armakola et al., 2012). These observations reinforce
the view that RNA has a central role to play in this disease. While
the role of such polypeptides in disease pathogenesis is unclear,
for example, whether their aggregation may actually be protec-
tive rather than pernicious, they are a curious set of products
driven by the unusual structure of expanded repeat RNAs. One
possibility is that rather than the homopolymeric polypeptides
themselves being toxic, the initiation of translation within the
repeats could give rise to N-terminal truncated proteins devoid
of upstream functional domains that could then act as domi-
nant negative competitors for the full-length functionally intact
proteins.
DOUBLE-STRANDED EXPANDED REPEAT RNA IS PATHOGENIC
Drosophila models of expanded repeat diseases have been
described that specifically investigate the intrinsic toxicity of both
translated and untranslated expanded repeat sequences (Lawlor
et al., 2011; van Eyk et al., 2011, 2012; Samaraweera et al., 2013).
In one study (Lawlor et al., 2011), a single line of Drosophila
expressing untranslated CAG was identified with a marked degen-
erative phenotype (whereas multiple other random insertion lines
of the same transgene had no such phenotype). Upon detailed
characterization, this degenerative phenotype line was found to
have the repeat transgene inserted into an endogenous gene
(cheerio) in the opposite orientation to normal transcription.
Transcripts containing expanded repeats would, therefore, orig-
inate from both strands via bi-directional transcription. This
finding coincided with numerous reports in the literature that
expanded repeat disease loci are typically transcribed from both
DNA strands (see Batra et al., 2010). Therefore, this Drosophila
line mimicked a previously uncharacterized property of these
disease genes. Bi-directional transcription was subsequently mod-
eled in a controlled manner by co-expression from two different
transgenes of expanded rCAG∼100 together with rCUG∼100 [giv-
ing rise to rCAG.rCUG∼100 or double-strand RNA (dsRNA)]
to produce repeat-containing dsRNA (Lawlor et al., 2011). Flies
expressing dsRNA showed Dicer-dependent toxicity. Addition-
ally dsRNA expression throughout the nervous system caused
an age-dependent neurodegenerative phenotype. An abundance
of r(CAG)7 also implicated specific Dicer processing of the
rCAG.rCUG∼100 dsRNA as a pathogenic pathway in this model
(Lawlor et al., 2011). Similar findings have also been reported
in an independent Drosophila model (Yu et al., 2011). There are,
with all animal models, caveats. In order to manifest a phenotype
in the time frame of laboratory experiments, these Drosophila
(and other animal) models employ copy numbers well in excess
of those that cause pathology (after several decades) in some of
these diseases. This is thought to be due to an inverse relation-
ship between repeat copy number and age-at-onset, the basis of
which could be somatic repeat instability over time (see Figure 2
in Richards, 2001 and Swami et al., 2009). Furthermore, the
level of expression of the repeat RNAs required to give an early
phenotype in animal models (Lawlor et al., 2011; Yu et al., 2011)
may be well in excess of that of the endogenous human disease
gene. Importantly, however, examination of HD patient samples
(Bañez-Coronel et al., 2012) revealed the presence of the same
r(CAG)7 cleavage product seen in the Drosophila models, pro-
viding evidence in support of the activity of this pathway in HD
pathogenesis.
In an effort to identify further components of expanded
repeat RNA pathogenesis in Drosophila, microarray analyses of
Drosophila expressing rCAG.rCUG∼100 dsRNA have been under-
taken (Samaraweera et al., 2013). Changes in transcription profiles
revealed candidate pathways for mediating the resultant patho-
genesis. Alterations in transcripts common to several pathways
were detected, including components of inflammation and innate
immunity. Hallmarks of immune activation, including elevated
plasma tumor necrosis factor (TNF), appear prior to clinical
symptoms of dominantly inherited expanded repeat human dis-
eases (Moreau et al., 2005; Björkqvist et al., 2008). Therefore, the
Drosophila model expressing rCAG.rCUG∼100 dsRNA was utilized
to test two key elements of immune activation – the Toll and
autophagy pathways for their contribution to expanded repeat
RNA pathogenesis. Toll signaling pathway was identified as essen-
tial for dsRNA pathogenesis and autophagy was found to reduce
toxicity in this model (Samaraweera et al., 2013). Furthermore,
multiple reports implicate glial cells in the pathology of expanded
repeat diseases. Neurons are dependent upon glial cell function
that includes the destruction and removal of the carcasses of dead
neurons. The rCAG.rCUG∼100 dsRNA was found to impact nerve
cell function even when exclusively expressed in glial cells (Sama-
raweera et al., 2013), providing evidence that dsRNA pathology in
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Drosophila is, like the human expanded repeat diseases, non-cell
autonomous (Ilieva et al., 2009; Furrer et al., 2011).
The requirement for Toll signaling pathway in this Drosophila
model is intriguing. Toll-like receptors (TLRs) function in nor-
mal biology to protect an organism from infection by viruses and
bacteria. They recognize foreign pathogen molecules including
DNA and RNA through specific receptors (such as endosomal
TLR3) and can distinguish these nucleic acids (as “non-self”)
from the endogenous nucleic acids (“self”). Therefore, while the
rCAG.rCUG∼100 dsRNA is being expressed endogenously in this
Drosophila model, it is being recognized by the Toll signaling path-
way as foreign or “non-self” – a recognition that then activates
innate inflammatory regulatory pathways, ultimately leading to
cell death.
PATHOGENIC MUTATIONS IN PROTEINS THAT
FUNCTIONALLY INTERACT WITH RNA
While it can be difficult to ascribe specific functions to RNA in
pathogenic pathways, there are some noteworthy instances of
disease-causing mutations in proteins that functionally interact
with RNAs. By implication, the RNAs that these proteins normally
act upon are, therefore, likely contributors to and/or mediators of
the relevant pathogenic process.
RNA-BINDING MOTIFS – THE RNAS THAT HAVE THEM AND THE
PROTEINS THAT RECOGNIZE THEM
Recent discoveries regarding the importance of RNA–protein
recognition in disease pathogenesis have led to a renewed inter-
est in the role that these interactions play in biological processes.
While they have long been recognized as key regulators of gene
expression, only a small fraction have been functionally charac-
terized. A recent compendium of RNA-binding motifs (Ray et al.,
2013) highlighted both the significance and scope of these interac-
tions. The human genome encodes at least 400 known or predicted
RNA-binding proteins with a diverse array of RNA sequence-
binding motifs. Indeed the number of such human RNA-binding
proteins appears to be much higher than this, with 860 identified
in HeLa cells alone (Castello et al., 2012). The scope and specificity
of RNA recognition is determined both by the number and vari-
ety of RNA-binding proteins and by the number and variety of
RNA-sequence motifs that they bind.
FRAGILE X SYNDROME IS DUE TO LOSS OF RNA-BINDING PROTEIN
FUNCTION
Fragile X syndrome is a striking example of the role of an RNA-
binding protein in human disease. FRAXA is due to the expanded
CGG repeat that is responsible for the FRAXA rare, folate-sensitive
chromosomal fragile site (Kremer et al., 1991), located in the
5′UTR of the FMR1 gene (Verkerk et al., 1991). Expansion of the
repeat beyond ∼230 copies results in inactivation of the gene and
consequent loss of encoded FMRP (fragile X mental retardation
protein) function (Pieretti et al., 1991). The FMRP is an RNA-
binding protein with KH- and RGG-binding motifs (Ashley et al.,
1993). The loss of function of this protein is responsible for the
clinical symptoms as rare cases of point mutation or deletion of
the FMR1 gene have similar clinical symptoms. Indeed one of
these pathogenic point mutations is at a highly conserved amino
acid in a KH domain of FMRP highlighting the significance of
the role of RNA interaction in FMRP function (De Boulle et al.,
1993). The FMRP has an impact on the translation of the mRNAs
with which it interacts (Darnell et al., 2001) and, therefore, its
absence leads to the dysregulation of the translation of these spe-
cific mRNAs. This is thought to be the proximal cause of the
symptoms of FRAXA.
THE INTRIGUING PATHOGENESIS OF AICARDI–GOUTIÈRES SYNDROME
Aicardi–Goutières syndrome (AGS) is a genetically heterogeneous
disorder that is due (at least in a substantial proportion of cases)
to the mutation of various nucleic acid-metabolizing enzymes,
including various subunits of ribonuclease H2 or the RNA-editing
enzyme ADAR1 (see Crow and Rehwinkel, 2009 and OMIM
#225750). AGS is characterized, in its more severe forms, by severe
neurological dysfunction in infancy that includes progressive
microcephaly, spasticity, dystonic posturing, profound psychomo-
tor retardation, and often death in early childhood (OMIM
#225750) (Figure 3). In its milder forms, these neurological
symptoms are diminished or even absent, but peripheral symp-
toms outside the nervous system are common to the phenotypic
spectrum and include thrombocytopenia, hepatosplenomegaly,
and elevated hepatic transaminases along with intermittent fever.
Chilblains are also a typical feature. Together these symptoms
demonstrate phenotypic overlap both with systemic lupus ery-
thematosus and with the sequelae of congenital infection (Crow
and Rehwinkel, 2009). The disease, therefore, appears to be due to
defects in the processes that remove and/or modify endogenous
nucleic acids. These endogenous unmodified nucleic acids then
accumulate and are sensed as “non-self” by TLRs, that, in turn,
activate innate inflammatory regulatory pathways. This bears a
striking resemblance to mechanisms we have identified as respon-
sible for dsRNA pathogenesis in the Drosophila model of expanded
repeat neurodegenerative diseases.
HYPOTHESIS
EXPANDED REPEAT RNAS AS PATHOGENIC AGENTS BY TOLL “SELF”
RNA RECOGNITION
Repeat RNA sequences represent a pivotal point of potential weak-
ness in processes that utilize RNA–protein recognition, as the
repeat RNA sequence will harbor either a paucity or excess of
sequence-binding motifs. Expansion of repeat RNA sequences,
therefore, clearly has the potential to give rise to too much or too
little of an interaction that is a rate-limiting factor in a crucial bio-
logical process. RNA modification is one process that is sequence
motif-dependent and known to be key to the distinction between
“self” and “non-self” by components of the innate immune path-
ways. Indeed, it has been shown that exogenous “non-self” RNAs
require in vitro modification in order to escape innate immune
recognition and activation when transferred in vivo (Warren et al.,
2007; Pan, 2013). The exposure of the innate immune activators to
unmodified nucleic acids, including RNA, appears to be the prox-
imal cause of AGS. We, therefore, hypothesize that this provides
a clear molecular mechanism for the ability of expanded repeat
RNA sequences, through their paucity of RNA modification, to
initiate pathogenesis in the dominantly inherited, expanded repeat
neurodegenerative diseases (Figure 4).
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FIGURE 3 | Pathogenic mutations in Aicardi–Goutières syndrome.
Mutations in genes in at least six distinct loci are able give rise to the
constellation of symptoms that defines Aicardi–Goutières syndrome. Four
of these (AGS2, AGS3, AGS4, and AGS6) are in genes that encode
RNA-metabolizing proteins. The remaining two that have been identified
(AGS1 and AGS5) are also in enzymes that have roles in nucleic acid
metabolism. Deficiencies in any one of these enzymes are thought to result
in the accumulation of endogenous nucleic acids that are sensed as
“non-self” by Toll -like receptors, that in turn activate innate inflammatory
pathways (Crow and Rehwinkel, 2009).
FIGURE 4 | Hypothesis: expanded repeat neurodegenerative diseases are
caused by theTLR recognition (and resultant innate inflammatory
response) of repeat RNA as “non-self” due to their paucity of “self”
modification that is exposed upon Dicer processing of double-strand
RNA. Open circles represent sequence motifs for RNA modifying proteins;
filled circles represent the modification of RNA at these specific sequence
motifs (e.g., by methylation or A > I editing). Dicer is required for pathology in
the Drosophila model and cleaves long high copy number repeat RNA down
to 21mers [mainly r(CAG)7 mers; Lawlor et al., 2011]. These r(CAG)7 mers are,
therefore, unmodified and recognized by TLRs as “non-self.” Toll -like receptor
pathways (most probably the endosomal TLR3 receptor) are required for
pathology (Samaraweera et al., 2013), through activation of the innate
inflammatory pathway. Autophagy reduces pathology, possibly by
metabolizing r(CAG)7 mers.
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ACTIVITY OF TOLL “SELF” RNA RECOGNITION IN
NEURODEGENERATIVE DISEASES
Double strand expanded repeat RNA pathology has been modeled
in Drosophila. What evidence is there that this pathway of TLR
recognition of expanded repeat RNA and subsequent activation
of the innate inflammatory cascade is active in the human dom-
inantly inherited neurodegenerative diseases due to expansion of
repeat sequences?
One of the key steps in dsRNA pathology is the generation
of r(CAG)7 21mers from the much greater copy number dou-
ble strand repeat RNA by Dicer. This r(CAG)7 21mer has been
identified in the brain RNA of individuals affected with HD
(Bañez-Coronel et al., 2012). The activity of Dicer is crucial to
the observed pathology in the Drosophila model (Lawlor et al.,
2011) and, therefore, it would appear that this step is a likely
proximal event in the observed phenotype. The appearance of
r(CAG)7 21mers in HD brain is therefore an important “molecu-
lar hallmark” of this pathway and a key indicator of its activity
in the human disease. Another, albeit less direct, indicator of
this pathway is seen in the increased activity of components of
the innate inflammatory response mechanism in human diseases
associated with expanded repeats. Elevated TNF is seen in the
Drosophila model as one read-out of innate immune activation
(Samaraweera et al., 2013) and both TNF and various interleukins
(i.e., IL-4, IL-5, IL-6, IL-8, and IL-10) have been found to be ele-
vated in people affected with the repeat expansion responsible for
HD even before clinical manifestation of the disease (Björkqvist
et al., 2008). Another indicator of innate immune activation in
HD is the abnormal peripheral chemokine profile that has been
observed in HD (Wild et al., 2011). Various reports indicate activa-
tion of innate adaptive immunity via TLR signaling in ALS (Casula
et al., 2011; Sta et al., 2011) – a disease that has recently been found,
at least in a proportion of instances, to be also due to an expanded
repeat (DeJesus-Hernandez et al., 2011; Renton et al., 2011).
CONCLUSION
A growing body of literature indicates a consistent asso-
ciation between innate immunity, neuroinflammation and
neurodegeneration (Shastri et al., 2013). Where there are exoge-
nous causes (e.g., trauma or infection), activation of the TLR
pathway can be attributed to an external agent (e.g., bacterial
lipopolysaccharide or viral RNA); however, a causal basis for
this relationship has not been clear when there is an endoge-
nous basis to the disease, e.g., expansion of a repeat sequence
beyond a pathogenic threshold. Recognition by the Toll receptor
pathway of expanded repeat RNA as “non-self” and consequent
activation of the innate immune inflammatory cascade pro-
vides a mechanism and a common pathogenic pathway for the
neurodegenerative diseases due to expanded repeats. This new
understanding, once proven in the relevant human diseases, will
provide new targets for intervention and ultimately, we hope, ther-
apeutic targets for drugs to delay onset and/or alleviate disease
progression.
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Neurodegenerative diseases comprise an array of progressive neurological disorders all
characterized by the selective death of neurons in the central nervous system. Although,
rare (familial) and common (sporadic) forms can occur for the same disease, it is
unclear whether this reflects several distinct pathogenic pathways or the convergence of
different causes into a common form of nerve cell death. Remarkably, neurodegenerative
diseases are increasingly found to be accompanied by activation of the innate immune
surveillance system normally associated with pathogen recognition and response. Innate
surveillance is the cell’s quality control system for the purpose of detecting such danger
signals and responding in an appropriate manner. Innate surveillance is an “intelligent
system,” in that the manner of response is relevant to the magnitude and duration of
the threat. If possible, the threat is dealt with within the cell in which it is detected,
by degrading the danger signal(s) and restoring homeostasis. If this is not successful
then an inflammatory response is instigated that is aimed at restricting the spread of the
threat by elevating degradative pathways, sensitizing neighboring cells, and recruiting
specialized cell types to the site. If the danger signal persists, then the ultimate response
can include not only the programmed cell death of the original cell, but the contents of this
dead cell can also bring about the death of adjacent sensitized cells. These responses
are clearly aimed at destroying the ability of the detected pathogen to propagate and
spread. Innate surveillance comprises intracellular, extracellular, non-cell autonomous
and systemic processes. Recent studies have revealed how multiple steps in these
processes involve proteins that, through their mutation, have been linked to many familial
forms of neurodegenerative disease. This suggests that individuals harboring these
mutations may have an amplified response to innate-mediated damage in neural tissues,
and renders innate surveillance mediated cell death a plausible common pathogenic
pathway responsible for neurodegenerative diseases, in both familial and sporadic forms.
Here we have assembled evidence in favor of the hypothesis that neurodegenerative
disease is the cumulative result of chronic activation of the innate surveillance pathway,
902
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triggered by endogenous or environmental danger or damage associated molecular
patterns in a progressively expanding cascade of inflammation, tissue damage and cell
death.
Keywords: dementia, innate autoimmunity, inflammation, neurodegeneration, Alzheimer’s, Parkinson’s,
Huntington’s
INTRODUCTION
Different chronic neurodegenerative diseases are distinguished
by the type of neurons and the regions of the brain that are
first affected. In each case the different initial symptoms and
functions lost are due to the progressive death of specific neurons.
Neurodegenerative diseases also tend to be diverse in their
timing, with some being congenital whereas others are late age-
at-onset. Those that progress, gradually exhibit commonalities.
A large number and wide variety of causes of neurodegeneration
have been identified. These range from inherited single gene
mutation effects, to environmental factors or complex mixtures
of both. It has been difficult to establish cause and effect
pathways and to reconcile how so many apparently disparate
conditions all result in similar outcomes. Either the diverse causes
trigger multiple pathogenic pathways, or alternatively they must
converge into a common mechanism of cell death and tissue
damage. Familial cases of neurodegeneration, while typically less
frequent than sporadic cases, have provided opportunities to
gain insight into the genetic factors and thereby the underlying
biological processes.
In this review we present evidence to support the hypothesis
that a common pathogenic mechanism for neurodegenerative
disease exists, and is mediated by innate surveillance-cell death.
OVERVIEW
Cell death is vital in the biology of multicellular organisms.
It is integral to tissue remodeling during development, where
programmed cell death is required to deconstruct, remove
and replace tissues. Cell death is also a vital defense strategy
in combating infection. Where cells harbor and are unable
to destroy pathogens then cell death is a means to limit
propagation and spread of the pathogen. Similarly, if a cell has
acquired somatic mutations that predispose to tumorigenesis,
then elimination by cell death is a means to neutralize the threat.
In each of these situations the innate immune surveillance system
programs the appropriate cell death pathways.
In the last few years, a growing body of literature has
appeared, pointing to innate surveillance system activity being
an early, elemental and consistent hallmark of neurodegenerative
disease. In particular recent genome wide association studies
in Alzheimer’s disease (see Table 1A) and genetic modification
studies in animal models of various neurodegenerative diseases
Abbreviations: Abbreviations: AGS, Aicardi-Goutieres Syndrome; ALS,
Amyotrophic Lateral Sclerosis; DAMPs, Danger Associated Molecular Patterns;
dAMPs, Damage Associated Molecular Patterns; FTD, Fronto-Temporal
Dementia; PAMP, Pathogen Associated Molecular Pattern; PRR, Pattern
Recognition Receptor; TLR, Toll-like Receptor; RLR, RIG-I-like Receptor.
(see Table 1B) have identified multiple components of the innate
surveillance system as genetic determinants. These findings are
inconsistent and difficult to reconcile with the prevailing theories
of neurodegenerative disease. There is now decisive evidence
supporting the hypothesis that innate surveillance mediated cell
death is a common cause, not simply a consequence, of nerve
cell death and therefore the principle causal mechanism of
neurodegenerative disease.
TABLE 1 | Innate surveillance hallmarks in human neurodegenerative
disease and their animal models.
Disease IS component(s) References/review
(A) INNATE SURVEILLANCE COMPONENTS IN HUMAN
NEURODEGENERATIVE DISEASE
AD “Innate immune” see Bettens et al., 2013;
Zhang et al., 2013
Glial cell activation see Mosher and Wyss-Coray,
2014
Astrocytosis see Rodriguez-Vieitez et al.,
2016
Various (by GWAS) Escott-Price et al., 2014
ALS Cytokines & immune Batra et al., 2016
AGS Interferon Crow, 2015; Rice et al., 2012,
2014
BSN Interferon Livingston et al., 2014
DM1, DM2 Interferon Rhodes et al., 2012
HD IL-4, 6, 8, 10, TNF Bjorkqvist et al., 2008
Multiple XBP-1 Dunys et al., 2014
Multiple Microglial priming see Perry and Holmes, 2014
PD Microglia Russo et al., 2014;
Schapansky et al., 2015
SP Interferon Crow et al., 2014
(B) INNATE SURVEILLANCE MODIFIERS/MARKERS IN ANIMAL MODELS
OF NEURODEGENERATIVE DISEASE
Disease Modifier/marker References
AD NLRP1 Tan et al., 2014
AD CD33/TREM2 Chan et al., 2015
AD CSF1R Olmos-Alonso et al., 2016
AGS (ADAR1) MDA-5 (IFIH1) Liddicoat et al., 2015; Pestal
et al., 2015
ALS (SOD1) XBP-1 Hetz et al., 2009
TLR4 Lee et al., 2015
FTD (toll, CHMP2B) Serpin5 Ahmad et al., 2009
PD (chemical) HMG-B1 Sasaki et al., 2016
PD (LRRK2) TLR4 Moehle et al., 2012
HD, SCAs TNF, drosomycin Samaraweera et al., 2013
SCA6 MyD88 Aikawa et al., 2015
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The innate surveillance and immune inflammatory response
system is a complex, highly integrated means of surveillance,
detection and response to pathogens and precancerous cells.
The current understanding of this system is almost certainly
incomplete and is the composite from studies in multiple species
and cell types that may well differ from one another in detail
(Beutler et al., 2007; Buchan et al., 2014; Liu et al., 2014; Pellegrino
et al., 2014). In the following sections we review the components
and attributes of this system from a perspective that sets a context
for its potential role in neurodegenerative disease pathogenesis.
THE INNATE IMMUNE INFLAMMATORY
RESPONSE TO PATHOGEN RECOGNITION
Innate Immune Surveillance System
Biological competition comes in various forms. In the host-
pathogen “arms race” a key requirement for host survival is
the ability to sense danger and respond appropriately. Integral
to this is the ability to distinguish “self ” from “non-self.” Such
recognition can be direct, by virtue of molecular patterns that
are either intrinsic or foreign to the host, or indirect, reflecting
the consequences of foreign intrusion, such as changes in
homeostasis or stress responses.
Activation occurs via one or more Pattern Recognition
Receptors (PRRs) that detect trigger molecules—foreign Pathogen
Associated Molecular Patterns (PAMPs) or endogenous Danger
Associated Molecular Patterns (DAMPs), the latter typically
being elevated in response to perturbation of homeostasis.
The immediate response is an escalation of appropriate
degradation pathways (e.g., autophagy) in order to eliminate
the intruder and/or restore homeostasis. Persistence of trigger
signal molecules provokes the production and release of pro-
inflammatory and anti-inflammatory cytokines, which sensitize
adjacent cells. This is followed by programmed death (by
necroptosis) of cells in which trigger molecules are detected (Wu
et al., 2012; Kaczmarek et al., 2013; Pasparakis and Vandenabeele,
2015). Cell death via necroptosis causes release of cell contents
that are recognized as Damage Associated Molecular Patterns
(dAMPs) by adjacent sensitized cells (Lu et al., 2014). In-
turn, this expands the foci of cells undergoing PRR-triggered
innate surveillance-mediated cell death. Cytokines also recruit
specialized cells to the focal response site, contributing to
its amplification, then ultimately containment and resolution
(Vanha-aho et al., 2015).
The innate surveillance system is ancient, having an integral
role in the biology of animals and plants. Its origins probably
trace back to bacteria where the defense system of restriction-
modification enabled bacteria to identify their own DNA and
selectively degrade that of an intruder. In plants and animals
the post-transcriptional modification of nucleic acids is common
(over 100 different types of modification to tRNAs alone). At
least some of this modification appears devoid of function,
other than to identify nucleic acids as belonging to the host.
Indeed, such modifications are required for exogenous mRNA to
avoid stimulating the innate surveillance response, even when its
sequence is identical to that of the endogenous mRNA (Warren
et al., 2007; Andries et al., 2013).
The selective pressure of the host-pathogen “arms race” has
seen this system both evolve rapidly and reach into most, if not
all, cellular compartments such that it monitors the surveillance
of a vast array of cellular processes. At least in some organisms,
certain elements participate in developmental processes. It is this
system that has also evolved to detect and respond to detrimental
consequences of somatic DNA mutations, such as those that can
increase the risk of neoplasia (Feng andMartin, 2015). Since such
mutations accumulate and are more likely to cause dysfunction
over time, there is good reason to think that longer-lived animals
are dependent upon this system to minimize the occurrence of
cancer, particularly later in life (Caulin and Maley, 2011). In this
regard it is noteworthy that this system appears to increase in
sensitivity with age (von Bernhardi et al., 2010).
The innate surveillance system therefore confers major
biological benefits in the front line of defense in detecting and
responding to pathogens and also in the monitoring and removal
of rogue endogenous cells that can threaten the host through
malignancy. These benefits come at a cost—in particular the
risk of bringing about the inappropriate death of host cells,
such as that seen in neurodegeneration and other examples of
inflammatory damage.
This raises the question of why some individuals and not
others are more susceptible to neurodegeneration at different
phases of the life course. It seems likely that disposition is
conferred by intrinsic errors in the system itself, i.e., mutations
in relevant genes, and/or threshold responses to environmental
factors that are detected as “danger” signals—each contributing
to cumulative risk of neurodegeneration. Importantly, the genetic
causes of neurodegenerative disease have led to the identification
of innate surveillance mediated cell death as the proximal
cause of, at least certain forms of, neurodegeneration. Many
of the genetic changes linked with neurodegeneration can be
demonstrated to specifically escalate the innate surveillance
pathway, as detailed in later sections of this review. First, it
is relevant to navigate the various cellular compartments and
systems that trigger the innate surveillance response.
Innate Surveillance—Mediated Cell Death
Sensing—Pathogen and Quality Control Sentinels
The first characterized components of the innate surveillance
system, Toll and spätzle, were initially identified for their role
in Drosophila development (Stein and Nüsslein-Volhard, 1992).
Subsequent demonstration (Lemaitre et al., 1996) that this
receptor-ligand combination also mediates antifungal responses
revealed that the innate surveillance system is not simply a
host-pathogen detection-response system, but is also integral to
normal biological processes. This functional diversity reflects the
capacity for innate surveillance to recognize specific endogenous
trigger molecules as well as foreign molecules that signal a danger
to the cell. Characterization of spätzle also revealed that activation
steps are sometimes invoked, to switch the pattern of a signal
molecule to one that is recognized by the relevant receptors
(Mizuguchi et al., 1998). More recently it has become clear that
the role of this surveillance system in development includes
cellular elimination based on cell competition and fitness (Meyer
et al., 2014).
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The sensing of pathogens occurs both directly and indirectly
in both the extracellular and intracellular compartments, the
latter as an extension of mechanisms that monitor and maintain
homeostasis. While quality control mechanisms likely exist for
all cellular compartments—that of the endoplasmic reticulum
unfolded protein response is best understood (Gardner et al.,
2013).
Endoplasmic Reticulum Stress Unfolded Protein Response
The endoplasmic reticulum (ER) interacts dynamically with
membranous structures in the cell including the Golgi apparatus,
mitochondria, peroxisomes, endosomes, lysosomes, and
autophagosomes. The ER plays a key role in protein biosynthesis
of cellular components and therefore it is a target for pathogens
seeking to co-opt this capacity for replication, as well as being a
risk site for the synthesis of aberrant proteins that can contribute
to tumourigenesis. Newly synthesized proteins entering the ER
are either folded into their required conformation for targeting
to organelles or identified as unfolded and are then destined for
degradation.
The unfolded protein response (UPR)monitors andmaintains
protein-folding homeostasis within the ER (Gardner et al., 2013;
Senft and Ronai, 2015). Yeast experiments demonstrate that this
ancient system comprises sentinel sensors (Gardner et al., 2013).
In the ER, proteins that exceed the protein-folding capacity
activate three stress sensor proteins—IRE1α, PERK, and ATF6.
At least one of these sentinels has evolved to trigger the innate
surveillance system. IRE1 is present in all eukaryotes and conveys
the UPR response to the innate surveillance system. IRE1α
cleaves endogenous XBP1 mRNA to remove an intron, enabling
the resultant mRNA to encode the active form of the XBP1
transcription factor, that in turn stimulates expression of proteins
involved in restoration of proteostasis, as well as cytokine
synthesis (Zeng et al., 2010). Cleavage of the XBP1 intron causes
the RNA to acquire an unusual 3′ cyclic phosphate that enables
its recognition as a DAMP by RIG-I, a cytosolic PRR of the innate
surveillance system (Cho et al., 2013; Eckard et al., 2014). Recent
studies reveal that this intron RNA is an endogenous DAMP
in Aicardi-Goutieres Syndrome, a congenital neurodegenerative
disease caused by mutation in one of a number of nucleic acid
metabolizing enzymes (Eckard et al., 2014). Communication
between ER components and the innate surveillance system
is further exemplified in Unc93-B, an ER resident membrane
protein that is indispensable to TLR3, TLR7, and TLR9 signaling
(Brinkmann et al., 2007; Nakano et al., 2010).
Mitochondrial Stress Unfolded Protein Response
A distinct system of unfolded protein response in the
mitochondria is best characterized in C. elegans (Haynes and
Ron, 2010; Pellegrino et al., 2014). Mitochondrial function is
essential for homeostasis and regulation of apoptosis. At least
one mechanism exists for sensing mitochondrial dysfunction.
The transcription factor ATFS-1 is normally imported into the
mitochondria, through the TOM/TIM import complex, where
it is degraded by the resident Lon protease. Disruption to this
mitochondrial import causes cytoplasmic accumulation, then
nuclear localization of ATFS-1, resulting in the expression of
mitochondria-specific protein folding machinery. An intriguing
gate-keeper of this mitochondrial import process is TOMM40,
the gene for which is located within the APOE block of linkage
disequilibrium that confers susceptibility to Alzheimer’s Disease
(Roses et al., 2010), as discussed later. Some, but not all of
the factors identified in C. elegans have orthologs in humans
indicating that additional components are likely to participate
in this process. Indeed PINK1 has been identified in humans
as a protein that in normal cells is partially imported into
the mitochondria, via the TOM/TIM complex. In dysfunctional
mitochondria this import is inhibited, resulting in an excess of
PINK1 accumulation in the outer membrane where it recruits
the ubiquitinating enzyme Parkin that then initiates mitophagy
(Harbauer et al., 2014). The details of this pathway for the
removal of dysfunctional mitochondria have recently been
elucidated (Celardo et al., 2014). Loss-of-function mutations
in either PINK1 or Parkin are the cause of familial cases of
Parkinson’s Disease (OMIM 608309 and 602544) implicating
defects in this pathway, in the pathogenesis of this form of
neurodegeneration.
Trigger Molecules
The host defense system operates in an environment comprising
a complex mixture of molecules - some pose a threat while others
are either harmless or beneficial. Recognition of threatening
molecules occurs on the basis of their molecular pattern
(Figure 1).
Pathogen Associated Molecular Patterns
Molecular patterns exhibited by a diverse array of exogenous,
foreign pathogen molecules of viral, bacterial and fungal origin
are recognized by the innate immune surveillance system
and trigger an inflammatory response. Some “non-pathogenic”
molecules also act as trigger molecules, invoking a sterile
inflammatory response. Suchmolecules may be threatening, such
as asbestos (Hamilton, 1980; Rock et al., 2010) and therefore
inflammation may aid in their removal. In general the distinction
between exogenous and endogenous molecules is clear, however
there are very important exceptions.
Danger Associated Molecular Patterns (DAMPs – see Box 1
Regarding Nomenclature)
In addition to pathogen-derived molecules, there are a variety
of endogenous agents that can act as triggers of the innate
surveillance response system. For endogenous agents the
distinction between “self ” and “non-self ” typically involves
modification of the molecular structure. RNA molecules are a
good example, with a multitude of modified forms, many of
which don’t affect function, but some of which distinguish "self ”
from “non-self.” A good example of this distinction is seen
in experiments of “induced pluripotent stem cells”. Fibroblasts
can be transformed into induced pluripotent stem cells by
transfection with four mRNAs encoding the required factors.
However thesemRNAs need to be subjected to RNAmodification
beforehand otherwise they will elicit an inflammatory response
in the fibroblasts (Warren et al., 2007). Such modifications can
occur via enzymes that recognize specific sequence motifs or
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FIGURE 1 | Simplified schematic of signaling junctions that integrate the recognition of pathogen, host or environmentally derived DAMPs and dAMPs
by their cognate receptors. Viral or host derived nucleic acids are recognized by several PRR families according to distinct structural characteristics and their
location. cGAS generates second messenger cGAMP to activate STING-dependent signaling (Hornung et al., 2014). Other cytoplasmic DNA sensors, such as IFI16,
converge on this pathway (Goubau et al., 2010). RIG-I has dual functions in inducing nuclear translocation of transcription factors such as NF-κB and IRF-3/7 through
MAVS (Yoneyama et al., 2016) and MAVS-independent inflammasome activation (Poeck et al., 2010). Like RIG-I, inflammasome forming PRRs AIM2 and NLRP1/3
direct procytokine conversion by activating caspase-1 (Kim et al., 2016; Thaiss et al., 2016; in response to stimuli such as bacteria-derived MDP or toxins (Wen et al.,
2013). Transcription factors NF-κB, AP-1, and IRF-3/7 can also translocate to the nucleus following activation of the endosomal TLRs which signal through either
Myd88 or TRIF. Membrane bound TLR2/4 innervate these pathways on detecting host derived dAMPs such as HSPs and MSU (Gelderblom et al., 2015). Binding of
pro-inflammatory ligands including AGEs, S100/calgranulin, amphoterin (HMGB1), and amyloid beta-peptide to RAGE, the receptor of advanced glycation
end-products, triggers an increase in proinflammatory molecules, oxidative stressors and cytokines (Ray et al., 2015). HMGB1 is a diverse PRR activator (Harris et al.,
2012). TLR3-mediated necrosis is via TRIF (Kaiser et al., 2013). A table of DAMPs/dAMPs and their respective PRRs is included in Supplementary Section. PRR,
pattern recognition receptor; cGAS, cyclic guanosine monophosphate-adenosine monophosphate synthase; STING, stimulator of IFN genes; IFI16, IFN-ϒ-inducible
protein 16; RIG-I, retinioc acid inducible gene-I; NF-κB, nuclear factor kappa B; IRF, interferon regulatory factor; MAVS, mitochondrial antiviral signaling protein; AIM2,
absent in melanoma 2; NLRP, NOD like receptor, pyrin domain containing 1 and 3; MDP, muramyl-dipeptide; AP1, activator protein 1; TLRs, Toll-like receptors;
Myd88, myeloid differentiation primary response 88; TRIF, Toll/interleukin-1 receptor domain containing adapter-inducing interferon-β; DAMPs, danger-associated
molecular patterns; dAMPs, damage-associated molecular patterns; AGEs, advanced glycation end products; HSPs, heat-shock proteins; MSU, monosodium urate.
appear at the RNA 5′ or 3′ends as a result of the type of enzymatic
cleavage of the RNA. For example, when activated as part of
the Unfolded Protein Response, IRE-1 cleaves not only XBP-1
mRNA (as described above) but other RNAs as well, producing
a pool of RNA products with unusual 3′ cyclic phosphates, that
trigger a “danger” response (Eckard et al., 2014). In this manner
endogenous RNA molecules are recruited to act as signaling
molecules in the innate surveillance system (Eckard et al., 2014).
Damage Associated Molecular Patterns (dAMPs—see Box 1
Regarding Nomenclature)
Non-autonomous cell death is part of the strategy to restrict
the spread of a persistent pathogen. Indeed the finding that
spätzle is an extracellular ligand for the cell surface receptor
Toll, is indicative of cell-cell signaling in the system (Mizuguchi
et al., 1998). Intracellular molecules released from one cell can
act as extracellular trigger molecules for the innate surveillance
response in another cell. Cell damage that results in release
of damage associated molecular patterns (dAMPs) can include
environmental causes (Bernard et al., 2012). Endogenous damage
molecules include RNAs (Bernard et al., 2012) and proteins such
as HMG-B1 (Kim et al., 2006; Harris et al., 2012; Gelderblom
et al., 2015) and F-Actin (Ahrens et al., 2012). These dAMPs
are recognized by members of the Toll-like Receptor family
(TLRs). TLRs have, at least in some cases, been induced in the
cells adjacent to the primary cell undergoing an inflammatory
response, by virtue of the cytokines that the primary response cell
produces (Khoo et al., 2011). This localized sensitization creates
a zone or field of cells that are able to detect products shed from
the dead primary cell.
Sentinels (Pattern Recognition Receptors, PRRs)
PRRs are the detectors or sentinels of the innate surveillance
system. They are sensors of an alarm system that not only detects
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BOX 1 | DANGER (DAMP) AND DAMAGE (dAMP) ASSOCIATED MOLECULAR PATTERNS.
While labeled in the literature with common and therefore confusing acronyms, two types of molecular patterns factor in the innate surveillance system—those that
signal danger, and those that arise from cell damage (the latter via specific forms of cell death). In an effort to distinguish these, we have used “D” for danger and
“d” for damage.
Pattern recognition is a major element of innate surveillance. While the host needs to be able to distinguish “self” from “non-self,” and do so in a manner uncorrupted
by pathogen mimicry, it also needs to monitor endogenous trigger molecules—those that act as sentinels of a developmental switch or a perturbation in homeostasis.
Post-transcriptional modification of RNA and post-translational modification of proteins are processes that cells utilize to either mask or unmask molecular patterns
that trigger recognition. Pathogen Associated Molecular Patterns (PAMPs) can be molecules derived from pathogens that either contain recognizable patterns
or are devoid of modifications that would otherwise mask their recognition. Pathogen RNAs will not have been exposed to the same post-transcriptional modifications
as host RNAs and can be distinguished on this basis (Nallagatla et al., 2008). Furthermore, some nuclease cleavage of RNA exposes structures that are recognized
by Pattern Recognition Receptors (e.g. RIG-I-mediated recognition of viral RNA bearing 5′-diphosphates (Goubau et al., 2014). In this manner, endogenous RNAs
can also be recognized as Danger Associated Molecular Patterns (DAMPs) and utilized as intracellular danger signaling molecules. Ribonuclease IRE-1 cleavage
produces a pool of RNA products with unusual 3′ cyclic phosphates, that are recognized by Pattern Recognition Receptors.
Cell death comes in various forms, certain types of which lead to the extracellular appearance of normally intracellular molecules. Some of these cell damage
molecules—damage Associated Molecular Patterns (dAMPs)—are also recognized by PRRs. Viruses that lyse cells or environmental damage (such as ischemic
stroke or head injury) can thereby activate the innate surveillance response. Forms of programmed cell death (such as necroptosis) facilitate the release of dAMPs
that are recognized by PRRs on adjacent cells. Sensitized adjacent cells can have elevated levels of PRRs thereby mediating their non-cell autonomous death. In
this manner dAMPs act as extracellular signaling molecules.
intruders but also danger signals that cells make to amplify
a local response to disturbed homeostasis. PRRs typically act
synergistically rather than in isolation (Nasirudeen et al., 2011). A
diverse multitude of trigger molecules are detected by PRRs, via
recognition of distinct patterns in the trigger molecules (e.g., the
presence or absence of a chemical modification). This recognition
occurs in intra- and extra-cellular compartments and is mediated
by families of related receptor proteins (Figure 1).
Toll-Like Receptors (TLRs)
Toll was discovered in Drosophila as a key regulator of both
development and host defense against pathogens. Toll is a
transmembrane receptor and binds the extracellular ligand
spätzle in its developmental role. Toll is related in structure to
the cytokine receptors and is one of a family of such proteins,
comprising 9 members in Drosophila (Valanne et al., 2011)and
13 in humans (Roach et al., 2005). Sequence comparison does
not reveal clear orthologous relationships—they are therefore
termed Toll-like receptors (TLRs) in vertebrates and Toll-related
receptors (TRRs) in Drosophila. Functional relationships are
likely based on their cellular localization, some common pattern
recognition and inter-connected signal transduction pathways
(Figure 1). This inter-connected signal transduction of TLRs
suggests that they function collectively as a network, to mount an
integrated response. TLRs sample the extracellular environment
and the interstices of endosomes, where they recognize
PAMPs and dAMPs. Endosomes can fuse with autophagosomes
(Klionsky et al., 2016), therefore endosomal TLRs are also
exposed to the internal constituents of autophagosomes, such as
RNA stress granules and defective mitochondria, that have been
targeted for degradation.
Other Pattern Recognition Receptors (RLRs, NLRs, and
CLRs)
At least three other families of Pattern Recognition Receptors
have been identified and characterized to varying extents
(Figure 1). The most thoroughly studied of these are the RIG-
I-like Receptors (RLRs) (Loo and Gale, 2011). They are located
in the cytoplasm and recognize both exogenous PAMPs and
endogenous DAMPs. The functional extent of this family is
uncertain, as there are no clear orthologs in some species. For
example in Drosophila the closest ortholog for the characterized
human RLRs isDicer 2 and there is good evidence thatDrosophila
Dicer 2 does indeed act as an intracellular PRR, in addition
to its role in miRNA biosynthesis (MacKay et al., 2014). Two
additional families of proteins, Nod-like Receptors (NLRs) and
C-type lectin receptors (CLRs), also act as PRRs (see references to
Figure 1), but the mechanisms by which they activate the innate
surveillance response are not well defined. Some PRRs may be
specific to certain specialized cells that are recruited to the site of
pattern recognition detection by the early response extracellular
signaling molecules (Applequist et al., 2002).
Early Response Mechanisms
The immediate response to activation of innate surveillance
appears aimed at degrading the danger signal(s) and restoring
homeostasis by reprogramming gene expression. In some cases
this includes the cessation of processes that contribute to the
trigger signal and increasing the activity of degradative pathways.
A diverse array of such degradative processes are activated
(Box 2, Figure 2).
Autophagy—in its Multiple Forms
The destruction of molecules deemed dangerous makes good
use of the cell’s normal recycling mechanism, autophagy. The
activity of autophagy varies above a basal state in response to
various stimuli including innate surveillance activation. Cross-
talk between the ER unfolded protein response, autophagy and
mitochondria underlies the cellular response to stress (Senft and
Ronai, 2015), with autophagosomes formed at ER-mitochondria
contact sites (Hamasaki et al., 2013). There are multiple sub-
types of autophagy dependent upon the materials being recycled
(Klionsky et al., 2016).
Granulophagy
In response to stress, cells reprogram translation—they
disassociate polysomes from mRNA and specific proteins
are aggregated into granules (Stress Granules and P-bodies;
Buchan et al., 2013). If the stress is transient and relieved then
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BOX 2 | CELLULAR CLEARANCE MECHANISMS IMPLICATED IN INNATE SURVEILLANCE RESPONSE.
Pathways responsible for proteostasis and RNAstasis in the event of stress response
Unfolded Protein Response (UPR)—integrated pathway for sensing and overcoming the accumulation of unfolded or mis-folded proteins within the ER, or in
the event of persistent accumulation, to induce innate surveillance-mediated cell death (Senft and Ronai, 2015). Involves 3 distinct activation pathways—ATF6/ATF6f;
PERK/ATF4; IRE1/XBP1s. IRE1 cleavage product of XBP-1 mRNA is recognized by the cytosolic pattern recognition receptor RIG-I of the innate surveillance system.
Endoplasmic Reticulum Associated Degradation (ERAD)—pathway is modulated by the UPR and targets misfolded proteins to the cytosol for their
ubiquitination and subsequent proteosomal degradation.
Autophagy—degradation of macromolecular complexes including protein aggregates and RNA granules, as well as damaged organelles through fusion with
lysosomes.
Granulophagy—in response to stress polysomes disassociate and their mRNAs form granules (stress granules or P-bodies) with specific RNA binding proteins
(including TDP43 and FUS). These stress granules hold the RNAs until the stress is relieved or failing this are transported (by VCP) to autophagosomes that then fuse
with lysosomes (regulated by the inhibitor CHMP2B) for degradation and subsequent recycling.
Mitochondrial Unfolded Protein Response (UPRmt)—the location of activating transcription factor associated with stress-1 (ATFS-1) is sensitive to unfolded
protein stress inside the mitochondria. Stress restricts mitochondrial importation of ATFS-1 resulting in higher cytosolic level, that in turn leads to its nuclear localization
where it activates target genes, the products of which act to protect the mitochondria. Failure to resolve the mitochondrial stress leads to autophagy (also known as
mitophagy) of the damaged mitochondria.
Heat Shock Response (HSR)—includes dissociation of heat shock factor-1 (HSF1) from inhibitory binding with heat shock factor 90 (HSP90). HSF-1 induces
heat shock target genes that in turn mediate protein quality control pathways.
Nonsense Mediated Decay (NMD)—a highly conserved RNA integrity surveillance pathway that not only leads to the elimination of faulty endogenous transcripts
and viral RNAs, but also regulates levels of ∼10% of normal cellular transcripts (Rigby and Rehwinkel, 2015).
Ubiquitin-Proteosome System (UPS)—the major pathway for non-lysosomal degradation of proteins.
RNA exosome (SKIV2L)—an exoribonuclease complex for RNA processing, quality control and turnover regulation. In low stress environments it efficiently digests
mRNAs including those encoding cytokines. It is negatively regulated by stress, resulting in greater stability of cytokine mRNAs (and therefore elevated cytokine
levels) as well as incomplete removal of IRE1 RNA digestion products that are recognized by RIG-Like Receptors (RLRs) of the innate surveillance system (e.g.,
XBP-1 RNA fragments that are recognized by RIG-I) resulting in its activation (Blin and Fitzgerald, 2015). The SKIV2L RNA exosome limits the activation of RIG-I-like
receptors (Eckard et al., 2014). Loss-of-function mutations in the EXOSC3 gene, encoding the RRP40 RNA exosome protein, are a cause of the inherited progressive
neurodegenerative disorder pontocerebellar hypoplasia (Wan et al., 2012).
these granules disaggregate, the mRNA is subject to polysome
reassembly and translation resumes. If the stress stimulus
continues then the granules are trafficked to an autophagosome
that then fuses with a lysosome—a vesicle containing degradative
enzymes. The contents of these autolysosomes are then degraded
to the building blocks for de novo transcription of genes,
including those that facilitate the cell’s response to the stress
stimulus. The genes for four proteins involved in this process
(TDP43, FUS, VCP, and CHMP2B) have mutations in various
familial cases of the neurodegenerative diseases fronto-temporal
dementia (FTD) or amyotrophic lateral sclerosis (ALS). While
TDP43 and FUS have multiple functions, both have been
found in RNA stress granules (Bentmann et al., 2013; Li
et al., 2013). Genetic screens in yeast have identified CDC48
(the ortholog of human protein VCP) as a regulator of the
trafficking of these aggregates for degradation (Buchan et al.,
2013). Mitochondrial function in neuronal cells depends on
VCP/Cdc48-mediated quality control (Fang et al., 2015). Loss-
of-function mutations in VCP have been detected in some
familial cases of ALS and FTD (Talbot and Ansorge, 2006).
CHMP2B also has multiple functions but one of these is an
inhibitor of autophagosome-lysosome fusion. Gain-of-function
mutations in CHMP2B are also found in familial cases of
ALS and FTD (Talbot and Ansorge, 2006). Loss of function
mutations in SamHD1, a regulator of stress granule assembly,
are another cause of the neurodegenerative disease known as
Aicardi-Gouitieres Disease (Hu et al., 2015 and see below). This
clustering of mutations around the autophagy function implies
that defective stress granule metabolism has a causal role to play
in neurodegenerative disease.
Mitophagy
Cellular metabolism of glucose occurs as a balance between
glycolysis and oxidative phosphorylation. Glycolysis in the
cytoplasm produces biosynthetic building blocks (e.g., pyruvate),
whereas oxidative phosphorylation in themitochondria produces
energy (ATP). Once cells cease dividing and differentiate they
have reduced biosynthetic requirements and shift to mainly
utilizing glucose as an energy source for cell function. Since
pathogens strive to replicate themselves, their biosynthesis
requires structural components and therefore a reduction in
mitochondrial metabolism, in favor of glycolysis, facilitates their
replication. Similarly cancer cells favor glycolysis as it facilitates
cell division. The state of the mitochondria and its perturbation
is therefore closely monitored, including the mechanism of
mitochondrial unfolded protein response (described above).
The functional integrity of the mitochondria is maintained
by mitophagy, a specific form of autophagy. Damaged or
dysfunctional mitochondria are recognized as such and shunted
into the autophagy process, for recycling and regeneration.
Defects in this process are detected by PRRs to trigger alarm in
the cell, resulting in an elevated response to the danger, including
increased mitophagy (Pellegrino and Haynes, 2015). If increased
mitophagy is unsuccessful in resolving the dysfunction then
ultimately the complete destruction of the cell is programmed
(Yu et al., 2015).
The benefit of mitochondrial-regulated innate immunity is
that it provides resistance to pathogen infection (Pellegrino and
Haynes, 2015). However there is also a cost in that loss of function
mutations in proteins that are required for mitophagy will lead
to inappropriate cell death. As discussed above, it is noteworthy
Frontiers in Neuroscience | www.frontiersin.org 7 May 2016 | Volume 10 | Article 193
908
Richards et al. Autoinflammatory Cause of Dementia Hypothesis
FIGURE 2 | Innate Surveillance Pathways and Genetic Contributions to Neurodegenerative Disease. In response to activation by trigger molecules, innate
surveillance recruits a diverse array of degradative processes to reduce the danger signal(s) and restore homeostasis. Genetic lesions in one or other of these
degradative pathways will lead to a build-up of danger signal (DAMP) levels beyond a threshold that elicits an escalated response. Pattern Recognition Receptors
(PRRs) orchestrate the release of signaling molecules directly (cytokines and interferon) and indirectly (damage-associated molecular patterns, dAMPs, from
programmed necrotizing cells) leading to sensitization and eventual non-autonomous death of adjacent cells. It is noteworthy that the ER stress response is activated
by amyloid beta in brain cells (Fonseca et al., 2013).
that mutations in two such proteins parkin and PINK1are known
causes of autosomal recessive early onset Parkinson Disease
(Kitada et al., 1998; Piccoli et al., 2008; Figure 2). Impaired
autophagy is also a hallmark of Alzheimer’s disease (Salminen
et al., 2013).
Other forms of autophagy almost certainly exist, indeed such
a mechanism involving the nucleus has just been described (Dou
et al., 2015), widening the scope of autophagy as part of the innate
surveillance monitoring and response system.
Cytokines—Sensitization Permissive of Focal Cell Death
Induction of intracellular and extracellular signals is another
element of the innate surveillance response. The innate
surveillance response includes the production of extracellular
signaling molecules (collectively termed cytokines, including
chemokines, interferons, interleukins, and tumor necrosis
factor). These molecules have been identified in different cell
types and model organisms and likely vary in composition and
function in different circumstances (e.g., Beutler et al., 2007).
They act as both feed-forward and feed-back controls, enabling a
mixture of responses and at varying distances, either in the trigger
cell, its neighbors or systemically.
Interferons comprise several families of structurally related
proteins that exhibit a wide range of biological activities (Pestka
et al., 2004). Type I interferons are an essential component
of the brain’s innate immune defense, conferring protection
against viral infection (McGlasson et al., 2015). Interferons
are both inducers of TLRs and are induced by activation
of TLRs (Khoo et al., 2011) and clearly act to amplify a
danger response. Similarly, tumor necrosis factor is required for
pathogen resistance in the CNS (Francisco et al., 2015) and acts
in sensitizing cells to programmed death pathways.
Mechanisms are also in place to limit the duration, spread
and extent of response. Negative feed-back controls include
miRNAs specific to the induced mRNAs (Zhou et al., 2011)
and ribonucleases (Regnase-1 and Roquin) specific to structures
found in cytokine mRNAs (Mino et al., 2015). Regnase-1 and
Roquin act in different compartments of the cell and also serve
to increase degradation of RNA P-bodies and stress granules.
Persistent Response Mechanisms—Programmed
Cell Death
In the early activation phase of innate surveillance, cytokine
release will create a zone of sensitized or primed cells that then
enables a focal response (Khoo et al., 2011). If the trigger persists,
a major integrated defense strategy is activated to ensure not
only the original cellular site of danger molecule detection is
eliminated, but also adjacent cells in the vicinity will undergo
non-autonomous cell death. This focal response restricts the
pathogen’s ability to survive, propagate and spread. Similarly,
rogue cells and perhaps their adjacent siblings or daughter cells,
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that have accumulated somatic mutations and therefore begun
the process of tumorigenesis, can be eliminated by a zone of
cell death around the primary trigger of innate surveillance
activation. As part of this process the manner of cell death has
an important role to play.
Given the importance of programmed cell death as a defense
mechanism and the intense selective pressure this system faces
from rapidly evolving pathogens, it is hardly surprising that
multiple forms of programmed cell death have evolved. There
appear to be two functionally distinct forms with respect to
the innate surveillance system—(1) those that release dAMPs
and/or pro-inflammatory cytokines to perpetuate and spread the
response, and (2) those that do not release dAMPs, and thereby
limit and contain the response.
Apoptosis is a well-characterized form of programmed cell
death (Elmore, 2007). It is utilized in normal developmental
processes as well as host-pathogen defense and typically involves
the degradation of cellular components commensurate with cell
death, either internally or by surrounding cells. Apoptosis is
therefore not normally associated with the release of dAMPs. The
molecular mechanism involves a cascade of activated caspases.
Caspases are broadly classified as initiator (caspase-2, 8, 9, 10),
effector (caspase-3, 6, 7) or inflammatory (caspase-1, 4, 5). The
intrinsic pathway of caspase activation involves mitochondria. A
variety of stimuli cause mitochondria to release cytochrome c,
that in turn binds to and sequesters the adaptor protein Apaf-1.
Apaf-1 binds, aggregates and cleaves procaspase-9 molecules,
to trigger a caspase cascade (Elmore, 2007). While apoptosis is
the canonical form of programmed cell death and has certain
conserved features, there are clearly variant forms that may differ
between cell types, species or have specific roles.
Pyroptosis is a distinct form of cell death that may be
restricted to only certain immune cell types and also may
vary between such cell types (Bortoluci and Medzhitov, 2010;
Nyström et al., 2013). These cells may either be resident or have
been attracted to the site of infection by chemokines released
by the initial responding cell. Such cells are activated through
a specific set of cytoplasmic PRRs, the Nod-like receptors
(NLRs)—although the mechanism of this activation is as yet
unclear (Harijith et al., 2014). These dying cells can in turn
release pro-inflammatory cytokines to amplify the response.
For example NLRP3-inflammasome activating dAMPs stimulate
an inflammatory response in glia that contributes to brain
inflammation after injury (Savage et al., 2012).
Necroptosis is another distinct form of programmed cell
death (Christofferson and Yuan, 2010; Wu et al., 2012). In
order to bring about the non-autonomous cell death of adjacent
sensitized cells, a distinct form of extracellular communication
occurs. dAMPs that are released upon the death of the trigger
cell act as activators of PRRs on adjacent sensitized cells. dAMPs
may include those originating from pathogens, but it is clear that
certain endogenous molecules are also able to act in this capacity.
Endogenous dAMPs include heat shock proteins (HSPs), the
nuclear protein HMGB1, F-Actin, RNA, and DNA (Kim et al.,
2006; Ahrens et al., 2012; Shichita et al., 2014; Gelderblom
et al., 2015). Various TLRs are specific receptors for dAMPs.
Intriguingly, HSPs and HMGB1 are also thought to mediate
inflammatory activation in ischemic stroke (Kim et al., 2006;
Gelderblom et al., 2015). It is noteworthy that anti-HMGB1
antibody has recently been found to exert neuroprotection
in a rat model of Parkinson’s disease (Sasaki et al., 2016).
Furthermore, Murakami et al. (2014) found that necroptosis,
not apoptosis, is a key mediator of cell loss and dAMP-mediated
inflammation in a mouse model of dsRNA-induced retinal
degeneration.
“Other”-optosis encompasses the fact that some organisms,
such as Drosophila, do not have orthologs for essential
components of pyroptosis or necroptosis (i.e., inflammasome
constituents or RIP1 and RIP3) yet they do exhibit Toll-like
receptor mediated cell death. This is due to the expression
of intracellular dAMPs (Samaraweera et al., 2013) indicating
that there are additional cell death pathways that lead to the
release of dAMPs, given the requirement of TLRs for activation
by extracellular signals. One such candidate pathway is that
mediated by Poly(ADP-Ribose) Polymerase (PARP-1) (Wu et al.,
2012). PARP-1 links nuclear and mitochondrial function and is
conserved in Drosophila. Dysfunction of mitochondria is a key
step in PARP-1-induced cell death, although the mechanism of
PARP-1 induced mitochondria dysfunction remains unknown.
Reactive oxygen species have frequently been linked to both
inflammation (Harijith et al., 2014) and neurodegenerative
disease and it is noteworthy that over-expression of superoxide
dismutase (SOD) protects against mitochondrial-initiated PARP-
mediated cell death (Kiningham et al., 1999). Kauppinen et al.
(2011) demonstrated a role for PARP in microglial responses to
amyloid beta, suggesting a role in the pathogenesis of Alzheimer’s
disease (Martire et al., 2015).
Neurodegenerative Diseases—Causes and
Correlations
The ever-growing emergence of one or more components of
the innate surveillance system in neurodegenerative pathogenesis
implicates this cell system as a common mechanism for
neurodegenerative disease (Tables 1, 2). Remarkably, plausible
mechanisms can be postulated by which each of the known
genetic causes of neurodegeneration feed into one or other
form of activation of the innate surveillance system. Moreover,
the genetic lesion as proximal trigger shows how activation
of the innate surveillance system is not simply a bystander
effect, but a central upstream cause of pathogenesis. These rare
genetic causes of disease can help delineate the responsible
pathogenic pathway for the more common, sporadic forms of
the disease. Furthermore, identification of responsible genes
enables the establishment of genetic animal models with which
to define and dissect the pathogenic pathway from mutation to
symptoms.
Genetic
Mendelian causes of neurodegeneration roughly fall into two
distinct groups exhibiting either recessive inheritance due to
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TABLE 2 | Summary of evidence for role of innate immunity in the etiology
of distinct forms of neurodegenerative disease
Disease Pathways or proteins involved in innate immunity
UPR/MAM ER Stress XPB-1 CHMP2B VCP IRG IL
AD +a,b +c +d
PD +d
FTD/ALS +d,e +f,g +h
HD* +d +i +j +k
AGS +l +m
IRG, interferon regulated genes; IL, interleukins; *, and other expanded repeat diseases.
References: aCornejo and Hetz, 2013, bLee et al., 2010, cFonseca et al., 2013, dDunys
et al., 2014, eHetz et al., 2009, fCox et al., 2010, gAhmad et al., 2009, hAzuma et al.,
2014, iHigashiyama et al., 2002 jRhodes et al., 2012, kBjorkqvist et al., 2008, lEckard
et al., 2014, mRice et al., 2014.
loss-of-function mutations, or dominant transmission typically
due to some form of gain-of-function.
Loss-of-function mutations inform on mechanisms of
pathophysiology, and also are instructive to indicate those
pathways that are candidates for sporadic forms of the disease.
Amyotrophic lateral sclerosis (ALS) and frontotemporal
dementia (FTD) exhibit overlap in both clinical and genetic
features. They share multiple common genetic causes and can
be found separately or co-incidentally in different members of
the same family (Lattante et al., 2015). The majority of cases of
ALS and FTD appear not to have a genetic cause and therefore
must have environmental origins. Genetic causes for ALS and
FTD can be loss of function mutations in a variety of proteins
including TDP43, FUS, and VCP. Until recently, a link between
these proteins has been difficult to pinpoint but remarkably, it
is now apparent that all of these proteins share the ability to
interact with RNA. TDP43, and FUS are both components of
RNA stress granules, while VCP is required for the trafficking
of these granules to autosomes. Reasonably, it can be seen that
loss of this degradative pathway can cause inflammation and
ultimately neurodegeneration by elevating endogenous RNA
“danger” signal(s)—DAMPs.
Evidence for RNA degradation as a key step in control of
the innate surveillance pathway also comes from the loss-of-
function mutations that cause Aicardi–Goutières Syndrome
(AGS). AGS is a genetically heterogeneous autosomal recessive
encephalopathy characterized in its most severe form by cerebral
atrophy, leukodystrophy, intracranial calcifications, chronic
cerebrospinal fluid (CSF) lymphocytosis, increased CSF alpha-
interferon (IFNA1), and negative serologic investigations for
common prenatal infections. AGS is phenotypically similar
to in utero viral infection. Severe neurologic dysfunction
becomes clinically apparent in infancy, and manifests as
progressive microcephaly, spasticity, dystonic posturing,
profound psychomotor retardation, and often death in early
childhood. Loss-of-function mutations in genes in at least six
distinct loci are able give rise to the constellation of symptoms
that defines Aicardi–Goutières Syndrome. Four of these
(RNAseH2A, RNAseH2B, RNAseH2C, and ADAR1) are in genes
that encode RNA-metabolizing proteins. The remaining two
genes that have been identified (TREX1 and SAMHD1) also
encode enzymes that have roles in nucleic acid metabolism,
and have recently both been shown to also have ribonuclease
activity (Ryoo et al., 2014; Yuan et al., 2015). Deficiency in any
one of these six enzymes is thought to result in the accumulation
of endogenous nucleic acids that are sensed as “non-self ” by
RIG-I-like receptors, that in turn activate innate inflammatory
pathways (Crow and Rehwinkel, 2009; Hofer and Campbell,
2013; Rigby and Rehwinkel, 2015), indeed AGS has been
termed an “interferonopathy” (Crow, 2011). The XBP-1 intronic
RNA generated by IRE-1 cleavage has been identified as an
endogenous danger RNA in the pathogenesis of AGS (Eckard
et al., 2014). A more general role for RNA degradation in
preventing neurodegeneration is indicated by loss-of-function
mutations in the RNA exosome component EXOSC3, that are a
cause of Pontocerebellar Hypoplasia (PCH1) (Wan et al., 2012;
Rigby and Rehwinkel, 2015). The RNA exosome has a key role in
innate sensing of RNA regulating cytokine production (Blin and
Fitzgerald, 2015).
Therefore, loss-of-function mutations in a variety of proteins
that are required for the degradation of RNA identify the
accumulation of specific RNA danger molecules that trigger
innate surveillance activation as a common causal mechanism
through which neurodegeneration is initiated.
Gain-of-function mutations in neurodegenerative diseases
have generally proven more difficult to attribute. In a few cases
the gain-of-function can be an enhancement of the normal
function of the relevant protein and a plausible pathway to
neurodegeneration is evident. For example, CHMP2B is an
inhibitor of autophagosome-lysosome fusion (West et al., 2015).
Therefore, dominant ALS/FTD causing mutations that enhance
inhibitory action of CHMP2B reduce the degradative capacity
of this pathway, decreasing the turn-over and causing a build-
up of danger associated molecular patterns (including trigger
RNAs). Similarly, dominant AGS-causing mutations in IFIH1
(MDA5) enhance its affinity for RNA DAMPs, with consequent
increased activation of downstream interferon signaling and
innate surveillance-mediated cell death.
In other cases, the pathophysiological pathway from the
gain-of-function mutation to clinical symptoms remains
evasive. There are approximately 20 dominantly inherited
neurodegenerative diseases caused by expanded repeat
mutations. The genes in which these repeats are located are
neither structurally nor functionally related, so either there are
many different pathogenic pathways or the gain-of-function
responsible is not an enhancement of the normal functions of
these proteins. Some proteins harbor the expanded repeat within
regions encoding polyglutamine, and the resulting accumulation
of polyglutamine has long been investigated as a possible
common toxic agent. However, this is difficult to reconcile with
observations that cells containing polyglutamine aggregates
have a survival advantage (Sisodia, 1998) and, at least in the
case of huntingtin protein, polyglutamine is substantially less
toxic within the context of the remaining protein (Barbaro et al.,
2015). A distinct form of repeat associated non-AUG translation
has been described in which polypeptides are translated from
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all reading frames of repeat RNA in the absence of an initiator
AUG. These polypeptides have also been found in patients with
expanded repeat diseases but again do not correlate well with
the sites of pathology (Mann, 2015; Mackenzie et al., 2015). In
addition, some diseases (ALS and FTD) have multiple genetic
causes in addition to an expanded repeat disease locus. Cases
of ALS/FTD that aren’t due to repeat expansion cannot feasibly
share an expanded polypeptide repeat. The only way to explain
these conflicting observations is to propose distinct pathogenic
pathways for these diseases or otherwise a single pathogenic
pathway, independent of expanded polypeptide toxicity.
RNA pathogenesis is one pathogenic pathway that
accommodates all of the existing evidence. Recognition
of expanded repeat RNA as an innate surveillance trigger
molecule is an alternative potential common mechanism for
neurodegeneration, since in all cases of dominantly inherited
expanded repeat disease, the expanded repeat DNA sequences
are transcribed into RNA.
A precedent for RNA as the causal pathogenic agent in
expanded repeat diseases has been proposed in myotonic
dystrophy (DM). This disease is due to expansion of either of
two repeat sequences. These repeats are transcribed as either
3′ untranslated RNA (CUG in DM1) or intronic RNA (CCUG
in DM2). Both of these expanded repeat RNAs bind and
sequester the alternative splicing factor muscleblind and as a
consequence, alter the balance of alternative splicing of multiple
genes in the muscle. The muscle-related component of the
disease phenotype can be modeled in mice by either muscle-
specific expression of the repeat RNA (Mankodi et al., 2000) or
by reduction in endogenous muscleblind protein (Kanadia et al.,
2003), providing clear evidence in support of expanded repeat
RNA being the causal pathogenic agent.
An additional mechanism for RNA pathology in expanded
repeat diseases has come from Drosophila models where RNA in
various forms has been tested for its ability to initiate cell death
(McLeod et al., 2005; Lawlor et al., 2011; van Eyk et al., 2011; Yu
et al., 2011; Samaraweera et al., 2013). Of these, double strand
CAG.CUG expanded repeat RNA was clearly found to cause
cell death (Lawlor et al., 2011; Yu et al., 2011). All dominantly
inherited expanded repeat disease loci exhibit bi-directional
transcription (Batra et al., 2010), so double-strand expanded
repeat RNA is plausible as a common cause in these diseases.
In the Drosophila model, expanded repeats of CAG.CUG100
were cleaved to CAG7mers. These CAG7mers have also been
detected in Huntington’s Disease brain RNA (Banez-Coronel
et al., 2012). Components of the innate surveillance pathway were
subsequently shown to be required for this form of cell death
in Drosophila (Samaraweera et al., 2013). Innate surveillance
activation is evident, through the elevation in expression levels of
its key targets drosomycin and cytokine eiger (ortholog of tumor
necrosis factor). These hallmark pathogen response changes in
Drosophila are consistent with observations of immune pathway
activation (increased circulating levels of IL-4, IL-6, IL-8, IL-
10, and TNF) before clinical onset in Huntington’s disease
Bjorkqvist et al. (2008). Mutant huntingtin protein does not
affect the intrinsic phenotype of human Huntington’s Disease
T lymphocytes (Miller et al., 2015) supporting the notion that
innate surveillance activation is responsible for the observed
increase in cytokine activity, rather than the adaptive immune
system. In the cataracts of either DM1 or DM2 individuals,
up-regulated genes are highly enriched in both interferon-
regulated genes (IRGs) and genes associated with response to
dsRNA (Rhodes et al., 2012), demonstrating the RNA-triggered
activation of innate surveillance in at least this symptom of
myotonic dystrophy pathology.
Further evidence of a causal role for innate surveillance
in expanded repeat disease comes from the finding that a
mouse model of SCA6 can be modified by MyD88, a major
adaptor protein in the conveyance of TLR signaling (Aikawa
et al., 2015). SCA6 is another expanded CAG repeat disease
thought to be caused by expanded polyglutamine. Histological
analysis of the cerebellum of this knock-in mouse model showed
the predominance of M1-like pro-inflammatory microglia and
this was concomitant with elevated expression levels of tumor
necrosis factor, interleukin-6, Toll-like receptors 2 and 7.
Until recently an expanded repeat at a single locus was
typically the sole identified mutation in these dominantly
inherited expanded repeat diseases. However, an exception to this
general rule is the genetically heterogeneous disease ALS/FTD.
Some inherited cases of ALS/FTD are due to expansion of a
6 base repeat in the intron of the C9orf72 gene, others are
due to non-repeat mutations in a variety of other genes. The
functions of these genes therefore give insight into how a single
pathogenic mechanism might be responsible. Animal models
for mutations in ALS/FTD genes have been instructive of the
molecular pathway of pathogenesis. A variety of mutations in
SOD1 cause ALS and a mouse model for one of these (SODG93A)
exhibits a phenotype consistent with the symptoms of the human
disease. The survival of SODG93A mice is extended by genetic
removal of the TLR4 pattern recognition receptor, indicating a
role for innate surveillance in the pathogenesis (Lee et al., 2015).
The normal function of ALS/FTD causing genes is instructive.
As discussed previously, loss-of-function mutations occur in
TDP-43 and FUS components of RNA stress granules (Ito and
Suzuki, 2011) and in VCP, required for trafficking of the granules
to the autophagosome (Azuma et al., 2014). Gain-of-function
mutations in CHMP2B also cause ALS and this protein acts as an
inhibitor of autophagosome-lysosome fusion (Cox et al., 2010).
Together these observations suggest that defects in granulophagy
are a likely cause of ALS/FTD. As detailed above, various
forms of autophagy are critical for the degradation of DAMPs,
including those of endogenous origin. Therefore, a clear path
for the activation of innate surveillance is again evident, as is
the potential for pathogens or environmental stress to contribute
to the etiology of these diseases by independently activating the
immune surveillance pathway.
Expansion of a GGGGCC repeat in the intron of the C9orf72
gene is a major cause of inherited ALS/FTD, adding further
weight to the argument for RNA being the best candidate for a
common trigger molecule in expanded repeat neurodegenerative
diseases. Indeed expanded GGGGCC repeat RNA does cause
neurodegeneration in a Drosophila model (Xu et al., 2013). The
pathogenic mechanism responsible for expanded GGGGCC
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repeat RNA to cause ALS/FTD is as yet unclear however
recent reports indicate that key regulators of nucleocytoplasmic
transport are compromised in Drosophila models (Freibaum
et al., 2015; Zhang et al., 2015). The GGGGCC repeat RNA is
retained in the nucleus not only in these Drosophila models
but also in cells derived from ALS/FTD affected individuals.
In ALS/FTD affected individuals the nucleolus exhibits stress
(Haeusler et al., 2014) and it will be of interest to see whether this
stress mediates the recently described nuclear autophagy (Dou
et al., 2015).
Parkinson’s Disease (PD) is a progressive neurodegenerative
disease that is thought to have both genetic and environmental
causes. Certain chemicals in the environment are strongly
associated with PD. These include the herbicides rotenone
and paraquat (Tanner et al., 2011). Rotenone is an inhibitor
of mitochondrial complex I, while paraquat is a cause of
oxidative stress. Mitochondrial dysfunction and oxidative stress
are both thought to be elements of PD pathogenesis and are
consistent with the rare genetic causes of the disease. The
chemical 6-hydroxydopamine has been used to establish rat
models of PD taking advantage of the specific accumulation of
this toxin into catecholaminergic neurons (Simola et al., 2007).
A role for innate surveillance in PD has recently been revealed
in this rat model by the finding that an antibody directed
against the dAMP HMG-B1 is neuroprotective (Sasaki et al.,
2016).
Multiple genetic loci have been identified for familial cases
of Parkinson’s Disease that can segregate in either a dominant
or recessive manner, most likely indicating gain- or loss-of-
function respectively. The responsible genes and their mutations
have been identified at many but not all loci and include SNCA,
PARK2, PINK1, LRRK2, DJ-1. Loss-of-function mutations in
either PARK2 (encoding parkin) or PINK1 cause early onset
recessive PD, with both proteins having important roles to
play in mitophagy (as described earlier). Drosophila models
reveal that mitochondrial dysfunction in PINK1 mutants is
complemented by parkin (Park et al., 2006) and that parkin
mutations lead to dopaminergic neuron loss, that can be rescued
by increased glutathione S-transferase activity (Whitworth
et al., 2005). Furthermore, Drosophila parkin mutants exhibit
elevated biomarkers of innate immune responses in pathogenesis
(e.g., Diptericin protein), indicating the activation of innate
surveillance (Greene et al., 2005). Finally, LRRK2 functionally
interacts with Parkin, DJ-1, and PINK-1 (Vendorova et al., 2009).
The relationship between these proteins and others, wherein
mutant forms cause PD, has been unclear (Schapansky
et al., 2015). However, Norris et al. (2015) recently report
convergence of Parkin, PINK1, and α-synuclein in stress-
induced mitochondrial remodeling. SNCA encodes α-synuclein
and mutations in this gene were the first described in familial
cases of PD. α-synuclein is also found in the protein aggregates
known as Lewy Bodies that are found in the brains of some,
but not all PD patients. The PD-causing SNCA mutations
occur on a single allele and can be either missense mutations
or increases in gene copy number, implicating a gain-of-
function mechanism in the contribution of SNCA to disease
pathogenesis. Expression of human α-synuclein in Drosophila
neurons recapitulates symptoms of PD including loss of motor
control, development of neuronal inclusions and degeneration
of dopaminergic neurons. This phenotype is again rescued by
expression of parkin indicating commonality in pathogenesis
(Haywood and Staveley, 2004).
α-synuclein is not located in the mitochondria itself but
in the mitochondria-associated membrane (MAM), a distinct
compartment of the endoplasmic reticulum (Guardia-Laguarta
et al., 2014; Figure 2). Disease-causing point mutations in α-
synuclein reduce its association with the MAM implicating
this localization in disease pathology. The MAM is the site of
autophagosome formation (Hamasaki et al., 2013) and therefore
a key component of a major degradative control pathway
for the innate surveillance response. In a further indicator
of commonality of pathogenesis, Ye et al. (2015) recently
reported Parkin-mediated mitophagy in mutant hAPP neurons
and Alzheimer’s disease patient brains.
Gain-of-function mutations in the LRRK2 gene are
responsible for the most frequent inherited cause of PD,
although with low disease penetrance of 32% at 80 years of
age (Goldwurm et al., 2007) suggesting interaction with other
genetic and/or environmental factors. LRRK2 has multiple
functions including roles in autophagy and mediating microglial
proinflammatory responses (Moehle et al., 2012; Schapansky
et al., 2014). These relationships have led to the conclusion that
inflammation has a causal role to play in Parkinson’s Disease
(Russo et al., 2014).
Alzheimer’s Disease (AD) occurs in both sporadic and familial
forms, with genetic causes or contributions to each form.
Familial forms are earlier onset, with mutations found in genes
that encode the amyloid precursor protein (APP) and two
components of its cleavage (presenilin 1 and 2) to amyloid beta
protein, a major component of amyloid plaques found in AD
brain. These findings led to the amyloid cascade hypothesis—
in essence that fragments of APP cause AD (Schellenberg and
Montine, 2012; Tanzi, 2012; Hardy et al., 2014; Masters et al.,
2015). This hypothesis has prevailed over the field of AD research
for more than 25 years (Hardy and Higgins, 1992). Failure to
progress to effective prevention or treatment of AD has provoked
a recent call to focus on testing alternative hypotheses (Herrup,
2015).
One competing hypothesis involves the pathogenic
interference with axonal transport of neurofilament and
neurotubule proteins (Iqbal et al., 1977), subsequently identified
as the microtubule associated protein tau (Grundke-Iqbal et al.,
1986). The brains of individuals with AD exhibit abnormal
phosphorylation and aggregation of tau into paired helical
filaments in the form of neurofibrillary tangles.
Amyloid beta plaques and neurofibrillary tangles are the
two main histopathological hallmarks of AD. Tau is encoded
by a single gene MAPT, that is mutated in some cases of
fronto-temporal dementia and certain other neurodegenerative
diseases (Iqbal et al., 2005) but somewhat surprisingly, not in
AD (Iqbal et al., 2015). Attempts to fuse these two hypotheses
include proposals that the hallmark features of pathology directly
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influence one another (Mudher and Lovestone, 2002), for
example the concept of “tauopathies” where aberrantly folded
proteins (including tau, amyloid beta and α–synuclein) lead to
the formation of toxic structures that spread through the brain,
in a similar manner to prions (Goedert, 2015). The contribution
of such structures to pathology has been challenged given the lack
of correlation between plaque load and cognitive impairment
in AD, with alternative forms of amyloid beta proposed as
the neurotoxic agent (Muller-Schiffmann et al., 2016). So while
unifying the field to some extent, this fused hypothesis has not
provided an agreed mechanism of toxicity, nor does it explain
additional genetic causes of, and risk factors for, Alzheimer’s
disease.
Like numerous other neurodegenerative diseases, increased
inflammation correlates with Alzheimer’s disease progression
and has therefore been proposed as a diseasemechanism (Heneka
and O’Banion, 2007; Heneka et al., 2014, 2015). However
since inflammation has been observed in a diverse array of
neurodegenerative diseases, with seemingly distinct causes, this
has led to the view that inflammation is a protective response
to neurodegeneration, rather than a cause of it. Recently,
genome-wide association studies of late-onset Alzheimer’s
disease have however identified susceptibility variants in loci
harboring innate immune-related genes, including CLU, CR1,
CD33, EPHA1, MS4A4E/MS4A6A, PTK2B, TREM1, TREM2,
and TREML2 (see Perry and Holmes, 2014). Several of these
proteins have now been found to functionally interact (Chan
et al., 2015). Therefore, elements of the innate surveillance and
response system are indeed rate-limiting for Alzheimer’s disease
pathogenesis. Intriguingly, these are proteins more typically
associated with microglia than neurons (Perry and Holmes,
2014), consistent with a non-cell autonomous mechanism for
neurodegeneration. Indeed microglial dysfunction is a hallmark
of the aging brain and Alzheimer’s disease (Mosher and Wyss-
Coray, 2014).
Conclusions Regarding Genetic Causes of Neurodegeneration
Together these observations form a compelling case that the
innate surveillance system is a central upstream cause of
neurodegenerative disease. The complexity of causal agents—
whether genetic or environmental—can be explained by
convergence around elevated susceptibility or active triggering
of inflammation through the innate surveillance pathway. The
key question is therefore not whether the innate surveillance
system has a role in neurodegenerative disease, but what kind of
role? Distinguishing whether innate surveillance has a pernicious
or protective role in neurodegeneration has been problematic
given its complex array of feed-forward and feed-back signaling
mechanisms. For example it has been proposed that the role of
innate surveillance in AD is in clearing amyloid beta plaques
from the brain (Guillot-Sestler et al., 2015). This hypothesis is
based on the observations that a reduction in anti-inflammatory
cytokine (IL-10) signaling mitigates AD-like pathology, while
over-expression reduces clearance in mouse models of cerebral
amyloidosis (Guillot-Sestler et al., 2015). The innate surveillance
system involves a mixture of anti- and pro-inflammatory
cytokines, local and systemic actions, with neuroinflammation
noted to have negative effects on neurogenesis and cognition
(Ryan and Nolan, 2016). Genetic causes define the proximal
defects and/or trigger molecules in pathways and on this basis
identify the role of innate surveillance in neurodegeneration as
causal.
The vast majority of AD cases are late age-at-onset and
in these instances the most striking genetic contribution is a
susceptibility locus on chromosome 19. A polymorphism within
the ApoE gene is an indicator of age-at-onset (Saunders et al.,
1993) and until recently it was assumed that variation in ApoE
protein is the biochemical basis of this variation possibly through
its impact on amyloid beta deposition (Masters et al., 2015).
ApoE also affects the activity of innate surveillance signaling
(Guillot-Sestler et al., 2015) providing an additional plausible
mechanism for its variation impacting on AD pathogenesis.
The ApoE gene is however located within a block of Linkage
Disequilibrium raising the possibility that another gene also
located within this block mediates AD susceptibility. One such
gene is TOMM40 that also contains a polymorphism predictive
of AD risk (Roses et al., 2010). TOMM40 is a component of
the mitochondrial protein import complex and in this capacity
is a key regulatory protein of mitochondrial function and the
mitochondrial unfolded protein response mediated by ATFS-1
transport (see above andGottschalk et al., 2015).Mitophagy plays
a key role in Parkinson’s disease pathogenesis, therefore variation
in TOMM40 is also a plausible means by which polymorphism
in the ApoE/TOMM40 linkage disequilibrium block can have a
causal role in AD.
Environmental
The vast majority of cases of neurodegeneration are thought to
have environmental agents as their principle cause. Pathogen
infection is likely to be one environmental cause. Sensitization is
a key component of innate surveillance mediated by extracellular
and systemic signaling molecules (DAMPs and dAMPs).
Pathogens either directly or indirectly generate such signaling
molecules, that the systemic component of innate surveillance
then utilizes to communicate the presence of infection and
primes the body to prepare for its potential spread. While such
sensitization provokes host cells to then actively restrict infection,
it also appears to increase susceptibility to other processes
mediated by innate surveillance—including neurodegeneration.
A very clear illustration of this phenomenon occurs following
sepsis. Long-term cognitive impairment and functional disability
are frequent consequences among survivors of severe sepsis
(Iwashyna et al., 2010). The mechanism responsible is yet to be
determined however the elevation of inflammation and resultant
systemic sensitization has been proposed (Sharshar et al., 2014;
Widmann and Heneka, 2014). Microglial activation plays a role
in experimentally induced sepsis in a rodent model (Michels
et al., 2015) and this is likely mediated by the dAMP HMG-
B1 (Chavan et al., 2012; Valdes-Ferrer et al., 2013). Physical
trauma, through head injury or ischemic stroke, are other factors
thought to contribute to increased risk of neurodegeneration.
Again HMG-B1 is a key mediator of immune mechanisms in
ischemic stroke (Kim et al., 2006) and brain injury (Laird et al.,
2014).
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Inverse Correlation between Cancer Incidence and
Neurodegenerative Disease
While the ability to defend against pathogens is clearly essential
for survival, the use of cell death as a defense strategy seems
a very high biological cost to pay. It is therefore noteworthy
that a clear inverse correlation has been found between the
incidence of cancer and Alzheimer’s disease (Driver et al.,
2012; Musicco et al., 2013; Li et al., 2014). This inverse
correlation with cancer incidence has also been observed for
additional neurodegenerative disorders (notably PD and HD)
in a large meta-analysis study (Catalá-López et al., 2014).
These observations are consistent with the hypothesis that
innate surveillance is the common mediator of both pre-
cancerous cell elimination and neurodegeneration, explaining
the trade-off between susceptibility to these conditions. A
more sensitive innate surveillance system is more effective at
detecting and eliminating dysfunctional, rogue cells that have
accumulated somatic mutations otherwise leading them on a
pathway of tumourigenesis. However this same sensitive innate
surveillance system is more readily able to detect genetic and/or
environmental danger and damage signals in the nervous system,
leading to increased susceptibility to neurodegenerative disease.
Conversely, a less sensitive innate surveillance system will confer
a lower risk of neurodegeneration, but a higher risk that pre-
cancerous cells will go undetected, and therefore lead to cancer.
Why are Nerve Cells Sensitive to Innate
Surveillance-Mediated Cell Death?
The central nervous system has characteristics that may go some
way to explaining its greater sensitivity to the consequences
of innate surveillance activation. Peripheral tissues utilize the
systemic component of innate surveillance to recruit specialized
cells (primarily histiocytes) to the site of activation (Vanha-aho
et al., 2015). These cells act in containment and resolution,
however until elimination is achieved the combined cell mass can
appear as a nodule referred to as a granuloma or inflammatory
pseudotumors. While such structures appear common to many
peripheral diseases they are very rare in the central nervous
system (Tekkok et al., 2000; Hausler et al., 2003; Lui et al., 2009).
This may be due to difficulty in attracting histiocytes into the
CNS and/or that microglial cells fulfill such a role in the CNS.
In any event the mechanics of resolving the cause of innate
surveillance activation in the CNS appears to be distinct from that
in peripheral tissues. Given the major role that microglial cells
play in nerve cell maintenance it is noteworthy that microglial
cell dynamics alter with age (Hefendhel et al., 2014), with a
general reduction in functional capacity. Such changes may well
confer a decreased ability to contain and resolve instances of
innate surveillance activation and therefore mediate increased
susceptibility to neurodegeneration with age.
If there is a Common Cause why are there are Different
Diseases?
Differing susceptibilities are nothing new in genetic causes of
disease. The same mutation in a single family can cause ALS or
FTD or both (see—OMIM 105550). The same ADAR1 mutation
can cause differing symptoms (Livingston et al., 2014). There are
a large number and variety of innate surveillance components. It
is likely that these components differ in their quantity and quality,
even among differing nerve cell types, indeed such variation
has already been reported (Applequist et al., 2002) with some
of this variation likely due to the requirement for pathway
components in normal developmental processes (Asakura et al.,
2015). Therefore, disease-causing components are likely rate-
limiting in some nerves, less so in others. Indeed neuronal
plasticity may overcome single cell loss through alternative
connections, but not the loss of the whole circuit. Finally, the
strategy of adjacent cell sensitization that leads to foci of cell
death, while working well in most tissues, may be ineffective in
the aging brain with diminished microglial function.
Future Perspectives
The hypothesis stated here, that innate surveillance mediated
cell death is the common cause of neurodegeneration, is a
paradigm shift. This model heralds the exciting prospect of
finally having a unifying view that accommodates all known
data and reconciles some of the long-standing incompatibilities
between previous models for neurodegenerative diseases. Until
now the accumulating body of data in support of this innate
surveillance hypothesis has been assembled from experiments
that have not been specifically designed to test it. So it will
now be important to directly challenge this hypothesis and its
predictions. Numerous animal models and a vast quantity of
clinical material are available for such targeted experiments and
analyses. These experiments will need to build in the distinct
possibility that innate surveillance is both protective early and
pernicious late in neurodegenerative disease. Such information
will be crucial for the design of clinical trials.
Detection and Intervention—Biomarkers for
Neurodegeneration
Reactive, presymptomatic biomarkers are needed, both to
predict the onset of impending symptoms and to monitor the
effectiveness of potential therapeutics in clinical trials. Given
that innate surveillance activation is the proximal cause of
neurodegeneration, it will be important to distinguish such
biomarkers that are specific for neurodegeneration from those
that possibly signal the activity of protective mechanisms
(Zetterberg et al., 2013). Informative, quantifiable biomarkers for
neurodegenerative disease are vital in assessing the effectiveness
of interventions, particularly given the very long time frames
involved for both age-at-onset and clinical progression for some
of these diseases.
New targets for preventative therapies and/or drug
interventions will be contingent not only upon defining
key molecular processes and the identification of their rate-
limiting steps, but also the window of time in which intervention
is able to be effective. An intervention at the wrong time could
impede a protective process rather than alleviate a pernicious
one.
Genetic Models of Neurodegenerative Disease
Distinguishing cause from consequence in the pathogenesis
of disease can be problematic. Experimental animal models
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(both invertebrate and mouse) of the defined genetic causes of
neurodegeneration in humans, are therefore a key strategy in
establishing cause and effect relationships in the pathophysiology
of neurodegenerative disease.
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Abstract
The notion that one common pathogenic pathway could account for the various clinically distinguishable, typically late-
onset neurodegenerative diseases might appear unlikely given the plethora of diverse primary causes of neurodegeneration.
On the contrary, an autoinflammatory pathogenic mechanism allows diverse genetic and environmental factors to converge
into a common chain of causality. Inflammation has long been known to correlate with neurodegeneration. Until recently
this relationship was seen as one of consequence rather than cause—with inflammatory cells and events acting to ‘clean up
the mess’ after neurological injury. This explanation is demonstrably inadequate and it is now clear that inflammation is at
the very least, rate-limiting for neurodegeneration (and more likely, a principal underlying cause in most if not all neurode-
generative diseases), protective in its initial acute phase, but pernicious in its latter chronic phase.
Introduction
Research to define the aetiology of neurodegeneration has been
dominated for decades by the hypothesis that aggregation of
amyloid-b is the principal basis of Alzheimer’s disease and re-
lated conditions. The disappointing results (1,2) of recent clini-
cal trials of interventions targeting amyloid-b aggregation have
shifted the focus to alternative hypotheses. One new hypothesis
invokes inflammation as a causal upstream driver of neurode-
generation. Inflammation is activated by a diverse array of stim-
uli and typically correlates with neurodegeneration, but to date
has largely been viewed as protective, rather than disease-
causing. Recent genetic evidence strongly implicates inflamma-
tion as the primary initiating lesion. Various inflammatory
response components and their regulators are common
amongst identified genetic susceptibility loci. Inflammatory
pathway genes are activated in affected tissues and elevated
inflammatory signals occur early in disease onset and precede
neurodegeneration, independently of any infectious aetiology.
Genetic and pharmacological ablation studies in animal models
of several neurodegenerative diseases demonstrate that inflam-
mation is required for pathology. We argue that this evidence is
highly compelling for Alzheimer’s and many related conditions,
and indeed it seems likely that inflammation will emerge as
pivotal in the full range of neurodegenerative diseases. The re-
search effort should now focus on evaluating interventions that
target pro-inflammatory mediators and their eliciting factors
and regulatory networks.
Systemic Inflammatory Activation
Inflammatory activation provides the body’s front-line defence
and quality surveillance system. Surveillance occurs both
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autonomously within the intracellular environment as well as
by cells that patrol the extra-cellular environment for threats,
damage and dysfunction. The initial acute inflammatory re-
sponse is protective—directed toward degrading the threat,
repairing the damage, correcting the defect and restoring ho-
meostasis. Persistent activation leads to a chronic response that
includes focal cell death as a containment strategy, denying po-
tential pathogens and pre-cancerous cells the ability to replicate
and spread (Box 1 and Fig. 1).
Rapid evolution and high genetic variation is a common
property of the host-pathogen arms race, as each side seeks to
discover new forms of advantage that can include beneficial
symbioses. Variation in resistance and susceptibility therefore
promotes competitive fitness in a host population (e.g. sampling
and discriminating potentially harmful from beneficial
microbes) and a likely reason why some components of the in-
flammatory response are themselves pathogen restriction fac-
tors (a noteworthy example is Ref(2)P that is a viral restriction
factor in Drosophila (3) while mutations in its human orthologue,
known as Sequestosome 1 or p62, are a cause of familial ALS) (4).
This is one of now many genes linked with human neurodegen-
erative disease genes that have roles in the activation or resolu-
tion of inflammation (Tables 1 and 2).
Autoinflammatory diseases were first recognized twenty
years ago and are defined as the presence of acute or chronic in-
flammation without the high-titer autoantibodies or antigen-
specific T cells seen in classic autoimmune diseases, and
without the necessity for infection. They include various mono-
genic disorders that have revealed new regulatory pathways in
the inflammatory response and its resolution (44). Systemic
autoinflammatory diseases are typically episodic, such that
individuals carrying genetic causes of these diseases can go for
extensive periods without symptoms. The likely explanation is
that incidental exposure to an environmental ‘second-hit’ to
elicit an inflammatory response is required for at-risk individu-
als to develop clinical manifestations. Geographic variation in
disease-susceptibility alleles is also consistent with the possibil-




Genetic lesions in components of the inflammatory response
are the origin of inherited autoinflammatory diseases—indeed
the characterization of these genes has been a major source of
discovery and definition of the innate inflammatory pathways
(44). While common pathways can be involved, the diseases ex-
hibit distinctive symptoms and tissue sensitivity, indicating
that different cell lineages have diverse rate-limiting compo-
nents in the underlying pathways. Lessons from systemic auto-
inflammatory diseases indicate that a plausible mechanism
for neuronal cell death in the neurodegenerative diseases is
recurrent or chronic inflammation, which mediates cell
Box 1. Inflammatory activation components (a partial inventory)
Trigger molecules/Danger signals
• PAMPs—pathogen associated molecular patterns—microbial foreign ‘non-self’ molecules
• DAMPs – danger associated molecular patterns – endogenous signals
• dAMPs (alarmins) – damage associated molecular patterns – signals released by lytic cell death
• HAMPs – homeostasis associated molecular patterns – signals induced by altered cellular physiology
Pattern recognition receptors (bind and transduce danger signals)
• Toll-like receptors (TLRs) – bind wide variety of molecules
• RIG-I-like receptors (RLRs) – recognize ‘non-self’ RNA
• cGAS/STING – recognizes ‘non-self’ DNA
• RAGE – recognizes advanced glycation end-products
Degradative pathways
• Autophagy (includes mitophagy, granulophagy, xenophagy)
• Integrated Stress Response (includes Unfolded Protein Response)
• Non-sense mediated decay




• Mitochondrial Activator Viral Signalling (MAVS)
• Inflammasomes, caspases
Signalling and defence molecules
• Cytokines (includes interleukins, interferons, tumour necrosis factor)
• Damage Associated Molecular Patterns (alarmins) – includes HMG-B1, amyloid-b, S100 proteins
• Antimicrobial Peptides – includes amyloid-b, serum amyloid A
Cell death mechanisms
• Non-lytic (Apoptosis) – protective
• Lytic (Necroptosis, Pyroptosis, Ferroptosis, others?) – pernicious (release damage associated molecular patterns)
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death after a transition from a protective acute inflammatory
response (44,45). It is noteworthy in this regard that amyloid de-
position is not unique to neurodegeneration but is also associ-
ated with at least some of the systemic autoinflammatory
diseases (e.g. serum amyloid A deposits in FMF). Consistent
with this notion, amyloid-b deposition has recently been shown
in a mouse model of AD to be mediated by the RAGE (receptor of
advanced glycation end-products) pattern recognition receptor
of the innate surveillance system (46). Furthermore, a functional
role for amyloid-b peptide in the innate inflammatory response
is evident in its ability to protect against disseminating micro-
bial infection in mouse and worm models of Alzheimer’s dis-
ease (16).
A direct connection between systemic autoinflammatory
disease and neurodegenerative disease has recently been made.
Specific mutations in the PLCG2 gene cause two distinct sys-
temic autoimmune (PLAID) and autoinflammatory (APLAID)
phenotypes (47,48). Remarkably, genetic variation in the PLCG2
gene is also a risk factor for Alzheimer’s disease (23).
While focal at its onset, an unresolved and persistent acute
inflammatory response may give rise to feed-forward signals
(IL-1b and TNF)—cytokines that are met in adjacent cells by
higher endogenous sensitivity to inflammatory activation due
to the genetic lesion. This elevated chronic inflammatory re-
sponse resists the normal resolution phase, leading to events
including cell death that typically spread beyond the initial le-
sion. Such systemic autoinflammatory cycles, including allevia-
tion of neurological systems, have been successfully broken by
treating affected individuals with inhibitors of IL-1b or TNF (44).
Inflammation in the central nervous system
Neuroinflammation in the central nervous system (CNS) can
arise in response to multiple causes and has both distinct and
common elements with its systemic counterpart. Focal
traumatic brain injury (TBI) (49) activates an inflammatory re-
sponse that is protective in its early acute phase—facilitating
remodelling and recovery. Indeed general suppression of in-
flammation in TBI affected individuals is disadvantageous.
While experimental models of TBI are typically sterile, natu-
ral instances of brain damage are unlikely to be sterile and
therefore, as well as promoting tissue repair, inflammatory acti-
vation would be a prophylactic defense against opportunistic
infection. The increased risk of neurodegenerative disease in
individuals who have survived an episode of sepsis indicates
that systemic components of the inflammatory response also
contribute to sensitization in the CNS (50). Indeed, gut micro-
biota influence neurodegeneration in a mouse model of
Parkinson’s disease (51) and microbes have been proposed as
the common causal agent for AD (52). Pathogens provide a
source of multiple trigger/danger molecules (pathogen associ-
ated molecular patterns—PAMPs) of widely variant structure.
Therefore, like their systemic autoinflammatory disease coun-
terparts, the onset of CNS autoinflammatory neurodegeneration
may be facilitated by PAMPs elevating the trigger molecule pool
above a threshold for chronic inflammatory activation.
Age is the greatest risk factor for neurodegenerative diseases
and indeed inflammation in the brain increases with age (53).
Somatic mutation in neurons increases with age and is more
prevalent in neurodegenerative disease (54). Such mutations
provide a source of truncated proteins that stimulate the un-
folded protein response and thereby account for age-dependant
increase in inflammatory activation.
Neuroinflammation involves many
cell lineages
The neurovascular unit (NVU) is the principal multicellular or-
ganizational unit in the CNS (Box 2). Each of the cell types in the
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Figure 1. Inflammatory acute and chronic responses and autoinflammatory disease. (A) Acute phase inflammatory response: (i) activated by trigger molecules/danger
signals, (ii) produces antimicrobial peptides and signalling molecules (cytokines), (iii) increase degradative processes (including various forms of autophagy and inte-
grated stress response) and (iv) directed towards resolution and restoration of homeostasis. (B) Chronic phase inflammatory response: (i) failed resolution by acute
phase and (ii) focal cell death (autonomous and non-cell autonomous) and subsequent containment and resolution as ‘pesudo-tumour’ or granuloma. (C)
Autoinflammatory disease: (i) genetic lesions activate inflammation by initiating or amplifying innate immune pathways by a number of mechanisms, including the
direct induction of danger signals, or the induction of downstream pathways independently of pattern recognition receptors (PRRs) or as an exaggerated response to
PRRs; (ii) cell death products also add to danger signals, dependant upon means of cell death; (iii) two functionally distinct forms of cell death—non-lytic (apoptosis—
typical in development) and lytic (e.g. necroptosis, pyroptosis, ferroptosis), differ in release of trigger molecules (damage associated molecular patterns) by lytic cell
death that contribute to danger signal load and perpetuate inflammatory response and its spread; and (iv) environmental trauma (infection, injury) can account for in-
stigation of autoinflammatory loop by sensitizing cells above a threshold required inflammatory activation.
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recruited peripheral immune cells participate in the inflamma-
tory response. Such observations have contributed to the view
that the neuroinflammatory response is simply a process to
clear debris and recover homeostasis (55,56). However genetic
variants in the microglia protein TREM2 (24) as well as PLCG2
and ABI3 (23) are risk factors for Alzheimer’s disease, indicating
that microglia-mediated innate inflammation is rate-limiting
for the disease.
Table 1. Human neurodegenerative disease genes with roles in inflammatory activation
Gene Disease Role in inflammation References
Disease causing mutations
ADAR1 Aicardi-Goutieres syndrome RNA modification (‘non-self’ to ‘self’) (5,6)
Bilateral striatal necrosis (5,6)
MDA5 (IFIH1) Aicardi-Goutieres syndrome RNA ‘non-self’ Pattern Recognition Receptor (5,6)
RNAseH subunits Aicardi-Goutieres syndrome RNA/DNA hybrid resolution, induce cGAS/STING (7)
SamHD1 Aicardi-Goutieres syndrome Retroviral restriction factor (8)
TREX Aicardi-Goutieres syndrome Degrades DNA to prevent spontaneous inflammatory disease (9)
TBK1 Amyotrophic lateral sclerosis Transduction of TLR signal with optineurin (10)
Optineurin Amyotrophic lateral sclerosis Role in TBK1 signal transduction (11)
P62 (sequestosome 1) Amyotrophic lateral sclerosis Ablation prevents mitophagy, enhances inflammasome activation (4)
Progranulin Amyotrophic lateral sclerosis TLR9 co-factor—deficiency promotes microglial pruning (12)
TDP43 Amyotrophic lateral sclerosis RNA Stress Granule, granulophagy (13)
FUS Amyotrophic lateral sclerosis RNA Stress Granule, granulophagy (13)
VCP Amyotrophic lateral sclerosis RNA Stress Granule transport to autophagosome (14)
CHMP2B Amyotrophic lateral sclerosis Granulophagy (autophagosome-lysosome fusion) (14)
Profilin-1 Amyotrophic lateral sclerosis RNA stress granule dynamics, granulophagy (15)
Amyloid-b Familial Alzheimer’s disease Antimicrobial peptide, damage-associated molecular pattern (16)
Tau Fronto-temporal dementia Mitochondrial transport, mitophagy (17)
a-synuclein Parkinsons disease Mitophagy (18)
PINK Parkinsons disease Mitophagy (18)
Parkin Parkinsons disease Mitophagy (18)
LRRK2 Parkinsons disease Mitophagy (18)
DJ-1 Parkinsons disease Mitophagy (18)
GBA Parkinsons disease Mitophagy (18)
ATPA13A2 Parkinsons disease Mitophagy (18)
EXOSCIII Ponto-cerebellar hypoplasia SKIVL (RNA exosome) ‘non-self’ RNA degradation (19)
TSEN2, 15, 34, 54 Ponto-cerebellar hypoplasia tRNA splicing endonucleases (20,21)
TBC1D23 Ponto-cerebellar hypoplasia between XBP1 and MYD88, TRIF in TLR4-NFKB1 pathway (22)
Risk-factor alleles
PLCG2 Alzheimer’s disease Phospholipase Cc2o signal transduction (23)
TREM2 Alzheimer’s disease Microglial proteino ApoE4 (24)
APOE Alzheimer’s disease Ligand for TREM2? (25)
TOMM40 Alzheimer’s disease Mitochondrial unfolded protein response?omitophagy (26,27)
IL-33 Alzheimer’s disease Cytokine signals (28)
Glucocerebrosidase Parkinson’s disease Diminished lysosome functiono autophagy (29)
Ataxin2 Amyotrophic lateral sclerosis RNA Stress Granule dynamicso granulophagy (30)
Table 2. Inflammatory response pathway genes required for symptoms in animal models of human neurodegenerative diseases
Gene/target Disease model References
Toll-related receptors Drosophila model of expanded CAG repeat diseases (31)
Toll-Like Receptor 4 mouse model of amyotrophic lateral sclerosis (SOD1) (32)
MyD88 mouse model of spino-cerebellar ataxia (SCA6) (33)
cGAS, STING rat model of ataxia telangiactasia (34)
relish (NFjB) Drosophila model of ataxia telangiactasia (35)
Ref(2)P (p62) Drosophila model of polyglutamine diseases (36)
p62 zebrafish model of amyotrophic lateral sclerosis (C9orf72 repeat RNA) (37)
Toll-Like Receptor 2, 3, 4 mouse model of Huntington’s disease (38)
HMGB1 rat model of Parkinson’s disease (39)
TREM2 mouse model of tau fronto-temporal dementia (40)
eIF-2a mouse model of tau fronto-temporal dementia (41)
eIF-2a mouse model of prion disease (41)
eIF-2a mouse model of traumatic brain injury (42)
eIF-2a Drosophila model of amyotrophic lateral sclerosis (TDP-43) (43)
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However, neurodegeneration is not necessarily a cell-
autonomous process. There is ample evidence for multiple cells
in the NVU having roles to play in non-cell autonomous neuronal
cell death (57). Astrocytes are determinants of disease progres-
sion in mouse models of inherited ALS (58). Astrocytes that are
activated by microglia, in turn kill neurons (59). Signalling mole-
cules (IL-1a, TNF and C1q) between microglia and astrocytes indi-
cate that the CNS has some unique components and others
shared with the systemic inflammatory system. Endothelial cells
activate neutrophils to acquire cytotoxic capability (60) however
the signals involved are not yet known. Indeed, expression of
mutant androgen receptor in muscle cells is able to drive nerve
cell degeneration in mouse models of Kennedy’s disease (spino-
bulbar muscular atrophy) (61). Cell-cell communication is there-
fore a typical requirement for neurodegeneration and while the
signals involved have not all been discovered, those that are well
characterized are typically cytokines and other signals of the in-
nate inflammatory response.
Ischemic stroke is a risk factor for vascular dementia and
Alzheimer’s disease (62). Neurovascular changes occur prior to
motor neuron degeneration in a mouse ALS model (63) and re-
cently depletion of coagulation factor XII has been shown to ame-
liorate brain pathology in AD model mice (64). Like many
contributors to the innate inflammatory response fibrin has mul-
tiple functions. In addition to its beneficial role in clot formation,
fibrin attracts cells that help with wound healing. However, like
other danger molecules, its persistence leads to chronic inflam-
matory activation that contributes to axonal damage in neuroin-
flammatory disease (65). Compartmentalization is another means
of harbouring/exposing danger signals. Various forms of ‘lytic’
cell death lead to the release of damage associated molecular pat-
terns (DAMPs/alarmins) including molecules such as HMGB1 and
the S100 proteins, as well as amyloid-b, that also acts as an anti-
microbial peptide (16). This assortment of DAMPs then bind to
multiple PRRs in adjacent cells and in so doing spread the inflam-
matory activation (66,67). Multiplicity of activation signals is a
common feature of this alarm system, presumably to override
pathogenic inhibition of any single pathway. It also explains why
pharmacological inhibition of a single DAMP signal (such as amy-
loid-b) is ineffective in preventing inflammatory-mediated cell
death (1,2,66).
Inflammation precedes neurodegeneration
Consistent with a causal role, inflammatory activation precedes
neuronal cell death with increased circulating cytokines found
in presymptomatic Huntington’s disease (68), a finding repli-
cated and extended with increased microglial activation as well
as cytokines in premanifest Huntington’s disease carriers (69).
In addition, inflammatory genes are activated in the cells des-
tined to undergo neurodegeneration. This includes interferon-
regulated genes induced in myotonic dystrophy DM1 and DM2
cataracts (70), increased inflammatory gene expression in HD
brain (71), inflammatory gene signatures of sporadic ALS motor
neurons (72). The observation that protein aggregates and fila-
ments are associated with Alzheimer’s disease has led to this
disease sometimes being referred to as a ‘prion-like’ disease.
Indeed the prion-like spread of protein aggregates has been
noted for multiple neurodegenerative diseases (73). It is there-
fore noteworthy that inflammatory activation precedes neuro-
degeneration in a mouse retinal nerve model of prion disease
(74), as well as a mouse model of AD (75).
Thus inflammation is activated at the right time and place to
be the causal common mechanism for neurodegenerative dis-
eases. Its characteristics are also consistent with the various ge-
netic and environmental determinants of neurodegenerative
diseases. Its genetic or pharmacological ablation in animal
models of neurodegenerative diseases typically results in rescue
of disease phenotypes—indicating that inflammatory activation
is required for pathogenesis (Table 2).
Monogenic Contributions to
Neurodegeneration
Like their systemic counterparts, numerous elements of the in-
flammatory response are sites for familial causes of neurode-
generative disease (Table 1). Inflammatory activation appears to
be threshold dependant and also the subject of feed-forward
(sensitization) as well as feed-back (inhibition) mechanisms.
Genetic lesions fall into three reasonably distinct categories
(Fig. 1C). Those that increase the abundance of trigger molecules
can do so directly through mutations that impact ‘non-self’ to
‘self’ modification of endogenous molecules (31). Alternatively,
mutations in degradative pathways can lead to an increase in
steady-state levels of these danger signal molecules through
their reduced turn-over (Table 1). Thirdly, mutations that result
in increased activation signals from the pattern recognition of
trigger molecules will also enhance inflammation.
Non-self mutations and direct increases in
trigger molecules
‘Non-self’ nucleic acid is a common trigger molecule arising
from invading pathogens that signals potential to cause harm.
Non-self RNA and dsDNA are detected by various pattern recog-
nition receptors to initiate inflammation. Modification of endog-
enous molecules is a common means of distinguishing self
from non-self molecules, including various forms of RNA
Box 2. Cells of the Neurovascular Unit
Smooth muscle cells - control localized blood flow
Endothelial cells - comprise the vasculature, blood-brain barrier integrity. Activate neutrophils as they traverse the blood-brain barrier
Pericytes - gate-keepers of the blood brain barrier, regulate endothelial cell function including molecular and cellular transport across
the blood-brain barrier
Oligodendrocytes myelin sheath, axonal remodelling and remyelination
Neurons specific function to the region of the CNS, synaptic and dendritic plasticity
Astrocytes - monitor and maintain neuron synapses, activated by microglia
Microglia - resident macrophages, myeloid origin from yolk sac, environmental surveillance, constantly sampling, maintain homeosta-
sis, perform synaptic pruning, phagocytose dead cells (99).
Neutrophils - by invitation, attracted by cytokines to location of inflammation, infiltration facilitated by pericytes, activated by endothe-
lial cells, contribute to inflammatory response and resolution (60).
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modification (31). Aberrant recognition of self RNA after insuffi-
cient modification is implicated as an upstream driver of RNA
repeat disorders that elicit neurodegenerative diseases.
Notably, loss of function mutations in the RNA editing enzyme
ADAR1 are a cause of Aicardi-Goutieres syndrome—a congenital
disease that includes neurodegeneration as one of its symp-
toms, with affected newborns having the appearance of being
subjected to in utero inflammatory injury (5,6). The absence of
ADAR1 editing renders certain endogenous RNAs (including Alu
element double-stranded RNAs) to be recognized as non-self by
the pattern recognition receptor IFIH1 that then activates in-
flammation (76–80). Indeed, gain-of-function mutations in IFIH1
are also a cause of Aicardi-Goutieres syndrome, while deletion
of IFIH1 rescues the phenotype caused by ADAR1 loss in mouse
models (81).
‘Non-self’ molecular patterns in proteins can also be
afforded by tertiary structure. Prions adopt a structure that is
recognized by pattern recognition receptors that then activate
inflammation (74). Furthermore the seeding of such protein ag-
gregate structures in neurodegeneration has been proposed as a
means of their spread during disease progression (73).
Elevated inflammatory activation signal
transduction pathways
A shift to elevated responsiveness to endogenous RNA can also
trigger neuroinflammation. Gain-of-function mutations in the
MDA-5 (IFIH1) pattern recognition receptor are a cause of
Aicardi-Goutieres syndrome by enhancing the affinity of the re-
ceptor for its RNA ligands (5,6) and therefore increasing the re-
sultant activation signal. Loss-of-function mutations in proteins
that are negative regulators of inflammatory activation signal-
ling give rise to familial ALS. TBK1 and optineurin participate in
toll-like receptor (TLR) signal transduction that contributes to
interferon response pathway (10,11). Progranulin is a TLR9 co-
factor and its deficiency promotes microglial pruning (12).
Loss of RNA degradation pathways
RNA stress granules and the integrated stress response
Cellular stress response and inflammatory activation are inte-
grated in various ways and include the management of mRNAs
and their selective translation and degradation. Cellular stress
causes a cessation in translation, the dissociation of polysomes
and transport of mRNAs to RNA stress granules. If the stress is
relieved the mRNAs are released for translation. If not, the RNA
stress granules are trafficked to autophagosomes for degrada-
tion. These RNA stress granules are also the sites of viral RNA
degradation. The antiviral RNA defense mechanism involves
the binding of multiple RIG-I-like pattern recognition receptors
along single molecules of RNA to form a filament structure that
is then bound by mitochondrial antiviral signalling protein
(MAVS) (82,83). A length requirement for the RNA molecule
appears related to the need for such filaments to exceed a
threshold for MAVS binding and/or activation (83,84). Mutations
in several protein components of RNA stress granules and their
trafficking are causes of familial ALS (Table 1). Plurality and in-
tegration are typical features of these responses. In stressed
cells RNA can also be subject to degradation by non-sense medi-
ated (NMD) decay (85) and in RNA exosomes. There is interplay
between these RNA degradation pathways, with NMD regulat-
ing integrated stress response components.
The endogenous RNAs recognized by IFIH1 include not only
Alu dsRNA but also products of the endoplasmic reticulum un-
folded protein response (ER-UPR) (86). The ER-UPR is orchestrated
by three proteins PERK, IRE-1 and ATF6. IRE-1 encodes a ribonu-
clease activity that cleaves XBP-1 mRNA in two places. Religation
(by a tRNA ligase) results in an mRNA that encodes XBP-1s tran-
scription factor that in turn stimulates expression of response
genes including interferon-b (87). This XBP-1 mRNA activation
process has been detected in multiple neurodegenerative dis-
eases (88). IRE-1 cleavage of other mRNAs not only attenuates
protein translation but generates unusual RNA 30 ends that are
ligands for the IFIH1 pattern recognition receptor thereby activat-
ing the inflammatory response (86). These endogenous non-self
RNAs are in turn degraded by the SKIVL RNA exosome. Notably
loss-of-function mutation in EXOSC3 from this SKIVL complex is
a cause of inherited ponto-cerebellar hypoplasia (PCH1B) (19) in-
dicating that this degradative pathway is crucial in avoiding the
build up of RNAs that result in neurodegenerative disease
(Table 1). Other genetic causes of PCH include mutations in genes
involved in tRNA splicing and synthesis, while another PCH caus-
ing gene, TBC1D23, acts downstream of MYD88 and TRIF and up-
stream of XBP1 in the TLR4-NFKB1 pathway, consistent with a
role in inflammatory activation (89). The IRE-1 pool of RNA cleav-
age products is also thought to contribute to the proximal cause
of Aicardi-Goutieres syndrome (5,6).
The ER-UPR is in turn part of the larger integrated stress re-
sponse (ISR) that includes sentinals for ER stress, viral infection,
amino acid deprivation and heme deprivation (90). From each of
these pathways one of four kinases, PERK, PKR, GCN2 and HRI is
able to phosphorylate a unique serine in the translation initia-
tion factor eIF2a. This eIF2a phosphorylation diminishes protein
synthesis, while allowing preferential translation of specific
mRNAs. The phosphorylation and de-phosphorylation of eIF2a
is therefore a common integral element. Indeed eIF2a is also a
central factor in RNA stress granule regulation.
Expanded repeat RNAs are not only ligands for pattern rec-
ognition receptors (31) but also the subject of non-canonical
translation (repeat-associated non-AUG RAN translation) giving
rise to repeat polypeptides that activate the integrated stress re-
sponse (91). Therefore, somewhat analogous to RNA viruses,
multiple gene products from expanded repeat disease loci are
able to instigate inflammatory activation.
Mitochondria and autophagy
Mitochondria are not only central to homeostasis but along with
NF-jB, are also key monitors and mediators of inflammatory acti-
vation (92). NF-jB is a transcription factor that transduces signals
from certain TLRs. NF-jB targets include competing pathways
mediated by p62 (sequestosome 1) and inflammasomes. p62 is a
signalling scaffold and adaptor that binds damaged macromole-
cules (including mitochondria) that have been targeted by ubiqui-
tination for degradation by autophagosomes. Autophagy is a
major recycling system for a wide range of cellular molecules and
structures including mitochondria (mitophagy) and RNA stress
granules (granulophagy) as well as foreign pathogens (xenophagy)
(26). Pink1 and parkin are two proteins responsible for the identifi-
cation and tagging of damaged mitochondria by ubiquitination.
LRRK2 controls mitochondrial fission (and fusion) that enables
mitophagy of discrete parts of the mitochondrial complex.
Multiple familial Parkinsons disease genes (a-synuclein, PINK1,
Parkin, LRRK2, DJ-1, GBA and ATP13A2) have roles in mitophagy
(18,93), while mutations in p62 are a cause of amyotrophic lateral
sclerosis (4). Furthermore the protein TOMM40 is gate-keeper of
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Pink1 mitochondrial import. The TOMM40 gene is located within
the APOE block of linkage disequilibrium that confers susceptibil-
ity to Alzheimer’s disease and its variation is a better predictor
than APOE of age of disease onset (27).
In the alternative pathway NF-jB-induced inflammasomes
activate gasdermin D, an extremely potent pore-forming cyto-
lytic protein that mediates cell death (92,94–97). Damaged mito-
chondria also contribute to inflammasome activation, so their
removal by mitophagy limits the activity of this pathway.
Defects in mitophagy therefore enhance cell death. While these
pathways have been characterized in systemic macrophages
they appear to be relevant to the processes in their CNS coun-
terparts, the microglia.
Mitochondria are also the sites of RNA stress granule/RNA
pattern recognition receptor filament interaction with MAVS/
IPS-1. This assembly leads to TRAFs/IKK mediated interferon ac-
tivation and cell death unless degraded by autophagy (98). As
noted previously, Ref(2)P, the Drosophila orthologue of p62, is a
viral restriction factor, with multiple alleles conferring variable
resistance/sensitivity to viral infection (3). Genetic variation in
components of pathways dependent upon autophagy can
thereby account for variable susceptibility to environmental
triggers that unless degraded, can lead to cell death.
Clinical Implications
Together this assembled evidence demonstrates that endoge-
nous inflammatory triggers and/or genetic mutations that accel-
erate, impede or redirect inflammatory processes, act in many
major neurodegenerative diseases. This builds a strong rationale
for invoking a shared autoinflammatory mechanism as central
and causal to neurodegenerative diseases. This hypothesis must
now be evaluated in genetic mouse models and clinical cohorts
to build the evidence that inflammation is not just a bystander,
but necessary and sufficient for neurodegenerative disease.
The pressing imperative for novel therapeutic strategies
stands to be advanced by this fresh approach. Recent animal
studies reveal the inflammation-driven integrated stress re-
sponse pathway is an effective target for intervention in several
neurodegenerative conditions. Excitingly, pharmacological inhi-
bition of eIF2a activity was effective in relieving symptoms in a
Drosophila model of amyotrophic lateral sclerosis and mouse
models of prion disease, tau fronto-temporal dementia and
traumatic brain injury (41–43). Although the long-term conse-
quences of ablation of the integrated stress response are as yet
unclear, this is just the tip of the iceberg of potential targets in
the inflammatory cascade. The initial promise offered by these
studies now justifies concerted research effort to explore rede-
ployment of existing therapies for autoinflammatory condi-
tions, and new drug targets, for clinical potential in the
enormous and growing burden of neurodegenerative diseases.
Outstanding questions
What is/are the mechanism(s) for transition from the acute
(protective) to chronic (pernicious) phase of inflammation? The
transition between these two phases would appear an ideal
therapeutic target. Will prolonging the acute phase and/or boost-
ing capacity to resolve inflammation in the transition to chronic
inflammatory-mediated cell death, delay onset or slow progres-
sion of neurodegenerative diseases? What systemic factor(s)/sig-
nals is/are responsible for increased risk after episodes of sepsis
or trauma? Age is the greatest risk factor for neurodegenerative
disease. CNS inflammation is known to increase with age—what
are the targets to limit the impact of age and are there protective
interventions to delay age-related onset and progression rate? Is
it possible to inhibit neurodegeneration in humans by manipulat-
ing a single inflammatory pathway, or would it be necessary to
modulate multiple pathways to obtain a clinical response? At
what point in the neurodegenerative process in humans would it
be too late to intervene?
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